{"docstore/data": {"8832ecd3-1ca7-4682-9aec-bb96b900ba30": {"__data__": {"id_": "8832ecd3-1ca7-4682-9aec-bb96b900ba30", "embedding": null, "metadata": {"window": " Corrected Transcript  \n \n \n1-877-FACTSET   www.callstreet.com  Total Pages : 20 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n03-Aug-2020  \nMcKesson Corp.   (MCK ) \nQ1 2021 Earnings Call    ", "original_text": " Corrected Transcript  \n \n \n1-877-FACTSET   www.callstreet.com  Total Pages : 20 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n03-Aug-2020  \nMcKesson Corp.  ", "page_label": "1", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5fa68102-c072-4c6f-b65a-e470ca43b79a", "node_type": "4", "metadata": {"page_label": "1", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e2802fbcbe9a1ab3dfb53e499a8d48925235f8a181d1dfb12f8d7e357d423e98", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "71a87bc7-ff33-4e4b-be2a-3abdb437d689", "node_type": "1", "metadata": {"window": " Corrected Transcript  \n \n \n1-877-FACTSET   www.callstreet.com  Total Pages : 20 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n03-Aug-2020  \nMcKesson Corp.   (MCK ) \nQ1 2021 Earnings Call    ", "original_text": "(MCK ) \nQ1 2021 Earnings Call    "}, "hash": "cac241c51fdf45ec4707349b258d24795c22715bb2d1c8cf3df494f2a7d90f0c", "class_name": "RelatedNodeInfo"}}, "text": " Corrected Transcript  \n \n \n1-877-FACTSET   www.callstreet.com  Total Pages : 20 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n03-Aug-2020  \nMcKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 165, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "71a87bc7-ff33-4e4b-be2a-3abdb437d689": {"__data__": {"id_": "71a87bc7-ff33-4e4b-be2a-3abdb437d689", "embedding": null, "metadata": {"window": " Corrected Transcript  \n \n \n1-877-FACTSET   www.callstreet.com  Total Pages : 20 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n03-Aug-2020  \nMcKesson Corp.   (MCK ) \nQ1 2021 Earnings Call    ", "original_text": "(MCK ) \nQ1 2021 Earnings Call    ", "page_label": "1", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5fa68102-c072-4c6f-b65a-e470ca43b79a", "node_type": "4", "metadata": {"page_label": "1", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e2802fbcbe9a1ab3dfb53e499a8d48925235f8a181d1dfb12f8d7e357d423e98", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8832ecd3-1ca7-4682-9aec-bb96b900ba30", "node_type": "1", "metadata": {"window": " Corrected Transcript  \n \n \n1-877-FACTSET   www.callstreet.com  Total Pages : 20 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n03-Aug-2020  \nMcKesson Corp.   (MCK ) \nQ1 2021 Earnings Call    ", "original_text": " Corrected Transcript  \n \n \n1-877-FACTSET   www.callstreet.com  Total Pages : 20 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n03-Aug-2020  \nMcKesson Corp.  ", "page_label": "1", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6c694e5efa09ebc8df2b4cfdbac8e6e637a55374c489ba287d051ff45e9831e7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e1630c33-7350-4e42-a533-3196f1ee5a3a", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  \n Brian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n ", "original_text": "McKesson Corp.  "}, "hash": "233aff0ba805742a7d9cb4921a70da71eb6a105172bfff7773475db4eb73f99c", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ1 2021 Earnings Call    ", "start_char_idx": 165, "end_char_idx": 198, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e1630c33-7350-4e42-a533-3196f1ee5a3a": {"__data__": {"id_": "e1630c33-7350-4e42-a533-3196f1ee5a3a", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  \n Brian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n ", "original_text": "McKesson Corp.  ", "page_label": "2", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "be75fc7f-5193-4a22-8ee5-e80bd9813438", "node_type": "4", "metadata": {"page_label": "2", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1e47fa9effc3207bfe76cc89472084d3eabb0099d187eb12da22fb57aaba46f9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "71a87bc7-ff33-4e4b-be2a-3abdb437d689", "node_type": "1", "metadata": {"window": " Corrected Transcript  \n \n \n1-877-FACTSET   www.callstreet.com  Total Pages : 20 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n03-Aug-2020  \nMcKesson Corp.   (MCK ) \nQ1 2021 Earnings Call    ", "original_text": "(MCK ) \nQ1 2021 Earnings Call    ", "page_label": "1", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4f6bc56e407d4237d058c15f84dd61d1d89d02eb7e572841f83eac8a561cfc11", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b17cbbd9-0e73-46e3-92c4-e904618fb425", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  \n Brian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  \n", "original_text": "(MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  \n"}, "hash": "b06e6bb2d767800e3a9872ce7718e52df41d1882df221caef3bbc0cb6bceb5c4", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b17cbbd9-0e73-46e3-92c4-e904618fb425": {"__data__": {"id_": "b17cbbd9-0e73-46e3-92c4-e904618fb425", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  \n Brian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  \n", "original_text": "(MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  \n", "page_label": "2", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "be75fc7f-5193-4a22-8ee5-e80bd9813438", "node_type": "4", "metadata": {"page_label": "2", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1e47fa9effc3207bfe76cc89472084d3eabb0099d187eb12da22fb57aaba46f9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e1630c33-7350-4e42-a533-3196f1ee5a3a", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  \n Brian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n ", "original_text": "McKesson Corp.  ", "page_label": "2", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5b934600000d714e09b06ea4a0d82e0e02c4f707cfa9a907afb19e095d0b885e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ea29bf7f-1481-4f4b-bbb8-3530c468f93f", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  \n Brian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  \n Charles Rhyee  \nAnalyst, Cowen & Co. ", "original_text": "Brian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  "}, "hash": "bbab93f7ddc87d90168cc464dbf42d6f8f718d03c4f172b731f130e7728e852b", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  \n", "start_char_idx": 16, "end_char_idx": 283, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ea29bf7f-1481-4f4b-bbb8-3530c468f93f": {"__data__": {"id_": "ea29bf7f-1481-4f4b-bbb8-3530c468f93f", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  \n Brian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  \n Charles Rhyee  \nAnalyst, Cowen & Co. ", "original_text": "Brian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "2", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "be75fc7f-5193-4a22-8ee5-e80bd9813438", "node_type": "4", "metadata": {"page_label": "2", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1e47fa9effc3207bfe76cc89472084d3eabb0099d187eb12da22fb57aaba46f9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b17cbbd9-0e73-46e3-92c4-e904618fb425", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  \n Brian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  \n", "original_text": "(MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  \n", "page_label": "2", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "be20a9a8d84bd7308b227e2d761caef74b855adc4f3479f8752890db3eb35106", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "284fc50e-5dfb-48b8-a117-14489e6742b1", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  \n Brian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  \n Charles Rhyee  \nAnalyst, Cowen & Co.  LLC  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  \n", "original_text": "Britt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n "}, "hash": "fa3123c424387762bade2be4fe5093685259e35abf66736db87251bfa8c33194", "class_name": "RelatedNodeInfo"}}, "text": "Brian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "start_char_idx": 283, "end_char_idx": 352, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "284fc50e-5dfb-48b8-a117-14489e6742b1": {"__data__": {"id_": "284fc50e-5dfb-48b8-a117-14489e6742b1", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  \n Brian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  \n Charles Rhyee  \nAnalyst, Cowen & Co.  LLC  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  \n", "original_text": "Britt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n ", "page_label": "2", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "be75fc7f-5193-4a22-8ee5-e80bd9813438", "node_type": "4", "metadata": {"page_label": "2", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1e47fa9effc3207bfe76cc89472084d3eabb0099d187eb12da22fb57aaba46f9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ea29bf7f-1481-4f4b-bbb8-3530c468f93f", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  \n Brian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  \n Charles Rhyee  \nAnalyst, Cowen & Co. ", "original_text": "Brian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "2", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b407993a049d599d16d40fe103861962fb1563544694df359c1b442d8d8acbe6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f23af7a1-fa64-40c7-9425-75af5096d0eb", "node_type": "1", "metadata": {"window": "(MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  \n Brian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  \n Charles Rhyee  \nAnalyst, Cowen & Co.  LLC  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  \n Steven Valiquette  \nAnalyst, Barclays Capital, In c. \nEric Percher  \nAnalyst, Nephron Research LLC  \nGlen Santangelo  \nAnalyst, Guggenheim Securities LLC  Stephen Baxter  \nAnalyst, Wolfe Research LLC  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  \n"}, "hash": "54e6ed60e343888375aaf436d57094bf4bbe81fb3941734b1f4f23eb9b653dc0", "class_name": "RelatedNodeInfo"}}, "text": "Britt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n ", "start_char_idx": 352, "end_char_idx": 442, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f23af7a1-fa64-40c7-9425-75af5096d0eb": {"__data__": {"id_": "f23af7a1-fa64-40c7-9425-75af5096d0eb", "embedding": null, "metadata": {"window": "(MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  \n Brian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  \n Charles Rhyee  \nAnalyst, Cowen & Co.  LLC  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  \n Steven Valiquette  \nAnalyst, Barclays Capital, In c. \nEric Percher  \nAnalyst, Nephron Research LLC  \nGlen Santangelo  \nAnalyst, Guggenheim Securities LLC  Stephen Baxter  \nAnalyst, Wolfe Research LLC  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  \n", "page_label": "2", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "be75fc7f-5193-4a22-8ee5-e80bd9813438", "node_type": "4", "metadata": {"page_label": "2", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1e47fa9effc3207bfe76cc89472084d3eabb0099d187eb12da22fb57aaba46f9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "284fc50e-5dfb-48b8-a117-14489e6742b1", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  \n Brian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  \n Charles Rhyee  \nAnalyst, Cowen & Co.  LLC  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  \n", "original_text": "Britt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n ", "page_label": "2", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e6b1ae697c896a9edf582bcc204ab92abf140c676481b19ee49ed8abf43963b5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "657739c5-854d-44ce-b2d9-fa81fa779696", "node_type": "1", "metadata": {"window": "Brian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  \n Charles Rhyee  \nAnalyst, Cowen & Co.  LLC  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  \n Steven Valiquette  \nAnalyst, Barclays Capital, In c. \nEric Percher  \nAnalyst, Nephron Research LLC  \nGlen Santangelo  \nAnalyst, Guggenheim Securities LLC  Stephen Baxter  \nAnalyst, Wolfe Research LLC  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co. ", "original_text": "Charles Rhyee  \nAnalyst, Cowen & Co. "}, "hash": "fb9f10be6f638676b8abe4c86b3906ab01cfbc8527bff8e09dcccfdacf99722a", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  \n", "start_char_idx": 442, "end_char_idx": 800, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "657739c5-854d-44ce-b2d9-fa81fa779696": {"__data__": {"id_": "657739c5-854d-44ce-b2d9-fa81fa779696", "embedding": null, "metadata": {"window": "Brian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  \n Charles Rhyee  \nAnalyst, Cowen & Co.  LLC  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  \n Steven Valiquette  \nAnalyst, Barclays Capital, In c. \nEric Percher  \nAnalyst, Nephron Research LLC  \nGlen Santangelo  \nAnalyst, Guggenheim Securities LLC  Stephen Baxter  \nAnalyst, Wolfe Research LLC  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co. ", "original_text": "Charles Rhyee  \nAnalyst, Cowen & Co. ", "page_label": "2", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "be75fc7f-5193-4a22-8ee5-e80bd9813438", "node_type": "4", "metadata": {"page_label": "2", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1e47fa9effc3207bfe76cc89472084d3eabb0099d187eb12da22fb57aaba46f9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f23af7a1-fa64-40c7-9425-75af5096d0eb", "node_type": "1", "metadata": {"window": "(MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  \n Brian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  \n Charles Rhyee  \nAnalyst, Cowen & Co.  LLC  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  \n Steven Valiquette  \nAnalyst, Barclays Capital, In c. \nEric Percher  \nAnalyst, Nephron Research LLC  \nGlen Santangelo  \nAnalyst, Guggenheim Securities LLC  Stephen Baxter  \nAnalyst, Wolfe Research LLC  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  \n", "page_label": "2", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "50095e587a58b0786e1dc90830c4ee013866efbdee462368a6f17aca167dd90d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "852d9709-c802-4a32-9ab4-ef33e6dbf182", "node_type": "1", "metadata": {"window": "Britt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  \n Charles Rhyee  \nAnalyst, Cowen & Co.  LLC  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  \n Steven Valiquette  \nAnalyst, Barclays Capital, In c. \nEric Percher  \nAnalyst, Nephron Research LLC  \nGlen Santangelo  \nAnalyst, Guggenheim Securities LLC  Stephen Baxter  \nAnalyst, Wolfe Research LLC  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co.  LLC  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.  \n  ", "original_text": "LLC  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  \n"}, "hash": "7c5b9d9c2ad40a50b45ee61a372098b2d13343bbd4b7b64ebb3ce46dfb68b26d", "class_name": "RelatedNodeInfo"}}, "text": "Charles Rhyee  \nAnalyst, Cowen & Co. ", "start_char_idx": 800, "end_char_idx": 837, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "852d9709-c802-4a32-9ab4-ef33e6dbf182": {"__data__": {"id_": "852d9709-c802-4a32-9ab4-ef33e6dbf182", "embedding": null, "metadata": {"window": "Britt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  \n Charles Rhyee  \nAnalyst, Cowen & Co.  LLC  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  \n Steven Valiquette  \nAnalyst, Barclays Capital, In c. \nEric Percher  \nAnalyst, Nephron Research LLC  \nGlen Santangelo  \nAnalyst, Guggenheim Securities LLC  Stephen Baxter  \nAnalyst, Wolfe Research LLC  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co.  LLC  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.  \n  ", "original_text": "LLC  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  \n", "page_label": "2", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "be75fc7f-5193-4a22-8ee5-e80bd9813438", "node_type": "4", "metadata": {"page_label": "2", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1e47fa9effc3207bfe76cc89472084d3eabb0099d187eb12da22fb57aaba46f9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "657739c5-854d-44ce-b2d9-fa81fa779696", "node_type": "1", "metadata": {"window": "Brian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  \n Charles Rhyee  \nAnalyst, Cowen & Co.  LLC  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  \n Steven Valiquette  \nAnalyst, Barclays Capital, In c. \nEric Percher  \nAnalyst, Nephron Research LLC  \nGlen Santangelo  \nAnalyst, Guggenheim Securities LLC  Stephen Baxter  \nAnalyst, Wolfe Research LLC  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co. ", "original_text": "Charles Rhyee  \nAnalyst, Cowen & Co. ", "page_label": "2", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bd7c088d021f20c7d5df48edda97533c6705209c8b6117b79534880d05f2aa2f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4e3b23f2-c5b0-4efc-a70b-fca725edb51f", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  \n Charles Rhyee  \nAnalyst, Cowen & Co.  LLC  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  \n Steven Valiquette  \nAnalyst, Barclays Capital, In c. \nEric Percher  \nAnalyst, Nephron Research LLC  \nGlen Santangelo  \nAnalyst, Guggenheim Securities LLC  Stephen Baxter  \nAnalyst, Wolfe Research LLC  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co.  LLC  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.  \n  ", "original_text": "Steven Valiquette  \nAnalyst, Barclays Capital, In c. \nEric Percher  \nAnalyst, Nephron Research LLC  \nGlen Santangelo  \nAnalyst, Guggenheim Securities LLC  Stephen Baxter  \nAnalyst, Wolfe Research LLC  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co. "}, "hash": "52b0b0f74e590ddb50f867df2b1fdf69e1ac48bfb18149ae60b4f59a328d298d", "class_name": "RelatedNodeInfo"}}, "text": "LLC  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  \n", "start_char_idx": 837, "end_char_idx": 893, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4e3b23f2-c5b0-4efc-a70b-fca725edb51f": {"__data__": {"id_": "4e3b23f2-c5b0-4efc-a70b-fca725edb51f", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  \n Charles Rhyee  \nAnalyst, Cowen & Co.  LLC  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  \n Steven Valiquette  \nAnalyst, Barclays Capital, In c. \nEric Percher  \nAnalyst, Nephron Research LLC  \nGlen Santangelo  \nAnalyst, Guggenheim Securities LLC  Stephen Baxter  \nAnalyst, Wolfe Research LLC  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co.  LLC  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.  \n  ", "original_text": "Steven Valiquette  \nAnalyst, Barclays Capital, In c. \nEric Percher  \nAnalyst, Nephron Research LLC  \nGlen Santangelo  \nAnalyst, Guggenheim Securities LLC  Stephen Baxter  \nAnalyst, Wolfe Research LLC  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co. ", "page_label": "2", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "be75fc7f-5193-4a22-8ee5-e80bd9813438", "node_type": "4", "metadata": {"page_label": "2", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1e47fa9effc3207bfe76cc89472084d3eabb0099d187eb12da22fb57aaba46f9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "852d9709-c802-4a32-9ab4-ef33e6dbf182", "node_type": "1", "metadata": {"window": "Britt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  \n Charles Rhyee  \nAnalyst, Cowen & Co.  LLC  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  \n Steven Valiquette  \nAnalyst, Barclays Capital, In c. \nEric Percher  \nAnalyst, Nephron Research LLC  \nGlen Santangelo  \nAnalyst, Guggenheim Securities LLC  Stephen Baxter  \nAnalyst, Wolfe Research LLC  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co.  LLC  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.  \n  ", "original_text": "LLC  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  \n", "page_label": "2", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5f95eedce425bc3b6d065dd51c06bc0320127ce22d575e7e7e1fafa4ba4c7a0a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "523453e7-af9e-475c-b691-8e257164d734", "node_type": "1", "metadata": {"window": "Charles Rhyee  \nAnalyst, Cowen & Co.  LLC  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  \n Steven Valiquette  \nAnalyst, Barclays Capital, In c. \nEric Percher  \nAnalyst, Nephron Research LLC  \nGlen Santangelo  \nAnalyst, Guggenheim Securities LLC  Stephen Baxter  \nAnalyst, Wolfe Research LLC  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co.  LLC  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.  \n  ", "original_text": "LLC  \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co. "}, "hash": "089e03a827e180cb1740c42aea890440a9b18a7ac38caec27d6b15d7edbcd39b", "class_name": "RelatedNodeInfo"}}, "text": "Steven Valiquette  \nAnalyst, Barclays Capital, In c. \nEric Percher  \nAnalyst, Nephron Research LLC  \nGlen Santangelo  \nAnalyst, Guggenheim Securities LLC  Stephen Baxter  \nAnalyst, Wolfe Research LLC  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co. ", "start_char_idx": 893, "end_char_idx": 1197, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "523453e7-af9e-475c-b691-8e257164d734": {"__data__": {"id_": "523453e7-af9e-475c-b691-8e257164d734", "embedding": null, "metadata": {"window": "Charles Rhyee  \nAnalyst, Cowen & Co.  LLC  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  \n Steven Valiquette  \nAnalyst, Barclays Capital, In c. \nEric Percher  \nAnalyst, Nephron Research LLC  \nGlen Santangelo  \nAnalyst, Guggenheim Securities LLC  Stephen Baxter  \nAnalyst, Wolfe Research LLC  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co.  LLC  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.  \n  ", "original_text": "LLC  \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co. ", "page_label": "2", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "be75fc7f-5193-4a22-8ee5-e80bd9813438", "node_type": "4", "metadata": {"page_label": "2", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1e47fa9effc3207bfe76cc89472084d3eabb0099d187eb12da22fb57aaba46f9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4e3b23f2-c5b0-4efc-a70b-fca725edb51f", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  \n Charles Rhyee  \nAnalyst, Cowen & Co.  LLC  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  \n Steven Valiquette  \nAnalyst, Barclays Capital, In c. \nEric Percher  \nAnalyst, Nephron Research LLC  \nGlen Santangelo  \nAnalyst, Guggenheim Securities LLC  Stephen Baxter  \nAnalyst, Wolfe Research LLC  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co.  LLC  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.  \n  ", "original_text": "Steven Valiquette  \nAnalyst, Barclays Capital, In c. \nEric Percher  \nAnalyst, Nephron Research LLC  \nGlen Santangelo  \nAnalyst, Guggenheim Securities LLC  Stephen Baxter  \nAnalyst, Wolfe Research LLC  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co. ", "page_label": "2", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e06898e6c7646d78bd3e84412ab08c8aa0c68cdc9e3f8d9156edd43a3fd4c587", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5c5171d9-f815-40d8-b8b0-9391cf6bf49a", "node_type": "1", "metadata": {"window": "LLC  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  \n Steven Valiquette  \nAnalyst, Barclays Capital, In c. \nEric Percher  \nAnalyst, Nephron Research LLC  \nGlen Santangelo  \nAnalyst, Guggenheim Securities LLC  Stephen Baxter  \nAnalyst, Wolfe Research LLC  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co.  LLC  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.  \n  ", "original_text": "LLC  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.  \n  "}, "hash": "ae2cd956d2c463ad729676f07bc6471e37f5a7ab97873e1e56230ab1ccf55550", "class_name": "RelatedNodeInfo"}}, "text": "LLC  \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co. ", "start_char_idx": 1197, "end_char_idx": 1250, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5c5171d9-f815-40d8-b8b0-9391cf6bf49a": {"__data__": {"id_": "5c5171d9-f815-40d8-b8b0-9391cf6bf49a", "embedding": null, "metadata": {"window": "LLC  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  \n Steven Valiquette  \nAnalyst, Barclays Capital, In c. \nEric Percher  \nAnalyst, Nephron Research LLC  \nGlen Santangelo  \nAnalyst, Guggenheim Securities LLC  Stephen Baxter  \nAnalyst, Wolfe Research LLC  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co.  LLC  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.  \n  ", "original_text": "LLC  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.  \n  ", "page_label": "2", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "be75fc7f-5193-4a22-8ee5-e80bd9813438", "node_type": "4", "metadata": {"page_label": "2", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1e47fa9effc3207bfe76cc89472084d3eabb0099d187eb12da22fb57aaba46f9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "523453e7-af9e-475c-b691-8e257164d734", "node_type": "1", "metadata": {"window": "Charles Rhyee  \nAnalyst, Cowen & Co.  LLC  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  \n Steven Valiquette  \nAnalyst, Barclays Capital, In c. \nEric Percher  \nAnalyst, Nephron Research LLC  \nGlen Santangelo  \nAnalyst, Guggenheim Securities LLC  Stephen Baxter  \nAnalyst, Wolfe Research LLC  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co.  LLC  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.  \n  ", "original_text": "LLC  \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co. ", "page_label": "2", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6578e36cbaf47ac2ea410fe32479852c3976b843882a812b4b0d691f7868b608", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "28f85752-c8fb-431b-9869-322fffe993bf", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to McKesson's First Quarter Earnings Call.  Today's conference is being recorded.  At this \ntime, I'd like to turn the call over to Holly Weiss. ", "original_text": "McKesson Corp.  "}, "hash": "a182bc02f6861f8a7860f9dc720f0b1e776be5c84f44317af24a2027368d3754", "class_name": "RelatedNodeInfo"}}, "text": "LLC  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.  \n  ", "start_char_idx": 1250, "end_char_idx": 1314, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "28f85752-c8fb-431b-9869-322fffe993bf": {"__data__": {"id_": "28f85752-c8fb-431b-9869-322fffe993bf", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to McKesson's First Quarter Earnings Call.  Today's conference is being recorded.  At this \ntime, I'd like to turn the call over to Holly Weiss. ", "original_text": "McKesson Corp.  ", "page_label": "3", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f2ea56d4-9ba8-40ce-8f1a-d30083a09b88", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5877ddfe3db966424172ad7268280081fac3e10094e047943d3193a022b9a8ed", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5c5171d9-f815-40d8-b8b0-9391cf6bf49a", "node_type": "1", "metadata": {"window": "LLC  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  \n Steven Valiquette  \nAnalyst, Barclays Capital, In c. \nEric Percher  \nAnalyst, Nephron Research LLC  \nGlen Santangelo  \nAnalyst, Guggenheim Securities LLC  Stephen Baxter  \nAnalyst, Wolfe Research LLC  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co.  LLC  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.  \n  ", "original_text": "LLC  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.  \n  ", "page_label": "2", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5b206383938f940434421239244670c826eda76f3d656895b5ec41813c7b37d3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "28e254e7-8c61-46d4-8075-6e25026c8268", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to McKesson's First Quarter Earnings Call.  Today's conference is being recorded.  At this \ntime, I'd like to turn the call over to Holly Weiss.  Please go ahead.  \n ", "original_text": "(MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to McKesson's First Quarter Earnings Call. "}, "hash": "5611f7477b7524500c3d4acf7b92debaf0fd77c95b067e83b060b6c1dccb94e5", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "28e254e7-8c61-46d4-8075-6e25026c8268": {"__data__": {"id_": "28e254e7-8c61-46d4-8075-6e25026c8268", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to McKesson's First Quarter Earnings Call.  Today's conference is being recorded.  At this \ntime, I'd like to turn the call over to Holly Weiss.  Please go ahead.  \n ", "original_text": "(MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to McKesson's First Quarter Earnings Call. ", "page_label": "3", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f2ea56d4-9ba8-40ce-8f1a-d30083a09b88", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5877ddfe3db966424172ad7268280081fac3e10094e047943d3193a022b9a8ed", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "28f85752-c8fb-431b-9869-322fffe993bf", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to McKesson's First Quarter Earnings Call.  Today's conference is being recorded.  At this \ntime, I'd like to turn the call over to Holly Weiss. ", "original_text": "McKesson Corp.  ", "page_label": "3", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4302a93263adcfbef37879801a77224d327995108814e0ef357e2da64db86d25", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fc96fdef-10a9-4bdf-918b-af678b048079", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to McKesson's First Quarter Earnings Call.  Today's conference is being recorded.  At this \ntime, I'd like to turn the call over to Holly Weiss.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  \n", "original_text": "Today's conference is being recorded. "}, "hash": "fa45c5e0f29fbb9a54f22a419bfa6d4df56b381ec63b766c387ec520f5e2d7ac", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to McKesson's First Quarter Earnings Call. ", "start_char_idx": 16, "end_char_idx": 279, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fc96fdef-10a9-4bdf-918b-af678b048079": {"__data__": {"id_": "fc96fdef-10a9-4bdf-918b-af678b048079", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to McKesson's First Quarter Earnings Call.  Today's conference is being recorded.  At this \ntime, I'd like to turn the call over to Holly Weiss.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  \n", "original_text": "Today's conference is being recorded. ", "page_label": "3", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f2ea56d4-9ba8-40ce-8f1a-d30083a09b88", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5877ddfe3db966424172ad7268280081fac3e10094e047943d3193a022b9a8ed", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "28e254e7-8c61-46d4-8075-6e25026c8268", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to McKesson's First Quarter Earnings Call.  Today's conference is being recorded.  At this \ntime, I'd like to turn the call over to Holly Weiss.  Please go ahead.  \n ", "original_text": "(MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to McKesson's First Quarter Earnings Call. ", "page_label": "3", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7ff5feff414c62786fcb3d924187afa471147213958b2d46a0acd6ed1abb3d19", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c98671b7-7ae3-40d2-a10c-118891404195", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to McKesson's First Quarter Earnings Call.  Today's conference is being recorded.  At this \ntime, I'd like to turn the call over to Holly Weiss.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  \n Thank you, Elisa. ", "original_text": "At this \ntime, I'd like to turn the call over to Holly Weiss. "}, "hash": "29f179954235bbb7ea3f619cc83ef967ad5643b01d3d2dcc114491646f288fa0", "class_name": "RelatedNodeInfo"}}, "text": "Today's conference is being recorded. ", "start_char_idx": 279, "end_char_idx": 317, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c98671b7-7ae3-40d2-a10c-118891404195": {"__data__": {"id_": "c98671b7-7ae3-40d2-a10c-118891404195", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to McKesson's First Quarter Earnings Call.  Today's conference is being recorded.  At this \ntime, I'd like to turn the call over to Holly Weiss.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  \n Thank you, Elisa. ", "original_text": "At this \ntime, I'd like to turn the call over to Holly Weiss. ", "page_label": "3", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f2ea56d4-9ba8-40ce-8f1a-d30083a09b88", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5877ddfe3db966424172ad7268280081fac3e10094e047943d3193a022b9a8ed", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fc96fdef-10a9-4bdf-918b-af678b048079", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to McKesson's First Quarter Earnings Call.  Today's conference is being recorded.  At this \ntime, I'd like to turn the call over to Holly Weiss.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  \n", "original_text": "Today's conference is being recorded. ", "page_label": "3", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "09d686c8f3256c51d74095429356fe589161b52855a953788866208992fa14bf", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5b3ea2b1-bf9a-42e0-93d3-abc32bd82e96", "node_type": "1", "metadata": {"window": "(MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to McKesson's First Quarter Earnings Call.  Today's conference is being recorded.  At this \ntime, I'd like to turn the call over to Holly Weiss.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  \n Thank you, Elisa.  Good morning and welcome everyone to McKesson's First Quarter fiscal 2021 earnings call. \n", "original_text": "Please go ahead.  \n "}, "hash": "769c2f6467a25187d79bf8465597edb53c60335484757197883546261ecd68ef", "class_name": "RelatedNodeInfo"}}, "text": "At this \ntime, I'd like to turn the call over to Holly Weiss. ", "start_char_idx": 317, "end_char_idx": 379, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5b3ea2b1-bf9a-42e0-93d3-abc32bd82e96": {"__data__": {"id_": "5b3ea2b1-bf9a-42e0-93d3-abc32bd82e96", "embedding": null, "metadata": {"window": "(MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to McKesson's First Quarter Earnings Call.  Today's conference is being recorded.  At this \ntime, I'd like to turn the call over to Holly Weiss.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  \n Thank you, Elisa.  Good morning and welcome everyone to McKesson's First Quarter fiscal 2021 earnings call. \n", "original_text": "Please go ahead.  \n ", "page_label": "3", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f2ea56d4-9ba8-40ce-8f1a-d30083a09b88", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5877ddfe3db966424172ad7268280081fac3e10094e047943d3193a022b9a8ed", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c98671b7-7ae3-40d2-a10c-118891404195", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to McKesson's First Quarter Earnings Call.  Today's conference is being recorded.  At this \ntime, I'd like to turn the call over to Holly Weiss.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  \n Thank you, Elisa. ", "original_text": "At this \ntime, I'd like to turn the call over to Holly Weiss. ", "page_label": "3", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b60aa2673de298dd178e3f56b3a39add306072d230fb900b0585ee447539156b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1045334e-cbe2-4180-9a11-2e008c34315e", "node_type": "1", "metadata": {"window": "Today's conference is being recorded.  At this \ntime, I'd like to turn the call over to Holly Weiss.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  \n Thank you, Elisa.  Good morning and welcome everyone to McKesson's First Quarter fiscal 2021 earnings call. \n Today, I'm joined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Officer. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  \n"}, "hash": "cbf2151aa86abcacf14cce5bb642a9580187d9132dc5ffa58ce2b680e998054d", "class_name": "RelatedNodeInfo"}}, "text": "Please go ahead.  \n ", "start_char_idx": 379, "end_char_idx": 399, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1045334e-cbe2-4180-9a11-2e008c34315e": {"__data__": {"id_": "1045334e-cbe2-4180-9a11-2e008c34315e", "embedding": null, "metadata": {"window": "Today's conference is being recorded.  At this \ntime, I'd like to turn the call over to Holly Weiss.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  \n Thank you, Elisa.  Good morning and welcome everyone to McKesson's First Quarter fiscal 2021 earnings call. \n Today, I'm joined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Officer. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  \n", "page_label": "3", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f2ea56d4-9ba8-40ce-8f1a-d30083a09b88", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5877ddfe3db966424172ad7268280081fac3e10094e047943d3193a022b9a8ed", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5b3ea2b1-bf9a-42e0-93d3-abc32bd82e96", "node_type": "1", "metadata": {"window": "(MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to McKesson's First Quarter Earnings Call.  Today's conference is being recorded.  At this \ntime, I'd like to turn the call over to Holly Weiss.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  \n Thank you, Elisa.  Good morning and welcome everyone to McKesson's First Quarter fiscal 2021 earnings call. \n", "original_text": "Please go ahead.  \n ", "page_label": "3", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "034dcc4eb1a7d326ed5eef8f9aead850e0044e5c29d0938887808fd775b42c23", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2c589dae-b77a-4c97-af83-edf099a735fe", "node_type": "1", "metadata": {"window": "At this \ntime, I'd like to turn the call over to Holly Weiss.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  \n Thank you, Elisa.  Good morning and welcome everyone to McKesson's First Quarter fiscal 2021 earnings call. \n Today, I'm joined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Officer.  Brian \nwill lead off, followed by Britt, and then we will move to a question -and-answer session.  \n \n", "original_text": "Thank you, Elisa. "}, "hash": "cfa051f752b5ebbf16a244876a40ff3986602dd56bd513f075cb41d95b892ef4", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  \n", "start_char_idx": 399, "end_char_idx": 745, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2c589dae-b77a-4c97-af83-edf099a735fe": {"__data__": {"id_": "2c589dae-b77a-4c97-af83-edf099a735fe", "embedding": null, "metadata": {"window": "At this \ntime, I'd like to turn the call over to Holly Weiss.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  \n Thank you, Elisa.  Good morning and welcome everyone to McKesson's First Quarter fiscal 2021 earnings call. \n Today, I'm joined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Officer.  Brian \nwill lead off, followed by Britt, and then we will move to a question -and-answer session.  \n \n", "original_text": "Thank you, Elisa. ", "page_label": "3", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f2ea56d4-9ba8-40ce-8f1a-d30083a09b88", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5877ddfe3db966424172ad7268280081fac3e10094e047943d3193a022b9a8ed", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1045334e-cbe2-4180-9a11-2e008c34315e", "node_type": "1", "metadata": {"window": "Today's conference is being recorded.  At this \ntime, I'd like to turn the call over to Holly Weiss.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  \n Thank you, Elisa.  Good morning and welcome everyone to McKesson's First Quarter fiscal 2021 earnings call. \n Today, I'm joined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Officer. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  \n", "page_label": "3", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "31a847da32841c87416e92ba5d7fea6092ada1be15713ed8db348dd2daa75e3d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2d4920c0-a2a0-4ca8-bad0-e7881e0cf6f8", "node_type": "1", "metadata": {"window": "Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  \n Thank you, Elisa.  Good morning and welcome everyone to McKesson's First Quarter fiscal 2021 earnings call. \n Today, I'm joined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Officer.  Brian \nwill lead off, followed by Britt, and then we will move to a question -and-answer session.  \n \n Today's discussion will include forward -looking statements , such as forecast about McKesson's operations and \nfuture results. ", "original_text": "Good morning and welcome everyone to McKesson's First Quarter fiscal 2021 earnings call. \n"}, "hash": "b85affc1d39243c98d9c80cfb045229ad85e281d29e67c2adfa245e9683f7f56", "class_name": "RelatedNodeInfo"}}, "text": "Thank you, Elisa. ", "start_char_idx": 745, "end_char_idx": 763, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2d4920c0-a2a0-4ca8-bad0-e7881e0cf6f8": {"__data__": {"id_": "2d4920c0-a2a0-4ca8-bad0-e7881e0cf6f8", "embedding": null, "metadata": {"window": "Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  \n Thank you, Elisa.  Good morning and welcome everyone to McKesson's First Quarter fiscal 2021 earnings call. \n Today, I'm joined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Officer.  Brian \nwill lead off, followed by Britt, and then we will move to a question -and-answer session.  \n \n Today's discussion will include forward -looking statements , such as forecast about McKesson's operations and \nfuture results. ", "original_text": "Good morning and welcome everyone to McKesson's First Quarter fiscal 2021 earnings call. \n", "page_label": "3", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f2ea56d4-9ba8-40ce-8f1a-d30083a09b88", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5877ddfe3db966424172ad7268280081fac3e10094e047943d3193a022b9a8ed", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2c589dae-b77a-4c97-af83-edf099a735fe", "node_type": "1", "metadata": {"window": "At this \ntime, I'd like to turn the call over to Holly Weiss.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  \n Thank you, Elisa.  Good morning and welcome everyone to McKesson's First Quarter fiscal 2021 earnings call. \n Today, I'm joined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Officer.  Brian \nwill lead off, followed by Britt, and then we will move to a question -and-answer session.  \n \n", "original_text": "Thank you, Elisa. ", "page_label": "3", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "df35ca1e0ac147c9a8cc5d4afbbc0ec8e902e43ee8a08142fec75fcc938fbc98", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "58166f8b-a63f-40a6-859b-d357b6c8837a", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  \n Thank you, Elisa.  Good morning and welcome everyone to McKesson's First Quarter fiscal 2021 earnings call. \n Today, I'm joined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Officer.  Brian \nwill lead off, followed by Britt, and then we will move to a question -and-answer session.  \n \n Today's discussion will include forward -looking statements , such as forecast about McKesson's operations and \nfuture results.  Please refer to the cautionary statements in today's press release and our slide presentation, and \nto the Risk Factors section of our periodic SEC filings for additional information concern ing risk factors that could \ncause our actual results to materially differ from those in our forward -looking statements.  \n \n", "original_text": "Today, I'm joined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Officer. "}, "hash": "bb464c21de086eabd790648696d41c06e9d2ff176bc84b476ca790333ba11613", "class_name": "RelatedNodeInfo"}}, "text": "Good morning and welcome everyone to McKesson's First Quarter fiscal 2021 earnings call. \n", "start_char_idx": 763, "end_char_idx": 853, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "58166f8b-a63f-40a6-859b-d357b6c8837a": {"__data__": {"id_": "58166f8b-a63f-40a6-859b-d357b6c8837a", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  \n Thank you, Elisa.  Good morning and welcome everyone to McKesson's First Quarter fiscal 2021 earnings call. \n Today, I'm joined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Officer.  Brian \nwill lead off, followed by Britt, and then we will move to a question -and-answer session.  \n \n Today's discussion will include forward -looking statements , such as forecast about McKesson's operations and \nfuture results.  Please refer to the cautionary statements in today's press release and our slide presentation, and \nto the Risk Factors section of our periodic SEC filings for additional information concern ing risk factors that could \ncause our actual results to materially differ from those in our forward -looking statements.  \n \n", "original_text": "Today, I'm joined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Officer. ", "page_label": "3", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f2ea56d4-9ba8-40ce-8f1a-d30083a09b88", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5877ddfe3db966424172ad7268280081fac3e10094e047943d3193a022b9a8ed", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2d4920c0-a2a0-4ca8-bad0-e7881e0cf6f8", "node_type": "1", "metadata": {"window": "Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  \n Thank you, Elisa.  Good morning and welcome everyone to McKesson's First Quarter fiscal 2021 earnings call. \n Today, I'm joined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Officer.  Brian \nwill lead off, followed by Britt, and then we will move to a question -and-answer session.  \n \n Today's discussion will include forward -looking statements , such as forecast about McKesson's operations and \nfuture results. ", "original_text": "Good morning and welcome everyone to McKesson's First Quarter fiscal 2021 earnings call. \n", "page_label": "3", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d4a303220642cb69cee5c388db067b5ddb7f803f7c934d32b81f6fb01f473d5d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6495e727-1814-4153-b190-9ba1e50d0cbd", "node_type": "1", "metadata": {"window": "Thank you, Elisa.  Good morning and welcome everyone to McKesson's First Quarter fiscal 2021 earnings call. \n Today, I'm joined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Officer.  Brian \nwill lead off, followed by Britt, and then we will move to a question -and-answer session.  \n \n Today's discussion will include forward -looking statements , such as forecast about McKesson's operations and \nfuture results.  Please refer to the cautionary statements in today's press release and our slide presentation, and \nto the Risk Factors section of our periodic SEC filings for additional information concern ing risk factors that could \ncause our actual results to materially differ from those in our forward -looking statements.  \n \n During this call, we will discuss non -GAAP financial measures. ", "original_text": "Brian \nwill lead off, followed by Britt, and then we will move to a question -and-answer session.  \n \n"}, "hash": "6e07a59888620c4cf9a6e0cd1f4763e0cc41460a526223179c41a4a2ac9e4ed9", "class_name": "RelatedNodeInfo"}}, "text": "Today, I'm joined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Officer. ", "start_char_idx": 853, "end_char_idx": 965, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6495e727-1814-4153-b190-9ba1e50d0cbd": {"__data__": {"id_": "6495e727-1814-4153-b190-9ba1e50d0cbd", "embedding": null, "metadata": {"window": "Thank you, Elisa.  Good morning and welcome everyone to McKesson's First Quarter fiscal 2021 earnings call. \n Today, I'm joined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Officer.  Brian \nwill lead off, followed by Britt, and then we will move to a question -and-answer session.  \n \n Today's discussion will include forward -looking statements , such as forecast about McKesson's operations and \nfuture results.  Please refer to the cautionary statements in today's press release and our slide presentation, and \nto the Risk Factors section of our periodic SEC filings for additional information concern ing risk factors that could \ncause our actual results to materially differ from those in our forward -looking statements.  \n \n During this call, we will discuss non -GAAP financial measures. ", "original_text": "Brian \nwill lead off, followed by Britt, and then we will move to a question -and-answer session.  \n \n", "page_label": "3", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f2ea56d4-9ba8-40ce-8f1a-d30083a09b88", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5877ddfe3db966424172ad7268280081fac3e10094e047943d3193a022b9a8ed", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "58166f8b-a63f-40a6-859b-d357b6c8837a", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  \n Thank you, Elisa.  Good morning and welcome everyone to McKesson's First Quarter fiscal 2021 earnings call. \n Today, I'm joined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Officer.  Brian \nwill lead off, followed by Britt, and then we will move to a question -and-answer session.  \n \n Today's discussion will include forward -looking statements , such as forecast about McKesson's operations and \nfuture results.  Please refer to the cautionary statements in today's press release and our slide presentation, and \nto the Risk Factors section of our periodic SEC filings for additional information concern ing risk factors that could \ncause our actual results to materially differ from those in our forward -looking statements.  \n \n", "original_text": "Today, I'm joined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Officer. ", "page_label": "3", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6fcd2ba415c37b038efad3642e9bc5dfe4a9865089feb3d3b1856bbaa1b272de", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c4b5f65d-7af0-45f8-a94c-a771401f5fef", "node_type": "1", "metadata": {"window": "Good morning and welcome everyone to McKesson's First Quarter fiscal 2021 earnings call. \n Today, I'm joined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Officer.  Brian \nwill lead off, followed by Britt, and then we will move to a question -and-answer session.  \n \n Today's discussion will include forward -looking statements , such as forecast about McKesson's operations and \nfuture results.  Please refer to the cautionary statements in today's press release and our slide presentation, and \nto the Risk Factors section of our periodic SEC filings for additional information concern ing risk factors that could \ncause our actual results to materially differ from those in our forward -looking statements.  \n \n During this call, we will discuss non -GAAP financial measures.  Additional information about our non -GAAP \nfinancial measures, including a reconciliation of those measures to GAAP results, is included in today's press \nrelease and presentation slides, which are available on our website at investor.mckesson.com.  \n \n", "original_text": "Today's discussion will include forward -looking statements , such as forecast about McKesson's operations and \nfuture results. "}, "hash": "8b2d66f48af0065044abc4807ced1ee1540bd448f5d0b6777fd9a5f81feaf67e", "class_name": "RelatedNodeInfo"}}, "text": "Brian \nwill lead off, followed by Britt, and then we will move to a question -and-answer session.  \n \n", "start_char_idx": 965, "end_char_idx": 1067, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c4b5f65d-7af0-45f8-a94c-a771401f5fef": {"__data__": {"id_": "c4b5f65d-7af0-45f8-a94c-a771401f5fef", "embedding": null, "metadata": {"window": "Good morning and welcome everyone to McKesson's First Quarter fiscal 2021 earnings call. \n Today, I'm joined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Officer.  Brian \nwill lead off, followed by Britt, and then we will move to a question -and-answer session.  \n \n Today's discussion will include forward -looking statements , such as forecast about McKesson's operations and \nfuture results.  Please refer to the cautionary statements in today's press release and our slide presentation, and \nto the Risk Factors section of our periodic SEC filings for additional information concern ing risk factors that could \ncause our actual results to materially differ from those in our forward -looking statements.  \n \n During this call, we will discuss non -GAAP financial measures.  Additional information about our non -GAAP \nfinancial measures, including a reconciliation of those measures to GAAP results, is included in today's press \nrelease and presentation slides, which are available on our website at investor.mckesson.com.  \n \n", "original_text": "Today's discussion will include forward -looking statements , such as forecast about McKesson's operations and \nfuture results. ", "page_label": "3", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f2ea56d4-9ba8-40ce-8f1a-d30083a09b88", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5877ddfe3db966424172ad7268280081fac3e10094e047943d3193a022b9a8ed", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6495e727-1814-4153-b190-9ba1e50d0cbd", "node_type": "1", "metadata": {"window": "Thank you, Elisa.  Good morning and welcome everyone to McKesson's First Quarter fiscal 2021 earnings call. \n Today, I'm joined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Officer.  Brian \nwill lead off, followed by Britt, and then we will move to a question -and-answer session.  \n \n Today's discussion will include forward -looking statements , such as forecast about McKesson's operations and \nfuture results.  Please refer to the cautionary statements in today's press release and our slide presentation, and \nto the Risk Factors section of our periodic SEC filings for additional information concern ing risk factors that could \ncause our actual results to materially differ from those in our forward -looking statements.  \n \n During this call, we will discuss non -GAAP financial measures. ", "original_text": "Brian \nwill lead off, followed by Britt, and then we will move to a question -and-answer session.  \n \n", "page_label": "3", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8a234e0ae365dcf30a2e92c322cc6eb8a5a0ab05c3d543101627b274655e6f8a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "63a648f8-4715-447b-a1c5-803205476ba8", "node_type": "1", "metadata": {"window": "Today, I'm joined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Officer.  Brian \nwill lead off, followed by Britt, and then we will move to a question -and-answer session.  \n \n Today's discussion will include forward -looking statements , such as forecast about McKesson's operations and \nfuture results.  Please refer to the cautionary statements in today's press release and our slide presentation, and \nto the Risk Factors section of our periodic SEC filings for additional information concern ing risk factors that could \ncause our actual results to materially differ from those in our forward -looking statements.  \n \n During this call, we will discuss non -GAAP financial measures.  Additional information about our non -GAAP \nfinancial measures, including a reconciliation of those measures to GAAP results, is included in today's press \nrelease and presentation slides, which are available on our website at investor.mckesson.com.  \n \n With that, let me turn it over to Brian.  \n ", "original_text": "Please refer to the cautionary statements in today's press release and our slide presentation, and \nto the Risk Factors section of our periodic SEC filings for additional information concern ing risk factors that could \ncause our actual results to materially differ from those in our forward -looking statements.  \n \n"}, "hash": "d2a9a48270daf86c8b64a70657cda50c74f86e7e3b06ba7943b1754aae4e854f", "class_name": "RelatedNodeInfo"}}, "text": "Today's discussion will include forward -looking statements , such as forecast about McKesson's operations and \nfuture results. ", "start_char_idx": 1067, "end_char_idx": 1195, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "63a648f8-4715-447b-a1c5-803205476ba8": {"__data__": {"id_": "63a648f8-4715-447b-a1c5-803205476ba8", "embedding": null, "metadata": {"window": "Today, I'm joined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Officer.  Brian \nwill lead off, followed by Britt, and then we will move to a question -and-answer session.  \n \n Today's discussion will include forward -looking statements , such as forecast about McKesson's operations and \nfuture results.  Please refer to the cautionary statements in today's press release and our slide presentation, and \nto the Risk Factors section of our periodic SEC filings for additional information concern ing risk factors that could \ncause our actual results to materially differ from those in our forward -looking statements.  \n \n During this call, we will discuss non -GAAP financial measures.  Additional information about our non -GAAP \nfinancial measures, including a reconciliation of those measures to GAAP results, is included in today's press \nrelease and presentation slides, which are available on our website at investor.mckesson.com.  \n \n With that, let me turn it over to Brian.  \n ", "original_text": "Please refer to the cautionary statements in today's press release and our slide presentation, and \nto the Risk Factors section of our periodic SEC filings for additional information concern ing risk factors that could \ncause our actual results to materially differ from those in our forward -looking statements.  \n \n", "page_label": "3", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f2ea56d4-9ba8-40ce-8f1a-d30083a09b88", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5877ddfe3db966424172ad7268280081fac3e10094e047943d3193a022b9a8ed", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c4b5f65d-7af0-45f8-a94c-a771401f5fef", "node_type": "1", "metadata": {"window": "Good morning and welcome everyone to McKesson's First Quarter fiscal 2021 earnings call. \n Today, I'm joined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Officer.  Brian \nwill lead off, followed by Britt, and then we will move to a question -and-answer session.  \n \n Today's discussion will include forward -looking statements , such as forecast about McKesson's operations and \nfuture results.  Please refer to the cautionary statements in today's press release and our slide presentation, and \nto the Risk Factors section of our periodic SEC filings for additional information concern ing risk factors that could \ncause our actual results to materially differ from those in our forward -looking statements.  \n \n During this call, we will discuss non -GAAP financial measures.  Additional information about our non -GAAP \nfinancial measures, including a reconciliation of those measures to GAAP results, is included in today's press \nrelease and presentation slides, which are available on our website at investor.mckesson.com.  \n \n", "original_text": "Today's discussion will include forward -looking statements , such as forecast about McKesson's operations and \nfuture results. ", "page_label": "3", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "525afcf465174950f90f4d1a70fccd478aa922d60ee0eccb5e9bd7d408e8ac9c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "eea4a3ba-81e7-4ebc-a18c-5166195f054a", "node_type": "1", "metadata": {"window": "Brian \nwill lead off, followed by Britt, and then we will move to a question -and-answer session.  \n \n Today's discussion will include forward -looking statements , such as forecast about McKesson's operations and \nfuture results.  Please refer to the cautionary statements in today's press release and our slide presentation, and \nto the Risk Factors section of our periodic SEC filings for additional information concern ing risk factors that could \ncause our actual results to materially differ from those in our forward -looking statements.  \n \n During this call, we will discuss non -GAAP financial measures.  Additional information about our non -GAAP \nfinancial measures, including a reconciliation of those measures to GAAP results, is included in today's press \nrelease and presentation slides, which are available on our website at investor.mckesson.com.  \n \n With that, let me turn it over to Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Office r & Director, McKesson Corp.  \n", "original_text": "During this call, we will discuss non -GAAP financial measures. "}, "hash": "c2c8707eb471625f81d1574aede5e8699d2409269b6381bde0c7d4545cdefb81", "class_name": "RelatedNodeInfo"}}, "text": "Please refer to the cautionary statements in today's press release and our slide presentation, and \nto the Risk Factors section of our periodic SEC filings for additional information concern ing risk factors that could \ncause our actual results to materially differ from those in our forward -looking statements.  \n \n", "start_char_idx": 1195, "end_char_idx": 1512, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "eea4a3ba-81e7-4ebc-a18c-5166195f054a": {"__data__": {"id_": "eea4a3ba-81e7-4ebc-a18c-5166195f054a", "embedding": null, "metadata": {"window": "Brian \nwill lead off, followed by Britt, and then we will move to a question -and-answer session.  \n \n Today's discussion will include forward -looking statements , such as forecast about McKesson's operations and \nfuture results.  Please refer to the cautionary statements in today's press release and our slide presentation, and \nto the Risk Factors section of our periodic SEC filings for additional information concern ing risk factors that could \ncause our actual results to materially differ from those in our forward -looking statements.  \n \n During this call, we will discuss non -GAAP financial measures.  Additional information about our non -GAAP \nfinancial measures, including a reconciliation of those measures to GAAP results, is included in today's press \nrelease and presentation slides, which are available on our website at investor.mckesson.com.  \n \n With that, let me turn it over to Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Office r & Director, McKesson Corp.  \n", "original_text": "During this call, we will discuss non -GAAP financial measures. ", "page_label": "3", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f2ea56d4-9ba8-40ce-8f1a-d30083a09b88", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5877ddfe3db966424172ad7268280081fac3e10094e047943d3193a022b9a8ed", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "63a648f8-4715-447b-a1c5-803205476ba8", "node_type": "1", "metadata": {"window": "Today, I'm joined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Officer.  Brian \nwill lead off, followed by Britt, and then we will move to a question -and-answer session.  \n \n Today's discussion will include forward -looking statements , such as forecast about McKesson's operations and \nfuture results.  Please refer to the cautionary statements in today's press release and our slide presentation, and \nto the Risk Factors section of our periodic SEC filings for additional information concern ing risk factors that could \ncause our actual results to materially differ from those in our forward -looking statements.  \n \n During this call, we will discuss non -GAAP financial measures.  Additional information about our non -GAAP \nfinancial measures, including a reconciliation of those measures to GAAP results, is included in today's press \nrelease and presentation slides, which are available on our website at investor.mckesson.com.  \n \n With that, let me turn it over to Brian.  \n ", "original_text": "Please refer to the cautionary statements in today's press release and our slide presentation, and \nto the Risk Factors section of our periodic SEC filings for additional information concern ing risk factors that could \ncause our actual results to materially differ from those in our forward -looking statements.  \n \n", "page_label": "3", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1670b3f73d53312336fa22ee514973b5f30b00c0698300490ae9cc38f6402289", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "63a68225-986e-4625-8c41-d74d9fc86233", "node_type": "1", "metadata": {"window": "Today's discussion will include forward -looking statements , such as forecast about McKesson's operations and \nfuture results.  Please refer to the cautionary statements in today's press release and our slide presentation, and \nto the Risk Factors section of our periodic SEC filings for additional information concern ing risk factors that could \ncause our actual results to materially differ from those in our forward -looking statements.  \n \n During this call, we will discuss non -GAAP financial measures.  Additional information about our non -GAAP \nfinancial measures, including a reconciliation of those measures to GAAP results, is included in today's press \nrelease and presentation slides, which are available on our website at investor.mckesson.com.  \n \n With that, let me turn it over to Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Office r & Director, McKesson Corp.  \n Thank you, Holly, and good morning everybody. ", "original_text": "Additional information about our non -GAAP \nfinancial measures, including a reconciliation of those measures to GAAP results, is included in today's press \nrelease and presentation slides, which are available on our website at investor.mckesson.com.  \n \n"}, "hash": "c7d9720c06578ceeb33060a78859b60b57c2dbdc611ba82eb30856265f2b8f48", "class_name": "RelatedNodeInfo"}}, "text": "During this call, we will discuss non -GAAP financial measures. ", "start_char_idx": 1512, "end_char_idx": 1576, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "63a68225-986e-4625-8c41-d74d9fc86233": {"__data__": {"id_": "63a68225-986e-4625-8c41-d74d9fc86233", "embedding": null, "metadata": {"window": "Today's discussion will include forward -looking statements , such as forecast about McKesson's operations and \nfuture results.  Please refer to the cautionary statements in today's press release and our slide presentation, and \nto the Risk Factors section of our periodic SEC filings for additional information concern ing risk factors that could \ncause our actual results to materially differ from those in our forward -looking statements.  \n \n During this call, we will discuss non -GAAP financial measures.  Additional information about our non -GAAP \nfinancial measures, including a reconciliation of those measures to GAAP results, is included in today's press \nrelease and presentation slides, which are available on our website at investor.mckesson.com.  \n \n With that, let me turn it over to Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Office r & Director, McKesson Corp.  \n Thank you, Holly, and good morning everybody. ", "original_text": "Additional information about our non -GAAP \nfinancial measures, including a reconciliation of those measures to GAAP results, is included in today's press \nrelease and presentation slides, which are available on our website at investor.mckesson.com.  \n \n", "page_label": "3", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f2ea56d4-9ba8-40ce-8f1a-d30083a09b88", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5877ddfe3db966424172ad7268280081fac3e10094e047943d3193a022b9a8ed", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "eea4a3ba-81e7-4ebc-a18c-5166195f054a", "node_type": "1", "metadata": {"window": "Brian \nwill lead off, followed by Britt, and then we will move to a question -and-answer session.  \n \n Today's discussion will include forward -looking statements , such as forecast about McKesson's operations and \nfuture results.  Please refer to the cautionary statements in today's press release and our slide presentation, and \nto the Risk Factors section of our periodic SEC filings for additional information concern ing risk factors that could \ncause our actual results to materially differ from those in our forward -looking statements.  \n \n During this call, we will discuss non -GAAP financial measures.  Additional information about our non -GAAP \nfinancial measures, including a reconciliation of those measures to GAAP results, is included in today's press \nrelease and presentation slides, which are available on our website at investor.mckesson.com.  \n \n With that, let me turn it over to Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Office r & Director, McKesson Corp.  \n", "original_text": "During this call, we will discuss non -GAAP financial measures. ", "page_label": "3", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "03dc5c36c472d28e75dd857666970014693a2d057ccc6081635d0a30ec59081c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "08c1c5e1-c37f-4c05-a82b-50a28284ef8b", "node_type": "1", "metadata": {"window": "Please refer to the cautionary statements in today's press release and our slide presentation, and \nto the Risk Factors section of our periodic SEC filings for additional information concern ing risk factors that could \ncause our actual results to materially differ from those in our forward -looking statements.  \n \n During this call, we will discuss non -GAAP financial measures.  Additional information about our non -GAAP \nfinancial measures, including a reconciliation of those measures to GAAP results, is included in today's press \nrelease and presentation slides, which are available on our website at investor.mckesson.com.  \n \n With that, let me turn it over to Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Office r & Director, McKesson Corp.  \n Thank you, Holly, and good morning everybody.  Thank you for being with us on this morning's call. ", "original_text": "With that, let me turn it over to Brian.  \n "}, "hash": "6cd1d98db8ba14d82208f00855957bbb4bd4002501f18204159da7e564ab2bf5", "class_name": "RelatedNodeInfo"}}, "text": "Additional information about our non -GAAP \nfinancial measures, including a reconciliation of those measures to GAAP results, is included in today's press \nrelease and presentation slides, which are available on our website at investor.mckesson.com.  \n \n", "start_char_idx": 1576, "end_char_idx": 1830, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "08c1c5e1-c37f-4c05-a82b-50a28284ef8b": {"__data__": {"id_": "08c1c5e1-c37f-4c05-a82b-50a28284ef8b", "embedding": null, "metadata": {"window": "Please refer to the cautionary statements in today's press release and our slide presentation, and \nto the Risk Factors section of our periodic SEC filings for additional information concern ing risk factors that could \ncause our actual results to materially differ from those in our forward -looking statements.  \n \n During this call, we will discuss non -GAAP financial measures.  Additional information about our non -GAAP \nfinancial measures, including a reconciliation of those measures to GAAP results, is included in today's press \nrelease and presentation slides, which are available on our website at investor.mckesson.com.  \n \n With that, let me turn it over to Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Office r & Director, McKesson Corp.  \n Thank you, Holly, and good morning everybody.  Thank you for being with us on this morning's call. ", "original_text": "With that, let me turn it over to Brian.  \n ", "page_label": "3", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f2ea56d4-9ba8-40ce-8f1a-d30083a09b88", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5877ddfe3db966424172ad7268280081fac3e10094e047943d3193a022b9a8ed", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "63a68225-986e-4625-8c41-d74d9fc86233", "node_type": "1", "metadata": {"window": "Today's discussion will include forward -looking statements , such as forecast about McKesson's operations and \nfuture results.  Please refer to the cautionary statements in today's press release and our slide presentation, and \nto the Risk Factors section of our periodic SEC filings for additional information concern ing risk factors that could \ncause our actual results to materially differ from those in our forward -looking statements.  \n \n During this call, we will discuss non -GAAP financial measures.  Additional information about our non -GAAP \nfinancial measures, including a reconciliation of those measures to GAAP results, is included in today's press \nrelease and presentation slides, which are available on our website at investor.mckesson.com.  \n \n With that, let me turn it over to Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Office r & Director, McKesson Corp.  \n Thank you, Holly, and good morning everybody. ", "original_text": "Additional information about our non -GAAP \nfinancial measures, including a reconciliation of those measures to GAAP results, is included in today's press \nrelease and presentation slides, which are available on our website at investor.mckesson.com.  \n \n", "page_label": "3", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8bf506484263a3b4ab843210bb77281b05a88e3d3c91bba8f2cba66d2498787a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b862892f-c3a6-4e8b-bfe7-f1a7edafc3a3", "node_type": "1", "metadata": {"window": "During this call, we will discuss non -GAAP financial measures.  Additional information about our non -GAAP \nfinancial measures, including a reconciliation of those measures to GAAP results, is included in today's press \nrelease and presentation slides, which are available on our website at investor.mckesson.com.  \n \n With that, let me turn it over to Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Office r & Director, McKesson Corp.  \n Thank you, Holly, and good morning everybody.  Thank you for being with us on this morning's call.  I hope that \nyou, your families and your communities are staying healthy and safe. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Office r & Director, McKesson Corp.  \n"}, "hash": "0077f9e462f653a55e09e2bffd5b6f648e1cf3bbefe527e65ce884e374e1d786", "class_name": "RelatedNodeInfo"}}, "text": "With that, let me turn it over to Brian.  \n ", "start_char_idx": 1830, "end_char_idx": 1874, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b862892f-c3a6-4e8b-bfe7-f1a7edafc3a3": {"__data__": {"id_": "b862892f-c3a6-4e8b-bfe7-f1a7edafc3a3", "embedding": null, "metadata": {"window": "During this call, we will discuss non -GAAP financial measures.  Additional information about our non -GAAP \nfinancial measures, including a reconciliation of those measures to GAAP results, is included in today's press \nrelease and presentation slides, which are available on our website at investor.mckesson.com.  \n \n With that, let me turn it over to Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Office r & Director, McKesson Corp.  \n Thank you, Holly, and good morning everybody.  Thank you for being with us on this morning's call.  I hope that \nyou, your families and your communities are staying healthy and safe. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Office r & Director, McKesson Corp.  \n", "page_label": "3", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f2ea56d4-9ba8-40ce-8f1a-d30083a09b88", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5877ddfe3db966424172ad7268280081fac3e10094e047943d3193a022b9a8ed", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "08c1c5e1-c37f-4c05-a82b-50a28284ef8b", "node_type": "1", "metadata": {"window": "Please refer to the cautionary statements in today's press release and our slide presentation, and \nto the Risk Factors section of our periodic SEC filings for additional information concern ing risk factors that could \ncause our actual results to materially differ from those in our forward -looking statements.  \n \n During this call, we will discuss non -GAAP financial measures.  Additional information about our non -GAAP \nfinancial measures, including a reconciliation of those measures to GAAP results, is included in today's press \nrelease and presentation slides, which are available on our website at investor.mckesson.com.  \n \n With that, let me turn it over to Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Office r & Director, McKesson Corp.  \n Thank you, Holly, and good morning everybody.  Thank you for being with us on this morning's call. ", "original_text": "With that, let me turn it over to Brian.  \n ", "page_label": "3", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a63e034a7e19be4b7a0a26c3a0ba763d78fa13691f8e96860f2f7edb7406f16a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f68d5ac6-6ac2-407c-8865-1bc6c5fa81b0", "node_type": "1", "metadata": {"window": "Additional information about our non -GAAP \nfinancial measures, including a reconciliation of those measures to GAAP results, is included in today's press \nrelease and presentation slides, which are available on our website at investor.mckesson.com.  \n \n With that, let me turn it over to Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Office r & Director, McKesson Corp.  \n Thank you, Holly, and good morning everybody.  Thank you for being with us on this morning's call.  I hope that \nyou, your families and your communities are staying healthy and safe.  On our fourth quarter call in May, I \ndiscussed  that we were entering the new fiscal year with macro uncertainties  and volatility in healthcare \nconsumption patterns as a result of the COVID -19 pandemic. ", "original_text": "Thank you, Holly, and good morning everybody. "}, "hash": "cc9d846135de114224f8d2a0ae8acbe7867c1d1f76e2ee898c0dbf663af9cecd", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Office r & Director, McKesson Corp.  \n", "start_char_idx": 1874, "end_char_idx": 2217, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f68d5ac6-6ac2-407c-8865-1bc6c5fa81b0": {"__data__": {"id_": "f68d5ac6-6ac2-407c-8865-1bc6c5fa81b0", "embedding": null, "metadata": {"window": "Additional information about our non -GAAP \nfinancial measures, including a reconciliation of those measures to GAAP results, is included in today's press \nrelease and presentation slides, which are available on our website at investor.mckesson.com.  \n \n With that, let me turn it over to Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Office r & Director, McKesson Corp.  \n Thank you, Holly, and good morning everybody.  Thank you for being with us on this morning's call.  I hope that \nyou, your families and your communities are staying healthy and safe.  On our fourth quarter call in May, I \ndiscussed  that we were entering the new fiscal year with macro uncertainties  and volatility in healthcare \nconsumption patterns as a result of the COVID -19 pandemic. ", "original_text": "Thank you, Holly, and good morning everybody. ", "page_label": "3", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f2ea56d4-9ba8-40ce-8f1a-d30083a09b88", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5877ddfe3db966424172ad7268280081fac3e10094e047943d3193a022b9a8ed", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b862892f-c3a6-4e8b-bfe7-f1a7edafc3a3", "node_type": "1", "metadata": {"window": "During this call, we will discuss non -GAAP financial measures.  Additional information about our non -GAAP \nfinancial measures, including a reconciliation of those measures to GAAP results, is included in today's press \nrelease and presentation slides, which are available on our website at investor.mckesson.com.  \n \n With that, let me turn it over to Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Office r & Director, McKesson Corp.  \n Thank you, Holly, and good morning everybody.  Thank you for being with us on this morning's call.  I hope that \nyou, your families and your communities are staying healthy and safe. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Office r & Director, McKesson Corp.  \n", "page_label": "3", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3e92e81ad9b7c0dcddc1e9d1a21cd04b98b0b280b3c8ec1f5f564b69a0759f46", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "91060db3-ad34-4ddf-9021-d082f6af7031", "node_type": "1", "metadata": {"window": "With that, let me turn it over to Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Office r & Director, McKesson Corp.  \n Thank you, Holly, and good morning everybody.  Thank you for being with us on this morning's call.  I hope that \nyou, your families and your communities are staying healthy and safe.  On our fourth quarter call in May, I \ndiscussed  that we were entering the new fiscal year with macro uncertainties  and volatility in healthcare \nconsumption patterns as a result of the COVID -19 pandemic.  And our first quarter results clearly reflect the \neffects of these dynamics.  \n \n", "original_text": "Thank you for being with us on this morning's call. "}, "hash": "3f23c7ecb894559a92200097eb26cbbc6b703678b09e035f200db490828a3285", "class_name": "RelatedNodeInfo"}}, "text": "Thank you, Holly, and good morning everybody. ", "start_char_idx": 2217, "end_char_idx": 2263, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "91060db3-ad34-4ddf-9021-d082f6af7031": {"__data__": {"id_": "91060db3-ad34-4ddf-9021-d082f6af7031", "embedding": null, "metadata": {"window": "With that, let me turn it over to Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Office r & Director, McKesson Corp.  \n Thank you, Holly, and good morning everybody.  Thank you for being with us on this morning's call.  I hope that \nyou, your families and your communities are staying healthy and safe.  On our fourth quarter call in May, I \ndiscussed  that we were entering the new fiscal year with macro uncertainties  and volatility in healthcare \nconsumption patterns as a result of the COVID -19 pandemic.  And our first quarter results clearly reflect the \neffects of these dynamics.  \n \n", "original_text": "Thank you for being with us on this morning's call. ", "page_label": "3", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f2ea56d4-9ba8-40ce-8f1a-d30083a09b88", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5877ddfe3db966424172ad7268280081fac3e10094e047943d3193a022b9a8ed", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f68d5ac6-6ac2-407c-8865-1bc6c5fa81b0", "node_type": "1", "metadata": {"window": "Additional information about our non -GAAP \nfinancial measures, including a reconciliation of those measures to GAAP results, is included in today's press \nrelease and presentation slides, which are available on our website at investor.mckesson.com.  \n \n With that, let me turn it over to Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Office r & Director, McKesson Corp.  \n Thank you, Holly, and good morning everybody.  Thank you for being with us on this morning's call.  I hope that \nyou, your families and your communities are staying healthy and safe.  On our fourth quarter call in May, I \ndiscussed  that we were entering the new fiscal year with macro uncertainties  and volatility in healthcare \nconsumption patterns as a result of the COVID -19 pandemic. ", "original_text": "Thank you, Holly, and good morning everybody. ", "page_label": "3", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "00b7fc9727039560b5fe948582d4b2e54478efe4cc6779f75dbed3b607ed5d6b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9e7e7562-80a1-4596-98db-77c339db48ac", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Office r & Director, McKesson Corp.  \n Thank you, Holly, and good morning everybody.  Thank you for being with us on this morning's call.  I hope that \nyou, your families and your communities are staying healthy and safe.  On our fourth quarter call in May, I \ndiscussed  that we were entering the new fiscal year with macro uncertainties  and volatility in healthcare \nconsumption patterns as a result of the COVID -19 pandemic.  And our first quarter results clearly reflect the \neffects of these dynamics.  \n \n Today we're reporting  results for one of the most complicated quarters in our company's history. ", "original_text": "I hope that \nyou, your families and your communities are staying healthy and safe. "}, "hash": "625431fee24e880085698cb704bf8e74435114331d5143677d71308436f33870", "class_name": "RelatedNodeInfo"}}, "text": "Thank you for being with us on this morning's call. ", "start_char_idx": 2263, "end_char_idx": 2315, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9e7e7562-80a1-4596-98db-77c339db48ac": {"__data__": {"id_": "9e7e7562-80a1-4596-98db-77c339db48ac", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Office r & Director, McKesson Corp.  \n Thank you, Holly, and good morning everybody.  Thank you for being with us on this morning's call.  I hope that \nyou, your families and your communities are staying healthy and safe.  On our fourth quarter call in May, I \ndiscussed  that we were entering the new fiscal year with macro uncertainties  and volatility in healthcare \nconsumption patterns as a result of the COVID -19 pandemic.  And our first quarter results clearly reflect the \neffects of these dynamics.  \n \n Today we're reporting  results for one of the most complicated quarters in our company's history. ", "original_text": "I hope that \nyou, your families and your communities are staying healthy and safe. ", "page_label": "3", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f2ea56d4-9ba8-40ce-8f1a-d30083a09b88", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5877ddfe3db966424172ad7268280081fac3e10094e047943d3193a022b9a8ed", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "91060db3-ad34-4ddf-9021-d082f6af7031", "node_type": "1", "metadata": {"window": "With that, let me turn it over to Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Office r & Director, McKesson Corp.  \n Thank you, Holly, and good morning everybody.  Thank you for being with us on this morning's call.  I hope that \nyou, your families and your communities are staying healthy and safe.  On our fourth quarter call in May, I \ndiscussed  that we were entering the new fiscal year with macro uncertainties  and volatility in healthcare \nconsumption patterns as a result of the COVID -19 pandemic.  And our first quarter results clearly reflect the \neffects of these dynamics.  \n \n", "original_text": "Thank you for being with us on this morning's call. ", "page_label": "3", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5b8f6f3be3a57f8d9986753669fb41c34e7695091c23dc39a2a662a8d1905ba6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "662cd78b-a27c-4eab-b37e-eff3352d70ca", "node_type": "1", "metadata": {"window": "Thank you, Holly, and good morning everybody.  Thank you for being with us on this morning's call.  I hope that \nyou, your families and your communities are staying healthy and safe.  On our fourth quarter call in May, I \ndiscussed  that we were entering the new fiscal year with macro uncertainties  and volatility in healthcare \nconsumption patterns as a result of the COVID -19 pandemic.  And our first quarter results clearly reflect the \neffects of these dynamics.  \n \n Today we're reporting  results for one of the most complicated quarters in our company's history.  Our first quarter \nadjusted results while materially down against prior year due to the pandemic, finished significantly above our \noriginal expectations. ", "original_text": "On our fourth quarter call in May, I \ndiscussed  that we were entering the new fiscal year with macro uncertainties  and volatility in healthcare \nconsumption patterns as a result of the COVID -19 pandemic. "}, "hash": "24342ae04062e30a0718d6b7ee495e9736bfc84d65d8caf4cd78fe44e40d678b", "class_name": "RelatedNodeInfo"}}, "text": "I hope that \nyou, your families and your communities are staying healthy and safe. ", "start_char_idx": 2315, "end_char_idx": 2398, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "662cd78b-a27c-4eab-b37e-eff3352d70ca": {"__data__": {"id_": "662cd78b-a27c-4eab-b37e-eff3352d70ca", "embedding": null, "metadata": {"window": "Thank you, Holly, and good morning everybody.  Thank you for being with us on this morning's call.  I hope that \nyou, your families and your communities are staying healthy and safe.  On our fourth quarter call in May, I \ndiscussed  that we were entering the new fiscal year with macro uncertainties  and volatility in healthcare \nconsumption patterns as a result of the COVID -19 pandemic.  And our first quarter results clearly reflect the \neffects of these dynamics.  \n \n Today we're reporting  results for one of the most complicated quarters in our company's history.  Our first quarter \nadjusted results while materially down against prior year due to the pandemic, finished significantly above our \noriginal expectations. ", "original_text": "On our fourth quarter call in May, I \ndiscussed  that we were entering the new fiscal year with macro uncertainties  and volatility in healthcare \nconsumption patterns as a result of the COVID -19 pandemic. ", "page_label": "3", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f2ea56d4-9ba8-40ce-8f1a-d30083a09b88", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5877ddfe3db966424172ad7268280081fac3e10094e047943d3193a022b9a8ed", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9e7e7562-80a1-4596-98db-77c339db48ac", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Office r & Director, McKesson Corp.  \n Thank you, Holly, and good morning everybody.  Thank you for being with us on this morning's call.  I hope that \nyou, your families and your communities are staying healthy and safe.  On our fourth quarter call in May, I \ndiscussed  that we were entering the new fiscal year with macro uncertainties  and volatility in healthcare \nconsumption patterns as a result of the COVID -19 pandemic.  And our first quarter results clearly reflect the \neffects of these dynamics.  \n \n Today we're reporting  results for one of the most complicated quarters in our company's history. ", "original_text": "I hope that \nyou, your families and your communities are staying healthy and safe. ", "page_label": "3", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "227975ce937567d1c05b245c3bf0196318d94997324aa6dbc0e13b2e62a40928", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bd53e9d1-938f-442e-b148-a3168cee4d0e", "node_type": "1", "metadata": {"window": "Thank you for being with us on this morning's call.  I hope that \nyou, your families and your communities are staying healthy and safe.  On our fourth quarter call in May, I \ndiscussed  that we were entering the new fiscal year with macro uncertainties  and volatility in healthcare \nconsumption patterns as a result of the COVID -19 pandemic.  And our first quarter results clearly reflect the \neffects of these dynamics.  \n \n Today we're reporting  results for one of the most complicated quarters in our company's history.  Our first quarter \nadjusted results while materially down against prior year due to the pandemic, finished significantly above our \noriginal expectations.  We reported first quarter t otal company revenues of $55.7 billion and adjusted earnings per \ndiluted share of $2.77. ", "original_text": "And our first quarter results clearly reflect the \neffects of these dynamics.  \n \n"}, "hash": "2d653b2cbd8e725d6fe590b1353e431df54b63b39abe090407df9d3a86b2812c", "class_name": "RelatedNodeInfo"}}, "text": "On our fourth quarter call in May, I \ndiscussed  that we were entering the new fiscal year with macro uncertainties  and volatility in healthcare \nconsumption patterns as a result of the COVID -19 pandemic. ", "start_char_idx": 2398, "end_char_idx": 2605, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bd53e9d1-938f-442e-b148-a3168cee4d0e": {"__data__": {"id_": "bd53e9d1-938f-442e-b148-a3168cee4d0e", "embedding": null, "metadata": {"window": "Thank you for being with us on this morning's call.  I hope that \nyou, your families and your communities are staying healthy and safe.  On our fourth quarter call in May, I \ndiscussed  that we were entering the new fiscal year with macro uncertainties  and volatility in healthcare \nconsumption patterns as a result of the COVID -19 pandemic.  And our first quarter results clearly reflect the \neffects of these dynamics.  \n \n Today we're reporting  results for one of the most complicated quarters in our company's history.  Our first quarter \nadjusted results while materially down against prior year due to the pandemic, finished significantly above our \noriginal expectations.  We reported first quarter t otal company revenues of $55.7 billion and adjusted earnings per \ndiluted share of $2.77. ", "original_text": "And our first quarter results clearly reflect the \neffects of these dynamics.  \n \n", "page_label": "3", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f2ea56d4-9ba8-40ce-8f1a-d30083a09b88", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5877ddfe3db966424172ad7268280081fac3e10094e047943d3193a022b9a8ed", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "662cd78b-a27c-4eab-b37e-eff3352d70ca", "node_type": "1", "metadata": {"window": "Thank you, Holly, and good morning everybody.  Thank you for being with us on this morning's call.  I hope that \nyou, your families and your communities are staying healthy and safe.  On our fourth quarter call in May, I \ndiscussed  that we were entering the new fiscal year with macro uncertainties  and volatility in healthcare \nconsumption patterns as a result of the COVID -19 pandemic.  And our first quarter results clearly reflect the \neffects of these dynamics.  \n \n Today we're reporting  results for one of the most complicated quarters in our company's history.  Our first quarter \nadjusted results while materially down against prior year due to the pandemic, finished significantly above our \noriginal expectations. ", "original_text": "On our fourth quarter call in May, I \ndiscussed  that we were entering the new fiscal year with macro uncertainties  and volatility in healthcare \nconsumption patterns as a result of the COVID -19 pandemic. ", "page_label": "3", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "10837af60ead9971d1c95c775923b0a801c81305f125fd5640c08d3f2c67c165", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f1e55d67-4db4-4081-b68e-da8008d43272", "node_type": "1", "metadata": {"window": "I hope that \nyou, your families and your communities are staying healthy and safe.  On our fourth quarter call in May, I \ndiscussed  that we were entering the new fiscal year with macro uncertainties  and volatility in healthcare \nconsumption patterns as a result of the COVID -19 pandemic.  And our first quarter results clearly reflect the \neffects of these dynamics.  \n \n Today we're reporting  results for one of the most complicated quarters in our company's history.  Our first quarter \nadjusted results while materially down against prior year due to the pandemic, finished significantly above our \noriginal expectations.  We reported first quarter t otal company revenues of $55.7 billion and adjusted earnings per \ndiluted share of $2.77.  Both ahead of our original expectations. ", "original_text": "Today we're reporting  results for one of the most complicated quarters in our company's history. "}, "hash": "a200cdc643598b7423b084ce383de8c0fe98407646b72ca944344f24d371d083", "class_name": "RelatedNodeInfo"}}, "text": "And our first quarter results clearly reflect the \neffects of these dynamics.  \n \n", "start_char_idx": 2605, "end_char_idx": 2687, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f1e55d67-4db4-4081-b68e-da8008d43272": {"__data__": {"id_": "f1e55d67-4db4-4081-b68e-da8008d43272", "embedding": null, "metadata": {"window": "I hope that \nyou, your families and your communities are staying healthy and safe.  On our fourth quarter call in May, I \ndiscussed  that we were entering the new fiscal year with macro uncertainties  and volatility in healthcare \nconsumption patterns as a result of the COVID -19 pandemic.  And our first quarter results clearly reflect the \neffects of these dynamics.  \n \n Today we're reporting  results for one of the most complicated quarters in our company's history.  Our first quarter \nadjusted results while materially down against prior year due to the pandemic, finished significantly above our \noriginal expectations.  We reported first quarter t otal company revenues of $55.7 billion and adjusted earnings per \ndiluted share of $2.77.  Both ahead of our original expectations. ", "original_text": "Today we're reporting  results for one of the most complicated quarters in our company's history. ", "page_label": "3", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f2ea56d4-9ba8-40ce-8f1a-d30083a09b88", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5877ddfe3db966424172ad7268280081fac3e10094e047943d3193a022b9a8ed", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bd53e9d1-938f-442e-b148-a3168cee4d0e", "node_type": "1", "metadata": {"window": "Thank you for being with us on this morning's call.  I hope that \nyou, your families and your communities are staying healthy and safe.  On our fourth quarter call in May, I \ndiscussed  that we were entering the new fiscal year with macro uncertainties  and volatility in healthcare \nconsumption patterns as a result of the COVID -19 pandemic.  And our first quarter results clearly reflect the \neffects of these dynamics.  \n \n Today we're reporting  results for one of the most complicated quarters in our company's history.  Our first quarter \nadjusted results while materially down against prior year due to the pandemic, finished significantly above our \noriginal expectations.  We reported first quarter t otal company revenues of $55.7 billion and adjusted earnings per \ndiluted share of $2.77. ", "original_text": "And our first quarter results clearly reflect the \neffects of these dynamics.  \n \n", "page_label": "3", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6183ffb32db28e39c809ced981a14282fbfe0fe619100de96c6912cb312e358e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f9f91683-0fcd-4f51-b323-11ccf47948b8", "node_type": "1", "metadata": {"window": "On our fourth quarter call in May, I \ndiscussed  that we were entering the new fiscal year with macro uncertainties  and volatility in healthcare \nconsumption patterns as a result of the COVID -19 pandemic.  And our first quarter results clearly reflect the \neffects of these dynamics.  \n \n Today we're reporting  results for one of the most complicated quarters in our company's history.  Our first quarter \nadjusted results while materially down against prior year due to the pandemic, finished significantly above our \noriginal expectations.  We reported first quarter t otal company revenues of $55.7 billion and adjusted earnings per \ndiluted share of $2.77.  Both ahead of our original expectations.  Through April and May, trends in the business \naligned closely with our original expectations. ", "original_text": "Our first quarter \nadjusted results while materially down against prior year due to the pandemic, finished significantly above our \noriginal expectations. "}, "hash": "ee863240d32044ee75f9d19a8fe0d8f8257f81beb7fe0ed6beb4512905a49049", "class_name": "RelatedNodeInfo"}}, "text": "Today we're reporting  results for one of the most complicated quarters in our company's history. ", "start_char_idx": 2687, "end_char_idx": 2785, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f9f91683-0fcd-4f51-b323-11ccf47948b8": {"__data__": {"id_": "f9f91683-0fcd-4f51-b323-11ccf47948b8", "embedding": null, "metadata": {"window": "On our fourth quarter call in May, I \ndiscussed  that we were entering the new fiscal year with macro uncertainties  and volatility in healthcare \nconsumption patterns as a result of the COVID -19 pandemic.  And our first quarter results clearly reflect the \neffects of these dynamics.  \n \n Today we're reporting  results for one of the most complicated quarters in our company's history.  Our first quarter \nadjusted results while materially down against prior year due to the pandemic, finished significantly above our \noriginal expectations.  We reported first quarter t otal company revenues of $55.7 billion and adjusted earnings per \ndiluted share of $2.77.  Both ahead of our original expectations.  Through April and May, trends in the business \naligned closely with our original expectations. ", "original_text": "Our first quarter \nadjusted results while materially down against prior year due to the pandemic, finished significantly above our \noriginal expectations. ", "page_label": "3", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f2ea56d4-9ba8-40ce-8f1a-d30083a09b88", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5877ddfe3db966424172ad7268280081fac3e10094e047943d3193a022b9a8ed", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f1e55d67-4db4-4081-b68e-da8008d43272", "node_type": "1", "metadata": {"window": "I hope that \nyou, your families and your communities are staying healthy and safe.  On our fourth quarter call in May, I \ndiscussed  that we were entering the new fiscal year with macro uncertainties  and volatility in healthcare \nconsumption patterns as a result of the COVID -19 pandemic.  And our first quarter results clearly reflect the \neffects of these dynamics.  \n \n Today we're reporting  results for one of the most complicated quarters in our company's history.  Our first quarter \nadjusted results while materially down against prior year due to the pandemic, finished significantly above our \noriginal expectations.  We reported first quarter t otal company revenues of $55.7 billion and adjusted earnings per \ndiluted share of $2.77.  Both ahead of our original expectations. ", "original_text": "Today we're reporting  results for one of the most complicated quarters in our company's history. ", "page_label": "3", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6d83c3837ca4a8227f1156a4c442f15734cbb4bb179fa5f0699a57e958d4249f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e79707ac-8a92-4f2f-bfa6-740452fbba70", "node_type": "1", "metadata": {"window": "And our first quarter results clearly reflect the \neffects of these dynamics.  \n \n Today we're reporting  results for one of the most complicated quarters in our company's history.  Our first quarter \nadjusted results while materially down against prior year due to the pandemic, finished significantly above our \noriginal expectations.  We reported first quarter t otal company revenues of $55.7 billion and adjusted earnings per \ndiluted share of $2.77.  Both ahead of our original expectations.  Through April and May, trends in the business \naligned closely with our original expectations.  However, we saw volumes across t he business improved \nsignificantly over the back half of June, resulting in a strong close to the quarter.  \n \n", "original_text": "We reported first quarter t otal company revenues of $55.7 billion and adjusted earnings per \ndiluted share of $2.77. "}, "hash": "5452640c50606c7da0a7139e290724668189e526aaf2538ce23af202ca06bb59", "class_name": "RelatedNodeInfo"}}, "text": "Our first quarter \nadjusted results while materially down against prior year due to the pandemic, finished significantly above our \noriginal expectations. ", "start_char_idx": 2785, "end_char_idx": 2940, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e79707ac-8a92-4f2f-bfa6-740452fbba70": {"__data__": {"id_": "e79707ac-8a92-4f2f-bfa6-740452fbba70", "embedding": null, "metadata": {"window": "And our first quarter results clearly reflect the \neffects of these dynamics.  \n \n Today we're reporting  results for one of the most complicated quarters in our company's history.  Our first quarter \nadjusted results while materially down against prior year due to the pandemic, finished significantly above our \noriginal expectations.  We reported first quarter t otal company revenues of $55.7 billion and adjusted earnings per \ndiluted share of $2.77.  Both ahead of our original expectations.  Through April and May, trends in the business \naligned closely with our original expectations.  However, we saw volumes across t he business improved \nsignificantly over the back half of June, resulting in a strong close to the quarter.  \n \n", "original_text": "We reported first quarter t otal company revenues of $55.7 billion and adjusted earnings per \ndiluted share of $2.77. ", "page_label": "3", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f2ea56d4-9ba8-40ce-8f1a-d30083a09b88", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5877ddfe3db966424172ad7268280081fac3e10094e047943d3193a022b9a8ed", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f9f91683-0fcd-4f51-b323-11ccf47948b8", "node_type": "1", "metadata": {"window": "On our fourth quarter call in May, I \ndiscussed  that we were entering the new fiscal year with macro uncertainties  and volatility in healthcare \nconsumption patterns as a result of the COVID -19 pandemic.  And our first quarter results clearly reflect the \neffects of these dynamics.  \n \n Today we're reporting  results for one of the most complicated quarters in our company's history.  Our first quarter \nadjusted results while materially down against prior year due to the pandemic, finished significantly above our \noriginal expectations.  We reported first quarter t otal company revenues of $55.7 billion and adjusted earnings per \ndiluted share of $2.77.  Both ahead of our original expectations.  Through April and May, trends in the business \naligned closely with our original expectations. ", "original_text": "Our first quarter \nadjusted results while materially down against prior year due to the pandemic, finished significantly above our \noriginal expectations. ", "page_label": "3", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c9146ce3c0071b33aa792c869f59f7827acea254736506b7d37a9d046764dd4a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7c841c3e-1c0b-4b6a-880a-21d4050479d1", "node_type": "1", "metadata": {"window": "Today we're reporting  results for one of the most complicated quarters in our company's history.  Our first quarter \nadjusted results while materially down against prior year due to the pandemic, finished significantly above our \noriginal expectations.  We reported first quarter t otal company revenues of $55.7 billion and adjusted earnings per \ndiluted share of $2.77.  Both ahead of our original expectations.  Through April and May, trends in the business \naligned closely with our original expectations.  However, we saw volumes across t he business improved \nsignificantly over the back half of June, resulting in a strong close to the quarter.  \n \n Based on our first quarter results, and the current shape of the recovery versus our original expectations, we're \nraising our fiscal 2021 adjusted e arnings per diluted share guidance range to  \n \n$14.70 to $15.50 per diluted share. ", "original_text": "Both ahead of our original expectations. "}, "hash": "79435e52c6426242c04943297c281f319fe0fab1585aec21a3f3c1c0da28e214", "class_name": "RelatedNodeInfo"}}, "text": "We reported first quarter t otal company revenues of $55.7 billion and adjusted earnings per \ndiluted share of $2.77. ", "start_char_idx": 2940, "end_char_idx": 3058, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7c841c3e-1c0b-4b6a-880a-21d4050479d1": {"__data__": {"id_": "7c841c3e-1c0b-4b6a-880a-21d4050479d1", "embedding": null, "metadata": {"window": "Today we're reporting  results for one of the most complicated quarters in our company's history.  Our first quarter \nadjusted results while materially down against prior year due to the pandemic, finished significantly above our \noriginal expectations.  We reported first quarter t otal company revenues of $55.7 billion and adjusted earnings per \ndiluted share of $2.77.  Both ahead of our original expectations.  Through April and May, trends in the business \naligned closely with our original expectations.  However, we saw volumes across t he business improved \nsignificantly over the back half of June, resulting in a strong close to the quarter.  \n \n Based on our first quarter results, and the current shape of the recovery versus our original expectations, we're \nraising our fiscal 2021 adjusted e arnings per diluted share guidance range to  \n \n$14.70 to $15.50 per diluted share. ", "original_text": "Both ahead of our original expectations. ", "page_label": "3", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f2ea56d4-9ba8-40ce-8f1a-d30083a09b88", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5877ddfe3db966424172ad7268280081fac3e10094e047943d3193a022b9a8ed", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e79707ac-8a92-4f2f-bfa6-740452fbba70", "node_type": "1", "metadata": {"window": "And our first quarter results clearly reflect the \neffects of these dynamics.  \n \n Today we're reporting  results for one of the most complicated quarters in our company's history.  Our first quarter \nadjusted results while materially down against prior year due to the pandemic, finished significantly above our \noriginal expectations.  We reported first quarter t otal company revenues of $55.7 billion and adjusted earnings per \ndiluted share of $2.77.  Both ahead of our original expectations.  Through April and May, trends in the business \naligned closely with our original expectations.  However, we saw volumes across t he business improved \nsignificantly over the back half of June, resulting in a strong close to the quarter.  \n \n", "original_text": "We reported first quarter t otal company revenues of $55.7 billion and adjusted earnings per \ndiluted share of $2.77. ", "page_label": "3", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "82db5f81bece3a3478ac7f5e125398a1960a3faf3b3fc1a325c6aff7ed598d1d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3c66dd66-4d0d-49b0-aa99-1bd9d5ba1856", "node_type": "1", "metadata": {"window": "Our first quarter \nadjusted results while materially down against prior year due to the pandemic, finished significantly above our \noriginal expectations.  We reported first quarter t otal company revenues of $55.7 billion and adjusted earnings per \ndiluted share of $2.77.  Both ahead of our original expectations.  Through April and May, trends in the business \naligned closely with our original expectations.  However, we saw volumes across t he business improved \nsignificantly over the back half of June, resulting in a strong close to the quarter.  \n \n Based on our first quarter results, and the current shape of the recovery versus our original expectations, we're \nraising our fiscal 2021 adjusted e arnings per diluted share guidance range to  \n \n$14.70 to $15.50 per diluted share.  This is up from our previous range of $13.95 to $14.75 per diluted share. \n", "original_text": "Through April and May, trends in the business \naligned closely with our original expectations. "}, "hash": "96c2ca932844b22c512f41a84885c36fcaab35d5f905c84d21f00754744cf362", "class_name": "RelatedNodeInfo"}}, "text": "Both ahead of our original expectations. ", "start_char_idx": 3058, "end_char_idx": 3099, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3c66dd66-4d0d-49b0-aa99-1bd9d5ba1856": {"__data__": {"id_": "3c66dd66-4d0d-49b0-aa99-1bd9d5ba1856", "embedding": null, "metadata": {"window": "Our first quarter \nadjusted results while materially down against prior year due to the pandemic, finished significantly above our \noriginal expectations.  We reported first quarter t otal company revenues of $55.7 billion and adjusted earnings per \ndiluted share of $2.77.  Both ahead of our original expectations.  Through April and May, trends in the business \naligned closely with our original expectations.  However, we saw volumes across t he business improved \nsignificantly over the back half of June, resulting in a strong close to the quarter.  \n \n Based on our first quarter results, and the current shape of the recovery versus our original expectations, we're \nraising our fiscal 2021 adjusted e arnings per diluted share guidance range to  \n \n$14.70 to $15.50 per diluted share.  This is up from our previous range of $13.95 to $14.75 per diluted share. \n", "original_text": "Through April and May, trends in the business \naligned closely with our original expectations. ", "page_label": "3", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f2ea56d4-9ba8-40ce-8f1a-d30083a09b88", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5877ddfe3db966424172ad7268280081fac3e10094e047943d3193a022b9a8ed", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7c841c3e-1c0b-4b6a-880a-21d4050479d1", "node_type": "1", "metadata": {"window": "Today we're reporting  results for one of the most complicated quarters in our company's history.  Our first quarter \nadjusted results while materially down against prior year due to the pandemic, finished significantly above our \noriginal expectations.  We reported first quarter t otal company revenues of $55.7 billion and adjusted earnings per \ndiluted share of $2.77.  Both ahead of our original expectations.  Through April and May, trends in the business \naligned closely with our original expectations.  However, we saw volumes across t he business improved \nsignificantly over the back half of June, resulting in a strong close to the quarter.  \n \n Based on our first quarter results, and the current shape of the recovery versus our original expectations, we're \nraising our fiscal 2021 adjusted e arnings per diluted share guidance range to  \n \n$14.70 to $15.50 per diluted share. ", "original_text": "Both ahead of our original expectations. ", "page_label": "3", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "37d439f0888a9ea47626f5f06c2d9523ce5588e99e98d0448f05b7a4a6afa3bd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "96f23ca5-5989-4b71-b0c0-01fb13169315", "node_type": "1", "metadata": {"window": "We reported first quarter t otal company revenues of $55.7 billion and adjusted earnings per \ndiluted share of $2.77.  Both ahead of our original expectations.  Through April and May, trends in the business \naligned closely with our original expectations.  However, we saw volumes across t he business improved \nsignificantly over the back half of June, resulting in a strong close to the quarter.  \n \n Based on our first quarter results, and the current shape of the recovery versus our original expectations, we're \nraising our fiscal 2021 adjusted e arnings per diluted share guidance range to  \n \n$14.70 to $15.50 per diluted share.  This is up from our previous range of $13.95 to $14.75 per diluted share. \n Despite the uncertainty brought on by the pandemic, our focus is on executing against what is within our control. \n", "original_text": "However, we saw volumes across t he business improved \nsignificantly over the back half of June, resulting in a strong close to the quarter.  \n \n"}, "hash": "775844090a8d58b35e3b35268efb057584ec88785aecae365b96a50fa57867a4", "class_name": "RelatedNodeInfo"}}, "text": "Through April and May, trends in the business \naligned closely with our original expectations. ", "start_char_idx": 3099, "end_char_idx": 3194, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "96f23ca5-5989-4b71-b0c0-01fb13169315": {"__data__": {"id_": "96f23ca5-5989-4b71-b0c0-01fb13169315", "embedding": null, "metadata": {"window": "We reported first quarter t otal company revenues of $55.7 billion and adjusted earnings per \ndiluted share of $2.77.  Both ahead of our original expectations.  Through April and May, trends in the business \naligned closely with our original expectations.  However, we saw volumes across t he business improved \nsignificantly over the back half of June, resulting in a strong close to the quarter.  \n \n Based on our first quarter results, and the current shape of the recovery versus our original expectations, we're \nraising our fiscal 2021 adjusted e arnings per diluted share guidance range to  \n \n$14.70 to $15.50 per diluted share.  This is up from our previous range of $13.95 to $14.75 per diluted share. \n Despite the uncertainty brought on by the pandemic, our focus is on executing against what is within our control. \n", "original_text": "However, we saw volumes across t he business improved \nsignificantly over the back half of June, resulting in a strong close to the quarter.  \n \n", "page_label": "3", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f2ea56d4-9ba8-40ce-8f1a-d30083a09b88", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5877ddfe3db966424172ad7268280081fac3e10094e047943d3193a022b9a8ed", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3c66dd66-4d0d-49b0-aa99-1bd9d5ba1856", "node_type": "1", "metadata": {"window": "Our first quarter \nadjusted results while materially down against prior year due to the pandemic, finished significantly above our \noriginal expectations.  We reported first quarter t otal company revenues of $55.7 billion and adjusted earnings per \ndiluted share of $2.77.  Both ahead of our original expectations.  Through April and May, trends in the business \naligned closely with our original expectations.  However, we saw volumes across t he business improved \nsignificantly over the back half of June, resulting in a strong close to the quarter.  \n \n Based on our first quarter results, and the current shape of the recovery versus our original expectations, we're \nraising our fiscal 2021 adjusted e arnings per diluted share guidance range to  \n \n$14.70 to $15.50 per diluted share.  This is up from our previous range of $13.95 to $14.75 per diluted share. \n", "original_text": "Through April and May, trends in the business \naligned closely with our original expectations. ", "page_label": "3", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "da0d9dc66150838fbb40cdb664f6be807644f893af9fbc49426502f6382959dd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1ea717b4-c066-4f6b-a076-fb04ea7d3283", "node_type": "1", "metadata": {"window": "Both ahead of our original expectations.  Through April and May, trends in the business \naligned closely with our original expectations.  However, we saw volumes across t he business improved \nsignificantly over the back half of June, resulting in a strong close to the quarter.  \n \n Based on our first quarter results, and the current shape of the recovery versus our original expectations, we're \nraising our fiscal 2021 adjusted e arnings per diluted share guidance range to  \n \n$14.70 to $15.50 per diluted share.  This is up from our previous range of $13.95 to $14.75 per diluted share. \n Despite the uncertainty brought on by the pandemic, our focus is on executing against what is within our control. \n And that execution really underp inned our strong finish to the quarter, as customer demand began to improve \nfrom the troughs we experienced in April and May. ", "original_text": "Based on our first quarter results, and the current shape of the recovery versus our original expectations, we're \nraising our fiscal 2021 adjusted e arnings per diluted share guidance range to  \n \n$14.70 to $15.50 per diluted share. "}, "hash": "f4cfb909012551e371f847115b957725eaf837ee4a802ec4e251bd55defe58a1", "class_name": "RelatedNodeInfo"}}, "text": "However, we saw volumes across t he business improved \nsignificantly over the back half of June, resulting in a strong close to the quarter.  \n \n", "start_char_idx": 3194, "end_char_idx": 3339, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1ea717b4-c066-4f6b-a076-fb04ea7d3283": {"__data__": {"id_": "1ea717b4-c066-4f6b-a076-fb04ea7d3283", "embedding": null, "metadata": {"window": "Both ahead of our original expectations.  Through April and May, trends in the business \naligned closely with our original expectations.  However, we saw volumes across t he business improved \nsignificantly over the back half of June, resulting in a strong close to the quarter.  \n \n Based on our first quarter results, and the current shape of the recovery versus our original expectations, we're \nraising our fiscal 2021 adjusted e arnings per diluted share guidance range to  \n \n$14.70 to $15.50 per diluted share.  This is up from our previous range of $13.95 to $14.75 per diluted share. \n Despite the uncertainty brought on by the pandemic, our focus is on executing against what is within our control. \n And that execution really underp inned our strong finish to the quarter, as customer demand began to improve \nfrom the troughs we experienced in April and May. ", "original_text": "Based on our first quarter results, and the current shape of the recovery versus our original expectations, we're \nraising our fiscal 2021 adjusted e arnings per diluted share guidance range to  \n \n$14.70 to $15.50 per diluted share. ", "page_label": "3", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f2ea56d4-9ba8-40ce-8f1a-d30083a09b88", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5877ddfe3db966424172ad7268280081fac3e10094e047943d3193a022b9a8ed", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "96f23ca5-5989-4b71-b0c0-01fb13169315", "node_type": "1", "metadata": {"window": "We reported first quarter t otal company revenues of $55.7 billion and adjusted earnings per \ndiluted share of $2.77.  Both ahead of our original expectations.  Through April and May, trends in the business \naligned closely with our original expectations.  However, we saw volumes across t he business improved \nsignificantly over the back half of June, resulting in a strong close to the quarter.  \n \n Based on our first quarter results, and the current shape of the recovery versus our original expectations, we're \nraising our fiscal 2021 adjusted e arnings per diluted share guidance range to  \n \n$14.70 to $15.50 per diluted share.  This is up from our previous range of $13.95 to $14.75 per diluted share. \n Despite the uncertainty brought on by the pandemic, our focus is on executing against what is within our control. \n", "original_text": "However, we saw volumes across t he business improved \nsignificantly over the back half of June, resulting in a strong close to the quarter.  \n \n", "page_label": "3", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2a22e705ca034458f548a9c03ec35a5a84989e4d44af17b6b1483c4f7dd54e54", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a9c39a8a-4f75-4a2c-9472-74f51eea4c5c", "node_type": "1", "metadata": {"window": "Through April and May, trends in the business \naligned closely with our original expectations.  However, we saw volumes across t he business improved \nsignificantly over the back half of June, resulting in a strong close to the quarter.  \n \n Based on our first quarter results, and the current shape of the recovery versus our original expectations, we're \nraising our fiscal 2021 adjusted e arnings per diluted share guidance range to  \n \n$14.70 to $15.50 per diluted share.  This is up from our previous range of $13.95 to $14.75 per diluted share. \n Despite the uncertainty brought on by the pandemic, our focus is on executing against what is within our control. \n And that execution really underp inned our strong finish to the quarter, as customer demand began to improve \nfrom the troughs we experienced in April and May.  From the beginning, our top priority has been to navigate the \nchallenges and the fluidity of the situation brought on by the pande mic by focusing first on protecting the health ", "original_text": "This is up from our previous range of $13.95 to $14.75 per diluted share. \n"}, "hash": "8737c1bb4d547a7dd811f6a8845ab4708c7383444c9f378a487f758dae74ff2b", "class_name": "RelatedNodeInfo"}}, "text": "Based on our first quarter results, and the current shape of the recovery versus our original expectations, we're \nraising our fiscal 2021 adjusted e arnings per diluted share guidance range to  \n \n$14.70 to $15.50 per diluted share. ", "start_char_idx": 3339, "end_char_idx": 3573, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a9c39a8a-4f75-4a2c-9472-74f51eea4c5c": {"__data__": {"id_": "a9c39a8a-4f75-4a2c-9472-74f51eea4c5c", "embedding": null, "metadata": {"window": "Through April and May, trends in the business \naligned closely with our original expectations.  However, we saw volumes across t he business improved \nsignificantly over the back half of June, resulting in a strong close to the quarter.  \n \n Based on our first quarter results, and the current shape of the recovery versus our original expectations, we're \nraising our fiscal 2021 adjusted e arnings per diluted share guidance range to  \n \n$14.70 to $15.50 per diluted share.  This is up from our previous range of $13.95 to $14.75 per diluted share. \n Despite the uncertainty brought on by the pandemic, our focus is on executing against what is within our control. \n And that execution really underp inned our strong finish to the quarter, as customer demand began to improve \nfrom the troughs we experienced in April and May.  From the beginning, our top priority has been to navigate the \nchallenges and the fluidity of the situation brought on by the pande mic by focusing first on protecting the health ", "original_text": "This is up from our previous range of $13.95 to $14.75 per diluted share. \n", "page_label": "3", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f2ea56d4-9ba8-40ce-8f1a-d30083a09b88", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5877ddfe3db966424172ad7268280081fac3e10094e047943d3193a022b9a8ed", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1ea717b4-c066-4f6b-a076-fb04ea7d3283", "node_type": "1", "metadata": {"window": "Both ahead of our original expectations.  Through April and May, trends in the business \naligned closely with our original expectations.  However, we saw volumes across t he business improved \nsignificantly over the back half of June, resulting in a strong close to the quarter.  \n \n Based on our first quarter results, and the current shape of the recovery versus our original expectations, we're \nraising our fiscal 2021 adjusted e arnings per diluted share guidance range to  \n \n$14.70 to $15.50 per diluted share.  This is up from our previous range of $13.95 to $14.75 per diluted share. \n Despite the uncertainty brought on by the pandemic, our focus is on executing against what is within our control. \n And that execution really underp inned our strong finish to the quarter, as customer demand began to improve \nfrom the troughs we experienced in April and May. ", "original_text": "Based on our first quarter results, and the current shape of the recovery versus our original expectations, we're \nraising our fiscal 2021 adjusted e arnings per diluted share guidance range to  \n \n$14.70 to $15.50 per diluted share. ", "page_label": "3", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1997d2180f257983943207a94fb0a78a7cdfe7cddac8a35aecfd5ebac1b116f8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e895f136-462d-4451-bf85-e4ceff4f5c5e", "node_type": "1", "metadata": {"window": "However, we saw volumes across t he business improved \nsignificantly over the back half of June, resulting in a strong close to the quarter.  \n \n Based on our first quarter results, and the current shape of the recovery versus our original expectations, we're \nraising our fiscal 2021 adjusted e arnings per diluted share guidance range to  \n \n$14.70 to $15.50 per diluted share.  This is up from our previous range of $13.95 to $14.75 per diluted share. \n Despite the uncertainty brought on by the pandemic, our focus is on executing against what is within our control. \n And that execution really underp inned our strong finish to the quarter, as customer demand began to improve \nfrom the troughs we experienced in April and May.  From the beginning, our top priority has been to navigate the \nchallenges and the fluidity of the situation brought on by the pande mic by focusing first on protecting the health ", "original_text": "Despite the uncertainty brought on by the pandemic, our focus is on executing against what is within our control. \n"}, "hash": "c61ce319fc184aadcbbc77f680e306eeef9f7eca8cf519929c9d93c5bea767d9", "class_name": "RelatedNodeInfo"}}, "text": "This is up from our previous range of $13.95 to $14.75 per diluted share. \n", "start_char_idx": 3573, "end_char_idx": 3648, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e895f136-462d-4451-bf85-e4ceff4f5c5e": {"__data__": {"id_": "e895f136-462d-4451-bf85-e4ceff4f5c5e", "embedding": null, "metadata": {"window": "However, we saw volumes across t he business improved \nsignificantly over the back half of June, resulting in a strong close to the quarter.  \n \n Based on our first quarter results, and the current shape of the recovery versus our original expectations, we're \nraising our fiscal 2021 adjusted e arnings per diluted share guidance range to  \n \n$14.70 to $15.50 per diluted share.  This is up from our previous range of $13.95 to $14.75 per diluted share. \n Despite the uncertainty brought on by the pandemic, our focus is on executing against what is within our control. \n And that execution really underp inned our strong finish to the quarter, as customer demand began to improve \nfrom the troughs we experienced in April and May.  From the beginning, our top priority has been to navigate the \nchallenges and the fluidity of the situation brought on by the pande mic by focusing first on protecting the health ", "original_text": "Despite the uncertainty brought on by the pandemic, our focus is on executing against what is within our control. \n", "page_label": "3", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f2ea56d4-9ba8-40ce-8f1a-d30083a09b88", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5877ddfe3db966424172ad7268280081fac3e10094e047943d3193a022b9a8ed", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a9c39a8a-4f75-4a2c-9472-74f51eea4c5c", "node_type": "1", "metadata": {"window": "Through April and May, trends in the business \naligned closely with our original expectations.  However, we saw volumes across t he business improved \nsignificantly over the back half of June, resulting in a strong close to the quarter.  \n \n Based on our first quarter results, and the current shape of the recovery versus our original expectations, we're \nraising our fiscal 2021 adjusted e arnings per diluted share guidance range to  \n \n$14.70 to $15.50 per diluted share.  This is up from our previous range of $13.95 to $14.75 per diluted share. \n Despite the uncertainty brought on by the pandemic, our focus is on executing against what is within our control. \n And that execution really underp inned our strong finish to the quarter, as customer demand began to improve \nfrom the troughs we experienced in April and May.  From the beginning, our top priority has been to navigate the \nchallenges and the fluidity of the situation brought on by the pande mic by focusing first on protecting the health ", "original_text": "This is up from our previous range of $13.95 to $14.75 per diluted share. \n", "page_label": "3", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "dfc99e021934bdd44d8c11dfa30dd562cb0c1023a15ae201d0a707766fe15167", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c64f91a1-2e37-4511-8a81-d05ecdd90f1a", "node_type": "1", "metadata": {"window": "Based on our first quarter results, and the current shape of the recovery versus our original expectations, we're \nraising our fiscal 2021 adjusted e arnings per diluted share guidance range to  \n \n$14.70 to $15.50 per diluted share.  This is up from our previous range of $13.95 to $14.75 per diluted share. \n Despite the uncertainty brought on by the pandemic, our focus is on executing against what is within our control. \n And that execution really underp inned our strong finish to the quarter, as customer demand began to improve \nfrom the troughs we experienced in April and May.  From the beginning, our top priority has been to navigate the \nchallenges and the fluidity of the situation brought on by the pande mic by focusing first on protecting the health ", "original_text": "And that execution really underp inned our strong finish to the quarter, as customer demand began to improve \nfrom the troughs we experienced in April and May. "}, "hash": "11bd3c61bb21298b4d2f36285049706100054f419a6be429e5721d85c2112a96", "class_name": "RelatedNodeInfo"}}, "text": "Despite the uncertainty brought on by the pandemic, our focus is on executing against what is within our control. \n", "start_char_idx": 3648, "end_char_idx": 3763, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c64f91a1-2e37-4511-8a81-d05ecdd90f1a": {"__data__": {"id_": "c64f91a1-2e37-4511-8a81-d05ecdd90f1a", "embedding": null, "metadata": {"window": "Based on our first quarter results, and the current shape of the recovery versus our original expectations, we're \nraising our fiscal 2021 adjusted e arnings per diluted share guidance range to  \n \n$14.70 to $15.50 per diluted share.  This is up from our previous range of $13.95 to $14.75 per diluted share. \n Despite the uncertainty brought on by the pandemic, our focus is on executing against what is within our control. \n And that execution really underp inned our strong finish to the quarter, as customer demand began to improve \nfrom the troughs we experienced in April and May.  From the beginning, our top priority has been to navigate the \nchallenges and the fluidity of the situation brought on by the pande mic by focusing first on protecting the health ", "original_text": "And that execution really underp inned our strong finish to the quarter, as customer demand began to improve \nfrom the troughs we experienced in April and May. ", "page_label": "3", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f2ea56d4-9ba8-40ce-8f1a-d30083a09b88", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5877ddfe3db966424172ad7268280081fac3e10094e047943d3193a022b9a8ed", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e895f136-462d-4451-bf85-e4ceff4f5c5e", "node_type": "1", "metadata": {"window": "However, we saw volumes across t he business improved \nsignificantly over the back half of June, resulting in a strong close to the quarter.  \n \n Based on our first quarter results, and the current shape of the recovery versus our original expectations, we're \nraising our fiscal 2021 adjusted e arnings per diluted share guidance range to  \n \n$14.70 to $15.50 per diluted share.  This is up from our previous range of $13.95 to $14.75 per diluted share. \n Despite the uncertainty brought on by the pandemic, our focus is on executing against what is within our control. \n And that execution really underp inned our strong finish to the quarter, as customer demand began to improve \nfrom the troughs we experienced in April and May.  From the beginning, our top priority has been to navigate the \nchallenges and the fluidity of the situation brought on by the pande mic by focusing first on protecting the health ", "original_text": "Despite the uncertainty brought on by the pandemic, our focus is on executing against what is within our control. \n", "page_label": "3", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "af6c89a10b78b20bd323a920b7e786e6d75174171629b64a548eff00a523baf3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1afd99ad-2b91-483f-808c-eaa5e8208c80", "node_type": "1", "metadata": {"window": "This is up from our previous range of $13.95 to $14.75 per diluted share. \n Despite the uncertainty brought on by the pandemic, our focus is on executing against what is within our control. \n And that execution really underp inned our strong finish to the quarter, as customer demand began to improve \nfrom the troughs we experienced in April and May.  From the beginning, our top priority has been to navigate the \nchallenges and the fluidity of the situation brought on by the pande mic by focusing first on protecting the health ", "original_text": "From the beginning, our top priority has been to navigate the \nchallenges and the fluidity of the situation brought on by the pande mic by focusing first on protecting the health "}, "hash": "4e03e5c2ff9e6f0abe13628f93eda62f63dfa998bde694fc8f557bd9a49f836f", "class_name": "RelatedNodeInfo"}}, "text": "And that execution really underp inned our strong finish to the quarter, as customer demand began to improve \nfrom the troughs we experienced in April and May. ", "start_char_idx": 3763, "end_char_idx": 3923, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1afd99ad-2b91-483f-808c-eaa5e8208c80": {"__data__": {"id_": "1afd99ad-2b91-483f-808c-eaa5e8208c80", "embedding": null, "metadata": {"window": "This is up from our previous range of $13.95 to $14.75 per diluted share. \n Despite the uncertainty brought on by the pandemic, our focus is on executing against what is within our control. \n And that execution really underp inned our strong finish to the quarter, as customer demand began to improve \nfrom the troughs we experienced in April and May.  From the beginning, our top priority has been to navigate the \nchallenges and the fluidity of the situation brought on by the pande mic by focusing first on protecting the health ", "original_text": "From the beginning, our top priority has been to navigate the \nchallenges and the fluidity of the situation brought on by the pande mic by focusing first on protecting the health ", "page_label": "3", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f2ea56d4-9ba8-40ce-8f1a-d30083a09b88", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5877ddfe3db966424172ad7268280081fac3e10094e047943d3193a022b9a8ed", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c64f91a1-2e37-4511-8a81-d05ecdd90f1a", "node_type": "1", "metadata": {"window": "Based on our first quarter results, and the current shape of the recovery versus our original expectations, we're \nraising our fiscal 2021 adjusted e arnings per diluted share guidance range to  \n \n$14.70 to $15.50 per diluted share.  This is up from our previous range of $13.95 to $14.75 per diluted share. \n Despite the uncertainty brought on by the pandemic, our focus is on executing against what is within our control. \n And that execution really underp inned our strong finish to the quarter, as customer demand began to improve \nfrom the troughs we experienced in April and May.  From the beginning, our top priority has been to navigate the \nchallenges and the fluidity of the situation brought on by the pande mic by focusing first on protecting the health ", "original_text": "And that execution really underp inned our strong finish to the quarter, as customer demand began to improve \nfrom the troughs we experienced in April and May. ", "page_label": "3", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fab8978ede2dd8c4e70cb092d783136c3a890313e7eceae4e8efda5cfb0eb24a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2280c3e2-269a-46fb-a70a-c15c429b8a31", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nand safety of our teams, so that we could continue to meet the needs of our customers and keep the healthcare \nsupply chain operating at a high level.  \n \n We've committed to increase safety measures for our employ ees and have maintained an unwavering \ncommitment to our customers and our communities.  In May, I talked about the essential role McKesson plays in \nthe fight against the COVID -19 pandemic, and the need to partner closely with manufacturers, and various \ngove rnment entities, so that we can react quickly, as demand patterns shift with the spread of the COVID -19 \nvirus. ", "original_text": "McKesson Corp.  "}, "hash": "4a562bb7e70daf181fa8ed6f052d8074a84ee79e6b049518599b68ac2ef9158b", "class_name": "RelatedNodeInfo"}}, "text": "From the beginning, our top priority has been to navigate the \nchallenges and the fluidity of the situation brought on by the pande mic by focusing first on protecting the health ", "start_char_idx": 3923, "end_char_idx": 4102, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2280c3e2-269a-46fb-a70a-c15c429b8a31": {"__data__": {"id_": "2280c3e2-269a-46fb-a70a-c15c429b8a31", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nand safety of our teams, so that we could continue to meet the needs of our customers and keep the healthcare \nsupply chain operating at a high level.  \n \n We've committed to increase safety measures for our employ ees and have maintained an unwavering \ncommitment to our customers and our communities.  In May, I talked about the essential role McKesson plays in \nthe fight against the COVID -19 pandemic, and the need to partner closely with manufacturers, and various \ngove rnment entities, so that we can react quickly, as demand patterns shift with the spread of the COVID -19 \nvirus. ", "original_text": "McKesson Corp.  ", "page_label": "4", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "71518e0c-2d29-463a-b5e5-d10bfe32ed2b", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4752fa50e2ceffd2079270047593412cd4cd1d2f8675eb305d4d5f0fc830f792", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1afd99ad-2b91-483f-808c-eaa5e8208c80", "node_type": "1", "metadata": {"window": "This is up from our previous range of $13.95 to $14.75 per diluted share. \n Despite the uncertainty brought on by the pandemic, our focus is on executing against what is within our control. \n And that execution really underp inned our strong finish to the quarter, as customer demand began to improve \nfrom the troughs we experienced in April and May.  From the beginning, our top priority has been to navigate the \nchallenges and the fluidity of the situation brought on by the pande mic by focusing first on protecting the health ", "original_text": "From the beginning, our top priority has been to navigate the \nchallenges and the fluidity of the situation brought on by the pande mic by focusing first on protecting the health ", "page_label": "3", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "eaa901944d8f0ac0f8ab084b18ec0535f7ed17be8a746cb07605e2f5d9490507", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a29934ad-db7c-48f8-bae5-a2c16aa13c4f", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nand safety of our teams, so that we could continue to meet the needs of our customers and keep the healthcare \nsupply chain operating at a high level.  \n \n We've committed to increase safety measures for our employ ees and have maintained an unwavering \ncommitment to our customers and our communities.  In May, I talked about the essential role McKesson plays in \nthe fight against the COVID -19 pandemic, and the need to partner closely with manufacturers, and various \ngove rnment entities, so that we can react quickly, as demand patterns shift with the spread of the COVID -19 \nvirus.  One such area that has evolved is the demand for personal protective equipment or PPE, as frontline \nworkers and our customers work to help treat and keep patients safe. ", "original_text": "(MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nand safety of our teams, so that we could continue to meet the needs of our customers and keep the healthcare \nsupply chain operating at a high level.  \n \n"}, "hash": "df609520cdc5daa32f27df044f308e4e96d2f2950537a474add798d824e7f041", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a29934ad-db7c-48f8-bae5-a2c16aa13c4f": {"__data__": {"id_": "a29934ad-db7c-48f8-bae5-a2c16aa13c4f", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nand safety of our teams, so that we could continue to meet the needs of our customers and keep the healthcare \nsupply chain operating at a high level.  \n \n We've committed to increase safety measures for our employ ees and have maintained an unwavering \ncommitment to our customers and our communities.  In May, I talked about the essential role McKesson plays in \nthe fight against the COVID -19 pandemic, and the need to partner closely with manufacturers, and various \ngove rnment entities, so that we can react quickly, as demand patterns shift with the spread of the COVID -19 \nvirus.  One such area that has evolved is the demand for personal protective equipment or PPE, as frontline \nworkers and our customers work to help treat and keep patients safe. ", "original_text": "(MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nand safety of our teams, so that we could continue to meet the needs of our customers and keep the healthcare \nsupply chain operating at a high level.  \n \n", "page_label": "4", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "71518e0c-2d29-463a-b5e5-d10bfe32ed2b", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4752fa50e2ceffd2079270047593412cd4cd1d2f8675eb305d4d5f0fc830f792", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2280c3e2-269a-46fb-a70a-c15c429b8a31", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nand safety of our teams, so that we could continue to meet the needs of our customers and keep the healthcare \nsupply chain operating at a high level.  \n \n We've committed to increase safety measures for our employ ees and have maintained an unwavering \ncommitment to our customers and our communities.  In May, I talked about the essential role McKesson plays in \nthe fight against the COVID -19 pandemic, and the need to partner closely with manufacturers, and various \ngove rnment entities, so that we can react quickly, as demand patterns shift with the spread of the COVID -19 \nvirus. ", "original_text": "McKesson Corp.  ", "page_label": "4", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "54304eccc6409f254dffbc842f82b6175bf5a94fbbd4bab681b741a976d279e6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d7517ab3-caf6-4db4-8e1e-504d24e0a7c6", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nand safety of our teams, so that we could continue to meet the needs of our customers and keep the healthcare \nsupply chain operating at a high level.  \n \n We've committed to increase safety measures for our employ ees and have maintained an unwavering \ncommitment to our customers and our communities.  In May, I talked about the essential role McKesson plays in \nthe fight against the COVID -19 pandemic, and the need to partner closely with manufacturers, and various \ngove rnment entities, so that we can react quickly, as demand patterns shift with the spread of the COVID -19 \nvirus.  One such area that has evolved is the demand for personal protective equipment or PPE, as frontline \nworkers and our customers work to help treat and keep patients safe.  We've worked with supplier partners \nfederal, state and local governments to get higher volumes of PPEs to areas of critical needs.  \n \n", "original_text": "We've committed to increase safety measures for our employ ees and have maintained an unwavering \ncommitment to our customers and our communities. "}, "hash": "1e8e5414151c5445f5d3d2b47b2250a1895d0b08c0686dba232e81a20b44f6e8", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nand safety of our teams, so that we could continue to meet the needs of our customers and keep the healthcare \nsupply chain operating at a high level.  \n \n", "start_char_idx": 16, "end_char_idx": 335, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d7517ab3-caf6-4db4-8e1e-504d24e0a7c6": {"__data__": {"id_": "d7517ab3-caf6-4db4-8e1e-504d24e0a7c6", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nand safety of our teams, so that we could continue to meet the needs of our customers and keep the healthcare \nsupply chain operating at a high level.  \n \n We've committed to increase safety measures for our employ ees and have maintained an unwavering \ncommitment to our customers and our communities.  In May, I talked about the essential role McKesson plays in \nthe fight against the COVID -19 pandemic, and the need to partner closely with manufacturers, and various \ngove rnment entities, so that we can react quickly, as demand patterns shift with the spread of the COVID -19 \nvirus.  One such area that has evolved is the demand for personal protective equipment or PPE, as frontline \nworkers and our customers work to help treat and keep patients safe.  We've worked with supplier partners \nfederal, state and local governments to get higher volumes of PPEs to areas of critical needs.  \n \n", "original_text": "We've committed to increase safety measures for our employ ees and have maintained an unwavering \ncommitment to our customers and our communities. ", "page_label": "4", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "71518e0c-2d29-463a-b5e5-d10bfe32ed2b", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4752fa50e2ceffd2079270047593412cd4cd1d2f8675eb305d4d5f0fc830f792", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a29934ad-db7c-48f8-bae5-a2c16aa13c4f", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nand safety of our teams, so that we could continue to meet the needs of our customers and keep the healthcare \nsupply chain operating at a high level.  \n \n We've committed to increase safety measures for our employ ees and have maintained an unwavering \ncommitment to our customers and our communities.  In May, I talked about the essential role McKesson plays in \nthe fight against the COVID -19 pandemic, and the need to partner closely with manufacturers, and various \ngove rnment entities, so that we can react quickly, as demand patterns shift with the spread of the COVID -19 \nvirus.  One such area that has evolved is the demand for personal protective equipment or PPE, as frontline \nworkers and our customers work to help treat and keep patients safe. ", "original_text": "(MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nand safety of our teams, so that we could continue to meet the needs of our customers and keep the healthcare \nsupply chain operating at a high level.  \n \n", "page_label": "4", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5e499103dfaf92043152b34ad2d07ade68051f9c30bab6f5630dbc18cd28e371", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "12504bf6-aafb-4fa7-93e3-966dba64d316", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nand safety of our teams, so that we could continue to meet the needs of our customers and keep the healthcare \nsupply chain operating at a high level.  \n \n We've committed to increase safety measures for our employ ees and have maintained an unwavering \ncommitment to our customers and our communities.  In May, I talked about the essential role McKesson plays in \nthe fight against the COVID -19 pandemic, and the need to partner closely with manufacturers, and various \ngove rnment entities, so that we can react quickly, as demand patterns shift with the spread of the COVID -19 \nvirus.  One such area that has evolved is the demand for personal protective equipment or PPE, as frontline \nworkers and our customers work to help treat and keep patients safe.  We've worked with supplier partners \nfederal, state and local governments to get higher volumes of PPEs to areas of critical needs.  \n \n Our partnership with Walmart to produce and deliver medical gowns in the US has continued to increas e total \ngown supply, with over 30 million gowns shipped to the US since April. ", "original_text": "In May, I talked about the essential role McKesson plays in \nthe fight against the COVID -19 pandemic, and the need to partner closely with manufacturers, and various \ngove rnment entities, so that we can react quickly, as demand patterns shift with the spread of the COVID -19 \nvirus. "}, "hash": "c2bf48b2f44849b441179c9a9c4225f0493afc592189003fcd050566ad0469cf", "class_name": "RelatedNodeInfo"}}, "text": "We've committed to increase safety measures for our employ ees and have maintained an unwavering \ncommitment to our customers and our communities. ", "start_char_idx": 335, "end_char_idx": 482, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "12504bf6-aafb-4fa7-93e3-966dba64d316": {"__data__": {"id_": "12504bf6-aafb-4fa7-93e3-966dba64d316", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nand safety of our teams, so that we could continue to meet the needs of our customers and keep the healthcare \nsupply chain operating at a high level.  \n \n We've committed to increase safety measures for our employ ees and have maintained an unwavering \ncommitment to our customers and our communities.  In May, I talked about the essential role McKesson plays in \nthe fight against the COVID -19 pandemic, and the need to partner closely with manufacturers, and various \ngove rnment entities, so that we can react quickly, as demand patterns shift with the spread of the COVID -19 \nvirus.  One such area that has evolved is the demand for personal protective equipment or PPE, as frontline \nworkers and our customers work to help treat and keep patients safe.  We've worked with supplier partners \nfederal, state and local governments to get higher volumes of PPEs to areas of critical needs.  \n \n Our partnership with Walmart to produce and deliver medical gowns in the US has continued to increas e total \ngown supply, with over 30 million gowns shipped to the US since April. ", "original_text": "In May, I talked about the essential role McKesson plays in \nthe fight against the COVID -19 pandemic, and the need to partner closely with manufacturers, and various \ngove rnment entities, so that we can react quickly, as demand patterns shift with the spread of the COVID -19 \nvirus. ", "page_label": "4", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "71518e0c-2d29-463a-b5e5-d10bfe32ed2b", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4752fa50e2ceffd2079270047593412cd4cd1d2f8675eb305d4d5f0fc830f792", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d7517ab3-caf6-4db4-8e1e-504d24e0a7c6", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nand safety of our teams, so that we could continue to meet the needs of our customers and keep the healthcare \nsupply chain operating at a high level.  \n \n We've committed to increase safety measures for our employ ees and have maintained an unwavering \ncommitment to our customers and our communities.  In May, I talked about the essential role McKesson plays in \nthe fight against the COVID -19 pandemic, and the need to partner closely with manufacturers, and various \ngove rnment entities, so that we can react quickly, as demand patterns shift with the spread of the COVID -19 \nvirus.  One such area that has evolved is the demand for personal protective equipment or PPE, as frontline \nworkers and our customers work to help treat and keep patients safe.  We've worked with supplier partners \nfederal, state and local governments to get higher volumes of PPEs to areas of critical needs.  \n \n", "original_text": "We've committed to increase safety measures for our employ ees and have maintained an unwavering \ncommitment to our customers and our communities. ", "page_label": "4", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5d4a46d307a9ccfeb53d1291cc7fa90a7d55823bb4cd853b07aaedb36095c267", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "25110e47-2faa-422b-ae0e-5888ebd5fa92", "node_type": "1", "metadata": {"window": "(MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nand safety of our teams, so that we could continue to meet the needs of our customers and keep the healthcare \nsupply chain operating at a high level.  \n \n We've committed to increase safety measures for our employ ees and have maintained an unwavering \ncommitment to our customers and our communities.  In May, I talked about the essential role McKesson plays in \nthe fight against the COVID -19 pandemic, and the need to partner closely with manufacturers, and various \ngove rnment entities, so that we can react quickly, as demand patterns shift with the spread of the COVID -19 \nvirus.  One such area that has evolved is the demand for personal protective equipment or PPE, as frontline \nworkers and our customers work to help treat and keep patients safe.  We've worked with supplier partners \nfederal, state and local governments to get higher volumes of PPEs to areas of critical needs.  \n \n Our partnership with Walmart to produce and deliver medical gowns in the US has continued to increas e total \ngown supply, with over 30 million gowns shipped to the US since April.  We're also continuing to invest in our \ncommunities. ", "original_text": "One such area that has evolved is the demand for personal protective equipment or PPE, as frontline \nworkers and our customers work to help treat and keep patients safe. "}, "hash": "3405ea5f468c9e98ec8ac477935f4121758d3889bdfaedfcd31ca6762266433a", "class_name": "RelatedNodeInfo"}}, "text": "In May, I talked about the essential role McKesson plays in \nthe fight against the COVID -19 pandemic, and the need to partner closely with manufacturers, and various \ngove rnment entities, so that we can react quickly, as demand patterns shift with the spread of the COVID -19 \nvirus. ", "start_char_idx": 482, "end_char_idx": 768, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "25110e47-2faa-422b-ae0e-5888ebd5fa92": {"__data__": {"id_": "25110e47-2faa-422b-ae0e-5888ebd5fa92", "embedding": null, "metadata": {"window": "(MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nand safety of our teams, so that we could continue to meet the needs of our customers and keep the healthcare \nsupply chain operating at a high level.  \n \n We've committed to increase safety measures for our employ ees and have maintained an unwavering \ncommitment to our customers and our communities.  In May, I talked about the essential role McKesson plays in \nthe fight against the COVID -19 pandemic, and the need to partner closely with manufacturers, and various \ngove rnment entities, so that we can react quickly, as demand patterns shift with the spread of the COVID -19 \nvirus.  One such area that has evolved is the demand for personal protective equipment or PPE, as frontline \nworkers and our customers work to help treat and keep patients safe.  We've worked with supplier partners \nfederal, state and local governments to get higher volumes of PPEs to areas of critical needs.  \n \n Our partnership with Walmart to produce and deliver medical gowns in the US has continued to increas e total \ngown supply, with over 30 million gowns shipped to the US since April.  We're also continuing to invest in our \ncommunities. ", "original_text": "One such area that has evolved is the demand for personal protective equipment or PPE, as frontline \nworkers and our customers work to help treat and keep patients safe. ", "page_label": "4", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "71518e0c-2d29-463a-b5e5-d10bfe32ed2b", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4752fa50e2ceffd2079270047593412cd4cd1d2f8675eb305d4d5f0fc830f792", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "12504bf6-aafb-4fa7-93e3-966dba64d316", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nand safety of our teams, so that we could continue to meet the needs of our customers and keep the healthcare \nsupply chain operating at a high level.  \n \n We've committed to increase safety measures for our employ ees and have maintained an unwavering \ncommitment to our customers and our communities.  In May, I talked about the essential role McKesson plays in \nthe fight against the COVID -19 pandemic, and the need to partner closely with manufacturers, and various \ngove rnment entities, so that we can react quickly, as demand patterns shift with the spread of the COVID -19 \nvirus.  One such area that has evolved is the demand for personal protective equipment or PPE, as frontline \nworkers and our customers work to help treat and keep patients safe.  We've worked with supplier partners \nfederal, state and local governments to get higher volumes of PPEs to areas of critical needs.  \n \n Our partnership with Walmart to produce and deliver medical gowns in the US has continued to increas e total \ngown supply, with over 30 million gowns shipped to the US since April. ", "original_text": "In May, I talked about the essential role McKesson plays in \nthe fight against the COVID -19 pandemic, and the need to partner closely with manufacturers, and various \ngove rnment entities, so that we can react quickly, as demand patterns shift with the spread of the COVID -19 \nvirus. ", "page_label": "4", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5755af480072a48bbb00e30a550f7e8ac916574af91919ade9604a35177c78ef", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "20427e21-e8b7-4318-9979-acee71ab560c", "node_type": "1", "metadata": {"window": "We've committed to increase safety measures for our employ ees and have maintained an unwavering \ncommitment to our customers and our communities.  In May, I talked about the essential role McKesson plays in \nthe fight against the COVID -19 pandemic, and the need to partner closely with manufacturers, and various \ngove rnment entities, so that we can react quickly, as demand patterns shift with the spread of the COVID -19 \nvirus.  One such area that has evolved is the demand for personal protective equipment or PPE, as frontline \nworkers and our customers work to help treat and keep patients safe.  We've worked with supplier partners \nfederal, state and local governments to get higher volumes of PPEs to areas of critical needs.  \n \n Our partnership with Walmart to produce and deliver medical gowns in the US has continued to increas e total \ngown supply, with over 30 million gowns shipped to the US since April.  We're also continuing to invest in our \ncommunities.  Our foundation made contributions to over a dozen food banks in some of the nation's most \nvulnerable areas. ", "original_text": "We've worked with supplier partners \nfederal, state and local governments to get higher volumes of PPEs to areas of critical needs.  \n \n"}, "hash": "c45350d5bb7092c7f9ffa4346dc0595f849617f5df481a55aa1d6e454b7191e5", "class_name": "RelatedNodeInfo"}}, "text": "One such area that has evolved is the demand for personal protective equipment or PPE, as frontline \nworkers and our customers work to help treat and keep patients safe. ", "start_char_idx": 768, "end_char_idx": 938, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "20427e21-e8b7-4318-9979-acee71ab560c": {"__data__": {"id_": "20427e21-e8b7-4318-9979-acee71ab560c", "embedding": null, "metadata": {"window": "We've committed to increase safety measures for our employ ees and have maintained an unwavering \ncommitment to our customers and our communities.  In May, I talked about the essential role McKesson plays in \nthe fight against the COVID -19 pandemic, and the need to partner closely with manufacturers, and various \ngove rnment entities, so that we can react quickly, as demand patterns shift with the spread of the COVID -19 \nvirus.  One such area that has evolved is the demand for personal protective equipment or PPE, as frontline \nworkers and our customers work to help treat and keep patients safe.  We've worked with supplier partners \nfederal, state and local governments to get higher volumes of PPEs to areas of critical needs.  \n \n Our partnership with Walmart to produce and deliver medical gowns in the US has continued to increas e total \ngown supply, with over 30 million gowns shipped to the US since April.  We're also continuing to invest in our \ncommunities.  Our foundation made contributions to over a dozen food banks in some of the nation's most \nvulnerable areas. ", "original_text": "We've worked with supplier partners \nfederal, state and local governments to get higher volumes of PPEs to areas of critical needs.  \n \n", "page_label": "4", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "71518e0c-2d29-463a-b5e5-d10bfe32ed2b", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4752fa50e2ceffd2079270047593412cd4cd1d2f8675eb305d4d5f0fc830f792", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "25110e47-2faa-422b-ae0e-5888ebd5fa92", "node_type": "1", "metadata": {"window": "(MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nand safety of our teams, so that we could continue to meet the needs of our customers and keep the healthcare \nsupply chain operating at a high level.  \n \n We've committed to increase safety measures for our employ ees and have maintained an unwavering \ncommitment to our customers and our communities.  In May, I talked about the essential role McKesson plays in \nthe fight against the COVID -19 pandemic, and the need to partner closely with manufacturers, and various \ngove rnment entities, so that we can react quickly, as demand patterns shift with the spread of the COVID -19 \nvirus.  One such area that has evolved is the demand for personal protective equipment or PPE, as frontline \nworkers and our customers work to help treat and keep patients safe.  We've worked with supplier partners \nfederal, state and local governments to get higher volumes of PPEs to areas of critical needs.  \n \n Our partnership with Walmart to produce and deliver medical gowns in the US has continued to increas e total \ngown supply, with over 30 million gowns shipped to the US since April.  We're also continuing to invest in our \ncommunities. ", "original_text": "One such area that has evolved is the demand for personal protective equipment or PPE, as frontline \nworkers and our customers work to help treat and keep patients safe. ", "page_label": "4", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8ce499c3b79057a89f33b795c6d04fb2c3dcf7d51fa2f6cf42bfce4e48591466", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7a209eb1-80a7-4ee5-a946-b91d2c01a99f", "node_type": "1", "metadata": {"window": "In May, I talked about the essential role McKesson plays in \nthe fight against the COVID -19 pandemic, and the need to partner closely with manufacturers, and various \ngove rnment entities, so that we can react quickly, as demand patterns shift with the spread of the COVID -19 \nvirus.  One such area that has evolved is the demand for personal protective equipment or PPE, as frontline \nworkers and our customers work to help treat and keep patients safe.  We've worked with supplier partners \nfederal, state and local governments to get higher volumes of PPEs to areas of critical needs.  \n \n Our partnership with Walmart to produce and deliver medical gowns in the US has continued to increas e total \ngown supply, with over 30 million gowns shipped to the US since April.  We're also continuing to invest in our \ncommunities.  Our foundation made contributions to over a dozen food banks in some of the nation's most \nvulnerable areas.  These investments  translate into more than 6 million meals for individuals who would otherwise \ngo hungry.  \n \n", "original_text": "Our partnership with Walmart to produce and deliver medical gowns in the US has continued to increas e total \ngown supply, with over 30 million gowns shipped to the US since April. "}, "hash": "5497e8a6140970bc9a2a8c5452b62f2875a2f8950334d14ec67f56533f764edc", "class_name": "RelatedNodeInfo"}}, "text": "We've worked with supplier partners \nfederal, state and local governments to get higher volumes of PPEs to areas of critical needs.  \n \n", "start_char_idx": 938, "end_char_idx": 1074, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7a209eb1-80a7-4ee5-a946-b91d2c01a99f": {"__data__": {"id_": "7a209eb1-80a7-4ee5-a946-b91d2c01a99f", "embedding": null, "metadata": {"window": "In May, I talked about the essential role McKesson plays in \nthe fight against the COVID -19 pandemic, and the need to partner closely with manufacturers, and various \ngove rnment entities, so that we can react quickly, as demand patterns shift with the spread of the COVID -19 \nvirus.  One such area that has evolved is the demand for personal protective equipment or PPE, as frontline \nworkers and our customers work to help treat and keep patients safe.  We've worked with supplier partners \nfederal, state and local governments to get higher volumes of PPEs to areas of critical needs.  \n \n Our partnership with Walmart to produce and deliver medical gowns in the US has continued to increas e total \ngown supply, with over 30 million gowns shipped to the US since April.  We're also continuing to invest in our \ncommunities.  Our foundation made contributions to over a dozen food banks in some of the nation's most \nvulnerable areas.  These investments  translate into more than 6 million meals for individuals who would otherwise \ngo hungry.  \n \n", "original_text": "Our partnership with Walmart to produce and deliver medical gowns in the US has continued to increas e total \ngown supply, with over 30 million gowns shipped to the US since April. ", "page_label": "4", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "71518e0c-2d29-463a-b5e5-d10bfe32ed2b", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4752fa50e2ceffd2079270047593412cd4cd1d2f8675eb305d4d5f0fc830f792", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "20427e21-e8b7-4318-9979-acee71ab560c", "node_type": "1", "metadata": {"window": "We've committed to increase safety measures for our employ ees and have maintained an unwavering \ncommitment to our customers and our communities.  In May, I talked about the essential role McKesson plays in \nthe fight against the COVID -19 pandemic, and the need to partner closely with manufacturers, and various \ngove rnment entities, so that we can react quickly, as demand patterns shift with the spread of the COVID -19 \nvirus.  One such area that has evolved is the demand for personal protective equipment or PPE, as frontline \nworkers and our customers work to help treat and keep patients safe.  We've worked with supplier partners \nfederal, state and local governments to get higher volumes of PPEs to areas of critical needs.  \n \n Our partnership with Walmart to produce and deliver medical gowns in the US has continued to increas e total \ngown supply, with over 30 million gowns shipped to the US since April.  We're also continuing to invest in our \ncommunities.  Our foundation made contributions to over a dozen food banks in some of the nation's most \nvulnerable areas. ", "original_text": "We've worked with supplier partners \nfederal, state and local governments to get higher volumes of PPEs to areas of critical needs.  \n \n", "page_label": "4", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cc54da3d37a496c7e89a3656e8807eefe2bd135182643fe6f6413f388a561073", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c0d16077-0a6b-411c-8b3f-34d963098e8b", "node_type": "1", "metadata": {"window": "One such area that has evolved is the demand for personal protective equipment or PPE, as frontline \nworkers and our customers work to help treat and keep patients safe.  We've worked with supplier partners \nfederal, state and local governments to get higher volumes of PPEs to areas of critical needs.  \n \n Our partnership with Walmart to produce and deliver medical gowns in the US has continued to increas e total \ngown supply, with over 30 million gowns shipped to the US since April.  We're also continuing to invest in our \ncommunities.  Our foundation made contributions to over a dozen food banks in some of the nation's most \nvulnerable areas.  These investments  translate into more than 6 million meals for individuals who would otherwise \ngo hungry.  \n \n Before I expand on our first quarter results, I want to provide just a brief update on the macro environment and the \ntrends we've seen over the past 75 days since we reported our fourth quarter fiscal 2020 results and issued our \nfiscal 2021 outlook.  \n \n", "original_text": "We're also continuing to invest in our \ncommunities. "}, "hash": "c4642c03198537a578e608f9083f67eae97d6500296c2287249a3d054e9d3295", "class_name": "RelatedNodeInfo"}}, "text": "Our partnership with Walmart to produce and deliver medical gowns in the US has continued to increas e total \ngown supply, with over 30 million gowns shipped to the US since April. ", "start_char_idx": 1074, "end_char_idx": 1255, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c0d16077-0a6b-411c-8b3f-34d963098e8b": {"__data__": {"id_": "c0d16077-0a6b-411c-8b3f-34d963098e8b", "embedding": null, "metadata": {"window": "One such area that has evolved is the demand for personal protective equipment or PPE, as frontline \nworkers and our customers work to help treat and keep patients safe.  We've worked with supplier partners \nfederal, state and local governments to get higher volumes of PPEs to areas of critical needs.  \n \n Our partnership with Walmart to produce and deliver medical gowns in the US has continued to increas e total \ngown supply, with over 30 million gowns shipped to the US since April.  We're also continuing to invest in our \ncommunities.  Our foundation made contributions to over a dozen food banks in some of the nation's most \nvulnerable areas.  These investments  translate into more than 6 million meals for individuals who would otherwise \ngo hungry.  \n \n Before I expand on our first quarter results, I want to provide just a brief update on the macro environment and the \ntrends we've seen over the past 75 days since we reported our fourth quarter fiscal 2020 results and issued our \nfiscal 2021 outlook.  \n \n", "original_text": "We're also continuing to invest in our \ncommunities. ", "page_label": "4", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "71518e0c-2d29-463a-b5e5-d10bfe32ed2b", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4752fa50e2ceffd2079270047593412cd4cd1d2f8675eb305d4d5f0fc830f792", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7a209eb1-80a7-4ee5-a946-b91d2c01a99f", "node_type": "1", "metadata": {"window": "In May, I talked about the essential role McKesson plays in \nthe fight against the COVID -19 pandemic, and the need to partner closely with manufacturers, and various \ngove rnment entities, so that we can react quickly, as demand patterns shift with the spread of the COVID -19 \nvirus.  One such area that has evolved is the demand for personal protective equipment or PPE, as frontline \nworkers and our customers work to help treat and keep patients safe.  We've worked with supplier partners \nfederal, state and local governments to get higher volumes of PPEs to areas of critical needs.  \n \n Our partnership with Walmart to produce and deliver medical gowns in the US has continued to increas e total \ngown supply, with over 30 million gowns shipped to the US since April.  We're also continuing to invest in our \ncommunities.  Our foundation made contributions to over a dozen food banks in some of the nation's most \nvulnerable areas.  These investments  translate into more than 6 million meals for individuals who would otherwise \ngo hungry.  \n \n", "original_text": "Our partnership with Walmart to produce and deliver medical gowns in the US has continued to increas e total \ngown supply, with over 30 million gowns shipped to the US since April. ", "page_label": "4", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "68c7bfb63d6463c7520d64a1b327ed53d42239a77297c4c024ad9640c013a8d6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "05c6a7f3-7746-4bea-8cc2-97d26f072ad8", "node_type": "1", "metadata": {"window": "We've worked with supplier partners \nfederal, state and local governments to get higher volumes of PPEs to areas of critical needs.  \n \n Our partnership with Walmart to produce and deliver medical gowns in the US has continued to increas e total \ngown supply, with over 30 million gowns shipped to the US since April.  We're also continuing to invest in our \ncommunities.  Our foundation made contributions to over a dozen food banks in some of the nation's most \nvulnerable areas.  These investments  translate into more than 6 million meals for individuals who would otherwise \ngo hungry.  \n \n Before I expand on our first quarter results, I want to provide just a brief update on the macro environment and the \ntrends we've seen over the past 75 days since we reported our fourth quarter fiscal 2020 results and issued our \nfiscal 2021 outlook.  \n \n COVID -19 has continued to progress and persist here in the US in ways we couldn't have predicted when we \ninitially provided our outlook for fiscal 2021. ", "original_text": "Our foundation made contributions to over a dozen food banks in some of the nation's most \nvulnerable areas. "}, "hash": "94e872c08177e6d7b4c2f970083d3ae86366d14af1e78bc5d0106cd18251ce82", "class_name": "RelatedNodeInfo"}}, "text": "We're also continuing to invest in our \ncommunities. ", "start_char_idx": 1255, "end_char_idx": 1308, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "05c6a7f3-7746-4bea-8cc2-97d26f072ad8": {"__data__": {"id_": "05c6a7f3-7746-4bea-8cc2-97d26f072ad8", "embedding": null, "metadata": {"window": "We've worked with supplier partners \nfederal, state and local governments to get higher volumes of PPEs to areas of critical needs.  \n \n Our partnership with Walmart to produce and deliver medical gowns in the US has continued to increas e total \ngown supply, with over 30 million gowns shipped to the US since April.  We're also continuing to invest in our \ncommunities.  Our foundation made contributions to over a dozen food banks in some of the nation's most \nvulnerable areas.  These investments  translate into more than 6 million meals for individuals who would otherwise \ngo hungry.  \n \n Before I expand on our first quarter results, I want to provide just a brief update on the macro environment and the \ntrends we've seen over the past 75 days since we reported our fourth quarter fiscal 2020 results and issued our \nfiscal 2021 outlook.  \n \n COVID -19 has continued to progress and persist here in the US in ways we couldn't have predicted when we \ninitially provided our outlook for fiscal 2021. ", "original_text": "Our foundation made contributions to over a dozen food banks in some of the nation's most \nvulnerable areas. ", "page_label": "4", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "71518e0c-2d29-463a-b5e5-d10bfe32ed2b", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4752fa50e2ceffd2079270047593412cd4cd1d2f8675eb305d4d5f0fc830f792", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c0d16077-0a6b-411c-8b3f-34d963098e8b", "node_type": "1", "metadata": {"window": "One such area that has evolved is the demand for personal protective equipment or PPE, as frontline \nworkers and our customers work to help treat and keep patients safe.  We've worked with supplier partners \nfederal, state and local governments to get higher volumes of PPEs to areas of critical needs.  \n \n Our partnership with Walmart to produce and deliver medical gowns in the US has continued to increas e total \ngown supply, with over 30 million gowns shipped to the US since April.  We're also continuing to invest in our \ncommunities.  Our foundation made contributions to over a dozen food banks in some of the nation's most \nvulnerable areas.  These investments  translate into more than 6 million meals for individuals who would otherwise \ngo hungry.  \n \n Before I expand on our first quarter results, I want to provide just a brief update on the macro environment and the \ntrends we've seen over the past 75 days since we reported our fourth quarter fiscal 2020 results and issued our \nfiscal 2021 outlook.  \n \n", "original_text": "We're also continuing to invest in our \ncommunities. ", "page_label": "4", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6942716b57d9d178a643dd14f4ae7489e1552f3b6b0c11b405f8ed9fd740bcfc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "521942cb-63f7-4c8f-8226-027b01ef79fc", "node_type": "1", "metadata": {"window": "Our partnership with Walmart to produce and deliver medical gowns in the US has continued to increas e total \ngown supply, with over 30 million gowns shipped to the US since April.  We're also continuing to invest in our \ncommunities.  Our foundation made contributions to over a dozen food banks in some of the nation's most \nvulnerable areas.  These investments  translate into more than 6 million meals for individuals who would otherwise \ngo hungry.  \n \n Before I expand on our first quarter results, I want to provide just a brief update on the macro environment and the \ntrends we've seen over the past 75 days since we reported our fourth quarter fiscal 2020 results and issued our \nfiscal 2021 outlook.  \n \n COVID -19 has continued to progress and persist here in the US in ways we couldn't have predicted when we \ninitially provided our outlook for fiscal 2021.  Several states, in cluding Texas, where I am today, are experiencing \nsignificantly higher numbers of cases, while others -- other parts of the country and frankly, the world are in very \ndifferent and various forms of recovery. ", "original_text": "These investments  translate into more than 6 million meals for individuals who would otherwise \ngo hungry.  \n \n"}, "hash": "e9e03f585a6f9e71c8fe3eed7c315cd42b9a1b91c7ce959736dca9fb614e0340", "class_name": "RelatedNodeInfo"}}, "text": "Our foundation made contributions to over a dozen food banks in some of the nation's most \nvulnerable areas. ", "start_char_idx": 1308, "end_char_idx": 1417, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "521942cb-63f7-4c8f-8226-027b01ef79fc": {"__data__": {"id_": "521942cb-63f7-4c8f-8226-027b01ef79fc", "embedding": null, "metadata": {"window": "Our partnership with Walmart to produce and deliver medical gowns in the US has continued to increas e total \ngown supply, with over 30 million gowns shipped to the US since April.  We're also continuing to invest in our \ncommunities.  Our foundation made contributions to over a dozen food banks in some of the nation's most \nvulnerable areas.  These investments  translate into more than 6 million meals for individuals who would otherwise \ngo hungry.  \n \n Before I expand on our first quarter results, I want to provide just a brief update on the macro environment and the \ntrends we've seen over the past 75 days since we reported our fourth quarter fiscal 2020 results and issued our \nfiscal 2021 outlook.  \n \n COVID -19 has continued to progress and persist here in the US in ways we couldn't have predicted when we \ninitially provided our outlook for fiscal 2021.  Several states, in cluding Texas, where I am today, are experiencing \nsignificantly higher numbers of cases, while others -- other parts of the country and frankly, the world are in very \ndifferent and various forms of recovery. ", "original_text": "These investments  translate into more than 6 million meals for individuals who would otherwise \ngo hungry.  \n \n", "page_label": "4", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "71518e0c-2d29-463a-b5e5-d10bfe32ed2b", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4752fa50e2ceffd2079270047593412cd4cd1d2f8675eb305d4d5f0fc830f792", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "05c6a7f3-7746-4bea-8cc2-97d26f072ad8", "node_type": "1", "metadata": {"window": "We've worked with supplier partners \nfederal, state and local governments to get higher volumes of PPEs to areas of critical needs.  \n \n Our partnership with Walmart to produce and deliver medical gowns in the US has continued to increas e total \ngown supply, with over 30 million gowns shipped to the US since April.  We're also continuing to invest in our \ncommunities.  Our foundation made contributions to over a dozen food banks in some of the nation's most \nvulnerable areas.  These investments  translate into more than 6 million meals for individuals who would otherwise \ngo hungry.  \n \n Before I expand on our first quarter results, I want to provide just a brief update on the macro environment and the \ntrends we've seen over the past 75 days since we reported our fourth quarter fiscal 2020 results and issued our \nfiscal 2021 outlook.  \n \n COVID -19 has continued to progress and persist here in the US in ways we couldn't have predicted when we \ninitially provided our outlook for fiscal 2021. ", "original_text": "Our foundation made contributions to over a dozen food banks in some of the nation's most \nvulnerable areas. ", "page_label": "4", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ee1c09f030969fdfa17bb107ff47f44d4290ddfe20482f22cb7a1e94ef6319c6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f8a3d68c-12cf-4f47-990f-841dbaea1d83", "node_type": "1", "metadata": {"window": "We're also continuing to invest in our \ncommunities.  Our foundation made contributions to over a dozen food banks in some of the nation's most \nvulnerable areas.  These investments  translate into more than 6 million meals for individuals who would otherwise \ngo hungry.  \n \n Before I expand on our first quarter results, I want to provide just a brief update on the macro environment and the \ntrends we've seen over the past 75 days since we reported our fourth quarter fiscal 2020 results and issued our \nfiscal 2021 outlook.  \n \n COVID -19 has continued to progress and persist here in the US in ways we couldn't have predicted when we \ninitially provided our outlook for fiscal 2021.  Several states, in cluding Texas, where I am today, are experiencing \nsignificantly higher numbers of cases, while others -- other parts of the country and frankly, the world are in very \ndifferent and various forms of recovery.  This variability makes predicting an aggregate t imeline for the recovery \nchallenging.  \n \n", "original_text": "Before I expand on our first quarter results, I want to provide just a brief update on the macro environment and the \ntrends we've seen over the past 75 days since we reported our fourth quarter fiscal 2020 results and issued our \nfiscal 2021 outlook.  \n \n"}, "hash": "8f98cf591a1384f5ac9786412b25771c36db8c8ccffcadf8cb4e959a53428ad2", "class_name": "RelatedNodeInfo"}}, "text": "These investments  translate into more than 6 million meals for individuals who would otherwise \ngo hungry.  \n \n", "start_char_idx": 1417, "end_char_idx": 1529, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f8a3d68c-12cf-4f47-990f-841dbaea1d83": {"__data__": {"id_": "f8a3d68c-12cf-4f47-990f-841dbaea1d83", "embedding": null, "metadata": {"window": "We're also continuing to invest in our \ncommunities.  Our foundation made contributions to over a dozen food banks in some of the nation's most \nvulnerable areas.  These investments  translate into more than 6 million meals for individuals who would otherwise \ngo hungry.  \n \n Before I expand on our first quarter results, I want to provide just a brief update on the macro environment and the \ntrends we've seen over the past 75 days since we reported our fourth quarter fiscal 2020 results and issued our \nfiscal 2021 outlook.  \n \n COVID -19 has continued to progress and persist here in the US in ways we couldn't have predicted when we \ninitially provided our outlook for fiscal 2021.  Several states, in cluding Texas, where I am today, are experiencing \nsignificantly higher numbers of cases, while others -- other parts of the country and frankly, the world are in very \ndifferent and various forms of recovery.  This variability makes predicting an aggregate t imeline for the recovery \nchallenging.  \n \n", "original_text": "Before I expand on our first quarter results, I want to provide just a brief update on the macro environment and the \ntrends we've seen over the past 75 days since we reported our fourth quarter fiscal 2020 results and issued our \nfiscal 2021 outlook.  \n \n", "page_label": "4", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "71518e0c-2d29-463a-b5e5-d10bfe32ed2b", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4752fa50e2ceffd2079270047593412cd4cd1d2f8675eb305d4d5f0fc830f792", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "521942cb-63f7-4c8f-8226-027b01ef79fc", "node_type": "1", "metadata": {"window": "Our partnership with Walmart to produce and deliver medical gowns in the US has continued to increas e total \ngown supply, with over 30 million gowns shipped to the US since April.  We're also continuing to invest in our \ncommunities.  Our foundation made contributions to over a dozen food banks in some of the nation's most \nvulnerable areas.  These investments  translate into more than 6 million meals for individuals who would otherwise \ngo hungry.  \n \n Before I expand on our first quarter results, I want to provide just a brief update on the macro environment and the \ntrends we've seen over the past 75 days since we reported our fourth quarter fiscal 2020 results and issued our \nfiscal 2021 outlook.  \n \n COVID -19 has continued to progress and persist here in the US in ways we couldn't have predicted when we \ninitially provided our outlook for fiscal 2021.  Several states, in cluding Texas, where I am today, are experiencing \nsignificantly higher numbers of cases, while others -- other parts of the country and frankly, the world are in very \ndifferent and various forms of recovery. ", "original_text": "These investments  translate into more than 6 million meals for individuals who would otherwise \ngo hungry.  \n \n", "page_label": "4", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "797573ef3825c10cb20fab812ef027d3bf3b4c34ba7a0343cd1ce94b804eab6d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4d1c5230-8fe1-4cd2-b394-d979f48504ec", "node_type": "1", "metadata": {"window": "Our foundation made contributions to over a dozen food banks in some of the nation's most \nvulnerable areas.  These investments  translate into more than 6 million meals for individuals who would otherwise \ngo hungry.  \n \n Before I expand on our first quarter results, I want to provide just a brief update on the macro environment and the \ntrends we've seen over the past 75 days since we reported our fourth quarter fiscal 2020 results and issued our \nfiscal 2021 outlook.  \n \n COVID -19 has continued to progress and persist here in the US in ways we couldn't have predicted when we \ninitially provided our outlook for fiscal 2021.  Several states, in cluding Texas, where I am today, are experiencing \nsignificantly higher numbers of cases, while others -- other parts of the country and frankly, the world are in very \ndifferent and various forms of recovery.  This variability makes predicting an aggregate t imeline for the recovery \nchallenging.  \n \n As we detailed on our fourth quarter call, we expected the most severe impacts to our business in the fiscal first \nquarter. ", "original_text": "COVID -19 has continued to progress and persist here in the US in ways we couldn't have predicted when we \ninitially provided our outlook for fiscal 2021. "}, "hash": "b0f030c6d5c77495f83c3244972580fdd239ddc67011cff53fce33240fa3c7e6", "class_name": "RelatedNodeInfo"}}, "text": "Before I expand on our first quarter results, I want to provide just a brief update on the macro environment and the \ntrends we've seen over the past 75 days since we reported our fourth quarter fiscal 2020 results and issued our \nfiscal 2021 outlook.  \n \n", "start_char_idx": 1529, "end_char_idx": 1785, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4d1c5230-8fe1-4cd2-b394-d979f48504ec": {"__data__": {"id_": "4d1c5230-8fe1-4cd2-b394-d979f48504ec", "embedding": null, "metadata": {"window": "Our foundation made contributions to over a dozen food banks in some of the nation's most \nvulnerable areas.  These investments  translate into more than 6 million meals for individuals who would otherwise \ngo hungry.  \n \n Before I expand on our first quarter results, I want to provide just a brief update on the macro environment and the \ntrends we've seen over the past 75 days since we reported our fourth quarter fiscal 2020 results and issued our \nfiscal 2021 outlook.  \n \n COVID -19 has continued to progress and persist here in the US in ways we couldn't have predicted when we \ninitially provided our outlook for fiscal 2021.  Several states, in cluding Texas, where I am today, are experiencing \nsignificantly higher numbers of cases, while others -- other parts of the country and frankly, the world are in very \ndifferent and various forms of recovery.  This variability makes predicting an aggregate t imeline for the recovery \nchallenging.  \n \n As we detailed on our fourth quarter call, we expected the most severe impacts to our business in the fiscal first \nquarter. ", "original_text": "COVID -19 has continued to progress and persist here in the US in ways we couldn't have predicted when we \ninitially provided our outlook for fiscal 2021. ", "page_label": "4", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "71518e0c-2d29-463a-b5e5-d10bfe32ed2b", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4752fa50e2ceffd2079270047593412cd4cd1d2f8675eb305d4d5f0fc830f792", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f8a3d68c-12cf-4f47-990f-841dbaea1d83", "node_type": "1", "metadata": {"window": "We're also continuing to invest in our \ncommunities.  Our foundation made contributions to over a dozen food banks in some of the nation's most \nvulnerable areas.  These investments  translate into more than 6 million meals for individuals who would otherwise \ngo hungry.  \n \n Before I expand on our first quarter results, I want to provide just a brief update on the macro environment and the \ntrends we've seen over the past 75 days since we reported our fourth quarter fiscal 2020 results and issued our \nfiscal 2021 outlook.  \n \n COVID -19 has continued to progress and persist here in the US in ways we couldn't have predicted when we \ninitially provided our outlook for fiscal 2021.  Several states, in cluding Texas, where I am today, are experiencing \nsignificantly higher numbers of cases, while others -- other parts of the country and frankly, the world are in very \ndifferent and various forms of recovery.  This variability makes predicting an aggregate t imeline for the recovery \nchallenging.  \n \n", "original_text": "Before I expand on our first quarter results, I want to provide just a brief update on the macro environment and the \ntrends we've seen over the past 75 days since we reported our fourth quarter fiscal 2020 results and issued our \nfiscal 2021 outlook.  \n \n", "page_label": "4", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9cfed4c011a20dd11282ebd31a18956809f38e1d7f0845170d51c3f582052289", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ff27085f-67d2-45d7-a907-5b528fb99963", "node_type": "1", "metadata": {"window": "These investments  translate into more than 6 million meals for individuals who would otherwise \ngo hungry.  \n \n Before I expand on our first quarter results, I want to provide just a brief update on the macro environment and the \ntrends we've seen over the past 75 days since we reported our fourth quarter fiscal 2020 results and issued our \nfiscal 2021 outlook.  \n \n COVID -19 has continued to progress and persist here in the US in ways we couldn't have predicted when we \ninitially provided our outlook for fiscal 2021.  Several states, in cluding Texas, where I am today, are experiencing \nsignificantly higher numbers of cases, while others -- other parts of the country and frankly, the world are in very \ndifferent and various forms of recovery.  This variability makes predicting an aggregate t imeline for the recovery \nchallenging.  \n \n As we detailed on our fourth quarter call, we expected the most severe impacts to our business in the fiscal first \nquarter.  And as a reminder, our original outlook assumed the pandemic would have the most material imp act on \nour businesses with physician and specialty provider and oncology exposure. ", "original_text": "Several states, in cluding Texas, where I am today, are experiencing \nsignificantly higher numbers of cases, while others -- other parts of the country and frankly, the world are in very \ndifferent and various forms of recovery. "}, "hash": "9d2e324380c8649eae17023811f33d77dd6971e040d8ee8d73a753ec4fafa8d9", "class_name": "RelatedNodeInfo"}}, "text": "COVID -19 has continued to progress and persist here in the US in ways we couldn't have predicted when we \ninitially provided our outlook for fiscal 2021. ", "start_char_idx": 1785, "end_char_idx": 1940, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ff27085f-67d2-45d7-a907-5b528fb99963": {"__data__": {"id_": "ff27085f-67d2-45d7-a907-5b528fb99963", "embedding": null, "metadata": {"window": "These investments  translate into more than 6 million meals for individuals who would otherwise \ngo hungry.  \n \n Before I expand on our first quarter results, I want to provide just a brief update on the macro environment and the \ntrends we've seen over the past 75 days since we reported our fourth quarter fiscal 2020 results and issued our \nfiscal 2021 outlook.  \n \n COVID -19 has continued to progress and persist here in the US in ways we couldn't have predicted when we \ninitially provided our outlook for fiscal 2021.  Several states, in cluding Texas, where I am today, are experiencing \nsignificantly higher numbers of cases, while others -- other parts of the country and frankly, the world are in very \ndifferent and various forms of recovery.  This variability makes predicting an aggregate t imeline for the recovery \nchallenging.  \n \n As we detailed on our fourth quarter call, we expected the most severe impacts to our business in the fiscal first \nquarter.  And as a reminder, our original outlook assumed the pandemic would have the most material imp act on \nour businesses with physician and specialty provider and oncology exposure. ", "original_text": "Several states, in cluding Texas, where I am today, are experiencing \nsignificantly higher numbers of cases, while others -- other parts of the country and frankly, the world are in very \ndifferent and various forms of recovery. ", "page_label": "4", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "71518e0c-2d29-463a-b5e5-d10bfe32ed2b", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4752fa50e2ceffd2079270047593412cd4cd1d2f8675eb305d4d5f0fc830f792", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4d1c5230-8fe1-4cd2-b394-d979f48504ec", "node_type": "1", "metadata": {"window": "Our foundation made contributions to over a dozen food banks in some of the nation's most \nvulnerable areas.  These investments  translate into more than 6 million meals for individuals who would otherwise \ngo hungry.  \n \n Before I expand on our first quarter results, I want to provide just a brief update on the macro environment and the \ntrends we've seen over the past 75 days since we reported our fourth quarter fiscal 2020 results and issued our \nfiscal 2021 outlook.  \n \n COVID -19 has continued to progress and persist here in the US in ways we couldn't have predicted when we \ninitially provided our outlook for fiscal 2021.  Several states, in cluding Texas, where I am today, are experiencing \nsignificantly higher numbers of cases, while others -- other parts of the country and frankly, the world are in very \ndifferent and various forms of recovery.  This variability makes predicting an aggregate t imeline for the recovery \nchallenging.  \n \n As we detailed on our fourth quarter call, we expected the most severe impacts to our business in the fiscal first \nquarter. ", "original_text": "COVID -19 has continued to progress and persist here in the US in ways we couldn't have predicted when we \ninitially provided our outlook for fiscal 2021. ", "page_label": "4", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a2b9c76490c694e8acd8c54d8fc2e327fde6c56a339c75d9d8e4144d54c8c135", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1e956443-ab78-4045-b807-555a8dcecc3a", "node_type": "1", "metadata": {"window": "Before I expand on our first quarter results, I want to provide just a brief update on the macro environment and the \ntrends we've seen over the past 75 days since we reported our fourth quarter fiscal 2020 results and issued our \nfiscal 2021 outlook.  \n \n COVID -19 has continued to progress and persist here in the US in ways we couldn't have predicted when we \ninitially provided our outlook for fiscal 2021.  Several states, in cluding Texas, where I am today, are experiencing \nsignificantly higher numbers of cases, while others -- other parts of the country and frankly, the world are in very \ndifferent and various forms of recovery.  This variability makes predicting an aggregate t imeline for the recovery \nchallenging.  \n \n As we detailed on our fourth quarter call, we expected the most severe impacts to our business in the fiscal first \nquarter.  And as a reminder, our original outlook assumed the pandemic would have the most material imp act on \nour businesses with physician and specialty provider and oncology exposure.  We expected a gradual stabilization \nbeginning in our fiscal second quarter and ramping over the remainder of the fiscal year as doctors offices reopen \nand patients return to  their treatments. ", "original_text": "This variability makes predicting an aggregate t imeline for the recovery \nchallenging.  \n \n"}, "hash": "275046296aca4ecb0e82a4a8d3e2a9ff16b6baaf4c1908f601b5b0a1ce759191", "class_name": "RelatedNodeInfo"}}, "text": "Several states, in cluding Texas, where I am today, are experiencing \nsignificantly higher numbers of cases, while others -- other parts of the country and frankly, the world are in very \ndifferent and various forms of recovery. ", "start_char_idx": 1940, "end_char_idx": 2169, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1e956443-ab78-4045-b807-555a8dcecc3a": {"__data__": {"id_": "1e956443-ab78-4045-b807-555a8dcecc3a", "embedding": null, "metadata": {"window": "Before I expand on our first quarter results, I want to provide just a brief update on the macro environment and the \ntrends we've seen over the past 75 days since we reported our fourth quarter fiscal 2020 results and issued our \nfiscal 2021 outlook.  \n \n COVID -19 has continued to progress and persist here in the US in ways we couldn't have predicted when we \ninitially provided our outlook for fiscal 2021.  Several states, in cluding Texas, where I am today, are experiencing \nsignificantly higher numbers of cases, while others -- other parts of the country and frankly, the world are in very \ndifferent and various forms of recovery.  This variability makes predicting an aggregate t imeline for the recovery \nchallenging.  \n \n As we detailed on our fourth quarter call, we expected the most severe impacts to our business in the fiscal first \nquarter.  And as a reminder, our original outlook assumed the pandemic would have the most material imp act on \nour businesses with physician and specialty provider and oncology exposure.  We expected a gradual stabilization \nbeginning in our fiscal second quarter and ramping over the remainder of the fiscal year as doctors offices reopen \nand patients return to  their treatments. ", "original_text": "This variability makes predicting an aggregate t imeline for the recovery \nchallenging.  \n \n", "page_label": "4", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "71518e0c-2d29-463a-b5e5-d10bfe32ed2b", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4752fa50e2ceffd2079270047593412cd4cd1d2f8675eb305d4d5f0fc830f792", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ff27085f-67d2-45d7-a907-5b528fb99963", "node_type": "1", "metadata": {"window": "These investments  translate into more than 6 million meals for individuals who would otherwise \ngo hungry.  \n \n Before I expand on our first quarter results, I want to provide just a brief update on the macro environment and the \ntrends we've seen over the past 75 days since we reported our fourth quarter fiscal 2020 results and issued our \nfiscal 2021 outlook.  \n \n COVID -19 has continued to progress and persist here in the US in ways we couldn't have predicted when we \ninitially provided our outlook for fiscal 2021.  Several states, in cluding Texas, where I am today, are experiencing \nsignificantly higher numbers of cases, while others -- other parts of the country and frankly, the world are in very \ndifferent and various forms of recovery.  This variability makes predicting an aggregate t imeline for the recovery \nchallenging.  \n \n As we detailed on our fourth quarter call, we expected the most severe impacts to our business in the fiscal first \nquarter.  And as a reminder, our original outlook assumed the pandemic would have the most material imp act on \nour businesses with physician and specialty provider and oncology exposure. ", "original_text": "Several states, in cluding Texas, where I am today, are experiencing \nsignificantly higher numbers of cases, while others -- other parts of the country and frankly, the world are in very \ndifferent and various forms of recovery. ", "page_label": "4", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5e95ee07d28cc6f904cd2f89ec645e733b1cd32efe20377333cdd604d7d43e0a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c51da3aa-5e15-48ae-8f21-a7760feea768", "node_type": "1", "metadata": {"window": "COVID -19 has continued to progress and persist here in the US in ways we couldn't have predicted when we \ninitially provided our outlook for fiscal 2021.  Several states, in cluding Texas, where I am today, are experiencing \nsignificantly higher numbers of cases, while others -- other parts of the country and frankly, the world are in very \ndifferent and various forms of recovery.  This variability makes predicting an aggregate t imeline for the recovery \nchallenging.  \n \n As we detailed on our fourth quarter call, we expected the most severe impacts to our business in the fiscal first \nquarter.  And as a reminder, our original outlook assumed the pandemic would have the most material imp act on \nour businesses with physician and specialty provider and oncology exposure.  We expected a gradual stabilization \nbeginning in our fiscal second quarter and ramping over the remainder of the fiscal year as doctors offices reopen \nand patients return to  their treatments.  Through April and May, our results were largely in line with our original \nexpectations, with volumes across the enterprise materially down versus the prior year and well below pre -COVID \nlevels.  \n \n", "original_text": "As we detailed on our fourth quarter call, we expected the most severe impacts to our business in the fiscal first \nquarter. "}, "hash": "190f65e45e75cfd750eaf68ce60d17f9ba3e6933b55224d7b38800e6c6215470", "class_name": "RelatedNodeInfo"}}, "text": "This variability makes predicting an aggregate t imeline for the recovery \nchallenging.  \n \n", "start_char_idx": 2169, "end_char_idx": 2261, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c51da3aa-5e15-48ae-8f21-a7760feea768": {"__data__": {"id_": "c51da3aa-5e15-48ae-8f21-a7760feea768", "embedding": null, "metadata": {"window": "COVID -19 has continued to progress and persist here in the US in ways we couldn't have predicted when we \ninitially provided our outlook for fiscal 2021.  Several states, in cluding Texas, where I am today, are experiencing \nsignificantly higher numbers of cases, while others -- other parts of the country and frankly, the world are in very \ndifferent and various forms of recovery.  This variability makes predicting an aggregate t imeline for the recovery \nchallenging.  \n \n As we detailed on our fourth quarter call, we expected the most severe impacts to our business in the fiscal first \nquarter.  And as a reminder, our original outlook assumed the pandemic would have the most material imp act on \nour businesses with physician and specialty provider and oncology exposure.  We expected a gradual stabilization \nbeginning in our fiscal second quarter and ramping over the remainder of the fiscal year as doctors offices reopen \nand patients return to  their treatments.  Through April and May, our results were largely in line with our original \nexpectations, with volumes across the enterprise materially down versus the prior year and well below pre -COVID \nlevels.  \n \n", "original_text": "As we detailed on our fourth quarter call, we expected the most severe impacts to our business in the fiscal first \nquarter. ", "page_label": "4", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "71518e0c-2d29-463a-b5e5-d10bfe32ed2b", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4752fa50e2ceffd2079270047593412cd4cd1d2f8675eb305d4d5f0fc830f792", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1e956443-ab78-4045-b807-555a8dcecc3a", "node_type": "1", "metadata": {"window": "Before I expand on our first quarter results, I want to provide just a brief update on the macro environment and the \ntrends we've seen over the past 75 days since we reported our fourth quarter fiscal 2020 results and issued our \nfiscal 2021 outlook.  \n \n COVID -19 has continued to progress and persist here in the US in ways we couldn't have predicted when we \ninitially provided our outlook for fiscal 2021.  Several states, in cluding Texas, where I am today, are experiencing \nsignificantly higher numbers of cases, while others -- other parts of the country and frankly, the world are in very \ndifferent and various forms of recovery.  This variability makes predicting an aggregate t imeline for the recovery \nchallenging.  \n \n As we detailed on our fourth quarter call, we expected the most severe impacts to our business in the fiscal first \nquarter.  And as a reminder, our original outlook assumed the pandemic would have the most material imp act on \nour businesses with physician and specialty provider and oncology exposure.  We expected a gradual stabilization \nbeginning in our fiscal second quarter and ramping over the remainder of the fiscal year as doctors offices reopen \nand patients return to  their treatments. ", "original_text": "This variability makes predicting an aggregate t imeline for the recovery \nchallenging.  \n \n", "page_label": "4", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f4d163777dc727126541fa59e17612fea03e8a0e627d6fa0db44fc325ff19ef6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ebf04942-9036-44a5-9d6d-157c392b8e65", "node_type": "1", "metadata": {"window": "Several states, in cluding Texas, where I am today, are experiencing \nsignificantly higher numbers of cases, while others -- other parts of the country and frankly, the world are in very \ndifferent and various forms of recovery.  This variability makes predicting an aggregate t imeline for the recovery \nchallenging.  \n \n As we detailed on our fourth quarter call, we expected the most severe impacts to our business in the fiscal first \nquarter.  And as a reminder, our original outlook assumed the pandemic would have the most material imp act on \nour businesses with physician and specialty provider and oncology exposure.  We expected a gradual stabilization \nbeginning in our fiscal second quarter and ramping over the remainder of the fiscal year as doctors offices reopen \nand patients return to  their treatments.  Through April and May, our results were largely in line with our original \nexpectations, with volumes across the enterprise materially down versus the prior year and well below pre -COVID \nlevels.  \n \n What we experienced in June, however, was an earlier than expected pace of recovery, particularly in the last \nweeks of the quarter, resulting in demand acceleration and higher volumes versus our original expectations. \n", "original_text": "And as a reminder, our original outlook assumed the pandemic would have the most material imp act on \nour businesses with physician and specialty provider and oncology exposure. "}, "hash": "d732251949deddc95d51c947d912c5ebd395131ae816215c82c4f99937dcb045", "class_name": "RelatedNodeInfo"}}, "text": "As we detailed on our fourth quarter call, we expected the most severe impacts to our business in the fiscal first \nquarter. ", "start_char_idx": 2261, "end_char_idx": 2386, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ebf04942-9036-44a5-9d6d-157c392b8e65": {"__data__": {"id_": "ebf04942-9036-44a5-9d6d-157c392b8e65", "embedding": null, "metadata": {"window": "Several states, in cluding Texas, where I am today, are experiencing \nsignificantly higher numbers of cases, while others -- other parts of the country and frankly, the world are in very \ndifferent and various forms of recovery.  This variability makes predicting an aggregate t imeline for the recovery \nchallenging.  \n \n As we detailed on our fourth quarter call, we expected the most severe impacts to our business in the fiscal first \nquarter.  And as a reminder, our original outlook assumed the pandemic would have the most material imp act on \nour businesses with physician and specialty provider and oncology exposure.  We expected a gradual stabilization \nbeginning in our fiscal second quarter and ramping over the remainder of the fiscal year as doctors offices reopen \nand patients return to  their treatments.  Through April and May, our results were largely in line with our original \nexpectations, with volumes across the enterprise materially down versus the prior year and well below pre -COVID \nlevels.  \n \n What we experienced in June, however, was an earlier than expected pace of recovery, particularly in the last \nweeks of the quarter, resulting in demand acceleration and higher volumes versus our original expectations. \n", "original_text": "And as a reminder, our original outlook assumed the pandemic would have the most material imp act on \nour businesses with physician and specialty provider and oncology exposure. ", "page_label": "4", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "71518e0c-2d29-463a-b5e5-d10bfe32ed2b", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4752fa50e2ceffd2079270047593412cd4cd1d2f8675eb305d4d5f0fc830f792", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c51da3aa-5e15-48ae-8f21-a7760feea768", "node_type": "1", "metadata": {"window": "COVID -19 has continued to progress and persist here in the US in ways we couldn't have predicted when we \ninitially provided our outlook for fiscal 2021.  Several states, in cluding Texas, where I am today, are experiencing \nsignificantly higher numbers of cases, while others -- other parts of the country and frankly, the world are in very \ndifferent and various forms of recovery.  This variability makes predicting an aggregate t imeline for the recovery \nchallenging.  \n \n As we detailed on our fourth quarter call, we expected the most severe impacts to our business in the fiscal first \nquarter.  And as a reminder, our original outlook assumed the pandemic would have the most material imp act on \nour businesses with physician and specialty provider and oncology exposure.  We expected a gradual stabilization \nbeginning in our fiscal second quarter and ramping over the remainder of the fiscal year as doctors offices reopen \nand patients return to  their treatments.  Through April and May, our results were largely in line with our original \nexpectations, with volumes across the enterprise materially down versus the prior year and well below pre -COVID \nlevels.  \n \n", "original_text": "As we detailed on our fourth quarter call, we expected the most severe impacts to our business in the fiscal first \nquarter. ", "page_label": "4", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ccbadd62d7ce3bfebe5cf13b23498b33ab9c27679aed82f55b512c29d026f1f2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c375ec00-674a-41b9-a8eb-5e7a260656f7", "node_type": "1", "metadata": {"window": "This variability makes predicting an aggregate t imeline for the recovery \nchallenging.  \n \n As we detailed on our fourth quarter call, we expected the most severe impacts to our business in the fiscal first \nquarter.  And as a reminder, our original outlook assumed the pandemic would have the most material imp act on \nour businesses with physician and specialty provider and oncology exposure.  We expected a gradual stabilization \nbeginning in our fiscal second quarter and ramping over the remainder of the fiscal year as doctors offices reopen \nand patients return to  their treatments.  Through April and May, our results were largely in line with our original \nexpectations, with volumes across the enterprise materially down versus the prior year and well below pre -COVID \nlevels.  \n \n What we experienced in June, however, was an earlier than expected pace of recovery, particularly in the last \nweeks of the quarter, resulting in demand acceleration and higher volumes versus our original expectations. \n These impacts were the most pronounced in the primary care business within our m edical segment. ", "original_text": "We expected a gradual stabilization \nbeginning in our fiscal second quarter and ramping over the remainder of the fiscal year as doctors offices reopen \nand patients return to  their treatments. "}, "hash": "8a3769d775d402e690a114e2d123177b2f6e077681fc6b5a035541fbb8309828", "class_name": "RelatedNodeInfo"}}, "text": "And as a reminder, our original outlook assumed the pandemic would have the most material imp act on \nour businesses with physician and specialty provider and oncology exposure. ", "start_char_idx": 2386, "end_char_idx": 2564, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c375ec00-674a-41b9-a8eb-5e7a260656f7": {"__data__": {"id_": "c375ec00-674a-41b9-a8eb-5e7a260656f7", "embedding": null, "metadata": {"window": "This variability makes predicting an aggregate t imeline for the recovery \nchallenging.  \n \n As we detailed on our fourth quarter call, we expected the most severe impacts to our business in the fiscal first \nquarter.  And as a reminder, our original outlook assumed the pandemic would have the most material imp act on \nour businesses with physician and specialty provider and oncology exposure.  We expected a gradual stabilization \nbeginning in our fiscal second quarter and ramping over the remainder of the fiscal year as doctors offices reopen \nand patients return to  their treatments.  Through April and May, our results were largely in line with our original \nexpectations, with volumes across the enterprise materially down versus the prior year and well below pre -COVID \nlevels.  \n \n What we experienced in June, however, was an earlier than expected pace of recovery, particularly in the last \nweeks of the quarter, resulting in demand acceleration and higher volumes versus our original expectations. \n These impacts were the most pronounced in the primary care business within our m edical segment. ", "original_text": "We expected a gradual stabilization \nbeginning in our fiscal second quarter and ramping over the remainder of the fiscal year as doctors offices reopen \nand patients return to  their treatments. ", "page_label": "4", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "71518e0c-2d29-463a-b5e5-d10bfe32ed2b", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4752fa50e2ceffd2079270047593412cd4cd1d2f8675eb305d4d5f0fc830f792", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ebf04942-9036-44a5-9d6d-157c392b8e65", "node_type": "1", "metadata": {"window": "Several states, in cluding Texas, where I am today, are experiencing \nsignificantly higher numbers of cases, while others -- other parts of the country and frankly, the world are in very \ndifferent and various forms of recovery.  This variability makes predicting an aggregate t imeline for the recovery \nchallenging.  \n \n As we detailed on our fourth quarter call, we expected the most severe impacts to our business in the fiscal first \nquarter.  And as a reminder, our original outlook assumed the pandemic would have the most material imp act on \nour businesses with physician and specialty provider and oncology exposure.  We expected a gradual stabilization \nbeginning in our fiscal second quarter and ramping over the remainder of the fiscal year as doctors offices reopen \nand patients return to  their treatments.  Through April and May, our results were largely in line with our original \nexpectations, with volumes across the enterprise materially down versus the prior year and well below pre -COVID \nlevels.  \n \n What we experienced in June, however, was an earlier than expected pace of recovery, particularly in the last \nweeks of the quarter, resulting in demand acceleration and higher volumes versus our original expectations. \n", "original_text": "And as a reminder, our original outlook assumed the pandemic would have the most material imp act on \nour businesses with physician and specialty provider and oncology exposure. ", "page_label": "4", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "72d8b70a303cdde684df165ea3b94686aa21c1b53c55e7d5bf74c97c6b130f36", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "255ca743-90eb-4f8c-94bd-6e6a1458ea3c", "node_type": "1", "metadata": {"window": "As we detailed on our fourth quarter call, we expected the most severe impacts to our business in the fiscal first \nquarter.  And as a reminder, our original outlook assumed the pandemic would have the most material imp act on \nour businesses with physician and specialty provider and oncology exposure.  We expected a gradual stabilization \nbeginning in our fiscal second quarter and ramping over the remainder of the fiscal year as doctors offices reopen \nand patients return to  their treatments.  Through April and May, our results were largely in line with our original \nexpectations, with volumes across the enterprise materially down versus the prior year and well below pre -COVID \nlevels.  \n \n What we experienced in June, however, was an earlier than expected pace of recovery, particularly in the last \nweeks of the quarter, resulting in demand acceleration and higher volumes versus our original expectations. \n These impacts were the most pronounced in the primary care business within our m edical segment.  Primary care \npatient visits showed encouraging signs of improvement in June as patients return to their doctors following the \nrelaxation of shelter -at-home guidelines.  \n \n", "original_text": "Through April and May, our results were largely in line with our original \nexpectations, with volumes across the enterprise materially down versus the prior year and well below pre -COVID \nlevels.  \n \n"}, "hash": "408f6d4ecb959c2624818f1ac09c223b9cb82155292ed1c8f3430ebf6de4f9b8", "class_name": "RelatedNodeInfo"}}, "text": "We expected a gradual stabilization \nbeginning in our fiscal second quarter and ramping over the remainder of the fiscal year as doctors offices reopen \nand patients return to  their treatments. ", "start_char_idx": 2564, "end_char_idx": 2759, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "255ca743-90eb-4f8c-94bd-6e6a1458ea3c": {"__data__": {"id_": "255ca743-90eb-4f8c-94bd-6e6a1458ea3c", "embedding": null, "metadata": {"window": "As we detailed on our fourth quarter call, we expected the most severe impacts to our business in the fiscal first \nquarter.  And as a reminder, our original outlook assumed the pandemic would have the most material imp act on \nour businesses with physician and specialty provider and oncology exposure.  We expected a gradual stabilization \nbeginning in our fiscal second quarter and ramping over the remainder of the fiscal year as doctors offices reopen \nand patients return to  their treatments.  Through April and May, our results were largely in line with our original \nexpectations, with volumes across the enterprise materially down versus the prior year and well below pre -COVID \nlevels.  \n \n What we experienced in June, however, was an earlier than expected pace of recovery, particularly in the last \nweeks of the quarter, resulting in demand acceleration and higher volumes versus our original expectations. \n These impacts were the most pronounced in the primary care business within our m edical segment.  Primary care \npatient visits showed encouraging signs of improvement in June as patients return to their doctors following the \nrelaxation of shelter -at-home guidelines.  \n \n", "original_text": "Through April and May, our results were largely in line with our original \nexpectations, with volumes across the enterprise materially down versus the prior year and well below pre -COVID \nlevels.  \n \n", "page_label": "4", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "71518e0c-2d29-463a-b5e5-d10bfe32ed2b", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4752fa50e2ceffd2079270047593412cd4cd1d2f8675eb305d4d5f0fc830f792", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c375ec00-674a-41b9-a8eb-5e7a260656f7", "node_type": "1", "metadata": {"window": "This variability makes predicting an aggregate t imeline for the recovery \nchallenging.  \n \n As we detailed on our fourth quarter call, we expected the most severe impacts to our business in the fiscal first \nquarter.  And as a reminder, our original outlook assumed the pandemic would have the most material imp act on \nour businesses with physician and specialty provider and oncology exposure.  We expected a gradual stabilization \nbeginning in our fiscal second quarter and ramping over the remainder of the fiscal year as doctors offices reopen \nand patients return to  their treatments.  Through April and May, our results were largely in line with our original \nexpectations, with volumes across the enterprise materially down versus the prior year and well below pre -COVID \nlevels.  \n \n What we experienced in June, however, was an earlier than expected pace of recovery, particularly in the last \nweeks of the quarter, resulting in demand acceleration and higher volumes versus our original expectations. \n These impacts were the most pronounced in the primary care business within our m edical segment. ", "original_text": "We expected a gradual stabilization \nbeginning in our fiscal second quarter and ramping over the remainder of the fiscal year as doctors offices reopen \nand patients return to  their treatments. ", "page_label": "4", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2ac349b9ffceacf47c31c5a6b52a6f057a67bd1954f0d884581b028076a9a3dd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2195d6d3-37e8-44ea-bb36-2520de00c598", "node_type": "1", "metadata": {"window": "And as a reminder, our original outlook assumed the pandemic would have the most material imp act on \nour businesses with physician and specialty provider and oncology exposure.  We expected a gradual stabilization \nbeginning in our fiscal second quarter and ramping over the remainder of the fiscal year as doctors offices reopen \nand patients return to  their treatments.  Through April and May, our results were largely in line with our original \nexpectations, with volumes across the enterprise materially down versus the prior year and well below pre -COVID \nlevels.  \n \n What we experienced in June, however, was an earlier than expected pace of recovery, particularly in the last \nweeks of the quarter, resulting in demand acceleration and higher volumes versus our original expectations. \n These impacts were the most pronounced in the primary care business within our m edical segment.  Primary care \npatient visits showed encouraging signs of improvement in June as patients return to their doctors following the \nrelaxation of shelter -at-home guidelines.  \n \n Now turning to the business. ", "original_text": "What we experienced in June, however, was an earlier than expected pace of recovery, particularly in the last \nweeks of the quarter, resulting in demand acceleration and higher volumes versus our original expectations. \n"}, "hash": "d2e4ae4a4ee337a49922295b4b80f723f159758c4c37859557e3893dca490829", "class_name": "RelatedNodeInfo"}}, "text": "Through April and May, our results were largely in line with our original \nexpectations, with volumes across the enterprise materially down versus the prior year and well below pre -COVID \nlevels.  \n \n", "start_char_idx": 2759, "end_char_idx": 2960, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2195d6d3-37e8-44ea-bb36-2520de00c598": {"__data__": {"id_": "2195d6d3-37e8-44ea-bb36-2520de00c598", "embedding": null, "metadata": {"window": "And as a reminder, our original outlook assumed the pandemic would have the most material imp act on \nour businesses with physician and specialty provider and oncology exposure.  We expected a gradual stabilization \nbeginning in our fiscal second quarter and ramping over the remainder of the fiscal year as doctors offices reopen \nand patients return to  their treatments.  Through April and May, our results were largely in line with our original \nexpectations, with volumes across the enterprise materially down versus the prior year and well below pre -COVID \nlevels.  \n \n What we experienced in June, however, was an earlier than expected pace of recovery, particularly in the last \nweeks of the quarter, resulting in demand acceleration and higher volumes versus our original expectations. \n These impacts were the most pronounced in the primary care business within our m edical segment.  Primary care \npatient visits showed encouraging signs of improvement in June as patients return to their doctors following the \nrelaxation of shelter -at-home guidelines.  \n \n Now turning to the business. ", "original_text": "What we experienced in June, however, was an earlier than expected pace of recovery, particularly in the last \nweeks of the quarter, resulting in demand acceleration and higher volumes versus our original expectations. \n", "page_label": "4", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "71518e0c-2d29-463a-b5e5-d10bfe32ed2b", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4752fa50e2ceffd2079270047593412cd4cd1d2f8675eb305d4d5f0fc830f792", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "255ca743-90eb-4f8c-94bd-6e6a1458ea3c", "node_type": "1", "metadata": {"window": "As we detailed on our fourth quarter call, we expected the most severe impacts to our business in the fiscal first \nquarter.  And as a reminder, our original outlook assumed the pandemic would have the most material imp act on \nour businesses with physician and specialty provider and oncology exposure.  We expected a gradual stabilization \nbeginning in our fiscal second quarter and ramping over the remainder of the fiscal year as doctors offices reopen \nand patients return to  their treatments.  Through April and May, our results were largely in line with our original \nexpectations, with volumes across the enterprise materially down versus the prior year and well below pre -COVID \nlevels.  \n \n What we experienced in June, however, was an earlier than expected pace of recovery, particularly in the last \nweeks of the quarter, resulting in demand acceleration and higher volumes versus our original expectations. \n These impacts were the most pronounced in the primary care business within our m edical segment.  Primary care \npatient visits showed encouraging signs of improvement in June as patients return to their doctors following the \nrelaxation of shelter -at-home guidelines.  \n \n", "original_text": "Through April and May, our results were largely in line with our original \nexpectations, with volumes across the enterprise materially down versus the prior year and well below pre -COVID \nlevels.  \n \n", "page_label": "4", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "18fca81d9b12557ffbc67a36572b0e634d9e3698bc05baba64351db4269ae757", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "078d3b36-3857-4c2d-86ca-aed29fc3cdb8", "node_type": "1", "metadata": {"window": "We expected a gradual stabilization \nbeginning in our fiscal second quarter and ramping over the remainder of the fiscal year as doctors offices reopen \nand patients return to  their treatments.  Through April and May, our results were largely in line with our original \nexpectations, with volumes across the enterprise materially down versus the prior year and well below pre -COVID \nlevels.  \n \n What we experienced in June, however, was an earlier than expected pace of recovery, particularly in the last \nweeks of the quarter, resulting in demand acceleration and higher volumes versus our original expectations. \n These impacts were the most pronounced in the primary care business within our m edical segment.  Primary care \npatient visits showed encouraging signs of improvement in June as patients return to their doctors following the \nrelaxation of shelter -at-home guidelines.  \n \n Now turning to the business.  I'll summarize the first quarter, and then  I'll turn the call over to Britt to elaborate. \n", "original_text": "These impacts were the most pronounced in the primary care business within our m edical segment. "}, "hash": "d80477b56502f5a15e33aea62c56c75f770d0816b69d8cd46980eec7799c39b6", "class_name": "RelatedNodeInfo"}}, "text": "What we experienced in June, however, was an earlier than expected pace of recovery, particularly in the last \nweeks of the quarter, resulting in demand acceleration and higher volumes versus our original expectations. \n", "start_char_idx": 2960, "end_char_idx": 3180, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "078d3b36-3857-4c2d-86ca-aed29fc3cdb8": {"__data__": {"id_": "078d3b36-3857-4c2d-86ca-aed29fc3cdb8", "embedding": null, "metadata": {"window": "We expected a gradual stabilization \nbeginning in our fiscal second quarter and ramping over the remainder of the fiscal year as doctors offices reopen \nand patients return to  their treatments.  Through April and May, our results were largely in line with our original \nexpectations, with volumes across the enterprise materially down versus the prior year and well below pre -COVID \nlevels.  \n \n What we experienced in June, however, was an earlier than expected pace of recovery, particularly in the last \nweeks of the quarter, resulting in demand acceleration and higher volumes versus our original expectations. \n These impacts were the most pronounced in the primary care business within our m edical segment.  Primary care \npatient visits showed encouraging signs of improvement in June as patients return to their doctors following the \nrelaxation of shelter -at-home guidelines.  \n \n Now turning to the business.  I'll summarize the first quarter, and then  I'll turn the call over to Britt to elaborate. \n", "original_text": "These impacts were the most pronounced in the primary care business within our m edical segment. ", "page_label": "4", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "71518e0c-2d29-463a-b5e5-d10bfe32ed2b", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4752fa50e2ceffd2079270047593412cd4cd1d2f8675eb305d4d5f0fc830f792", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2195d6d3-37e8-44ea-bb36-2520de00c598", "node_type": "1", "metadata": {"window": "And as a reminder, our original outlook assumed the pandemic would have the most material imp act on \nour businesses with physician and specialty provider and oncology exposure.  We expected a gradual stabilization \nbeginning in our fiscal second quarter and ramping over the remainder of the fiscal year as doctors offices reopen \nand patients return to  their treatments.  Through April and May, our results were largely in line with our original \nexpectations, with volumes across the enterprise materially down versus the prior year and well below pre -COVID \nlevels.  \n \n What we experienced in June, however, was an earlier than expected pace of recovery, particularly in the last \nweeks of the quarter, resulting in demand acceleration and higher volumes versus our original expectations. \n These impacts were the most pronounced in the primary care business within our m edical segment.  Primary care \npatient visits showed encouraging signs of improvement in June as patients return to their doctors following the \nrelaxation of shelter -at-home guidelines.  \n \n Now turning to the business. ", "original_text": "What we experienced in June, however, was an earlier than expected pace of recovery, particularly in the last \nweeks of the quarter, resulting in demand acceleration and higher volumes versus our original expectations. \n", "page_label": "4", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "958a5de662dd1b3e1853d5f788610e8554c8a295bf1fee61fec5f9063cf85375", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2260d5fa-7ae2-47d5-a088-05c89eb366ee", "node_type": "1", "metadata": {"window": "Through April and May, our results were largely in line with our original \nexpectations, with volumes across the enterprise materially down versus the prior year and well below pre -COVID \nlevels.  \n \n What we experienced in June, however, was an earlier than expected pace of recovery, particularly in the last \nweeks of the quarter, resulting in demand acceleration and higher volumes versus our original expectations. \n These impacts were the most pronounced in the primary care business within our m edical segment.  Primary care \npatient visits showed encouraging signs of improvement in June as patients return to their doctors following the \nrelaxation of shelter -at-home guidelines.  \n \n Now turning to the business.  I'll summarize the first quarter, and then  I'll turn the call over to Britt to elaborate. \n U.S. ", "original_text": "Primary care \npatient visits showed encouraging signs of improvement in June as patients return to their doctors following the \nrelaxation of shelter -at-home guidelines.  \n \n"}, "hash": "a3eeb27f3b0e13e4212bf842dc9decab4446ac667d9a9814a883435a4dcf9ade", "class_name": "RelatedNodeInfo"}}, "text": "These impacts were the most pronounced in the primary care business within our m edical segment. ", "start_char_idx": 3180, "end_char_idx": 3277, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2260d5fa-7ae2-47d5-a088-05c89eb366ee": {"__data__": {"id_": "2260d5fa-7ae2-47d5-a088-05c89eb366ee", "embedding": null, "metadata": {"window": "Through April and May, our results were largely in line with our original \nexpectations, with volumes across the enterprise materially down versus the prior year and well below pre -COVID \nlevels.  \n \n What we experienced in June, however, was an earlier than expected pace of recovery, particularly in the last \nweeks of the quarter, resulting in demand acceleration and higher volumes versus our original expectations. \n These impacts were the most pronounced in the primary care business within our m edical segment.  Primary care \npatient visits showed encouraging signs of improvement in June as patients return to their doctors following the \nrelaxation of shelter -at-home guidelines.  \n \n Now turning to the business.  I'll summarize the first quarter, and then  I'll turn the call over to Britt to elaborate. \n U.S. ", "original_text": "Primary care \npatient visits showed encouraging signs of improvement in June as patients return to their doctors following the \nrelaxation of shelter -at-home guidelines.  \n \n", "page_label": "4", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "71518e0c-2d29-463a-b5e5-d10bfe32ed2b", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4752fa50e2ceffd2079270047593412cd4cd1d2f8675eb305d4d5f0fc830f792", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "078d3b36-3857-4c2d-86ca-aed29fc3cdb8", "node_type": "1", "metadata": {"window": "We expected a gradual stabilization \nbeginning in our fiscal second quarter and ramping over the remainder of the fiscal year as doctors offices reopen \nand patients return to  their treatments.  Through April and May, our results were largely in line with our original \nexpectations, with volumes across the enterprise materially down versus the prior year and well below pre -COVID \nlevels.  \n \n What we experienced in June, however, was an earlier than expected pace of recovery, particularly in the last \nweeks of the quarter, resulting in demand acceleration and higher volumes versus our original expectations. \n These impacts were the most pronounced in the primary care business within our m edical segment.  Primary care \npatient visits showed encouraging signs of improvement in June as patients return to their doctors following the \nrelaxation of shelter -at-home guidelines.  \n \n Now turning to the business.  I'll summarize the first quarter, and then  I'll turn the call over to Britt to elaborate. \n", "original_text": "These impacts were the most pronounced in the primary care business within our m edical segment. ", "page_label": "4", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e686919f177cc2d902f6a1e1c8af4371a6a41b559e514a733bb1ca30bce2b50c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "73f574b0-d426-4ba9-b0c4-f015a6a60491", "node_type": "1", "metadata": {"window": "What we experienced in June, however, was an earlier than expected pace of recovery, particularly in the last \nweeks of the quarter, resulting in demand acceleration and higher volumes versus our original expectations. \n These impacts were the most pronounced in the primary care business within our m edical segment.  Primary care \npatient visits showed encouraging signs of improvement in June as patients return to their doctors following the \nrelaxation of shelter -at-home guidelines.  \n \n Now turning to the business.  I'll summarize the first quarter, and then  I'll turn the call over to Britt to elaborate. \n U.S.  Pharmaceutical and Specialty Solutions exceeded our original expectations in the quarter, underpinned by \nstrong execution and improving volume trends in the business in the back half of June. ", "original_text": "Now turning to the business. "}, "hash": "e623a1e23aed36ffdd32276e82a965ca1abe11da2d1f8403350833a07a782cb3", "class_name": "RelatedNodeInfo"}}, "text": "Primary care \npatient visits showed encouraging signs of improvement in June as patients return to their doctors following the \nrelaxation of shelter -at-home guidelines.  \n \n", "start_char_idx": 3277, "end_char_idx": 3452, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "73f574b0-d426-4ba9-b0c4-f015a6a60491": {"__data__": {"id_": "73f574b0-d426-4ba9-b0c4-f015a6a60491", "embedding": null, "metadata": {"window": "What we experienced in June, however, was an earlier than expected pace of recovery, particularly in the last \nweeks of the quarter, resulting in demand acceleration and higher volumes versus our original expectations. \n These impacts were the most pronounced in the primary care business within our m edical segment.  Primary care \npatient visits showed encouraging signs of improvement in June as patients return to their doctors following the \nrelaxation of shelter -at-home guidelines.  \n \n Now turning to the business.  I'll summarize the first quarter, and then  I'll turn the call over to Britt to elaborate. \n U.S.  Pharmaceutical and Specialty Solutions exceeded our original expectations in the quarter, underpinned by \nstrong execution and improving volume trends in the business in the back half of June. ", "original_text": "Now turning to the business. ", "page_label": "4", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "71518e0c-2d29-463a-b5e5-d10bfe32ed2b", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4752fa50e2ceffd2079270047593412cd4cd1d2f8675eb305d4d5f0fc830f792", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2260d5fa-7ae2-47d5-a088-05c89eb366ee", "node_type": "1", "metadata": {"window": "Through April and May, our results were largely in line with our original \nexpectations, with volumes across the enterprise materially down versus the prior year and well below pre -COVID \nlevels.  \n \n What we experienced in June, however, was an earlier than expected pace of recovery, particularly in the last \nweeks of the quarter, resulting in demand acceleration and higher volumes versus our original expectations. \n These impacts were the most pronounced in the primary care business within our m edical segment.  Primary care \npatient visits showed encouraging signs of improvement in June as patients return to their doctors following the \nrelaxation of shelter -at-home guidelines.  \n \n Now turning to the business.  I'll summarize the first quarter, and then  I'll turn the call over to Britt to elaborate. \n U.S. ", "original_text": "Primary care \npatient visits showed encouraging signs of improvement in June as patients return to their doctors following the \nrelaxation of shelter -at-home guidelines.  \n \n", "page_label": "4", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "81e1b179a80f69993204488947339121aa0ee6b33894bfcce81e39cec32568e8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "05978cdf-0644-499a-89e2-9b7db9097fc0", "node_type": "1", "metadata": {"window": "These impacts were the most pronounced in the primary care business within our m edical segment.  Primary care \npatient visits showed encouraging signs of improvement in June as patients return to their doctors following the \nrelaxation of shelter -at-home guidelines.  \n \n Now turning to the business.  I'll summarize the first quarter, and then  I'll turn the call over to Britt to elaborate. \n U.S.  Pharmaceutical and Specialty Solutions exceeded our original expectations in the quarter, underpinned by \nstrong execution and improving volume trends in the business in the back half of June.  Market stab ility, our \ndisciplined approach to pricing and a growing specialty market continue to be foundations for us to build upon.  \n \n", "original_text": "I'll summarize the first quarter, and then  I'll turn the call over to Britt to elaborate. \n"}, "hash": "fd161d422348453c99bcb62eb7f9865d3bf4d8b4988624aa3ec9404808fe5ca8", "class_name": "RelatedNodeInfo"}}, "text": "Now turning to the business. ", "start_char_idx": 3452, "end_char_idx": 3481, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "05978cdf-0644-499a-89e2-9b7db9097fc0": {"__data__": {"id_": "05978cdf-0644-499a-89e2-9b7db9097fc0", "embedding": null, "metadata": {"window": "These impacts were the most pronounced in the primary care business within our m edical segment.  Primary care \npatient visits showed encouraging signs of improvement in June as patients return to their doctors following the \nrelaxation of shelter -at-home guidelines.  \n \n Now turning to the business.  I'll summarize the first quarter, and then  I'll turn the call over to Britt to elaborate. \n U.S.  Pharmaceutical and Specialty Solutions exceeded our original expectations in the quarter, underpinned by \nstrong execution and improving volume trends in the business in the back half of June.  Market stab ility, our \ndisciplined approach to pricing and a growing specialty market continue to be foundations for us to build upon.  \n \n", "original_text": "I'll summarize the first quarter, and then  I'll turn the call over to Britt to elaborate. \n", "page_label": "4", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "71518e0c-2d29-463a-b5e5-d10bfe32ed2b", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4752fa50e2ceffd2079270047593412cd4cd1d2f8675eb305d4d5f0fc830f792", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "73f574b0-d426-4ba9-b0c4-f015a6a60491", "node_type": "1", "metadata": {"window": "What we experienced in June, however, was an earlier than expected pace of recovery, particularly in the last \nweeks of the quarter, resulting in demand acceleration and higher volumes versus our original expectations. \n These impacts were the most pronounced in the primary care business within our m edical segment.  Primary care \npatient visits showed encouraging signs of improvement in June as patients return to their doctors following the \nrelaxation of shelter -at-home guidelines.  \n \n Now turning to the business.  I'll summarize the first quarter, and then  I'll turn the call over to Britt to elaborate. \n U.S.  Pharmaceutical and Specialty Solutions exceeded our original expectations in the quarter, underpinned by \nstrong execution and improving volume trends in the business in the back half of June. ", "original_text": "Now turning to the business. ", "page_label": "4", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "783cf5617b001c519293d02b6fdfebb51c0ab321bc7a2b333b8483bade9641bc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8cbf1359-3c64-436d-887d-7c0b925b431c", "node_type": "1", "metadata": {"window": "Primary care \npatient visits showed encouraging signs of improvement in June as patients return to their doctors following the \nrelaxation of shelter -at-home guidelines.  \n \n Now turning to the business.  I'll summarize the first quarter, and then  I'll turn the call over to Britt to elaborate. \n U.S.  Pharmaceutical and Specialty Solutions exceeded our original expectations in the quarter, underpinned by \nstrong execution and improving volume trends in the business in the back half of June.  Market stab ility, our \ndisciplined approach to pricing and a growing specialty market continue to be foundations for us to build upon.  \n \n We're very pleased to have recently renewed our distribution agreement with [ph] The Buyers Alliance (00:07:25) \nsometimes refer to a s TBA, and doing so while maintaining our disciplined approach to the market. ", "original_text": "U.S. "}, "hash": "30fec5218713dfb53867851b8bd0c2d059c02e275a748289c038a7a2fd4f1e28", "class_name": "RelatedNodeInfo"}}, "text": "I'll summarize the first quarter, and then  I'll turn the call over to Britt to elaborate. \n", "start_char_idx": 3481, "end_char_idx": 3573, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8cbf1359-3c64-436d-887d-7c0b925b431c": {"__data__": {"id_": "8cbf1359-3c64-436d-887d-7c0b925b431c", "embedding": null, "metadata": {"window": "Primary care \npatient visits showed encouraging signs of improvement in June as patients return to their doctors following the \nrelaxation of shelter -at-home guidelines.  \n \n Now turning to the business.  I'll summarize the first quarter, and then  I'll turn the call over to Britt to elaborate. \n U.S.  Pharmaceutical and Specialty Solutions exceeded our original expectations in the quarter, underpinned by \nstrong execution and improving volume trends in the business in the back half of June.  Market stab ility, our \ndisciplined approach to pricing and a growing specialty market continue to be foundations for us to build upon.  \n \n We're very pleased to have recently renewed our distribution agreement with [ph] The Buyers Alliance (00:07:25) \nsometimes refer to a s TBA, and doing so while maintaining our disciplined approach to the market. ", "original_text": "U.S. ", "page_label": "4", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "71518e0c-2d29-463a-b5e5-d10bfe32ed2b", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4752fa50e2ceffd2079270047593412cd4cd1d2f8675eb305d4d5f0fc830f792", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "05978cdf-0644-499a-89e2-9b7db9097fc0", "node_type": "1", "metadata": {"window": "These impacts were the most pronounced in the primary care business within our m edical segment.  Primary care \npatient visits showed encouraging signs of improvement in June as patients return to their doctors following the \nrelaxation of shelter -at-home guidelines.  \n \n Now turning to the business.  I'll summarize the first quarter, and then  I'll turn the call over to Britt to elaborate. \n U.S.  Pharmaceutical and Specialty Solutions exceeded our original expectations in the quarter, underpinned by \nstrong execution and improving volume trends in the business in the back half of June.  Market stab ility, our \ndisciplined approach to pricing and a growing specialty market continue to be foundations for us to build upon.  \n \n", "original_text": "I'll summarize the first quarter, and then  I'll turn the call over to Britt to elaborate. \n", "page_label": "4", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5f5643d0323d3427b2c7a49677caa1e9152d394a8a1ddc2e4fdd9ade2ce7e2e3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2502de08-b5ed-4867-bffb-f90fec4ceb8a", "node_type": "1", "metadata": {"window": "Now turning to the business.  I'll summarize the first quarter, and then  I'll turn the call over to Britt to elaborate. \n U.S.  Pharmaceutical and Specialty Solutions exceeded our original expectations in the quarter, underpinned by \nstrong execution and improving volume trends in the business in the back half of June.  Market stab ility, our \ndisciplined approach to pricing and a growing specialty market continue to be foundations for us to build upon.  \n \n We're very pleased to have recently renewed our distribution agreement with [ph] The Buyers Alliance (00:07:25) \nsometimes refer to a s TBA, and doing so while maintaining our disciplined approach to the market.  I would remind ", "original_text": "Pharmaceutical and Specialty Solutions exceeded our original expectations in the quarter, underpinned by \nstrong execution and improving volume trends in the business in the back half of June. "}, "hash": "c090032fae89e266d4639d691a6184398f22f482d9c5014d351e06c913009cdf", "class_name": "RelatedNodeInfo"}}, "text": "U.S. ", "start_char_idx": 3573, "end_char_idx": 3578, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2502de08-b5ed-4867-bffb-f90fec4ceb8a": {"__data__": {"id_": "2502de08-b5ed-4867-bffb-f90fec4ceb8a", "embedding": null, "metadata": {"window": "Now turning to the business.  I'll summarize the first quarter, and then  I'll turn the call over to Britt to elaborate. \n U.S.  Pharmaceutical and Specialty Solutions exceeded our original expectations in the quarter, underpinned by \nstrong execution and improving volume trends in the business in the back half of June.  Market stab ility, our \ndisciplined approach to pricing and a growing specialty market continue to be foundations for us to build upon.  \n \n We're very pleased to have recently renewed our distribution agreement with [ph] The Buyers Alliance (00:07:25) \nsometimes refer to a s TBA, and doing so while maintaining our disciplined approach to the market.  I would remind ", "original_text": "Pharmaceutical and Specialty Solutions exceeded our original expectations in the quarter, underpinned by \nstrong execution and improving volume trends in the business in the back half of June. ", "page_label": "4", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "71518e0c-2d29-463a-b5e5-d10bfe32ed2b", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4752fa50e2ceffd2079270047593412cd4cd1d2f8675eb305d4d5f0fc830f792", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8cbf1359-3c64-436d-887d-7c0b925b431c", "node_type": "1", "metadata": {"window": "Primary care \npatient visits showed encouraging signs of improvement in June as patients return to their doctors following the \nrelaxation of shelter -at-home guidelines.  \n \n Now turning to the business.  I'll summarize the first quarter, and then  I'll turn the call over to Britt to elaborate. \n U.S.  Pharmaceutical and Specialty Solutions exceeded our original expectations in the quarter, underpinned by \nstrong execution and improving volume trends in the business in the back half of June.  Market stab ility, our \ndisciplined approach to pricing and a growing specialty market continue to be foundations for us to build upon.  \n \n We're very pleased to have recently renewed our distribution agreement with [ph] The Buyers Alliance (00:07:25) \nsometimes refer to a s TBA, and doing so while maintaining our disciplined approach to the market. ", "original_text": "U.S. ", "page_label": "4", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "85400cf07983f35f4e0da0eb7927eec9659d89a5c5c287e64a3ddd29d0857f9a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9b83df33-8543-4f60-88e8-ea19c34ee148", "node_type": "1", "metadata": {"window": "I'll summarize the first quarter, and then  I'll turn the call over to Britt to elaborate. \n U.S.  Pharmaceutical and Specialty Solutions exceeded our original expectations in the quarter, underpinned by \nstrong execution and improving volume trends in the business in the back half of June.  Market stab ility, our \ndisciplined approach to pricing and a growing specialty market continue to be foundations for us to build upon.  \n \n We're very pleased to have recently renewed our distribution agreement with [ph] The Buyers Alliance (00:07:25) \nsometimes refer to a s TBA, and doing so while maintaining our disciplined approach to the market.  I would remind ", "original_text": "Market stab ility, our \ndisciplined approach to pricing and a growing specialty market continue to be foundations for us to build upon.  \n \n"}, "hash": "bd7517965652d2062dac02f175d2bc39eb67f19256b6a07f85f84b17362c4c3a", "class_name": "RelatedNodeInfo"}}, "text": "Pharmaceutical and Specialty Solutions exceeded our original expectations in the quarter, underpinned by \nstrong execution and improving volume trends in the business in the back half of June. ", "start_char_idx": 3578, "end_char_idx": 3771, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9b83df33-8543-4f60-88e8-ea19c34ee148": {"__data__": {"id_": "9b83df33-8543-4f60-88e8-ea19c34ee148", "embedding": null, "metadata": {"window": "I'll summarize the first quarter, and then  I'll turn the call over to Britt to elaborate. \n U.S.  Pharmaceutical and Specialty Solutions exceeded our original expectations in the quarter, underpinned by \nstrong execution and improving volume trends in the business in the back half of June.  Market stab ility, our \ndisciplined approach to pricing and a growing specialty market continue to be foundations for us to build upon.  \n \n We're very pleased to have recently renewed our distribution agreement with [ph] The Buyers Alliance (00:07:25) \nsometimes refer to a s TBA, and doing so while maintaining our disciplined approach to the market.  I would remind ", "original_text": "Market stab ility, our \ndisciplined approach to pricing and a growing specialty market continue to be foundations for us to build upon.  \n \n", "page_label": "4", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "71518e0c-2d29-463a-b5e5-d10bfe32ed2b", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4752fa50e2ceffd2079270047593412cd4cd1d2f8675eb305d4d5f0fc830f792", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2502de08-b5ed-4867-bffb-f90fec4ceb8a", "node_type": "1", "metadata": {"window": "Now turning to the business.  I'll summarize the first quarter, and then  I'll turn the call over to Britt to elaborate. \n U.S.  Pharmaceutical and Specialty Solutions exceeded our original expectations in the quarter, underpinned by \nstrong execution and improving volume trends in the business in the back half of June.  Market stab ility, our \ndisciplined approach to pricing and a growing specialty market continue to be foundations for us to build upon.  \n \n We're very pleased to have recently renewed our distribution agreement with [ph] The Buyers Alliance (00:07:25) \nsometimes refer to a s TBA, and doing so while maintaining our disciplined approach to the market.  I would remind ", "original_text": "Pharmaceutical and Specialty Solutions exceeded our original expectations in the quarter, underpinned by \nstrong execution and improving volume trends in the business in the back half of June. ", "page_label": "4", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0ca3275e991152c8db195fdc2e11cc57f0a3bcff5232b69186cf9e1650fa53b8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "866617ac-527d-4ddc-948d-e18b819a388b", "node_type": "1", "metadata": {"window": "U.S.  Pharmaceutical and Specialty Solutions exceeded our original expectations in the quarter, underpinned by \nstrong execution and improving volume trends in the business in the back half of June.  Market stab ility, our \ndisciplined approach to pricing and a growing specialty market continue to be foundations for us to build upon.  \n \n We're very pleased to have recently renewed our distribution agreement with [ph] The Buyers Alliance (00:07:25) \nsometimes refer to a s TBA, and doing so while maintaining our disciplined approach to the market.  I would remind ", "original_text": "We're very pleased to have recently renewed our distribution agreement with [ph] The Buyers Alliance (00:07:25) \nsometimes refer to a s TBA, and doing so while maintaining our disciplined approach to the market. "}, "hash": "3d9419b911b22ccf04f424d74a3d674363009296b7c31e599e806d1735a2aad0", "class_name": "RelatedNodeInfo"}}, "text": "Market stab ility, our \ndisciplined approach to pricing and a growing specialty market continue to be foundations for us to build upon.  \n \n", "start_char_idx": 3771, "end_char_idx": 3911, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "866617ac-527d-4ddc-948d-e18b819a388b": {"__data__": {"id_": "866617ac-527d-4ddc-948d-e18b819a388b", "embedding": null, "metadata": {"window": "U.S.  Pharmaceutical and Specialty Solutions exceeded our original expectations in the quarter, underpinned by \nstrong execution and improving volume trends in the business in the back half of June.  Market stab ility, our \ndisciplined approach to pricing and a growing specialty market continue to be foundations for us to build upon.  \n \n We're very pleased to have recently renewed our distribution agreement with [ph] The Buyers Alliance (00:07:25) \nsometimes refer to a s TBA, and doing so while maintaining our disciplined approach to the market.  I would remind ", "original_text": "We're very pleased to have recently renewed our distribution agreement with [ph] The Buyers Alliance (00:07:25) \nsometimes refer to a s TBA, and doing so while maintaining our disciplined approach to the market. ", "page_label": "4", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "71518e0c-2d29-463a-b5e5-d10bfe32ed2b", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4752fa50e2ceffd2079270047593412cd4cd1d2f8675eb305d4d5f0fc830f792", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9b83df33-8543-4f60-88e8-ea19c34ee148", "node_type": "1", "metadata": {"window": "I'll summarize the first quarter, and then  I'll turn the call over to Britt to elaborate. \n U.S.  Pharmaceutical and Specialty Solutions exceeded our original expectations in the quarter, underpinned by \nstrong execution and improving volume trends in the business in the back half of June.  Market stab ility, our \ndisciplined approach to pricing and a growing specialty market continue to be foundations for us to build upon.  \n \n We're very pleased to have recently renewed our distribution agreement with [ph] The Buyers Alliance (00:07:25) \nsometimes refer to a s TBA, and doing so while maintaining our disciplined approach to the market.  I would remind ", "original_text": "Market stab ility, our \ndisciplined approach to pricing and a growing specialty market continue to be foundations for us to build upon.  \n \n", "page_label": "4", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3998e0a6fbaaf18a09f966f4df761829b04f0cd2d706df6092105ebd798cfda8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0127bbe9-afc9-4a5d-b094-73cf6e127321", "node_type": "1", "metadata": {"window": "Pharmaceutical and Specialty Solutions exceeded our original expectations in the quarter, underpinned by \nstrong execution and improving volume trends in the business in the back half of June.  Market stab ility, our \ndisciplined approach to pricing and a growing specialty market continue to be foundations for us to build upon.  \n \n We're very pleased to have recently renewed our distribution agreement with [ph] The Buyers Alliance (00:07:25) \nsometimes refer to a s TBA, and doing so while maintaining our disciplined approach to the market.  I would remind ", "original_text": "I would remind "}, "hash": "d0c2ede042886782944081a81955daf08973f2a2011721efbd2c0520e617d4b2", "class_name": "RelatedNodeInfo"}}, "text": "We're very pleased to have recently renewed our distribution agreement with [ph] The Buyers Alliance (00:07:25) \nsometimes refer to a s TBA, and doing so while maintaining our disciplined approach to the market. ", "start_char_idx": 3911, "end_char_idx": 4123, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0127bbe9-afc9-4a5d-b094-73cf6e127321": {"__data__": {"id_": "0127bbe9-afc9-4a5d-b094-73cf6e127321", "embedding": null, "metadata": {"window": "Pharmaceutical and Specialty Solutions exceeded our original expectations in the quarter, underpinned by \nstrong execution and improving volume trends in the business in the back half of June.  Market stab ility, our \ndisciplined approach to pricing and a growing specialty market continue to be foundations for us to build upon.  \n \n We're very pleased to have recently renewed our distribution agreement with [ph] The Buyers Alliance (00:07:25) \nsometimes refer to a s TBA, and doing so while maintaining our disciplined approach to the market.  I would remind ", "original_text": "I would remind ", "page_label": "4", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "71518e0c-2d29-463a-b5e5-d10bfe32ed2b", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4752fa50e2ceffd2079270047593412cd4cd1d2f8675eb305d4d5f0fc830f792", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "866617ac-527d-4ddc-948d-e18b819a388b", "node_type": "1", "metadata": {"window": "U.S.  Pharmaceutical and Specialty Solutions exceeded our original expectations in the quarter, underpinned by \nstrong execution and improving volume trends in the business in the back half of June.  Market stab ility, our \ndisciplined approach to pricing and a growing specialty market continue to be foundations for us to build upon.  \n \n We're very pleased to have recently renewed our distribution agreement with [ph] The Buyers Alliance (00:07:25) \nsometimes refer to a s TBA, and doing so while maintaining our disciplined approach to the market.  I would remind ", "original_text": "We're very pleased to have recently renewed our distribution agreement with [ph] The Buyers Alliance (00:07:25) \nsometimes refer to a s TBA, and doing so while maintaining our disciplined approach to the market. ", "page_label": "4", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c2aee7eb36dba34fa8fe2ac2fee1e6d0e887ef3a2532358f6d0f5b8bbcfa2e48", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7f7ea861-a630-4b0c-8740-ff7430aa5ff2", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nyou, TBA is a group consisting of several health systems, retail national accounts and small and medium chain \npharmacies.  \n \n We're always looking for how we can best  serve our customers and help them grow their business.  This was \nevidenced by the growth in our specialty provider business in the midst of this pandemic driven in small part by \nimproved adoption of biosimilars in the quarter. ", "original_text": "McKesson Corp.  "}, "hash": "fa7b3bf78a1fb8e09f848e31f5e2540e964ac4df35c5dde88d8edee61c7c07f7", "class_name": "RelatedNodeInfo"}}, "text": "I would remind ", "start_char_idx": 4123, "end_char_idx": 4138, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7f7ea861-a630-4b0c-8740-ff7430aa5ff2": {"__data__": {"id_": "7f7ea861-a630-4b0c-8740-ff7430aa5ff2", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nyou, TBA is a group consisting of several health systems, retail national accounts and small and medium chain \npharmacies.  \n \n We're always looking for how we can best  serve our customers and help them grow their business.  This was \nevidenced by the growth in our specialty provider business in the midst of this pandemic driven in small part by \nimproved adoption of biosimilars in the quarter. ", "original_text": "McKesson Corp.  ", "page_label": "5", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2b6fa81b-d6e8-4046-a002-579e9e14ad02", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f979e56f55121861d8368ca4fe9d5a492f8ab49f3de018ae9a4ece2eb1f430a2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0127bbe9-afc9-4a5d-b094-73cf6e127321", "node_type": "1", "metadata": {"window": "Pharmaceutical and Specialty Solutions exceeded our original expectations in the quarter, underpinned by \nstrong execution and improving volume trends in the business in the back half of June.  Market stab ility, our \ndisciplined approach to pricing and a growing specialty market continue to be foundations for us to build upon.  \n \n We're very pleased to have recently renewed our distribution agreement with [ph] The Buyers Alliance (00:07:25) \nsometimes refer to a s TBA, and doing so while maintaining our disciplined approach to the market.  I would remind ", "original_text": "I would remind ", "page_label": "4", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2c775fc1cf9b5af54d24c3c58c504eb04c60146a79618050e79a613a4877aa07", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bda5d8d2-b4c2-4bd5-bac6-aef17a1537f3", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nyou, TBA is a group consisting of several health systems, retail national accounts and small and medium chain \npharmacies.  \n \n We're always looking for how we can best  serve our customers and help them grow their business.  This was \nevidenced by the growth in our specialty provider business in the midst of this pandemic driven in small part by \nimproved adoption of biosimilars in the quarter.  While our specialty business recovered more quickly than we had \nassumed following the initial downturns in demand, we have certainly had to adapt to meet the needs of patients. \n", "original_text": "(MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nyou, TBA is a group consisting of several health systems, retail national accounts and small and medium chain \npharmacies.  \n \n"}, "hash": "0344e608959717d61fcfd12d7820c834593091c47eb8f0f98ff4d778e645968d", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bda5d8d2-b4c2-4bd5-bac6-aef17a1537f3": {"__data__": {"id_": "bda5d8d2-b4c2-4bd5-bac6-aef17a1537f3", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nyou, TBA is a group consisting of several health systems, retail national accounts and small and medium chain \npharmacies.  \n \n We're always looking for how we can best  serve our customers and help them grow their business.  This was \nevidenced by the growth in our specialty provider business in the midst of this pandemic driven in small part by \nimproved adoption of biosimilars in the quarter.  While our specialty business recovered more quickly than we had \nassumed following the initial downturns in demand, we have certainly had to adapt to meet the needs of patients. \n", "original_text": "(MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nyou, TBA is a group consisting of several health systems, retail national accounts and small and medium chain \npharmacies.  \n \n", "page_label": "5", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2b6fa81b-d6e8-4046-a002-579e9e14ad02", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f979e56f55121861d8368ca4fe9d5a492f8ab49f3de018ae9a4ece2eb1f430a2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7f7ea861-a630-4b0c-8740-ff7430aa5ff2", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nyou, TBA is a group consisting of several health systems, retail national accounts and small and medium chain \npharmacies.  \n \n We're always looking for how we can best  serve our customers and help them grow their business.  This was \nevidenced by the growth in our specialty provider business in the midst of this pandemic driven in small part by \nimproved adoption of biosimilars in the quarter. ", "original_text": "McKesson Corp.  ", "page_label": "5", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c77e5581abe3b0aae98b8274506b0875b2797b2185ec6d556a61c8c641f99443", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "544f6404-fc2a-4cf6-87f5-62f83805b2e0", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nyou, TBA is a group consisting of several health systems, retail national accounts and small and medium chain \npharmacies.  \n \n We're always looking for how we can best  serve our customers and help them grow their business.  This was \nevidenced by the growth in our specialty provider business in the midst of this pandemic driven in small part by \nimproved adoption of biosimilars in the quarter.  While our specialty business recovered more quickly than we had \nassumed following the initial downturns in demand, we have certainly had to adapt to meet the needs of patients. \n At the onset of the pandemic, the US oncology network developed a rollout plan for telemedicine. ", "original_text": "We're always looking for how we can best  serve our customers and help them grow their business. "}, "hash": "b269bb5be088722cbd3c74e82e3be3944beb13c326460b3198de1ad42c415351", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nyou, TBA is a group consisting of several health systems, retail national accounts and small and medium chain \npharmacies.  \n \n", "start_char_idx": 16, "end_char_idx": 307, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "544f6404-fc2a-4cf6-87f5-62f83805b2e0": {"__data__": {"id_": "544f6404-fc2a-4cf6-87f5-62f83805b2e0", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nyou, TBA is a group consisting of several health systems, retail national accounts and small and medium chain \npharmacies.  \n \n We're always looking for how we can best  serve our customers and help them grow their business.  This was \nevidenced by the growth in our specialty provider business in the midst of this pandemic driven in small part by \nimproved adoption of biosimilars in the quarter.  While our specialty business recovered more quickly than we had \nassumed following the initial downturns in demand, we have certainly had to adapt to meet the needs of patients. \n At the onset of the pandemic, the US oncology network developed a rollout plan for telemedicine. ", "original_text": "We're always looking for how we can best  serve our customers and help them grow their business. ", "page_label": "5", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2b6fa81b-d6e8-4046-a002-579e9e14ad02", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f979e56f55121861d8368ca4fe9d5a492f8ab49f3de018ae9a4ece2eb1f430a2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bda5d8d2-b4c2-4bd5-bac6-aef17a1537f3", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nyou, TBA is a group consisting of several health systems, retail national accounts and small and medium chain \npharmacies.  \n \n We're always looking for how we can best  serve our customers and help them grow their business.  This was \nevidenced by the growth in our specialty provider business in the midst of this pandemic driven in small part by \nimproved adoption of biosimilars in the quarter.  While our specialty business recovered more quickly than we had \nassumed following the initial downturns in demand, we have certainly had to adapt to meet the needs of patients. \n", "original_text": "(MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nyou, TBA is a group consisting of several health systems, retail national accounts and small and medium chain \npharmacies.  \n \n", "page_label": "5", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a61816799e64484e6ba0e7b84e4610058c85b0f07f832400432cd75dfe506aae", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "818a91d5-e536-431e-b956-a2028fd9a151", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nyou, TBA is a group consisting of several health systems, retail national accounts and small and medium chain \npharmacies.  \n \n We're always looking for how we can best  serve our customers and help them grow their business.  This was \nevidenced by the growth in our specialty provider business in the midst of this pandemic driven in small part by \nimproved adoption of biosimilars in the quarter.  While our specialty business recovered more quickly than we had \nassumed following the initial downturns in demand, we have certainly had to adapt to meet the needs of patients. \n At the onset of the pandemic, the US oncology network developed a rollout plan for telemedicine.  And within four \nweeks, 80% of our network physicians were able to initiate telemedicine follow -up visits and new consultations \nwith their patients.  \n \n", "original_text": "This was \nevidenced by the growth in our specialty provider business in the midst of this pandemic driven in small part by \nimproved adoption of biosimilars in the quarter. "}, "hash": "478a127279d889788fb35cea0f81ccd088ef9d904d6aa80b994a7b41438580de", "class_name": "RelatedNodeInfo"}}, "text": "We're always looking for how we can best  serve our customers and help them grow their business. ", "start_char_idx": 307, "end_char_idx": 404, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "818a91d5-e536-431e-b956-a2028fd9a151": {"__data__": {"id_": "818a91d5-e536-431e-b956-a2028fd9a151", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nyou, TBA is a group consisting of several health systems, retail national accounts and small and medium chain \npharmacies.  \n \n We're always looking for how we can best  serve our customers and help them grow their business.  This was \nevidenced by the growth in our specialty provider business in the midst of this pandemic driven in small part by \nimproved adoption of biosimilars in the quarter.  While our specialty business recovered more quickly than we had \nassumed following the initial downturns in demand, we have certainly had to adapt to meet the needs of patients. \n At the onset of the pandemic, the US oncology network developed a rollout plan for telemedicine.  And within four \nweeks, 80% of our network physicians were able to initiate telemedicine follow -up visits and new consultations \nwith their patients.  \n \n", "original_text": "This was \nevidenced by the growth in our specialty provider business in the midst of this pandemic driven in small part by \nimproved adoption of biosimilars in the quarter. ", "page_label": "5", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2b6fa81b-d6e8-4046-a002-579e9e14ad02", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f979e56f55121861d8368ca4fe9d5a492f8ab49f3de018ae9a4ece2eb1f430a2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "544f6404-fc2a-4cf6-87f5-62f83805b2e0", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nyou, TBA is a group consisting of several health systems, retail national accounts and small and medium chain \npharmacies.  \n \n We're always looking for how we can best  serve our customers and help them grow their business.  This was \nevidenced by the growth in our specialty provider business in the midst of this pandemic driven in small part by \nimproved adoption of biosimilars in the quarter.  While our specialty business recovered more quickly than we had \nassumed following the initial downturns in demand, we have certainly had to adapt to meet the needs of patients. \n At the onset of the pandemic, the US oncology network developed a rollout plan for telemedicine. ", "original_text": "We're always looking for how we can best  serve our customers and help them grow their business. ", "page_label": "5", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "feaf7af9583a73a514e99f39fd2164c4e1000602c5f72b77bb9d718b645d1ca8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9c9e6c9c-84f7-4380-abe5-bdd4d824fcc2", "node_type": "1", "metadata": {"window": "(MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nyou, TBA is a group consisting of several health systems, retail national accounts and small and medium chain \npharmacies.  \n \n We're always looking for how we can best  serve our customers and help them grow their business.  This was \nevidenced by the growth in our specialty provider business in the midst of this pandemic driven in small part by \nimproved adoption of biosimilars in the quarter.  While our specialty business recovered more quickly than we had \nassumed following the initial downturns in demand, we have certainly had to adapt to meet the needs of patients. \n At the onset of the pandemic, the US oncology network developed a rollout plan for telemedicine.  And within four \nweeks, 80% of our network physicians were able to initiate telemedicine follow -up visits and new consultations \nwith their patients.  \n \n To-date, more than 120,000 telemedicine visits have taken place with over 1,250 providers. ", "original_text": "While our specialty business recovered more quickly than we had \nassumed following the initial downturns in demand, we have certainly had to adapt to meet the needs of patients. \n"}, "hash": "f2f818d76a12d9fe339a7263a3d8ef71c1ecd7a8a0c939699c82e93d80dc55a3", "class_name": "RelatedNodeInfo"}}, "text": "This was \nevidenced by the growth in our specialty provider business in the midst of this pandemic driven in small part by \nimproved adoption of biosimilars in the quarter. ", "start_char_idx": 404, "end_char_idx": 577, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9c9e6c9c-84f7-4380-abe5-bdd4d824fcc2": {"__data__": {"id_": "9c9e6c9c-84f7-4380-abe5-bdd4d824fcc2", "embedding": null, "metadata": {"window": "(MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nyou, TBA is a group consisting of several health systems, retail national accounts and small and medium chain \npharmacies.  \n \n We're always looking for how we can best  serve our customers and help them grow their business.  This was \nevidenced by the growth in our specialty provider business in the midst of this pandemic driven in small part by \nimproved adoption of biosimilars in the quarter.  While our specialty business recovered more quickly than we had \nassumed following the initial downturns in demand, we have certainly had to adapt to meet the needs of patients. \n At the onset of the pandemic, the US oncology network developed a rollout plan for telemedicine.  And within four \nweeks, 80% of our network physicians were able to initiate telemedicine follow -up visits and new consultations \nwith their patients.  \n \n To-date, more than 120,000 telemedicine visits have taken place with over 1,250 providers. ", "original_text": "While our specialty business recovered more quickly than we had \nassumed following the initial downturns in demand, we have certainly had to adapt to meet the needs of patients. \n", "page_label": "5", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2b6fa81b-d6e8-4046-a002-579e9e14ad02", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f979e56f55121861d8368ca4fe9d5a492f8ab49f3de018ae9a4ece2eb1f430a2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "818a91d5-e536-431e-b956-a2028fd9a151", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nyou, TBA is a group consisting of several health systems, retail national accounts and small and medium chain \npharmacies.  \n \n We're always looking for how we can best  serve our customers and help them grow their business.  This was \nevidenced by the growth in our specialty provider business in the midst of this pandemic driven in small part by \nimproved adoption of biosimilars in the quarter.  While our specialty business recovered more quickly than we had \nassumed following the initial downturns in demand, we have certainly had to adapt to meet the needs of patients. \n At the onset of the pandemic, the US oncology network developed a rollout plan for telemedicine.  And within four \nweeks, 80% of our network physicians were able to initiate telemedicine follow -up visits and new consultations \nwith their patients.  \n \n", "original_text": "This was \nevidenced by the growth in our specialty provider business in the midst of this pandemic driven in small part by \nimproved adoption of biosimilars in the quarter. ", "page_label": "5", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bc166638421f620a40f8f1ee9e88807f79b8fbe9e4302e075067d9cf47b2ee97", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "639f0dc6-0ef4-4519-8900-9007f603a87a", "node_type": "1", "metadata": {"window": "We're always looking for how we can best  serve our customers and help them grow their business.  This was \nevidenced by the growth in our specialty provider business in the midst of this pandemic driven in small part by \nimproved adoption of biosimilars in the quarter.  While our specialty business recovered more quickly than we had \nassumed following the initial downturns in demand, we have certainly had to adapt to meet the needs of patients. \n At the onset of the pandemic, the US oncology network developed a rollout plan for telemedicine.  And within four \nweeks, 80% of our network physicians were able to initiate telemedicine follow -up visits and new consultations \nwith their patients.  \n \n To-date, more than 120,000 telemedicine visits have taken place with over 1,250 providers.  Our improved outlook \nfor fiscal 2021 in the segment reflects the positive trends we saw in the quarter across the portfolio versus our \noriginal expectations. ", "original_text": "At the onset of the pandemic, the US oncology network developed a rollout plan for telemedicine. "}, "hash": "df0e3a84bf60a5f0827b77f1c0660ac1cc809eaa7cb176dabfb696a8be1e4aac", "class_name": "RelatedNodeInfo"}}, "text": "While our specialty business recovered more quickly than we had \nassumed following the initial downturns in demand, we have certainly had to adapt to meet the needs of patients. \n", "start_char_idx": 577, "end_char_idx": 756, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "639f0dc6-0ef4-4519-8900-9007f603a87a": {"__data__": {"id_": "639f0dc6-0ef4-4519-8900-9007f603a87a", "embedding": null, "metadata": {"window": "We're always looking for how we can best  serve our customers and help them grow their business.  This was \nevidenced by the growth in our specialty provider business in the midst of this pandemic driven in small part by \nimproved adoption of biosimilars in the quarter.  While our specialty business recovered more quickly than we had \nassumed following the initial downturns in demand, we have certainly had to adapt to meet the needs of patients. \n At the onset of the pandemic, the US oncology network developed a rollout plan for telemedicine.  And within four \nweeks, 80% of our network physicians were able to initiate telemedicine follow -up visits and new consultations \nwith their patients.  \n \n To-date, more than 120,000 telemedicine visits have taken place with over 1,250 providers.  Our improved outlook \nfor fiscal 2021 in the segment reflects the positive trends we saw in the quarter across the portfolio versus our \noriginal expectations. ", "original_text": "At the onset of the pandemic, the US oncology network developed a rollout plan for telemedicine. ", "page_label": "5", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2b6fa81b-d6e8-4046-a002-579e9e14ad02", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f979e56f55121861d8368ca4fe9d5a492f8ab49f3de018ae9a4ece2eb1f430a2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9c9e6c9c-84f7-4380-abe5-bdd4d824fcc2", "node_type": "1", "metadata": {"window": "(MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nyou, TBA is a group consisting of several health systems, retail national accounts and small and medium chain \npharmacies.  \n \n We're always looking for how we can best  serve our customers and help them grow their business.  This was \nevidenced by the growth in our specialty provider business in the midst of this pandemic driven in small part by \nimproved adoption of biosimilars in the quarter.  While our specialty business recovered more quickly than we had \nassumed following the initial downturns in demand, we have certainly had to adapt to meet the needs of patients. \n At the onset of the pandemic, the US oncology network developed a rollout plan for telemedicine.  And within four \nweeks, 80% of our network physicians were able to initiate telemedicine follow -up visits and new consultations \nwith their patients.  \n \n To-date, more than 120,000 telemedicine visits have taken place with over 1,250 providers. ", "original_text": "While our specialty business recovered more quickly than we had \nassumed following the initial downturns in demand, we have certainly had to adapt to meet the needs of patients. \n", "page_label": "5", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "639669d57e31a6364de6e706603099053a4bf07f461158ffbc1c32bc213bc052", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2110b589-637f-4205-8262-25b7b48c31c1", "node_type": "1", "metadata": {"window": "This was \nevidenced by the growth in our specialty provider business in the midst of this pandemic driven in small part by \nimproved adoption of biosimilars in the quarter.  While our specialty business recovered more quickly than we had \nassumed following the initial downturns in demand, we have certainly had to adapt to meet the needs of patients. \n At the onset of the pandemic, the US oncology network developed a rollout plan for telemedicine.  And within four \nweeks, 80% of our network physicians were able to initiate telemedicine follow -up visits and new consultations \nwith their patients.  \n \n To-date, more than 120,000 telemedicine visits have taken place with over 1,250 providers.  Our improved outlook \nfor fiscal 2021 in the segment reflects the positive trends we saw in the quarter across the portfolio versus our \noriginal expectations.  Let me make a few comments on Europe. ", "original_text": "And within four \nweeks, 80% of our network physicians were able to initiate telemedicine follow -up visits and new consultations \nwith their patients.  \n \n"}, "hash": "552fa935967300fbf44f5473bfef9d45258805b5d37680b66fb6509d96320cc3", "class_name": "RelatedNodeInfo"}}, "text": "At the onset of the pandemic, the US oncology network developed a rollout plan for telemedicine. ", "start_char_idx": 756, "end_char_idx": 853, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2110b589-637f-4205-8262-25b7b48c31c1": {"__data__": {"id_": "2110b589-637f-4205-8262-25b7b48c31c1", "embedding": null, "metadata": {"window": "This was \nevidenced by the growth in our specialty provider business in the midst of this pandemic driven in small part by \nimproved adoption of biosimilars in the quarter.  While our specialty business recovered more quickly than we had \nassumed following the initial downturns in demand, we have certainly had to adapt to meet the needs of patients. \n At the onset of the pandemic, the US oncology network developed a rollout plan for telemedicine.  And within four \nweeks, 80% of our network physicians were able to initiate telemedicine follow -up visits and new consultations \nwith their patients.  \n \n To-date, more than 120,000 telemedicine visits have taken place with over 1,250 providers.  Our improved outlook \nfor fiscal 2021 in the segment reflects the positive trends we saw in the quarter across the portfolio versus our \noriginal expectations.  Let me make a few comments on Europe. ", "original_text": "And within four \nweeks, 80% of our network physicians were able to initiate telemedicine follow -up visits and new consultations \nwith their patients.  \n \n", "page_label": "5", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2b6fa81b-d6e8-4046-a002-579e9e14ad02", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f979e56f55121861d8368ca4fe9d5a492f8ab49f3de018ae9a4ece2eb1f430a2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "639f0dc6-0ef4-4519-8900-9007f603a87a", "node_type": "1", "metadata": {"window": "We're always looking for how we can best  serve our customers and help them grow their business.  This was \nevidenced by the growth in our specialty provider business in the midst of this pandemic driven in small part by \nimproved adoption of biosimilars in the quarter.  While our specialty business recovered more quickly than we had \nassumed following the initial downturns in demand, we have certainly had to adapt to meet the needs of patients. \n At the onset of the pandemic, the US oncology network developed a rollout plan for telemedicine.  And within four \nweeks, 80% of our network physicians were able to initiate telemedicine follow -up visits and new consultations \nwith their patients.  \n \n To-date, more than 120,000 telemedicine visits have taken place with over 1,250 providers.  Our improved outlook \nfor fiscal 2021 in the segment reflects the positive trends we saw in the quarter across the portfolio versus our \noriginal expectations. ", "original_text": "At the onset of the pandemic, the US oncology network developed a rollout plan for telemedicine. ", "page_label": "5", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4954358bce414ac435c0a90140e0780d7efaf480b999bc365055d28836c68825", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "16f44cc7-755d-46b5-8e20-e06c80b34364", "node_type": "1", "metadata": {"window": "While our specialty business recovered more quickly than we had \nassumed following the initial downturns in demand, we have certainly had to adapt to meet the needs of patients. \n At the onset of the pandemic, the US oncology network developed a rollout plan for telemedicine.  And within four \nweeks, 80% of our network physicians were able to initiate telemedicine follow -up visits and new consultations \nwith their patients.  \n \n To-date, more than 120,000 telemedicine visits have taken place with over 1,250 providers.  Our improved outlook \nfor fiscal 2021 in the segment reflects the positive trends we saw in the quarter across the portfolio versus our \noriginal expectations.  Let me make a few comments on Europe.  While each of the 13 countries we operate in, \nhave had different responses and recoveri es during the pandemic, we're encouraged by the segment's results in \nthe first quarter.  \n \n", "original_text": "To-date, more than 120,000 telemedicine visits have taken place with over 1,250 providers. "}, "hash": "58147f45b2d8a66f21aa96b8898e16e5da8b502cadd8c6b1a658c10d928760a4", "class_name": "RelatedNodeInfo"}}, "text": "And within four \nweeks, 80% of our network physicians were able to initiate telemedicine follow -up visits and new consultations \nwith their patients.  \n \n", "start_char_idx": 853, "end_char_idx": 1008, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "16f44cc7-755d-46b5-8e20-e06c80b34364": {"__data__": {"id_": "16f44cc7-755d-46b5-8e20-e06c80b34364", "embedding": null, "metadata": {"window": "While our specialty business recovered more quickly than we had \nassumed following the initial downturns in demand, we have certainly had to adapt to meet the needs of patients. \n At the onset of the pandemic, the US oncology network developed a rollout plan for telemedicine.  And within four \nweeks, 80% of our network physicians were able to initiate telemedicine follow -up visits and new consultations \nwith their patients.  \n \n To-date, more than 120,000 telemedicine visits have taken place with over 1,250 providers.  Our improved outlook \nfor fiscal 2021 in the segment reflects the positive trends we saw in the quarter across the portfolio versus our \noriginal expectations.  Let me make a few comments on Europe.  While each of the 13 countries we operate in, \nhave had different responses and recoveri es during the pandemic, we're encouraged by the segment's results in \nthe first quarter.  \n \n", "original_text": "To-date, more than 120,000 telemedicine visits have taken place with over 1,250 providers. ", "page_label": "5", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2b6fa81b-d6e8-4046-a002-579e9e14ad02", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f979e56f55121861d8368ca4fe9d5a492f8ab49f3de018ae9a4ece2eb1f430a2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2110b589-637f-4205-8262-25b7b48c31c1", "node_type": "1", "metadata": {"window": "This was \nevidenced by the growth in our specialty provider business in the midst of this pandemic driven in small part by \nimproved adoption of biosimilars in the quarter.  While our specialty business recovered more quickly than we had \nassumed following the initial downturns in demand, we have certainly had to adapt to meet the needs of patients. \n At the onset of the pandemic, the US oncology network developed a rollout plan for telemedicine.  And within four \nweeks, 80% of our network physicians were able to initiate telemedicine follow -up visits and new consultations \nwith their patients.  \n \n To-date, more than 120,000 telemedicine visits have taken place with over 1,250 providers.  Our improved outlook \nfor fiscal 2021 in the segment reflects the positive trends we saw in the quarter across the portfolio versus our \noriginal expectations.  Let me make a few comments on Europe. ", "original_text": "And within four \nweeks, 80% of our network physicians were able to initiate telemedicine follow -up visits and new consultations \nwith their patients.  \n \n", "page_label": "5", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5909b4b62b0da3f87aec3d2c35fc2872938089e23d4aad02d0a2cf8a692b4405", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "890add9a-e8dd-4cbe-bba1-ddcae36c79da", "node_type": "1", "metadata": {"window": "At the onset of the pandemic, the US oncology network developed a rollout plan for telemedicine.  And within four \nweeks, 80% of our network physicians were able to initiate telemedicine follow -up visits and new consultations \nwith their patients.  \n \n To-date, more than 120,000 telemedicine visits have taken place with over 1,250 providers.  Our improved outlook \nfor fiscal 2021 in the segment reflects the positive trends we saw in the quarter across the portfolio versus our \noriginal expectations.  Let me make a few comments on Europe.  While each of the 13 countries we operate in, \nhave had different responses and recoveri es during the pandemic, we're encouraged by the segment's results in \nthe first quarter.  \n \n We also continue to take actions to better position the business for future growth, as evidenced by our ongoing \nefforts to evaluate our footprint and cost structure in  our largest market, the UK. ", "original_text": "Our improved outlook \nfor fiscal 2021 in the segment reflects the positive trends we saw in the quarter across the portfolio versus our \noriginal expectations. "}, "hash": "c57146942b7b0ac86a713ec664f1043a8d9cfbf829bf3f7041e6d092f4c827b9", "class_name": "RelatedNodeInfo"}}, "text": "To-date, more than 120,000 telemedicine visits have taken place with over 1,250 providers. ", "start_char_idx": 1008, "end_char_idx": 1099, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "890add9a-e8dd-4cbe-bba1-ddcae36c79da": {"__data__": {"id_": "890add9a-e8dd-4cbe-bba1-ddcae36c79da", "embedding": null, "metadata": {"window": "At the onset of the pandemic, the US oncology network developed a rollout plan for telemedicine.  And within four \nweeks, 80% of our network physicians were able to initiate telemedicine follow -up visits and new consultations \nwith their patients.  \n \n To-date, more than 120,000 telemedicine visits have taken place with over 1,250 providers.  Our improved outlook \nfor fiscal 2021 in the segment reflects the positive trends we saw in the quarter across the portfolio versus our \noriginal expectations.  Let me make a few comments on Europe.  While each of the 13 countries we operate in, \nhave had different responses and recoveri es during the pandemic, we're encouraged by the segment's results in \nthe first quarter.  \n \n We also continue to take actions to better position the business for future growth, as evidenced by our ongoing \nefforts to evaluate our footprint and cost structure in  our largest market, the UK. ", "original_text": "Our improved outlook \nfor fiscal 2021 in the segment reflects the positive trends we saw in the quarter across the portfolio versus our \noriginal expectations. ", "page_label": "5", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2b6fa81b-d6e8-4046-a002-579e9e14ad02", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f979e56f55121861d8368ca4fe9d5a492f8ab49f3de018ae9a4ece2eb1f430a2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "16f44cc7-755d-46b5-8e20-e06c80b34364", "node_type": "1", "metadata": {"window": "While our specialty business recovered more quickly than we had \nassumed following the initial downturns in demand, we have certainly had to adapt to meet the needs of patients. \n At the onset of the pandemic, the US oncology network developed a rollout plan for telemedicine.  And within four \nweeks, 80% of our network physicians were able to initiate telemedicine follow -up visits and new consultations \nwith their patients.  \n \n To-date, more than 120,000 telemedicine visits have taken place with over 1,250 providers.  Our improved outlook \nfor fiscal 2021 in the segment reflects the positive trends we saw in the quarter across the portfolio versus our \noriginal expectations.  Let me make a few comments on Europe.  While each of the 13 countries we operate in, \nhave had different responses and recoveri es during the pandemic, we're encouraged by the segment's results in \nthe first quarter.  \n \n", "original_text": "To-date, more than 120,000 telemedicine visits have taken place with over 1,250 providers. ", "page_label": "5", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8420ee09f1b8082ee7d7d7cef7bc5755c4da97614810e124d2b31efc37ec132f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0ab0d51e-dd8e-4270-bd90-f08a9bfde0ac", "node_type": "1", "metadata": {"window": "And within four \nweeks, 80% of our network physicians were able to initiate telemedicine follow -up visits and new consultations \nwith their patients.  \n \n To-date, more than 120,000 telemedicine visits have taken place with over 1,250 providers.  Our improved outlook \nfor fiscal 2021 in the segment reflects the positive trends we saw in the quarter across the portfolio versus our \noriginal expectations.  Let me make a few comments on Europe.  While each of the 13 countries we operate in, \nhave had different responses and recoveri es during the pandemic, we're encouraged by the segment's results in \nthe first quarter.  \n \n We also continue to take actions to better position the business for future growth, as evidenced by our ongoing \nefforts to evaluate our footprint and cost structure in  our largest market, the UK.  In the UK market, I'd remind you \nthat our owned retail pharmacies are very health care -focused, with up to 90% of our mix coming from \npharmaceutical volumes. ", "original_text": "Let me make a few comments on Europe. "}, "hash": "adf51589668bda299ff6b0880fb0b049a1de438dffc24246a2cc9adeeb35513a", "class_name": "RelatedNodeInfo"}}, "text": "Our improved outlook \nfor fiscal 2021 in the segment reflects the positive trends we saw in the quarter across the portfolio versus our \noriginal expectations. ", "start_char_idx": 1099, "end_char_idx": 1259, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0ab0d51e-dd8e-4270-bd90-f08a9bfde0ac": {"__data__": {"id_": "0ab0d51e-dd8e-4270-bd90-f08a9bfde0ac", "embedding": null, "metadata": {"window": "And within four \nweeks, 80% of our network physicians were able to initiate telemedicine follow -up visits and new consultations \nwith their patients.  \n \n To-date, more than 120,000 telemedicine visits have taken place with over 1,250 providers.  Our improved outlook \nfor fiscal 2021 in the segment reflects the positive trends we saw in the quarter across the portfolio versus our \noriginal expectations.  Let me make a few comments on Europe.  While each of the 13 countries we operate in, \nhave had different responses and recoveri es during the pandemic, we're encouraged by the segment's results in \nthe first quarter.  \n \n We also continue to take actions to better position the business for future growth, as evidenced by our ongoing \nefforts to evaluate our footprint and cost structure in  our largest market, the UK.  In the UK market, I'd remind you \nthat our owned retail pharmacies are very health care -focused, with up to 90% of our mix coming from \npharmaceutical volumes. ", "original_text": "Let me make a few comments on Europe. ", "page_label": "5", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2b6fa81b-d6e8-4046-a002-579e9e14ad02", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f979e56f55121861d8368ca4fe9d5a492f8ab49f3de018ae9a4ece2eb1f430a2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "890add9a-e8dd-4cbe-bba1-ddcae36c79da", "node_type": "1", "metadata": {"window": "At the onset of the pandemic, the US oncology network developed a rollout plan for telemedicine.  And within four \nweeks, 80% of our network physicians were able to initiate telemedicine follow -up visits and new consultations \nwith their patients.  \n \n To-date, more than 120,000 telemedicine visits have taken place with over 1,250 providers.  Our improved outlook \nfor fiscal 2021 in the segment reflects the positive trends we saw in the quarter across the portfolio versus our \noriginal expectations.  Let me make a few comments on Europe.  While each of the 13 countries we operate in, \nhave had different responses and recoveri es during the pandemic, we're encouraged by the segment's results in \nthe first quarter.  \n \n We also continue to take actions to better position the business for future growth, as evidenced by our ongoing \nefforts to evaluate our footprint and cost structure in  our largest market, the UK. ", "original_text": "Our improved outlook \nfor fiscal 2021 in the segment reflects the positive trends we saw in the quarter across the portfolio versus our \noriginal expectations. ", "page_label": "5", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "83948882037aca707983811f0207e054637cb693243ef10574eeb64b00a720b5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "24feaeee-f058-4248-8883-f0fbe3983773", "node_type": "1", "metadata": {"window": "To-date, more than 120,000 telemedicine visits have taken place with over 1,250 providers.  Our improved outlook \nfor fiscal 2021 in the segment reflects the positive trends we saw in the quarter across the portfolio versus our \noriginal expectations.  Let me make a few comments on Europe.  While each of the 13 countries we operate in, \nhave had different responses and recoveri es during the pandemic, we're encouraged by the segment's results in \nthe first quarter.  \n \n We also continue to take actions to better position the business for future growth, as evidenced by our ongoing \nefforts to evaluate our footprint and cost structure in  our largest market, the UK.  In the UK market, I'd remind you \nthat our owned retail pharmacies are very health care -focused, with up to 90% of our mix coming from \npharmaceutical volumes.  While lower foot traffic through our pharmacies was a headwind in the  quarter, our \ndownside was limited due to our relatively small exposure to the front shop categories.  \n \n", "original_text": "While each of the 13 countries we operate in, \nhave had different responses and recoveri es during the pandemic, we're encouraged by the segment's results in \nthe first quarter.  \n \n"}, "hash": "6c0b4bdde72724cd6080020961d0afd6c97af1e8e2f272fa45ede6b9c2ad2c62", "class_name": "RelatedNodeInfo"}}, "text": "Let me make a few comments on Europe. ", "start_char_idx": 1259, "end_char_idx": 1297, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "24feaeee-f058-4248-8883-f0fbe3983773": {"__data__": {"id_": "24feaeee-f058-4248-8883-f0fbe3983773", "embedding": null, "metadata": {"window": "To-date, more than 120,000 telemedicine visits have taken place with over 1,250 providers.  Our improved outlook \nfor fiscal 2021 in the segment reflects the positive trends we saw in the quarter across the portfolio versus our \noriginal expectations.  Let me make a few comments on Europe.  While each of the 13 countries we operate in, \nhave had different responses and recoveri es during the pandemic, we're encouraged by the segment's results in \nthe first quarter.  \n \n We also continue to take actions to better position the business for future growth, as evidenced by our ongoing \nefforts to evaluate our footprint and cost structure in  our largest market, the UK.  In the UK market, I'd remind you \nthat our owned retail pharmacies are very health care -focused, with up to 90% of our mix coming from \npharmaceutical volumes.  While lower foot traffic through our pharmacies was a headwind in the  quarter, our \ndownside was limited due to our relatively small exposure to the front shop categories.  \n \n", "original_text": "While each of the 13 countries we operate in, \nhave had different responses and recoveri es during the pandemic, we're encouraged by the segment's results in \nthe first quarter.  \n \n", "page_label": "5", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2b6fa81b-d6e8-4046-a002-579e9e14ad02", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f979e56f55121861d8368ca4fe9d5a492f8ab49f3de018ae9a4ece2eb1f430a2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0ab0d51e-dd8e-4270-bd90-f08a9bfde0ac", "node_type": "1", "metadata": {"window": "And within four \nweeks, 80% of our network physicians were able to initiate telemedicine follow -up visits and new consultations \nwith their patients.  \n \n To-date, more than 120,000 telemedicine visits have taken place with over 1,250 providers.  Our improved outlook \nfor fiscal 2021 in the segment reflects the positive trends we saw in the quarter across the portfolio versus our \noriginal expectations.  Let me make a few comments on Europe.  While each of the 13 countries we operate in, \nhave had different responses and recoveri es during the pandemic, we're encouraged by the segment's results in \nthe first quarter.  \n \n We also continue to take actions to better position the business for future growth, as evidenced by our ongoing \nefforts to evaluate our footprint and cost structure in  our largest market, the UK.  In the UK market, I'd remind you \nthat our owned retail pharmacies are very health care -focused, with up to 90% of our mix coming from \npharmaceutical volumes. ", "original_text": "Let me make a few comments on Europe. ", "page_label": "5", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6b56aef556b46aea03ea902014cae0a9c9ac107880b43938f6572be30e67697c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2c19cc6e-7d83-4990-962e-36ef045924d1", "node_type": "1", "metadata": {"window": "Our improved outlook \nfor fiscal 2021 in the segment reflects the positive trends we saw in the quarter across the portfolio versus our \noriginal expectations.  Let me make a few comments on Europe.  While each of the 13 countries we operate in, \nhave had different responses and recoveri es during the pandemic, we're encouraged by the segment's results in \nthe first quarter.  \n \n We also continue to take actions to better position the business for future growth, as evidenced by our ongoing \nefforts to evaluate our footprint and cost structure in  our largest market, the UK.  In the UK market, I'd remind you \nthat our owned retail pharmacies are very health care -focused, with up to 90% of our mix coming from \npharmaceutical volumes.  While lower foot traffic through our pharmacies was a headwind in the  quarter, our \ndownside was limited due to our relatively small exposure to the front shop categories.  \n \n A good example of how we're evolving this business is our 2019 acquisition of a company called Echo, now \noperating as Echo by LloydsPharmacy. ", "original_text": "We also continue to take actions to better position the business for future growth, as evidenced by our ongoing \nefforts to evaluate our footprint and cost structure in  our largest market, the UK. "}, "hash": "83318db1ced5620c190f613e31d4f70ea1af6d0d4978d189d7ffb05a1108e19d", "class_name": "RelatedNodeInfo"}}, "text": "While each of the 13 countries we operate in, \nhave had different responses and recoveri es during the pandemic, we're encouraged by the segment's results in \nthe first quarter.  \n \n", "start_char_idx": 1297, "end_char_idx": 1479, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2c19cc6e-7d83-4990-962e-36ef045924d1": {"__data__": {"id_": "2c19cc6e-7d83-4990-962e-36ef045924d1", "embedding": null, "metadata": {"window": "Our improved outlook \nfor fiscal 2021 in the segment reflects the positive trends we saw in the quarter across the portfolio versus our \noriginal expectations.  Let me make a few comments on Europe.  While each of the 13 countries we operate in, \nhave had different responses and recoveri es during the pandemic, we're encouraged by the segment's results in \nthe first quarter.  \n \n We also continue to take actions to better position the business for future growth, as evidenced by our ongoing \nefforts to evaluate our footprint and cost structure in  our largest market, the UK.  In the UK market, I'd remind you \nthat our owned retail pharmacies are very health care -focused, with up to 90% of our mix coming from \npharmaceutical volumes.  While lower foot traffic through our pharmacies was a headwind in the  quarter, our \ndownside was limited due to our relatively small exposure to the front shop categories.  \n \n A good example of how we're evolving this business is our 2019 acquisition of a company called Echo, now \noperating as Echo by LloydsPharmacy. ", "original_text": "We also continue to take actions to better position the business for future growth, as evidenced by our ongoing \nefforts to evaluate our footprint and cost structure in  our largest market, the UK. ", "page_label": "5", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2b6fa81b-d6e8-4046-a002-579e9e14ad02", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f979e56f55121861d8368ca4fe9d5a492f8ab49f3de018ae9a4ece2eb1f430a2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "24feaeee-f058-4248-8883-f0fbe3983773", "node_type": "1", "metadata": {"window": "To-date, more than 120,000 telemedicine visits have taken place with over 1,250 providers.  Our improved outlook \nfor fiscal 2021 in the segment reflects the positive trends we saw in the quarter across the portfolio versus our \noriginal expectations.  Let me make a few comments on Europe.  While each of the 13 countries we operate in, \nhave had different responses and recoveri es during the pandemic, we're encouraged by the segment's results in \nthe first quarter.  \n \n We also continue to take actions to better position the business for future growth, as evidenced by our ongoing \nefforts to evaluate our footprint and cost structure in  our largest market, the UK.  In the UK market, I'd remind you \nthat our owned retail pharmacies are very health care -focused, with up to 90% of our mix coming from \npharmaceutical volumes.  While lower foot traffic through our pharmacies was a headwind in the  quarter, our \ndownside was limited due to our relatively small exposure to the front shop categories.  \n \n", "original_text": "While each of the 13 countries we operate in, \nhave had different responses and recoveri es during the pandemic, we're encouraged by the segment's results in \nthe first quarter.  \n \n", "page_label": "5", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6b3cebe31d67527ff8968e446851a8a5976c3e9bc9683508ef9cb6748102ce9f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a1a27fe7-72f2-4154-8790-9543b8499ab6", "node_type": "1", "metadata": {"window": "Let me make a few comments on Europe.  While each of the 13 countries we operate in, \nhave had different responses and recoveri es during the pandemic, we're encouraged by the segment's results in \nthe first quarter.  \n \n We also continue to take actions to better position the business for future growth, as evidenced by our ongoing \nefforts to evaluate our footprint and cost structure in  our largest market, the UK.  In the UK market, I'd remind you \nthat our owned retail pharmacies are very health care -focused, with up to 90% of our mix coming from \npharmaceutical volumes.  While lower foot traffic through our pharmacies was a headwind in the  quarter, our \ndownside was limited due to our relatively small exposure to the front shop categories.  \n \n A good example of how we're evolving this business is our 2019 acquisition of a company called Echo, now \noperating as Echo by LloydsPharmacy.  This is an online prescription fulfillment business in the UK. ", "original_text": "In the UK market, I'd remind you \nthat our owned retail pharmacies are very health care -focused, with up to 90% of our mix coming from \npharmaceutical volumes. "}, "hash": "662549c90dafd3b0d7124f8a2d27df7a2d2275b565730305863ffaf088ff0dc8", "class_name": "RelatedNodeInfo"}}, "text": "We also continue to take actions to better position the business for future growth, as evidenced by our ongoing \nefforts to evaluate our footprint and cost structure in  our largest market, the UK. ", "start_char_idx": 1479, "end_char_idx": 1677, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a1a27fe7-72f2-4154-8790-9543b8499ab6": {"__data__": {"id_": "a1a27fe7-72f2-4154-8790-9543b8499ab6", "embedding": null, "metadata": {"window": "Let me make a few comments on Europe.  While each of the 13 countries we operate in, \nhave had different responses and recoveri es during the pandemic, we're encouraged by the segment's results in \nthe first quarter.  \n \n We also continue to take actions to better position the business for future growth, as evidenced by our ongoing \nefforts to evaluate our footprint and cost structure in  our largest market, the UK.  In the UK market, I'd remind you \nthat our owned retail pharmacies are very health care -focused, with up to 90% of our mix coming from \npharmaceutical volumes.  While lower foot traffic through our pharmacies was a headwind in the  quarter, our \ndownside was limited due to our relatively small exposure to the front shop categories.  \n \n A good example of how we're evolving this business is our 2019 acquisition of a company called Echo, now \noperating as Echo by LloydsPharmacy.  This is an online prescription fulfillment business in the UK. ", "original_text": "In the UK market, I'd remind you \nthat our owned retail pharmacies are very health care -focused, with up to 90% of our mix coming from \npharmaceutical volumes. ", "page_label": "5", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2b6fa81b-d6e8-4046-a002-579e9e14ad02", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f979e56f55121861d8368ca4fe9d5a492f8ab49f3de018ae9a4ece2eb1f430a2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2c19cc6e-7d83-4990-962e-36ef045924d1", "node_type": "1", "metadata": {"window": "Our improved outlook \nfor fiscal 2021 in the segment reflects the positive trends we saw in the quarter across the portfolio versus our \noriginal expectations.  Let me make a few comments on Europe.  While each of the 13 countries we operate in, \nhave had different responses and recoveri es during the pandemic, we're encouraged by the segment's results in \nthe first quarter.  \n \n We also continue to take actions to better position the business for future growth, as evidenced by our ongoing \nefforts to evaluate our footprint and cost structure in  our largest market, the UK.  In the UK market, I'd remind you \nthat our owned retail pharmacies are very health care -focused, with up to 90% of our mix coming from \npharmaceutical volumes.  While lower foot traffic through our pharmacies was a headwind in the  quarter, our \ndownside was limited due to our relatively small exposure to the front shop categories.  \n \n A good example of how we're evolving this business is our 2019 acquisition of a company called Echo, now \noperating as Echo by LloydsPharmacy. ", "original_text": "We also continue to take actions to better position the business for future growth, as evidenced by our ongoing \nefforts to evaluate our footprint and cost structure in  our largest market, the UK. ", "page_label": "5", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "17eacfbd9dca83c73d9f80ab737ce34f83d8653084888eaea8cab3ba4997b914", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "804f9448-56ee-4088-af11-d219dae25c55", "node_type": "1", "metadata": {"window": "While each of the 13 countries we operate in, \nhave had different responses and recoveri es during the pandemic, we're encouraged by the segment's results in \nthe first quarter.  \n \n We also continue to take actions to better position the business for future growth, as evidenced by our ongoing \nefforts to evaluate our footprint and cost structure in  our largest market, the UK.  In the UK market, I'd remind you \nthat our owned retail pharmacies are very health care -focused, with up to 90% of our mix coming from \npharmaceutical volumes.  While lower foot traffic through our pharmacies was a headwind in the  quarter, our \ndownside was limited due to our relatively small exposure to the front shop categories.  \n \n A good example of how we're evolving this business is our 2019 acquisition of a company called Echo, now \noperating as Echo by LloydsPharmacy.  This is an online prescription fulfillment business in the UK.  It was a timely \nacquisition for us, particularly given the impacts of the pandemic. ", "original_text": "While lower foot traffic through our pharmacies was a headwind in the  quarter, our \ndownside was limited due to our relatively small exposure to the front shop categories.  \n \n"}, "hash": "a288ca573d352ee70dfd02f545b32b852dc7137a98d46e9091d25c9d4b0e936a", "class_name": "RelatedNodeInfo"}}, "text": "In the UK market, I'd remind you \nthat our owned retail pharmacies are very health care -focused, with up to 90% of our mix coming from \npharmaceutical volumes. ", "start_char_idx": 1677, "end_char_idx": 1838, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "804f9448-56ee-4088-af11-d219dae25c55": {"__data__": {"id_": "804f9448-56ee-4088-af11-d219dae25c55", "embedding": null, "metadata": {"window": "While each of the 13 countries we operate in, \nhave had different responses and recoveri es during the pandemic, we're encouraged by the segment's results in \nthe first quarter.  \n \n We also continue to take actions to better position the business for future growth, as evidenced by our ongoing \nefforts to evaluate our footprint and cost structure in  our largest market, the UK.  In the UK market, I'd remind you \nthat our owned retail pharmacies are very health care -focused, with up to 90% of our mix coming from \npharmaceutical volumes.  While lower foot traffic through our pharmacies was a headwind in the  quarter, our \ndownside was limited due to our relatively small exposure to the front shop categories.  \n \n A good example of how we're evolving this business is our 2019 acquisition of a company called Echo, now \noperating as Echo by LloydsPharmacy.  This is an online prescription fulfillment business in the UK.  It was a timely \nacquisition for us, particularly given the impacts of the pandemic. ", "original_text": "While lower foot traffic through our pharmacies was a headwind in the  quarter, our \ndownside was limited due to our relatively small exposure to the front shop categories.  \n \n", "page_label": "5", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2b6fa81b-d6e8-4046-a002-579e9e14ad02", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f979e56f55121861d8368ca4fe9d5a492f8ab49f3de018ae9a4ece2eb1f430a2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a1a27fe7-72f2-4154-8790-9543b8499ab6", "node_type": "1", "metadata": {"window": "Let me make a few comments on Europe.  While each of the 13 countries we operate in, \nhave had different responses and recoveri es during the pandemic, we're encouraged by the segment's results in \nthe first quarter.  \n \n We also continue to take actions to better position the business for future growth, as evidenced by our ongoing \nefforts to evaluate our footprint and cost structure in  our largest market, the UK.  In the UK market, I'd remind you \nthat our owned retail pharmacies are very health care -focused, with up to 90% of our mix coming from \npharmaceutical volumes.  While lower foot traffic through our pharmacies was a headwind in the  quarter, our \ndownside was limited due to our relatively small exposure to the front shop categories.  \n \n A good example of how we're evolving this business is our 2019 acquisition of a company called Echo, now \noperating as Echo by LloydsPharmacy.  This is an online prescription fulfillment business in the UK. ", "original_text": "In the UK market, I'd remind you \nthat our owned retail pharmacies are very health care -focused, with up to 90% of our mix coming from \npharmaceutical volumes. ", "page_label": "5", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4b897e5dd7d259ed26c05519f51cf46ca7b319dae0ed94395de3e3a7baf14b16", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5333f2c9-45df-4851-a9c9-be2aeadc5a0d", "node_type": "1", "metadata": {"window": "We also continue to take actions to better position the business for future growth, as evidenced by our ongoing \nefforts to evaluate our footprint and cost structure in  our largest market, the UK.  In the UK market, I'd remind you \nthat our owned retail pharmacies are very health care -focused, with up to 90% of our mix coming from \npharmaceutical volumes.  While lower foot traffic through our pharmacies was a headwind in the  quarter, our \ndownside was limited due to our relatively small exposure to the front shop categories.  \n \n A good example of how we're evolving this business is our 2019 acquisition of a company called Echo, now \noperating as Echo by LloydsPharmacy.  This is an online prescription fulfillment business in the UK.  It was a timely \nacquisition for us, particularly given the impacts of the pandemic.  To meet customer demands in uncertain times, \nour investment in our digital health care strategy in the UK has helped pos ition the business to benefit from \nmovement of patients to home and to omnichannel services.  \n \n", "original_text": "A good example of how we're evolving this business is our 2019 acquisition of a company called Echo, now \noperating as Echo by LloydsPharmacy. "}, "hash": "f0f9c28a408bdb2bbbe0111ca82de64246df87acbdebf710368368020162325f", "class_name": "RelatedNodeInfo"}}, "text": "While lower foot traffic through our pharmacies was a headwind in the  quarter, our \ndownside was limited due to our relatively small exposure to the front shop categories.  \n \n", "start_char_idx": 1838, "end_char_idx": 2015, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5333f2c9-45df-4851-a9c9-be2aeadc5a0d": {"__data__": {"id_": "5333f2c9-45df-4851-a9c9-be2aeadc5a0d", "embedding": null, "metadata": {"window": "We also continue to take actions to better position the business for future growth, as evidenced by our ongoing \nefforts to evaluate our footprint and cost structure in  our largest market, the UK.  In the UK market, I'd remind you \nthat our owned retail pharmacies are very health care -focused, with up to 90% of our mix coming from \npharmaceutical volumes.  While lower foot traffic through our pharmacies was a headwind in the  quarter, our \ndownside was limited due to our relatively small exposure to the front shop categories.  \n \n A good example of how we're evolving this business is our 2019 acquisition of a company called Echo, now \noperating as Echo by LloydsPharmacy.  This is an online prescription fulfillment business in the UK.  It was a timely \nacquisition for us, particularly given the impacts of the pandemic.  To meet customer demands in uncertain times, \nour investment in our digital health care strategy in the UK has helped pos ition the business to benefit from \nmovement of patients to home and to omnichannel services.  \n \n", "original_text": "A good example of how we're evolving this business is our 2019 acquisition of a company called Echo, now \noperating as Echo by LloydsPharmacy. ", "page_label": "5", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2b6fa81b-d6e8-4046-a002-579e9e14ad02", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f979e56f55121861d8368ca4fe9d5a492f8ab49f3de018ae9a4ece2eb1f430a2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "804f9448-56ee-4088-af11-d219dae25c55", "node_type": "1", "metadata": {"window": "While each of the 13 countries we operate in, \nhave had different responses and recoveri es during the pandemic, we're encouraged by the segment's results in \nthe first quarter.  \n \n We also continue to take actions to better position the business for future growth, as evidenced by our ongoing \nefforts to evaluate our footprint and cost structure in  our largest market, the UK.  In the UK market, I'd remind you \nthat our owned retail pharmacies are very health care -focused, with up to 90% of our mix coming from \npharmaceutical volumes.  While lower foot traffic through our pharmacies was a headwind in the  quarter, our \ndownside was limited due to our relatively small exposure to the front shop categories.  \n \n A good example of how we're evolving this business is our 2019 acquisition of a company called Echo, now \noperating as Echo by LloydsPharmacy.  This is an online prescription fulfillment business in the UK.  It was a timely \nacquisition for us, particularly given the impacts of the pandemic. ", "original_text": "While lower foot traffic through our pharmacies was a headwind in the  quarter, our \ndownside was limited due to our relatively small exposure to the front shop categories.  \n \n", "page_label": "5", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "83061624feb6cecc59268c5b213b0619f78744140bd7cd743d8f70d93e134e1e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "580fc0cb-abc8-472c-87d7-6e02301daf69", "node_type": "1", "metadata": {"window": "In the UK market, I'd remind you \nthat our owned retail pharmacies are very health care -focused, with up to 90% of our mix coming from \npharmaceutical volumes.  While lower foot traffic through our pharmacies was a headwind in the  quarter, our \ndownside was limited due to our relatively small exposure to the front shop categories.  \n \n A good example of how we're evolving this business is our 2019 acquisition of a company called Echo, now \noperating as Echo by LloydsPharmacy.  This is an online prescription fulfillment business in the UK.  It was a timely \nacquisition for us, particularly given the impacts of the pandemic.  To meet customer demands in uncertain times, \nour investment in our digital health care strategy in the UK has helped pos ition the business to benefit from \nmovement of patients to home and to omnichannel services.  \n \n Let me move on to Medical. ", "original_text": "This is an online prescription fulfillment business in the UK. "}, "hash": "de2d0f9017f6595f5a82f5237303234270bdaba090e944a2f7da361e5bdd7994", "class_name": "RelatedNodeInfo"}}, "text": "A good example of how we're evolving this business is our 2019 acquisition of a company called Echo, now \noperating as Echo by LloydsPharmacy. ", "start_char_idx": 2015, "end_char_idx": 2158, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "580fc0cb-abc8-472c-87d7-6e02301daf69": {"__data__": {"id_": "580fc0cb-abc8-472c-87d7-6e02301daf69", "embedding": null, "metadata": {"window": "In the UK market, I'd remind you \nthat our owned retail pharmacies are very health care -focused, with up to 90% of our mix coming from \npharmaceutical volumes.  While lower foot traffic through our pharmacies was a headwind in the  quarter, our \ndownside was limited due to our relatively small exposure to the front shop categories.  \n \n A good example of how we're evolving this business is our 2019 acquisition of a company called Echo, now \noperating as Echo by LloydsPharmacy.  This is an online prescription fulfillment business in the UK.  It was a timely \nacquisition for us, particularly given the impacts of the pandemic.  To meet customer demands in uncertain times, \nour investment in our digital health care strategy in the UK has helped pos ition the business to benefit from \nmovement of patients to home and to omnichannel services.  \n \n Let me move on to Medical. ", "original_text": "This is an online prescription fulfillment business in the UK. ", "page_label": "5", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2b6fa81b-d6e8-4046-a002-579e9e14ad02", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f979e56f55121861d8368ca4fe9d5a492f8ab49f3de018ae9a4ece2eb1f430a2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5333f2c9-45df-4851-a9c9-be2aeadc5a0d", "node_type": "1", "metadata": {"window": "We also continue to take actions to better position the business for future growth, as evidenced by our ongoing \nefforts to evaluate our footprint and cost structure in  our largest market, the UK.  In the UK market, I'd remind you \nthat our owned retail pharmacies are very health care -focused, with up to 90% of our mix coming from \npharmaceutical volumes.  While lower foot traffic through our pharmacies was a headwind in the  quarter, our \ndownside was limited due to our relatively small exposure to the front shop categories.  \n \n A good example of how we're evolving this business is our 2019 acquisition of a company called Echo, now \noperating as Echo by LloydsPharmacy.  This is an online prescription fulfillment business in the UK.  It was a timely \nacquisition for us, particularly given the impacts of the pandemic.  To meet customer demands in uncertain times, \nour investment in our digital health care strategy in the UK has helped pos ition the business to benefit from \nmovement of patients to home and to omnichannel services.  \n \n", "original_text": "A good example of how we're evolving this business is our 2019 acquisition of a company called Echo, now \noperating as Echo by LloydsPharmacy. ", "page_label": "5", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ed493b54be2df7dd8723bf98e4795a708a204775bd8de9308665f750f598c6f1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "241ea05e-72c0-4332-8203-78e581e437df", "node_type": "1", "metadata": {"window": "While lower foot traffic through our pharmacies was a headwind in the  quarter, our \ndownside was limited due to our relatively small exposure to the front shop categories.  \n \n A good example of how we're evolving this business is our 2019 acquisition of a company called Echo, now \noperating as Echo by LloydsPharmacy.  This is an online prescription fulfillment business in the UK.  It was a timely \nacquisition for us, particularly given the impacts of the pandemic.  To meet customer demands in uncertain times, \nour investment in our digital health care strategy in the UK has helped pos ition the business to benefit from \nmovement of patients to home and to omnichannel services.  \n \n Let me move on to Medical.  As I discussed earlier, in June, we experienced a sharp increase in demand across \nour primary care sites. ", "original_text": "It was a timely \nacquisition for us, particularly given the impacts of the pandemic. "}, "hash": "86fe1a7c5e84c94c23c04c7e8d9a1e2eb92ed6be2ac87bb20ab8bbeed7d664cf", "class_name": "RelatedNodeInfo"}}, "text": "This is an online prescription fulfillment business in the UK. ", "start_char_idx": 2158, "end_char_idx": 2221, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "241ea05e-72c0-4332-8203-78e581e437df": {"__data__": {"id_": "241ea05e-72c0-4332-8203-78e581e437df", "embedding": null, "metadata": {"window": "While lower foot traffic through our pharmacies was a headwind in the  quarter, our \ndownside was limited due to our relatively small exposure to the front shop categories.  \n \n A good example of how we're evolving this business is our 2019 acquisition of a company called Echo, now \noperating as Echo by LloydsPharmacy.  This is an online prescription fulfillment business in the UK.  It was a timely \nacquisition for us, particularly given the impacts of the pandemic.  To meet customer demands in uncertain times, \nour investment in our digital health care strategy in the UK has helped pos ition the business to benefit from \nmovement of patients to home and to omnichannel services.  \n \n Let me move on to Medical.  As I discussed earlier, in June, we experienced a sharp increase in demand across \nour primary care sites. ", "original_text": "It was a timely \nacquisition for us, particularly given the impacts of the pandemic. ", "page_label": "5", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2b6fa81b-d6e8-4046-a002-579e9e14ad02", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f979e56f55121861d8368ca4fe9d5a492f8ab49f3de018ae9a4ece2eb1f430a2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "580fc0cb-abc8-472c-87d7-6e02301daf69", "node_type": "1", "metadata": {"window": "In the UK market, I'd remind you \nthat our owned retail pharmacies are very health care -focused, with up to 90% of our mix coming from \npharmaceutical volumes.  While lower foot traffic through our pharmacies was a headwind in the  quarter, our \ndownside was limited due to our relatively small exposure to the front shop categories.  \n \n A good example of how we're evolving this business is our 2019 acquisition of a company called Echo, now \noperating as Echo by LloydsPharmacy.  This is an online prescription fulfillment business in the UK.  It was a timely \nacquisition for us, particularly given the impacts of the pandemic.  To meet customer demands in uncertain times, \nour investment in our digital health care strategy in the UK has helped pos ition the business to benefit from \nmovement of patients to home and to omnichannel services.  \n \n Let me move on to Medical. ", "original_text": "This is an online prescription fulfillment business in the UK. ", "page_label": "5", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "72b8b85050ca6096cb8c4980961194e2e8fe276a2ff0a95e70452914f6bd1329", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d8f2a106-7c05-4078-b1be-e3324818f77c", "node_type": "1", "metadata": {"window": "A good example of how we're evolving this business is our 2019 acquisition of a company called Echo, now \noperating as Echo by LloydsPharmacy.  This is an online prescription fulfillment business in the UK.  It was a timely \nacquisition for us, particularly given the impacts of the pandemic.  To meet customer demands in uncertain times, \nour investment in our digital health care strategy in the UK has helped pos ition the business to benefit from \nmovement of patients to home and to omnichannel services.  \n \n Let me move on to Medical.  As I discussed earlier, in June, we experienced a sharp increase in demand across \nour primary care sites.  This directly correlates to t he reopening of physician offices and resumption of performing \nelective procedures as patients started to feel more comfortable returning to their doctors and health care \nproviders.  \n \n", "original_text": "To meet customer demands in uncertain times, \nour investment in our digital health care strategy in the UK has helped pos ition the business to benefit from \nmovement of patients to home and to omnichannel services.  \n \n"}, "hash": "19e7853ae538adbef1fe3c02a4a2b8a14e1a104514eaed00414e1c89644d180d", "class_name": "RelatedNodeInfo"}}, "text": "It was a timely \nacquisition for us, particularly given the impacts of the pandemic. ", "start_char_idx": 2221, "end_char_idx": 2306, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d8f2a106-7c05-4078-b1be-e3324818f77c": {"__data__": {"id_": "d8f2a106-7c05-4078-b1be-e3324818f77c", "embedding": null, "metadata": {"window": "A good example of how we're evolving this business is our 2019 acquisition of a company called Echo, now \noperating as Echo by LloydsPharmacy.  This is an online prescription fulfillment business in the UK.  It was a timely \nacquisition for us, particularly given the impacts of the pandemic.  To meet customer demands in uncertain times, \nour investment in our digital health care strategy in the UK has helped pos ition the business to benefit from \nmovement of patients to home and to omnichannel services.  \n \n Let me move on to Medical.  As I discussed earlier, in June, we experienced a sharp increase in demand across \nour primary care sites.  This directly correlates to t he reopening of physician offices and resumption of performing \nelective procedures as patients started to feel more comfortable returning to their doctors and health care \nproviders.  \n \n", "original_text": "To meet customer demands in uncertain times, \nour investment in our digital health care strategy in the UK has helped pos ition the business to benefit from \nmovement of patients to home and to omnichannel services.  \n \n", "page_label": "5", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2b6fa81b-d6e8-4046-a002-579e9e14ad02", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f979e56f55121861d8368ca4fe9d5a492f8ab49f3de018ae9a4ece2eb1f430a2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "241ea05e-72c0-4332-8203-78e581e437df", "node_type": "1", "metadata": {"window": "While lower foot traffic through our pharmacies was a headwind in the  quarter, our \ndownside was limited due to our relatively small exposure to the front shop categories.  \n \n A good example of how we're evolving this business is our 2019 acquisition of a company called Echo, now \noperating as Echo by LloydsPharmacy.  This is an online prescription fulfillment business in the UK.  It was a timely \nacquisition for us, particularly given the impacts of the pandemic.  To meet customer demands in uncertain times, \nour investment in our digital health care strategy in the UK has helped pos ition the business to benefit from \nmovement of patients to home and to omnichannel services.  \n \n Let me move on to Medical.  As I discussed earlier, in June, we experienced a sharp increase in demand across \nour primary care sites. ", "original_text": "It was a timely \nacquisition for us, particularly given the impacts of the pandemic. ", "page_label": "5", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "115d525ca1f42f62c12d2e2a50abc96c05b3b2959956123af677e13d9ae4b6c3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1c3a6877-906a-4cff-8ed5-9b18482ca5a5", "node_type": "1", "metadata": {"window": "This is an online prescription fulfillment business in the UK.  It was a timely \nacquisition for us, particularly given the impacts of the pandemic.  To meet customer demands in uncertain times, \nour investment in our digital health care strategy in the UK has helped pos ition the business to benefit from \nmovement of patients to home and to omnichannel services.  \n \n Let me move on to Medical.  As I discussed earlier, in June, we experienced a sharp increase in demand across \nour primary care sites.  This directly correlates to t he reopening of physician offices and resumption of performing \nelective procedures as patients started to feel more comfortable returning to their doctors and health care \nproviders.  \n \n In addition, to a stabilization in primary care volumes as the quarter cl osed, our leading position in our lab \nbusiness also puts us in a good place to respond to customer and patient needs during the pandemic. ", "original_text": "Let me move on to Medical. "}, "hash": "004393730a67913fc0fc33ba4f262603a7d2e3a5c37ecd684a3b43fe51d1043e", "class_name": "RelatedNodeInfo"}}, "text": "To meet customer demands in uncertain times, \nour investment in our digital health care strategy in the UK has helped pos ition the business to benefit from \nmovement of patients to home and to omnichannel services.  \n \n", "start_char_idx": 2306, "end_char_idx": 2526, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1c3a6877-906a-4cff-8ed5-9b18482ca5a5": {"__data__": {"id_": "1c3a6877-906a-4cff-8ed5-9b18482ca5a5", "embedding": null, "metadata": {"window": "This is an online prescription fulfillment business in the UK.  It was a timely \nacquisition for us, particularly given the impacts of the pandemic.  To meet customer demands in uncertain times, \nour investment in our digital health care strategy in the UK has helped pos ition the business to benefit from \nmovement of patients to home and to omnichannel services.  \n \n Let me move on to Medical.  As I discussed earlier, in June, we experienced a sharp increase in demand across \nour primary care sites.  This directly correlates to t he reopening of physician offices and resumption of performing \nelective procedures as patients started to feel more comfortable returning to their doctors and health care \nproviders.  \n \n In addition, to a stabilization in primary care volumes as the quarter cl osed, our leading position in our lab \nbusiness also puts us in a good place to respond to customer and patient needs during the pandemic. ", "original_text": "Let me move on to Medical. ", "page_label": "5", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2b6fa81b-d6e8-4046-a002-579e9e14ad02", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f979e56f55121861d8368ca4fe9d5a492f8ab49f3de018ae9a4ece2eb1f430a2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d8f2a106-7c05-4078-b1be-e3324818f77c", "node_type": "1", "metadata": {"window": "A good example of how we're evolving this business is our 2019 acquisition of a company called Echo, now \noperating as Echo by LloydsPharmacy.  This is an online prescription fulfillment business in the UK.  It was a timely \nacquisition for us, particularly given the impacts of the pandemic.  To meet customer demands in uncertain times, \nour investment in our digital health care strategy in the UK has helped pos ition the business to benefit from \nmovement of patients to home and to omnichannel services.  \n \n Let me move on to Medical.  As I discussed earlier, in June, we experienced a sharp increase in demand across \nour primary care sites.  This directly correlates to t he reopening of physician offices and resumption of performing \nelective procedures as patients started to feel more comfortable returning to their doctors and health care \nproviders.  \n \n", "original_text": "To meet customer demands in uncertain times, \nour investment in our digital health care strategy in the UK has helped pos ition the business to benefit from \nmovement of patients to home and to omnichannel services.  \n \n", "page_label": "5", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "58ccb24c0ffa0580b0018716b6576d375de2465e3ce2a92fc4c626e078782b77", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d089f954-57ae-436e-935b-b529f3352374", "node_type": "1", "metadata": {"window": "It was a timely \nacquisition for us, particularly given the impacts of the pandemic.  To meet customer demands in uncertain times, \nour investment in our digital health care strategy in the UK has helped pos ition the business to benefit from \nmovement of patients to home and to omnichannel services.  \n \n Let me move on to Medical.  As I discussed earlier, in June, we experienced a sharp increase in demand across \nour primary care sites.  This directly correlates to t he reopening of physician offices and resumption of performing \nelective procedures as patients started to feel more comfortable returning to their doctors and health care \nproviders.  \n \n In addition, to a stabilization in primary care volumes as the quarter cl osed, our leading position in our lab \nbusiness also puts us in a good place to respond to customer and patient needs during the pandemic.  We have a \nstrong history in this channel. ", "original_text": "As I discussed earlier, in June, we experienced a sharp increase in demand across \nour primary care sites. "}, "hash": "fad82edeac66b3ee1e16677f3d05f3eb499fae11facd1f8d4f916cb2e6c49007", "class_name": "RelatedNodeInfo"}}, "text": "Let me move on to Medical. ", "start_char_idx": 2526, "end_char_idx": 2553, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d089f954-57ae-436e-935b-b529f3352374": {"__data__": {"id_": "d089f954-57ae-436e-935b-b529f3352374", "embedding": null, "metadata": {"window": "It was a timely \nacquisition for us, particularly given the impacts of the pandemic.  To meet customer demands in uncertain times, \nour investment in our digital health care strategy in the UK has helped pos ition the business to benefit from \nmovement of patients to home and to omnichannel services.  \n \n Let me move on to Medical.  As I discussed earlier, in June, we experienced a sharp increase in demand across \nour primary care sites.  This directly correlates to t he reopening of physician offices and resumption of performing \nelective procedures as patients started to feel more comfortable returning to their doctors and health care \nproviders.  \n \n In addition, to a stabilization in primary care volumes as the quarter cl osed, our leading position in our lab \nbusiness also puts us in a good place to respond to customer and patient needs during the pandemic.  We have a \nstrong history in this channel. ", "original_text": "As I discussed earlier, in June, we experienced a sharp increase in demand across \nour primary care sites. ", "page_label": "5", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2b6fa81b-d6e8-4046-a002-579e9e14ad02", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f979e56f55121861d8368ca4fe9d5a492f8ab49f3de018ae9a4ece2eb1f430a2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1c3a6877-906a-4cff-8ed5-9b18482ca5a5", "node_type": "1", "metadata": {"window": "This is an online prescription fulfillment business in the UK.  It was a timely \nacquisition for us, particularly given the impacts of the pandemic.  To meet customer demands in uncertain times, \nour investment in our digital health care strategy in the UK has helped pos ition the business to benefit from \nmovement of patients to home and to omnichannel services.  \n \n Let me move on to Medical.  As I discussed earlier, in June, we experienced a sharp increase in demand across \nour primary care sites.  This directly correlates to t he reopening of physician offices and resumption of performing \nelective procedures as patients started to feel more comfortable returning to their doctors and health care \nproviders.  \n \n In addition, to a stabilization in primary care volumes as the quarter cl osed, our leading position in our lab \nbusiness also puts us in a good place to respond to customer and patient needs during the pandemic. ", "original_text": "Let me move on to Medical. ", "page_label": "5", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6e16c3bad2cd5bb4d6b72222ac397b191630c823448d68e36ac05e67d5b2e453", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9df15c19-9d55-4af1-b5e2-3e3a1a549153", "node_type": "1", "metadata": {"window": "To meet customer demands in uncertain times, \nour investment in our digital health care strategy in the UK has helped pos ition the business to benefit from \nmovement of patients to home and to omnichannel services.  \n \n Let me move on to Medical.  As I discussed earlier, in June, we experienced a sharp increase in demand across \nour primary care sites.  This directly correlates to t he reopening of physician offices and resumption of performing \nelective procedures as patients started to feel more comfortable returning to their doctors and health care \nproviders.  \n \n In addition, to a stabilization in primary care volumes as the quarter cl osed, our leading position in our lab \nbusiness also puts us in a good place to respond to customer and patient needs during the pandemic.  We have a \nstrong history in this channel.  And as customers need solutions for COVID -19 and as our manufacturer partner s \ndevelop and launch testing solutions, we remain a partner of choice and a leader across alternate site \u2013 settings \nof care. ", "original_text": "This directly correlates to t he reopening of physician offices and resumption of performing \nelective procedures as patients started to feel more comfortable returning to their doctors and health care \nproviders.  \n \n"}, "hash": "39bbad0ddd9f434d2033bd3de28129bb84e500f76e498544cd57598831d4af59", "class_name": "RelatedNodeInfo"}}, "text": "As I discussed earlier, in June, we experienced a sharp increase in demand across \nour primary care sites. ", "start_char_idx": 2553, "end_char_idx": 2660, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9df15c19-9d55-4af1-b5e2-3e3a1a549153": {"__data__": {"id_": "9df15c19-9d55-4af1-b5e2-3e3a1a549153", "embedding": null, "metadata": {"window": "To meet customer demands in uncertain times, \nour investment in our digital health care strategy in the UK has helped pos ition the business to benefit from \nmovement of patients to home and to omnichannel services.  \n \n Let me move on to Medical.  As I discussed earlier, in June, we experienced a sharp increase in demand across \nour primary care sites.  This directly correlates to t he reopening of physician offices and resumption of performing \nelective procedures as patients started to feel more comfortable returning to their doctors and health care \nproviders.  \n \n In addition, to a stabilization in primary care volumes as the quarter cl osed, our leading position in our lab \nbusiness also puts us in a good place to respond to customer and patient needs during the pandemic.  We have a \nstrong history in this channel.  And as customers need solutions for COVID -19 and as our manufacturer partner s \ndevelop and launch testing solutions, we remain a partner of choice and a leader across alternate site \u2013 settings \nof care. ", "original_text": "This directly correlates to t he reopening of physician offices and resumption of performing \nelective procedures as patients started to feel more comfortable returning to their doctors and health care \nproviders.  \n \n", "page_label": "5", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2b6fa81b-d6e8-4046-a002-579e9e14ad02", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f979e56f55121861d8368ca4fe9d5a492f8ab49f3de018ae9a4ece2eb1f430a2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d089f954-57ae-436e-935b-b529f3352374", "node_type": "1", "metadata": {"window": "It was a timely \nacquisition for us, particularly given the impacts of the pandemic.  To meet customer demands in uncertain times, \nour investment in our digital health care strategy in the UK has helped pos ition the business to benefit from \nmovement of patients to home and to omnichannel services.  \n \n Let me move on to Medical.  As I discussed earlier, in June, we experienced a sharp increase in demand across \nour primary care sites.  This directly correlates to t he reopening of physician offices and resumption of performing \nelective procedures as patients started to feel more comfortable returning to their doctors and health care \nproviders.  \n \n In addition, to a stabilization in primary care volumes as the quarter cl osed, our leading position in our lab \nbusiness also puts us in a good place to respond to customer and patient needs during the pandemic.  We have a \nstrong history in this channel. ", "original_text": "As I discussed earlier, in June, we experienced a sharp increase in demand across \nour primary care sites. ", "page_label": "5", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5f74dc0e91ff6fc64e357515ec489276815bcf6cd1fed932733577af0858ad68", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7cc94b20-e1d7-434c-81f6-1cf7c9758b38", "node_type": "1", "metadata": {"window": "Let me move on to Medical.  As I discussed earlier, in June, we experienced a sharp increase in demand across \nour primary care sites.  This directly correlates to t he reopening of physician offices and resumption of performing \nelective procedures as patients started to feel more comfortable returning to their doctors and health care \nproviders.  \n \n In addition, to a stabilization in primary care volumes as the quarter cl osed, our leading position in our lab \nbusiness also puts us in a good place to respond to customer and patient needs during the pandemic.  We have a \nstrong history in this channel.  And as customers need solutions for COVID -19 and as our manufacturer partner s \ndevelop and launch testing solutions, we remain a partner of choice and a leader across alternate site \u2013 settings \nof care.  The trends we witnessed in June, combined with our improved outlook for the business over the \nremainder of this fiscal year, give u s confidence in our significantly improved outlook for the segment.  \n \n", "original_text": "In addition, to a stabilization in primary care volumes as the quarter cl osed, our leading position in our lab \nbusiness also puts us in a good place to respond to customer and patient needs during the pandemic. "}, "hash": "42ca12a4019ad2760416f0183408a8f40c0fcd60b9e1051d3c9410acabaafdb5", "class_name": "RelatedNodeInfo"}}, "text": "This directly correlates to t he reopening of physician offices and resumption of performing \nelective procedures as patients started to feel more comfortable returning to their doctors and health care \nproviders.  \n \n", "start_char_idx": 2660, "end_char_idx": 2878, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7cc94b20-e1d7-434c-81f6-1cf7c9758b38": {"__data__": {"id_": "7cc94b20-e1d7-434c-81f6-1cf7c9758b38", "embedding": null, "metadata": {"window": "Let me move on to Medical.  As I discussed earlier, in June, we experienced a sharp increase in demand across \nour primary care sites.  This directly correlates to t he reopening of physician offices and resumption of performing \nelective procedures as patients started to feel more comfortable returning to their doctors and health care \nproviders.  \n \n In addition, to a stabilization in primary care volumes as the quarter cl osed, our leading position in our lab \nbusiness also puts us in a good place to respond to customer and patient needs during the pandemic.  We have a \nstrong history in this channel.  And as customers need solutions for COVID -19 and as our manufacturer partner s \ndevelop and launch testing solutions, we remain a partner of choice and a leader across alternate site \u2013 settings \nof care.  The trends we witnessed in June, combined with our improved outlook for the business over the \nremainder of this fiscal year, give u s confidence in our significantly improved outlook for the segment.  \n \n", "original_text": "In addition, to a stabilization in primary care volumes as the quarter cl osed, our leading position in our lab \nbusiness also puts us in a good place to respond to customer and patient needs during the pandemic. ", "page_label": "5", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2b6fa81b-d6e8-4046-a002-579e9e14ad02", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f979e56f55121861d8368ca4fe9d5a492f8ab49f3de018ae9a4ece2eb1f430a2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9df15c19-9d55-4af1-b5e2-3e3a1a549153", "node_type": "1", "metadata": {"window": "To meet customer demands in uncertain times, \nour investment in our digital health care strategy in the UK has helped pos ition the business to benefit from \nmovement of patients to home and to omnichannel services.  \n \n Let me move on to Medical.  As I discussed earlier, in June, we experienced a sharp increase in demand across \nour primary care sites.  This directly correlates to t he reopening of physician offices and resumption of performing \nelective procedures as patients started to feel more comfortable returning to their doctors and health care \nproviders.  \n \n In addition, to a stabilization in primary care volumes as the quarter cl osed, our leading position in our lab \nbusiness also puts us in a good place to respond to customer and patient needs during the pandemic.  We have a \nstrong history in this channel.  And as customers need solutions for COVID -19 and as our manufacturer partner s \ndevelop and launch testing solutions, we remain a partner of choice and a leader across alternate site \u2013 settings \nof care. ", "original_text": "This directly correlates to t he reopening of physician offices and resumption of performing \nelective procedures as patients started to feel more comfortable returning to their doctors and health care \nproviders.  \n \n", "page_label": "5", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "eddce4b1a7bdcff9a50a1528cc28e12f62389592ab110b1863f2636aefcc8cf3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9aa51914-8d6a-4d4c-a76c-a24ae6458080", "node_type": "1", "metadata": {"window": "As I discussed earlier, in June, we experienced a sharp increase in demand across \nour primary care sites.  This directly correlates to t he reopening of physician offices and resumption of performing \nelective procedures as patients started to feel more comfortable returning to their doctors and health care \nproviders.  \n \n In addition, to a stabilization in primary care volumes as the quarter cl osed, our leading position in our lab \nbusiness also puts us in a good place to respond to customer and patient needs during the pandemic.  We have a \nstrong history in this channel.  And as customers need solutions for COVID -19 and as our manufacturer partner s \ndevelop and launch testing solutions, we remain a partner of choice and a leader across alternate site \u2013 settings \nof care.  The trends we witnessed in June, combined with our improved outlook for the business over the \nremainder of this fiscal year, give u s confidence in our significantly improved outlook for the segment.  \n \n Turning to Other, which now primarily consists of Canada and McKesson Prescription Technology Solutions \nfollowing the separation of our investment in Change Healthcare in fiscal 2020. ", "original_text": "We have a \nstrong history in this channel. "}, "hash": "dc71481961a6c2be238a922377e4b093e279b43bc10cfce8ef2baf1de81560b7", "class_name": "RelatedNodeInfo"}}, "text": "In addition, to a stabilization in primary care volumes as the quarter cl osed, our leading position in our lab \nbusiness also puts us in a good place to respond to customer and patient needs during the pandemic. ", "start_char_idx": 2878, "end_char_idx": 3091, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9aa51914-8d6a-4d4c-a76c-a24ae6458080": {"__data__": {"id_": "9aa51914-8d6a-4d4c-a76c-a24ae6458080", "embedding": null, "metadata": {"window": "As I discussed earlier, in June, we experienced a sharp increase in demand across \nour primary care sites.  This directly correlates to t he reopening of physician offices and resumption of performing \nelective procedures as patients started to feel more comfortable returning to their doctors and health care \nproviders.  \n \n In addition, to a stabilization in primary care volumes as the quarter cl osed, our leading position in our lab \nbusiness also puts us in a good place to respond to customer and patient needs during the pandemic.  We have a \nstrong history in this channel.  And as customers need solutions for COVID -19 and as our manufacturer partner s \ndevelop and launch testing solutions, we remain a partner of choice and a leader across alternate site \u2013 settings \nof care.  The trends we witnessed in June, combined with our improved outlook for the business over the \nremainder of this fiscal year, give u s confidence in our significantly improved outlook for the segment.  \n \n Turning to Other, which now primarily consists of Canada and McKesson Prescription Technology Solutions \nfollowing the separation of our investment in Change Healthcare in fiscal 2020. ", "original_text": "We have a \nstrong history in this channel. ", "page_label": "5", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2b6fa81b-d6e8-4046-a002-579e9e14ad02", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f979e56f55121861d8368ca4fe9d5a492f8ab49f3de018ae9a4ece2eb1f430a2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7cc94b20-e1d7-434c-81f6-1cf7c9758b38", "node_type": "1", "metadata": {"window": "Let me move on to Medical.  As I discussed earlier, in June, we experienced a sharp increase in demand across \nour primary care sites.  This directly correlates to t he reopening of physician offices and resumption of performing \nelective procedures as patients started to feel more comfortable returning to their doctors and health care \nproviders.  \n \n In addition, to a stabilization in primary care volumes as the quarter cl osed, our leading position in our lab \nbusiness also puts us in a good place to respond to customer and patient needs during the pandemic.  We have a \nstrong history in this channel.  And as customers need solutions for COVID -19 and as our manufacturer partner s \ndevelop and launch testing solutions, we remain a partner of choice and a leader across alternate site \u2013 settings \nof care.  The trends we witnessed in June, combined with our improved outlook for the business over the \nremainder of this fiscal year, give u s confidence in our significantly improved outlook for the segment.  \n \n", "original_text": "In addition, to a stabilization in primary care volumes as the quarter cl osed, our leading position in our lab \nbusiness also puts us in a good place to respond to customer and patient needs during the pandemic. ", "page_label": "5", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "232172b85e78ceeb15554bbc06d7cb5216c3b1dfeff7f844c3b9a7ca6438503c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "70d5ba2b-5ae7-4c3b-bf67-8186c9d034aa", "node_type": "1", "metadata": {"window": "This directly correlates to t he reopening of physician offices and resumption of performing \nelective procedures as patients started to feel more comfortable returning to their doctors and health care \nproviders.  \n \n In addition, to a stabilization in primary care volumes as the quarter cl osed, our leading position in our lab \nbusiness also puts us in a good place to respond to customer and patient needs during the pandemic.  We have a \nstrong history in this channel.  And as customers need solutions for COVID -19 and as our manufacturer partner s \ndevelop and launch testing solutions, we remain a partner of choice and a leader across alternate site \u2013 settings \nof care.  The trends we witnessed in June, combined with our improved outlook for the business over the \nremainder of this fiscal year, give u s confidence in our significantly improved outlook for the segment.  \n \n Turning to Other, which now primarily consists of Canada and McKesson Prescription Technology Solutions \nfollowing the separation of our investment in Change Healthcare in fiscal 2020.  We're encouraged by the trends \nwe saw in Canada to end the quarter as volumes began to approach pre -COVID levels in our distribution and \nretail businesses.  \n \n", "original_text": "And as customers need solutions for COVID -19 and as our manufacturer partner s \ndevelop and launch testing solutions, we remain a partner of choice and a leader across alternate site \u2013 settings \nof care. "}, "hash": "c7badb884cec5bf1c68da1553e655fb4bfe29b7d9725ce97d8168a3a6bc38d5b", "class_name": "RelatedNodeInfo"}}, "text": "We have a \nstrong history in this channel. ", "start_char_idx": 3091, "end_char_idx": 3134, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "70d5ba2b-5ae7-4c3b-bf67-8186c9d034aa": {"__data__": {"id_": "70d5ba2b-5ae7-4c3b-bf67-8186c9d034aa", "embedding": null, "metadata": {"window": "This directly correlates to t he reopening of physician offices and resumption of performing \nelective procedures as patients started to feel more comfortable returning to their doctors and health care \nproviders.  \n \n In addition, to a stabilization in primary care volumes as the quarter cl osed, our leading position in our lab \nbusiness also puts us in a good place to respond to customer and patient needs during the pandemic.  We have a \nstrong history in this channel.  And as customers need solutions for COVID -19 and as our manufacturer partner s \ndevelop and launch testing solutions, we remain a partner of choice and a leader across alternate site \u2013 settings \nof care.  The trends we witnessed in June, combined with our improved outlook for the business over the \nremainder of this fiscal year, give u s confidence in our significantly improved outlook for the segment.  \n \n Turning to Other, which now primarily consists of Canada and McKesson Prescription Technology Solutions \nfollowing the separation of our investment in Change Healthcare in fiscal 2020.  We're encouraged by the trends \nwe saw in Canada to end the quarter as volumes began to approach pre -COVID levels in our distribution and \nretail businesses.  \n \n", "original_text": "And as customers need solutions for COVID -19 and as our manufacturer partner s \ndevelop and launch testing solutions, we remain a partner of choice and a leader across alternate site \u2013 settings \nof care. ", "page_label": "5", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2b6fa81b-d6e8-4046-a002-579e9e14ad02", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f979e56f55121861d8368ca4fe9d5a492f8ab49f3de018ae9a4ece2eb1f430a2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9aa51914-8d6a-4d4c-a76c-a24ae6458080", "node_type": "1", "metadata": {"window": "As I discussed earlier, in June, we experienced a sharp increase in demand across \nour primary care sites.  This directly correlates to t he reopening of physician offices and resumption of performing \nelective procedures as patients started to feel more comfortable returning to their doctors and health care \nproviders.  \n \n In addition, to a stabilization in primary care volumes as the quarter cl osed, our leading position in our lab \nbusiness also puts us in a good place to respond to customer and patient needs during the pandemic.  We have a \nstrong history in this channel.  And as customers need solutions for COVID -19 and as our manufacturer partner s \ndevelop and launch testing solutions, we remain a partner of choice and a leader across alternate site \u2013 settings \nof care.  The trends we witnessed in June, combined with our improved outlook for the business over the \nremainder of this fiscal year, give u s confidence in our significantly improved outlook for the segment.  \n \n Turning to Other, which now primarily consists of Canada and McKesson Prescription Technology Solutions \nfollowing the separation of our investment in Change Healthcare in fiscal 2020. ", "original_text": "We have a \nstrong history in this channel. ", "page_label": "5", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bbeedac3ce04ca2c902f7a34653a04b3068cad13fe7b4f24638d07edec559e6b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "56c9e5ee-be13-4513-a262-73b973493c8f", "node_type": "1", "metadata": {"window": "In addition, to a stabilization in primary care volumes as the quarter cl osed, our leading position in our lab \nbusiness also puts us in a good place to respond to customer and patient needs during the pandemic.  We have a \nstrong history in this channel.  And as customers need solutions for COVID -19 and as our manufacturer partner s \ndevelop and launch testing solutions, we remain a partner of choice and a leader across alternate site \u2013 settings \nof care.  The trends we witnessed in June, combined with our improved outlook for the business over the \nremainder of this fiscal year, give u s confidence in our significantly improved outlook for the segment.  \n \n Turning to Other, which now primarily consists of Canada and McKesson Prescription Technology Solutions \nfollowing the separation of our investment in Change Healthcare in fiscal 2020.  We're encouraged by the trends \nwe saw in Canada to end the quarter as volumes began to approach pre -COVID levels in our distribution and \nretail businesses.  \n \n Within the retail setting, our focus remains on building an enhanced customer experience through in vestments in \npeople and reconfigured pharmacy formats. ", "original_text": "The trends we witnessed in June, combined with our improved outlook for the business over the \nremainder of this fiscal year, give u s confidence in our significantly improved outlook for the segment.  \n \n"}, "hash": "fb8107f782c1e711ad2e5d5ab239576eebcbc95f07de99bfd74f5389541e3c45", "class_name": "RelatedNodeInfo"}}, "text": "And as customers need solutions for COVID -19 and as our manufacturer partner s \ndevelop and launch testing solutions, we remain a partner of choice and a leader across alternate site \u2013 settings \nof care. ", "start_char_idx": 3134, "end_char_idx": 3339, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "56c9e5ee-be13-4513-a262-73b973493c8f": {"__data__": {"id_": "56c9e5ee-be13-4513-a262-73b973493c8f", "embedding": null, "metadata": {"window": "In addition, to a stabilization in primary care volumes as the quarter cl osed, our leading position in our lab \nbusiness also puts us in a good place to respond to customer and patient needs during the pandemic.  We have a \nstrong history in this channel.  And as customers need solutions for COVID -19 and as our manufacturer partner s \ndevelop and launch testing solutions, we remain a partner of choice and a leader across alternate site \u2013 settings \nof care.  The trends we witnessed in June, combined with our improved outlook for the business over the \nremainder of this fiscal year, give u s confidence in our significantly improved outlook for the segment.  \n \n Turning to Other, which now primarily consists of Canada and McKesson Prescription Technology Solutions \nfollowing the separation of our investment in Change Healthcare in fiscal 2020.  We're encouraged by the trends \nwe saw in Canada to end the quarter as volumes began to approach pre -COVID levels in our distribution and \nretail businesses.  \n \n Within the retail setting, our focus remains on building an enhanced customer experience through in vestments in \npeople and reconfigured pharmacy formats. ", "original_text": "The trends we witnessed in June, combined with our improved outlook for the business over the \nremainder of this fiscal year, give u s confidence in our significantly improved outlook for the segment.  \n \n", "page_label": "5", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2b6fa81b-d6e8-4046-a002-579e9e14ad02", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f979e56f55121861d8368ca4fe9d5a492f8ab49f3de018ae9a4ece2eb1f430a2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "70d5ba2b-5ae7-4c3b-bf67-8186c9d034aa", "node_type": "1", "metadata": {"window": "This directly correlates to t he reopening of physician offices and resumption of performing \nelective procedures as patients started to feel more comfortable returning to their doctors and health care \nproviders.  \n \n In addition, to a stabilization in primary care volumes as the quarter cl osed, our leading position in our lab \nbusiness also puts us in a good place to respond to customer and patient needs during the pandemic.  We have a \nstrong history in this channel.  And as customers need solutions for COVID -19 and as our manufacturer partner s \ndevelop and launch testing solutions, we remain a partner of choice and a leader across alternate site \u2013 settings \nof care.  The trends we witnessed in June, combined with our improved outlook for the business over the \nremainder of this fiscal year, give u s confidence in our significantly improved outlook for the segment.  \n \n Turning to Other, which now primarily consists of Canada and McKesson Prescription Technology Solutions \nfollowing the separation of our investment in Change Healthcare in fiscal 2020.  We're encouraged by the trends \nwe saw in Canada to end the quarter as volumes began to approach pre -COVID levels in our distribution and \nretail businesses.  \n \n", "original_text": "And as customers need solutions for COVID -19 and as our manufacturer partner s \ndevelop and launch testing solutions, we remain a partner of choice and a leader across alternate site \u2013 settings \nof care. ", "page_label": "5", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6d4f442bd6a05284a645a0931a510be8755cc2ecb9bf1388580d8d629676f1d6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9eee3a3a-4f24-48a5-a7e2-8d17099861c9", "node_type": "1", "metadata": {"window": "We have a \nstrong history in this channel.  And as customers need solutions for COVID -19 and as our manufacturer partner s \ndevelop and launch testing solutions, we remain a partner of choice and a leader across alternate site \u2013 settings \nof care.  The trends we witnessed in June, combined with our improved outlook for the business over the \nremainder of this fiscal year, give u s confidence in our significantly improved outlook for the segment.  \n \n Turning to Other, which now primarily consists of Canada and McKesson Prescription Technology Solutions \nfollowing the separation of our investment in Change Healthcare in fiscal 2020.  We're encouraged by the trends \nwe saw in Canada to end the quarter as volumes began to approach pre -COVID levels in our distribution and \nretail businesses.  \n \n Within the retail setting, our focus remains on building an enhanced customer experience through in vestments in \npeople and reconfigured pharmacy formats.  This has helped to strengthen our fundamentals and the role that ", "original_text": "Turning to Other, which now primarily consists of Canada and McKesson Prescription Technology Solutions \nfollowing the separation of our investment in Change Healthcare in fiscal 2020. "}, "hash": "55f4713fc47eda5681ae04b445b5d69e4f0fd48e85c14b67411fec603f4a344d", "class_name": "RelatedNodeInfo"}}, "text": "The trends we witnessed in June, combined with our improved outlook for the business over the \nremainder of this fiscal year, give u s confidence in our significantly improved outlook for the segment.  \n \n", "start_char_idx": 3339, "end_char_idx": 3544, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9eee3a3a-4f24-48a5-a7e2-8d17099861c9": {"__data__": {"id_": "9eee3a3a-4f24-48a5-a7e2-8d17099861c9", "embedding": null, "metadata": {"window": "We have a \nstrong history in this channel.  And as customers need solutions for COVID -19 and as our manufacturer partner s \ndevelop and launch testing solutions, we remain a partner of choice and a leader across alternate site \u2013 settings \nof care.  The trends we witnessed in June, combined with our improved outlook for the business over the \nremainder of this fiscal year, give u s confidence in our significantly improved outlook for the segment.  \n \n Turning to Other, which now primarily consists of Canada and McKesson Prescription Technology Solutions \nfollowing the separation of our investment in Change Healthcare in fiscal 2020.  We're encouraged by the trends \nwe saw in Canada to end the quarter as volumes began to approach pre -COVID levels in our distribution and \nretail businesses.  \n \n Within the retail setting, our focus remains on building an enhanced customer experience through in vestments in \npeople and reconfigured pharmacy formats.  This has helped to strengthen our fundamentals and the role that ", "original_text": "Turning to Other, which now primarily consists of Canada and McKesson Prescription Technology Solutions \nfollowing the separation of our investment in Change Healthcare in fiscal 2020. ", "page_label": "5", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2b6fa81b-d6e8-4046-a002-579e9e14ad02", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f979e56f55121861d8368ca4fe9d5a492f8ab49f3de018ae9a4ece2eb1f430a2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "56c9e5ee-be13-4513-a262-73b973493c8f", "node_type": "1", "metadata": {"window": "In addition, to a stabilization in primary care volumes as the quarter cl osed, our leading position in our lab \nbusiness also puts us in a good place to respond to customer and patient needs during the pandemic.  We have a \nstrong history in this channel.  And as customers need solutions for COVID -19 and as our manufacturer partner s \ndevelop and launch testing solutions, we remain a partner of choice and a leader across alternate site \u2013 settings \nof care.  The trends we witnessed in June, combined with our improved outlook for the business over the \nremainder of this fiscal year, give u s confidence in our significantly improved outlook for the segment.  \n \n Turning to Other, which now primarily consists of Canada and McKesson Prescription Technology Solutions \nfollowing the separation of our investment in Change Healthcare in fiscal 2020.  We're encouraged by the trends \nwe saw in Canada to end the quarter as volumes began to approach pre -COVID levels in our distribution and \nretail businesses.  \n \n Within the retail setting, our focus remains on building an enhanced customer experience through in vestments in \npeople and reconfigured pharmacy formats. ", "original_text": "The trends we witnessed in June, combined with our improved outlook for the business over the \nremainder of this fiscal year, give u s confidence in our significantly improved outlook for the segment.  \n \n", "page_label": "5", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1e7397c5f136f01dc60d1cd1de1540b32ce9ee58833e2e451ff7ed791b3adcfe", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4e99c27c-2499-4686-bd29-551b9fbf0ec6", "node_type": "1", "metadata": {"window": "And as customers need solutions for COVID -19 and as our manufacturer partner s \ndevelop and launch testing solutions, we remain a partner of choice and a leader across alternate site \u2013 settings \nof care.  The trends we witnessed in June, combined with our improved outlook for the business over the \nremainder of this fiscal year, give u s confidence in our significantly improved outlook for the segment.  \n \n Turning to Other, which now primarily consists of Canada and McKesson Prescription Technology Solutions \nfollowing the separation of our investment in Change Healthcare in fiscal 2020.  We're encouraged by the trends \nwe saw in Canada to end the quarter as volumes began to approach pre -COVID levels in our distribution and \nretail businesses.  \n \n Within the retail setting, our focus remains on building an enhanced customer experience through in vestments in \npeople and reconfigured pharmacy formats.  This has helped to strengthen our fundamentals and the role that ", "original_text": "We're encouraged by the trends \nwe saw in Canada to end the quarter as volumes began to approach pre -COVID levels in our distribution and \nretail businesses.  \n \n"}, "hash": "c78cb74d6e78158b28bd50f6ec7951e62a4e767477d34320af171cf3a6a88cf8", "class_name": "RelatedNodeInfo"}}, "text": "Turning to Other, which now primarily consists of Canada and McKesson Prescription Technology Solutions \nfollowing the separation of our investment in Change Healthcare in fiscal 2020. ", "start_char_idx": 3544, "end_char_idx": 3729, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4e99c27c-2499-4686-bd29-551b9fbf0ec6": {"__data__": {"id_": "4e99c27c-2499-4686-bd29-551b9fbf0ec6", "embedding": null, "metadata": {"window": "And as customers need solutions for COVID -19 and as our manufacturer partner s \ndevelop and launch testing solutions, we remain a partner of choice and a leader across alternate site \u2013 settings \nof care.  The trends we witnessed in June, combined with our improved outlook for the business over the \nremainder of this fiscal year, give u s confidence in our significantly improved outlook for the segment.  \n \n Turning to Other, which now primarily consists of Canada and McKesson Prescription Technology Solutions \nfollowing the separation of our investment in Change Healthcare in fiscal 2020.  We're encouraged by the trends \nwe saw in Canada to end the quarter as volumes began to approach pre -COVID levels in our distribution and \nretail businesses.  \n \n Within the retail setting, our focus remains on building an enhanced customer experience through in vestments in \npeople and reconfigured pharmacy formats.  This has helped to strengthen our fundamentals and the role that ", "original_text": "We're encouraged by the trends \nwe saw in Canada to end the quarter as volumes began to approach pre -COVID levels in our distribution and \nretail businesses.  \n \n", "page_label": "5", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2b6fa81b-d6e8-4046-a002-579e9e14ad02", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f979e56f55121861d8368ca4fe9d5a492f8ab49f3de018ae9a4ece2eb1f430a2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9eee3a3a-4f24-48a5-a7e2-8d17099861c9", "node_type": "1", "metadata": {"window": "We have a \nstrong history in this channel.  And as customers need solutions for COVID -19 and as our manufacturer partner s \ndevelop and launch testing solutions, we remain a partner of choice and a leader across alternate site \u2013 settings \nof care.  The trends we witnessed in June, combined with our improved outlook for the business over the \nremainder of this fiscal year, give u s confidence in our significantly improved outlook for the segment.  \n \n Turning to Other, which now primarily consists of Canada and McKesson Prescription Technology Solutions \nfollowing the separation of our investment in Change Healthcare in fiscal 2020.  We're encouraged by the trends \nwe saw in Canada to end the quarter as volumes began to approach pre -COVID levels in our distribution and \nretail businesses.  \n \n Within the retail setting, our focus remains on building an enhanced customer experience through in vestments in \npeople and reconfigured pharmacy formats.  This has helped to strengthen our fundamentals and the role that ", "original_text": "Turning to Other, which now primarily consists of Canada and McKesson Prescription Technology Solutions \nfollowing the separation of our investment in Change Healthcare in fiscal 2020. ", "page_label": "5", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5414fffd5f4239b19162caf4e3052b8eb0ebe9f3aed540ea517a38c434890b7f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "128192e9-47ce-465b-adb6-025c28c346e5", "node_type": "1", "metadata": {"window": "The trends we witnessed in June, combined with our improved outlook for the business over the \nremainder of this fiscal year, give u s confidence in our significantly improved outlook for the segment.  \n \n Turning to Other, which now primarily consists of Canada and McKesson Prescription Technology Solutions \nfollowing the separation of our investment in Change Healthcare in fiscal 2020.  We're encouraged by the trends \nwe saw in Canada to end the quarter as volumes began to approach pre -COVID levels in our distribution and \nretail businesses.  \n \n Within the retail setting, our focus remains on building an enhanced customer experience through in vestments in \npeople and reconfigured pharmacy formats.  This has helped to strengthen our fundamentals and the role that ", "original_text": "Within the retail setting, our focus remains on building an enhanced customer experience through in vestments in \npeople and reconfigured pharmacy formats. "}, "hash": "804a7772f719298f8f394f86597a378268b17f0fff5b16b21eb6b7b6f4fafb9e", "class_name": "RelatedNodeInfo"}}, "text": "We're encouraged by the trends \nwe saw in Canada to end the quarter as volumes began to approach pre -COVID levels in our distribution and \nretail businesses.  \n \n", "start_char_idx": 3729, "end_char_idx": 3892, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "128192e9-47ce-465b-adb6-025c28c346e5": {"__data__": {"id_": "128192e9-47ce-465b-adb6-025c28c346e5", "embedding": null, "metadata": {"window": "The trends we witnessed in June, combined with our improved outlook for the business over the \nremainder of this fiscal year, give u s confidence in our significantly improved outlook for the segment.  \n \n Turning to Other, which now primarily consists of Canada and McKesson Prescription Technology Solutions \nfollowing the separation of our investment in Change Healthcare in fiscal 2020.  We're encouraged by the trends \nwe saw in Canada to end the quarter as volumes began to approach pre -COVID levels in our distribution and \nretail businesses.  \n \n Within the retail setting, our focus remains on building an enhanced customer experience through in vestments in \npeople and reconfigured pharmacy formats.  This has helped to strengthen our fundamentals and the role that ", "original_text": "Within the retail setting, our focus remains on building an enhanced customer experience through in vestments in \npeople and reconfigured pharmacy formats. ", "page_label": "5", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2b6fa81b-d6e8-4046-a002-579e9e14ad02", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f979e56f55121861d8368ca4fe9d5a492f8ab49f3de018ae9a4ece2eb1f430a2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4e99c27c-2499-4686-bd29-551b9fbf0ec6", "node_type": "1", "metadata": {"window": "And as customers need solutions for COVID -19 and as our manufacturer partner s \ndevelop and launch testing solutions, we remain a partner of choice and a leader across alternate site \u2013 settings \nof care.  The trends we witnessed in June, combined with our improved outlook for the business over the \nremainder of this fiscal year, give u s confidence in our significantly improved outlook for the segment.  \n \n Turning to Other, which now primarily consists of Canada and McKesson Prescription Technology Solutions \nfollowing the separation of our investment in Change Healthcare in fiscal 2020.  We're encouraged by the trends \nwe saw in Canada to end the quarter as volumes began to approach pre -COVID levels in our distribution and \nretail businesses.  \n \n Within the retail setting, our focus remains on building an enhanced customer experience through in vestments in \npeople and reconfigured pharmacy formats.  This has helped to strengthen our fundamentals and the role that ", "original_text": "We're encouraged by the trends \nwe saw in Canada to end the quarter as volumes began to approach pre -COVID levels in our distribution and \nretail businesses.  \n \n", "page_label": "5", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cd594e1acb90996219ac47155b8a8dbaa2e50704d7cb551ce72375c8eb4eba8a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0937be29-1b77-4acf-9884-c099e3f6a844", "node_type": "1", "metadata": {"window": "Turning to Other, which now primarily consists of Canada and McKesson Prescription Technology Solutions \nfollowing the separation of our investment in Change Healthcare in fiscal 2020.  We're encouraged by the trends \nwe saw in Canada to end the quarter as volumes began to approach pre -COVID levels in our distribution and \nretail businesses.  \n \n Within the retail setting, our focus remains on building an enhanced customer experience through in vestments in \npeople and reconfigured pharmacy formats.  This has helped to strengthen our fundamentals and the role that ", "original_text": "This has helped to strengthen our fundamentals and the role that "}, "hash": "5e8b8b59246e4533f23162532cdcf2616f0e5fe1492664b7f7cfebfde6f3402c", "class_name": "RelatedNodeInfo"}}, "text": "Within the retail setting, our focus remains on building an enhanced customer experience through in vestments in \npeople and reconfigured pharmacy formats. ", "start_char_idx": 3892, "end_char_idx": 4048, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0937be29-1b77-4acf-9884-c099e3f6a844": {"__data__": {"id_": "0937be29-1b77-4acf-9884-c099e3f6a844", "embedding": null, "metadata": {"window": "Turning to Other, which now primarily consists of Canada and McKesson Prescription Technology Solutions \nfollowing the separation of our investment in Change Healthcare in fiscal 2020.  We're encouraged by the trends \nwe saw in Canada to end the quarter as volumes began to approach pre -COVID levels in our distribution and \nretail businesses.  \n \n Within the retail setting, our focus remains on building an enhanced customer experience through in vestments in \npeople and reconfigured pharmacy formats.  This has helped to strengthen our fundamentals and the role that ", "original_text": "This has helped to strengthen our fundamentals and the role that ", "page_label": "5", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2b6fa81b-d6e8-4046-a002-579e9e14ad02", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f979e56f55121861d8368ca4fe9d5a492f8ab49f3de018ae9a4ece2eb1f430a2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "128192e9-47ce-465b-adb6-025c28c346e5", "node_type": "1", "metadata": {"window": "The trends we witnessed in June, combined with our improved outlook for the business over the \nremainder of this fiscal year, give u s confidence in our significantly improved outlook for the segment.  \n \n Turning to Other, which now primarily consists of Canada and McKesson Prescription Technology Solutions \nfollowing the separation of our investment in Change Healthcare in fiscal 2020.  We're encouraged by the trends \nwe saw in Canada to end the quarter as volumes began to approach pre -COVID levels in our distribution and \nretail businesses.  \n \n Within the retail setting, our focus remains on building an enhanced customer experience through in vestments in \npeople and reconfigured pharmacy formats.  This has helped to strengthen our fundamentals and the role that ", "original_text": "Within the retail setting, our focus remains on building an enhanced customer experience through in vestments in \npeople and reconfigured pharmacy formats. ", "page_label": "5", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7515dd34bff0e163de5f69d185c163b77af04372b591840765fb323991b16058", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9a2462da-b695-477b-a955-2d1ceff730b7", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \ncommunity pharmacy plays in the Canadian health care system, which is especially important in times like these. \n Our own Canadian pharmac ies are continuing to evolve and will soon offer e -commerce and e -prescribing \nplatforms, creating additional options for Canadian consumers, who want both a physical and digital shopping \nexperience.  \n \n Within MRxTS, we're making progress with our investments  to create technology offerings that resonate with our \nretail and biopharma customers. ", "original_text": "McKesson Corp.  "}, "hash": "f0cc6db35711a15f78569b579f03e3f12fe1500328861dcaede835b0e2178aeb", "class_name": "RelatedNodeInfo"}}, "text": "This has helped to strengthen our fundamentals and the role that ", "start_char_idx": 4048, "end_char_idx": 4113, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9a2462da-b695-477b-a955-2d1ceff730b7": {"__data__": {"id_": "9a2462da-b695-477b-a955-2d1ceff730b7", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \ncommunity pharmacy plays in the Canadian health care system, which is especially important in times like these. \n Our own Canadian pharmac ies are continuing to evolve and will soon offer e -commerce and e -prescribing \nplatforms, creating additional options for Canadian consumers, who want both a physical and digital shopping \nexperience.  \n \n Within MRxTS, we're making progress with our investments  to create technology offerings that resonate with our \nretail and biopharma customers. ", "original_text": "McKesson Corp.  ", "page_label": "6", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "fec4a8f1-855e-450a-b1f2-9b9b254694e1", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a239d471a470eea39c38eff204665dc357ce59752fbef1112eed677a51da3cb9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0937be29-1b77-4acf-9884-c099e3f6a844", "node_type": "1", "metadata": {"window": "Turning to Other, which now primarily consists of Canada and McKesson Prescription Technology Solutions \nfollowing the separation of our investment in Change Healthcare in fiscal 2020.  We're encouraged by the trends \nwe saw in Canada to end the quarter as volumes began to approach pre -COVID levels in our distribution and \nretail businesses.  \n \n Within the retail setting, our focus remains on building an enhanced customer experience through in vestments in \npeople and reconfigured pharmacy formats.  This has helped to strengthen our fundamentals and the role that ", "original_text": "This has helped to strengthen our fundamentals and the role that ", "page_label": "5", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "dedd31731524f3ca9bfb03082d5df61c61d97c3373e2d5ef5bde798884dc8942", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "319e7aed-1474-42e2-b7fd-0771437b25cc", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \ncommunity pharmacy plays in the Canadian health care system, which is especially important in times like these. \n Our own Canadian pharmac ies are continuing to evolve and will soon offer e -commerce and e -prescribing \nplatforms, creating additional options for Canadian consumers, who want both a physical and digital shopping \nexperience.  \n \n Within MRxTS, we're making progress with our investments  to create technology offerings that resonate with our \nretail and biopharma customers.  Since launching in September of 2019, Access for More Patients, a product we \ncall AMP, has helped automate access to therapies for complex and chronic diseases, reducing  the time to \ntherapy by 18 days on average, and we're continuing to expand the brand taking advantage of this offering.  \n \n", "original_text": "(MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \ncommunity pharmacy plays in the Canadian health care system, which is especially important in times like these. \n"}, "hash": "00be2cd57d31f12652c4ed7a333f27777bf70014d1656db48a32f463109fe7ae", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "319e7aed-1474-42e2-b7fd-0771437b25cc": {"__data__": {"id_": "319e7aed-1474-42e2-b7fd-0771437b25cc", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \ncommunity pharmacy plays in the Canadian health care system, which is especially important in times like these. \n Our own Canadian pharmac ies are continuing to evolve and will soon offer e -commerce and e -prescribing \nplatforms, creating additional options for Canadian consumers, who want both a physical and digital shopping \nexperience.  \n \n Within MRxTS, we're making progress with our investments  to create technology offerings that resonate with our \nretail and biopharma customers.  Since launching in September of 2019, Access for More Patients, a product we \ncall AMP, has helped automate access to therapies for complex and chronic diseases, reducing  the time to \ntherapy by 18 days on average, and we're continuing to expand the brand taking advantage of this offering.  \n \n", "original_text": "(MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \ncommunity pharmacy plays in the Canadian health care system, which is especially important in times like these. \n", "page_label": "6", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "fec4a8f1-855e-450a-b1f2-9b9b254694e1", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a239d471a470eea39c38eff204665dc357ce59752fbef1112eed677a51da3cb9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9a2462da-b695-477b-a955-2d1ceff730b7", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \ncommunity pharmacy plays in the Canadian health care system, which is especially important in times like these. \n Our own Canadian pharmac ies are continuing to evolve and will soon offer e -commerce and e -prescribing \nplatforms, creating additional options for Canadian consumers, who want both a physical and digital shopping \nexperience.  \n \n Within MRxTS, we're making progress with our investments  to create technology offerings that resonate with our \nretail and biopharma customers. ", "original_text": "McKesson Corp.  ", "page_label": "6", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b7d475772f86523bc97903a320247975c26a91e09c60ec5631958f00beafcee5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f7ca8fd1-41d4-468c-8210-1c8ed90b513c", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \ncommunity pharmacy plays in the Canadian health care system, which is especially important in times like these. \n Our own Canadian pharmac ies are continuing to evolve and will soon offer e -commerce and e -prescribing \nplatforms, creating additional options for Canadian consumers, who want both a physical and digital shopping \nexperience.  \n \n Within MRxTS, we're making progress with our investments  to create technology offerings that resonate with our \nretail and biopharma customers.  Since launching in September of 2019, Access for More Patients, a product we \ncall AMP, has helped automate access to therapies for complex and chronic diseases, reducing  the time to \ntherapy by 18 days on average, and we're continuing to expand the brand taking advantage of this offering.  \n \n The collaboration between our RxCrossroads and CoverMymeds businesses to develop AMP is a good example \nof how our business evolves to m eet the needs of our customers. ", "original_text": "Our own Canadian pharmac ies are continuing to evolve and will soon offer e -commerce and e -prescribing \nplatforms, creating additional options for Canadian consumers, who want both a physical and digital shopping \nexperience.  \n \n"}, "hash": "7082527b75de880cfa76ad627b84fcdd950621fe61e3e9bcdda186cd10fa9047", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \ncommunity pharmacy plays in the Canadian health care system, which is especially important in times like these. \n", "start_char_idx": 16, "end_char_idx": 293, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f7ca8fd1-41d4-468c-8210-1c8ed90b513c": {"__data__": {"id_": "f7ca8fd1-41d4-468c-8210-1c8ed90b513c", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \ncommunity pharmacy plays in the Canadian health care system, which is especially important in times like these. \n Our own Canadian pharmac ies are continuing to evolve and will soon offer e -commerce and e -prescribing \nplatforms, creating additional options for Canadian consumers, who want both a physical and digital shopping \nexperience.  \n \n Within MRxTS, we're making progress with our investments  to create technology offerings that resonate with our \nretail and biopharma customers.  Since launching in September of 2019, Access for More Patients, a product we \ncall AMP, has helped automate access to therapies for complex and chronic diseases, reducing  the time to \ntherapy by 18 days on average, and we're continuing to expand the brand taking advantage of this offering.  \n \n The collaboration between our RxCrossroads and CoverMymeds businesses to develop AMP is a good example \nof how our business evolves to m eet the needs of our customers. ", "original_text": "Our own Canadian pharmac ies are continuing to evolve and will soon offer e -commerce and e -prescribing \nplatforms, creating additional options for Canadian consumers, who want both a physical and digital shopping \nexperience.  \n \n", "page_label": "6", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "fec4a8f1-855e-450a-b1f2-9b9b254694e1", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a239d471a470eea39c38eff204665dc357ce59752fbef1112eed677a51da3cb9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "319e7aed-1474-42e2-b7fd-0771437b25cc", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \ncommunity pharmacy plays in the Canadian health care system, which is especially important in times like these. \n Our own Canadian pharmac ies are continuing to evolve and will soon offer e -commerce and e -prescribing \nplatforms, creating additional options for Canadian consumers, who want both a physical and digital shopping \nexperience.  \n \n Within MRxTS, we're making progress with our investments  to create technology offerings that resonate with our \nretail and biopharma customers.  Since launching in September of 2019, Access for More Patients, a product we \ncall AMP, has helped automate access to therapies for complex and chronic diseases, reducing  the time to \ntherapy by 18 days on average, and we're continuing to expand the brand taking advantage of this offering.  \n \n", "original_text": "(MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \ncommunity pharmacy plays in the Canadian health care system, which is especially important in times like these. \n", "page_label": "6", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1f4ee3f74fd91369747d9ad97828ae1291239e3152df48b964b8b870004fab05", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "65a0dbf1-30af-4c44-8889-b86d8bf355f9", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \ncommunity pharmacy plays in the Canadian health care system, which is especially important in times like these. \n Our own Canadian pharmac ies are continuing to evolve and will soon offer e -commerce and e -prescribing \nplatforms, creating additional options for Canadian consumers, who want both a physical and digital shopping \nexperience.  \n \n Within MRxTS, we're making progress with our investments  to create technology offerings that resonate with our \nretail and biopharma customers.  Since launching in September of 2019, Access for More Patients, a product we \ncall AMP, has helped automate access to therapies for complex and chronic diseases, reducing  the time to \ntherapy by 18 days on average, and we're continuing to expand the brand taking advantage of this offering.  \n \n The collaboration between our RxCrossroads and CoverMymeds businesses to develop AMP is a good example \nof how our business evolves to m eet the needs of our customers.  As part of our ongoing evolution, on July 1, we \nannounced the resegmentation of our businesses effective in the second quarter of this fiscal year. ", "original_text": "Within MRxTS, we're making progress with our investments  to create technology offerings that resonate with our \nretail and biopharma customers. "}, "hash": "401cafae67283bd1f2771f5676984e4d645c30f9ac0b42004efd9cb449471a95", "class_name": "RelatedNodeInfo"}}, "text": "Our own Canadian pharmac ies are continuing to evolve and will soon offer e -commerce and e -prescribing \nplatforms, creating additional options for Canadian consumers, who want both a physical and digital shopping \nexperience.  \n \n", "start_char_idx": 293, "end_char_idx": 525, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "65a0dbf1-30af-4c44-8889-b86d8bf355f9": {"__data__": {"id_": "65a0dbf1-30af-4c44-8889-b86d8bf355f9", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \ncommunity pharmacy plays in the Canadian health care system, which is especially important in times like these. \n Our own Canadian pharmac ies are continuing to evolve and will soon offer e -commerce and e -prescribing \nplatforms, creating additional options for Canadian consumers, who want both a physical and digital shopping \nexperience.  \n \n Within MRxTS, we're making progress with our investments  to create technology offerings that resonate with our \nretail and biopharma customers.  Since launching in September of 2019, Access for More Patients, a product we \ncall AMP, has helped automate access to therapies for complex and chronic diseases, reducing  the time to \ntherapy by 18 days on average, and we're continuing to expand the brand taking advantage of this offering.  \n \n The collaboration between our RxCrossroads and CoverMymeds businesses to develop AMP is a good example \nof how our business evolves to m eet the needs of our customers.  As part of our ongoing evolution, on July 1, we \nannounced the resegmentation of our businesses effective in the second quarter of this fiscal year. ", "original_text": "Within MRxTS, we're making progress with our investments  to create technology offerings that resonate with our \nretail and biopharma customers. ", "page_label": "6", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "fec4a8f1-855e-450a-b1f2-9b9b254694e1", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a239d471a470eea39c38eff204665dc357ce59752fbef1112eed677a51da3cb9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f7ca8fd1-41d4-468c-8210-1c8ed90b513c", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \ncommunity pharmacy plays in the Canadian health care system, which is especially important in times like these. \n Our own Canadian pharmac ies are continuing to evolve and will soon offer e -commerce and e -prescribing \nplatforms, creating additional options for Canadian consumers, who want both a physical and digital shopping \nexperience.  \n \n Within MRxTS, we're making progress with our investments  to create technology offerings that resonate with our \nretail and biopharma customers.  Since launching in September of 2019, Access for More Patients, a product we \ncall AMP, has helped automate access to therapies for complex and chronic diseases, reducing  the time to \ntherapy by 18 days on average, and we're continuing to expand the brand taking advantage of this offering.  \n \n The collaboration between our RxCrossroads and CoverMymeds businesses to develop AMP is a good example \nof how our business evolves to m eet the needs of our customers. ", "original_text": "Our own Canadian pharmac ies are continuing to evolve and will soon offer e -commerce and e -prescribing \nplatforms, creating additional options for Canadian consumers, who want both a physical and digital shopping \nexperience.  \n \n", "page_label": "6", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bd1b71f2995d6f4fe8bffcd0abae45daeacfb6cf7a8a1c56172e9b44ecc97cc8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a1af1e9c-fbe9-48f1-829b-ff663eed09a2", "node_type": "1", "metadata": {"window": "(MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \ncommunity pharmacy plays in the Canadian health care system, which is especially important in times like these. \n Our own Canadian pharmac ies are continuing to evolve and will soon offer e -commerce and e -prescribing \nplatforms, creating additional options for Canadian consumers, who want both a physical and digital shopping \nexperience.  \n \n Within MRxTS, we're making progress with our investments  to create technology offerings that resonate with our \nretail and biopharma customers.  Since launching in September of 2019, Access for More Patients, a product we \ncall AMP, has helped automate access to therapies for complex and chronic diseases, reducing  the time to \ntherapy by 18 days on average, and we're continuing to expand the brand taking advantage of this offering.  \n \n The collaboration between our RxCrossroads and CoverMymeds businesses to develop AMP is a good example \nof how our business evolves to m eet the needs of our customers.  As part of our ongoing evolution, on July 1, we \nannounced the resegmentation of our businesses effective in the second quarter of this fiscal year.  We believe \nthat this new organization structure better positions McKesson to  focus and execute against our growth strategies \nand to meet the changing needs of our customers.  \n \n", "original_text": "Since launching in September of 2019, Access for More Patients, a product we \ncall AMP, has helped automate access to therapies for complex and chronic diseases, reducing  the time to \ntherapy by 18 days on average, and we're continuing to expand the brand taking advantage of this offering.  \n \n"}, "hash": "8cbe2550fecbdac1637e04165f8cfab3c1a61d6e71b8ccf968723c055acae571", "class_name": "RelatedNodeInfo"}}, "text": "Within MRxTS, we're making progress with our investments  to create technology offerings that resonate with our \nretail and biopharma customers. ", "start_char_idx": 525, "end_char_idx": 670, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a1af1e9c-fbe9-48f1-829b-ff663eed09a2": {"__data__": {"id_": "a1af1e9c-fbe9-48f1-829b-ff663eed09a2", "embedding": null, "metadata": {"window": "(MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \ncommunity pharmacy plays in the Canadian health care system, which is especially important in times like these. \n Our own Canadian pharmac ies are continuing to evolve and will soon offer e -commerce and e -prescribing \nplatforms, creating additional options for Canadian consumers, who want both a physical and digital shopping \nexperience.  \n \n Within MRxTS, we're making progress with our investments  to create technology offerings that resonate with our \nretail and biopharma customers.  Since launching in September of 2019, Access for More Patients, a product we \ncall AMP, has helped automate access to therapies for complex and chronic diseases, reducing  the time to \ntherapy by 18 days on average, and we're continuing to expand the brand taking advantage of this offering.  \n \n The collaboration between our RxCrossroads and CoverMymeds businesses to develop AMP is a good example \nof how our business evolves to m eet the needs of our customers.  As part of our ongoing evolution, on July 1, we \nannounced the resegmentation of our businesses effective in the second quarter of this fiscal year.  We believe \nthat this new organization structure better positions McKesson to  focus and execute against our growth strategies \nand to meet the changing needs of our customers.  \n \n", "original_text": "Since launching in September of 2019, Access for More Patients, a product we \ncall AMP, has helped automate access to therapies for complex and chronic diseases, reducing  the time to \ntherapy by 18 days on average, and we're continuing to expand the brand taking advantage of this offering.  \n \n", "page_label": "6", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "fec4a8f1-855e-450a-b1f2-9b9b254694e1", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a239d471a470eea39c38eff204665dc357ce59752fbef1112eed677a51da3cb9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "65a0dbf1-30af-4c44-8889-b86d8bf355f9", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \ncommunity pharmacy plays in the Canadian health care system, which is especially important in times like these. \n Our own Canadian pharmac ies are continuing to evolve and will soon offer e -commerce and e -prescribing \nplatforms, creating additional options for Canadian consumers, who want both a physical and digital shopping \nexperience.  \n \n Within MRxTS, we're making progress with our investments  to create technology offerings that resonate with our \nretail and biopharma customers.  Since launching in September of 2019, Access for More Patients, a product we \ncall AMP, has helped automate access to therapies for complex and chronic diseases, reducing  the time to \ntherapy by 18 days on average, and we're continuing to expand the brand taking advantage of this offering.  \n \n The collaboration between our RxCrossroads and CoverMymeds businesses to develop AMP is a good example \nof how our business evolves to m eet the needs of our customers.  As part of our ongoing evolution, on July 1, we \nannounced the resegmentation of our businesses effective in the second quarter of this fiscal year. ", "original_text": "Within MRxTS, we're making progress with our investments  to create technology offerings that resonate with our \nretail and biopharma customers. ", "page_label": "6", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "53a26d0f5a23d65388d543ddef24d748a4cdc07ce7b8bc8ae3c52d8c4a5f1029", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1f18831e-d5d5-42f0-bb9a-a89ee863cb47", "node_type": "1", "metadata": {"window": "Our own Canadian pharmac ies are continuing to evolve and will soon offer e -commerce and e -prescribing \nplatforms, creating additional options for Canadian consumers, who want both a physical and digital shopping \nexperience.  \n \n Within MRxTS, we're making progress with our investments  to create technology offerings that resonate with our \nretail and biopharma customers.  Since launching in September of 2019, Access for More Patients, a product we \ncall AMP, has helped automate access to therapies for complex and chronic diseases, reducing  the time to \ntherapy by 18 days on average, and we're continuing to expand the brand taking advantage of this offering.  \n \n The collaboration between our RxCrossroads and CoverMymeds businesses to develop AMP is a good example \nof how our business evolves to m eet the needs of our customers.  As part of our ongoing evolution, on July 1, we \nannounced the resegmentation of our businesses effective in the second quarter of this fiscal year.  We believe \nthat this new organization structure better positions McKesson to  focus and execute against our growth strategies \nand to meet the changing needs of our customers.  \n \n With this resegmentation, two new segments have been established: International and Prescription Technology \nSolutions. ", "original_text": "The collaboration between our RxCrossroads and CoverMymeds businesses to develop AMP is a good example \nof how our business evolves to m eet the needs of our customers. "}, "hash": "5a116d5556e3c93ba3cc8c9854574916fcf7d0359c9ea8b0cc64d1d0470049bb", "class_name": "RelatedNodeInfo"}}, "text": "Since launching in September of 2019, Access for More Patients, a product we \ncall AMP, has helped automate access to therapies for complex and chronic diseases, reducing  the time to \ntherapy by 18 days on average, and we're continuing to expand the brand taking advantage of this offering.  \n \n", "start_char_idx": 670, "end_char_idx": 966, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1f18831e-d5d5-42f0-bb9a-a89ee863cb47": {"__data__": {"id_": "1f18831e-d5d5-42f0-bb9a-a89ee863cb47", "embedding": null, "metadata": {"window": "Our own Canadian pharmac ies are continuing to evolve and will soon offer e -commerce and e -prescribing \nplatforms, creating additional options for Canadian consumers, who want both a physical and digital shopping \nexperience.  \n \n Within MRxTS, we're making progress with our investments  to create technology offerings that resonate with our \nretail and biopharma customers.  Since launching in September of 2019, Access for More Patients, a product we \ncall AMP, has helped automate access to therapies for complex and chronic diseases, reducing  the time to \ntherapy by 18 days on average, and we're continuing to expand the brand taking advantage of this offering.  \n \n The collaboration between our RxCrossroads and CoverMymeds businesses to develop AMP is a good example \nof how our business evolves to m eet the needs of our customers.  As part of our ongoing evolution, on July 1, we \nannounced the resegmentation of our businesses effective in the second quarter of this fiscal year.  We believe \nthat this new organization structure better positions McKesson to  focus and execute against our growth strategies \nand to meet the changing needs of our customers.  \n \n With this resegmentation, two new segments have been established: International and Prescription Technology \nSolutions. ", "original_text": "The collaboration between our RxCrossroads and CoverMymeds businesses to develop AMP is a good example \nof how our business evolves to m eet the needs of our customers. ", "page_label": "6", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "fec4a8f1-855e-450a-b1f2-9b9b254694e1", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a239d471a470eea39c38eff204665dc357ce59752fbef1112eed677a51da3cb9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a1af1e9c-fbe9-48f1-829b-ff663eed09a2", "node_type": "1", "metadata": {"window": "(MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \ncommunity pharmacy plays in the Canadian health care system, which is especially important in times like these. \n Our own Canadian pharmac ies are continuing to evolve and will soon offer e -commerce and e -prescribing \nplatforms, creating additional options for Canadian consumers, who want both a physical and digital shopping \nexperience.  \n \n Within MRxTS, we're making progress with our investments  to create technology offerings that resonate with our \nretail and biopharma customers.  Since launching in September of 2019, Access for More Patients, a product we \ncall AMP, has helped automate access to therapies for complex and chronic diseases, reducing  the time to \ntherapy by 18 days on average, and we're continuing to expand the brand taking advantage of this offering.  \n \n The collaboration between our RxCrossroads and CoverMymeds businesses to develop AMP is a good example \nof how our business evolves to m eet the needs of our customers.  As part of our ongoing evolution, on July 1, we \nannounced the resegmentation of our businesses effective in the second quarter of this fiscal year.  We believe \nthat this new organization structure better positions McKesson to  focus and execute against our growth strategies \nand to meet the changing needs of our customers.  \n \n", "original_text": "Since launching in September of 2019, Access for More Patients, a product we \ncall AMP, has helped automate access to therapies for complex and chronic diseases, reducing  the time to \ntherapy by 18 days on average, and we're continuing to expand the brand taking advantage of this offering.  \n \n", "page_label": "6", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8ddda94c632aab495c13e816f7499e5a06f172dc96d890cf780f957975ab7be2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e29877c2-b301-401c-a043-57e48ab1acc3", "node_type": "1", "metadata": {"window": "Within MRxTS, we're making progress with our investments  to create technology offerings that resonate with our \nretail and biopharma customers.  Since launching in September of 2019, Access for More Patients, a product we \ncall AMP, has helped automate access to therapies for complex and chronic diseases, reducing  the time to \ntherapy by 18 days on average, and we're continuing to expand the brand taking advantage of this offering.  \n \n The collaboration between our RxCrossroads and CoverMymeds businesses to develop AMP is a good example \nof how our business evolves to m eet the needs of our customers.  As part of our ongoing evolution, on July 1, we \nannounced the resegmentation of our businesses effective in the second quarter of this fiscal year.  We believe \nthat this new organization structure better positions McKesson to  focus and execute against our growth strategies \nand to meet the changing needs of our customers.  \n \n With this resegmentation, two new segments have been established: International and Prescription Technology \nSolutions.  Kevin Kettler has assumed responsibili ty for the new International segment, which combines McKesson \nEurope and our Canadian business. ", "original_text": "As part of our ongoing evolution, on July 1, we \nannounced the resegmentation of our businesses effective in the second quarter of this fiscal year. "}, "hash": "6457a74cf8351b819760141f8e33ecf39f4e0159ed95da8c1e9c36811c8bb243", "class_name": "RelatedNodeInfo"}}, "text": "The collaboration between our RxCrossroads and CoverMymeds businesses to develop AMP is a good example \nof how our business evolves to m eet the needs of our customers. ", "start_char_idx": 966, "end_char_idx": 1135, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e29877c2-b301-401c-a043-57e48ab1acc3": {"__data__": {"id_": "e29877c2-b301-401c-a043-57e48ab1acc3", "embedding": null, "metadata": {"window": "Within MRxTS, we're making progress with our investments  to create technology offerings that resonate with our \nretail and biopharma customers.  Since launching in September of 2019, Access for More Patients, a product we \ncall AMP, has helped automate access to therapies for complex and chronic diseases, reducing  the time to \ntherapy by 18 days on average, and we're continuing to expand the brand taking advantage of this offering.  \n \n The collaboration between our RxCrossroads and CoverMymeds businesses to develop AMP is a good example \nof how our business evolves to m eet the needs of our customers.  As part of our ongoing evolution, on July 1, we \nannounced the resegmentation of our businesses effective in the second quarter of this fiscal year.  We believe \nthat this new organization structure better positions McKesson to  focus and execute against our growth strategies \nand to meet the changing needs of our customers.  \n \n With this resegmentation, two new segments have been established: International and Prescription Technology \nSolutions.  Kevin Kettler has assumed responsibili ty for the new International segment, which combines McKesson \nEurope and our Canadian business. ", "original_text": "As part of our ongoing evolution, on July 1, we \nannounced the resegmentation of our businesses effective in the second quarter of this fiscal year. ", "page_label": "6", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "fec4a8f1-855e-450a-b1f2-9b9b254694e1", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a239d471a470eea39c38eff204665dc357ce59752fbef1112eed677a51da3cb9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1f18831e-d5d5-42f0-bb9a-a89ee863cb47", "node_type": "1", "metadata": {"window": "Our own Canadian pharmac ies are continuing to evolve and will soon offer e -commerce and e -prescribing \nplatforms, creating additional options for Canadian consumers, who want both a physical and digital shopping \nexperience.  \n \n Within MRxTS, we're making progress with our investments  to create technology offerings that resonate with our \nretail and biopharma customers.  Since launching in September of 2019, Access for More Patients, a product we \ncall AMP, has helped automate access to therapies for complex and chronic diseases, reducing  the time to \ntherapy by 18 days on average, and we're continuing to expand the brand taking advantage of this offering.  \n \n The collaboration between our RxCrossroads and CoverMymeds businesses to develop AMP is a good example \nof how our business evolves to m eet the needs of our customers.  As part of our ongoing evolution, on July 1, we \nannounced the resegmentation of our businesses effective in the second quarter of this fiscal year.  We believe \nthat this new organization structure better positions McKesson to  focus and execute against our growth strategies \nand to meet the changing needs of our customers.  \n \n With this resegmentation, two new segments have been established: International and Prescription Technology \nSolutions. ", "original_text": "The collaboration between our RxCrossroads and CoverMymeds businesses to develop AMP is a good example \nof how our business evolves to m eet the needs of our customers. ", "page_label": "6", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1095719acb25b798fbf63b2738f7f987f4def434e6831fc5c682486a0e24acb6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "af5aad95-ba86-42d3-9182-7f39e074255c", "node_type": "1", "metadata": {"window": "Since launching in September of 2019, Access for More Patients, a product we \ncall AMP, has helped automate access to therapies for complex and chronic diseases, reducing  the time to \ntherapy by 18 days on average, and we're continuing to expand the brand taking advantage of this offering.  \n \n The collaboration between our RxCrossroads and CoverMymeds businesses to develop AMP is a good example \nof how our business evolves to m eet the needs of our customers.  As part of our ongoing evolution, on July 1, we \nannounced the resegmentation of our businesses effective in the second quarter of this fiscal year.  We believe \nthat this new organization structure better positions McKesson to  focus and execute against our growth strategies \nand to meet the changing needs of our customers.  \n \n With this resegmentation, two new segments have been established: International and Prescription Technology \nSolutions.  Kevin Kettler has assumed responsibili ty for the new International segment, which combines McKesson \nEurope and our Canadian business.  Nathan Mott will lead the new Prescription Technology Solutions segment, \nwhich has been expanded to include the RxCrossroads business, formerly reported as part  of McKesson Life \nSciences within our U.S. ", "original_text": "We believe \nthat this new organization structure better positions McKesson to  focus and execute against our growth strategies \nand to meet the changing needs of our customers.  \n \n"}, "hash": "71c6f421f0ed0c6ca5ca25d83e5596a297f4cf84251ac18121fd360e713b8f56", "class_name": "RelatedNodeInfo"}}, "text": "As part of our ongoing evolution, on July 1, we \nannounced the resegmentation of our businesses effective in the second quarter of this fiscal year. ", "start_char_idx": 1135, "end_char_idx": 1284, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "af5aad95-ba86-42d3-9182-7f39e074255c": {"__data__": {"id_": "af5aad95-ba86-42d3-9182-7f39e074255c", "embedding": null, "metadata": {"window": "Since launching in September of 2019, Access for More Patients, a product we \ncall AMP, has helped automate access to therapies for complex and chronic diseases, reducing  the time to \ntherapy by 18 days on average, and we're continuing to expand the brand taking advantage of this offering.  \n \n The collaboration between our RxCrossroads and CoverMymeds businesses to develop AMP is a good example \nof how our business evolves to m eet the needs of our customers.  As part of our ongoing evolution, on July 1, we \nannounced the resegmentation of our businesses effective in the second quarter of this fiscal year.  We believe \nthat this new organization structure better positions McKesson to  focus and execute against our growth strategies \nand to meet the changing needs of our customers.  \n \n With this resegmentation, two new segments have been established: International and Prescription Technology \nSolutions.  Kevin Kettler has assumed responsibili ty for the new International segment, which combines McKesson \nEurope and our Canadian business.  Nathan Mott will lead the new Prescription Technology Solutions segment, \nwhich has been expanded to include the RxCrossroads business, formerly reported as part  of McKesson Life \nSciences within our U.S. ", "original_text": "We believe \nthat this new organization structure better positions McKesson to  focus and execute against our growth strategies \nand to meet the changing needs of our customers.  \n \n", "page_label": "6", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "fec4a8f1-855e-450a-b1f2-9b9b254694e1", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a239d471a470eea39c38eff204665dc357ce59752fbef1112eed677a51da3cb9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e29877c2-b301-401c-a043-57e48ab1acc3", "node_type": "1", "metadata": {"window": "Within MRxTS, we're making progress with our investments  to create technology offerings that resonate with our \nretail and biopharma customers.  Since launching in September of 2019, Access for More Patients, a product we \ncall AMP, has helped automate access to therapies for complex and chronic diseases, reducing  the time to \ntherapy by 18 days on average, and we're continuing to expand the brand taking advantage of this offering.  \n \n The collaboration between our RxCrossroads and CoverMymeds businesses to develop AMP is a good example \nof how our business evolves to m eet the needs of our customers.  As part of our ongoing evolution, on July 1, we \nannounced the resegmentation of our businesses effective in the second quarter of this fiscal year.  We believe \nthat this new organization structure better positions McKesson to  focus and execute against our growth strategies \nand to meet the changing needs of our customers.  \n \n With this resegmentation, two new segments have been established: International and Prescription Technology \nSolutions.  Kevin Kettler has assumed responsibili ty for the new International segment, which combines McKesson \nEurope and our Canadian business. ", "original_text": "As part of our ongoing evolution, on July 1, we \nannounced the resegmentation of our businesses effective in the second quarter of this fiscal year. ", "page_label": "6", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8dbcd73cd5db47291dd35757494cd05a4873cddf8a712726d3a1f2f53c33d456", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d43eb8bf-d9a0-47f2-a5bd-6da7b47a67e8", "node_type": "1", "metadata": {"window": "The collaboration between our RxCrossroads and CoverMymeds businesses to develop AMP is a good example \nof how our business evolves to m eet the needs of our customers.  As part of our ongoing evolution, on July 1, we \nannounced the resegmentation of our businesses effective in the second quarter of this fiscal year.  We believe \nthat this new organization structure better positions McKesson to  focus and execute against our growth strategies \nand to meet the changing needs of our customers.  \n \n With this resegmentation, two new segments have been established: International and Prescription Technology \nSolutions.  Kevin Kettler has assumed responsibili ty for the new International segment, which combines McKesson \nEurope and our Canadian business.  Nathan Mott will lead the new Prescription Technology Solutions segment, \nwhich has been expanded to include the RxCrossroads business, formerly reported as part  of McKesson Life \nSciences within our U.S.  Pharmaceutical and Specialty Solutions segment.  \n \n", "original_text": "With this resegmentation, two new segments have been established: International and Prescription Technology \nSolutions. "}, "hash": "0f89b7055e7e305dc45378e0b4b8f34a94bc184412bd8d64ef8f8a8cac177a34", "class_name": "RelatedNodeInfo"}}, "text": "We believe \nthat this new organization structure better positions McKesson to  focus and execute against our growth strategies \nand to meet the changing needs of our customers.  \n \n", "start_char_idx": 1284, "end_char_idx": 1465, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d43eb8bf-d9a0-47f2-a5bd-6da7b47a67e8": {"__data__": {"id_": "d43eb8bf-d9a0-47f2-a5bd-6da7b47a67e8", "embedding": null, "metadata": {"window": "The collaboration between our RxCrossroads and CoverMymeds businesses to develop AMP is a good example \nof how our business evolves to m eet the needs of our customers.  As part of our ongoing evolution, on July 1, we \nannounced the resegmentation of our businesses effective in the second quarter of this fiscal year.  We believe \nthat this new organization structure better positions McKesson to  focus and execute against our growth strategies \nand to meet the changing needs of our customers.  \n \n With this resegmentation, two new segments have been established: International and Prescription Technology \nSolutions.  Kevin Kettler has assumed responsibili ty for the new International segment, which combines McKesson \nEurope and our Canadian business.  Nathan Mott will lead the new Prescription Technology Solutions segment, \nwhich has been expanded to include the RxCrossroads business, formerly reported as part  of McKesson Life \nSciences within our U.S.  Pharmaceutical and Specialty Solutions segment.  \n \n", "original_text": "With this resegmentation, two new segments have been established: International and Prescription Technology \nSolutions. ", "page_label": "6", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "fec4a8f1-855e-450a-b1f2-9b9b254694e1", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a239d471a470eea39c38eff204665dc357ce59752fbef1112eed677a51da3cb9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "af5aad95-ba86-42d3-9182-7f39e074255c", "node_type": "1", "metadata": {"window": "Since launching in September of 2019, Access for More Patients, a product we \ncall AMP, has helped automate access to therapies for complex and chronic diseases, reducing  the time to \ntherapy by 18 days on average, and we're continuing to expand the brand taking advantage of this offering.  \n \n The collaboration between our RxCrossroads and CoverMymeds businesses to develop AMP is a good example \nof how our business evolves to m eet the needs of our customers.  As part of our ongoing evolution, on July 1, we \nannounced the resegmentation of our businesses effective in the second quarter of this fiscal year.  We believe \nthat this new organization structure better positions McKesson to  focus and execute against our growth strategies \nand to meet the changing needs of our customers.  \n \n With this resegmentation, two new segments have been established: International and Prescription Technology \nSolutions.  Kevin Kettler has assumed responsibili ty for the new International segment, which combines McKesson \nEurope and our Canadian business.  Nathan Mott will lead the new Prescription Technology Solutions segment, \nwhich has been expanded to include the RxCrossroads business, formerly reported as part  of McKesson Life \nSciences within our U.S. ", "original_text": "We believe \nthat this new organization structure better positions McKesson to  focus and execute against our growth strategies \nand to meet the changing needs of our customers.  \n \n", "page_label": "6", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "95ba444d6c2486174d719f5edfe622857dfa1003556d9efb0251bb07c5db3a7c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e19587bb-4749-4775-9cfe-63abe8b6858b", "node_type": "1", "metadata": {"window": "As part of our ongoing evolution, on July 1, we \nannounced the resegmentation of our businesses effective in the second quarter of this fiscal year.  We believe \nthat this new organization structure better positions McKesson to  focus and execute against our growth strategies \nand to meet the changing needs of our customers.  \n \n With this resegmentation, two new segments have been established: International and Prescription Technology \nSolutions.  Kevin Kettler has assumed responsibili ty for the new International segment, which combines McKesson \nEurope and our Canadian business.  Nathan Mott will lead the new Prescription Technology Solutions segment, \nwhich has been expanded to include the RxCrossroads business, formerly reported as part  of McKesson Life \nSciences within our U.S.  Pharmaceutical and Specialty Solutions segment.  \n \n In the quarter, we also appointed Tom Rodgers as Executive Vice President and Chief Strategy and Business \nDevelopment Officer. ", "original_text": "Kevin Kettler has assumed responsibili ty for the new International segment, which combines McKesson \nEurope and our Canadian business. "}, "hash": "af41b4b12ca52c64b71b7e9a857fcd77e12331376b905014d1c3e0635622145c", "class_name": "RelatedNodeInfo"}}, "text": "With this resegmentation, two new segments have been established: International and Prescription Technology \nSolutions. ", "start_char_idx": 1465, "end_char_idx": 1585, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e19587bb-4749-4775-9cfe-63abe8b6858b": {"__data__": {"id_": "e19587bb-4749-4775-9cfe-63abe8b6858b", "embedding": null, "metadata": {"window": "As part of our ongoing evolution, on July 1, we \nannounced the resegmentation of our businesses effective in the second quarter of this fiscal year.  We believe \nthat this new organization structure better positions McKesson to  focus and execute against our growth strategies \nand to meet the changing needs of our customers.  \n \n With this resegmentation, two new segments have been established: International and Prescription Technology \nSolutions.  Kevin Kettler has assumed responsibili ty for the new International segment, which combines McKesson \nEurope and our Canadian business.  Nathan Mott will lead the new Prescription Technology Solutions segment, \nwhich has been expanded to include the RxCrossroads business, formerly reported as part  of McKesson Life \nSciences within our U.S.  Pharmaceutical and Specialty Solutions segment.  \n \n In the quarter, we also appointed Tom Rodgers as Executive Vice President and Chief Strategy and Business \nDevelopment Officer. ", "original_text": "Kevin Kettler has assumed responsibili ty for the new International segment, which combines McKesson \nEurope and our Canadian business. ", "page_label": "6", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "fec4a8f1-855e-450a-b1f2-9b9b254694e1", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a239d471a470eea39c38eff204665dc357ce59752fbef1112eed677a51da3cb9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d43eb8bf-d9a0-47f2-a5bd-6da7b47a67e8", "node_type": "1", "metadata": {"window": "The collaboration between our RxCrossroads and CoverMymeds businesses to develop AMP is a good example \nof how our business evolves to m eet the needs of our customers.  As part of our ongoing evolution, on July 1, we \nannounced the resegmentation of our businesses effective in the second quarter of this fiscal year.  We believe \nthat this new organization structure better positions McKesson to  focus and execute against our growth strategies \nand to meet the changing needs of our customers.  \n \n With this resegmentation, two new segments have been established: International and Prescription Technology \nSolutions.  Kevin Kettler has assumed responsibili ty for the new International segment, which combines McKesson \nEurope and our Canadian business.  Nathan Mott will lead the new Prescription Technology Solutions segment, \nwhich has been expanded to include the RxCrossroads business, formerly reported as part  of McKesson Life \nSciences within our U.S.  Pharmaceutical and Specialty Solutions segment.  \n \n", "original_text": "With this resegmentation, two new segments have been established: International and Prescription Technology \nSolutions. ", "page_label": "6", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c80a234fa7a6de813b9934e174025c6e00b482c793aad5fa6382bd495dbfc2b1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a1d4c1c9-4e16-4e37-b8af-bb94c59defb3", "node_type": "1", "metadata": {"window": "We believe \nthat this new organization structure better positions McKesson to  focus and execute against our growth strategies \nand to meet the changing needs of our customers.  \n \n With this resegmentation, two new segments have been established: International and Prescription Technology \nSolutions.  Kevin Kettler has assumed responsibili ty for the new International segment, which combines McKesson \nEurope and our Canadian business.  Nathan Mott will lead the new Prescription Technology Solutions segment, \nwhich has been expanded to include the RxCrossroads business, formerly reported as part  of McKesson Life \nSciences within our U.S.  Pharmaceutical and Specialty Solutions segment.  \n \n In the quarter, we also appointed Tom Rodgers as Executive Vice President and Chief Strategy and Business \nDevelopment Officer.  Tom brings more than 25 years of expe rience working in both emerging companies and \nlarge health care environments.  \n \n", "original_text": "Nathan Mott will lead the new Prescription Technology Solutions segment, \nwhich has been expanded to include the RxCrossroads business, formerly reported as part  of McKesson Life \nSciences within our U.S. "}, "hash": "d079409917337fee99bb641b170bc77d5e1459b15a7f983714e4422e70279e7f", "class_name": "RelatedNodeInfo"}}, "text": "Kevin Kettler has assumed responsibili ty for the new International segment, which combines McKesson \nEurope and our Canadian business. ", "start_char_idx": 1585, "end_char_idx": 1721, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a1d4c1c9-4e16-4e37-b8af-bb94c59defb3": {"__data__": {"id_": "a1d4c1c9-4e16-4e37-b8af-bb94c59defb3", "embedding": null, "metadata": {"window": "We believe \nthat this new organization structure better positions McKesson to  focus and execute against our growth strategies \nand to meet the changing needs of our customers.  \n \n With this resegmentation, two new segments have been established: International and Prescription Technology \nSolutions.  Kevin Kettler has assumed responsibili ty for the new International segment, which combines McKesson \nEurope and our Canadian business.  Nathan Mott will lead the new Prescription Technology Solutions segment, \nwhich has been expanded to include the RxCrossroads business, formerly reported as part  of McKesson Life \nSciences within our U.S.  Pharmaceutical and Specialty Solutions segment.  \n \n In the quarter, we also appointed Tom Rodgers as Executive Vice President and Chief Strategy and Business \nDevelopment Officer.  Tom brings more than 25 years of expe rience working in both emerging companies and \nlarge health care environments.  \n \n", "original_text": "Nathan Mott will lead the new Prescription Technology Solutions segment, \nwhich has been expanded to include the RxCrossroads business, formerly reported as part  of McKesson Life \nSciences within our U.S. ", "page_label": "6", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "fec4a8f1-855e-450a-b1f2-9b9b254694e1", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a239d471a470eea39c38eff204665dc357ce59752fbef1112eed677a51da3cb9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e19587bb-4749-4775-9cfe-63abe8b6858b", "node_type": "1", "metadata": {"window": "As part of our ongoing evolution, on July 1, we \nannounced the resegmentation of our businesses effective in the second quarter of this fiscal year.  We believe \nthat this new organization structure better positions McKesson to  focus and execute against our growth strategies \nand to meet the changing needs of our customers.  \n \n With this resegmentation, two new segments have been established: International and Prescription Technology \nSolutions.  Kevin Kettler has assumed responsibili ty for the new International segment, which combines McKesson \nEurope and our Canadian business.  Nathan Mott will lead the new Prescription Technology Solutions segment, \nwhich has been expanded to include the RxCrossroads business, formerly reported as part  of McKesson Life \nSciences within our U.S.  Pharmaceutical and Specialty Solutions segment.  \n \n In the quarter, we also appointed Tom Rodgers as Executive Vice President and Chief Strategy and Business \nDevelopment Officer. ", "original_text": "Kevin Kettler has assumed responsibili ty for the new International segment, which combines McKesson \nEurope and our Canadian business. ", "page_label": "6", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f36240a0a9e761e909bf01f74a41f7d666fd19dacd370414fb29af893f253e19", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f286a33a-f518-4f3d-9241-d64f2de298cb", "node_type": "1", "metadata": {"window": "With this resegmentation, two new segments have been established: International and Prescription Technology \nSolutions.  Kevin Kettler has assumed responsibili ty for the new International segment, which combines McKesson \nEurope and our Canadian business.  Nathan Mott will lead the new Prescription Technology Solutions segment, \nwhich has been expanded to include the RxCrossroads business, formerly reported as part  of McKesson Life \nSciences within our U.S.  Pharmaceutical and Specialty Solutions segment.  \n \n In the quarter, we also appointed Tom Rodgers as Executive Vice President and Chief Strategy and Business \nDevelopment Officer.  Tom brings more than 25 years of expe rience working in both emerging companies and \nlarge health care environments.  \n \n In summary, we certainly faced unprecedented headwinds to begin fiscal 2021, but we're encouraged by the \nsigns of recovery across our businesses as we exit our first quarter. ", "original_text": "Pharmaceutical and Specialty Solutions segment.  \n \n"}, "hash": "96ca1a4477886abeada3602057692cf706951042ce60738e09e10428a0a92d90", "class_name": "RelatedNodeInfo"}}, "text": "Nathan Mott will lead the new Prescription Technology Solutions segment, \nwhich has been expanded to include the RxCrossroads business, formerly reported as part  of McKesson Life \nSciences within our U.S. ", "start_char_idx": 1721, "end_char_idx": 1927, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f286a33a-f518-4f3d-9241-d64f2de298cb": {"__data__": {"id_": "f286a33a-f518-4f3d-9241-d64f2de298cb", "embedding": null, "metadata": {"window": "With this resegmentation, two new segments have been established: International and Prescription Technology \nSolutions.  Kevin Kettler has assumed responsibili ty for the new International segment, which combines McKesson \nEurope and our Canadian business.  Nathan Mott will lead the new Prescription Technology Solutions segment, \nwhich has been expanded to include the RxCrossroads business, formerly reported as part  of McKesson Life \nSciences within our U.S.  Pharmaceutical and Specialty Solutions segment.  \n \n In the quarter, we also appointed Tom Rodgers as Executive Vice President and Chief Strategy and Business \nDevelopment Officer.  Tom brings more than 25 years of expe rience working in both emerging companies and \nlarge health care environments.  \n \n In summary, we certainly faced unprecedented headwinds to begin fiscal 2021, but we're encouraged by the \nsigns of recovery across our businesses as we exit our first quarter. ", "original_text": "Pharmaceutical and Specialty Solutions segment.  \n \n", "page_label": "6", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "fec4a8f1-855e-450a-b1f2-9b9b254694e1", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a239d471a470eea39c38eff204665dc357ce59752fbef1112eed677a51da3cb9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a1d4c1c9-4e16-4e37-b8af-bb94c59defb3", "node_type": "1", "metadata": {"window": "We believe \nthat this new organization structure better positions McKesson to  focus and execute against our growth strategies \nand to meet the changing needs of our customers.  \n \n With this resegmentation, two new segments have been established: International and Prescription Technology \nSolutions.  Kevin Kettler has assumed responsibili ty for the new International segment, which combines McKesson \nEurope and our Canadian business.  Nathan Mott will lead the new Prescription Technology Solutions segment, \nwhich has been expanded to include the RxCrossroads business, formerly reported as part  of McKesson Life \nSciences within our U.S.  Pharmaceutical and Specialty Solutions segment.  \n \n In the quarter, we also appointed Tom Rodgers as Executive Vice President and Chief Strategy and Business \nDevelopment Officer.  Tom brings more than 25 years of expe rience working in both emerging companies and \nlarge health care environments.  \n \n", "original_text": "Nathan Mott will lead the new Prescription Technology Solutions segment, \nwhich has been expanded to include the RxCrossroads business, formerly reported as part  of McKesson Life \nSciences within our U.S. ", "page_label": "6", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "deb6209d87033d85c24364fca76660cecf354a881469c4588ee6b644ca46be36", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f27ed826-6976-4325-9dd3-a0293e22731b", "node_type": "1", "metadata": {"window": "Kevin Kettler has assumed responsibili ty for the new International segment, which combines McKesson \nEurope and our Canadian business.  Nathan Mott will lead the new Prescription Technology Solutions segment, \nwhich has been expanded to include the RxCrossroads business, formerly reported as part  of McKesson Life \nSciences within our U.S.  Pharmaceutical and Specialty Solutions segment.  \n \n In the quarter, we also appointed Tom Rodgers as Executive Vice President and Chief Strategy and Business \nDevelopment Officer.  Tom brings more than 25 years of expe rience working in both emerging companies and \nlarge health care environments.  \n \n In summary, we certainly faced unprecedented headwinds to begin fiscal 2021, but we're encouraged by the \nsigns of recovery across our businesses as we exit our first quarter.  We  still believe the first quarter will be the \ntrough of the recovery curve with the most material impacts in the business. ", "original_text": "In the quarter, we also appointed Tom Rodgers as Executive Vice President and Chief Strategy and Business \nDevelopment Officer. "}, "hash": "4de4b6d824d251db15f5f2233914dd85f752124a11d6eb1da5bdab638951a078", "class_name": "RelatedNodeInfo"}}, "text": "Pharmaceutical and Specialty Solutions segment.  \n \n", "start_char_idx": 1927, "end_char_idx": 1979, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f27ed826-6976-4325-9dd3-a0293e22731b": {"__data__": {"id_": "f27ed826-6976-4325-9dd3-a0293e22731b", "embedding": null, "metadata": {"window": "Kevin Kettler has assumed responsibili ty for the new International segment, which combines McKesson \nEurope and our Canadian business.  Nathan Mott will lead the new Prescription Technology Solutions segment, \nwhich has been expanded to include the RxCrossroads business, formerly reported as part  of McKesson Life \nSciences within our U.S.  Pharmaceutical and Specialty Solutions segment.  \n \n In the quarter, we also appointed Tom Rodgers as Executive Vice President and Chief Strategy and Business \nDevelopment Officer.  Tom brings more than 25 years of expe rience working in both emerging companies and \nlarge health care environments.  \n \n In summary, we certainly faced unprecedented headwinds to begin fiscal 2021, but we're encouraged by the \nsigns of recovery across our businesses as we exit our first quarter.  We  still believe the first quarter will be the \ntrough of the recovery curve with the most material impacts in the business. ", "original_text": "In the quarter, we also appointed Tom Rodgers as Executive Vice President and Chief Strategy and Business \nDevelopment Officer. ", "page_label": "6", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "fec4a8f1-855e-450a-b1f2-9b9b254694e1", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a239d471a470eea39c38eff204665dc357ce59752fbef1112eed677a51da3cb9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f286a33a-f518-4f3d-9241-d64f2de298cb", "node_type": "1", "metadata": {"window": "With this resegmentation, two new segments have been established: International and Prescription Technology \nSolutions.  Kevin Kettler has assumed responsibili ty for the new International segment, which combines McKesson \nEurope and our Canadian business.  Nathan Mott will lead the new Prescription Technology Solutions segment, \nwhich has been expanded to include the RxCrossroads business, formerly reported as part  of McKesson Life \nSciences within our U.S.  Pharmaceutical and Specialty Solutions segment.  \n \n In the quarter, we also appointed Tom Rodgers as Executive Vice President and Chief Strategy and Business \nDevelopment Officer.  Tom brings more than 25 years of expe rience working in both emerging companies and \nlarge health care environments.  \n \n In summary, we certainly faced unprecedented headwinds to begin fiscal 2021, but we're encouraged by the \nsigns of recovery across our businesses as we exit our first quarter. ", "original_text": "Pharmaceutical and Specialty Solutions segment.  \n \n", "page_label": "6", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c7654405351588f32376a91ac4b7431f1cc724f0be1b412e07d1c875725ee25f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "004699e4-cbbe-4f9e-9d66-b6c3c6ee1659", "node_type": "1", "metadata": {"window": "Nathan Mott will lead the new Prescription Technology Solutions segment, \nwhich has been expanded to include the RxCrossroads business, formerly reported as part  of McKesson Life \nSciences within our U.S.  Pharmaceutical and Specialty Solutions segment.  \n \n In the quarter, we also appointed Tom Rodgers as Executive Vice President and Chief Strategy and Business \nDevelopment Officer.  Tom brings more than 25 years of expe rience working in both emerging companies and \nlarge health care environments.  \n \n In summary, we certainly faced unprecedented headwinds to begin fiscal 2021, but we're encouraged by the \nsigns of recovery across our businesses as we exit our first quarter.  We  still believe the first quarter will be the \ntrough of the recovery curve with the most material impacts in the business.  We are pleased our first quarter \nresults exceeded our expectations, reflecting great execution by our teams. ", "original_text": "Tom brings more than 25 years of expe rience working in both emerging companies and \nlarge health care environments.  \n \n"}, "hash": "6e29b1a71b5520222c74344b2b494904ff25e430b9e672746c586d129902b170", "class_name": "RelatedNodeInfo"}}, "text": "In the quarter, we also appointed Tom Rodgers as Executive Vice President and Chief Strategy and Business \nDevelopment Officer. ", "start_char_idx": 1979, "end_char_idx": 2107, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "004699e4-cbbe-4f9e-9d66-b6c3c6ee1659": {"__data__": {"id_": "004699e4-cbbe-4f9e-9d66-b6c3c6ee1659", "embedding": null, "metadata": {"window": "Nathan Mott will lead the new Prescription Technology Solutions segment, \nwhich has been expanded to include the RxCrossroads business, formerly reported as part  of McKesson Life \nSciences within our U.S.  Pharmaceutical and Specialty Solutions segment.  \n \n In the quarter, we also appointed Tom Rodgers as Executive Vice President and Chief Strategy and Business \nDevelopment Officer.  Tom brings more than 25 years of expe rience working in both emerging companies and \nlarge health care environments.  \n \n In summary, we certainly faced unprecedented headwinds to begin fiscal 2021, but we're encouraged by the \nsigns of recovery across our businesses as we exit our first quarter.  We  still believe the first quarter will be the \ntrough of the recovery curve with the most material impacts in the business.  We are pleased our first quarter \nresults exceeded our expectations, reflecting great execution by our teams. ", "original_text": "Tom brings more than 25 years of expe rience working in both emerging companies and \nlarge health care environments.  \n \n", "page_label": "6", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "fec4a8f1-855e-450a-b1f2-9b9b254694e1", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a239d471a470eea39c38eff204665dc357ce59752fbef1112eed677a51da3cb9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f27ed826-6976-4325-9dd3-a0293e22731b", "node_type": "1", "metadata": {"window": "Kevin Kettler has assumed responsibili ty for the new International segment, which combines McKesson \nEurope and our Canadian business.  Nathan Mott will lead the new Prescription Technology Solutions segment, \nwhich has been expanded to include the RxCrossroads business, formerly reported as part  of McKesson Life \nSciences within our U.S.  Pharmaceutical and Specialty Solutions segment.  \n \n In the quarter, we also appointed Tom Rodgers as Executive Vice President and Chief Strategy and Business \nDevelopment Officer.  Tom brings more than 25 years of expe rience working in both emerging companies and \nlarge health care environments.  \n \n In summary, we certainly faced unprecedented headwinds to begin fiscal 2021, but we're encouraged by the \nsigns of recovery across our businesses as we exit our first quarter.  We  still believe the first quarter will be the \ntrough of the recovery curve with the most material impacts in the business. ", "original_text": "In the quarter, we also appointed Tom Rodgers as Executive Vice President and Chief Strategy and Business \nDevelopment Officer. ", "page_label": "6", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "aa63b784329a68dd1797576ce4409117e5c3da495fa5bf34d75d0b02267b43c9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "045e5096-aa5e-4181-aa4f-1fef162002bf", "node_type": "1", "metadata": {"window": "Pharmaceutical and Specialty Solutions segment.  \n \n In the quarter, we also appointed Tom Rodgers as Executive Vice President and Chief Strategy and Business \nDevelopment Officer.  Tom brings more than 25 years of expe rience working in both emerging companies and \nlarge health care environments.  \n \n In summary, we certainly faced unprecedented headwinds to begin fiscal 2021, but we're encouraged by the \nsigns of recovery across our businesses as we exit our first quarter.  We  still believe the first quarter will be the \ntrough of the recovery curve with the most material impacts in the business.  We are pleased our first quarter \nresults exceeded our expectations, reflecting great execution by our teams.  The path to recovery over  the \nremainder of our fiscal year is unlikely to be linear, and we will continue to closely monitor the progression of \nCOVID -19 through our communities and its implications for our business.  \n \n", "original_text": "In summary, we certainly faced unprecedented headwinds to begin fiscal 2021, but we're encouraged by the \nsigns of recovery across our businesses as we exit our first quarter. "}, "hash": "8a4147e11a8054c18e00eb5a0bc03316fc93fdadee9ef678793bdf3c5b443ba0", "class_name": "RelatedNodeInfo"}}, "text": "Tom brings more than 25 years of expe rience working in both emerging companies and \nlarge health care environments.  \n \n", "start_char_idx": 2107, "end_char_idx": 2228, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "045e5096-aa5e-4181-aa4f-1fef162002bf": {"__data__": {"id_": "045e5096-aa5e-4181-aa4f-1fef162002bf", "embedding": null, "metadata": {"window": "Pharmaceutical and Specialty Solutions segment.  \n \n In the quarter, we also appointed Tom Rodgers as Executive Vice President and Chief Strategy and Business \nDevelopment Officer.  Tom brings more than 25 years of expe rience working in both emerging companies and \nlarge health care environments.  \n \n In summary, we certainly faced unprecedented headwinds to begin fiscal 2021, but we're encouraged by the \nsigns of recovery across our businesses as we exit our first quarter.  We  still believe the first quarter will be the \ntrough of the recovery curve with the most material impacts in the business.  We are pleased our first quarter \nresults exceeded our expectations, reflecting great execution by our teams.  The path to recovery over  the \nremainder of our fiscal year is unlikely to be linear, and we will continue to closely monitor the progression of \nCOVID -19 through our communities and its implications for our business.  \n \n", "original_text": "In summary, we certainly faced unprecedented headwinds to begin fiscal 2021, but we're encouraged by the \nsigns of recovery across our businesses as we exit our first quarter. ", "page_label": "6", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "fec4a8f1-855e-450a-b1f2-9b9b254694e1", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a239d471a470eea39c38eff204665dc357ce59752fbef1112eed677a51da3cb9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "004699e4-cbbe-4f9e-9d66-b6c3c6ee1659", "node_type": "1", "metadata": {"window": "Nathan Mott will lead the new Prescription Technology Solutions segment, \nwhich has been expanded to include the RxCrossroads business, formerly reported as part  of McKesson Life \nSciences within our U.S.  Pharmaceutical and Specialty Solutions segment.  \n \n In the quarter, we also appointed Tom Rodgers as Executive Vice President and Chief Strategy and Business \nDevelopment Officer.  Tom brings more than 25 years of expe rience working in both emerging companies and \nlarge health care environments.  \n \n In summary, we certainly faced unprecedented headwinds to begin fiscal 2021, but we're encouraged by the \nsigns of recovery across our businesses as we exit our first quarter.  We  still believe the first quarter will be the \ntrough of the recovery curve with the most material impacts in the business.  We are pleased our first quarter \nresults exceeded our expectations, reflecting great execution by our teams. ", "original_text": "Tom brings more than 25 years of expe rience working in both emerging companies and \nlarge health care environments.  \n \n", "page_label": "6", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "be981d215e46a40224832883de6b6c3a8ecd1a41b47e7690f70596b4a1c2e418", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b975f639-2523-4bd7-8ede-5d10acfb8e46", "node_type": "1", "metadata": {"window": "In the quarter, we also appointed Tom Rodgers as Executive Vice President and Chief Strategy and Business \nDevelopment Officer.  Tom brings more than 25 years of expe rience working in both emerging companies and \nlarge health care environments.  \n \n In summary, we certainly faced unprecedented headwinds to begin fiscal 2021, but we're encouraged by the \nsigns of recovery across our businesses as we exit our first quarter.  We  still believe the first quarter will be the \ntrough of the recovery curve with the most material impacts in the business.  We are pleased our first quarter \nresults exceeded our expectations, reflecting great execution by our teams.  The path to recovery over  the \nremainder of our fiscal year is unlikely to be linear, and we will continue to closely monitor the progression of \nCOVID -19 through our communities and its implications for our business.  \n \n The pandemic has reinforced the need for us to be agile in respo nse to both customer demand and the ways in \nwhich patients choose to consume health care. ", "original_text": "We  still believe the first quarter will be the \ntrough of the recovery curve with the most material impacts in the business. "}, "hash": "5c8e68c717ce5efce199f2698d198ddfa7b5892c3c079343cafc569dd8822934", "class_name": "RelatedNodeInfo"}}, "text": "In summary, we certainly faced unprecedented headwinds to begin fiscal 2021, but we're encouraged by the \nsigns of recovery across our businesses as we exit our first quarter. ", "start_char_idx": 2228, "end_char_idx": 2404, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b975f639-2523-4bd7-8ede-5d10acfb8e46": {"__data__": {"id_": "b975f639-2523-4bd7-8ede-5d10acfb8e46", "embedding": null, "metadata": {"window": "In the quarter, we also appointed Tom Rodgers as Executive Vice President and Chief Strategy and Business \nDevelopment Officer.  Tom brings more than 25 years of expe rience working in both emerging companies and \nlarge health care environments.  \n \n In summary, we certainly faced unprecedented headwinds to begin fiscal 2021, but we're encouraged by the \nsigns of recovery across our businesses as we exit our first quarter.  We  still believe the first quarter will be the \ntrough of the recovery curve with the most material impacts in the business.  We are pleased our first quarter \nresults exceeded our expectations, reflecting great execution by our teams.  The path to recovery over  the \nremainder of our fiscal year is unlikely to be linear, and we will continue to closely monitor the progression of \nCOVID -19 through our communities and its implications for our business.  \n \n The pandemic has reinforced the need for us to be agile in respo nse to both customer demand and the ways in \nwhich patients choose to consume health care. ", "original_text": "We  still believe the first quarter will be the \ntrough of the recovery curve with the most material impacts in the business. ", "page_label": "6", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "fec4a8f1-855e-450a-b1f2-9b9b254694e1", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a239d471a470eea39c38eff204665dc357ce59752fbef1112eed677a51da3cb9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "045e5096-aa5e-4181-aa4f-1fef162002bf", "node_type": "1", "metadata": {"window": "Pharmaceutical and Specialty Solutions segment.  \n \n In the quarter, we also appointed Tom Rodgers as Executive Vice President and Chief Strategy and Business \nDevelopment Officer.  Tom brings more than 25 years of expe rience working in both emerging companies and \nlarge health care environments.  \n \n In summary, we certainly faced unprecedented headwinds to begin fiscal 2021, but we're encouraged by the \nsigns of recovery across our businesses as we exit our first quarter.  We  still believe the first quarter will be the \ntrough of the recovery curve with the most material impacts in the business.  We are pleased our first quarter \nresults exceeded our expectations, reflecting great execution by our teams.  The path to recovery over  the \nremainder of our fiscal year is unlikely to be linear, and we will continue to closely monitor the progression of \nCOVID -19 through our communities and its implications for our business.  \n \n", "original_text": "In summary, we certainly faced unprecedented headwinds to begin fiscal 2021, but we're encouraged by the \nsigns of recovery across our businesses as we exit our first quarter. ", "page_label": "6", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "25f17d372d8a7e6257845859defc7fb4b2d19c08efbfadf37afa0d0ad5359584", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e4f1e553-729f-4608-af9c-0d4d9ca00892", "node_type": "1", "metadata": {"window": "Tom brings more than 25 years of expe rience working in both emerging companies and \nlarge health care environments.  \n \n In summary, we certainly faced unprecedented headwinds to begin fiscal 2021, but we're encouraged by the \nsigns of recovery across our businesses as we exit our first quarter.  We  still believe the first quarter will be the \ntrough of the recovery curve with the most material impacts in the business.  We are pleased our first quarter \nresults exceeded our expectations, reflecting great execution by our teams.  The path to recovery over  the \nremainder of our fiscal year is unlikely to be linear, and we will continue to closely monitor the progression of \nCOVID -19 through our communities and its implications for our business.  \n \n The pandemic has reinforced the need for us to be agile in respo nse to both customer demand and the ways in \nwhich patients choose to consume health care.  One theme through the pandemic has been changed, and I \nbelieve McKesson is well positioned to respond to change as the macro environment around us continues to \nevolve , McKesson will continue to evolve.  \n \n", "original_text": "We are pleased our first quarter \nresults exceeded our expectations, reflecting great execution by our teams. "}, "hash": "e35137fadba59d9756324ef2981c903e49b203339483002c4e18499bb865290f", "class_name": "RelatedNodeInfo"}}, "text": "We  still believe the first quarter will be the \ntrough of the recovery curve with the most material impacts in the business. ", "start_char_idx": 2404, "end_char_idx": 2530, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e4f1e553-729f-4608-af9c-0d4d9ca00892": {"__data__": {"id_": "e4f1e553-729f-4608-af9c-0d4d9ca00892", "embedding": null, "metadata": {"window": "Tom brings more than 25 years of expe rience working in both emerging companies and \nlarge health care environments.  \n \n In summary, we certainly faced unprecedented headwinds to begin fiscal 2021, but we're encouraged by the \nsigns of recovery across our businesses as we exit our first quarter.  We  still believe the first quarter will be the \ntrough of the recovery curve with the most material impacts in the business.  We are pleased our first quarter \nresults exceeded our expectations, reflecting great execution by our teams.  The path to recovery over  the \nremainder of our fiscal year is unlikely to be linear, and we will continue to closely monitor the progression of \nCOVID -19 through our communities and its implications for our business.  \n \n The pandemic has reinforced the need for us to be agile in respo nse to both customer demand and the ways in \nwhich patients choose to consume health care.  One theme through the pandemic has been changed, and I \nbelieve McKesson is well positioned to respond to change as the macro environment around us continues to \nevolve , McKesson will continue to evolve.  \n \n", "original_text": "We are pleased our first quarter \nresults exceeded our expectations, reflecting great execution by our teams. ", "page_label": "6", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "fec4a8f1-855e-450a-b1f2-9b9b254694e1", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a239d471a470eea39c38eff204665dc357ce59752fbef1112eed677a51da3cb9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b975f639-2523-4bd7-8ede-5d10acfb8e46", "node_type": "1", "metadata": {"window": "In the quarter, we also appointed Tom Rodgers as Executive Vice President and Chief Strategy and Business \nDevelopment Officer.  Tom brings more than 25 years of expe rience working in both emerging companies and \nlarge health care environments.  \n \n In summary, we certainly faced unprecedented headwinds to begin fiscal 2021, but we're encouraged by the \nsigns of recovery across our businesses as we exit our first quarter.  We  still believe the first quarter will be the \ntrough of the recovery curve with the most material impacts in the business.  We are pleased our first quarter \nresults exceeded our expectations, reflecting great execution by our teams.  The path to recovery over  the \nremainder of our fiscal year is unlikely to be linear, and we will continue to closely monitor the progression of \nCOVID -19 through our communities and its implications for our business.  \n \n The pandemic has reinforced the need for us to be agile in respo nse to both customer demand and the ways in \nwhich patients choose to consume health care. ", "original_text": "We  still believe the first quarter will be the \ntrough of the recovery curve with the most material impacts in the business. ", "page_label": "6", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "383495f26bf3f3d86edf96e9d1318c612471713e5df652252667ab0ee7f4f737", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "41433351-040b-43d2-817b-a8d5bbdd8216", "node_type": "1", "metadata": {"window": "In summary, we certainly faced unprecedented headwinds to begin fiscal 2021, but we're encouraged by the \nsigns of recovery across our businesses as we exit our first quarter.  We  still believe the first quarter will be the \ntrough of the recovery curve with the most material impacts in the business.  We are pleased our first quarter \nresults exceeded our expectations, reflecting great execution by our teams.  The path to recovery over  the \nremainder of our fiscal year is unlikely to be linear, and we will continue to closely monitor the progression of \nCOVID -19 through our communities and its implications for our business.  \n \n The pandemic has reinforced the need for us to be agile in respo nse to both customer demand and the ways in \nwhich patients choose to consume health care.  One theme through the pandemic has been changed, and I \nbelieve McKesson is well positioned to respond to change as the macro environment around us continues to \nevolve , McKesson will continue to evolve.  \n \n I believe we have exited the quarter in a much stronger position than we entered it, stable fundamentals across \nthe business, paired with focused execution against our strategic growth initiatives, give me confidence th at \nMcKesson will adapt to the near -term uncertainties and ultimately be positioned to thrive long term. ", "original_text": "The path to recovery over  the \nremainder of our fiscal year is unlikely to be linear, and we will continue to closely monitor the progression of \nCOVID -19 through our communities and its implications for our business.  \n \n"}, "hash": "827d37db560b9170d3dd67f063eb0fbdec547390649abb264d1b9ad6ea3a5ae0", "class_name": "RelatedNodeInfo"}}, "text": "We are pleased our first quarter \nresults exceeded our expectations, reflecting great execution by our teams. ", "start_char_idx": 2530, "end_char_idx": 2640, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "41433351-040b-43d2-817b-a8d5bbdd8216": {"__data__": {"id_": "41433351-040b-43d2-817b-a8d5bbdd8216", "embedding": null, "metadata": {"window": "In summary, we certainly faced unprecedented headwinds to begin fiscal 2021, but we're encouraged by the \nsigns of recovery across our businesses as we exit our first quarter.  We  still believe the first quarter will be the \ntrough of the recovery curve with the most material impacts in the business.  We are pleased our first quarter \nresults exceeded our expectations, reflecting great execution by our teams.  The path to recovery over  the \nremainder of our fiscal year is unlikely to be linear, and we will continue to closely monitor the progression of \nCOVID -19 through our communities and its implications for our business.  \n \n The pandemic has reinforced the need for us to be agile in respo nse to both customer demand and the ways in \nwhich patients choose to consume health care.  One theme through the pandemic has been changed, and I \nbelieve McKesson is well positioned to respond to change as the macro environment around us continues to \nevolve , McKesson will continue to evolve.  \n \n I believe we have exited the quarter in a much stronger position than we entered it, stable fundamentals across \nthe business, paired with focused execution against our strategic growth initiatives, give me confidence th at \nMcKesson will adapt to the near -term uncertainties and ultimately be positioned to thrive long term. ", "original_text": "The path to recovery over  the \nremainder of our fiscal year is unlikely to be linear, and we will continue to closely monitor the progression of \nCOVID -19 through our communities and its implications for our business.  \n \n", "page_label": "6", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "fec4a8f1-855e-450a-b1f2-9b9b254694e1", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a239d471a470eea39c38eff204665dc357ce59752fbef1112eed677a51da3cb9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e4f1e553-729f-4608-af9c-0d4d9ca00892", "node_type": "1", "metadata": {"window": "Tom brings more than 25 years of expe rience working in both emerging companies and \nlarge health care environments.  \n \n In summary, we certainly faced unprecedented headwinds to begin fiscal 2021, but we're encouraged by the \nsigns of recovery across our businesses as we exit our first quarter.  We  still believe the first quarter will be the \ntrough of the recovery curve with the most material impacts in the business.  We are pleased our first quarter \nresults exceeded our expectations, reflecting great execution by our teams.  The path to recovery over  the \nremainder of our fiscal year is unlikely to be linear, and we will continue to closely monitor the progression of \nCOVID -19 through our communities and its implications for our business.  \n \n The pandemic has reinforced the need for us to be agile in respo nse to both customer demand and the ways in \nwhich patients choose to consume health care.  One theme through the pandemic has been changed, and I \nbelieve McKesson is well positioned to respond to change as the macro environment around us continues to \nevolve , McKesson will continue to evolve.  \n \n", "original_text": "We are pleased our first quarter \nresults exceeded our expectations, reflecting great execution by our teams. ", "page_label": "6", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1f7e772a28154c2d6a36ad923ae014091270a75ed5821b96b6674f50ade99fc3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "da1fbbb4-46c6-412f-8214-c8fafdaa200a", "node_type": "1", "metadata": {"window": "We  still believe the first quarter will be the \ntrough of the recovery curve with the most material impacts in the business.  We are pleased our first quarter \nresults exceeded our expectations, reflecting great execution by our teams.  The path to recovery over  the \nremainder of our fiscal year is unlikely to be linear, and we will continue to closely monitor the progression of \nCOVID -19 through our communities and its implications for our business.  \n \n The pandemic has reinforced the need for us to be agile in respo nse to both customer demand and the ways in \nwhich patients choose to consume health care.  One theme through the pandemic has been changed, and I \nbelieve McKesson is well positioned to respond to change as the macro environment around us continues to \nevolve , McKesson will continue to evolve.  \n \n I believe we have exited the quarter in a much stronger position than we entered it, stable fundamentals across \nthe business, paired with focused execution against our strategic growth initiatives, give me confidence th at \nMcKesson will adapt to the near -term uncertainties and ultimately be positioned to thrive long term.  Thank you \nvery much for your time.  \n \n", "original_text": "The pandemic has reinforced the need for us to be agile in respo nse to both customer demand and the ways in \nwhich patients choose to consume health care. "}, "hash": "4eab328c5ca50a6529481cadccfd2fd77e947cdb0b75fe95607088a741678433", "class_name": "RelatedNodeInfo"}}, "text": "The path to recovery over  the \nremainder of our fiscal year is unlikely to be linear, and we will continue to closely monitor the progression of \nCOVID -19 through our communities and its implications for our business.  \n \n", "start_char_idx": 2640, "end_char_idx": 2864, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "da1fbbb4-46c6-412f-8214-c8fafdaa200a": {"__data__": {"id_": "da1fbbb4-46c6-412f-8214-c8fafdaa200a", "embedding": null, "metadata": {"window": "We  still believe the first quarter will be the \ntrough of the recovery curve with the most material impacts in the business.  We are pleased our first quarter \nresults exceeded our expectations, reflecting great execution by our teams.  The path to recovery over  the \nremainder of our fiscal year is unlikely to be linear, and we will continue to closely monitor the progression of \nCOVID -19 through our communities and its implications for our business.  \n \n The pandemic has reinforced the need for us to be agile in respo nse to both customer demand and the ways in \nwhich patients choose to consume health care.  One theme through the pandemic has been changed, and I \nbelieve McKesson is well positioned to respond to change as the macro environment around us continues to \nevolve , McKesson will continue to evolve.  \n \n I believe we have exited the quarter in a much stronger position than we entered it, stable fundamentals across \nthe business, paired with focused execution against our strategic growth initiatives, give me confidence th at \nMcKesson will adapt to the near -term uncertainties and ultimately be positioned to thrive long term.  Thank you \nvery much for your time.  \n \n", "original_text": "The pandemic has reinforced the need for us to be agile in respo nse to both customer demand and the ways in \nwhich patients choose to consume health care. ", "page_label": "6", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "fec4a8f1-855e-450a-b1f2-9b9b254694e1", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a239d471a470eea39c38eff204665dc357ce59752fbef1112eed677a51da3cb9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "41433351-040b-43d2-817b-a8d5bbdd8216", "node_type": "1", "metadata": {"window": "In summary, we certainly faced unprecedented headwinds to begin fiscal 2021, but we're encouraged by the \nsigns of recovery across our businesses as we exit our first quarter.  We  still believe the first quarter will be the \ntrough of the recovery curve with the most material impacts in the business.  We are pleased our first quarter \nresults exceeded our expectations, reflecting great execution by our teams.  The path to recovery over  the \nremainder of our fiscal year is unlikely to be linear, and we will continue to closely monitor the progression of \nCOVID -19 through our communities and its implications for our business.  \n \n The pandemic has reinforced the need for us to be agile in respo nse to both customer demand and the ways in \nwhich patients choose to consume health care.  One theme through the pandemic has been changed, and I \nbelieve McKesson is well positioned to respond to change as the macro environment around us continues to \nevolve , McKesson will continue to evolve.  \n \n I believe we have exited the quarter in a much stronger position than we entered it, stable fundamentals across \nthe business, paired with focused execution against our strategic growth initiatives, give me confidence th at \nMcKesson will adapt to the near -term uncertainties and ultimately be positioned to thrive long term. ", "original_text": "The path to recovery over  the \nremainder of our fiscal year is unlikely to be linear, and we will continue to closely monitor the progression of \nCOVID -19 through our communities and its implications for our business.  \n \n", "page_label": "6", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "814458c2b706af5a02e4f750726b6bda8e25289fe39f177fab40535421db0821", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cf09e37e-1690-42d8-bf40-a56707b5783b", "node_type": "1", "metadata": {"window": "We are pleased our first quarter \nresults exceeded our expectations, reflecting great execution by our teams.  The path to recovery over  the \nremainder of our fiscal year is unlikely to be linear, and we will continue to closely monitor the progression of \nCOVID -19 through our communities and its implications for our business.  \n \n The pandemic has reinforced the need for us to be agile in respo nse to both customer demand and the ways in \nwhich patients choose to consume health care.  One theme through the pandemic has been changed, and I \nbelieve McKesson is well positioned to respond to change as the macro environment around us continues to \nevolve , McKesson will continue to evolve.  \n \n I believe we have exited the quarter in a much stronger position than we entered it, stable fundamentals across \nthe business, paired with focused execution against our strategic growth initiatives, give me confidence th at \nMcKesson will adapt to the near -term uncertainties and ultimately be positioned to thrive long term.  Thank you \nvery much for your time.  \n \n With that, I'll hand it over to you, Britt.  \n ", "original_text": "One theme through the pandemic has been changed, and I \nbelieve McKesson is well positioned to respond to change as the macro environment around us continues to \nevolve , McKesson will continue to evolve.  \n \n"}, "hash": "866693419c8915f5a7ad3ba60e077834f4b41ad5fbd7860d9f7e5ef68b119bca", "class_name": "RelatedNodeInfo"}}, "text": "The pandemic has reinforced the need for us to be agile in respo nse to both customer demand and the ways in \nwhich patients choose to consume health care. ", "start_char_idx": 2864, "end_char_idx": 3020, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cf09e37e-1690-42d8-bf40-a56707b5783b": {"__data__": {"id_": "cf09e37e-1690-42d8-bf40-a56707b5783b", "embedding": null, "metadata": {"window": "We are pleased our first quarter \nresults exceeded our expectations, reflecting great execution by our teams.  The path to recovery over  the \nremainder of our fiscal year is unlikely to be linear, and we will continue to closely monitor the progression of \nCOVID -19 through our communities and its implications for our business.  \n \n The pandemic has reinforced the need for us to be agile in respo nse to both customer demand and the ways in \nwhich patients choose to consume health care.  One theme through the pandemic has been changed, and I \nbelieve McKesson is well positioned to respond to change as the macro environment around us continues to \nevolve , McKesson will continue to evolve.  \n \n I believe we have exited the quarter in a much stronger position than we entered it, stable fundamentals across \nthe business, paired with focused execution against our strategic growth initiatives, give me confidence th at \nMcKesson will adapt to the near -term uncertainties and ultimately be positioned to thrive long term.  Thank you \nvery much for your time.  \n \n With that, I'll hand it over to you, Britt.  \n ", "original_text": "One theme through the pandemic has been changed, and I \nbelieve McKesson is well positioned to respond to change as the macro environment around us continues to \nevolve , McKesson will continue to evolve.  \n \n", "page_label": "6", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "fec4a8f1-855e-450a-b1f2-9b9b254694e1", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a239d471a470eea39c38eff204665dc357ce59752fbef1112eed677a51da3cb9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "da1fbbb4-46c6-412f-8214-c8fafdaa200a", "node_type": "1", "metadata": {"window": "We  still believe the first quarter will be the \ntrough of the recovery curve with the most material impacts in the business.  We are pleased our first quarter \nresults exceeded our expectations, reflecting great execution by our teams.  The path to recovery over  the \nremainder of our fiscal year is unlikely to be linear, and we will continue to closely monitor the progression of \nCOVID -19 through our communities and its implications for our business.  \n \n The pandemic has reinforced the need for us to be agile in respo nse to both customer demand and the ways in \nwhich patients choose to consume health care.  One theme through the pandemic has been changed, and I \nbelieve McKesson is well positioned to respond to change as the macro environment around us continues to \nevolve , McKesson will continue to evolve.  \n \n I believe we have exited the quarter in a much stronger position than we entered it, stable fundamentals across \nthe business, paired with focused execution against our strategic growth initiatives, give me confidence th at \nMcKesson will adapt to the near -term uncertainties and ultimately be positioned to thrive long term.  Thank you \nvery much for your time.  \n \n", "original_text": "The pandemic has reinforced the need for us to be agile in respo nse to both customer demand and the ways in \nwhich patients choose to consume health care. ", "page_label": "6", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "acbcabcf63b44f910518dcb242d6c780797a9865c606f9ab68c33f0c8b985b2d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0530e465-7c05-43fa-8431-110507163d57", "node_type": "1", "metadata": {"window": "The path to recovery over  the \nremainder of our fiscal year is unlikely to be linear, and we will continue to closely monitor the progression of \nCOVID -19 through our communities and its implications for our business.  \n \n The pandemic has reinforced the need for us to be agile in respo nse to both customer demand and the ways in \nwhich patients choose to consume health care.  One theme through the pandemic has been changed, and I \nbelieve McKesson is well positioned to respond to change as the macro environment around us continues to \nevolve , McKesson will continue to evolve.  \n \n I believe we have exited the quarter in a much stronger position than we entered it, stable fundamentals across \nthe business, paired with focused execution against our strategic growth initiatives, give me confidence th at \nMcKesson will adapt to the near -term uncertainties and ultimately be positioned to thrive long term.  Thank you \nvery much for your time.  \n \n With that, I'll hand it over to you, Britt.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "original_text": "I believe we have exited the quarter in a much stronger position than we entered it, stable fundamentals across \nthe business, paired with focused execution against our strategic growth initiatives, give me confidence th at \nMcKesson will adapt to the near -term uncertainties and ultimately be positioned to thrive long term. "}, "hash": "6f09ee26fae9a3462247cbbde106ae32934aa09a1820a559d27fea71910d3f12", "class_name": "RelatedNodeInfo"}}, "text": "One theme through the pandemic has been changed, and I \nbelieve McKesson is well positioned to respond to change as the macro environment around us continues to \nevolve , McKesson will continue to evolve.  \n \n", "start_char_idx": 3020, "end_char_idx": 3229, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0530e465-7c05-43fa-8431-110507163d57": {"__data__": {"id_": "0530e465-7c05-43fa-8431-110507163d57", "embedding": null, "metadata": {"window": "The path to recovery over  the \nremainder of our fiscal year is unlikely to be linear, and we will continue to closely monitor the progression of \nCOVID -19 through our communities and its implications for our business.  \n \n The pandemic has reinforced the need for us to be agile in respo nse to both customer demand and the ways in \nwhich patients choose to consume health care.  One theme through the pandemic has been changed, and I \nbelieve McKesson is well positioned to respond to change as the macro environment around us continues to \nevolve , McKesson will continue to evolve.  \n \n I believe we have exited the quarter in a much stronger position than we entered it, stable fundamentals across \nthe business, paired with focused execution against our strategic growth initiatives, give me confidence th at \nMcKesson will adapt to the near -term uncertainties and ultimately be positioned to thrive long term.  Thank you \nvery much for your time.  \n \n With that, I'll hand it over to you, Britt.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "original_text": "I believe we have exited the quarter in a much stronger position than we entered it, stable fundamentals across \nthe business, paired with focused execution against our strategic growth initiatives, give me confidence th at \nMcKesson will adapt to the near -term uncertainties and ultimately be positioned to thrive long term. ", "page_label": "6", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "fec4a8f1-855e-450a-b1f2-9b9b254694e1", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a239d471a470eea39c38eff204665dc357ce59752fbef1112eed677a51da3cb9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cf09e37e-1690-42d8-bf40-a56707b5783b", "node_type": "1", "metadata": {"window": "We are pleased our first quarter \nresults exceeded our expectations, reflecting great execution by our teams.  The path to recovery over  the \nremainder of our fiscal year is unlikely to be linear, and we will continue to closely monitor the progression of \nCOVID -19 through our communities and its implications for our business.  \n \n The pandemic has reinforced the need for us to be agile in respo nse to both customer demand and the ways in \nwhich patients choose to consume health care.  One theme through the pandemic has been changed, and I \nbelieve McKesson is well positioned to respond to change as the macro environment around us continues to \nevolve , McKesson will continue to evolve.  \n \n I believe we have exited the quarter in a much stronger position than we entered it, stable fundamentals across \nthe business, paired with focused execution against our strategic growth initiatives, give me confidence th at \nMcKesson will adapt to the near -term uncertainties and ultimately be positioned to thrive long term.  Thank you \nvery much for your time.  \n \n With that, I'll hand it over to you, Britt.  \n ", "original_text": "One theme through the pandemic has been changed, and I \nbelieve McKesson is well positioned to respond to change as the macro environment around us continues to \nevolve , McKesson will continue to evolve.  \n \n", "page_label": "6", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ef0ec5543e2853bd23bbb20bac6de38bf3aeadf2105e9c141020707e491c1ac8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0f159bc5-9bfe-48f8-8ae7-839a2011ae40", "node_type": "1", "metadata": {"window": "The pandemic has reinforced the need for us to be agile in respo nse to both customer demand and the ways in \nwhich patients choose to consume health care.  One theme through the pandemic has been changed, and I \nbelieve McKesson is well positioned to respond to change as the macro environment around us continues to \nevolve , McKesson will continue to evolve.  \n \n I believe we have exited the quarter in a much stronger position than we entered it, stable fundamentals across \nthe business, paired with focused execution against our strategic growth initiatives, give me confidence th at \nMcKesson will adapt to the near -term uncertainties and ultimately be positioned to thrive long term.  Thank you \nvery much for your time.  \n \n With that, I'll hand it over to you, Britt.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "original_text": "Thank you \nvery much for your time.  \n \n"}, "hash": "b6923574c6a37630d1e13b1dc9a05b2526f9b6cda23d56517ab9d6f3932f82fd", "class_name": "RelatedNodeInfo"}}, "text": "I believe we have exited the quarter in a much stronger position than we entered it, stable fundamentals across \nthe business, paired with focused execution against our strategic growth initiatives, give me confidence th at \nMcKesson will adapt to the near -term uncertainties and ultimately be positioned to thrive long term. ", "start_char_idx": 3229, "end_char_idx": 3556, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0f159bc5-9bfe-48f8-8ae7-839a2011ae40": {"__data__": {"id_": "0f159bc5-9bfe-48f8-8ae7-839a2011ae40", "embedding": null, "metadata": {"window": "The pandemic has reinforced the need for us to be agile in respo nse to both customer demand and the ways in \nwhich patients choose to consume health care.  One theme through the pandemic has been changed, and I \nbelieve McKesson is well positioned to respond to change as the macro environment around us continues to \nevolve , McKesson will continue to evolve.  \n \n I believe we have exited the quarter in a much stronger position than we entered it, stable fundamentals across \nthe business, paired with focused execution against our strategic growth initiatives, give me confidence th at \nMcKesson will adapt to the near -term uncertainties and ultimately be positioned to thrive long term.  Thank you \nvery much for your time.  \n \n With that, I'll hand it over to you, Britt.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "original_text": "Thank you \nvery much for your time.  \n \n", "page_label": "6", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "fec4a8f1-855e-450a-b1f2-9b9b254694e1", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a239d471a470eea39c38eff204665dc357ce59752fbef1112eed677a51da3cb9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0530e465-7c05-43fa-8431-110507163d57", "node_type": "1", "metadata": {"window": "The path to recovery over  the \nremainder of our fiscal year is unlikely to be linear, and we will continue to closely monitor the progression of \nCOVID -19 through our communities and its implications for our business.  \n \n The pandemic has reinforced the need for us to be agile in respo nse to both customer demand and the ways in \nwhich patients choose to consume health care.  One theme through the pandemic has been changed, and I \nbelieve McKesson is well positioned to respond to change as the macro environment around us continues to \nevolve , McKesson will continue to evolve.  \n \n I believe we have exited the quarter in a much stronger position than we entered it, stable fundamentals across \nthe business, paired with focused execution against our strategic growth initiatives, give me confidence th at \nMcKesson will adapt to the near -term uncertainties and ultimately be positioned to thrive long term.  Thank you \nvery much for your time.  \n \n With that, I'll hand it over to you, Britt.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "original_text": "I believe we have exited the quarter in a much stronger position than we entered it, stable fundamentals across \nthe business, paired with focused execution against our strategic growth initiatives, give me confidence th at \nMcKesson will adapt to the near -term uncertainties and ultimately be positioned to thrive long term. ", "page_label": "6", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c9d6dfdcd8e080033e51ac31eba67843abdfca21d725264bb5116a145ca91aaa", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "dd0fc70d-1712-4cd7-83ef-76f981df3759", "node_type": "1", "metadata": {"window": "One theme through the pandemic has been changed, and I \nbelieve McKesson is well positioned to respond to change as the macro environment around us continues to \nevolve , McKesson will continue to evolve.  \n \n I believe we have exited the quarter in a much stronger position than we entered it, stable fundamentals across \nthe business, paired with focused execution against our strategic growth initiatives, give me confidence th at \nMcKesson will adapt to the near -term uncertainties and ultimately be positioned to thrive long term.  Thank you \nvery much for your time.  \n \n With that, I'll hand it over to you, Britt.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "original_text": "With that, I'll hand it over to you, Britt.  \n "}, "hash": "87a40ee3e352f1d164f5f36c61c4f537ebcd4ec4dc1807ee357698b97ff532a6", "class_name": "RelatedNodeInfo"}}, "text": "Thank you \nvery much for your time.  \n \n", "start_char_idx": 3556, "end_char_idx": 3596, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "dd0fc70d-1712-4cd7-83ef-76f981df3759": {"__data__": {"id_": "dd0fc70d-1712-4cd7-83ef-76f981df3759", "embedding": null, "metadata": {"window": "One theme through the pandemic has been changed, and I \nbelieve McKesson is well positioned to respond to change as the macro environment around us continues to \nevolve , McKesson will continue to evolve.  \n \n I believe we have exited the quarter in a much stronger position than we entered it, stable fundamentals across \nthe business, paired with focused execution against our strategic growth initiatives, give me confidence th at \nMcKesson will adapt to the near -term uncertainties and ultimately be positioned to thrive long term.  Thank you \nvery much for your time.  \n \n With that, I'll hand it over to you, Britt.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "original_text": "With that, I'll hand it over to you, Britt.  \n ", "page_label": "6", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "fec4a8f1-855e-450a-b1f2-9b9b254694e1", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a239d471a470eea39c38eff204665dc357ce59752fbef1112eed677a51da3cb9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0f159bc5-9bfe-48f8-8ae7-839a2011ae40", "node_type": "1", "metadata": {"window": "The pandemic has reinforced the need for us to be agile in respo nse to both customer demand and the ways in \nwhich patients choose to consume health care.  One theme through the pandemic has been changed, and I \nbelieve McKesson is well positioned to respond to change as the macro environment around us continues to \nevolve , McKesson will continue to evolve.  \n \n I believe we have exited the quarter in a much stronger position than we entered it, stable fundamentals across \nthe business, paired with focused execution against our strategic growth initiatives, give me confidence th at \nMcKesson will adapt to the near -term uncertainties and ultimately be positioned to thrive long term.  Thank you \nvery much for your time.  \n \n With that, I'll hand it over to you, Britt.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "original_text": "Thank you \nvery much for your time.  \n \n", "page_label": "6", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "74b6bfcf19b2023ec60a5729be65c32d8f8771319d17d91e7db20b45ca455a23", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cddf3323-9134-46d6-af4b-09bec0229426", "node_type": "1", "metadata": {"window": "I believe we have exited the quarter in a much stronger position than we entered it, stable fundamentals across \nthe business, paired with focused execution against our strategic growth initiatives, give me confidence th at \nMcKesson will adapt to the near -term uncertainties and ultimately be positioned to thrive long term.  Thank you \nvery much for your time.  \n \n With that, I'll hand it over to you, Britt.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  "}, "hash": "9d16935d94ffedfe657b45fa4ba5c03be8a6eb89abdf31da9dc59be6f7395b8d", "class_name": "RelatedNodeInfo"}}, "text": "With that, I'll hand it over to you, Britt.  \n ", "start_char_idx": 3596, "end_char_idx": 3643, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cddf3323-9134-46d6-af4b-09bec0229426": {"__data__": {"id_": "cddf3323-9134-46d6-af4b-09bec0229426", "embedding": null, "metadata": {"window": "I believe we have exited the quarter in a much stronger position than we entered it, stable fundamentals across \nthe business, paired with focused execution against our strategic growth initiatives, give me confidence th at \nMcKesson will adapt to the near -term uncertainties and ultimately be positioned to thrive long term.  Thank you \nvery much for your time.  \n \n With that, I'll hand it over to you, Britt.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "page_label": "6", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "fec4a8f1-855e-450a-b1f2-9b9b254694e1", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a239d471a470eea39c38eff204665dc357ce59752fbef1112eed677a51da3cb9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "dd0fc70d-1712-4cd7-83ef-76f981df3759", "node_type": "1", "metadata": {"window": "One theme through the pandemic has been changed, and I \nbelieve McKesson is well positioned to respond to change as the macro environment around us continues to \nevolve , McKesson will continue to evolve.  \n \n I believe we have exited the quarter in a much stronger position than we entered it, stable fundamentals across \nthe business, paired with focused execution against our strategic growth initiatives, give me confidence th at \nMcKesson will adapt to the near -term uncertainties and ultimately be positioned to thrive long term.  Thank you \nvery much for your time.  \n \n With that, I'll hand it over to you, Britt.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "original_text": "With that, I'll hand it over to you, Britt.  \n ", "page_label": "6", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0c9d72da443da4348fb08b41989c62a03fc823ba856c7eb818400fdb89d63dce", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c355dc70-61b0-48ea-afbf-e531a3705f95", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nThank you, Brian, and good morning, everyone.  My comments today will relate to our existing segment structure. \n As Brian discussed in his opening comments, effective the second quarter of fiscal 2021, we'll begin to report our \nfinancial results in four reportable segments; U.S. ", "original_text": "McKesson Corp.  "}, "hash": "f6bf47093a3fe28506899c16736d6fcf488603bbdbccec41c0c8cf1efbd3fe4f", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "start_char_idx": 3643, "end_char_idx": 4003, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c355dc70-61b0-48ea-afbf-e531a3705f95": {"__data__": {"id_": "c355dc70-61b0-48ea-afbf-e531a3705f95", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nThank you, Brian, and good morning, everyone.  My comments today will relate to our existing segment structure. \n As Brian discussed in his opening comments, effective the second quarter of fiscal 2021, we'll begin to report our \nfinancial results in four reportable segments; U.S. ", "original_text": "McKesson Corp.  ", "page_label": "7", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5e1e3bfe-18ed-4cc7-9082-9a79812e2f1c", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "793a5abc15ad136f6b4965d2f2ee05bc8fee9de5acc167c2c4df187061eb82f8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cddf3323-9134-46d6-af4b-09bec0229426", "node_type": "1", "metadata": {"window": "I believe we have exited the quarter in a much stronger position than we entered it, stable fundamentals across \nthe business, paired with focused execution against our strategic growth initiatives, give me confidence th at \nMcKesson will adapt to the near -term uncertainties and ultimately be positioned to thrive long term.  Thank you \nvery much for your time.  \n \n With that, I'll hand it over to you, Britt.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "page_label": "6", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5c0f683e743c55afa00cf917ddafa8eb8c1c979c7ebbe0ccd99b18a35dc4bca0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1296d68c-816a-49f9-a192-21d9afb78f71", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nThank you, Brian, and good morning, everyone.  My comments today will relate to our existing segment structure. \n As Brian discussed in his opening comments, effective the second quarter of fiscal 2021, we'll begin to report our \nfinancial results in four reportable segments; U.S.  Pharmaceutical, International, Medical -Surgical Solutions and \nPrescription Technology Solutions. ", "original_text": "(MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nThank you, Brian, and good morning, everyone. "}, "hash": "20d82b767fe68a14b37e5640d71c11f8d8e7c409d7e318d1a9df938da6be0b40", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1296d68c-816a-49f9-a192-21d9afb78f71": {"__data__": {"id_": "1296d68c-816a-49f9-a192-21d9afb78f71", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nThank you, Brian, and good morning, everyone.  My comments today will relate to our existing segment structure. \n As Brian discussed in his opening comments, effective the second quarter of fiscal 2021, we'll begin to report our \nfinancial results in four reportable segments; U.S.  Pharmaceutical, International, Medical -Surgical Solutions and \nPrescription Technology Solutions. ", "original_text": "(MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nThank you, Brian, and good morning, everyone. ", "page_label": "7", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5e1e3bfe-18ed-4cc7-9082-9a79812e2f1c", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "793a5abc15ad136f6b4965d2f2ee05bc8fee9de5acc167c2c4df187061eb82f8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c355dc70-61b0-48ea-afbf-e531a3705f95", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nThank you, Brian, and good morning, everyone.  My comments today will relate to our existing segment structure. \n As Brian discussed in his opening comments, effective the second quarter of fiscal 2021, we'll begin to report our \nfinancial results in four reportable segments; U.S. ", "original_text": "McKesson Corp.  ", "page_label": "7", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2cc47e12fbeff13b9bbed578b3b967a024cef6bb4a0c08706f6c36d29eaf8498", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "908db5ec-934b-4616-93a3-8b5921614d4b", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nThank you, Brian, and good morning, everyone.  My comments today will relate to our existing segment structure. \n As Brian discussed in his opening comments, effective the second quarter of fiscal 2021, we'll begin to report our \nfinancial results in four reportable segments; U.S.  Pharmaceutical, International, Medical -Surgical Solutions and \nPrescription Technology Solutions.  We will issue a recast of financials in the new segment structure, ahead of our \nsecond quarter earnings call to assis t with the modeling under the new structure.  \n \n", "original_text": "My comments today will relate to our existing segment structure. \n"}, "hash": "f38bfaa454b56ef6998a0d9ebc2b798adef12b63087d6f06cbf333512479b5e5", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nThank you, Brian, and good morning, everyone. ", "start_char_idx": 16, "end_char_idx": 226, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "908db5ec-934b-4616-93a3-8b5921614d4b": {"__data__": {"id_": "908db5ec-934b-4616-93a3-8b5921614d4b", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nThank you, Brian, and good morning, everyone.  My comments today will relate to our existing segment structure. \n As Brian discussed in his opening comments, effective the second quarter of fiscal 2021, we'll begin to report our \nfinancial results in four reportable segments; U.S.  Pharmaceutical, International, Medical -Surgical Solutions and \nPrescription Technology Solutions.  We will issue a recast of financials in the new segment structure, ahead of our \nsecond quarter earnings call to assis t with the modeling under the new structure.  \n \n", "original_text": "My comments today will relate to our existing segment structure. \n", "page_label": "7", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5e1e3bfe-18ed-4cc7-9082-9a79812e2f1c", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "793a5abc15ad136f6b4965d2f2ee05bc8fee9de5acc167c2c4df187061eb82f8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1296d68c-816a-49f9-a192-21d9afb78f71", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nThank you, Brian, and good morning, everyone.  My comments today will relate to our existing segment structure. \n As Brian discussed in his opening comments, effective the second quarter of fiscal 2021, we'll begin to report our \nfinancial results in four reportable segments; U.S.  Pharmaceutical, International, Medical -Surgical Solutions and \nPrescription Technology Solutions. ", "original_text": "(MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nThank you, Brian, and good morning, everyone. ", "page_label": "7", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e6e60c59ce0d1d43305c278e8c49bf068be0a51e3db4d17aa9bd8ed313da1a7d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "871a330c-dd92-4f98-871f-62d35fa7a43b", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nThank you, Brian, and good morning, everyone.  My comments today will relate to our existing segment structure. \n As Brian discussed in his opening comments, effective the second quarter of fiscal 2021, we'll begin to report our \nfinancial results in four reportable segments; U.S.  Pharmaceutical, International, Medical -Surgical Solutions and \nPrescription Technology Solutions.  We will issue a recast of financials in the new segment structure, ahead of our \nsecond quarter earnings call to assis t with the modeling under the new structure.  \n \n Our June quarter was a testament to McKesson's ability to execute during challenging times. ", "original_text": "As Brian discussed in his opening comments, effective the second quarter of fiscal 2021, we'll begin to report our \nfinancial results in four reportable segments; U.S. "}, "hash": "d62d6daf25c1e293b84c00d52ac00c474080e06b73f612438fa9a332378f9bc6", "class_name": "RelatedNodeInfo"}}, "text": "My comments today will relate to our existing segment structure. \n", "start_char_idx": 226, "end_char_idx": 292, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "871a330c-dd92-4f98-871f-62d35fa7a43b": {"__data__": {"id_": "871a330c-dd92-4f98-871f-62d35fa7a43b", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nThank you, Brian, and good morning, everyone.  My comments today will relate to our existing segment structure. \n As Brian discussed in his opening comments, effective the second quarter of fiscal 2021, we'll begin to report our \nfinancial results in four reportable segments; U.S.  Pharmaceutical, International, Medical -Surgical Solutions and \nPrescription Technology Solutions.  We will issue a recast of financials in the new segment structure, ahead of our \nsecond quarter earnings call to assis t with the modeling under the new structure.  \n \n Our June quarter was a testament to McKesson's ability to execute during challenging times. ", "original_text": "As Brian discussed in his opening comments, effective the second quarter of fiscal 2021, we'll begin to report our \nfinancial results in four reportable segments; U.S. ", "page_label": "7", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5e1e3bfe-18ed-4cc7-9082-9a79812e2f1c", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "793a5abc15ad136f6b4965d2f2ee05bc8fee9de5acc167c2c4df187061eb82f8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "908db5ec-934b-4616-93a3-8b5921614d4b", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nThank you, Brian, and good morning, everyone.  My comments today will relate to our existing segment structure. \n As Brian discussed in his opening comments, effective the second quarter of fiscal 2021, we'll begin to report our \nfinancial results in four reportable segments; U.S.  Pharmaceutical, International, Medical -Surgical Solutions and \nPrescription Technology Solutions.  We will issue a recast of financials in the new segment structure, ahead of our \nsecond quarter earnings call to assis t with the modeling under the new structure.  \n \n", "original_text": "My comments today will relate to our existing segment structure. \n", "page_label": "7", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "43e06e123a771d1730d17aaa38adf1bb064f8189a3efd6f48aaba7d89fd3b127", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "32a139d2-1676-45a3-a1d3-ccdf5f9e8616", "node_type": "1", "metadata": {"window": "(MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nThank you, Brian, and good morning, everyone.  My comments today will relate to our existing segment structure. \n As Brian discussed in his opening comments, effective the second quarter of fiscal 2021, we'll begin to report our \nfinancial results in four reportable segments; U.S.  Pharmaceutical, International, Medical -Surgical Solutions and \nPrescription Technology Solutions.  We will issue a recast of financials in the new segment structure, ahead of our \nsecond quarter earnings call to assis t with the modeling under the new structure.  \n \n Our June quarter was a testament to McKesson's ability to execute during challenging times.  Our results speak to \nthe dedication of our people, the resilience of our business, and the important leadership role t hat McKesson \nplays in the health care supply chain. ", "original_text": "Pharmaceutical, International, Medical -Surgical Solutions and \nPrescription Technology Solutions. "}, "hash": "9a686cc6bc9ffd51d081d881b8307c44ad49db341d6755377777b4b52581ccb3", "class_name": "RelatedNodeInfo"}}, "text": "As Brian discussed in his opening comments, effective the second quarter of fiscal 2021, we'll begin to report our \nfinancial results in four reportable segments; U.S. ", "start_char_idx": 292, "end_char_idx": 460, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "32a139d2-1676-45a3-a1d3-ccdf5f9e8616": {"__data__": {"id_": "32a139d2-1676-45a3-a1d3-ccdf5f9e8616", "embedding": null, "metadata": {"window": "(MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nThank you, Brian, and good morning, everyone.  My comments today will relate to our existing segment structure. \n As Brian discussed in his opening comments, effective the second quarter of fiscal 2021, we'll begin to report our \nfinancial results in four reportable segments; U.S.  Pharmaceutical, International, Medical -Surgical Solutions and \nPrescription Technology Solutions.  We will issue a recast of financials in the new segment structure, ahead of our \nsecond quarter earnings call to assis t with the modeling under the new structure.  \n \n Our June quarter was a testament to McKesson's ability to execute during challenging times.  Our results speak to \nthe dedication of our people, the resilience of our business, and the important leadership role t hat McKesson \nplays in the health care supply chain. ", "original_text": "Pharmaceutical, International, Medical -Surgical Solutions and \nPrescription Technology Solutions. ", "page_label": "7", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5e1e3bfe-18ed-4cc7-9082-9a79812e2f1c", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "793a5abc15ad136f6b4965d2f2ee05bc8fee9de5acc167c2c4df187061eb82f8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "871a330c-dd92-4f98-871f-62d35fa7a43b", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nThank you, Brian, and good morning, everyone.  My comments today will relate to our existing segment structure. \n As Brian discussed in his opening comments, effective the second quarter of fiscal 2021, we'll begin to report our \nfinancial results in four reportable segments; U.S.  Pharmaceutical, International, Medical -Surgical Solutions and \nPrescription Technology Solutions.  We will issue a recast of financials in the new segment structure, ahead of our \nsecond quarter earnings call to assis t with the modeling under the new structure.  \n \n Our June quarter was a testament to McKesson's ability to execute during challenging times. ", "original_text": "As Brian discussed in his opening comments, effective the second quarter of fiscal 2021, we'll begin to report our \nfinancial results in four reportable segments; U.S. ", "page_label": "7", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3e6f05a1aafb477b3f1323367f97b3cc768d5e61599df2f1227eedf4c7d7b1e7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8c9e2825-15aa-4755-9391-42f11ead0475", "node_type": "1", "metadata": {"window": "My comments today will relate to our existing segment structure. \n As Brian discussed in his opening comments, effective the second quarter of fiscal 2021, we'll begin to report our \nfinancial results in four reportable segments; U.S.  Pharmaceutical, International, Medical -Surgical Solutions and \nPrescription Technology Solutions.  We will issue a recast of financials in the new segment structure, ahead of our \nsecond quarter earnings call to assis t with the modeling under the new structure.  \n \n Our June quarter was a testament to McKesson's ability to execute during challenging times.  Our results speak to \nthe dedication of our people, the resilience of our business, and the important leadership role t hat McKesson \nplays in the health care supply chain.  This morning, I'll provide commentary on our first quarter results, and I'll \nprovide an update on the key assumptions that underpin our outlook for the balance of fiscal 2021. ", "original_text": "We will issue a recast of financials in the new segment structure, ahead of our \nsecond quarter earnings call to assis t with the modeling under the new structure.  \n \n"}, "hash": "509c30715708a72390165f98616bcc2160bf051b76600d8d092bf6e07e42c797", "class_name": "RelatedNodeInfo"}}, "text": "Pharmaceutical, International, Medical -Surgical Solutions and \nPrescription Technology Solutions. ", "start_char_idx": 460, "end_char_idx": 559, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8c9e2825-15aa-4755-9391-42f11ead0475": {"__data__": {"id_": "8c9e2825-15aa-4755-9391-42f11ead0475", "embedding": null, "metadata": {"window": "My comments today will relate to our existing segment structure. \n As Brian discussed in his opening comments, effective the second quarter of fiscal 2021, we'll begin to report our \nfinancial results in four reportable segments; U.S.  Pharmaceutical, International, Medical -Surgical Solutions and \nPrescription Technology Solutions.  We will issue a recast of financials in the new segment structure, ahead of our \nsecond quarter earnings call to assis t with the modeling under the new structure.  \n \n Our June quarter was a testament to McKesson's ability to execute during challenging times.  Our results speak to \nthe dedication of our people, the resilience of our business, and the important leadership role t hat McKesson \nplays in the health care supply chain.  This morning, I'll provide commentary on our first quarter results, and I'll \nprovide an update on the key assumptions that underpin our outlook for the balance of fiscal 2021. ", "original_text": "We will issue a recast of financials in the new segment structure, ahead of our \nsecond quarter earnings call to assis t with the modeling under the new structure.  \n \n", "page_label": "7", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5e1e3bfe-18ed-4cc7-9082-9a79812e2f1c", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "793a5abc15ad136f6b4965d2f2ee05bc8fee9de5acc167c2c4df187061eb82f8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "32a139d2-1676-45a3-a1d3-ccdf5f9e8616", "node_type": "1", "metadata": {"window": "(MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nThank you, Brian, and good morning, everyone.  My comments today will relate to our existing segment structure. \n As Brian discussed in his opening comments, effective the second quarter of fiscal 2021, we'll begin to report our \nfinancial results in four reportable segments; U.S.  Pharmaceutical, International, Medical -Surgical Solutions and \nPrescription Technology Solutions.  We will issue a recast of financials in the new segment structure, ahead of our \nsecond quarter earnings call to assis t with the modeling under the new structure.  \n \n Our June quarter was a testament to McKesson's ability to execute during challenging times.  Our results speak to \nthe dedication of our people, the resilience of our business, and the important leadership role t hat McKesson \nplays in the health care supply chain. ", "original_text": "Pharmaceutical, International, Medical -Surgical Solutions and \nPrescription Technology Solutions. ", "page_label": "7", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "64f3f55f85149fe5c649d9739c580dfb5471ae6ff10ef640ebaa7da3b26f8230", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3e19467a-b0f7-44a3-a36b-0223838a41f0", "node_type": "1", "metadata": {"window": "As Brian discussed in his opening comments, effective the second quarter of fiscal 2021, we'll begin to report our \nfinancial results in four reportable segments; U.S.  Pharmaceutical, International, Medical -Surgical Solutions and \nPrescription Technology Solutions.  We will issue a recast of financials in the new segment structure, ahead of our \nsecond quarter earnings call to assis t with the modeling under the new structure.  \n \n Our June quarter was a testament to McKesson's ability to execute during challenging times.  Our results speak to \nthe dedication of our people, the resilience of our business, and the important leadership role t hat McKesson \nplays in the health care supply chain.  This morning, I'll provide commentary on our first quarter results, and I'll \nprovide an update on the key assumptions that underpin our outlook for the balance of fiscal 2021.  Throughout \nmy comments this morning, I'll provide an update of the recent trends we are observing and the implications to \nour fiscal 2021 results.  \n \n", "original_text": "Our June quarter was a testament to McKesson's ability to execute during challenging times. "}, "hash": "a027618dd20f3151fb4327254cea0cd632dd0439acfc188b55035987332c9f11", "class_name": "RelatedNodeInfo"}}, "text": "We will issue a recast of financials in the new segment structure, ahead of our \nsecond quarter earnings call to assis t with the modeling under the new structure.  \n \n", "start_char_idx": 559, "end_char_idx": 727, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3e19467a-b0f7-44a3-a36b-0223838a41f0": {"__data__": {"id_": "3e19467a-b0f7-44a3-a36b-0223838a41f0", "embedding": null, "metadata": {"window": "As Brian discussed in his opening comments, effective the second quarter of fiscal 2021, we'll begin to report our \nfinancial results in four reportable segments; U.S.  Pharmaceutical, International, Medical -Surgical Solutions and \nPrescription Technology Solutions.  We will issue a recast of financials in the new segment structure, ahead of our \nsecond quarter earnings call to assis t with the modeling under the new structure.  \n \n Our June quarter was a testament to McKesson's ability to execute during challenging times.  Our results speak to \nthe dedication of our people, the resilience of our business, and the important leadership role t hat McKesson \nplays in the health care supply chain.  This morning, I'll provide commentary on our first quarter results, and I'll \nprovide an update on the key assumptions that underpin our outlook for the balance of fiscal 2021.  Throughout \nmy comments this morning, I'll provide an update of the recent trends we are observing and the implications to \nour fiscal 2021 results.  \n \n", "original_text": "Our June quarter was a testament to McKesson's ability to execute during challenging times. ", "page_label": "7", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5e1e3bfe-18ed-4cc7-9082-9a79812e2f1c", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "793a5abc15ad136f6b4965d2f2ee05bc8fee9de5acc167c2c4df187061eb82f8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8c9e2825-15aa-4755-9391-42f11ead0475", "node_type": "1", "metadata": {"window": "My comments today will relate to our existing segment structure. \n As Brian discussed in his opening comments, effective the second quarter of fiscal 2021, we'll begin to report our \nfinancial results in four reportable segments; U.S.  Pharmaceutical, International, Medical -Surgical Solutions and \nPrescription Technology Solutions.  We will issue a recast of financials in the new segment structure, ahead of our \nsecond quarter earnings call to assis t with the modeling under the new structure.  \n \n Our June quarter was a testament to McKesson's ability to execute during challenging times.  Our results speak to \nthe dedication of our people, the resilience of our business, and the important leadership role t hat McKesson \nplays in the health care supply chain.  This morning, I'll provide commentary on our first quarter results, and I'll \nprovide an update on the key assumptions that underpin our outlook for the balance of fiscal 2021. ", "original_text": "We will issue a recast of financials in the new segment structure, ahead of our \nsecond quarter earnings call to assis t with the modeling under the new structure.  \n \n", "page_label": "7", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c892707e101c9027da6bdd1a7e837ce449429510d5bee29bd65f4d82a8d637f3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "18c9b545-771b-45dd-9cff-cbd348ec3952", "node_type": "1", "metadata": {"window": "Pharmaceutical, International, Medical -Surgical Solutions and \nPrescription Technology Solutions.  We will issue a recast of financials in the new segment structure, ahead of our \nsecond quarter earnings call to assis t with the modeling under the new structure.  \n \n Our June quarter was a testament to McKesson's ability to execute during challenging times.  Our results speak to \nthe dedication of our people, the resilience of our business, and the important leadership role t hat McKesson \nplays in the health care supply chain.  This morning, I'll provide commentary on our first quarter results, and I'll \nprovide an update on the key assumptions that underpin our outlook for the balance of fiscal 2021.  Throughout \nmy comments this morning, I'll provide an update of the recent trends we are observing and the implications to \nour fiscal 2021 results.  \n \n As expected, our first quarter was severely impacted by the global pandemic, as lockdown and social distancing \nrequirements placed uniqu e pressures on our customers and patients. ", "original_text": "Our results speak to \nthe dedication of our people, the resilience of our business, and the important leadership role t hat McKesson \nplays in the health care supply chain. "}, "hash": "df2d26b274b81bd567960864f89f910a365ebc5ee5352f3a1c0bf895abc2a7b7", "class_name": "RelatedNodeInfo"}}, "text": "Our June quarter was a testament to McKesson's ability to execute during challenging times. ", "start_char_idx": 727, "end_char_idx": 819, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "18c9b545-771b-45dd-9cff-cbd348ec3952": {"__data__": {"id_": "18c9b545-771b-45dd-9cff-cbd348ec3952", "embedding": null, "metadata": {"window": "Pharmaceutical, International, Medical -Surgical Solutions and \nPrescription Technology Solutions.  We will issue a recast of financials in the new segment structure, ahead of our \nsecond quarter earnings call to assis t with the modeling under the new structure.  \n \n Our June quarter was a testament to McKesson's ability to execute during challenging times.  Our results speak to \nthe dedication of our people, the resilience of our business, and the important leadership role t hat McKesson \nplays in the health care supply chain.  This morning, I'll provide commentary on our first quarter results, and I'll \nprovide an update on the key assumptions that underpin our outlook for the balance of fiscal 2021.  Throughout \nmy comments this morning, I'll provide an update of the recent trends we are observing and the implications to \nour fiscal 2021 results.  \n \n As expected, our first quarter was severely impacted by the global pandemic, as lockdown and social distancing \nrequirements placed uniqu e pressures on our customers and patients. ", "original_text": "Our results speak to \nthe dedication of our people, the resilience of our business, and the important leadership role t hat McKesson \nplays in the health care supply chain. ", "page_label": "7", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5e1e3bfe-18ed-4cc7-9082-9a79812e2f1c", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "793a5abc15ad136f6b4965d2f2ee05bc8fee9de5acc167c2c4df187061eb82f8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3e19467a-b0f7-44a3-a36b-0223838a41f0", "node_type": "1", "metadata": {"window": "As Brian discussed in his opening comments, effective the second quarter of fiscal 2021, we'll begin to report our \nfinancial results in four reportable segments; U.S.  Pharmaceutical, International, Medical -Surgical Solutions and \nPrescription Technology Solutions.  We will issue a recast of financials in the new segment structure, ahead of our \nsecond quarter earnings call to assis t with the modeling under the new structure.  \n \n Our June quarter was a testament to McKesson's ability to execute during challenging times.  Our results speak to \nthe dedication of our people, the resilience of our business, and the important leadership role t hat McKesson \nplays in the health care supply chain.  This morning, I'll provide commentary on our first quarter results, and I'll \nprovide an update on the key assumptions that underpin our outlook for the balance of fiscal 2021.  Throughout \nmy comments this morning, I'll provide an update of the recent trends we are observing and the implications to \nour fiscal 2021 results.  \n \n", "original_text": "Our June quarter was a testament to McKesson's ability to execute during challenging times. ", "page_label": "7", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a5d3c166f7248f5aa47f9d425d1bfc289e875af4713719f8bed80d46cfb8478a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5d80d718-5523-4147-a039-989111c8d6fd", "node_type": "1", "metadata": {"window": "We will issue a recast of financials in the new segment structure, ahead of our \nsecond quarter earnings call to assis t with the modeling under the new structure.  \n \n Our June quarter was a testament to McKesson's ability to execute during challenging times.  Our results speak to \nthe dedication of our people, the resilience of our business, and the important leadership role t hat McKesson \nplays in the health care supply chain.  This morning, I'll provide commentary on our first quarter results, and I'll \nprovide an update on the key assumptions that underpin our outlook for the balance of fiscal 2021.  Throughout \nmy comments this morning, I'll provide an update of the recent trends we are observing and the implications to \nour fiscal 2021 results.  \n \n As expected, our first quarter was severely impacted by the global pandemic, as lockdown and social distancing \nrequirements placed uniqu e pressures on our customers and patients.  We navigated the quarter with a \ncombination of discipline and focus to what we continue to believe will be peak levels of global lockdown and \nrestrictions. ", "original_text": "This morning, I'll provide commentary on our first quarter results, and I'll \nprovide an update on the key assumptions that underpin our outlook for the balance of fiscal 2021. "}, "hash": "40164f114f418030c23d0830f1043c491d230af27eac4c536ab9c627cbf73145", "class_name": "RelatedNodeInfo"}}, "text": "Our results speak to \nthe dedication of our people, the resilience of our business, and the important leadership role t hat McKesson \nplays in the health care supply chain. ", "start_char_idx": 819, "end_char_idx": 992, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5d80d718-5523-4147-a039-989111c8d6fd": {"__data__": {"id_": "5d80d718-5523-4147-a039-989111c8d6fd", "embedding": null, "metadata": {"window": "We will issue a recast of financials in the new segment structure, ahead of our \nsecond quarter earnings call to assis t with the modeling under the new structure.  \n \n Our June quarter was a testament to McKesson's ability to execute during challenging times.  Our results speak to \nthe dedication of our people, the resilience of our business, and the important leadership role t hat McKesson \nplays in the health care supply chain.  This morning, I'll provide commentary on our first quarter results, and I'll \nprovide an update on the key assumptions that underpin our outlook for the balance of fiscal 2021.  Throughout \nmy comments this morning, I'll provide an update of the recent trends we are observing and the implications to \nour fiscal 2021 results.  \n \n As expected, our first quarter was severely impacted by the global pandemic, as lockdown and social distancing \nrequirements placed uniqu e pressures on our customers and patients.  We navigated the quarter with a \ncombination of discipline and focus to what we continue to believe will be peak levels of global lockdown and \nrestrictions. ", "original_text": "This morning, I'll provide commentary on our first quarter results, and I'll \nprovide an update on the key assumptions that underpin our outlook for the balance of fiscal 2021. ", "page_label": "7", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5e1e3bfe-18ed-4cc7-9082-9a79812e2f1c", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "793a5abc15ad136f6b4965d2f2ee05bc8fee9de5acc167c2c4df187061eb82f8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "18c9b545-771b-45dd-9cff-cbd348ec3952", "node_type": "1", "metadata": {"window": "Pharmaceutical, International, Medical -Surgical Solutions and \nPrescription Technology Solutions.  We will issue a recast of financials in the new segment structure, ahead of our \nsecond quarter earnings call to assis t with the modeling under the new structure.  \n \n Our June quarter was a testament to McKesson's ability to execute during challenging times.  Our results speak to \nthe dedication of our people, the resilience of our business, and the important leadership role t hat McKesson \nplays in the health care supply chain.  This morning, I'll provide commentary on our first quarter results, and I'll \nprovide an update on the key assumptions that underpin our outlook for the balance of fiscal 2021.  Throughout \nmy comments this morning, I'll provide an update of the recent trends we are observing and the implications to \nour fiscal 2021 results.  \n \n As expected, our first quarter was severely impacted by the global pandemic, as lockdown and social distancing \nrequirements placed uniqu e pressures on our customers and patients. ", "original_text": "Our results speak to \nthe dedication of our people, the resilience of our business, and the important leadership role t hat McKesson \nplays in the health care supply chain. ", "page_label": "7", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "730a657435abd2dbfc5f5da2502193c5dc2b4964d80a15a742c81efe7acbf4fb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b1a91d49-a53b-4d19-bf0b-0ef937f990ff", "node_type": "1", "metadata": {"window": "Our June quarter was a testament to McKesson's ability to execute during challenging times.  Our results speak to \nthe dedication of our people, the resilience of our business, and the important leadership role t hat McKesson \nplays in the health care supply chain.  This morning, I'll provide commentary on our first quarter results, and I'll \nprovide an update on the key assumptions that underpin our outlook for the balance of fiscal 2021.  Throughout \nmy comments this morning, I'll provide an update of the recent trends we are observing and the implications to \nour fiscal 2021 results.  \n \n As expected, our first quarter was severely impacted by the global pandemic, as lockdown and social distancing \nrequirements placed uniqu e pressures on our customers and patients.  We navigated the quarter with a \ncombination of discipline and focus to what we continue to believe will be peak levels of global lockdown and \nrestrictions.  In the first quarter, we finished ahead of the expectatio ns that we laid out in May on our fourth quarter \nfiscal 2020 earnings call. ", "original_text": "Throughout \nmy comments this morning, I'll provide an update of the recent trends we are observing and the implications to \nour fiscal 2021 results.  \n \n"}, "hash": "f83369c80cdb7201861417080f812aedd2422cc640ab0e6dd58e61778a8e2675", "class_name": "RelatedNodeInfo"}}, "text": "This morning, I'll provide commentary on our first quarter results, and I'll \nprovide an update on the key assumptions that underpin our outlook for the balance of fiscal 2021. ", "start_char_idx": 992, "end_char_idx": 1169, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b1a91d49-a53b-4d19-bf0b-0ef937f990ff": {"__data__": {"id_": "b1a91d49-a53b-4d19-bf0b-0ef937f990ff", "embedding": null, "metadata": {"window": "Our June quarter was a testament to McKesson's ability to execute during challenging times.  Our results speak to \nthe dedication of our people, the resilience of our business, and the important leadership role t hat McKesson \nplays in the health care supply chain.  This morning, I'll provide commentary on our first quarter results, and I'll \nprovide an update on the key assumptions that underpin our outlook for the balance of fiscal 2021.  Throughout \nmy comments this morning, I'll provide an update of the recent trends we are observing and the implications to \nour fiscal 2021 results.  \n \n As expected, our first quarter was severely impacted by the global pandemic, as lockdown and social distancing \nrequirements placed uniqu e pressures on our customers and patients.  We navigated the quarter with a \ncombination of discipline and focus to what we continue to believe will be peak levels of global lockdown and \nrestrictions.  In the first quarter, we finished ahead of the expectatio ns that we laid out in May on our fourth quarter \nfiscal 2020 earnings call. ", "original_text": "Throughout \nmy comments this morning, I'll provide an update of the recent trends we are observing and the implications to \nour fiscal 2021 results.  \n \n", "page_label": "7", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5e1e3bfe-18ed-4cc7-9082-9a79812e2f1c", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "793a5abc15ad136f6b4965d2f2ee05bc8fee9de5acc167c2c4df187061eb82f8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5d80d718-5523-4147-a039-989111c8d6fd", "node_type": "1", "metadata": {"window": "We will issue a recast of financials in the new segment structure, ahead of our \nsecond quarter earnings call to assis t with the modeling under the new structure.  \n \n Our June quarter was a testament to McKesson's ability to execute during challenging times.  Our results speak to \nthe dedication of our people, the resilience of our business, and the important leadership role t hat McKesson \nplays in the health care supply chain.  This morning, I'll provide commentary on our first quarter results, and I'll \nprovide an update on the key assumptions that underpin our outlook for the balance of fiscal 2021.  Throughout \nmy comments this morning, I'll provide an update of the recent trends we are observing and the implications to \nour fiscal 2021 results.  \n \n As expected, our first quarter was severely impacted by the global pandemic, as lockdown and social distancing \nrequirements placed uniqu e pressures on our customers and patients.  We navigated the quarter with a \ncombination of discipline and focus to what we continue to believe will be peak levels of global lockdown and \nrestrictions. ", "original_text": "This morning, I'll provide commentary on our first quarter results, and I'll \nprovide an update on the key assumptions that underpin our outlook for the balance of fiscal 2021. ", "page_label": "7", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6a05430c7db46338d0a3fa1f3e4c5b1f3eb4e2dd2c44c42cff0cf8a304985460", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c672be4a-2f01-46ad-99ea-4d431ee3161e", "node_type": "1", "metadata": {"window": "Our results speak to \nthe dedication of our people, the resilience of our business, and the important leadership role t hat McKesson \nplays in the health care supply chain.  This morning, I'll provide commentary on our first quarter results, and I'll \nprovide an update on the key assumptions that underpin our outlook for the balance of fiscal 2021.  Throughout \nmy comments this morning, I'll provide an update of the recent trends we are observing and the implications to \nour fiscal 2021 results.  \n \n As expected, our first quarter was severely impacted by the global pandemic, as lockdown and social distancing \nrequirements placed uniqu e pressures on our customers and patients.  We navigated the quarter with a \ncombination of discipline and focus to what we continue to believe will be peak levels of global lockdown and \nrestrictions.  In the first quarter, we finished ahead of the expectatio ns that we laid out in May on our fourth quarter \nfiscal 2020 earnings call.  Those expectations included our assumption that patient visits in the physician, specialty \nprovider and oncology segments and pharmacy interactions in our US, Canadian and European  markets would \nbottom out and gradually improve beginning with our second quarter.  \n \n", "original_text": "As expected, our first quarter was severely impacted by the global pandemic, as lockdown and social distancing \nrequirements placed uniqu e pressures on our customers and patients. "}, "hash": "bc047a2b497529d3ea0fd380f039a6a2596205d4ea2b92cde6f3ff1887deabd1", "class_name": "RelatedNodeInfo"}}, "text": "Throughout \nmy comments this morning, I'll provide an update of the recent trends we are observing and the implications to \nour fiscal 2021 results.  \n \n", "start_char_idx": 1169, "end_char_idx": 1322, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c672be4a-2f01-46ad-99ea-4d431ee3161e": {"__data__": {"id_": "c672be4a-2f01-46ad-99ea-4d431ee3161e", "embedding": null, "metadata": {"window": "Our results speak to \nthe dedication of our people, the resilience of our business, and the important leadership role t hat McKesson \nplays in the health care supply chain.  This morning, I'll provide commentary on our first quarter results, and I'll \nprovide an update on the key assumptions that underpin our outlook for the balance of fiscal 2021.  Throughout \nmy comments this morning, I'll provide an update of the recent trends we are observing and the implications to \nour fiscal 2021 results.  \n \n As expected, our first quarter was severely impacted by the global pandemic, as lockdown and social distancing \nrequirements placed uniqu e pressures on our customers and patients.  We navigated the quarter with a \ncombination of discipline and focus to what we continue to believe will be peak levels of global lockdown and \nrestrictions.  In the first quarter, we finished ahead of the expectatio ns that we laid out in May on our fourth quarter \nfiscal 2020 earnings call.  Those expectations included our assumption that patient visits in the physician, specialty \nprovider and oncology segments and pharmacy interactions in our US, Canadian and European  markets would \nbottom out and gradually improve beginning with our second quarter.  \n \n", "original_text": "As expected, our first quarter was severely impacted by the global pandemic, as lockdown and social distancing \nrequirements placed uniqu e pressures on our customers and patients. ", "page_label": "7", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5e1e3bfe-18ed-4cc7-9082-9a79812e2f1c", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "793a5abc15ad136f6b4965d2f2ee05bc8fee9de5acc167c2c4df187061eb82f8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b1a91d49-a53b-4d19-bf0b-0ef937f990ff", "node_type": "1", "metadata": {"window": "Our June quarter was a testament to McKesson's ability to execute during challenging times.  Our results speak to \nthe dedication of our people, the resilience of our business, and the important leadership role t hat McKesson \nplays in the health care supply chain.  This morning, I'll provide commentary on our first quarter results, and I'll \nprovide an update on the key assumptions that underpin our outlook for the balance of fiscal 2021.  Throughout \nmy comments this morning, I'll provide an update of the recent trends we are observing and the implications to \nour fiscal 2021 results.  \n \n As expected, our first quarter was severely impacted by the global pandemic, as lockdown and social distancing \nrequirements placed uniqu e pressures on our customers and patients.  We navigated the quarter with a \ncombination of discipline and focus to what we continue to believe will be peak levels of global lockdown and \nrestrictions.  In the first quarter, we finished ahead of the expectatio ns that we laid out in May on our fourth quarter \nfiscal 2020 earnings call. ", "original_text": "Throughout \nmy comments this morning, I'll provide an update of the recent trends we are observing and the implications to \nour fiscal 2021 results.  \n \n", "page_label": "7", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c69ee848e69ca8f94cb6c4e31de58fbb700ff6930c90ab100d5128d58dfb2c3f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "145b5716-3445-4260-8a1b-db6db776ce99", "node_type": "1", "metadata": {"window": "This morning, I'll provide commentary on our first quarter results, and I'll \nprovide an update on the key assumptions that underpin our outlook for the balance of fiscal 2021.  Throughout \nmy comments this morning, I'll provide an update of the recent trends we are observing and the implications to \nour fiscal 2021 results.  \n \n As expected, our first quarter was severely impacted by the global pandemic, as lockdown and social distancing \nrequirements placed uniqu e pressures on our customers and patients.  We navigated the quarter with a \ncombination of discipline and focus to what we continue to believe will be peak levels of global lockdown and \nrestrictions.  In the first quarter, we finished ahead of the expectatio ns that we laid out in May on our fourth quarter \nfiscal 2020 earnings call.  Those expectations included our assumption that patient visits in the physician, specialty \nprovider and oncology segments and pharmacy interactions in our US, Canadian and European  markets would \nbottom out and gradually improve beginning with our second quarter.  \n \n Through April and May, the relative shape of the recovery curve was in line with this original guidance framework. \n", "original_text": "We navigated the quarter with a \ncombination of discipline and focus to what we continue to believe will be peak levels of global lockdown and \nrestrictions. "}, "hash": "0fef70f11d58154a14cee490baf56612fafe531df5073ad88525adb7f5627465", "class_name": "RelatedNodeInfo"}}, "text": "As expected, our first quarter was severely impacted by the global pandemic, as lockdown and social distancing \nrequirements placed uniqu e pressures on our customers and patients. ", "start_char_idx": 1322, "end_char_idx": 1503, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "145b5716-3445-4260-8a1b-db6db776ce99": {"__data__": {"id_": "145b5716-3445-4260-8a1b-db6db776ce99", "embedding": null, "metadata": {"window": "This morning, I'll provide commentary on our first quarter results, and I'll \nprovide an update on the key assumptions that underpin our outlook for the balance of fiscal 2021.  Throughout \nmy comments this morning, I'll provide an update of the recent trends we are observing and the implications to \nour fiscal 2021 results.  \n \n As expected, our first quarter was severely impacted by the global pandemic, as lockdown and social distancing \nrequirements placed uniqu e pressures on our customers and patients.  We navigated the quarter with a \ncombination of discipline and focus to what we continue to believe will be peak levels of global lockdown and \nrestrictions.  In the first quarter, we finished ahead of the expectatio ns that we laid out in May on our fourth quarter \nfiscal 2020 earnings call.  Those expectations included our assumption that patient visits in the physician, specialty \nprovider and oncology segments and pharmacy interactions in our US, Canadian and European  markets would \nbottom out and gradually improve beginning with our second quarter.  \n \n Through April and May, the relative shape of the recovery curve was in line with this original guidance framework. \n", "original_text": "We navigated the quarter with a \ncombination of discipline and focus to what we continue to believe will be peak levels of global lockdown and \nrestrictions. ", "page_label": "7", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5e1e3bfe-18ed-4cc7-9082-9a79812e2f1c", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "793a5abc15ad136f6b4965d2f2ee05bc8fee9de5acc167c2c4df187061eb82f8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c672be4a-2f01-46ad-99ea-4d431ee3161e", "node_type": "1", "metadata": {"window": "Our results speak to \nthe dedication of our people, the resilience of our business, and the important leadership role t hat McKesson \nplays in the health care supply chain.  This morning, I'll provide commentary on our first quarter results, and I'll \nprovide an update on the key assumptions that underpin our outlook for the balance of fiscal 2021.  Throughout \nmy comments this morning, I'll provide an update of the recent trends we are observing and the implications to \nour fiscal 2021 results.  \n \n As expected, our first quarter was severely impacted by the global pandemic, as lockdown and social distancing \nrequirements placed uniqu e pressures on our customers and patients.  We navigated the quarter with a \ncombination of discipline and focus to what we continue to believe will be peak levels of global lockdown and \nrestrictions.  In the first quarter, we finished ahead of the expectatio ns that we laid out in May on our fourth quarter \nfiscal 2020 earnings call.  Those expectations included our assumption that patient visits in the physician, specialty \nprovider and oncology segments and pharmacy interactions in our US, Canadian and European  markets would \nbottom out and gradually improve beginning with our second quarter.  \n \n", "original_text": "As expected, our first quarter was severely impacted by the global pandemic, as lockdown and social distancing \nrequirements placed uniqu e pressures on our customers and patients. ", "page_label": "7", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9d5c1c8fd03b6c8f3b8863ee551b176a08ecbb4b1ea50643d5b6ad75e005f525", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "50a2dfe7-d731-43c5-adbb-dfc3f078b3a8", "node_type": "1", "metadata": {"window": "Throughout \nmy comments this morning, I'll provide an update of the recent trends we are observing and the implications to \nour fiscal 2021 results.  \n \n As expected, our first quarter was severely impacted by the global pandemic, as lockdown and social distancing \nrequirements placed uniqu e pressures on our customers and patients.  We navigated the quarter with a \ncombination of discipline and focus to what we continue to believe will be peak levels of global lockdown and \nrestrictions.  In the first quarter, we finished ahead of the expectatio ns that we laid out in May on our fourth quarter \nfiscal 2020 earnings call.  Those expectations included our assumption that patient visits in the physician, specialty \nprovider and oncology segments and pharmacy interactions in our US, Canadian and European  markets would \nbottom out and gradually improve beginning with our second quarter.  \n \n Through April and May, the relative shape of the recovery curve was in line with this original guidance framework. \n However, as we progressed through June, we began to see a n acceleration of demand as volumes across our \nbusinesses recovered at an earlier pace than our original outlook had contemplated. ", "original_text": "In the first quarter, we finished ahead of the expectatio ns that we laid out in May on our fourth quarter \nfiscal 2020 earnings call. "}, "hash": "d7fa4b1eeee02150e3b430c942f75c5a3333cdbd119492f61ad9ccb7faab2043", "class_name": "RelatedNodeInfo"}}, "text": "We navigated the quarter with a \ncombination of discipline and focus to what we continue to believe will be peak levels of global lockdown and \nrestrictions. ", "start_char_idx": 1503, "end_char_idx": 1661, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "50a2dfe7-d731-43c5-adbb-dfc3f078b3a8": {"__data__": {"id_": "50a2dfe7-d731-43c5-adbb-dfc3f078b3a8", "embedding": null, "metadata": {"window": "Throughout \nmy comments this morning, I'll provide an update of the recent trends we are observing and the implications to \nour fiscal 2021 results.  \n \n As expected, our first quarter was severely impacted by the global pandemic, as lockdown and social distancing \nrequirements placed uniqu e pressures on our customers and patients.  We navigated the quarter with a \ncombination of discipline and focus to what we continue to believe will be peak levels of global lockdown and \nrestrictions.  In the first quarter, we finished ahead of the expectatio ns that we laid out in May on our fourth quarter \nfiscal 2020 earnings call.  Those expectations included our assumption that patient visits in the physician, specialty \nprovider and oncology segments and pharmacy interactions in our US, Canadian and European  markets would \nbottom out and gradually improve beginning with our second quarter.  \n \n Through April and May, the relative shape of the recovery curve was in line with this original guidance framework. \n However, as we progressed through June, we began to see a n acceleration of demand as volumes across our \nbusinesses recovered at an earlier pace than our original outlook had contemplated. ", "original_text": "In the first quarter, we finished ahead of the expectatio ns that we laid out in May on our fourth quarter \nfiscal 2020 earnings call. ", "page_label": "7", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5e1e3bfe-18ed-4cc7-9082-9a79812e2f1c", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "793a5abc15ad136f6b4965d2f2ee05bc8fee9de5acc167c2c4df187061eb82f8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "145b5716-3445-4260-8a1b-db6db776ce99", "node_type": "1", "metadata": {"window": "This morning, I'll provide commentary on our first quarter results, and I'll \nprovide an update on the key assumptions that underpin our outlook for the balance of fiscal 2021.  Throughout \nmy comments this morning, I'll provide an update of the recent trends we are observing and the implications to \nour fiscal 2021 results.  \n \n As expected, our first quarter was severely impacted by the global pandemic, as lockdown and social distancing \nrequirements placed uniqu e pressures on our customers and patients.  We navigated the quarter with a \ncombination of discipline and focus to what we continue to believe will be peak levels of global lockdown and \nrestrictions.  In the first quarter, we finished ahead of the expectatio ns that we laid out in May on our fourth quarter \nfiscal 2020 earnings call.  Those expectations included our assumption that patient visits in the physician, specialty \nprovider and oncology segments and pharmacy interactions in our US, Canadian and European  markets would \nbottom out and gradually improve beginning with our second quarter.  \n \n Through April and May, the relative shape of the recovery curve was in line with this original guidance framework. \n", "original_text": "We navigated the quarter with a \ncombination of discipline and focus to what we continue to believe will be peak levels of global lockdown and \nrestrictions. ", "page_label": "7", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "52bc762aad93af93f8fb1a3f2afa74184a433a185c15cefe2a8cea5c389acd8b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "821672ec-d35d-478e-881a-f46b09cefa1c", "node_type": "1", "metadata": {"window": "As expected, our first quarter was severely impacted by the global pandemic, as lockdown and social distancing \nrequirements placed uniqu e pressures on our customers and patients.  We navigated the quarter with a \ncombination of discipline and focus to what we continue to believe will be peak levels of global lockdown and \nrestrictions.  In the first quarter, we finished ahead of the expectatio ns that we laid out in May on our fourth quarter \nfiscal 2020 earnings call.  Those expectations included our assumption that patient visits in the physician, specialty \nprovider and oncology segments and pharmacy interactions in our US, Canadian and European  markets would \nbottom out and gradually improve beginning with our second quarter.  \n \n Through April and May, the relative shape of the recovery curve was in line with this original guidance framework. \n However, as we progressed through June, we began to see a n acceleration of demand as volumes across our \nbusinesses recovered at an earlier pace than our original outlook had contemplated.  This increase in demand \nlargely tracked the easing of restrictions in openings of markets across the world. ", "original_text": "Those expectations included our assumption that patient visits in the physician, specialty \nprovider and oncology segments and pharmacy interactions in our US, Canadian and European  markets would \nbottom out and gradually improve beginning with our second quarter.  \n \n"}, "hash": "dde0521d5a52e320a43fe7f213fc0f83e0767375fcd49e34736139d61f23c72a", "class_name": "RelatedNodeInfo"}}, "text": "In the first quarter, we finished ahead of the expectatio ns that we laid out in May on our fourth quarter \nfiscal 2020 earnings call. ", "start_char_idx": 1661, "end_char_idx": 1796, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "821672ec-d35d-478e-881a-f46b09cefa1c": {"__data__": {"id_": "821672ec-d35d-478e-881a-f46b09cefa1c", "embedding": null, "metadata": {"window": "As expected, our first quarter was severely impacted by the global pandemic, as lockdown and social distancing \nrequirements placed uniqu e pressures on our customers and patients.  We navigated the quarter with a \ncombination of discipline and focus to what we continue to believe will be peak levels of global lockdown and \nrestrictions.  In the first quarter, we finished ahead of the expectatio ns that we laid out in May on our fourth quarter \nfiscal 2020 earnings call.  Those expectations included our assumption that patient visits in the physician, specialty \nprovider and oncology segments and pharmacy interactions in our US, Canadian and European  markets would \nbottom out and gradually improve beginning with our second quarter.  \n \n Through April and May, the relative shape of the recovery curve was in line with this original guidance framework. \n However, as we progressed through June, we began to see a n acceleration of demand as volumes across our \nbusinesses recovered at an earlier pace than our original outlook had contemplated.  This increase in demand \nlargely tracked the easing of restrictions in openings of markets across the world. ", "original_text": "Those expectations included our assumption that patient visits in the physician, specialty \nprovider and oncology segments and pharmacy interactions in our US, Canadian and European  markets would \nbottom out and gradually improve beginning with our second quarter.  \n \n", "page_label": "7", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5e1e3bfe-18ed-4cc7-9082-9a79812e2f1c", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "793a5abc15ad136f6b4965d2f2ee05bc8fee9de5acc167c2c4df187061eb82f8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "50a2dfe7-d731-43c5-adbb-dfc3f078b3a8", "node_type": "1", "metadata": {"window": "Throughout \nmy comments this morning, I'll provide an update of the recent trends we are observing and the implications to \nour fiscal 2021 results.  \n \n As expected, our first quarter was severely impacted by the global pandemic, as lockdown and social distancing \nrequirements placed uniqu e pressures on our customers and patients.  We navigated the quarter with a \ncombination of discipline and focus to what we continue to believe will be peak levels of global lockdown and \nrestrictions.  In the first quarter, we finished ahead of the expectatio ns that we laid out in May on our fourth quarter \nfiscal 2020 earnings call.  Those expectations included our assumption that patient visits in the physician, specialty \nprovider and oncology segments and pharmacy interactions in our US, Canadian and European  markets would \nbottom out and gradually improve beginning with our second quarter.  \n \n Through April and May, the relative shape of the recovery curve was in line with this original guidance framework. \n However, as we progressed through June, we began to see a n acceleration of demand as volumes across our \nbusinesses recovered at an earlier pace than our original outlook had contemplated. ", "original_text": "In the first quarter, we finished ahead of the expectatio ns that we laid out in May on our fourth quarter \nfiscal 2020 earnings call. ", "page_label": "7", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e1469dbe791d7fbb30a3fe96fa56fb61bc2a35998136b392f526d3c97d01dfa1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4ba31012-e734-4b63-8965-5b2d7c23b483", "node_type": "1", "metadata": {"window": "We navigated the quarter with a \ncombination of discipline and focus to what we continue to believe will be peak levels of global lockdown and \nrestrictions.  In the first quarter, we finished ahead of the expectatio ns that we laid out in May on our fourth quarter \nfiscal 2020 earnings call.  Those expectations included our assumption that patient visits in the physician, specialty \nprovider and oncology segments and pharmacy interactions in our US, Canadian and European  markets would \nbottom out and gradually improve beginning with our second quarter.  \n \n Through April and May, the relative shape of the recovery curve was in line with this original guidance framework. \n However, as we progressed through June, we began to see a n acceleration of demand as volumes across our \nbusinesses recovered at an earlier pace than our original outlook had contemplated.  This increase in demand \nlargely tracked the easing of restrictions in openings of markets across the world.  Prescription tran sactions, \npatient interactions and elective procedures began to recover sooner than we had anticipated and had favorable \nvolume impacts that were most pronounced in the Medical Surgical and Specialty businesses.  \n \n", "original_text": "Through April and May, the relative shape of the recovery curve was in line with this original guidance framework. \n"}, "hash": "f7f8cab46e025698381ab1951e349f5ecfd6f70c16a444d73901a005dd35f587", "class_name": "RelatedNodeInfo"}}, "text": "Those expectations included our assumption that patient visits in the physician, specialty \nprovider and oncology segments and pharmacy interactions in our US, Canadian and European  markets would \nbottom out and gradually improve beginning with our second quarter.  \n \n", "start_char_idx": 1796, "end_char_idx": 2066, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4ba31012-e734-4b63-8965-5b2d7c23b483": {"__data__": {"id_": "4ba31012-e734-4b63-8965-5b2d7c23b483", "embedding": null, "metadata": {"window": "We navigated the quarter with a \ncombination of discipline and focus to what we continue to believe will be peak levels of global lockdown and \nrestrictions.  In the first quarter, we finished ahead of the expectatio ns that we laid out in May on our fourth quarter \nfiscal 2020 earnings call.  Those expectations included our assumption that patient visits in the physician, specialty \nprovider and oncology segments and pharmacy interactions in our US, Canadian and European  markets would \nbottom out and gradually improve beginning with our second quarter.  \n \n Through April and May, the relative shape of the recovery curve was in line with this original guidance framework. \n However, as we progressed through June, we began to see a n acceleration of demand as volumes across our \nbusinesses recovered at an earlier pace than our original outlook had contemplated.  This increase in demand \nlargely tracked the easing of restrictions in openings of markets across the world.  Prescription tran sactions, \npatient interactions and elective procedures began to recover sooner than we had anticipated and had favorable \nvolume impacts that were most pronounced in the Medical Surgical and Specialty businesses.  \n \n", "original_text": "Through April and May, the relative shape of the recovery curve was in line with this original guidance framework. \n", "page_label": "7", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5e1e3bfe-18ed-4cc7-9082-9a79812e2f1c", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "793a5abc15ad136f6b4965d2f2ee05bc8fee9de5acc167c2c4df187061eb82f8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "821672ec-d35d-478e-881a-f46b09cefa1c", "node_type": "1", "metadata": {"window": "As expected, our first quarter was severely impacted by the global pandemic, as lockdown and social distancing \nrequirements placed uniqu e pressures on our customers and patients.  We navigated the quarter with a \ncombination of discipline and focus to what we continue to believe will be peak levels of global lockdown and \nrestrictions.  In the first quarter, we finished ahead of the expectatio ns that we laid out in May on our fourth quarter \nfiscal 2020 earnings call.  Those expectations included our assumption that patient visits in the physician, specialty \nprovider and oncology segments and pharmacy interactions in our US, Canadian and European  markets would \nbottom out and gradually improve beginning with our second quarter.  \n \n Through April and May, the relative shape of the recovery curve was in line with this original guidance framework. \n However, as we progressed through June, we began to see a n acceleration of demand as volumes across our \nbusinesses recovered at an earlier pace than our original outlook had contemplated.  This increase in demand \nlargely tracked the easing of restrictions in openings of markets across the world. ", "original_text": "Those expectations included our assumption that patient visits in the physician, specialty \nprovider and oncology segments and pharmacy interactions in our US, Canadian and European  markets would \nbottom out and gradually improve beginning with our second quarter.  \n \n", "page_label": "7", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "94ee059c81444ae98ed6c891283df0ad6d3b6d30ec31fc0aebf8a87de853e698", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4c19e08d-97e2-4e42-b828-b9ca150f242c", "node_type": "1", "metadata": {"window": "In the first quarter, we finished ahead of the expectatio ns that we laid out in May on our fourth quarter \nfiscal 2020 earnings call.  Those expectations included our assumption that patient visits in the physician, specialty \nprovider and oncology segments and pharmacy interactions in our US, Canadian and European  markets would \nbottom out and gradually improve beginning with our second quarter.  \n \n Through April and May, the relative shape of the recovery curve was in line with this original guidance framework. \n However, as we progressed through June, we began to see a n acceleration of demand as volumes across our \nbusinesses recovered at an earlier pace than our original outlook had contemplated.  This increase in demand \nlargely tracked the easing of restrictions in openings of markets across the world.  Prescription tran sactions, \npatient interactions and elective procedures began to recover sooner than we had anticipated and had favorable \nvolume impacts that were most pronounced in the Medical Surgical and Specialty businesses.  \n \n Let me turn now to our first quarter result s. A summary of our first quarter results and updated guidance \nassumptions can be found in our first quarter earnings slide presentation which is posted on the Investors section \nof our website. ", "original_text": "However, as we progressed through June, we began to see a n acceleration of demand as volumes across our \nbusinesses recovered at an earlier pace than our original outlook had contemplated. "}, "hash": "a16ad8cbbfa63ca88f155152e6108e0a83358ce227c7173df8a98b2c88e917fc", "class_name": "RelatedNodeInfo"}}, "text": "Through April and May, the relative shape of the recovery curve was in line with this original guidance framework. \n", "start_char_idx": 2066, "end_char_idx": 2182, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4c19e08d-97e2-4e42-b828-b9ca150f242c": {"__data__": {"id_": "4c19e08d-97e2-4e42-b828-b9ca150f242c", "embedding": null, "metadata": {"window": "In the first quarter, we finished ahead of the expectatio ns that we laid out in May on our fourth quarter \nfiscal 2020 earnings call.  Those expectations included our assumption that patient visits in the physician, specialty \nprovider and oncology segments and pharmacy interactions in our US, Canadian and European  markets would \nbottom out and gradually improve beginning with our second quarter.  \n \n Through April and May, the relative shape of the recovery curve was in line with this original guidance framework. \n However, as we progressed through June, we began to see a n acceleration of demand as volumes across our \nbusinesses recovered at an earlier pace than our original outlook had contemplated.  This increase in demand \nlargely tracked the easing of restrictions in openings of markets across the world.  Prescription tran sactions, \npatient interactions and elective procedures began to recover sooner than we had anticipated and had favorable \nvolume impacts that were most pronounced in the Medical Surgical and Specialty businesses.  \n \n Let me turn now to our first quarter result s. A summary of our first quarter results and updated guidance \nassumptions can be found in our first quarter earnings slide presentation which is posted on the Investors section \nof our website. ", "original_text": "However, as we progressed through June, we began to see a n acceleration of demand as volumes across our \nbusinesses recovered at an earlier pace than our original outlook had contemplated. ", "page_label": "7", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5e1e3bfe-18ed-4cc7-9082-9a79812e2f1c", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "793a5abc15ad136f6b4965d2f2ee05bc8fee9de5acc167c2c4df187061eb82f8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4ba31012-e734-4b63-8965-5b2d7c23b483", "node_type": "1", "metadata": {"window": "We navigated the quarter with a \ncombination of discipline and focus to what we continue to believe will be peak levels of global lockdown and \nrestrictions.  In the first quarter, we finished ahead of the expectatio ns that we laid out in May on our fourth quarter \nfiscal 2020 earnings call.  Those expectations included our assumption that patient visits in the physician, specialty \nprovider and oncology segments and pharmacy interactions in our US, Canadian and European  markets would \nbottom out and gradually improve beginning with our second quarter.  \n \n Through April and May, the relative shape of the recovery curve was in line with this original guidance framework. \n However, as we progressed through June, we began to see a n acceleration of demand as volumes across our \nbusinesses recovered at an earlier pace than our original outlook had contemplated.  This increase in demand \nlargely tracked the easing of restrictions in openings of markets across the world.  Prescription tran sactions, \npatient interactions and elective procedures began to recover sooner than we had anticipated and had favorable \nvolume impacts that were most pronounced in the Medical Surgical and Specialty businesses.  \n \n", "original_text": "Through April and May, the relative shape of the recovery curve was in line with this original guidance framework. \n", "page_label": "7", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "df0445cd9c43f8fcff49edb890b2c76b98dbd02151526173523fe8b4c300eb4d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ac4c4b7b-2fe3-45b2-9be8-605486ee643e", "node_type": "1", "metadata": {"window": "Those expectations included our assumption that patient visits in the physician, specialty \nprovider and oncology segments and pharmacy interactions in our US, Canadian and European  markets would \nbottom out and gradually improve beginning with our second quarter.  \n \n Through April and May, the relative shape of the recovery curve was in line with this original guidance framework. \n However, as we progressed through June, we began to see a n acceleration of demand as volumes across our \nbusinesses recovered at an earlier pace than our original outlook had contemplated.  This increase in demand \nlargely tracked the easing of restrictions in openings of markets across the world.  Prescription tran sactions, \npatient interactions and elective procedures began to recover sooner than we had anticipated and had favorable \nvolume impacts that were most pronounced in the Medical Surgical and Specialty businesses.  \n \n Let me turn now to our first quarter result s. A summary of our first quarter results and updated guidance \nassumptions can be found in our first quarter earnings slide presentation which is posted on the Investors section \nof our website.  Before I provide more details on our first quarter adjusted re sults, I want to point out one item that \nimpacted our GAAP -only results in the quarter. ", "original_text": "This increase in demand \nlargely tracked the easing of restrictions in openings of markets across the world. "}, "hash": "0f05dc9091d157f9195c6a213b77f76ec78597c909b8d6bd4ba8295cb0c7f6d7", "class_name": "RelatedNodeInfo"}}, "text": "However, as we progressed through June, we began to see a n acceleration of demand as volumes across our \nbusinesses recovered at an earlier pace than our original outlook had contemplated. ", "start_char_idx": 2182, "end_char_idx": 2372, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ac4c4b7b-2fe3-45b2-9be8-605486ee643e": {"__data__": {"id_": "ac4c4b7b-2fe3-45b2-9be8-605486ee643e", "embedding": null, "metadata": {"window": "Those expectations included our assumption that patient visits in the physician, specialty \nprovider and oncology segments and pharmacy interactions in our US, Canadian and European  markets would \nbottom out and gradually improve beginning with our second quarter.  \n \n Through April and May, the relative shape of the recovery curve was in line with this original guidance framework. \n However, as we progressed through June, we began to see a n acceleration of demand as volumes across our \nbusinesses recovered at an earlier pace than our original outlook had contemplated.  This increase in demand \nlargely tracked the easing of restrictions in openings of markets across the world.  Prescription tran sactions, \npatient interactions and elective procedures began to recover sooner than we had anticipated and had favorable \nvolume impacts that were most pronounced in the Medical Surgical and Specialty businesses.  \n \n Let me turn now to our first quarter result s. A summary of our first quarter results and updated guidance \nassumptions can be found in our first quarter earnings slide presentation which is posted on the Investors section \nof our website.  Before I provide more details on our first quarter adjusted re sults, I want to point out one item that \nimpacted our GAAP -only results in the quarter. ", "original_text": "This increase in demand \nlargely tracked the easing of restrictions in openings of markets across the world. ", "page_label": "7", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5e1e3bfe-18ed-4cc7-9082-9a79812e2f1c", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "793a5abc15ad136f6b4965d2f2ee05bc8fee9de5acc167c2c4df187061eb82f8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4c19e08d-97e2-4e42-b828-b9ca150f242c", "node_type": "1", "metadata": {"window": "In the first quarter, we finished ahead of the expectatio ns that we laid out in May on our fourth quarter \nfiscal 2020 earnings call.  Those expectations included our assumption that patient visits in the physician, specialty \nprovider and oncology segments and pharmacy interactions in our US, Canadian and European  markets would \nbottom out and gradually improve beginning with our second quarter.  \n \n Through April and May, the relative shape of the recovery curve was in line with this original guidance framework. \n However, as we progressed through June, we began to see a n acceleration of demand as volumes across our \nbusinesses recovered at an earlier pace than our original outlook had contemplated.  This increase in demand \nlargely tracked the easing of restrictions in openings of markets across the world.  Prescription tran sactions, \npatient interactions and elective procedures began to recover sooner than we had anticipated and had favorable \nvolume impacts that were most pronounced in the Medical Surgical and Specialty businesses.  \n \n Let me turn now to our first quarter result s. A summary of our first quarter results and updated guidance \nassumptions can be found in our first quarter earnings slide presentation which is posted on the Investors section \nof our website. ", "original_text": "However, as we progressed through June, we began to see a n acceleration of demand as volumes across our \nbusinesses recovered at an earlier pace than our original outlook had contemplated. ", "page_label": "7", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "db000a0ee2c43c7c6b7cbb4171215693fc3e2f39bad3987743ab26c8bd3b9953", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6586c622-9332-41e3-be0f-6ea700a11d1c", "node_type": "1", "metadata": {"window": "Through April and May, the relative shape of the recovery curve was in line with this original guidance framework. \n However, as we progressed through June, we began to see a n acceleration of demand as volumes across our \nbusinesses recovered at an earlier pace than our original outlook had contemplated.  This increase in demand \nlargely tracked the easing of restrictions in openings of markets across the world.  Prescription tran sactions, \npatient interactions and elective procedures began to recover sooner than we had anticipated and had favorable \nvolume impacts that were most pronounced in the Medical Surgical and Specialty businesses.  \n \n Let me turn now to our first quarter result s. A summary of our first quarter results and updated guidance \nassumptions can be found in our first quarter earnings slide presentation which is posted on the Investors section \nof our website.  Before I provide more details on our first quarter adjusted re sults, I want to point out one item that \nimpacted our GAAP -only results in the quarter.  During the first quarter, we recorded an after -tax gain of $97 \nmillion for insurance proceeds received in connection with the settlement of the shareholder derivative a ction \nrelated to McKesson's controlled substances monitoring program.  \n \n", "original_text": "Prescription tran sactions, \npatient interactions and elective procedures began to recover sooner than we had anticipated and had favorable \nvolume impacts that were most pronounced in the Medical Surgical and Specialty businesses.  \n \n"}, "hash": "32339c25bd37cbb59feb625d080e125aad8e9494c87b8dd218e702ff11951607", "class_name": "RelatedNodeInfo"}}, "text": "This increase in demand \nlargely tracked the easing of restrictions in openings of markets across the world. ", "start_char_idx": 2372, "end_char_idx": 2481, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6586c622-9332-41e3-be0f-6ea700a11d1c": {"__data__": {"id_": "6586c622-9332-41e3-be0f-6ea700a11d1c", "embedding": null, "metadata": {"window": "Through April and May, the relative shape of the recovery curve was in line with this original guidance framework. \n However, as we progressed through June, we began to see a n acceleration of demand as volumes across our \nbusinesses recovered at an earlier pace than our original outlook had contemplated.  This increase in demand \nlargely tracked the easing of restrictions in openings of markets across the world.  Prescription tran sactions, \npatient interactions and elective procedures began to recover sooner than we had anticipated and had favorable \nvolume impacts that were most pronounced in the Medical Surgical and Specialty businesses.  \n \n Let me turn now to our first quarter result s. A summary of our first quarter results and updated guidance \nassumptions can be found in our first quarter earnings slide presentation which is posted on the Investors section \nof our website.  Before I provide more details on our first quarter adjusted re sults, I want to point out one item that \nimpacted our GAAP -only results in the quarter.  During the first quarter, we recorded an after -tax gain of $97 \nmillion for insurance proceeds received in connection with the settlement of the shareholder derivative a ction \nrelated to McKesson's controlled substances monitoring program.  \n \n", "original_text": "Prescription tran sactions, \npatient interactions and elective procedures began to recover sooner than we had anticipated and had favorable \nvolume impacts that were most pronounced in the Medical Surgical and Specialty businesses.  \n \n", "page_label": "7", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5e1e3bfe-18ed-4cc7-9082-9a79812e2f1c", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "793a5abc15ad136f6b4965d2f2ee05bc8fee9de5acc167c2c4df187061eb82f8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ac4c4b7b-2fe3-45b2-9be8-605486ee643e", "node_type": "1", "metadata": {"window": "Those expectations included our assumption that patient visits in the physician, specialty \nprovider and oncology segments and pharmacy interactions in our US, Canadian and European  markets would \nbottom out and gradually improve beginning with our second quarter.  \n \n Through April and May, the relative shape of the recovery curve was in line with this original guidance framework. \n However, as we progressed through June, we began to see a n acceleration of demand as volumes across our \nbusinesses recovered at an earlier pace than our original outlook had contemplated.  This increase in demand \nlargely tracked the easing of restrictions in openings of markets across the world.  Prescription tran sactions, \npatient interactions and elective procedures began to recover sooner than we had anticipated and had favorable \nvolume impacts that were most pronounced in the Medical Surgical and Specialty businesses.  \n \n Let me turn now to our first quarter result s. A summary of our first quarter results and updated guidance \nassumptions can be found in our first quarter earnings slide presentation which is posted on the Investors section \nof our website.  Before I provide more details on our first quarter adjusted re sults, I want to point out one item that \nimpacted our GAAP -only results in the quarter. ", "original_text": "This increase in demand \nlargely tracked the easing of restrictions in openings of markets across the world. ", "page_label": "7", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "62287973c9b01ed63185857650394367573cdd68a1c8f96f3a81a5e7eb1967d9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3ac8f8d5-085c-44c4-bf8a-363bac289b9b", "node_type": "1", "metadata": {"window": "However, as we progressed through June, we began to see a n acceleration of demand as volumes across our \nbusinesses recovered at an earlier pace than our original outlook had contemplated.  This increase in demand \nlargely tracked the easing of restrictions in openings of markets across the world.  Prescription tran sactions, \npatient interactions and elective procedures began to recover sooner than we had anticipated and had favorable \nvolume impacts that were most pronounced in the Medical Surgical and Specialty businesses.  \n \n Let me turn now to our first quarter result s. A summary of our first quarter results and updated guidance \nassumptions can be found in our first quarter earnings slide presentation which is posted on the Investors section \nof our website.  Before I provide more details on our first quarter adjusted re sults, I want to point out one item that \nimpacted our GAAP -only results in the quarter.  During the first quarter, we recorded an after -tax gain of $97 \nmillion for insurance proceeds received in connection with the settlement of the shareholder derivative a ction \nrelated to McKesson's controlled substances monitoring program.  \n \n Now let's transition to a discussion of our adjusted earnings results for the first quarter, starting with our \nconsolidated results on slide 4. ", "original_text": "Let me turn now to our first quarter result s. A summary of our first quarter results and updated guidance \nassumptions can be found in our first quarter earnings slide presentation which is posted on the Investors section \nof our website. "}, "hash": "41a2590e55165bc88c395a1ad1662bb6eec46847313d596d41e8779886fd391f", "class_name": "RelatedNodeInfo"}}, "text": "Prescription tran sactions, \npatient interactions and elective procedures began to recover sooner than we had anticipated and had favorable \nvolume impacts that were most pronounced in the Medical Surgical and Specialty businesses.  \n \n", "start_char_idx": 2481, "end_char_idx": 2717, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3ac8f8d5-085c-44c4-bf8a-363bac289b9b": {"__data__": {"id_": "3ac8f8d5-085c-44c4-bf8a-363bac289b9b", "embedding": null, "metadata": {"window": "However, as we progressed through June, we began to see a n acceleration of demand as volumes across our \nbusinesses recovered at an earlier pace than our original outlook had contemplated.  This increase in demand \nlargely tracked the easing of restrictions in openings of markets across the world.  Prescription tran sactions, \npatient interactions and elective procedures began to recover sooner than we had anticipated and had favorable \nvolume impacts that were most pronounced in the Medical Surgical and Specialty businesses.  \n \n Let me turn now to our first quarter result s. A summary of our first quarter results and updated guidance \nassumptions can be found in our first quarter earnings slide presentation which is posted on the Investors section \nof our website.  Before I provide more details on our first quarter adjusted re sults, I want to point out one item that \nimpacted our GAAP -only results in the quarter.  During the first quarter, we recorded an after -tax gain of $97 \nmillion for insurance proceeds received in connection with the settlement of the shareholder derivative a ction \nrelated to McKesson's controlled substances monitoring program.  \n \n Now let's transition to a discussion of our adjusted earnings results for the first quarter, starting with our \nconsolidated results on slide 4. ", "original_text": "Let me turn now to our first quarter result s. A summary of our first quarter results and updated guidance \nassumptions can be found in our first quarter earnings slide presentation which is posted on the Investors section \nof our website. ", "page_label": "7", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5e1e3bfe-18ed-4cc7-9082-9a79812e2f1c", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "793a5abc15ad136f6b4965d2f2ee05bc8fee9de5acc167c2c4df187061eb82f8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6586c622-9332-41e3-be0f-6ea700a11d1c", "node_type": "1", "metadata": {"window": "Through April and May, the relative shape of the recovery curve was in line with this original guidance framework. \n However, as we progressed through June, we began to see a n acceleration of demand as volumes across our \nbusinesses recovered at an earlier pace than our original outlook had contemplated.  This increase in demand \nlargely tracked the easing of restrictions in openings of markets across the world.  Prescription tran sactions, \npatient interactions and elective procedures began to recover sooner than we had anticipated and had favorable \nvolume impacts that were most pronounced in the Medical Surgical and Specialty businesses.  \n \n Let me turn now to our first quarter result s. A summary of our first quarter results and updated guidance \nassumptions can be found in our first quarter earnings slide presentation which is posted on the Investors section \nof our website.  Before I provide more details on our first quarter adjusted re sults, I want to point out one item that \nimpacted our GAAP -only results in the quarter.  During the first quarter, we recorded an after -tax gain of $97 \nmillion for insurance proceeds received in connection with the settlement of the shareholder derivative a ction \nrelated to McKesson's controlled substances monitoring program.  \n \n", "original_text": "Prescription tran sactions, \npatient interactions and elective procedures began to recover sooner than we had anticipated and had favorable \nvolume impacts that were most pronounced in the Medical Surgical and Specialty businesses.  \n \n", "page_label": "7", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1e4fb48171d0aef6da3d3c35522e0e8ea3644dc33137f6e0d18ac3b946150f32", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9a292f2e-9c91-4102-bff1-5dd52867b7f5", "node_type": "1", "metadata": {"window": "This increase in demand \nlargely tracked the easing of restrictions in openings of markets across the world.  Prescription tran sactions, \npatient interactions and elective procedures began to recover sooner than we had anticipated and had favorable \nvolume impacts that were most pronounced in the Medical Surgical and Specialty businesses.  \n \n Let me turn now to our first quarter result s. A summary of our first quarter results and updated guidance \nassumptions can be found in our first quarter earnings slide presentation which is posted on the Investors section \nof our website.  Before I provide more details on our first quarter adjusted re sults, I want to point out one item that \nimpacted our GAAP -only results in the quarter.  During the first quarter, we recorded an after -tax gain of $97 \nmillion for insurance proceeds received in connection with the settlement of the shareholder derivative a ction \nrelated to McKesson's controlled substances monitoring program.  \n \n Now let's transition to a discussion of our adjusted earnings results for the first quarter, starting with our \nconsolidated results on slide 4.  First quarter consolidated revenues of $5 5.7 billion were flat compared to the prior \nyear. ", "original_text": "Before I provide more details on our first quarter adjusted re sults, I want to point out one item that \nimpacted our GAAP -only results in the quarter. "}, "hash": "11025cb7a09e331d92a3f5c3b89a7b5a7b2e179dd96249d6f53bdef7f341d4e0", "class_name": "RelatedNodeInfo"}}, "text": "Let me turn now to our first quarter result s. A summary of our first quarter results and updated guidance \nassumptions can be found in our first quarter earnings slide presentation which is posted on the Investors section \nof our website. ", "start_char_idx": 2717, "end_char_idx": 2957, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9a292f2e-9c91-4102-bff1-5dd52867b7f5": {"__data__": {"id_": "9a292f2e-9c91-4102-bff1-5dd52867b7f5", "embedding": null, "metadata": {"window": "This increase in demand \nlargely tracked the easing of restrictions in openings of markets across the world.  Prescription tran sactions, \npatient interactions and elective procedures began to recover sooner than we had anticipated and had favorable \nvolume impacts that were most pronounced in the Medical Surgical and Specialty businesses.  \n \n Let me turn now to our first quarter result s. A summary of our first quarter results and updated guidance \nassumptions can be found in our first quarter earnings slide presentation which is posted on the Investors section \nof our website.  Before I provide more details on our first quarter adjusted re sults, I want to point out one item that \nimpacted our GAAP -only results in the quarter.  During the first quarter, we recorded an after -tax gain of $97 \nmillion for insurance proceeds received in connection with the settlement of the shareholder derivative a ction \nrelated to McKesson's controlled substances monitoring program.  \n \n Now let's transition to a discussion of our adjusted earnings results for the first quarter, starting with our \nconsolidated results on slide 4.  First quarter consolidated revenues of $5 5.7 billion were flat compared to the prior \nyear. ", "original_text": "Before I provide more details on our first quarter adjusted re sults, I want to point out one item that \nimpacted our GAAP -only results in the quarter. ", "page_label": "7", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5e1e3bfe-18ed-4cc7-9082-9a79812e2f1c", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "793a5abc15ad136f6b4965d2f2ee05bc8fee9de5acc167c2c4df187061eb82f8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3ac8f8d5-085c-44c4-bf8a-363bac289b9b", "node_type": "1", "metadata": {"window": "However, as we progressed through June, we began to see a n acceleration of demand as volumes across our \nbusinesses recovered at an earlier pace than our original outlook had contemplated.  This increase in demand \nlargely tracked the easing of restrictions in openings of markets across the world.  Prescription tran sactions, \npatient interactions and elective procedures began to recover sooner than we had anticipated and had favorable \nvolume impacts that were most pronounced in the Medical Surgical and Specialty businesses.  \n \n Let me turn now to our first quarter result s. A summary of our first quarter results and updated guidance \nassumptions can be found in our first quarter earnings slide presentation which is posted on the Investors section \nof our website.  Before I provide more details on our first quarter adjusted re sults, I want to point out one item that \nimpacted our GAAP -only results in the quarter.  During the first quarter, we recorded an after -tax gain of $97 \nmillion for insurance proceeds received in connection with the settlement of the shareholder derivative a ction \nrelated to McKesson's controlled substances monitoring program.  \n \n Now let's transition to a discussion of our adjusted earnings results for the first quarter, starting with our \nconsolidated results on slide 4. ", "original_text": "Let me turn now to our first quarter result s. A summary of our first quarter results and updated guidance \nassumptions can be found in our first quarter earnings slide presentation which is posted on the Investors section \nof our website. ", "page_label": "7", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a8b3c0033f7637d3cca67b70c367e7eb3ead346f9d05b7dae7ad2e10fa48ee8b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "19dae4f0-e90a-4e9b-9f1f-26bcaf38f1cc", "node_type": "1", "metadata": {"window": "Prescription tran sactions, \npatient interactions and elective procedures began to recover sooner than we had anticipated and had favorable \nvolume impacts that were most pronounced in the Medical Surgical and Specialty businesses.  \n \n Let me turn now to our first quarter result s. A summary of our first quarter results and updated guidance \nassumptions can be found in our first quarter earnings slide presentation which is posted on the Investors section \nof our website.  Before I provide more details on our first quarter adjusted re sults, I want to point out one item that \nimpacted our GAAP -only results in the quarter.  During the first quarter, we recorded an after -tax gain of $97 \nmillion for insurance proceeds received in connection with the settlement of the shareholder derivative a ction \nrelated to McKesson's controlled substances monitoring program.  \n \n Now let's transition to a discussion of our adjusted earnings results for the first quarter, starting with our \nconsolidated results on slide 4.  First quarter consolidated revenues of $5 5.7 billion were flat compared to the prior \nyear.  Market growth and higher retail national account volumes within the U.S. ", "original_text": "During the first quarter, we recorded an after -tax gain of $97 \nmillion for insurance proceeds received in connection with the settlement of the shareholder derivative a ction \nrelated to McKesson's controlled substances monitoring program.  \n \n"}, "hash": "1d1f263420a8c644a8ce57b68513dbdcaa4f141c3c4239e805aba3050d7086d4", "class_name": "RelatedNodeInfo"}}, "text": "Before I provide more details on our first quarter adjusted re sults, I want to point out one item that \nimpacted our GAAP -only results in the quarter. ", "start_char_idx": 2957, "end_char_idx": 3110, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "19dae4f0-e90a-4e9b-9f1f-26bcaf38f1cc": {"__data__": {"id_": "19dae4f0-e90a-4e9b-9f1f-26bcaf38f1cc", "embedding": null, "metadata": {"window": "Prescription tran sactions, \npatient interactions and elective procedures began to recover sooner than we had anticipated and had favorable \nvolume impacts that were most pronounced in the Medical Surgical and Specialty businesses.  \n \n Let me turn now to our first quarter result s. A summary of our first quarter results and updated guidance \nassumptions can be found in our first quarter earnings slide presentation which is posted on the Investors section \nof our website.  Before I provide more details on our first quarter adjusted re sults, I want to point out one item that \nimpacted our GAAP -only results in the quarter.  During the first quarter, we recorded an after -tax gain of $97 \nmillion for insurance proceeds received in connection with the settlement of the shareholder derivative a ction \nrelated to McKesson's controlled substances monitoring program.  \n \n Now let's transition to a discussion of our adjusted earnings results for the first quarter, starting with our \nconsolidated results on slide 4.  First quarter consolidated revenues of $5 5.7 billion were flat compared to the prior \nyear.  Market growth and higher retail national account volumes within the U.S. ", "original_text": "During the first quarter, we recorded an after -tax gain of $97 \nmillion for insurance proceeds received in connection with the settlement of the shareholder derivative a ction \nrelated to McKesson's controlled substances monitoring program.  \n \n", "page_label": "7", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5e1e3bfe-18ed-4cc7-9082-9a79812e2f1c", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "793a5abc15ad136f6b4965d2f2ee05bc8fee9de5acc167c2c4df187061eb82f8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9a292f2e-9c91-4102-bff1-5dd52867b7f5", "node_type": "1", "metadata": {"window": "This increase in demand \nlargely tracked the easing of restrictions in openings of markets across the world.  Prescription tran sactions, \npatient interactions and elective procedures began to recover sooner than we had anticipated and had favorable \nvolume impacts that were most pronounced in the Medical Surgical and Specialty businesses.  \n \n Let me turn now to our first quarter result s. A summary of our first quarter results and updated guidance \nassumptions can be found in our first quarter earnings slide presentation which is posted on the Investors section \nof our website.  Before I provide more details on our first quarter adjusted re sults, I want to point out one item that \nimpacted our GAAP -only results in the quarter.  During the first quarter, we recorded an after -tax gain of $97 \nmillion for insurance proceeds received in connection with the settlement of the shareholder derivative a ction \nrelated to McKesson's controlled substances monitoring program.  \n \n Now let's transition to a discussion of our adjusted earnings results for the first quarter, starting with our \nconsolidated results on slide 4.  First quarter consolidated revenues of $5 5.7 billion were flat compared to the prior \nyear. ", "original_text": "Before I provide more details on our first quarter adjusted re sults, I want to point out one item that \nimpacted our GAAP -only results in the quarter. ", "page_label": "7", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b602d627aba42883cd64557868bb8aa665591b35851a3b553c65992e3f545550", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fe825b3d-0263-43d9-901e-60cbb7edc7b1", "node_type": "1", "metadata": {"window": "Let me turn now to our first quarter result s. A summary of our first quarter results and updated guidance \nassumptions can be found in our first quarter earnings slide presentation which is posted on the Investors section \nof our website.  Before I provide more details on our first quarter adjusted re sults, I want to point out one item that \nimpacted our GAAP -only results in the quarter.  During the first quarter, we recorded an after -tax gain of $97 \nmillion for insurance proceeds received in connection with the settlement of the shareholder derivative a ction \nrelated to McKesson's controlled substances monitoring program.  \n \n Now let's transition to a discussion of our adjusted earnings results for the first quarter, starting with our \nconsolidated results on slide 4.  First quarter consolidated revenues of $5 5.7 billion were flat compared to the prior \nyear.  Market growth and higher retail national account volumes within the U.S.  Pharmaceutical and Specialty \nSolutions segment were offset by lower prescription volumes in primary care patient visits, primarily a result of the \nnegative impact from COVID -19. ", "original_text": "Now let's transition to a discussion of our adjusted earnings results for the first quarter, starting with our \nconsolidated results on slide 4. "}, "hash": "e42bf7b668cab74ac7cf4768072aca0dfe8d45fad9d75aecdbd13a07b1bee026", "class_name": "RelatedNodeInfo"}}, "text": "During the first quarter, we recorded an after -tax gain of $97 \nmillion for insurance proceeds received in connection with the settlement of the shareholder derivative a ction \nrelated to McKesson's controlled substances monitoring program.  \n \n", "start_char_idx": 3110, "end_char_idx": 3356, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fe825b3d-0263-43d9-901e-60cbb7edc7b1": {"__data__": {"id_": "fe825b3d-0263-43d9-901e-60cbb7edc7b1", "embedding": null, "metadata": {"window": "Let me turn now to our first quarter result s. A summary of our first quarter results and updated guidance \nassumptions can be found in our first quarter earnings slide presentation which is posted on the Investors section \nof our website.  Before I provide more details on our first quarter adjusted re sults, I want to point out one item that \nimpacted our GAAP -only results in the quarter.  During the first quarter, we recorded an after -tax gain of $97 \nmillion for insurance proceeds received in connection with the settlement of the shareholder derivative a ction \nrelated to McKesson's controlled substances monitoring program.  \n \n Now let's transition to a discussion of our adjusted earnings results for the first quarter, starting with our \nconsolidated results on slide 4.  First quarter consolidated revenues of $5 5.7 billion were flat compared to the prior \nyear.  Market growth and higher retail national account volumes within the U.S.  Pharmaceutical and Specialty \nSolutions segment were offset by lower prescription volumes in primary care patient visits, primarily a result of the \nnegative impact from COVID -19. ", "original_text": "Now let's transition to a discussion of our adjusted earnings results for the first quarter, starting with our \nconsolidated results on slide 4. ", "page_label": "7", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5e1e3bfe-18ed-4cc7-9082-9a79812e2f1c", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "793a5abc15ad136f6b4965d2f2ee05bc8fee9de5acc167c2c4df187061eb82f8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "19dae4f0-e90a-4e9b-9f1f-26bcaf38f1cc", "node_type": "1", "metadata": {"window": "Prescription tran sactions, \npatient interactions and elective procedures began to recover sooner than we had anticipated and had favorable \nvolume impacts that were most pronounced in the Medical Surgical and Specialty businesses.  \n \n Let me turn now to our first quarter result s. A summary of our first quarter results and updated guidance \nassumptions can be found in our first quarter earnings slide presentation which is posted on the Investors section \nof our website.  Before I provide more details on our first quarter adjusted re sults, I want to point out one item that \nimpacted our GAAP -only results in the quarter.  During the first quarter, we recorded an after -tax gain of $97 \nmillion for insurance proceeds received in connection with the settlement of the shareholder derivative a ction \nrelated to McKesson's controlled substances monitoring program.  \n \n Now let's transition to a discussion of our adjusted earnings results for the first quarter, starting with our \nconsolidated results on slide 4.  First quarter consolidated revenues of $5 5.7 billion were flat compared to the prior \nyear.  Market growth and higher retail national account volumes within the U.S. ", "original_text": "During the first quarter, we recorded an after -tax gain of $97 \nmillion for insurance proceeds received in connection with the settlement of the shareholder derivative a ction \nrelated to McKesson's controlled substances monitoring program.  \n \n", "page_label": "7", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3ec1a9732e630f4d49ff7b051543b22280c20e2d56f59a5ed3e6e5cb843df536", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "138683da-99a3-4de4-8167-18dfafe4f255", "node_type": "1", "metadata": {"window": "Before I provide more details on our first quarter adjusted re sults, I want to point out one item that \nimpacted our GAAP -only results in the quarter.  During the first quarter, we recorded an after -tax gain of $97 \nmillion for insurance proceeds received in connection with the settlement of the shareholder derivative a ction \nrelated to McKesson's controlled substances monitoring program.  \n \n Now let's transition to a discussion of our adjusted earnings results for the first quarter, starting with our \nconsolidated results on slide 4.  First quarter consolidated revenues of $5 5.7 billion were flat compared to the prior \nyear.  Market growth and higher retail national account volumes within the U.S.  Pharmaceutical and Specialty \nSolutions segment were offset by lower prescription volumes in primary care patient visits, primarily a result of the \nnegative impact from COVID -19.  Although flat to prior year, this result exceeded our original expectations for the \nquarter.  \n \n", "original_text": "First quarter consolidated revenues of $5 5.7 billion were flat compared to the prior \nyear. "}, "hash": "64a321b25ffd4be891d87a52d492ae46a02375545c474b0535dc0977206435ee", "class_name": "RelatedNodeInfo"}}, "text": "Now let's transition to a discussion of our adjusted earnings results for the first quarter, starting with our \nconsolidated results on slide 4. ", "start_char_idx": 3356, "end_char_idx": 3501, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "138683da-99a3-4de4-8167-18dfafe4f255": {"__data__": {"id_": "138683da-99a3-4de4-8167-18dfafe4f255", "embedding": null, "metadata": {"window": "Before I provide more details on our first quarter adjusted re sults, I want to point out one item that \nimpacted our GAAP -only results in the quarter.  During the first quarter, we recorded an after -tax gain of $97 \nmillion for insurance proceeds received in connection with the settlement of the shareholder derivative a ction \nrelated to McKesson's controlled substances monitoring program.  \n \n Now let's transition to a discussion of our adjusted earnings results for the first quarter, starting with our \nconsolidated results on slide 4.  First quarter consolidated revenues of $5 5.7 billion were flat compared to the prior \nyear.  Market growth and higher retail national account volumes within the U.S.  Pharmaceutical and Specialty \nSolutions segment were offset by lower prescription volumes in primary care patient visits, primarily a result of the \nnegative impact from COVID -19.  Although flat to prior year, this result exceeded our original expectations for the \nquarter.  \n \n", "original_text": "First quarter consolidated revenues of $5 5.7 billion were flat compared to the prior \nyear. ", "page_label": "7", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5e1e3bfe-18ed-4cc7-9082-9a79812e2f1c", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "793a5abc15ad136f6b4965d2f2ee05bc8fee9de5acc167c2c4df187061eb82f8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fe825b3d-0263-43d9-901e-60cbb7edc7b1", "node_type": "1", "metadata": {"window": "Let me turn now to our first quarter result s. A summary of our first quarter results and updated guidance \nassumptions can be found in our first quarter earnings slide presentation which is posted on the Investors section \nof our website.  Before I provide more details on our first quarter adjusted re sults, I want to point out one item that \nimpacted our GAAP -only results in the quarter.  During the first quarter, we recorded an after -tax gain of $97 \nmillion for insurance proceeds received in connection with the settlement of the shareholder derivative a ction \nrelated to McKesson's controlled substances monitoring program.  \n \n Now let's transition to a discussion of our adjusted earnings results for the first quarter, starting with our \nconsolidated results on slide 4.  First quarter consolidated revenues of $5 5.7 billion were flat compared to the prior \nyear.  Market growth and higher retail national account volumes within the U.S.  Pharmaceutical and Specialty \nSolutions segment were offset by lower prescription volumes in primary care patient visits, primarily a result of the \nnegative impact from COVID -19. ", "original_text": "Now let's transition to a discussion of our adjusted earnings results for the first quarter, starting with our \nconsolidated results on slide 4. ", "page_label": "7", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "890ece689109e7d1dbd5f0bffd757d133e67c109039fbd8d5ade3b82205ca674", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "71072f52-fc76-4dbf-a828-da986647a42d", "node_type": "1", "metadata": {"window": "During the first quarter, we recorded an after -tax gain of $97 \nmillion for insurance proceeds received in connection with the settlement of the shareholder derivative a ction \nrelated to McKesson's controlled substances monitoring program.  \n \n Now let's transition to a discussion of our adjusted earnings results for the first quarter, starting with our \nconsolidated results on slide 4.  First quarter consolidated revenues of $5 5.7 billion were flat compared to the prior \nyear.  Market growth and higher retail national account volumes within the U.S.  Pharmaceutical and Specialty \nSolutions segment were offset by lower prescription volumes in primary care patient visits, primarily a result of the \nnegative impact from COVID -19.  Although flat to prior year, this result exceeded our original expectations for the \nquarter.  \n \n First quarter adjusted gross profit was down 4% year -over-year as lower prescription transaction volumes and mix \nwere  a result of the pandemic. ", "original_text": "Market growth and higher retail national account volumes within the U.S. "}, "hash": "e9f21a15ecd15e272885d900c98eca60ba16d171cc754a85a46560c4e2aa091e", "class_name": "RelatedNodeInfo"}}, "text": "First quarter consolidated revenues of $5 5.7 billion were flat compared to the prior \nyear. ", "start_char_idx": 3501, "end_char_idx": 3594, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "71072f52-fc76-4dbf-a828-da986647a42d": {"__data__": {"id_": "71072f52-fc76-4dbf-a828-da986647a42d", "embedding": null, "metadata": {"window": "During the first quarter, we recorded an after -tax gain of $97 \nmillion for insurance proceeds received in connection with the settlement of the shareholder derivative a ction \nrelated to McKesson's controlled substances monitoring program.  \n \n Now let's transition to a discussion of our adjusted earnings results for the first quarter, starting with our \nconsolidated results on slide 4.  First quarter consolidated revenues of $5 5.7 billion were flat compared to the prior \nyear.  Market growth and higher retail national account volumes within the U.S.  Pharmaceutical and Specialty \nSolutions segment were offset by lower prescription volumes in primary care patient visits, primarily a result of the \nnegative impact from COVID -19.  Although flat to prior year, this result exceeded our original expectations for the \nquarter.  \n \n First quarter adjusted gross profit was down 4% year -over-year as lower prescription transaction volumes and mix \nwere  a result of the pandemic. ", "original_text": "Market growth and higher retail national account volumes within the U.S. ", "page_label": "7", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5e1e3bfe-18ed-4cc7-9082-9a79812e2f1c", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "793a5abc15ad136f6b4965d2f2ee05bc8fee9de5acc167c2c4df187061eb82f8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "138683da-99a3-4de4-8167-18dfafe4f255", "node_type": "1", "metadata": {"window": "Before I provide more details on our first quarter adjusted re sults, I want to point out one item that \nimpacted our GAAP -only results in the quarter.  During the first quarter, we recorded an after -tax gain of $97 \nmillion for insurance proceeds received in connection with the settlement of the shareholder derivative a ction \nrelated to McKesson's controlled substances monitoring program.  \n \n Now let's transition to a discussion of our adjusted earnings results for the first quarter, starting with our \nconsolidated results on slide 4.  First quarter consolidated revenues of $5 5.7 billion were flat compared to the prior \nyear.  Market growth and higher retail national account volumes within the U.S.  Pharmaceutical and Specialty \nSolutions segment were offset by lower prescription volumes in primary care patient visits, primarily a result of the \nnegative impact from COVID -19.  Although flat to prior year, this result exceeded our original expectations for the \nquarter.  \n \n", "original_text": "First quarter consolidated revenues of $5 5.7 billion were flat compared to the prior \nyear. ", "page_label": "7", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cb5f76351a2761da0637651b1ef461916a14fe221bfdcdf4e9e3d8f9ea42cc59", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e847793d-3384-4a92-b311-b002f04769c4", "node_type": "1", "metadata": {"window": "Now let's transition to a discussion of our adjusted earnings results for the first quarter, starting with our \nconsolidated results on slide 4.  First quarter consolidated revenues of $5 5.7 billion were flat compared to the prior \nyear.  Market growth and higher retail national account volumes within the U.S.  Pharmaceutical and Specialty \nSolutions segment were offset by lower prescription volumes in primary care patient visits, primarily a result of the \nnegative impact from COVID -19.  Although flat to prior year, this result exceeded our original expectations for the \nquarter.  \n \n First quarter adjusted gross profit was down 4% year -over-year as lower prescription transaction volumes and mix \nwere  a result of the pandemic.  First quarter adjusted operating expenses decreased 2% year -over-year driven by \ncost mitigation efforts in response to the headwinds presented by the COVID -19 pandemic. ", "original_text": "Pharmaceutical and Specialty \nSolutions segment were offset by lower prescription volumes in primary care patient visits, primarily a result of the \nnegative impact from COVID -19. "}, "hash": "2735163a1280f9b6ed2be47d798d2b7847d9f7e80d23c1ac8355a6b5be31db1a", "class_name": "RelatedNodeInfo"}}, "text": "Market growth and higher retail national account volumes within the U.S. ", "start_char_idx": 3594, "end_char_idx": 3667, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e847793d-3384-4a92-b311-b002f04769c4": {"__data__": {"id_": "e847793d-3384-4a92-b311-b002f04769c4", "embedding": null, "metadata": {"window": "Now let's transition to a discussion of our adjusted earnings results for the first quarter, starting with our \nconsolidated results on slide 4.  First quarter consolidated revenues of $5 5.7 billion were flat compared to the prior \nyear.  Market growth and higher retail national account volumes within the U.S.  Pharmaceutical and Specialty \nSolutions segment were offset by lower prescription volumes in primary care patient visits, primarily a result of the \nnegative impact from COVID -19.  Although flat to prior year, this result exceeded our original expectations for the \nquarter.  \n \n First quarter adjusted gross profit was down 4% year -over-year as lower prescription transaction volumes and mix \nwere  a result of the pandemic.  First quarter adjusted operating expenses decreased 2% year -over-year driven by \ncost mitigation efforts in response to the headwinds presented by the COVID -19 pandemic. ", "original_text": "Pharmaceutical and Specialty \nSolutions segment were offset by lower prescription volumes in primary care patient visits, primarily a result of the \nnegative impact from COVID -19. ", "page_label": "7", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5e1e3bfe-18ed-4cc7-9082-9a79812e2f1c", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "793a5abc15ad136f6b4965d2f2ee05bc8fee9de5acc167c2c4df187061eb82f8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "71072f52-fc76-4dbf-a828-da986647a42d", "node_type": "1", "metadata": {"window": "During the first quarter, we recorded an after -tax gain of $97 \nmillion for insurance proceeds received in connection with the settlement of the shareholder derivative a ction \nrelated to McKesson's controlled substances monitoring program.  \n \n Now let's transition to a discussion of our adjusted earnings results for the first quarter, starting with our \nconsolidated results on slide 4.  First quarter consolidated revenues of $5 5.7 billion were flat compared to the prior \nyear.  Market growth and higher retail national account volumes within the U.S.  Pharmaceutical and Specialty \nSolutions segment were offset by lower prescription volumes in primary care patient visits, primarily a result of the \nnegative impact from COVID -19.  Although flat to prior year, this result exceeded our original expectations for the \nquarter.  \n \n First quarter adjusted gross profit was down 4% year -over-year as lower prescription transaction volumes and mix \nwere  a result of the pandemic. ", "original_text": "Market growth and higher retail national account volumes within the U.S. ", "page_label": "7", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4606e46fc37bf6f4d02b927eff2f67ba8b5da08badd48a21a528400715ad2d3f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e7b2af5a-bf2d-4bdd-971a-0785bd70ae54", "node_type": "1", "metadata": {"window": "First quarter consolidated revenues of $5 5.7 billion were flat compared to the prior \nyear.  Market growth and higher retail national account volumes within the U.S.  Pharmaceutical and Specialty \nSolutions segment were offset by lower prescription volumes in primary care patient visits, primarily a result of the \nnegative impact from COVID -19.  Although flat to prior year, this result exceeded our original expectations for the \nquarter.  \n \n First quarter adjusted gross profit was down 4% year -over-year as lower prescription transaction volumes and mix \nwere  a result of the pandemic.  First quarter adjusted operating expenses decreased 2% year -over-year driven by \ncost mitigation efforts in response to the headwinds presented by the COVID -19 pandemic.  These were partially \noffset by increased investments in the business. ", "original_text": "Although flat to prior year, this result exceeded our original expectations for the \nquarter.  \n \n"}, "hash": "67da35126031cdc9cd4e32e66227eda04980191fe365f2bd6b77e13125490b4a", "class_name": "RelatedNodeInfo"}}, "text": "Pharmaceutical and Specialty \nSolutions segment were offset by lower prescription volumes in primary care patient visits, primarily a result of the \nnegative impact from COVID -19. ", "start_char_idx": 3667, "end_char_idx": 3848, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e7b2af5a-bf2d-4bdd-971a-0785bd70ae54": {"__data__": {"id_": "e7b2af5a-bf2d-4bdd-971a-0785bd70ae54", "embedding": null, "metadata": {"window": "First quarter consolidated revenues of $5 5.7 billion were flat compared to the prior \nyear.  Market growth and higher retail national account volumes within the U.S.  Pharmaceutical and Specialty \nSolutions segment were offset by lower prescription volumes in primary care patient visits, primarily a result of the \nnegative impact from COVID -19.  Although flat to prior year, this result exceeded our original expectations for the \nquarter.  \n \n First quarter adjusted gross profit was down 4% year -over-year as lower prescription transaction volumes and mix \nwere  a result of the pandemic.  First quarter adjusted operating expenses decreased 2% year -over-year driven by \ncost mitigation efforts in response to the headwinds presented by the COVID -19 pandemic.  These were partially \noffset by increased investments in the business. ", "original_text": "Although flat to prior year, this result exceeded our original expectations for the \nquarter.  \n \n", "page_label": "7", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5e1e3bfe-18ed-4cc7-9082-9a79812e2f1c", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "793a5abc15ad136f6b4965d2f2ee05bc8fee9de5acc167c2c4df187061eb82f8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e847793d-3384-4a92-b311-b002f04769c4", "node_type": "1", "metadata": {"window": "Now let's transition to a discussion of our adjusted earnings results for the first quarter, starting with our \nconsolidated results on slide 4.  First quarter consolidated revenues of $5 5.7 billion were flat compared to the prior \nyear.  Market growth and higher retail national account volumes within the U.S.  Pharmaceutical and Specialty \nSolutions segment were offset by lower prescription volumes in primary care patient visits, primarily a result of the \nnegative impact from COVID -19.  Although flat to prior year, this result exceeded our original expectations for the \nquarter.  \n \n First quarter adjusted gross profit was down 4% year -over-year as lower prescription transaction volumes and mix \nwere  a result of the pandemic.  First quarter adjusted operating expenses decreased 2% year -over-year driven by \ncost mitigation efforts in response to the headwinds presented by the COVID -19 pandemic. ", "original_text": "Pharmaceutical and Specialty \nSolutions segment were offset by lower prescription volumes in primary care patient visits, primarily a result of the \nnegative impact from COVID -19. ", "page_label": "7", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5f82a5672145ff49b81e21e38da5f4496849ea18668187b6c42942a59a45bc0a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "be60416d-4247-4b06-abf5-41e7db4ef64e", "node_type": "1", "metadata": {"window": "Market growth and higher retail national account volumes within the U.S.  Pharmaceutical and Specialty \nSolutions segment were offset by lower prescription volumes in primary care patient visits, primarily a result of the \nnegative impact from COVID -19.  Although flat to prior year, this result exceeded our original expectations for the \nquarter.  \n \n First quarter adjusted gross profit was down 4% year -over-year as lower prescription transaction volumes and mix \nwere  a result of the pandemic.  First quarter adjusted operating expenses decreased 2% year -over-year driven by \ncost mitigation efforts in response to the headwinds presented by the COVID -19 pandemic.  These were partially \noffset by increased investments in the business.  Adjusted operating profit was $707 million for the quarter, a \ndecrease of 24% as compared to the prior year. ", "original_text": "First quarter adjusted gross profit was down 4% year -over-year as lower prescription transaction volumes and mix \nwere  a result of the pandemic. "}, "hash": "f3ce987901378122de84f03efbefb545fad77e79720530489c69c52b2c7e4916", "class_name": "RelatedNodeInfo"}}, "text": "Although flat to prior year, this result exceeded our original expectations for the \nquarter.  \n \n", "start_char_idx": 3848, "end_char_idx": 3946, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "be60416d-4247-4b06-abf5-41e7db4ef64e": {"__data__": {"id_": "be60416d-4247-4b06-abf5-41e7db4ef64e", "embedding": null, "metadata": {"window": "Market growth and higher retail national account volumes within the U.S.  Pharmaceutical and Specialty \nSolutions segment were offset by lower prescription volumes in primary care patient visits, primarily a result of the \nnegative impact from COVID -19.  Although flat to prior year, this result exceeded our original expectations for the \nquarter.  \n \n First quarter adjusted gross profit was down 4% year -over-year as lower prescription transaction volumes and mix \nwere  a result of the pandemic.  First quarter adjusted operating expenses decreased 2% year -over-year driven by \ncost mitigation efforts in response to the headwinds presented by the COVID -19 pandemic.  These were partially \noffset by increased investments in the business.  Adjusted operating profit was $707 million for the quarter, a \ndecrease of 24% as compared to the prior year. ", "original_text": "First quarter adjusted gross profit was down 4% year -over-year as lower prescription transaction volumes and mix \nwere  a result of the pandemic. ", "page_label": "7", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5e1e3bfe-18ed-4cc7-9082-9a79812e2f1c", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "793a5abc15ad136f6b4965d2f2ee05bc8fee9de5acc167c2c4df187061eb82f8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e7b2af5a-bf2d-4bdd-971a-0785bd70ae54", "node_type": "1", "metadata": {"window": "First quarter consolidated revenues of $5 5.7 billion were flat compared to the prior \nyear.  Market growth and higher retail national account volumes within the U.S.  Pharmaceutical and Specialty \nSolutions segment were offset by lower prescription volumes in primary care patient visits, primarily a result of the \nnegative impact from COVID -19.  Although flat to prior year, this result exceeded our original expectations for the \nquarter.  \n \n First quarter adjusted gross profit was down 4% year -over-year as lower prescription transaction volumes and mix \nwere  a result of the pandemic.  First quarter adjusted operating expenses decreased 2% year -over-year driven by \ncost mitigation efforts in response to the headwinds presented by the COVID -19 pandemic.  These were partially \noffset by increased investments in the business. ", "original_text": "Although flat to prior year, this result exceeded our original expectations for the \nquarter.  \n \n", "page_label": "7", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b18391c4e9c331dbfec07f17fcefe11cfd1c21ac8964d8fb9e05bf0e15943f96", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "da118de1-f34c-45f5-b52a-10f33d67a8c5", "node_type": "1", "metadata": {"window": "Pharmaceutical and Specialty \nSolutions segment were offset by lower prescription volumes in primary care patient visits, primarily a result of the \nnegative impact from COVID -19.  Although flat to prior year, this result exceeded our original expectations for the \nquarter.  \n \n First quarter adjusted gross profit was down 4% year -over-year as lower prescription transaction volumes and mix \nwere  a result of the pandemic.  First quarter adjusted operating expenses decreased 2% year -over-year driven by \ncost mitigation efforts in response to the headwinds presented by the COVID -19 pandemic.  These were partially \noffset by increased investments in the business.  Adjusted operating profit was $707 million for the quarter, a \ndecrease of 24% as compared to the prior year.  When excluding the results of Change Healthcare from the prior ", "original_text": "First quarter adjusted operating expenses decreased 2% year -over-year driven by \ncost mitigation efforts in response to the headwinds presented by the COVID -19 pandemic. "}, "hash": "6c2771a3c2032272dddf2aba09404483beae8bb026d1fc5587bd33133080a5e0", "class_name": "RelatedNodeInfo"}}, "text": "First quarter adjusted gross profit was down 4% year -over-year as lower prescription transaction volumes and mix \nwere  a result of the pandemic. ", "start_char_idx": 3946, "end_char_idx": 4093, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "da118de1-f34c-45f5-b52a-10f33d67a8c5": {"__data__": {"id_": "da118de1-f34c-45f5-b52a-10f33d67a8c5", "embedding": null, "metadata": {"window": "Pharmaceutical and Specialty \nSolutions segment were offset by lower prescription volumes in primary care patient visits, primarily a result of the \nnegative impact from COVID -19.  Although flat to prior year, this result exceeded our original expectations for the \nquarter.  \n \n First quarter adjusted gross profit was down 4% year -over-year as lower prescription transaction volumes and mix \nwere  a result of the pandemic.  First quarter adjusted operating expenses decreased 2% year -over-year driven by \ncost mitigation efforts in response to the headwinds presented by the COVID -19 pandemic.  These were partially \noffset by increased investments in the business.  Adjusted operating profit was $707 million for the quarter, a \ndecrease of 24% as compared to the prior year.  When excluding the results of Change Healthcare from the prior ", "original_text": "First quarter adjusted operating expenses decreased 2% year -over-year driven by \ncost mitigation efforts in response to the headwinds presented by the COVID -19 pandemic. ", "page_label": "7", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5e1e3bfe-18ed-4cc7-9082-9a79812e2f1c", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "793a5abc15ad136f6b4965d2f2ee05bc8fee9de5acc167c2c4df187061eb82f8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "be60416d-4247-4b06-abf5-41e7db4ef64e", "node_type": "1", "metadata": {"window": "Market growth and higher retail national account volumes within the U.S.  Pharmaceutical and Specialty \nSolutions segment were offset by lower prescription volumes in primary care patient visits, primarily a result of the \nnegative impact from COVID -19.  Although flat to prior year, this result exceeded our original expectations for the \nquarter.  \n \n First quarter adjusted gross profit was down 4% year -over-year as lower prescription transaction volumes and mix \nwere  a result of the pandemic.  First quarter adjusted operating expenses decreased 2% year -over-year driven by \ncost mitigation efforts in response to the headwinds presented by the COVID -19 pandemic.  These were partially \noffset by increased investments in the business.  Adjusted operating profit was $707 million for the quarter, a \ndecrease of 24% as compared to the prior year. ", "original_text": "First quarter adjusted gross profit was down 4% year -over-year as lower prescription transaction volumes and mix \nwere  a result of the pandemic. ", "page_label": "7", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ddb9b46eff518d7b5030edf4668ccc62193d775642d00faa4bcbecee8136eef6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b5fda7e8-90a1-4f95-90c8-bb8c0ad1e934", "node_type": "1", "metadata": {"window": "Although flat to prior year, this result exceeded our original expectations for the \nquarter.  \n \n First quarter adjusted gross profit was down 4% year -over-year as lower prescription transaction volumes and mix \nwere  a result of the pandemic.  First quarter adjusted operating expenses decreased 2% year -over-year driven by \ncost mitigation efforts in response to the headwinds presented by the COVID -19 pandemic.  These were partially \noffset by increased investments in the business.  Adjusted operating profit was $707 million for the quarter, a \ndecrease of 24% as compared to the prior year.  When excluding the results of Change Healthcare from the prior ", "original_text": "These were partially \noffset by increased investments in the business. "}, "hash": "8e64d68b6db17fc4863b556804df4082804ed653434a1718888875b8990e7f08", "class_name": "RelatedNodeInfo"}}, "text": "First quarter adjusted operating expenses decreased 2% year -over-year driven by \ncost mitigation efforts in response to the headwinds presented by the COVID -19 pandemic. ", "start_char_idx": 4093, "end_char_idx": 4265, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b5fda7e8-90a1-4f95-90c8-bb8c0ad1e934": {"__data__": {"id_": "b5fda7e8-90a1-4f95-90c8-bb8c0ad1e934", "embedding": null, "metadata": {"window": "Although flat to prior year, this result exceeded our original expectations for the \nquarter.  \n \n First quarter adjusted gross profit was down 4% year -over-year as lower prescription transaction volumes and mix \nwere  a result of the pandemic.  First quarter adjusted operating expenses decreased 2% year -over-year driven by \ncost mitigation efforts in response to the headwinds presented by the COVID -19 pandemic.  These were partially \noffset by increased investments in the business.  Adjusted operating profit was $707 million for the quarter, a \ndecrease of 24% as compared to the prior year.  When excluding the results of Change Healthcare from the prior ", "original_text": "These were partially \noffset by increased investments in the business. ", "page_label": "7", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5e1e3bfe-18ed-4cc7-9082-9a79812e2f1c", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "793a5abc15ad136f6b4965d2f2ee05bc8fee9de5acc167c2c4df187061eb82f8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "da118de1-f34c-45f5-b52a-10f33d67a8c5", "node_type": "1", "metadata": {"window": "Pharmaceutical and Specialty \nSolutions segment were offset by lower prescription volumes in primary care patient visits, primarily a result of the \nnegative impact from COVID -19.  Although flat to prior year, this result exceeded our original expectations for the \nquarter.  \n \n First quarter adjusted gross profit was down 4% year -over-year as lower prescription transaction volumes and mix \nwere  a result of the pandemic.  First quarter adjusted operating expenses decreased 2% year -over-year driven by \ncost mitigation efforts in response to the headwinds presented by the COVID -19 pandemic.  These were partially \noffset by increased investments in the business.  Adjusted operating profit was $707 million for the quarter, a \ndecrease of 24% as compared to the prior year.  When excluding the results of Change Healthcare from the prior ", "original_text": "First quarter adjusted operating expenses decreased 2% year -over-year driven by \ncost mitigation efforts in response to the headwinds presented by the COVID -19 pandemic. ", "page_label": "7", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "10732a83711e7fbf892a04ed46cedd97fd91d5f0fdfa3334bb3e16c40a22a158", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5ae9f0a8-9ef2-4f27-b75e-68e1dd96995c", "node_type": "1", "metadata": {"window": "First quarter adjusted gross profit was down 4% year -over-year as lower prescription transaction volumes and mix \nwere  a result of the pandemic.  First quarter adjusted operating expenses decreased 2% year -over-year driven by \ncost mitigation efforts in response to the headwinds presented by the COVID -19 pandemic.  These were partially \noffset by increased investments in the business.  Adjusted operating profit was $707 million for the quarter, a \ndecrease of 24% as compared to the prior year.  When excluding the results of Change Healthcare from the prior ", "original_text": "Adjusted operating profit was $707 million for the quarter, a \ndecrease of 24% as compared to the prior year. "}, "hash": "6e262c932e8e493522e56ccb3713d6d26e66f2029756d0f6c935453e76b8ef06", "class_name": "RelatedNodeInfo"}}, "text": "These were partially \noffset by increased investments in the business. ", "start_char_idx": 4265, "end_char_idx": 4336, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5ae9f0a8-9ef2-4f27-b75e-68e1dd96995c": {"__data__": {"id_": "5ae9f0a8-9ef2-4f27-b75e-68e1dd96995c", "embedding": null, "metadata": {"window": "First quarter adjusted gross profit was down 4% year -over-year as lower prescription transaction volumes and mix \nwere  a result of the pandemic.  First quarter adjusted operating expenses decreased 2% year -over-year driven by \ncost mitigation efforts in response to the headwinds presented by the COVID -19 pandemic.  These were partially \noffset by increased investments in the business.  Adjusted operating profit was $707 million for the quarter, a \ndecrease of 24% as compared to the prior year.  When excluding the results of Change Healthcare from the prior ", "original_text": "Adjusted operating profit was $707 million for the quarter, a \ndecrease of 24% as compared to the prior year. ", "page_label": "7", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5e1e3bfe-18ed-4cc7-9082-9a79812e2f1c", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "793a5abc15ad136f6b4965d2f2ee05bc8fee9de5acc167c2c4df187061eb82f8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b5fda7e8-90a1-4f95-90c8-bb8c0ad1e934", "node_type": "1", "metadata": {"window": "Although flat to prior year, this result exceeded our original expectations for the \nquarter.  \n \n First quarter adjusted gross profit was down 4% year -over-year as lower prescription transaction volumes and mix \nwere  a result of the pandemic.  First quarter adjusted operating expenses decreased 2% year -over-year driven by \ncost mitigation efforts in response to the headwinds presented by the COVID -19 pandemic.  These were partially \noffset by increased investments in the business.  Adjusted operating profit was $707 million for the quarter, a \ndecrease of 24% as compared to the prior year.  When excluding the results of Change Healthcare from the prior ", "original_text": "These were partially \noffset by increased investments in the business. ", "page_label": "7", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2fcc2eb6d253f3ede4ab44521f4166775a1a646730a80e5644881de298415b30", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4cdba34a-0d08-4be2-847c-08cfc5b25824", "node_type": "1", "metadata": {"window": "First quarter adjusted operating expenses decreased 2% year -over-year driven by \ncost mitigation efforts in response to the headwinds presented by the COVID -19 pandemic.  These were partially \noffset by increased investments in the business.  Adjusted operating profit was $707 million for the quarter, a \ndecrease of 24% as compared to the prior year.  When excluding the results of Change Healthcare from the prior ", "original_text": "When excluding the results of Change Healthcare from the prior "}, "hash": "20113b81c37c17b7e7e3a51ce402b41629305db3477fbb66974ee092b363d72a", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted operating profit was $707 million for the quarter, a \ndecrease of 24% as compared to the prior year. ", "start_char_idx": 4336, "end_char_idx": 4446, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4cdba34a-0d08-4be2-847c-08cfc5b25824": {"__data__": {"id_": "4cdba34a-0d08-4be2-847c-08cfc5b25824", "embedding": null, "metadata": {"window": "First quarter adjusted operating expenses decreased 2% year -over-year driven by \ncost mitigation efforts in response to the headwinds presented by the COVID -19 pandemic.  These were partially \noffset by increased investments in the business.  Adjusted operating profit was $707 million for the quarter, a \ndecrease of 24% as compared to the prior year.  When excluding the results of Change Healthcare from the prior ", "original_text": "When excluding the results of Change Healthcare from the prior ", "page_label": "7", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5e1e3bfe-18ed-4cc7-9082-9a79812e2f1c", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "793a5abc15ad136f6b4965d2f2ee05bc8fee9de5acc167c2c4df187061eb82f8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5ae9f0a8-9ef2-4f27-b75e-68e1dd96995c", "node_type": "1", "metadata": {"window": "First quarter adjusted gross profit was down 4% year -over-year as lower prescription transaction volumes and mix \nwere  a result of the pandemic.  First quarter adjusted operating expenses decreased 2% year -over-year driven by \ncost mitigation efforts in response to the headwinds presented by the COVID -19 pandemic.  These were partially \noffset by increased investments in the business.  Adjusted operating profit was $707 million for the quarter, a \ndecrease of 24% as compared to the prior year.  When excluding the results of Change Healthcare from the prior ", "original_text": "Adjusted operating profit was $707 million for the quarter, a \ndecrease of 24% as compared to the prior year. ", "page_label": "7", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "40d0685b5a78253841013b9faa58f254820786c747af1e12b3ceecbc50eb514b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "eca22406-91cf-4aae-b798-41d4bfd1efe0", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nyear, adjusted operating profit was down approximately 14%, again, ahead o f our expectations.  Interest expense \nwas $60 million in the quarter, an increase of 7% compared to the prior year.  \n \n Our adjusted tax rate was 22.3% for the quarter. ", "original_text": "McKesson Corp.  "}, "hash": "7094930354bcf10ce91044411dd2125c4f2fc26a949f6bd2cee80ebd742c5f5f", "class_name": "RelatedNodeInfo"}}, "text": "When excluding the results of Change Healthcare from the prior ", "start_char_idx": 4446, "end_char_idx": 4509, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "eca22406-91cf-4aae-b798-41d4bfd1efe0": {"__data__": {"id_": "eca22406-91cf-4aae-b798-41d4bfd1efe0", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nyear, adjusted operating profit was down approximately 14%, again, ahead o f our expectations.  Interest expense \nwas $60 million in the quarter, an increase of 7% compared to the prior year.  \n \n Our adjusted tax rate was 22.3% for the quarter. ", "original_text": "McKesson Corp.  ", "page_label": "8", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b6da9e8d-146b-433f-beae-4978bb0cbe32", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "82062705c7e888894d29ef3bbea6819854e5854c7884f1e9eeac85d774595533", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4cdba34a-0d08-4be2-847c-08cfc5b25824", "node_type": "1", "metadata": {"window": "First quarter adjusted operating expenses decreased 2% year -over-year driven by \ncost mitigation efforts in response to the headwinds presented by the COVID -19 pandemic.  These were partially \noffset by increased investments in the business.  Adjusted operating profit was $707 million for the quarter, a \ndecrease of 24% as compared to the prior year.  When excluding the results of Change Healthcare from the prior ", "original_text": "When excluding the results of Change Healthcare from the prior ", "page_label": "7", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c5fb1c8194d3c6dcd1979180db801b72aa6387043420a8f451d98cb75f28839e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b9c4e9f4-2a2d-49f0-b136-71a3f35cfcfe", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nyear, adjusted operating profit was down approximately 14%, again, ahead o f our expectations.  Interest expense \nwas $60 million in the quarter, an increase of 7% compared to the prior year.  \n \n Our adjusted tax rate was 22.3% for the quarter.  We continue to assume a full year adjusted tax rate of \napproximately 18% to 20%, which may vary from quarter -to-quarter and includes anticipated discrete tax items \nthat we expect to realize during the course of the year. ", "original_text": "(MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nyear, adjusted operating profit was down approximately 14%, again, ahead o f our expectations. "}, "hash": "03ba440f61f49f30261df969c18c8b0b8b5c77b684801e39fbf0045e7597bf18", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b9c4e9f4-2a2d-49f0-b136-71a3f35cfcfe": {"__data__": {"id_": "b9c4e9f4-2a2d-49f0-b136-71a3f35cfcfe", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nyear, adjusted operating profit was down approximately 14%, again, ahead o f our expectations.  Interest expense \nwas $60 million in the quarter, an increase of 7% compared to the prior year.  \n \n Our adjusted tax rate was 22.3% for the quarter.  We continue to assume a full year adjusted tax rate of \napproximately 18% to 20%, which may vary from quarter -to-quarter and includes anticipated discrete tax items \nthat we expect to realize during the course of the year. ", "original_text": "(MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nyear, adjusted operating profit was down approximately 14%, again, ahead o f our expectations. ", "page_label": "8", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b6da9e8d-146b-433f-beae-4978bb0cbe32", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "82062705c7e888894d29ef3bbea6819854e5854c7884f1e9eeac85d774595533", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "eca22406-91cf-4aae-b798-41d4bfd1efe0", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nyear, adjusted operating profit was down approximately 14%, again, ahead o f our expectations.  Interest expense \nwas $60 million in the quarter, an increase of 7% compared to the prior year.  \n \n Our adjusted tax rate was 22.3% for the quarter. ", "original_text": "McKesson Corp.  ", "page_label": "8", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ac73bbce5b897725bbfdafc8dfa767cd87a3b3662edd2485dc0b3bd4a1d81827", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5600640b-4eec-46e7-9223-2ce61fd9f1c2", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nyear, adjusted operating profit was down approximately 14%, again, ahead o f our expectations.  Interest expense \nwas $60 million in the quarter, an increase of 7% compared to the prior year.  \n \n Our adjusted tax rate was 22.3% for the quarter.  We continue to assume a full year adjusted tax rate of \napproximately 18% to 20%, which may vary from quarter -to-quarter and includes anticipated discrete tax items \nthat we expect to realize during the course of the year.  We anticipate recording a favorable tax discrete item in \nour fiscal second quarter, which would result in a second quarter adj usted tax rate of approximately 5% to 10%.  \n \n", "original_text": "Interest expense \nwas $60 million in the quarter, an increase of 7% compared to the prior year.  \n \n"}, "hash": "7a95a48fa922c146cd56d083d0f9918604666a8455508255fdc4e9040e2b2174", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nyear, adjusted operating profit was down approximately 14%, again, ahead o f our expectations. ", "start_char_idx": 16, "end_char_idx": 275, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5600640b-4eec-46e7-9223-2ce61fd9f1c2": {"__data__": {"id_": "5600640b-4eec-46e7-9223-2ce61fd9f1c2", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nyear, adjusted operating profit was down approximately 14%, again, ahead o f our expectations.  Interest expense \nwas $60 million in the quarter, an increase of 7% compared to the prior year.  \n \n Our adjusted tax rate was 22.3% for the quarter.  We continue to assume a full year adjusted tax rate of \napproximately 18% to 20%, which may vary from quarter -to-quarter and includes anticipated discrete tax items \nthat we expect to realize during the course of the year.  We anticipate recording a favorable tax discrete item in \nour fiscal second quarter, which would result in a second quarter adj usted tax rate of approximately 5% to 10%.  \n \n", "original_text": "Interest expense \nwas $60 million in the quarter, an increase of 7% compared to the prior year.  \n \n", "page_label": "8", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b6da9e8d-146b-433f-beae-4978bb0cbe32", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "82062705c7e888894d29ef3bbea6819854e5854c7884f1e9eeac85d774595533", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b9c4e9f4-2a2d-49f0-b136-71a3f35cfcfe", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nyear, adjusted operating profit was down approximately 14%, again, ahead o f our expectations.  Interest expense \nwas $60 million in the quarter, an increase of 7% compared to the prior year.  \n \n Our adjusted tax rate was 22.3% for the quarter.  We continue to assume a full year adjusted tax rate of \napproximately 18% to 20%, which may vary from quarter -to-quarter and includes anticipated discrete tax items \nthat we expect to realize during the course of the year. ", "original_text": "(MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nyear, adjusted operating profit was down approximately 14%, again, ahead o f our expectations. ", "page_label": "8", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "56a2f878775381cf5c45552c6b511f21ef347df6fae9dc14fd3b990482439fc7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a898a7fb-8332-407e-b716-956bcbba330c", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nyear, adjusted operating profit was down approximately 14%, again, ahead o f our expectations.  Interest expense \nwas $60 million in the quarter, an increase of 7% compared to the prior year.  \n \n Our adjusted tax rate was 22.3% for the quarter.  We continue to assume a full year adjusted tax rate of \napproximately 18% to 20%, which may vary from quarter -to-quarter and includes anticipated discrete tax items \nthat we expect to realize during the course of the year.  We anticipate recording a favorable tax discrete item in \nour fiscal second quarter, which would result in a second quarter adj usted tax rate of approximately 5% to 10%.  \n \n I would remind you that this could vary as a result of the mix of our worldwide earnings. ", "original_text": "Our adjusted tax rate was 22.3% for the quarter. "}, "hash": "61d1b70f40db01897bccbfffde8f0b5fda3465750694fb0dfabd9e91bb65db1a", "class_name": "RelatedNodeInfo"}}, "text": "Interest expense \nwas $60 million in the quarter, an increase of 7% compared to the prior year.  \n \n", "start_char_idx": 275, "end_char_idx": 375, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a898a7fb-8332-407e-b716-956bcbba330c": {"__data__": {"id_": "a898a7fb-8332-407e-b716-956bcbba330c", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nyear, adjusted operating profit was down approximately 14%, again, ahead o f our expectations.  Interest expense \nwas $60 million in the quarter, an increase of 7% compared to the prior year.  \n \n Our adjusted tax rate was 22.3% for the quarter.  We continue to assume a full year adjusted tax rate of \napproximately 18% to 20%, which may vary from quarter -to-quarter and includes anticipated discrete tax items \nthat we expect to realize during the course of the year.  We anticipate recording a favorable tax discrete item in \nour fiscal second quarter, which would result in a second quarter adj usted tax rate of approximately 5% to 10%.  \n \n I would remind you that this could vary as a result of the mix of our worldwide earnings. ", "original_text": "Our adjusted tax rate was 22.3% for the quarter. ", "page_label": "8", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b6da9e8d-146b-433f-beae-4978bb0cbe32", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "82062705c7e888894d29ef3bbea6819854e5854c7884f1e9eeac85d774595533", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5600640b-4eec-46e7-9223-2ce61fd9f1c2", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nyear, adjusted operating profit was down approximately 14%, again, ahead o f our expectations.  Interest expense \nwas $60 million in the quarter, an increase of 7% compared to the prior year.  \n \n Our adjusted tax rate was 22.3% for the quarter.  We continue to assume a full year adjusted tax rate of \napproximately 18% to 20%, which may vary from quarter -to-quarter and includes anticipated discrete tax items \nthat we expect to realize during the course of the year.  We anticipate recording a favorable tax discrete item in \nour fiscal second quarter, which would result in a second quarter adj usted tax rate of approximately 5% to 10%.  \n \n", "original_text": "Interest expense \nwas $60 million in the quarter, an increase of 7% compared to the prior year.  \n \n", "page_label": "8", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "446d1e34df54c878fec9b71666f5bf20d49512b1a688b963f2815caf518a609c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "385a8c98-94ef-4859-9bff-2b3dc925c859", "node_type": "1", "metadata": {"window": "(MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nyear, adjusted operating profit was down approximately 14%, again, ahead o f our expectations.  Interest expense \nwas $60 million in the quarter, an increase of 7% compared to the prior year.  \n \n Our adjusted tax rate was 22.3% for the quarter.  We continue to assume a full year adjusted tax rate of \napproximately 18% to 20%, which may vary from quarter -to-quarter and includes anticipated discrete tax items \nthat we expect to realize during the course of the year.  We anticipate recording a favorable tax discrete item in \nour fiscal second quarter, which would result in a second quarter adj usted tax rate of approximately 5% to 10%.  \n \n I would remind you that this could vary as a result of the mix of our worldwide earnings.  First quarter adjusted \nearnings per diluted share was $2.77, down 16% in the quarter compared to the prior year primarily driven by the \nnegative impact of the COVID -19 pandemic across the business and the lapping of prior year contribution from \nthe company's investment in Change Healthcare. ", "original_text": "We continue to assume a full year adjusted tax rate of \napproximately 18% to 20%, which may vary from quarter -to-quarter and includes anticipated discrete tax items \nthat we expect to realize during the course of the year. "}, "hash": "a94fec3ca6fbf34115a281eb285497eedbfeba159ed057d7486ba7b0dd2401ac", "class_name": "RelatedNodeInfo"}}, "text": "Our adjusted tax rate was 22.3% for the quarter. ", "start_char_idx": 375, "end_char_idx": 424, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "385a8c98-94ef-4859-9bff-2b3dc925c859": {"__data__": {"id_": "385a8c98-94ef-4859-9bff-2b3dc925c859", "embedding": null, "metadata": {"window": "(MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nyear, adjusted operating profit was down approximately 14%, again, ahead o f our expectations.  Interest expense \nwas $60 million in the quarter, an increase of 7% compared to the prior year.  \n \n Our adjusted tax rate was 22.3% for the quarter.  We continue to assume a full year adjusted tax rate of \napproximately 18% to 20%, which may vary from quarter -to-quarter and includes anticipated discrete tax items \nthat we expect to realize during the course of the year.  We anticipate recording a favorable tax discrete item in \nour fiscal second quarter, which would result in a second quarter adj usted tax rate of approximately 5% to 10%.  \n \n I would remind you that this could vary as a result of the mix of our worldwide earnings.  First quarter adjusted \nearnings per diluted share was $2.77, down 16% in the quarter compared to the prior year primarily driven by the \nnegative impact of the COVID -19 pandemic across the business and the lapping of prior year contribution from \nthe company's investment in Change Healthcare. ", "original_text": "We continue to assume a full year adjusted tax rate of \napproximately 18% to 20%, which may vary from quarter -to-quarter and includes anticipated discrete tax items \nthat we expect to realize during the course of the year. ", "page_label": "8", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b6da9e8d-146b-433f-beae-4978bb0cbe32", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "82062705c7e888894d29ef3bbea6819854e5854c7884f1e9eeac85d774595533", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a898a7fb-8332-407e-b716-956bcbba330c", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nyear, adjusted operating profit was down approximately 14%, again, ahead o f our expectations.  Interest expense \nwas $60 million in the quarter, an increase of 7% compared to the prior year.  \n \n Our adjusted tax rate was 22.3% for the quarter.  We continue to assume a full year adjusted tax rate of \napproximately 18% to 20%, which may vary from quarter -to-quarter and includes anticipated discrete tax items \nthat we expect to realize during the course of the year.  We anticipate recording a favorable tax discrete item in \nour fiscal second quarter, which would result in a second quarter adj usted tax rate of approximately 5% to 10%.  \n \n I would remind you that this could vary as a result of the mix of our worldwide earnings. ", "original_text": "Our adjusted tax rate was 22.3% for the quarter. ", "page_label": "8", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7f2f352a70febf22b4504ad1fb1cb78cb12189e6f8348781b7cbc92705f7a71c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ed080ebe-2e32-4cfd-9902-71552dfff084", "node_type": "1", "metadata": {"window": "Interest expense \nwas $60 million in the quarter, an increase of 7% compared to the prior year.  \n \n Our adjusted tax rate was 22.3% for the quarter.  We continue to assume a full year adjusted tax rate of \napproximately 18% to 20%, which may vary from quarter -to-quarter and includes anticipated discrete tax items \nthat we expect to realize during the course of the year.  We anticipate recording a favorable tax discrete item in \nour fiscal second quarter, which would result in a second quarter adj usted tax rate of approximately 5% to 10%.  \n \n I would remind you that this could vary as a result of the mix of our worldwide earnings.  First quarter adjusted \nearnings per diluted share was $2.77, down 16% in the quarter compared to the prior year primarily driven by the \nnegative impact of the COVID -19 pandemic across the business and the lapping of prior year contribution from \nthe company's investment in Change Healthcare.  These items were partially offset by a lower share count \ncompared to the prior year.  \n \n", "original_text": "We anticipate recording a favorable tax discrete item in \nour fiscal second quarter, which would result in a second quarter adj usted tax rate of approximately 5% to 10%.  \n \n"}, "hash": "8473f4461f87e0f7711591b60615cbe65fd9035b50153da4519e2259963f051b", "class_name": "RelatedNodeInfo"}}, "text": "We continue to assume a full year adjusted tax rate of \napproximately 18% to 20%, which may vary from quarter -to-quarter and includes anticipated discrete tax items \nthat we expect to realize during the course of the year. ", "start_char_idx": 424, "end_char_idx": 648, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ed080ebe-2e32-4cfd-9902-71552dfff084": {"__data__": {"id_": "ed080ebe-2e32-4cfd-9902-71552dfff084", "embedding": null, "metadata": {"window": "Interest expense \nwas $60 million in the quarter, an increase of 7% compared to the prior year.  \n \n Our adjusted tax rate was 22.3% for the quarter.  We continue to assume a full year adjusted tax rate of \napproximately 18% to 20%, which may vary from quarter -to-quarter and includes anticipated discrete tax items \nthat we expect to realize during the course of the year.  We anticipate recording a favorable tax discrete item in \nour fiscal second quarter, which would result in a second quarter adj usted tax rate of approximately 5% to 10%.  \n \n I would remind you that this could vary as a result of the mix of our worldwide earnings.  First quarter adjusted \nearnings per diluted share was $2.77, down 16% in the quarter compared to the prior year primarily driven by the \nnegative impact of the COVID -19 pandemic across the business and the lapping of prior year contribution from \nthe company's investment in Change Healthcare.  These items were partially offset by a lower share count \ncompared to the prior year.  \n \n", "original_text": "We anticipate recording a favorable tax discrete item in \nour fiscal second quarter, which would result in a second quarter adj usted tax rate of approximately 5% to 10%.  \n \n", "page_label": "8", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b6da9e8d-146b-433f-beae-4978bb0cbe32", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "82062705c7e888894d29ef3bbea6819854e5854c7884f1e9eeac85d774595533", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "385a8c98-94ef-4859-9bff-2b3dc925c859", "node_type": "1", "metadata": {"window": "(MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nyear, adjusted operating profit was down approximately 14%, again, ahead o f our expectations.  Interest expense \nwas $60 million in the quarter, an increase of 7% compared to the prior year.  \n \n Our adjusted tax rate was 22.3% for the quarter.  We continue to assume a full year adjusted tax rate of \napproximately 18% to 20%, which may vary from quarter -to-quarter and includes anticipated discrete tax items \nthat we expect to realize during the course of the year.  We anticipate recording a favorable tax discrete item in \nour fiscal second quarter, which would result in a second quarter adj usted tax rate of approximately 5% to 10%.  \n \n I would remind you that this could vary as a result of the mix of our worldwide earnings.  First quarter adjusted \nearnings per diluted share was $2.77, down 16% in the quarter compared to the prior year primarily driven by the \nnegative impact of the COVID -19 pandemic across the business and the lapping of prior year contribution from \nthe company's investment in Change Healthcare. ", "original_text": "We continue to assume a full year adjusted tax rate of \napproximately 18% to 20%, which may vary from quarter -to-quarter and includes anticipated discrete tax items \nthat we expect to realize during the course of the year. ", "page_label": "8", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d388e02956e9e02114b4bb7636d39b7337da6cafcc62ad70cfdcebbf6678a77b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1a6477c9-4fd8-46da-b820-1eb23903953e", "node_type": "1", "metadata": {"window": "Our adjusted tax rate was 22.3% for the quarter.  We continue to assume a full year adjusted tax rate of \napproximately 18% to 20%, which may vary from quarter -to-quarter and includes anticipated discrete tax items \nthat we expect to realize during the course of the year.  We anticipate recording a favorable tax discrete item in \nour fiscal second quarter, which would result in a second quarter adj usted tax rate of approximately 5% to 10%.  \n \n I would remind you that this could vary as a result of the mix of our worldwide earnings.  First quarter adjusted \nearnings per diluted share was $2.77, down 16% in the quarter compared to the prior year primarily driven by the \nnegative impact of the COVID -19 pandemic across the business and the lapping of prior year contribution from \nthe company's investment in Change Healthcare.  These items were partially offset by a lower share count \ncompared to the prior year.  \n \n In wrapping up our consolidated results, our first quarter diluted weighted average shares were 163 million, a \ndecrease of 14% year -over-year driven by the successful exit of our investment in Change Healthcare, which \nlowered our shares outstanding by appr oximately 15.4 million shares and due to prior year share repurchases.  \n \n", "original_text": "I would remind you that this could vary as a result of the mix of our worldwide earnings. "}, "hash": "50ebddb4c42c99474069f105dd6c186974bab252557b5bc85fadb94b02680e84", "class_name": "RelatedNodeInfo"}}, "text": "We anticipate recording a favorable tax discrete item in \nour fiscal second quarter, which would result in a second quarter adj usted tax rate of approximately 5% to 10%.  \n \n", "start_char_idx": 648, "end_char_idx": 823, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1a6477c9-4fd8-46da-b820-1eb23903953e": {"__data__": {"id_": "1a6477c9-4fd8-46da-b820-1eb23903953e", "embedding": null, "metadata": {"window": "Our adjusted tax rate was 22.3% for the quarter.  We continue to assume a full year adjusted tax rate of \napproximately 18% to 20%, which may vary from quarter -to-quarter and includes anticipated discrete tax items \nthat we expect to realize during the course of the year.  We anticipate recording a favorable tax discrete item in \nour fiscal second quarter, which would result in a second quarter adj usted tax rate of approximately 5% to 10%.  \n \n I would remind you that this could vary as a result of the mix of our worldwide earnings.  First quarter adjusted \nearnings per diluted share was $2.77, down 16% in the quarter compared to the prior year primarily driven by the \nnegative impact of the COVID -19 pandemic across the business and the lapping of prior year contribution from \nthe company's investment in Change Healthcare.  These items were partially offset by a lower share count \ncompared to the prior year.  \n \n In wrapping up our consolidated results, our first quarter diluted weighted average shares were 163 million, a \ndecrease of 14% year -over-year driven by the successful exit of our investment in Change Healthcare, which \nlowered our shares outstanding by appr oximately 15.4 million shares and due to prior year share repurchases.  \n \n", "original_text": "I would remind you that this could vary as a result of the mix of our worldwide earnings. ", "page_label": "8", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b6da9e8d-146b-433f-beae-4978bb0cbe32", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "82062705c7e888894d29ef3bbea6819854e5854c7884f1e9eeac85d774595533", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ed080ebe-2e32-4cfd-9902-71552dfff084", "node_type": "1", "metadata": {"window": "Interest expense \nwas $60 million in the quarter, an increase of 7% compared to the prior year.  \n \n Our adjusted tax rate was 22.3% for the quarter.  We continue to assume a full year adjusted tax rate of \napproximately 18% to 20%, which may vary from quarter -to-quarter and includes anticipated discrete tax items \nthat we expect to realize during the course of the year.  We anticipate recording a favorable tax discrete item in \nour fiscal second quarter, which would result in a second quarter adj usted tax rate of approximately 5% to 10%.  \n \n I would remind you that this could vary as a result of the mix of our worldwide earnings.  First quarter adjusted \nearnings per diluted share was $2.77, down 16% in the quarter compared to the prior year primarily driven by the \nnegative impact of the COVID -19 pandemic across the business and the lapping of prior year contribution from \nthe company's investment in Change Healthcare.  These items were partially offset by a lower share count \ncompared to the prior year.  \n \n", "original_text": "We anticipate recording a favorable tax discrete item in \nour fiscal second quarter, which would result in a second quarter adj usted tax rate of approximately 5% to 10%.  \n \n", "page_label": "8", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e180750b83bcff5ba5d093b8e80c4207b311662930dcf4942b8dc117633f9021", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1afa4feb-77b2-460d-a06c-3f2d49df1768", "node_type": "1", "metadata": {"window": "We continue to assume a full year adjusted tax rate of \napproximately 18% to 20%, which may vary from quarter -to-quarter and includes anticipated discrete tax items \nthat we expect to realize during the course of the year.  We anticipate recording a favorable tax discrete item in \nour fiscal second quarter, which would result in a second quarter adj usted tax rate of approximately 5% to 10%.  \n \n I would remind you that this could vary as a result of the mix of our worldwide earnings.  First quarter adjusted \nearnings per diluted share was $2.77, down 16% in the quarter compared to the prior year primarily driven by the \nnegative impact of the COVID -19 pandemic across the business and the lapping of prior year contribution from \nthe company's investment in Change Healthcare.  These items were partially offset by a lower share count \ncompared to the prior year.  \n \n In wrapping up our consolidated results, our first quarter diluted weighted average shares were 163 million, a \ndecrease of 14% year -over-year driven by the successful exit of our investment in Change Healthcare, which \nlowered our shares outstanding by appr oximately 15.4 million shares and due to prior year share repurchases.  \n \n Next, I'll review our segment results, which can be found on slides 5 through 7, and I'll start with U.S. \n", "original_text": "First quarter adjusted \nearnings per diluted share was $2.77, down 16% in the quarter compared to the prior year primarily driven by the \nnegative impact of the COVID -19 pandemic across the business and the lapping of prior year contribution from \nthe company's investment in Change Healthcare. "}, "hash": "3f471d2b8201e6294a82a00500d0063bce7e2bedfcdcb0ab52f9fca94d89009f", "class_name": "RelatedNodeInfo"}}, "text": "I would remind you that this could vary as a result of the mix of our worldwide earnings. ", "start_char_idx": 823, "end_char_idx": 913, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1afa4feb-77b2-460d-a06c-3f2d49df1768": {"__data__": {"id_": "1afa4feb-77b2-460d-a06c-3f2d49df1768", "embedding": null, "metadata": {"window": "We continue to assume a full year adjusted tax rate of \napproximately 18% to 20%, which may vary from quarter -to-quarter and includes anticipated discrete tax items \nthat we expect to realize during the course of the year.  We anticipate recording a favorable tax discrete item in \nour fiscal second quarter, which would result in a second quarter adj usted tax rate of approximately 5% to 10%.  \n \n I would remind you that this could vary as a result of the mix of our worldwide earnings.  First quarter adjusted \nearnings per diluted share was $2.77, down 16% in the quarter compared to the prior year primarily driven by the \nnegative impact of the COVID -19 pandemic across the business and the lapping of prior year contribution from \nthe company's investment in Change Healthcare.  These items were partially offset by a lower share count \ncompared to the prior year.  \n \n In wrapping up our consolidated results, our first quarter diluted weighted average shares were 163 million, a \ndecrease of 14% year -over-year driven by the successful exit of our investment in Change Healthcare, which \nlowered our shares outstanding by appr oximately 15.4 million shares and due to prior year share repurchases.  \n \n Next, I'll review our segment results, which can be found on slides 5 through 7, and I'll start with U.S. \n", "original_text": "First quarter adjusted \nearnings per diluted share was $2.77, down 16% in the quarter compared to the prior year primarily driven by the \nnegative impact of the COVID -19 pandemic across the business and the lapping of prior year contribution from \nthe company's investment in Change Healthcare. ", "page_label": "8", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b6da9e8d-146b-433f-beae-4978bb0cbe32", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "82062705c7e888894d29ef3bbea6819854e5854c7884f1e9eeac85d774595533", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1a6477c9-4fd8-46da-b820-1eb23903953e", "node_type": "1", "metadata": {"window": "Our adjusted tax rate was 22.3% for the quarter.  We continue to assume a full year adjusted tax rate of \napproximately 18% to 20%, which may vary from quarter -to-quarter and includes anticipated discrete tax items \nthat we expect to realize during the course of the year.  We anticipate recording a favorable tax discrete item in \nour fiscal second quarter, which would result in a second quarter adj usted tax rate of approximately 5% to 10%.  \n \n I would remind you that this could vary as a result of the mix of our worldwide earnings.  First quarter adjusted \nearnings per diluted share was $2.77, down 16% in the quarter compared to the prior year primarily driven by the \nnegative impact of the COVID -19 pandemic across the business and the lapping of prior year contribution from \nthe company's investment in Change Healthcare.  These items were partially offset by a lower share count \ncompared to the prior year.  \n \n In wrapping up our consolidated results, our first quarter diluted weighted average shares were 163 million, a \ndecrease of 14% year -over-year driven by the successful exit of our investment in Change Healthcare, which \nlowered our shares outstanding by appr oximately 15.4 million shares and due to prior year share repurchases.  \n \n", "original_text": "I would remind you that this could vary as a result of the mix of our worldwide earnings. ", "page_label": "8", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5f6e14a609fd2561a70ef3fb2a3cbd5fb69e35936cf5fb0c9fad2809fe08ff2c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bd2928bb-4754-4a89-a432-442cab27f9c2", "node_type": "1", "metadata": {"window": "We anticipate recording a favorable tax discrete item in \nour fiscal second quarter, which would result in a second quarter adj usted tax rate of approximately 5% to 10%.  \n \n I would remind you that this could vary as a result of the mix of our worldwide earnings.  First quarter adjusted \nearnings per diluted share was $2.77, down 16% in the quarter compared to the prior year primarily driven by the \nnegative impact of the COVID -19 pandemic across the business and the lapping of prior year contribution from \nthe company's investment in Change Healthcare.  These items were partially offset by a lower share count \ncompared to the prior year.  \n \n In wrapping up our consolidated results, our first quarter diluted weighted average shares were 163 million, a \ndecrease of 14% year -over-year driven by the successful exit of our investment in Change Healthcare, which \nlowered our shares outstanding by appr oximately 15.4 million shares and due to prior year share repurchases.  \n \n Next, I'll review our segment results, which can be found on slides 5 through 7, and I'll start with U.S. \n Pharmaceutical and Specialty Solutions. ", "original_text": "These items were partially offset by a lower share count \ncompared to the prior year.  \n \n"}, "hash": "db4d31976c362ed2e20230c55cadba2638d4a267871c962d7aaa6964c379da87", "class_name": "RelatedNodeInfo"}}, "text": "First quarter adjusted \nearnings per diluted share was $2.77, down 16% in the quarter compared to the prior year primarily driven by the \nnegative impact of the COVID -19 pandemic across the business and the lapping of prior year contribution from \nthe company's investment in Change Healthcare. ", "start_char_idx": 913, "end_char_idx": 1209, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bd2928bb-4754-4a89-a432-442cab27f9c2": {"__data__": {"id_": "bd2928bb-4754-4a89-a432-442cab27f9c2", "embedding": null, "metadata": {"window": "We anticipate recording a favorable tax discrete item in \nour fiscal second quarter, which would result in a second quarter adj usted tax rate of approximately 5% to 10%.  \n \n I would remind you that this could vary as a result of the mix of our worldwide earnings.  First quarter adjusted \nearnings per diluted share was $2.77, down 16% in the quarter compared to the prior year primarily driven by the \nnegative impact of the COVID -19 pandemic across the business and the lapping of prior year contribution from \nthe company's investment in Change Healthcare.  These items were partially offset by a lower share count \ncompared to the prior year.  \n \n In wrapping up our consolidated results, our first quarter diluted weighted average shares were 163 million, a \ndecrease of 14% year -over-year driven by the successful exit of our investment in Change Healthcare, which \nlowered our shares outstanding by appr oximately 15.4 million shares and due to prior year share repurchases.  \n \n Next, I'll review our segment results, which can be found on slides 5 through 7, and I'll start with U.S. \n Pharmaceutical and Specialty Solutions. ", "original_text": "These items were partially offset by a lower share count \ncompared to the prior year.  \n \n", "page_label": "8", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b6da9e8d-146b-433f-beae-4978bb0cbe32", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "82062705c7e888894d29ef3bbea6819854e5854c7884f1e9eeac85d774595533", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1afa4feb-77b2-460d-a06c-3f2d49df1768", "node_type": "1", "metadata": {"window": "We continue to assume a full year adjusted tax rate of \napproximately 18% to 20%, which may vary from quarter -to-quarter and includes anticipated discrete tax items \nthat we expect to realize during the course of the year.  We anticipate recording a favorable tax discrete item in \nour fiscal second quarter, which would result in a second quarter adj usted tax rate of approximately 5% to 10%.  \n \n I would remind you that this could vary as a result of the mix of our worldwide earnings.  First quarter adjusted \nearnings per diluted share was $2.77, down 16% in the quarter compared to the prior year primarily driven by the \nnegative impact of the COVID -19 pandemic across the business and the lapping of prior year contribution from \nthe company's investment in Change Healthcare.  These items were partially offset by a lower share count \ncompared to the prior year.  \n \n In wrapping up our consolidated results, our first quarter diluted weighted average shares were 163 million, a \ndecrease of 14% year -over-year driven by the successful exit of our investment in Change Healthcare, which \nlowered our shares outstanding by appr oximately 15.4 million shares and due to prior year share repurchases.  \n \n Next, I'll review our segment results, which can be found on slides 5 through 7, and I'll start with U.S. \n", "original_text": "First quarter adjusted \nearnings per diluted share was $2.77, down 16% in the quarter compared to the prior year primarily driven by the \nnegative impact of the COVID -19 pandemic across the business and the lapping of prior year contribution from \nthe company's investment in Change Healthcare. ", "page_label": "8", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "91e0174357d8477124ad46ddc861c33e411ffd45edc5fb3c84bcac4757a2ac67", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "affd00e5-c760-4d67-bf70-e3bada39f368", "node_type": "1", "metadata": {"window": "I would remind you that this could vary as a result of the mix of our worldwide earnings.  First quarter adjusted \nearnings per diluted share was $2.77, down 16% in the quarter compared to the prior year primarily driven by the \nnegative impact of the COVID -19 pandemic across the business and the lapping of prior year contribution from \nthe company's investment in Change Healthcare.  These items were partially offset by a lower share count \ncompared to the prior year.  \n \n In wrapping up our consolidated results, our first quarter diluted weighted average shares were 163 million, a \ndecrease of 14% year -over-year driven by the successful exit of our investment in Change Healthcare, which \nlowered our shares outstanding by appr oximately 15.4 million shares and due to prior year share repurchases.  \n \n Next, I'll review our segment results, which can be found on slides 5 through 7, and I'll start with U.S. \n Pharmaceutical and Specialty Solutions.  Revenues were $45.1 billion for the quarter, which were up 2% driven by \nmarket growth and higher retail national account volumes. ", "original_text": "In wrapping up our consolidated results, our first quarter diluted weighted average shares were 163 million, a \ndecrease of 14% year -over-year driven by the successful exit of our investment in Change Healthcare, which \nlowered our shares outstanding by appr oximately 15.4 million shares and due to prior year share repurchases.  \n \n"}, "hash": "d5222c5ebdc5269baf13d8e2fb9f902df0dee67b2689fd27ef7fe92480d5809e", "class_name": "RelatedNodeInfo"}}, "text": "These items were partially offset by a lower share count \ncompared to the prior year.  \n \n", "start_char_idx": 1209, "end_char_idx": 1299, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "affd00e5-c760-4d67-bf70-e3bada39f368": {"__data__": {"id_": "affd00e5-c760-4d67-bf70-e3bada39f368", "embedding": null, "metadata": {"window": "I would remind you that this could vary as a result of the mix of our worldwide earnings.  First quarter adjusted \nearnings per diluted share was $2.77, down 16% in the quarter compared to the prior year primarily driven by the \nnegative impact of the COVID -19 pandemic across the business and the lapping of prior year contribution from \nthe company's investment in Change Healthcare.  These items were partially offset by a lower share count \ncompared to the prior year.  \n \n In wrapping up our consolidated results, our first quarter diluted weighted average shares were 163 million, a \ndecrease of 14% year -over-year driven by the successful exit of our investment in Change Healthcare, which \nlowered our shares outstanding by appr oximately 15.4 million shares and due to prior year share repurchases.  \n \n Next, I'll review our segment results, which can be found on slides 5 through 7, and I'll start with U.S. \n Pharmaceutical and Specialty Solutions.  Revenues were $45.1 billion for the quarter, which were up 2% driven by \nmarket growth and higher retail national account volumes. ", "original_text": "In wrapping up our consolidated results, our first quarter diluted weighted average shares were 163 million, a \ndecrease of 14% year -over-year driven by the successful exit of our investment in Change Healthcare, which \nlowered our shares outstanding by appr oximately 15.4 million shares and due to prior year share repurchases.  \n \n", "page_label": "8", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b6da9e8d-146b-433f-beae-4978bb0cbe32", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "82062705c7e888894d29ef3bbea6819854e5854c7884f1e9eeac85d774595533", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bd2928bb-4754-4a89-a432-442cab27f9c2", "node_type": "1", "metadata": {"window": "We anticipate recording a favorable tax discrete item in \nour fiscal second quarter, which would result in a second quarter adj usted tax rate of approximately 5% to 10%.  \n \n I would remind you that this could vary as a result of the mix of our worldwide earnings.  First quarter adjusted \nearnings per diluted share was $2.77, down 16% in the quarter compared to the prior year primarily driven by the \nnegative impact of the COVID -19 pandemic across the business and the lapping of prior year contribution from \nthe company's investment in Change Healthcare.  These items were partially offset by a lower share count \ncompared to the prior year.  \n \n In wrapping up our consolidated results, our first quarter diluted weighted average shares were 163 million, a \ndecrease of 14% year -over-year driven by the successful exit of our investment in Change Healthcare, which \nlowered our shares outstanding by appr oximately 15.4 million shares and due to prior year share repurchases.  \n \n Next, I'll review our segment results, which can be found on slides 5 through 7, and I'll start with U.S. \n Pharmaceutical and Specialty Solutions. ", "original_text": "These items were partially offset by a lower share count \ncompared to the prior year.  \n \n", "page_label": "8", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "43bdf10519130f995440e91af6bab8759252e5a2e8fda1e64a8a22b254ffcf9e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7076c7d3-51dc-40f8-b83f-274bd0b55063", "node_type": "1", "metadata": {"window": "First quarter adjusted \nearnings per diluted share was $2.77, down 16% in the quarter compared to the prior year primarily driven by the \nnegative impact of the COVID -19 pandemic across the business and the lapping of prior year contribution from \nthe company's investment in Change Healthcare.  These items were partially offset by a lower share count \ncompared to the prior year.  \n \n In wrapping up our consolidated results, our first quarter diluted weighted average shares were 163 million, a \ndecrease of 14% year -over-year driven by the successful exit of our investment in Change Healthcare, which \nlowered our shares outstanding by appr oximately 15.4 million shares and due to prior year share repurchases.  \n \n Next, I'll review our segment results, which can be found on slides 5 through 7, and I'll start with U.S. \n Pharmaceutical and Specialty Solutions.  Revenues were $45.1 billion for the quarter, which were up 2% driven by \nmarket growth and higher retail national account volumes.  This was partially offset by branded generic \nconversions and the negative impact of COVID -19 on prescription transaction volumes.  \n \n", "original_text": "Next, I'll review our segment results, which can be found on slides 5 through 7, and I'll start with U.S. \n"}, "hash": "ca4c33847b4bbb076d76539d4ce03664914a01f2abf45b3021c3c0254d12553d", "class_name": "RelatedNodeInfo"}}, "text": "In wrapping up our consolidated results, our first quarter diluted weighted average shares were 163 million, a \ndecrease of 14% year -over-year driven by the successful exit of our investment in Change Healthcare, which \nlowered our shares outstanding by appr oximately 15.4 million shares and due to prior year share repurchases.  \n \n", "start_char_idx": 1299, "end_char_idx": 1634, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7076c7d3-51dc-40f8-b83f-274bd0b55063": {"__data__": {"id_": "7076c7d3-51dc-40f8-b83f-274bd0b55063", "embedding": null, "metadata": {"window": "First quarter adjusted \nearnings per diluted share was $2.77, down 16% in the quarter compared to the prior year primarily driven by the \nnegative impact of the COVID -19 pandemic across the business and the lapping of prior year contribution from \nthe company's investment in Change Healthcare.  These items were partially offset by a lower share count \ncompared to the prior year.  \n \n In wrapping up our consolidated results, our first quarter diluted weighted average shares were 163 million, a \ndecrease of 14% year -over-year driven by the successful exit of our investment in Change Healthcare, which \nlowered our shares outstanding by appr oximately 15.4 million shares and due to prior year share repurchases.  \n \n Next, I'll review our segment results, which can be found on slides 5 through 7, and I'll start with U.S. \n Pharmaceutical and Specialty Solutions.  Revenues were $45.1 billion for the quarter, which were up 2% driven by \nmarket growth and higher retail national account volumes.  This was partially offset by branded generic \nconversions and the negative impact of COVID -19 on prescription transaction volumes.  \n \n", "original_text": "Next, I'll review our segment results, which can be found on slides 5 through 7, and I'll start with U.S. \n", "page_label": "8", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b6da9e8d-146b-433f-beae-4978bb0cbe32", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "82062705c7e888894d29ef3bbea6819854e5854c7884f1e9eeac85d774595533", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "affd00e5-c760-4d67-bf70-e3bada39f368", "node_type": "1", "metadata": {"window": "I would remind you that this could vary as a result of the mix of our worldwide earnings.  First quarter adjusted \nearnings per diluted share was $2.77, down 16% in the quarter compared to the prior year primarily driven by the \nnegative impact of the COVID -19 pandemic across the business and the lapping of prior year contribution from \nthe company's investment in Change Healthcare.  These items were partially offset by a lower share count \ncompared to the prior year.  \n \n In wrapping up our consolidated results, our first quarter diluted weighted average shares were 163 million, a \ndecrease of 14% year -over-year driven by the successful exit of our investment in Change Healthcare, which \nlowered our shares outstanding by appr oximately 15.4 million shares and due to prior year share repurchases.  \n \n Next, I'll review our segment results, which can be found on slides 5 through 7, and I'll start with U.S. \n Pharmaceutical and Specialty Solutions.  Revenues were $45.1 billion for the quarter, which were up 2% driven by \nmarket growth and higher retail national account volumes. ", "original_text": "In wrapping up our consolidated results, our first quarter diluted weighted average shares were 163 million, a \ndecrease of 14% year -over-year driven by the successful exit of our investment in Change Healthcare, which \nlowered our shares outstanding by appr oximately 15.4 million shares and due to prior year share repurchases.  \n \n", "page_label": "8", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e3d17d1090494a85765f0e694b1d8454427553bd8f0938cebda67429c4cc521a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "453fd921-2380-47bb-8d3e-fa840e0add66", "node_type": "1", "metadata": {"window": "These items were partially offset by a lower share count \ncompared to the prior year.  \n \n In wrapping up our consolidated results, our first quarter diluted weighted average shares were 163 million, a \ndecrease of 14% year -over-year driven by the successful exit of our investment in Change Healthcare, which \nlowered our shares outstanding by appr oximately 15.4 million shares and due to prior year share repurchases.  \n \n Next, I'll review our segment results, which can be found on slides 5 through 7, and I'll start with U.S. \n Pharmaceutical and Specialty Solutions.  Revenues were $45.1 billion for the quarter, which were up 2% driven by \nmarket growth and higher retail national account volumes.  This was partially offset by branded generic \nconversions and the negative impact of COVID -19 on prescription transaction volumes.  \n \n Prescription transaction volumes were uneven in April and May, improved throughout the quarter and were above \nour expectations in June. ", "original_text": "Pharmaceutical and Specialty Solutions. "}, "hash": "8d687705742ec1927cd2d53c1a12f63fe2c08ea689e6e59c49b8008d4fbc545f", "class_name": "RelatedNodeInfo"}}, "text": "Next, I'll review our segment results, which can be found on slides 5 through 7, and I'll start with U.S. \n", "start_char_idx": 1634, "end_char_idx": 1741, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "453fd921-2380-47bb-8d3e-fa840e0add66": {"__data__": {"id_": "453fd921-2380-47bb-8d3e-fa840e0add66", "embedding": null, "metadata": {"window": "These items were partially offset by a lower share count \ncompared to the prior year.  \n \n In wrapping up our consolidated results, our first quarter diluted weighted average shares were 163 million, a \ndecrease of 14% year -over-year driven by the successful exit of our investment in Change Healthcare, which \nlowered our shares outstanding by appr oximately 15.4 million shares and due to prior year share repurchases.  \n \n Next, I'll review our segment results, which can be found on slides 5 through 7, and I'll start with U.S. \n Pharmaceutical and Specialty Solutions.  Revenues were $45.1 billion for the quarter, which were up 2% driven by \nmarket growth and higher retail national account volumes.  This was partially offset by branded generic \nconversions and the negative impact of COVID -19 on prescription transaction volumes.  \n \n Prescription transaction volumes were uneven in April and May, improved throughout the quarter and were above \nour expectations in June. ", "original_text": "Pharmaceutical and Specialty Solutions. ", "page_label": "8", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b6da9e8d-146b-433f-beae-4978bb0cbe32", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "82062705c7e888894d29ef3bbea6819854e5854c7884f1e9eeac85d774595533", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7076c7d3-51dc-40f8-b83f-274bd0b55063", "node_type": "1", "metadata": {"window": "First quarter adjusted \nearnings per diluted share was $2.77, down 16% in the quarter compared to the prior year primarily driven by the \nnegative impact of the COVID -19 pandemic across the business and the lapping of prior year contribution from \nthe company's investment in Change Healthcare.  These items were partially offset by a lower share count \ncompared to the prior year.  \n \n In wrapping up our consolidated results, our first quarter diluted weighted average shares were 163 million, a \ndecrease of 14% year -over-year driven by the successful exit of our investment in Change Healthcare, which \nlowered our shares outstanding by appr oximately 15.4 million shares and due to prior year share repurchases.  \n \n Next, I'll review our segment results, which can be found on slides 5 through 7, and I'll start with U.S. \n Pharmaceutical and Specialty Solutions.  Revenues were $45.1 billion for the quarter, which were up 2% driven by \nmarket growth and higher retail national account volumes.  This was partially offset by branded generic \nconversions and the negative impact of COVID -19 on prescription transaction volumes.  \n \n", "original_text": "Next, I'll review our segment results, which can be found on slides 5 through 7, and I'll start with U.S. \n", "page_label": "8", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b1c6a54486badc9e25f918640647e16fec548cd7f6b4274fe92f20744cbefc7c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6ed1b786-d677-4a88-8886-141ce9b139d2", "node_type": "1", "metadata": {"window": "In wrapping up our consolidated results, our first quarter diluted weighted average shares were 163 million, a \ndecrease of 14% year -over-year driven by the successful exit of our investment in Change Healthcare, which \nlowered our shares outstanding by appr oximately 15.4 million shares and due to prior year share repurchases.  \n \n Next, I'll review our segment results, which can be found on slides 5 through 7, and I'll start with U.S. \n Pharmaceutical and Specialty Solutions.  Revenues were $45.1 billion for the quarter, which were up 2% driven by \nmarket growth and higher retail national account volumes.  This was partially offset by branded generic \nconversions and the negative impact of COVID -19 on prescription transaction volumes.  \n \n Prescription transaction volumes were uneven in April and May, improved throughout the quarter and were above \nour expectations in June.  Oncology visits were approximately 70% of pre -pandemic levels in April, however, \nimproved to over 95% in June. ", "original_text": "Revenues were $45.1 billion for the quarter, which were up 2% driven by \nmarket growth and higher retail national account volumes. "}, "hash": "b175ec3c530d1d26bee35ba02d473135f1654aeb70a67a2110a15fa404595890", "class_name": "RelatedNodeInfo"}}, "text": "Pharmaceutical and Specialty Solutions. ", "start_char_idx": 1741, "end_char_idx": 1781, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6ed1b786-d677-4a88-8886-141ce9b139d2": {"__data__": {"id_": "6ed1b786-d677-4a88-8886-141ce9b139d2", "embedding": null, "metadata": {"window": "In wrapping up our consolidated results, our first quarter diluted weighted average shares were 163 million, a \ndecrease of 14% year -over-year driven by the successful exit of our investment in Change Healthcare, which \nlowered our shares outstanding by appr oximately 15.4 million shares and due to prior year share repurchases.  \n \n Next, I'll review our segment results, which can be found on slides 5 through 7, and I'll start with U.S. \n Pharmaceutical and Specialty Solutions.  Revenues were $45.1 billion for the quarter, which were up 2% driven by \nmarket growth and higher retail national account volumes.  This was partially offset by branded generic \nconversions and the negative impact of COVID -19 on prescription transaction volumes.  \n \n Prescription transaction volumes were uneven in April and May, improved throughout the quarter and were above \nour expectations in June.  Oncology visits were approximately 70% of pre -pandemic levels in April, however, \nimproved to over 95% in June. ", "original_text": "Revenues were $45.1 billion for the quarter, which were up 2% driven by \nmarket growth and higher retail national account volumes. ", "page_label": "8", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b6da9e8d-146b-433f-beae-4978bb0cbe32", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "82062705c7e888894d29ef3bbea6819854e5854c7884f1e9eeac85d774595533", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "453fd921-2380-47bb-8d3e-fa840e0add66", "node_type": "1", "metadata": {"window": "These items were partially offset by a lower share count \ncompared to the prior year.  \n \n In wrapping up our consolidated results, our first quarter diluted weighted average shares were 163 million, a \ndecrease of 14% year -over-year driven by the successful exit of our investment in Change Healthcare, which \nlowered our shares outstanding by appr oximately 15.4 million shares and due to prior year share repurchases.  \n \n Next, I'll review our segment results, which can be found on slides 5 through 7, and I'll start with U.S. \n Pharmaceutical and Specialty Solutions.  Revenues were $45.1 billion for the quarter, which were up 2% driven by \nmarket growth and higher retail national account volumes.  This was partially offset by branded generic \nconversions and the negative impact of COVID -19 on prescription transaction volumes.  \n \n Prescription transaction volumes were uneven in April and May, improved throughout the quarter and were above \nour expectations in June. ", "original_text": "Pharmaceutical and Specialty Solutions. ", "page_label": "8", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "dc35cb9fa522a271859c658b40c6be8f254162f5c697f5bb823db8f9f3cb1986", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5c6636a6-724d-4089-9adc-c6541ac8dd0c", "node_type": "1", "metadata": {"window": "Next, I'll review our segment results, which can be found on slides 5 through 7, and I'll start with U.S. \n Pharmaceutical and Specialty Solutions.  Revenues were $45.1 billion for the quarter, which were up 2% driven by \nmarket growth and higher retail national account volumes.  This was partially offset by branded generic \nconversions and the negative impact of COVID -19 on prescription transaction volumes.  \n \n Prescription transaction volumes were uneven in April and May, improved throughout the quarter and were above \nour expectations in June.  Oncology visits were approximately 70% of pre -pandemic levels in April, however, \nimproved to over 95% in June.  And telemedicine visits in our onc ology practices now account for up to 15% of all \nvisits.  \n \n", "original_text": "This was partially offset by branded generic \nconversions and the negative impact of COVID -19 on prescription transaction volumes.  \n \n"}, "hash": "f972d0c34ee2a6ef6dbbf028947ff71213c61a5f18ca13249f70410ccd9273b5", "class_name": "RelatedNodeInfo"}}, "text": "Revenues were $45.1 billion for the quarter, which were up 2% driven by \nmarket growth and higher retail national account volumes. ", "start_char_idx": 1781, "end_char_idx": 1912, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5c6636a6-724d-4089-9adc-c6541ac8dd0c": {"__data__": {"id_": "5c6636a6-724d-4089-9adc-c6541ac8dd0c", "embedding": null, "metadata": {"window": "Next, I'll review our segment results, which can be found on slides 5 through 7, and I'll start with U.S. \n Pharmaceutical and Specialty Solutions.  Revenues were $45.1 billion for the quarter, which were up 2% driven by \nmarket growth and higher retail national account volumes.  This was partially offset by branded generic \nconversions and the negative impact of COVID -19 on prescription transaction volumes.  \n \n Prescription transaction volumes were uneven in April and May, improved throughout the quarter and were above \nour expectations in June.  Oncology visits were approximately 70% of pre -pandemic levels in April, however, \nimproved to over 95% in June.  And telemedicine visits in our onc ology practices now account for up to 15% of all \nvisits.  \n \n", "original_text": "This was partially offset by branded generic \nconversions and the negative impact of COVID -19 on prescription transaction volumes.  \n \n", "page_label": "8", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b6da9e8d-146b-433f-beae-4978bb0cbe32", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "82062705c7e888894d29ef3bbea6819854e5854c7884f1e9eeac85d774595533", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6ed1b786-d677-4a88-8886-141ce9b139d2", "node_type": "1", "metadata": {"window": "In wrapping up our consolidated results, our first quarter diluted weighted average shares were 163 million, a \ndecrease of 14% year -over-year driven by the successful exit of our investment in Change Healthcare, which \nlowered our shares outstanding by appr oximately 15.4 million shares and due to prior year share repurchases.  \n \n Next, I'll review our segment results, which can be found on slides 5 through 7, and I'll start with U.S. \n Pharmaceutical and Specialty Solutions.  Revenues were $45.1 billion for the quarter, which were up 2% driven by \nmarket growth and higher retail national account volumes.  This was partially offset by branded generic \nconversions and the negative impact of COVID -19 on prescription transaction volumes.  \n \n Prescription transaction volumes were uneven in April and May, improved throughout the quarter and were above \nour expectations in June.  Oncology visits were approximately 70% of pre -pandemic levels in April, however, \nimproved to over 95% in June. ", "original_text": "Revenues were $45.1 billion for the quarter, which were up 2% driven by \nmarket growth and higher retail national account volumes. ", "page_label": "8", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bd50280eb4283fab45803c54dbe8bec64ec6c92b6c6efe14efa6740c43eec844", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1cc4adce-8b59-4eb2-a30a-ce849fa2a960", "node_type": "1", "metadata": {"window": "Pharmaceutical and Specialty Solutions.  Revenues were $45.1 billion for the quarter, which were up 2% driven by \nmarket growth and higher retail national account volumes.  This was partially offset by branded generic \nconversions and the negative impact of COVID -19 on prescription transaction volumes.  \n \n Prescription transaction volumes were uneven in April and May, improved throughout the quarter and were above \nour expectations in June.  Oncology visits were approximately 70% of pre -pandemic levels in April, however, \nimproved to over 95% in June.  And telemedicine visits in our onc ology practices now account for up to 15% of all \nvisits.  \n \n First quarter adjusted operating profit decreased 2% to $589 million, driven by lower volumes as a results of the \npandemic and strategic investments, including our oncology portfolio. ", "original_text": "Prescription transaction volumes were uneven in April and May, improved throughout the quarter and were above \nour expectations in June. "}, "hash": "d3ad73e0b1ab333c087c0379bef4d48b68ba2f1fb7dfbe36d91da6ea0f394a48", "class_name": "RelatedNodeInfo"}}, "text": "This was partially offset by branded generic \nconversions and the negative impact of COVID -19 on prescription transaction volumes.  \n \n", "start_char_idx": 1912, "end_char_idx": 2048, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1cc4adce-8b59-4eb2-a30a-ce849fa2a960": {"__data__": {"id_": "1cc4adce-8b59-4eb2-a30a-ce849fa2a960", "embedding": null, "metadata": {"window": "Pharmaceutical and Specialty Solutions.  Revenues were $45.1 billion for the quarter, which were up 2% driven by \nmarket growth and higher retail national account volumes.  This was partially offset by branded generic \nconversions and the negative impact of COVID -19 on prescription transaction volumes.  \n \n Prescription transaction volumes were uneven in April and May, improved throughout the quarter and were above \nour expectations in June.  Oncology visits were approximately 70% of pre -pandemic levels in April, however, \nimproved to over 95% in June.  And telemedicine visits in our onc ology practices now account for up to 15% of all \nvisits.  \n \n First quarter adjusted operating profit decreased 2% to $589 million, driven by lower volumes as a results of the \npandemic and strategic investments, including our oncology portfolio. ", "original_text": "Prescription transaction volumes were uneven in April and May, improved throughout the quarter and were above \nour expectations in June. ", "page_label": "8", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b6da9e8d-146b-433f-beae-4978bb0cbe32", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "82062705c7e888894d29ef3bbea6819854e5854c7884f1e9eeac85d774595533", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5c6636a6-724d-4089-9adc-c6541ac8dd0c", "node_type": "1", "metadata": {"window": "Next, I'll review our segment results, which can be found on slides 5 through 7, and I'll start with U.S. \n Pharmaceutical and Specialty Solutions.  Revenues were $45.1 billion for the quarter, which were up 2% driven by \nmarket growth and higher retail national account volumes.  This was partially offset by branded generic \nconversions and the negative impact of COVID -19 on prescription transaction volumes.  \n \n Prescription transaction volumes were uneven in April and May, improved throughout the quarter and were above \nour expectations in June.  Oncology visits were approximately 70% of pre -pandemic levels in April, however, \nimproved to over 95% in June.  And telemedicine visits in our onc ology practices now account for up to 15% of all \nvisits.  \n \n", "original_text": "This was partially offset by branded generic \nconversions and the negative impact of COVID -19 on prescription transaction volumes.  \n \n", "page_label": "8", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "11ddf235b4cb2a30c8c647369a24c404d9945343d79b71b04b0f8eba2af49c76", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7a7478f2-f4c6-40ad-ae79-0663f2ffe6dc", "node_type": "1", "metadata": {"window": "Revenues were $45.1 billion for the quarter, which were up 2% driven by \nmarket growth and higher retail national account volumes.  This was partially offset by branded generic \nconversions and the negative impact of COVID -19 on prescription transaction volumes.  \n \n Prescription transaction volumes were uneven in April and May, improved throughout the quarter and were above \nour expectations in June.  Oncology visits were approximately 70% of pre -pandemic levels in April, however, \nimproved to over 95% in June.  And telemedicine visits in our onc ology practices now account for up to 15% of all \nvisits.  \n \n First quarter adjusted operating profit decreased 2% to $589 million, driven by lower volumes as a results of the \npandemic and strategic investments, including our oncology portfolio.  Partially offs et by growth in the provider \nsolutions business. ", "original_text": "Oncology visits were approximately 70% of pre -pandemic levels in April, however, \nimproved to over 95% in June. "}, "hash": "244b1b80ce8d3256640327a1eb404216a1efcf7afc7e19eaaccaab53b26b40ee", "class_name": "RelatedNodeInfo"}}, "text": "Prescription transaction volumes were uneven in April and May, improved throughout the quarter and were above \nour expectations in June. ", "start_char_idx": 2048, "end_char_idx": 2185, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7a7478f2-f4c6-40ad-ae79-0663f2ffe6dc": {"__data__": {"id_": "7a7478f2-f4c6-40ad-ae79-0663f2ffe6dc", "embedding": null, "metadata": {"window": "Revenues were $45.1 billion for the quarter, which were up 2% driven by \nmarket growth and higher retail national account volumes.  This was partially offset by branded generic \nconversions and the negative impact of COVID -19 on prescription transaction volumes.  \n \n Prescription transaction volumes were uneven in April and May, improved throughout the quarter and were above \nour expectations in June.  Oncology visits were approximately 70% of pre -pandemic levels in April, however, \nimproved to over 95% in June.  And telemedicine visits in our onc ology practices now account for up to 15% of all \nvisits.  \n \n First quarter adjusted operating profit decreased 2% to $589 million, driven by lower volumes as a results of the \npandemic and strategic investments, including our oncology portfolio.  Partially offs et by growth in the provider \nsolutions business. ", "original_text": "Oncology visits were approximately 70% of pre -pandemic levels in April, however, \nimproved to over 95% in June. ", "page_label": "8", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b6da9e8d-146b-433f-beae-4978bb0cbe32", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "82062705c7e888894d29ef3bbea6819854e5854c7884f1e9eeac85d774595533", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1cc4adce-8b59-4eb2-a30a-ce849fa2a960", "node_type": "1", "metadata": {"window": "Pharmaceutical and Specialty Solutions.  Revenues were $45.1 billion for the quarter, which were up 2% driven by \nmarket growth and higher retail national account volumes.  This was partially offset by branded generic \nconversions and the negative impact of COVID -19 on prescription transaction volumes.  \n \n Prescription transaction volumes were uneven in April and May, improved throughout the quarter and were above \nour expectations in June.  Oncology visits were approximately 70% of pre -pandemic levels in April, however, \nimproved to over 95% in June.  And telemedicine visits in our onc ology practices now account for up to 15% of all \nvisits.  \n \n First quarter adjusted operating profit decreased 2% to $589 million, driven by lower volumes as a results of the \npandemic and strategic investments, including our oncology portfolio. ", "original_text": "Prescription transaction volumes were uneven in April and May, improved throughout the quarter and were above \nour expectations in June. ", "page_label": "8", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5c7b3d19f7b320b83fc824fd0200c53e02628c2a759f72b87d1672ff1fc1f339", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c9a3bdf0-0c4f-41b7-a8c0-8626cb27e2b8", "node_type": "1", "metadata": {"window": "This was partially offset by branded generic \nconversions and the negative impact of COVID -19 on prescription transaction volumes.  \n \n Prescription transaction volumes were uneven in April and May, improved throughout the quarter and were above \nour expectations in June.  Oncology visits were approximately 70% of pre -pandemic levels in April, however, \nimproved to over 95% in June.  And telemedicine visits in our onc ology practices now account for up to 15% of all \nvisits.  \n \n First quarter adjusted operating profit decreased 2% to $589 million, driven by lower volumes as a results of the \npandemic and strategic investments, including our oncology portfolio.  Partially offs et by growth in the provider \nsolutions business.  The segment adjusted operating margin for the first quarter was 131 basis points, a decrease \nof 5 basis points.  \n \n", "original_text": "And telemedicine visits in our onc ology practices now account for up to 15% of all \nvisits.  \n \n"}, "hash": "53fa54a67dfada24d6d464567802029965bb6b09d97f81f052a51d0319d75a72", "class_name": "RelatedNodeInfo"}}, "text": "Oncology visits were approximately 70% of pre -pandemic levels in April, however, \nimproved to over 95% in June. ", "start_char_idx": 2185, "end_char_idx": 2298, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c9a3bdf0-0c4f-41b7-a8c0-8626cb27e2b8": {"__data__": {"id_": "c9a3bdf0-0c4f-41b7-a8c0-8626cb27e2b8", "embedding": null, "metadata": {"window": "This was partially offset by branded generic \nconversions and the negative impact of COVID -19 on prescription transaction volumes.  \n \n Prescription transaction volumes were uneven in April and May, improved throughout the quarter and were above \nour expectations in June.  Oncology visits were approximately 70% of pre -pandemic levels in April, however, \nimproved to over 95% in June.  And telemedicine visits in our onc ology practices now account for up to 15% of all \nvisits.  \n \n First quarter adjusted operating profit decreased 2% to $589 million, driven by lower volumes as a results of the \npandemic and strategic investments, including our oncology portfolio.  Partially offs et by growth in the provider \nsolutions business.  The segment adjusted operating margin for the first quarter was 131 basis points, a decrease \nof 5 basis points.  \n \n", "original_text": "And telemedicine visits in our onc ology practices now account for up to 15% of all \nvisits.  \n \n", "page_label": "8", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b6da9e8d-146b-433f-beae-4978bb0cbe32", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "82062705c7e888894d29ef3bbea6819854e5854c7884f1e9eeac85d774595533", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7a7478f2-f4c6-40ad-ae79-0663f2ffe6dc", "node_type": "1", "metadata": {"window": "Revenues were $45.1 billion for the quarter, which were up 2% driven by \nmarket growth and higher retail national account volumes.  This was partially offset by branded generic \nconversions and the negative impact of COVID -19 on prescription transaction volumes.  \n \n Prescription transaction volumes were uneven in April and May, improved throughout the quarter and were above \nour expectations in June.  Oncology visits were approximately 70% of pre -pandemic levels in April, however, \nimproved to over 95% in June.  And telemedicine visits in our onc ology practices now account for up to 15% of all \nvisits.  \n \n First quarter adjusted operating profit decreased 2% to $589 million, driven by lower volumes as a results of the \npandemic and strategic investments, including our oncology portfolio.  Partially offs et by growth in the provider \nsolutions business. ", "original_text": "Oncology visits were approximately 70% of pre -pandemic levels in April, however, \nimproved to over 95% in June. ", "page_label": "8", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b9738f44d71d300f351007cf6c024dfde2926b6bb054141525eb75f8c4d398a2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "93e180dd-d91e-4cfb-ba51-67b421e11b60", "node_type": "1", "metadata": {"window": "Prescription transaction volumes were uneven in April and May, improved throughout the quarter and were above \nour expectations in June.  Oncology visits were approximately 70% of pre -pandemic levels in April, however, \nimproved to over 95% in June.  And telemedicine visits in our onc ology practices now account for up to 15% of all \nvisits.  \n \n First quarter adjusted operating profit decreased 2% to $589 million, driven by lower volumes as a results of the \npandemic and strategic investments, including our oncology portfolio.  Partially offs et by growth in the provider \nsolutions business.  The segment adjusted operating margin for the first quarter was 131 basis points, a decrease \nof 5 basis points.  \n \n Next, I'll talk about European Pharmaceutical Solutions, where revenues were $6.2 billion for the quarter, a \ndecrease of 7% year -over-year. ", "original_text": "First quarter adjusted operating profit decreased 2% to $589 million, driven by lower volumes as a results of the \npandemic and strategic investments, including our oncology portfolio. "}, "hash": "767b3e46af19b760113e9d28b3f3e700b052df25bd04d020a38a44dd970e6400", "class_name": "RelatedNodeInfo"}}, "text": "And telemedicine visits in our onc ology practices now account for up to 15% of all \nvisits.  \n \n", "start_char_idx": 2298, "end_char_idx": 2395, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "93e180dd-d91e-4cfb-ba51-67b421e11b60": {"__data__": {"id_": "93e180dd-d91e-4cfb-ba51-67b421e11b60", "embedding": null, "metadata": {"window": "Prescription transaction volumes were uneven in April and May, improved throughout the quarter and were above \nour expectations in June.  Oncology visits were approximately 70% of pre -pandemic levels in April, however, \nimproved to over 95% in June.  And telemedicine visits in our onc ology practices now account for up to 15% of all \nvisits.  \n \n First quarter adjusted operating profit decreased 2% to $589 million, driven by lower volumes as a results of the \npandemic and strategic investments, including our oncology portfolio.  Partially offs et by growth in the provider \nsolutions business.  The segment adjusted operating margin for the first quarter was 131 basis points, a decrease \nof 5 basis points.  \n \n Next, I'll talk about European Pharmaceutical Solutions, where revenues were $6.2 billion for the quarter, a \ndecrease of 7% year -over-year. ", "original_text": "First quarter adjusted operating profit decreased 2% to $589 million, driven by lower volumes as a results of the \npandemic and strategic investments, including our oncology portfolio. ", "page_label": "8", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b6da9e8d-146b-433f-beae-4978bb0cbe32", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "82062705c7e888894d29ef3bbea6819854e5854c7884f1e9eeac85d774595533", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c9a3bdf0-0c4f-41b7-a8c0-8626cb27e2b8", "node_type": "1", "metadata": {"window": "This was partially offset by branded generic \nconversions and the negative impact of COVID -19 on prescription transaction volumes.  \n \n Prescription transaction volumes were uneven in April and May, improved throughout the quarter and were above \nour expectations in June.  Oncology visits were approximately 70% of pre -pandemic levels in April, however, \nimproved to over 95% in June.  And telemedicine visits in our onc ology practices now account for up to 15% of all \nvisits.  \n \n First quarter adjusted operating profit decreased 2% to $589 million, driven by lower volumes as a results of the \npandemic and strategic investments, including our oncology portfolio.  Partially offs et by growth in the provider \nsolutions business.  The segment adjusted operating margin for the first quarter was 131 basis points, a decrease \nof 5 basis points.  \n \n", "original_text": "And telemedicine visits in our onc ology practices now account for up to 15% of all \nvisits.  \n \n", "page_label": "8", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "84344d3628b0fb51a4d2bf1ebbc9310d8923f3226d78005537b8a1e8e810deb4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ca27606e-3f30-4ac0-b636-a8d47fd44859", "node_type": "1", "metadata": {"window": "Oncology visits were approximately 70% of pre -pandemic levels in April, however, \nimproved to over 95% in June.  And telemedicine visits in our onc ology practices now account for up to 15% of all \nvisits.  \n \n First quarter adjusted operating profit decreased 2% to $589 million, driven by lower volumes as a results of the \npandemic and strategic investments, including our oncology portfolio.  Partially offs et by growth in the provider \nsolutions business.  The segment adjusted operating margin for the first quarter was 131 basis points, a decrease \nof 5 basis points.  \n \n Next, I'll talk about European Pharmaceutical Solutions, where revenues were $6.2 billion for the quarter, a \ndecrease of 7% year -over-year.  On an FX -adjusted basis, revenues decreased 4% driven by the negative impact \nof the pandemic on the pharmaceutical distribution and retail pharmacy businesses, partially offset by two extra \nsell days in the per iod compared to the prior year. ", "original_text": "Partially offs et by growth in the provider \nsolutions business. "}, "hash": "71f6aaf8cbfbf782bfdbe84aa4e641c201aae108f59bdd0e9bbb4ea80efebb83", "class_name": "RelatedNodeInfo"}}, "text": "First quarter adjusted operating profit decreased 2% to $589 million, driven by lower volumes as a results of the \npandemic and strategic investments, including our oncology portfolio. ", "start_char_idx": 2395, "end_char_idx": 2580, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ca27606e-3f30-4ac0-b636-a8d47fd44859": {"__data__": {"id_": "ca27606e-3f30-4ac0-b636-a8d47fd44859", "embedding": null, "metadata": {"window": "Oncology visits were approximately 70% of pre -pandemic levels in April, however, \nimproved to over 95% in June.  And telemedicine visits in our onc ology practices now account for up to 15% of all \nvisits.  \n \n First quarter adjusted operating profit decreased 2% to $589 million, driven by lower volumes as a results of the \npandemic and strategic investments, including our oncology portfolio.  Partially offs et by growth in the provider \nsolutions business.  The segment adjusted operating margin for the first quarter was 131 basis points, a decrease \nof 5 basis points.  \n \n Next, I'll talk about European Pharmaceutical Solutions, where revenues were $6.2 billion for the quarter, a \ndecrease of 7% year -over-year.  On an FX -adjusted basis, revenues decreased 4% driven by the negative impact \nof the pandemic on the pharmaceutical distribution and retail pharmacy businesses, partially offset by two extra \nsell days in the per iod compared to the prior year. ", "original_text": "Partially offs et by growth in the provider \nsolutions business. ", "page_label": "8", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b6da9e8d-146b-433f-beae-4978bb0cbe32", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "82062705c7e888894d29ef3bbea6819854e5854c7884f1e9eeac85d774595533", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "93e180dd-d91e-4cfb-ba51-67b421e11b60", "node_type": "1", "metadata": {"window": "Prescription transaction volumes were uneven in April and May, improved throughout the quarter and were above \nour expectations in June.  Oncology visits were approximately 70% of pre -pandemic levels in April, however, \nimproved to over 95% in June.  And telemedicine visits in our onc ology practices now account for up to 15% of all \nvisits.  \n \n First quarter adjusted operating profit decreased 2% to $589 million, driven by lower volumes as a results of the \npandemic and strategic investments, including our oncology portfolio.  Partially offs et by growth in the provider \nsolutions business.  The segment adjusted operating margin for the first quarter was 131 basis points, a decrease \nof 5 basis points.  \n \n Next, I'll talk about European Pharmaceutical Solutions, where revenues were $6.2 billion for the quarter, a \ndecrease of 7% year -over-year. ", "original_text": "First quarter adjusted operating profit decreased 2% to $589 million, driven by lower volumes as a results of the \npandemic and strategic investments, including our oncology portfolio. ", "page_label": "8", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "632c892d16714aa5524538054da23e0d5acd3b42d899ceef4afda8963d40944c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0097e15d-5e35-483c-add8-27fde0a0c5d7", "node_type": "1", "metadata": {"window": "And telemedicine visits in our onc ology practices now account for up to 15% of all \nvisits.  \n \n First quarter adjusted operating profit decreased 2% to $589 million, driven by lower volumes as a results of the \npandemic and strategic investments, including our oncology portfolio.  Partially offs et by growth in the provider \nsolutions business.  The segment adjusted operating margin for the first quarter was 131 basis points, a decrease \nof 5 basis points.  \n \n Next, I'll talk about European Pharmaceutical Solutions, where revenues were $6.2 billion for the quarter, a \ndecrease of 7% year -over-year.  On an FX -adjusted basis, revenues decreased 4% driven by the negative impact \nof the pandemic on the pharmaceutical distribution and retail pharmacy businesses, partially offset by two extra \nsell days in the per iod compared to the prior year.  First quarter adjusted operating profit was flat year -over-year at \n$35 million.  \n \n", "original_text": "The segment adjusted operating margin for the first quarter was 131 basis points, a decrease \nof 5 basis points.  \n \n"}, "hash": "bf5b4a34e1505a59c494b0c3ff0d3f0ea7e658c9392d5a1cd50e8e18b5bd001b", "class_name": "RelatedNodeInfo"}}, "text": "Partially offs et by growth in the provider \nsolutions business. ", "start_char_idx": 2580, "end_char_idx": 2645, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0097e15d-5e35-483c-add8-27fde0a0c5d7": {"__data__": {"id_": "0097e15d-5e35-483c-add8-27fde0a0c5d7", "embedding": null, "metadata": {"window": "And telemedicine visits in our onc ology practices now account for up to 15% of all \nvisits.  \n \n First quarter adjusted operating profit decreased 2% to $589 million, driven by lower volumes as a results of the \npandemic and strategic investments, including our oncology portfolio.  Partially offs et by growth in the provider \nsolutions business.  The segment adjusted operating margin for the first quarter was 131 basis points, a decrease \nof 5 basis points.  \n \n Next, I'll talk about European Pharmaceutical Solutions, where revenues were $6.2 billion for the quarter, a \ndecrease of 7% year -over-year.  On an FX -adjusted basis, revenues decreased 4% driven by the negative impact \nof the pandemic on the pharmaceutical distribution and retail pharmacy businesses, partially offset by two extra \nsell days in the per iod compared to the prior year.  First quarter adjusted operating profit was flat year -over-year at \n$35 million.  \n \n", "original_text": "The segment adjusted operating margin for the first quarter was 131 basis points, a decrease \nof 5 basis points.  \n \n", "page_label": "8", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b6da9e8d-146b-433f-beae-4978bb0cbe32", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "82062705c7e888894d29ef3bbea6819854e5854c7884f1e9eeac85d774595533", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ca27606e-3f30-4ac0-b636-a8d47fd44859", "node_type": "1", "metadata": {"window": "Oncology visits were approximately 70% of pre -pandemic levels in April, however, \nimproved to over 95% in June.  And telemedicine visits in our onc ology practices now account for up to 15% of all \nvisits.  \n \n First quarter adjusted operating profit decreased 2% to $589 million, driven by lower volumes as a results of the \npandemic and strategic investments, including our oncology portfolio.  Partially offs et by growth in the provider \nsolutions business.  The segment adjusted operating margin for the first quarter was 131 basis points, a decrease \nof 5 basis points.  \n \n Next, I'll talk about European Pharmaceutical Solutions, where revenues were $6.2 billion for the quarter, a \ndecrease of 7% year -over-year.  On an FX -adjusted basis, revenues decreased 4% driven by the negative impact \nof the pandemic on the pharmaceutical distribution and retail pharmacy businesses, partially offset by two extra \nsell days in the per iod compared to the prior year. ", "original_text": "Partially offs et by growth in the provider \nsolutions business. ", "page_label": "8", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "80395485b8e3a2bcf884db3f928a29b43b108905d9b45165dde9e7e9cf13464f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b0d487dd-e5d6-4d3d-9ff4-c65a796b5a12", "node_type": "1", "metadata": {"window": "First quarter adjusted operating profit decreased 2% to $589 million, driven by lower volumes as a results of the \npandemic and strategic investments, including our oncology portfolio.  Partially offs et by growth in the provider \nsolutions business.  The segment adjusted operating margin for the first quarter was 131 basis points, a decrease \nof 5 basis points.  \n \n Next, I'll talk about European Pharmaceutical Solutions, where revenues were $6.2 billion for the quarter, a \ndecrease of 7% year -over-year.  On an FX -adjusted basis, revenues decreased 4% driven by the negative impact \nof the pandemic on the pharmaceutical distribution and retail pharmacy businesses, partially offset by two extra \nsell days in the per iod compared to the prior year.  First quarter adjusted operating profit was flat year -over-year at \n$35 million.  \n \n On an FX -adjusted basis, adjusted operating profit increased 3% to $36 million driven by lower operating expense \nand two additional sell days i n the period when compared to the prior year, partially offset by lower volumes due \nto the pandemic. ", "original_text": "Next, I'll talk about European Pharmaceutical Solutions, where revenues were $6.2 billion for the quarter, a \ndecrease of 7% year -over-year. "}, "hash": "74b1c70787986adce9571a629aad59261bcd3fb1492b9ce377f78093e313c834", "class_name": "RelatedNodeInfo"}}, "text": "The segment adjusted operating margin for the first quarter was 131 basis points, a decrease \nof 5 basis points.  \n \n", "start_char_idx": 2645, "end_char_idx": 2762, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b0d487dd-e5d6-4d3d-9ff4-c65a796b5a12": {"__data__": {"id_": "b0d487dd-e5d6-4d3d-9ff4-c65a796b5a12", "embedding": null, "metadata": {"window": "First quarter adjusted operating profit decreased 2% to $589 million, driven by lower volumes as a results of the \npandemic and strategic investments, including our oncology portfolio.  Partially offs et by growth in the provider \nsolutions business.  The segment adjusted operating margin for the first quarter was 131 basis points, a decrease \nof 5 basis points.  \n \n Next, I'll talk about European Pharmaceutical Solutions, where revenues were $6.2 billion for the quarter, a \ndecrease of 7% year -over-year.  On an FX -adjusted basis, revenues decreased 4% driven by the negative impact \nof the pandemic on the pharmaceutical distribution and retail pharmacy businesses, partially offset by two extra \nsell days in the per iod compared to the prior year.  First quarter adjusted operating profit was flat year -over-year at \n$35 million.  \n \n On an FX -adjusted basis, adjusted operating profit increased 3% to $36 million driven by lower operating expense \nand two additional sell days i n the period when compared to the prior year, partially offset by lower volumes due \nto the pandemic. ", "original_text": "Next, I'll talk about European Pharmaceutical Solutions, where revenues were $6.2 billion for the quarter, a \ndecrease of 7% year -over-year. ", "page_label": "8", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b6da9e8d-146b-433f-beae-4978bb0cbe32", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "82062705c7e888894d29ef3bbea6819854e5854c7884f1e9eeac85d774595533", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0097e15d-5e35-483c-add8-27fde0a0c5d7", "node_type": "1", "metadata": {"window": "And telemedicine visits in our onc ology practices now account for up to 15% of all \nvisits.  \n \n First quarter adjusted operating profit decreased 2% to $589 million, driven by lower volumes as a results of the \npandemic and strategic investments, including our oncology portfolio.  Partially offs et by growth in the provider \nsolutions business.  The segment adjusted operating margin for the first quarter was 131 basis points, a decrease \nof 5 basis points.  \n \n Next, I'll talk about European Pharmaceutical Solutions, where revenues were $6.2 billion for the quarter, a \ndecrease of 7% year -over-year.  On an FX -adjusted basis, revenues decreased 4% driven by the negative impact \nof the pandemic on the pharmaceutical distribution and retail pharmacy businesses, partially offset by two extra \nsell days in the per iod compared to the prior year.  First quarter adjusted operating profit was flat year -over-year at \n$35 million.  \n \n", "original_text": "The segment adjusted operating margin for the first quarter was 131 basis points, a decrease \nof 5 basis points.  \n \n", "page_label": "8", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4d07a957e24d645dce3787eb6e554ed49a31c656b7305867aac609cec94046cf", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6edffcf9-bf4d-4353-aa81-b62429350787", "node_type": "1", "metadata": {"window": "Partially offs et by growth in the provider \nsolutions business.  The segment adjusted operating margin for the first quarter was 131 basis points, a decrease \nof 5 basis points.  \n \n Next, I'll talk about European Pharmaceutical Solutions, where revenues were $6.2 billion for the quarter, a \ndecrease of 7% year -over-year.  On an FX -adjusted basis, revenues decreased 4% driven by the negative impact \nof the pandemic on the pharmaceutical distribution and retail pharmacy businesses, partially offset by two extra \nsell days in the per iod compared to the prior year.  First quarter adjusted operating profit was flat year -over-year at \n$35 million.  \n \n On an FX -adjusted basis, adjusted operating profit increased 3% to $36 million driven by lower operating expense \nand two additional sell days i n the period when compared to the prior year, partially offset by lower volumes due \nto the pandemic.  The segment adjusted operating margin for the first quarter was 56 basis points an increase of \nfour basis points.  \n \n", "original_text": "On an FX -adjusted basis, revenues decreased 4% driven by the negative impact \nof the pandemic on the pharmaceutical distribution and retail pharmacy businesses, partially offset by two extra \nsell days in the per iod compared to the prior year. "}, "hash": "2e6fcf70b6eef19b950bef9680d0f7efaf515eb9bf69c6a4331f499123f58cea", "class_name": "RelatedNodeInfo"}}, "text": "Next, I'll talk about European Pharmaceutical Solutions, where revenues were $6.2 billion for the quarter, a \ndecrease of 7% year -over-year. ", "start_char_idx": 2762, "end_char_idx": 2904, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6edffcf9-bf4d-4353-aa81-b62429350787": {"__data__": {"id_": "6edffcf9-bf4d-4353-aa81-b62429350787", "embedding": null, "metadata": {"window": "Partially offs et by growth in the provider \nsolutions business.  The segment adjusted operating margin for the first quarter was 131 basis points, a decrease \nof 5 basis points.  \n \n Next, I'll talk about European Pharmaceutical Solutions, where revenues were $6.2 billion for the quarter, a \ndecrease of 7% year -over-year.  On an FX -adjusted basis, revenues decreased 4% driven by the negative impact \nof the pandemic on the pharmaceutical distribution and retail pharmacy businesses, partially offset by two extra \nsell days in the per iod compared to the prior year.  First quarter adjusted operating profit was flat year -over-year at \n$35 million.  \n \n On an FX -adjusted basis, adjusted operating profit increased 3% to $36 million driven by lower operating expense \nand two additional sell days i n the period when compared to the prior year, partially offset by lower volumes due \nto the pandemic.  The segment adjusted operating margin for the first quarter was 56 basis points an increase of \nfour basis points.  \n \n", "original_text": "On an FX -adjusted basis, revenues decreased 4% driven by the negative impact \nof the pandemic on the pharmaceutical distribution and retail pharmacy businesses, partially offset by two extra \nsell days in the per iod compared to the prior year. ", "page_label": "8", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b6da9e8d-146b-433f-beae-4978bb0cbe32", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "82062705c7e888894d29ef3bbea6819854e5854c7884f1e9eeac85d774595533", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b0d487dd-e5d6-4d3d-9ff4-c65a796b5a12", "node_type": "1", "metadata": {"window": "First quarter adjusted operating profit decreased 2% to $589 million, driven by lower volumes as a results of the \npandemic and strategic investments, including our oncology portfolio.  Partially offs et by growth in the provider \nsolutions business.  The segment adjusted operating margin for the first quarter was 131 basis points, a decrease \nof 5 basis points.  \n \n Next, I'll talk about European Pharmaceutical Solutions, where revenues were $6.2 billion for the quarter, a \ndecrease of 7% year -over-year.  On an FX -adjusted basis, revenues decreased 4% driven by the negative impact \nof the pandemic on the pharmaceutical distribution and retail pharmacy businesses, partially offset by two extra \nsell days in the per iod compared to the prior year.  First quarter adjusted operating profit was flat year -over-year at \n$35 million.  \n \n On an FX -adjusted basis, adjusted operating profit increased 3% to $36 million driven by lower operating expense \nand two additional sell days i n the period when compared to the prior year, partially offset by lower volumes due \nto the pandemic. ", "original_text": "Next, I'll talk about European Pharmaceutical Solutions, where revenues were $6.2 billion for the quarter, a \ndecrease of 7% year -over-year. ", "page_label": "8", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "35133b7de14600152b8e2e5b33d88ea45e0086ca38b668631f4e0b8d18064b87", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d3d044a1-2763-4abc-bd8c-df7e7fad0541", "node_type": "1", "metadata": {"window": "The segment adjusted operating margin for the first quarter was 131 basis points, a decrease \nof 5 basis points.  \n \n Next, I'll talk about European Pharmaceutical Solutions, where revenues were $6.2 billion for the quarter, a \ndecrease of 7% year -over-year.  On an FX -adjusted basis, revenues decreased 4% driven by the negative impact \nof the pandemic on the pharmaceutical distribution and retail pharmacy businesses, partially offset by two extra \nsell days in the per iod compared to the prior year.  First quarter adjusted operating profit was flat year -over-year at \n$35 million.  \n \n On an FX -adjusted basis, adjusted operating profit increased 3% to $36 million driven by lower operating expense \nand two additional sell days i n the period when compared to the prior year, partially offset by lower volumes due \nto the pandemic.  The segment adjusted operating margin for the first quarter was 56 basis points an increase of \nfour basis points.  \n \n I'd like to spend a minute on the action s taken in the UK, which Brian discussed earlier. ", "original_text": "First quarter adjusted operating profit was flat year -over-year at \n$35 million.  \n \n"}, "hash": "0b1db38353e82de6c91024b40d31f93f8a60744dbd4b9218e9930360f7710768", "class_name": "RelatedNodeInfo"}}, "text": "On an FX -adjusted basis, revenues decreased 4% driven by the negative impact \nof the pandemic on the pharmaceutical distribution and retail pharmacy businesses, partially offset by two extra \nsell days in the per iod compared to the prior year. ", "start_char_idx": 2904, "end_char_idx": 3150, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d3d044a1-2763-4abc-bd8c-df7e7fad0541": {"__data__": {"id_": "d3d044a1-2763-4abc-bd8c-df7e7fad0541", "embedding": null, "metadata": {"window": "The segment adjusted operating margin for the first quarter was 131 basis points, a decrease \nof 5 basis points.  \n \n Next, I'll talk about European Pharmaceutical Solutions, where revenues were $6.2 billion for the quarter, a \ndecrease of 7% year -over-year.  On an FX -adjusted basis, revenues decreased 4% driven by the negative impact \nof the pandemic on the pharmaceutical distribution and retail pharmacy businesses, partially offset by two extra \nsell days in the per iod compared to the prior year.  First quarter adjusted operating profit was flat year -over-year at \n$35 million.  \n \n On an FX -adjusted basis, adjusted operating profit increased 3% to $36 million driven by lower operating expense \nand two additional sell days i n the period when compared to the prior year, partially offset by lower volumes due \nto the pandemic.  The segment adjusted operating margin for the first quarter was 56 basis points an increase of \nfour basis points.  \n \n I'd like to spend a minute on the action s taken in the UK, which Brian discussed earlier. ", "original_text": "First quarter adjusted operating profit was flat year -over-year at \n$35 million.  \n \n", "page_label": "8", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b6da9e8d-146b-433f-beae-4978bb0cbe32", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "82062705c7e888894d29ef3bbea6819854e5854c7884f1e9eeac85d774595533", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6edffcf9-bf4d-4353-aa81-b62429350787", "node_type": "1", "metadata": {"window": "Partially offs et by growth in the provider \nsolutions business.  The segment adjusted operating margin for the first quarter was 131 basis points, a decrease \nof 5 basis points.  \n \n Next, I'll talk about European Pharmaceutical Solutions, where revenues were $6.2 billion for the quarter, a \ndecrease of 7% year -over-year.  On an FX -adjusted basis, revenues decreased 4% driven by the negative impact \nof the pandemic on the pharmaceutical distribution and retail pharmacy businesses, partially offset by two extra \nsell days in the per iod compared to the prior year.  First quarter adjusted operating profit was flat year -over-year at \n$35 million.  \n \n On an FX -adjusted basis, adjusted operating profit increased 3% to $36 million driven by lower operating expense \nand two additional sell days i n the period when compared to the prior year, partially offset by lower volumes due \nto the pandemic.  The segment adjusted operating margin for the first quarter was 56 basis points an increase of \nfour basis points.  \n \n", "original_text": "On an FX -adjusted basis, revenues decreased 4% driven by the negative impact \nof the pandemic on the pharmaceutical distribution and retail pharmacy businesses, partially offset by two extra \nsell days in the per iod compared to the prior year. ", "page_label": "8", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "474f96895ab7b782ec3c652575a38df89d4dbb6ccf25cf24c6e90f0f76ab9e2b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "afa96779-0585-4de7-b907-f9f30d0a5336", "node_type": "1", "metadata": {"window": "Next, I'll talk about European Pharmaceutical Solutions, where revenues were $6.2 billion for the quarter, a \ndecrease of 7% year -over-year.  On an FX -adjusted basis, revenues decreased 4% driven by the negative impact \nof the pandemic on the pharmaceutical distribution and retail pharmacy businesses, partially offset by two extra \nsell days in the per iod compared to the prior year.  First quarter adjusted operating profit was flat year -over-year at \n$35 million.  \n \n On an FX -adjusted basis, adjusted operating profit increased 3% to $36 million driven by lower operating expense \nand two additional sell days i n the period when compared to the prior year, partially offset by lower volumes due \nto the pandemic.  The segment adjusted operating margin for the first quarter was 56 basis points an increase of \nfour basis points.  \n \n I'd like to spend a minute on the action s taken in the UK, which Brian discussed earlier.  The first quarter was a \nvery difficult quarter and the COVID pandemic has had a greater impact in our UK operations than the rest of our \nEuropean operations. ", "original_text": "On an FX -adjusted basis, adjusted operating profit increased 3% to $36 million driven by lower operating expense \nand two additional sell days i n the period when compared to the prior year, partially offset by lower volumes due \nto the pandemic. "}, "hash": "00220c0f0d799c06968299285819e991a74fafe3b9188329a308dd678b3b952a", "class_name": "RelatedNodeInfo"}}, "text": "First quarter adjusted operating profit was flat year -over-year at \n$35 million.  \n \n", "start_char_idx": 3150, "end_char_idx": 3236, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "afa96779-0585-4de7-b907-f9f30d0a5336": {"__data__": {"id_": "afa96779-0585-4de7-b907-f9f30d0a5336", "embedding": null, "metadata": {"window": "Next, I'll talk about European Pharmaceutical Solutions, where revenues were $6.2 billion for the quarter, a \ndecrease of 7% year -over-year.  On an FX -adjusted basis, revenues decreased 4% driven by the negative impact \nof the pandemic on the pharmaceutical distribution and retail pharmacy businesses, partially offset by two extra \nsell days in the per iod compared to the prior year.  First quarter adjusted operating profit was flat year -over-year at \n$35 million.  \n \n On an FX -adjusted basis, adjusted operating profit increased 3% to $36 million driven by lower operating expense \nand two additional sell days i n the period when compared to the prior year, partially offset by lower volumes due \nto the pandemic.  The segment adjusted operating margin for the first quarter was 56 basis points an increase of \nfour basis points.  \n \n I'd like to spend a minute on the action s taken in the UK, which Brian discussed earlier.  The first quarter was a \nvery difficult quarter and the COVID pandemic has had a greater impact in our UK operations than the rest of our \nEuropean operations. ", "original_text": "On an FX -adjusted basis, adjusted operating profit increased 3% to $36 million driven by lower operating expense \nand two additional sell days i n the period when compared to the prior year, partially offset by lower volumes due \nto the pandemic. ", "page_label": "8", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b6da9e8d-146b-433f-beae-4978bb0cbe32", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "82062705c7e888894d29ef3bbea6819854e5854c7884f1e9eeac85d774595533", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d3d044a1-2763-4abc-bd8c-df7e7fad0541", "node_type": "1", "metadata": {"window": "The segment adjusted operating margin for the first quarter was 131 basis points, a decrease \nof 5 basis points.  \n \n Next, I'll talk about European Pharmaceutical Solutions, where revenues were $6.2 billion for the quarter, a \ndecrease of 7% year -over-year.  On an FX -adjusted basis, revenues decreased 4% driven by the negative impact \nof the pandemic on the pharmaceutical distribution and retail pharmacy businesses, partially offset by two extra \nsell days in the per iod compared to the prior year.  First quarter adjusted operating profit was flat year -over-year at \n$35 million.  \n \n On an FX -adjusted basis, adjusted operating profit increased 3% to $36 million driven by lower operating expense \nand two additional sell days i n the period when compared to the prior year, partially offset by lower volumes due \nto the pandemic.  The segment adjusted operating margin for the first quarter was 56 basis points an increase of \nfour basis points.  \n \n I'd like to spend a minute on the action s taken in the UK, which Brian discussed earlier. ", "original_text": "First quarter adjusted operating profit was flat year -over-year at \n$35 million.  \n \n", "page_label": "8", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1f1cc86b1e0c52f60be777f2388ea4acc0bb0cf76bfd2465e908fca273a1717b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "faab4b8d-2e34-4dda-92e0-65ff4da4747d", "node_type": "1", "metadata": {"window": "On an FX -adjusted basis, revenues decreased 4% driven by the negative impact \nof the pandemic on the pharmaceutical distribution and retail pharmacy businesses, partially offset by two extra \nsell days in the per iod compared to the prior year.  First quarter adjusted operating profit was flat year -over-year at \n$35 million.  \n \n On an FX -adjusted basis, adjusted operating profit increased 3% to $36 million driven by lower operating expense \nand two additional sell days i n the period when compared to the prior year, partially offset by lower volumes due \nto the pandemic.  The segment adjusted operating margin for the first quarter was 56 basis points an increase of \nfour basis points.  \n \n I'd like to spend a minute on the action s taken in the UK, which Brian discussed earlier.  The first quarter was a \nvery difficult quarter and the COVID pandemic has had a greater impact in our UK operations than the rest of our \nEuropean operations.  Our teams have adapted to a changing operating e nvironment in the wake of COVID -19. ", "original_text": "The segment adjusted operating margin for the first quarter was 56 basis points an increase of \nfour basis points.  \n \n"}, "hash": "e4c2fa97f3d8d6e4117041b8a2e18853795344c45dab160cd7053f3f1084570f", "class_name": "RelatedNodeInfo"}}, "text": "On an FX -adjusted basis, adjusted operating profit increased 3% to $36 million driven by lower operating expense \nand two additional sell days i n the period when compared to the prior year, partially offset by lower volumes due \nto the pandemic. ", "start_char_idx": 3236, "end_char_idx": 3484, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "faab4b8d-2e34-4dda-92e0-65ff4da4747d": {"__data__": {"id_": "faab4b8d-2e34-4dda-92e0-65ff4da4747d", "embedding": null, "metadata": {"window": "On an FX -adjusted basis, revenues decreased 4% driven by the negative impact \nof the pandemic on the pharmaceutical distribution and retail pharmacy businesses, partially offset by two extra \nsell days in the per iod compared to the prior year.  First quarter adjusted operating profit was flat year -over-year at \n$35 million.  \n \n On an FX -adjusted basis, adjusted operating profit increased 3% to $36 million driven by lower operating expense \nand two additional sell days i n the period when compared to the prior year, partially offset by lower volumes due \nto the pandemic.  The segment adjusted operating margin for the first quarter was 56 basis points an increase of \nfour basis points.  \n \n I'd like to spend a minute on the action s taken in the UK, which Brian discussed earlier.  The first quarter was a \nvery difficult quarter and the COVID pandemic has had a greater impact in our UK operations than the rest of our \nEuropean operations.  Our teams have adapted to a changing operating e nvironment in the wake of COVID -19. ", "original_text": "The segment adjusted operating margin for the first quarter was 56 basis points an increase of \nfour basis points.  \n \n", "page_label": "8", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b6da9e8d-146b-433f-beae-4978bb0cbe32", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "82062705c7e888894d29ef3bbea6819854e5854c7884f1e9eeac85d774595533", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "afa96779-0585-4de7-b907-f9f30d0a5336", "node_type": "1", "metadata": {"window": "Next, I'll talk about European Pharmaceutical Solutions, where revenues were $6.2 billion for the quarter, a \ndecrease of 7% year -over-year.  On an FX -adjusted basis, revenues decreased 4% driven by the negative impact \nof the pandemic on the pharmaceutical distribution and retail pharmacy businesses, partially offset by two extra \nsell days in the per iod compared to the prior year.  First quarter adjusted operating profit was flat year -over-year at \n$35 million.  \n \n On an FX -adjusted basis, adjusted operating profit increased 3% to $36 million driven by lower operating expense \nand two additional sell days i n the period when compared to the prior year, partially offset by lower volumes due \nto the pandemic.  The segment adjusted operating margin for the first quarter was 56 basis points an increase of \nfour basis points.  \n \n I'd like to spend a minute on the action s taken in the UK, which Brian discussed earlier.  The first quarter was a \nvery difficult quarter and the COVID pandemic has had a greater impact in our UK operations than the rest of our \nEuropean operations. ", "original_text": "On an FX -adjusted basis, adjusted operating profit increased 3% to $36 million driven by lower operating expense \nand two additional sell days i n the period when compared to the prior year, partially offset by lower volumes due \nto the pandemic. ", "page_label": "8", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "33fe8387a72980a13cf47754c1b3b65b4daa2027759e3e0e99585f2b793f6a73", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cda1a1f8-ed31-4e47-bf76-d6a89a10b33d", "node_type": "1", "metadata": {"window": "First quarter adjusted operating profit was flat year -over-year at \n$35 million.  \n \n On an FX -adjusted basis, adjusted operating profit increased 3% to $36 million driven by lower operating expense \nand two additional sell days i n the period when compared to the prior year, partially offset by lower volumes due \nto the pandemic.  The segment adjusted operating margin for the first quarter was 56 basis points an increase of \nfour basis points.  \n \n I'd like to spend a minute on the action s taken in the UK, which Brian discussed earlier.  The first quarter was a \nvery difficult quarter and the COVID pandemic has had a greater impact in our UK operations than the rest of our \nEuropean operations.  Our teams have adapted to a changing operating e nvironment in the wake of COVID -19. ", "original_text": "I'd like to spend a minute on the action s taken in the UK, which Brian discussed earlier. "}, "hash": "77fa95c21acd830b06515cf912c878911fd0a3a4e7882bf6d134228028a162a8", "class_name": "RelatedNodeInfo"}}, "text": "The segment adjusted operating margin for the first quarter was 56 basis points an increase of \nfour basis points.  \n \n", "start_char_idx": 3484, "end_char_idx": 3603, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cda1a1f8-ed31-4e47-bf76-d6a89a10b33d": {"__data__": {"id_": "cda1a1f8-ed31-4e47-bf76-d6a89a10b33d", "embedding": null, "metadata": {"window": "First quarter adjusted operating profit was flat year -over-year at \n$35 million.  \n \n On an FX -adjusted basis, adjusted operating profit increased 3% to $36 million driven by lower operating expense \nand two additional sell days i n the period when compared to the prior year, partially offset by lower volumes due \nto the pandemic.  The segment adjusted operating margin for the first quarter was 56 basis points an increase of \nfour basis points.  \n \n I'd like to spend a minute on the action s taken in the UK, which Brian discussed earlier.  The first quarter was a \nvery difficult quarter and the COVID pandemic has had a greater impact in our UK operations than the rest of our \nEuropean operations.  Our teams have adapted to a changing operating e nvironment in the wake of COVID -19. ", "original_text": "I'd like to spend a minute on the action s taken in the UK, which Brian discussed earlier. ", "page_label": "8", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b6da9e8d-146b-433f-beae-4978bb0cbe32", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "82062705c7e888894d29ef3bbea6819854e5854c7884f1e9eeac85d774595533", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "faab4b8d-2e34-4dda-92e0-65ff4da4747d", "node_type": "1", "metadata": {"window": "On an FX -adjusted basis, revenues decreased 4% driven by the negative impact \nof the pandemic on the pharmaceutical distribution and retail pharmacy businesses, partially offset by two extra \nsell days in the per iod compared to the prior year.  First quarter adjusted operating profit was flat year -over-year at \n$35 million.  \n \n On an FX -adjusted basis, adjusted operating profit increased 3% to $36 million driven by lower operating expense \nand two additional sell days i n the period when compared to the prior year, partially offset by lower volumes due \nto the pandemic.  The segment adjusted operating margin for the first quarter was 56 basis points an increase of \nfour basis points.  \n \n I'd like to spend a minute on the action s taken in the UK, which Brian discussed earlier.  The first quarter was a \nvery difficult quarter and the COVID pandemic has had a greater impact in our UK operations than the rest of our \nEuropean operations.  Our teams have adapted to a changing operating e nvironment in the wake of COVID -19. ", "original_text": "The segment adjusted operating margin for the first quarter was 56 basis points an increase of \nfour basis points.  \n \n", "page_label": "8", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "607ff9308ca770adf26fe4223c6f9abc710612c5eacc1a390da002e5d242a7e4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "692e7084-347f-48db-9aeb-87e9acf5d42f", "node_type": "1", "metadata": {"window": "On an FX -adjusted basis, adjusted operating profit increased 3% to $36 million driven by lower operating expense \nand two additional sell days i n the period when compared to the prior year, partially offset by lower volumes due \nto the pandemic.  The segment adjusted operating margin for the first quarter was 56 basis points an increase of \nfour basis points.  \n \n I'd like to spend a minute on the action s taken in the UK, which Brian discussed earlier.  The first quarter was a \nvery difficult quarter and the COVID pandemic has had a greater impact in our UK operations than the rest of our \nEuropean operations.  Our teams have adapted to a changing operating e nvironment in the wake of COVID -19. ", "original_text": "The first quarter was a \nvery difficult quarter and the COVID pandemic has had a greater impact in our UK operations than the rest of our \nEuropean operations. "}, "hash": "11202c78f57b24bb0086127e28d1e2bde6f68b125172e0343bb34350b135014e", "class_name": "RelatedNodeInfo"}}, "text": "I'd like to spend a minute on the action s taken in the UK, which Brian discussed earlier. ", "start_char_idx": 3603, "end_char_idx": 3694, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "692e7084-347f-48db-9aeb-87e9acf5d42f": {"__data__": {"id_": "692e7084-347f-48db-9aeb-87e9acf5d42f", "embedding": null, "metadata": {"window": "On an FX -adjusted basis, adjusted operating profit increased 3% to $36 million driven by lower operating expense \nand two additional sell days i n the period when compared to the prior year, partially offset by lower volumes due \nto the pandemic.  The segment adjusted operating margin for the first quarter was 56 basis points an increase of \nfour basis points.  \n \n I'd like to spend a minute on the action s taken in the UK, which Brian discussed earlier.  The first quarter was a \nvery difficult quarter and the COVID pandemic has had a greater impact in our UK operations than the rest of our \nEuropean operations.  Our teams have adapted to a changing operating e nvironment in the wake of COVID -19. ", "original_text": "The first quarter was a \nvery difficult quarter and the COVID pandemic has had a greater impact in our UK operations than the rest of our \nEuropean operations. ", "page_label": "8", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b6da9e8d-146b-433f-beae-4978bb0cbe32", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "82062705c7e888894d29ef3bbea6819854e5854c7884f1e9eeac85d774595533", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cda1a1f8-ed31-4e47-bf76-d6a89a10b33d", "node_type": "1", "metadata": {"window": "First quarter adjusted operating profit was flat year -over-year at \n$35 million.  \n \n On an FX -adjusted basis, adjusted operating profit increased 3% to $36 million driven by lower operating expense \nand two additional sell days i n the period when compared to the prior year, partially offset by lower volumes due \nto the pandemic.  The segment adjusted operating margin for the first quarter was 56 basis points an increase of \nfour basis points.  \n \n I'd like to spend a minute on the action s taken in the UK, which Brian discussed earlier.  The first quarter was a \nvery difficult quarter and the COVID pandemic has had a greater impact in our UK operations than the rest of our \nEuropean operations.  Our teams have adapted to a changing operating e nvironment in the wake of COVID -19. ", "original_text": "I'd like to spend a minute on the action s taken in the UK, which Brian discussed earlier. ", "page_label": "8", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ab960e0106705f8ae51e3d354b0864cda10ed861efa36dd21625e4cb21559bd1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c940b079-6c56-4d91-80e7-fffc04895f26", "node_type": "1", "metadata": {"window": "The segment adjusted operating margin for the first quarter was 56 basis points an increase of \nfour basis points.  \n \n I'd like to spend a minute on the action s taken in the UK, which Brian discussed earlier.  The first quarter was a \nvery difficult quarter and the COVID pandemic has had a greater impact in our UK operations than the rest of our \nEuropean operations.  Our teams have adapted to a changing operating e nvironment in the wake of COVID -19. ", "original_text": "Our teams have adapted to a changing operating e nvironment in the wake of COVID -19. "}, "hash": "43500c2424487315373565a03e5b5269908960eb12eaee7199322fdacde0095b", "class_name": "RelatedNodeInfo"}}, "text": "The first quarter was a \nvery difficult quarter and the COVID pandemic has had a greater impact in our UK operations than the rest of our \nEuropean operations. ", "start_char_idx": 3694, "end_char_idx": 3854, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c940b079-6c56-4d91-80e7-fffc04895f26": {"__data__": {"id_": "c940b079-6c56-4d91-80e7-fffc04895f26", "embedding": null, "metadata": {"window": "The segment adjusted operating margin for the first quarter was 56 basis points an increase of \nfour basis points.  \n \n I'd like to spend a minute on the action s taken in the UK, which Brian discussed earlier.  The first quarter was a \nvery difficult quarter and the COVID pandemic has had a greater impact in our UK operations than the rest of our \nEuropean operations.  Our teams have adapted to a changing operating e nvironment in the wake of COVID -19. ", "original_text": "Our teams have adapted to a changing operating e nvironment in the wake of COVID -19. ", "page_label": "8", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b6da9e8d-146b-433f-beae-4978bb0cbe32", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "82062705c7e888894d29ef3bbea6819854e5854c7884f1e9eeac85d774595533", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "692e7084-347f-48db-9aeb-87e9acf5d42f", "node_type": "1", "metadata": {"window": "On an FX -adjusted basis, adjusted operating profit increased 3% to $36 million driven by lower operating expense \nand two additional sell days i n the period when compared to the prior year, partially offset by lower volumes due \nto the pandemic.  The segment adjusted operating margin for the first quarter was 56 basis points an increase of \nfour basis points.  \n \n I'd like to spend a minute on the action s taken in the UK, which Brian discussed earlier.  The first quarter was a \nvery difficult quarter and the COVID pandemic has had a greater impact in our UK operations than the rest of our \nEuropean operations.  Our teams have adapted to a changing operating e nvironment in the wake of COVID -19. ", "original_text": "The first quarter was a \nvery difficult quarter and the COVID pandemic has had a greater impact in our UK operations than the rest of our \nEuropean operations. ", "page_label": "8", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8c0d984599c4542f6c1e56eefa03f4ea6b845f91509e5eae36284d45e57cdec8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0a4903e6-43d5-497e-8744-4a5b17f81695", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nWe saw increased demand prior to the lockdown, but material reductions after the stay -at-home orders were \nimposed.  Volumes have remained steady, however, below pre -pandemic levels.  \n \n In our UK business, we identified an o pportunity to accelerate our transition to digital. ", "original_text": "McKesson Corp.  "}, "hash": "f8ef32c221a7b25cf27926273b8248be952584566b2e55696cc4843d74760908", "class_name": "RelatedNodeInfo"}}, "text": "Our teams have adapted to a changing operating e nvironment in the wake of COVID -19. ", "start_char_idx": 3854, "end_char_idx": 3940, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0a4903e6-43d5-497e-8744-4a5b17f81695": {"__data__": {"id_": "0a4903e6-43d5-497e-8744-4a5b17f81695", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nWe saw increased demand prior to the lockdown, but material reductions after the stay -at-home orders were \nimposed.  Volumes have remained steady, however, below pre -pandemic levels.  \n \n In our UK business, we identified an o pportunity to accelerate our transition to digital. ", "original_text": "McKesson Corp.  ", "page_label": "9", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e6763537-8e0b-4f34-ba9a-81920191e975", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f597ca48f373ba59aee380110f1eb95b1f75682f116e5ec6ca0710508c820240", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c940b079-6c56-4d91-80e7-fffc04895f26", "node_type": "1", "metadata": {"window": "The segment adjusted operating margin for the first quarter was 56 basis points an increase of \nfour basis points.  \n \n I'd like to spend a minute on the action s taken in the UK, which Brian discussed earlier.  The first quarter was a \nvery difficult quarter and the COVID pandemic has had a greater impact in our UK operations than the rest of our \nEuropean operations.  Our teams have adapted to a changing operating e nvironment in the wake of COVID -19. ", "original_text": "Our teams have adapted to a changing operating e nvironment in the wake of COVID -19. ", "page_label": "8", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6904d89bf22f52d5ea1360e2f564b9dfb8f2e8b6b9ab35ecb5da850da8d57bac", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4225fde5-d61f-4b9a-a298-859bce8aa255", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nWe saw increased demand prior to the lockdown, but material reductions after the stay -at-home orders were \nimposed.  Volumes have remained steady, however, below pre -pandemic levels.  \n \n In our UK business, we identified an o pportunity to accelerate our transition to digital.  Our investment in Echo and \nour digital capabilities led to strong growth in our online business, and we moved quickly to increase capacity. \n", "original_text": "(MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nWe saw increased demand prior to the lockdown, but material reductions after the stay -at-home orders were \nimposed. "}, "hash": "c57752abd53f0323de1a2a66234be72ba6d99334ca04496e3b1811af0152cc29", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4225fde5-d61f-4b9a-a298-859bce8aa255": {"__data__": {"id_": "4225fde5-d61f-4b9a-a298-859bce8aa255", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nWe saw increased demand prior to the lockdown, but material reductions after the stay -at-home orders were \nimposed.  Volumes have remained steady, however, below pre -pandemic levels.  \n \n In our UK business, we identified an o pportunity to accelerate our transition to digital.  Our investment in Echo and \nour digital capabilities led to strong growth in our online business, and we moved quickly to increase capacity. \n", "original_text": "(MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nWe saw increased demand prior to the lockdown, but material reductions after the stay -at-home orders were \nimposed. ", "page_label": "9", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e6763537-8e0b-4f34-ba9a-81920191e975", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f597ca48f373ba59aee380110f1eb95b1f75682f116e5ec6ca0710508c820240", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0a4903e6-43d5-497e-8744-4a5b17f81695", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nWe saw increased demand prior to the lockdown, but material reductions after the stay -at-home orders were \nimposed.  Volumes have remained steady, however, below pre -pandemic levels.  \n \n In our UK business, we identified an o pportunity to accelerate our transition to digital. ", "original_text": "McKesson Corp.  ", "page_label": "9", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "20474274a567baf5140640088f5282b928844ad403f285d8519d5b52987fca42", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0dfd43ca-f415-4aea-9a75-e2f3da22fff7", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nWe saw increased demand prior to the lockdown, but material reductions after the stay -at-home orders were \nimposed.  Volumes have remained steady, however, below pre -pandemic levels.  \n \n In our UK business, we identified an o pportunity to accelerate our transition to digital.  Our investment in Echo and \nour digital capabilities led to strong growth in our online business, and we moved quickly to increase capacity. \n Revenues from our Echo business grew over 300% from pre -pandemic  levels and continue on a strong growth \ntrajectory.  \n \n", "original_text": "Volumes have remained steady, however, below pre -pandemic levels.  \n \n"}, "hash": "0b46007619cf7909ea38602c20ba9af198c95ba9f719f4c1c9646596fb084ca3", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nWe saw increased demand prior to the lockdown, but material reductions after the stay -at-home orders were \nimposed. ", "start_char_idx": 16, "end_char_idx": 297, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0dfd43ca-f415-4aea-9a75-e2f3da22fff7": {"__data__": {"id_": "0dfd43ca-f415-4aea-9a75-e2f3da22fff7", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nWe saw increased demand prior to the lockdown, but material reductions after the stay -at-home orders were \nimposed.  Volumes have remained steady, however, below pre -pandemic levels.  \n \n In our UK business, we identified an o pportunity to accelerate our transition to digital.  Our investment in Echo and \nour digital capabilities led to strong growth in our online business, and we moved quickly to increase capacity. \n Revenues from our Echo business grew over 300% from pre -pandemic  levels and continue on a strong growth \ntrajectory.  \n \n", "original_text": "Volumes have remained steady, however, below pre -pandemic levels.  \n \n", "page_label": "9", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e6763537-8e0b-4f34-ba9a-81920191e975", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f597ca48f373ba59aee380110f1eb95b1f75682f116e5ec6ca0710508c820240", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4225fde5-d61f-4b9a-a298-859bce8aa255", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nWe saw increased demand prior to the lockdown, but material reductions after the stay -at-home orders were \nimposed.  Volumes have remained steady, however, below pre -pandemic levels.  \n \n In our UK business, we identified an o pportunity to accelerate our transition to digital.  Our investment in Echo and \nour digital capabilities led to strong growth in our online business, and we moved quickly to increase capacity. \n", "original_text": "(MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nWe saw increased demand prior to the lockdown, but material reductions after the stay -at-home orders were \nimposed. ", "page_label": "9", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bca49d517a51c1029a072d90ff7315034ee5cee92f69696e2257f381c07c94d9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d0a0955a-aef8-4787-a0ad-b1a15cdd3728", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nWe saw increased demand prior to the lockdown, but material reductions after the stay -at-home orders were \nimposed.  Volumes have remained steady, however, below pre -pandemic levels.  \n \n In our UK business, we identified an o pportunity to accelerate our transition to digital.  Our investment in Echo and \nour digital capabilities led to strong growth in our online business, and we moved quickly to increase capacity. \n Revenues from our Echo business grew over 300% from pre -pandemic  levels and continue on a strong growth \ntrajectory.  \n \n Our investment in digital health care strategy in the UK positions us to benefit from the movement of patients to a \ndigital environment. ", "original_text": "In our UK business, we identified an o pportunity to accelerate our transition to digital. "}, "hash": "e64588e0320785381dcd507a8ec278c8a8c3e0c9544df449bc0e675fab54e24b", "class_name": "RelatedNodeInfo"}}, "text": "Volumes have remained steady, however, below pre -pandemic levels.  \n \n", "start_char_idx": 297, "end_char_idx": 368, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d0a0955a-aef8-4787-a0ad-b1a15cdd3728": {"__data__": {"id_": "d0a0955a-aef8-4787-a0ad-b1a15cdd3728", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nWe saw increased demand prior to the lockdown, but material reductions after the stay -at-home orders were \nimposed.  Volumes have remained steady, however, below pre -pandemic levels.  \n \n In our UK business, we identified an o pportunity to accelerate our transition to digital.  Our investment in Echo and \nour digital capabilities led to strong growth in our online business, and we moved quickly to increase capacity. \n Revenues from our Echo business grew over 300% from pre -pandemic  levels and continue on a strong growth \ntrajectory.  \n \n Our investment in digital health care strategy in the UK positions us to benefit from the movement of patients to a \ndigital environment. ", "original_text": "In our UK business, we identified an o pportunity to accelerate our transition to digital. ", "page_label": "9", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e6763537-8e0b-4f34-ba9a-81920191e975", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f597ca48f373ba59aee380110f1eb95b1f75682f116e5ec6ca0710508c820240", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0dfd43ca-f415-4aea-9a75-e2f3da22fff7", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nWe saw increased demand prior to the lockdown, but material reductions after the stay -at-home orders were \nimposed.  Volumes have remained steady, however, below pre -pandemic levels.  \n \n In our UK business, we identified an o pportunity to accelerate our transition to digital.  Our investment in Echo and \nour digital capabilities led to strong growth in our online business, and we moved quickly to increase capacity. \n Revenues from our Echo business grew over 300% from pre -pandemic  levels and continue on a strong growth \ntrajectory.  \n \n", "original_text": "Volumes have remained steady, however, below pre -pandemic levels.  \n \n", "page_label": "9", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5d3d132007c579537b6d2366818817b32f2bcb40427cc98ad457b2a8c3f5319e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8e64a980-9937-42a3-8f82-61fc4ffc4faa", "node_type": "1", "metadata": {"window": "(MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nWe saw increased demand prior to the lockdown, but material reductions after the stay -at-home orders were \nimposed.  Volumes have remained steady, however, below pre -pandemic levels.  \n \n In our UK business, we identified an o pportunity to accelerate our transition to digital.  Our investment in Echo and \nour digital capabilities led to strong growth in our online business, and we moved quickly to increase capacity. \n Revenues from our Echo business grew over 300% from pre -pandemic  levels and continue on a strong growth \ntrajectory.  \n \n Our investment in digital health care strategy in the UK positions us to benefit from the movement of patients to a \ndigital environment.  However, given the severity of the COVID impact and the uncertain outlook, we are \naccelerating actions in our UK business.  \n \n", "original_text": "Our investment in Echo and \nour digital capabilities led to strong growth in our online business, and we moved quickly to increase capacity. \n"}, "hash": "528467300c63a3681f0a77c0062c4ab6be9b76165ff2bd7f8e478f8a190f2aee", "class_name": "RelatedNodeInfo"}}, "text": "In our UK business, we identified an o pportunity to accelerate our transition to digital. ", "start_char_idx": 368, "end_char_idx": 459, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8e64a980-9937-42a3-8f82-61fc4ffc4faa": {"__data__": {"id_": "8e64a980-9937-42a3-8f82-61fc4ffc4faa", "embedding": null, "metadata": {"window": "(MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nWe saw increased demand prior to the lockdown, but material reductions after the stay -at-home orders were \nimposed.  Volumes have remained steady, however, below pre -pandemic levels.  \n \n In our UK business, we identified an o pportunity to accelerate our transition to digital.  Our investment in Echo and \nour digital capabilities led to strong growth in our online business, and we moved quickly to increase capacity. \n Revenues from our Echo business grew over 300% from pre -pandemic  levels and continue on a strong growth \ntrajectory.  \n \n Our investment in digital health care strategy in the UK positions us to benefit from the movement of patients to a \ndigital environment.  However, given the severity of the COVID impact and the uncertain outlook, we are \naccelerating actions in our UK business.  \n \n", "original_text": "Our investment in Echo and \nour digital capabilities led to strong growth in our online business, and we moved quickly to increase capacity. \n", "page_label": "9", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e6763537-8e0b-4f34-ba9a-81920191e975", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f597ca48f373ba59aee380110f1eb95b1f75682f116e5ec6ca0710508c820240", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d0a0955a-aef8-4787-a0ad-b1a15cdd3728", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nWe saw increased demand prior to the lockdown, but material reductions after the stay -at-home orders were \nimposed.  Volumes have remained steady, however, below pre -pandemic levels.  \n \n In our UK business, we identified an o pportunity to accelerate our transition to digital.  Our investment in Echo and \nour digital capabilities led to strong growth in our online business, and we moved quickly to increase capacity. \n Revenues from our Echo business grew over 300% from pre -pandemic  levels and continue on a strong growth \ntrajectory.  \n \n Our investment in digital health care strategy in the UK positions us to benefit from the movement of patients to a \ndigital environment. ", "original_text": "In our UK business, we identified an o pportunity to accelerate our transition to digital. ", "page_label": "9", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a8aaac27930f4d4bec15f83a4c76db5dc35f06d16dbb990a02e18be165e37041", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0e536704-f6cd-4e9d-8b58-bad24a493abf", "node_type": "1", "metadata": {"window": "Volumes have remained steady, however, below pre -pandemic levels.  \n \n In our UK business, we identified an o pportunity to accelerate our transition to digital.  Our investment in Echo and \nour digital capabilities led to strong growth in our online business, and we moved quickly to increase capacity. \n Revenues from our Echo business grew over 300% from pre -pandemic  levels and continue on a strong growth \ntrajectory.  \n \n Our investment in digital health care strategy in the UK positions us to benefit from the movement of patients to a \ndigital environment.  However, given the severity of the COVID impact and the uncertain outlook, we are \naccelerating actions in our UK business.  \n \n During the quarter, we announced restructuring actions in the UK to adapt to the difficult and evolving operating \nenvironment in the wake of COVID and to continue to better position the business for  future profitability. ", "original_text": "Revenues from our Echo business grew over 300% from pre -pandemic  levels and continue on a strong growth \ntrajectory.  \n \n"}, "hash": "17bb5d8666f21906b98a19d210cf5d9af2e367907e8feadb5010e39a159a23fa", "class_name": "RelatedNodeInfo"}}, "text": "Our investment in Echo and \nour digital capabilities led to strong growth in our online business, and we moved quickly to increase capacity. \n", "start_char_idx": 459, "end_char_idx": 601, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0e536704-f6cd-4e9d-8b58-bad24a493abf": {"__data__": {"id_": "0e536704-f6cd-4e9d-8b58-bad24a493abf", "embedding": null, "metadata": {"window": "Volumes have remained steady, however, below pre -pandemic levels.  \n \n In our UK business, we identified an o pportunity to accelerate our transition to digital.  Our investment in Echo and \nour digital capabilities led to strong growth in our online business, and we moved quickly to increase capacity. \n Revenues from our Echo business grew over 300% from pre -pandemic  levels and continue on a strong growth \ntrajectory.  \n \n Our investment in digital health care strategy in the UK positions us to benefit from the movement of patients to a \ndigital environment.  However, given the severity of the COVID impact and the uncertain outlook, we are \naccelerating actions in our UK business.  \n \n During the quarter, we announced restructuring actions in the UK to adapt to the difficult and evolving operating \nenvironment in the wake of COVID and to continue to better position the business for  future profitability. ", "original_text": "Revenues from our Echo business grew over 300% from pre -pandemic  levels and continue on a strong growth \ntrajectory.  \n \n", "page_label": "9", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e6763537-8e0b-4f34-ba9a-81920191e975", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f597ca48f373ba59aee380110f1eb95b1f75682f116e5ec6ca0710508c820240", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8e64a980-9937-42a3-8f82-61fc4ffc4faa", "node_type": "1", "metadata": {"window": "(MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nWe saw increased demand prior to the lockdown, but material reductions after the stay -at-home orders were \nimposed.  Volumes have remained steady, however, below pre -pandemic levels.  \n \n In our UK business, we identified an o pportunity to accelerate our transition to digital.  Our investment in Echo and \nour digital capabilities led to strong growth in our online business, and we moved quickly to increase capacity. \n Revenues from our Echo business grew over 300% from pre -pandemic  levels and continue on a strong growth \ntrajectory.  \n \n Our investment in digital health care strategy in the UK positions us to benefit from the movement of patients to a \ndigital environment.  However, given the severity of the COVID impact and the uncertain outlook, we are \naccelerating actions in our UK business.  \n \n", "original_text": "Our investment in Echo and \nour digital capabilities led to strong growth in our online business, and we moved quickly to increase capacity. \n", "page_label": "9", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "76d38cf00574de288d4cf89c996fd500b630335e2f2adf34b2b1abbbd0e5d93c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "86ad7eaf-ad05-4ef3-91e0-0eedcf44f933", "node_type": "1", "metadata": {"window": "In our UK business, we identified an o pportunity to accelerate our transition to digital.  Our investment in Echo and \nour digital capabilities led to strong growth in our online business, and we moved quickly to increase capacity. \n Revenues from our Echo business grew over 300% from pre -pandemic  levels and continue on a strong growth \ntrajectory.  \n \n Our investment in digital health care strategy in the UK positions us to benefit from the movement of patients to a \ndigital environment.  However, given the severity of the COVID impact and the uncertain outlook, we are \naccelerating actions in our UK business.  \n \n During the quarter, we announced restructuring actions in the UK to adapt to the difficult and evolving operating \nenvironment in the wake of COVID and to continue to better position the business for  future profitability.  As a \nresult, we took incremental charges in the quarter, which include further rationalization of our footprint in UK along \nwith additional cost optimization efforts.  \n \n", "original_text": "Our investment in digital health care strategy in the UK positions us to benefit from the movement of patients to a \ndigital environment. "}, "hash": "e5733d66a137feee59f6f188812b7363081faf9cdb1c36fba61c3ebe9c2c93bb", "class_name": "RelatedNodeInfo"}}, "text": "Revenues from our Echo business grew over 300% from pre -pandemic  levels and continue on a strong growth \ntrajectory.  \n \n", "start_char_idx": 601, "end_char_idx": 724, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "86ad7eaf-ad05-4ef3-91e0-0eedcf44f933": {"__data__": {"id_": "86ad7eaf-ad05-4ef3-91e0-0eedcf44f933", "embedding": null, "metadata": {"window": "In our UK business, we identified an o pportunity to accelerate our transition to digital.  Our investment in Echo and \nour digital capabilities led to strong growth in our online business, and we moved quickly to increase capacity. \n Revenues from our Echo business grew over 300% from pre -pandemic  levels and continue on a strong growth \ntrajectory.  \n \n Our investment in digital health care strategy in the UK positions us to benefit from the movement of patients to a \ndigital environment.  However, given the severity of the COVID impact and the uncertain outlook, we are \naccelerating actions in our UK business.  \n \n During the quarter, we announced restructuring actions in the UK to adapt to the difficult and evolving operating \nenvironment in the wake of COVID and to continue to better position the business for  future profitability.  As a \nresult, we took incremental charges in the quarter, which include further rationalization of our footprint in UK along \nwith additional cost optimization efforts.  \n \n", "original_text": "Our investment in digital health care strategy in the UK positions us to benefit from the movement of patients to a \ndigital environment. ", "page_label": "9", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e6763537-8e0b-4f34-ba9a-81920191e975", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f597ca48f373ba59aee380110f1eb95b1f75682f116e5ec6ca0710508c820240", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0e536704-f6cd-4e9d-8b58-bad24a493abf", "node_type": "1", "metadata": {"window": "Volumes have remained steady, however, below pre -pandemic levels.  \n \n In our UK business, we identified an o pportunity to accelerate our transition to digital.  Our investment in Echo and \nour digital capabilities led to strong growth in our online business, and we moved quickly to increase capacity. \n Revenues from our Echo business grew over 300% from pre -pandemic  levels and continue on a strong growth \ntrajectory.  \n \n Our investment in digital health care strategy in the UK positions us to benefit from the movement of patients to a \ndigital environment.  However, given the severity of the COVID impact and the uncertain outlook, we are \naccelerating actions in our UK business.  \n \n During the quarter, we announced restructuring actions in the UK to adapt to the difficult and evolving operating \nenvironment in the wake of COVID and to continue to better position the business for  future profitability. ", "original_text": "Revenues from our Echo business grew over 300% from pre -pandemic  levels and continue on a strong growth \ntrajectory.  \n \n", "page_label": "9", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "99dc40dd6319f22ea3b18a9965174767f789fde7f07368ff537f6505e237b7d8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5a627c50-4887-4679-bf81-f570fe35e63d", "node_type": "1", "metadata": {"window": "Our investment in Echo and \nour digital capabilities led to strong growth in our online business, and we moved quickly to increase capacity. \n Revenues from our Echo business grew over 300% from pre -pandemic  levels and continue on a strong growth \ntrajectory.  \n \n Our investment in digital health care strategy in the UK positions us to benefit from the movement of patients to a \ndigital environment.  However, given the severity of the COVID impact and the uncertain outlook, we are \naccelerating actions in our UK business.  \n \n During the quarter, we announced restructuring actions in the UK to adapt to the difficult and evolving operating \nenvironment in the wake of COVID and to continue to better position the business for  future profitability.  As a \nresult, we took incremental charges in the quarter, which include further rationalization of our footprint in UK along \nwith additional cost optimization efforts.  \n \n Moving now to Medical -Surgical Solutions. ", "original_text": "However, given the severity of the COVID impact and the uncertain outlook, we are \naccelerating actions in our UK business.  \n \n"}, "hash": "701b870e627589b426ba89211906f7fbfc0714e4e672b576609fccbf982a6b86", "class_name": "RelatedNodeInfo"}}, "text": "Our investment in digital health care strategy in the UK positions us to benefit from the movement of patients to a \ndigital environment. ", "start_char_idx": 724, "end_char_idx": 862, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5a627c50-4887-4679-bf81-f570fe35e63d": {"__data__": {"id_": "5a627c50-4887-4679-bf81-f570fe35e63d", "embedding": null, "metadata": {"window": "Our investment in Echo and \nour digital capabilities led to strong growth in our online business, and we moved quickly to increase capacity. \n Revenues from our Echo business grew over 300% from pre -pandemic  levels and continue on a strong growth \ntrajectory.  \n \n Our investment in digital health care strategy in the UK positions us to benefit from the movement of patients to a \ndigital environment.  However, given the severity of the COVID impact and the uncertain outlook, we are \naccelerating actions in our UK business.  \n \n During the quarter, we announced restructuring actions in the UK to adapt to the difficult and evolving operating \nenvironment in the wake of COVID and to continue to better position the business for  future profitability.  As a \nresult, we took incremental charges in the quarter, which include further rationalization of our footprint in UK along \nwith additional cost optimization efforts.  \n \n Moving now to Medical -Surgical Solutions. ", "original_text": "However, given the severity of the COVID impact and the uncertain outlook, we are \naccelerating actions in our UK business.  \n \n", "page_label": "9", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e6763537-8e0b-4f34-ba9a-81920191e975", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f597ca48f373ba59aee380110f1eb95b1f75682f116e5ec6ca0710508c820240", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "86ad7eaf-ad05-4ef3-91e0-0eedcf44f933", "node_type": "1", "metadata": {"window": "In our UK business, we identified an o pportunity to accelerate our transition to digital.  Our investment in Echo and \nour digital capabilities led to strong growth in our online business, and we moved quickly to increase capacity. \n Revenues from our Echo business grew over 300% from pre -pandemic  levels and continue on a strong growth \ntrajectory.  \n \n Our investment in digital health care strategy in the UK positions us to benefit from the movement of patients to a \ndigital environment.  However, given the severity of the COVID impact and the uncertain outlook, we are \naccelerating actions in our UK business.  \n \n During the quarter, we announced restructuring actions in the UK to adapt to the difficult and evolving operating \nenvironment in the wake of COVID and to continue to better position the business for  future profitability.  As a \nresult, we took incremental charges in the quarter, which include further rationalization of our footprint in UK along \nwith additional cost optimization efforts.  \n \n", "original_text": "Our investment in digital health care strategy in the UK positions us to benefit from the movement of patients to a \ndigital environment. ", "page_label": "9", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4aef7f5c5e034a788ba4b8d1764cf9bde3e9b40a7ba0f06d77fadcd643f4781d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "30519e88-16c0-41f9-a4b4-b7bf437c4df9", "node_type": "1", "metadata": {"window": "Revenues from our Echo business grew over 300% from pre -pandemic  levels and continue on a strong growth \ntrajectory.  \n \n Our investment in digital health care strategy in the UK positions us to benefit from the movement of patients to a \ndigital environment.  However, given the severity of the COVID impact and the uncertain outlook, we are \naccelerating actions in our UK business.  \n \n During the quarter, we announced restructuring actions in the UK to adapt to the difficult and evolving operating \nenvironment in the wake of COVID and to continue to better position the business for  future profitability.  As a \nresult, we took incremental charges in the quarter, which include further rationalization of our footprint in UK along \nwith additional cost optimization efforts.  \n \n Moving now to Medical -Surgical Solutions.  We're encouraged to see  improved patient mobility and procedures \nstarting to return versus what we saw at the onset of the pandemic. ", "original_text": "During the quarter, we announced restructuring actions in the UK to adapt to the difficult and evolving operating \nenvironment in the wake of COVID and to continue to better position the business for  future profitability. "}, "hash": "cda1f5cfa68fa61e8a01640bc7ac4721183547fa6fed317019f9f80e66a226d5", "class_name": "RelatedNodeInfo"}}, "text": "However, given the severity of the COVID impact and the uncertain outlook, we are \naccelerating actions in our UK business.  \n \n", "start_char_idx": 862, "end_char_idx": 990, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "30519e88-16c0-41f9-a4b4-b7bf437c4df9": {"__data__": {"id_": "30519e88-16c0-41f9-a4b4-b7bf437c4df9", "embedding": null, "metadata": {"window": "Revenues from our Echo business grew over 300% from pre -pandemic  levels and continue on a strong growth \ntrajectory.  \n \n Our investment in digital health care strategy in the UK positions us to benefit from the movement of patients to a \ndigital environment.  However, given the severity of the COVID impact and the uncertain outlook, we are \naccelerating actions in our UK business.  \n \n During the quarter, we announced restructuring actions in the UK to adapt to the difficult and evolving operating \nenvironment in the wake of COVID and to continue to better position the business for  future profitability.  As a \nresult, we took incremental charges in the quarter, which include further rationalization of our footprint in UK along \nwith additional cost optimization efforts.  \n \n Moving now to Medical -Surgical Solutions.  We're encouraged to see  improved patient mobility and procedures \nstarting to return versus what we saw at the onset of the pandemic. ", "original_text": "During the quarter, we announced restructuring actions in the UK to adapt to the difficult and evolving operating \nenvironment in the wake of COVID and to continue to better position the business for  future profitability. ", "page_label": "9", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e6763537-8e0b-4f34-ba9a-81920191e975", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f597ca48f373ba59aee380110f1eb95b1f75682f116e5ec6ca0710508c820240", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5a627c50-4887-4679-bf81-f570fe35e63d", "node_type": "1", "metadata": {"window": "Our investment in Echo and \nour digital capabilities led to strong growth in our online business, and we moved quickly to increase capacity. \n Revenues from our Echo business grew over 300% from pre -pandemic  levels and continue on a strong growth \ntrajectory.  \n \n Our investment in digital health care strategy in the UK positions us to benefit from the movement of patients to a \ndigital environment.  However, given the severity of the COVID impact and the uncertain outlook, we are \naccelerating actions in our UK business.  \n \n During the quarter, we announced restructuring actions in the UK to adapt to the difficult and evolving operating \nenvironment in the wake of COVID and to continue to better position the business for  future profitability.  As a \nresult, we took incremental charges in the quarter, which include further rationalization of our footprint in UK along \nwith additional cost optimization efforts.  \n \n Moving now to Medical -Surgical Solutions. ", "original_text": "However, given the severity of the COVID impact and the uncertain outlook, we are \naccelerating actions in our UK business.  \n \n", "page_label": "9", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "516ab6ee15607d917ab8bba7e0f324494e568f2ee36c736957f28387bdd6a8ab", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "45426c9e-fd2c-4c85-ae5d-83e1429f3864", "node_type": "1", "metadata": {"window": "Our investment in digital health care strategy in the UK positions us to benefit from the movement of patients to a \ndigital environment.  However, given the severity of the COVID impact and the uncertain outlook, we are \naccelerating actions in our UK business.  \n \n During the quarter, we announced restructuring actions in the UK to adapt to the difficult and evolving operating \nenvironment in the wake of COVID and to continue to better position the business for  future profitability.  As a \nresult, we took incremental charges in the quarter, which include further rationalization of our footprint in UK along \nwith additional cost optimization efforts.  \n \n Moving now to Medical -Surgical Solutions.  We're encouraged to see  improved patient mobility and procedures \nstarting to return versus what we saw at the onset of the pandemic.  For example, according to IQVIA, April in \nperson primary care visits were down nearly 70% and that improved to approximately 10% to 15% declines a s of \nlate June.  \n \n", "original_text": "As a \nresult, we took incremental charges in the quarter, which include further rationalization of our footprint in UK along \nwith additional cost optimization efforts.  \n \n"}, "hash": "a589f52110e2d84a15d914f239a8301cdd54bee2c2cae8b41d1dc2442a5408ee", "class_name": "RelatedNodeInfo"}}, "text": "During the quarter, we announced restructuring actions in the UK to adapt to the difficult and evolving operating \nenvironment in the wake of COVID and to continue to better position the business for  future profitability. ", "start_char_idx": 990, "end_char_idx": 1213, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "45426c9e-fd2c-4c85-ae5d-83e1429f3864": {"__data__": {"id_": "45426c9e-fd2c-4c85-ae5d-83e1429f3864", "embedding": null, "metadata": {"window": "Our investment in digital health care strategy in the UK positions us to benefit from the movement of patients to a \ndigital environment.  However, given the severity of the COVID impact and the uncertain outlook, we are \naccelerating actions in our UK business.  \n \n During the quarter, we announced restructuring actions in the UK to adapt to the difficult and evolving operating \nenvironment in the wake of COVID and to continue to better position the business for  future profitability.  As a \nresult, we took incremental charges in the quarter, which include further rationalization of our footprint in UK along \nwith additional cost optimization efforts.  \n \n Moving now to Medical -Surgical Solutions.  We're encouraged to see  improved patient mobility and procedures \nstarting to return versus what we saw at the onset of the pandemic.  For example, according to IQVIA, April in \nperson primary care visits were down nearly 70% and that improved to approximately 10% to 15% declines a s of \nlate June.  \n \n", "original_text": "As a \nresult, we took incremental charges in the quarter, which include further rationalization of our footprint in UK along \nwith additional cost optimization efforts.  \n \n", "page_label": "9", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e6763537-8e0b-4f34-ba9a-81920191e975", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f597ca48f373ba59aee380110f1eb95b1f75682f116e5ec6ca0710508c820240", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "30519e88-16c0-41f9-a4b4-b7bf437c4df9", "node_type": "1", "metadata": {"window": "Revenues from our Echo business grew over 300% from pre -pandemic  levels and continue on a strong growth \ntrajectory.  \n \n Our investment in digital health care strategy in the UK positions us to benefit from the movement of patients to a \ndigital environment.  However, given the severity of the COVID impact and the uncertain outlook, we are \naccelerating actions in our UK business.  \n \n During the quarter, we announced restructuring actions in the UK to adapt to the difficult and evolving operating \nenvironment in the wake of COVID and to continue to better position the business for  future profitability.  As a \nresult, we took incremental charges in the quarter, which include further rationalization of our footprint in UK along \nwith additional cost optimization efforts.  \n \n Moving now to Medical -Surgical Solutions.  We're encouraged to see  improved patient mobility and procedures \nstarting to return versus what we saw at the onset of the pandemic. ", "original_text": "During the quarter, we announced restructuring actions in the UK to adapt to the difficult and evolving operating \nenvironment in the wake of COVID and to continue to better position the business for  future profitability. ", "page_label": "9", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3583debd97d84c8a8f3804d83785aaa2e6ebb7bca48090db8940aae2fef6593d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b261580d-a592-494d-9a34-b7d7be10407b", "node_type": "1", "metadata": {"window": "However, given the severity of the COVID impact and the uncertain outlook, we are \naccelerating actions in our UK business.  \n \n During the quarter, we announced restructuring actions in the UK to adapt to the difficult and evolving operating \nenvironment in the wake of COVID and to continue to better position the business for  future profitability.  As a \nresult, we took incremental charges in the quarter, which include further rationalization of our footprint in UK along \nwith additional cost optimization efforts.  \n \n Moving now to Medical -Surgical Solutions.  We're encouraged to see  improved patient mobility and procedures \nstarting to return versus what we saw at the onset of the pandemic.  For example, according to IQVIA, April in \nperson primary care visits were down nearly 70% and that improved to approximately 10% to 15% declines a s of \nlate June.  \n \n Revenues were $1.8 billion for the quarter, which were down 5% driven by the pandemic's impact on volume in \nour primary care business, partially offset by growth in the extended care business. ", "original_text": "Moving now to Medical -Surgical Solutions. "}, "hash": "f62adfa412008dd9f10d4a3dee15ed174f8a720ecf8a58df09d3176380fb1917", "class_name": "RelatedNodeInfo"}}, "text": "As a \nresult, we took incremental charges in the quarter, which include further rationalization of our footprint in UK along \nwith additional cost optimization efforts.  \n \n", "start_char_idx": 1213, "end_char_idx": 1386, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b261580d-a592-494d-9a34-b7d7be10407b": {"__data__": {"id_": "b261580d-a592-494d-9a34-b7d7be10407b", "embedding": null, "metadata": {"window": "However, given the severity of the COVID impact and the uncertain outlook, we are \naccelerating actions in our UK business.  \n \n During the quarter, we announced restructuring actions in the UK to adapt to the difficult and evolving operating \nenvironment in the wake of COVID and to continue to better position the business for  future profitability.  As a \nresult, we took incremental charges in the quarter, which include further rationalization of our footprint in UK along \nwith additional cost optimization efforts.  \n \n Moving now to Medical -Surgical Solutions.  We're encouraged to see  improved patient mobility and procedures \nstarting to return versus what we saw at the onset of the pandemic.  For example, according to IQVIA, April in \nperson primary care visits were down nearly 70% and that improved to approximately 10% to 15% declines a s of \nlate June.  \n \n Revenues were $1.8 billion for the quarter, which were down 5% driven by the pandemic's impact on volume in \nour primary care business, partially offset by growth in the extended care business. ", "original_text": "Moving now to Medical -Surgical Solutions. ", "page_label": "9", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e6763537-8e0b-4f34-ba9a-81920191e975", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f597ca48f373ba59aee380110f1eb95b1f75682f116e5ec6ca0710508c820240", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "45426c9e-fd2c-4c85-ae5d-83e1429f3864", "node_type": "1", "metadata": {"window": "Our investment in digital health care strategy in the UK positions us to benefit from the movement of patients to a \ndigital environment.  However, given the severity of the COVID impact and the uncertain outlook, we are \naccelerating actions in our UK business.  \n \n During the quarter, we announced restructuring actions in the UK to adapt to the difficult and evolving operating \nenvironment in the wake of COVID and to continue to better position the business for  future profitability.  As a \nresult, we took incremental charges in the quarter, which include further rationalization of our footprint in UK along \nwith additional cost optimization efforts.  \n \n Moving now to Medical -Surgical Solutions.  We're encouraged to see  improved patient mobility and procedures \nstarting to return versus what we saw at the onset of the pandemic.  For example, according to IQVIA, April in \nperson primary care visits were down nearly 70% and that improved to approximately 10% to 15% declines a s of \nlate June.  \n \n", "original_text": "As a \nresult, we took incremental charges in the quarter, which include further rationalization of our footprint in UK along \nwith additional cost optimization efforts.  \n \n", "page_label": "9", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cb05b4249c71b2eb0cca59bc068bc7a4d437aa7f2b27545c3c6387cfc7202299", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "24ebe660-588e-44bf-8c10-11d64c786ce7", "node_type": "1", "metadata": {"window": "During the quarter, we announced restructuring actions in the UK to adapt to the difficult and evolving operating \nenvironment in the wake of COVID and to continue to better position the business for  future profitability.  As a \nresult, we took incremental charges in the quarter, which include further rationalization of our footprint in UK along \nwith additional cost optimization efforts.  \n \n Moving now to Medical -Surgical Solutions.  We're encouraged to see  improved patient mobility and procedures \nstarting to return versus what we saw at the onset of the pandemic.  For example, according to IQVIA, April in \nperson primary care visits were down nearly 70% and that improved to approximately 10% to 15% declines a s of \nlate June.  \n \n Revenues were $1.8 billion for the quarter, which were down 5% driven by the pandemic's impact on volume in \nour primary care business, partially offset by growth in the extended care business.  First quarter revenues include \nincreased volum es of personal protective equipment.  \n \n", "original_text": "We're encouraged to see  improved patient mobility and procedures \nstarting to return versus what we saw at the onset of the pandemic. "}, "hash": "510f5c4cfd40fd3ae14b71d1275d1adc0b8a1f2b5610451a369ff7d4dc19b6a7", "class_name": "RelatedNodeInfo"}}, "text": "Moving now to Medical -Surgical Solutions. ", "start_char_idx": 1386, "end_char_idx": 1429, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "24ebe660-588e-44bf-8c10-11d64c786ce7": {"__data__": {"id_": "24ebe660-588e-44bf-8c10-11d64c786ce7", "embedding": null, "metadata": {"window": "During the quarter, we announced restructuring actions in the UK to adapt to the difficult and evolving operating \nenvironment in the wake of COVID and to continue to better position the business for  future profitability.  As a \nresult, we took incremental charges in the quarter, which include further rationalization of our footprint in UK along \nwith additional cost optimization efforts.  \n \n Moving now to Medical -Surgical Solutions.  We're encouraged to see  improved patient mobility and procedures \nstarting to return versus what we saw at the onset of the pandemic.  For example, according to IQVIA, April in \nperson primary care visits were down nearly 70% and that improved to approximately 10% to 15% declines a s of \nlate June.  \n \n Revenues were $1.8 billion for the quarter, which were down 5% driven by the pandemic's impact on volume in \nour primary care business, partially offset by growth in the extended care business.  First quarter revenues include \nincreased volum es of personal protective equipment.  \n \n", "original_text": "We're encouraged to see  improved patient mobility and procedures \nstarting to return versus what we saw at the onset of the pandemic. ", "page_label": "9", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e6763537-8e0b-4f34-ba9a-81920191e975", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f597ca48f373ba59aee380110f1eb95b1f75682f116e5ec6ca0710508c820240", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b261580d-a592-494d-9a34-b7d7be10407b", "node_type": "1", "metadata": {"window": "However, given the severity of the COVID impact and the uncertain outlook, we are \naccelerating actions in our UK business.  \n \n During the quarter, we announced restructuring actions in the UK to adapt to the difficult and evolving operating \nenvironment in the wake of COVID and to continue to better position the business for  future profitability.  As a \nresult, we took incremental charges in the quarter, which include further rationalization of our footprint in UK along \nwith additional cost optimization efforts.  \n \n Moving now to Medical -Surgical Solutions.  We're encouraged to see  improved patient mobility and procedures \nstarting to return versus what we saw at the onset of the pandemic.  For example, according to IQVIA, April in \nperson primary care visits were down nearly 70% and that improved to approximately 10% to 15% declines a s of \nlate June.  \n \n Revenues were $1.8 billion for the quarter, which were down 5% driven by the pandemic's impact on volume in \nour primary care business, partially offset by growth in the extended care business. ", "original_text": "Moving now to Medical -Surgical Solutions. ", "page_label": "9", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b5292b946f39b4628f072270088114f0f112e2410a23705c1338575ff86b135d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b840aca7-2518-473e-946e-ffa1e306f6f9", "node_type": "1", "metadata": {"window": "As a \nresult, we took incremental charges in the quarter, which include further rationalization of our footprint in UK along \nwith additional cost optimization efforts.  \n \n Moving now to Medical -Surgical Solutions.  We're encouraged to see  improved patient mobility and procedures \nstarting to return versus what we saw at the onset of the pandemic.  For example, according to IQVIA, April in \nperson primary care visits were down nearly 70% and that improved to approximately 10% to 15% declines a s of \nlate June.  \n \n Revenues were $1.8 billion for the quarter, which were down 5% driven by the pandemic's impact on volume in \nour primary care business, partially offset by growth in the extended care business.  First quarter revenues include \nincreased volum es of personal protective equipment.  \n \n First quarter adjusted operating profit decreased 22% to $124 million, driven by lower demand in the primary care \nbusiness, in part due to temporary closures of physician offices across the US, as a result of shelter -in-place \nguidelines. ", "original_text": "For example, according to IQVIA, April in \nperson primary care visits were down nearly 70% and that improved to approximately 10% to 15% declines a s of \nlate June.  \n \n"}, "hash": "b45c29a46a4e4c27cfccbfd8e01e8c6b1215f13fc124629f3c2a8b6e220fe93a", "class_name": "RelatedNodeInfo"}}, "text": "We're encouraged to see  improved patient mobility and procedures \nstarting to return versus what we saw at the onset of the pandemic. ", "start_char_idx": 1429, "end_char_idx": 1564, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b840aca7-2518-473e-946e-ffa1e306f6f9": {"__data__": {"id_": "b840aca7-2518-473e-946e-ffa1e306f6f9", "embedding": null, "metadata": {"window": "As a \nresult, we took incremental charges in the quarter, which include further rationalization of our footprint in UK along \nwith additional cost optimization efforts.  \n \n Moving now to Medical -Surgical Solutions.  We're encouraged to see  improved patient mobility and procedures \nstarting to return versus what we saw at the onset of the pandemic.  For example, according to IQVIA, April in \nperson primary care visits were down nearly 70% and that improved to approximately 10% to 15% declines a s of \nlate June.  \n \n Revenues were $1.8 billion for the quarter, which were down 5% driven by the pandemic's impact on volume in \nour primary care business, partially offset by growth in the extended care business.  First quarter revenues include \nincreased volum es of personal protective equipment.  \n \n First quarter adjusted operating profit decreased 22% to $124 million, driven by lower demand in the primary care \nbusiness, in part due to temporary closures of physician offices across the US, as a result of shelter -in-place \nguidelines. ", "original_text": "For example, according to IQVIA, April in \nperson primary care visits were down nearly 70% and that improved to approximately 10% to 15% declines a s of \nlate June.  \n \n", "page_label": "9", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e6763537-8e0b-4f34-ba9a-81920191e975", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f597ca48f373ba59aee380110f1eb95b1f75682f116e5ec6ca0710508c820240", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "24ebe660-588e-44bf-8c10-11d64c786ce7", "node_type": "1", "metadata": {"window": "During the quarter, we announced restructuring actions in the UK to adapt to the difficult and evolving operating \nenvironment in the wake of COVID and to continue to better position the business for  future profitability.  As a \nresult, we took incremental charges in the quarter, which include further rationalization of our footprint in UK along \nwith additional cost optimization efforts.  \n \n Moving now to Medical -Surgical Solutions.  We're encouraged to see  improved patient mobility and procedures \nstarting to return versus what we saw at the onset of the pandemic.  For example, according to IQVIA, April in \nperson primary care visits were down nearly 70% and that improved to approximately 10% to 15% declines a s of \nlate June.  \n \n Revenues were $1.8 billion for the quarter, which were down 5% driven by the pandemic's impact on volume in \nour primary care business, partially offset by growth in the extended care business.  First quarter revenues include \nincreased volum es of personal protective equipment.  \n \n", "original_text": "We're encouraged to see  improved patient mobility and procedures \nstarting to return versus what we saw at the onset of the pandemic. ", "page_label": "9", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "92a2e919e837f890944688c91e8a9b873134f1dc3295668a7736f3e3de7df463", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "49dc44da-305b-42d0-bdfc-3fd21ccfb803", "node_type": "1", "metadata": {"window": "Moving now to Medical -Surgical Solutions.  We're encouraged to see  improved patient mobility and procedures \nstarting to return versus what we saw at the onset of the pandemic.  For example, according to IQVIA, April in \nperson primary care visits were down nearly 70% and that improved to approximately 10% to 15% declines a s of \nlate June.  \n \n Revenues were $1.8 billion for the quarter, which were down 5% driven by the pandemic's impact on volume in \nour primary care business, partially offset by growth in the extended care business.  First quarter revenues include \nincreased volum es of personal protective equipment.  \n \n First quarter adjusted operating profit decreased 22% to $124 million, driven by lower demand in the primary care \nbusiness, in part due to temporary closures of physician offices across the US, as a result of shelter -in-place \nguidelines.  Segment adjusted operating margin for the first quarter was 689 basis points, a decrease of 147 basis \npoints driven primarily by customer and product mix.  \n \n", "original_text": "Revenues were $1.8 billion for the quarter, which were down 5% driven by the pandemic's impact on volume in \nour primary care business, partially offset by growth in the extended care business. "}, "hash": "4493e9a9b48ba474bd766e02bd1c494505d33f4adca94589a5a37c8f8c9299df", "class_name": "RelatedNodeInfo"}}, "text": "For example, according to IQVIA, April in \nperson primary care visits were down nearly 70% and that improved to approximately 10% to 15% declines a s of \nlate June.  \n \n", "start_char_idx": 1564, "end_char_idx": 1733, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "49dc44da-305b-42d0-bdfc-3fd21ccfb803": {"__data__": {"id_": "49dc44da-305b-42d0-bdfc-3fd21ccfb803", "embedding": null, "metadata": {"window": "Moving now to Medical -Surgical Solutions.  We're encouraged to see  improved patient mobility and procedures \nstarting to return versus what we saw at the onset of the pandemic.  For example, according to IQVIA, April in \nperson primary care visits were down nearly 70% and that improved to approximately 10% to 15% declines a s of \nlate June.  \n \n Revenues were $1.8 billion for the quarter, which were down 5% driven by the pandemic's impact on volume in \nour primary care business, partially offset by growth in the extended care business.  First quarter revenues include \nincreased volum es of personal protective equipment.  \n \n First quarter adjusted operating profit decreased 22% to $124 million, driven by lower demand in the primary care \nbusiness, in part due to temporary closures of physician offices across the US, as a result of shelter -in-place \nguidelines.  Segment adjusted operating margin for the first quarter was 689 basis points, a decrease of 147 basis \npoints driven primarily by customer and product mix.  \n \n", "original_text": "Revenues were $1.8 billion for the quarter, which were down 5% driven by the pandemic's impact on volume in \nour primary care business, partially offset by growth in the extended care business. ", "page_label": "9", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e6763537-8e0b-4f34-ba9a-81920191e975", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f597ca48f373ba59aee380110f1eb95b1f75682f116e5ec6ca0710508c820240", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b840aca7-2518-473e-946e-ffa1e306f6f9", "node_type": "1", "metadata": {"window": "As a \nresult, we took incremental charges in the quarter, which include further rationalization of our footprint in UK along \nwith additional cost optimization efforts.  \n \n Moving now to Medical -Surgical Solutions.  We're encouraged to see  improved patient mobility and procedures \nstarting to return versus what we saw at the onset of the pandemic.  For example, according to IQVIA, April in \nperson primary care visits were down nearly 70% and that improved to approximately 10% to 15% declines a s of \nlate June.  \n \n Revenues were $1.8 billion for the quarter, which were down 5% driven by the pandemic's impact on volume in \nour primary care business, partially offset by growth in the extended care business.  First quarter revenues include \nincreased volum es of personal protective equipment.  \n \n First quarter adjusted operating profit decreased 22% to $124 million, driven by lower demand in the primary care \nbusiness, in part due to temporary closures of physician offices across the US, as a result of shelter -in-place \nguidelines. ", "original_text": "For example, according to IQVIA, April in \nperson primary care visits were down nearly 70% and that improved to approximately 10% to 15% declines a s of \nlate June.  \n \n", "page_label": "9", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "90c361c45b6fce9b787c484329766dd1db5c7454a91219e5630cd8bbbab18634", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "54bf5c73-da44-4798-aa41-9a5b31128ac8", "node_type": "1", "metadata": {"window": "We're encouraged to see  improved patient mobility and procedures \nstarting to return versus what we saw at the onset of the pandemic.  For example, according to IQVIA, April in \nperson primary care visits were down nearly 70% and that improved to approximately 10% to 15% declines a s of \nlate June.  \n \n Revenues were $1.8 billion for the quarter, which were down 5% driven by the pandemic's impact on volume in \nour primary care business, partially offset by growth in the extended care business.  First quarter revenues include \nincreased volum es of personal protective equipment.  \n \n First quarter adjusted operating profit decreased 22% to $124 million, driven by lower demand in the primary care \nbusiness, in part due to temporary closures of physician offices across the US, as a result of shelter -in-place \nguidelines.  Segment adjusted operating margin for the first quarter was 689 basis points, a decrease of 147 basis \npoints driven primarily by customer and product mix.  \n \n And finishing our business review with Other. ", "original_text": "First quarter revenues include \nincreased volum es of personal protective equipment.  \n \n"}, "hash": "49dab164829f541d21e8a9a7df61109496bc184ca9a3e5bbc9c58e5667800689", "class_name": "RelatedNodeInfo"}}, "text": "Revenues were $1.8 billion for the quarter, which were down 5% driven by the pandemic's impact on volume in \nour primary care business, partially offset by growth in the extended care business. ", "start_char_idx": 1733, "end_char_idx": 1927, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "54bf5c73-da44-4798-aa41-9a5b31128ac8": {"__data__": {"id_": "54bf5c73-da44-4798-aa41-9a5b31128ac8", "embedding": null, "metadata": {"window": "We're encouraged to see  improved patient mobility and procedures \nstarting to return versus what we saw at the onset of the pandemic.  For example, according to IQVIA, April in \nperson primary care visits were down nearly 70% and that improved to approximately 10% to 15% declines a s of \nlate June.  \n \n Revenues were $1.8 billion for the quarter, which were down 5% driven by the pandemic's impact on volume in \nour primary care business, partially offset by growth in the extended care business.  First quarter revenues include \nincreased volum es of personal protective equipment.  \n \n First quarter adjusted operating profit decreased 22% to $124 million, driven by lower demand in the primary care \nbusiness, in part due to temporary closures of physician offices across the US, as a result of shelter -in-place \nguidelines.  Segment adjusted operating margin for the first quarter was 689 basis points, a decrease of 147 basis \npoints driven primarily by customer and product mix.  \n \n And finishing our business review with Other. ", "original_text": "First quarter revenues include \nincreased volum es of personal protective equipment.  \n \n", "page_label": "9", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e6763537-8e0b-4f34-ba9a-81920191e975", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f597ca48f373ba59aee380110f1eb95b1f75682f116e5ec6ca0710508c820240", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "49dc44da-305b-42d0-bdfc-3fd21ccfb803", "node_type": "1", "metadata": {"window": "Moving now to Medical -Surgical Solutions.  We're encouraged to see  improved patient mobility and procedures \nstarting to return versus what we saw at the onset of the pandemic.  For example, according to IQVIA, April in \nperson primary care visits were down nearly 70% and that improved to approximately 10% to 15% declines a s of \nlate June.  \n \n Revenues were $1.8 billion for the quarter, which were down 5% driven by the pandemic's impact on volume in \nour primary care business, partially offset by growth in the extended care business.  First quarter revenues include \nincreased volum es of personal protective equipment.  \n \n First quarter adjusted operating profit decreased 22% to $124 million, driven by lower demand in the primary care \nbusiness, in part due to temporary closures of physician offices across the US, as a result of shelter -in-place \nguidelines.  Segment adjusted operating margin for the first quarter was 689 basis points, a decrease of 147 basis \npoints driven primarily by customer and product mix.  \n \n", "original_text": "Revenues were $1.8 billion for the quarter, which were down 5% driven by the pandemic's impact on volume in \nour primary care business, partially offset by growth in the extended care business. ", "page_label": "9", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f6866a24a979e7f5a1c41ae284017eced68345f6e8fd59ae5605be3f2ae61fa0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "53b548ea-1e7f-448b-89b8-1920e1985edf", "node_type": "1", "metadata": {"window": "For example, according to IQVIA, April in \nperson primary care visits were down nearly 70% and that improved to approximately 10% to 15% declines a s of \nlate June.  \n \n Revenues were $1.8 billion for the quarter, which were down 5% driven by the pandemic's impact on volume in \nour primary care business, partially offset by growth in the extended care business.  First quarter revenues include \nincreased volum es of personal protective equipment.  \n \n First quarter adjusted operating profit decreased 22% to $124 million, driven by lower demand in the primary care \nbusiness, in part due to temporary closures of physician offices across the US, as a result of shelter -in-place \nguidelines.  Segment adjusted operating margin for the first quarter was 689 basis points, a decrease of 147 basis \npoints driven primarily by customer and product mix.  \n \n And finishing our business review with Other.  Revenues were $2.6 billion for the  quarter, a decrease of 13% year -\nover-year. ", "original_text": "First quarter adjusted operating profit decreased 22% to $124 million, driven by lower demand in the primary care \nbusiness, in part due to temporary closures of physician offices across the US, as a result of shelter -in-place \nguidelines. "}, "hash": "420e174674d1d782762a763e489c215d4e8de4e990cc833ebca29f02612d0662", "class_name": "RelatedNodeInfo"}}, "text": "First quarter revenues include \nincreased volum es of personal protective equipment.  \n \n", "start_char_idx": 1927, "end_char_idx": 2016, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "53b548ea-1e7f-448b-89b8-1920e1985edf": {"__data__": {"id_": "53b548ea-1e7f-448b-89b8-1920e1985edf", "embedding": null, "metadata": {"window": "For example, according to IQVIA, April in \nperson primary care visits were down nearly 70% and that improved to approximately 10% to 15% declines a s of \nlate June.  \n \n Revenues were $1.8 billion for the quarter, which were down 5% driven by the pandemic's impact on volume in \nour primary care business, partially offset by growth in the extended care business.  First quarter revenues include \nincreased volum es of personal protective equipment.  \n \n First quarter adjusted operating profit decreased 22% to $124 million, driven by lower demand in the primary care \nbusiness, in part due to temporary closures of physician offices across the US, as a result of shelter -in-place \nguidelines.  Segment adjusted operating margin for the first quarter was 689 basis points, a decrease of 147 basis \npoints driven primarily by customer and product mix.  \n \n And finishing our business review with Other.  Revenues were $2.6 billion for the  quarter, a decrease of 13% year -\nover-year. ", "original_text": "First quarter adjusted operating profit decreased 22% to $124 million, driven by lower demand in the primary care \nbusiness, in part due to temporary closures of physician offices across the US, as a result of shelter -in-place \nguidelines. ", "page_label": "9", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e6763537-8e0b-4f34-ba9a-81920191e975", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f597ca48f373ba59aee380110f1eb95b1f75682f116e5ec6ca0710508c820240", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "54bf5c73-da44-4798-aa41-9a5b31128ac8", "node_type": "1", "metadata": {"window": "We're encouraged to see  improved patient mobility and procedures \nstarting to return versus what we saw at the onset of the pandemic.  For example, according to IQVIA, April in \nperson primary care visits were down nearly 70% and that improved to approximately 10% to 15% declines a s of \nlate June.  \n \n Revenues were $1.8 billion for the quarter, which were down 5% driven by the pandemic's impact on volume in \nour primary care business, partially offset by growth in the extended care business.  First quarter revenues include \nincreased volum es of personal protective equipment.  \n \n First quarter adjusted operating profit decreased 22% to $124 million, driven by lower demand in the primary care \nbusiness, in part due to temporary closures of physician offices across the US, as a result of shelter -in-place \nguidelines.  Segment adjusted operating margin for the first quarter was 689 basis points, a decrease of 147 basis \npoints driven primarily by customer and product mix.  \n \n And finishing our business review with Other. ", "original_text": "First quarter revenues include \nincreased volum es of personal protective equipment.  \n \n", "page_label": "9", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f687f838895574e01308aa5bfdd7ef52b2220d861b933f88240e2b51ead2e6bb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4406edd2-a4f2-4aad-8b3b-1a949f9743c9", "node_type": "1", "metadata": {"window": "Revenues were $1.8 billion for the quarter, which were down 5% driven by the pandemic's impact on volume in \nour primary care business, partially offset by growth in the extended care business.  First quarter revenues include \nincreased volum es of personal protective equipment.  \n \n First quarter adjusted operating profit decreased 22% to $124 million, driven by lower demand in the primary care \nbusiness, in part due to temporary closures of physician offices across the US, as a result of shelter -in-place \nguidelines.  Segment adjusted operating margin for the first quarter was 689 basis points, a decrease of 147 basis \npoints driven primarily by customer and product mix.  \n \n And finishing our business review with Other.  Revenues were $2.6 billion for the  quarter, a decrease of 13% year -\nover-year.  On an FX -adjusted basis, revenues decreased 10% driven by lower volumes in the Canadian \nbusiness, which includes both the exit of an unprofitable customer at the onset of the fiscal year and the negative \nimpact o f the pandemic. ", "original_text": "Segment adjusted operating margin for the first quarter was 689 basis points, a decrease of 147 basis \npoints driven primarily by customer and product mix.  \n \n"}, "hash": "e5a910226b3b85998b7f96a43b1ceade68589ecf901a38a926a5218acc677447", "class_name": "RelatedNodeInfo"}}, "text": "First quarter adjusted operating profit decreased 22% to $124 million, driven by lower demand in the primary care \nbusiness, in part due to temporary closures of physician offices across the US, as a result of shelter -in-place \nguidelines. ", "start_char_idx": 2016, "end_char_idx": 2257, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4406edd2-a4f2-4aad-8b3b-1a949f9743c9": {"__data__": {"id_": "4406edd2-a4f2-4aad-8b3b-1a949f9743c9", "embedding": null, "metadata": {"window": "Revenues were $1.8 billion for the quarter, which were down 5% driven by the pandemic's impact on volume in \nour primary care business, partially offset by growth in the extended care business.  First quarter revenues include \nincreased volum es of personal protective equipment.  \n \n First quarter adjusted operating profit decreased 22% to $124 million, driven by lower demand in the primary care \nbusiness, in part due to temporary closures of physician offices across the US, as a result of shelter -in-place \nguidelines.  Segment adjusted operating margin for the first quarter was 689 basis points, a decrease of 147 basis \npoints driven primarily by customer and product mix.  \n \n And finishing our business review with Other.  Revenues were $2.6 billion for the  quarter, a decrease of 13% year -\nover-year.  On an FX -adjusted basis, revenues decreased 10% driven by lower volumes in the Canadian \nbusiness, which includes both the exit of an unprofitable customer at the onset of the fiscal year and the negative \nimpact o f the pandemic. ", "original_text": "Segment adjusted operating margin for the first quarter was 689 basis points, a decrease of 147 basis \npoints driven primarily by customer and product mix.  \n \n", "page_label": "9", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e6763537-8e0b-4f34-ba9a-81920191e975", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f597ca48f373ba59aee380110f1eb95b1f75682f116e5ec6ca0710508c820240", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "53b548ea-1e7f-448b-89b8-1920e1985edf", "node_type": "1", "metadata": {"window": "For example, according to IQVIA, April in \nperson primary care visits were down nearly 70% and that improved to approximately 10% to 15% declines a s of \nlate June.  \n \n Revenues were $1.8 billion for the quarter, which were down 5% driven by the pandemic's impact on volume in \nour primary care business, partially offset by growth in the extended care business.  First quarter revenues include \nincreased volum es of personal protective equipment.  \n \n First quarter adjusted operating profit decreased 22% to $124 million, driven by lower demand in the primary care \nbusiness, in part due to temporary closures of physician offices across the US, as a result of shelter -in-place \nguidelines.  Segment adjusted operating margin for the first quarter was 689 basis points, a decrease of 147 basis \npoints driven primarily by customer and product mix.  \n \n And finishing our business review with Other.  Revenues were $2.6 billion for the  quarter, a decrease of 13% year -\nover-year. ", "original_text": "First quarter adjusted operating profit decreased 22% to $124 million, driven by lower demand in the primary care \nbusiness, in part due to temporary closures of physician offices across the US, as a result of shelter -in-place \nguidelines. ", "page_label": "9", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3ceaba04fa203595af581723783bf2d6da247f061c2353c421c8fe26b810a8eb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "09664206-9c6a-46ae-aa12-5508fd4e421c", "node_type": "1", "metadata": {"window": "First quarter revenues include \nincreased volum es of personal protective equipment.  \n \n First quarter adjusted operating profit decreased 22% to $124 million, driven by lower demand in the primary care \nbusiness, in part due to temporary closures of physician offices across the US, as a result of shelter -in-place \nguidelines.  Segment adjusted operating margin for the first quarter was 689 basis points, a decrease of 147 basis \npoints driven primarily by customer and product mix.  \n \n And finishing our business review with Other.  Revenues were $2.6 billion for the  quarter, a decrease of 13% year -\nover-year.  On an FX -adjusted basis, revenues decreased 10% driven by lower volumes in the Canadian \nbusiness, which includes both the exit of an unprofitable customer at the onset of the fiscal year and the negative \nimpact o f the pandemic.  First quarter adjusted operating profit was $137 million, down 50% on both the reported \nand FX -adjusted basis driven primarily by the lapping of the prior year contribution of $108 million from the \ncompany's investment in Change Healthcare,  along with the negative impact of the pandemic on the businesses \nwithin other. ", "original_text": "And finishing our business review with Other. "}, "hash": "87b2c677665948c7426c807a82f84dbb0797578effbed103dcb94b0e7341027f", "class_name": "RelatedNodeInfo"}}, "text": "Segment adjusted operating margin for the first quarter was 689 basis points, a decrease of 147 basis \npoints driven primarily by customer and product mix.  \n \n", "start_char_idx": 2257, "end_char_idx": 2417, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "09664206-9c6a-46ae-aa12-5508fd4e421c": {"__data__": {"id_": "09664206-9c6a-46ae-aa12-5508fd4e421c", "embedding": null, "metadata": {"window": "First quarter revenues include \nincreased volum es of personal protective equipment.  \n \n First quarter adjusted operating profit decreased 22% to $124 million, driven by lower demand in the primary care \nbusiness, in part due to temporary closures of physician offices across the US, as a result of shelter -in-place \nguidelines.  Segment adjusted operating margin for the first quarter was 689 basis points, a decrease of 147 basis \npoints driven primarily by customer and product mix.  \n \n And finishing our business review with Other.  Revenues were $2.6 billion for the  quarter, a decrease of 13% year -\nover-year.  On an FX -adjusted basis, revenues decreased 10% driven by lower volumes in the Canadian \nbusiness, which includes both the exit of an unprofitable customer at the onset of the fiscal year and the negative \nimpact o f the pandemic.  First quarter adjusted operating profit was $137 million, down 50% on both the reported \nand FX -adjusted basis driven primarily by the lapping of the prior year contribution of $108 million from the \ncompany's investment in Change Healthcare,  along with the negative impact of the pandemic on the businesses \nwithin other. ", "original_text": "And finishing our business review with Other. ", "page_label": "9", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e6763537-8e0b-4f34-ba9a-81920191e975", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f597ca48f373ba59aee380110f1eb95b1f75682f116e5ec6ca0710508c820240", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4406edd2-a4f2-4aad-8b3b-1a949f9743c9", "node_type": "1", "metadata": {"window": "Revenues were $1.8 billion for the quarter, which were down 5% driven by the pandemic's impact on volume in \nour primary care business, partially offset by growth in the extended care business.  First quarter revenues include \nincreased volum es of personal protective equipment.  \n \n First quarter adjusted operating profit decreased 22% to $124 million, driven by lower demand in the primary care \nbusiness, in part due to temporary closures of physician offices across the US, as a result of shelter -in-place \nguidelines.  Segment adjusted operating margin for the first quarter was 689 basis points, a decrease of 147 basis \npoints driven primarily by customer and product mix.  \n \n And finishing our business review with Other.  Revenues were $2.6 billion for the  quarter, a decrease of 13% year -\nover-year.  On an FX -adjusted basis, revenues decreased 10% driven by lower volumes in the Canadian \nbusiness, which includes both the exit of an unprofitable customer at the onset of the fiscal year and the negative \nimpact o f the pandemic. ", "original_text": "Segment adjusted operating margin for the first quarter was 689 basis points, a decrease of 147 basis \npoints driven primarily by customer and product mix.  \n \n", "page_label": "9", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8b6d663dd57e6020f8afa04628c513456db70856ce50ea4bb46863e73a751cbb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1b2f27c0-f7c7-421f-9c89-1b57e8c4bc3c", "node_type": "1", "metadata": {"window": "First quarter adjusted operating profit decreased 22% to $124 million, driven by lower demand in the primary care \nbusiness, in part due to temporary closures of physician offices across the US, as a result of shelter -in-place \nguidelines.  Segment adjusted operating margin for the first quarter was 689 basis points, a decrease of 147 basis \npoints driven primarily by customer and product mix.  \n \n And finishing our business review with Other.  Revenues were $2.6 billion for the  quarter, a decrease of 13% year -\nover-year.  On an FX -adjusted basis, revenues decreased 10% driven by lower volumes in the Canadian \nbusiness, which includes both the exit of an unprofitable customer at the onset of the fiscal year and the negative \nimpact o f the pandemic.  First quarter adjusted operating profit was $137 million, down 50% on both the reported \nand FX -adjusted basis driven primarily by the lapping of the prior year contribution of $108 million from the \ncompany's investment in Change Healthcare,  along with the negative impact of the pandemic on the businesses \nwithin other.  Excluding the prior year contribution from Change, Other was down approximately 18% year -over-\nyear.  \n \n", "original_text": "Revenues were $2.6 billion for the  quarter, a decrease of 13% year -\nover-year. "}, "hash": "8e434e0ed0223973bfe3edcc4bcf0293497b5edf6d8341060b737641d6f44166", "class_name": "RelatedNodeInfo"}}, "text": "And finishing our business review with Other. ", "start_char_idx": 2417, "end_char_idx": 2463, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1b2f27c0-f7c7-421f-9c89-1b57e8c4bc3c": {"__data__": {"id_": "1b2f27c0-f7c7-421f-9c89-1b57e8c4bc3c", "embedding": null, "metadata": {"window": "First quarter adjusted operating profit decreased 22% to $124 million, driven by lower demand in the primary care \nbusiness, in part due to temporary closures of physician offices across the US, as a result of shelter -in-place \nguidelines.  Segment adjusted operating margin for the first quarter was 689 basis points, a decrease of 147 basis \npoints driven primarily by customer and product mix.  \n \n And finishing our business review with Other.  Revenues were $2.6 billion for the  quarter, a decrease of 13% year -\nover-year.  On an FX -adjusted basis, revenues decreased 10% driven by lower volumes in the Canadian \nbusiness, which includes both the exit of an unprofitable customer at the onset of the fiscal year and the negative \nimpact o f the pandemic.  First quarter adjusted operating profit was $137 million, down 50% on both the reported \nand FX -adjusted basis driven primarily by the lapping of the prior year contribution of $108 million from the \ncompany's investment in Change Healthcare,  along with the negative impact of the pandemic on the businesses \nwithin other.  Excluding the prior year contribution from Change, Other was down approximately 18% year -over-\nyear.  \n \n", "original_text": "Revenues were $2.6 billion for the  quarter, a decrease of 13% year -\nover-year. ", "page_label": "9", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e6763537-8e0b-4f34-ba9a-81920191e975", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f597ca48f373ba59aee380110f1eb95b1f75682f116e5ec6ca0710508c820240", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "09664206-9c6a-46ae-aa12-5508fd4e421c", "node_type": "1", "metadata": {"window": "First quarter revenues include \nincreased volum es of personal protective equipment.  \n \n First quarter adjusted operating profit decreased 22% to $124 million, driven by lower demand in the primary care \nbusiness, in part due to temporary closures of physician offices across the US, as a result of shelter -in-place \nguidelines.  Segment adjusted operating margin for the first quarter was 689 basis points, a decrease of 147 basis \npoints driven primarily by customer and product mix.  \n \n And finishing our business review with Other.  Revenues were $2.6 billion for the  quarter, a decrease of 13% year -\nover-year.  On an FX -adjusted basis, revenues decreased 10% driven by lower volumes in the Canadian \nbusiness, which includes both the exit of an unprofitable customer at the onset of the fiscal year and the negative \nimpact o f the pandemic.  First quarter adjusted operating profit was $137 million, down 50% on both the reported \nand FX -adjusted basis driven primarily by the lapping of the prior year contribution of $108 million from the \ncompany's investment in Change Healthcare,  along with the negative impact of the pandemic on the businesses \nwithin other. ", "original_text": "And finishing our business review with Other. ", "page_label": "9", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b3da478e4a68df36cb51b77dd6bbb98d6fa9488490b0b3d263dce4ad70d01130", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8e875de9-2b60-4dd3-ad72-1fdf4c7189b1", "node_type": "1", "metadata": {"window": "Segment adjusted operating margin for the first quarter was 689 basis points, a decrease of 147 basis \npoints driven primarily by customer and product mix.  \n \n And finishing our business review with Other.  Revenues were $2.6 billion for the  quarter, a decrease of 13% year -\nover-year.  On an FX -adjusted basis, revenues decreased 10% driven by lower volumes in the Canadian \nbusiness, which includes both the exit of an unprofitable customer at the onset of the fiscal year and the negative \nimpact o f the pandemic.  First quarter adjusted operating profit was $137 million, down 50% on both the reported \nand FX -adjusted basis driven primarily by the lapping of the prior year contribution of $108 million from the \ncompany's investment in Change Healthcare,  along with the negative impact of the pandemic on the businesses \nwithin other.  Excluding the prior year contribution from Change, Other was down approximately 18% year -over-\nyear.  \n \n And moving to Corporate. ", "original_text": "On an FX -adjusted basis, revenues decreased 10% driven by lower volumes in the Canadian \nbusiness, which includes both the exit of an unprofitable customer at the onset of the fiscal year and the negative \nimpact o f the pandemic. "}, "hash": "2b065422c7460044aa86e7c696e61895eb9892fb4bbab4781f50a8a2235df71a", "class_name": "RelatedNodeInfo"}}, "text": "Revenues were $2.6 billion for the  quarter, a decrease of 13% year -\nover-year. ", "start_char_idx": 2463, "end_char_idx": 2544, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8e875de9-2b60-4dd3-ad72-1fdf4c7189b1": {"__data__": {"id_": "8e875de9-2b60-4dd3-ad72-1fdf4c7189b1", "embedding": null, "metadata": {"window": "Segment adjusted operating margin for the first quarter was 689 basis points, a decrease of 147 basis \npoints driven primarily by customer and product mix.  \n \n And finishing our business review with Other.  Revenues were $2.6 billion for the  quarter, a decrease of 13% year -\nover-year.  On an FX -adjusted basis, revenues decreased 10% driven by lower volumes in the Canadian \nbusiness, which includes both the exit of an unprofitable customer at the onset of the fiscal year and the negative \nimpact o f the pandemic.  First quarter adjusted operating profit was $137 million, down 50% on both the reported \nand FX -adjusted basis driven primarily by the lapping of the prior year contribution of $108 million from the \ncompany's investment in Change Healthcare,  along with the negative impact of the pandemic on the businesses \nwithin other.  Excluding the prior year contribution from Change, Other was down approximately 18% year -over-\nyear.  \n \n And moving to Corporate. ", "original_text": "On an FX -adjusted basis, revenues decreased 10% driven by lower volumes in the Canadian \nbusiness, which includes both the exit of an unprofitable customer at the onset of the fiscal year and the negative \nimpact o f the pandemic. ", "page_label": "9", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e6763537-8e0b-4f34-ba9a-81920191e975", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f597ca48f373ba59aee380110f1eb95b1f75682f116e5ec6ca0710508c820240", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1b2f27c0-f7c7-421f-9c89-1b57e8c4bc3c", "node_type": "1", "metadata": {"window": "First quarter adjusted operating profit decreased 22% to $124 million, driven by lower demand in the primary care \nbusiness, in part due to temporary closures of physician offices across the US, as a result of shelter -in-place \nguidelines.  Segment adjusted operating margin for the first quarter was 689 basis points, a decrease of 147 basis \npoints driven primarily by customer and product mix.  \n \n And finishing our business review with Other.  Revenues were $2.6 billion for the  quarter, a decrease of 13% year -\nover-year.  On an FX -adjusted basis, revenues decreased 10% driven by lower volumes in the Canadian \nbusiness, which includes both the exit of an unprofitable customer at the onset of the fiscal year and the negative \nimpact o f the pandemic.  First quarter adjusted operating profit was $137 million, down 50% on both the reported \nand FX -adjusted basis driven primarily by the lapping of the prior year contribution of $108 million from the \ncompany's investment in Change Healthcare,  along with the negative impact of the pandemic on the businesses \nwithin other.  Excluding the prior year contribution from Change, Other was down approximately 18% year -over-\nyear.  \n \n", "original_text": "Revenues were $2.6 billion for the  quarter, a decrease of 13% year -\nover-year. ", "page_label": "9", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7fc1b59d77c391bba92a9ebd42572644d47cccba0f84d461b836191fa840435e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c8cf16d8-8084-4527-a1d6-ca35f800c4a1", "node_type": "1", "metadata": {"window": "And finishing our business review with Other.  Revenues were $2.6 billion for the  quarter, a decrease of 13% year -\nover-year.  On an FX -adjusted basis, revenues decreased 10% driven by lower volumes in the Canadian \nbusiness, which includes both the exit of an unprofitable customer at the onset of the fiscal year and the negative \nimpact o f the pandemic.  First quarter adjusted operating profit was $137 million, down 50% on both the reported \nand FX -adjusted basis driven primarily by the lapping of the prior year contribution of $108 million from the \ncompany's investment in Change Healthcare,  along with the negative impact of the pandemic on the businesses \nwithin other.  Excluding the prior year contribution from Change, Other was down approximately 18% year -over-\nyear.  \n \n And moving to Corporate.  McKesson recorded $178 million in adjusted corpora te expenses in the quarter, an \nincrease of 30% year -over-year, which was primarily driven by the lapping of a prior year onetime gain from \ninvestment activities and an increase in opioid litigation costs compared to the prior year. ", "original_text": "First quarter adjusted operating profit was $137 million, down 50% on both the reported \nand FX -adjusted basis driven primarily by the lapping of the prior year contribution of $108 million from the \ncompany's investment in Change Healthcare,  along with the negative impact of the pandemic on the businesses \nwithin other. "}, "hash": "92aa0b6ae2fee5b20d15f667cec89e698be01daec0250fb3d76913139a76704d", "class_name": "RelatedNodeInfo"}}, "text": "On an FX -adjusted basis, revenues decreased 10% driven by lower volumes in the Canadian \nbusiness, which includes both the exit of an unprofitable customer at the onset of the fiscal year and the negative \nimpact o f the pandemic. ", "start_char_idx": 2544, "end_char_idx": 2776, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c8cf16d8-8084-4527-a1d6-ca35f800c4a1": {"__data__": {"id_": "c8cf16d8-8084-4527-a1d6-ca35f800c4a1", "embedding": null, "metadata": {"window": "And finishing our business review with Other.  Revenues were $2.6 billion for the  quarter, a decrease of 13% year -\nover-year.  On an FX -adjusted basis, revenues decreased 10% driven by lower volumes in the Canadian \nbusiness, which includes both the exit of an unprofitable customer at the onset of the fiscal year and the negative \nimpact o f the pandemic.  First quarter adjusted operating profit was $137 million, down 50% on both the reported \nand FX -adjusted basis driven primarily by the lapping of the prior year contribution of $108 million from the \ncompany's investment in Change Healthcare,  along with the negative impact of the pandemic on the businesses \nwithin other.  Excluding the prior year contribution from Change, Other was down approximately 18% year -over-\nyear.  \n \n And moving to Corporate.  McKesson recorded $178 million in adjusted corpora te expenses in the quarter, an \nincrease of 30% year -over-year, which was primarily driven by the lapping of a prior year onetime gain from \ninvestment activities and an increase in opioid litigation costs compared to the prior year. ", "original_text": "First quarter adjusted operating profit was $137 million, down 50% on both the reported \nand FX -adjusted basis driven primarily by the lapping of the prior year contribution of $108 million from the \ncompany's investment in Change Healthcare,  along with the negative impact of the pandemic on the businesses \nwithin other. ", "page_label": "9", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e6763537-8e0b-4f34-ba9a-81920191e975", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f597ca48f373ba59aee380110f1eb95b1f75682f116e5ec6ca0710508c820240", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8e875de9-2b60-4dd3-ad72-1fdf4c7189b1", "node_type": "1", "metadata": {"window": "Segment adjusted operating margin for the first quarter was 689 basis points, a decrease of 147 basis \npoints driven primarily by customer and product mix.  \n \n And finishing our business review with Other.  Revenues were $2.6 billion for the  quarter, a decrease of 13% year -\nover-year.  On an FX -adjusted basis, revenues decreased 10% driven by lower volumes in the Canadian \nbusiness, which includes both the exit of an unprofitable customer at the onset of the fiscal year and the negative \nimpact o f the pandemic.  First quarter adjusted operating profit was $137 million, down 50% on both the reported \nand FX -adjusted basis driven primarily by the lapping of the prior year contribution of $108 million from the \ncompany's investment in Change Healthcare,  along with the negative impact of the pandemic on the businesses \nwithin other.  Excluding the prior year contribution from Change, Other was down approximately 18% year -over-\nyear.  \n \n And moving to Corporate. ", "original_text": "On an FX -adjusted basis, revenues decreased 10% driven by lower volumes in the Canadian \nbusiness, which includes both the exit of an unprofitable customer at the onset of the fiscal year and the negative \nimpact o f the pandemic. ", "page_label": "9", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fc5b434537cc055f6eb3eb4d4347905216698bc48d8417d792f4cdbfa6801e59", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2709f77b-cdc1-41b8-849a-43c040701cd1", "node_type": "1", "metadata": {"window": "Revenues were $2.6 billion for the  quarter, a decrease of 13% year -\nover-year.  On an FX -adjusted basis, revenues decreased 10% driven by lower volumes in the Canadian \nbusiness, which includes both the exit of an unprofitable customer at the onset of the fiscal year and the negative \nimpact o f the pandemic.  First quarter adjusted operating profit was $137 million, down 50% on both the reported \nand FX -adjusted basis driven primarily by the lapping of the prior year contribution of $108 million from the \ncompany's investment in Change Healthcare,  along with the negative impact of the pandemic on the businesses \nwithin other.  Excluding the prior year contribution from Change, Other was down approximately 18% year -over-\nyear.  \n \n And moving to Corporate.  McKesson recorded $178 million in adjusted corpora te expenses in the quarter, an \nincrease of 30% year -over-year, which was primarily driven by the lapping of a prior year onetime gain from \ninvestment activities and an increase in opioid litigation costs compared to the prior year.  Excluding the prior year  \nonetime benefit, corporate expenses increased to approximately 10% year -over-year. ", "original_text": "Excluding the prior year contribution from Change, Other was down approximately 18% year -over-\nyear.  \n \n"}, "hash": "580fd7f7dee1a36c0719fbd22b510d82761c51d732cf331c65ab36f1ef30a538", "class_name": "RelatedNodeInfo"}}, "text": "First quarter adjusted operating profit was $137 million, down 50% on both the reported \nand FX -adjusted basis driven primarily by the lapping of the prior year contribution of $108 million from the \ncompany's investment in Change Healthcare,  along with the negative impact of the pandemic on the businesses \nwithin other. ", "start_char_idx": 2776, "end_char_idx": 3101, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2709f77b-cdc1-41b8-849a-43c040701cd1": {"__data__": {"id_": "2709f77b-cdc1-41b8-849a-43c040701cd1", "embedding": null, "metadata": {"window": "Revenues were $2.6 billion for the  quarter, a decrease of 13% year -\nover-year.  On an FX -adjusted basis, revenues decreased 10% driven by lower volumes in the Canadian \nbusiness, which includes both the exit of an unprofitable customer at the onset of the fiscal year and the negative \nimpact o f the pandemic.  First quarter adjusted operating profit was $137 million, down 50% on both the reported \nand FX -adjusted basis driven primarily by the lapping of the prior year contribution of $108 million from the \ncompany's investment in Change Healthcare,  along with the negative impact of the pandemic on the businesses \nwithin other.  Excluding the prior year contribution from Change, Other was down approximately 18% year -over-\nyear.  \n \n And moving to Corporate.  McKesson recorded $178 million in adjusted corpora te expenses in the quarter, an \nincrease of 30% year -over-year, which was primarily driven by the lapping of a prior year onetime gain from \ninvestment activities and an increase in opioid litigation costs compared to the prior year.  Excluding the prior year  \nonetime benefit, corporate expenses increased to approximately 10% year -over-year. ", "original_text": "Excluding the prior year contribution from Change, Other was down approximately 18% year -over-\nyear.  \n \n", "page_label": "9", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e6763537-8e0b-4f34-ba9a-81920191e975", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f597ca48f373ba59aee380110f1eb95b1f75682f116e5ec6ca0710508c820240", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c8cf16d8-8084-4527-a1d6-ca35f800c4a1", "node_type": "1", "metadata": {"window": "And finishing our business review with Other.  Revenues were $2.6 billion for the  quarter, a decrease of 13% year -\nover-year.  On an FX -adjusted basis, revenues decreased 10% driven by lower volumes in the Canadian \nbusiness, which includes both the exit of an unprofitable customer at the onset of the fiscal year and the negative \nimpact o f the pandemic.  First quarter adjusted operating profit was $137 million, down 50% on both the reported \nand FX -adjusted basis driven primarily by the lapping of the prior year contribution of $108 million from the \ncompany's investment in Change Healthcare,  along with the negative impact of the pandemic on the businesses \nwithin other.  Excluding the prior year contribution from Change, Other was down approximately 18% year -over-\nyear.  \n \n And moving to Corporate.  McKesson recorded $178 million in adjusted corpora te expenses in the quarter, an \nincrease of 30% year -over-year, which was primarily driven by the lapping of a prior year onetime gain from \ninvestment activities and an increase in opioid litigation costs compared to the prior year. ", "original_text": "First quarter adjusted operating profit was $137 million, down 50% on both the reported \nand FX -adjusted basis driven primarily by the lapping of the prior year contribution of $108 million from the \ncompany's investment in Change Healthcare,  along with the negative impact of the pandemic on the businesses \nwithin other. ", "page_label": "9", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8471d99058aeb5445dd4cd42f79cb0749231104ecae96acfc2e36ecee88a4b34", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1c9e7dbe-c661-4df6-bb5a-4d43ff80d4af", "node_type": "1", "metadata": {"window": "On an FX -adjusted basis, revenues decreased 10% driven by lower volumes in the Canadian \nbusiness, which includes both the exit of an unprofitable customer at the onset of the fiscal year and the negative \nimpact o f the pandemic.  First quarter adjusted operating profit was $137 million, down 50% on both the reported \nand FX -adjusted basis driven primarily by the lapping of the prior year contribution of $108 million from the \ncompany's investment in Change Healthcare,  along with the negative impact of the pandemic on the businesses \nwithin other.  Excluding the prior year contribution from Change, Other was down approximately 18% year -over-\nyear.  \n \n And moving to Corporate.  McKesson recorded $178 million in adjusted corpora te expenses in the quarter, an \nincrease of 30% year -over-year, which was primarily driven by the lapping of a prior year onetime gain from \ninvestment activities and an increase in opioid litigation costs compared to the prior year.  Excluding the prior year  \nonetime benefit, corporate expenses increased to approximately 10% year -over-year.  For the first quarter, we \nreported net opioid -related litigation expenses of $43 million.  \n \n", "original_text": "And moving to Corporate. "}, "hash": "c960fba7b8c887ab6f0158ab9f0443a43939538843f06e28eb9bd556fe707f77", "class_name": "RelatedNodeInfo"}}, "text": "Excluding the prior year contribution from Change, Other was down approximately 18% year -over-\nyear.  \n \n", "start_char_idx": 3101, "end_char_idx": 3207, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1c9e7dbe-c661-4df6-bb5a-4d43ff80d4af": {"__data__": {"id_": "1c9e7dbe-c661-4df6-bb5a-4d43ff80d4af", "embedding": null, "metadata": {"window": "On an FX -adjusted basis, revenues decreased 10% driven by lower volumes in the Canadian \nbusiness, which includes both the exit of an unprofitable customer at the onset of the fiscal year and the negative \nimpact o f the pandemic.  First quarter adjusted operating profit was $137 million, down 50% on both the reported \nand FX -adjusted basis driven primarily by the lapping of the prior year contribution of $108 million from the \ncompany's investment in Change Healthcare,  along with the negative impact of the pandemic on the businesses \nwithin other.  Excluding the prior year contribution from Change, Other was down approximately 18% year -over-\nyear.  \n \n And moving to Corporate.  McKesson recorded $178 million in adjusted corpora te expenses in the quarter, an \nincrease of 30% year -over-year, which was primarily driven by the lapping of a prior year onetime gain from \ninvestment activities and an increase in opioid litigation costs compared to the prior year.  Excluding the prior year  \nonetime benefit, corporate expenses increased to approximately 10% year -over-year.  For the first quarter, we \nreported net opioid -related litigation expenses of $43 million.  \n \n", "original_text": "And moving to Corporate. ", "page_label": "9", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e6763537-8e0b-4f34-ba9a-81920191e975", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f597ca48f373ba59aee380110f1eb95b1f75682f116e5ec6ca0710508c820240", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2709f77b-cdc1-41b8-849a-43c040701cd1", "node_type": "1", "metadata": {"window": "Revenues were $2.6 billion for the  quarter, a decrease of 13% year -\nover-year.  On an FX -adjusted basis, revenues decreased 10% driven by lower volumes in the Canadian \nbusiness, which includes both the exit of an unprofitable customer at the onset of the fiscal year and the negative \nimpact o f the pandemic.  First quarter adjusted operating profit was $137 million, down 50% on both the reported \nand FX -adjusted basis driven primarily by the lapping of the prior year contribution of $108 million from the \ncompany's investment in Change Healthcare,  along with the negative impact of the pandemic on the businesses \nwithin other.  Excluding the prior year contribution from Change, Other was down approximately 18% year -over-\nyear.  \n \n And moving to Corporate.  McKesson recorded $178 million in adjusted corpora te expenses in the quarter, an \nincrease of 30% year -over-year, which was primarily driven by the lapping of a prior year onetime gain from \ninvestment activities and an increase in opioid litigation costs compared to the prior year.  Excluding the prior year  \nonetime benefit, corporate expenses increased to approximately 10% year -over-year. ", "original_text": "Excluding the prior year contribution from Change, Other was down approximately 18% year -over-\nyear.  \n \n", "page_label": "9", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b9bf184edce1c5f1dc9ce53d0734efc03fff6370467401670eb66e1ee243998b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "80e8dfac-d54d-4716-bce8-093f02c47c81", "node_type": "1", "metadata": {"window": "First quarter adjusted operating profit was $137 million, down 50% on both the reported \nand FX -adjusted basis driven primarily by the lapping of the prior year contribution of $108 million from the \ncompany's investment in Change Healthcare,  along with the negative impact of the pandemic on the businesses \nwithin other.  Excluding the prior year contribution from Change, Other was down approximately 18% year -over-\nyear.  \n \n And moving to Corporate.  McKesson recorded $178 million in adjusted corpora te expenses in the quarter, an \nincrease of 30% year -over-year, which was primarily driven by the lapping of a prior year onetime gain from \ninvestment activities and an increase in opioid litigation costs compared to the prior year.  Excluding the prior year  \nonetime benefit, corporate expenses increased to approximately 10% year -over-year.  For the first quarter, we \nreported net opioid -related litigation expenses of $43 million.  \n \n Now on to cash, which can be found on slide 10. ", "original_text": "McKesson recorded $178 million in adjusted corpora te expenses in the quarter, an \nincrease of 30% year -over-year, which was primarily driven by the lapping of a prior year onetime gain from \ninvestment activities and an increase in opioid litigation costs compared to the prior year. "}, "hash": "4cc57d7e577060b5d3585249fef081a544b3dd2fcb1db859c456dc71a18fbd02", "class_name": "RelatedNodeInfo"}}, "text": "And moving to Corporate. ", "start_char_idx": 3207, "end_char_idx": 3232, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "80e8dfac-d54d-4716-bce8-093f02c47c81": {"__data__": {"id_": "80e8dfac-d54d-4716-bce8-093f02c47c81", "embedding": null, "metadata": {"window": "First quarter adjusted operating profit was $137 million, down 50% on both the reported \nand FX -adjusted basis driven primarily by the lapping of the prior year contribution of $108 million from the \ncompany's investment in Change Healthcare,  along with the negative impact of the pandemic on the businesses \nwithin other.  Excluding the prior year contribution from Change, Other was down approximately 18% year -over-\nyear.  \n \n And moving to Corporate.  McKesson recorded $178 million in adjusted corpora te expenses in the quarter, an \nincrease of 30% year -over-year, which was primarily driven by the lapping of a prior year onetime gain from \ninvestment activities and an increase in opioid litigation costs compared to the prior year.  Excluding the prior year  \nonetime benefit, corporate expenses increased to approximately 10% year -over-year.  For the first quarter, we \nreported net opioid -related litigation expenses of $43 million.  \n \n Now on to cash, which can be found on slide 10. ", "original_text": "McKesson recorded $178 million in adjusted corpora te expenses in the quarter, an \nincrease of 30% year -over-year, which was primarily driven by the lapping of a prior year onetime gain from \ninvestment activities and an increase in opioid litigation costs compared to the prior year. ", "page_label": "9", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e6763537-8e0b-4f34-ba9a-81920191e975", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f597ca48f373ba59aee380110f1eb95b1f75682f116e5ec6ca0710508c820240", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1c9e7dbe-c661-4df6-bb5a-4d43ff80d4af", "node_type": "1", "metadata": {"window": "On an FX -adjusted basis, revenues decreased 10% driven by lower volumes in the Canadian \nbusiness, which includes both the exit of an unprofitable customer at the onset of the fiscal year and the negative \nimpact o f the pandemic.  First quarter adjusted operating profit was $137 million, down 50% on both the reported \nand FX -adjusted basis driven primarily by the lapping of the prior year contribution of $108 million from the \ncompany's investment in Change Healthcare,  along with the negative impact of the pandemic on the businesses \nwithin other.  Excluding the prior year contribution from Change, Other was down approximately 18% year -over-\nyear.  \n \n And moving to Corporate.  McKesson recorded $178 million in adjusted corpora te expenses in the quarter, an \nincrease of 30% year -over-year, which was primarily driven by the lapping of a prior year onetime gain from \ninvestment activities and an increase in opioid litigation costs compared to the prior year.  Excluding the prior year  \nonetime benefit, corporate expenses increased to approximately 10% year -over-year.  For the first quarter, we \nreported net opioid -related litigation expenses of $43 million.  \n \n", "original_text": "And moving to Corporate. ", "page_label": "9", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3d61e3e82e026758a6ed10d9718a6a0d902d2c27c1c777c1da704a7f56d35b5c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8c2dc65e-04b4-4da2-9497-2e5485b88a25", "node_type": "1", "metadata": {"window": "Excluding the prior year contribution from Change, Other was down approximately 18% year -over-\nyear.  \n \n And moving to Corporate.  McKesson recorded $178 million in adjusted corpora te expenses in the quarter, an \nincrease of 30% year -over-year, which was primarily driven by the lapping of a prior year onetime gain from \ninvestment activities and an increase in opioid litigation costs compared to the prior year.  Excluding the prior year  \nonetime benefit, corporate expenses increased to approximately 10% year -over-year.  For the first quarter, we \nreported net opioid -related litigation expenses of $43 million.  \n \n Now on to cash, which can be found on slide 10.  And we ended the quarter with a c ash balance of $2.9 billion. \n", "original_text": "Excluding the prior year  \nonetime benefit, corporate expenses increased to approximately 10% year -over-year. "}, "hash": "4b111726c8c422b574c7a8778f2e2c1d9f9ec219c3497411bf4db1f04012ad1b", "class_name": "RelatedNodeInfo"}}, "text": "McKesson recorded $178 million in adjusted corpora te expenses in the quarter, an \nincrease of 30% year -over-year, which was primarily driven by the lapping of a prior year onetime gain from \ninvestment activities and an increase in opioid litigation costs compared to the prior year. ", "start_char_idx": 3232, "end_char_idx": 3518, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8c2dc65e-04b4-4da2-9497-2e5485b88a25": {"__data__": {"id_": "8c2dc65e-04b4-4da2-9497-2e5485b88a25", "embedding": null, "metadata": {"window": "Excluding the prior year contribution from Change, Other was down approximately 18% year -over-\nyear.  \n \n And moving to Corporate.  McKesson recorded $178 million in adjusted corpora te expenses in the quarter, an \nincrease of 30% year -over-year, which was primarily driven by the lapping of a prior year onetime gain from \ninvestment activities and an increase in opioid litigation costs compared to the prior year.  Excluding the prior year  \nonetime benefit, corporate expenses increased to approximately 10% year -over-year.  For the first quarter, we \nreported net opioid -related litigation expenses of $43 million.  \n \n Now on to cash, which can be found on slide 10.  And we ended the quarter with a c ash balance of $2.9 billion. \n", "original_text": "Excluding the prior year  \nonetime benefit, corporate expenses increased to approximately 10% year -over-year. ", "page_label": "9", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e6763537-8e0b-4f34-ba9a-81920191e975", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f597ca48f373ba59aee380110f1eb95b1f75682f116e5ec6ca0710508c820240", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "80e8dfac-d54d-4716-bce8-093f02c47c81", "node_type": "1", "metadata": {"window": "First quarter adjusted operating profit was $137 million, down 50% on both the reported \nand FX -adjusted basis driven primarily by the lapping of the prior year contribution of $108 million from the \ncompany's investment in Change Healthcare,  along with the negative impact of the pandemic on the businesses \nwithin other.  Excluding the prior year contribution from Change, Other was down approximately 18% year -over-\nyear.  \n \n And moving to Corporate.  McKesson recorded $178 million in adjusted corpora te expenses in the quarter, an \nincrease of 30% year -over-year, which was primarily driven by the lapping of a prior year onetime gain from \ninvestment activities and an increase in opioid litigation costs compared to the prior year.  Excluding the prior year  \nonetime benefit, corporate expenses increased to approximately 10% year -over-year.  For the first quarter, we \nreported net opioid -related litigation expenses of $43 million.  \n \n Now on to cash, which can be found on slide 10. ", "original_text": "McKesson recorded $178 million in adjusted corpora te expenses in the quarter, an \nincrease of 30% year -over-year, which was primarily driven by the lapping of a prior year onetime gain from \ninvestment activities and an increase in opioid litigation costs compared to the prior year. ", "page_label": "9", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "782a1e50ed97b464349392d3c5298c7f0582efb5d76894aa147dbc4131917fe2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f73b567b-be80-4386-9a53-a9ff10ca1ad0", "node_type": "1", "metadata": {"window": "And moving to Corporate.  McKesson recorded $178 million in adjusted corpora te expenses in the quarter, an \nincrease of 30% year -over-year, which was primarily driven by the lapping of a prior year onetime gain from \ninvestment activities and an increase in opioid litigation costs compared to the prior year.  Excluding the prior year  \nonetime benefit, corporate expenses increased to approximately 10% year -over-year.  For the first quarter, we \nreported net opioid -related litigation expenses of $43 million.  \n \n Now on to cash, which can be found on slide 10.  And we ended the quarter with a c ash balance of $2.9 billion. \n During the quarter, we had negative free cash flow of $1.2 billion. ", "original_text": "For the first quarter, we \nreported net opioid -related litigation expenses of $43 million.  \n \n"}, "hash": "7b2521579cca1a5f5183c2fc9f837936804ebe748eb012b7f180bf6e45d6c5f1", "class_name": "RelatedNodeInfo"}}, "text": "Excluding the prior year  \nonetime benefit, corporate expenses increased to approximately 10% year -over-year. ", "start_char_idx": 3518, "end_char_idx": 3629, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f73b567b-be80-4386-9a53-a9ff10ca1ad0": {"__data__": {"id_": "f73b567b-be80-4386-9a53-a9ff10ca1ad0", "embedding": null, "metadata": {"window": "And moving to Corporate.  McKesson recorded $178 million in adjusted corpora te expenses in the quarter, an \nincrease of 30% year -over-year, which was primarily driven by the lapping of a prior year onetime gain from \ninvestment activities and an increase in opioid litigation costs compared to the prior year.  Excluding the prior year  \nonetime benefit, corporate expenses increased to approximately 10% year -over-year.  For the first quarter, we \nreported net opioid -related litigation expenses of $43 million.  \n \n Now on to cash, which can be found on slide 10.  And we ended the quarter with a c ash balance of $2.9 billion. \n During the quarter, we had negative free cash flow of $1.2 billion. ", "original_text": "For the first quarter, we \nreported net opioid -related litigation expenses of $43 million.  \n \n", "page_label": "9", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e6763537-8e0b-4f34-ba9a-81920191e975", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f597ca48f373ba59aee380110f1eb95b1f75682f116e5ec6ca0710508c820240", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8c2dc65e-04b4-4da2-9497-2e5485b88a25", "node_type": "1", "metadata": {"window": "Excluding the prior year contribution from Change, Other was down approximately 18% year -over-\nyear.  \n \n And moving to Corporate.  McKesson recorded $178 million in adjusted corpora te expenses in the quarter, an \nincrease of 30% year -over-year, which was primarily driven by the lapping of a prior year onetime gain from \ninvestment activities and an increase in opioid litigation costs compared to the prior year.  Excluding the prior year  \nonetime benefit, corporate expenses increased to approximately 10% year -over-year.  For the first quarter, we \nreported net opioid -related litigation expenses of $43 million.  \n \n Now on to cash, which can be found on slide 10.  And we ended the quarter with a c ash balance of $2.9 billion. \n", "original_text": "Excluding the prior year  \nonetime benefit, corporate expenses increased to approximately 10% year -over-year. ", "page_label": "9", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cafa06faedb757e987c7f82f8e5dd41eafd740234ae8a4629201c1f01682a481", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d0ab9e72-0e12-43d4-9bee-c6dc1c0ae627", "node_type": "1", "metadata": {"window": "McKesson recorded $178 million in adjusted corpora te expenses in the quarter, an \nincrease of 30% year -over-year, which was primarily driven by the lapping of a prior year onetime gain from \ninvestment activities and an increase in opioid litigation costs compared to the prior year.  Excluding the prior year  \nonetime benefit, corporate expenses increased to approximately 10% year -over-year.  For the first quarter, we \nreported net opioid -related litigation expenses of $43 million.  \n \n Now on to cash, which can be found on slide 10.  And we ended the quarter with a c ash balance of $2.9 billion. \n During the quarter, we had negative free cash flow of $1.2 billion.  Our working capital metrics and resulting free ", "original_text": "Now on to cash, which can be found on slide 10. "}, "hash": "c76f7191320214ff22de25928b713daca5e76208e1958ad90459bf3633f2ea8a", "class_name": "RelatedNodeInfo"}}, "text": "For the first quarter, we \nreported net opioid -related litigation expenses of $43 million.  \n \n", "start_char_idx": 3629, "end_char_idx": 3725, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d0ab9e72-0e12-43d4-9bee-c6dc1c0ae627": {"__data__": {"id_": "d0ab9e72-0e12-43d4-9bee-c6dc1c0ae627", "embedding": null, "metadata": {"window": "McKesson recorded $178 million in adjusted corpora te expenses in the quarter, an \nincrease of 30% year -over-year, which was primarily driven by the lapping of a prior year onetime gain from \ninvestment activities and an increase in opioid litigation costs compared to the prior year.  Excluding the prior year  \nonetime benefit, corporate expenses increased to approximately 10% year -over-year.  For the first quarter, we \nreported net opioid -related litigation expenses of $43 million.  \n \n Now on to cash, which can be found on slide 10.  And we ended the quarter with a c ash balance of $2.9 billion. \n During the quarter, we had negative free cash flow of $1.2 billion.  Our working capital metrics and resulting free ", "original_text": "Now on to cash, which can be found on slide 10. ", "page_label": "9", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e6763537-8e0b-4f34-ba9a-81920191e975", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f597ca48f373ba59aee380110f1eb95b1f75682f116e5ec6ca0710508c820240", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f73b567b-be80-4386-9a53-a9ff10ca1ad0", "node_type": "1", "metadata": {"window": "And moving to Corporate.  McKesson recorded $178 million in adjusted corpora te expenses in the quarter, an \nincrease of 30% year -over-year, which was primarily driven by the lapping of a prior year onetime gain from \ninvestment activities and an increase in opioid litigation costs compared to the prior year.  Excluding the prior year  \nonetime benefit, corporate expenses increased to approximately 10% year -over-year.  For the first quarter, we \nreported net opioid -related litigation expenses of $43 million.  \n \n Now on to cash, which can be found on slide 10.  And we ended the quarter with a c ash balance of $2.9 billion. \n During the quarter, we had negative free cash flow of $1.2 billion. ", "original_text": "For the first quarter, we \nreported net opioid -related litigation expenses of $43 million.  \n \n", "page_label": "9", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a045adfb443b47facaacaa86a5aa00bef390fb95825ec2f17ecdeeccc8a014ff", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "00c7db14-4704-4304-afcd-57dd5c1ce9ba", "node_type": "1", "metadata": {"window": "Excluding the prior year  \nonetime benefit, corporate expenses increased to approximately 10% year -over-year.  For the first quarter, we \nreported net opioid -related litigation expenses of $43 million.  \n \n Now on to cash, which can be found on slide 10.  And we ended the quarter with a c ash balance of $2.9 billion. \n During the quarter, we had negative free cash flow of $1.2 billion.  Our working capital metrics and resulting free ", "original_text": "And we ended the quarter with a c ash balance of $2.9 billion. \n"}, "hash": "10438112eaad23239d538d26093c5df3c27d3b61c1d227e8579790b5f367a44b", "class_name": "RelatedNodeInfo"}}, "text": "Now on to cash, which can be found on slide 10. ", "start_char_idx": 3725, "end_char_idx": 3773, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "00c7db14-4704-4304-afcd-57dd5c1ce9ba": {"__data__": {"id_": "00c7db14-4704-4304-afcd-57dd5c1ce9ba", "embedding": null, "metadata": {"window": "Excluding the prior year  \nonetime benefit, corporate expenses increased to approximately 10% year -over-year.  For the first quarter, we \nreported net opioid -related litigation expenses of $43 million.  \n \n Now on to cash, which can be found on slide 10.  And we ended the quarter with a c ash balance of $2.9 billion. \n During the quarter, we had negative free cash flow of $1.2 billion.  Our working capital metrics and resulting free ", "original_text": "And we ended the quarter with a c ash balance of $2.9 billion. \n", "page_label": "9", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e6763537-8e0b-4f34-ba9a-81920191e975", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f597ca48f373ba59aee380110f1eb95b1f75682f116e5ec6ca0710508c820240", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d0ab9e72-0e12-43d4-9bee-c6dc1c0ae627", "node_type": "1", "metadata": {"window": "McKesson recorded $178 million in adjusted corpora te expenses in the quarter, an \nincrease of 30% year -over-year, which was primarily driven by the lapping of a prior year onetime gain from \ninvestment activities and an increase in opioid litigation costs compared to the prior year.  Excluding the prior year  \nonetime benefit, corporate expenses increased to approximately 10% year -over-year.  For the first quarter, we \nreported net opioid -related litigation expenses of $43 million.  \n \n Now on to cash, which can be found on slide 10.  And we ended the quarter with a c ash balance of $2.9 billion. \n During the quarter, we had negative free cash flow of $1.2 billion.  Our working capital metrics and resulting free ", "original_text": "Now on to cash, which can be found on slide 10. ", "page_label": "9", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "681f42dd39cb2fabfeb5154a2686bd0b8888411808673626e534398cc4895ce9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8142fc3b-62ff-44ef-b70e-3beacce5e720", "node_type": "1", "metadata": {"window": "For the first quarter, we \nreported net opioid -related litigation expenses of $43 million.  \n \n Now on to cash, which can be found on slide 10.  And we ended the quarter with a c ash balance of $2.9 billion. \n During the quarter, we had negative free cash flow of $1.2 billion.  Our working capital metrics and resulting free ", "original_text": "During the quarter, we had negative free cash flow of $1.2 billion. "}, "hash": "be63673661b7d0295f0bdd6655f0a4b1d5427b42a5a94da21925322ebdc443cf", "class_name": "RelatedNodeInfo"}}, "text": "And we ended the quarter with a c ash balance of $2.9 billion. \n", "start_char_idx": 3773, "end_char_idx": 3837, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8142fc3b-62ff-44ef-b70e-3beacce5e720": {"__data__": {"id_": "8142fc3b-62ff-44ef-b70e-3beacce5e720", "embedding": null, "metadata": {"window": "For the first quarter, we \nreported net opioid -related litigation expenses of $43 million.  \n \n Now on to cash, which can be found on slide 10.  And we ended the quarter with a c ash balance of $2.9 billion. \n During the quarter, we had negative free cash flow of $1.2 billion.  Our working capital metrics and resulting free ", "original_text": "During the quarter, we had negative free cash flow of $1.2 billion. ", "page_label": "9", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e6763537-8e0b-4f34-ba9a-81920191e975", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f597ca48f373ba59aee380110f1eb95b1f75682f116e5ec6ca0710508c820240", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "00c7db14-4704-4304-afcd-57dd5c1ce9ba", "node_type": "1", "metadata": {"window": "Excluding the prior year  \nonetime benefit, corporate expenses increased to approximately 10% year -over-year.  For the first quarter, we \nreported net opioid -related litigation expenses of $43 million.  \n \n Now on to cash, which can be found on slide 10.  And we ended the quarter with a c ash balance of $2.9 billion. \n During the quarter, we had negative free cash flow of $1.2 billion.  Our working capital metrics and resulting free ", "original_text": "And we ended the quarter with a c ash balance of $2.9 billion. \n", "page_label": "9", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f0f07c6ccc98fb83f2a0fa6a9bb5abb2e441f83c63ea6d685cc7e839374427fa", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "086c45c9-b62e-4a14-85ef-ec31e6b9adb3", "node_type": "1", "metadata": {"window": "Now on to cash, which can be found on slide 10.  And we ended the quarter with a c ash balance of $2.9 billion. \n During the quarter, we had negative free cash flow of $1.2 billion.  Our working capital metrics and resulting free ", "original_text": "Our working capital metrics and resulting free "}, "hash": "b249508c1e6a1d436055b98fb31826e9ea1cfd9d921d847cd2db093a38cb8fb4", "class_name": "RelatedNodeInfo"}}, "text": "During the quarter, we had negative free cash flow of $1.2 billion. ", "start_char_idx": 3837, "end_char_idx": 3905, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "086c45c9-b62e-4a14-85ef-ec31e6b9adb3": {"__data__": {"id_": "086c45c9-b62e-4a14-85ef-ec31e6b9adb3", "embedding": null, "metadata": {"window": "Now on to cash, which can be found on slide 10.  And we ended the quarter with a c ash balance of $2.9 billion. \n During the quarter, we had negative free cash flow of $1.2 billion.  Our working capital metrics and resulting free ", "original_text": "Our working capital metrics and resulting free ", "page_label": "9", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e6763537-8e0b-4f34-ba9a-81920191e975", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f597ca48f373ba59aee380110f1eb95b1f75682f116e5ec6ca0710508c820240", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8142fc3b-62ff-44ef-b70e-3beacce5e720", "node_type": "1", "metadata": {"window": "For the first quarter, we \nreported net opioid -related litigation expenses of $43 million.  \n \n Now on to cash, which can be found on slide 10.  And we ended the quarter with a c ash balance of $2.9 billion. \n During the quarter, we had negative free cash flow of $1.2 billion.  Our working capital metrics and resulting free ", "original_text": "During the quarter, we had negative free cash flow of $1.2 billion. ", "page_label": "9", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "da1617055fd927fd76535f1c72be16719a413942d42606651638e2080c1b3ad2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0d202777-8a72-423d-a984-86606312701c", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \ncash flow will vary from quarter -to-quarter, impacted by timing, including the day of the week that marks the cl ose \nof a quarter.  The dynamics of the current operating environment resulting from the effects of COVID -19 has \nintroduced further volatility in our cash flow.  \n \n However, improving volumes and strong working capital fundamentals give us confidence we will continue to \ngenerate solid free cash flow. ", "original_text": "McKesson Corp.  "}, "hash": "5e4c27ae549bfab36fb736f668b92c165b36e7572c39d4f2516c06b150a9c713", "class_name": "RelatedNodeInfo"}}, "text": "Our working capital metrics and resulting free ", "start_char_idx": 3905, "end_char_idx": 3952, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0d202777-8a72-423d-a984-86606312701c": {"__data__": {"id_": "0d202777-8a72-423d-a984-86606312701c", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \ncash flow will vary from quarter -to-quarter, impacted by timing, including the day of the week that marks the cl ose \nof a quarter.  The dynamics of the current operating environment resulting from the effects of COVID -19 has \nintroduced further volatility in our cash flow.  \n \n However, improving volumes and strong working capital fundamentals give us confidence we will continue to \ngenerate solid free cash flow. ", "original_text": "McKesson Corp.  ", "page_label": "10", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a2fe6c7d-f0eb-4895-b27b-02b6ca730d5e", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8094901027b565718c61bbce19b58cecced8539c3683fb394088de434926fec8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "086c45c9-b62e-4a14-85ef-ec31e6b9adb3", "node_type": "1", "metadata": {"window": "Now on to cash, which can be found on slide 10.  And we ended the quarter with a c ash balance of $2.9 billion. \n During the quarter, we had negative free cash flow of $1.2 billion.  Our working capital metrics and resulting free ", "original_text": "Our working capital metrics and resulting free ", "page_label": "9", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1a04fcd06e1d4bafe2ef44cf33d9673835b7e96ff2b9d16bbc98067d1c8efb0f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e48dc77c-b3a7-4bb1-8eea-2fc70742203c", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \ncash flow will vary from quarter -to-quarter, impacted by timing, including the day of the week that marks the cl ose \nof a quarter.  The dynamics of the current operating environment resulting from the effects of COVID -19 has \nintroduced further volatility in our cash flow.  \n \n However, improving volumes and strong working capital fundamentals give us confidence we will continue to \ngenerate solid free cash flow.  Investment in growth opportunities remains a key priority for McKesson. ", "original_text": "(MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \ncash flow will vary from quarter -to-quarter, impacted by timing, including the day of the week that marks the cl ose \nof a quarter. "}, "hash": "10c2f195fc924930ee4d685396605359c14c5b0a536f6f64d3d22fa1e17e3c46", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e48dc77c-b3a7-4bb1-8eea-2fc70742203c": {"__data__": {"id_": "e48dc77c-b3a7-4bb1-8eea-2fc70742203c", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \ncash flow will vary from quarter -to-quarter, impacted by timing, including the day of the week that marks the cl ose \nof a quarter.  The dynamics of the current operating environment resulting from the effects of COVID -19 has \nintroduced further volatility in our cash flow.  \n \n However, improving volumes and strong working capital fundamentals give us confidence we will continue to \ngenerate solid free cash flow.  Investment in growth opportunities remains a key priority for McKesson. ", "original_text": "(MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \ncash flow will vary from quarter -to-quarter, impacted by timing, including the day of the week that marks the cl ose \nof a quarter. ", "page_label": "10", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a2fe6c7d-f0eb-4895-b27b-02b6ca730d5e", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8094901027b565718c61bbce19b58cecced8539c3683fb394088de434926fec8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0d202777-8a72-423d-a984-86606312701c", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \ncash flow will vary from quarter -to-quarter, impacted by timing, including the day of the week that marks the cl ose \nof a quarter.  The dynamics of the current operating environment resulting from the effects of COVID -19 has \nintroduced further volatility in our cash flow.  \n \n However, improving volumes and strong working capital fundamentals give us confidence we will continue to \ngenerate solid free cash flow. ", "original_text": "McKesson Corp.  ", "page_label": "10", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "407f5179fac6c30933d9449777891e6b5bf557f126e4d2cef15bd493ca235c4d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6ef99712-6dab-46dc-8057-9ae7e3c6a0f9", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \ncash flow will vary from quarter -to-quarter, impacted by timing, including the day of the week that marks the cl ose \nof a quarter.  The dynamics of the current operating environment resulting from the effects of COVID -19 has \nintroduced further volatility in our cash flow.  \n \n However, improving volumes and strong working capital fundamentals give us confidence we will continue to \ngenerate solid free cash flow.  Investment in growth opportunities remains a key priority for McKesson.  And during \nthe quarter, we made $117 million of capital expenditures. ", "original_text": "The dynamics of the current operating environment resulting from the effects of COVID -19 has \nintroduced further volatility in our cash flow.  \n \n"}, "hash": "334d549ff852c7c417c17161160674d3c12c0192a495298d26e14960e8ac7ecf", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \ncash flow will vary from quarter -to-quarter, impacted by timing, including the day of the week that marks the cl ose \nof a quarter. ", "start_char_idx": 16, "end_char_idx": 314, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6ef99712-6dab-46dc-8057-9ae7e3c6a0f9": {"__data__": {"id_": "6ef99712-6dab-46dc-8057-9ae7e3c6a0f9", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \ncash flow will vary from quarter -to-quarter, impacted by timing, including the day of the week that marks the cl ose \nof a quarter.  The dynamics of the current operating environment resulting from the effects of COVID -19 has \nintroduced further volatility in our cash flow.  \n \n However, improving volumes and strong working capital fundamentals give us confidence we will continue to \ngenerate solid free cash flow.  Investment in growth opportunities remains a key priority for McKesson.  And during \nthe quarter, we made $117 million of capital expenditures. ", "original_text": "The dynamics of the current operating environment resulting from the effects of COVID -19 has \nintroduced further volatility in our cash flow.  \n \n", "page_label": "10", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a2fe6c7d-f0eb-4895-b27b-02b6ca730d5e", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8094901027b565718c61bbce19b58cecced8539c3683fb394088de434926fec8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e48dc77c-b3a7-4bb1-8eea-2fc70742203c", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \ncash flow will vary from quarter -to-quarter, impacted by timing, including the day of the week that marks the cl ose \nof a quarter.  The dynamics of the current operating environment resulting from the effects of COVID -19 has \nintroduced further volatility in our cash flow.  \n \n However, improving volumes and strong working capital fundamentals give us confidence we will continue to \ngenerate solid free cash flow.  Investment in growth opportunities remains a key priority for McKesson. ", "original_text": "(MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \ncash flow will vary from quarter -to-quarter, impacted by timing, including the day of the week that marks the cl ose \nof a quarter. ", "page_label": "10", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6c3e4baf7db2162c65c2861e474341e6650c5959ebae9014a76bd6bbe0cc4499", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d350c258-647d-485a-bb81-1b4f10e09c88", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \ncash flow will vary from quarter -to-quarter, impacted by timing, including the day of the week that marks the cl ose \nof a quarter.  The dynamics of the current operating environment resulting from the effects of COVID -19 has \nintroduced further volatility in our cash flow.  \n \n However, improving volumes and strong working capital fundamentals give us confidence we will continue to \ngenerate solid free cash flow.  Investment in growth opportunities remains a key priority for McKesson.  And during \nthe quarter, we made $117 million of capital expenditures.  We continue to focus on internal investments in areas \nsuch as technolog y and our strategic growth initiatives.  \n \n", "original_text": "However, improving volumes and strong working capital fundamentals give us confidence we will continue to \ngenerate solid free cash flow. "}, "hash": "2bbc8ef4b67152133a56b232585c99a40411a6ba6f823bc0b6945eba15add73e", "class_name": "RelatedNodeInfo"}}, "text": "The dynamics of the current operating environment resulting from the effects of COVID -19 has \nintroduced further volatility in our cash flow.  \n \n", "start_char_idx": 314, "end_char_idx": 461, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d350c258-647d-485a-bb81-1b4f10e09c88": {"__data__": {"id_": "d350c258-647d-485a-bb81-1b4f10e09c88", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \ncash flow will vary from quarter -to-quarter, impacted by timing, including the day of the week that marks the cl ose \nof a quarter.  The dynamics of the current operating environment resulting from the effects of COVID -19 has \nintroduced further volatility in our cash flow.  \n \n However, improving volumes and strong working capital fundamentals give us confidence we will continue to \ngenerate solid free cash flow.  Investment in growth opportunities remains a key priority for McKesson.  And during \nthe quarter, we made $117 million of capital expenditures.  We continue to focus on internal investments in areas \nsuch as technolog y and our strategic growth initiatives.  \n \n", "original_text": "However, improving volumes and strong working capital fundamentals give us confidence we will continue to \ngenerate solid free cash flow. ", "page_label": "10", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a2fe6c7d-f0eb-4895-b27b-02b6ca730d5e", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8094901027b565718c61bbce19b58cecced8539c3683fb394088de434926fec8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6ef99712-6dab-46dc-8057-9ae7e3c6a0f9", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \ncash flow will vary from quarter -to-quarter, impacted by timing, including the day of the week that marks the cl ose \nof a quarter.  The dynamics of the current operating environment resulting from the effects of COVID -19 has \nintroduced further volatility in our cash flow.  \n \n However, improving volumes and strong working capital fundamentals give us confidence we will continue to \ngenerate solid free cash flow.  Investment in growth opportunities remains a key priority for McKesson.  And during \nthe quarter, we made $117 million of capital expenditures. ", "original_text": "The dynamics of the current operating environment resulting from the effects of COVID -19 has \nintroduced further volatility in our cash flow.  \n \n", "page_label": "10", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1fc43e891765f67be996646ed1b550a61534063786a14e9dcd8f94587ebb4e4d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1620a5ba-26e6-4a94-8f4b-3777dce6bbb6", "node_type": "1", "metadata": {"window": "(MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \ncash flow will vary from quarter -to-quarter, impacted by timing, including the day of the week that marks the cl ose \nof a quarter.  The dynamics of the current operating environment resulting from the effects of COVID -19 has \nintroduced further volatility in our cash flow.  \n \n However, improving volumes and strong working capital fundamentals give us confidence we will continue to \ngenerate solid free cash flow.  Investment in growth opportunities remains a key priority for McKesson.  And during \nthe quarter, we made $117 million of capital expenditures.  We continue to focus on internal investments in areas \nsuch as technolog y and our strategic growth initiatives.  \n \n We returned cash to our shareholders through the payment of $74 million in dividend. ", "original_text": "Investment in growth opportunities remains a key priority for McKesson. "}, "hash": "90c9ad3b138b119cdf7aa23aea155ca9fb06c068ba765f7f474b208f58026785", "class_name": "RelatedNodeInfo"}}, "text": "However, improving volumes and strong working capital fundamentals give us confidence we will continue to \ngenerate solid free cash flow. ", "start_char_idx": 461, "end_char_idx": 599, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1620a5ba-26e6-4a94-8f4b-3777dce6bbb6": {"__data__": {"id_": "1620a5ba-26e6-4a94-8f4b-3777dce6bbb6", "embedding": null, "metadata": {"window": "(MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \ncash flow will vary from quarter -to-quarter, impacted by timing, including the day of the week that marks the cl ose \nof a quarter.  The dynamics of the current operating environment resulting from the effects of COVID -19 has \nintroduced further volatility in our cash flow.  \n \n However, improving volumes and strong working capital fundamentals give us confidence we will continue to \ngenerate solid free cash flow.  Investment in growth opportunities remains a key priority for McKesson.  And during \nthe quarter, we made $117 million of capital expenditures.  We continue to focus on internal investments in areas \nsuch as technolog y and our strategic growth initiatives.  \n \n We returned cash to our shareholders through the payment of $74 million in dividend. ", "original_text": "Investment in growth opportunities remains a key priority for McKesson. ", "page_label": "10", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a2fe6c7d-f0eb-4895-b27b-02b6ca730d5e", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8094901027b565718c61bbce19b58cecced8539c3683fb394088de434926fec8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d350c258-647d-485a-bb81-1b4f10e09c88", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \ncash flow will vary from quarter -to-quarter, impacted by timing, including the day of the week that marks the cl ose \nof a quarter.  The dynamics of the current operating environment resulting from the effects of COVID -19 has \nintroduced further volatility in our cash flow.  \n \n However, improving volumes and strong working capital fundamentals give us confidence we will continue to \ngenerate solid free cash flow.  Investment in growth opportunities remains a key priority for McKesson.  And during \nthe quarter, we made $117 million of capital expenditures.  We continue to focus on internal investments in areas \nsuch as technolog y and our strategic growth initiatives.  \n \n", "original_text": "However, improving volumes and strong working capital fundamentals give us confidence we will continue to \ngenerate solid free cash flow. ", "page_label": "10", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a54a79dd9182055d8eea44d9e4d4e6acd05b16ea87b0ff25ba9f7b08860e2d24", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "398b72a5-60aa-4239-935a-87d14a8bdd9b", "node_type": "1", "metadata": {"window": "The dynamics of the current operating environment resulting from the effects of COVID -19 has \nintroduced further volatility in our cash flow.  \n \n However, improving volumes and strong working capital fundamentals give us confidence we will continue to \ngenerate solid free cash flow.  Investment in growth opportunities remains a key priority for McKesson.  And during \nthe quarter, we made $117 million of capital expenditures.  We continue to focus on internal investments in areas \nsuch as technolog y and our strategic growth initiatives.  \n \n We returned cash to our shareholders through the payment of $74 million in dividend.  We have $1.5 billion \nremaining on our share repurchase authorization. ", "original_text": "And during \nthe quarter, we made $117 million of capital expenditures. "}, "hash": "cb477ae6666d46dcd7af06b77b2df0eeeb0af04f67fb10497933cb8d1dedf87f", "class_name": "RelatedNodeInfo"}}, "text": "Investment in growth opportunities remains a key priority for McKesson. ", "start_char_idx": 599, "end_char_idx": 671, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "398b72a5-60aa-4239-935a-87d14a8bdd9b": {"__data__": {"id_": "398b72a5-60aa-4239-935a-87d14a8bdd9b", "embedding": null, "metadata": {"window": "The dynamics of the current operating environment resulting from the effects of COVID -19 has \nintroduced further volatility in our cash flow.  \n \n However, improving volumes and strong working capital fundamentals give us confidence we will continue to \ngenerate solid free cash flow.  Investment in growth opportunities remains a key priority for McKesson.  And during \nthe quarter, we made $117 million of capital expenditures.  We continue to focus on internal investments in areas \nsuch as technolog y and our strategic growth initiatives.  \n \n We returned cash to our shareholders through the payment of $74 million in dividend.  We have $1.5 billion \nremaining on our share repurchase authorization. ", "original_text": "And during \nthe quarter, we made $117 million of capital expenditures. ", "page_label": "10", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a2fe6c7d-f0eb-4895-b27b-02b6ca730d5e", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8094901027b565718c61bbce19b58cecced8539c3683fb394088de434926fec8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1620a5ba-26e6-4a94-8f4b-3777dce6bbb6", "node_type": "1", "metadata": {"window": "(MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \ncash flow will vary from quarter -to-quarter, impacted by timing, including the day of the week that marks the cl ose \nof a quarter.  The dynamics of the current operating environment resulting from the effects of COVID -19 has \nintroduced further volatility in our cash flow.  \n \n However, improving volumes and strong working capital fundamentals give us confidence we will continue to \ngenerate solid free cash flow.  Investment in growth opportunities remains a key priority for McKesson.  And during \nthe quarter, we made $117 million of capital expenditures.  We continue to focus on internal investments in areas \nsuch as technolog y and our strategic growth initiatives.  \n \n We returned cash to our shareholders through the payment of $74 million in dividend. ", "original_text": "Investment in growth opportunities remains a key priority for McKesson. ", "page_label": "10", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0456e5d0899fa0de4e0502142770edb7384c69be31a9f38e82f093207d0500da", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "07b838c1-f5a3-460d-ba35-80ec302a438e", "node_type": "1", "metadata": {"window": "However, improving volumes and strong working capital fundamentals give us confidence we will continue to \ngenerate solid free cash flow.  Investment in growth opportunities remains a key priority for McKesson.  And during \nthe quarter, we made $117 million of capital expenditures.  We continue to focus on internal investments in areas \nsuch as technolog y and our strategic growth initiatives.  \n \n We returned cash to our shareholders through the payment of $74 million in dividend.  We have $1.5 billion \nremaining on our share repurchase authorization.  We continue to expect weighted shares outstanding in the \nrange of 161 million to 163 million. ", "original_text": "We continue to focus on internal investments in areas \nsuch as technolog y and our strategic growth initiatives.  \n \n"}, "hash": "08d57cd7e6db921b3e74529c0022dba4729910ade6e365af4236bb90987ceba2", "class_name": "RelatedNodeInfo"}}, "text": "And during \nthe quarter, we made $117 million of capital expenditures. ", "start_char_idx": 671, "end_char_idx": 742, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "07b838c1-f5a3-460d-ba35-80ec302a438e": {"__data__": {"id_": "07b838c1-f5a3-460d-ba35-80ec302a438e", "embedding": null, "metadata": {"window": "However, improving volumes and strong working capital fundamentals give us confidence we will continue to \ngenerate solid free cash flow.  Investment in growth opportunities remains a key priority for McKesson.  And during \nthe quarter, we made $117 million of capital expenditures.  We continue to focus on internal investments in areas \nsuch as technolog y and our strategic growth initiatives.  \n \n We returned cash to our shareholders through the payment of $74 million in dividend.  We have $1.5 billion \nremaining on our share repurchase authorization.  We continue to expect weighted shares outstanding in the \nrange of 161 million to 163 million. ", "original_text": "We continue to focus on internal investments in areas \nsuch as technolog y and our strategic growth initiatives.  \n \n", "page_label": "10", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a2fe6c7d-f0eb-4895-b27b-02b6ca730d5e", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8094901027b565718c61bbce19b58cecced8539c3683fb394088de434926fec8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "398b72a5-60aa-4239-935a-87d14a8bdd9b", "node_type": "1", "metadata": {"window": "The dynamics of the current operating environment resulting from the effects of COVID -19 has \nintroduced further volatility in our cash flow.  \n \n However, improving volumes and strong working capital fundamentals give us confidence we will continue to \ngenerate solid free cash flow.  Investment in growth opportunities remains a key priority for McKesson.  And during \nthe quarter, we made $117 million of capital expenditures.  We continue to focus on internal investments in areas \nsuch as technolog y and our strategic growth initiatives.  \n \n We returned cash to our shareholders through the payment of $74 million in dividend.  We have $1.5 billion \nremaining on our share repurchase authorization. ", "original_text": "And during \nthe quarter, we made $117 million of capital expenditures. ", "page_label": "10", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "19624046c37bf44435c84741e60bf10d285e35dd8adb149b58c598b578479f4c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c6939212-ae8e-4d87-befe-0efc09be4655", "node_type": "1", "metadata": {"window": "Investment in growth opportunities remains a key priority for McKesson.  And during \nthe quarter, we made $117 million of capital expenditures.  We continue to focus on internal investments in areas \nsuch as technolog y and our strategic growth initiatives.  \n \n We returned cash to our shareholders through the payment of $74 million in dividend.  We have $1.5 billion \nremaining on our share repurchase authorization.  We continue to expect weighted shares outstanding in the \nrange of 161 million to 163 million.  We also continue to anticipate free cash flow in the range of $2.3 to $2.7 billion \nfor fiscal 2021.  \n \n", "original_text": "We returned cash to our shareholders through the payment of $74 million in dividend. "}, "hash": "69f1246356fd91ed04a0dc20367a610a61690c97875a8bb5d0c99271bca9955f", "class_name": "RelatedNodeInfo"}}, "text": "We continue to focus on internal investments in areas \nsuch as technolog y and our strategic growth initiatives.  \n \n", "start_char_idx": 742, "end_char_idx": 859, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c6939212-ae8e-4d87-befe-0efc09be4655": {"__data__": {"id_": "c6939212-ae8e-4d87-befe-0efc09be4655", "embedding": null, "metadata": {"window": "Investment in growth opportunities remains a key priority for McKesson.  And during \nthe quarter, we made $117 million of capital expenditures.  We continue to focus on internal investments in areas \nsuch as technolog y and our strategic growth initiatives.  \n \n We returned cash to our shareholders through the payment of $74 million in dividend.  We have $1.5 billion \nremaining on our share repurchase authorization.  We continue to expect weighted shares outstanding in the \nrange of 161 million to 163 million.  We also continue to anticipate free cash flow in the range of $2.3 to $2.7 billion \nfor fiscal 2021.  \n \n", "original_text": "We returned cash to our shareholders through the payment of $74 million in dividend. ", "page_label": "10", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a2fe6c7d-f0eb-4895-b27b-02b6ca730d5e", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8094901027b565718c61bbce19b58cecced8539c3683fb394088de434926fec8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "07b838c1-f5a3-460d-ba35-80ec302a438e", "node_type": "1", "metadata": {"window": "However, improving volumes and strong working capital fundamentals give us confidence we will continue to \ngenerate solid free cash flow.  Investment in growth opportunities remains a key priority for McKesson.  And during \nthe quarter, we made $117 million of capital expenditures.  We continue to focus on internal investments in areas \nsuch as technolog y and our strategic growth initiatives.  \n \n We returned cash to our shareholders through the payment of $74 million in dividend.  We have $1.5 billion \nremaining on our share repurchase authorization.  We continue to expect weighted shares outstanding in the \nrange of 161 million to 163 million. ", "original_text": "We continue to focus on internal investments in areas \nsuch as technolog y and our strategic growth initiatives.  \n \n", "page_label": "10", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "94de655df8da24561f5eab007f6d531cddd538bfb91479933659173a4d3e12a8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "47975624-14f0-4478-9dc5-f96535a6ea38", "node_type": "1", "metadata": {"window": "And during \nthe quarter, we made $117 million of capital expenditures.  We continue to focus on internal investments in areas \nsuch as technolog y and our strategic growth initiatives.  \n \n We returned cash to our shareholders through the payment of $74 million in dividend.  We have $1.5 billion \nremaining on our share repurchase authorization.  We continue to expect weighted shares outstanding in the \nrange of 161 million to 163 million.  We also continue to anticipate free cash flow in the range of $2.3 to $2.7 billion \nfor fiscal 2021.  \n \n Let me transition now and talk about our outlook for the balance of fiscal 2021. ", "original_text": "We have $1.5 billion \nremaining on our share repurchase authorization. "}, "hash": "8f37665b7e5e9bb7898e6565fb714246be56b9ea01c4a1a7c5df0a93d3718191", "class_name": "RelatedNodeInfo"}}, "text": "We returned cash to our shareholders through the payment of $74 million in dividend. ", "start_char_idx": 859, "end_char_idx": 944, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "47975624-14f0-4478-9dc5-f96535a6ea38": {"__data__": {"id_": "47975624-14f0-4478-9dc5-f96535a6ea38", "embedding": null, "metadata": {"window": "And during \nthe quarter, we made $117 million of capital expenditures.  We continue to focus on internal investments in areas \nsuch as technolog y and our strategic growth initiatives.  \n \n We returned cash to our shareholders through the payment of $74 million in dividend.  We have $1.5 billion \nremaining on our share repurchase authorization.  We continue to expect weighted shares outstanding in the \nrange of 161 million to 163 million.  We also continue to anticipate free cash flow in the range of $2.3 to $2.7 billion \nfor fiscal 2021.  \n \n Let me transition now and talk about our outlook for the balance of fiscal 2021. ", "original_text": "We have $1.5 billion \nremaining on our share repurchase authorization. ", "page_label": "10", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a2fe6c7d-f0eb-4895-b27b-02b6ca730d5e", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8094901027b565718c61bbce19b58cecced8539c3683fb394088de434926fec8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c6939212-ae8e-4d87-befe-0efc09be4655", "node_type": "1", "metadata": {"window": "Investment in growth opportunities remains a key priority for McKesson.  And during \nthe quarter, we made $117 million of capital expenditures.  We continue to focus on internal investments in areas \nsuch as technolog y and our strategic growth initiatives.  \n \n We returned cash to our shareholders through the payment of $74 million in dividend.  We have $1.5 billion \nremaining on our share repurchase authorization.  We continue to expect weighted shares outstanding in the \nrange of 161 million to 163 million.  We also continue to anticipate free cash flow in the range of $2.3 to $2.7 billion \nfor fiscal 2021.  \n \n", "original_text": "We returned cash to our shareholders through the payment of $74 million in dividend. ", "page_label": "10", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8c8def2be73fc927f5d75fac6211adefa84a8cfed065be5b4425539faac4ac45", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c8252015-1335-4285-9ba3-e16c5345e67b", "node_type": "1", "metadata": {"window": "We continue to focus on internal investments in areas \nsuch as technolog y and our strategic growth initiatives.  \n \n We returned cash to our shareholders through the payment of $74 million in dividend.  We have $1.5 billion \nremaining on our share repurchase authorization.  We continue to expect weighted shares outstanding in the \nrange of 161 million to 163 million.  We also continue to anticipate free cash flow in the range of $2.3 to $2.7 billion \nfor fiscal 2021.  \n \n Let me transition now and talk about our outlook for the balance of fiscal 2021.  We continue to believe we are well \nposit ioned in the markets we compete with a clear strategy and a differentiated set of assets and capabilities. ", "original_text": "We continue to expect weighted shares outstanding in the \nrange of 161 million to 163 million. "}, "hash": "332258bdf88008222ec58d7ce27438a79ac99af3ff5709599758dbabcf42c6bf", "class_name": "RelatedNodeInfo"}}, "text": "We have $1.5 billion \nremaining on our share repurchase authorization. ", "start_char_idx": 944, "end_char_idx": 1015, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c8252015-1335-4285-9ba3-e16c5345e67b": {"__data__": {"id_": "c8252015-1335-4285-9ba3-e16c5345e67b", "embedding": null, "metadata": {"window": "We continue to focus on internal investments in areas \nsuch as technolog y and our strategic growth initiatives.  \n \n We returned cash to our shareholders through the payment of $74 million in dividend.  We have $1.5 billion \nremaining on our share repurchase authorization.  We continue to expect weighted shares outstanding in the \nrange of 161 million to 163 million.  We also continue to anticipate free cash flow in the range of $2.3 to $2.7 billion \nfor fiscal 2021.  \n \n Let me transition now and talk about our outlook for the balance of fiscal 2021.  We continue to believe we are well \nposit ioned in the markets we compete with a clear strategy and a differentiated set of assets and capabilities. ", "original_text": "We continue to expect weighted shares outstanding in the \nrange of 161 million to 163 million. ", "page_label": "10", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a2fe6c7d-f0eb-4895-b27b-02b6ca730d5e", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8094901027b565718c61bbce19b58cecced8539c3683fb394088de434926fec8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "47975624-14f0-4478-9dc5-f96535a6ea38", "node_type": "1", "metadata": {"window": "And during \nthe quarter, we made $117 million of capital expenditures.  We continue to focus on internal investments in areas \nsuch as technolog y and our strategic growth initiatives.  \n \n We returned cash to our shareholders through the payment of $74 million in dividend.  We have $1.5 billion \nremaining on our share repurchase authorization.  We continue to expect weighted shares outstanding in the \nrange of 161 million to 163 million.  We also continue to anticipate free cash flow in the range of $2.3 to $2.7 billion \nfor fiscal 2021.  \n \n Let me transition now and talk about our outlook for the balance of fiscal 2021. ", "original_text": "We have $1.5 billion \nremaining on our share repurchase authorization. ", "page_label": "10", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a072613060190584cefd01dfb468ba33001074d0f472f7bb33bc37031fbe9430", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8cdf2090-2acf-441f-b5a8-a9d39ba4020d", "node_type": "1", "metadata": {"window": "We returned cash to our shareholders through the payment of $74 million in dividend.  We have $1.5 billion \nremaining on our share repurchase authorization.  We continue to expect weighted shares outstanding in the \nrange of 161 million to 163 million.  We also continue to anticipate free cash flow in the range of $2.3 to $2.7 billion \nfor fiscal 2021.  \n \n Let me transition now and talk about our outlook for the balance of fiscal 2021.  We continue to believe we are well \nposit ioned in the markets we compete with a clear strategy and a differentiated set of assets and capabilities.  We \nremain confident in our long -term prospects, which are rooted in the important role we play in the health care \nsupply chain.  \n \n", "original_text": "We also continue to anticipate free cash flow in the range of $2.3 to $2.7 billion \nfor fiscal 2021.  \n \n"}, "hash": "805a634570731029da95cc1d1c15d33763b510a8949eb5ba08235a3bb5d873e5", "class_name": "RelatedNodeInfo"}}, "text": "We continue to expect weighted shares outstanding in the \nrange of 161 million to 163 million. ", "start_char_idx": 1015, "end_char_idx": 1110, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8cdf2090-2acf-441f-b5a8-a9d39ba4020d": {"__data__": {"id_": "8cdf2090-2acf-441f-b5a8-a9d39ba4020d", "embedding": null, "metadata": {"window": "We returned cash to our shareholders through the payment of $74 million in dividend.  We have $1.5 billion \nremaining on our share repurchase authorization.  We continue to expect weighted shares outstanding in the \nrange of 161 million to 163 million.  We also continue to anticipate free cash flow in the range of $2.3 to $2.7 billion \nfor fiscal 2021.  \n \n Let me transition now and talk about our outlook for the balance of fiscal 2021.  We continue to believe we are well \nposit ioned in the markets we compete with a clear strategy and a differentiated set of assets and capabilities.  We \nremain confident in our long -term prospects, which are rooted in the important role we play in the health care \nsupply chain.  \n \n", "original_text": "We also continue to anticipate free cash flow in the range of $2.3 to $2.7 billion \nfor fiscal 2021.  \n \n", "page_label": "10", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a2fe6c7d-f0eb-4895-b27b-02b6ca730d5e", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8094901027b565718c61bbce19b58cecced8539c3683fb394088de434926fec8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c8252015-1335-4285-9ba3-e16c5345e67b", "node_type": "1", "metadata": {"window": "We continue to focus on internal investments in areas \nsuch as technolog y and our strategic growth initiatives.  \n \n We returned cash to our shareholders through the payment of $74 million in dividend.  We have $1.5 billion \nremaining on our share repurchase authorization.  We continue to expect weighted shares outstanding in the \nrange of 161 million to 163 million.  We also continue to anticipate free cash flow in the range of $2.3 to $2.7 billion \nfor fiscal 2021.  \n \n Let me transition now and talk about our outlook for the balance of fiscal 2021.  We continue to believe we are well \nposit ioned in the markets we compete with a clear strategy and a differentiated set of assets and capabilities. ", "original_text": "We continue to expect weighted shares outstanding in the \nrange of 161 million to 163 million. ", "page_label": "10", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fbb1ed75ade0249e7c974d3e069827c42095249b7da2dcb5f44f2d4241cab012", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "67bdcc92-97ae-4f57-90f4-1d4670cc5297", "node_type": "1", "metadata": {"window": "We have $1.5 billion \nremaining on our share repurchase authorization.  We continue to expect weighted shares outstanding in the \nrange of 161 million to 163 million.  We also continue to anticipate free cash flow in the range of $2.3 to $2.7 billion \nfor fiscal 2021.  \n \n Let me transition now and talk about our outlook for the balance of fiscal 2021.  We continue to believe we are well \nposit ioned in the markets we compete with a clear strategy and a differentiated set of assets and capabilities.  We \nremain confident in our long -term prospects, which are rooted in the important role we play in the health care \nsupply chain.  \n \n In May, we outlined two-key macro assumptions, which I am reiterating today. ", "original_text": "Let me transition now and talk about our outlook for the balance of fiscal 2021. "}, "hash": "528a15f938df1f3d1bd5ca82ad2ee226c896a1990b282123da99f1eded55acba", "class_name": "RelatedNodeInfo"}}, "text": "We also continue to anticipate free cash flow in the range of $2.3 to $2.7 billion \nfor fiscal 2021.  \n \n", "start_char_idx": 1110, "end_char_idx": 1215, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "67bdcc92-97ae-4f57-90f4-1d4670cc5297": {"__data__": {"id_": "67bdcc92-97ae-4f57-90f4-1d4670cc5297", "embedding": null, "metadata": {"window": "We have $1.5 billion \nremaining on our share repurchase authorization.  We continue to expect weighted shares outstanding in the \nrange of 161 million to 163 million.  We also continue to anticipate free cash flow in the range of $2.3 to $2.7 billion \nfor fiscal 2021.  \n \n Let me transition now and talk about our outlook for the balance of fiscal 2021.  We continue to believe we are well \nposit ioned in the markets we compete with a clear strategy and a differentiated set of assets and capabilities.  We \nremain confident in our long -term prospects, which are rooted in the important role we play in the health care \nsupply chain.  \n \n In May, we outlined two-key macro assumptions, which I am reiterating today. ", "original_text": "Let me transition now and talk about our outlook for the balance of fiscal 2021. ", "page_label": "10", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a2fe6c7d-f0eb-4895-b27b-02b6ca730d5e", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8094901027b565718c61bbce19b58cecced8539c3683fb394088de434926fec8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8cdf2090-2acf-441f-b5a8-a9d39ba4020d", "node_type": "1", "metadata": {"window": "We returned cash to our shareholders through the payment of $74 million in dividend.  We have $1.5 billion \nremaining on our share repurchase authorization.  We continue to expect weighted shares outstanding in the \nrange of 161 million to 163 million.  We also continue to anticipate free cash flow in the range of $2.3 to $2.7 billion \nfor fiscal 2021.  \n \n Let me transition now and talk about our outlook for the balance of fiscal 2021.  We continue to believe we are well \nposit ioned in the markets we compete with a clear strategy and a differentiated set of assets and capabilities.  We \nremain confident in our long -term prospects, which are rooted in the important role we play in the health care \nsupply chain.  \n \n", "original_text": "We also continue to anticipate free cash flow in the range of $2.3 to $2.7 billion \nfor fiscal 2021.  \n \n", "page_label": "10", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2f0eedd58f71edfd03e8e6a000e2fbf705adb4bb20d424923bb0bab677e47817", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "67aeb439-9552-4b50-9c35-50b067429ee5", "node_type": "1", "metadata": {"window": "We continue to expect weighted shares outstanding in the \nrange of 161 million to 163 million.  We also continue to anticipate free cash flow in the range of $2.3 to $2.7 billion \nfor fiscal 2021.  \n \n Let me transition now and talk about our outlook for the balance of fiscal 2021.  We continue to believe we are well \nposit ioned in the markets we compete with a clear strategy and a differentiated set of assets and capabilities.  We \nremain confident in our long -term prospects, which are rooted in the important role we play in the health care \nsupply chain.  \n \n In May, we outlined two-key macro assumptions, which I am reiterating today.  First, we do not assume a second \nwave of COVID -19, which would lead to shelter at home and economic lockdowns. ", "original_text": "We continue to believe we are well \nposit ioned in the markets we compete with a clear strategy and a differentiated set of assets and capabilities. "}, "hash": "a6f994611d8eaafd9614abdec3b7ab03626d249c2ea429f98d93f5387a7b0b95", "class_name": "RelatedNodeInfo"}}, "text": "Let me transition now and talk about our outlook for the balance of fiscal 2021. ", "start_char_idx": 1215, "end_char_idx": 1296, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "67aeb439-9552-4b50-9c35-50b067429ee5": {"__data__": {"id_": "67aeb439-9552-4b50-9c35-50b067429ee5", "embedding": null, "metadata": {"window": "We continue to expect weighted shares outstanding in the \nrange of 161 million to 163 million.  We also continue to anticipate free cash flow in the range of $2.3 to $2.7 billion \nfor fiscal 2021.  \n \n Let me transition now and talk about our outlook for the balance of fiscal 2021.  We continue to believe we are well \nposit ioned in the markets we compete with a clear strategy and a differentiated set of assets and capabilities.  We \nremain confident in our long -term prospects, which are rooted in the important role we play in the health care \nsupply chain.  \n \n In May, we outlined two-key macro assumptions, which I am reiterating today.  First, we do not assume a second \nwave of COVID -19, which would lead to shelter at home and economic lockdowns. ", "original_text": "We continue to believe we are well \nposit ioned in the markets we compete with a clear strategy and a differentiated set of assets and capabilities. ", "page_label": "10", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a2fe6c7d-f0eb-4895-b27b-02b6ca730d5e", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8094901027b565718c61bbce19b58cecced8539c3683fb394088de434926fec8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "67bdcc92-97ae-4f57-90f4-1d4670cc5297", "node_type": "1", "metadata": {"window": "We have $1.5 billion \nremaining on our share repurchase authorization.  We continue to expect weighted shares outstanding in the \nrange of 161 million to 163 million.  We also continue to anticipate free cash flow in the range of $2.3 to $2.7 billion \nfor fiscal 2021.  \n \n Let me transition now and talk about our outlook for the balance of fiscal 2021.  We continue to believe we are well \nposit ioned in the markets we compete with a clear strategy and a differentiated set of assets and capabilities.  We \nremain confident in our long -term prospects, which are rooted in the important role we play in the health care \nsupply chain.  \n \n In May, we outlined two-key macro assumptions, which I am reiterating today. ", "original_text": "Let me transition now and talk about our outlook for the balance of fiscal 2021. ", "page_label": "10", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "982e8e8b66f4dacaa596845646d6d1b0712771d190973508b4a0054d4b8f8cdb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8d20175d-8d42-4170-80a4-27e6cd23bc16", "node_type": "1", "metadata": {"window": "We also continue to anticipate free cash flow in the range of $2.3 to $2.7 billion \nfor fiscal 2021.  \n \n Let me transition now and talk about our outlook for the balance of fiscal 2021.  We continue to believe we are well \nposit ioned in the markets we compete with a clear strategy and a differentiated set of assets and capabilities.  We \nremain confident in our long -term prospects, which are rooted in the important role we play in the health care \nsupply chain.  \n \n In May, we outlined two-key macro assumptions, which I am reiterating today.  First, we do not assume a second \nwave of COVID -19, which would lead to shelter at home and economic lockdowns.  And second, we do not \nassume any systemic customer insolvency events.  \n \n", "original_text": "We \nremain confident in our long -term prospects, which are rooted in the important role we play in the health care \nsupply chain.  \n \n"}, "hash": "e1933a69de4558c91f833e1c088d0a17ef008edb01d7bc967413fb9309643b80", "class_name": "RelatedNodeInfo"}}, "text": "We continue to believe we are well \nposit ioned in the markets we compete with a clear strategy and a differentiated set of assets and capabilities. ", "start_char_idx": 1296, "end_char_idx": 1445, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8d20175d-8d42-4170-80a4-27e6cd23bc16": {"__data__": {"id_": "8d20175d-8d42-4170-80a4-27e6cd23bc16", "embedding": null, "metadata": {"window": "We also continue to anticipate free cash flow in the range of $2.3 to $2.7 billion \nfor fiscal 2021.  \n \n Let me transition now and talk about our outlook for the balance of fiscal 2021.  We continue to believe we are well \nposit ioned in the markets we compete with a clear strategy and a differentiated set of assets and capabilities.  We \nremain confident in our long -term prospects, which are rooted in the important role we play in the health care \nsupply chain.  \n \n In May, we outlined two-key macro assumptions, which I am reiterating today.  First, we do not assume a second \nwave of COVID -19, which would lead to shelter at home and economic lockdowns.  And second, we do not \nassume any systemic customer insolvency events.  \n \n", "original_text": "We \nremain confident in our long -term prospects, which are rooted in the important role we play in the health care \nsupply chain.  \n \n", "page_label": "10", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a2fe6c7d-f0eb-4895-b27b-02b6ca730d5e", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8094901027b565718c61bbce19b58cecced8539c3683fb394088de434926fec8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "67aeb439-9552-4b50-9c35-50b067429ee5", "node_type": "1", "metadata": {"window": "We continue to expect weighted shares outstanding in the \nrange of 161 million to 163 million.  We also continue to anticipate free cash flow in the range of $2.3 to $2.7 billion \nfor fiscal 2021.  \n \n Let me transition now and talk about our outlook for the balance of fiscal 2021.  We continue to believe we are well \nposit ioned in the markets we compete with a clear strategy and a differentiated set of assets and capabilities.  We \nremain confident in our long -term prospects, which are rooted in the important role we play in the health care \nsupply chain.  \n \n In May, we outlined two-key macro assumptions, which I am reiterating today.  First, we do not assume a second \nwave of COVID -19, which would lead to shelter at home and economic lockdowns. ", "original_text": "We continue to believe we are well \nposit ioned in the markets we compete with a clear strategy and a differentiated set of assets and capabilities. ", "page_label": "10", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "374d0b511270b2bbbac6fb723eb38702a261069008c46b86c173178a7c63c20e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7d0de43b-40ee-43c3-a405-9446314e9d6d", "node_type": "1", "metadata": {"window": "Let me transition now and talk about our outlook for the balance of fiscal 2021.  We continue to believe we are well \nposit ioned in the markets we compete with a clear strategy and a differentiated set of assets and capabilities.  We \nremain confident in our long -term prospects, which are rooted in the important role we play in the health care \nsupply chain.  \n \n In May, we outlined two-key macro assumptions, which I am reiterating today.  First, we do not assume a second \nwave of COVID -19, which would lead to shelter at home and economic lockdowns.  And second, we do not \nassume any systemic customer insolvency events.  \n \n Similar to my com ments in May, I'd reiterate that one certainty is that events will occur in the coming days and \nweeks that could cause these underlying assumptions to change from what we know today. ", "original_text": "In May, we outlined two-key macro assumptions, which I am reiterating today. "}, "hash": "3bec0b5b047dc37e309c4cad5b75b24ff914a9b12f312cd10f3ad8ad79d6e5f7", "class_name": "RelatedNodeInfo"}}, "text": "We \nremain confident in our long -term prospects, which are rooted in the important role we play in the health care \nsupply chain.  \n \n", "start_char_idx": 1445, "end_char_idx": 1580, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7d0de43b-40ee-43c3-a405-9446314e9d6d": {"__data__": {"id_": "7d0de43b-40ee-43c3-a405-9446314e9d6d", "embedding": null, "metadata": {"window": "Let me transition now and talk about our outlook for the balance of fiscal 2021.  We continue to believe we are well \nposit ioned in the markets we compete with a clear strategy and a differentiated set of assets and capabilities.  We \nremain confident in our long -term prospects, which are rooted in the important role we play in the health care \nsupply chain.  \n \n In May, we outlined two-key macro assumptions, which I am reiterating today.  First, we do not assume a second \nwave of COVID -19, which would lead to shelter at home and economic lockdowns.  And second, we do not \nassume any systemic customer insolvency events.  \n \n Similar to my com ments in May, I'd reiterate that one certainty is that events will occur in the coming days and \nweeks that could cause these underlying assumptions to change from what we know today. ", "original_text": "In May, we outlined two-key macro assumptions, which I am reiterating today. ", "page_label": "10", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a2fe6c7d-f0eb-4895-b27b-02b6ca730d5e", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8094901027b565718c61bbce19b58cecced8539c3683fb394088de434926fec8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8d20175d-8d42-4170-80a4-27e6cd23bc16", "node_type": "1", "metadata": {"window": "We also continue to anticipate free cash flow in the range of $2.3 to $2.7 billion \nfor fiscal 2021.  \n \n Let me transition now and talk about our outlook for the balance of fiscal 2021.  We continue to believe we are well \nposit ioned in the markets we compete with a clear strategy and a differentiated set of assets and capabilities.  We \nremain confident in our long -term prospects, which are rooted in the important role we play in the health care \nsupply chain.  \n \n In May, we outlined two-key macro assumptions, which I am reiterating today.  First, we do not assume a second \nwave of COVID -19, which would lead to shelter at home and economic lockdowns.  And second, we do not \nassume any systemic customer insolvency events.  \n \n", "original_text": "We \nremain confident in our long -term prospects, which are rooted in the important role we play in the health care \nsupply chain.  \n \n", "page_label": "10", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c2463a6c17e2b6305c5377379095c6ddab36e1bf283e548e13287c27cf89970e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "69a767cd-57b4-480f-9649-43172209d3b3", "node_type": "1", "metadata": {"window": "We continue to believe we are well \nposit ioned in the markets we compete with a clear strategy and a differentiated set of assets and capabilities.  We \nremain confident in our long -term prospects, which are rooted in the important role we play in the health care \nsupply chain.  \n \n In May, we outlined two-key macro assumptions, which I am reiterating today.  First, we do not assume a second \nwave of COVID -19, which would lead to shelter at home and economic lockdowns.  And second, we do not \nassume any systemic customer insolvency events.  \n \n Similar to my com ments in May, I'd reiterate that one certainty is that events will occur in the coming days and \nweeks that could cause these underlying assumptions to change from what we know today.  As you think about \nour outlook, I'd highlight the strong relationship of our performance with two -key factors. ", "original_text": "First, we do not assume a second \nwave of COVID -19, which would lead to shelter at home and economic lockdowns. "}, "hash": "bff657052d9cf6e7b106fa6b3dd6f0f9d79911e1e4509f893e8ae209f27f6088", "class_name": "RelatedNodeInfo"}}, "text": "In May, we outlined two-key macro assumptions, which I am reiterating today. ", "start_char_idx": 1580, "end_char_idx": 1657, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "69a767cd-57b4-480f-9649-43172209d3b3": {"__data__": {"id_": "69a767cd-57b4-480f-9649-43172209d3b3", "embedding": null, "metadata": {"window": "We continue to believe we are well \nposit ioned in the markets we compete with a clear strategy and a differentiated set of assets and capabilities.  We \nremain confident in our long -term prospects, which are rooted in the important role we play in the health care \nsupply chain.  \n \n In May, we outlined two-key macro assumptions, which I am reiterating today.  First, we do not assume a second \nwave of COVID -19, which would lead to shelter at home and economic lockdowns.  And second, we do not \nassume any systemic customer insolvency events.  \n \n Similar to my com ments in May, I'd reiterate that one certainty is that events will occur in the coming days and \nweeks that could cause these underlying assumptions to change from what we know today.  As you think about \nour outlook, I'd highlight the strong relationship of our performance with two -key factors. ", "original_text": "First, we do not assume a second \nwave of COVID -19, which would lead to shelter at home and economic lockdowns. ", "page_label": "10", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a2fe6c7d-f0eb-4895-b27b-02b6ca730d5e", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8094901027b565718c61bbce19b58cecced8539c3683fb394088de434926fec8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7d0de43b-40ee-43c3-a405-9446314e9d6d", "node_type": "1", "metadata": {"window": "Let me transition now and talk about our outlook for the balance of fiscal 2021.  We continue to believe we are well \nposit ioned in the markets we compete with a clear strategy and a differentiated set of assets and capabilities.  We \nremain confident in our long -term prospects, which are rooted in the important role we play in the health care \nsupply chain.  \n \n In May, we outlined two-key macro assumptions, which I am reiterating today.  First, we do not assume a second \nwave of COVID -19, which would lead to shelter at home and economic lockdowns.  And second, we do not \nassume any systemic customer insolvency events.  \n \n Similar to my com ments in May, I'd reiterate that one certainty is that events will occur in the coming days and \nweeks that could cause these underlying assumptions to change from what we know today. ", "original_text": "In May, we outlined two-key macro assumptions, which I am reiterating today. ", "page_label": "10", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "acee8aba09b160caab660043e8ab7433243a4e2280c16a71bd2fb76bc4778eaf", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b13a442b-5285-43d8-a383-885439fa3237", "node_type": "1", "metadata": {"window": "We \nremain confident in our long -term prospects, which are rooted in the important role we play in the health care \nsupply chain.  \n \n In May, we outlined two-key macro assumptions, which I am reiterating today.  First, we do not assume a second \nwave of COVID -19, which would lead to shelter at home and economic lockdowns.  And second, we do not \nassume any systemic customer insolvency events.  \n \n Similar to my com ments in May, I'd reiterate that one certainty is that events will occur in the coming days and \nweeks that could cause these underlying assumptions to change from what we know today.  As you think about \nour outlook, I'd highlight the strong relationship of our performance with two -key factors.  First, the macroeconomic \nenvironment and the intersection of prescription volumes and patient behavior; and second, our ability to continue \nto execute our strategy with a disciplined approach to invest and position our selves for growth in the areas of \nspecialty, oncology and biopharma services. ", "original_text": "And second, we do not \nassume any systemic customer insolvency events.  \n \n"}, "hash": "d11d0fef5a687ff9962201d17b519185676a04cc1f43d5aed50728aa660016d3", "class_name": "RelatedNodeInfo"}}, "text": "First, we do not assume a second \nwave of COVID -19, which would lead to shelter at home and economic lockdowns. ", "start_char_idx": 1657, "end_char_idx": 1770, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b13a442b-5285-43d8-a383-885439fa3237": {"__data__": {"id_": "b13a442b-5285-43d8-a383-885439fa3237", "embedding": null, "metadata": {"window": "We \nremain confident in our long -term prospects, which are rooted in the important role we play in the health care \nsupply chain.  \n \n In May, we outlined two-key macro assumptions, which I am reiterating today.  First, we do not assume a second \nwave of COVID -19, which would lead to shelter at home and economic lockdowns.  And second, we do not \nassume any systemic customer insolvency events.  \n \n Similar to my com ments in May, I'd reiterate that one certainty is that events will occur in the coming days and \nweeks that could cause these underlying assumptions to change from what we know today.  As you think about \nour outlook, I'd highlight the strong relationship of our performance with two -key factors.  First, the macroeconomic \nenvironment and the intersection of prescription volumes and patient behavior; and second, our ability to continue \nto execute our strategy with a disciplined approach to invest and position our selves for growth in the areas of \nspecialty, oncology and biopharma services. ", "original_text": "And second, we do not \nassume any systemic customer insolvency events.  \n \n", "page_label": "10", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a2fe6c7d-f0eb-4895-b27b-02b6ca730d5e", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8094901027b565718c61bbce19b58cecced8539c3683fb394088de434926fec8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "69a767cd-57b4-480f-9649-43172209d3b3", "node_type": "1", "metadata": {"window": "We continue to believe we are well \nposit ioned in the markets we compete with a clear strategy and a differentiated set of assets and capabilities.  We \nremain confident in our long -term prospects, which are rooted in the important role we play in the health care \nsupply chain.  \n \n In May, we outlined two-key macro assumptions, which I am reiterating today.  First, we do not assume a second \nwave of COVID -19, which would lead to shelter at home and economic lockdowns.  And second, we do not \nassume any systemic customer insolvency events.  \n \n Similar to my com ments in May, I'd reiterate that one certainty is that events will occur in the coming days and \nweeks that could cause these underlying assumptions to change from what we know today.  As you think about \nour outlook, I'd highlight the strong relationship of our performance with two -key factors. ", "original_text": "First, we do not assume a second \nwave of COVID -19, which would lead to shelter at home and economic lockdowns. ", "page_label": "10", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b4f7eccecdd0ac788cbbcc09b1da88b227d0d7c0c0eae8bf78c106c8515a9078", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e2fe6db0-4db7-479e-92fd-08ff344e4824", "node_type": "1", "metadata": {"window": "In May, we outlined two-key macro assumptions, which I am reiterating today.  First, we do not assume a second \nwave of COVID -19, which would lead to shelter at home and economic lockdowns.  And second, we do not \nassume any systemic customer insolvency events.  \n \n Similar to my com ments in May, I'd reiterate that one certainty is that events will occur in the coming days and \nweeks that could cause these underlying assumptions to change from what we know today.  As you think about \nour outlook, I'd highlight the strong relationship of our performance with two -key factors.  First, the macroeconomic \nenvironment and the intersection of prescription volumes and patient behavior; and second, our ability to continue \nto execute our strategy with a disciplined approach to invest and position our selves for growth in the areas of \nspecialty, oncology and biopharma services.  This remains a dynamic environment. ", "original_text": "Similar to my com ments in May, I'd reiterate that one certainty is that events will occur in the coming days and \nweeks that could cause these underlying assumptions to change from what we know today. "}, "hash": "1fac4ca6661a70ea852b5a709332f2dc8dbdd3ab80c5e26d81793c1ac8d971b2", "class_name": "RelatedNodeInfo"}}, "text": "And second, we do not \nassume any systemic customer insolvency events.  \n \n", "start_char_idx": 1770, "end_char_idx": 1845, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e2fe6db0-4db7-479e-92fd-08ff344e4824": {"__data__": {"id_": "e2fe6db0-4db7-479e-92fd-08ff344e4824", "embedding": null, "metadata": {"window": "In May, we outlined two-key macro assumptions, which I am reiterating today.  First, we do not assume a second \nwave of COVID -19, which would lead to shelter at home and economic lockdowns.  And second, we do not \nassume any systemic customer insolvency events.  \n \n Similar to my com ments in May, I'd reiterate that one certainty is that events will occur in the coming days and \nweeks that could cause these underlying assumptions to change from what we know today.  As you think about \nour outlook, I'd highlight the strong relationship of our performance with two -key factors.  First, the macroeconomic \nenvironment and the intersection of prescription volumes and patient behavior; and second, our ability to continue \nto execute our strategy with a disciplined approach to invest and position our selves for growth in the areas of \nspecialty, oncology and biopharma services.  This remains a dynamic environment. ", "original_text": "Similar to my com ments in May, I'd reiterate that one certainty is that events will occur in the coming days and \nweeks that could cause these underlying assumptions to change from what we know today. ", "page_label": "10", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a2fe6c7d-f0eb-4895-b27b-02b6ca730d5e", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8094901027b565718c61bbce19b58cecced8539c3683fb394088de434926fec8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b13a442b-5285-43d8-a383-885439fa3237", "node_type": "1", "metadata": {"window": "We \nremain confident in our long -term prospects, which are rooted in the important role we play in the health care \nsupply chain.  \n \n In May, we outlined two-key macro assumptions, which I am reiterating today.  First, we do not assume a second \nwave of COVID -19, which would lead to shelter at home and economic lockdowns.  And second, we do not \nassume any systemic customer insolvency events.  \n \n Similar to my com ments in May, I'd reiterate that one certainty is that events will occur in the coming days and \nweeks that could cause these underlying assumptions to change from what we know today.  As you think about \nour outlook, I'd highlight the strong relationship of our performance with two -key factors.  First, the macroeconomic \nenvironment and the intersection of prescription volumes and patient behavior; and second, our ability to continue \nto execute our strategy with a disciplined approach to invest and position our selves for growth in the areas of \nspecialty, oncology and biopharma services. ", "original_text": "And second, we do not \nassume any systemic customer insolvency events.  \n \n", "page_label": "10", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6577649249bf2b3cdf1093b00d7e985c61055e32dea174fbfd9dfa318d542ac8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f35fcf61-15c7-48d6-ae2e-5f706c6264a1", "node_type": "1", "metadata": {"window": "First, we do not assume a second \nwave of COVID -19, which would lead to shelter at home and economic lockdowns.  And second, we do not \nassume any systemic customer insolvency events.  \n \n Similar to my com ments in May, I'd reiterate that one certainty is that events will occur in the coming days and \nweeks that could cause these underlying assumptions to change from what we know today.  As you think about \nour outlook, I'd highlight the strong relationship of our performance with two -key factors.  First, the macroeconomic \nenvironment and the intersection of prescription volumes and patient behavior; and second, our ability to continue \nto execute our strategy with a disciplined approach to invest and position our selves for growth in the areas of \nspecialty, oncology and biopharma services.  This remains a dynamic environment.  And while the situation has \nundoubtedly improved, the reality remains that the virus is not completely under control, with many areas seeing \nincreased positive cases and hospitalizations.  \n \n", "original_text": "As you think about \nour outlook, I'd highlight the strong relationship of our performance with two -key factors. "}, "hash": "2fbd832b3283b9c6f31ef1820e23368ef0eeb91cadf10f87376e932a1d2169f7", "class_name": "RelatedNodeInfo"}}, "text": "Similar to my com ments in May, I'd reiterate that one certainty is that events will occur in the coming days and \nweeks that could cause these underlying assumptions to change from what we know today. ", "start_char_idx": 1845, "end_char_idx": 2047, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f35fcf61-15c7-48d6-ae2e-5f706c6264a1": {"__data__": {"id_": "f35fcf61-15c7-48d6-ae2e-5f706c6264a1", "embedding": null, "metadata": {"window": "First, we do not assume a second \nwave of COVID -19, which would lead to shelter at home and economic lockdowns.  And second, we do not \nassume any systemic customer insolvency events.  \n \n Similar to my com ments in May, I'd reiterate that one certainty is that events will occur in the coming days and \nweeks that could cause these underlying assumptions to change from what we know today.  As you think about \nour outlook, I'd highlight the strong relationship of our performance with two -key factors.  First, the macroeconomic \nenvironment and the intersection of prescription volumes and patient behavior; and second, our ability to continue \nto execute our strategy with a disciplined approach to invest and position our selves for growth in the areas of \nspecialty, oncology and biopharma services.  This remains a dynamic environment.  And while the situation has \nundoubtedly improved, the reality remains that the virus is not completely under control, with many areas seeing \nincreased positive cases and hospitalizations.  \n \n", "original_text": "As you think about \nour outlook, I'd highlight the strong relationship of our performance with two -key factors. ", "page_label": "10", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a2fe6c7d-f0eb-4895-b27b-02b6ca730d5e", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8094901027b565718c61bbce19b58cecced8539c3683fb394088de434926fec8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e2fe6db0-4db7-479e-92fd-08ff344e4824", "node_type": "1", "metadata": {"window": "In May, we outlined two-key macro assumptions, which I am reiterating today.  First, we do not assume a second \nwave of COVID -19, which would lead to shelter at home and economic lockdowns.  And second, we do not \nassume any systemic customer insolvency events.  \n \n Similar to my com ments in May, I'd reiterate that one certainty is that events will occur in the coming days and \nweeks that could cause these underlying assumptions to change from what we know today.  As you think about \nour outlook, I'd highlight the strong relationship of our performance with two -key factors.  First, the macroeconomic \nenvironment and the intersection of prescription volumes and patient behavior; and second, our ability to continue \nto execute our strategy with a disciplined approach to invest and position our selves for growth in the areas of \nspecialty, oncology and biopharma services.  This remains a dynamic environment. ", "original_text": "Similar to my com ments in May, I'd reiterate that one certainty is that events will occur in the coming days and \nweeks that could cause these underlying assumptions to change from what we know today. ", "page_label": "10", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "312e7ab99a0aac9d58396b18e440f1435e76b623af13623653a72e4d69e96a0d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "aaf87a8f-e138-4ea2-af53-91dce50565af", "node_type": "1", "metadata": {"window": "And second, we do not \nassume any systemic customer insolvency events.  \n \n Similar to my com ments in May, I'd reiterate that one certainty is that events will occur in the coming days and \nweeks that could cause these underlying assumptions to change from what we know today.  As you think about \nour outlook, I'd highlight the strong relationship of our performance with two -key factors.  First, the macroeconomic \nenvironment and the intersection of prescription volumes and patient behavior; and second, our ability to continue \nto execute our strategy with a disciplined approach to invest and position our selves for growth in the areas of \nspecialty, oncology and biopharma services.  This remains a dynamic environment.  And while the situation has \nundoubtedly improved, the reality remains that the virus is not completely under control, with many areas seeing \nincreased positive cases and hospitalizations.  \n \n The impact of the pandemic is highly fluid and likely to continue evolving over the coming weeks and months. ", "original_text": "First, the macroeconomic \nenvironment and the intersection of prescription volumes and patient behavior; and second, our ability to continue \nto execute our strategy with a disciplined approach to invest and position our selves for growth in the areas of \nspecialty, oncology and biopharma services. "}, "hash": "dedbb37b729c67c203c4f0f35f1ee935a0eeffcc954dcf6177b9c326efe90ba4", "class_name": "RelatedNodeInfo"}}, "text": "As you think about \nour outlook, I'd highlight the strong relationship of our performance with two -key factors. ", "start_char_idx": 2047, "end_char_idx": 2160, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "aaf87a8f-e138-4ea2-af53-91dce50565af": {"__data__": {"id_": "aaf87a8f-e138-4ea2-af53-91dce50565af", "embedding": null, "metadata": {"window": "And second, we do not \nassume any systemic customer insolvency events.  \n \n Similar to my com ments in May, I'd reiterate that one certainty is that events will occur in the coming days and \nweeks that could cause these underlying assumptions to change from what we know today.  As you think about \nour outlook, I'd highlight the strong relationship of our performance with two -key factors.  First, the macroeconomic \nenvironment and the intersection of prescription volumes and patient behavior; and second, our ability to continue \nto execute our strategy with a disciplined approach to invest and position our selves for growth in the areas of \nspecialty, oncology and biopharma services.  This remains a dynamic environment.  And while the situation has \nundoubtedly improved, the reality remains that the virus is not completely under control, with many areas seeing \nincreased positive cases and hospitalizations.  \n \n The impact of the pandemic is highly fluid and likely to continue evolving over the coming weeks and months. ", "original_text": "First, the macroeconomic \nenvironment and the intersection of prescription volumes and patient behavior; and second, our ability to continue \nto execute our strategy with a disciplined approach to invest and position our selves for growth in the areas of \nspecialty, oncology and biopharma services. ", "page_label": "10", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a2fe6c7d-f0eb-4895-b27b-02b6ca730d5e", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8094901027b565718c61bbce19b58cecced8539c3683fb394088de434926fec8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f35fcf61-15c7-48d6-ae2e-5f706c6264a1", "node_type": "1", "metadata": {"window": "First, we do not assume a second \nwave of COVID -19, which would lead to shelter at home and economic lockdowns.  And second, we do not \nassume any systemic customer insolvency events.  \n \n Similar to my com ments in May, I'd reiterate that one certainty is that events will occur in the coming days and \nweeks that could cause these underlying assumptions to change from what we know today.  As you think about \nour outlook, I'd highlight the strong relationship of our performance with two -key factors.  First, the macroeconomic \nenvironment and the intersection of prescription volumes and patient behavior; and second, our ability to continue \nto execute our strategy with a disciplined approach to invest and position our selves for growth in the areas of \nspecialty, oncology and biopharma services.  This remains a dynamic environment.  And while the situation has \nundoubtedly improved, the reality remains that the virus is not completely under control, with many areas seeing \nincreased positive cases and hospitalizations.  \n \n", "original_text": "As you think about \nour outlook, I'd highlight the strong relationship of our performance with two -key factors. ", "page_label": "10", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7ff45a40aee822b0afebd3d1943f4fc762cb1bc2cf1ea7fb4a03946cd5905e99", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c17fd2f4-47b6-4e7d-9d77-b0f898cea98f", "node_type": "1", "metadata": {"window": "Similar to my com ments in May, I'd reiterate that one certainty is that events will occur in the coming days and \nweeks that could cause these underlying assumptions to change from what we know today.  As you think about \nour outlook, I'd highlight the strong relationship of our performance with two -key factors.  First, the macroeconomic \nenvironment and the intersection of prescription volumes and patient behavior; and second, our ability to continue \nto execute our strategy with a disciplined approach to invest and position our selves for growth in the areas of \nspecialty, oncology and biopharma services.  This remains a dynamic environment.  And while the situation has \nundoubtedly improved, the reality remains that the virus is not completely under control, with many areas seeing \nincreased positive cases and hospitalizations.  \n \n The impact of the pandemic is highly fluid and likely to continue evolving over the coming weeks and months.  We \ncontinue to expect the trajectory of the recovery to correlate closely to the level of mobility o f patients, prescription \ntransaction volumes and the demand for health care interactions with primary care physicians, oncologists and \nelective procedure levels.  \n \n", "original_text": "This remains a dynamic environment. "}, "hash": "daca8ed258a9502aba45ef7d117570c0a5387ffdd0387e917d272bbf113c03a2", "class_name": "RelatedNodeInfo"}}, "text": "First, the macroeconomic \nenvironment and the intersection of prescription volumes and patient behavior; and second, our ability to continue \nto execute our strategy with a disciplined approach to invest and position our selves for growth in the areas of \nspecialty, oncology and biopharma services. ", "start_char_idx": 2160, "end_char_idx": 2460, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c17fd2f4-47b6-4e7d-9d77-b0f898cea98f": {"__data__": {"id_": "c17fd2f4-47b6-4e7d-9d77-b0f898cea98f", "embedding": null, "metadata": {"window": "Similar to my com ments in May, I'd reiterate that one certainty is that events will occur in the coming days and \nweeks that could cause these underlying assumptions to change from what we know today.  As you think about \nour outlook, I'd highlight the strong relationship of our performance with two -key factors.  First, the macroeconomic \nenvironment and the intersection of prescription volumes and patient behavior; and second, our ability to continue \nto execute our strategy with a disciplined approach to invest and position our selves for growth in the areas of \nspecialty, oncology and biopharma services.  This remains a dynamic environment.  And while the situation has \nundoubtedly improved, the reality remains that the virus is not completely under control, with many areas seeing \nincreased positive cases and hospitalizations.  \n \n The impact of the pandemic is highly fluid and likely to continue evolving over the coming weeks and months.  We \ncontinue to expect the trajectory of the recovery to correlate closely to the level of mobility o f patients, prescription \ntransaction volumes and the demand for health care interactions with primary care physicians, oncologists and \nelective procedure levels.  \n \n", "original_text": "This remains a dynamic environment. ", "page_label": "10", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a2fe6c7d-f0eb-4895-b27b-02b6ca730d5e", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8094901027b565718c61bbce19b58cecced8539c3683fb394088de434926fec8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "aaf87a8f-e138-4ea2-af53-91dce50565af", "node_type": "1", "metadata": {"window": "And second, we do not \nassume any systemic customer insolvency events.  \n \n Similar to my com ments in May, I'd reiterate that one certainty is that events will occur in the coming days and \nweeks that could cause these underlying assumptions to change from what we know today.  As you think about \nour outlook, I'd highlight the strong relationship of our performance with two -key factors.  First, the macroeconomic \nenvironment and the intersection of prescription volumes and patient behavior; and second, our ability to continue \nto execute our strategy with a disciplined approach to invest and position our selves for growth in the areas of \nspecialty, oncology and biopharma services.  This remains a dynamic environment.  And while the situation has \nundoubtedly improved, the reality remains that the virus is not completely under control, with many areas seeing \nincreased positive cases and hospitalizations.  \n \n The impact of the pandemic is highly fluid and likely to continue evolving over the coming weeks and months. ", "original_text": "First, the macroeconomic \nenvironment and the intersection of prescription volumes and patient behavior; and second, our ability to continue \nto execute our strategy with a disciplined approach to invest and position our selves for growth in the areas of \nspecialty, oncology and biopharma services. ", "page_label": "10", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fe58317c58b69fdc72cee8691c9056f7201757de5afa5cc1b325f434fbe96ba2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d2a26281-e3d2-4929-996e-b85ddb17458b", "node_type": "1", "metadata": {"window": "As you think about \nour outlook, I'd highlight the strong relationship of our performance with two -key factors.  First, the macroeconomic \nenvironment and the intersection of prescription volumes and patient behavior; and second, our ability to continue \nto execute our strategy with a disciplined approach to invest and position our selves for growth in the areas of \nspecialty, oncology and biopharma services.  This remains a dynamic environment.  And while the situation has \nundoubtedly improved, the reality remains that the virus is not completely under control, with many areas seeing \nincreased positive cases and hospitalizations.  \n \n The impact of the pandemic is highly fluid and likely to continue evolving over the coming weeks and months.  We \ncontinue to expect the trajectory of the recovery to correlate closely to the level of mobility o f patients, prescription \ntransaction volumes and the demand for health care interactions with primary care physicians, oncologists and \nelective procedure levels.  \n \n We continue to believe the first quarter will be the most severely impacted, and we expect to  see sequential \nrevenue and adjusted operating profit improvement over the balance of the fiscal year. ", "original_text": "And while the situation has \nundoubtedly improved, the reality remains that the virus is not completely under control, with many areas seeing \nincreased positive cases and hospitalizations.  \n \n"}, "hash": "4ef93a106c8a30986ffc0f5743b9031103ea1933484f8695275756e78760a4c1", "class_name": "RelatedNodeInfo"}}, "text": "This remains a dynamic environment. ", "start_char_idx": 2460, "end_char_idx": 2496, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d2a26281-e3d2-4929-996e-b85ddb17458b": {"__data__": {"id_": "d2a26281-e3d2-4929-996e-b85ddb17458b", "embedding": null, "metadata": {"window": "As you think about \nour outlook, I'd highlight the strong relationship of our performance with two -key factors.  First, the macroeconomic \nenvironment and the intersection of prescription volumes and patient behavior; and second, our ability to continue \nto execute our strategy with a disciplined approach to invest and position our selves for growth in the areas of \nspecialty, oncology and biopharma services.  This remains a dynamic environment.  And while the situation has \nundoubtedly improved, the reality remains that the virus is not completely under control, with many areas seeing \nincreased positive cases and hospitalizations.  \n \n The impact of the pandemic is highly fluid and likely to continue evolving over the coming weeks and months.  We \ncontinue to expect the trajectory of the recovery to correlate closely to the level of mobility o f patients, prescription \ntransaction volumes and the demand for health care interactions with primary care physicians, oncologists and \nelective procedure levels.  \n \n We continue to believe the first quarter will be the most severely impacted, and we expect to  see sequential \nrevenue and adjusted operating profit improvement over the balance of the fiscal year. ", "original_text": "And while the situation has \nundoubtedly improved, the reality remains that the virus is not completely under control, with many areas seeing \nincreased positive cases and hospitalizations.  \n \n", "page_label": "10", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a2fe6c7d-f0eb-4895-b27b-02b6ca730d5e", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8094901027b565718c61bbce19b58cecced8539c3683fb394088de434926fec8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c17fd2f4-47b6-4e7d-9d77-b0f898cea98f", "node_type": "1", "metadata": {"window": "Similar to my com ments in May, I'd reiterate that one certainty is that events will occur in the coming days and \nweeks that could cause these underlying assumptions to change from what we know today.  As you think about \nour outlook, I'd highlight the strong relationship of our performance with two -key factors.  First, the macroeconomic \nenvironment and the intersection of prescription volumes and patient behavior; and second, our ability to continue \nto execute our strategy with a disciplined approach to invest and position our selves for growth in the areas of \nspecialty, oncology and biopharma services.  This remains a dynamic environment.  And while the situation has \nundoubtedly improved, the reality remains that the virus is not completely under control, with many areas seeing \nincreased positive cases and hospitalizations.  \n \n The impact of the pandemic is highly fluid and likely to continue evolving over the coming weeks and months.  We \ncontinue to expect the trajectory of the recovery to correlate closely to the level of mobility o f patients, prescription \ntransaction volumes and the demand for health care interactions with primary care physicians, oncologists and \nelective procedure levels.  \n \n", "original_text": "This remains a dynamic environment. ", "page_label": "10", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "96869b5eae92600fceed1a3b8700ac4e79d767b1ed133da290442c1b2c95fb25", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a2a12f25-ee00-4848-8648-3ba75b48e37e", "node_type": "1", "metadata": {"window": "First, the macroeconomic \nenvironment and the intersection of prescription volumes and patient behavior; and second, our ability to continue \nto execute our strategy with a disciplined approach to invest and position our selves for growth in the areas of \nspecialty, oncology and biopharma services.  This remains a dynamic environment.  And while the situation has \nundoubtedly improved, the reality remains that the virus is not completely under control, with many areas seeing \nincreased positive cases and hospitalizations.  \n \n The impact of the pandemic is highly fluid and likely to continue evolving over the coming weeks and months.  We \ncontinue to expect the trajectory of the recovery to correlate closely to the level of mobility o f patients, prescription \ntransaction volumes and the demand for health care interactions with primary care physicians, oncologists and \nelective procedure levels.  \n \n We continue to believe the first quarter will be the most severely impacted, and we expect to  see sequential \nrevenue and adjusted operating profit improvement over the balance of the fiscal year.  However, we do not \nbelieve the recovery in our business will be linear. ", "original_text": "The impact of the pandemic is highly fluid and likely to continue evolving over the coming weeks and months. "}, "hash": "91c4f108088e1a8862c4837f5df70aa30ca7869df181858eab04bc0513150edc", "class_name": "RelatedNodeInfo"}}, "text": "And while the situation has \nundoubtedly improved, the reality remains that the virus is not completely under control, with many areas seeing \nincreased positive cases and hospitalizations.  \n \n", "start_char_idx": 2496, "end_char_idx": 2690, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a2a12f25-ee00-4848-8648-3ba75b48e37e": {"__data__": {"id_": "a2a12f25-ee00-4848-8648-3ba75b48e37e", "embedding": null, "metadata": {"window": "First, the macroeconomic \nenvironment and the intersection of prescription volumes and patient behavior; and second, our ability to continue \nto execute our strategy with a disciplined approach to invest and position our selves for growth in the areas of \nspecialty, oncology and biopharma services.  This remains a dynamic environment.  And while the situation has \nundoubtedly improved, the reality remains that the virus is not completely under control, with many areas seeing \nincreased positive cases and hospitalizations.  \n \n The impact of the pandemic is highly fluid and likely to continue evolving over the coming weeks and months.  We \ncontinue to expect the trajectory of the recovery to correlate closely to the level of mobility o f patients, prescription \ntransaction volumes and the demand for health care interactions with primary care physicians, oncologists and \nelective procedure levels.  \n \n We continue to believe the first quarter will be the most severely impacted, and we expect to  see sequential \nrevenue and adjusted operating profit improvement over the balance of the fiscal year.  However, we do not \nbelieve the recovery in our business will be linear. ", "original_text": "The impact of the pandemic is highly fluid and likely to continue evolving over the coming weeks and months. ", "page_label": "10", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a2fe6c7d-f0eb-4895-b27b-02b6ca730d5e", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8094901027b565718c61bbce19b58cecced8539c3683fb394088de434926fec8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d2a26281-e3d2-4929-996e-b85ddb17458b", "node_type": "1", "metadata": {"window": "As you think about \nour outlook, I'd highlight the strong relationship of our performance with two -key factors.  First, the macroeconomic \nenvironment and the intersection of prescription volumes and patient behavior; and second, our ability to continue \nto execute our strategy with a disciplined approach to invest and position our selves for growth in the areas of \nspecialty, oncology and biopharma services.  This remains a dynamic environment.  And while the situation has \nundoubtedly improved, the reality remains that the virus is not completely under control, with many areas seeing \nincreased positive cases and hospitalizations.  \n \n The impact of the pandemic is highly fluid and likely to continue evolving over the coming weeks and months.  We \ncontinue to expect the trajectory of the recovery to correlate closely to the level of mobility o f patients, prescription \ntransaction volumes and the demand for health care interactions with primary care physicians, oncologists and \nelective procedure levels.  \n \n We continue to believe the first quarter will be the most severely impacted, and we expect to  see sequential \nrevenue and adjusted operating profit improvement over the balance of the fiscal year. ", "original_text": "And while the situation has \nundoubtedly improved, the reality remains that the virus is not completely under control, with many areas seeing \nincreased positive cases and hospitalizations.  \n \n", "page_label": "10", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "452e7720d1b5f1eb2ce67c95c9b5598ec0d64e8df61f46bb4a31087551926f40", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "100b572c-d476-4c6b-a52a-6f7108352da5", "node_type": "1", "metadata": {"window": "This remains a dynamic environment.  And while the situation has \nundoubtedly improved, the reality remains that the virus is not completely under control, with many areas seeing \nincreased positive cases and hospitalizations.  \n \n The impact of the pandemic is highly fluid and likely to continue evolving over the coming weeks and months.  We \ncontinue to expect the trajectory of the recovery to correlate closely to the level of mobility o f patients, prescription \ntransaction volumes and the demand for health care interactions with primary care physicians, oncologists and \nelective procedure levels.  \n \n We continue to believe the first quarter will be the most severely impacted, and we expect to  see sequential \nrevenue and adjusted operating profit improvement over the balance of the fiscal year.  However, we do not \nbelieve the recovery in our business will be linear.  Based on what we have observed in the past 75 days, we \nbelieve that a full recove ry may take longer than originally contemplated. ", "original_text": "We \ncontinue to expect the trajectory of the recovery to correlate closely to the level of mobility o f patients, prescription \ntransaction volumes and the demand for health care interactions with primary care physicians, oncologists and \nelective procedure levels.  \n \n"}, "hash": "45cfd01513867be14ecc445566e31fa2d805ba5c69fb9cc753bb350d51952cd0", "class_name": "RelatedNodeInfo"}}, "text": "The impact of the pandemic is highly fluid and likely to continue evolving over the coming weeks and months. ", "start_char_idx": 2690, "end_char_idx": 2799, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "100b572c-d476-4c6b-a52a-6f7108352da5": {"__data__": {"id_": "100b572c-d476-4c6b-a52a-6f7108352da5", "embedding": null, "metadata": {"window": "This remains a dynamic environment.  And while the situation has \nundoubtedly improved, the reality remains that the virus is not completely under control, with many areas seeing \nincreased positive cases and hospitalizations.  \n \n The impact of the pandemic is highly fluid and likely to continue evolving over the coming weeks and months.  We \ncontinue to expect the trajectory of the recovery to correlate closely to the level of mobility o f patients, prescription \ntransaction volumes and the demand for health care interactions with primary care physicians, oncologists and \nelective procedure levels.  \n \n We continue to believe the first quarter will be the most severely impacted, and we expect to  see sequential \nrevenue and adjusted operating profit improvement over the balance of the fiscal year.  However, we do not \nbelieve the recovery in our business will be linear.  Based on what we have observed in the past 75 days, we \nbelieve that a full recove ry may take longer than originally contemplated. ", "original_text": "We \ncontinue to expect the trajectory of the recovery to correlate closely to the level of mobility o f patients, prescription \ntransaction volumes and the demand for health care interactions with primary care physicians, oncologists and \nelective procedure levels.  \n \n", "page_label": "10", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a2fe6c7d-f0eb-4895-b27b-02b6ca730d5e", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8094901027b565718c61bbce19b58cecced8539c3683fb394088de434926fec8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a2a12f25-ee00-4848-8648-3ba75b48e37e", "node_type": "1", "metadata": {"window": "First, the macroeconomic \nenvironment and the intersection of prescription volumes and patient behavior; and second, our ability to continue \nto execute our strategy with a disciplined approach to invest and position our selves for growth in the areas of \nspecialty, oncology and biopharma services.  This remains a dynamic environment.  And while the situation has \nundoubtedly improved, the reality remains that the virus is not completely under control, with many areas seeing \nincreased positive cases and hospitalizations.  \n \n The impact of the pandemic is highly fluid and likely to continue evolving over the coming weeks and months.  We \ncontinue to expect the trajectory of the recovery to correlate closely to the level of mobility o f patients, prescription \ntransaction volumes and the demand for health care interactions with primary care physicians, oncologists and \nelective procedure levels.  \n \n We continue to believe the first quarter will be the most severely impacted, and we expect to  see sequential \nrevenue and adjusted operating profit improvement over the balance of the fiscal year.  However, we do not \nbelieve the recovery in our business will be linear. ", "original_text": "The impact of the pandemic is highly fluid and likely to continue evolving over the coming weeks and months. ", "page_label": "10", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "746205052daa7c6d46acbb2b0357b9e76b8b6a4203c63dd24ece9eb65119ffd2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8da32229-728e-4fff-93ba-bfd3bca582c5", "node_type": "1", "metadata": {"window": "And while the situation has \nundoubtedly improved, the reality remains that the virus is not completely under control, with many areas seeing \nincreased positive cases and hospitalizations.  \n \n The impact of the pandemic is highly fluid and likely to continue evolving over the coming weeks and months.  We \ncontinue to expect the trajectory of the recovery to correlate closely to the level of mobility o f patients, prescription \ntransaction volumes and the demand for health care interactions with primary care physicians, oncologists and \nelective procedure levels.  \n \n We continue to believe the first quarter will be the most severely impacted, and we expect to  see sequential \nrevenue and adjusted operating profit improvement over the balance of the fiscal year.  However, we do not \nbelieve the recovery in our business will be linear.  Based on what we have observed in the past 75 days, we \nbelieve that a full recove ry may take longer than originally contemplated.  However, we continue to expect growth \nin the second half of the year as compared to the prior year.  \n \n", "original_text": "We continue to believe the first quarter will be the most severely impacted, and we expect to  see sequential \nrevenue and adjusted operating profit improvement over the balance of the fiscal year. "}, "hash": "5c9869109caa059711b496e239d51bb4854bc75b13a3f537a357404324072a67", "class_name": "RelatedNodeInfo"}}, "text": "We \ncontinue to expect the trajectory of the recovery to correlate closely to the level of mobility o f patients, prescription \ntransaction volumes and the demand for health care interactions with primary care physicians, oncologists and \nelective procedure levels.  \n \n", "start_char_idx": 2799, "end_char_idx": 3069, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8da32229-728e-4fff-93ba-bfd3bca582c5": {"__data__": {"id_": "8da32229-728e-4fff-93ba-bfd3bca582c5", "embedding": null, "metadata": {"window": "And while the situation has \nundoubtedly improved, the reality remains that the virus is not completely under control, with many areas seeing \nincreased positive cases and hospitalizations.  \n \n The impact of the pandemic is highly fluid and likely to continue evolving over the coming weeks and months.  We \ncontinue to expect the trajectory of the recovery to correlate closely to the level of mobility o f patients, prescription \ntransaction volumes and the demand for health care interactions with primary care physicians, oncologists and \nelective procedure levels.  \n \n We continue to believe the first quarter will be the most severely impacted, and we expect to  see sequential \nrevenue and adjusted operating profit improvement over the balance of the fiscal year.  However, we do not \nbelieve the recovery in our business will be linear.  Based on what we have observed in the past 75 days, we \nbelieve that a full recove ry may take longer than originally contemplated.  However, we continue to expect growth \nin the second half of the year as compared to the prior year.  \n \n", "original_text": "We continue to believe the first quarter will be the most severely impacted, and we expect to  see sequential \nrevenue and adjusted operating profit improvement over the balance of the fiscal year. ", "page_label": "10", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a2fe6c7d-f0eb-4895-b27b-02b6ca730d5e", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8094901027b565718c61bbce19b58cecced8539c3683fb394088de434926fec8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "100b572c-d476-4c6b-a52a-6f7108352da5", "node_type": "1", "metadata": {"window": "This remains a dynamic environment.  And while the situation has \nundoubtedly improved, the reality remains that the virus is not completely under control, with many areas seeing \nincreased positive cases and hospitalizations.  \n \n The impact of the pandemic is highly fluid and likely to continue evolving over the coming weeks and months.  We \ncontinue to expect the trajectory of the recovery to correlate closely to the level of mobility o f patients, prescription \ntransaction volumes and the demand for health care interactions with primary care physicians, oncologists and \nelective procedure levels.  \n \n We continue to believe the first quarter will be the most severely impacted, and we expect to  see sequential \nrevenue and adjusted operating profit improvement over the balance of the fiscal year.  However, we do not \nbelieve the recovery in our business will be linear.  Based on what we have observed in the past 75 days, we \nbelieve that a full recove ry may take longer than originally contemplated. ", "original_text": "We \ncontinue to expect the trajectory of the recovery to correlate closely to the level of mobility o f patients, prescription \ntransaction volumes and the demand for health care interactions with primary care physicians, oncologists and \nelective procedure levels.  \n \n", "page_label": "10", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9ecc939fee7520a7cb27bfe44f393c465ffd940d3d50f965bb7eb1f696044b4c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "52e6a909-4bd5-49dc-addf-9d638185cada", "node_type": "1", "metadata": {"window": "The impact of the pandemic is highly fluid and likely to continue evolving over the coming weeks and months.  We \ncontinue to expect the trajectory of the recovery to correlate closely to the level of mobility o f patients, prescription \ntransaction volumes and the demand for health care interactions with primary care physicians, oncologists and \nelective procedure levels.  \n \n We continue to believe the first quarter will be the most severely impacted, and we expect to  see sequential \nrevenue and adjusted operating profit improvement over the balance of the fiscal year.  However, we do not \nbelieve the recovery in our business will be linear.  Based on what we have observed in the past 75 days, we \nbelieve that a full recove ry may take longer than originally contemplated.  However, we continue to expect growth \nin the second half of the year as compared to the prior year.  \n \n Let me provide a few details of our outlook. ", "original_text": "However, we do not \nbelieve the recovery in our business will be linear. "}, "hash": "6c2a6987949a92cf9d3a27038dfff7ec5cf97ceed1a30a961aef6fd75ba89b40", "class_name": "RelatedNodeInfo"}}, "text": "We continue to believe the first quarter will be the most severely impacted, and we expect to  see sequential \nrevenue and adjusted operating profit improvement over the balance of the fiscal year. ", "start_char_idx": 3069, "end_char_idx": 3267, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "52e6a909-4bd5-49dc-addf-9d638185cada": {"__data__": {"id_": "52e6a909-4bd5-49dc-addf-9d638185cada", "embedding": null, "metadata": {"window": "The impact of the pandemic is highly fluid and likely to continue evolving over the coming weeks and months.  We \ncontinue to expect the trajectory of the recovery to correlate closely to the level of mobility o f patients, prescription \ntransaction volumes and the demand for health care interactions with primary care physicians, oncologists and \nelective procedure levels.  \n \n We continue to believe the first quarter will be the most severely impacted, and we expect to  see sequential \nrevenue and adjusted operating profit improvement over the balance of the fiscal year.  However, we do not \nbelieve the recovery in our business will be linear.  Based on what we have observed in the past 75 days, we \nbelieve that a full recove ry may take longer than originally contemplated.  However, we continue to expect growth \nin the second half of the year as compared to the prior year.  \n \n Let me provide a few details of our outlook. ", "original_text": "However, we do not \nbelieve the recovery in our business will be linear. ", "page_label": "10", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a2fe6c7d-f0eb-4895-b27b-02b6ca730d5e", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8094901027b565718c61bbce19b58cecced8539c3683fb394088de434926fec8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8da32229-728e-4fff-93ba-bfd3bca582c5", "node_type": "1", "metadata": {"window": "And while the situation has \nundoubtedly improved, the reality remains that the virus is not completely under control, with many areas seeing \nincreased positive cases and hospitalizations.  \n \n The impact of the pandemic is highly fluid and likely to continue evolving over the coming weeks and months.  We \ncontinue to expect the trajectory of the recovery to correlate closely to the level of mobility o f patients, prescription \ntransaction volumes and the demand for health care interactions with primary care physicians, oncologists and \nelective procedure levels.  \n \n We continue to believe the first quarter will be the most severely impacted, and we expect to  see sequential \nrevenue and adjusted operating profit improvement over the balance of the fiscal year.  However, we do not \nbelieve the recovery in our business will be linear.  Based on what we have observed in the past 75 days, we \nbelieve that a full recove ry may take longer than originally contemplated.  However, we continue to expect growth \nin the second half of the year as compared to the prior year.  \n \n", "original_text": "We continue to believe the first quarter will be the most severely impacted, and we expect to  see sequential \nrevenue and adjusted operating profit improvement over the balance of the fiscal year. ", "page_label": "10", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2c7000b893ae117c7ad73c2910a6549f84d63bdd249cdd0b5ae97cd0c908dcaa", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "dbe0d40c-01bd-4f56-ba38-3e13e33df77f", "node_type": "1", "metadata": {"window": "We \ncontinue to expect the trajectory of the recovery to correlate closely to the level of mobility o f patients, prescription \ntransaction volumes and the demand for health care interactions with primary care physicians, oncologists and \nelective procedure levels.  \n \n We continue to believe the first quarter will be the most severely impacted, and we expect to  see sequential \nrevenue and adjusted operating profit improvement over the balance of the fiscal year.  However, we do not \nbelieve the recovery in our business will be linear.  Based on what we have observed in the past 75 days, we \nbelieve that a full recove ry may take longer than originally contemplated.  However, we continue to expect growth \nin the second half of the year as compared to the prior year.  \n \n Let me provide a few details of our outlook.  As a result of earlier recovery in volumes versus original ex pectations, \nwe now anticipate consolidated revenues to increase on the high end of the previously provided range of 2% to \n4% growth for fiscal 2021.  \n ", "original_text": "Based on what we have observed in the past 75 days, we \nbelieve that a full recove ry may take longer than originally contemplated. "}, "hash": "56159ac09cf1e02bc21b644ae31f90213d8f1249dd243d5e98655023526ea1ad", "class_name": "RelatedNodeInfo"}}, "text": "However, we do not \nbelieve the recovery in our business will be linear. ", "start_char_idx": 3267, "end_char_idx": 3340, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "dbe0d40c-01bd-4f56-ba38-3e13e33df77f": {"__data__": {"id_": "dbe0d40c-01bd-4f56-ba38-3e13e33df77f", "embedding": null, "metadata": {"window": "We \ncontinue to expect the trajectory of the recovery to correlate closely to the level of mobility o f patients, prescription \ntransaction volumes and the demand for health care interactions with primary care physicians, oncologists and \nelective procedure levels.  \n \n We continue to believe the first quarter will be the most severely impacted, and we expect to  see sequential \nrevenue and adjusted operating profit improvement over the balance of the fiscal year.  However, we do not \nbelieve the recovery in our business will be linear.  Based on what we have observed in the past 75 days, we \nbelieve that a full recove ry may take longer than originally contemplated.  However, we continue to expect growth \nin the second half of the year as compared to the prior year.  \n \n Let me provide a few details of our outlook.  As a result of earlier recovery in volumes versus original ex pectations, \nwe now anticipate consolidated revenues to increase on the high end of the previously provided range of 2% to \n4% growth for fiscal 2021.  \n ", "original_text": "Based on what we have observed in the past 75 days, we \nbelieve that a full recove ry may take longer than originally contemplated. ", "page_label": "10", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a2fe6c7d-f0eb-4895-b27b-02b6ca730d5e", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8094901027b565718c61bbce19b58cecced8539c3683fb394088de434926fec8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "52e6a909-4bd5-49dc-addf-9d638185cada", "node_type": "1", "metadata": {"window": "The impact of the pandemic is highly fluid and likely to continue evolving over the coming weeks and months.  We \ncontinue to expect the trajectory of the recovery to correlate closely to the level of mobility o f patients, prescription \ntransaction volumes and the demand for health care interactions with primary care physicians, oncologists and \nelective procedure levels.  \n \n We continue to believe the first quarter will be the most severely impacted, and we expect to  see sequential \nrevenue and adjusted operating profit improvement over the balance of the fiscal year.  However, we do not \nbelieve the recovery in our business will be linear.  Based on what we have observed in the past 75 days, we \nbelieve that a full recove ry may take longer than originally contemplated.  However, we continue to expect growth \nin the second half of the year as compared to the prior year.  \n \n Let me provide a few details of our outlook. ", "original_text": "However, we do not \nbelieve the recovery in our business will be linear. ", "page_label": "10", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "da65444f80f38793549f7a40a29dbf31b57ef65a8db9a8b9aedd657f658e1f5b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "88dd47c5-4020-41f5-80ae-da307c8bdd96", "node_type": "1", "metadata": {"window": "We continue to believe the first quarter will be the most severely impacted, and we expect to  see sequential \nrevenue and adjusted operating profit improvement over the balance of the fiscal year.  However, we do not \nbelieve the recovery in our business will be linear.  Based on what we have observed in the past 75 days, we \nbelieve that a full recove ry may take longer than originally contemplated.  However, we continue to expect growth \nin the second half of the year as compared to the prior year.  \n \n Let me provide a few details of our outlook.  As a result of earlier recovery in volumes versus original ex pectations, \nwe now anticipate consolidated revenues to increase on the high end of the previously provided range of 2% to \n4% growth for fiscal 2021.  \n ", "original_text": "However, we continue to expect growth \nin the second half of the year as compared to the prior year.  \n \n"}, "hash": "84cb078c50b86a64e34ee4eaabe536171a85b6a3c4fdcc2d9636ac1fd561ba75", "class_name": "RelatedNodeInfo"}}, "text": "Based on what we have observed in the past 75 days, we \nbelieve that a full recove ry may take longer than originally contemplated. ", "start_char_idx": 3340, "end_char_idx": 3472, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "88dd47c5-4020-41f5-80ae-da307c8bdd96": {"__data__": {"id_": "88dd47c5-4020-41f5-80ae-da307c8bdd96", "embedding": null, "metadata": {"window": "We continue to believe the first quarter will be the most severely impacted, and we expect to  see sequential \nrevenue and adjusted operating profit improvement over the balance of the fiscal year.  However, we do not \nbelieve the recovery in our business will be linear.  Based on what we have observed in the past 75 days, we \nbelieve that a full recove ry may take longer than originally contemplated.  However, we continue to expect growth \nin the second half of the year as compared to the prior year.  \n \n Let me provide a few details of our outlook.  As a result of earlier recovery in volumes versus original ex pectations, \nwe now anticipate consolidated revenues to increase on the high end of the previously provided range of 2% to \n4% growth for fiscal 2021.  \n ", "original_text": "However, we continue to expect growth \nin the second half of the year as compared to the prior year.  \n \n", "page_label": "10", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a2fe6c7d-f0eb-4895-b27b-02b6ca730d5e", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8094901027b565718c61bbce19b58cecced8539c3683fb394088de434926fec8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "dbe0d40c-01bd-4f56-ba38-3e13e33df77f", "node_type": "1", "metadata": {"window": "We \ncontinue to expect the trajectory of the recovery to correlate closely to the level of mobility o f patients, prescription \ntransaction volumes and the demand for health care interactions with primary care physicians, oncologists and \nelective procedure levels.  \n \n We continue to believe the first quarter will be the most severely impacted, and we expect to  see sequential \nrevenue and adjusted operating profit improvement over the balance of the fiscal year.  However, we do not \nbelieve the recovery in our business will be linear.  Based on what we have observed in the past 75 days, we \nbelieve that a full recove ry may take longer than originally contemplated.  However, we continue to expect growth \nin the second half of the year as compared to the prior year.  \n \n Let me provide a few details of our outlook.  As a result of earlier recovery in volumes versus original ex pectations, \nwe now anticipate consolidated revenues to increase on the high end of the previously provided range of 2% to \n4% growth for fiscal 2021.  \n ", "original_text": "Based on what we have observed in the past 75 days, we \nbelieve that a full recove ry may take longer than originally contemplated. ", "page_label": "10", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "be9d827dc11226a744a30139c7ba33c74e04e65410bc1e428f86b5c00640d07d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0801e9b0-e9bc-4d39-b9a7-0ce1ef3b69f7", "node_type": "1", "metadata": {"window": "However, we do not \nbelieve the recovery in our business will be linear.  Based on what we have observed in the past 75 days, we \nbelieve that a full recove ry may take longer than originally contemplated.  However, we continue to expect growth \nin the second half of the year as compared to the prior year.  \n \n Let me provide a few details of our outlook.  As a result of earlier recovery in volumes versus original ex pectations, \nwe now anticipate consolidated revenues to increase on the high end of the previously provided range of 2% to \n4% growth for fiscal 2021.  \n ", "original_text": "Let me provide a few details of our outlook. "}, "hash": "98634727d770d59b3ab95831d5e2bb1ec4f1323a314bbb37f4154a4d25d0249d", "class_name": "RelatedNodeInfo"}}, "text": "However, we continue to expect growth \nin the second half of the year as compared to the prior year.  \n \n", "start_char_idx": 3472, "end_char_idx": 3577, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0801e9b0-e9bc-4d39-b9a7-0ce1ef3b69f7": {"__data__": {"id_": "0801e9b0-e9bc-4d39-b9a7-0ce1ef3b69f7", "embedding": null, "metadata": {"window": "However, we do not \nbelieve the recovery in our business will be linear.  Based on what we have observed in the past 75 days, we \nbelieve that a full recove ry may take longer than originally contemplated.  However, we continue to expect growth \nin the second half of the year as compared to the prior year.  \n \n Let me provide a few details of our outlook.  As a result of earlier recovery in volumes versus original ex pectations, \nwe now anticipate consolidated revenues to increase on the high end of the previously provided range of 2% to \n4% growth for fiscal 2021.  \n ", "original_text": "Let me provide a few details of our outlook. ", "page_label": "10", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a2fe6c7d-f0eb-4895-b27b-02b6ca730d5e", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8094901027b565718c61bbce19b58cecced8539c3683fb394088de434926fec8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "88dd47c5-4020-41f5-80ae-da307c8bdd96", "node_type": "1", "metadata": {"window": "We continue to believe the first quarter will be the most severely impacted, and we expect to  see sequential \nrevenue and adjusted operating profit improvement over the balance of the fiscal year.  However, we do not \nbelieve the recovery in our business will be linear.  Based on what we have observed in the past 75 days, we \nbelieve that a full recove ry may take longer than originally contemplated.  However, we continue to expect growth \nin the second half of the year as compared to the prior year.  \n \n Let me provide a few details of our outlook.  As a result of earlier recovery in volumes versus original ex pectations, \nwe now anticipate consolidated revenues to increase on the high end of the previously provided range of 2% to \n4% growth for fiscal 2021.  \n ", "original_text": "However, we continue to expect growth \nin the second half of the year as compared to the prior year.  \n \n", "page_label": "10", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "40a3959ce414e78a7bdbdfc478d5605cf628fc56a9ea660bd3023b700c4262e1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "657669e0-ea45-412d-a39f-6a91afddb2e7", "node_type": "1", "metadata": {"window": "Based on what we have observed in the past 75 days, we \nbelieve that a full recove ry may take longer than originally contemplated.  However, we continue to expect growth \nin the second half of the year as compared to the prior year.  \n \n Let me provide a few details of our outlook.  As a result of earlier recovery in volumes versus original ex pectations, \nwe now anticipate consolidated revenues to increase on the high end of the previously provided range of 2% to \n4% growth for fiscal 2021.  \n ", "original_text": "As a result of earlier recovery in volumes versus original ex pectations, \nwe now anticipate consolidated revenues to increase on the high end of the previously provided range of 2% to \n4% growth for fiscal 2021.  \n "}, "hash": "8129ca26a7829229d867673caf1ccda8ed446067988f4fd307f6e8f046b62c70", "class_name": "RelatedNodeInfo"}}, "text": "Let me provide a few details of our outlook. ", "start_char_idx": 3577, "end_char_idx": 3622, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "657669e0-ea45-412d-a39f-6a91afddb2e7": {"__data__": {"id_": "657669e0-ea45-412d-a39f-6a91afddb2e7", "embedding": null, "metadata": {"window": "Based on what we have observed in the past 75 days, we \nbelieve that a full recove ry may take longer than originally contemplated.  However, we continue to expect growth \nin the second half of the year as compared to the prior year.  \n \n Let me provide a few details of our outlook.  As a result of earlier recovery in volumes versus original ex pectations, \nwe now anticipate consolidated revenues to increase on the high end of the previously provided range of 2% to \n4% growth for fiscal 2021.  \n ", "original_text": "As a result of earlier recovery in volumes versus original ex pectations, \nwe now anticipate consolidated revenues to increase on the high end of the previously provided range of 2% to \n4% growth for fiscal 2021.  \n ", "page_label": "10", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a2fe6c7d-f0eb-4895-b27b-02b6ca730d5e", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8094901027b565718c61bbce19b58cecced8539c3683fb394088de434926fec8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0801e9b0-e9bc-4d39-b9a7-0ce1ef3b69f7", "node_type": "1", "metadata": {"window": "However, we do not \nbelieve the recovery in our business will be linear.  Based on what we have observed in the past 75 days, we \nbelieve that a full recove ry may take longer than originally contemplated.  However, we continue to expect growth \nin the second half of the year as compared to the prior year.  \n \n Let me provide a few details of our outlook.  As a result of earlier recovery in volumes versus original ex pectations, \nwe now anticipate consolidated revenues to increase on the high end of the previously provided range of 2% to \n4% growth for fiscal 2021.  \n ", "original_text": "Let me provide a few details of our outlook. ", "page_label": "10", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "81ea04f0084ef14dbeaa4f6c564385f9877265bbbf5e4ce44f65807771affd8a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "00749a44-61f7-417c-9603-bb00ece296d2", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nWe now expect the consolidated adjusted operating profit will decline between 1% and 4% for the full year,  when \nyou exclude the results of Change Healthcare from the prior year.  And this is up from our original guidance, the \ndecline between 5% and 8%.  And as I mentioned earlier, we anticipate enterprise adjusted operating profit to \ngrow sequentially throughout  fiscal 2021 and continue to expect growth in the second half of the fiscal year on a \nyear-over-year basis.  \n \n", "original_text": "McKesson Corp.  "}, "hash": "62ac792cf46cc9127dc3bb9f698eeac967eb7359204aac636a7ce75c0062df0e", "class_name": "RelatedNodeInfo"}}, "text": "As a result of earlier recovery in volumes versus original ex pectations, \nwe now anticipate consolidated revenues to increase on the high end of the previously provided range of 2% to \n4% growth for fiscal 2021.  \n ", "start_char_idx": 3622, "end_char_idx": 3838, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "00749a44-61f7-417c-9603-bb00ece296d2": {"__data__": {"id_": "00749a44-61f7-417c-9603-bb00ece296d2", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nWe now expect the consolidated adjusted operating profit will decline between 1% and 4% for the full year,  when \nyou exclude the results of Change Healthcare from the prior year.  And this is up from our original guidance, the \ndecline between 5% and 8%.  And as I mentioned earlier, we anticipate enterprise adjusted operating profit to \ngrow sequentially throughout  fiscal 2021 and continue to expect growth in the second half of the fiscal year on a \nyear-over-year basis.  \n \n", "original_text": "McKesson Corp.  ", "page_label": "11", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7d2b4c06-f5b1-4a4f-9127-7f73d68a375e", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "afc8b717477192d484d10841cdee6bad2bd0877d53ae1ac68fbfae214a578968", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "657669e0-ea45-412d-a39f-6a91afddb2e7", "node_type": "1", "metadata": {"window": "Based on what we have observed in the past 75 days, we \nbelieve that a full recove ry may take longer than originally contemplated.  However, we continue to expect growth \nin the second half of the year as compared to the prior year.  \n \n Let me provide a few details of our outlook.  As a result of earlier recovery in volumes versus original ex pectations, \nwe now anticipate consolidated revenues to increase on the high end of the previously provided range of 2% to \n4% growth for fiscal 2021.  \n ", "original_text": "As a result of earlier recovery in volumes versus original ex pectations, \nwe now anticipate consolidated revenues to increase on the high end of the previously provided range of 2% to \n4% growth for fiscal 2021.  \n ", "page_label": "10", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3d2df647756d17e9ef3d2e2a5fed1f7f44aaf195d16c5aefc409f80d1cf45494", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d4ea6700-611c-4f31-b584-69eea12318e5", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nWe now expect the consolidated adjusted operating profit will decline between 1% and 4% for the full year,  when \nyou exclude the results of Change Healthcare from the prior year.  And this is up from our original guidance, the \ndecline between 5% and 8%.  And as I mentioned earlier, we anticipate enterprise adjusted operating profit to \ngrow sequentially throughout  fiscal 2021 and continue to expect growth in the second half of the fiscal year on a \nyear-over-year basis.  \n \n Let me talk a little bit about the segments. ", "original_text": "(MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nWe now expect the consolidated adjusted operating profit will decline between 1% and 4% for the full year,  when \nyou exclude the results of Change Healthcare from the prior year. "}, "hash": "8757c166eb24326cbe0ec7dd11823d9bc0604fbb45eedf5ff0cafe80066bb092", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d4ea6700-611c-4f31-b584-69eea12318e5": {"__data__": {"id_": "d4ea6700-611c-4f31-b584-69eea12318e5", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nWe now expect the consolidated adjusted operating profit will decline between 1% and 4% for the full year,  when \nyou exclude the results of Change Healthcare from the prior year.  And this is up from our original guidance, the \ndecline between 5% and 8%.  And as I mentioned earlier, we anticipate enterprise adjusted operating profit to \ngrow sequentially throughout  fiscal 2021 and continue to expect growth in the second half of the fiscal year on a \nyear-over-year basis.  \n \n Let me talk a little bit about the segments. ", "original_text": "(MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nWe now expect the consolidated adjusted operating profit will decline between 1% and 4% for the full year,  when \nyou exclude the results of Change Healthcare from the prior year. ", "page_label": "11", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7d2b4c06-f5b1-4a4f-9127-7f73d68a375e", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "afc8b717477192d484d10841cdee6bad2bd0877d53ae1ac68fbfae214a578968", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "00749a44-61f7-417c-9603-bb00ece296d2", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nWe now expect the consolidated adjusted operating profit will decline between 1% and 4% for the full year,  when \nyou exclude the results of Change Healthcare from the prior year.  And this is up from our original guidance, the \ndecline between 5% and 8%.  And as I mentioned earlier, we anticipate enterprise adjusted operating profit to \ngrow sequentially throughout  fiscal 2021 and continue to expect growth in the second half of the fiscal year on a \nyear-over-year basis.  \n \n", "original_text": "McKesson Corp.  ", "page_label": "11", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ee375e65c2d6bb26e6887e41c7046a6a1fc76149cc4794bef3c1b40548cfd01f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "40557a2c-f32f-47b5-aca7-eb7835cea461", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nWe now expect the consolidated adjusted operating profit will decline between 1% and 4% for the full year,  when \nyou exclude the results of Change Healthcare from the prior year.  And this is up from our original guidance, the \ndecline between 5% and 8%.  And as I mentioned earlier, we anticipate enterprise adjusted operating profit to \ngrow sequentially throughout  fiscal 2021 and continue to expect growth in the second half of the fiscal year on a \nyear-over-year basis.  \n \n Let me talk a little bit about the segments.  Given the earlier than anticipated recovery of the Provider Solutions \nbusiness in the quarter and impr oved outlook for fiscal 2021, we now expect U.S. ", "original_text": "And this is up from our original guidance, the \ndecline between 5% and 8%. "}, "hash": "2a2db79d12f4480c2cc6cf19c981d9f7e527bff2ef6f6a6b530e5654dfcc7050", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nWe now expect the consolidated adjusted operating profit will decline between 1% and 4% for the full year,  when \nyou exclude the results of Change Healthcare from the prior year. ", "start_char_idx": 16, "end_char_idx": 361, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "40557a2c-f32f-47b5-aca7-eb7835cea461": {"__data__": {"id_": "40557a2c-f32f-47b5-aca7-eb7835cea461", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nWe now expect the consolidated adjusted operating profit will decline between 1% and 4% for the full year,  when \nyou exclude the results of Change Healthcare from the prior year.  And this is up from our original guidance, the \ndecline between 5% and 8%.  And as I mentioned earlier, we anticipate enterprise adjusted operating profit to \ngrow sequentially throughout  fiscal 2021 and continue to expect growth in the second half of the fiscal year on a \nyear-over-year basis.  \n \n Let me talk a little bit about the segments.  Given the earlier than anticipated recovery of the Provider Solutions \nbusiness in the quarter and impr oved outlook for fiscal 2021, we now expect U.S. ", "original_text": "And this is up from our original guidance, the \ndecline between 5% and 8%. ", "page_label": "11", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7d2b4c06-f5b1-4a4f-9127-7f73d68a375e", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "afc8b717477192d484d10841cdee6bad2bd0877d53ae1ac68fbfae214a578968", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d4ea6700-611c-4f31-b584-69eea12318e5", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nWe now expect the consolidated adjusted operating profit will decline between 1% and 4% for the full year,  when \nyou exclude the results of Change Healthcare from the prior year.  And this is up from our original guidance, the \ndecline between 5% and 8%.  And as I mentioned earlier, we anticipate enterprise adjusted operating profit to \ngrow sequentially throughout  fiscal 2021 and continue to expect growth in the second half of the fiscal year on a \nyear-over-year basis.  \n \n Let me talk a little bit about the segments. ", "original_text": "(MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nWe now expect the consolidated adjusted operating profit will decline between 1% and 4% for the full year,  when \nyou exclude the results of Change Healthcare from the prior year. ", "page_label": "11", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "add66f905d41d49811dcefaea6a074b9a2a2e423b56bff44ed8d51e9e95bee23", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f7f956e9-22bd-4481-af73-a455bedbe333", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nWe now expect the consolidated adjusted operating profit will decline between 1% and 4% for the full year,  when \nyou exclude the results of Change Healthcare from the prior year.  And this is up from our original guidance, the \ndecline between 5% and 8%.  And as I mentioned earlier, we anticipate enterprise adjusted operating profit to \ngrow sequentially throughout  fiscal 2021 and continue to expect growth in the second half of the fiscal year on a \nyear-over-year basis.  \n \n Let me talk a little bit about the segments.  Given the earlier than anticipated recovery of the Provider Solutions \nbusiness in the quarter and impr oved outlook for fiscal 2021, we now expect U.S.  Pharmaceutical and Specialty \nSolutions full year segment adjusted operating profit to be in the range of down 2% to up 2% compared to prior \nyear. ", "original_text": "And as I mentioned earlier, we anticipate enterprise adjusted operating profit to \ngrow sequentially throughout  fiscal 2021 and continue to expect growth in the second half of the fiscal year on a \nyear-over-year basis.  \n \n"}, "hash": "127df0caaa9ab676f53aa594926204052199d2884652d71615cd420a247d0318", "class_name": "RelatedNodeInfo"}}, "text": "And this is up from our original guidance, the \ndecline between 5% and 8%. ", "start_char_idx": 361, "end_char_idx": 436, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f7f956e9-22bd-4481-af73-a455bedbe333": {"__data__": {"id_": "f7f956e9-22bd-4481-af73-a455bedbe333", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nWe now expect the consolidated adjusted operating profit will decline between 1% and 4% for the full year,  when \nyou exclude the results of Change Healthcare from the prior year.  And this is up from our original guidance, the \ndecline between 5% and 8%.  And as I mentioned earlier, we anticipate enterprise adjusted operating profit to \ngrow sequentially throughout  fiscal 2021 and continue to expect growth in the second half of the fiscal year on a \nyear-over-year basis.  \n \n Let me talk a little bit about the segments.  Given the earlier than anticipated recovery of the Provider Solutions \nbusiness in the quarter and impr oved outlook for fiscal 2021, we now expect U.S.  Pharmaceutical and Specialty \nSolutions full year segment adjusted operating profit to be in the range of down 2% to up 2% compared to prior \nyear. ", "original_text": "And as I mentioned earlier, we anticipate enterprise adjusted operating profit to \ngrow sequentially throughout  fiscal 2021 and continue to expect growth in the second half of the fiscal year on a \nyear-over-year basis.  \n \n", "page_label": "11", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7d2b4c06-f5b1-4a4f-9127-7f73d68a375e", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "afc8b717477192d484d10841cdee6bad2bd0877d53ae1ac68fbfae214a578968", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "40557a2c-f32f-47b5-aca7-eb7835cea461", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nWe now expect the consolidated adjusted operating profit will decline between 1% and 4% for the full year,  when \nyou exclude the results of Change Healthcare from the prior year.  And this is up from our original guidance, the \ndecline between 5% and 8%.  And as I mentioned earlier, we anticipate enterprise adjusted operating profit to \ngrow sequentially throughout  fiscal 2021 and continue to expect growth in the second half of the fiscal year on a \nyear-over-year basis.  \n \n Let me talk a little bit about the segments.  Given the earlier than anticipated recovery of the Provider Solutions \nbusiness in the quarter and impr oved outlook for fiscal 2021, we now expect U.S. ", "original_text": "And this is up from our original guidance, the \ndecline between 5% and 8%. ", "page_label": "11", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7cb56019802afcad0a2e07c8b816590a1b2a6a6b344b463516dc2fd44d56cf9c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8af287de-32fa-41d0-8867-89f7c205ea25", "node_type": "1", "metadata": {"window": "(MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nWe now expect the consolidated adjusted operating profit will decline between 1% and 4% for the full year,  when \nyou exclude the results of Change Healthcare from the prior year.  And this is up from our original guidance, the \ndecline between 5% and 8%.  And as I mentioned earlier, we anticipate enterprise adjusted operating profit to \ngrow sequentially throughout  fiscal 2021 and continue to expect growth in the second half of the fiscal year on a \nyear-over-year basis.  \n \n Let me talk a little bit about the segments.  Given the earlier than anticipated recovery of the Provider Solutions \nbusiness in the quarter and impr oved outlook for fiscal 2021, we now expect U.S.  Pharmaceutical and Specialty \nSolutions full year segment adjusted operating profit to be in the range of down 2% to up 2% compared to prior \nyear.  In the second half of our fiscal year, we continue to expect adjusted operating profit of flat to 3% growth \ncompared to the prior year.  \n \n", "original_text": "Let me talk a little bit about the segments. "}, "hash": "403940ea9be740ea70f1516e483f13ed4c57f35bc4532737349c08d9ef10cd3c", "class_name": "RelatedNodeInfo"}}, "text": "And as I mentioned earlier, we anticipate enterprise adjusted operating profit to \ngrow sequentially throughout  fiscal 2021 and continue to expect growth in the second half of the fiscal year on a \nyear-over-year basis.  \n \n", "start_char_idx": 436, "end_char_idx": 661, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8af287de-32fa-41d0-8867-89f7c205ea25": {"__data__": {"id_": "8af287de-32fa-41d0-8867-89f7c205ea25", "embedding": null, "metadata": {"window": "(MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nWe now expect the consolidated adjusted operating profit will decline between 1% and 4% for the full year,  when \nyou exclude the results of Change Healthcare from the prior year.  And this is up from our original guidance, the \ndecline between 5% and 8%.  And as I mentioned earlier, we anticipate enterprise adjusted operating profit to \ngrow sequentially throughout  fiscal 2021 and continue to expect growth in the second half of the fiscal year on a \nyear-over-year basis.  \n \n Let me talk a little bit about the segments.  Given the earlier than anticipated recovery of the Provider Solutions \nbusiness in the quarter and impr oved outlook for fiscal 2021, we now expect U.S.  Pharmaceutical and Specialty \nSolutions full year segment adjusted operating profit to be in the range of down 2% to up 2% compared to prior \nyear.  In the second half of our fiscal year, we continue to expect adjusted operating profit of flat to 3% growth \ncompared to the prior year.  \n \n", "original_text": "Let me talk a little bit about the segments. ", "page_label": "11", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7d2b4c06-f5b1-4a4f-9127-7f73d68a375e", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "afc8b717477192d484d10841cdee6bad2bd0877d53ae1ac68fbfae214a578968", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f7f956e9-22bd-4481-af73-a455bedbe333", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nWe now expect the consolidated adjusted operating profit will decline between 1% and 4% for the full year,  when \nyou exclude the results of Change Healthcare from the prior year.  And this is up from our original guidance, the \ndecline between 5% and 8%.  And as I mentioned earlier, we anticipate enterprise adjusted operating profit to \ngrow sequentially throughout  fiscal 2021 and continue to expect growth in the second half of the fiscal year on a \nyear-over-year basis.  \n \n Let me talk a little bit about the segments.  Given the earlier than anticipated recovery of the Provider Solutions \nbusiness in the quarter and impr oved outlook for fiscal 2021, we now expect U.S.  Pharmaceutical and Specialty \nSolutions full year segment adjusted operating profit to be in the range of down 2% to up 2% compared to prior \nyear. ", "original_text": "And as I mentioned earlier, we anticipate enterprise adjusted operating profit to \ngrow sequentially throughout  fiscal 2021 and continue to expect growth in the second half of the fiscal year on a \nyear-over-year basis.  \n \n", "page_label": "11", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ae38cceb509f31f1e57091323028cffd9d104c4d054262fe12d5664a5a70c9f3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "353dc385-6450-484e-a448-f8e39835b5b2", "node_type": "1", "metadata": {"window": "And this is up from our original guidance, the \ndecline between 5% and 8%.  And as I mentioned earlier, we anticipate enterprise adjusted operating profit to \ngrow sequentially throughout  fiscal 2021 and continue to expect growth in the second half of the fiscal year on a \nyear-over-year basis.  \n \n Let me talk a little bit about the segments.  Given the earlier than anticipated recovery of the Provider Solutions \nbusiness in the quarter and impr oved outlook for fiscal 2021, we now expect U.S.  Pharmaceutical and Specialty \nSolutions full year segment adjusted operating profit to be in the range of down 2% to up 2% compared to prior \nyear.  In the second half of our fiscal year, we continue to expect adjusted operating profit of flat to 3% growth \ncompared to the prior year.  \n \n In Europe, our first quarter segment results were above expectations, driven by increased cost mitigation activities \nin response to the pandemic. ", "original_text": "Given the earlier than anticipated recovery of the Provider Solutions \nbusiness in the quarter and impr oved outlook for fiscal 2021, we now expect U.S. "}, "hash": "e932b0bffe6ed17eedd1564c9c2fd28c6178a7e6819f6653842885214acdee98", "class_name": "RelatedNodeInfo"}}, "text": "Let me talk a little bit about the segments. ", "start_char_idx": 661, "end_char_idx": 706, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "353dc385-6450-484e-a448-f8e39835b5b2": {"__data__": {"id_": "353dc385-6450-484e-a448-f8e39835b5b2", "embedding": null, "metadata": {"window": "And this is up from our original guidance, the \ndecline between 5% and 8%.  And as I mentioned earlier, we anticipate enterprise adjusted operating profit to \ngrow sequentially throughout  fiscal 2021 and continue to expect growth in the second half of the fiscal year on a \nyear-over-year basis.  \n \n Let me talk a little bit about the segments.  Given the earlier than anticipated recovery of the Provider Solutions \nbusiness in the quarter and impr oved outlook for fiscal 2021, we now expect U.S.  Pharmaceutical and Specialty \nSolutions full year segment adjusted operating profit to be in the range of down 2% to up 2% compared to prior \nyear.  In the second half of our fiscal year, we continue to expect adjusted operating profit of flat to 3% growth \ncompared to the prior year.  \n \n In Europe, our first quarter segment results were above expectations, driven by increased cost mitigation activities \nin response to the pandemic. ", "original_text": "Given the earlier than anticipated recovery of the Provider Solutions \nbusiness in the quarter and impr oved outlook for fiscal 2021, we now expect U.S. ", "page_label": "11", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7d2b4c06-f5b1-4a4f-9127-7f73d68a375e", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "afc8b717477192d484d10841cdee6bad2bd0877d53ae1ac68fbfae214a578968", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8af287de-32fa-41d0-8867-89f7c205ea25", "node_type": "1", "metadata": {"window": "(MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nWe now expect the consolidated adjusted operating profit will decline between 1% and 4% for the full year,  when \nyou exclude the results of Change Healthcare from the prior year.  And this is up from our original guidance, the \ndecline between 5% and 8%.  And as I mentioned earlier, we anticipate enterprise adjusted operating profit to \ngrow sequentially throughout  fiscal 2021 and continue to expect growth in the second half of the fiscal year on a \nyear-over-year basis.  \n \n Let me talk a little bit about the segments.  Given the earlier than anticipated recovery of the Provider Solutions \nbusiness in the quarter and impr oved outlook for fiscal 2021, we now expect U.S.  Pharmaceutical and Specialty \nSolutions full year segment adjusted operating profit to be in the range of down 2% to up 2% compared to prior \nyear.  In the second half of our fiscal year, we continue to expect adjusted operating profit of flat to 3% growth \ncompared to the prior year.  \n \n", "original_text": "Let me talk a little bit about the segments. ", "page_label": "11", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4184d3cb6f4f7187c11d9e1dc35e72e98075e787f13680b989c92962e968d29f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ef24ac2c-e3ac-450d-9545-b0caafc517c5", "node_type": "1", "metadata": {"window": "And as I mentioned earlier, we anticipate enterprise adjusted operating profit to \ngrow sequentially throughout  fiscal 2021 and continue to expect growth in the second half of the fiscal year on a \nyear-over-year basis.  \n \n Let me talk a little bit about the segments.  Given the earlier than anticipated recovery of the Provider Solutions \nbusiness in the quarter and impr oved outlook for fiscal 2021, we now expect U.S.  Pharmaceutical and Specialty \nSolutions full year segment adjusted operating profit to be in the range of down 2% to up 2% compared to prior \nyear.  In the second half of our fiscal year, we continue to expect adjusted operating profit of flat to 3% growth \ncompared to the prior year.  \n \n In Europe, our first quarter segment results were above expectations, driven by increased cost mitigation activities \nin response to the pandemic.  As a result of this first quarter performance and modest improvement in the \naggregate recovery timeline across Europe, we now expect European segment revenues to be in the range of \ndown 3% to up 1% compared to prior year. ", "original_text": "Pharmaceutical and Specialty \nSolutions full year segment adjusted operating profit to be in the range of down 2% to up 2% compared to prior \nyear. "}, "hash": "8ccb12b27ee3d6d3b7200f120401341147290cec896e6714ae64f3396f740797", "class_name": "RelatedNodeInfo"}}, "text": "Given the earlier than anticipated recovery of the Provider Solutions \nbusiness in the quarter and impr oved outlook for fiscal 2021, we now expect U.S. ", "start_char_idx": 706, "end_char_idx": 859, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ef24ac2c-e3ac-450d-9545-b0caafc517c5": {"__data__": {"id_": "ef24ac2c-e3ac-450d-9545-b0caafc517c5", "embedding": null, "metadata": {"window": "And as I mentioned earlier, we anticipate enterprise adjusted operating profit to \ngrow sequentially throughout  fiscal 2021 and continue to expect growth in the second half of the fiscal year on a \nyear-over-year basis.  \n \n Let me talk a little bit about the segments.  Given the earlier than anticipated recovery of the Provider Solutions \nbusiness in the quarter and impr oved outlook for fiscal 2021, we now expect U.S.  Pharmaceutical and Specialty \nSolutions full year segment adjusted operating profit to be in the range of down 2% to up 2% compared to prior \nyear.  In the second half of our fiscal year, we continue to expect adjusted operating profit of flat to 3% growth \ncompared to the prior year.  \n \n In Europe, our first quarter segment results were above expectations, driven by increased cost mitigation activities \nin response to the pandemic.  As a result of this first quarter performance and modest improvement in the \naggregate recovery timeline across Europe, we now expect European segment revenues to be in the range of \ndown 3% to up 1% compared to prior year. ", "original_text": "Pharmaceutical and Specialty \nSolutions full year segment adjusted operating profit to be in the range of down 2% to up 2% compared to prior \nyear. ", "page_label": "11", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7d2b4c06-f5b1-4a4f-9127-7f73d68a375e", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "afc8b717477192d484d10841cdee6bad2bd0877d53ae1ac68fbfae214a578968", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "353dc385-6450-484e-a448-f8e39835b5b2", "node_type": "1", "metadata": {"window": "And this is up from our original guidance, the \ndecline between 5% and 8%.  And as I mentioned earlier, we anticipate enterprise adjusted operating profit to \ngrow sequentially throughout  fiscal 2021 and continue to expect growth in the second half of the fiscal year on a \nyear-over-year basis.  \n \n Let me talk a little bit about the segments.  Given the earlier than anticipated recovery of the Provider Solutions \nbusiness in the quarter and impr oved outlook for fiscal 2021, we now expect U.S.  Pharmaceutical and Specialty \nSolutions full year segment adjusted operating profit to be in the range of down 2% to up 2% compared to prior \nyear.  In the second half of our fiscal year, we continue to expect adjusted operating profit of flat to 3% growth \ncompared to the prior year.  \n \n In Europe, our first quarter segment results were above expectations, driven by increased cost mitigation activities \nin response to the pandemic. ", "original_text": "Given the earlier than anticipated recovery of the Provider Solutions \nbusiness in the quarter and impr oved outlook for fiscal 2021, we now expect U.S. ", "page_label": "11", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ff1c7a38d998620e61ba6e402e4fe99ec9f7bf306ee7d684f8f6ac2c3408ba6c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0b04f4a7-4697-41dc-96f4-0de788cd0013", "node_type": "1", "metadata": {"window": "Let me talk a little bit about the segments.  Given the earlier than anticipated recovery of the Provider Solutions \nbusiness in the quarter and impr oved outlook for fiscal 2021, we now expect U.S.  Pharmaceutical and Specialty \nSolutions full year segment adjusted operating profit to be in the range of down 2% to up 2% compared to prior \nyear.  In the second half of our fiscal year, we continue to expect adjusted operating profit of flat to 3% growth \ncompared to the prior year.  \n \n In Europe, our first quarter segment results were above expectations, driven by increased cost mitigation activities \nin response to the pandemic.  As a result of this first quarter performance and modest improvement in the \naggregate recovery timeline across Europe, we now expect European segment revenues to be in the range of \ndown 3% to up 1% compared to prior year.  Additionally, we now expect segment adjusted operating profit to \ndecline between 4% and 9% for fiscal 2021. ", "original_text": "In the second half of our fiscal year, we continue to expect adjusted operating profit of flat to 3% growth \ncompared to the prior year.  \n \n"}, "hash": "5b09f1561ce4bba8bfeb4c93a1fb9334bf120911066d895a3484fdb59442c8cf", "class_name": "RelatedNodeInfo"}}, "text": "Pharmaceutical and Specialty \nSolutions full year segment adjusted operating profit to be in the range of down 2% to up 2% compared to prior \nyear. ", "start_char_idx": 859, "end_char_idx": 1007, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0b04f4a7-4697-41dc-96f4-0de788cd0013": {"__data__": {"id_": "0b04f4a7-4697-41dc-96f4-0de788cd0013", "embedding": null, "metadata": {"window": "Let me talk a little bit about the segments.  Given the earlier than anticipated recovery of the Provider Solutions \nbusiness in the quarter and impr oved outlook for fiscal 2021, we now expect U.S.  Pharmaceutical and Specialty \nSolutions full year segment adjusted operating profit to be in the range of down 2% to up 2% compared to prior \nyear.  In the second half of our fiscal year, we continue to expect adjusted operating profit of flat to 3% growth \ncompared to the prior year.  \n \n In Europe, our first quarter segment results were above expectations, driven by increased cost mitigation activities \nin response to the pandemic.  As a result of this first quarter performance and modest improvement in the \naggregate recovery timeline across Europe, we now expect European segment revenues to be in the range of \ndown 3% to up 1% compared to prior year.  Additionally, we now expect segment adjusted operating profit to \ndecline between 4% and 9% for fiscal 2021. ", "original_text": "In the second half of our fiscal year, we continue to expect adjusted operating profit of flat to 3% growth \ncompared to the prior year.  \n \n", "page_label": "11", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7d2b4c06-f5b1-4a4f-9127-7f73d68a375e", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "afc8b717477192d484d10841cdee6bad2bd0877d53ae1ac68fbfae214a578968", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ef24ac2c-e3ac-450d-9545-b0caafc517c5", "node_type": "1", "metadata": {"window": "And as I mentioned earlier, we anticipate enterprise adjusted operating profit to \ngrow sequentially throughout  fiscal 2021 and continue to expect growth in the second half of the fiscal year on a \nyear-over-year basis.  \n \n Let me talk a little bit about the segments.  Given the earlier than anticipated recovery of the Provider Solutions \nbusiness in the quarter and impr oved outlook for fiscal 2021, we now expect U.S.  Pharmaceutical and Specialty \nSolutions full year segment adjusted operating profit to be in the range of down 2% to up 2% compared to prior \nyear.  In the second half of our fiscal year, we continue to expect adjusted operating profit of flat to 3% growth \ncompared to the prior year.  \n \n In Europe, our first quarter segment results were above expectations, driven by increased cost mitigation activities \nin response to the pandemic.  As a result of this first quarter performance and modest improvement in the \naggregate recovery timeline across Europe, we now expect European segment revenues to be in the range of \ndown 3% to up 1% compared to prior year. ", "original_text": "Pharmaceutical and Specialty \nSolutions full year segment adjusted operating profit to be in the range of down 2% to up 2% compared to prior \nyear. ", "page_label": "11", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cc85989a60d933d8b19486a8bc7017859b509b3289790ad035bedcc7e263558e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1ba1dbe0-64b3-4b40-8906-84f2a5db7f18", "node_type": "1", "metadata": {"window": "Given the earlier than anticipated recovery of the Provider Solutions \nbusiness in the quarter and impr oved outlook for fiscal 2021, we now expect U.S.  Pharmaceutical and Specialty \nSolutions full year segment adjusted operating profit to be in the range of down 2% to up 2% compared to prior \nyear.  In the second half of our fiscal year, we continue to expect adjusted operating profit of flat to 3% growth \ncompared to the prior year.  \n \n In Europe, our first quarter segment results were above expectations, driven by increased cost mitigation activities \nin response to the pandemic.  As a result of this first quarter performance and modest improvement in the \naggregate recovery timeline across Europe, we now expect European segment revenues to be in the range of \ndown 3% to up 1% compared to prior year.  Additionally, we now expect segment adjusted operating profit to \ndecline between 4% and 9% for fiscal 2021.  The operating environment remains challenging in many markets. \n", "original_text": "In Europe, our first quarter segment results were above expectations, driven by increased cost mitigation activities \nin response to the pandemic. "}, "hash": "ade30547e70615238bbe401f7656c05c8eebae53bd7cdb2bb4a91db545ca366c", "class_name": "RelatedNodeInfo"}}, "text": "In the second half of our fiscal year, we continue to expect adjusted operating profit of flat to 3% growth \ncompared to the prior year.  \n \n", "start_char_idx": 1007, "end_char_idx": 1148, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1ba1dbe0-64b3-4b40-8906-84f2a5db7f18": {"__data__": {"id_": "1ba1dbe0-64b3-4b40-8906-84f2a5db7f18", "embedding": null, "metadata": {"window": "Given the earlier than anticipated recovery of the Provider Solutions \nbusiness in the quarter and impr oved outlook for fiscal 2021, we now expect U.S.  Pharmaceutical and Specialty \nSolutions full year segment adjusted operating profit to be in the range of down 2% to up 2% compared to prior \nyear.  In the second half of our fiscal year, we continue to expect adjusted operating profit of flat to 3% growth \ncompared to the prior year.  \n \n In Europe, our first quarter segment results were above expectations, driven by increased cost mitigation activities \nin response to the pandemic.  As a result of this first quarter performance and modest improvement in the \naggregate recovery timeline across Europe, we now expect European segment revenues to be in the range of \ndown 3% to up 1% compared to prior year.  Additionally, we now expect segment adjusted operating profit to \ndecline between 4% and 9% for fiscal 2021.  The operating environment remains challenging in many markets. \n", "original_text": "In Europe, our first quarter segment results were above expectations, driven by increased cost mitigation activities \nin response to the pandemic. ", "page_label": "11", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7d2b4c06-f5b1-4a4f-9127-7f73d68a375e", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "afc8b717477192d484d10841cdee6bad2bd0877d53ae1ac68fbfae214a578968", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0b04f4a7-4697-41dc-96f4-0de788cd0013", "node_type": "1", "metadata": {"window": "Let me talk a little bit about the segments.  Given the earlier than anticipated recovery of the Provider Solutions \nbusiness in the quarter and impr oved outlook for fiscal 2021, we now expect U.S.  Pharmaceutical and Specialty \nSolutions full year segment adjusted operating profit to be in the range of down 2% to up 2% compared to prior \nyear.  In the second half of our fiscal year, we continue to expect adjusted operating profit of flat to 3% growth \ncompared to the prior year.  \n \n In Europe, our first quarter segment results were above expectations, driven by increased cost mitigation activities \nin response to the pandemic.  As a result of this first quarter performance and modest improvement in the \naggregate recovery timeline across Europe, we now expect European segment revenues to be in the range of \ndown 3% to up 1% compared to prior year.  Additionally, we now expect segment adjusted operating profit to \ndecline between 4% and 9% for fiscal 2021. ", "original_text": "In the second half of our fiscal year, we continue to expect adjusted operating profit of flat to 3% growth \ncompared to the prior year.  \n \n", "page_label": "11", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c8c23f04398ee6cb338f65cce13fb5cae6e69840748a4e8014076c6b45fc3142", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "dee47a4f-4d10-416e-9803-2a070664b6c4", "node_type": "1", "metadata": {"window": "Pharmaceutical and Specialty \nSolutions full year segment adjusted operating profit to be in the range of down 2% to up 2% compared to prior \nyear.  In the second half of our fiscal year, we continue to expect adjusted operating profit of flat to 3% growth \ncompared to the prior year.  \n \n In Europe, our first quarter segment results were above expectations, driven by increased cost mitigation activities \nin response to the pandemic.  As a result of this first quarter performance and modest improvement in the \naggregate recovery timeline across Europe, we now expect European segment revenues to be in the range of \ndown 3% to up 1% compared to prior year.  Additionally, we now expect segment adjusted operating profit to \ndecline between 4% and 9% for fiscal 2021.  The operating environment remains challenging in many markets. \n Due to the earlier recovery and the flattening of the recovery curve, we now expect second half adjusted \noperating profit to decline between 4% and 6% in  Europe.  \n \n", "original_text": "As a result of this first quarter performance and modest improvement in the \naggregate recovery timeline across Europe, we now expect European segment revenues to be in the range of \ndown 3% to up 1% compared to prior year. "}, "hash": "265b2d8be85261e4ebfa4a37029cd31e47a104532809a049422e69aaf5e06bac", "class_name": "RelatedNodeInfo"}}, "text": "In Europe, our first quarter segment results were above expectations, driven by increased cost mitigation activities \nin response to the pandemic. ", "start_char_idx": 1148, "end_char_idx": 1295, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "dee47a4f-4d10-416e-9803-2a070664b6c4": {"__data__": {"id_": "dee47a4f-4d10-416e-9803-2a070664b6c4", "embedding": null, "metadata": {"window": "Pharmaceutical and Specialty \nSolutions full year segment adjusted operating profit to be in the range of down 2% to up 2% compared to prior \nyear.  In the second half of our fiscal year, we continue to expect adjusted operating profit of flat to 3% growth \ncompared to the prior year.  \n \n In Europe, our first quarter segment results were above expectations, driven by increased cost mitigation activities \nin response to the pandemic.  As a result of this first quarter performance and modest improvement in the \naggregate recovery timeline across Europe, we now expect European segment revenues to be in the range of \ndown 3% to up 1% compared to prior year.  Additionally, we now expect segment adjusted operating profit to \ndecline between 4% and 9% for fiscal 2021.  The operating environment remains challenging in many markets. \n Due to the earlier recovery and the flattening of the recovery curve, we now expect second half adjusted \noperating profit to decline between 4% and 6% in  Europe.  \n \n", "original_text": "As a result of this first quarter performance and modest improvement in the \naggregate recovery timeline across Europe, we now expect European segment revenues to be in the range of \ndown 3% to up 1% compared to prior year. ", "page_label": "11", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7d2b4c06-f5b1-4a4f-9127-7f73d68a375e", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "afc8b717477192d484d10841cdee6bad2bd0877d53ae1ac68fbfae214a578968", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1ba1dbe0-64b3-4b40-8906-84f2a5db7f18", "node_type": "1", "metadata": {"window": "Given the earlier than anticipated recovery of the Provider Solutions \nbusiness in the quarter and impr oved outlook for fiscal 2021, we now expect U.S.  Pharmaceutical and Specialty \nSolutions full year segment adjusted operating profit to be in the range of down 2% to up 2% compared to prior \nyear.  In the second half of our fiscal year, we continue to expect adjusted operating profit of flat to 3% growth \ncompared to the prior year.  \n \n In Europe, our first quarter segment results were above expectations, driven by increased cost mitigation activities \nin response to the pandemic.  As a result of this first quarter performance and modest improvement in the \naggregate recovery timeline across Europe, we now expect European segment revenues to be in the range of \ndown 3% to up 1% compared to prior year.  Additionally, we now expect segment adjusted operating profit to \ndecline between 4% and 9% for fiscal 2021.  The operating environment remains challenging in many markets. \n", "original_text": "In Europe, our first quarter segment results were above expectations, driven by increased cost mitigation activities \nin response to the pandemic. ", "page_label": "11", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e309bed6ab7b83cdc67631d165e97c37b5a95ff3531690674f07027da10547b7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b7455b1d-944a-4485-a2c7-7b8764d082e7", "node_type": "1", "metadata": {"window": "In the second half of our fiscal year, we continue to expect adjusted operating profit of flat to 3% growth \ncompared to the prior year.  \n \n In Europe, our first quarter segment results were above expectations, driven by increased cost mitigation activities \nin response to the pandemic.  As a result of this first quarter performance and modest improvement in the \naggregate recovery timeline across Europe, we now expect European segment revenues to be in the range of \ndown 3% to up 1% compared to prior year.  Additionally, we now expect segment adjusted operating profit to \ndecline between 4% and 9% for fiscal 2021.  The operating environment remains challenging in many markets. \n Due to the earlier recovery and the flattening of the recovery curve, we now expect second half adjusted \noperating profit to decline between 4% and 6% in  Europe.  \n \n Turning to our Medical -Surgical segment. ", "original_text": "Additionally, we now expect segment adjusted operating profit to \ndecline between 4% and 9% for fiscal 2021. "}, "hash": "17f27330522d79cf5b4bd0ef6708bb93347562e11d2dd4c43a2c2e77b7e2cd20", "class_name": "RelatedNodeInfo"}}, "text": "As a result of this first quarter performance and modest improvement in the \naggregate recovery timeline across Europe, we now expect European segment revenues to be in the range of \ndown 3% to up 1% compared to prior year. ", "start_char_idx": 1295, "end_char_idx": 1519, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b7455b1d-944a-4485-a2c7-7b8764d082e7": {"__data__": {"id_": "b7455b1d-944a-4485-a2c7-7b8764d082e7", "embedding": null, "metadata": {"window": "In the second half of our fiscal year, we continue to expect adjusted operating profit of flat to 3% growth \ncompared to the prior year.  \n \n In Europe, our first quarter segment results were above expectations, driven by increased cost mitigation activities \nin response to the pandemic.  As a result of this first quarter performance and modest improvement in the \naggregate recovery timeline across Europe, we now expect European segment revenues to be in the range of \ndown 3% to up 1% compared to prior year.  Additionally, we now expect segment adjusted operating profit to \ndecline between 4% and 9% for fiscal 2021.  The operating environment remains challenging in many markets. \n Due to the earlier recovery and the flattening of the recovery curve, we now expect second half adjusted \noperating profit to decline between 4% and 6% in  Europe.  \n \n Turning to our Medical -Surgical segment. ", "original_text": "Additionally, we now expect segment adjusted operating profit to \ndecline between 4% and 9% for fiscal 2021. ", "page_label": "11", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7d2b4c06-f5b1-4a4f-9127-7f73d68a375e", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "afc8b717477192d484d10841cdee6bad2bd0877d53ae1ac68fbfae214a578968", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "dee47a4f-4d10-416e-9803-2a070664b6c4", "node_type": "1", "metadata": {"window": "Pharmaceutical and Specialty \nSolutions full year segment adjusted operating profit to be in the range of down 2% to up 2% compared to prior \nyear.  In the second half of our fiscal year, we continue to expect adjusted operating profit of flat to 3% growth \ncompared to the prior year.  \n \n In Europe, our first quarter segment results were above expectations, driven by increased cost mitigation activities \nin response to the pandemic.  As a result of this first quarter performance and modest improvement in the \naggregate recovery timeline across Europe, we now expect European segment revenues to be in the range of \ndown 3% to up 1% compared to prior year.  Additionally, we now expect segment adjusted operating profit to \ndecline between 4% and 9% for fiscal 2021.  The operating environment remains challenging in many markets. \n Due to the earlier recovery and the flattening of the recovery curve, we now expect second half adjusted \noperating profit to decline between 4% and 6% in  Europe.  \n \n", "original_text": "As a result of this first quarter performance and modest improvement in the \naggregate recovery timeline across Europe, we now expect European segment revenues to be in the range of \ndown 3% to up 1% compared to prior year. ", "page_label": "11", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b32ac5fcea94d3eb0b8b2aa8a1cdf4c3e8385d138fc52a51547aeb17aeb265cd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "011e5dba-1c03-487f-8104-38e19da864d1", "node_type": "1", "metadata": {"window": "In Europe, our first quarter segment results were above expectations, driven by increased cost mitigation activities \nin response to the pandemic.  As a result of this first quarter performance and modest improvement in the \naggregate recovery timeline across Europe, we now expect European segment revenues to be in the range of \ndown 3% to up 1% compared to prior year.  Additionally, we now expect segment adjusted operating profit to \ndecline between 4% and 9% for fiscal 2021.  The operating environment remains challenging in many markets. \n Due to the earlier recovery and the flattening of the recovery curve, we now expect second half adjusted \noperating profit to decline between 4% and 6% in  Europe.  \n \n Turning to our Medical -Surgical segment.  As discussed in my opening remarks, we began to see volume \nimprovements in the primary care business in the month of June. ", "original_text": "The operating environment remains challenging in many markets. \n"}, "hash": "fd9d6282b3d9289b9c538af2b4fc278768ea14a9ce06354b50b0c651a6da0d60", "class_name": "RelatedNodeInfo"}}, "text": "Additionally, we now expect segment adjusted operating profit to \ndecline between 4% and 9% for fiscal 2021. ", "start_char_idx": 1519, "end_char_idx": 1628, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "011e5dba-1c03-487f-8104-38e19da864d1": {"__data__": {"id_": "011e5dba-1c03-487f-8104-38e19da864d1", "embedding": null, "metadata": {"window": "In Europe, our first quarter segment results were above expectations, driven by increased cost mitigation activities \nin response to the pandemic.  As a result of this first quarter performance and modest improvement in the \naggregate recovery timeline across Europe, we now expect European segment revenues to be in the range of \ndown 3% to up 1% compared to prior year.  Additionally, we now expect segment adjusted operating profit to \ndecline between 4% and 9% for fiscal 2021.  The operating environment remains challenging in many markets. \n Due to the earlier recovery and the flattening of the recovery curve, we now expect second half adjusted \noperating profit to decline between 4% and 6% in  Europe.  \n \n Turning to our Medical -Surgical segment.  As discussed in my opening remarks, we began to see volume \nimprovements in the primary care business in the month of June. ", "original_text": "The operating environment remains challenging in many markets. \n", "page_label": "11", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7d2b4c06-f5b1-4a4f-9127-7f73d68a375e", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "afc8b717477192d484d10841cdee6bad2bd0877d53ae1ac68fbfae214a578968", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b7455b1d-944a-4485-a2c7-7b8764d082e7", "node_type": "1", "metadata": {"window": "In the second half of our fiscal year, we continue to expect adjusted operating profit of flat to 3% growth \ncompared to the prior year.  \n \n In Europe, our first quarter segment results were above expectations, driven by increased cost mitigation activities \nin response to the pandemic.  As a result of this first quarter performance and modest improvement in the \naggregate recovery timeline across Europe, we now expect European segment revenues to be in the range of \ndown 3% to up 1% compared to prior year.  Additionally, we now expect segment adjusted operating profit to \ndecline between 4% and 9% for fiscal 2021.  The operating environment remains challenging in many markets. \n Due to the earlier recovery and the flattening of the recovery curve, we now expect second half adjusted \noperating profit to decline between 4% and 6% in  Europe.  \n \n Turning to our Medical -Surgical segment. ", "original_text": "Additionally, we now expect segment adjusted operating profit to \ndecline between 4% and 9% for fiscal 2021. ", "page_label": "11", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "57d5e7eaac7ca8e8f761c7a6a5e85a610048f22406130e8cc7bca88989e08395", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d679fcf6-f9be-4a2c-a303-7398369a2f5b", "node_type": "1", "metadata": {"window": "As a result of this first quarter performance and modest improvement in the \naggregate recovery timeline across Europe, we now expect European segment revenues to be in the range of \ndown 3% to up 1% compared to prior year.  Additionally, we now expect segment adjusted operating profit to \ndecline between 4% and 9% for fiscal 2021.  The operating environment remains challenging in many markets. \n Due to the earlier recovery and the flattening of the recovery curve, we now expect second half adjusted \noperating profit to decline between 4% and 6% in  Europe.  \n \n Turning to our Medical -Surgical segment.  As discussed in my opening remarks, we began to see volume \nimprovements in the primary care business in the month of June.  As a result of the pace of the recovery within \nprimary care in the segment, and hi gher volumes within extended care, we are updating our outlook for the \nsegment. ", "original_text": "Due to the earlier recovery and the flattening of the recovery curve, we now expect second half adjusted \noperating profit to decline between 4% and 6% in  Europe.  \n \n"}, "hash": "60ab3b0e2539332f24aa4ea3f78458546b500c8df1e644692a00eb51fc36180b", "class_name": "RelatedNodeInfo"}}, "text": "The operating environment remains challenging in many markets. \n", "start_char_idx": 1628, "end_char_idx": 1692, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d679fcf6-f9be-4a2c-a303-7398369a2f5b": {"__data__": {"id_": "d679fcf6-f9be-4a2c-a303-7398369a2f5b", "embedding": null, "metadata": {"window": "As a result of this first quarter performance and modest improvement in the \naggregate recovery timeline across Europe, we now expect European segment revenues to be in the range of \ndown 3% to up 1% compared to prior year.  Additionally, we now expect segment adjusted operating profit to \ndecline between 4% and 9% for fiscal 2021.  The operating environment remains challenging in many markets. \n Due to the earlier recovery and the flattening of the recovery curve, we now expect second half adjusted \noperating profit to decline between 4% and 6% in  Europe.  \n \n Turning to our Medical -Surgical segment.  As discussed in my opening remarks, we began to see volume \nimprovements in the primary care business in the month of June.  As a result of the pace of the recovery within \nprimary care in the segment, and hi gher volumes within extended care, we are updating our outlook for the \nsegment. ", "original_text": "Due to the earlier recovery and the flattening of the recovery curve, we now expect second half adjusted \noperating profit to decline between 4% and 6% in  Europe.  \n \n", "page_label": "11", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7d2b4c06-f5b1-4a4f-9127-7f73d68a375e", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "afc8b717477192d484d10841cdee6bad2bd0877d53ae1ac68fbfae214a578968", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "011e5dba-1c03-487f-8104-38e19da864d1", "node_type": "1", "metadata": {"window": "In Europe, our first quarter segment results were above expectations, driven by increased cost mitigation activities \nin response to the pandemic.  As a result of this first quarter performance and modest improvement in the \naggregate recovery timeline across Europe, we now expect European segment revenues to be in the range of \ndown 3% to up 1% compared to prior year.  Additionally, we now expect segment adjusted operating profit to \ndecline between 4% and 9% for fiscal 2021.  The operating environment remains challenging in many markets. \n Due to the earlier recovery and the flattening of the recovery curve, we now expect second half adjusted \noperating profit to decline between 4% and 6% in  Europe.  \n \n Turning to our Medical -Surgical segment.  As discussed in my opening remarks, we began to see volume \nimprovements in the primary care business in the month of June. ", "original_text": "The operating environment remains challenging in many markets. \n", "page_label": "11", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9f72e882dd2f0afe26faf3890abac121a2460047e322cb70655904161de34422", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f7bac80d-c17e-4b6c-ba63-3d52602fc3f5", "node_type": "1", "metadata": {"window": "Additionally, we now expect segment adjusted operating profit to \ndecline between 4% and 9% for fiscal 2021.  The operating environment remains challenging in many markets. \n Due to the earlier recovery and the flattening of the recovery curve, we now expect second half adjusted \noperating profit to decline between 4% and 6% in  Europe.  \n \n Turning to our Medical -Surgical segment.  As discussed in my opening remarks, we began to see volume \nimprovements in the primary care business in the month of June.  As a result of the pace of the recovery within \nprimary care in the segment, and hi gher volumes within extended care, we are updating our outlook for the \nsegment.  We now expect fiscal 2021 segment revenue to increase between 8% and 12%, and segment adjusted \noperating profit in the range of down 3% to an increase of 3%. ", "original_text": "Turning to our Medical -Surgical segment. "}, "hash": "f36d0a1d0b1ddbaeacefb8b5d675843f36ac4121afcfc497ce9056de03875d3b", "class_name": "RelatedNodeInfo"}}, "text": "Due to the earlier recovery and the flattening of the recovery curve, we now expect second half adjusted \noperating profit to decline between 4% and 6% in  Europe.  \n \n", "start_char_idx": 1692, "end_char_idx": 1860, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f7bac80d-c17e-4b6c-ba63-3d52602fc3f5": {"__data__": {"id_": "f7bac80d-c17e-4b6c-ba63-3d52602fc3f5", "embedding": null, "metadata": {"window": "Additionally, we now expect segment adjusted operating profit to \ndecline between 4% and 9% for fiscal 2021.  The operating environment remains challenging in many markets. \n Due to the earlier recovery and the flattening of the recovery curve, we now expect second half adjusted \noperating profit to decline between 4% and 6% in  Europe.  \n \n Turning to our Medical -Surgical segment.  As discussed in my opening remarks, we began to see volume \nimprovements in the primary care business in the month of June.  As a result of the pace of the recovery within \nprimary care in the segment, and hi gher volumes within extended care, we are updating our outlook for the \nsegment.  We now expect fiscal 2021 segment revenue to increase between 8% and 12%, and segment adjusted \noperating profit in the range of down 3% to an increase of 3%. ", "original_text": "Turning to our Medical -Surgical segment. ", "page_label": "11", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7d2b4c06-f5b1-4a4f-9127-7f73d68a375e", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "afc8b717477192d484d10841cdee6bad2bd0877d53ae1ac68fbfae214a578968", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d679fcf6-f9be-4a2c-a303-7398369a2f5b", "node_type": "1", "metadata": {"window": "As a result of this first quarter performance and modest improvement in the \naggregate recovery timeline across Europe, we now expect European segment revenues to be in the range of \ndown 3% to up 1% compared to prior year.  Additionally, we now expect segment adjusted operating profit to \ndecline between 4% and 9% for fiscal 2021.  The operating environment remains challenging in many markets. \n Due to the earlier recovery and the flattening of the recovery curve, we now expect second half adjusted \noperating profit to decline between 4% and 6% in  Europe.  \n \n Turning to our Medical -Surgical segment.  As discussed in my opening remarks, we began to see volume \nimprovements in the primary care business in the month of June.  As a result of the pace of the recovery within \nprimary care in the segment, and hi gher volumes within extended care, we are updating our outlook for the \nsegment. ", "original_text": "Due to the earlier recovery and the flattening of the recovery curve, we now expect second half adjusted \noperating profit to decline between 4% and 6% in  Europe.  \n \n", "page_label": "11", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8c31215fcf338826a19fa3de28fd3e5b905ed1f1a7b31cc84d5ace3205a9fd13", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f6e53508-92ad-4121-b40b-06b5809fe2fc", "node_type": "1", "metadata": {"window": "The operating environment remains challenging in many markets. \n Due to the earlier recovery and the flattening of the recovery curve, we now expect second half adjusted \noperating profit to decline between 4% and 6% in  Europe.  \n \n Turning to our Medical -Surgical segment.  As discussed in my opening remarks, we began to see volume \nimprovements in the primary care business in the month of June.  As a result of the pace of the recovery within \nprimary care in the segment, and hi gher volumes within extended care, we are updating our outlook for the \nsegment.  We now expect fiscal 2021 segment revenue to increase between 8% and 12%, and segment adjusted \noperating profit in the range of down 3% to an increase of 3%.  We continue to exp ect growth in the second half of \nthe fiscal year compared to the prior year and now project to be between 10% and 15%.  \n \n", "original_text": "As discussed in my opening remarks, we began to see volume \nimprovements in the primary care business in the month of June. "}, "hash": "1b9f5debb25516e3839eea54dd88959634e6d21caa257c31c2affbdf52f1f209", "class_name": "RelatedNodeInfo"}}, "text": "Turning to our Medical -Surgical segment. ", "start_char_idx": 1860, "end_char_idx": 1902, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f6e53508-92ad-4121-b40b-06b5809fe2fc": {"__data__": {"id_": "f6e53508-92ad-4121-b40b-06b5809fe2fc", "embedding": null, "metadata": {"window": "The operating environment remains challenging in many markets. \n Due to the earlier recovery and the flattening of the recovery curve, we now expect second half adjusted \noperating profit to decline between 4% and 6% in  Europe.  \n \n Turning to our Medical -Surgical segment.  As discussed in my opening remarks, we began to see volume \nimprovements in the primary care business in the month of June.  As a result of the pace of the recovery within \nprimary care in the segment, and hi gher volumes within extended care, we are updating our outlook for the \nsegment.  We now expect fiscal 2021 segment revenue to increase between 8% and 12%, and segment adjusted \noperating profit in the range of down 3% to an increase of 3%.  We continue to exp ect growth in the second half of \nthe fiscal year compared to the prior year and now project to be between 10% and 15%.  \n \n", "original_text": "As discussed in my opening remarks, we began to see volume \nimprovements in the primary care business in the month of June. ", "page_label": "11", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7d2b4c06-f5b1-4a4f-9127-7f73d68a375e", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "afc8b717477192d484d10841cdee6bad2bd0877d53ae1ac68fbfae214a578968", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f7bac80d-c17e-4b6c-ba63-3d52602fc3f5", "node_type": "1", "metadata": {"window": "Additionally, we now expect segment adjusted operating profit to \ndecline between 4% and 9% for fiscal 2021.  The operating environment remains challenging in many markets. \n Due to the earlier recovery and the flattening of the recovery curve, we now expect second half adjusted \noperating profit to decline between 4% and 6% in  Europe.  \n \n Turning to our Medical -Surgical segment.  As discussed in my opening remarks, we began to see volume \nimprovements in the primary care business in the month of June.  As a result of the pace of the recovery within \nprimary care in the segment, and hi gher volumes within extended care, we are updating our outlook for the \nsegment.  We now expect fiscal 2021 segment revenue to increase between 8% and 12%, and segment adjusted \noperating profit in the range of down 3% to an increase of 3%. ", "original_text": "Turning to our Medical -Surgical segment. ", "page_label": "11", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a97a8bc110165a4925a37b72668cb256c9b0c4acf3507e8ef08a01a19cbd72cf", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c30f5be6-f0ad-40aa-b2a9-b934380fa8c5", "node_type": "1", "metadata": {"window": "Due to the earlier recovery and the flattening of the recovery curve, we now expect second half adjusted \noperating profit to decline between 4% and 6% in  Europe.  \n \n Turning to our Medical -Surgical segment.  As discussed in my opening remarks, we began to see volume \nimprovements in the primary care business in the month of June.  As a result of the pace of the recovery within \nprimary care in the segment, and hi gher volumes within extended care, we are updating our outlook for the \nsegment.  We now expect fiscal 2021 segment revenue to increase between 8% and 12%, and segment adjusted \noperating profit in the range of down 3% to an increase of 3%.  We continue to exp ect growth in the second half of \nthe fiscal year compared to the prior year and now project to be between 10% and 15%.  \n \n Turning to Other. ", "original_text": "As a result of the pace of the recovery within \nprimary care in the segment, and hi gher volumes within extended care, we are updating our outlook for the \nsegment. "}, "hash": "1682112ee378ece5a777d8e6abb5b94474557871633f60fe1f8fa6b758869ed0", "class_name": "RelatedNodeInfo"}}, "text": "As discussed in my opening remarks, we began to see volume \nimprovements in the primary care business in the month of June. ", "start_char_idx": 1902, "end_char_idx": 2026, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c30f5be6-f0ad-40aa-b2a9-b934380fa8c5": {"__data__": {"id_": "c30f5be6-f0ad-40aa-b2a9-b934380fa8c5", "embedding": null, "metadata": {"window": "Due to the earlier recovery and the flattening of the recovery curve, we now expect second half adjusted \noperating profit to decline between 4% and 6% in  Europe.  \n \n Turning to our Medical -Surgical segment.  As discussed in my opening remarks, we began to see volume \nimprovements in the primary care business in the month of June.  As a result of the pace of the recovery within \nprimary care in the segment, and hi gher volumes within extended care, we are updating our outlook for the \nsegment.  We now expect fiscal 2021 segment revenue to increase between 8% and 12%, and segment adjusted \noperating profit in the range of down 3% to an increase of 3%.  We continue to exp ect growth in the second half of \nthe fiscal year compared to the prior year and now project to be between 10% and 15%.  \n \n Turning to Other. ", "original_text": "As a result of the pace of the recovery within \nprimary care in the segment, and hi gher volumes within extended care, we are updating our outlook for the \nsegment. ", "page_label": "11", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7d2b4c06-f5b1-4a4f-9127-7f73d68a375e", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "afc8b717477192d484d10841cdee6bad2bd0877d53ae1ac68fbfae214a578968", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f6e53508-92ad-4121-b40b-06b5809fe2fc", "node_type": "1", "metadata": {"window": "The operating environment remains challenging in many markets. \n Due to the earlier recovery and the flattening of the recovery curve, we now expect second half adjusted \noperating profit to decline between 4% and 6% in  Europe.  \n \n Turning to our Medical -Surgical segment.  As discussed in my opening remarks, we began to see volume \nimprovements in the primary care business in the month of June.  As a result of the pace of the recovery within \nprimary care in the segment, and hi gher volumes within extended care, we are updating our outlook for the \nsegment.  We now expect fiscal 2021 segment revenue to increase between 8% and 12%, and segment adjusted \noperating profit in the range of down 3% to an increase of 3%.  We continue to exp ect growth in the second half of \nthe fiscal year compared to the prior year and now project to be between 10% and 15%.  \n \n", "original_text": "As discussed in my opening remarks, we began to see volume \nimprovements in the primary care business in the month of June. ", "page_label": "11", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "344de2af4c45640f2c0b60aa93d5455b4881e9b74a9b8a0f832c644292cd69aa", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7daffaab-d6a4-4a6f-8b10-23d4d3042eb6", "node_type": "1", "metadata": {"window": "Turning to our Medical -Surgical segment.  As discussed in my opening remarks, we began to see volume \nimprovements in the primary care business in the month of June.  As a result of the pace of the recovery within \nprimary care in the segment, and hi gher volumes within extended care, we are updating our outlook for the \nsegment.  We now expect fiscal 2021 segment revenue to increase between 8% and 12%, and segment adjusted \noperating profit in the range of down 3% to an increase of 3%.  We continue to exp ect growth in the second half of \nthe fiscal year compared to the prior year and now project to be between 10% and 15%.  \n \n Turning to Other.  As a result of the return to more normalized volumes in the Canadian business in the back half \nof June, we now anticip ate segment revenues to decline between 5% and 10% for fiscal 2021. ", "original_text": "We now expect fiscal 2021 segment revenue to increase between 8% and 12%, and segment adjusted \noperating profit in the range of down 3% to an increase of 3%. "}, "hash": "26a1a1f251f5f8bc9f8c94378d18f609a235ee0ffed18bb0bcf0748dfeb0e2e4", "class_name": "RelatedNodeInfo"}}, "text": "As a result of the pace of the recovery within \nprimary care in the segment, and hi gher volumes within extended care, we are updating our outlook for the \nsegment. ", "start_char_idx": 2026, "end_char_idx": 2191, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7daffaab-d6a4-4a6f-8b10-23d4d3042eb6": {"__data__": {"id_": "7daffaab-d6a4-4a6f-8b10-23d4d3042eb6", "embedding": null, "metadata": {"window": "Turning to our Medical -Surgical segment.  As discussed in my opening remarks, we began to see volume \nimprovements in the primary care business in the month of June.  As a result of the pace of the recovery within \nprimary care in the segment, and hi gher volumes within extended care, we are updating our outlook for the \nsegment.  We now expect fiscal 2021 segment revenue to increase between 8% and 12%, and segment adjusted \noperating profit in the range of down 3% to an increase of 3%.  We continue to exp ect growth in the second half of \nthe fiscal year compared to the prior year and now project to be between 10% and 15%.  \n \n Turning to Other.  As a result of the return to more normalized volumes in the Canadian business in the back half \nof June, we now anticip ate segment revenues to decline between 5% and 10% for fiscal 2021. ", "original_text": "We now expect fiscal 2021 segment revenue to increase between 8% and 12%, and segment adjusted \noperating profit in the range of down 3% to an increase of 3%. ", "page_label": "11", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7d2b4c06-f5b1-4a4f-9127-7f73d68a375e", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "afc8b717477192d484d10841cdee6bad2bd0877d53ae1ac68fbfae214a578968", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c30f5be6-f0ad-40aa-b2a9-b934380fa8c5", "node_type": "1", "metadata": {"window": "Due to the earlier recovery and the flattening of the recovery curve, we now expect second half adjusted \noperating profit to decline between 4% and 6% in  Europe.  \n \n Turning to our Medical -Surgical segment.  As discussed in my opening remarks, we began to see volume \nimprovements in the primary care business in the month of June.  As a result of the pace of the recovery within \nprimary care in the segment, and hi gher volumes within extended care, we are updating our outlook for the \nsegment.  We now expect fiscal 2021 segment revenue to increase between 8% and 12%, and segment adjusted \noperating profit in the range of down 3% to an increase of 3%.  We continue to exp ect growth in the second half of \nthe fiscal year compared to the prior year and now project to be between 10% and 15%.  \n \n Turning to Other. ", "original_text": "As a result of the pace of the recovery within \nprimary care in the segment, and hi gher volumes within extended care, we are updating our outlook for the \nsegment. ", "page_label": "11", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fc5d81aab505959ffbf78c41e7f8079cfd70645daa721a57e56852b11c897e3a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c40b3b82-5ccd-4710-a73c-c1f485714c41", "node_type": "1", "metadata": {"window": "As discussed in my opening remarks, we began to see volume \nimprovements in the primary care business in the month of June.  As a result of the pace of the recovery within \nprimary care in the segment, and hi gher volumes within extended care, we are updating our outlook for the \nsegment.  We now expect fiscal 2021 segment revenue to increase between 8% and 12%, and segment adjusted \noperating profit in the range of down 3% to an increase of 3%.  We continue to exp ect growth in the second half of \nthe fiscal year compared to the prior year and now project to be between 10% and 15%.  \n \n Turning to Other.  As a result of the return to more normalized volumes in the Canadian business in the back half \nof June, we now anticip ate segment revenues to decline between 5% and 10% for fiscal 2021.  Excluding the \nimpact of Change Healthcare, we continue to expect greater than 10% growth in the second half of the fiscal year \nwhen compared to the prior year.  \n \n", "original_text": "We continue to exp ect growth in the second half of \nthe fiscal year compared to the prior year and now project to be between 10% and 15%.  \n \n"}, "hash": "386f29c531b581b41810cddef99eb027b8d97c965954ccde628ce9ced377d57e", "class_name": "RelatedNodeInfo"}}, "text": "We now expect fiscal 2021 segment revenue to increase between 8% and 12%, and segment adjusted \noperating profit in the range of down 3% to an increase of 3%. ", "start_char_idx": 2191, "end_char_idx": 2350, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c40b3b82-5ccd-4710-a73c-c1f485714c41": {"__data__": {"id_": "c40b3b82-5ccd-4710-a73c-c1f485714c41", "embedding": null, "metadata": {"window": "As discussed in my opening remarks, we began to see volume \nimprovements in the primary care business in the month of June.  As a result of the pace of the recovery within \nprimary care in the segment, and hi gher volumes within extended care, we are updating our outlook for the \nsegment.  We now expect fiscal 2021 segment revenue to increase between 8% and 12%, and segment adjusted \noperating profit in the range of down 3% to an increase of 3%.  We continue to exp ect growth in the second half of \nthe fiscal year compared to the prior year and now project to be between 10% and 15%.  \n \n Turning to Other.  As a result of the return to more normalized volumes in the Canadian business in the back half \nof June, we now anticip ate segment revenues to decline between 5% and 10% for fiscal 2021.  Excluding the \nimpact of Change Healthcare, we continue to expect greater than 10% growth in the second half of the fiscal year \nwhen compared to the prior year.  \n \n", "original_text": "We continue to exp ect growth in the second half of \nthe fiscal year compared to the prior year and now project to be between 10% and 15%.  \n \n", "page_label": "11", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7d2b4c06-f5b1-4a4f-9127-7f73d68a375e", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "afc8b717477192d484d10841cdee6bad2bd0877d53ae1ac68fbfae214a578968", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7daffaab-d6a4-4a6f-8b10-23d4d3042eb6", "node_type": "1", "metadata": {"window": "Turning to our Medical -Surgical segment.  As discussed in my opening remarks, we began to see volume \nimprovements in the primary care business in the month of June.  As a result of the pace of the recovery within \nprimary care in the segment, and hi gher volumes within extended care, we are updating our outlook for the \nsegment.  We now expect fiscal 2021 segment revenue to increase between 8% and 12%, and segment adjusted \noperating profit in the range of down 3% to an increase of 3%.  We continue to exp ect growth in the second half of \nthe fiscal year compared to the prior year and now project to be between 10% and 15%.  \n \n Turning to Other.  As a result of the return to more normalized volumes in the Canadian business in the back half \nof June, we now anticip ate segment revenues to decline between 5% and 10% for fiscal 2021. ", "original_text": "We now expect fiscal 2021 segment revenue to increase between 8% and 12%, and segment adjusted \noperating profit in the range of down 3% to an increase of 3%. ", "page_label": "11", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "027792dba9ffd62483a12f154a01c72bd6482672dd45fe3160ee665ad37ffe3a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b09cda71-2596-4324-b45d-8d35ce256215", "node_type": "1", "metadata": {"window": "As a result of the pace of the recovery within \nprimary care in the segment, and hi gher volumes within extended care, we are updating our outlook for the \nsegment.  We now expect fiscal 2021 segment revenue to increase between 8% and 12%, and segment adjusted \noperating profit in the range of down 3% to an increase of 3%.  We continue to exp ect growth in the second half of \nthe fiscal year compared to the prior year and now project to be between 10% and 15%.  \n \n Turning to Other.  As a result of the return to more normalized volumes in the Canadian business in the back half \nof June, we now anticip ate segment revenues to decline between 5% and 10% for fiscal 2021.  Excluding the \nimpact of Change Healthcare, we continue to expect greater than 10% growth in the second half of the fiscal year \nwhen compared to the prior year.  \n \n Within our Corporate segmen t for fiscal 2021, we now anticipate that opioid -related costs will approximately be \n$160 million. ", "original_text": "Turning to Other. "}, "hash": "90946440e17e23dc18b9d0d2993a6bbefce7fbecced312beecc0a05daab24e70", "class_name": "RelatedNodeInfo"}}, "text": "We continue to exp ect growth in the second half of \nthe fiscal year compared to the prior year and now project to be between 10% and 15%.  \n \n", "start_char_idx": 2350, "end_char_idx": 2493, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b09cda71-2596-4324-b45d-8d35ce256215": {"__data__": {"id_": "b09cda71-2596-4324-b45d-8d35ce256215", "embedding": null, "metadata": {"window": "As a result of the pace of the recovery within \nprimary care in the segment, and hi gher volumes within extended care, we are updating our outlook for the \nsegment.  We now expect fiscal 2021 segment revenue to increase between 8% and 12%, and segment adjusted \noperating profit in the range of down 3% to an increase of 3%.  We continue to exp ect growth in the second half of \nthe fiscal year compared to the prior year and now project to be between 10% and 15%.  \n \n Turning to Other.  As a result of the return to more normalized volumes in the Canadian business in the back half \nof June, we now anticip ate segment revenues to decline between 5% and 10% for fiscal 2021.  Excluding the \nimpact of Change Healthcare, we continue to expect greater than 10% growth in the second half of the fiscal year \nwhen compared to the prior year.  \n \n Within our Corporate segmen t for fiscal 2021, we now anticipate that opioid -related costs will approximately be \n$160 million. ", "original_text": "Turning to Other. ", "page_label": "11", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7d2b4c06-f5b1-4a4f-9127-7f73d68a375e", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "afc8b717477192d484d10841cdee6bad2bd0877d53ae1ac68fbfae214a578968", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c40b3b82-5ccd-4710-a73c-c1f485714c41", "node_type": "1", "metadata": {"window": "As discussed in my opening remarks, we began to see volume \nimprovements in the primary care business in the month of June.  As a result of the pace of the recovery within \nprimary care in the segment, and hi gher volumes within extended care, we are updating our outlook for the \nsegment.  We now expect fiscal 2021 segment revenue to increase between 8% and 12%, and segment adjusted \noperating profit in the range of down 3% to an increase of 3%.  We continue to exp ect growth in the second half of \nthe fiscal year compared to the prior year and now project to be between 10% and 15%.  \n \n Turning to Other.  As a result of the return to more normalized volumes in the Canadian business in the back half \nof June, we now anticip ate segment revenues to decline between 5% and 10% for fiscal 2021.  Excluding the \nimpact of Change Healthcare, we continue to expect greater than 10% growth in the second half of the fiscal year \nwhen compared to the prior year.  \n \n", "original_text": "We continue to exp ect growth in the second half of \nthe fiscal year compared to the prior year and now project to be between 10% and 15%.  \n \n", "page_label": "11", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "be1756e71c097e8db0fab8656651d5948a206a2bbbfa1fc74cf1c4b8c70cb1be", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "39fb63d1-abdb-4333-a6c0-08a26d799c0a", "node_type": "1", "metadata": {"window": "We now expect fiscal 2021 segment revenue to increase between 8% and 12%, and segment adjusted \noperating profit in the range of down 3% to an increase of 3%.  We continue to exp ect growth in the second half of \nthe fiscal year compared to the prior year and now project to be between 10% and 15%.  \n \n Turning to Other.  As a result of the return to more normalized volumes in the Canadian business in the back half \nof June, we now anticip ate segment revenues to decline between 5% and 10% for fiscal 2021.  Excluding the \nimpact of Change Healthcare, we continue to expect greater than 10% growth in the second half of the fiscal year \nwhen compared to the prior year.  \n \n Within our Corporate segmen t for fiscal 2021, we now anticipate that opioid -related costs will approximately be \n$160 million.  Based on higher opioid -related costs and increased investment in the business, including \ntechnology, versus our original outlook, we now anticipate corporate  expenses to be in the range of $690 million \nto $740 million.  \n \n", "original_text": "As a result of the return to more normalized volumes in the Canadian business in the back half \nof June, we now anticip ate segment revenues to decline between 5% and 10% for fiscal 2021. "}, "hash": "10f54f14ac2bd58d1ee82338b3bb7a5123bb7c9ca348c5641da6df6fe90a5d31", "class_name": "RelatedNodeInfo"}}, "text": "Turning to Other. ", "start_char_idx": 2493, "end_char_idx": 2511, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "39fb63d1-abdb-4333-a6c0-08a26d799c0a": {"__data__": {"id_": "39fb63d1-abdb-4333-a6c0-08a26d799c0a", "embedding": null, "metadata": {"window": "We now expect fiscal 2021 segment revenue to increase between 8% and 12%, and segment adjusted \noperating profit in the range of down 3% to an increase of 3%.  We continue to exp ect growth in the second half of \nthe fiscal year compared to the prior year and now project to be between 10% and 15%.  \n \n Turning to Other.  As a result of the return to more normalized volumes in the Canadian business in the back half \nof June, we now anticip ate segment revenues to decline between 5% and 10% for fiscal 2021.  Excluding the \nimpact of Change Healthcare, we continue to expect greater than 10% growth in the second half of the fiscal year \nwhen compared to the prior year.  \n \n Within our Corporate segmen t for fiscal 2021, we now anticipate that opioid -related costs will approximately be \n$160 million.  Based on higher opioid -related costs and increased investment in the business, including \ntechnology, versus our original outlook, we now anticipate corporate  expenses to be in the range of $690 million \nto $740 million.  \n \n", "original_text": "As a result of the return to more normalized volumes in the Canadian business in the back half \nof June, we now anticip ate segment revenues to decline between 5% and 10% for fiscal 2021. ", "page_label": "11", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7d2b4c06-f5b1-4a4f-9127-7f73d68a375e", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "afc8b717477192d484d10841cdee6bad2bd0877d53ae1ac68fbfae214a578968", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b09cda71-2596-4324-b45d-8d35ce256215", "node_type": "1", "metadata": {"window": "As a result of the pace of the recovery within \nprimary care in the segment, and hi gher volumes within extended care, we are updating our outlook for the \nsegment.  We now expect fiscal 2021 segment revenue to increase between 8% and 12%, and segment adjusted \noperating profit in the range of down 3% to an increase of 3%.  We continue to exp ect growth in the second half of \nthe fiscal year compared to the prior year and now project to be between 10% and 15%.  \n \n Turning to Other.  As a result of the return to more normalized volumes in the Canadian business in the back half \nof June, we now anticip ate segment revenues to decline between 5% and 10% for fiscal 2021.  Excluding the \nimpact of Change Healthcare, we continue to expect greater than 10% growth in the second half of the fiscal year \nwhen compared to the prior year.  \n \n Within our Corporate segmen t for fiscal 2021, we now anticipate that opioid -related costs will approximately be \n$160 million. ", "original_text": "Turning to Other. ", "page_label": "11", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "50ffa838717dcf07d8a5706819d95910819d42d18a470d480e02a710e5062998", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b05d732d-0bfd-4da5-a5b6-e48f8c21919d", "node_type": "1", "metadata": {"window": "We continue to exp ect growth in the second half of \nthe fiscal year compared to the prior year and now project to be between 10% and 15%.  \n \n Turning to Other.  As a result of the return to more normalized volumes in the Canadian business in the back half \nof June, we now anticip ate segment revenues to decline between 5% and 10% for fiscal 2021.  Excluding the \nimpact of Change Healthcare, we continue to expect greater than 10% growth in the second half of the fiscal year \nwhen compared to the prior year.  \n \n Within our Corporate segmen t for fiscal 2021, we now anticipate that opioid -related costs will approximately be \n$160 million.  Based on higher opioid -related costs and increased investment in the business, including \ntechnology, versus our original outlook, we now anticipate corporate  expenses to be in the range of $690 million \nto $740 million.  \n \n We have a solid balance sheet, healthy cash generation and financial flexibility, which underpins our investment -\ngrade credit rating. ", "original_text": "Excluding the \nimpact of Change Healthcare, we continue to expect greater than 10% growth in the second half of the fiscal year \nwhen compared to the prior year.  \n \n"}, "hash": "ec175c9ed2abe389c1ae08e9791ff5a0a900ae61d9e436cdd49a12f584bad7b0", "class_name": "RelatedNodeInfo"}}, "text": "As a result of the return to more normalized volumes in the Canadian business in the back half \nof June, we now anticip ate segment revenues to decline between 5% and 10% for fiscal 2021. ", "start_char_idx": 2511, "end_char_idx": 2699, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b05d732d-0bfd-4da5-a5b6-e48f8c21919d": {"__data__": {"id_": "b05d732d-0bfd-4da5-a5b6-e48f8c21919d", "embedding": null, "metadata": {"window": "We continue to exp ect growth in the second half of \nthe fiscal year compared to the prior year and now project to be between 10% and 15%.  \n \n Turning to Other.  As a result of the return to more normalized volumes in the Canadian business in the back half \nof June, we now anticip ate segment revenues to decline between 5% and 10% for fiscal 2021.  Excluding the \nimpact of Change Healthcare, we continue to expect greater than 10% growth in the second half of the fiscal year \nwhen compared to the prior year.  \n \n Within our Corporate segmen t for fiscal 2021, we now anticipate that opioid -related costs will approximately be \n$160 million.  Based on higher opioid -related costs and increased investment in the business, including \ntechnology, versus our original outlook, we now anticipate corporate  expenses to be in the range of $690 million \nto $740 million.  \n \n We have a solid balance sheet, healthy cash generation and financial flexibility, which underpins our investment -\ngrade credit rating. ", "original_text": "Excluding the \nimpact of Change Healthcare, we continue to expect greater than 10% growth in the second half of the fiscal year \nwhen compared to the prior year.  \n \n", "page_label": "11", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7d2b4c06-f5b1-4a4f-9127-7f73d68a375e", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "afc8b717477192d484d10841cdee6bad2bd0877d53ae1ac68fbfae214a578968", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "39fb63d1-abdb-4333-a6c0-08a26d799c0a", "node_type": "1", "metadata": {"window": "We now expect fiscal 2021 segment revenue to increase between 8% and 12%, and segment adjusted \noperating profit in the range of down 3% to an increase of 3%.  We continue to exp ect growth in the second half of \nthe fiscal year compared to the prior year and now project to be between 10% and 15%.  \n \n Turning to Other.  As a result of the return to more normalized volumes in the Canadian business in the back half \nof June, we now anticip ate segment revenues to decline between 5% and 10% for fiscal 2021.  Excluding the \nimpact of Change Healthcare, we continue to expect greater than 10% growth in the second half of the fiscal year \nwhen compared to the prior year.  \n \n Within our Corporate segmen t for fiscal 2021, we now anticipate that opioid -related costs will approximately be \n$160 million.  Based on higher opioid -related costs and increased investment in the business, including \ntechnology, versus our original outlook, we now anticipate corporate  expenses to be in the range of $690 million \nto $740 million.  \n \n", "original_text": "As a result of the return to more normalized volumes in the Canadian business in the back half \nof June, we now anticip ate segment revenues to decline between 5% and 10% for fiscal 2021. ", "page_label": "11", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6b84aa43fec5414e94f37872bfa1dc7721369ea265172bc2a7b0c5d9d3f6be4c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3ba09699-9a0f-4d5b-858d-85460d1a9967", "node_type": "1", "metadata": {"window": "Turning to Other.  As a result of the return to more normalized volumes in the Canadian business in the back half \nof June, we now anticip ate segment revenues to decline between 5% and 10% for fiscal 2021.  Excluding the \nimpact of Change Healthcare, we continue to expect greater than 10% growth in the second half of the fiscal year \nwhen compared to the prior year.  \n \n Within our Corporate segmen t for fiscal 2021, we now anticipate that opioid -related costs will approximately be \n$160 million.  Based on higher opioid -related costs and increased investment in the business, including \ntechnology, versus our original outlook, we now anticipate corporate  expenses to be in the range of $690 million \nto $740 million.  \n \n We have a solid balance sheet, healthy cash generation and financial flexibility, which underpins our investment -\ngrade credit rating.  These dynamics form the foundation for a balanced approach to capital deployment. ", "original_text": "Within our Corporate segmen t for fiscal 2021, we now anticipate that opioid -related costs will approximately be \n$160 million. "}, "hash": "93838b2d7bdeff7ef699dfc039594a63ed732641ace93ca6c38c2309c05b0c9d", "class_name": "RelatedNodeInfo"}}, "text": "Excluding the \nimpact of Change Healthcare, we continue to expect greater than 10% growth in the second half of the fiscal year \nwhen compared to the prior year.  \n \n", "start_char_idx": 2699, "end_char_idx": 2865, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3ba09699-9a0f-4d5b-858d-85460d1a9967": {"__data__": {"id_": "3ba09699-9a0f-4d5b-858d-85460d1a9967", "embedding": null, "metadata": {"window": "Turning to Other.  As a result of the return to more normalized volumes in the Canadian business in the back half \nof June, we now anticip ate segment revenues to decline between 5% and 10% for fiscal 2021.  Excluding the \nimpact of Change Healthcare, we continue to expect greater than 10% growth in the second half of the fiscal year \nwhen compared to the prior year.  \n \n Within our Corporate segmen t for fiscal 2021, we now anticipate that opioid -related costs will approximately be \n$160 million.  Based on higher opioid -related costs and increased investment in the business, including \ntechnology, versus our original outlook, we now anticipate corporate  expenses to be in the range of $690 million \nto $740 million.  \n \n We have a solid balance sheet, healthy cash generation and financial flexibility, which underpins our investment -\ngrade credit rating.  These dynamics form the foundation for a balanced approach to capital deployment. ", "original_text": "Within our Corporate segmen t for fiscal 2021, we now anticipate that opioid -related costs will approximately be \n$160 million. ", "page_label": "11", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7d2b4c06-f5b1-4a4f-9127-7f73d68a375e", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "afc8b717477192d484d10841cdee6bad2bd0877d53ae1ac68fbfae214a578968", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b05d732d-0bfd-4da5-a5b6-e48f8c21919d", "node_type": "1", "metadata": {"window": "We continue to exp ect growth in the second half of \nthe fiscal year compared to the prior year and now project to be between 10% and 15%.  \n \n Turning to Other.  As a result of the return to more normalized volumes in the Canadian business in the back half \nof June, we now anticip ate segment revenues to decline between 5% and 10% for fiscal 2021.  Excluding the \nimpact of Change Healthcare, we continue to expect greater than 10% growth in the second half of the fiscal year \nwhen compared to the prior year.  \n \n Within our Corporate segmen t for fiscal 2021, we now anticipate that opioid -related costs will approximately be \n$160 million.  Based on higher opioid -related costs and increased investment in the business, including \ntechnology, versus our original outlook, we now anticipate corporate  expenses to be in the range of $690 million \nto $740 million.  \n \n We have a solid balance sheet, healthy cash generation and financial flexibility, which underpins our investment -\ngrade credit rating. ", "original_text": "Excluding the \nimpact of Change Healthcare, we continue to expect greater than 10% growth in the second half of the fiscal year \nwhen compared to the prior year.  \n \n", "page_label": "11", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2af38b30aeea88874a0ce19eeaabf487d03797f2501aa9a5e658866118d38b50", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cb164a2a-196a-4270-bf94-7bdc036713b2", "node_type": "1", "metadata": {"window": "As a result of the return to more normalized volumes in the Canadian business in the back half \nof June, we now anticip ate segment revenues to decline between 5% and 10% for fiscal 2021.  Excluding the \nimpact of Change Healthcare, we continue to expect greater than 10% growth in the second half of the fiscal year \nwhen compared to the prior year.  \n \n Within our Corporate segmen t for fiscal 2021, we now anticipate that opioid -related costs will approximately be \n$160 million.  Based on higher opioid -related costs and increased investment in the business, including \ntechnology, versus our original outlook, we now anticipate corporate  expenses to be in the range of $690 million \nto $740 million.  \n \n We have a solid balance sheet, healthy cash generation and financial flexibility, which underpins our investment -\ngrade credit rating.  These dynamics form the foundation for a balanced approach to capital deployment.  Investing \nin growth areas aligned to our strategy and returning cash to our shareholders. ", "original_text": "Based on higher opioid -related costs and increased investment in the business, including \ntechnology, versus our original outlook, we now anticipate corporate  expenses to be in the range of $690 million \nto $740 million.  \n \n"}, "hash": "c283b31559b2671ff76c4a90337a84381ec951c42c6d4f2970d2ff42ad26f6f7", "class_name": "RelatedNodeInfo"}}, "text": "Within our Corporate segmen t for fiscal 2021, we now anticipate that opioid -related costs will approximately be \n$160 million. ", "start_char_idx": 2865, "end_char_idx": 2994, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cb164a2a-196a-4270-bf94-7bdc036713b2": {"__data__": {"id_": "cb164a2a-196a-4270-bf94-7bdc036713b2", "embedding": null, "metadata": {"window": "As a result of the return to more normalized volumes in the Canadian business in the back half \nof June, we now anticip ate segment revenues to decline between 5% and 10% for fiscal 2021.  Excluding the \nimpact of Change Healthcare, we continue to expect greater than 10% growth in the second half of the fiscal year \nwhen compared to the prior year.  \n \n Within our Corporate segmen t for fiscal 2021, we now anticipate that opioid -related costs will approximately be \n$160 million.  Based on higher opioid -related costs and increased investment in the business, including \ntechnology, versus our original outlook, we now anticipate corporate  expenses to be in the range of $690 million \nto $740 million.  \n \n We have a solid balance sheet, healthy cash generation and financial flexibility, which underpins our investment -\ngrade credit rating.  These dynamics form the foundation for a balanced approach to capital deployment.  Investing \nin growth areas aligned to our strategy and returning cash to our shareholders. ", "original_text": "Based on higher opioid -related costs and increased investment in the business, including \ntechnology, versus our original outlook, we now anticipate corporate  expenses to be in the range of $690 million \nto $740 million.  \n \n", "page_label": "11", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7d2b4c06-f5b1-4a4f-9127-7f73d68a375e", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "afc8b717477192d484d10841cdee6bad2bd0877d53ae1ac68fbfae214a578968", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3ba09699-9a0f-4d5b-858d-85460d1a9967", "node_type": "1", "metadata": {"window": "Turning to Other.  As a result of the return to more normalized volumes in the Canadian business in the back half \nof June, we now anticip ate segment revenues to decline between 5% and 10% for fiscal 2021.  Excluding the \nimpact of Change Healthcare, we continue to expect greater than 10% growth in the second half of the fiscal year \nwhen compared to the prior year.  \n \n Within our Corporate segmen t for fiscal 2021, we now anticipate that opioid -related costs will approximately be \n$160 million.  Based on higher opioid -related costs and increased investment in the business, including \ntechnology, versus our original outlook, we now anticipate corporate  expenses to be in the range of $690 million \nto $740 million.  \n \n We have a solid balance sheet, healthy cash generation and financial flexibility, which underpins our investment -\ngrade credit rating.  These dynamics form the foundation for a balanced approach to capital deployment. ", "original_text": "Within our Corporate segmen t for fiscal 2021, we now anticipate that opioid -related costs will approximately be \n$160 million. ", "page_label": "11", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fe572bb5be34e29ac64fb75ce092955177d27c315adcc3900193e457d6c45461", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5e7dc32b-5b05-47a1-ba62-ee7bfc162dd6", "node_type": "1", "metadata": {"window": "Excluding the \nimpact of Change Healthcare, we continue to expect greater than 10% growth in the second half of the fiscal year \nwhen compared to the prior year.  \n \n Within our Corporate segmen t for fiscal 2021, we now anticipate that opioid -related costs will approximately be \n$160 million.  Based on higher opioid -related costs and increased investment in the business, including \ntechnology, versus our original outlook, we now anticipate corporate  expenses to be in the range of $690 million \nto $740 million.  \n \n We have a solid balance sheet, healthy cash generation and financial flexibility, which underpins our investment -\ngrade credit rating.  These dynamics form the foundation for a balanced approach to capital deployment.  Investing \nin growth areas aligned to our strategy and returning cash to our shareholders.  Based on our solid first quarter \nresults, our view of the macro environment and our updated outlook on transaction volumes across the business,  \nwe are raising the full year fiscal 2021 adjusted earnings per share outlook to a range of $14.70 to $15.50 per \ndiluted share from our previous outlook of $13.95 to $14.75 per diluted share.  \n \n", "original_text": "We have a solid balance sheet, healthy cash generation and financial flexibility, which underpins our investment -\ngrade credit rating. "}, "hash": "fb4e3b93b9167053d02a8500b961b066918c19324bef9b1360915a647bd5740c", "class_name": "RelatedNodeInfo"}}, "text": "Based on higher opioid -related costs and increased investment in the business, including \ntechnology, versus our original outlook, we now anticipate corporate  expenses to be in the range of $690 million \nto $740 million.  \n \n", "start_char_idx": 2994, "end_char_idx": 3221, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5e7dc32b-5b05-47a1-ba62-ee7bfc162dd6": {"__data__": {"id_": "5e7dc32b-5b05-47a1-ba62-ee7bfc162dd6", "embedding": null, "metadata": {"window": "Excluding the \nimpact of Change Healthcare, we continue to expect greater than 10% growth in the second half of the fiscal year \nwhen compared to the prior year.  \n \n Within our Corporate segmen t for fiscal 2021, we now anticipate that opioid -related costs will approximately be \n$160 million.  Based on higher opioid -related costs and increased investment in the business, including \ntechnology, versus our original outlook, we now anticipate corporate  expenses to be in the range of $690 million \nto $740 million.  \n \n We have a solid balance sheet, healthy cash generation and financial flexibility, which underpins our investment -\ngrade credit rating.  These dynamics form the foundation for a balanced approach to capital deployment.  Investing \nin growth areas aligned to our strategy and returning cash to our shareholders.  Based on our solid first quarter \nresults, our view of the macro environment and our updated outlook on transaction volumes across the business,  \nwe are raising the full year fiscal 2021 adjusted earnings per share outlook to a range of $14.70 to $15.50 per \ndiluted share from our previous outlook of $13.95 to $14.75 per diluted share.  \n \n", "original_text": "We have a solid balance sheet, healthy cash generation and financial flexibility, which underpins our investment -\ngrade credit rating. ", "page_label": "11", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7d2b4c06-f5b1-4a4f-9127-7f73d68a375e", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "afc8b717477192d484d10841cdee6bad2bd0877d53ae1ac68fbfae214a578968", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cb164a2a-196a-4270-bf94-7bdc036713b2", "node_type": "1", "metadata": {"window": "As a result of the return to more normalized volumes in the Canadian business in the back half \nof June, we now anticip ate segment revenues to decline between 5% and 10% for fiscal 2021.  Excluding the \nimpact of Change Healthcare, we continue to expect greater than 10% growth in the second half of the fiscal year \nwhen compared to the prior year.  \n \n Within our Corporate segmen t for fiscal 2021, we now anticipate that opioid -related costs will approximately be \n$160 million.  Based on higher opioid -related costs and increased investment in the business, including \ntechnology, versus our original outlook, we now anticipate corporate  expenses to be in the range of $690 million \nto $740 million.  \n \n We have a solid balance sheet, healthy cash generation and financial flexibility, which underpins our investment -\ngrade credit rating.  These dynamics form the foundation for a balanced approach to capital deployment.  Investing \nin growth areas aligned to our strategy and returning cash to our shareholders. ", "original_text": "Based on higher opioid -related costs and increased investment in the business, including \ntechnology, versus our original outlook, we now anticipate corporate  expenses to be in the range of $690 million \nto $740 million.  \n \n", "page_label": "11", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "92bbfad39d7938f25292a5a8332ad5321ad98097b6ce53446707997b1f950c03", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1b16bf12-8931-46b3-9540-7f8b982d8258", "node_type": "1", "metadata": {"window": "Within our Corporate segmen t for fiscal 2021, we now anticipate that opioid -related costs will approximately be \n$160 million.  Based on higher opioid -related costs and increased investment in the business, including \ntechnology, versus our original outlook, we now anticipate corporate  expenses to be in the range of $690 million \nto $740 million.  \n \n We have a solid balance sheet, healthy cash generation and financial flexibility, which underpins our investment -\ngrade credit rating.  These dynamics form the foundation for a balanced approach to capital deployment.  Investing \nin growth areas aligned to our strategy and returning cash to our shareholders.  Based on our solid first quarter \nresults, our view of the macro environment and our updated outlook on transaction volumes across the business,  \nwe are raising the full year fiscal 2021 adjusted earnings per share outlook to a range of $14.70 to $15.50 per \ndiluted share from our previous outlook of $13.95 to $14.75 per diluted share.  \n \n In closing, we're pleased with the results of our fiscal first quarter, and we're proud of how we responded to a \ndynamic environment, supporting our customers despite the uncertainties that were brought on by this pandemic. \n", "original_text": "These dynamics form the foundation for a balanced approach to capital deployment. "}, "hash": "90fdc73fb182a3de545afc13da4511d725d5834f1ce8587687d2ab7fb317cb20", "class_name": "RelatedNodeInfo"}}, "text": "We have a solid balance sheet, healthy cash generation and financial flexibility, which underpins our investment -\ngrade credit rating. ", "start_char_idx": 3221, "end_char_idx": 3357, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1b16bf12-8931-46b3-9540-7f8b982d8258": {"__data__": {"id_": "1b16bf12-8931-46b3-9540-7f8b982d8258", "embedding": null, "metadata": {"window": "Within our Corporate segmen t for fiscal 2021, we now anticipate that opioid -related costs will approximately be \n$160 million.  Based on higher opioid -related costs and increased investment in the business, including \ntechnology, versus our original outlook, we now anticipate corporate  expenses to be in the range of $690 million \nto $740 million.  \n \n We have a solid balance sheet, healthy cash generation and financial flexibility, which underpins our investment -\ngrade credit rating.  These dynamics form the foundation for a balanced approach to capital deployment.  Investing \nin growth areas aligned to our strategy and returning cash to our shareholders.  Based on our solid first quarter \nresults, our view of the macro environment and our updated outlook on transaction volumes across the business,  \nwe are raising the full year fiscal 2021 adjusted earnings per share outlook to a range of $14.70 to $15.50 per \ndiluted share from our previous outlook of $13.95 to $14.75 per diluted share.  \n \n In closing, we're pleased with the results of our fiscal first quarter, and we're proud of how we responded to a \ndynamic environment, supporting our customers despite the uncertainties that were brought on by this pandemic. \n", "original_text": "These dynamics form the foundation for a balanced approach to capital deployment. ", "page_label": "11", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7d2b4c06-f5b1-4a4f-9127-7f73d68a375e", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "afc8b717477192d484d10841cdee6bad2bd0877d53ae1ac68fbfae214a578968", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5e7dc32b-5b05-47a1-ba62-ee7bfc162dd6", "node_type": "1", "metadata": {"window": "Excluding the \nimpact of Change Healthcare, we continue to expect greater than 10% growth in the second half of the fiscal year \nwhen compared to the prior year.  \n \n Within our Corporate segmen t for fiscal 2021, we now anticipate that opioid -related costs will approximately be \n$160 million.  Based on higher opioid -related costs and increased investment in the business, including \ntechnology, versus our original outlook, we now anticipate corporate  expenses to be in the range of $690 million \nto $740 million.  \n \n We have a solid balance sheet, healthy cash generation and financial flexibility, which underpins our investment -\ngrade credit rating.  These dynamics form the foundation for a balanced approach to capital deployment.  Investing \nin growth areas aligned to our strategy and returning cash to our shareholders.  Based on our solid first quarter \nresults, our view of the macro environment and our updated outlook on transaction volumes across the business,  \nwe are raising the full year fiscal 2021 adjusted earnings per share outlook to a range of $14.70 to $15.50 per \ndiluted share from our previous outlook of $13.95 to $14.75 per diluted share.  \n \n", "original_text": "We have a solid balance sheet, healthy cash generation and financial flexibility, which underpins our investment -\ngrade credit rating. ", "page_label": "11", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0948af6d1bb0287f54a4044a5c30f04280209151d9dab735be3051116b1abfcb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "90e4eb8d-b972-441d-a7d7-991cdb6137b5", "node_type": "1", "metadata": {"window": "Based on higher opioid -related costs and increased investment in the business, including \ntechnology, versus our original outlook, we now anticipate corporate  expenses to be in the range of $690 million \nto $740 million.  \n \n We have a solid balance sheet, healthy cash generation and financial flexibility, which underpins our investment -\ngrade credit rating.  These dynamics form the foundation for a balanced approach to capital deployment.  Investing \nin growth areas aligned to our strategy and returning cash to our shareholders.  Based on our solid first quarter \nresults, our view of the macro environment and our updated outlook on transaction volumes across the business,  \nwe are raising the full year fiscal 2021 adjusted earnings per share outlook to a range of $14.70 to $15.50 per \ndiluted share from our previous outlook of $13.95 to $14.75 per diluted share.  \n \n In closing, we're pleased with the results of our fiscal first quarter, and we're proud of how we responded to a \ndynamic environment, supporting our customers despite the uncertainties that were brought on by this pandemic. \n Our disciplined execution delivered solid results. ", "original_text": "Investing \nin growth areas aligned to our strategy and returning cash to our shareholders. "}, "hash": "f61d6182d81e173d852fa362d6610c5a96b219dbdfafac99dc660556874d642a", "class_name": "RelatedNodeInfo"}}, "text": "These dynamics form the foundation for a balanced approach to capital deployment. ", "start_char_idx": 3357, "end_char_idx": 3439, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "90e4eb8d-b972-441d-a7d7-991cdb6137b5": {"__data__": {"id_": "90e4eb8d-b972-441d-a7d7-991cdb6137b5", "embedding": null, "metadata": {"window": "Based on higher opioid -related costs and increased investment in the business, including \ntechnology, versus our original outlook, we now anticipate corporate  expenses to be in the range of $690 million \nto $740 million.  \n \n We have a solid balance sheet, healthy cash generation and financial flexibility, which underpins our investment -\ngrade credit rating.  These dynamics form the foundation for a balanced approach to capital deployment.  Investing \nin growth areas aligned to our strategy and returning cash to our shareholders.  Based on our solid first quarter \nresults, our view of the macro environment and our updated outlook on transaction volumes across the business,  \nwe are raising the full year fiscal 2021 adjusted earnings per share outlook to a range of $14.70 to $15.50 per \ndiluted share from our previous outlook of $13.95 to $14.75 per diluted share.  \n \n In closing, we're pleased with the results of our fiscal first quarter, and we're proud of how we responded to a \ndynamic environment, supporting our customers despite the uncertainties that were brought on by this pandemic. \n Our disciplined execution delivered solid results. ", "original_text": "Investing \nin growth areas aligned to our strategy and returning cash to our shareholders. ", "page_label": "11", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7d2b4c06-f5b1-4a4f-9127-7f73d68a375e", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "afc8b717477192d484d10841cdee6bad2bd0877d53ae1ac68fbfae214a578968", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1b16bf12-8931-46b3-9540-7f8b982d8258", "node_type": "1", "metadata": {"window": "Within our Corporate segmen t for fiscal 2021, we now anticipate that opioid -related costs will approximately be \n$160 million.  Based on higher opioid -related costs and increased investment in the business, including \ntechnology, versus our original outlook, we now anticipate corporate  expenses to be in the range of $690 million \nto $740 million.  \n \n We have a solid balance sheet, healthy cash generation and financial flexibility, which underpins our investment -\ngrade credit rating.  These dynamics form the foundation for a balanced approach to capital deployment.  Investing \nin growth areas aligned to our strategy and returning cash to our shareholders.  Based on our solid first quarter \nresults, our view of the macro environment and our updated outlook on transaction volumes across the business,  \nwe are raising the full year fiscal 2021 adjusted earnings per share outlook to a range of $14.70 to $15.50 per \ndiluted share from our previous outlook of $13.95 to $14.75 per diluted share.  \n \n In closing, we're pleased with the results of our fiscal first quarter, and we're proud of how we responded to a \ndynamic environment, supporting our customers despite the uncertainties that were brought on by this pandemic. \n", "original_text": "These dynamics form the foundation for a balanced approach to capital deployment. ", "page_label": "11", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e6397b2dd5fc07c10a2dc25ca4f7bf2a5855aa81bf57e752d2abb656c824b830", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3d5808fd-b3eb-490b-8d24-a59740d24c38", "node_type": "1", "metadata": {"window": "We have a solid balance sheet, healthy cash generation and financial flexibility, which underpins our investment -\ngrade credit rating.  These dynamics form the foundation for a balanced approach to capital deployment.  Investing \nin growth areas aligned to our strategy and returning cash to our shareholders.  Based on our solid first quarter \nresults, our view of the macro environment and our updated outlook on transaction volumes across the business,  \nwe are raising the full year fiscal 2021 adjusted earnings per share outlook to a range of $14.70 to $15.50 per \ndiluted share from our previous outlook of $13.95 to $14.75 per diluted share.  \n \n In closing, we're pleased with the results of our fiscal first quarter, and we're proud of how we responded to a \ndynamic environment, supporting our customers despite the uncertainties that were brought on by this pandemic. \n Our disciplined execution delivered solid results.  Combined with our strong balance sheet and f inancial position, \nwe're well positioned to deliver growth in the second half of the year as compared to the prior year. ", "original_text": "Based on our solid first quarter \nresults, our view of the macro environment and our updated outlook on transaction volumes across the business,  \nwe are raising the full year fiscal 2021 adjusted earnings per share outlook to a range of $14.70 to $15.50 per \ndiluted share from our previous outlook of $13.95 to $14.75 per diluted share.  \n \n"}, "hash": "636950e875e5a2bbb2a3e015a4dfbd207564c3298055d45d46d4a336cf676877", "class_name": "RelatedNodeInfo"}}, "text": "Investing \nin growth areas aligned to our strategy and returning cash to our shareholders. ", "start_char_idx": 3439, "end_char_idx": 3530, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3d5808fd-b3eb-490b-8d24-a59740d24c38": {"__data__": {"id_": "3d5808fd-b3eb-490b-8d24-a59740d24c38", "embedding": null, "metadata": {"window": "We have a solid balance sheet, healthy cash generation and financial flexibility, which underpins our investment -\ngrade credit rating.  These dynamics form the foundation for a balanced approach to capital deployment.  Investing \nin growth areas aligned to our strategy and returning cash to our shareholders.  Based on our solid first quarter \nresults, our view of the macro environment and our updated outlook on transaction volumes across the business,  \nwe are raising the full year fiscal 2021 adjusted earnings per share outlook to a range of $14.70 to $15.50 per \ndiluted share from our previous outlook of $13.95 to $14.75 per diluted share.  \n \n In closing, we're pleased with the results of our fiscal first quarter, and we're proud of how we responded to a \ndynamic environment, supporting our customers despite the uncertainties that were brought on by this pandemic. \n Our disciplined execution delivered solid results.  Combined with our strong balance sheet and f inancial position, \nwe're well positioned to deliver growth in the second half of the year as compared to the prior year. ", "original_text": "Based on our solid first quarter \nresults, our view of the macro environment and our updated outlook on transaction volumes across the business,  \nwe are raising the full year fiscal 2021 adjusted earnings per share outlook to a range of $14.70 to $15.50 per \ndiluted share from our previous outlook of $13.95 to $14.75 per diluted share.  \n \n", "page_label": "11", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7d2b4c06-f5b1-4a4f-9127-7f73d68a375e", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "afc8b717477192d484d10841cdee6bad2bd0877d53ae1ac68fbfae214a578968", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "90e4eb8d-b972-441d-a7d7-991cdb6137b5", "node_type": "1", "metadata": {"window": "Based on higher opioid -related costs and increased investment in the business, including \ntechnology, versus our original outlook, we now anticipate corporate  expenses to be in the range of $690 million \nto $740 million.  \n \n We have a solid balance sheet, healthy cash generation and financial flexibility, which underpins our investment -\ngrade credit rating.  These dynamics form the foundation for a balanced approach to capital deployment.  Investing \nin growth areas aligned to our strategy and returning cash to our shareholders.  Based on our solid first quarter \nresults, our view of the macro environment and our updated outlook on transaction volumes across the business,  \nwe are raising the full year fiscal 2021 adjusted earnings per share outlook to a range of $14.70 to $15.50 per \ndiluted share from our previous outlook of $13.95 to $14.75 per diluted share.  \n \n In closing, we're pleased with the results of our fiscal first quarter, and we're proud of how we responded to a \ndynamic environment, supporting our customers despite the uncertainties that were brought on by this pandemic. \n Our disciplined execution delivered solid results. ", "original_text": "Investing \nin growth areas aligned to our strategy and returning cash to our shareholders. ", "page_label": "11", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "463f76dff0af85131949f31fedbbf7de7f8ad8f6a191093c8ac4e14e7918193b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "761bc3ab-56d1-45ae-9155-04e1aee02a0c", "node_type": "1", "metadata": {"window": "These dynamics form the foundation for a balanced approach to capital deployment.  Investing \nin growth areas aligned to our strategy and returning cash to our shareholders.  Based on our solid first quarter \nresults, our view of the macro environment and our updated outlook on transaction volumes across the business,  \nwe are raising the full year fiscal 2021 adjusted earnings per share outlook to a range of $14.70 to $15.50 per \ndiluted share from our previous outlook of $13.95 to $14.75 per diluted share.  \n \n In closing, we're pleased with the results of our fiscal first quarter, and we're proud of how we responded to a \ndynamic environment, supporting our customers despite the uncertainties that were brought on by this pandemic. \n Our disciplined execution delivered solid results.  Combined with our strong balance sheet and f inancial position, \nwe're well positioned to deliver growth in the second half of the year as compared to the prior year.  The external ", "original_text": "In closing, we're pleased with the results of our fiscal first quarter, and we're proud of how we responded to a \ndynamic environment, supporting our customers despite the uncertainties that were brought on by this pandemic. \n"}, "hash": "4bc03d9083580a89a74c2e2d81af2afd3943e089fcfe33aec0228ffa96951ec9", "class_name": "RelatedNodeInfo"}}, "text": "Based on our solid first quarter \nresults, our view of the macro environment and our updated outlook on transaction volumes across the business,  \nwe are raising the full year fiscal 2021 adjusted earnings per share outlook to a range of $14.70 to $15.50 per \ndiluted share from our previous outlook of $13.95 to $14.75 per diluted share.  \n \n", "start_char_idx": 3530, "end_char_idx": 3873, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "761bc3ab-56d1-45ae-9155-04e1aee02a0c": {"__data__": {"id_": "761bc3ab-56d1-45ae-9155-04e1aee02a0c", "embedding": null, "metadata": {"window": "These dynamics form the foundation for a balanced approach to capital deployment.  Investing \nin growth areas aligned to our strategy and returning cash to our shareholders.  Based on our solid first quarter \nresults, our view of the macro environment and our updated outlook on transaction volumes across the business,  \nwe are raising the full year fiscal 2021 adjusted earnings per share outlook to a range of $14.70 to $15.50 per \ndiluted share from our previous outlook of $13.95 to $14.75 per diluted share.  \n \n In closing, we're pleased with the results of our fiscal first quarter, and we're proud of how we responded to a \ndynamic environment, supporting our customers despite the uncertainties that were brought on by this pandemic. \n Our disciplined execution delivered solid results.  Combined with our strong balance sheet and f inancial position, \nwe're well positioned to deliver growth in the second half of the year as compared to the prior year.  The external ", "original_text": "In closing, we're pleased with the results of our fiscal first quarter, and we're proud of how we responded to a \ndynamic environment, supporting our customers despite the uncertainties that were brought on by this pandemic. \n", "page_label": "11", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7d2b4c06-f5b1-4a4f-9127-7f73d68a375e", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "afc8b717477192d484d10841cdee6bad2bd0877d53ae1ac68fbfae214a578968", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3d5808fd-b3eb-490b-8d24-a59740d24c38", "node_type": "1", "metadata": {"window": "We have a solid balance sheet, healthy cash generation and financial flexibility, which underpins our investment -\ngrade credit rating.  These dynamics form the foundation for a balanced approach to capital deployment.  Investing \nin growth areas aligned to our strategy and returning cash to our shareholders.  Based on our solid first quarter \nresults, our view of the macro environment and our updated outlook on transaction volumes across the business,  \nwe are raising the full year fiscal 2021 adjusted earnings per share outlook to a range of $14.70 to $15.50 per \ndiluted share from our previous outlook of $13.95 to $14.75 per diluted share.  \n \n In closing, we're pleased with the results of our fiscal first quarter, and we're proud of how we responded to a \ndynamic environment, supporting our customers despite the uncertainties that were brought on by this pandemic. \n Our disciplined execution delivered solid results.  Combined with our strong balance sheet and f inancial position, \nwe're well positioned to deliver growth in the second half of the year as compared to the prior year. ", "original_text": "Based on our solid first quarter \nresults, our view of the macro environment and our updated outlook on transaction volumes across the business,  \nwe are raising the full year fiscal 2021 adjusted earnings per share outlook to a range of $14.70 to $15.50 per \ndiluted share from our previous outlook of $13.95 to $14.75 per diluted share.  \n \n", "page_label": "11", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ad76a371d0790ce2c41ea0b5a14ba84fb3d69a34fad2c7488eab1274d2e2a291", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ad82a548-f46f-4af4-8afa-6e6b200dff65", "node_type": "1", "metadata": {"window": "Investing \nin growth areas aligned to our strategy and returning cash to our shareholders.  Based on our solid first quarter \nresults, our view of the macro environment and our updated outlook on transaction volumes across the business,  \nwe are raising the full year fiscal 2021 adjusted earnings per share outlook to a range of $14.70 to $15.50 per \ndiluted share from our previous outlook of $13.95 to $14.75 per diluted share.  \n \n In closing, we're pleased with the results of our fiscal first quarter, and we're proud of how we responded to a \ndynamic environment, supporting our customers despite the uncertainties that were brought on by this pandemic. \n Our disciplined execution delivered solid results.  Combined with our strong balance sheet and f inancial position, \nwe're well positioned to deliver growth in the second half of the year as compared to the prior year.  The external ", "original_text": "Our disciplined execution delivered solid results. "}, "hash": "70b6f623946b4217f7ae4c9775d19e6c5d11f28ff71b7bd0ce382ead5782e505", "class_name": "RelatedNodeInfo"}}, "text": "In closing, we're pleased with the results of our fiscal first quarter, and we're proud of how we responded to a \ndynamic environment, supporting our customers despite the uncertainties that were brought on by this pandemic. \n", "start_char_idx": 3873, "end_char_idx": 4099, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ad82a548-f46f-4af4-8afa-6e6b200dff65": {"__data__": {"id_": "ad82a548-f46f-4af4-8afa-6e6b200dff65", "embedding": null, "metadata": {"window": "Investing \nin growth areas aligned to our strategy and returning cash to our shareholders.  Based on our solid first quarter \nresults, our view of the macro environment and our updated outlook on transaction volumes across the business,  \nwe are raising the full year fiscal 2021 adjusted earnings per share outlook to a range of $14.70 to $15.50 per \ndiluted share from our previous outlook of $13.95 to $14.75 per diluted share.  \n \n In closing, we're pleased with the results of our fiscal first quarter, and we're proud of how we responded to a \ndynamic environment, supporting our customers despite the uncertainties that were brought on by this pandemic. \n Our disciplined execution delivered solid results.  Combined with our strong balance sheet and f inancial position, \nwe're well positioned to deliver growth in the second half of the year as compared to the prior year.  The external ", "original_text": "Our disciplined execution delivered solid results. ", "page_label": "11", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7d2b4c06-f5b1-4a4f-9127-7f73d68a375e", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "afc8b717477192d484d10841cdee6bad2bd0877d53ae1ac68fbfae214a578968", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "761bc3ab-56d1-45ae-9155-04e1aee02a0c", "node_type": "1", "metadata": {"window": "These dynamics form the foundation for a balanced approach to capital deployment.  Investing \nin growth areas aligned to our strategy and returning cash to our shareholders.  Based on our solid first quarter \nresults, our view of the macro environment and our updated outlook on transaction volumes across the business,  \nwe are raising the full year fiscal 2021 adjusted earnings per share outlook to a range of $14.70 to $15.50 per \ndiluted share from our previous outlook of $13.95 to $14.75 per diluted share.  \n \n In closing, we're pleased with the results of our fiscal first quarter, and we're proud of how we responded to a \ndynamic environment, supporting our customers despite the uncertainties that were brought on by this pandemic. \n Our disciplined execution delivered solid results.  Combined with our strong balance sheet and f inancial position, \nwe're well positioned to deliver growth in the second half of the year as compared to the prior year.  The external ", "original_text": "In closing, we're pleased with the results of our fiscal first quarter, and we're proud of how we responded to a \ndynamic environment, supporting our customers despite the uncertainties that were brought on by this pandemic. \n", "page_label": "11", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "dc3d173acc1a306134df0b7163b9444ea8e38d6553de4ed15c2d5acd484c1836", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e816f77e-ec74-4e7b-b687-336f0a596954", "node_type": "1", "metadata": {"window": "Based on our solid first quarter \nresults, our view of the macro environment and our updated outlook on transaction volumes across the business,  \nwe are raising the full year fiscal 2021 adjusted earnings per share outlook to a range of $14.70 to $15.50 per \ndiluted share from our previous outlook of $13.95 to $14.75 per diluted share.  \n \n In closing, we're pleased with the results of our fiscal first quarter, and we're proud of how we responded to a \ndynamic environment, supporting our customers despite the uncertainties that were brought on by this pandemic. \n Our disciplined execution delivered solid results.  Combined with our strong balance sheet and f inancial position, \nwe're well positioned to deliver growth in the second half of the year as compared to the prior year.  The external ", "original_text": "Combined with our strong balance sheet and f inancial position, \nwe're well positioned to deliver growth in the second half of the year as compared to the prior year. "}, "hash": "b9f525e0563faad1a99365a65db763a3805ca789cb834a98403eba88f4e0a7f7", "class_name": "RelatedNodeInfo"}}, "text": "Our disciplined execution delivered solid results. ", "start_char_idx": 4099, "end_char_idx": 4150, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e816f77e-ec74-4e7b-b687-336f0a596954": {"__data__": {"id_": "e816f77e-ec74-4e7b-b687-336f0a596954", "embedding": null, "metadata": {"window": "Based on our solid first quarter \nresults, our view of the macro environment and our updated outlook on transaction volumes across the business,  \nwe are raising the full year fiscal 2021 adjusted earnings per share outlook to a range of $14.70 to $15.50 per \ndiluted share from our previous outlook of $13.95 to $14.75 per diluted share.  \n \n In closing, we're pleased with the results of our fiscal first quarter, and we're proud of how we responded to a \ndynamic environment, supporting our customers despite the uncertainties that were brought on by this pandemic. \n Our disciplined execution delivered solid results.  Combined with our strong balance sheet and f inancial position, \nwe're well positioned to deliver growth in the second half of the year as compared to the prior year.  The external ", "original_text": "Combined with our strong balance sheet and f inancial position, \nwe're well positioned to deliver growth in the second half of the year as compared to the prior year. ", "page_label": "11", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7d2b4c06-f5b1-4a4f-9127-7f73d68a375e", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "afc8b717477192d484d10841cdee6bad2bd0877d53ae1ac68fbfae214a578968", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ad82a548-f46f-4af4-8afa-6e6b200dff65", "node_type": "1", "metadata": {"window": "Investing \nin growth areas aligned to our strategy and returning cash to our shareholders.  Based on our solid first quarter \nresults, our view of the macro environment and our updated outlook on transaction volumes across the business,  \nwe are raising the full year fiscal 2021 adjusted earnings per share outlook to a range of $14.70 to $15.50 per \ndiluted share from our previous outlook of $13.95 to $14.75 per diluted share.  \n \n In closing, we're pleased with the results of our fiscal first quarter, and we're proud of how we responded to a \ndynamic environment, supporting our customers despite the uncertainties that were brought on by this pandemic. \n Our disciplined execution delivered solid results.  Combined with our strong balance sheet and f inancial position, \nwe're well positioned to deliver growth in the second half of the year as compared to the prior year.  The external ", "original_text": "Our disciplined execution delivered solid results. ", "page_label": "11", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c277484d21992976016ba46b3a2aabe16a5a51f75b23296f8850ca9e2e905ac0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c7186334-534c-45db-b38b-3b8eaf940c93", "node_type": "1", "metadata": {"window": "In closing, we're pleased with the results of our fiscal first quarter, and we're proud of how we responded to a \ndynamic environment, supporting our customers despite the uncertainties that were brought on by this pandemic. \n Our disciplined execution delivered solid results.  Combined with our strong balance sheet and f inancial position, \nwe're well positioned to deliver growth in the second half of the year as compared to the prior year.  The external ", "original_text": "The external "}, "hash": "4d04c2423fe7b03a80ca43f8913baec19c709e1a31e102c05f7363500cecef67", "class_name": "RelatedNodeInfo"}}, "text": "Combined with our strong balance sheet and f inancial position, \nwe're well positioned to deliver growth in the second half of the year as compared to the prior year. ", "start_char_idx": 4150, "end_char_idx": 4317, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c7186334-534c-45db-b38b-3b8eaf940c93": {"__data__": {"id_": "c7186334-534c-45db-b38b-3b8eaf940c93", "embedding": null, "metadata": {"window": "In closing, we're pleased with the results of our fiscal first quarter, and we're proud of how we responded to a \ndynamic environment, supporting our customers despite the uncertainties that were brought on by this pandemic. \n Our disciplined execution delivered solid results.  Combined with our strong balance sheet and f inancial position, \nwe're well positioned to deliver growth in the second half of the year as compared to the prior year.  The external ", "original_text": "The external ", "page_label": "11", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7d2b4c06-f5b1-4a4f-9127-7f73d68a375e", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "afc8b717477192d484d10841cdee6bad2bd0877d53ae1ac68fbfae214a578968", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e816f77e-ec74-4e7b-b687-336f0a596954", "node_type": "1", "metadata": {"window": "Based on our solid first quarter \nresults, our view of the macro environment and our updated outlook on transaction volumes across the business,  \nwe are raising the full year fiscal 2021 adjusted earnings per share outlook to a range of $14.70 to $15.50 per \ndiluted share from our previous outlook of $13.95 to $14.75 per diluted share.  \n \n In closing, we're pleased with the results of our fiscal first quarter, and we're proud of how we responded to a \ndynamic environment, supporting our customers despite the uncertainties that were brought on by this pandemic. \n Our disciplined execution delivered solid results.  Combined with our strong balance sheet and f inancial position, \nwe're well positioned to deliver growth in the second half of the year as compared to the prior year.  The external ", "original_text": "Combined with our strong balance sheet and f inancial position, \nwe're well positioned to deliver growth in the second half of the year as compared to the prior year. ", "page_label": "11", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b6994df6a37386d391760379b53afbf1ea7895a55d2a15767667decf35ef4c28", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1e92c18f-9163-4e9a-a56f-14455ced5b05", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nenvironment continues to present many unknowns, but our businesses have continued to be resilient, with strong \nexecution a nd stable fundamentals.  \n \n With that, I'll turn the call over to the operator for your questions.  In the interest of time, I'd ask that you limit \nyourself to just one question to allow others an opportunity to participate. ", "original_text": "McKesson Corp.  "}, "hash": "10979c02b741545097eb6f6b20af6e770dd6585ba6e681cc026fabd86bf70b77", "class_name": "RelatedNodeInfo"}}, "text": "The external ", "start_char_idx": 4317, "end_char_idx": 4330, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1e92c18f-9163-4e9a-a56f-14455ced5b05": {"__data__": {"id_": "1e92c18f-9163-4e9a-a56f-14455ced5b05", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nenvironment continues to present many unknowns, but our businesses have continued to be resilient, with strong \nexecution a nd stable fundamentals.  \n \n With that, I'll turn the call over to the operator for your questions.  In the interest of time, I'd ask that you limit \nyourself to just one question to allow others an opportunity to participate. ", "original_text": "McKesson Corp.  ", "page_label": "12", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cde69cac-dee0-4cfb-8e4c-635bb17fb3bd", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8d71fcbe793211d50e1e1dc81e16817fb098a34fa65b9a4815726ae7786ef1ba", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c7186334-534c-45db-b38b-3b8eaf940c93", "node_type": "1", "metadata": {"window": "In closing, we're pleased with the results of our fiscal first quarter, and we're proud of how we responded to a \ndynamic environment, supporting our customers despite the uncertainties that were brought on by this pandemic. \n Our disciplined execution delivered solid results.  Combined with our strong balance sheet and f inancial position, \nwe're well positioned to deliver growth in the second half of the year as compared to the prior year.  The external ", "original_text": "The external ", "page_label": "11", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "732c23a808ee32992aa443f65647979be5f3f1f16f771ab76affd19fcade0354", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5256dd93-607e-48f5-a9b4-dd0bf502c400", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nenvironment continues to present many unknowns, but our businesses have continued to be resilient, with strong \nexecution a nd stable fundamentals.  \n \n With that, I'll turn the call over to the operator for your questions.  In the interest of time, I'd ask that you limit \nyourself to just one question to allow others an opportunity to participate.  Turn over to the operator.  \n ", "original_text": "(MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nenvironment continues to present many unknowns, but our businesses have continued to be resilient, with strong \nexecution a nd stable fundamentals.  \n \n"}, "hash": "78d25d8e413969ebe7fc12a5049a343ca726609d9a5b121a7d8e08b0884ab659", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5256dd93-607e-48f5-a9b4-dd0bf502c400": {"__data__": {"id_": "5256dd93-607e-48f5-a9b4-dd0bf502c400", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nenvironment continues to present many unknowns, but our businesses have continued to be resilient, with strong \nexecution a nd stable fundamentals.  \n \n With that, I'll turn the call over to the operator for your questions.  In the interest of time, I'd ask that you limit \nyourself to just one question to allow others an opportunity to participate.  Turn over to the operator.  \n ", "original_text": "(MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nenvironment continues to present many unknowns, but our businesses have continued to be resilient, with strong \nexecution a nd stable fundamentals.  \n \n", "page_label": "12", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cde69cac-dee0-4cfb-8e4c-635bb17fb3bd", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8d71fcbe793211d50e1e1dc81e16817fb098a34fa65b9a4815726ae7786ef1ba", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1e92c18f-9163-4e9a-a56f-14455ced5b05", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nenvironment continues to present many unknowns, but our businesses have continued to be resilient, with strong \nexecution a nd stable fundamentals.  \n \n With that, I'll turn the call over to the operator for your questions.  In the interest of time, I'd ask that you limit \nyourself to just one question to allow others an opportunity to participate. ", "original_text": "McKesson Corp.  ", "page_label": "12", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0eb4ea4cf1d9aee42cd5ee05f6c6179cd107ae16c9f47f668a6f27ed3027e971", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a2cee608-fed3-49a1-a0a6-843027f36bcf", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nenvironment continues to present many unknowns, but our businesses have continued to be resilient, with strong \nexecution a nd stable fundamentals.  \n \n With that, I'll turn the call over to the operator for your questions.  In the interest of time, I'd ask that you limit \nyourself to just one question to allow others an opportunity to participate.  Turn over to the operator.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nQUEST ION AND ANSWER SECTION  \n  \nOperator : [Operator Instructions] And our first question will come from Eric Coldwell with Robert W. Baird.  \n ", "original_text": "With that, I'll turn the call over to the operator for your questions. "}, "hash": "7801dff1cf0e896a2668798180c2504bdcd23e64eb9ccebc6213d3e6b1dbf812", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nenvironment continues to present many unknowns, but our businesses have continued to be resilient, with strong \nexecution a nd stable fundamentals.  \n \n", "start_char_idx": 16, "end_char_idx": 333, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a2cee608-fed3-49a1-a0a6-843027f36bcf": {"__data__": {"id_": "a2cee608-fed3-49a1-a0a6-843027f36bcf", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nenvironment continues to present many unknowns, but our businesses have continued to be resilient, with strong \nexecution a nd stable fundamentals.  \n \n With that, I'll turn the call over to the operator for your questions.  In the interest of time, I'd ask that you limit \nyourself to just one question to allow others an opportunity to participate.  Turn over to the operator.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nQUEST ION AND ANSWER SECTION  \n  \nOperator : [Operator Instructions] And our first question will come from Eric Coldwell with Robert W. Baird.  \n ", "original_text": "With that, I'll turn the call over to the operator for your questions. ", "page_label": "12", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cde69cac-dee0-4cfb-8e4c-635bb17fb3bd", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8d71fcbe793211d50e1e1dc81e16817fb098a34fa65b9a4815726ae7786ef1ba", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5256dd93-607e-48f5-a9b4-dd0bf502c400", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nenvironment continues to present many unknowns, but our businesses have continued to be resilient, with strong \nexecution a nd stable fundamentals.  \n \n With that, I'll turn the call over to the operator for your questions.  In the interest of time, I'd ask that you limit \nyourself to just one question to allow others an opportunity to participate.  Turn over to the operator.  \n ", "original_text": "(MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nenvironment continues to present many unknowns, but our businesses have continued to be resilient, with strong \nexecution a nd stable fundamentals.  \n \n", "page_label": "12", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "82afb042a7dedd1d1d8dca3a146b7ca20780ddc992fdd34f9d557c3f3254db89", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ed4de0b1-82f0-4528-b7e4-1ddff533ab04", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nenvironment continues to present many unknowns, but our businesses have continued to be resilient, with strong \nexecution a nd stable fundamentals.  \n \n With that, I'll turn the call over to the operator for your questions.  In the interest of time, I'd ask that you limit \nyourself to just one question to allow others an opportunity to participate.  Turn over to the operator.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nQUEST ION AND ANSWER SECTION  \n  \nOperator : [Operator Instructions] And our first question will come from Eric Coldwell with Robert W. Baird.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  ", "original_text": "In the interest of time, I'd ask that you limit \nyourself to just one question to allow others an opportunity to participate. "}, "hash": "479f4ed8ede1309962f03dc0d82fca17499f8eb2281710b222b61ac83af836b3", "class_name": "RelatedNodeInfo"}}, "text": "With that, I'll turn the call over to the operator for your questions. ", "start_char_idx": 333, "end_char_idx": 404, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ed4de0b1-82f0-4528-b7e4-1ddff533ab04": {"__data__": {"id_": "ed4de0b1-82f0-4528-b7e4-1ddff533ab04", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nenvironment continues to present many unknowns, but our businesses have continued to be resilient, with strong \nexecution a nd stable fundamentals.  \n \n With that, I'll turn the call over to the operator for your questions.  In the interest of time, I'd ask that you limit \nyourself to just one question to allow others an opportunity to participate.  Turn over to the operator.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nQUEST ION AND ANSWER SECTION  \n  \nOperator : [Operator Instructions] And our first question will come from Eric Coldwell with Robert W. Baird.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  ", "original_text": "In the interest of time, I'd ask that you limit \nyourself to just one question to allow others an opportunity to participate. ", "page_label": "12", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cde69cac-dee0-4cfb-8e4c-635bb17fb3bd", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8d71fcbe793211d50e1e1dc81e16817fb098a34fa65b9a4815726ae7786ef1ba", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a2cee608-fed3-49a1-a0a6-843027f36bcf", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nenvironment continues to present many unknowns, but our businesses have continued to be resilient, with strong \nexecution a nd stable fundamentals.  \n \n With that, I'll turn the call over to the operator for your questions.  In the interest of time, I'd ask that you limit \nyourself to just one question to allow others an opportunity to participate.  Turn over to the operator.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nQUEST ION AND ANSWER SECTION  \n  \nOperator : [Operator Instructions] And our first question will come from Eric Coldwell with Robert W. Baird.  \n ", "original_text": "With that, I'll turn the call over to the operator for your questions. ", "page_label": "12", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4e9d7cf20cd55f13f9e551821b1919350a328afc9bec380e5d6d43d2bebb8e58", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "50d98052-7ad5-4dd7-82ce-9f860f1bf048", "node_type": "1", "metadata": {"window": "(MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nenvironment continues to present many unknowns, but our businesses have continued to be resilient, with strong \nexecution a nd stable fundamentals.  \n \n With that, I'll turn the call over to the operator for your questions.  In the interest of time, I'd ask that you limit \nyourself to just one question to allow others an opportunity to participate.  Turn over to the operator.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nQUEST ION AND ANSWER SECTION  \n  \nOperator : [Operator Instructions] And our first question will come from Eric Coldwell with Robert W. Baird.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.   Q \nThanks very much. ", "original_text": "Turn over to the operator.  \n "}, "hash": "5146967a74c7aa14041fe4504877e306776bd33f1e29e7828783f6a44fff7dcb", "class_name": "RelatedNodeInfo"}}, "text": "In the interest of time, I'd ask that you limit \nyourself to just one question to allow others an opportunity to participate. ", "start_char_idx": 404, "end_char_idx": 530, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "50d98052-7ad5-4dd7-82ce-9f860f1bf048": {"__data__": {"id_": "50d98052-7ad5-4dd7-82ce-9f860f1bf048", "embedding": null, "metadata": {"window": "(MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nenvironment continues to present many unknowns, but our businesses have continued to be resilient, with strong \nexecution a nd stable fundamentals.  \n \n With that, I'll turn the call over to the operator for your questions.  In the interest of time, I'd ask that you limit \nyourself to just one question to allow others an opportunity to participate.  Turn over to the operator.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nQUEST ION AND ANSWER SECTION  \n  \nOperator : [Operator Instructions] And our first question will come from Eric Coldwell with Robert W. Baird.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.   Q \nThanks very much. ", "original_text": "Turn over to the operator.  \n ", "page_label": "12", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cde69cac-dee0-4cfb-8e4c-635bb17fb3bd", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8d71fcbe793211d50e1e1dc81e16817fb098a34fa65b9a4815726ae7786ef1ba", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ed4de0b1-82f0-4528-b7e4-1ddff533ab04", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nenvironment continues to present many unknowns, but our businesses have continued to be resilient, with strong \nexecution a nd stable fundamentals.  \n \n With that, I'll turn the call over to the operator for your questions.  In the interest of time, I'd ask that you limit \nyourself to just one question to allow others an opportunity to participate.  Turn over to the operator.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nQUEST ION AND ANSWER SECTION  \n  \nOperator : [Operator Instructions] And our first question will come from Eric Coldwell with Robert W. Baird.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  ", "original_text": "In the interest of time, I'd ask that you limit \nyourself to just one question to allow others an opportunity to participate. ", "page_label": "12", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9330058a89a4f54ceab2add42c0e82ae2357f287832a4c61b19b0cbf14e37e96", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c0c89981-143d-4ec6-a02c-6fd5f181414e", "node_type": "1", "metadata": {"window": "With that, I'll turn the call over to the operator for your questions.  In the interest of time, I'd ask that you limit \nyourself to just one question to allow others an opportunity to participate.  Turn over to the operator.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nQUEST ION AND ANSWER SECTION  \n  \nOperator : [Operator Instructions] And our first question will come from Eric Coldwell with Robert W. Baird.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.   Q \nThanks very much.  Congrats on navigating the tough environment. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nQUEST ION AND ANSWER SECTION  \n  \nOperator : [Operator Instructions] And our first question will come from Eric Coldwell with Robert W. Baird.  \n "}, "hash": "476b1b26d1ce468eb47cefcea58a94a978129df0f329e2f17f58dc4c257ee8a9", "class_name": "RelatedNodeInfo"}}, "text": "Turn over to the operator.  \n ", "start_char_idx": 530, "end_char_idx": 560, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c0c89981-143d-4ec6-a02c-6fd5f181414e": {"__data__": {"id_": "c0c89981-143d-4ec6-a02c-6fd5f181414e", "embedding": null, "metadata": {"window": "With that, I'll turn the call over to the operator for your questions.  In the interest of time, I'd ask that you limit \nyourself to just one question to allow others an opportunity to participate.  Turn over to the operator.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nQUEST ION AND ANSWER SECTION  \n  \nOperator : [Operator Instructions] And our first question will come from Eric Coldwell with Robert W. Baird.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.   Q \nThanks very much.  Congrats on navigating the tough environment. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nQUEST ION AND ANSWER SECTION  \n  \nOperator : [Operator Instructions] And our first question will come from Eric Coldwell with Robert W. Baird.  \n ", "page_label": "12", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cde69cac-dee0-4cfb-8e4c-635bb17fb3bd", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8d71fcbe793211d50e1e1dc81e16817fb098a34fa65b9a4815726ae7786ef1ba", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "50d98052-7ad5-4dd7-82ce-9f860f1bf048", "node_type": "1", "metadata": {"window": "(MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nenvironment continues to present many unknowns, but our businesses have continued to be resilient, with strong \nexecution a nd stable fundamentals.  \n \n With that, I'll turn the call over to the operator for your questions.  In the interest of time, I'd ask that you limit \nyourself to just one question to allow others an opportunity to participate.  Turn over to the operator.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nQUEST ION AND ANSWER SECTION  \n  \nOperator : [Operator Instructions] And our first question will come from Eric Coldwell with Robert W. Baird.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.   Q \nThanks very much. ", "original_text": "Turn over to the operator.  \n ", "page_label": "12", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "eb61ed4c37147da5779eb2225da53c3d17d3c46e7828ca7d3a1c22b5ccf318a8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "42ec2acf-f4fa-414b-8721-2d88a3c6fb68", "node_type": "1", "metadata": {"window": "In the interest of time, I'd ask that you limit \nyourself to just one question to allow others an opportunity to participate.  Turn over to the operator.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nQUEST ION AND ANSWER SECTION  \n  \nOperator : [Operator Instructions] And our first question will come from Eric Coldwell with Robert W. Baird.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.   Q \nThanks very much.  Congrats on navigating the tough environment.  The question is pretty simple. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  "}, "hash": "b72a7efdc95e837a5a4ef822b0602c0ddc59056b7e90044a48c0a671477de6db", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nQUEST ION AND ANSWER SECTION  \n  \nOperator : [Operator Instructions] And our first question will come from Eric Coldwell with Robert W. Baird.  \n ", "start_char_idx": 560, "end_char_idx": 980, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "42ec2acf-f4fa-414b-8721-2d88a3c6fb68": {"__data__": {"id_": "42ec2acf-f4fa-414b-8721-2d88a3c6fb68", "embedding": null, "metadata": {"window": "In the interest of time, I'd ask that you limit \nyourself to just one question to allow others an opportunity to participate.  Turn over to the operator.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nQUEST ION AND ANSWER SECTION  \n  \nOperator : [Operator Instructions] And our first question will come from Eric Coldwell with Robert W. Baird.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.   Q \nThanks very much.  Congrats on navigating the tough environment.  The question is pretty simple. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  ", "page_label": "12", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cde69cac-dee0-4cfb-8e4c-635bb17fb3bd", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8d71fcbe793211d50e1e1dc81e16817fb098a34fa65b9a4815726ae7786ef1ba", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c0c89981-143d-4ec6-a02c-6fd5f181414e", "node_type": "1", "metadata": {"window": "With that, I'll turn the call over to the operator for your questions.  In the interest of time, I'd ask that you limit \nyourself to just one question to allow others an opportunity to participate.  Turn over to the operator.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nQUEST ION AND ANSWER SECTION  \n  \nOperator : [Operator Instructions] And our first question will come from Eric Coldwell with Robert W. Baird.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.   Q \nThanks very much.  Congrats on navigating the tough environment. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nQUEST ION AND ANSWER SECTION  \n  \nOperator : [Operator Instructions] And our first question will come from Eric Coldwell with Robert W. Baird.  \n ", "page_label": "12", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "97c686043efd2e43cc910d45bd68c9179299d7bad96d8354b88ce947017317e2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5a02a702-ed64-43c7-a06b-d75ed8ddba74", "node_type": "1", "metadata": {"window": "Turn over to the operator.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nQUEST ION AND ANSWER SECTION  \n  \nOperator : [Operator Instructions] And our first question will come from Eric Coldwell with Robert W. Baird.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.   Q \nThanks very much.  Congrats on navigating the tough environment.  The question is pretty simple.  It's on PPE. ", "original_text": "Q \nThanks very much. "}, "hash": "b8a2c973b7973547e7b400a8c9d1f674d521d958a674d36c0b5af17bee9dd29b", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  ", "start_char_idx": 980, "end_char_idx": 1312, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5a02a702-ed64-43c7-a06b-d75ed8ddba74": {"__data__": {"id_": "5a02a702-ed64-43c7-a06b-d75ed8ddba74", "embedding": null, "metadata": {"window": "Turn over to the operator.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nQUEST ION AND ANSWER SECTION  \n  \nOperator : [Operator Instructions] And our first question will come from Eric Coldwell with Robert W. Baird.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.   Q \nThanks very much.  Congrats on navigating the tough environment.  The question is pretty simple.  It's on PPE. ", "original_text": "Q \nThanks very much. ", "page_label": "12", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cde69cac-dee0-4cfb-8e4c-635bb17fb3bd", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8d71fcbe793211d50e1e1dc81e16817fb098a34fa65b9a4815726ae7786ef1ba", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "42ec2acf-f4fa-414b-8721-2d88a3c6fb68", "node_type": "1", "metadata": {"window": "In the interest of time, I'd ask that you limit \nyourself to just one question to allow others an opportunity to participate.  Turn over to the operator.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nQUEST ION AND ANSWER SECTION  \n  \nOperator : [Operator Instructions] And our first question will come from Eric Coldwell with Robert W. Baird.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.   Q \nThanks very much.  Congrats on navigating the tough environment.  The question is pretty simple. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  ", "page_label": "12", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9b396e7104f3fb2091f6456c4d52b3041447d90cf17a0d06f668413a388bc73b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e115c33e-bc96-4088-b0bb-cdabff889802", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nQUEST ION AND ANSWER SECTION  \n  \nOperator : [Operator Instructions] And our first question will come from Eric Coldwell with Robert W. Baird.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.   Q \nThanks very much.  Congrats on navigating the tough environment.  The question is pretty simple.  It's on PPE.  I'm \ncurious if you can give us a sense on how much PPE demand helped the growth or offset the challenges in \nMedical -Surgical. ", "original_text": "Congrats on navigating the tough environment. "}, "hash": "d3caf9ed7e0d0a91280b96823efedb7b27c030bdf8c9a8a2fe24854d241c8d30", "class_name": "RelatedNodeInfo"}}, "text": "Q \nThanks very much. ", "start_char_idx": 1312, "end_char_idx": 1333, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e115c33e-bc96-4088-b0bb-cdabff889802": {"__data__": {"id_": "e115c33e-bc96-4088-b0bb-cdabff889802", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nQUEST ION AND ANSWER SECTION  \n  \nOperator : [Operator Instructions] And our first question will come from Eric Coldwell with Robert W. Baird.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.   Q \nThanks very much.  Congrats on navigating the tough environment.  The question is pretty simple.  It's on PPE.  I'm \ncurious if you can give us a sense on how much PPE demand helped the growth or offset the challenges in \nMedical -Surgical. ", "original_text": "Congrats on navigating the tough environment. ", "page_label": "12", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cde69cac-dee0-4cfb-8e4c-635bb17fb3bd", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8d71fcbe793211d50e1e1dc81e16817fb098a34fa65b9a4815726ae7786ef1ba", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5a02a702-ed64-43c7-a06b-d75ed8ddba74", "node_type": "1", "metadata": {"window": "Turn over to the operator.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nQUEST ION AND ANSWER SECTION  \n  \nOperator : [Operator Instructions] And our first question will come from Eric Coldwell with Robert W. Baird.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.   Q \nThanks very much.  Congrats on navigating the tough environment.  The question is pretty simple.  It's on PPE. ", "original_text": "Q \nThanks very much. ", "page_label": "12", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bc72dbe68a6be0c68bf3ed035fdbcf5cbf971a54895d0b47ee92f42a2f37a9a5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e3270874-6c01-430f-a502-12deaf4d0993", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.   Q \nThanks very much.  Congrats on navigating the tough environment.  The question is pretty simple.  It's on PPE.  I'm \ncurious if you can give us a sense on how much PPE demand helped the growth or offset the challenges in \nMedical -Surgical.  And then longer term, do you see opportunities in PPE that expand beyond your core customer \nbase, other industries that might be in need of these products and whether you have an interest in addressing that \nas well. ", "original_text": "The question is pretty simple. "}, "hash": "7dd25727eb7f96100f2b913ca4243458a99ba6b90518607974d7e323a7650045", "class_name": "RelatedNodeInfo"}}, "text": "Congrats on navigating the tough environment. ", "start_char_idx": 1333, "end_char_idx": 1379, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e3270874-6c01-430f-a502-12deaf4d0993": {"__data__": {"id_": "e3270874-6c01-430f-a502-12deaf4d0993", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.   Q \nThanks very much.  Congrats on navigating the tough environment.  The question is pretty simple.  It's on PPE.  I'm \ncurious if you can give us a sense on how much PPE demand helped the growth or offset the challenges in \nMedical -Surgical.  And then longer term, do you see opportunities in PPE that expand beyond your core customer \nbase, other industries that might be in need of these products and whether you have an interest in addressing that \nas well. ", "original_text": "The question is pretty simple. ", "page_label": "12", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cde69cac-dee0-4cfb-8e4c-635bb17fb3bd", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8d71fcbe793211d50e1e1dc81e16817fb098a34fa65b9a4815726ae7786ef1ba", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e115c33e-bc96-4088-b0bb-cdabff889802", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nQUEST ION AND ANSWER SECTION  \n  \nOperator : [Operator Instructions] And our first question will come from Eric Coldwell with Robert W. Baird.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.   Q \nThanks very much.  Congrats on navigating the tough environment.  The question is pretty simple.  It's on PPE.  I'm \ncurious if you can give us a sense on how much PPE demand helped the growth or offset the challenges in \nMedical -Surgical. ", "original_text": "Congrats on navigating the tough environment. ", "page_label": "12", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "22433ae87c6b8da62e410147a33494c476c253ff18563b07becf837325395383", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0b69f6b6-1230-4bcd-bde7-d4e3bc2b7526", "node_type": "1", "metadata": {"window": "Q \nThanks very much.  Congrats on navigating the tough environment.  The question is pretty simple.  It's on PPE.  I'm \ncurious if you can give us a sense on how much PPE demand helped the growth or offset the challenges in \nMedical -Surgical.  And then longer term, do you see opportunities in PPE that expand beyond your core customer \nbase, other industries that might be in need of these products and whether you have an interest in addressing that \nas well.  Thanks.  \n ", "original_text": "It's on PPE. "}, "hash": "cbdd1be8c5d57fc6337e4e1069ff093c02264e6770f83dfb4843e26f8e652db9", "class_name": "RelatedNodeInfo"}}, "text": "The question is pretty simple. ", "start_char_idx": 1379, "end_char_idx": 1410, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0b69f6b6-1230-4bcd-bde7-d4e3bc2b7526": {"__data__": {"id_": "0b69f6b6-1230-4bcd-bde7-d4e3bc2b7526", "embedding": null, "metadata": {"window": "Q \nThanks very much.  Congrats on navigating the tough environment.  The question is pretty simple.  It's on PPE.  I'm \ncurious if you can give us a sense on how much PPE demand helped the growth or offset the challenges in \nMedical -Surgical.  And then longer term, do you see opportunities in PPE that expand beyond your core customer \nbase, other industries that might be in need of these products and whether you have an interest in addressing that \nas well.  Thanks.  \n ", "original_text": "It's on PPE. ", "page_label": "12", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cde69cac-dee0-4cfb-8e4c-635bb17fb3bd", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8d71fcbe793211d50e1e1dc81e16817fb098a34fa65b9a4815726ae7786ef1ba", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e3270874-6c01-430f-a502-12deaf4d0993", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.   Q \nThanks very much.  Congrats on navigating the tough environment.  The question is pretty simple.  It's on PPE.  I'm \ncurious if you can give us a sense on how much PPE demand helped the growth or offset the challenges in \nMedical -Surgical.  And then longer term, do you see opportunities in PPE that expand beyond your core customer \nbase, other industries that might be in need of these products and whether you have an interest in addressing that \nas well. ", "original_text": "The question is pretty simple. ", "page_label": "12", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6187e7367387f158146917a4c3e6a5d4f6443a8f74318f7d86f727aeafbf732c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "02ac8005-1a5e-4a9c-b18a-119c7c4068dd", "node_type": "1", "metadata": {"window": "Congrats on navigating the tough environment.  The question is pretty simple.  It's on PPE.  I'm \ncurious if you can give us a sense on how much PPE demand helped the growth or offset the challenges in \nMedical -Surgical.  And then longer term, do you see opportunities in PPE that expand beyond your core customer \nbase, other industries that might be in need of these products and whether you have an interest in addressing that \nas well.  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "I'm \ncurious if you can give us a sense on how much PPE demand helped the growth or offset the challenges in \nMedical -Surgical. "}, "hash": "3719f30d1d9217486e3a610f5bacdbebaff739b35d96e02b95429a19ef341d1c", "class_name": "RelatedNodeInfo"}}, "text": "It's on PPE. ", "start_char_idx": 1410, "end_char_idx": 1423, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "02ac8005-1a5e-4a9c-b18a-119c7c4068dd": {"__data__": {"id_": "02ac8005-1a5e-4a9c-b18a-119c7c4068dd", "embedding": null, "metadata": {"window": "Congrats on navigating the tough environment.  The question is pretty simple.  It's on PPE.  I'm \ncurious if you can give us a sense on how much PPE demand helped the growth or offset the challenges in \nMedical -Surgical.  And then longer term, do you see opportunities in PPE that expand beyond your core customer \nbase, other industries that might be in need of these products and whether you have an interest in addressing that \nas well.  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "I'm \ncurious if you can give us a sense on how much PPE demand helped the growth or offset the challenges in \nMedical -Surgical. ", "page_label": "12", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cde69cac-dee0-4cfb-8e4c-635bb17fb3bd", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8d71fcbe793211d50e1e1dc81e16817fb098a34fa65b9a4815726ae7786ef1ba", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0b69f6b6-1230-4bcd-bde7-d4e3bc2b7526", "node_type": "1", "metadata": {"window": "Q \nThanks very much.  Congrats on navigating the tough environment.  The question is pretty simple.  It's on PPE.  I'm \ncurious if you can give us a sense on how much PPE demand helped the growth or offset the challenges in \nMedical -Surgical.  And then longer term, do you see opportunities in PPE that expand beyond your core customer \nbase, other industries that might be in need of these products and whether you have an interest in addressing that \nas well.  Thanks.  \n ", "original_text": "It's on PPE. ", "page_label": "12", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2be26467c92ee35f9206961762d9e5ed020c198031af31d94302e63a18836b5f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "08bdb6ed-41fe-4a02-8c14-21b5d8d9d85b", "node_type": "1", "metadata": {"window": "The question is pretty simple.  It's on PPE.  I'm \ncurious if you can give us a sense on how much PPE demand helped the growth or offset the challenges in \nMedical -Surgical.  And then longer term, do you see opportunities in PPE that expand beyond your core customer \nbase, other industries that might be in need of these products and whether you have an interest in addressing that \nas well.  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThank you, Eric. ", "original_text": "And then longer term, do you see opportunities in PPE that expand beyond your core customer \nbase, other industries that might be in need of these products and whether you have an interest in addressing that \nas well. "}, "hash": "0d15a365a90015fc28e3dbe4885329e2d4a207f8fc404335e08a94ee080e8c15", "class_name": "RelatedNodeInfo"}}, "text": "I'm \ncurious if you can give us a sense on how much PPE demand helped the growth or offset the challenges in \nMedical -Surgical. ", "start_char_idx": 1423, "end_char_idx": 1552, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "08bdb6ed-41fe-4a02-8c14-21b5d8d9d85b": {"__data__": {"id_": "08bdb6ed-41fe-4a02-8c14-21b5d8d9d85b", "embedding": null, "metadata": {"window": "The question is pretty simple.  It's on PPE.  I'm \ncurious if you can give us a sense on how much PPE demand helped the growth or offset the challenges in \nMedical -Surgical.  And then longer term, do you see opportunities in PPE that expand beyond your core customer \nbase, other industries that might be in need of these products and whether you have an interest in addressing that \nas well.  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThank you, Eric. ", "original_text": "And then longer term, do you see opportunities in PPE that expand beyond your core customer \nbase, other industries that might be in need of these products and whether you have an interest in addressing that \nas well. ", "page_label": "12", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cde69cac-dee0-4cfb-8e4c-635bb17fb3bd", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8d71fcbe793211d50e1e1dc81e16817fb098a34fa65b9a4815726ae7786ef1ba", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "02ac8005-1a5e-4a9c-b18a-119c7c4068dd", "node_type": "1", "metadata": {"window": "Congrats on navigating the tough environment.  The question is pretty simple.  It's on PPE.  I'm \ncurious if you can give us a sense on how much PPE demand helped the growth or offset the challenges in \nMedical -Surgical.  And then longer term, do you see opportunities in PPE that expand beyond your core customer \nbase, other industries that might be in need of these products and whether you have an interest in addressing that \nas well.  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "I'm \ncurious if you can give us a sense on how much PPE demand helped the growth or offset the challenges in \nMedical -Surgical. ", "page_label": "12", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "26d760bbf03160f2c402ba4abd0b7bd2db04dbde1f3cfc439e03cc38fb6a7c7a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a1b90829-f923-40b5-9b26-7969d5947fe3", "node_type": "1", "metadata": {"window": "It's on PPE.  I'm \ncurious if you can give us a sense on how much PPE demand helped the growth or offset the challenges in \nMedical -Surgical.  And then longer term, do you see opportunities in PPE that expand beyond your core customer \nbase, other industries that might be in need of these products and whether you have an interest in addressing that \nas well.  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThank you, Eric.  I mean, the \u2013 it probably goes without saying the demand for PPE is up significantly, whether \nyou're talking about core health care markets or schools or workplaces, we certainly see that increased demand \nfor PPE. ", "original_text": "Thanks.  \n "}, "hash": "6c8a6ed8a543884cedd0976b94570eedbb5ba610414da6c8ba29adc1dfd3672d", "class_name": "RelatedNodeInfo"}}, "text": "And then longer term, do you see opportunities in PPE that expand beyond your core customer \nbase, other industries that might be in need of these products and whether you have an interest in addressing that \nas well. ", "start_char_idx": 1552, "end_char_idx": 1770, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a1b90829-f923-40b5-9b26-7969d5947fe3": {"__data__": {"id_": "a1b90829-f923-40b5-9b26-7969d5947fe3", "embedding": null, "metadata": {"window": "It's on PPE.  I'm \ncurious if you can give us a sense on how much PPE demand helped the growth or offset the challenges in \nMedical -Surgical.  And then longer term, do you see opportunities in PPE that expand beyond your core customer \nbase, other industries that might be in need of these products and whether you have an interest in addressing that \nas well.  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThank you, Eric.  I mean, the \u2013 it probably goes without saying the demand for PPE is up significantly, whether \nyou're talking about core health care markets or schools or workplaces, we certainly see that increased demand \nfor PPE. ", "original_text": "Thanks.  \n ", "page_label": "12", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cde69cac-dee0-4cfb-8e4c-635bb17fb3bd", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8d71fcbe793211d50e1e1dc81e16817fb098a34fa65b9a4815726ae7786ef1ba", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "08bdb6ed-41fe-4a02-8c14-21b5d8d9d85b", "node_type": "1", "metadata": {"window": "The question is pretty simple.  It's on PPE.  I'm \ncurious if you can give us a sense on how much PPE demand helped the growth or offset the challenges in \nMedical -Surgical.  And then longer term, do you see opportunities in PPE that expand beyond your core customer \nbase, other industries that might be in need of these products and whether you have an interest in addressing that \nas well.  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThank you, Eric. ", "original_text": "And then longer term, do you see opportunities in PPE that expand beyond your core customer \nbase, other industries that might be in need of these products and whether you have an interest in addressing that \nas well. ", "page_label": "12", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b1dd969500dcb627be36d2c587b94b8f8e1691b1b7c4e67ac1e7f63dd4b8f056", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d724a26b-6a0b-4a4a-8d80-d45c44428a1d", "node_type": "1", "metadata": {"window": "I'm \ncurious if you can give us a sense on how much PPE demand helped the growth or offset the challenges in \nMedical -Surgical.  And then longer term, do you see opportunities in PPE that expand beyond your core customer \nbase, other industries that might be in need of these products and whether you have an interest in addressing that \nas well.  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThank you, Eric.  I mean, the \u2013 it probably goes without saying the demand for PPE is up significantly, whether \nyou're talking about core health care markets or schools or workplaces, we certainly see that increased demand \nfor PPE.  And that reflects \u2013 that does reflect in the medical group' s results for the quarter.  \n \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  "}, "hash": "ccc2bd3ffbcf0b93dfebe50034be7acae14844f32eec110d9c81041ff1112e0c", "class_name": "RelatedNodeInfo"}}, "text": "Thanks.  \n ", "start_char_idx": 1770, "end_char_idx": 1781, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d724a26b-6a0b-4a4a-8d80-d45c44428a1d": {"__data__": {"id_": "d724a26b-6a0b-4a4a-8d80-d45c44428a1d", "embedding": null, "metadata": {"window": "I'm \ncurious if you can give us a sense on how much PPE demand helped the growth or offset the challenges in \nMedical -Surgical.  And then longer term, do you see opportunities in PPE that expand beyond your core customer \nbase, other industries that might be in need of these products and whether you have an interest in addressing that \nas well.  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThank you, Eric.  I mean, the \u2013 it probably goes without saying the demand for PPE is up significantly, whether \nyou're talking about core health care markets or schools or workplaces, we certainly see that increased demand \nfor PPE.  And that reflects \u2013 that does reflect in the medical group' s results for the quarter.  \n \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "12", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cde69cac-dee0-4cfb-8e4c-635bb17fb3bd", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8d71fcbe793211d50e1e1dc81e16817fb098a34fa65b9a4815726ae7786ef1ba", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a1b90829-f923-40b5-9b26-7969d5947fe3", "node_type": "1", "metadata": {"window": "It's on PPE.  I'm \ncurious if you can give us a sense on how much PPE demand helped the growth or offset the challenges in \nMedical -Surgical.  And then longer term, do you see opportunities in PPE that expand beyond your core customer \nbase, other industries that might be in need of these products and whether you have an interest in addressing that \nas well.  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThank you, Eric.  I mean, the \u2013 it probably goes without saying the demand for PPE is up significantly, whether \nyou're talking about core health care markets or schools or workplaces, we certainly see that increased demand \nfor PPE. ", "original_text": "Thanks.  \n ", "page_label": "12", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2f1a785a9114f0c0ec328ecf6cdf8ccd6978cc50bd079e06b89e5c6d61514f85", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "98bfd195-ffbe-4be3-867d-3628b8f726a2", "node_type": "1", "metadata": {"window": "And then longer term, do you see opportunities in PPE that expand beyond your core customer \nbase, other industries that might be in need of these products and whether you have an interest in addressing that \nas well.  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThank you, Eric.  I mean, the \u2013 it probably goes without saying the demand for PPE is up significantly, whether \nyou're talking about core health care markets or schools or workplaces, we certainly see that increased demand \nfor PPE.  And that reflects \u2013 that does reflect in the medical group' s results for the quarter.  \n \n Our priority internally has been and continues to be to make sure we support the frontline caregivers and that we \nget the necessary PPE to them. ", "original_text": "A \nThank you, Eric. "}, "hash": "4400dda94c9e5da4971411abfbda2fc5711ce85dbf390bfb51d7a96b425c0335", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "start_char_idx": 1781, "end_char_idx": 2122, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "98bfd195-ffbe-4be3-867d-3628b8f726a2": {"__data__": {"id_": "98bfd195-ffbe-4be3-867d-3628b8f726a2", "embedding": null, "metadata": {"window": "And then longer term, do you see opportunities in PPE that expand beyond your core customer \nbase, other industries that might be in need of these products and whether you have an interest in addressing that \nas well.  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThank you, Eric.  I mean, the \u2013 it probably goes without saying the demand for PPE is up significantly, whether \nyou're talking about core health care markets or schools or workplaces, we certainly see that increased demand \nfor PPE.  And that reflects \u2013 that does reflect in the medical group' s results for the quarter.  \n \n Our priority internally has been and continues to be to make sure we support the frontline caregivers and that we \nget the necessary PPE to them. ", "original_text": "A \nThank you, Eric. ", "page_label": "12", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cde69cac-dee0-4cfb-8e4c-635bb17fb3bd", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8d71fcbe793211d50e1e1dc81e16817fb098a34fa65b9a4815726ae7786ef1ba", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d724a26b-6a0b-4a4a-8d80-d45c44428a1d", "node_type": "1", "metadata": {"window": "I'm \ncurious if you can give us a sense on how much PPE demand helped the growth or offset the challenges in \nMedical -Surgical.  And then longer term, do you see opportunities in PPE that expand beyond your core customer \nbase, other industries that might be in need of these products and whether you have an interest in addressing that \nas well.  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThank you, Eric.  I mean, the \u2013 it probably goes without saying the demand for PPE is up significantly, whether \nyou're talking about core health care markets or schools or workplaces, we certainly see that increased demand \nfor PPE.  And that reflects \u2013 that does reflect in the medical group' s results for the quarter.  \n \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "12", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c833b7ba60d32d5373296b2fb79abc2dc4de8323dcc926907524e7917bf7195a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ceee9fd8-69bb-4abb-a838-63931e8684d5", "node_type": "1", "metadata": {"window": "Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThank you, Eric.  I mean, the \u2013 it probably goes without saying the demand for PPE is up significantly, whether \nyou're talking about core health care markets or schools or workplaces, we certainly see that increased demand \nfor PPE.  And that reflects \u2013 that does reflect in the medical group' s results for the quarter.  \n \n Our priority internally has been and continues to be to make sure we support the frontline caregivers and that we \nget the necessary PPE to them.  And quite honestly, some of these customer segments historically didn't have a \nlot of demand for some of the products like N95 mask, it just wasn't necessary in the way they ran their \nbusinesses, that's obviously changed.  \n \n", "original_text": "I mean, the \u2013 it probably goes without saying the demand for PPE is up significantly, whether \nyou're talking about core health care markets or schools or workplaces, we certainly see that increased demand \nfor PPE. "}, "hash": "b4d548408cc3a25240e38707452b59ad8d2d8a35cd04d88a5b52c872d42e0d4d", "class_name": "RelatedNodeInfo"}}, "text": "A \nThank you, Eric. ", "start_char_idx": 2122, "end_char_idx": 2142, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ceee9fd8-69bb-4abb-a838-63931e8684d5": {"__data__": {"id_": "ceee9fd8-69bb-4abb-a838-63931e8684d5", "embedding": null, "metadata": {"window": "Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThank you, Eric.  I mean, the \u2013 it probably goes without saying the demand for PPE is up significantly, whether \nyou're talking about core health care markets or schools or workplaces, we certainly see that increased demand \nfor PPE.  And that reflects \u2013 that does reflect in the medical group' s results for the quarter.  \n \n Our priority internally has been and continues to be to make sure we support the frontline caregivers and that we \nget the necessary PPE to them.  And quite honestly, some of these customer segments historically didn't have a \nlot of demand for some of the products like N95 mask, it just wasn't necessary in the way they ran their \nbusinesses, that's obviously changed.  \n \n", "original_text": "I mean, the \u2013 it probably goes without saying the demand for PPE is up significantly, whether \nyou're talking about core health care markets or schools or workplaces, we certainly see that increased demand \nfor PPE. ", "page_label": "12", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cde69cac-dee0-4cfb-8e4c-635bb17fb3bd", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8d71fcbe793211d50e1e1dc81e16817fb098a34fa65b9a4815726ae7786ef1ba", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "98bfd195-ffbe-4be3-867d-3628b8f726a2", "node_type": "1", "metadata": {"window": "And then longer term, do you see opportunities in PPE that expand beyond your core customer \nbase, other industries that might be in need of these products and whether you have an interest in addressing that \nas well.  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThank you, Eric.  I mean, the \u2013 it probably goes without saying the demand for PPE is up significantly, whether \nyou're talking about core health care markets or schools or workplaces, we certainly see that increased demand \nfor PPE.  And that reflects \u2013 that does reflect in the medical group' s results for the quarter.  \n \n Our priority internally has been and continues to be to make sure we support the frontline caregivers and that we \nget the necessary PPE to them. ", "original_text": "A \nThank you, Eric. ", "page_label": "12", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bfc6789e03e4c3976b163ca86a167d9e3cb7d8626402429e978a064c200befcb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "352da687-8504-438f-8da8-13595bb773ba", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThank you, Eric.  I mean, the \u2013 it probably goes without saying the demand for PPE is up significantly, whether \nyou're talking about core health care markets or schools or workplaces, we certainly see that increased demand \nfor PPE.  And that reflects \u2013 that does reflect in the medical group' s results for the quarter.  \n \n Our priority internally has been and continues to be to make sure we support the frontline caregivers and that we \nget the necessary PPE to them.  And quite honestly, some of these customer segments historically didn't have a \nlot of demand for some of the products like N95 mask, it just wasn't necessary in the way they ran their \nbusinesses, that's obviously changed.  \n \n And so we're working hard to source. ", "original_text": "And that reflects \u2013 that does reflect in the medical group' s results for the quarter.  \n \n"}, "hash": "a985bf164f0c341eb4a32a29b72ecbebc47992c4af1ccf289957b5bdb04b98fd", "class_name": "RelatedNodeInfo"}}, "text": "I mean, the \u2013 it probably goes without saying the demand for PPE is up significantly, whether \nyou're talking about core health care markets or schools or workplaces, we certainly see that increased demand \nfor PPE. ", "start_char_idx": 2142, "end_char_idx": 2358, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "352da687-8504-438f-8da8-13595bb773ba": {"__data__": {"id_": "352da687-8504-438f-8da8-13595bb773ba", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThank you, Eric.  I mean, the \u2013 it probably goes without saying the demand for PPE is up significantly, whether \nyou're talking about core health care markets or schools or workplaces, we certainly see that increased demand \nfor PPE.  And that reflects \u2013 that does reflect in the medical group' s results for the quarter.  \n \n Our priority internally has been and continues to be to make sure we support the frontline caregivers and that we \nget the necessary PPE to them.  And quite honestly, some of these customer segments historically didn't have a \nlot of demand for some of the products like N95 mask, it just wasn't necessary in the way they ran their \nbusinesses, that's obviously changed.  \n \n And so we're working hard to source. ", "original_text": "And that reflects \u2013 that does reflect in the medical group' s results for the quarter.  \n \n", "page_label": "12", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cde69cac-dee0-4cfb-8e4c-635bb17fb3bd", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8d71fcbe793211d50e1e1dc81e16817fb098a34fa65b9a4815726ae7786ef1ba", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ceee9fd8-69bb-4abb-a838-63931e8684d5", "node_type": "1", "metadata": {"window": "Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThank you, Eric.  I mean, the \u2013 it probably goes without saying the demand for PPE is up significantly, whether \nyou're talking about core health care markets or schools or workplaces, we certainly see that increased demand \nfor PPE.  And that reflects \u2013 that does reflect in the medical group' s results for the quarter.  \n \n Our priority internally has been and continues to be to make sure we support the frontline caregivers and that we \nget the necessary PPE to them.  And quite honestly, some of these customer segments historically didn't have a \nlot of demand for some of the products like N95 mask, it just wasn't necessary in the way they ran their \nbusinesses, that's obviously changed.  \n \n", "original_text": "I mean, the \u2013 it probably goes without saying the demand for PPE is up significantly, whether \nyou're talking about core health care markets or schools or workplaces, we certainly see that increased demand \nfor PPE. ", "page_label": "12", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3bc8324cf5c75614e4d31f914cf5778c344fed009eec49264cc915c47243ba4d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "97177d89-771e-4473-94e4-da7bbabe4b05", "node_type": "1", "metadata": {"window": "A \nThank you, Eric.  I mean, the \u2013 it probably goes without saying the demand for PPE is up significantly, whether \nyou're talking about core health care markets or schools or workplaces, we certainly see that increased demand \nfor PPE.  And that reflects \u2013 that does reflect in the medical group' s results for the quarter.  \n \n Our priority internally has been and continues to be to make sure we support the frontline caregivers and that we \nget the necessary PPE to them.  And quite honestly, some of these customer segments historically didn't have a \nlot of demand for some of the products like N95 mask, it just wasn't necessary in the way they ran their \nbusinesses, that's obviously changed.  \n \n And so we're working hard to source.  Our sourcing teams are very active with various partners, manufacturers \naround the world really to continue to make sure we can meet the needs of those health care customers. ", "original_text": "Our priority internally has been and continues to be to make sure we support the frontline caregivers and that we \nget the necessary PPE to them. "}, "hash": "6377130aee74af7ea54613e856b0df717c48c8ad8a29a3336355ee2283be0f00", "class_name": "RelatedNodeInfo"}}, "text": "And that reflects \u2013 that does reflect in the medical group' s results for the quarter.  \n \n", "start_char_idx": 2358, "end_char_idx": 2449, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "97177d89-771e-4473-94e4-da7bbabe4b05": {"__data__": {"id_": "97177d89-771e-4473-94e4-da7bbabe4b05", "embedding": null, "metadata": {"window": "A \nThank you, Eric.  I mean, the \u2013 it probably goes without saying the demand for PPE is up significantly, whether \nyou're talking about core health care markets or schools or workplaces, we certainly see that increased demand \nfor PPE.  And that reflects \u2013 that does reflect in the medical group' s results for the quarter.  \n \n Our priority internally has been and continues to be to make sure we support the frontline caregivers and that we \nget the necessary PPE to them.  And quite honestly, some of these customer segments historically didn't have a \nlot of demand for some of the products like N95 mask, it just wasn't necessary in the way they ran their \nbusinesses, that's obviously changed.  \n \n And so we're working hard to source.  Our sourcing teams are very active with various partners, manufacturers \naround the world really to continue to make sure we can meet the needs of those health care customers. ", "original_text": "Our priority internally has been and continues to be to make sure we support the frontline caregivers and that we \nget the necessary PPE to them. ", "page_label": "12", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cde69cac-dee0-4cfb-8e4c-635bb17fb3bd", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8d71fcbe793211d50e1e1dc81e16817fb098a34fa65b9a4815726ae7786ef1ba", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "352da687-8504-438f-8da8-13595bb773ba", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThank you, Eric.  I mean, the \u2013 it probably goes without saying the demand for PPE is up significantly, whether \nyou're talking about core health care markets or schools or workplaces, we certainly see that increased demand \nfor PPE.  And that reflects \u2013 that does reflect in the medical group' s results for the quarter.  \n \n Our priority internally has been and continues to be to make sure we support the frontline caregivers and that we \nget the necessary PPE to them.  And quite honestly, some of these customer segments historically didn't have a \nlot of demand for some of the products like N95 mask, it just wasn't necessary in the way they ran their \nbusinesses, that's obviously changed.  \n \n And so we're working hard to source. ", "original_text": "And that reflects \u2013 that does reflect in the medical group' s results for the quarter.  \n \n", "page_label": "12", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "04745ad386803c5a7c824656108e25afd89cc97bbadc6f859ff0315dee5251f8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4603e04d-15de-425f-a1a0-63d74da06367", "node_type": "1", "metadata": {"window": "I mean, the \u2013 it probably goes without saying the demand for PPE is up significantly, whether \nyou're talking about core health care markets or schools or workplaces, we certainly see that increased demand \nfor PPE.  And that reflects \u2013 that does reflect in the medical group' s results for the quarter.  \n \n Our priority internally has been and continues to be to make sure we support the frontline caregivers and that we \nget the necessary PPE to them.  And quite honestly, some of these customer segments historically didn't have a \nlot of demand for some of the products like N95 mask, it just wasn't necessary in the way they ran their \nbusinesses, that's obviously changed.  \n \n And so we're working hard to source.  Our sourcing teams are very active with various partners, manufacturers \naround the world really to continue to make sure we can meet the needs of those health care customers.  And we \nwould not be looking to expand into industrial or other lines until we felt confident we could meet the core needs of \nthe health care \u2013 our health care c ustomers today.  \n ", "original_text": "And quite honestly, some of these customer segments historically didn't have a \nlot of demand for some of the products like N95 mask, it just wasn't necessary in the way they ran their \nbusinesses, that's obviously changed.  \n \n"}, "hash": "0880f4d3f4c03221636fdd5525dfc66403df75be4741b3931b86ff97e98df9e1", "class_name": "RelatedNodeInfo"}}, "text": "Our priority internally has been and continues to be to make sure we support the frontline caregivers and that we \nget the necessary PPE to them. ", "start_char_idx": 2449, "end_char_idx": 2595, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4603e04d-15de-425f-a1a0-63d74da06367": {"__data__": {"id_": "4603e04d-15de-425f-a1a0-63d74da06367", "embedding": null, "metadata": {"window": "I mean, the \u2013 it probably goes without saying the demand for PPE is up significantly, whether \nyou're talking about core health care markets or schools or workplaces, we certainly see that increased demand \nfor PPE.  And that reflects \u2013 that does reflect in the medical group' s results for the quarter.  \n \n Our priority internally has been and continues to be to make sure we support the frontline caregivers and that we \nget the necessary PPE to them.  And quite honestly, some of these customer segments historically didn't have a \nlot of demand for some of the products like N95 mask, it just wasn't necessary in the way they ran their \nbusinesses, that's obviously changed.  \n \n And so we're working hard to source.  Our sourcing teams are very active with various partners, manufacturers \naround the world really to continue to make sure we can meet the needs of those health care customers.  And we \nwould not be looking to expand into industrial or other lines until we felt confident we could meet the core needs of \nthe health care \u2013 our health care c ustomers today.  \n ", "original_text": "And quite honestly, some of these customer segments historically didn't have a \nlot of demand for some of the products like N95 mask, it just wasn't necessary in the way they ran their \nbusinesses, that's obviously changed.  \n \n", "page_label": "12", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cde69cac-dee0-4cfb-8e4c-635bb17fb3bd", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8d71fcbe793211d50e1e1dc81e16817fb098a34fa65b9a4815726ae7786ef1ba", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "97177d89-771e-4473-94e4-da7bbabe4b05", "node_type": "1", "metadata": {"window": "A \nThank you, Eric.  I mean, the \u2013 it probably goes without saying the demand for PPE is up significantly, whether \nyou're talking about core health care markets or schools or workplaces, we certainly see that increased demand \nfor PPE.  And that reflects \u2013 that does reflect in the medical group' s results for the quarter.  \n \n Our priority internally has been and continues to be to make sure we support the frontline caregivers and that we \nget the necessary PPE to them.  And quite honestly, some of these customer segments historically didn't have a \nlot of demand for some of the products like N95 mask, it just wasn't necessary in the way they ran their \nbusinesses, that's obviously changed.  \n \n And so we're working hard to source.  Our sourcing teams are very active with various partners, manufacturers \naround the world really to continue to make sure we can meet the needs of those health care customers. ", "original_text": "Our priority internally has been and continues to be to make sure we support the frontline caregivers and that we \nget the necessary PPE to them. ", "page_label": "12", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d4321ac32229592166391c0add658138374c3f916652b6b302c71ffdb52de093", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "50ae749d-fb4e-4034-af6a-8d6960549bb5", "node_type": "1", "metadata": {"window": "And that reflects \u2013 that does reflect in the medical group' s results for the quarter.  \n \n Our priority internally has been and continues to be to make sure we support the frontline caregivers and that we \nget the necessary PPE to them.  And quite honestly, some of these customer segments historically didn't have a \nlot of demand for some of the products like N95 mask, it just wasn't necessary in the way they ran their \nbusinesses, that's obviously changed.  \n \n And so we're working hard to source.  Our sourcing teams are very active with various partners, manufacturers \naround the world really to continue to make sure we can meet the needs of those health care customers.  And we \nwould not be looking to expand into industrial or other lines until we felt confident we could meet the core needs of \nthe health care \u2013 our health care c ustomers today.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "original_text": "And so we're working hard to source. "}, "hash": "4313445967ddc60e17cf0907415470c6ff9b37b6543ca821f7a92df2a95535fd", "class_name": "RelatedNodeInfo"}}, "text": "And quite honestly, some of these customer segments historically didn't have a \nlot of demand for some of the products like N95 mask, it just wasn't necessary in the way they ran their \nbusinesses, that's obviously changed.  \n \n", "start_char_idx": 2595, "end_char_idx": 2823, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "50ae749d-fb4e-4034-af6a-8d6960549bb5": {"__data__": {"id_": "50ae749d-fb4e-4034-af6a-8d6960549bb5", "embedding": null, "metadata": {"window": "And that reflects \u2013 that does reflect in the medical group' s results for the quarter.  \n \n Our priority internally has been and continues to be to make sure we support the frontline caregivers and that we \nget the necessary PPE to them.  And quite honestly, some of these customer segments historically didn't have a \nlot of demand for some of the products like N95 mask, it just wasn't necessary in the way they ran their \nbusinesses, that's obviously changed.  \n \n And so we're working hard to source.  Our sourcing teams are very active with various partners, manufacturers \naround the world really to continue to make sure we can meet the needs of those health care customers.  And we \nwould not be looking to expand into industrial or other lines until we felt confident we could meet the core needs of \nthe health care \u2013 our health care c ustomers today.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "original_text": "And so we're working hard to source. ", "page_label": "12", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cde69cac-dee0-4cfb-8e4c-635bb17fb3bd", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8d71fcbe793211d50e1e1dc81e16817fb098a34fa65b9a4815726ae7786ef1ba", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4603e04d-15de-425f-a1a0-63d74da06367", "node_type": "1", "metadata": {"window": "I mean, the \u2013 it probably goes without saying the demand for PPE is up significantly, whether \nyou're talking about core health care markets or schools or workplaces, we certainly see that increased demand \nfor PPE.  And that reflects \u2013 that does reflect in the medical group' s results for the quarter.  \n \n Our priority internally has been and continues to be to make sure we support the frontline caregivers and that we \nget the necessary PPE to them.  And quite honestly, some of these customer segments historically didn't have a \nlot of demand for some of the products like N95 mask, it just wasn't necessary in the way they ran their \nbusinesses, that's obviously changed.  \n \n And so we're working hard to source.  Our sourcing teams are very active with various partners, manufacturers \naround the world really to continue to make sure we can meet the needs of those health care customers.  And we \nwould not be looking to expand into industrial or other lines until we felt confident we could meet the core needs of \nthe health care \u2013 our health care c ustomers today.  \n ", "original_text": "And quite honestly, some of these customer segments historically didn't have a \nlot of demand for some of the products like N95 mask, it just wasn't necessary in the way they ran their \nbusinesses, that's obviously changed.  \n \n", "page_label": "12", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f7a21faa9a398072d95bfeaa4e594b0543b2b0337d0afdaff0e15f7394ee4af8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8675529e-f7ae-4e7a-ab02-bc42cc043cf5", "node_type": "1", "metadata": {"window": "Our priority internally has been and continues to be to make sure we support the frontline caregivers and that we \nget the necessary PPE to them.  And quite honestly, some of these customer segments historically didn't have a \nlot of demand for some of the products like N95 mask, it just wasn't necessary in the way they ran their \nbusinesses, that's obviously changed.  \n \n And so we're working hard to source.  Our sourcing teams are very active with various partners, manufacturers \naround the world really to continue to make sure we can meet the needs of those health care customers.  And we \nwould not be looking to expand into industrial or other lines until we felt confident we could meet the core needs of \nthe health care \u2013 our health care c ustomers today.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nEric, I guess what I would add to that. ", "original_text": "Our sourcing teams are very active with various partners, manufacturers \naround the world really to continue to make sure we can meet the needs of those health care customers. "}, "hash": "4988a377fcf2706bded053def04b88a4e83bc16a8eff0f72a9b04b9d4ed071eb", "class_name": "RelatedNodeInfo"}}, "text": "And so we're working hard to source. ", "start_char_idx": 2823, "end_char_idx": 2860, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8675529e-f7ae-4e7a-ab02-bc42cc043cf5": {"__data__": {"id_": "8675529e-f7ae-4e7a-ab02-bc42cc043cf5", "embedding": null, "metadata": {"window": "Our priority internally has been and continues to be to make sure we support the frontline caregivers and that we \nget the necessary PPE to them.  And quite honestly, some of these customer segments historically didn't have a \nlot of demand for some of the products like N95 mask, it just wasn't necessary in the way they ran their \nbusinesses, that's obviously changed.  \n \n And so we're working hard to source.  Our sourcing teams are very active with various partners, manufacturers \naround the world really to continue to make sure we can meet the needs of those health care customers.  And we \nwould not be looking to expand into industrial or other lines until we felt confident we could meet the core needs of \nthe health care \u2013 our health care c ustomers today.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nEric, I guess what I would add to that. ", "original_text": "Our sourcing teams are very active with various partners, manufacturers \naround the world really to continue to make sure we can meet the needs of those health care customers. ", "page_label": "12", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cde69cac-dee0-4cfb-8e4c-635bb17fb3bd", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8d71fcbe793211d50e1e1dc81e16817fb098a34fa65b9a4815726ae7786ef1ba", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "50ae749d-fb4e-4034-af6a-8d6960549bb5", "node_type": "1", "metadata": {"window": "And that reflects \u2013 that does reflect in the medical group' s results for the quarter.  \n \n Our priority internally has been and continues to be to make sure we support the frontline caregivers and that we \nget the necessary PPE to them.  And quite honestly, some of these customer segments historically didn't have a \nlot of demand for some of the products like N95 mask, it just wasn't necessary in the way they ran their \nbusinesses, that's obviously changed.  \n \n And so we're working hard to source.  Our sourcing teams are very active with various partners, manufacturers \naround the world really to continue to make sure we can meet the needs of those health care customers.  And we \nwould not be looking to expand into industrial or other lines until we felt confident we could meet the core needs of \nthe health care \u2013 our health care c ustomers today.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "original_text": "And so we're working hard to source. ", "page_label": "12", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "57d7b1b186f2699fb6693aadf26e60a07262d1fa99f5127f17c7457ba7ae917f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d51c2ca5-2040-4980-8157-0a12147700b5", "node_type": "1", "metadata": {"window": "And quite honestly, some of these customer segments historically didn't have a \nlot of demand for some of the products like N95 mask, it just wasn't necessary in the way they ran their \nbusinesses, that's obviously changed.  \n \n And so we're working hard to source.  Our sourcing teams are very active with various partners, manufacturers \naround the world really to continue to make sure we can meet the needs of those health care customers.  And we \nwould not be looking to expand into industrial or other lines until we felt confident we could meet the core needs of \nthe health care \u2013 our health care c ustomers today.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nEric, I guess what I would add to that.  You probably noticed that in addition to the strong volumes we saw in \nprimary care in June, PPE contributed to  that, and that was part of the reason why we increased our revenue \nguide for the year. ", "original_text": "And we \nwould not be looking to expand into industrial or other lines until we felt confident we could meet the core needs of \nthe health care \u2013 our health care c ustomers today.  \n "}, "hash": "f7351ebc6e2a55d0252e45c573747cd5277edff6541fa26fef71a9bee84008cb", "class_name": "RelatedNodeInfo"}}, "text": "Our sourcing teams are very active with various partners, manufacturers \naround the world really to continue to make sure we can meet the needs of those health care customers. ", "start_char_idx": 2860, "end_char_idx": 3036, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d51c2ca5-2040-4980-8157-0a12147700b5": {"__data__": {"id_": "d51c2ca5-2040-4980-8157-0a12147700b5", "embedding": null, "metadata": {"window": "And quite honestly, some of these customer segments historically didn't have a \nlot of demand for some of the products like N95 mask, it just wasn't necessary in the way they ran their \nbusinesses, that's obviously changed.  \n \n And so we're working hard to source.  Our sourcing teams are very active with various partners, manufacturers \naround the world really to continue to make sure we can meet the needs of those health care customers.  And we \nwould not be looking to expand into industrial or other lines until we felt confident we could meet the core needs of \nthe health care \u2013 our health care c ustomers today.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nEric, I guess what I would add to that.  You probably noticed that in addition to the strong volumes we saw in \nprimary care in June, PPE contributed to  that, and that was part of the reason why we increased our revenue \nguide for the year. ", "original_text": "And we \nwould not be looking to expand into industrial or other lines until we felt confident we could meet the core needs of \nthe health care \u2013 our health care c ustomers today.  \n ", "page_label": "12", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cde69cac-dee0-4cfb-8e4c-635bb17fb3bd", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8d71fcbe793211d50e1e1dc81e16817fb098a34fa65b9a4815726ae7786ef1ba", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8675529e-f7ae-4e7a-ab02-bc42cc043cf5", "node_type": "1", "metadata": {"window": "Our priority internally has been and continues to be to make sure we support the frontline caregivers and that we \nget the necessary PPE to them.  And quite honestly, some of these customer segments historically didn't have a \nlot of demand for some of the products like N95 mask, it just wasn't necessary in the way they ran their \nbusinesses, that's obviously changed.  \n \n And so we're working hard to source.  Our sourcing teams are very active with various partners, manufacturers \naround the world really to continue to make sure we can meet the needs of those health care customers.  And we \nwould not be looking to expand into industrial or other lines until we felt confident we could meet the core needs of \nthe health care \u2013 our health care c ustomers today.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nEric, I guess what I would add to that. ", "original_text": "Our sourcing teams are very active with various partners, manufacturers \naround the world really to continue to make sure we can meet the needs of those health care customers. ", "page_label": "12", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "889fabef2f59944e64cde8bb0afab27a6c0bdc973a84f79b7a08ca4e7302e537", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cfd0cf7b-cc8b-4e2c-8fa2-abccf7372d0a", "node_type": "1", "metadata": {"window": "And so we're working hard to source.  Our sourcing teams are very active with various partners, manufacturers \naround the world really to continue to make sure we can meet the needs of those health care customers.  And we \nwould not be looking to expand into industrial or other lines until we felt confident we could meet the core needs of \nthe health care \u2013 our health care c ustomers today.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nEric, I guess what I would add to that.  You probably noticed that in addition to the strong volumes we saw in \nprimary care in June, PPE contributed to  that, and that was part of the reason why we increased our revenue \nguide for the year.  If you recall, our original guidance for the Medical segment was revenue to be down 3% to 8% \nyear-over-year. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  "}, "hash": "789b78397e50a742750b34c7933542f6816d8e851b0bd82bc3c70e7ca817a973", "class_name": "RelatedNodeInfo"}}, "text": "And we \nwould not be looking to expand into industrial or other lines until we felt confident we could meet the core needs of \nthe health care \u2013 our health care c ustomers today.  \n ", "start_char_idx": 3036, "end_char_idx": 3218, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cfd0cf7b-cc8b-4e2c-8fa2-abccf7372d0a": {"__data__": {"id_": "cfd0cf7b-cc8b-4e2c-8fa2-abccf7372d0a", "embedding": null, "metadata": {"window": "And so we're working hard to source.  Our sourcing teams are very active with various partners, manufacturers \naround the world really to continue to make sure we can meet the needs of those health care customers.  And we \nwould not be looking to expand into industrial or other lines until we felt confident we could meet the core needs of \nthe health care \u2013 our health care c ustomers today.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nEric, I guess what I would add to that.  You probably noticed that in addition to the strong volumes we saw in \nprimary care in June, PPE contributed to  that, and that was part of the reason why we increased our revenue \nguide for the year.  If you recall, our original guidance for the Medical segment was revenue to be down 3% to 8% \nyear-over-year. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "page_label": "12", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cde69cac-dee0-4cfb-8e4c-635bb17fb3bd", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8d71fcbe793211d50e1e1dc81e16817fb098a34fa65b9a4815726ae7786ef1ba", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d51c2ca5-2040-4980-8157-0a12147700b5", "node_type": "1", "metadata": {"window": "And quite honestly, some of these customer segments historically didn't have a \nlot of demand for some of the products like N95 mask, it just wasn't necessary in the way they ran their \nbusinesses, that's obviously changed.  \n \n And so we're working hard to source.  Our sourcing teams are very active with various partners, manufacturers \naround the world really to continue to make sure we can meet the needs of those health care customers.  And we \nwould not be looking to expand into industrial or other lines until we felt confident we could meet the core needs of \nthe health care \u2013 our health care c ustomers today.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nEric, I guess what I would add to that.  You probably noticed that in addition to the strong volumes we saw in \nprimary care in June, PPE contributed to  that, and that was part of the reason why we increased our revenue \nguide for the year. ", "original_text": "And we \nwould not be looking to expand into industrial or other lines until we felt confident we could meet the core needs of \nthe health care \u2013 our health care c ustomers today.  \n ", "page_label": "12", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ccf6c67108d0bac423fb0d436c63a7680e56bd8b437327041990a5c79f1e7a22", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b484bddf-9cf2-4059-bf87-65b3d2d67da0", "node_type": "1", "metadata": {"window": "Our sourcing teams are very active with various partners, manufacturers \naround the world really to continue to make sure we can meet the needs of those health care customers.  And we \nwould not be looking to expand into industrial or other lines until we felt confident we could meet the core needs of \nthe health care \u2013 our health care c ustomers today.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nEric, I guess what I would add to that.  You probably noticed that in addition to the strong volumes we saw in \nprimary care in June, PPE contributed to  that, and that was part of the reason why we increased our revenue \nguide for the year.  If you recall, our original guidance for the Medical segment was revenue to be down 3% to 8% \nyear-over-year.  We've now upped that to 8% to 12% growth and PPE was a part  of that in addition to the strong \nprimary care volumes that we saw at the back half of June.  \n ", "original_text": "A \nEric, I guess what I would add to that. "}, "hash": "ef1873fa06798a5ddd1d0c6aa863fec62cc3d0dda3f3100abaaba76ffceba8d9", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "start_char_idx": 3218, "end_char_idx": 3578, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b484bddf-9cf2-4059-bf87-65b3d2d67da0": {"__data__": {"id_": "b484bddf-9cf2-4059-bf87-65b3d2d67da0", "embedding": null, "metadata": {"window": "Our sourcing teams are very active with various partners, manufacturers \naround the world really to continue to make sure we can meet the needs of those health care customers.  And we \nwould not be looking to expand into industrial or other lines until we felt confident we could meet the core needs of \nthe health care \u2013 our health care c ustomers today.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nEric, I guess what I would add to that.  You probably noticed that in addition to the strong volumes we saw in \nprimary care in June, PPE contributed to  that, and that was part of the reason why we increased our revenue \nguide for the year.  If you recall, our original guidance for the Medical segment was revenue to be down 3% to 8% \nyear-over-year.  We've now upped that to 8% to 12% growth and PPE was a part  of that in addition to the strong \nprimary care volumes that we saw at the back half of June.  \n ", "original_text": "A \nEric, I guess what I would add to that. ", "page_label": "12", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cde69cac-dee0-4cfb-8e4c-635bb17fb3bd", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8d71fcbe793211d50e1e1dc81e16817fb098a34fa65b9a4815726ae7786ef1ba", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cfd0cf7b-cc8b-4e2c-8fa2-abccf7372d0a", "node_type": "1", "metadata": {"window": "And so we're working hard to source.  Our sourcing teams are very active with various partners, manufacturers \naround the world really to continue to make sure we can meet the needs of those health care customers.  And we \nwould not be looking to expand into industrial or other lines until we felt confident we could meet the core needs of \nthe health care \u2013 our health care c ustomers today.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nEric, I guess what I would add to that.  You probably noticed that in addition to the strong volumes we saw in \nprimary care in June, PPE contributed to  that, and that was part of the reason why we increased our revenue \nguide for the year.  If you recall, our original guidance for the Medical segment was revenue to be down 3% to 8% \nyear-over-year. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "page_label": "12", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6134d1e8c1faf2febe14b0655eb617afa309019b69b01929d247a9e3f634b9a9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0a9faccc-383e-4113-9794-62064e68cbd3", "node_type": "1", "metadata": {"window": "And we \nwould not be looking to expand into industrial or other lines until we felt confident we could meet the core needs of \nthe health care \u2013 our health care c ustomers today.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nEric, I guess what I would add to that.  You probably noticed that in addition to the strong volumes we saw in \nprimary care in June, PPE contributed to  that, and that was part of the reason why we increased our revenue \nguide for the year.  If you recall, our original guidance for the Medical segment was revenue to be down 3% to 8% \nyear-over-year.  We've now upped that to 8% to 12% growth and PPE was a part  of that in addition to the strong \nprimary care volumes that we saw at the back half of June.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  ", "original_text": "You probably noticed that in addition to the strong volumes we saw in \nprimary care in June, PPE contributed to  that, and that was part of the reason why we increased our revenue \nguide for the year. "}, "hash": "a46a99f407ff0f5cf14f88c8d579e8e683d9a189e97ff5e880cc9e6565d93b8a", "class_name": "RelatedNodeInfo"}}, "text": "A \nEric, I guess what I would add to that. ", "start_char_idx": 3578, "end_char_idx": 3621, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0a9faccc-383e-4113-9794-62064e68cbd3": {"__data__": {"id_": "0a9faccc-383e-4113-9794-62064e68cbd3", "embedding": null, "metadata": {"window": "And we \nwould not be looking to expand into industrial or other lines until we felt confident we could meet the core needs of \nthe health care \u2013 our health care c ustomers today.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nEric, I guess what I would add to that.  You probably noticed that in addition to the strong volumes we saw in \nprimary care in June, PPE contributed to  that, and that was part of the reason why we increased our revenue \nguide for the year.  If you recall, our original guidance for the Medical segment was revenue to be down 3% to 8% \nyear-over-year.  We've now upped that to 8% to 12% growth and PPE was a part  of that in addition to the strong \nprimary care volumes that we saw at the back half of June.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  ", "original_text": "You probably noticed that in addition to the strong volumes we saw in \nprimary care in June, PPE contributed to  that, and that was part of the reason why we increased our revenue \nguide for the year. ", "page_label": "12", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cde69cac-dee0-4cfb-8e4c-635bb17fb3bd", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8d71fcbe793211d50e1e1dc81e16817fb098a34fa65b9a4815726ae7786ef1ba", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b484bddf-9cf2-4059-bf87-65b3d2d67da0", "node_type": "1", "metadata": {"window": "Our sourcing teams are very active with various partners, manufacturers \naround the world really to continue to make sure we can meet the needs of those health care customers.  And we \nwould not be looking to expand into industrial or other lines until we felt confident we could meet the core needs of \nthe health care \u2013 our health care c ustomers today.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nEric, I guess what I would add to that.  You probably noticed that in addition to the strong volumes we saw in \nprimary care in June, PPE contributed to  that, and that was part of the reason why we increased our revenue \nguide for the year.  If you recall, our original guidance for the Medical segment was revenue to be down 3% to 8% \nyear-over-year.  We've now upped that to 8% to 12% growth and PPE was a part  of that in addition to the strong \nprimary care volumes that we saw at the back half of June.  \n ", "original_text": "A \nEric, I guess what I would add to that. ", "page_label": "12", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d8657719a84cc004c6b771c641c711a9e13486424b1b3d960b6b3300098e7c55", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b4f06a0d-54c0-43c0-92a1-59b76892cfe6", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nEric, I guess what I would add to that.  You probably noticed that in addition to the strong volumes we saw in \nprimary care in June, PPE contributed to  that, and that was part of the reason why we increased our revenue \nguide for the year.  If you recall, our original guidance for the Medical segment was revenue to be down 3% to 8% \nyear-over-year.  We've now upped that to 8% to 12% growth and PPE was a part  of that in addition to the strong \nprimary care volumes that we saw at the back half of June.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question.  ", "original_text": "If you recall, our original guidance for the Medical segment was revenue to be down 3% to 8% \nyear-over-year. "}, "hash": "cc3b1679f630f0980664cac77e02b0de11da6737bd5aea7857048acc3816275a", "class_name": "RelatedNodeInfo"}}, "text": "You probably noticed that in addition to the strong volumes we saw in \nprimary care in June, PPE contributed to  that, and that was part of the reason why we increased our revenue \nguide for the year. ", "start_char_idx": 3621, "end_char_idx": 3822, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b4f06a0d-54c0-43c0-92a1-59b76892cfe6": {"__data__": {"id_": "b4f06a0d-54c0-43c0-92a1-59b76892cfe6", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nEric, I guess what I would add to that.  You probably noticed that in addition to the strong volumes we saw in \nprimary care in June, PPE contributed to  that, and that was part of the reason why we increased our revenue \nguide for the year.  If you recall, our original guidance for the Medical segment was revenue to be down 3% to 8% \nyear-over-year.  We've now upped that to 8% to 12% growth and PPE was a part  of that in addition to the strong \nprimary care volumes that we saw at the back half of June.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question.  ", "original_text": "If you recall, our original guidance for the Medical segment was revenue to be down 3% to 8% \nyear-over-year. ", "page_label": "12", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cde69cac-dee0-4cfb-8e4c-635bb17fb3bd", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8d71fcbe793211d50e1e1dc81e16817fb098a34fa65b9a4815726ae7786ef1ba", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0a9faccc-383e-4113-9794-62064e68cbd3", "node_type": "1", "metadata": {"window": "And we \nwould not be looking to expand into industrial or other lines until we felt confident we could meet the core needs of \nthe health care \u2013 our health care c ustomers today.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nEric, I guess what I would add to that.  You probably noticed that in addition to the strong volumes we saw in \nprimary care in June, PPE contributed to  that, and that was part of the reason why we increased our revenue \nguide for the year.  If you recall, our original guidance for the Medical segment was revenue to be down 3% to 8% \nyear-over-year.  We've now upped that to 8% to 12% growth and PPE was a part  of that in addition to the strong \nprimary care volumes that we saw at the back half of June.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  ", "original_text": "You probably noticed that in addition to the strong volumes we saw in \nprimary care in June, PPE contributed to  that, and that was part of the reason why we increased our revenue \nguide for the year. ", "page_label": "12", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "62938ad581de32cfa7146ce77b84e8b5bf06f97b7a8996cfa87b44c0342cd2e9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "70cb394c-3edb-4c1d-890e-9adaf8a102a1", "node_type": "1", "metadata": {"window": "A \nEric, I guess what I would add to that.  You probably noticed that in addition to the strong volumes we saw in \nprimary care in June, PPE contributed to  that, and that was part of the reason why we increased our revenue \nguide for the year.  If you recall, our original guidance for the Medical segment was revenue to be down 3% to 8% \nyear-over-year.  We've now upped that to 8% to 12% growth and PPE was a part  of that in addition to the strong \nprimary care volumes that we saw at the back half of June.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question.  ", "original_text": "We've now upped that to 8% to 12% growth and PPE was a part  of that in addition to the strong \nprimary care volumes that we saw at the back half of June.  \n "}, "hash": "a8c987e284dc8621ab757e308d35c3a59afee829827a47da0c7c980225f65676", "class_name": "RelatedNodeInfo"}}, "text": "If you recall, our original guidance for the Medical segment was revenue to be down 3% to 8% \nyear-over-year. ", "start_char_idx": 3822, "end_char_idx": 3932, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "70cb394c-3edb-4c1d-890e-9adaf8a102a1": {"__data__": {"id_": "70cb394c-3edb-4c1d-890e-9adaf8a102a1", "embedding": null, "metadata": {"window": "A \nEric, I guess what I would add to that.  You probably noticed that in addition to the strong volumes we saw in \nprimary care in June, PPE contributed to  that, and that was part of the reason why we increased our revenue \nguide for the year.  If you recall, our original guidance for the Medical segment was revenue to be down 3% to 8% \nyear-over-year.  We've now upped that to 8% to 12% growth and PPE was a part  of that in addition to the strong \nprimary care volumes that we saw at the back half of June.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question.  ", "original_text": "We've now upped that to 8% to 12% growth and PPE was a part  of that in addition to the strong \nprimary care volumes that we saw at the back half of June.  \n ", "page_label": "12", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cde69cac-dee0-4cfb-8e4c-635bb17fb3bd", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8d71fcbe793211d50e1e1dc81e16817fb098a34fa65b9a4815726ae7786ef1ba", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b4f06a0d-54c0-43c0-92a1-59b76892cfe6", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nEric, I guess what I would add to that.  You probably noticed that in addition to the strong volumes we saw in \nprimary care in June, PPE contributed to  that, and that was part of the reason why we increased our revenue \nguide for the year.  If you recall, our original guidance for the Medical segment was revenue to be down 3% to 8% \nyear-over-year.  We've now upped that to 8% to 12% growth and PPE was a part  of that in addition to the strong \nprimary care volumes that we saw at the back half of June.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question.  ", "original_text": "If you recall, our original guidance for the Medical segment was revenue to be down 3% to 8% \nyear-over-year. ", "page_label": "12", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "eb0d0b3ea6d7bf6aec13f1b14ba24bc5fe2ac903042ebea0c6893c433e1e840d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c93a4baa-b160-451a-9371-c36bc970f7a1", "node_type": "1", "metadata": {"window": "You probably noticed that in addition to the strong volumes we saw in \nprimary care in June, PPE contributed to  that, and that was part of the reason why we increased our revenue \nguide for the year.  If you recall, our original guidance for the Medical segment was revenue to be down 3% to 8% \nyear-over-year.  We've now upped that to 8% to 12% growth and PPE was a part  of that in addition to the strong \nprimary care volumes that we saw at the back half of June.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question.  ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  "}, "hash": "872b21a2704a5bb61adb6310db76fa6c6a15785cb96127244ea74d264a262688", "class_name": "RelatedNodeInfo"}}, "text": "We've now upped that to 8% to 12% growth and PPE was a part  of that in addition to the strong \nprimary care volumes that we saw at the back half of June.  \n ", "start_char_idx": 3932, "end_char_idx": 4090, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c93a4baa-b160-451a-9371-c36bc970f7a1": {"__data__": {"id_": "c93a4baa-b160-451a-9371-c36bc970f7a1", "embedding": null, "metadata": {"window": "You probably noticed that in addition to the strong volumes we saw in \nprimary care in June, PPE contributed to  that, and that was part of the reason why we increased our revenue \nguide for the year.  If you recall, our original guidance for the Medical segment was revenue to be down 3% to 8% \nyear-over-year.  We've now upped that to 8% to 12% growth and PPE was a part  of that in addition to the strong \nprimary care volumes that we saw at the back half of June.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question.  ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  ", "page_label": "12", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cde69cac-dee0-4cfb-8e4c-635bb17fb3bd", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8d71fcbe793211d50e1e1dc81e16817fb098a34fa65b9a4815726ae7786ef1ba", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "70cb394c-3edb-4c1d-890e-9adaf8a102a1", "node_type": "1", "metadata": {"window": "A \nEric, I guess what I would add to that.  You probably noticed that in addition to the strong volumes we saw in \nprimary care in June, PPE contributed to  that, and that was part of the reason why we increased our revenue \nguide for the year.  If you recall, our original guidance for the Medical segment was revenue to be down 3% to 8% \nyear-over-year.  We've now upped that to 8% to 12% growth and PPE was a part  of that in addition to the strong \nprimary care volumes that we saw at the back half of June.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question.  ", "original_text": "We've now upped that to 8% to 12% growth and PPE was a part  of that in addition to the strong \nprimary care volumes that we saw at the back half of June.  \n ", "page_label": "12", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "35a74bb7bd05a50491b7d78426b2a6584c210589e1a2d84a5b8cd26fac6caf56", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9251c2dc-6c25-4dd2-b295-fcec1976eac9", "node_type": "1", "metadata": {"window": "If you recall, our original guidance for the Medical segment was revenue to be down 3% to 8% \nyear-over-year.  We've now upped that to 8% to 12% growth and PPE was a part  of that in addition to the strong \nprimary care volumes that we saw at the back half of June.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question.  ", "original_text": "A \nNext question.  "}, "hash": "9ce7e92bd8ecbb88af3ac1aab9726f8a4444bd7eec924b2052a0a2c3231b92f4", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  ", "start_char_idx": 4090, "end_char_idx": 4435, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9251c2dc-6c25-4dd2-b295-fcec1976eac9": {"__data__": {"id_": "9251c2dc-6c25-4dd2-b295-fcec1976eac9", "embedding": null, "metadata": {"window": "If you recall, our original guidance for the Medical segment was revenue to be down 3% to 8% \nyear-over-year.  We've now upped that to 8% to 12% growth and PPE was a part  of that in addition to the strong \nprimary care volumes that we saw at the back half of June.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question.  ", "original_text": "A \nNext question.  ", "page_label": "12", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cde69cac-dee0-4cfb-8e4c-635bb17fb3bd", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8d71fcbe793211d50e1e1dc81e16817fb098a34fa65b9a4815726ae7786ef1ba", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c93a4baa-b160-451a-9371-c36bc970f7a1", "node_type": "1", "metadata": {"window": "You probably noticed that in addition to the strong volumes we saw in \nprimary care in June, PPE contributed to  that, and that was part of the reason why we increased our revenue \nguide for the year.  If you recall, our original guidance for the Medical segment was revenue to be down 3% to 8% \nyear-over-year.  We've now upped that to 8% to 12% growth and PPE was a part  of that in addition to the strong \nprimary care volumes that we saw at the back half of June.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question.  ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  ", "page_label": "12", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fa9f0edf5a12ff5d231398cae521a95d9c9e85573972fecc2da3af6a84639bb1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "24d96533-cb23-415f-a1b9-435036a6a0e9", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \nOperator : And next will be Charles Rhyee with Cowen & Company.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nYes. ", "original_text": "McKesson Corp.  "}, "hash": "236153906a2beca402b6c687f53b80ed1dd39cfeb07955c1834a72ae8bfcac02", "class_name": "RelatedNodeInfo"}}, "text": "A \nNext question.  ", "start_char_idx": 4435, "end_char_idx": 4454, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "24d96533-cb23-415f-a1b9-435036a6a0e9": {"__data__": {"id_": "24d96533-cb23-415f-a1b9-435036a6a0e9", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \nOperator : And next will be Charles Rhyee with Cowen & Company.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nYes. ", "original_text": "McKesson Corp.  ", "page_label": "13", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f085fb6c-4660-42dc-89e2-bdb89b579fde", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2c3e458755c16dedbe502e38df9d4e7b055cf6cc93ed201578660c86c61cf792", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9251c2dc-6c25-4dd2-b295-fcec1976eac9", "node_type": "1", "metadata": {"window": "If you recall, our original guidance for the Medical segment was revenue to be down 3% to 8% \nyear-over-year.  We've now upped that to 8% to 12% growth and PPE was a part  of that in addition to the strong \nprimary care volumes that we saw at the back half of June.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question.  ", "original_text": "A \nNext question.  ", "page_label": "12", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "80ebeaafa16fef1bc3ff41d9dc23d04d89e7503920256a2c314294672a2cdb8b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "55a15501-519b-400d-9540-a0164e37c210", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \nOperator : And next will be Charles Rhyee with Cowen & Company.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nYes.  Thanks for taking the question. ", "original_text": "(MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \nOperator : And next will be Charles Rhyee with Cowen & Company.  \n "}, "hash": "f197a6e3ad26821276182accaeacad4f3cc5ec52061c5ad207a5a7c53c287d40", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "55a15501-519b-400d-9540-a0164e37c210": {"__data__": {"id_": "55a15501-519b-400d-9540-a0164e37c210", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \nOperator : And next will be Charles Rhyee with Cowen & Company.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nYes.  Thanks for taking the question. ", "original_text": "(MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \nOperator : And next will be Charles Rhyee with Cowen & Company.  \n ", "page_label": "13", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f085fb6c-4660-42dc-89e2-bdb89b579fde", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2c3e458755c16dedbe502e38df9d4e7b055cf6cc93ed201578660c86c61cf792", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "24d96533-cb23-415f-a1b9-435036a6a0e9", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \nOperator : And next will be Charles Rhyee with Cowen & Company.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nYes. ", "original_text": "McKesson Corp.  ", "page_label": "13", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3e158c957a9d4e18ea1d3b60359978a835c7ff4ced18e63b6d40415703c941db", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c026519c-584f-47cf-ae2f-bed834361036", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \nOperator : And next will be Charles Rhyee with Cowen & Company.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nYes.  Thanks for taking the question.  You guys noted a strong recovery in June. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, Cowen & Co. "}, "hash": "bd2ef7c54d5f730f0b05b1a16a61d5369cd94ac592232d7d2ab944c9849cd972", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \nOperator : And next will be Charles Rhyee with Cowen & Company.  \n ", "start_char_idx": 16, "end_char_idx": 250, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c026519c-584f-47cf-ae2f-bed834361036": {"__data__": {"id_": "c026519c-584f-47cf-ae2f-bed834361036", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \nOperator : And next will be Charles Rhyee with Cowen & Company.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nYes.  Thanks for taking the question.  You guys noted a strong recovery in June. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, Cowen & Co. ", "page_label": "13", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f085fb6c-4660-42dc-89e2-bdb89b579fde", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2c3e458755c16dedbe502e38df9d4e7b055cf6cc93ed201578660c86c61cf792", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "55a15501-519b-400d-9540-a0164e37c210", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \nOperator : And next will be Charles Rhyee with Cowen & Company.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nYes.  Thanks for taking the question. ", "original_text": "(MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \nOperator : And next will be Charles Rhyee with Cowen & Company.  \n ", "page_label": "13", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4c158f60b4d4bb0ac8394fbf9e0c3d434fc5d109c14b51e8d50ce8f342222794", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "030e7605-ae10-44f1-bb34-9fbf8af4d20a", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \nOperator : And next will be Charles Rhyee with Cowen & Company.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nYes.  Thanks for taking the question.  You guys noted a strong recovery in June.  Maybe you can give us a sense \non how July has looked then? ", "original_text": "LLC  Q \nYes. "}, "hash": "221174a4d3f6c4abc2155de81e8ff133a2a3f14c04946c3a6d67ad8c512eb0e2", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, Cowen & Co. ", "start_char_idx": 250, "end_char_idx": 559, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "030e7605-ae10-44f1-bb34-9fbf8af4d20a": {"__data__": {"id_": "030e7605-ae10-44f1-bb34-9fbf8af4d20a", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \nOperator : And next will be Charles Rhyee with Cowen & Company.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nYes.  Thanks for taking the question.  You guys noted a strong recovery in June.  Maybe you can give us a sense \non how July has looked then? ", "original_text": "LLC  Q \nYes. ", "page_label": "13", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f085fb6c-4660-42dc-89e2-bdb89b579fde", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2c3e458755c16dedbe502e38df9d4e7b055cf6cc93ed201578660c86c61cf792", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c026519c-584f-47cf-ae2f-bed834361036", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \nOperator : And next will be Charles Rhyee with Cowen & Company.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nYes.  Thanks for taking the question.  You guys noted a strong recovery in June. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, Cowen & Co. ", "page_label": "13", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e28f5b84577a6eeeb33592c7eca54e945e16ba35c26403802182f393817a26fe", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8856beb8-7749-45f9-a74f-0d5832408af0", "node_type": "1", "metadata": {"window": "(MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \nOperator : And next will be Charles Rhyee with Cowen & Company.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nYes.  Thanks for taking the question.  You guys noted a strong recovery in June.  Maybe you can give us a sense \non how July has looked then?  And has volumes remained at the June levels? ", "original_text": "Thanks for taking the question. "}, "hash": "9a2ff5585d8cde637f6ab76d67b4f681ff2c5b2f3892258b9c4ff9aa0b3b3ce1", "class_name": "RelatedNodeInfo"}}, "text": "LLC  Q \nYes. ", "start_char_idx": 559, "end_char_idx": 572, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8856beb8-7749-45f9-a74f-0d5832408af0": {"__data__": {"id_": "8856beb8-7749-45f9-a74f-0d5832408af0", "embedding": null, "metadata": {"window": "(MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \nOperator : And next will be Charles Rhyee with Cowen & Company.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nYes.  Thanks for taking the question.  You guys noted a strong recovery in June.  Maybe you can give us a sense \non how July has looked then?  And has volumes remained at the June levels? ", "original_text": "Thanks for taking the question. ", "page_label": "13", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f085fb6c-4660-42dc-89e2-bdb89b579fde", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2c3e458755c16dedbe502e38df9d4e7b055cf6cc93ed201578660c86c61cf792", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "030e7605-ae10-44f1-bb34-9fbf8af4d20a", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \nOperator : And next will be Charles Rhyee with Cowen & Company.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nYes.  Thanks for taking the question.  You guys noted a strong recovery in June.  Maybe you can give us a sense \non how July has looked then? ", "original_text": "LLC  Q \nYes. ", "page_label": "13", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "549b37b0670036ff7839a7fecb47a188e2d7e3d31083a97a771fe998210245e2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "26f9e74c-6dc6-4a3e-aabd-403a8c1cab64", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nYes.  Thanks for taking the question.  You guys noted a strong recovery in June.  Maybe you can give us a sense \non how July has looked then?  And has volumes remained at the June levels?  Or are you continuing to see a \nfurther acceleration, particularly as we've seen more surges here in states like Texas, California and Florida, \nbecause it sounds like you're saying you're not assuming a second wave. ", "original_text": "You guys noted a strong recovery in June. "}, "hash": "d0d36d376b76b0f1c14b29dec4dbe180e3c54c4ec0a16a743a257ad7d5aa9523", "class_name": "RelatedNodeInfo"}}, "text": "Thanks for taking the question. ", "start_char_idx": 572, "end_char_idx": 604, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "26f9e74c-6dc6-4a3e-aabd-403a8c1cab64": {"__data__": {"id_": "26f9e74c-6dc6-4a3e-aabd-403a8c1cab64", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nYes.  Thanks for taking the question.  You guys noted a strong recovery in June.  Maybe you can give us a sense \non how July has looked then?  And has volumes remained at the June levels?  Or are you continuing to see a \nfurther acceleration, particularly as we've seen more surges here in states like Texas, California and Florida, \nbecause it sounds like you're saying you're not assuming a second wave. ", "original_text": "You guys noted a strong recovery in June. ", "page_label": "13", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f085fb6c-4660-42dc-89e2-bdb89b579fde", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2c3e458755c16dedbe502e38df9d4e7b055cf6cc93ed201578660c86c61cf792", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8856beb8-7749-45f9-a74f-0d5832408af0", "node_type": "1", "metadata": {"window": "(MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \nOperator : And next will be Charles Rhyee with Cowen & Company.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nYes.  Thanks for taking the question.  You guys noted a strong recovery in June.  Maybe you can give us a sense \non how July has looked then?  And has volumes remained at the June levels? ", "original_text": "Thanks for taking the question. ", "page_label": "13", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b002c737532ce9157a282922638bd7aa951c7667fdf46a7facf19b4ce466d95f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "18fdb3e4-8c79-4f34-aa6a-328dc2fe5c80", "node_type": "1", "metadata": {"window": "LLC  Q \nYes.  Thanks for taking the question.  You guys noted a strong recovery in June.  Maybe you can give us a sense \non how July has looked then?  And has volumes remained at the June levels?  Or are you continuing to see a \nfurther acceleration, particularly as we've seen more surges here in states like Texas, California and Florida, \nbecause it sounds like you're saying you're not assuming a second wave.  So is it kind of the assumption that \nunlike the beginning of the pandemi c where everything kind of shut down, you're assuming that these states \nlargely stay open which kind of changes how volume should be affected? ", "original_text": "Maybe you can give us a sense \non how July has looked then? "}, "hash": "489e34126afe33e5cf8332d1d759f7e6d58d5acb3423b2cdd62bf4f612a06acc", "class_name": "RelatedNodeInfo"}}, "text": "You guys noted a strong recovery in June. ", "start_char_idx": 604, "end_char_idx": 646, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "18fdb3e4-8c79-4f34-aa6a-328dc2fe5c80": {"__data__": {"id_": "18fdb3e4-8c79-4f34-aa6a-328dc2fe5c80", "embedding": null, "metadata": {"window": "LLC  Q \nYes.  Thanks for taking the question.  You guys noted a strong recovery in June.  Maybe you can give us a sense \non how July has looked then?  And has volumes remained at the June levels?  Or are you continuing to see a \nfurther acceleration, particularly as we've seen more surges here in states like Texas, California and Florida, \nbecause it sounds like you're saying you're not assuming a second wave.  So is it kind of the assumption that \nunlike the beginning of the pandemi c where everything kind of shut down, you're assuming that these states \nlargely stay open which kind of changes how volume should be affected? ", "original_text": "Maybe you can give us a sense \non how July has looked then? ", "page_label": "13", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f085fb6c-4660-42dc-89e2-bdb89b579fde", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2c3e458755c16dedbe502e38df9d4e7b055cf6cc93ed201578660c86c61cf792", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "26f9e74c-6dc6-4a3e-aabd-403a8c1cab64", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nYes.  Thanks for taking the question.  You guys noted a strong recovery in June.  Maybe you can give us a sense \non how July has looked then?  And has volumes remained at the June levels?  Or are you continuing to see a \nfurther acceleration, particularly as we've seen more surges here in states like Texas, California and Florida, \nbecause it sounds like you're saying you're not assuming a second wave. ", "original_text": "You guys noted a strong recovery in June. ", "page_label": "13", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1dd444a3a6f9bed50a7ae33b0dbb26ced1b999a62375eb97e88eab1bfcfdf256", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4cc14b33-14df-437e-ae32-0780a7b8e5b8", "node_type": "1", "metadata": {"window": "Thanks for taking the question.  You guys noted a strong recovery in June.  Maybe you can give us a sense \non how July has looked then?  And has volumes remained at the June levels?  Or are you continuing to see a \nfurther acceleration, particularly as we've seen more surges here in states like Texas, California and Florida, \nbecause it sounds like you're saying you're not assuming a second wave.  So is it kind of the assumption that \nunlike the beginning of the pandemi c where everything kind of shut down, you're assuming that these states \nlargely stay open which kind of changes how volume should be affected?  Thanks.  \n ", "original_text": "And has volumes remained at the June levels? "}, "hash": "6439176bb9e77b4f856aa26e54b0e901a67ade8a909ac7190c86e07b24548aae", "class_name": "RelatedNodeInfo"}}, "text": "Maybe you can give us a sense \non how July has looked then? ", "start_char_idx": 646, "end_char_idx": 706, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4cc14b33-14df-437e-ae32-0780a7b8e5b8": {"__data__": {"id_": "4cc14b33-14df-437e-ae32-0780a7b8e5b8", "embedding": null, "metadata": {"window": "Thanks for taking the question.  You guys noted a strong recovery in June.  Maybe you can give us a sense \non how July has looked then?  And has volumes remained at the June levels?  Or are you continuing to see a \nfurther acceleration, particularly as we've seen more surges here in states like Texas, California and Florida, \nbecause it sounds like you're saying you're not assuming a second wave.  So is it kind of the assumption that \nunlike the beginning of the pandemi c where everything kind of shut down, you're assuming that these states \nlargely stay open which kind of changes how volume should be affected?  Thanks.  \n ", "original_text": "And has volumes remained at the June levels? ", "page_label": "13", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f085fb6c-4660-42dc-89e2-bdb89b579fde", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2c3e458755c16dedbe502e38df9d4e7b055cf6cc93ed201578660c86c61cf792", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "18fdb3e4-8c79-4f34-aa6a-328dc2fe5c80", "node_type": "1", "metadata": {"window": "LLC  Q \nYes.  Thanks for taking the question.  You guys noted a strong recovery in June.  Maybe you can give us a sense \non how July has looked then?  And has volumes remained at the June levels?  Or are you continuing to see a \nfurther acceleration, particularly as we've seen more surges here in states like Texas, California and Florida, \nbecause it sounds like you're saying you're not assuming a second wave.  So is it kind of the assumption that \nunlike the beginning of the pandemi c where everything kind of shut down, you're assuming that these states \nlargely stay open which kind of changes how volume should be affected? ", "original_text": "Maybe you can give us a sense \non how July has looked then? ", "page_label": "13", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "16fdd5e6af17fbcf6eb244de96346eb5c48262349dc326d8a169b7573146dcf3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "21a23cbc-c718-46a9-a305-0d61891c4363", "node_type": "1", "metadata": {"window": "You guys noted a strong recovery in June.  Maybe you can give us a sense \non how July has looked then?  And has volumes remained at the June levels?  Or are you continuing to see a \nfurther acceleration, particularly as we've seen more surges here in states like Texas, California and Florida, \nbecause it sounds like you're saying you're not assuming a second wave.  So is it kind of the assumption that \nunlike the beginning of the pandemi c where everything kind of shut down, you're assuming that these states \nlargely stay open which kind of changes how volume should be affected?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "Or are you continuing to see a \nfurther acceleration, particularly as we've seen more surges here in states like Texas, California and Florida, \nbecause it sounds like you're saying you're not assuming a second wave. "}, "hash": "6f7755d0f13f2c93302eee03286e3e24e15724239c8ec525c4d72820b0616216", "class_name": "RelatedNodeInfo"}}, "text": "And has volumes remained at the June levels? ", "start_char_idx": 706, "end_char_idx": 751, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "21a23cbc-c718-46a9-a305-0d61891c4363": {"__data__": {"id_": "21a23cbc-c718-46a9-a305-0d61891c4363", "embedding": null, "metadata": {"window": "You guys noted a strong recovery in June.  Maybe you can give us a sense \non how July has looked then?  And has volumes remained at the June levels?  Or are you continuing to see a \nfurther acceleration, particularly as we've seen more surges here in states like Texas, California and Florida, \nbecause it sounds like you're saying you're not assuming a second wave.  So is it kind of the assumption that \nunlike the beginning of the pandemi c where everything kind of shut down, you're assuming that these states \nlargely stay open which kind of changes how volume should be affected?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "Or are you continuing to see a \nfurther acceleration, particularly as we've seen more surges here in states like Texas, California and Florida, \nbecause it sounds like you're saying you're not assuming a second wave. ", "page_label": "13", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f085fb6c-4660-42dc-89e2-bdb89b579fde", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2c3e458755c16dedbe502e38df9d4e7b055cf6cc93ed201578660c86c61cf792", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4cc14b33-14df-437e-ae32-0780a7b8e5b8", "node_type": "1", "metadata": {"window": "Thanks for taking the question.  You guys noted a strong recovery in June.  Maybe you can give us a sense \non how July has looked then?  And has volumes remained at the June levels?  Or are you continuing to see a \nfurther acceleration, particularly as we've seen more surges here in states like Texas, California and Florida, \nbecause it sounds like you're saying you're not assuming a second wave.  So is it kind of the assumption that \nunlike the beginning of the pandemi c where everything kind of shut down, you're assuming that these states \nlargely stay open which kind of changes how volume should be affected?  Thanks.  \n ", "original_text": "And has volumes remained at the June levels? ", "page_label": "13", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cc3979044d55bc19ca9394de76faae29cd4bc698b6064b38ab51fdd9139e5826", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d4a484e5-47e6-4ab6-9259-9b9da7e3fcc9", "node_type": "1", "metadata": {"window": "Maybe you can give us a sense \non how July has looked then?  And has volumes remained at the June levels?  Or are you continuing to see a \nfurther acceleration, particularly as we've seen more surges here in states like Texas, California and Florida, \nbecause it sounds like you're saying you're not assuming a second wave.  So is it kind of the assumption that \nunlike the beginning of the pandemi c where everything kind of shut down, you're assuming that these states \nlargely stay open which kind of changes how volume should be affected?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThank you, Charles. ", "original_text": "So is it kind of the assumption that \nunlike the beginning of the pandemi c where everything kind of shut down, you're assuming that these states \nlargely stay open which kind of changes how volume should be affected? "}, "hash": "356fc98353e5dbdb0d5ba21fe820f633b9901158fdd9852059ed25f1d208e883", "class_name": "RelatedNodeInfo"}}, "text": "Or are you continuing to see a \nfurther acceleration, particularly as we've seen more surges here in states like Texas, California and Florida, \nbecause it sounds like you're saying you're not assuming a second wave. ", "start_char_idx": 751, "end_char_idx": 968, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d4a484e5-47e6-4ab6-9259-9b9da7e3fcc9": {"__data__": {"id_": "d4a484e5-47e6-4ab6-9259-9b9da7e3fcc9", "embedding": null, "metadata": {"window": "Maybe you can give us a sense \non how July has looked then?  And has volumes remained at the June levels?  Or are you continuing to see a \nfurther acceleration, particularly as we've seen more surges here in states like Texas, California and Florida, \nbecause it sounds like you're saying you're not assuming a second wave.  So is it kind of the assumption that \nunlike the beginning of the pandemi c where everything kind of shut down, you're assuming that these states \nlargely stay open which kind of changes how volume should be affected?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThank you, Charles. ", "original_text": "So is it kind of the assumption that \nunlike the beginning of the pandemi c where everything kind of shut down, you're assuming that these states \nlargely stay open which kind of changes how volume should be affected? ", "page_label": "13", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f085fb6c-4660-42dc-89e2-bdb89b579fde", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2c3e458755c16dedbe502e38df9d4e7b055cf6cc93ed201578660c86c61cf792", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "21a23cbc-c718-46a9-a305-0d61891c4363", "node_type": "1", "metadata": {"window": "You guys noted a strong recovery in June.  Maybe you can give us a sense \non how July has looked then?  And has volumes remained at the June levels?  Or are you continuing to see a \nfurther acceleration, particularly as we've seen more surges here in states like Texas, California and Florida, \nbecause it sounds like you're saying you're not assuming a second wave.  So is it kind of the assumption that \nunlike the beginning of the pandemi c where everything kind of shut down, you're assuming that these states \nlargely stay open which kind of changes how volume should be affected?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "Or are you continuing to see a \nfurther acceleration, particularly as we've seen more surges here in states like Texas, California and Florida, \nbecause it sounds like you're saying you're not assuming a second wave. ", "page_label": "13", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "405af782672c14511f8c44c857f8debfaec87837f83d8e3c49e54c48e56d6bac", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d9910a44-2f6e-4a98-bc40-08c906fd709b", "node_type": "1", "metadata": {"window": "And has volumes remained at the June levels?  Or are you continuing to see a \nfurther acceleration, particularly as we've seen more surges here in states like Texas, California and Florida, \nbecause it sounds like you're saying you're not assuming a second wave.  So is it kind of the assumption that \nunlike the beginning of the pandemi c where everything kind of shut down, you're assuming that these states \nlargely stay open which kind of changes how volume should be affected?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThank you, Charles.  Certainly, April was a very soft month. ", "original_text": "Thanks.  \n "}, "hash": "9d2c4038a1629f64062d89c44e80593e3e957649185c7c0279c47932e5da0a86", "class_name": "RelatedNodeInfo"}}, "text": "So is it kind of the assumption that \nunlike the beginning of the pandemi c where everything kind of shut down, you're assuming that these states \nlargely stay open which kind of changes how volume should be affected? ", "start_char_idx": 968, "end_char_idx": 1186, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d9910a44-2f6e-4a98-bc40-08c906fd709b": {"__data__": {"id_": "d9910a44-2f6e-4a98-bc40-08c906fd709b", "embedding": null, "metadata": {"window": "And has volumes remained at the June levels?  Or are you continuing to see a \nfurther acceleration, particularly as we've seen more surges here in states like Texas, California and Florida, \nbecause it sounds like you're saying you're not assuming a second wave.  So is it kind of the assumption that \nunlike the beginning of the pandemi c where everything kind of shut down, you're assuming that these states \nlargely stay open which kind of changes how volume should be affected?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThank you, Charles.  Certainly, April was a very soft month. ", "original_text": "Thanks.  \n ", "page_label": "13", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f085fb6c-4660-42dc-89e2-bdb89b579fde", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2c3e458755c16dedbe502e38df9d4e7b055cf6cc93ed201578660c86c61cf792", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d4a484e5-47e6-4ab6-9259-9b9da7e3fcc9", "node_type": "1", "metadata": {"window": "Maybe you can give us a sense \non how July has looked then?  And has volumes remained at the June levels?  Or are you continuing to see a \nfurther acceleration, particularly as we've seen more surges here in states like Texas, California and Florida, \nbecause it sounds like you're saying you're not assuming a second wave.  So is it kind of the assumption that \nunlike the beginning of the pandemi c where everything kind of shut down, you're assuming that these states \nlargely stay open which kind of changes how volume should be affected?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThank you, Charles. ", "original_text": "So is it kind of the assumption that \nunlike the beginning of the pandemi c where everything kind of shut down, you're assuming that these states \nlargely stay open which kind of changes how volume should be affected? ", "page_label": "13", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a7c402f76f6dbcf57b9b798705890fd713bf9a3bfc20d6735871e828b2e90fbf", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "367375d1-99b1-43fc-98bd-fd4d49789220", "node_type": "1", "metadata": {"window": "Or are you continuing to see a \nfurther acceleration, particularly as we've seen more surges here in states like Texas, California and Florida, \nbecause it sounds like you're saying you're not assuming a second wave.  So is it kind of the assumption that \nunlike the beginning of the pandemi c where everything kind of shut down, you're assuming that these states \nlargely stay open which kind of changes how volume should be affected?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThank you, Charles.  Certainly, April was a very soft month.  I think we signaled that when we talked about our \nguidance for the year. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  "}, "hash": "3229c2199b01a16bcfb781dd8ffc1caf7bee25486e2c4d69f2d3df38d9fc9b54", "class_name": "RelatedNodeInfo"}}, "text": "Thanks.  \n ", "start_char_idx": 1186, "end_char_idx": 1197, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "367375d1-99b1-43fc-98bd-fd4d49789220": {"__data__": {"id_": "367375d1-99b1-43fc-98bd-fd4d49789220", "embedding": null, "metadata": {"window": "Or are you continuing to see a \nfurther acceleration, particularly as we've seen more surges here in states like Texas, California and Florida, \nbecause it sounds like you're saying you're not assuming a second wave.  So is it kind of the assumption that \nunlike the beginning of the pandemi c where everything kind of shut down, you're assuming that these states \nlargely stay open which kind of changes how volume should be affected?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThank you, Charles.  Certainly, April was a very soft month.  I think we signaled that when we talked about our \nguidance for the year. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "13", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f085fb6c-4660-42dc-89e2-bdb89b579fde", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2c3e458755c16dedbe502e38df9d4e7b055cf6cc93ed201578660c86c61cf792", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d9910a44-2f6e-4a98-bc40-08c906fd709b", "node_type": "1", "metadata": {"window": "And has volumes remained at the June levels?  Or are you continuing to see a \nfurther acceleration, particularly as we've seen more surges here in states like Texas, California and Florida, \nbecause it sounds like you're saying you're not assuming a second wave.  So is it kind of the assumption that \nunlike the beginning of the pandemi c where everything kind of shut down, you're assuming that these states \nlargely stay open which kind of changes how volume should be affected?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThank you, Charles.  Certainly, April was a very soft month. ", "original_text": "Thanks.  \n ", "page_label": "13", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b76815c427738fe7e7fcec2bdc6463dcbdb177692915745293379aee529b9dc0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0d85c418-3ff1-47e6-a8d9-88928d150bb3", "node_type": "1", "metadata": {"window": "So is it kind of the assumption that \nunlike the beginning of the pandemi c where everything kind of shut down, you're assuming that these states \nlargely stay open which kind of changes how volume should be affected?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThank you, Charles.  Certainly, April was a very soft month.  I think we signaled that when we talked about our \nguidance for the year.  April and may more or less tracked to the assumptions that we had laid out as we saw the \nrecovery progressing. ", "original_text": "A \nThank you, Charles. "}, "hash": "484f3da6552e9897932741c82e214dd3c586d6b29f1d0519677bfec2929cdb92", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "start_char_idx": 1197, "end_char_idx": 1538, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0d85c418-3ff1-47e6-a8d9-88928d150bb3": {"__data__": {"id_": "0d85c418-3ff1-47e6-a8d9-88928d150bb3", "embedding": null, "metadata": {"window": "So is it kind of the assumption that \nunlike the beginning of the pandemi c where everything kind of shut down, you're assuming that these states \nlargely stay open which kind of changes how volume should be affected?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThank you, Charles.  Certainly, April was a very soft month.  I think we signaled that when we talked about our \nguidance for the year.  April and may more or less tracked to the assumptions that we had laid out as we saw the \nrecovery progressing. ", "original_text": "A \nThank you, Charles. ", "page_label": "13", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f085fb6c-4660-42dc-89e2-bdb89b579fde", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2c3e458755c16dedbe502e38df9d4e7b055cf6cc93ed201578660c86c61cf792", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "367375d1-99b1-43fc-98bd-fd4d49789220", "node_type": "1", "metadata": {"window": "Or are you continuing to see a \nfurther acceleration, particularly as we've seen more surges here in states like Texas, California and Florida, \nbecause it sounds like you're saying you're not assuming a second wave.  So is it kind of the assumption that \nunlike the beginning of the pandemi c where everything kind of shut down, you're assuming that these states \nlargely stay open which kind of changes how volume should be affected?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThank you, Charles.  Certainly, April was a very soft month.  I think we signaled that when we talked about our \nguidance for the year. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "13", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ef2bdae483b8d27aa052c6c90ebcc1f7a4b7ac3ba79bb377aee8bf8414a24395", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "af146a46-16e9-479e-b402-e4488c5020bf", "node_type": "1", "metadata": {"window": "Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThank you, Charles.  Certainly, April was a very soft month.  I think we signaled that when we talked about our \nguidance for the year.  April and may more or less tracked to the assumptions that we had laid out as we saw the \nrecovery progressing.  That held up early part of June, and then i t really accelerated, and it's pretty correlated to, if \nyou look at the timing of when states kind of relax their restrictions on movement and local economy, markets got \nopened back up and people got back to the business of health care. ", "original_text": "Certainly, April was a very soft month. "}, "hash": "351038e86a0107a4048efd63479d73edc49011a9f06423bd09ab1a34b440dcf2", "class_name": "RelatedNodeInfo"}}, "text": "A \nThank you, Charles. ", "start_char_idx": 1538, "end_char_idx": 1561, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "af146a46-16e9-479e-b402-e4488c5020bf": {"__data__": {"id_": "af146a46-16e9-479e-b402-e4488c5020bf", "embedding": null, "metadata": {"window": "Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThank you, Charles.  Certainly, April was a very soft month.  I think we signaled that when we talked about our \nguidance for the year.  April and may more or less tracked to the assumptions that we had laid out as we saw the \nrecovery progressing.  That held up early part of June, and then i t really accelerated, and it's pretty correlated to, if \nyou look at the timing of when states kind of relax their restrictions on movement and local economy, markets got \nopened back up and people got back to the business of health care. ", "original_text": "Certainly, April was a very soft month. ", "page_label": "13", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f085fb6c-4660-42dc-89e2-bdb89b579fde", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2c3e458755c16dedbe502e38df9d4e7b055cf6cc93ed201578660c86c61cf792", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0d85c418-3ff1-47e6-a8d9-88928d150bb3", "node_type": "1", "metadata": {"window": "So is it kind of the assumption that \nunlike the beginning of the pandemi c where everything kind of shut down, you're assuming that these states \nlargely stay open which kind of changes how volume should be affected?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThank you, Charles.  Certainly, April was a very soft month.  I think we signaled that when we talked about our \nguidance for the year.  April and may more or less tracked to the assumptions that we had laid out as we saw the \nrecovery progressing. ", "original_text": "A \nThank you, Charles. ", "page_label": "13", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "eddc1ccd50ff1a021e88d49476eea092868e1690dc04eccd69bc62ac4ca7a7d0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6e619b6c-da55-4095-a429-161f1e7e22ae", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThank you, Charles.  Certainly, April was a very soft month.  I think we signaled that when we talked about our \nguidance for the year.  April and may more or less tracked to the assumptions that we had laid out as we saw the \nrecovery progressing.  That held up early part of June, and then i t really accelerated, and it's pretty correlated to, if \nyou look at the timing of when states kind of relax their restrictions on movement and local economy, markets got \nopened back up and people got back to the business of health care.  And we saw those vo lumes strengthened for \nus really through the conclusion of our June quarter. ", "original_text": "I think we signaled that when we talked about our \nguidance for the year. "}, "hash": "af59b8d1e8f349ebcae29f589b09eb533c3c3cb5e0beccde946f48624003124f", "class_name": "RelatedNodeInfo"}}, "text": "Certainly, April was a very soft month. ", "start_char_idx": 1561, "end_char_idx": 1601, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6e619b6c-da55-4095-a429-161f1e7e22ae": {"__data__": {"id_": "6e619b6c-da55-4095-a429-161f1e7e22ae", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThank you, Charles.  Certainly, April was a very soft month.  I think we signaled that when we talked about our \nguidance for the year.  April and may more or less tracked to the assumptions that we had laid out as we saw the \nrecovery progressing.  That held up early part of June, and then i t really accelerated, and it's pretty correlated to, if \nyou look at the timing of when states kind of relax their restrictions on movement and local economy, markets got \nopened back up and people got back to the business of health care.  And we saw those vo lumes strengthened for \nus really through the conclusion of our June quarter. ", "original_text": "I think we signaled that when we talked about our \nguidance for the year. ", "page_label": "13", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f085fb6c-4660-42dc-89e2-bdb89b579fde", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2c3e458755c16dedbe502e38df9d4e7b055cf6cc93ed201578660c86c61cf792", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "af146a46-16e9-479e-b402-e4488c5020bf", "node_type": "1", "metadata": {"window": "Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThank you, Charles.  Certainly, April was a very soft month.  I think we signaled that when we talked about our \nguidance for the year.  April and may more or less tracked to the assumptions that we had laid out as we saw the \nrecovery progressing.  That held up early part of June, and then i t really accelerated, and it's pretty correlated to, if \nyou look at the timing of when states kind of relax their restrictions on movement and local economy, markets got \nopened back up and people got back to the business of health care. ", "original_text": "Certainly, April was a very soft month. ", "page_label": "13", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "98f536dacdf58348c2d8e3889b1f78022350bcb6638b27571c6ef3f53a7ed297", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e4987031-dcd9-489e-87b8-7a01b1b51508", "node_type": "1", "metadata": {"window": "A \nThank you, Charles.  Certainly, April was a very soft month.  I think we signaled that when we talked about our \nguidance for the year.  April and may more or less tracked to the assumptions that we had laid out as we saw the \nrecovery progressing.  That held up early part of June, and then i t really accelerated, and it's pretty correlated to, if \nyou look at the timing of when states kind of relax their restrictions on movement and local economy, markets got \nopened back up and people got back to the business of health care.  And we saw those vo lumes strengthened for \nus really through the conclusion of our June quarter.  June ended right prior to 4th of July holiday. ", "original_text": "April and may more or less tracked to the assumptions that we had laid out as we saw the \nrecovery progressing. "}, "hash": "c9df7f4e28bea6aafc22ef0b866888596e0940829b28e45c70f52d6e1d66cb87", "class_name": "RelatedNodeInfo"}}, "text": "I think we signaled that when we talked about our \nguidance for the year. ", "start_char_idx": 1601, "end_char_idx": 1675, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e4987031-dcd9-489e-87b8-7a01b1b51508": {"__data__": {"id_": "e4987031-dcd9-489e-87b8-7a01b1b51508", "embedding": null, "metadata": {"window": "A \nThank you, Charles.  Certainly, April was a very soft month.  I think we signaled that when we talked about our \nguidance for the year.  April and may more or less tracked to the assumptions that we had laid out as we saw the \nrecovery progressing.  That held up early part of June, and then i t really accelerated, and it's pretty correlated to, if \nyou look at the timing of when states kind of relax their restrictions on movement and local economy, markets got \nopened back up and people got back to the business of health care.  And we saw those vo lumes strengthened for \nus really through the conclusion of our June quarter.  June ended right prior to 4th of July holiday. ", "original_text": "April and may more or less tracked to the assumptions that we had laid out as we saw the \nrecovery progressing. ", "page_label": "13", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f085fb6c-4660-42dc-89e2-bdb89b579fde", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2c3e458755c16dedbe502e38df9d4e7b055cf6cc93ed201578660c86c61cf792", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6e619b6c-da55-4095-a429-161f1e7e22ae", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThank you, Charles.  Certainly, April was a very soft month.  I think we signaled that when we talked about our \nguidance for the year.  April and may more or less tracked to the assumptions that we had laid out as we saw the \nrecovery progressing.  That held up early part of June, and then i t really accelerated, and it's pretty correlated to, if \nyou look at the timing of when states kind of relax their restrictions on movement and local economy, markets got \nopened back up and people got back to the business of health care.  And we saw those vo lumes strengthened for \nus really through the conclusion of our June quarter. ", "original_text": "I think we signaled that when we talked about our \nguidance for the year. ", "page_label": "13", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e8bc81ee14951c5b3137bc19b7c9ba86a1a312dd893bdcb566d936f18d18f380", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a2b04634-daa4-46ba-a435-52b8a790b586", "node_type": "1", "metadata": {"window": "Certainly, April was a very soft month.  I think we signaled that when we talked about our \nguidance for the year.  April and may more or less tracked to the assumptions that we had laid out as we saw the \nrecovery progressing.  That held up early part of June, and then i t really accelerated, and it's pretty correlated to, if \nyou look at the timing of when states kind of relax their restrictions on movement and local economy, markets got \nopened back up and people got back to the business of health care.  And we saw those vo lumes strengthened for \nus really through the conclusion of our June quarter.  June ended right prior to 4th of July holiday.  So there's \nalways nuances around timing of events like that.  \n \n", "original_text": "That held up early part of June, and then i t really accelerated, and it's pretty correlated to, if \nyou look at the timing of when states kind of relax their restrictions on movement and local economy, markets got \nopened back up and people got back to the business of health care. "}, "hash": "494bbef429222b30650f5fb453832ce4ce1c2f4fcdf95234e8a575f11e2359ff", "class_name": "RelatedNodeInfo"}}, "text": "April and may more or less tracked to the assumptions that we had laid out as we saw the \nrecovery progressing. ", "start_char_idx": 1675, "end_char_idx": 1787, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a2b04634-daa4-46ba-a435-52b8a790b586": {"__data__": {"id_": "a2b04634-daa4-46ba-a435-52b8a790b586", "embedding": null, "metadata": {"window": "Certainly, April was a very soft month.  I think we signaled that when we talked about our \nguidance for the year.  April and may more or less tracked to the assumptions that we had laid out as we saw the \nrecovery progressing.  That held up early part of June, and then i t really accelerated, and it's pretty correlated to, if \nyou look at the timing of when states kind of relax their restrictions on movement and local economy, markets got \nopened back up and people got back to the business of health care.  And we saw those vo lumes strengthened for \nus really through the conclusion of our June quarter.  June ended right prior to 4th of July holiday.  So there's \nalways nuances around timing of events like that.  \n \n", "original_text": "That held up early part of June, and then i t really accelerated, and it's pretty correlated to, if \nyou look at the timing of when states kind of relax their restrictions on movement and local economy, markets got \nopened back up and people got back to the business of health care. ", "page_label": "13", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f085fb6c-4660-42dc-89e2-bdb89b579fde", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2c3e458755c16dedbe502e38df9d4e7b055cf6cc93ed201578660c86c61cf792", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e4987031-dcd9-489e-87b8-7a01b1b51508", "node_type": "1", "metadata": {"window": "A \nThank you, Charles.  Certainly, April was a very soft month.  I think we signaled that when we talked about our \nguidance for the year.  April and may more or less tracked to the assumptions that we had laid out as we saw the \nrecovery progressing.  That held up early part of June, and then i t really accelerated, and it's pretty correlated to, if \nyou look at the timing of when states kind of relax their restrictions on movement and local economy, markets got \nopened back up and people got back to the business of health care.  And we saw those vo lumes strengthened for \nus really through the conclusion of our June quarter.  June ended right prior to 4th of July holiday. ", "original_text": "April and may more or less tracked to the assumptions that we had laid out as we saw the \nrecovery progressing. ", "page_label": "13", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e8199636dba4abfd2b3363dd9902eaa7bc46ec4a648c344723c22db3a5defa70", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1b106550-fb4f-4b91-bd1d-54df8a42e3fc", "node_type": "1", "metadata": {"window": "I think we signaled that when we talked about our \nguidance for the year.  April and may more or less tracked to the assumptions that we had laid out as we saw the \nrecovery progressing.  That held up early part of June, and then i t really accelerated, and it's pretty correlated to, if \nyou look at the timing of when states kind of relax their restrictions on movement and local economy, markets got \nopened back up and people got back to the business of health care.  And we saw those vo lumes strengthened for \nus really through the conclusion of our June quarter.  June ended right prior to 4th of July holiday.  So there's \nalways nuances around timing of events like that.  \n \n I think as we think about going forward, you're exactly right. ", "original_text": "And we saw those vo lumes strengthened for \nus really through the conclusion of our June quarter. "}, "hash": "c1132d200876b19e3158e484442ce60c3c14282870c2773194c6569f0e1275f2", "class_name": "RelatedNodeInfo"}}, "text": "That held up early part of June, and then i t really accelerated, and it's pretty correlated to, if \nyou look at the timing of when states kind of relax their restrictions on movement and local economy, markets got \nopened back up and people got back to the business of health care. ", "start_char_idx": 1787, "end_char_idx": 2070, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1b106550-fb4f-4b91-bd1d-54df8a42e3fc": {"__data__": {"id_": "1b106550-fb4f-4b91-bd1d-54df8a42e3fc", "embedding": null, "metadata": {"window": "I think we signaled that when we talked about our \nguidance for the year.  April and may more or less tracked to the assumptions that we had laid out as we saw the \nrecovery progressing.  That held up early part of June, and then i t really accelerated, and it's pretty correlated to, if \nyou look at the timing of when states kind of relax their restrictions on movement and local economy, markets got \nopened back up and people got back to the business of health care.  And we saw those vo lumes strengthened for \nus really through the conclusion of our June quarter.  June ended right prior to 4th of July holiday.  So there's \nalways nuances around timing of events like that.  \n \n I think as we think about going forward, you're exactly right. ", "original_text": "And we saw those vo lumes strengthened for \nus really through the conclusion of our June quarter. ", "page_label": "13", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f085fb6c-4660-42dc-89e2-bdb89b579fde", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2c3e458755c16dedbe502e38df9d4e7b055cf6cc93ed201578660c86c61cf792", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a2b04634-daa4-46ba-a435-52b8a790b586", "node_type": "1", "metadata": {"window": "Certainly, April was a very soft month.  I think we signaled that when we talked about our \nguidance for the year.  April and may more or less tracked to the assumptions that we had laid out as we saw the \nrecovery progressing.  That held up early part of June, and then i t really accelerated, and it's pretty correlated to, if \nyou look at the timing of when states kind of relax their restrictions on movement and local economy, markets got \nopened back up and people got back to the business of health care.  And we saw those vo lumes strengthened for \nus really through the conclusion of our June quarter.  June ended right prior to 4th of July holiday.  So there's \nalways nuances around timing of events like that.  \n \n", "original_text": "That held up early part of June, and then i t really accelerated, and it's pretty correlated to, if \nyou look at the timing of when states kind of relax their restrictions on movement and local economy, markets got \nopened back up and people got back to the business of health care. ", "page_label": "13", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "64bb2982d0fc4b87a383e07d2a3f14300b4f8a227f442f3c5e24080b59191b10", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2dd2a762-8de9-4961-9242-17815d159241", "node_type": "1", "metadata": {"window": "April and may more or less tracked to the assumptions that we had laid out as we saw the \nrecovery progressing.  That held up early part of June, and then i t really accelerated, and it's pretty correlated to, if \nyou look at the timing of when states kind of relax their restrictions on movement and local economy, markets got \nopened back up and people got back to the business of health care.  And we saw those vo lumes strengthened for \nus really through the conclusion of our June quarter.  June ended right prior to 4th of July holiday.  So there's \nalways nuances around timing of events like that.  \n \n I think as we think about going forward, you're exactly right.  We are not -- we have not built this plan around a \npresumption of a second lockdown, so to speak. ", "original_text": "June ended right prior to 4th of July holiday. "}, "hash": "9c357df4089f22b86da9d22249c5d2fc85ed9f38ea6713710699d6d2ca68eab1", "class_name": "RelatedNodeInfo"}}, "text": "And we saw those vo lumes strengthened for \nus really through the conclusion of our June quarter. ", "start_char_idx": 2070, "end_char_idx": 2168, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2dd2a762-8de9-4961-9242-17815d159241": {"__data__": {"id_": "2dd2a762-8de9-4961-9242-17815d159241", "embedding": null, "metadata": {"window": "April and may more or less tracked to the assumptions that we had laid out as we saw the \nrecovery progressing.  That held up early part of June, and then i t really accelerated, and it's pretty correlated to, if \nyou look at the timing of when states kind of relax their restrictions on movement and local economy, markets got \nopened back up and people got back to the business of health care.  And we saw those vo lumes strengthened for \nus really through the conclusion of our June quarter.  June ended right prior to 4th of July holiday.  So there's \nalways nuances around timing of events like that.  \n \n I think as we think about going forward, you're exactly right.  We are not -- we have not built this plan around a \npresumption of a second lockdown, so to speak. ", "original_text": "June ended right prior to 4th of July holiday. ", "page_label": "13", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f085fb6c-4660-42dc-89e2-bdb89b579fde", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2c3e458755c16dedbe502e38df9d4e7b055cf6cc93ed201578660c86c61cf792", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1b106550-fb4f-4b91-bd1d-54df8a42e3fc", "node_type": "1", "metadata": {"window": "I think we signaled that when we talked about our \nguidance for the year.  April and may more or less tracked to the assumptions that we had laid out as we saw the \nrecovery progressing.  That held up early part of June, and then i t really accelerated, and it's pretty correlated to, if \nyou look at the timing of when states kind of relax their restrictions on movement and local economy, markets got \nopened back up and people got back to the business of health care.  And we saw those vo lumes strengthened for \nus really through the conclusion of our June quarter.  June ended right prior to 4th of July holiday.  So there's \nalways nuances around timing of events like that.  \n \n I think as we think about going forward, you're exactly right. ", "original_text": "And we saw those vo lumes strengthened for \nus really through the conclusion of our June quarter. ", "page_label": "13", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f202f1850b01b43eab6270671cfc1afc784ffa605b5d6139a16eac1a2c65d24a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1cc88be2-aebd-4133-b9cb-05b37abdbc97", "node_type": "1", "metadata": {"window": "That held up early part of June, and then i t really accelerated, and it's pretty correlated to, if \nyou look at the timing of when states kind of relax their restrictions on movement and local economy, markets got \nopened back up and people got back to the business of health care.  And we saw those vo lumes strengthened for \nus really through the conclusion of our June quarter.  June ended right prior to 4th of July holiday.  So there's \nalways nuances around timing of events like that.  \n \n I think as we think about going forward, you're exactly right.  We are not -- we have not built this plan around a \npresumption of a second lockdown, so to speak.  We think economies will continue to stay open. ", "original_text": "So there's \nalways nuances around timing of events like that.  \n \n"}, "hash": "1a7081e7e5dba98d5a59af801230ace6a8cd283fb2e7b4937d6e8c0efe4bfcf1", "class_name": "RelatedNodeInfo"}}, "text": "June ended right prior to 4th of July holiday. ", "start_char_idx": 2168, "end_char_idx": 2215, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1cc88be2-aebd-4133-b9cb-05b37abdbc97": {"__data__": {"id_": "1cc88be2-aebd-4133-b9cb-05b37abdbc97", "embedding": null, "metadata": {"window": "That held up early part of June, and then i t really accelerated, and it's pretty correlated to, if \nyou look at the timing of when states kind of relax their restrictions on movement and local economy, markets got \nopened back up and people got back to the business of health care.  And we saw those vo lumes strengthened for \nus really through the conclusion of our June quarter.  June ended right prior to 4th of July holiday.  So there's \nalways nuances around timing of events like that.  \n \n I think as we think about going forward, you're exactly right.  We are not -- we have not built this plan around a \npresumption of a second lockdown, so to speak.  We think economies will continue to stay open. ", "original_text": "So there's \nalways nuances around timing of events like that.  \n \n", "page_label": "13", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f085fb6c-4660-42dc-89e2-bdb89b579fde", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2c3e458755c16dedbe502e38df9d4e7b055cf6cc93ed201578660c86c61cf792", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2dd2a762-8de9-4961-9242-17815d159241", "node_type": "1", "metadata": {"window": "April and may more or less tracked to the assumptions that we had laid out as we saw the \nrecovery progressing.  That held up early part of June, and then i t really accelerated, and it's pretty correlated to, if \nyou look at the timing of when states kind of relax their restrictions on movement and local economy, markets got \nopened back up and people got back to the business of health care.  And we saw those vo lumes strengthened for \nus really through the conclusion of our June quarter.  June ended right prior to 4th of July holiday.  So there's \nalways nuances around timing of events like that.  \n \n I think as we think about going forward, you're exactly right.  We are not -- we have not built this plan around a \npresumption of a second lockdown, so to speak. ", "original_text": "June ended right prior to 4th of July holiday. ", "page_label": "13", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e8b4ecee9c4e677cbf5e3ee0334871ee2ea706c21db97cdc6b6847497954497b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "334c2f84-cf45-438f-8bfe-679913724343", "node_type": "1", "metadata": {"window": "And we saw those vo lumes strengthened for \nus really through the conclusion of our June quarter.  June ended right prior to 4th of July holiday.  So there's \nalways nuances around timing of events like that.  \n \n I think as we think about going forward, you're exactly right.  We are not -- we have not built this plan around a \npresumption of a second lockdown, so to speak.  We think economies will continue to stay open.  I do think if you \nreflect on what's happened in Texas and Florida and Arizona and what's occurring now in other states  as those \nstates start to bend their curves downward, that's where we get to this idea. ", "original_text": "I think as we think about going forward, you're exactly right. "}, "hash": "e2b8d5e40bd79119ffbdd3583ad2bc0f3d5c9e8667265c1840fe2f0355178dc6", "class_name": "RelatedNodeInfo"}}, "text": "So there's \nalways nuances around timing of events like that.  \n \n", "start_char_idx": 2215, "end_char_idx": 2281, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "334c2f84-cf45-438f-8bfe-679913724343": {"__data__": {"id_": "334c2f84-cf45-438f-8bfe-679913724343", "embedding": null, "metadata": {"window": "And we saw those vo lumes strengthened for \nus really through the conclusion of our June quarter.  June ended right prior to 4th of July holiday.  So there's \nalways nuances around timing of events like that.  \n \n I think as we think about going forward, you're exactly right.  We are not -- we have not built this plan around a \npresumption of a second lockdown, so to speak.  We think economies will continue to stay open.  I do think if you \nreflect on what's happened in Texas and Florida and Arizona and what's occurring now in other states  as those \nstates start to bend their curves downward, that's where we get to this idea. ", "original_text": "I think as we think about going forward, you're exactly right. ", "page_label": "13", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f085fb6c-4660-42dc-89e2-bdb89b579fde", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2c3e458755c16dedbe502e38df9d4e7b055cf6cc93ed201578660c86c61cf792", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1cc88be2-aebd-4133-b9cb-05b37abdbc97", "node_type": "1", "metadata": {"window": "That held up early part of June, and then i t really accelerated, and it's pretty correlated to, if \nyou look at the timing of when states kind of relax their restrictions on movement and local economy, markets got \nopened back up and people got back to the business of health care.  And we saw those vo lumes strengthened for \nus really through the conclusion of our June quarter.  June ended right prior to 4th of July holiday.  So there's \nalways nuances around timing of events like that.  \n \n I think as we think about going forward, you're exactly right.  We are not -- we have not built this plan around a \npresumption of a second lockdown, so to speak.  We think economies will continue to stay open. ", "original_text": "So there's \nalways nuances around timing of events like that.  \n \n", "page_label": "13", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "54e4626e31869cddc158ac5aaa4f2778a4504c25cacfc99a3369b158964ead80", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ad4f54f9-8732-4a00-9785-1595ba316dcb", "node_type": "1", "metadata": {"window": "June ended right prior to 4th of July holiday.  So there's \nalways nuances around timing of events like that.  \n \n I think as we think about going forward, you're exactly right.  We are not -- we have not built this plan around a \npresumption of a second lockdown, so to speak.  We think economies will continue to stay open.  I do think if you \nreflect on what's happened in Texas and Florida and Arizona and what's occurring now in other states  as those \nstates start to bend their curves downward, that's where we get to this idea.  I think the word we use was linear. \n", "original_text": "We are not -- we have not built this plan around a \npresumption of a second lockdown, so to speak. "}, "hash": "aaa9cfd43f121c1faab50bcda068deac69501c7085e302658d28cc00fa020296", "class_name": "RelatedNodeInfo"}}, "text": "I think as we think about going forward, you're exactly right. ", "start_char_idx": 2281, "end_char_idx": 2344, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ad4f54f9-8732-4a00-9785-1595ba316dcb": {"__data__": {"id_": "ad4f54f9-8732-4a00-9785-1595ba316dcb", "embedding": null, "metadata": {"window": "June ended right prior to 4th of July holiday.  So there's \nalways nuances around timing of events like that.  \n \n I think as we think about going forward, you're exactly right.  We are not -- we have not built this plan around a \npresumption of a second lockdown, so to speak.  We think economies will continue to stay open.  I do think if you \nreflect on what's happened in Texas and Florida and Arizona and what's occurring now in other states  as those \nstates start to bend their curves downward, that's where we get to this idea.  I think the word we use was linear. \n", "original_text": "We are not -- we have not built this plan around a \npresumption of a second lockdown, so to speak. ", "page_label": "13", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f085fb6c-4660-42dc-89e2-bdb89b579fde", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2c3e458755c16dedbe502e38df9d4e7b055cf6cc93ed201578660c86c61cf792", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "334c2f84-cf45-438f-8bfe-679913724343", "node_type": "1", "metadata": {"window": "And we saw those vo lumes strengthened for \nus really through the conclusion of our June quarter.  June ended right prior to 4th of July holiday.  So there's \nalways nuances around timing of events like that.  \n \n I think as we think about going forward, you're exactly right.  We are not -- we have not built this plan around a \npresumption of a second lockdown, so to speak.  We think economies will continue to stay open.  I do think if you \nreflect on what's happened in Texas and Florida and Arizona and what's occurring now in other states  as those \nstates start to bend their curves downward, that's where we get to this idea. ", "original_text": "I think as we think about going forward, you're exactly right. ", "page_label": "13", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c8324b97688ed903426f7084f0a5ee15b6c9491b718b203d605525bb2d75c102", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d70b1c28-b86c-4481-b050-4a1e25806ffe", "node_type": "1", "metadata": {"window": "So there's \nalways nuances around timing of events like that.  \n \n I think as we think about going forward, you're exactly right.  We are not -- we have not built this plan around a \npresumption of a second lockdown, so to speak.  We think economies will continue to stay open.  I do think if you \nreflect on what's happened in Texas and Florida and Arizona and what's occurring now in other states  as those \nstates start to bend their curves downward, that's where we get to this idea.  I think the word we use was linear. \n We don't think it's going to be steady progression. ", "original_text": "We think economies will continue to stay open. "}, "hash": "ce34a7ce356dcd4a8e8b6c1e23b908b2eb49eed4957bb98302c72414997d1123", "class_name": "RelatedNodeInfo"}}, "text": "We are not -- we have not built this plan around a \npresumption of a second lockdown, so to speak. ", "start_char_idx": 2344, "end_char_idx": 2443, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d70b1c28-b86c-4481-b050-4a1e25806ffe": {"__data__": {"id_": "d70b1c28-b86c-4481-b050-4a1e25806ffe", "embedding": null, "metadata": {"window": "So there's \nalways nuances around timing of events like that.  \n \n I think as we think about going forward, you're exactly right.  We are not -- we have not built this plan around a \npresumption of a second lockdown, so to speak.  We think economies will continue to stay open.  I do think if you \nreflect on what's happened in Texas and Florida and Arizona and what's occurring now in other states  as those \nstates start to bend their curves downward, that's where we get to this idea.  I think the word we use was linear. \n We don't think it's going to be steady progression. ", "original_text": "We think economies will continue to stay open. ", "page_label": "13", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f085fb6c-4660-42dc-89e2-bdb89b579fde", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2c3e458755c16dedbe502e38df9d4e7b055cf6cc93ed201578660c86c61cf792", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ad4f54f9-8732-4a00-9785-1595ba316dcb", "node_type": "1", "metadata": {"window": "June ended right prior to 4th of July holiday.  So there's \nalways nuances around timing of events like that.  \n \n I think as we think about going forward, you're exactly right.  We are not -- we have not built this plan around a \npresumption of a second lockdown, so to speak.  We think economies will continue to stay open.  I do think if you \nreflect on what's happened in Texas and Florida and Arizona and what's occurring now in other states  as those \nstates start to bend their curves downward, that's where we get to this idea.  I think the word we use was linear. \n", "original_text": "We are not -- we have not built this plan around a \npresumption of a second lockdown, so to speak. ", "page_label": "13", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1c1f03e98b3b9c323e24e54739800d621b4823e3131ce605723b75f17959e044", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "180d6faf-ca44-43db-8f5d-eee1929affb7", "node_type": "1", "metadata": {"window": "I think as we think about going forward, you're exactly right.  We are not -- we have not built this plan around a \npresumption of a second lockdown, so to speak.  We think economies will continue to stay open.  I do think if you \nreflect on what's happened in Texas and Florida and Arizona and what's occurring now in other states  as those \nstates start to bend their curves downward, that's where we get to this idea.  I think the word we use was linear. \n We don't think it's going to be steady progression.  I mean based on states and cities and municipalities and how \nthe virus accelerat es or decelerates, we'll see some variability. ", "original_text": "I do think if you \nreflect on what's happened in Texas and Florida and Arizona and what's occurring now in other states  as those \nstates start to bend their curves downward, that's where we get to this idea. "}, "hash": "5caf2145cab04d84cb7435160707e4ff2344be77f08e6d4684df4c53115e2ed0", "class_name": "RelatedNodeInfo"}}, "text": "We think economies will continue to stay open. ", "start_char_idx": 2443, "end_char_idx": 2490, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "180d6faf-ca44-43db-8f5d-eee1929affb7": {"__data__": {"id_": "180d6faf-ca44-43db-8f5d-eee1929affb7", "embedding": null, "metadata": {"window": "I think as we think about going forward, you're exactly right.  We are not -- we have not built this plan around a \npresumption of a second lockdown, so to speak.  We think economies will continue to stay open.  I do think if you \nreflect on what's happened in Texas and Florida and Arizona and what's occurring now in other states  as those \nstates start to bend their curves downward, that's where we get to this idea.  I think the word we use was linear. \n We don't think it's going to be steady progression.  I mean based on states and cities and municipalities and how \nthe virus accelerat es or decelerates, we'll see some variability. ", "original_text": "I do think if you \nreflect on what's happened in Texas and Florida and Arizona and what's occurring now in other states  as those \nstates start to bend their curves downward, that's where we get to this idea. ", "page_label": "13", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f085fb6c-4660-42dc-89e2-bdb89b579fde", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2c3e458755c16dedbe502e38df9d4e7b055cf6cc93ed201578660c86c61cf792", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d70b1c28-b86c-4481-b050-4a1e25806ffe", "node_type": "1", "metadata": {"window": "So there's \nalways nuances around timing of events like that.  \n \n I think as we think about going forward, you're exactly right.  We are not -- we have not built this plan around a \npresumption of a second lockdown, so to speak.  We think economies will continue to stay open.  I do think if you \nreflect on what's happened in Texas and Florida and Arizona and what's occurring now in other states  as those \nstates start to bend their curves downward, that's where we get to this idea.  I think the word we use was linear. \n We don't think it's going to be steady progression. ", "original_text": "We think economies will continue to stay open. ", "page_label": "13", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f9246f4d1462411bab45a7f0f04af548ae50012ced3dc916558fbd060f56931a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9ffde07e-36ab-42ed-8976-82441ea0ca50", "node_type": "1", "metadata": {"window": "We are not -- we have not built this plan around a \npresumption of a second lockdown, so to speak.  We think economies will continue to stay open.  I do think if you \nreflect on what's happened in Texas and Florida and Arizona and what's occurring now in other states  as those \nstates start to bend their curves downward, that's where we get to this idea.  I think the word we use was linear. \n We don't think it's going to be steady progression.  I mean based on states and cities and municipalities and how \nthe virus accelerat es or decelerates, we'll see some variability.  But we are not anticipating a return to shelter in \nplace, like we saw in the March timeframe.  \n ", "original_text": "I think the word we use was linear. \n"}, "hash": "93dc369f7a59aad4917afe5a6daddb1221627abd2e98103215af96fdda63b30f", "class_name": "RelatedNodeInfo"}}, "text": "I do think if you \nreflect on what's happened in Texas and Florida and Arizona and what's occurring now in other states  as those \nstates start to bend their curves downward, that's where we get to this idea. ", "start_char_idx": 2490, "end_char_idx": 2699, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9ffde07e-36ab-42ed-8976-82441ea0ca50": {"__data__": {"id_": "9ffde07e-36ab-42ed-8976-82441ea0ca50", "embedding": null, "metadata": {"window": "We are not -- we have not built this plan around a \npresumption of a second lockdown, so to speak.  We think economies will continue to stay open.  I do think if you \nreflect on what's happened in Texas and Florida and Arizona and what's occurring now in other states  as those \nstates start to bend their curves downward, that's where we get to this idea.  I think the word we use was linear. \n We don't think it's going to be steady progression.  I mean based on states and cities and municipalities and how \nthe virus accelerat es or decelerates, we'll see some variability.  But we are not anticipating a return to shelter in \nplace, like we saw in the March timeframe.  \n ", "original_text": "I think the word we use was linear. \n", "page_label": "13", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f085fb6c-4660-42dc-89e2-bdb89b579fde", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2c3e458755c16dedbe502e38df9d4e7b055cf6cc93ed201578660c86c61cf792", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "180d6faf-ca44-43db-8f5d-eee1929affb7", "node_type": "1", "metadata": {"window": "I think as we think about going forward, you're exactly right.  We are not -- we have not built this plan around a \npresumption of a second lockdown, so to speak.  We think economies will continue to stay open.  I do think if you \nreflect on what's happened in Texas and Florida and Arizona and what's occurring now in other states  as those \nstates start to bend their curves downward, that's where we get to this idea.  I think the word we use was linear. \n We don't think it's going to be steady progression.  I mean based on states and cities and municipalities and how \nthe virus accelerat es or decelerates, we'll see some variability. ", "original_text": "I do think if you \nreflect on what's happened in Texas and Florida and Arizona and what's occurring now in other states  as those \nstates start to bend their curves downward, that's where we get to this idea. ", "page_label": "13", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a11efb38105a33943fea439f3c83585e9d5dad583de89942dafa260b6dfe00a2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "61e801b4-527b-43ba-a561-ca78db650dbc", "node_type": "1", "metadata": {"window": "We think economies will continue to stay open.  I do think if you \nreflect on what's happened in Texas and Florida and Arizona and what's occurring now in other states  as those \nstates start to bend their curves downward, that's where we get to this idea.  I think the word we use was linear. \n We don't think it's going to be steady progression.  I mean based on states and cities and municipalities and how \nthe virus accelerat es or decelerates, we'll see some variability.  But we are not anticipating a return to shelter in \nplace, like we saw in the March timeframe.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  ", "original_text": "We don't think it's going to be steady progression. "}, "hash": "02105c9254b4d9494f71e43202797309399c1b6948c5ae3e29a91a318648778a", "class_name": "RelatedNodeInfo"}}, "text": "I think the word we use was linear. \n", "start_char_idx": 2699, "end_char_idx": 2736, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "61e801b4-527b-43ba-a561-ca78db650dbc": {"__data__": {"id_": "61e801b4-527b-43ba-a561-ca78db650dbc", "embedding": null, "metadata": {"window": "We think economies will continue to stay open.  I do think if you \nreflect on what's happened in Texas and Florida and Arizona and what's occurring now in other states  as those \nstates start to bend their curves downward, that's where we get to this idea.  I think the word we use was linear. \n We don't think it's going to be steady progression.  I mean based on states and cities and municipalities and how \nthe virus accelerat es or decelerates, we'll see some variability.  But we are not anticipating a return to shelter in \nplace, like we saw in the March timeframe.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  ", "original_text": "We don't think it's going to be steady progression. ", "page_label": "13", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f085fb6c-4660-42dc-89e2-bdb89b579fde", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2c3e458755c16dedbe502e38df9d4e7b055cf6cc93ed201578660c86c61cf792", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9ffde07e-36ab-42ed-8976-82441ea0ca50", "node_type": "1", "metadata": {"window": "We are not -- we have not built this plan around a \npresumption of a second lockdown, so to speak.  We think economies will continue to stay open.  I do think if you \nreflect on what's happened in Texas and Florida and Arizona and what's occurring now in other states  as those \nstates start to bend their curves downward, that's where we get to this idea.  I think the word we use was linear. \n We don't think it's going to be steady progression.  I mean based on states and cities and municipalities and how \nthe virus accelerat es or decelerates, we'll see some variability.  But we are not anticipating a return to shelter in \nplace, like we saw in the March timeframe.  \n ", "original_text": "I think the word we use was linear. \n", "page_label": "13", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "df396293e9c7d8de80e1790887567f9f4300ba05bc041d6f4663bc8e9234590a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d75cc162-f184-463b-ba35-65d9a29070ee", "node_type": "1", "metadata": {"window": "I do think if you \nreflect on what's happened in Texas and Florida and Arizona and what's occurring now in other states  as those \nstates start to bend their curves downward, that's where we get to this idea.  I think the word we use was linear. \n We don't think it's going to be steady progression.  I mean based on states and cities and municipalities and how \nthe virus accelerat es or decelerates, we'll see some variability.  But we are not anticipating a return to shelter in \nplace, like we saw in the March timeframe.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question.  \n ", "original_text": "I mean based on states and cities and municipalities and how \nthe virus accelerat es or decelerates, we'll see some variability. "}, "hash": "42a8876544058049d864f18b7630f86d980d13612233f95b8813e9d0b02a4971", "class_name": "RelatedNodeInfo"}}, "text": "We don't think it's going to be steady progression. ", "start_char_idx": 2736, "end_char_idx": 2788, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d75cc162-f184-463b-ba35-65d9a29070ee": {"__data__": {"id_": "d75cc162-f184-463b-ba35-65d9a29070ee", "embedding": null, "metadata": {"window": "I do think if you \nreflect on what's happened in Texas and Florida and Arizona and what's occurring now in other states  as those \nstates start to bend their curves downward, that's where we get to this idea.  I think the word we use was linear. \n We don't think it's going to be steady progression.  I mean based on states and cities and municipalities and how \nthe virus accelerat es or decelerates, we'll see some variability.  But we are not anticipating a return to shelter in \nplace, like we saw in the March timeframe.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question.  \n ", "original_text": "I mean based on states and cities and municipalities and how \nthe virus accelerat es or decelerates, we'll see some variability. ", "page_label": "13", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f085fb6c-4660-42dc-89e2-bdb89b579fde", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2c3e458755c16dedbe502e38df9d4e7b055cf6cc93ed201578660c86c61cf792", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "61e801b4-527b-43ba-a561-ca78db650dbc", "node_type": "1", "metadata": {"window": "We think economies will continue to stay open.  I do think if you \nreflect on what's happened in Texas and Florida and Arizona and what's occurring now in other states  as those \nstates start to bend their curves downward, that's where we get to this idea.  I think the word we use was linear. \n We don't think it's going to be steady progression.  I mean based on states and cities and municipalities and how \nthe virus accelerat es or decelerates, we'll see some variability.  But we are not anticipating a return to shelter in \nplace, like we saw in the March timeframe.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  ", "original_text": "We don't think it's going to be steady progression. ", "page_label": "13", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3d3fb74d49d5fa1518b28bd8122ae2a2cfad606a4f5d74b4a52158f1c625553c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a89dadbc-54d0-4fb8-8aa3-77873803c918", "node_type": "1", "metadata": {"window": "I think the word we use was linear. \n We don't think it's going to be steady progression.  I mean based on states and cities and municipalities and how \nthe virus accelerat es or decelerates, we'll see some variability.  But we are not anticipating a return to shelter in \nplace, like we saw in the March timeframe.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next wil l be Michael Cherny with Bank of America Securities.  \n ", "original_text": "But we are not anticipating a return to shelter in \nplace, like we saw in the March timeframe.  \n "}, "hash": "fdbfd3277d021733f68b521073aca107ca7b7e2c8041b3ce06fb6368ba13aa13", "class_name": "RelatedNodeInfo"}}, "text": "I mean based on states and cities and municipalities and how \nthe virus accelerat es or decelerates, we'll see some variability. ", "start_char_idx": 2788, "end_char_idx": 2917, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a89dadbc-54d0-4fb8-8aa3-77873803c918": {"__data__": {"id_": "a89dadbc-54d0-4fb8-8aa3-77873803c918", "embedding": null, "metadata": {"window": "I think the word we use was linear. \n We don't think it's going to be steady progression.  I mean based on states and cities and municipalities and how \nthe virus accelerat es or decelerates, we'll see some variability.  But we are not anticipating a return to shelter in \nplace, like we saw in the March timeframe.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next wil l be Michael Cherny with Bank of America Securities.  \n ", "original_text": "But we are not anticipating a return to shelter in \nplace, like we saw in the March timeframe.  \n ", "page_label": "13", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f085fb6c-4660-42dc-89e2-bdb89b579fde", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2c3e458755c16dedbe502e38df9d4e7b055cf6cc93ed201578660c86c61cf792", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d75cc162-f184-463b-ba35-65d9a29070ee", "node_type": "1", "metadata": {"window": "I do think if you \nreflect on what's happened in Texas and Florida and Arizona and what's occurring now in other states  as those \nstates start to bend their curves downward, that's where we get to this idea.  I think the word we use was linear. \n We don't think it's going to be steady progression.  I mean based on states and cities and municipalities and how \nthe virus accelerat es or decelerates, we'll see some variability.  But we are not anticipating a return to shelter in \nplace, like we saw in the March timeframe.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question.  \n ", "original_text": "I mean based on states and cities and municipalities and how \nthe virus accelerat es or decelerates, we'll see some variability. ", "page_label": "13", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b7e88078f659c45c338d4fccd5b13b606798c0ff94d9fd26a4cfbde3edb8b493", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "139ce5c8-7e2c-4423-b8b1-f1aff5499f59", "node_type": "1", "metadata": {"window": "We don't think it's going to be steady progression.  I mean based on states and cities and municipalities and how \nthe virus accelerat es or decelerates, we'll see some variability.  But we are not anticipating a return to shelter in \nplace, like we saw in the March timeframe.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next wil l be Michael Cherny with Bank of America Securities.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  "}, "hash": "66530a1c4ad8a96d05f7d00c6b18933954734c01f9ebf89d4fd358a0de54f486", "class_name": "RelatedNodeInfo"}}, "text": "But we are not anticipating a return to shelter in \nplace, like we saw in the March timeframe.  \n ", "start_char_idx": 2917, "end_char_idx": 3015, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "139ce5c8-7e2c-4423-b8b1-f1aff5499f59": {"__data__": {"id_": "139ce5c8-7e2c-4423-b8b1-f1aff5499f59", "embedding": null, "metadata": {"window": "We don't think it's going to be steady progression.  I mean based on states and cities and municipalities and how \nthe virus accelerat es or decelerates, we'll see some variability.  But we are not anticipating a return to shelter in \nplace, like we saw in the March timeframe.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next wil l be Michael Cherny with Bank of America Securities.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  ", "page_label": "13", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f085fb6c-4660-42dc-89e2-bdb89b579fde", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2c3e458755c16dedbe502e38df9d4e7b055cf6cc93ed201578660c86c61cf792", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a89dadbc-54d0-4fb8-8aa3-77873803c918", "node_type": "1", "metadata": {"window": "I think the word we use was linear. \n We don't think it's going to be steady progression.  I mean based on states and cities and municipalities and how \nthe virus accelerat es or decelerates, we'll see some variability.  But we are not anticipating a return to shelter in \nplace, like we saw in the March timeframe.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next wil l be Michael Cherny with Bank of America Securities.  \n ", "original_text": "But we are not anticipating a return to shelter in \nplace, like we saw in the March timeframe.  \n ", "page_label": "13", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b606fa9e092f8144cd2c467ffae48aebbb66e41b2c66523567ab2fee0aaa859f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3a450d77-7c6c-43b4-b348-6d94e307a272", "node_type": "1", "metadata": {"window": "I mean based on states and cities and municipalities and how \nthe virus accelerat es or decelerates, we'll see some variability.  But we are not anticipating a return to shelter in \nplace, like we saw in the March timeframe.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next wil l be Michael Cherny with Bank of America Securities.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.   Q \nGood morning and congratulations on the strong results. ", "original_text": "A \nNext question.  \n "}, "hash": "f17a68478fd4d4e6b1ae92b877a507378c2e8f11a11484ad583f3e27d91b889d", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  ", "start_char_idx": 3015, "end_char_idx": 3360, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3a450d77-7c6c-43b4-b348-6d94e307a272": {"__data__": {"id_": "3a450d77-7c6c-43b4-b348-6d94e307a272", "embedding": null, "metadata": {"window": "I mean based on states and cities and municipalities and how \nthe virus accelerat es or decelerates, we'll see some variability.  But we are not anticipating a return to shelter in \nplace, like we saw in the March timeframe.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next wil l be Michael Cherny with Bank of America Securities.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.   Q \nGood morning and congratulations on the strong results. ", "original_text": "A \nNext question.  \n ", "page_label": "13", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f085fb6c-4660-42dc-89e2-bdb89b579fde", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2c3e458755c16dedbe502e38df9d4e7b055cf6cc93ed201578660c86c61cf792", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "139ce5c8-7e2c-4423-b8b1-f1aff5499f59", "node_type": "1", "metadata": {"window": "We don't think it's going to be steady progression.  I mean based on states and cities and municipalities and how \nthe virus accelerat es or decelerates, we'll see some variability.  But we are not anticipating a return to shelter in \nplace, like we saw in the March timeframe.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next wil l be Michael Cherny with Bank of America Securities.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  ", "page_label": "13", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "56f57ada77cb55354b80683f4fff35eb096f2cc11dbb7b5fe2d369d530797253", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "246f5d56-0ca3-40c2-b173-9ac2d81eb6db", "node_type": "1", "metadata": {"window": "But we are not anticipating a return to shelter in \nplace, like we saw in the March timeframe.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next wil l be Michael Cherny with Bank of America Securities.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.   Q \nGood morning and congratulations on the strong results.  I want to dive in a little bit to the pharma segment. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next wil l be Michael Cherny with Bank of America Securities.  \n "}, "hash": "f04489afae73aa2f4b0d98a2cbbd8abd20dc6df4c8041a72d39b86dabf8d3cd1", "class_name": "RelatedNodeInfo"}}, "text": "A \nNext question.  \n ", "start_char_idx": 3360, "end_char_idx": 3381, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "246f5d56-0ca3-40c2-b173-9ac2d81eb6db": {"__data__": {"id_": "246f5d56-0ca3-40c2-b173-9ac2d81eb6db", "embedding": null, "metadata": {"window": "But we are not anticipating a return to shelter in \nplace, like we saw in the March timeframe.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next wil l be Michael Cherny with Bank of America Securities.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.   Q \nGood morning and congratulations on the strong results.  I want to dive in a little bit to the pharma segment. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next wil l be Michael Cherny with Bank of America Securities.  \n ", "page_label": "13", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f085fb6c-4660-42dc-89e2-bdb89b579fde", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2c3e458755c16dedbe502e38df9d4e7b055cf6cc93ed201578660c86c61cf792", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3a450d77-7c6c-43b4-b348-6d94e307a272", "node_type": "1", "metadata": {"window": "I mean based on states and cities and municipalities and how \nthe virus accelerat es or decelerates, we'll see some variability.  But we are not anticipating a return to shelter in \nplace, like we saw in the March timeframe.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next wil l be Michael Cherny with Bank of America Securities.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.   Q \nGood morning and congratulations on the strong results. ", "original_text": "A \nNext question.  \n ", "page_label": "13", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "77fb0dbabae0e4280fe596bd9f0e53d98c9e35f6bb6bb2414c89a29fd457affc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b8b636f7-714c-45c0-b72d-2d10100244db", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next wil l be Michael Cherny with Bank of America Securities.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.   Q \nGood morning and congratulations on the strong results.  I want to dive in a little bit to the pharma segment.  You \nhad a comment in your release about the strength in national accounts, you talked about that going forward. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  "}, "hash": "218e85ae4fdd59ff5a4e75acd840701f120701f53f53bbcedcfd120b58eef88c", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next wil l be Michael Cherny with Bank of America Securities.  \n ", "start_char_idx": 3381, "end_char_idx": 3735, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b8b636f7-714c-45c0-b72d-2d10100244db": {"__data__": {"id_": "b8b636f7-714c-45c0-b72d-2d10100244db", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next wil l be Michael Cherny with Bank of America Securities.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.   Q \nGood morning and congratulations on the strong results.  I want to dive in a little bit to the pharma segment.  You \nhad a comment in your release about the strength in national accounts, you talked about that going forward. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  ", "page_label": "13", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f085fb6c-4660-42dc-89e2-bdb89b579fde", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2c3e458755c16dedbe502e38df9d4e7b055cf6cc93ed201578660c86c61cf792", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "246f5d56-0ca3-40c2-b173-9ac2d81eb6db", "node_type": "1", "metadata": {"window": "But we are not anticipating a return to shelter in \nplace, like we saw in the March timeframe.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next wil l be Michael Cherny with Bank of America Securities.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.   Q \nGood morning and congratulations on the strong results.  I want to dive in a little bit to the pharma segment. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next wil l be Michael Cherny with Bank of America Securities.  \n ", "page_label": "13", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6fdb6db55c127babe66bc5db9395d3471fad39604766780e03adb362968a99e5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c633a7c0-5246-4de1-84b2-1406f7dc362b", "node_type": "1", "metadata": {"window": "A \nNext question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next wil l be Michael Cherny with Bank of America Securities.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.   Q \nGood morning and congratulations on the strong results.  I want to dive in a little bit to the pharma segment.  You \nhad a comment in your release about the strength in national accounts, you talked about that going forward.  Can \nyou maybe bifurcate a little bit in terms of the pacing of recovery you're seeing, the differences you're seeing \nbroadly between those national accounts versus some of the independ ent pharmacies that you've traditionally \nserved and how those should dovetail going forward given the various different pacings of openings across the \ncountry?  \n ", "original_text": "Q \nGood morning and congratulations on the strong results. "}, "hash": "343d69bc4650c6677d61c925ba4b5058ec44b524acafc81bfed0e66448ab9d15", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  ", "start_char_idx": 3735, "end_char_idx": 4056, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c633a7c0-5246-4de1-84b2-1406f7dc362b": {"__data__": {"id_": "c633a7c0-5246-4de1-84b2-1406f7dc362b", "embedding": null, "metadata": {"window": "A \nNext question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next wil l be Michael Cherny with Bank of America Securities.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.   Q \nGood morning and congratulations on the strong results.  I want to dive in a little bit to the pharma segment.  You \nhad a comment in your release about the strength in national accounts, you talked about that going forward.  Can \nyou maybe bifurcate a little bit in terms of the pacing of recovery you're seeing, the differences you're seeing \nbroadly between those national accounts versus some of the independ ent pharmacies that you've traditionally \nserved and how those should dovetail going forward given the various different pacings of openings across the \ncountry?  \n ", "original_text": "Q \nGood morning and congratulations on the strong results. ", "page_label": "13", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f085fb6c-4660-42dc-89e2-bdb89b579fde", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2c3e458755c16dedbe502e38df9d4e7b055cf6cc93ed201578660c86c61cf792", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b8b636f7-714c-45c0-b72d-2d10100244db", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next wil l be Michael Cherny with Bank of America Securities.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.   Q \nGood morning and congratulations on the strong results.  I want to dive in a little bit to the pharma segment.  You \nhad a comment in your release about the strength in national accounts, you talked about that going forward. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  ", "page_label": "13", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9eff5e55b4043fe68fdd022e38cc89f33db867e7b0b13e2ba067ca19f1ba8804", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9a23614e-c7c3-4412-ac36-207c6a390d57", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next wil l be Michael Cherny with Bank of America Securities.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.   Q \nGood morning and congratulations on the strong results.  I want to dive in a little bit to the pharma segment.  You \nhad a comment in your release about the strength in national accounts, you talked about that going forward.  Can \nyou maybe bifurcate a little bit in terms of the pacing of recovery you're seeing, the differences you're seeing \nbroadly between those national accounts versus some of the independ ent pharmacies that you've traditionally \nserved and how those should dovetail going forward given the various different pacings of openings across the \ncountry?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "I want to dive in a little bit to the pharma segment. "}, "hash": "bb87cb7ecc6bd19ff5e9d25a4aaf28fc661917c07cc82049936fee1588192d68", "class_name": "RelatedNodeInfo"}}, "text": "Q \nGood morning and congratulations on the strong results. ", "start_char_idx": 4056, "end_char_idx": 4115, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9a23614e-c7c3-4412-ac36-207c6a390d57": {"__data__": {"id_": "9a23614e-c7c3-4412-ac36-207c6a390d57", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next wil l be Michael Cherny with Bank of America Securities.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.   Q \nGood morning and congratulations on the strong results.  I want to dive in a little bit to the pharma segment.  You \nhad a comment in your release about the strength in national accounts, you talked about that going forward.  Can \nyou maybe bifurcate a little bit in terms of the pacing of recovery you're seeing, the differences you're seeing \nbroadly between those national accounts versus some of the independ ent pharmacies that you've traditionally \nserved and how those should dovetail going forward given the various different pacings of openings across the \ncountry?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "I want to dive in a little bit to the pharma segment. ", "page_label": "13", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f085fb6c-4660-42dc-89e2-bdb89b579fde", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2c3e458755c16dedbe502e38df9d4e7b055cf6cc93ed201578660c86c61cf792", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c633a7c0-5246-4de1-84b2-1406f7dc362b", "node_type": "1", "metadata": {"window": "A \nNext question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next wil l be Michael Cherny with Bank of America Securities.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.   Q \nGood morning and congratulations on the strong results.  I want to dive in a little bit to the pharma segment.  You \nhad a comment in your release about the strength in national accounts, you talked about that going forward.  Can \nyou maybe bifurcate a little bit in terms of the pacing of recovery you're seeing, the differences you're seeing \nbroadly between those national accounts versus some of the independ ent pharmacies that you've traditionally \nserved and how those should dovetail going forward given the various different pacings of openings across the \ncountry?  \n ", "original_text": "Q \nGood morning and congratulations on the strong results. ", "page_label": "13", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "25bf18158138b0593cdead1cadcb276cc1bfd0e483d6676bd18b3c1b7aea243f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ef718386-b747-43f4-a513-f24ba8eb2955", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.   Q \nGood morning and congratulations on the strong results.  I want to dive in a little bit to the pharma segment.  You \nhad a comment in your release about the strength in national accounts, you talked about that going forward.  Can \nyou maybe bifurcate a little bit in terms of the pacing of recovery you're seeing, the differences you're seeing \nbroadly between those national accounts versus some of the independ ent pharmacies that you've traditionally \nserved and how those should dovetail going forward given the various different pacings of openings across the \ncountry?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A ", "original_text": "You \nhad a comment in your release about the strength in national accounts, you talked about that going forward. "}, "hash": "85d3b85aac47f873971a8a24c41b1933407a63fb721dc4d782f10d283ece0686", "class_name": "RelatedNodeInfo"}}, "text": "I want to dive in a little bit to the pharma segment. ", "start_char_idx": 4115, "end_char_idx": 4169, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ef718386-b747-43f4-a513-f24ba8eb2955": {"__data__": {"id_": "ef718386-b747-43f4-a513-f24ba8eb2955", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.   Q \nGood morning and congratulations on the strong results.  I want to dive in a little bit to the pharma segment.  You \nhad a comment in your release about the strength in national accounts, you talked about that going forward.  Can \nyou maybe bifurcate a little bit in terms of the pacing of recovery you're seeing, the differences you're seeing \nbroadly between those national accounts versus some of the independ ent pharmacies that you've traditionally \nserved and how those should dovetail going forward given the various different pacings of openings across the \ncountry?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A ", "original_text": "You \nhad a comment in your release about the strength in national accounts, you talked about that going forward. ", "page_label": "13", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f085fb6c-4660-42dc-89e2-bdb89b579fde", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2c3e458755c16dedbe502e38df9d4e7b055cf6cc93ed201578660c86c61cf792", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9a23614e-c7c3-4412-ac36-207c6a390d57", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next wil l be Michael Cherny with Bank of America Securities.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.   Q \nGood morning and congratulations on the strong results.  I want to dive in a little bit to the pharma segment.  You \nhad a comment in your release about the strength in national accounts, you talked about that going forward.  Can \nyou maybe bifurcate a little bit in terms of the pacing of recovery you're seeing, the differences you're seeing \nbroadly between those national accounts versus some of the independ ent pharmacies that you've traditionally \nserved and how those should dovetail going forward given the various different pacings of openings across the \ncountry?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "I want to dive in a little bit to the pharma segment. ", "page_label": "13", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "192ea8c5293d7e2db0ecae4ab57b761969e79cb058acf64c3ab9fe542518d82f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9cdc62f6-7401-4a99-9359-4b105a2794db", "node_type": "1", "metadata": {"window": "Q \nGood morning and congratulations on the strong results.  I want to dive in a little bit to the pharma segment.  You \nhad a comment in your release about the strength in national accounts, you talked about that going forward.  Can \nyou maybe bifurcate a little bit in terms of the pacing of recovery you're seeing, the differences you're seeing \nbroadly between those national accounts versus some of the independ ent pharmacies that you've traditionally \nserved and how those should dovetail going forward given the various different pacings of openings across the \ncountry?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A ", "original_text": "Can \nyou maybe bifurcate a little bit in terms of the pacing of recovery you're seeing, the differences you're seeing \nbroadly between those national accounts versus some of the independ ent pharmacies that you've traditionally \nserved and how those should dovetail going forward given the various different pacings of openings across the \ncountry?  \n "}, "hash": "0b8f117b86b1d057bacbe11357144fe6fd1400be58b9e920e7cef1f2f3db5b4c", "class_name": "RelatedNodeInfo"}}, "text": "You \nhad a comment in your release about the strength in national accounts, you talked about that going forward. ", "start_char_idx": 4169, "end_char_idx": 4282, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9cdc62f6-7401-4a99-9359-4b105a2794db": {"__data__": {"id_": "9cdc62f6-7401-4a99-9359-4b105a2794db", "embedding": null, "metadata": {"window": "Q \nGood morning and congratulations on the strong results.  I want to dive in a little bit to the pharma segment.  You \nhad a comment in your release about the strength in national accounts, you talked about that going forward.  Can \nyou maybe bifurcate a little bit in terms of the pacing of recovery you're seeing, the differences you're seeing \nbroadly between those national accounts versus some of the independ ent pharmacies that you've traditionally \nserved and how those should dovetail going forward given the various different pacings of openings across the \ncountry?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A ", "original_text": "Can \nyou maybe bifurcate a little bit in terms of the pacing of recovery you're seeing, the differences you're seeing \nbroadly between those national accounts versus some of the independ ent pharmacies that you've traditionally \nserved and how those should dovetail going forward given the various different pacings of openings across the \ncountry?  \n ", "page_label": "13", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f085fb6c-4660-42dc-89e2-bdb89b579fde", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2c3e458755c16dedbe502e38df9d4e7b055cf6cc93ed201578660c86c61cf792", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ef718386-b747-43f4-a513-f24ba8eb2955", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.   Q \nGood morning and congratulations on the strong results.  I want to dive in a little bit to the pharma segment.  You \nhad a comment in your release about the strength in national accounts, you talked about that going forward.  Can \nyou maybe bifurcate a little bit in terms of the pacing of recovery you're seeing, the differences you're seeing \nbroadly between those national accounts versus some of the independ ent pharmacies that you've traditionally \nserved and how those should dovetail going forward given the various different pacings of openings across the \ncountry?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A ", "original_text": "You \nhad a comment in your release about the strength in national accounts, you talked about that going forward. ", "page_label": "13", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4e3f74e5881f8ae6e12c14a4d2ee94528effb5a106e0d43bc32d6ab0e909231b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "90bea696-4582-4e89-8d53-8ff185b540fb", "node_type": "1", "metadata": {"window": "I want to dive in a little bit to the pharma segment.  You \nhad a comment in your release about the strength in national accounts, you talked about that going forward.  Can \nyou maybe bifurcate a little bit in terms of the pacing of recovery you're seeing, the differences you're seeing \nbroadly between those national accounts versus some of the independ ent pharmacies that you've traditionally \nserved and how those should dovetail going forward given the various different pacings of openings across the \ncountry?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  "}, "hash": "283498bcd54b94f3f465d29517b91c93145759769e0e9e5935aab6e5cad2b4af", "class_name": "RelatedNodeInfo"}}, "text": "Can \nyou maybe bifurcate a little bit in terms of the pacing of recovery you're seeing, the differences you're seeing \nbroadly between those national accounts versus some of the independ ent pharmacies that you've traditionally \nserved and how those should dovetail going forward given the various different pacings of openings across the \ncountry?  \n ", "start_char_idx": 4282, "end_char_idx": 4634, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "90bea696-4582-4e89-8d53-8ff185b540fb": {"__data__": {"id_": "90bea696-4582-4e89-8d53-8ff185b540fb", "embedding": null, "metadata": {"window": "I want to dive in a little bit to the pharma segment.  You \nhad a comment in your release about the strength in national accounts, you talked about that going forward.  Can \nyou maybe bifurcate a little bit in terms of the pacing of recovery you're seeing, the differences you're seeing \nbroadly between those national accounts versus some of the independ ent pharmacies that you've traditionally \nserved and how those should dovetail going forward given the various different pacings of openings across the \ncountry?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "13", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f085fb6c-4660-42dc-89e2-bdb89b579fde", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2c3e458755c16dedbe502e38df9d4e7b055cf6cc93ed201578660c86c61cf792", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9cdc62f6-7401-4a99-9359-4b105a2794db", "node_type": "1", "metadata": {"window": "Q \nGood morning and congratulations on the strong results.  I want to dive in a little bit to the pharma segment.  You \nhad a comment in your release about the strength in national accounts, you talked about that going forward.  Can \nyou maybe bifurcate a little bit in terms of the pacing of recovery you're seeing, the differences you're seeing \nbroadly between those national accounts versus some of the independ ent pharmacies that you've traditionally \nserved and how those should dovetail going forward given the various different pacings of openings across the \ncountry?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A ", "original_text": "Can \nyou maybe bifurcate a little bit in terms of the pacing of recovery you're seeing, the differences you're seeing \nbroadly between those national accounts versus some of the independ ent pharmacies that you've traditionally \nserved and how those should dovetail going forward given the various different pacings of openings across the \ncountry?  \n ", "page_label": "13", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5d502530452d2ba454c7dcc06d13257f0ced3acdfe222060f9b1fb79eb1b0493", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ebdedf06-6dbb-4a0e-8428-b4cf148d6d2e", "node_type": "1", "metadata": {"window": "You \nhad a comment in your release about the strength in national accounts, you talked about that going forward.  Can \nyou maybe bifurcate a little bit in terms of the pacing of recovery you're seeing, the differences you're seeing \nbroadly between those national accounts versus some of the independ ent pharmacies that you've traditionally \nserved and how those should dovetail going forward given the various different pacings of openings across the \ncountry?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A ", "original_text": "A "}, "hash": "e4d22d3109df85c06986cad742a702f8cd3961b5fb4ff69eccd8cabd0adb997f", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "start_char_idx": 1197, "end_char_idx": 1538, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ebdedf06-6dbb-4a0e-8428-b4cf148d6d2e": {"__data__": {"id_": "ebdedf06-6dbb-4a0e-8428-b4cf148d6d2e", "embedding": null, "metadata": {"window": "You \nhad a comment in your release about the strength in national accounts, you talked about that going forward.  Can \nyou maybe bifurcate a little bit in terms of the pacing of recovery you're seeing, the differences you're seeing \nbroadly between those national accounts versus some of the independ ent pharmacies that you've traditionally \nserved and how those should dovetail going forward given the various different pacings of openings across the \ncountry?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A ", "original_text": "A ", "page_label": "13", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f085fb6c-4660-42dc-89e2-bdb89b579fde", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2c3e458755c16dedbe502e38df9d4e7b055cf6cc93ed201578660c86c61cf792", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "90bea696-4582-4e89-8d53-8ff185b540fb", "node_type": "1", "metadata": {"window": "I want to dive in a little bit to the pharma segment.  You \nhad a comment in your release about the strength in national accounts, you talked about that going forward.  Can \nyou maybe bifurcate a little bit in terms of the pacing of recovery you're seeing, the differences you're seeing \nbroadly between those national accounts versus some of the independ ent pharmacies that you've traditionally \nserved and how those should dovetail going forward given the various different pacings of openings across the \ncountry?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "13", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e513fa43364ee775ef26e3b7cd538b5f2a82ebe5fe7c19c85fd0ed5d1d098beb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6bc090c6-5e71-43b3-b7a4-e39ff5754f00", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nSure.  I would say as a ge neral characterization, the pacing has been pretty consistent retail national account \nversus independent.  Meaning the macro trend of when we saw volume soften in April, start to recover in May, \ncontinue to bounce back in June. ", "original_text": "McKesson Corp.  "}, "hash": "63f50c44a164194690e343d3c10765c7f2415f90146b116326281f45e0afee18", "class_name": "RelatedNodeInfo"}}, "text": "A ", "start_char_idx": 1538, "end_char_idx": 1540, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6bc090c6-5e71-43b3-b7a4-e39ff5754f00": {"__data__": {"id_": "6bc090c6-5e71-43b3-b7a4-e39ff5754f00", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nSure.  I would say as a ge neral characterization, the pacing has been pretty consistent retail national account \nversus independent.  Meaning the macro trend of when we saw volume soften in April, start to recover in May, \ncontinue to bounce back in June. ", "original_text": "McKesson Corp.  ", "page_label": "14", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f3e49820-b6cd-4d4a-91ea-9dc1750852df", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "59c3942a2d303414eda505b9f65d9736e4825436bfba4ef5c5e10b14336b6ca8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ebdedf06-6dbb-4a0e-8428-b4cf148d6d2e", "node_type": "1", "metadata": {"window": "You \nhad a comment in your release about the strength in national accounts, you talked about that going forward.  Can \nyou maybe bifurcate a little bit in terms of the pacing of recovery you're seeing, the differences you're seeing \nbroadly between those national accounts versus some of the independ ent pharmacies that you've traditionally \nserved and how those should dovetail going forward given the various different pacings of openings across the \ncountry?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A ", "original_text": "A ", "page_label": "13", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e43b8994ef5501c3e68641ddc280873ed496b918824b58ac4a2912e4f03a1915", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "683fbde6-e239-4ae3-a233-3e6d5693b8c0", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nSure.  I would say as a ge neral characterization, the pacing has been pretty consistent retail national account \nversus independent.  Meaning the macro trend of when we saw volume soften in April, start to recover in May, \ncontinue to bounce back in June.  I think those trend lines are  largely consistent. ", "original_text": "(MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nSure. "}, "hash": "693426ed7878f8a0710cb204b88fd8816bff0cb6397d79b079aec72a605d4c0c", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "683fbde6-e239-4ae3-a233-3e6d5693b8c0": {"__data__": {"id_": "683fbde6-e239-4ae3-a233-3e6d5693b8c0", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nSure.  I would say as a ge neral characterization, the pacing has been pretty consistent retail national account \nversus independent.  Meaning the macro trend of when we saw volume soften in April, start to recover in May, \ncontinue to bounce back in June.  I think those trend lines are  largely consistent. ", "original_text": "(MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nSure. ", "page_label": "14", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f3e49820-b6cd-4d4a-91ea-9dc1750852df", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "59c3942a2d303414eda505b9f65d9736e4825436bfba4ef5c5e10b14336b6ca8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6bc090c6-5e71-43b3-b7a4-e39ff5754f00", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nSure.  I would say as a ge neral characterization, the pacing has been pretty consistent retail national account \nversus independent.  Meaning the macro trend of when we saw volume soften in April, start to recover in May, \ncontinue to bounce back in June. ", "original_text": "McKesson Corp.  ", "page_label": "14", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e458eedde8ca3ff4c42f2443b4e320a56992f15036f10df06f150e1d4d52922a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "004ca8d7-3af7-4d84-b747-5a9205347009", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nSure.  I would say as a ge neral characterization, the pacing has been pretty consistent retail national account \nversus independent.  Meaning the macro trend of when we saw volume soften in April, start to recover in May, \ncontinue to bounce back in June.  I think those trend lines are  largely consistent.  A national chain probably has a \nlittle less exposure, to a particular state or community that might be experiencing a better or worse, COVID \nprogression. ", "original_text": "I would say as a ge neral characterization, the pacing has been pretty consistent retail national account \nversus independent. "}, "hash": "6bf60df181e408e2e1d571e715f9a3e7702811e2c37c4a1395e56375f68d5407", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nSure. ", "start_char_idx": 16, "end_char_idx": 187, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "004ca8d7-3af7-4d84-b747-5a9205347009": {"__data__": {"id_": "004ca8d7-3af7-4d84-b747-5a9205347009", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nSure.  I would say as a ge neral characterization, the pacing has been pretty consistent retail national account \nversus independent.  Meaning the macro trend of when we saw volume soften in April, start to recover in May, \ncontinue to bounce back in June.  I think those trend lines are  largely consistent.  A national chain probably has a \nlittle less exposure, to a particular state or community that might be experiencing a better or worse, COVID \nprogression. ", "original_text": "I would say as a ge neral characterization, the pacing has been pretty consistent retail national account \nversus independent. ", "page_label": "14", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f3e49820-b6cd-4d4a-91ea-9dc1750852df", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "59c3942a2d303414eda505b9f65d9736e4825436bfba4ef5c5e10b14336b6ca8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "683fbde6-e239-4ae3-a233-3e6d5693b8c0", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nSure.  I would say as a ge neral characterization, the pacing has been pretty consistent retail national account \nversus independent.  Meaning the macro trend of when we saw volume soften in April, start to recover in May, \ncontinue to bounce back in June.  I think those trend lines are  largely consistent. ", "original_text": "(MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nSure. ", "page_label": "14", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3514dc614d9119df700a3b9de99e9e10cc5891ef3ae435843c2cf018a5b14709", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6ce1395d-3d3f-4ad9-8353-8c9d9c6f779f", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nSure.  I would say as a ge neral characterization, the pacing has been pretty consistent retail national account \nversus independent.  Meaning the macro trend of when we saw volume soften in April, start to recover in May, \ncontinue to bounce back in June.  I think those trend lines are  largely consistent.  A national chain probably has a \nlittle less exposure, to a particular state or community that might be experiencing a better or worse, COVID \nprogression.  So obviously, there's some almost built -in risk mitigation from being a national chain.  \n \n", "original_text": "Meaning the macro trend of when we saw volume soften in April, start to recover in May, \ncontinue to bounce back in June. "}, "hash": "91361675ec82e746a4e59f837b4b546b5549b27ed6031f977b45f8fac81b24a1", "class_name": "RelatedNodeInfo"}}, "text": "I would say as a ge neral characterization, the pacing has been pretty consistent retail national account \nversus independent. ", "start_char_idx": 187, "end_char_idx": 314, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6ce1395d-3d3f-4ad9-8353-8c9d9c6f779f": {"__data__": {"id_": "6ce1395d-3d3f-4ad9-8353-8c9d9c6f779f", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nSure.  I would say as a ge neral characterization, the pacing has been pretty consistent retail national account \nversus independent.  Meaning the macro trend of when we saw volume soften in April, start to recover in May, \ncontinue to bounce back in June.  I think those trend lines are  largely consistent.  A national chain probably has a \nlittle less exposure, to a particular state or community that might be experiencing a better or worse, COVID \nprogression.  So obviously, there's some almost built -in risk mitigation from being a national chain.  \n \n", "original_text": "Meaning the macro trend of when we saw volume soften in April, start to recover in May, \ncontinue to bounce back in June. ", "page_label": "14", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f3e49820-b6cd-4d4a-91ea-9dc1750852df", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "59c3942a2d303414eda505b9f65d9736e4825436bfba4ef5c5e10b14336b6ca8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "004ca8d7-3af7-4d84-b747-5a9205347009", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nSure.  I would say as a ge neral characterization, the pacing has been pretty consistent retail national account \nversus independent.  Meaning the macro trend of when we saw volume soften in April, start to recover in May, \ncontinue to bounce back in June.  I think those trend lines are  largely consistent.  A national chain probably has a \nlittle less exposure, to a particular state or community that might be experiencing a better or worse, COVID \nprogression. ", "original_text": "I would say as a ge neral characterization, the pacing has been pretty consistent retail national account \nversus independent. ", "page_label": "14", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "90fa48597a2c7db21fc1353c91d8efd6a36156db6b6a5d4d0b9216c065710e6d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "42e85c84-3e85-4071-88e4-8ed05a268c08", "node_type": "1", "metadata": {"window": "(MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nSure.  I would say as a ge neral characterization, the pacing has been pretty consistent retail national account \nversus independent.  Meaning the macro trend of when we saw volume soften in April, start to recover in May, \ncontinue to bounce back in June.  I think those trend lines are  largely consistent.  A national chain probably has a \nlittle less exposure, to a particular state or community that might be experiencing a better or worse, COVID \nprogression.  So obviously, there's some almost built -in risk mitigation from being a national chain.  \n \n But by and large, I think the independents have held up pretty well. ", "original_text": "I think those trend lines are  largely consistent. "}, "hash": "93826677641f37ae14b0991faeaa4e3eb09ae80adc25b4e05bd0f74e123056d0", "class_name": "RelatedNodeInfo"}}, "text": "Meaning the macro trend of when we saw volume soften in April, start to recover in May, \ncontinue to bounce back in June. ", "start_char_idx": 314, "end_char_idx": 436, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "42e85c84-3e85-4071-88e4-8ed05a268c08": {"__data__": {"id_": "42e85c84-3e85-4071-88e4-8ed05a268c08", "embedding": null, "metadata": {"window": "(MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nSure.  I would say as a ge neral characterization, the pacing has been pretty consistent retail national account \nversus independent.  Meaning the macro trend of when we saw volume soften in April, start to recover in May, \ncontinue to bounce back in June.  I think those trend lines are  largely consistent.  A national chain probably has a \nlittle less exposure, to a particular state or community that might be experiencing a better or worse, COVID \nprogression.  So obviously, there's some almost built -in risk mitigation from being a national chain.  \n \n But by and large, I think the independents have held up pretty well. ", "original_text": "I think those trend lines are  largely consistent. ", "page_label": "14", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f3e49820-b6cd-4d4a-91ea-9dc1750852df", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "59c3942a2d303414eda505b9f65d9736e4825436bfba4ef5c5e10b14336b6ca8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6ce1395d-3d3f-4ad9-8353-8c9d9c6f779f", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nSure.  I would say as a ge neral characterization, the pacing has been pretty consistent retail national account \nversus independent.  Meaning the macro trend of when we saw volume soften in April, start to recover in May, \ncontinue to bounce back in June.  I think those trend lines are  largely consistent.  A national chain probably has a \nlittle less exposure, to a particular state or community that might be experiencing a better or worse, COVID \nprogression.  So obviously, there's some almost built -in risk mitigation from being a national chain.  \n \n", "original_text": "Meaning the macro trend of when we saw volume soften in April, start to recover in May, \ncontinue to bounce back in June. ", "page_label": "14", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6e069dcdf0c079355b6b27722b91d20815699bd0f66d3365c773dc07217611c8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "96c5aa32-36ca-4949-9c22-90a1d1be3543", "node_type": "1", "metadata": {"window": "I would say as a ge neral characterization, the pacing has been pretty consistent retail national account \nversus independent.  Meaning the macro trend of when we saw volume soften in April, start to recover in May, \ncontinue to bounce back in June.  I think those trend lines are  largely consistent.  A national chain probably has a \nlittle less exposure, to a particular state or community that might be experiencing a better or worse, COVID \nprogression.  So obviously, there's some almost built -in risk mitigation from being a national chain.  \n \n But by and large, I think the independents have held up pretty well.  We have \u2013 we stay obviously in close contact \nwith them. ", "original_text": "A national chain probably has a \nlittle less exposure, to a particular state or community that might be experiencing a better or worse, COVID \nprogression. "}, "hash": "76d3d080a03c37bcbe47f954ba91dd66dbdf340d14cdc9cfa3e35d2e9b16b74a", "class_name": "RelatedNodeInfo"}}, "text": "I think those trend lines are  largely consistent. ", "start_char_idx": 436, "end_char_idx": 487, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "96c5aa32-36ca-4949-9c22-90a1d1be3543": {"__data__": {"id_": "96c5aa32-36ca-4949-9c22-90a1d1be3543", "embedding": null, "metadata": {"window": "I would say as a ge neral characterization, the pacing has been pretty consistent retail national account \nversus independent.  Meaning the macro trend of when we saw volume soften in April, start to recover in May, \ncontinue to bounce back in June.  I think those trend lines are  largely consistent.  A national chain probably has a \nlittle less exposure, to a particular state or community that might be experiencing a better or worse, COVID \nprogression.  So obviously, there's some almost built -in risk mitigation from being a national chain.  \n \n But by and large, I think the independents have held up pretty well.  We have \u2013 we stay obviously in close contact \nwith them. ", "original_text": "A national chain probably has a \nlittle less exposure, to a particular state or community that might be experiencing a better or worse, COVID \nprogression. ", "page_label": "14", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f3e49820-b6cd-4d4a-91ea-9dc1750852df", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "59c3942a2d303414eda505b9f65d9736e4825436bfba4ef5c5e10b14336b6ca8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "42e85c84-3e85-4071-88e4-8ed05a268c08", "node_type": "1", "metadata": {"window": "(MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nSure.  I would say as a ge neral characterization, the pacing has been pretty consistent retail national account \nversus independent.  Meaning the macro trend of when we saw volume soften in April, start to recover in May, \ncontinue to bounce back in June.  I think those trend lines are  largely consistent.  A national chain probably has a \nlittle less exposure, to a particular state or community that might be experiencing a better or worse, COVID \nprogression.  So obviously, there's some almost built -in risk mitigation from being a national chain.  \n \n But by and large, I think the independents have held up pretty well. ", "original_text": "I think those trend lines are  largely consistent. ", "page_label": "14", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "872e33afa46ac183ef142afc6ef532fdf256928db484b42e1585e86780a0af1a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8a567351-ca20-446a-b721-770a2e83c658", "node_type": "1", "metadata": {"window": "Meaning the macro trend of when we saw volume soften in April, start to recover in May, \ncontinue to bounce back in June.  I think those trend lines are  largely consistent.  A national chain probably has a \nlittle less exposure, to a particular state or community that might be experiencing a better or worse, COVID \nprogression.  So obviously, there's some almost built -in risk mitigation from being a national chain.  \n \n But by and large, I think the independents have held up pretty well.  We have \u2013 we stay obviously in close contact \nwith them.  We see many of, for example, our Health Marts, participating in some of the testing. ", "original_text": "So obviously, there's some almost built -in risk mitigation from being a national chain.  \n \n"}, "hash": "c7cda4390cbbfdcf3d5ba7a65840e4473bdc58895c51ae4d43206616a0c001bb", "class_name": "RelatedNodeInfo"}}, "text": "A national chain probably has a \nlittle less exposure, to a particular state or community that might be experiencing a better or worse, COVID \nprogression. ", "start_char_idx": 487, "end_char_idx": 643, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8a567351-ca20-446a-b721-770a2e83c658": {"__data__": {"id_": "8a567351-ca20-446a-b721-770a2e83c658", "embedding": null, "metadata": {"window": "Meaning the macro trend of when we saw volume soften in April, start to recover in May, \ncontinue to bounce back in June.  I think those trend lines are  largely consistent.  A national chain probably has a \nlittle less exposure, to a particular state or community that might be experiencing a better or worse, COVID \nprogression.  So obviously, there's some almost built -in risk mitigation from being a national chain.  \n \n But by and large, I think the independents have held up pretty well.  We have \u2013 we stay obviously in close contact \nwith them.  We see many of, for example, our Health Marts, participating in some of the testing. ", "original_text": "So obviously, there's some almost built -in risk mitigation from being a national chain.  \n \n", "page_label": "14", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f3e49820-b6cd-4d4a-91ea-9dc1750852df", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "59c3942a2d303414eda505b9f65d9736e4825436bfba4ef5c5e10b14336b6ca8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "96c5aa32-36ca-4949-9c22-90a1d1be3543", "node_type": "1", "metadata": {"window": "I would say as a ge neral characterization, the pacing has been pretty consistent retail national account \nversus independent.  Meaning the macro trend of when we saw volume soften in April, start to recover in May, \ncontinue to bounce back in June.  I think those trend lines are  largely consistent.  A national chain probably has a \nlittle less exposure, to a particular state or community that might be experiencing a better or worse, COVID \nprogression.  So obviously, there's some almost built -in risk mitigation from being a national chain.  \n \n But by and large, I think the independents have held up pretty well.  We have \u2013 we stay obviously in close contact \nwith them. ", "original_text": "A national chain probably has a \nlittle less exposure, to a particular state or community that might be experiencing a better or worse, COVID \nprogression. ", "page_label": "14", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "371add07dba92c3d8592a7a729d82925f02203f2e02aa0a6e6607e2448e003fb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ff5f3892-f386-4a57-a963-96af8ddd6d5b", "node_type": "1", "metadata": {"window": "I think those trend lines are  largely consistent.  A national chain probably has a \nlittle less exposure, to a particular state or community that might be experiencing a better or worse, COVID \nprogression.  So obviously, there's some almost built -in risk mitigation from being a national chain.  \n \n But by and large, I think the independents have held up pretty well.  We have \u2013 we stay obviously in close contact \nwith them.  We see many of, for example, our Health Marts, participating in some of the testing.  And I think people \nreflect now more th an ever, the important role of community care and pharmacists as a point of community care in \nthe recovery. ", "original_text": "But by and large, I think the independents have held up pretty well. "}, "hash": "2ed2e01b4e62e477f8b42a6423f4e17e53dda49026410a602cd46973856ad28e", "class_name": "RelatedNodeInfo"}}, "text": "So obviously, there's some almost built -in risk mitigation from being a national chain.  \n \n", "start_char_idx": 643, "end_char_idx": 736, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ff5f3892-f386-4a57-a963-96af8ddd6d5b": {"__data__": {"id_": "ff5f3892-f386-4a57-a963-96af8ddd6d5b", "embedding": null, "metadata": {"window": "I think those trend lines are  largely consistent.  A national chain probably has a \nlittle less exposure, to a particular state or community that might be experiencing a better or worse, COVID \nprogression.  So obviously, there's some almost built -in risk mitigation from being a national chain.  \n \n But by and large, I think the independents have held up pretty well.  We have \u2013 we stay obviously in close contact \nwith them.  We see many of, for example, our Health Marts, participating in some of the testing.  And I think people \nreflect now more th an ever, the important role of community care and pharmacists as a point of community care in \nthe recovery. ", "original_text": "But by and large, I think the independents have held up pretty well. ", "page_label": "14", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f3e49820-b6cd-4d4a-91ea-9dc1750852df", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "59c3942a2d303414eda505b9f65d9736e4825436bfba4ef5c5e10b14336b6ca8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8a567351-ca20-446a-b721-770a2e83c658", "node_type": "1", "metadata": {"window": "Meaning the macro trend of when we saw volume soften in April, start to recover in May, \ncontinue to bounce back in June.  I think those trend lines are  largely consistent.  A national chain probably has a \nlittle less exposure, to a particular state or community that might be experiencing a better or worse, COVID \nprogression.  So obviously, there's some almost built -in risk mitigation from being a national chain.  \n \n But by and large, I think the independents have held up pretty well.  We have \u2013 we stay obviously in close contact \nwith them.  We see many of, for example, our Health Marts, participating in some of the testing. ", "original_text": "So obviously, there's some almost built -in risk mitigation from being a national chain.  \n \n", "page_label": "14", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "68e4c9a38f468ba650a37c4c3e1c9b88c4db4b3495f11fda9786730d2bc5dd80", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "478c3e02-4301-4338-9831-28ac0167629e", "node_type": "1", "metadata": {"window": "A national chain probably has a \nlittle less exposure, to a particular state or community that might be experiencing a better or worse, COVID \nprogression.  So obviously, there's some almost built -in risk mitigation from being a national chain.  \n \n But by and large, I think the independents have held up pretty well.  We have \u2013 we stay obviously in close contact \nwith them.  We see many of, for example, our Health Marts, participating in some of the testing.  And I think people \nreflect now more th an ever, the important role of community care and pharmacists as a point of community care in \nthe recovery.  So I don't think there's anything I would draw other than that.  \n ", "original_text": "We have \u2013 we stay obviously in close contact \nwith them. "}, "hash": "b2685181eb4ea53b9ccea06685ee214812737f51f5b7d924261e9042dc45f166", "class_name": "RelatedNodeInfo"}}, "text": "But by and large, I think the independents have held up pretty well. ", "start_char_idx": 736, "end_char_idx": 805, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "478c3e02-4301-4338-9831-28ac0167629e": {"__data__": {"id_": "478c3e02-4301-4338-9831-28ac0167629e", "embedding": null, "metadata": {"window": "A national chain probably has a \nlittle less exposure, to a particular state or community that might be experiencing a better or worse, COVID \nprogression.  So obviously, there's some almost built -in risk mitigation from being a national chain.  \n \n But by and large, I think the independents have held up pretty well.  We have \u2013 we stay obviously in close contact \nwith them.  We see many of, for example, our Health Marts, participating in some of the testing.  And I think people \nreflect now more th an ever, the important role of community care and pharmacists as a point of community care in \nthe recovery.  So I don't think there's anything I would draw other than that.  \n ", "original_text": "We have \u2013 we stay obviously in close contact \nwith them. ", "page_label": "14", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f3e49820-b6cd-4d4a-91ea-9dc1750852df", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "59c3942a2d303414eda505b9f65d9736e4825436bfba4ef5c5e10b14336b6ca8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ff5f3892-f386-4a57-a963-96af8ddd6d5b", "node_type": "1", "metadata": {"window": "I think those trend lines are  largely consistent.  A national chain probably has a \nlittle less exposure, to a particular state or community that might be experiencing a better or worse, COVID \nprogression.  So obviously, there's some almost built -in risk mitigation from being a national chain.  \n \n But by and large, I think the independents have held up pretty well.  We have \u2013 we stay obviously in close contact \nwith them.  We see many of, for example, our Health Marts, participating in some of the testing.  And I think people \nreflect now more th an ever, the important role of community care and pharmacists as a point of community care in \nthe recovery. ", "original_text": "But by and large, I think the independents have held up pretty well. ", "page_label": "14", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "475be201dcaf186d811c049d676f693529229b69d6ece5c01056107d51f18c9f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "948f4412-2c11-42ee-85b5-b36159415198", "node_type": "1", "metadata": {"window": "So obviously, there's some almost built -in risk mitigation from being a national chain.  \n \n But by and large, I think the independents have held up pretty well.  We have \u2013 we stay obviously in close contact \nwith them.  We see many of, for example, our Health Marts, participating in some of the testing.  And I think people \nreflect now more th an ever, the important role of community care and pharmacists as a point of community care in \nthe recovery.  So I don't think there's anything I would draw other than that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Cor p. A \nYeah. ", "original_text": "We see many of, for example, our Health Marts, participating in some of the testing. "}, "hash": "d3c545fbc8ecdfa04bc4040b7be4e8b5d9a4f4fa2e6586adebdada3999bf99dc", "class_name": "RelatedNodeInfo"}}, "text": "We have \u2013 we stay obviously in close contact \nwith them. ", "start_char_idx": 805, "end_char_idx": 862, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "948f4412-2c11-42ee-85b5-b36159415198": {"__data__": {"id_": "948f4412-2c11-42ee-85b5-b36159415198", "embedding": null, "metadata": {"window": "So obviously, there's some almost built -in risk mitigation from being a national chain.  \n \n But by and large, I think the independents have held up pretty well.  We have \u2013 we stay obviously in close contact \nwith them.  We see many of, for example, our Health Marts, participating in some of the testing.  And I think people \nreflect now more th an ever, the important role of community care and pharmacists as a point of community care in \nthe recovery.  So I don't think there's anything I would draw other than that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Cor p. A \nYeah. ", "original_text": "We see many of, for example, our Health Marts, participating in some of the testing. ", "page_label": "14", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f3e49820-b6cd-4d4a-91ea-9dc1750852df", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "59c3942a2d303414eda505b9f65d9736e4825436bfba4ef5c5e10b14336b6ca8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "478c3e02-4301-4338-9831-28ac0167629e", "node_type": "1", "metadata": {"window": "A national chain probably has a \nlittle less exposure, to a particular state or community that might be experiencing a better or worse, COVID \nprogression.  So obviously, there's some almost built -in risk mitigation from being a national chain.  \n \n But by and large, I think the independents have held up pretty well.  We have \u2013 we stay obviously in close contact \nwith them.  We see many of, for example, our Health Marts, participating in some of the testing.  And I think people \nreflect now more th an ever, the important role of community care and pharmacists as a point of community care in \nthe recovery.  So I don't think there's anything I would draw other than that.  \n ", "original_text": "We have \u2013 we stay obviously in close contact \nwith them. ", "page_label": "14", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "795bf94fdf1d70022394b53f07f18f55de0ff2c22ee30d8990158e9250515bfd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6bb3d428-842b-49c8-a23c-ecacf632c15b", "node_type": "1", "metadata": {"window": "But by and large, I think the independents have held up pretty well.  We have \u2013 we stay obviously in close contact \nwith them.  We see many of, for example, our Health Marts, participating in some of the testing.  And I think people \nreflect now more th an ever, the important role of community care and pharmacists as a point of community care in \nthe recovery.  So I don't think there's anything I would draw other than that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Cor p. A \nYeah.  I think it goes without saying that national accounts just based on their size, have a greater proportion of \nthe segment. ", "original_text": "And I think people \nreflect now more th an ever, the important role of community care and pharmacists as a point of community care in \nthe recovery. "}, "hash": "c2b10ed862b5e9444957ff7fa413b32d068efa5db713afbb08ba579fe5511b68", "class_name": "RelatedNodeInfo"}}, "text": "We see many of, for example, our Health Marts, participating in some of the testing. ", "start_char_idx": 862, "end_char_idx": 947, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6bb3d428-842b-49c8-a23c-ecacf632c15b": {"__data__": {"id_": "6bb3d428-842b-49c8-a23c-ecacf632c15b", "embedding": null, "metadata": {"window": "But by and large, I think the independents have held up pretty well.  We have \u2013 we stay obviously in close contact \nwith them.  We see many of, for example, our Health Marts, participating in some of the testing.  And I think people \nreflect now more th an ever, the important role of community care and pharmacists as a point of community care in \nthe recovery.  So I don't think there's anything I would draw other than that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Cor p. A \nYeah.  I think it goes without saying that national accounts just based on their size, have a greater proportion of \nthe segment. ", "original_text": "And I think people \nreflect now more th an ever, the important role of community care and pharmacists as a point of community care in \nthe recovery. ", "page_label": "14", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f3e49820-b6cd-4d4a-91ea-9dc1750852df", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "59c3942a2d303414eda505b9f65d9736e4825436bfba4ef5c5e10b14336b6ca8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "948f4412-2c11-42ee-85b5-b36159415198", "node_type": "1", "metadata": {"window": "So obviously, there's some almost built -in risk mitigation from being a national chain.  \n \n But by and large, I think the independents have held up pretty well.  We have \u2013 we stay obviously in close contact \nwith them.  We see many of, for example, our Health Marts, participating in some of the testing.  And I think people \nreflect now more th an ever, the important role of community care and pharmacists as a point of community care in \nthe recovery.  So I don't think there's anything I would draw other than that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Cor p. A \nYeah. ", "original_text": "We see many of, for example, our Health Marts, participating in some of the testing. ", "page_label": "14", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5ad77401b0cb154d0ff86b6e38e1866cba0da7bbd47fa1b64c43fda6214b61df", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c9fd8150-3d3f-4be0-8b9e-02cb8c678ae2", "node_type": "1", "metadata": {"window": "We have \u2013 we stay obviously in close contact \nwith them.  We see many of, for example, our Health Marts, participating in some of the testing.  And I think people \nreflect now more th an ever, the important role of community care and pharmacists as a point of community care in \nthe recovery.  So I don't think there's anything I would draw other than that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Cor p. A \nYeah.  I think it goes without saying that national accounts just based on their size, have a greater proportion of \nthe segment.  And I don't think you should take that as one part of the segment grew faster than the other, \n[indiscernible] (00:44:28) j ust given the proportion that national accounts makeup within that segment, they had a \nbigger impact.  \n ", "original_text": "So I don't think there's anything I would draw other than that.  \n "}, "hash": "4fc9fef72741e2db8fc7edfe947d95148f690d67980d48cf92a70ccd70bee7f0", "class_name": "RelatedNodeInfo"}}, "text": "And I think people \nreflect now more th an ever, the important role of community care and pharmacists as a point of community care in \nthe recovery. ", "start_char_idx": 947, "end_char_idx": 1096, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c9fd8150-3d3f-4be0-8b9e-02cb8c678ae2": {"__data__": {"id_": "c9fd8150-3d3f-4be0-8b9e-02cb8c678ae2", "embedding": null, "metadata": {"window": "We have \u2013 we stay obviously in close contact \nwith them.  We see many of, for example, our Health Marts, participating in some of the testing.  And I think people \nreflect now more th an ever, the important role of community care and pharmacists as a point of community care in \nthe recovery.  So I don't think there's anything I would draw other than that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Cor p. A \nYeah.  I think it goes without saying that national accounts just based on their size, have a greater proportion of \nthe segment.  And I don't think you should take that as one part of the segment grew faster than the other, \n[indiscernible] (00:44:28) j ust given the proportion that national accounts makeup within that segment, they had a \nbigger impact.  \n ", "original_text": "So I don't think there's anything I would draw other than that.  \n ", "page_label": "14", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f3e49820-b6cd-4d4a-91ea-9dc1750852df", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "59c3942a2d303414eda505b9f65d9736e4825436bfba4ef5c5e10b14336b6ca8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6bb3d428-842b-49c8-a23c-ecacf632c15b", "node_type": "1", "metadata": {"window": "But by and large, I think the independents have held up pretty well.  We have \u2013 we stay obviously in close contact \nwith them.  We see many of, for example, our Health Marts, participating in some of the testing.  And I think people \nreflect now more th an ever, the important role of community care and pharmacists as a point of community care in \nthe recovery.  So I don't think there's anything I would draw other than that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Cor p. A \nYeah.  I think it goes without saying that national accounts just based on their size, have a greater proportion of \nthe segment. ", "original_text": "And I think people \nreflect now more th an ever, the important role of community care and pharmacists as a point of community care in \nthe recovery. ", "page_label": "14", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "947e54491d7ddf595858c7e452a94bc69d292236ef2fe38a343957a8cd209050", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "01640716-2064-4ee8-a47a-68089663ccfd", "node_type": "1", "metadata": {"window": "We see many of, for example, our Health Marts, participating in some of the testing.  And I think people \nreflect now more th an ever, the important role of community care and pharmacists as a point of community care in \nthe recovery.  So I don't think there's anything I would draw other than that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Cor p. A \nYeah.  I think it goes without saying that national accounts just based on their size, have a greater proportion of \nthe segment.  And I don't think you should take that as one part of the segment grew faster than the other, \n[indiscernible] (00:44:28) j ust given the proportion that national accounts makeup within that segment, they had a \nbigger impact.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Cor p. A \nYeah. "}, "hash": "2c27bf1245fe3f2ec1ccd55a291fcc1e0d23f231bfcb11545e43728fcd173103", "class_name": "RelatedNodeInfo"}}, "text": "So I don't think there's anything I would draw other than that.  \n ", "start_char_idx": 1096, "end_char_idx": 1163, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "01640716-2064-4ee8-a47a-68089663ccfd": {"__data__": {"id_": "01640716-2064-4ee8-a47a-68089663ccfd", "embedding": null, "metadata": {"window": "We see many of, for example, our Health Marts, participating in some of the testing.  And I think people \nreflect now more th an ever, the important role of community care and pharmacists as a point of community care in \nthe recovery.  So I don't think there's anything I would draw other than that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Cor p. A \nYeah.  I think it goes without saying that national accounts just based on their size, have a greater proportion of \nthe segment.  And I don't think you should take that as one part of the segment grew faster than the other, \n[indiscernible] (00:44:28) j ust given the proportion that national accounts makeup within that segment, they had a \nbigger impact.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Cor p. A \nYeah. ", "page_label": "14", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f3e49820-b6cd-4d4a-91ea-9dc1750852df", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "59c3942a2d303414eda505b9f65d9736e4825436bfba4ef5c5e10b14336b6ca8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c9fd8150-3d3f-4be0-8b9e-02cb8c678ae2", "node_type": "1", "metadata": {"window": "We have \u2013 we stay obviously in close contact \nwith them.  We see many of, for example, our Health Marts, participating in some of the testing.  And I think people \nreflect now more th an ever, the important role of community care and pharmacists as a point of community care in \nthe recovery.  So I don't think there's anything I would draw other than that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Cor p. A \nYeah.  I think it goes without saying that national accounts just based on their size, have a greater proportion of \nthe segment.  And I don't think you should take that as one part of the segment grew faster than the other, \n[indiscernible] (00:44:28) j ust given the proportion that national accounts makeup within that segment, they had a \nbigger impact.  \n ", "original_text": "So I don't think there's anything I would draw other than that.  \n ", "page_label": "14", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "af0cb2d605f224d16545b62f80c399640e9abf84bd5a0aaf70b1e35a732fc1aa", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9ff58bec-de0c-42ca-a495-6cce76a9a727", "node_type": "1", "metadata": {"window": "And I think people \nreflect now more th an ever, the important role of community care and pharmacists as a point of community care in \nthe recovery.  So I don't think there's anything I would draw other than that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Cor p. A \nYeah.  I think it goes without saying that national accounts just based on their size, have a greater proportion of \nthe segment.  And I don't think you should take that as one part of the segment grew faster than the other, \n[indiscernible] (00:44:28) j ust given the proportion that national accounts makeup within that segment, they had a \nbigger impact.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question?  \n ", "original_text": "I think it goes without saying that national accounts just based on their size, have a greater proportion of \nthe segment. "}, "hash": "2b8460b09dae32e63d8ea19261a492cce515181f9bb55deb916209d316523ac9", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Cor p. A \nYeah. ", "start_char_idx": 1163, "end_char_idx": 1532, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9ff58bec-de0c-42ca-a495-6cce76a9a727": {"__data__": {"id_": "9ff58bec-de0c-42ca-a495-6cce76a9a727", "embedding": null, "metadata": {"window": "And I think people \nreflect now more th an ever, the important role of community care and pharmacists as a point of community care in \nthe recovery.  So I don't think there's anything I would draw other than that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Cor p. A \nYeah.  I think it goes without saying that national accounts just based on their size, have a greater proportion of \nthe segment.  And I don't think you should take that as one part of the segment grew faster than the other, \n[indiscernible] (00:44:28) j ust given the proportion that national accounts makeup within that segment, they had a \nbigger impact.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question?  \n ", "original_text": "I think it goes without saying that national accounts just based on their size, have a greater proportion of \nthe segment. ", "page_label": "14", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f3e49820-b6cd-4d4a-91ea-9dc1750852df", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "59c3942a2d303414eda505b9f65d9736e4825436bfba4ef5c5e10b14336b6ca8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "01640716-2064-4ee8-a47a-68089663ccfd", "node_type": "1", "metadata": {"window": "We see many of, for example, our Health Marts, participating in some of the testing.  And I think people \nreflect now more th an ever, the important role of community care and pharmacists as a point of community care in \nthe recovery.  So I don't think there's anything I would draw other than that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Cor p. A \nYeah.  I think it goes without saying that national accounts just based on their size, have a greater proportion of \nthe segment.  And I don't think you should take that as one part of the segment grew faster than the other, \n[indiscernible] (00:44:28) j ust given the proportion that national accounts makeup within that segment, they had a \nbigger impact.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Cor p. A \nYeah. ", "page_label": "14", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "abef786d2ef907603efa1357ab85fa9119d6957d355dda100b4034cd2e58be78", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a526b23e-7143-4a32-99d5-7e2642f2d9f0", "node_type": "1", "metadata": {"window": "So I don't think there's anything I would draw other than that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Cor p. A \nYeah.  I think it goes without saying that national accounts just based on their size, have a greater proportion of \nthe segment.  And I don't think you should take that as one part of the segment grew faster than the other, \n[indiscernible] (00:44:28) j ust given the proportion that national accounts makeup within that segment, they had a \nbigger impact.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Steven Valiquette with Barclays.  \n ", "original_text": "And I don't think you should take that as one part of the segment grew faster than the other, \n[indiscernible] (00:44:28) j ust given the proportion that national accounts makeup within that segment, they had a \nbigger impact.  \n "}, "hash": "3afacfdc0b3e60429a3b48d241fa844ef3cc908cc8040588c53d7b50cfd13d96", "class_name": "RelatedNodeInfo"}}, "text": "I think it goes without saying that national accounts just based on their size, have a greater proportion of \nthe segment. ", "start_char_idx": 1532, "end_char_idx": 1655, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a526b23e-7143-4a32-99d5-7e2642f2d9f0": {"__data__": {"id_": "a526b23e-7143-4a32-99d5-7e2642f2d9f0", "embedding": null, "metadata": {"window": "So I don't think there's anything I would draw other than that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Cor p. A \nYeah.  I think it goes without saying that national accounts just based on their size, have a greater proportion of \nthe segment.  And I don't think you should take that as one part of the segment grew faster than the other, \n[indiscernible] (00:44:28) j ust given the proportion that national accounts makeup within that segment, they had a \nbigger impact.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Steven Valiquette with Barclays.  \n ", "original_text": "And I don't think you should take that as one part of the segment grew faster than the other, \n[indiscernible] (00:44:28) j ust given the proportion that national accounts makeup within that segment, they had a \nbigger impact.  \n ", "page_label": "14", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f3e49820-b6cd-4d4a-91ea-9dc1750852df", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "59c3942a2d303414eda505b9f65d9736e4825436bfba4ef5c5e10b14336b6ca8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9ff58bec-de0c-42ca-a495-6cce76a9a727", "node_type": "1", "metadata": {"window": "And I think people \nreflect now more th an ever, the important role of community care and pharmacists as a point of community care in \nthe recovery.  So I don't think there's anything I would draw other than that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Cor p. A \nYeah.  I think it goes without saying that national accounts just based on their size, have a greater proportion of \nthe segment.  And I don't think you should take that as one part of the segment grew faster than the other, \n[indiscernible] (00:44:28) j ust given the proportion that national accounts makeup within that segment, they had a \nbigger impact.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question?  \n ", "original_text": "I think it goes without saying that national accounts just based on their size, have a greater proportion of \nthe segment. ", "page_label": "14", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "eb3612632067b1f07b9e12de7fde4eba2f3643336afbdac4a1f437d591304f61", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1a978c21-40c3-4d70-85ba-a3b8d2a625d3", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Cor p. A \nYeah.  I think it goes without saying that national accounts just based on their size, have a greater proportion of \nthe segment.  And I don't think you should take that as one part of the segment grew faster than the other, \n[indiscernible] (00:44:28) j ust given the proportion that national accounts makeup within that segment, they had a \nbigger impact.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Steven Valiquette with Barclays.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nSteven Valiquette  \nAnalyst, Barclays Capital, Inc.  ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  "}, "hash": "0153b5998b0b5956a1ea3a85ae5646fcab2f974330b00d6a5c667a3cd7f9208d", "class_name": "RelatedNodeInfo"}}, "text": "And I don't think you should take that as one part of the segment grew faster than the other, \n[indiscernible] (00:44:28) j ust given the proportion that national accounts makeup within that segment, they had a \nbigger impact.  \n ", "start_char_idx": 1655, "end_char_idx": 1885, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1a978c21-40c3-4d70-85ba-a3b8d2a625d3": {"__data__": {"id_": "1a978c21-40c3-4d70-85ba-a3b8d2a625d3", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Cor p. A \nYeah.  I think it goes without saying that national accounts just based on their size, have a greater proportion of \nthe segment.  And I don't think you should take that as one part of the segment grew faster than the other, \n[indiscernible] (00:44:28) j ust given the proportion that national accounts makeup within that segment, they had a \nbigger impact.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Steven Valiquette with Barclays.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nSteven Valiquette  \nAnalyst, Barclays Capital, Inc.  ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  ", "page_label": "14", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f3e49820-b6cd-4d4a-91ea-9dc1750852df", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "59c3942a2d303414eda505b9f65d9736e4825436bfba4ef5c5e10b14336b6ca8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a526b23e-7143-4a32-99d5-7e2642f2d9f0", "node_type": "1", "metadata": {"window": "So I don't think there's anything I would draw other than that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Cor p. A \nYeah.  I think it goes without saying that national accounts just based on their size, have a greater proportion of \nthe segment.  And I don't think you should take that as one part of the segment grew faster than the other, \n[indiscernible] (00:44:28) j ust given the proportion that national accounts makeup within that segment, they had a \nbigger impact.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Steven Valiquette with Barclays.  \n ", "original_text": "And I don't think you should take that as one part of the segment grew faster than the other, \n[indiscernible] (00:44:28) j ust given the proportion that national accounts makeup within that segment, they had a \nbigger impact.  \n ", "page_label": "14", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "452644307438ce90af987a97ec464cd5f0b2ea5187f8730732507c4e53cea44e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "64872c0a-d114-4d47-86cd-8d2ff849c06d", "node_type": "1", "metadata": {"window": "I think it goes without saying that national accounts just based on their size, have a greater proportion of \nthe segment.  And I don't think you should take that as one part of the segment grew faster than the other, \n[indiscernible] (00:44:28) j ust given the proportion that national accounts makeup within that segment, they had a \nbigger impact.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Steven Valiquette with Barclays.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nSteven Valiquette  \nAnalyst, Barclays Capital, Inc.   Q \nGreat. ", "original_text": "A \nNext question?  \n "}, "hash": "c0a6e070e22a8faf66f9fedb93b894563fc7018f6e67cec8a1ee1d477058db06", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  ", "start_char_idx": 1885, "end_char_idx": 2230, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "64872c0a-d114-4d47-86cd-8d2ff849c06d": {"__data__": {"id_": "64872c0a-d114-4d47-86cd-8d2ff849c06d", "embedding": null, "metadata": {"window": "I think it goes without saying that national accounts just based on their size, have a greater proportion of \nthe segment.  And I don't think you should take that as one part of the segment grew faster than the other, \n[indiscernible] (00:44:28) j ust given the proportion that national accounts makeup within that segment, they had a \nbigger impact.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Steven Valiquette with Barclays.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nSteven Valiquette  \nAnalyst, Barclays Capital, Inc.   Q \nGreat. ", "original_text": "A \nNext question?  \n ", "page_label": "14", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f3e49820-b6cd-4d4a-91ea-9dc1750852df", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "59c3942a2d303414eda505b9f65d9736e4825436bfba4ef5c5e10b14336b6ca8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1a978c21-40c3-4d70-85ba-a3b8d2a625d3", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Cor p. A \nYeah.  I think it goes without saying that national accounts just based on their size, have a greater proportion of \nthe segment.  And I don't think you should take that as one part of the segment grew faster than the other, \n[indiscernible] (00:44:28) j ust given the proportion that national accounts makeup within that segment, they had a \nbigger impact.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Steven Valiquette with Barclays.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nSteven Valiquette  \nAnalyst, Barclays Capital, Inc.  ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  ", "page_label": "14", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "60214a68a9ed904030a02a20c27930b837bada2b50bcc0b78bfdc4b43d661cbc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2f0feecb-6be7-46aa-ba48-aaf16ef6f936", "node_type": "1", "metadata": {"window": "And I don't think you should take that as one part of the segment grew faster than the other, \n[indiscernible] (00:44:28) j ust given the proportion that national accounts makeup within that segment, they had a \nbigger impact.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Steven Valiquette with Barclays.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nSteven Valiquette  \nAnalyst, Barclays Capital, Inc.   Q \nGreat.  Thanks. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Steven Valiquette with Barclays.  \n "}, "hash": "5eceb53c97802c014887898a60254179701f6023395bd61f6f4ac752cfcff397", "class_name": "RelatedNodeInfo"}}, "text": "A \nNext question?  \n ", "start_char_idx": 2230, "end_char_idx": 2251, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2f0feecb-6be7-46aa-ba48-aaf16ef6f936": {"__data__": {"id_": "2f0feecb-6be7-46aa-ba48-aaf16ef6f936", "embedding": null, "metadata": {"window": "And I don't think you should take that as one part of the segment grew faster than the other, \n[indiscernible] (00:44:28) j ust given the proportion that national accounts makeup within that segment, they had a \nbigger impact.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Steven Valiquette with Barclays.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nSteven Valiquette  \nAnalyst, Barclays Capital, Inc.   Q \nGreat.  Thanks. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Steven Valiquette with Barclays.  \n ", "page_label": "14", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f3e49820-b6cd-4d4a-91ea-9dc1750852df", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "59c3942a2d303414eda505b9f65d9736e4825436bfba4ef5c5e10b14336b6ca8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "64872c0a-d114-4d47-86cd-8d2ff849c06d", "node_type": "1", "metadata": {"window": "I think it goes without saying that national accounts just based on their size, have a greater proportion of \nthe segment.  And I don't think you should take that as one part of the segment grew faster than the other, \n[indiscernible] (00:44:28) j ust given the proportion that national accounts makeup within that segment, they had a \nbigger impact.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Steven Valiquette with Barclays.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nSteven Valiquette  \nAnalyst, Barclays Capital, Inc.   Q \nGreat. ", "original_text": "A \nNext question?  \n ", "page_label": "14", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6ac123f3518f5b4586c47b51fda9dd71df08bbe75cca6aec5b89c1ad6f71c38f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cb8dc87b-958c-4f7f-85f5-ff6e35d30b8f", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Steven Valiquette with Barclays.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nSteven Valiquette  \nAnalyst, Barclays Capital, Inc.   Q \nGreat.  Thanks.  Good morning. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nSteven Valiquette  \nAnalyst, Barclays Capital, Inc.  "}, "hash": "ca074cf46a7761b83987f0ed4601a13524c84c9bf4a669a8855a995da4c09b25", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Steven Valiquette with Barclays.  \n ", "start_char_idx": 2251, "end_char_idx": 2589, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cb8dc87b-958c-4f7f-85f5-ff6e35d30b8f": {"__data__": {"id_": "cb8dc87b-958c-4f7f-85f5-ff6e35d30b8f", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Steven Valiquette with Barclays.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nSteven Valiquette  \nAnalyst, Barclays Capital, Inc.   Q \nGreat.  Thanks.  Good morning. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nSteven Valiquette  \nAnalyst, Barclays Capital, Inc.  ", "page_label": "14", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f3e49820-b6cd-4d4a-91ea-9dc1750852df", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "59c3942a2d303414eda505b9f65d9736e4825436bfba4ef5c5e10b14336b6ca8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2f0feecb-6be7-46aa-ba48-aaf16ef6f936", "node_type": "1", "metadata": {"window": "And I don't think you should take that as one part of the segment grew faster than the other, \n[indiscernible] (00:44:28) j ust given the proportion that national accounts makeup within that segment, they had a \nbigger impact.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Steven Valiquette with Barclays.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nSteven Valiquette  \nAnalyst, Barclays Capital, Inc.   Q \nGreat.  Thanks. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Steven Valiquette with Barclays.  \n ", "page_label": "14", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "be8c59edc50cc18691747644eb040254758ea8690871df5d389aefe7e651dd97", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "80da1509-19e3-4090-8548-b645480c8a81", "node_type": "1", "metadata": {"window": "A \nNext question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Steven Valiquette with Barclays.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nSteven Valiquette  \nAnalyst, Barclays Capital, Inc.   Q \nGreat.  Thanks.  Good morning.  Brian and Britt, thanks for taking the question. ", "original_text": "Q \nGreat. "}, "hash": "b504e71554611c5c1c8142b1b29448abb454b8c2f706746c35cea8958bb09042", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nSteven Valiquette  \nAnalyst, Barclays Capital, Inc.  ", "start_char_idx": 2589, "end_char_idx": 2914, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "80da1509-19e3-4090-8548-b645480c8a81": {"__data__": {"id_": "80da1509-19e3-4090-8548-b645480c8a81", "embedding": null, "metadata": {"window": "A \nNext question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Steven Valiquette with Barclays.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nSteven Valiquette  \nAnalyst, Barclays Capital, Inc.   Q \nGreat.  Thanks.  Good morning.  Brian and Britt, thanks for taking the question. ", "original_text": "Q \nGreat. ", "page_label": "14", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f3e49820-b6cd-4d4a-91ea-9dc1750852df", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "59c3942a2d303414eda505b9f65d9736e4825436bfba4ef5c5e10b14336b6ca8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cb8dc87b-958c-4f7f-85f5-ff6e35d30b8f", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Steven Valiquette with Barclays.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nSteven Valiquette  \nAnalyst, Barclays Capital, Inc.   Q \nGreat.  Thanks.  Good morning. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nSteven Valiquette  \nAnalyst, Barclays Capital, Inc.  ", "page_label": "14", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ad4d3ea38f06b302771a0d1970ffdcbd8a82f9d3f1756e9d4bf6624170f59120", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f0bcd546-6d5f-40b9-93c4-7c731284e3be", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Steven Valiquette with Barclays.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nSteven Valiquette  \nAnalyst, Barclays Capital, Inc.   Q \nGreat.  Thanks.  Good morning.  Brian and Britt, thanks for taking the question.  I guess, if you go back about three \nmonths ago, there was a lot of chatter in the US prescription marketplace, about mail or der, Rx, taking share from \nretail Rx. ", "original_text": "Thanks. "}, "hash": "015fe1e689dde1cd185002d85be109f0a1a0c004bb9d5f6143898a12894f085d", "class_name": "RelatedNodeInfo"}}, "text": "Q \nGreat. ", "start_char_idx": 2914, "end_char_idx": 2924, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f0bcd546-6d5f-40b9-93c4-7c731284e3be": {"__data__": {"id_": "f0bcd546-6d5f-40b9-93c4-7c731284e3be", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Steven Valiquette with Barclays.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nSteven Valiquette  \nAnalyst, Barclays Capital, Inc.   Q \nGreat.  Thanks.  Good morning.  Brian and Britt, thanks for taking the question.  I guess, if you go back about three \nmonths ago, there was a lot of chatter in the US prescription marketplace, about mail or der, Rx, taking share from \nretail Rx. ", "original_text": "Thanks. ", "page_label": "14", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f3e49820-b6cd-4d4a-91ea-9dc1750852df", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "59c3942a2d303414eda505b9f65d9736e4825436bfba4ef5c5e10b14336b6ca8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "80da1509-19e3-4090-8548-b645480c8a81", "node_type": "1", "metadata": {"window": "A \nNext question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Steven Valiquette with Barclays.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nSteven Valiquette  \nAnalyst, Barclays Capital, Inc.   Q \nGreat.  Thanks.  Good morning.  Brian and Britt, thanks for taking the question. ", "original_text": "Q \nGreat. ", "page_label": "14", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8fed0997da4a198ca20457cb5994fe4e40e97518a3bbc47f811c4179b174d8a6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "14497484-77e5-42b0-bae3-e9327f7225f9", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nSteven Valiquette  \nAnalyst, Barclays Capital, Inc.   Q \nGreat.  Thanks.  Good morning.  Brian and Britt, thanks for taking the question.  I guess, if you go back about three \nmonths ago, there was a lot of chatter in the US prescription marketplace, about mail or der, Rx, taking share from \nretail Rx.  I guess, I'm curious, just based on reorder patterns that you might be seeing as the June quarter \nprogressed and into July, are there any notable trends for your own book of business, just on the strength of \nreorders i n the mail order channel versus retail channel? ", "original_text": "Good morning. "}, "hash": "410f6c5af1fd461bb33f97708bb7ba6391124ef1bfd9ae02fd443d2c4d447c7c", "class_name": "RelatedNodeInfo"}}, "text": "Thanks. ", "start_char_idx": 2924, "end_char_idx": 2932, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "14497484-77e5-42b0-bae3-e9327f7225f9": {"__data__": {"id_": "14497484-77e5-42b0-bae3-e9327f7225f9", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nSteven Valiquette  \nAnalyst, Barclays Capital, Inc.   Q \nGreat.  Thanks.  Good morning.  Brian and Britt, thanks for taking the question.  I guess, if you go back about three \nmonths ago, there was a lot of chatter in the US prescription marketplace, about mail or der, Rx, taking share from \nretail Rx.  I guess, I'm curious, just based on reorder patterns that you might be seeing as the June quarter \nprogressed and into July, are there any notable trends for your own book of business, just on the strength of \nreorders i n the mail order channel versus retail channel? ", "original_text": "Good morning. ", "page_label": "14", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f3e49820-b6cd-4d4a-91ea-9dc1750852df", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "59c3942a2d303414eda505b9f65d9736e4825436bfba4ef5c5e10b14336b6ca8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f0bcd546-6d5f-40b9-93c4-7c731284e3be", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Steven Valiquette with Barclays.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nSteven Valiquette  \nAnalyst, Barclays Capital, Inc.   Q \nGreat.  Thanks.  Good morning.  Brian and Britt, thanks for taking the question.  I guess, if you go back about three \nmonths ago, there was a lot of chatter in the US prescription marketplace, about mail or der, Rx, taking share from \nretail Rx. ", "original_text": "Thanks. ", "page_label": "14", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e847dbf53a5ebb5aed2478663fd989b9a3e3ac2ca1b72aa8b4f590439ecf65fc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0cbf6adf-9378-480e-851f-7b3dff8c824e", "node_type": "1", "metadata": {"window": "Q \nGreat.  Thanks.  Good morning.  Brian and Britt, thanks for taking the question.  I guess, if you go back about three \nmonths ago, there was a lot of chatter in the US prescription marketplace, about mail or der, Rx, taking share from \nretail Rx.  I guess, I'm curious, just based on reorder patterns that you might be seeing as the June quarter \nprogressed and into July, are there any notable trends for your own book of business, just on the strength of \nreorders i n the mail order channel versus retail channel?  Thanks.  \n ", "original_text": "Brian and Britt, thanks for taking the question. "}, "hash": "c26e4f8bd1c4b33e2e69587a53fa5ae1791a71632a1aa0ebfcf30b7fd9aa8b5d", "class_name": "RelatedNodeInfo"}}, "text": "Good morning. ", "start_char_idx": 2932, "end_char_idx": 2946, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0cbf6adf-9378-480e-851f-7b3dff8c824e": {"__data__": {"id_": "0cbf6adf-9378-480e-851f-7b3dff8c824e", "embedding": null, "metadata": {"window": "Q \nGreat.  Thanks.  Good morning.  Brian and Britt, thanks for taking the question.  I guess, if you go back about three \nmonths ago, there was a lot of chatter in the US prescription marketplace, about mail or der, Rx, taking share from \nretail Rx.  I guess, I'm curious, just based on reorder patterns that you might be seeing as the June quarter \nprogressed and into July, are there any notable trends for your own book of business, just on the strength of \nreorders i n the mail order channel versus retail channel?  Thanks.  \n ", "original_text": "Brian and Britt, thanks for taking the question. ", "page_label": "14", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f3e49820-b6cd-4d4a-91ea-9dc1750852df", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "59c3942a2d303414eda505b9f65d9736e4825436bfba4ef5c5e10b14336b6ca8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "14497484-77e5-42b0-bae3-e9327f7225f9", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nSteven Valiquette  \nAnalyst, Barclays Capital, Inc.   Q \nGreat.  Thanks.  Good morning.  Brian and Britt, thanks for taking the question.  I guess, if you go back about three \nmonths ago, there was a lot of chatter in the US prescription marketplace, about mail or der, Rx, taking share from \nretail Rx.  I guess, I'm curious, just based on reorder patterns that you might be seeing as the June quarter \nprogressed and into July, are there any notable trends for your own book of business, just on the strength of \nreorders i n the mail order channel versus retail channel? ", "original_text": "Good morning. ", "page_label": "14", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a90c292c089fa81455662b06385c752679468288645ebf8107f7f6fe3dd458fc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "afb6d406-74f8-474c-99ba-e07fded4c0e1", "node_type": "1", "metadata": {"window": "Thanks.  Good morning.  Brian and Britt, thanks for taking the question.  I guess, if you go back about three \nmonths ago, there was a lot of chatter in the US prescription marketplace, about mail or der, Rx, taking share from \nretail Rx.  I guess, I'm curious, just based on reorder patterns that you might be seeing as the June quarter \nprogressed and into July, are there any notable trends for your own book of business, just on the strength of \nreorders i n the mail order channel versus retail channel?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "I guess, if you go back about three \nmonths ago, there was a lot of chatter in the US prescription marketplace, about mail or der, Rx, taking share from \nretail Rx. "}, "hash": "a7d715c3034886b76c95fcb80339fa07e5d76dd88ea919a05f3cc6ea9658cb36", "class_name": "RelatedNodeInfo"}}, "text": "Brian and Britt, thanks for taking the question. ", "start_char_idx": 2946, "end_char_idx": 2995, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "afb6d406-74f8-474c-99ba-e07fded4c0e1": {"__data__": {"id_": "afb6d406-74f8-474c-99ba-e07fded4c0e1", "embedding": null, "metadata": {"window": "Thanks.  Good morning.  Brian and Britt, thanks for taking the question.  I guess, if you go back about three \nmonths ago, there was a lot of chatter in the US prescription marketplace, about mail or der, Rx, taking share from \nretail Rx.  I guess, I'm curious, just based on reorder patterns that you might be seeing as the June quarter \nprogressed and into July, are there any notable trends for your own book of business, just on the strength of \nreorders i n the mail order channel versus retail channel?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "I guess, if you go back about three \nmonths ago, there was a lot of chatter in the US prescription marketplace, about mail or der, Rx, taking share from \nretail Rx. ", "page_label": "14", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f3e49820-b6cd-4d4a-91ea-9dc1750852df", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "59c3942a2d303414eda505b9f65d9736e4825436bfba4ef5c5e10b14336b6ca8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0cbf6adf-9378-480e-851f-7b3dff8c824e", "node_type": "1", "metadata": {"window": "Q \nGreat.  Thanks.  Good morning.  Brian and Britt, thanks for taking the question.  I guess, if you go back about three \nmonths ago, there was a lot of chatter in the US prescription marketplace, about mail or der, Rx, taking share from \nretail Rx.  I guess, I'm curious, just based on reorder patterns that you might be seeing as the June quarter \nprogressed and into July, are there any notable trends for your own book of business, just on the strength of \nreorders i n the mail order channel versus retail channel?  Thanks.  \n ", "original_text": "Brian and Britt, thanks for taking the question. ", "page_label": "14", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "29ec60574012cbd2154e66a818060437dff8de51b0f9e869f22ea4c2aba33951", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ca40a06b-1411-4275-9f89-25927aab3a64", "node_type": "1", "metadata": {"window": "Good morning.  Brian and Britt, thanks for taking the question.  I guess, if you go back about three \nmonths ago, there was a lot of chatter in the US prescription marketplace, about mail or der, Rx, taking share from \nretail Rx.  I guess, I'm curious, just based on reorder patterns that you might be seeing as the June quarter \nprogressed and into July, are there any notable trends for your own book of business, just on the strength of \nreorders i n the mail order channel versus retail channel?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThank you for the question, Steven. ", "original_text": "I guess, I'm curious, just based on reorder patterns that you might be seeing as the June quarter \nprogressed and into July, are there any notable trends for your own book of business, just on the strength of \nreorders i n the mail order channel versus retail channel? "}, "hash": "27c3732acbd19106541952b1978421d1003fac9b5bc581663de62ee721a2329c", "class_name": "RelatedNodeInfo"}}, "text": "I guess, if you go back about three \nmonths ago, there was a lot of chatter in the US prescription marketplace, about mail or der, Rx, taking share from \nretail Rx. ", "start_char_idx": 2995, "end_char_idx": 3160, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ca40a06b-1411-4275-9f89-25927aab3a64": {"__data__": {"id_": "ca40a06b-1411-4275-9f89-25927aab3a64", "embedding": null, "metadata": {"window": "Good morning.  Brian and Britt, thanks for taking the question.  I guess, if you go back about three \nmonths ago, there was a lot of chatter in the US prescription marketplace, about mail or der, Rx, taking share from \nretail Rx.  I guess, I'm curious, just based on reorder patterns that you might be seeing as the June quarter \nprogressed and into July, are there any notable trends for your own book of business, just on the strength of \nreorders i n the mail order channel versus retail channel?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThank you for the question, Steven. ", "original_text": "I guess, I'm curious, just based on reorder patterns that you might be seeing as the June quarter \nprogressed and into July, are there any notable trends for your own book of business, just on the strength of \nreorders i n the mail order channel versus retail channel? ", "page_label": "14", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f3e49820-b6cd-4d4a-91ea-9dc1750852df", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "59c3942a2d303414eda505b9f65d9736e4825436bfba4ef5c5e10b14336b6ca8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "afb6d406-74f8-474c-99ba-e07fded4c0e1", "node_type": "1", "metadata": {"window": "Thanks.  Good morning.  Brian and Britt, thanks for taking the question.  I guess, if you go back about three \nmonths ago, there was a lot of chatter in the US prescription marketplace, about mail or der, Rx, taking share from \nretail Rx.  I guess, I'm curious, just based on reorder patterns that you might be seeing as the June quarter \nprogressed and into July, are there any notable trends for your own book of business, just on the strength of \nreorders i n the mail order channel versus retail channel?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "I guess, if you go back about three \nmonths ago, there was a lot of chatter in the US prescription marketplace, about mail or der, Rx, taking share from \nretail Rx. ", "page_label": "14", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "de838c0c1f1dd0eded452a90bc91919380d977c1fc155d34dd8d2ee2c5b19345", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "27e6fff5-02ec-49d0-b5c1-27b5732a5f5e", "node_type": "1", "metadata": {"window": "Brian and Britt, thanks for taking the question.  I guess, if you go back about three \nmonths ago, there was a lot of chatter in the US prescription marketplace, about mail or der, Rx, taking share from \nretail Rx.  I guess, I'm curious, just based on reorder patterns that you might be seeing as the June quarter \nprogressed and into July, are there any notable trends for your own book of business, just on the strength of \nreorders i n the mail order channel versus retail channel?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThank you for the question, Steven.  I mean, we obviously [ph] when (00:45:18) early in the lockdown period and \npayers and health plans started relaxing some of their, or changing some of their policies, there was an uptick in \nmail order. ", "original_text": "Thanks.  \n "}, "hash": "63990cca941b01bf73f6f900f1ed69375c15db51fc08e164f96d7dee239c92c7", "class_name": "RelatedNodeInfo"}}, "text": "I guess, I'm curious, just based on reorder patterns that you might be seeing as the June quarter \nprogressed and into July, are there any notable trends for your own book of business, just on the strength of \nreorders i n the mail order channel versus retail channel? ", "start_char_idx": 3160, "end_char_idx": 3429, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "27e6fff5-02ec-49d0-b5c1-27b5732a5f5e": {"__data__": {"id_": "27e6fff5-02ec-49d0-b5c1-27b5732a5f5e", "embedding": null, "metadata": {"window": "Brian and Britt, thanks for taking the question.  I guess, if you go back about three \nmonths ago, there was a lot of chatter in the US prescription marketplace, about mail or der, Rx, taking share from \nretail Rx.  I guess, I'm curious, just based on reorder patterns that you might be seeing as the June quarter \nprogressed and into July, are there any notable trends for your own book of business, just on the strength of \nreorders i n the mail order channel versus retail channel?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThank you for the question, Steven.  I mean, we obviously [ph] when (00:45:18) early in the lockdown period and \npayers and health plans started relaxing some of their, or changing some of their policies, there was an uptick in \nmail order. ", "original_text": "Thanks.  \n ", "page_label": "14", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f3e49820-b6cd-4d4a-91ea-9dc1750852df", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "59c3942a2d303414eda505b9f65d9736e4825436bfba4ef5c5e10b14336b6ca8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ca40a06b-1411-4275-9f89-25927aab3a64", "node_type": "1", "metadata": {"window": "Good morning.  Brian and Britt, thanks for taking the question.  I guess, if you go back about three \nmonths ago, there was a lot of chatter in the US prescription marketplace, about mail or der, Rx, taking share from \nretail Rx.  I guess, I'm curious, just based on reorder patterns that you might be seeing as the June quarter \nprogressed and into July, are there any notable trends for your own book of business, just on the strength of \nreorders i n the mail order channel versus retail channel?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThank you for the question, Steven. ", "original_text": "I guess, I'm curious, just based on reorder patterns that you might be seeing as the June quarter \nprogressed and into July, are there any notable trends for your own book of business, just on the strength of \nreorders i n the mail order channel versus retail channel? ", "page_label": "14", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "aa7768906aa55eb47faed81f612f2805894069d6899a8c8cf268102da5d83052", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1cf12911-11c8-4dac-b5b2-b9d611d74dd3", "node_type": "1", "metadata": {"window": "I guess, if you go back about three \nmonths ago, there was a lot of chatter in the US prescription marketplace, about mail or der, Rx, taking share from \nretail Rx.  I guess, I'm curious, just based on reorder patterns that you might be seeing as the June quarter \nprogressed and into July, are there any notable trends for your own book of business, just on the strength of \nreorders i n the mail order channel versus retail channel?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThank you for the question, Steven.  I mean, we obviously [ph] when (00:45:18) early in the lockdown period and \npayers and health plans started relaxing some of their, or changing some of their policies, there was an uptick in \nmail order.  If you actually look at the trend lines for mail order and retail, though, after that sort of initial -- just take \nthat initial period out, they ac tually are tracking pretty consistently. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  "}, "hash": "09786bb6b080aa74c89d58d6908bf974d7ee233ee5b80ba1b6333a858a266617", "class_name": "RelatedNodeInfo"}}, "text": "Thanks.  \n ", "start_char_idx": 3429, "end_char_idx": 3440, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1cf12911-11c8-4dac-b5b2-b9d611d74dd3": {"__data__": {"id_": "1cf12911-11c8-4dac-b5b2-b9d611d74dd3", "embedding": null, "metadata": {"window": "I guess, if you go back about three \nmonths ago, there was a lot of chatter in the US prescription marketplace, about mail or der, Rx, taking share from \nretail Rx.  I guess, I'm curious, just based on reorder patterns that you might be seeing as the June quarter \nprogressed and into July, are there any notable trends for your own book of business, just on the strength of \nreorders i n the mail order channel versus retail channel?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThank you for the question, Steven.  I mean, we obviously [ph] when (00:45:18) early in the lockdown period and \npayers and health plans started relaxing some of their, or changing some of their policies, there was an uptick in \nmail order.  If you actually look at the trend lines for mail order and retail, though, after that sort of initial -- just take \nthat initial period out, they ac tually are tracking pretty consistently. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "14", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f3e49820-b6cd-4d4a-91ea-9dc1750852df", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "59c3942a2d303414eda505b9f65d9736e4825436bfba4ef5c5e10b14336b6ca8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "27e6fff5-02ec-49d0-b5c1-27b5732a5f5e", "node_type": "1", "metadata": {"window": "Brian and Britt, thanks for taking the question.  I guess, if you go back about three \nmonths ago, there was a lot of chatter in the US prescription marketplace, about mail or der, Rx, taking share from \nretail Rx.  I guess, I'm curious, just based on reorder patterns that you might be seeing as the June quarter \nprogressed and into July, are there any notable trends for your own book of business, just on the strength of \nreorders i n the mail order channel versus retail channel?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThank you for the question, Steven.  I mean, we obviously [ph] when (00:45:18) early in the lockdown period and \npayers and health plans started relaxing some of their, or changing some of their policies, there was an uptick in \nmail order. ", "original_text": "Thanks.  \n ", "page_label": "14", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1e1efad4bea8d7cca7c4e02f5e38c6e584d20e086d45dd8d46e100aa0d6222d3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9f9b889d-2773-4cbe-a85c-51a0a56402a3", "node_type": "1", "metadata": {"window": "I guess, I'm curious, just based on reorder patterns that you might be seeing as the June quarter \nprogressed and into July, are there any notable trends for your own book of business, just on the strength of \nreorders i n the mail order channel versus retail channel?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThank you for the question, Steven.  I mean, we obviously [ph] when (00:45:18) early in the lockdown period and \npayers and health plans started relaxing some of their, or changing some of their policies, there was an uptick in \nmail order.  If you actually look at the trend lines for mail order and retail, though, after that sort of initial -- just take \nthat initial period out, they ac tually are tracking pretty consistently.  So we don't -- there one week, you can get a \nswing, one way or the other. ", "original_text": "A \nThank you for the question, Steven. "}, "hash": "fdbcc0dc0625b486ee9a68835559f0d4204be422beb1311f67915c2e8afa7d1c", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "start_char_idx": 3440, "end_char_idx": 3781, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9f9b889d-2773-4cbe-a85c-51a0a56402a3": {"__data__": {"id_": "9f9b889d-2773-4cbe-a85c-51a0a56402a3", "embedding": null, "metadata": {"window": "I guess, I'm curious, just based on reorder patterns that you might be seeing as the June quarter \nprogressed and into July, are there any notable trends for your own book of business, just on the strength of \nreorders i n the mail order channel versus retail channel?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThank you for the question, Steven.  I mean, we obviously [ph] when (00:45:18) early in the lockdown period and \npayers and health plans started relaxing some of their, or changing some of their policies, there was an uptick in \nmail order.  If you actually look at the trend lines for mail order and retail, though, after that sort of initial -- just take \nthat initial period out, they ac tually are tracking pretty consistently.  So we don't -- there one week, you can get a \nswing, one way or the other. ", "original_text": "A \nThank you for the question, Steven. ", "page_label": "14", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f3e49820-b6cd-4d4a-91ea-9dc1750852df", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "59c3942a2d303414eda505b9f65d9736e4825436bfba4ef5c5e10b14336b6ca8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1cf12911-11c8-4dac-b5b2-b9d611d74dd3", "node_type": "1", "metadata": {"window": "I guess, if you go back about three \nmonths ago, there was a lot of chatter in the US prescription marketplace, about mail or der, Rx, taking share from \nretail Rx.  I guess, I'm curious, just based on reorder patterns that you might be seeing as the June quarter \nprogressed and into July, are there any notable trends for your own book of business, just on the strength of \nreorders i n the mail order channel versus retail channel?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThank you for the question, Steven.  I mean, we obviously [ph] when (00:45:18) early in the lockdown period and \npayers and health plans started relaxing some of their, or changing some of their policies, there was an uptick in \nmail order.  If you actually look at the trend lines for mail order and retail, though, after that sort of initial -- just take \nthat initial period out, they ac tually are tracking pretty consistently. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "14", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "17f156f3798d1fff25246069567cee05f08aab08c580e7b116924577ce80b9ea", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f797cd6b-59e6-462e-90bb-4c5ebfa118f2", "node_type": "1", "metadata": {"window": "Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThank you for the question, Steven.  I mean, we obviously [ph] when (00:45:18) early in the lockdown period and \npayers and health plans started relaxing some of their, or changing some of their policies, there was an uptick in \nmail order.  If you actually look at the trend lines for mail order and retail, though, after that sort of initial -- just take \nthat initial period out, they ac tually are tracking pretty consistently.  So we don't -- there one week, you can get a \nswing, one way or the other.  But if you looked over a period of a couple of months, they're actually tracking, I \nwould say, in kind of in locksteps. ", "original_text": "I mean, we obviously [ph] when (00:45:18) early in the lockdown period and \npayers and health plans started relaxing some of their, or changing some of their policies, there was an uptick in \nmail order. "}, "hash": "6128d3eecc9f04703ca6b30def01e1db9ea38a974820c5c5215d5563a1a6ff03", "class_name": "RelatedNodeInfo"}}, "text": "A \nThank you for the question, Steven. ", "start_char_idx": 3781, "end_char_idx": 3820, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f797cd6b-59e6-462e-90bb-4c5ebfa118f2": {"__data__": {"id_": "f797cd6b-59e6-462e-90bb-4c5ebfa118f2", "embedding": null, "metadata": {"window": "Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThank you for the question, Steven.  I mean, we obviously [ph] when (00:45:18) early in the lockdown period and \npayers and health plans started relaxing some of their, or changing some of their policies, there was an uptick in \nmail order.  If you actually look at the trend lines for mail order and retail, though, after that sort of initial -- just take \nthat initial period out, they ac tually are tracking pretty consistently.  So we don't -- there one week, you can get a \nswing, one way or the other.  But if you looked over a period of a couple of months, they're actually tracking, I \nwould say, in kind of in locksteps. ", "original_text": "I mean, we obviously [ph] when (00:45:18) early in the lockdown period and \npayers and health plans started relaxing some of their, or changing some of their policies, there was an uptick in \nmail order. ", "page_label": "14", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f3e49820-b6cd-4d4a-91ea-9dc1750852df", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "59c3942a2d303414eda505b9f65d9736e4825436bfba4ef5c5e10b14336b6ca8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9f9b889d-2773-4cbe-a85c-51a0a56402a3", "node_type": "1", "metadata": {"window": "I guess, I'm curious, just based on reorder patterns that you might be seeing as the June quarter \nprogressed and into July, are there any notable trends for your own book of business, just on the strength of \nreorders i n the mail order channel versus retail channel?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThank you for the question, Steven.  I mean, we obviously [ph] when (00:45:18) early in the lockdown period and \npayers and health plans started relaxing some of their, or changing some of their policies, there was an uptick in \nmail order.  If you actually look at the trend lines for mail order and retail, though, after that sort of initial -- just take \nthat initial period out, they ac tually are tracking pretty consistently.  So we don't -- there one week, you can get a \nswing, one way or the other. ", "original_text": "A \nThank you for the question, Steven. ", "page_label": "14", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9df80adb03d907fe5730a9f146d7e9ae79deac7d6531414265f861a97e034865", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ddae9c58-9ba4-4a53-a01a-433799d95e1e", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThank you for the question, Steven.  I mean, we obviously [ph] when (00:45:18) early in the lockdown period and \npayers and health plans started relaxing some of their, or changing some of their policies, there was an uptick in \nmail order.  If you actually look at the trend lines for mail order and retail, though, after that sort of initial -- just take \nthat initial period out, they ac tually are tracking pretty consistently.  So we don't -- there one week, you can get a \nswing, one way or the other.  But if you looked over a period of a couple of months, they're actually tracking, I \nwould say, in kind of in locksteps.  So I don't see anythi ng systemic, in terms of the way the market is going to \nchange because of this.  \n ", "original_text": "If you actually look at the trend lines for mail order and retail, though, after that sort of initial -- just take \nthat initial period out, they ac tually are tracking pretty consistently. "}, "hash": "556fb4e98c490a8ca477228352f24e2e0509d009e6a96796a7e13e0a8d2fd7ca", "class_name": "RelatedNodeInfo"}}, "text": "I mean, we obviously [ph] when (00:45:18) early in the lockdown period and \npayers and health plans started relaxing some of their, or changing some of their policies, there was an uptick in \nmail order. ", "start_char_idx": 3820, "end_char_idx": 4024, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ddae9c58-9ba4-4a53-a01a-433799d95e1e": {"__data__": {"id_": "ddae9c58-9ba4-4a53-a01a-433799d95e1e", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThank you for the question, Steven.  I mean, we obviously [ph] when (00:45:18) early in the lockdown period and \npayers and health plans started relaxing some of their, or changing some of their policies, there was an uptick in \nmail order.  If you actually look at the trend lines for mail order and retail, though, after that sort of initial -- just take \nthat initial period out, they ac tually are tracking pretty consistently.  So we don't -- there one week, you can get a \nswing, one way or the other.  But if you looked over a period of a couple of months, they're actually tracking, I \nwould say, in kind of in locksteps.  So I don't see anythi ng systemic, in terms of the way the market is going to \nchange because of this.  \n ", "original_text": "If you actually look at the trend lines for mail order and retail, though, after that sort of initial -- just take \nthat initial period out, they ac tually are tracking pretty consistently. ", "page_label": "14", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f3e49820-b6cd-4d4a-91ea-9dc1750852df", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "59c3942a2d303414eda505b9f65d9736e4825436bfba4ef5c5e10b14336b6ca8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f797cd6b-59e6-462e-90bb-4c5ebfa118f2", "node_type": "1", "metadata": {"window": "Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThank you for the question, Steven.  I mean, we obviously [ph] when (00:45:18) early in the lockdown period and \npayers and health plans started relaxing some of their, or changing some of their policies, there was an uptick in \nmail order.  If you actually look at the trend lines for mail order and retail, though, after that sort of initial -- just take \nthat initial period out, they ac tually are tracking pretty consistently.  So we don't -- there one week, you can get a \nswing, one way or the other.  But if you looked over a period of a couple of months, they're actually tracking, I \nwould say, in kind of in locksteps. ", "original_text": "I mean, we obviously [ph] when (00:45:18) early in the lockdown period and \npayers and health plans started relaxing some of their, or changing some of their policies, there was an uptick in \nmail order. ", "page_label": "14", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1a738485487ccc285a2f0e7c77160bcb3892fa7f31344e712f46cb22f76247a5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "50f43e68-feb2-4c3f-b7d6-28ea534560d1", "node_type": "1", "metadata": {"window": "A \nThank you for the question, Steven.  I mean, we obviously [ph] when (00:45:18) early in the lockdown period and \npayers and health plans started relaxing some of their, or changing some of their policies, there was an uptick in \nmail order.  If you actually look at the trend lines for mail order and retail, though, after that sort of initial -- just take \nthat initial period out, they ac tually are tracking pretty consistently.  So we don't -- there one week, you can get a \nswing, one way or the other.  But if you looked over a period of a couple of months, they're actually tracking, I \nwould say, in kind of in locksteps.  So I don't see anythi ng systemic, in terms of the way the market is going to \nchange because of this.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  ", "original_text": "So we don't -- there one week, you can get a \nswing, one way or the other. "}, "hash": "6591aaeb44dffba6900c91224208f07cedfa0ee80edea8246a989dec8cf97b05", "class_name": "RelatedNodeInfo"}}, "text": "If you actually look at the trend lines for mail order and retail, though, after that sort of initial -- just take \nthat initial period out, they ac tually are tracking pretty consistently. ", "start_char_idx": 4024, "end_char_idx": 4214, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "50f43e68-feb2-4c3f-b7d6-28ea534560d1": {"__data__": {"id_": "50f43e68-feb2-4c3f-b7d6-28ea534560d1", "embedding": null, "metadata": {"window": "A \nThank you for the question, Steven.  I mean, we obviously [ph] when (00:45:18) early in the lockdown period and \npayers and health plans started relaxing some of their, or changing some of their policies, there was an uptick in \nmail order.  If you actually look at the trend lines for mail order and retail, though, after that sort of initial -- just take \nthat initial period out, they ac tually are tracking pretty consistently.  So we don't -- there one week, you can get a \nswing, one way or the other.  But if you looked over a period of a couple of months, they're actually tracking, I \nwould say, in kind of in locksteps.  So I don't see anythi ng systemic, in terms of the way the market is going to \nchange because of this.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  ", "original_text": "So we don't -- there one week, you can get a \nswing, one way or the other. ", "page_label": "14", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f3e49820-b6cd-4d4a-91ea-9dc1750852df", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "59c3942a2d303414eda505b9f65d9736e4825436bfba4ef5c5e10b14336b6ca8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ddae9c58-9ba4-4a53-a01a-433799d95e1e", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThank you for the question, Steven.  I mean, we obviously [ph] when (00:45:18) early in the lockdown period and \npayers and health plans started relaxing some of their, or changing some of their policies, there was an uptick in \nmail order.  If you actually look at the trend lines for mail order and retail, though, after that sort of initial -- just take \nthat initial period out, they ac tually are tracking pretty consistently.  So we don't -- there one week, you can get a \nswing, one way or the other.  But if you looked over a period of a couple of months, they're actually tracking, I \nwould say, in kind of in locksteps.  So I don't see anythi ng systemic, in terms of the way the market is going to \nchange because of this.  \n ", "original_text": "If you actually look at the trend lines for mail order and retail, though, after that sort of initial -- just take \nthat initial period out, they ac tually are tracking pretty consistently. ", "page_label": "14", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "68112761c982ba9280fa522d93c6b8a3543153d99aaa6caa88cca7c4deb26ccd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "92d3542c-790a-4d32-b245-3d37a1ad0de1", "node_type": "1", "metadata": {"window": "I mean, we obviously [ph] when (00:45:18) early in the lockdown period and \npayers and health plans started relaxing some of their, or changing some of their policies, there was an uptick in \nmail order.  If you actually look at the trend lines for mail order and retail, though, after that sort of initial -- just take \nthat initial period out, they ac tually are tracking pretty consistently.  So we don't -- there one week, you can get a \nswing, one way or the other.  But if you looked over a period of a couple of months, they're actually tracking, I \nwould say, in kind of in locksteps.  So I don't see anythi ng systemic, in terms of the way the market is going to \nchange because of this.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question.  \n ", "original_text": "But if you looked over a period of a couple of months, they're actually tracking, I \nwould say, in kind of in locksteps. "}, "hash": "d87dcd044ee8323f449c0ea9861c2526c16f3a67f255823d81ebdf78fbc02866", "class_name": "RelatedNodeInfo"}}, "text": "So we don't -- there one week, you can get a \nswing, one way or the other. ", "start_char_idx": 4214, "end_char_idx": 4289, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "92d3542c-790a-4d32-b245-3d37a1ad0de1": {"__data__": {"id_": "92d3542c-790a-4d32-b245-3d37a1ad0de1", "embedding": null, "metadata": {"window": "I mean, we obviously [ph] when (00:45:18) early in the lockdown period and \npayers and health plans started relaxing some of their, or changing some of their policies, there was an uptick in \nmail order.  If you actually look at the trend lines for mail order and retail, though, after that sort of initial -- just take \nthat initial period out, they ac tually are tracking pretty consistently.  So we don't -- there one week, you can get a \nswing, one way or the other.  But if you looked over a period of a couple of months, they're actually tracking, I \nwould say, in kind of in locksteps.  So I don't see anythi ng systemic, in terms of the way the market is going to \nchange because of this.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question.  \n ", "original_text": "But if you looked over a period of a couple of months, they're actually tracking, I \nwould say, in kind of in locksteps. ", "page_label": "14", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f3e49820-b6cd-4d4a-91ea-9dc1750852df", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "59c3942a2d303414eda505b9f65d9736e4825436bfba4ef5c5e10b14336b6ca8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "50f43e68-feb2-4c3f-b7d6-28ea534560d1", "node_type": "1", "metadata": {"window": "A \nThank you for the question, Steven.  I mean, we obviously [ph] when (00:45:18) early in the lockdown period and \npayers and health plans started relaxing some of their, or changing some of their policies, there was an uptick in \nmail order.  If you actually look at the trend lines for mail order and retail, though, after that sort of initial -- just take \nthat initial period out, they ac tually are tracking pretty consistently.  So we don't -- there one week, you can get a \nswing, one way or the other.  But if you looked over a period of a couple of months, they're actually tracking, I \nwould say, in kind of in locksteps.  So I don't see anythi ng systemic, in terms of the way the market is going to \nchange because of this.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  ", "original_text": "So we don't -- there one week, you can get a \nswing, one way or the other. ", "page_label": "14", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "58c0f812e639db989459c6d2e677d2bdaf01909be74ce17c93f4bb3d3c70eb18", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8cf9d13b-3a32-4f70-95b9-dd81825a0f93", "node_type": "1", "metadata": {"window": "If you actually look at the trend lines for mail order and retail, though, after that sort of initial -- just take \nthat initial period out, they ac tually are tracking pretty consistently.  So we don't -- there one week, you can get a \nswing, one way or the other.  But if you looked over a period of a couple of months, they're actually tracking, I \nwould say, in kind of in locksteps.  So I don't see anythi ng systemic, in terms of the way the market is going to \nchange because of this.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n ", "original_text": "So I don't see anythi ng systemic, in terms of the way the market is going to \nchange because of this.  \n "}, "hash": "6ce52062c0ec6b517680e273d61e56fc92f413378d3f1bf8b8a124cc46574bb1", "class_name": "RelatedNodeInfo"}}, "text": "But if you looked over a period of a couple of months, they're actually tracking, I \nwould say, in kind of in locksteps. ", "start_char_idx": 4289, "end_char_idx": 4410, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8cf9d13b-3a32-4f70-95b9-dd81825a0f93": {"__data__": {"id_": "8cf9d13b-3a32-4f70-95b9-dd81825a0f93", "embedding": null, "metadata": {"window": "If you actually look at the trend lines for mail order and retail, though, after that sort of initial -- just take \nthat initial period out, they ac tually are tracking pretty consistently.  So we don't -- there one week, you can get a \nswing, one way or the other.  But if you looked over a period of a couple of months, they're actually tracking, I \nwould say, in kind of in locksteps.  So I don't see anythi ng systemic, in terms of the way the market is going to \nchange because of this.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n ", "original_text": "So I don't see anythi ng systemic, in terms of the way the market is going to \nchange because of this.  \n ", "page_label": "14", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f3e49820-b6cd-4d4a-91ea-9dc1750852df", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "59c3942a2d303414eda505b9f65d9736e4825436bfba4ef5c5e10b14336b6ca8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "92d3542c-790a-4d32-b245-3d37a1ad0de1", "node_type": "1", "metadata": {"window": "I mean, we obviously [ph] when (00:45:18) early in the lockdown period and \npayers and health plans started relaxing some of their, or changing some of their policies, there was an uptick in \nmail order.  If you actually look at the trend lines for mail order and retail, though, after that sort of initial -- just take \nthat initial period out, they ac tually are tracking pretty consistently.  So we don't -- there one week, you can get a \nswing, one way or the other.  But if you looked over a period of a couple of months, they're actually tracking, I \nwould say, in kind of in locksteps.  So I don't see anythi ng systemic, in terms of the way the market is going to \nchange because of this.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question.  \n ", "original_text": "But if you looked over a period of a couple of months, they're actually tracking, I \nwould say, in kind of in locksteps. ", "page_label": "14", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "54ed683c28bb06114d53418415db306a579f4b6baa7ba7d781779f3e0497f6ef", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ddcedac7-027a-4f63-99e7-f8109d88cfd4", "node_type": "1", "metadata": {"window": "So we don't -- there one week, you can get a \nswing, one way or the other.  But if you looked over a period of a couple of months, they're actually tracking, I \nwould say, in kind of in locksteps.  So I don't see anythi ng systemic, in terms of the way the market is going to \nchange because of this.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  "}, "hash": "22d2a5ec572b06fc9dbd73c005d12b9b5b33f3582cc4f2d1edc593af1952a844", "class_name": "RelatedNodeInfo"}}, "text": "So I don't see anythi ng systemic, in terms of the way the market is going to \nchange because of this.  \n ", "start_char_idx": 4410, "end_char_idx": 4516, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ddcedac7-027a-4f63-99e7-f8109d88cfd4": {"__data__": {"id_": "ddcedac7-027a-4f63-99e7-f8109d88cfd4", "embedding": null, "metadata": {"window": "So we don't -- there one week, you can get a \nswing, one way or the other.  But if you looked over a period of a couple of months, they're actually tracking, I \nwould say, in kind of in locksteps.  So I don't see anythi ng systemic, in terms of the way the market is going to \nchange because of this.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  ", "page_label": "14", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f3e49820-b6cd-4d4a-91ea-9dc1750852df", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "59c3942a2d303414eda505b9f65d9736e4825436bfba4ef5c5e10b14336b6ca8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8cf9d13b-3a32-4f70-95b9-dd81825a0f93", "node_type": "1", "metadata": {"window": "If you actually look at the trend lines for mail order and retail, though, after that sort of initial -- just take \nthat initial period out, they ac tually are tracking pretty consistently.  So we don't -- there one week, you can get a \nswing, one way or the other.  But if you looked over a period of a couple of months, they're actually tracking, I \nwould say, in kind of in locksteps.  So I don't see anythi ng systemic, in terms of the way the market is going to \nchange because of this.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n ", "original_text": "So I don't see anythi ng systemic, in terms of the way the market is going to \nchange because of this.  \n ", "page_label": "14", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "02a1f10f969cc0f11c7dbf23dbd802913200f52c0e60c1423d0b795730f87e36", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "aae40073-8562-401a-8665-40aa28483494", "node_type": "1", "metadata": {"window": "But if you looked over a period of a couple of months, they're actually tracking, I \nwould say, in kind of in locksteps.  So I don't see anythi ng systemic, in terms of the way the market is going to \nchange because of this.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n ", "original_text": "A \nNext question.  \n "}, "hash": "38e022fe844187b582511b044f3a4bbd727aba35fa47132784d508313d19618e", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  ", "start_char_idx": 1885, "end_char_idx": 2230, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "aae40073-8562-401a-8665-40aa28483494": {"__data__": {"id_": "aae40073-8562-401a-8665-40aa28483494", "embedding": null, "metadata": {"window": "But if you looked over a period of a couple of months, they're actually tracking, I \nwould say, in kind of in locksteps.  So I don't see anythi ng systemic, in terms of the way the market is going to \nchange because of this.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n ", "original_text": "A \nNext question.  \n ", "page_label": "14", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f3e49820-b6cd-4d4a-91ea-9dc1750852df", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "59c3942a2d303414eda505b9f65d9736e4825436bfba4ef5c5e10b14336b6ca8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ddcedac7-027a-4f63-99e7-f8109d88cfd4", "node_type": "1", "metadata": {"window": "So we don't -- there one week, you can get a \nswing, one way or the other.  But if you looked over a period of a couple of months, they're actually tracking, I \nwould say, in kind of in locksteps.  So I don't see anythi ng systemic, in terms of the way the market is going to \nchange because of this.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  ", "page_label": "14", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "54b52ad6ac395469a01a48f4a284f958a6fb3249d90fb797074b2f8112be6cd5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "58bf1dcb-a3b4-44ca-9d9a-9d346aaddd89", "node_type": "1", "metadata": {"window": "So I don't see anythi ng systemic, in terms of the way the market is going to \nchange because of this.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n "}, "hash": "c2ec0e16fcf8143c5369c087e96f46dcd8d0994577824ddf0132ffec5cc6cc52", "class_name": "RelatedNodeInfo"}}, "text": "A \nNext question.  \n ", "start_char_idx": 4861, "end_char_idx": 4882, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "58bf1dcb-a3b4-44ca-9d9a-9d346aaddd89": {"__data__": {"id_": "58bf1dcb-a3b4-44ca-9d9a-9d346aaddd89", "embedding": null, "metadata": {"window": "So I don't see anythi ng systemic, in terms of the way the market is going to \nchange because of this.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n ", "page_label": "14", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f3e49820-b6cd-4d4a-91ea-9dc1750852df", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "59c3942a2d303414eda505b9f65d9736e4825436bfba4ef5c5e10b14336b6ca8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "aae40073-8562-401a-8665-40aa28483494", "node_type": "1", "metadata": {"window": "But if you looked over a period of a couple of months, they're actually tracking, I \nwould say, in kind of in locksteps.  So I don't see anythi ng systemic, in terms of the way the market is going to \nchange because of this.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n ", "original_text": "A \nNext question.  \n ", "page_label": "14", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b5aca58bb80aeefba32bc961f27e42b7b425224b87e03c88ba0260af1fa1f73f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b41d719c-f0c2-441a-88dd-6c44aa519458", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nOperator : The next will be from Eric Percher with Nephron Research.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you.  A question on the specialty business, I think you mentioned 70% volumes at one point in oncology. \n", "original_text": "McKesson Corp.  "}, "hash": "1b1f32d5c36bd1bb2c3da2d4be0a7f0b2b36f675ae388790e55ccb2a819f4669", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n ", "start_char_idx": 2251, "end_char_idx": 2524, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b41d719c-f0c2-441a-88dd-6c44aa519458": {"__data__": {"id_": "b41d719c-f0c2-441a-88dd-6c44aa519458", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nOperator : The next will be from Eric Percher with Nephron Research.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you.  A question on the specialty business, I think you mentioned 70% volumes at one point in oncology. \n", "original_text": "McKesson Corp.  ", "page_label": "15", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ff79878d-cd7a-4d1f-8101-b4311053d1e7", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2c328c6f973454907a463e5fc91a78491646447a046e2c3d70620671703f559d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "58bf1dcb-a3b4-44ca-9d9a-9d346aaddd89", "node_type": "1", "metadata": {"window": "So I don't see anythi ng systemic, in terms of the way the market is going to \nchange because of this.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n ", "page_label": "14", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8793a4c21090dfe288bf76b01112c36023406e753da11d48a8687594dfe50adc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e03e1783-faf2-46df-926b-89056b56ef95", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nOperator : The next will be from Eric Percher with Nephron Research.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you.  A question on the specialty business, I think you mentioned 70% volumes at one point in oncology. \n Certainly, the volumes don't look or your U.S. ", "original_text": "(MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nOperator : The next will be from Eric Percher with Nephron Research.  \n "}, "hash": "58a6ceceb7f89b3e85edbe3670713ce74a713a94876800b82197e871d22816fe", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e03e1783-faf2-46df-926b-89056b56ef95": {"__data__": {"id_": "e03e1783-faf2-46df-926b-89056b56ef95", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nOperator : The next will be from Eric Percher with Nephron Research.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you.  A question on the specialty business, I think you mentioned 70% volumes at one point in oncology. \n Certainly, the volumes don't look or your U.S. ", "original_text": "(MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nOperator : The next will be from Eric Percher with Nephron Research.  \n ", "page_label": "15", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ff79878d-cd7a-4d1f-8101-b4311053d1e7", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2c328c6f973454907a463e5fc91a78491646447a046e2c3d70620671703f559d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b41d719c-f0c2-441a-88dd-6c44aa519458", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nOperator : The next will be from Eric Percher with Nephron Research.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you.  A question on the specialty business, I think you mentioned 70% volumes at one point in oncology. \n", "original_text": "McKesson Corp.  ", "page_label": "15", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5d726c9a030db355d051458e3257e75c450d50ca9a9d26aabaffbe7ac6c1a91c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "81eacea9-a37d-4834-8413-8428c5649cf7", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nOperator : The next will be from Eric Percher with Nephron Research.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you.  A question on the specialty business, I think you mentioned 70% volumes at one point in oncology. \n Certainly, the volumes don't look or your U.S.  Pharma volumes don't look, like you saw that type of impact. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you. "}, "hash": "14464a0da487405b8f707f4567ec8b0fcfc40ea6f42dbcb57e96e918bfa6d9d1", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nOperator : The next will be from Eric Percher with Nephron Research.  \n ", "start_char_idx": 16, "end_char_idx": 253, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "81eacea9-a37d-4834-8413-8428c5649cf7": {"__data__": {"id_": "81eacea9-a37d-4834-8413-8428c5649cf7", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nOperator : The next will be from Eric Percher with Nephron Research.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you.  A question on the specialty business, I think you mentioned 70% volumes at one point in oncology. \n Certainly, the volumes don't look or your U.S.  Pharma volumes don't look, like you saw that type of impact. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you. ", "page_label": "15", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ff79878d-cd7a-4d1f-8101-b4311053d1e7", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2c328c6f973454907a463e5fc91a78491646447a046e2c3d70620671703f559d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e03e1783-faf2-46df-926b-89056b56ef95", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nOperator : The next will be from Eric Percher with Nephron Research.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you.  A question on the specialty business, I think you mentioned 70% volumes at one point in oncology. \n Certainly, the volumes don't look or your U.S. ", "original_text": "(MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nOperator : The next will be from Eric Percher with Nephron Research.  \n ", "page_label": "15", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "97dcd5e946240fd5eaabf76976d41424d53bf1eba483c7033255a77bbef324a2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "215bdc4b-988a-4679-acd2-b407a5f99e5a", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nOperator : The next will be from Eric Percher with Nephron Research.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you.  A question on the specialty business, I think you mentioned 70% volumes at one point in oncology. \n Certainly, the volumes don't look or your U.S.  Pharma volumes don't look, like you saw that type of impact.  Is it \nsafe to assume that, that was visits and that administration has remained much more stable? ", "original_text": "A question on the specialty business, I think you mentioned 70% volumes at one point in oncology. \n"}, "hash": "57cee3917940e7c16de3aeb2dad835446b1bed2317b38163f6def722cc2977e4", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you. ", "start_char_idx": 253, "end_char_idx": 585, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "215bdc4b-988a-4679-acd2-b407a5f99e5a": {"__data__": {"id_": "215bdc4b-988a-4679-acd2-b407a5f99e5a", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nOperator : The next will be from Eric Percher with Nephron Research.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you.  A question on the specialty business, I think you mentioned 70% volumes at one point in oncology. \n Certainly, the volumes don't look or your U.S.  Pharma volumes don't look, like you saw that type of impact.  Is it \nsafe to assume that, that was visits and that administration has remained much more stable? ", "original_text": "A question on the specialty business, I think you mentioned 70% volumes at one point in oncology. \n", "page_label": "15", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ff79878d-cd7a-4d1f-8101-b4311053d1e7", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2c328c6f973454907a463e5fc91a78491646447a046e2c3d70620671703f559d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "81eacea9-a37d-4834-8413-8428c5649cf7", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nOperator : The next will be from Eric Percher with Nephron Research.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you.  A question on the specialty business, I think you mentioned 70% volumes at one point in oncology. \n Certainly, the volumes don't look or your U.S.  Pharma volumes don't look, like you saw that type of impact. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you. ", "page_label": "15", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a53bf04e048472ec07182401ab69f349043f6bc1575b5c4d5168db9ebb8ab2b5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5e9a9db8-3fb1-4165-acce-6d03be816629", "node_type": "1", "metadata": {"window": "(MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nOperator : The next will be from Eric Percher with Nephron Research.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you.  A question on the specialty business, I think you mentioned 70% volumes at one point in oncology. \n Certainly, the volumes don't look or your U.S.  Pharma volumes don't look, like you saw that type of impact.  Is it \nsafe to assume that, that was visits and that administration has remained much more stable?  And then any \ncommentary on the non -oncology would be appreciated.  \n ", "original_text": "Certainly, the volumes don't look or your U.S. "}, "hash": "83050f363b7567598a4838e1a93109fbdcc674b8a92f263aca82bf99de603ee2", "class_name": "RelatedNodeInfo"}}, "text": "A question on the specialty business, I think you mentioned 70% volumes at one point in oncology. \n", "start_char_idx": 585, "end_char_idx": 684, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5e9a9db8-3fb1-4165-acce-6d03be816629": {"__data__": {"id_": "5e9a9db8-3fb1-4165-acce-6d03be816629", "embedding": null, "metadata": {"window": "(MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nOperator : The next will be from Eric Percher with Nephron Research.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you.  A question on the specialty business, I think you mentioned 70% volumes at one point in oncology. \n Certainly, the volumes don't look or your U.S.  Pharma volumes don't look, like you saw that type of impact.  Is it \nsafe to assume that, that was visits and that administration has remained much more stable?  And then any \ncommentary on the non -oncology would be appreciated.  \n ", "original_text": "Certainly, the volumes don't look or your U.S. ", "page_label": "15", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ff79878d-cd7a-4d1f-8101-b4311053d1e7", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2c328c6f973454907a463e5fc91a78491646447a046e2c3d70620671703f559d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "215bdc4b-988a-4679-acd2-b407a5f99e5a", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nOperator : The next will be from Eric Percher with Nephron Research.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you.  A question on the specialty business, I think you mentioned 70% volumes at one point in oncology. \n Certainly, the volumes don't look or your U.S.  Pharma volumes don't look, like you saw that type of impact.  Is it \nsafe to assume that, that was visits and that administration has remained much more stable? ", "original_text": "A question on the specialty business, I think you mentioned 70% volumes at one point in oncology. \n", "page_label": "15", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "328f1ba6070e57c4faea693a7da4aabe44ec4e521728efcb3dc3fa105ecb62d8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c07028c5-6347-464d-b168-5775e60013b4", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you.  A question on the specialty business, I think you mentioned 70% volumes at one point in oncology. \n Certainly, the volumes don't look or your U.S.  Pharma volumes don't look, like you saw that type of impact.  Is it \nsafe to assume that, that was visits and that administration has remained much more stable?  And then any \ncommentary on the non -oncology would be appreciated.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "original_text": "Pharma volumes don't look, like you saw that type of impact. "}, "hash": "e73ade6aad57dc4f50e59c0f0c094928be53c7834468f385fdca948d05bdfcd8", "class_name": "RelatedNodeInfo"}}, "text": "Certainly, the volumes don't look or your U.S. ", "start_char_idx": 684, "end_char_idx": 731, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c07028c5-6347-464d-b168-5775e60013b4": {"__data__": {"id_": "c07028c5-6347-464d-b168-5775e60013b4", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you.  A question on the specialty business, I think you mentioned 70% volumes at one point in oncology. \n Certainly, the volumes don't look or your U.S.  Pharma volumes don't look, like you saw that type of impact.  Is it \nsafe to assume that, that was visits and that administration has remained much more stable?  And then any \ncommentary on the non -oncology would be appreciated.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "original_text": "Pharma volumes don't look, like you saw that type of impact. ", "page_label": "15", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ff79878d-cd7a-4d1f-8101-b4311053d1e7", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2c328c6f973454907a463e5fc91a78491646447a046e2c3d70620671703f559d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5e9a9db8-3fb1-4165-acce-6d03be816629", "node_type": "1", "metadata": {"window": "(MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nOperator : The next will be from Eric Percher with Nephron Research.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you.  A question on the specialty business, I think you mentioned 70% volumes at one point in oncology. \n Certainly, the volumes don't look or your U.S.  Pharma volumes don't look, like you saw that type of impact.  Is it \nsafe to assume that, that was visits and that administration has remained much more stable?  And then any \ncommentary on the non -oncology would be appreciated.  \n ", "original_text": "Certainly, the volumes don't look or your U.S. ", "page_label": "15", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e9f4f657818f86a0d3cb976de219da6b071d76a18bffbf65acb5447960245173", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8b9a4fa9-5a4a-401f-b718-3446fdc66f60", "node_type": "1", "metadata": {"window": "A question on the specialty business, I think you mentioned 70% volumes at one point in oncology. \n Certainly, the volumes don't look or your U.S.  Pharma volumes don't look, like you saw that type of impact.  Is it \nsafe to assume that, that was visits and that administration has remained much more stable?  And then any \ncommentary on the non -oncology would be appreciated.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nEric, le t me start, and then Brian can add. ", "original_text": "Is it \nsafe to assume that, that was visits and that administration has remained much more stable? "}, "hash": "1c6a855bde414dd638b3fa38aca3d3f9218ef2ec567629c852d2648e80342cbe", "class_name": "RelatedNodeInfo"}}, "text": "Pharma volumes don't look, like you saw that type of impact. ", "start_char_idx": 731, "end_char_idx": 792, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8b9a4fa9-5a4a-401f-b718-3446fdc66f60": {"__data__": {"id_": "8b9a4fa9-5a4a-401f-b718-3446fdc66f60", "embedding": null, "metadata": {"window": "A question on the specialty business, I think you mentioned 70% volumes at one point in oncology. \n Certainly, the volumes don't look or your U.S.  Pharma volumes don't look, like you saw that type of impact.  Is it \nsafe to assume that, that was visits and that administration has remained much more stable?  And then any \ncommentary on the non -oncology would be appreciated.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nEric, le t me start, and then Brian can add. ", "original_text": "Is it \nsafe to assume that, that was visits and that administration has remained much more stable? ", "page_label": "15", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ff79878d-cd7a-4d1f-8101-b4311053d1e7", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2c328c6f973454907a463e5fc91a78491646447a046e2c3d70620671703f559d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c07028c5-6347-464d-b168-5775e60013b4", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you.  A question on the specialty business, I think you mentioned 70% volumes at one point in oncology. \n Certainly, the volumes don't look or your U.S.  Pharma volumes don't look, like you saw that type of impact.  Is it \nsafe to assume that, that was visits and that administration has remained much more stable?  And then any \ncommentary on the non -oncology would be appreciated.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "original_text": "Pharma volumes don't look, like you saw that type of impact. ", "page_label": "15", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "49025d30ff27a9ef1ce7168288c50e26c315fbfa7e3d82f4755d8cbfe1c9a4ca", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5aa1e20b-a523-41b2-b3bf-dac0db7108f0", "node_type": "1", "metadata": {"window": "Certainly, the volumes don't look or your U.S.  Pharma volumes don't look, like you saw that type of impact.  Is it \nsafe to assume that, that was visits and that administration has remained much more stable?  And then any \ncommentary on the non -oncology would be appreciated.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nEric, le t me start, and then Brian can add.  Just to clarify, my comments were really related to visits. ", "original_text": "And then any \ncommentary on the non -oncology would be appreciated.  \n "}, "hash": "316090404537736f44f8fc4088af6f8b32d534c75da3c457ffa16f5198f65e44", "class_name": "RelatedNodeInfo"}}, "text": "Is it \nsafe to assume that, that was visits and that administration has remained much more stable? ", "start_char_idx": 792, "end_char_idx": 891, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5aa1e20b-a523-41b2-b3bf-dac0db7108f0": {"__data__": {"id_": "5aa1e20b-a523-41b2-b3bf-dac0db7108f0", "embedding": null, "metadata": {"window": "Certainly, the volumes don't look or your U.S.  Pharma volumes don't look, like you saw that type of impact.  Is it \nsafe to assume that, that was visits and that administration has remained much more stable?  And then any \ncommentary on the non -oncology would be appreciated.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nEric, le t me start, and then Brian can add.  Just to clarify, my comments were really related to visits. ", "original_text": "And then any \ncommentary on the non -oncology would be appreciated.  \n ", "page_label": "15", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ff79878d-cd7a-4d1f-8101-b4311053d1e7", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2c328c6f973454907a463e5fc91a78491646447a046e2c3d70620671703f559d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8b9a4fa9-5a4a-401f-b718-3446fdc66f60", "node_type": "1", "metadata": {"window": "A question on the specialty business, I think you mentioned 70% volumes at one point in oncology. \n Certainly, the volumes don't look or your U.S.  Pharma volumes don't look, like you saw that type of impact.  Is it \nsafe to assume that, that was visits and that administration has remained much more stable?  And then any \ncommentary on the non -oncology would be appreciated.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nEric, le t me start, and then Brian can add. ", "original_text": "Is it \nsafe to assume that, that was visits and that administration has remained much more stable? ", "page_label": "15", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2c3b93ae712048a9c8a999556a81ed8b156ebc63147a59506c360b4109b57f9f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d4297ef8-03a2-4ed4-b2b1-bb8c9e5626fb", "node_type": "1", "metadata": {"window": "Pharma volumes don't look, like you saw that type of impact.  Is it \nsafe to assume that, that was visits and that administration has remained much more stable?  And then any \ncommentary on the non -oncology would be appreciated.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nEric, le t me start, and then Brian can add.  Just to clarify, my comments were really related to visits.  And so what \nwe saw at the beginning of the quarter right after the pandemic is that, visits ticked down to about that 70% level. \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  "}, "hash": "bbae017a8aeca763e17bac62291c8fb600e9841357d293160469151f1b5eca06", "class_name": "RelatedNodeInfo"}}, "text": "And then any \ncommentary on the non -oncology would be appreciated.  \n ", "start_char_idx": 891, "end_char_idx": 962, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d4297ef8-03a2-4ed4-b2b1-bb8c9e5626fb": {"__data__": {"id_": "d4297ef8-03a2-4ed4-b2b1-bb8c9e5626fb", "embedding": null, "metadata": {"window": "Pharma volumes don't look, like you saw that type of impact.  Is it \nsafe to assume that, that was visits and that administration has remained much more stable?  And then any \ncommentary on the non -oncology would be appreciated.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nEric, le t me start, and then Brian can add.  Just to clarify, my comments were really related to visits.  And so what \nwe saw at the beginning of the quarter right after the pandemic is that, visits ticked down to about that 70% level. \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "page_label": "15", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ff79878d-cd7a-4d1f-8101-b4311053d1e7", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2c328c6f973454907a463e5fc91a78491646447a046e2c3d70620671703f559d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5aa1e20b-a523-41b2-b3bf-dac0db7108f0", "node_type": "1", "metadata": {"window": "Certainly, the volumes don't look or your U.S.  Pharma volumes don't look, like you saw that type of impact.  Is it \nsafe to assume that, that was visits and that administration has remained much more stable?  And then any \ncommentary on the non -oncology would be appreciated.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nEric, le t me start, and then Brian can add.  Just to clarify, my comments were really related to visits. ", "original_text": "And then any \ncommentary on the non -oncology would be appreciated.  \n ", "page_label": "15", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "37013e6dceb7e54fc99f51e362d2be5c194d80043d473e3c82bcdf2007770e81", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4eab0c6f-c55b-45ba-9cc6-8da711d4fad1", "node_type": "1", "metadata": {"window": "Is it \nsafe to assume that, that was visits and that administration has remained much more stable?  And then any \ncommentary on the non -oncology would be appreciated.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nEric, le t me start, and then Brian can add.  Just to clarify, my comments were really related to visits.  And so what \nwe saw at the beginning of the quarter right after the pandemic is that, visits ticked down to about that 70% level. \n And we saw pretty steady growth  throughout the quarter to roughly the 95%, at the end of the quarter that I \nreferenced. ", "original_text": "A \nEric, le t me start, and then Brian can add. "}, "hash": "d805dcaae6b3da9c00ea92350b5368d7dde13003b13790885e4cbbd7535de8b8", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "start_char_idx": 962, "end_char_idx": 1322, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4eab0c6f-c55b-45ba-9cc6-8da711d4fad1": {"__data__": {"id_": "4eab0c6f-c55b-45ba-9cc6-8da711d4fad1", "embedding": null, "metadata": {"window": "Is it \nsafe to assume that, that was visits and that administration has remained much more stable?  And then any \ncommentary on the non -oncology would be appreciated.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nEric, le t me start, and then Brian can add.  Just to clarify, my comments were really related to visits.  And so what \nwe saw at the beginning of the quarter right after the pandemic is that, visits ticked down to about that 70% level. \n And we saw pretty steady growth  throughout the quarter to roughly the 95%, at the end of the quarter that I \nreferenced. ", "original_text": "A \nEric, le t me start, and then Brian can add. ", "page_label": "15", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ff79878d-cd7a-4d1f-8101-b4311053d1e7", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2c328c6f973454907a463e5fc91a78491646447a046e2c3d70620671703f559d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d4297ef8-03a2-4ed4-b2b1-bb8c9e5626fb", "node_type": "1", "metadata": {"window": "Pharma volumes don't look, like you saw that type of impact.  Is it \nsafe to assume that, that was visits and that administration has remained much more stable?  And then any \ncommentary on the non -oncology would be appreciated.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nEric, le t me start, and then Brian can add.  Just to clarify, my comments were really related to visits.  And so what \nwe saw at the beginning of the quarter right after the pandemic is that, visits ticked down to about that 70% level. \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "page_label": "15", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "78d843406a9fc694f4944ef5593db70bad2d6d7b31cade9d422eb365972e0378", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fcaabf17-a700-4778-a0d5-c5ec63d1b5a9", "node_type": "1", "metadata": {"window": "And then any \ncommentary on the non -oncology would be appreciated.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nEric, le t me start, and then Brian can add.  Just to clarify, my comments were really related to visits.  And so what \nwe saw at the beginning of the quarter right after the pandemic is that, visits ticked down to about that 70% level. \n And we saw pretty steady growth  throughout the quarter to roughly the 95%, at the end of the quarter that I \nreferenced.  And we also saw an increase in telemedicine visits, which I think helped the practices from an \nefficiency standpoint as well. ", "original_text": "Just to clarify, my comments were really related to visits. "}, "hash": "53a06308339b3f268fa4b77568fd875914234e54f9917d4923fe43bee7c10a2d", "class_name": "RelatedNodeInfo"}}, "text": "A \nEric, le t me start, and then Brian can add. ", "start_char_idx": 1322, "end_char_idx": 1370, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fcaabf17-a700-4778-a0d5-c5ec63d1b5a9": {"__data__": {"id_": "fcaabf17-a700-4778-a0d5-c5ec63d1b5a9", "embedding": null, "metadata": {"window": "And then any \ncommentary on the non -oncology would be appreciated.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nEric, le t me start, and then Brian can add.  Just to clarify, my comments were really related to visits.  And so what \nwe saw at the beginning of the quarter right after the pandemic is that, visits ticked down to about that 70% level. \n And we saw pretty steady growth  throughout the quarter to roughly the 95%, at the end of the quarter that I \nreferenced.  And we also saw an increase in telemedicine visits, which I think helped the practices from an \nefficiency standpoint as well. ", "original_text": "Just to clarify, my comments were really related to visits. ", "page_label": "15", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ff79878d-cd7a-4d1f-8101-b4311053d1e7", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2c328c6f973454907a463e5fc91a78491646447a046e2c3d70620671703f559d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4eab0c6f-c55b-45ba-9cc6-8da711d4fad1", "node_type": "1", "metadata": {"window": "Is it \nsafe to assume that, that was visits and that administration has remained much more stable?  And then any \ncommentary on the non -oncology would be appreciated.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nEric, le t me start, and then Brian can add.  Just to clarify, my comments were really related to visits.  And so what \nwe saw at the beginning of the quarter right after the pandemic is that, visits ticked down to about that 70% level. \n And we saw pretty steady growth  throughout the quarter to roughly the 95%, at the end of the quarter that I \nreferenced. ", "original_text": "A \nEric, le t me start, and then Brian can add. ", "page_label": "15", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "aeaf3d194ac812e63de5c31e54ffe92f73d6da9d1127991c86be9c4330f74dd5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "057c2d7c-1db7-4c83-b943-7b2aa6270633", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nEric, le t me start, and then Brian can add.  Just to clarify, my comments were really related to visits.  And so what \nwe saw at the beginning of the quarter right after the pandemic is that, visits ticked down to about that 70% level. \n And we saw pretty steady growth  throughout the quarter to roughly the 95%, at the end of the quarter that I \nreferenced.  And we also saw an increase in telemedicine visits, which I think helped the practices from an \nefficiency standpoint as well.  So a comment, just to clarify, was really  based on visits.  \n ", "original_text": "And so what \nwe saw at the beginning of the quarter right after the pandemic is that, visits ticked down to about that 70% level. \n"}, "hash": "766ce3ceec701671303ae3f5d5e7d38e291e3a3b15e931030f7e6796531528b4", "class_name": "RelatedNodeInfo"}}, "text": "Just to clarify, my comments were really related to visits. ", "start_char_idx": 1370, "end_char_idx": 1430, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "057c2d7c-1db7-4c83-b943-7b2aa6270633": {"__data__": {"id_": "057c2d7c-1db7-4c83-b943-7b2aa6270633", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nEric, le t me start, and then Brian can add.  Just to clarify, my comments were really related to visits.  And so what \nwe saw at the beginning of the quarter right after the pandemic is that, visits ticked down to about that 70% level. \n And we saw pretty steady growth  throughout the quarter to roughly the 95%, at the end of the quarter that I \nreferenced.  And we also saw an increase in telemedicine visits, which I think helped the practices from an \nefficiency standpoint as well.  So a comment, just to clarify, was really  based on visits.  \n ", "original_text": "And so what \nwe saw at the beginning of the quarter right after the pandemic is that, visits ticked down to about that 70% level. \n", "page_label": "15", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ff79878d-cd7a-4d1f-8101-b4311053d1e7", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2c328c6f973454907a463e5fc91a78491646447a046e2c3d70620671703f559d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fcaabf17-a700-4778-a0d5-c5ec63d1b5a9", "node_type": "1", "metadata": {"window": "And then any \ncommentary on the non -oncology would be appreciated.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nEric, le t me start, and then Brian can add.  Just to clarify, my comments were really related to visits.  And so what \nwe saw at the beginning of the quarter right after the pandemic is that, visits ticked down to about that 70% level. \n And we saw pretty steady growth  throughout the quarter to roughly the 95%, at the end of the quarter that I \nreferenced.  And we also saw an increase in telemedicine visits, which I think helped the practices from an \nefficiency standpoint as well. ", "original_text": "Just to clarify, my comments were really related to visits. ", "page_label": "15", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "344364b16a967cf879bf36f0eb3349c4736f506a2edbe249fbfa57c970ae00eb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cc3e792c-1f77-46fa-8ec6-d0a43ce4a9ae", "node_type": "1", "metadata": {"window": "A \nEric, le t me start, and then Brian can add.  Just to clarify, my comments were really related to visits.  And so what \nwe saw at the beginning of the quarter right after the pandemic is that, visits ticked down to about that 70% level. \n And we saw pretty steady growth  throughout the quarter to roughly the 95%, at the end of the quarter that I \nreferenced.  And we also saw an increase in telemedicine visits, which I think helped the practices from an \nefficiency standpoint as well.  So a comment, just to clarify, was really  based on visits.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "And we saw pretty steady growth  throughout the quarter to roughly the 95%, at the end of the quarter that I \nreferenced. "}, "hash": "6a7657143e8fc21df811b2285329760e21b0f60a225b49c3ac75bbda1c35ce58", "class_name": "RelatedNodeInfo"}}, "text": "And so what \nwe saw at the beginning of the quarter right after the pandemic is that, visits ticked down to about that 70% level. \n", "start_char_idx": 1430, "end_char_idx": 1561, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cc3e792c-1f77-46fa-8ec6-d0a43ce4a9ae": {"__data__": {"id_": "cc3e792c-1f77-46fa-8ec6-d0a43ce4a9ae", "embedding": null, "metadata": {"window": "A \nEric, le t me start, and then Brian can add.  Just to clarify, my comments were really related to visits.  And so what \nwe saw at the beginning of the quarter right after the pandemic is that, visits ticked down to about that 70% level. \n And we saw pretty steady growth  throughout the quarter to roughly the 95%, at the end of the quarter that I \nreferenced.  And we also saw an increase in telemedicine visits, which I think helped the practices from an \nefficiency standpoint as well.  So a comment, just to clarify, was really  based on visits.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "And we saw pretty steady growth  throughout the quarter to roughly the 95%, at the end of the quarter that I \nreferenced. ", "page_label": "15", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ff79878d-cd7a-4d1f-8101-b4311053d1e7", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2c328c6f973454907a463e5fc91a78491646447a046e2c3d70620671703f559d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "057c2d7c-1db7-4c83-b943-7b2aa6270633", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nEric, le t me start, and then Brian can add.  Just to clarify, my comments were really related to visits.  And so what \nwe saw at the beginning of the quarter right after the pandemic is that, visits ticked down to about that 70% level. \n And we saw pretty steady growth  throughout the quarter to roughly the 95%, at the end of the quarter that I \nreferenced.  And we also saw an increase in telemedicine visits, which I think helped the practices from an \nefficiency standpoint as well.  So a comment, just to clarify, was really  based on visits.  \n ", "original_text": "And so what \nwe saw at the beginning of the quarter right after the pandemic is that, visits ticked down to about that 70% level. \n", "page_label": "15", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "db4e0680f5f38dcb01e72b9106f1c3489ac53f1508d51b845cfd66cd77e20369", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "480d15b7-aca5-4b43-ab2b-f6c6653eb252", "node_type": "1", "metadata": {"window": "Just to clarify, my comments were really related to visits.  And so what \nwe saw at the beginning of the quarter right after the pandemic is that, visits ticked down to about that 70% level. \n And we saw pretty steady growth  throughout the quarter to roughly the 95%, at the end of the quarter that I \nreferenced.  And we also saw an increase in telemedicine visits, which I think helped the practices from an \nefficiency standpoint as well.  So a comment, just to clarify, was really  based on visits.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThe [ph] only (00:47:24) thing I would add to that is, obviously, we had a lot of tremendous insight into oncology. \n", "original_text": "And we also saw an increase in telemedicine visits, which I think helped the practices from an \nefficiency standpoint as well. "}, "hash": "b598d3497fc0926590356ffe1ac7f21e8a85b6ad856fc6ac4520444b16b617a5", "class_name": "RelatedNodeInfo"}}, "text": "And we saw pretty steady growth  throughout the quarter to roughly the 95%, at the end of the quarter that I \nreferenced. ", "start_char_idx": 1561, "end_char_idx": 1683, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "480d15b7-aca5-4b43-ab2b-f6c6653eb252": {"__data__": {"id_": "480d15b7-aca5-4b43-ab2b-f6c6653eb252", "embedding": null, "metadata": {"window": "Just to clarify, my comments were really related to visits.  And so what \nwe saw at the beginning of the quarter right after the pandemic is that, visits ticked down to about that 70% level. \n And we saw pretty steady growth  throughout the quarter to roughly the 95%, at the end of the quarter that I \nreferenced.  And we also saw an increase in telemedicine visits, which I think helped the practices from an \nefficiency standpoint as well.  So a comment, just to clarify, was really  based on visits.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThe [ph] only (00:47:24) thing I would add to that is, obviously, we had a lot of tremendous insight into oncology. \n", "original_text": "And we also saw an increase in telemedicine visits, which I think helped the practices from an \nefficiency standpoint as well. ", "page_label": "15", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ff79878d-cd7a-4d1f-8101-b4311053d1e7", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2c328c6f973454907a463e5fc91a78491646447a046e2c3d70620671703f559d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cc3e792c-1f77-46fa-8ec6-d0a43ce4a9ae", "node_type": "1", "metadata": {"window": "A \nEric, le t me start, and then Brian can add.  Just to clarify, my comments were really related to visits.  And so what \nwe saw at the beginning of the quarter right after the pandemic is that, visits ticked down to about that 70% level. \n And we saw pretty steady growth  throughout the quarter to roughly the 95%, at the end of the quarter that I \nreferenced.  And we also saw an increase in telemedicine visits, which I think helped the practices from an \nefficiency standpoint as well.  So a comment, just to clarify, was really  based on visits.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "And we saw pretty steady growth  throughout the quarter to roughly the 95%, at the end of the quarter that I \nreferenced. ", "page_label": "15", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "aa63f6d344f8d1c756b07438b6266aa96bb583ff61de6c63996b4868f460b052", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d635d0ec-7529-4cd1-80e8-1fb7fb5e3293", "node_type": "1", "metadata": {"window": "And so what \nwe saw at the beginning of the quarter right after the pandemic is that, visits ticked down to about that 70% level. \n And we saw pretty steady growth  throughout the quarter to roughly the 95%, at the end of the quarter that I \nreferenced.  And we also saw an increase in telemedicine visits, which I think helped the practices from an \nefficiency standpoint as well.  So a comment, just to clarify, was really  based on visits.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThe [ph] only (00:47:24) thing I would add to that is, obviously, we had a lot of tremendous insight into oncology. \n We're in a lot of other specialties. ", "original_text": "So a comment, just to clarify, was really  based on visits.  \n "}, "hash": "83dba759f7b168e4c55a96c11b56951eca1ed49323d99ea9ad1af7bca3af9df5", "class_name": "RelatedNodeInfo"}}, "text": "And we also saw an increase in telemedicine visits, which I think helped the practices from an \nefficiency standpoint as well. ", "start_char_idx": 1683, "end_char_idx": 1810, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d635d0ec-7529-4cd1-80e8-1fb7fb5e3293": {"__data__": {"id_": "d635d0ec-7529-4cd1-80e8-1fb7fb5e3293", "embedding": null, "metadata": {"window": "And so what \nwe saw at the beginning of the quarter right after the pandemic is that, visits ticked down to about that 70% level. \n And we saw pretty steady growth  throughout the quarter to roughly the 95%, at the end of the quarter that I \nreferenced.  And we also saw an increase in telemedicine visits, which I think helped the practices from an \nefficiency standpoint as well.  So a comment, just to clarify, was really  based on visits.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThe [ph] only (00:47:24) thing I would add to that is, obviously, we had a lot of tremendous insight into oncology. \n We're in a lot of other specialties. ", "original_text": "So a comment, just to clarify, was really  based on visits.  \n ", "page_label": "15", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ff79878d-cd7a-4d1f-8101-b4311053d1e7", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2c328c6f973454907a463e5fc91a78491646447a046e2c3d70620671703f559d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "480d15b7-aca5-4b43-ab2b-f6c6653eb252", "node_type": "1", "metadata": {"window": "Just to clarify, my comments were really related to visits.  And so what \nwe saw at the beginning of the quarter right after the pandemic is that, visits ticked down to about that 70% level. \n And we saw pretty steady growth  throughout the quarter to roughly the 95%, at the end of the quarter that I \nreferenced.  And we also saw an increase in telemedicine visits, which I think helped the practices from an \nefficiency standpoint as well.  So a comment, just to clarify, was really  based on visits.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThe [ph] only (00:47:24) thing I would add to that is, obviously, we had a lot of tremendous insight into oncology. \n", "original_text": "And we also saw an increase in telemedicine visits, which I think helped the practices from an \nefficiency standpoint as well. ", "page_label": "15", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bec79a001c7f92c0c573976d026f8c138b8bff6d993e65596f4ad2b2fd93a374", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bbc5341b-e812-453e-ad03-fa9d904606e2", "node_type": "1", "metadata": {"window": "And we saw pretty steady growth  throughout the quarter to roughly the 95%, at the end of the quarter that I \nreferenced.  And we also saw an increase in telemedicine visits, which I think helped the practices from an \nefficiency standpoint as well.  So a comment, just to clarify, was really  based on visits.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThe [ph] only (00:47:24) thing I would add to that is, obviously, we had a lot of tremendous insight into oncology. \n We're in a lot of other specialties.  And it's one o f the, I guess, nuances to the environment we're in right now is \nthat each specialty, just like each of our market segments has got a bit of their own recovery curve and timing just \nkind of dependent on what's the nature of the disease, what's the nature o f the therapies, what's the interaction \nwith physicians, what's the applicability of telehealth versus not. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  "}, "hash": "846a8139e7a65d98376fd5fa3f9ebd6d6c79a9e6f39a593887fa4b5131ab372c", "class_name": "RelatedNodeInfo"}}, "text": "So a comment, just to clarify, was really  based on visits.  \n ", "start_char_idx": 1810, "end_char_idx": 1873, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bbc5341b-e812-453e-ad03-fa9d904606e2": {"__data__": {"id_": "bbc5341b-e812-453e-ad03-fa9d904606e2", "embedding": null, "metadata": {"window": "And we saw pretty steady growth  throughout the quarter to roughly the 95%, at the end of the quarter that I \nreferenced.  And we also saw an increase in telemedicine visits, which I think helped the practices from an \nefficiency standpoint as well.  So a comment, just to clarify, was really  based on visits.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThe [ph] only (00:47:24) thing I would add to that is, obviously, we had a lot of tremendous insight into oncology. \n We're in a lot of other specialties.  And it's one o f the, I guess, nuances to the environment we're in right now is \nthat each specialty, just like each of our market segments has got a bit of their own recovery curve and timing just \nkind of dependent on what's the nature of the disease, what's the nature o f the therapies, what's the interaction \nwith physicians, what's the applicability of telehealth versus not. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "15", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ff79878d-cd7a-4d1f-8101-b4311053d1e7", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2c328c6f973454907a463e5fc91a78491646447a046e2c3d70620671703f559d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d635d0ec-7529-4cd1-80e8-1fb7fb5e3293", "node_type": "1", "metadata": {"window": "And so what \nwe saw at the beginning of the quarter right after the pandemic is that, visits ticked down to about that 70% level. \n And we saw pretty steady growth  throughout the quarter to roughly the 95%, at the end of the quarter that I \nreferenced.  And we also saw an increase in telemedicine visits, which I think helped the practices from an \nefficiency standpoint as well.  So a comment, just to clarify, was really  based on visits.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThe [ph] only (00:47:24) thing I would add to that is, obviously, we had a lot of tremendous insight into oncology. \n We're in a lot of other specialties. ", "original_text": "So a comment, just to clarify, was really  based on visits.  \n ", "page_label": "15", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c18be1c1725cf2be25c14e1bb3b8609105b89fdf4071ffaabc12248a796773f0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a4faa206-6fcc-46d4-9711-a0ae3860462f", "node_type": "1", "metadata": {"window": "And we also saw an increase in telemedicine visits, which I think helped the practices from an \nefficiency standpoint as well.  So a comment, just to clarify, was really  based on visits.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThe [ph] only (00:47:24) thing I would add to that is, obviously, we had a lot of tremendous insight into oncology. \n We're in a lot of other specialties.  And it's one o f the, I guess, nuances to the environment we're in right now is \nthat each specialty, just like each of our market segments has got a bit of their own recovery curve and timing just \nkind of dependent on what's the nature of the disease, what's the nature o f the therapies, what's the interaction \nwith physicians, what's the applicability of telehealth versus not.  So we really watch this by each of the various \ndisease states.  \n ", "original_text": "A \nThe [ph] only (00:47:24) thing I would add to that is, obviously, we had a lot of tremendous insight into oncology. \n"}, "hash": "d19f982163550dfde2729cddfd3a69c94fed028c6fe57c22cf941062cafe0b88", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "start_char_idx": 1873, "end_char_idx": 2214, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a4faa206-6fcc-46d4-9711-a0ae3860462f": {"__data__": {"id_": "a4faa206-6fcc-46d4-9711-a0ae3860462f", "embedding": null, "metadata": {"window": "And we also saw an increase in telemedicine visits, which I think helped the practices from an \nefficiency standpoint as well.  So a comment, just to clarify, was really  based on visits.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThe [ph] only (00:47:24) thing I would add to that is, obviously, we had a lot of tremendous insight into oncology. \n We're in a lot of other specialties.  And it's one o f the, I guess, nuances to the environment we're in right now is \nthat each specialty, just like each of our market segments has got a bit of their own recovery curve and timing just \nkind of dependent on what's the nature of the disease, what's the nature o f the therapies, what's the interaction \nwith physicians, what's the applicability of telehealth versus not.  So we really watch this by each of the various \ndisease states.  \n ", "original_text": "A \nThe [ph] only (00:47:24) thing I would add to that is, obviously, we had a lot of tremendous insight into oncology. \n", "page_label": "15", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ff79878d-cd7a-4d1f-8101-b4311053d1e7", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2c328c6f973454907a463e5fc91a78491646447a046e2c3d70620671703f559d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bbc5341b-e812-453e-ad03-fa9d904606e2", "node_type": "1", "metadata": {"window": "And we saw pretty steady growth  throughout the quarter to roughly the 95%, at the end of the quarter that I \nreferenced.  And we also saw an increase in telemedicine visits, which I think helped the practices from an \nefficiency standpoint as well.  So a comment, just to clarify, was really  based on visits.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThe [ph] only (00:47:24) thing I would add to that is, obviously, we had a lot of tremendous insight into oncology. \n We're in a lot of other specialties.  And it's one o f the, I guess, nuances to the environment we're in right now is \nthat each specialty, just like each of our market segments has got a bit of their own recovery curve and timing just \nkind of dependent on what's the nature of the disease, what's the nature o f the therapies, what's the interaction \nwith physicians, what's the applicability of telehealth versus not. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "15", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "66442f7f39466d5ea7d321bffcd3f701cbd7aa86886cf264817f60a55fc3873c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f82625aa-60e5-4103-95d0-02004f711cf6", "node_type": "1", "metadata": {"window": "So a comment, just to clarify, was really  based on visits.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThe [ph] only (00:47:24) thing I would add to that is, obviously, we had a lot of tremendous insight into oncology. \n We're in a lot of other specialties.  And it's one o f the, I guess, nuances to the environment we're in right now is \nthat each specialty, just like each of our market segments has got a bit of their own recovery curve and timing just \nkind of dependent on what's the nature of the disease, what's the nature o f the therapies, what's the interaction \nwith physicians, what's the applicability of telehealth versus not.  So we really watch this by each of the various \ndisease states.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  ", "original_text": "We're in a lot of other specialties. "}, "hash": "240c0c3f7cc503cf71a4119ae89f98158ae49a3507bd0571039dd7c5d05ff362", "class_name": "RelatedNodeInfo"}}, "text": "A \nThe [ph] only (00:47:24) thing I would add to that is, obviously, we had a lot of tremendous insight into oncology. \n", "start_char_idx": 2214, "end_char_idx": 2334, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f82625aa-60e5-4103-95d0-02004f711cf6": {"__data__": {"id_": "f82625aa-60e5-4103-95d0-02004f711cf6", "embedding": null, "metadata": {"window": "So a comment, just to clarify, was really  based on visits.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThe [ph] only (00:47:24) thing I would add to that is, obviously, we had a lot of tremendous insight into oncology. \n We're in a lot of other specialties.  And it's one o f the, I guess, nuances to the environment we're in right now is \nthat each specialty, just like each of our market segments has got a bit of their own recovery curve and timing just \nkind of dependent on what's the nature of the disease, what's the nature o f the therapies, what's the interaction \nwith physicians, what's the applicability of telehealth versus not.  So we really watch this by each of the various \ndisease states.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  ", "original_text": "We're in a lot of other specialties. ", "page_label": "15", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ff79878d-cd7a-4d1f-8101-b4311053d1e7", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2c328c6f973454907a463e5fc91a78491646447a046e2c3d70620671703f559d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a4faa206-6fcc-46d4-9711-a0ae3860462f", "node_type": "1", "metadata": {"window": "And we also saw an increase in telemedicine visits, which I think helped the practices from an \nefficiency standpoint as well.  So a comment, just to clarify, was really  based on visits.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThe [ph] only (00:47:24) thing I would add to that is, obviously, we had a lot of tremendous insight into oncology. \n We're in a lot of other specialties.  And it's one o f the, I guess, nuances to the environment we're in right now is \nthat each specialty, just like each of our market segments has got a bit of their own recovery curve and timing just \nkind of dependent on what's the nature of the disease, what's the nature o f the therapies, what's the interaction \nwith physicians, what's the applicability of telehealth versus not.  So we really watch this by each of the various \ndisease states.  \n ", "original_text": "A \nThe [ph] only (00:47:24) thing I would add to that is, obviously, we had a lot of tremendous insight into oncology. \n", "page_label": "15", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b280cf0aa2b7d4e51c04b02a14dd2d2a492b6b53d6a5779d4c12c1700fafd2cf", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "53a0530f-71a6-417b-8615-25588c0ed1d8", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThe [ph] only (00:47:24) thing I would add to that is, obviously, we had a lot of tremendous insight into oncology. \n We're in a lot of other specialties.  And it's one o f the, I guess, nuances to the environment we're in right now is \nthat each specialty, just like each of our market segments has got a bit of their own recovery curve and timing just \nkind of dependent on what's the nature of the disease, what's the nature o f the therapies, what's the interaction \nwith physicians, what's the applicability of telehealth versus not.  So we really watch this by each of the various \ndisease states.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question.  \n ", "original_text": "And it's one o f the, I guess, nuances to the environment we're in right now is \nthat each specialty, just like each of our market segments has got a bit of their own recovery curve and timing just \nkind of dependent on what's the nature of the disease, what's the nature o f the therapies, what's the interaction \nwith physicians, what's the applicability of telehealth versus not. "}, "hash": "29eaeafbce49f948c8cec6fe4fbd8e7b80faca8a8fa22d7018a3db34291eb6dd", "class_name": "RelatedNodeInfo"}}, "text": "We're in a lot of other specialties. ", "start_char_idx": 2334, "end_char_idx": 2371, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "53a0530f-71a6-417b-8615-25588c0ed1d8": {"__data__": {"id_": "53a0530f-71a6-417b-8615-25588c0ed1d8", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThe [ph] only (00:47:24) thing I would add to that is, obviously, we had a lot of tremendous insight into oncology. \n We're in a lot of other specialties.  And it's one o f the, I guess, nuances to the environment we're in right now is \nthat each specialty, just like each of our market segments has got a bit of their own recovery curve and timing just \nkind of dependent on what's the nature of the disease, what's the nature o f the therapies, what's the interaction \nwith physicians, what's the applicability of telehealth versus not.  So we really watch this by each of the various \ndisease states.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question.  \n ", "original_text": "And it's one o f the, I guess, nuances to the environment we're in right now is \nthat each specialty, just like each of our market segments has got a bit of their own recovery curve and timing just \nkind of dependent on what's the nature of the disease, what's the nature o f the therapies, what's the interaction \nwith physicians, what's the applicability of telehealth versus not. ", "page_label": "15", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ff79878d-cd7a-4d1f-8101-b4311053d1e7", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2c328c6f973454907a463e5fc91a78491646447a046e2c3d70620671703f559d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f82625aa-60e5-4103-95d0-02004f711cf6", "node_type": "1", "metadata": {"window": "So a comment, just to clarify, was really  based on visits.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThe [ph] only (00:47:24) thing I would add to that is, obviously, we had a lot of tremendous insight into oncology. \n We're in a lot of other specialties.  And it's one o f the, I guess, nuances to the environment we're in right now is \nthat each specialty, just like each of our market segments has got a bit of their own recovery curve and timing just \nkind of dependent on what's the nature of the disease, what's the nature o f the therapies, what's the interaction \nwith physicians, what's the applicability of telehealth versus not.  So we really watch this by each of the various \ndisease states.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  ", "original_text": "We're in a lot of other specialties. ", "page_label": "15", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "95162cb43c5bd7de35d2614b14004256b6ce0c73841795e8d731df0d29955e30", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "eeeabd3e-66f0-40ea-93ba-0f4a49390928", "node_type": "1", "metadata": {"window": "A \nThe [ph] only (00:47:24) thing I would add to that is, obviously, we had a lot of tremendous insight into oncology. \n We're in a lot of other specialties.  And it's one o f the, I guess, nuances to the environment we're in right now is \nthat each specialty, just like each of our market segments has got a bit of their own recovery curve and timing just \nkind of dependent on what's the nature of the disease, what's the nature o f the therapies, what's the interaction \nwith physicians, what's the applicability of telehealth versus not.  So we really watch this by each of the various \ndisease states.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Next will be Glen Santangelo with Guggenheim.  \n ", "original_text": "So we really watch this by each of the various \ndisease states.  \n "}, "hash": "1b533dd9b29bf8fb43e5263ca75b93fe5640db5fdc7ef236b4278793441189c3", "class_name": "RelatedNodeInfo"}}, "text": "And it's one o f the, I guess, nuances to the environment we're in right now is \nthat each specialty, just like each of our market segments has got a bit of their own recovery curve and timing just \nkind of dependent on what's the nature of the disease, what's the nature o f the therapies, what's the interaction \nwith physicians, what's the applicability of telehealth versus not. ", "start_char_idx": 2371, "end_char_idx": 2754, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "eeeabd3e-66f0-40ea-93ba-0f4a49390928": {"__data__": {"id_": "eeeabd3e-66f0-40ea-93ba-0f4a49390928", "embedding": null, "metadata": {"window": "A \nThe [ph] only (00:47:24) thing I would add to that is, obviously, we had a lot of tremendous insight into oncology. \n We're in a lot of other specialties.  And it's one o f the, I guess, nuances to the environment we're in right now is \nthat each specialty, just like each of our market segments has got a bit of their own recovery curve and timing just \nkind of dependent on what's the nature of the disease, what's the nature o f the therapies, what's the interaction \nwith physicians, what's the applicability of telehealth versus not.  So we really watch this by each of the various \ndisease states.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Next will be Glen Santangelo with Guggenheim.  \n ", "original_text": "So we really watch this by each of the various \ndisease states.  \n ", "page_label": "15", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ff79878d-cd7a-4d1f-8101-b4311053d1e7", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2c328c6f973454907a463e5fc91a78491646447a046e2c3d70620671703f559d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "53a0530f-71a6-417b-8615-25588c0ed1d8", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThe [ph] only (00:47:24) thing I would add to that is, obviously, we had a lot of tremendous insight into oncology. \n We're in a lot of other specialties.  And it's one o f the, I guess, nuances to the environment we're in right now is \nthat each specialty, just like each of our market segments has got a bit of their own recovery curve and timing just \nkind of dependent on what's the nature of the disease, what's the nature o f the therapies, what's the interaction \nwith physicians, what's the applicability of telehealth versus not.  So we really watch this by each of the various \ndisease states.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question.  \n ", "original_text": "And it's one o f the, I guess, nuances to the environment we're in right now is \nthat each specialty, just like each of our market segments has got a bit of their own recovery curve and timing just \nkind of dependent on what's the nature of the disease, what's the nature o f the therapies, what's the interaction \nwith physicians, what's the applicability of telehealth versus not. ", "page_label": "15", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cb0f632dd5213cdb40e56b9d653c844174c6e951b4c7ecc94a72be89252aab0a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "758edcd7-3431-4bb1-8c75-71ad002102ec", "node_type": "1", "metadata": {"window": "We're in a lot of other specialties.  And it's one o f the, I guess, nuances to the environment we're in right now is \nthat each specialty, just like each of our market segments has got a bit of their own recovery curve and timing just \nkind of dependent on what's the nature of the disease, what's the nature o f the therapies, what's the interaction \nwith physicians, what's the applicability of telehealth versus not.  So we really watch this by each of the various \ndisease states.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Next will be Glen Santangelo with Guggenheim.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nGlen Santangelo  \nAnalyst, Guggenheim Securities LLC  Q \nYes, hi. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  "}, "hash": "c63e2da056add185ae7693dd09e6127d7ceeec8eef9102d978123e0025ba6faa", "class_name": "RelatedNodeInfo"}}, "text": "So we really watch this by each of the various \ndisease states.  \n ", "start_char_idx": 2754, "end_char_idx": 2821, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "758edcd7-3431-4bb1-8c75-71ad002102ec": {"__data__": {"id_": "758edcd7-3431-4bb1-8c75-71ad002102ec", "embedding": null, "metadata": {"window": "We're in a lot of other specialties.  And it's one o f the, I guess, nuances to the environment we're in right now is \nthat each specialty, just like each of our market segments has got a bit of their own recovery curve and timing just \nkind of dependent on what's the nature of the disease, what's the nature o f the therapies, what's the interaction \nwith physicians, what's the applicability of telehealth versus not.  So we really watch this by each of the various \ndisease states.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Next will be Glen Santangelo with Guggenheim.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nGlen Santangelo  \nAnalyst, Guggenheim Securities LLC  Q \nYes, hi. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  ", "page_label": "15", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ff79878d-cd7a-4d1f-8101-b4311053d1e7", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2c328c6f973454907a463e5fc91a78491646447a046e2c3d70620671703f559d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "eeeabd3e-66f0-40ea-93ba-0f4a49390928", "node_type": "1", "metadata": {"window": "A \nThe [ph] only (00:47:24) thing I would add to that is, obviously, we had a lot of tremendous insight into oncology. \n We're in a lot of other specialties.  And it's one o f the, I guess, nuances to the environment we're in right now is \nthat each specialty, just like each of our market segments has got a bit of their own recovery curve and timing just \nkind of dependent on what's the nature of the disease, what's the nature o f the therapies, what's the interaction \nwith physicians, what's the applicability of telehealth versus not.  So we really watch this by each of the various \ndisease states.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Next will be Glen Santangelo with Guggenheim.  \n ", "original_text": "So we really watch this by each of the various \ndisease states.  \n ", "page_label": "15", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "104d0e9b9908e499f870a532e3b400c858b4a2f30b07433faf38c984b471b98b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4ec26a79-0326-4b65-806c-c6852595af57", "node_type": "1", "metadata": {"window": "And it's one o f the, I guess, nuances to the environment we're in right now is \nthat each specialty, just like each of our market segments has got a bit of their own recovery curve and timing just \nkind of dependent on what's the nature of the disease, what's the nature o f the therapies, what's the interaction \nwith physicians, what's the applicability of telehealth versus not.  So we really watch this by each of the various \ndisease states.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Next will be Glen Santangelo with Guggenheim.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nGlen Santangelo  \nAnalyst, Guggenheim Securities LLC  Q \nYes, hi.  Thanks for taking my questions. ", "original_text": "A \nNext question.  \n "}, "hash": "16c4ec8e2cd2dd5cb12bf45ec82ced6a38094642dda4091cbddd4702c3025c69", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  ", "start_char_idx": 2821, "end_char_idx": 3166, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4ec26a79-0326-4b65-806c-c6852595af57": {"__data__": {"id_": "4ec26a79-0326-4b65-806c-c6852595af57", "embedding": null, "metadata": {"window": "And it's one o f the, I guess, nuances to the environment we're in right now is \nthat each specialty, just like each of our market segments has got a bit of their own recovery curve and timing just \nkind of dependent on what's the nature of the disease, what's the nature o f the therapies, what's the interaction \nwith physicians, what's the applicability of telehealth versus not.  So we really watch this by each of the various \ndisease states.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Next will be Glen Santangelo with Guggenheim.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nGlen Santangelo  \nAnalyst, Guggenheim Securities LLC  Q \nYes, hi.  Thanks for taking my questions. ", "original_text": "A \nNext question.  \n ", "page_label": "15", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ff79878d-cd7a-4d1f-8101-b4311053d1e7", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2c328c6f973454907a463e5fc91a78491646447a046e2c3d70620671703f559d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "758edcd7-3431-4bb1-8c75-71ad002102ec", "node_type": "1", "metadata": {"window": "We're in a lot of other specialties.  And it's one o f the, I guess, nuances to the environment we're in right now is \nthat each specialty, just like each of our market segments has got a bit of their own recovery curve and timing just \nkind of dependent on what's the nature of the disease, what's the nature o f the therapies, what's the interaction \nwith physicians, what's the applicability of telehealth versus not.  So we really watch this by each of the various \ndisease states.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Next will be Glen Santangelo with Guggenheim.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nGlen Santangelo  \nAnalyst, Guggenheim Securities LLC  Q \nYes, hi. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  ", "page_label": "15", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a875db5947eb94d2b7a89a2e8d5f48ddb88593f6638bfcb866d36302b00c2c2c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a4b91c1d-3851-4322-b5d3-625e17bbe77f", "node_type": "1", "metadata": {"window": "So we really watch this by each of the various \ndisease states.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Next will be Glen Santangelo with Guggenheim.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nGlen Santangelo  \nAnalyst, Guggenheim Securities LLC  Q \nYes, hi.  Thanks for taking my questions.  I just had two quick financial ones. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Next will be Glen Santangelo with Guggenheim.  \n "}, "hash": "6bf94ec85b80eb248860c83fddc22bb550dcab57dc8fc8015c260f120b313105", "class_name": "RelatedNodeInfo"}}, "text": "A \nNext question.  \n ", "start_char_idx": 3166, "end_char_idx": 3187, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a4b91c1d-3851-4322-b5d3-625e17bbe77f": {"__data__": {"id_": "a4b91c1d-3851-4322-b5d3-625e17bbe77f", "embedding": null, "metadata": {"window": "So we really watch this by each of the various \ndisease states.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Next will be Glen Santangelo with Guggenheim.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nGlen Santangelo  \nAnalyst, Guggenheim Securities LLC  Q \nYes, hi.  Thanks for taking my questions.  I just had two quick financial ones. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Next will be Glen Santangelo with Guggenheim.  \n ", "page_label": "15", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ff79878d-cd7a-4d1f-8101-b4311053d1e7", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2c328c6f973454907a463e5fc91a78491646447a046e2c3d70620671703f559d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4ec26a79-0326-4b65-806c-c6852595af57", "node_type": "1", "metadata": {"window": "And it's one o f the, I guess, nuances to the environment we're in right now is \nthat each specialty, just like each of our market segments has got a bit of their own recovery curve and timing just \nkind of dependent on what's the nature of the disease, what's the nature o f the therapies, what's the interaction \nwith physicians, what's the applicability of telehealth versus not.  So we really watch this by each of the various \ndisease states.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Next will be Glen Santangelo with Guggenheim.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nGlen Santangelo  \nAnalyst, Guggenheim Securities LLC  Q \nYes, hi.  Thanks for taking my questions. ", "original_text": "A \nNext question.  \n ", "page_label": "15", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "dcec64a30344a3a45b8cbafb5d9adfb0d4e4e013c51d9cc6252eafe29a6d1b82", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "aa87afae-8735-432b-b81e-a065bd4240f0", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Next will be Glen Santangelo with Guggenheim.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nGlen Santangelo  \nAnalyst, Guggenheim Securities LLC  Q \nYes, hi.  Thanks for taking my questions.  I just had two quick financial ones.  Britt, you raised the adjusted EPS \nnumber by $0.75 at  the midpoint. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nGlen Santangelo  \nAnalyst, Guggenheim Securities LLC  Q \nYes, hi. "}, "hash": "33a361154093479b82909e10ae77031fa6213d7a6641c64c5c8a8c516f5d0707", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Next will be Glen Santangelo with Guggenheim.  \n ", "start_char_idx": 3187, "end_char_idx": 3521, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "aa87afae-8735-432b-b81e-a065bd4240f0": {"__data__": {"id_": "aa87afae-8735-432b-b81e-a065bd4240f0", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Next will be Glen Santangelo with Guggenheim.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nGlen Santangelo  \nAnalyst, Guggenheim Securities LLC  Q \nYes, hi.  Thanks for taking my questions.  I just had two quick financial ones.  Britt, you raised the adjusted EPS \nnumber by $0.75 at  the midpoint. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nGlen Santangelo  \nAnalyst, Guggenheim Securities LLC  Q \nYes, hi. ", "page_label": "15", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ff79878d-cd7a-4d1f-8101-b4311053d1e7", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2c328c6f973454907a463e5fc91a78491646447a046e2c3d70620671703f559d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a4b91c1d-3851-4322-b5d3-625e17bbe77f", "node_type": "1", "metadata": {"window": "So we really watch this by each of the various \ndisease states.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Next will be Glen Santangelo with Guggenheim.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nGlen Santangelo  \nAnalyst, Guggenheim Securities LLC  Q \nYes, hi.  Thanks for taking my questions.  I just had two quick financial ones. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Next will be Glen Santangelo with Guggenheim.  \n ", "page_label": "15", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "104d01d2e6fa0426deb074c4d71b583b01737d4c5c9acfb17ab9e3c8a6fd6faf", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "061b7ab0-35ae-44f7-9075-a48e9c1ed722", "node_type": "1", "metadata": {"window": "A \nNext question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Next will be Glen Santangelo with Guggenheim.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nGlen Santangelo  \nAnalyst, Guggenheim Securities LLC  Q \nYes, hi.  Thanks for taking my questions.  I just had two quick financial ones.  Britt, you raised the adjusted EPS \nnumber by $0.75 at  the midpoint.  I just want to be clear that this doesn't include any of the gain from the \ninsurance proceeds or the one -time benefit that sounds like it's coming in 2Q?  \n \n", "original_text": "Thanks for taking my questions. "}, "hash": "bcdb09f60413555350ead84fd3fd92b9f2d8d711f439712d4eb42db0aaadf138", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nGlen Santangelo  \nAnalyst, Guggenheim Securities LLC  Q \nYes, hi. ", "start_char_idx": 3521, "end_char_idx": 3859, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "061b7ab0-35ae-44f7-9075-a48e9c1ed722": {"__data__": {"id_": "061b7ab0-35ae-44f7-9075-a48e9c1ed722", "embedding": null, "metadata": {"window": "A \nNext question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Next will be Glen Santangelo with Guggenheim.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nGlen Santangelo  \nAnalyst, Guggenheim Securities LLC  Q \nYes, hi.  Thanks for taking my questions.  I just had two quick financial ones.  Britt, you raised the adjusted EPS \nnumber by $0.75 at  the midpoint.  I just want to be clear that this doesn't include any of the gain from the \ninsurance proceeds or the one -time benefit that sounds like it's coming in 2Q?  \n \n", "original_text": "Thanks for taking my questions. ", "page_label": "15", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ff79878d-cd7a-4d1f-8101-b4311053d1e7", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2c328c6f973454907a463e5fc91a78491646447a046e2c3d70620671703f559d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "aa87afae-8735-432b-b81e-a065bd4240f0", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Next will be Glen Santangelo with Guggenheim.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nGlen Santangelo  \nAnalyst, Guggenheim Securities LLC  Q \nYes, hi.  Thanks for taking my questions.  I just had two quick financial ones.  Britt, you raised the adjusted EPS \nnumber by $0.75 at  the midpoint. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nGlen Santangelo  \nAnalyst, Guggenheim Securities LLC  Q \nYes, hi. ", "page_label": "15", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "439c9e331811d9c9194f2dd803ec8076c274c75c2c950bfd44e387afaf02b741", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "af60dc25-5aa8-44d2-a54c-f46daec6154b", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Next will be Glen Santangelo with Guggenheim.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nGlen Santangelo  \nAnalyst, Guggenheim Securities LLC  Q \nYes, hi.  Thanks for taking my questions.  I just had two quick financial ones.  Britt, you raised the adjusted EPS \nnumber by $0.75 at  the midpoint.  I just want to be clear that this doesn't include any of the gain from the \ninsurance proceeds or the one -time benefit that sounds like it's coming in 2Q?  \n \n And then secondly, you raised operating profit and your EPS outlook, but could you may be discuss the impact on \ncash flows because, obviously, we had the negative timing thing in 1Q, you maintained the free cash flow \nguidance for the year despite raising the operating profit, and it seems like you have no repo in the guidance. ", "original_text": "I just had two quick financial ones. "}, "hash": "23e14e386d6b6d0c78b8612aa3a3d00870bc995de7b7d478fc8b6f644821f2da", "class_name": "RelatedNodeInfo"}}, "text": "Thanks for taking my questions. ", "start_char_idx": 3859, "end_char_idx": 3891, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "af60dc25-5aa8-44d2-a54c-f46daec6154b": {"__data__": {"id_": "af60dc25-5aa8-44d2-a54c-f46daec6154b", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Next will be Glen Santangelo with Guggenheim.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nGlen Santangelo  \nAnalyst, Guggenheim Securities LLC  Q \nYes, hi.  Thanks for taking my questions.  I just had two quick financial ones.  Britt, you raised the adjusted EPS \nnumber by $0.75 at  the midpoint.  I just want to be clear that this doesn't include any of the gain from the \ninsurance proceeds or the one -time benefit that sounds like it's coming in 2Q?  \n \n And then secondly, you raised operating profit and your EPS outlook, but could you may be discuss the impact on \ncash flows because, obviously, we had the negative timing thing in 1Q, you maintained the free cash flow \nguidance for the year despite raising the operating profit, and it seems like you have no repo in the guidance. ", "original_text": "I just had two quick financial ones. ", "page_label": "15", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ff79878d-cd7a-4d1f-8101-b4311053d1e7", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2c328c6f973454907a463e5fc91a78491646447a046e2c3d70620671703f559d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "061b7ab0-35ae-44f7-9075-a48e9c1ed722", "node_type": "1", "metadata": {"window": "A \nNext question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Next will be Glen Santangelo with Guggenheim.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nGlen Santangelo  \nAnalyst, Guggenheim Securities LLC  Q \nYes, hi.  Thanks for taking my questions.  I just had two quick financial ones.  Britt, you raised the adjusted EPS \nnumber by $0.75 at  the midpoint.  I just want to be clear that this doesn't include any of the gain from the \ninsurance proceeds or the one -time benefit that sounds like it's coming in 2Q?  \n \n", "original_text": "Thanks for taking my questions. ", "page_label": "15", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e2137bb513fc1cba93c0e01c1a78283084a5a16212f83bd6384368377a8cd061", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "88309284-aeba-4eda-8e64-37ea77dc9b62", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nGlen Santangelo  \nAnalyst, Guggenheim Securities LLC  Q \nYes, hi.  Thanks for taking my questions.  I just had two quick financial ones.  Britt, you raised the adjusted EPS \nnumber by $0.75 at  the midpoint.  I just want to be clear that this doesn't include any of the gain from the \ninsurance proceeds or the one -time benefit that sounds like it's coming in 2Q?  \n \n And then secondly, you raised operating profit and your EPS outlook, but could you may be discuss the impact on \ncash flows because, obviously, we had the negative timing thing in 1Q, you maintained the free cash flow \nguidance for the year despite raising the operating profit, and it seems like you have no repo in the guidance.  So I \njust want  to make sure I have all those pieces clear. ", "original_text": "Britt, you raised the adjusted EPS \nnumber by $0.75 at  the midpoint. "}, "hash": "708ab41d829ca7755a7e068c2676368b6aa69361bf9d7f64912028bedaf931ff", "class_name": "RelatedNodeInfo"}}, "text": "I just had two quick financial ones. ", "start_char_idx": 3891, "end_char_idx": 3928, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "88309284-aeba-4eda-8e64-37ea77dc9b62": {"__data__": {"id_": "88309284-aeba-4eda-8e64-37ea77dc9b62", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nGlen Santangelo  \nAnalyst, Guggenheim Securities LLC  Q \nYes, hi.  Thanks for taking my questions.  I just had two quick financial ones.  Britt, you raised the adjusted EPS \nnumber by $0.75 at  the midpoint.  I just want to be clear that this doesn't include any of the gain from the \ninsurance proceeds or the one -time benefit that sounds like it's coming in 2Q?  \n \n And then secondly, you raised operating profit and your EPS outlook, but could you may be discuss the impact on \ncash flows because, obviously, we had the negative timing thing in 1Q, you maintained the free cash flow \nguidance for the year despite raising the operating profit, and it seems like you have no repo in the guidance.  So I \njust want  to make sure I have all those pieces clear. ", "original_text": "Britt, you raised the adjusted EPS \nnumber by $0.75 at  the midpoint. ", "page_label": "15", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ff79878d-cd7a-4d1f-8101-b4311053d1e7", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2c328c6f973454907a463e5fc91a78491646447a046e2c3d70620671703f559d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "af60dc25-5aa8-44d2-a54c-f46daec6154b", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Next will be Glen Santangelo with Guggenheim.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nGlen Santangelo  \nAnalyst, Guggenheim Securities LLC  Q \nYes, hi.  Thanks for taking my questions.  I just had two quick financial ones.  Britt, you raised the adjusted EPS \nnumber by $0.75 at  the midpoint.  I just want to be clear that this doesn't include any of the gain from the \ninsurance proceeds or the one -time benefit that sounds like it's coming in 2Q?  \n \n And then secondly, you raised operating profit and your EPS outlook, but could you may be discuss the impact on \ncash flows because, obviously, we had the negative timing thing in 1Q, you maintained the free cash flow \nguidance for the year despite raising the operating profit, and it seems like you have no repo in the guidance. ", "original_text": "I just had two quick financial ones. ", "page_label": "15", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "13a314c5d8d53dfff5de5bcd56a18300745d78a65a029cbf7b33fe3086db36eb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "376a00a2-150b-4c27-8c64-8559973e9e3b", "node_type": "1", "metadata": {"window": "Thanks for taking my questions.  I just had two quick financial ones.  Britt, you raised the adjusted EPS \nnumber by $0.75 at  the midpoint.  I just want to be clear that this doesn't include any of the gain from the \ninsurance proceeds or the one -time benefit that sounds like it's coming in 2Q?  \n \n And then secondly, you raised operating profit and your EPS outlook, but could you may be discuss the impact on \ncash flows because, obviously, we had the negative timing thing in 1Q, you maintained the free cash flow \nguidance for the year despite raising the operating profit, and it seems like you have no repo in the guidance.  So I \njust want  to make sure I have all those pieces clear.  Thanks.  \n ", "original_text": "I just want to be clear that this doesn't include any of the gain from the \ninsurance proceeds or the one -time benefit that sounds like it's coming in 2Q?  \n \n"}, "hash": "b8336c1ab10022645ac6f2207239ebaa91f4318df6dedf085c53fd598906d3d8", "class_name": "RelatedNodeInfo"}}, "text": "Britt, you raised the adjusted EPS \nnumber by $0.75 at  the midpoint. ", "start_char_idx": 3928, "end_char_idx": 3998, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "376a00a2-150b-4c27-8c64-8559973e9e3b": {"__data__": {"id_": "376a00a2-150b-4c27-8c64-8559973e9e3b", "embedding": null, "metadata": {"window": "Thanks for taking my questions.  I just had two quick financial ones.  Britt, you raised the adjusted EPS \nnumber by $0.75 at  the midpoint.  I just want to be clear that this doesn't include any of the gain from the \ninsurance proceeds or the one -time benefit that sounds like it's coming in 2Q?  \n \n And then secondly, you raised operating profit and your EPS outlook, but could you may be discuss the impact on \ncash flows because, obviously, we had the negative timing thing in 1Q, you maintained the free cash flow \nguidance for the year despite raising the operating profit, and it seems like you have no repo in the guidance.  So I \njust want  to make sure I have all those pieces clear.  Thanks.  \n ", "original_text": "I just want to be clear that this doesn't include any of the gain from the \ninsurance proceeds or the one -time benefit that sounds like it's coming in 2Q?  \n \n", "page_label": "15", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ff79878d-cd7a-4d1f-8101-b4311053d1e7", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2c328c6f973454907a463e5fc91a78491646447a046e2c3d70620671703f559d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "88309284-aeba-4eda-8e64-37ea77dc9b62", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nGlen Santangelo  \nAnalyst, Guggenheim Securities LLC  Q \nYes, hi.  Thanks for taking my questions.  I just had two quick financial ones.  Britt, you raised the adjusted EPS \nnumber by $0.75 at  the midpoint.  I just want to be clear that this doesn't include any of the gain from the \ninsurance proceeds or the one -time benefit that sounds like it's coming in 2Q?  \n \n And then secondly, you raised operating profit and your EPS outlook, but could you may be discuss the impact on \ncash flows because, obviously, we had the negative timing thing in 1Q, you maintained the free cash flow \nguidance for the year despite raising the operating profit, and it seems like you have no repo in the guidance.  So I \njust want  to make sure I have all those pieces clear. ", "original_text": "Britt, you raised the adjusted EPS \nnumber by $0.75 at  the midpoint. ", "page_label": "15", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1bbb7d3be725e329eeb3ad1d1d3be321b76109720e75b39a7c47b17dcfb356c0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "acedc22f-18e3-459f-9fab-b6cc20c64bba", "node_type": "1", "metadata": {"window": "I just had two quick financial ones.  Britt, you raised the adjusted EPS \nnumber by $0.75 at  the midpoint.  I just want to be clear that this doesn't include any of the gain from the \ninsurance proceeds or the one -time benefit that sounds like it's coming in 2Q?  \n \n And then secondly, you raised operating profit and your EPS outlook, but could you may be discuss the impact on \ncash flows because, obviously, we had the negative timing thing in 1Q, you maintained the free cash flow \nguidance for the year despite raising the operating profit, and it seems like you have no repo in the guidance.  So I \njust want  to make sure I have all those pieces clear.  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "original_text": "And then secondly, you raised operating profit and your EPS outlook, but could you may be discuss the impact on \ncash flows because, obviously, we had the negative timing thing in 1Q, you maintained the free cash flow \nguidance for the year despite raising the operating profit, and it seems like you have no repo in the guidance. "}, "hash": "fdc555d72201e470e269dbc4deadcae317fd2312aa4d155c664c974a5f18b5f2", "class_name": "RelatedNodeInfo"}}, "text": "I just want to be clear that this doesn't include any of the gain from the \ninsurance proceeds or the one -time benefit that sounds like it's coming in 2Q?  \n \n", "start_char_idx": 3998, "end_char_idx": 4158, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "acedc22f-18e3-459f-9fab-b6cc20c64bba": {"__data__": {"id_": "acedc22f-18e3-459f-9fab-b6cc20c64bba", "embedding": null, "metadata": {"window": "I just had two quick financial ones.  Britt, you raised the adjusted EPS \nnumber by $0.75 at  the midpoint.  I just want to be clear that this doesn't include any of the gain from the \ninsurance proceeds or the one -time benefit that sounds like it's coming in 2Q?  \n \n And then secondly, you raised operating profit and your EPS outlook, but could you may be discuss the impact on \ncash flows because, obviously, we had the negative timing thing in 1Q, you maintained the free cash flow \nguidance for the year despite raising the operating profit, and it seems like you have no repo in the guidance.  So I \njust want  to make sure I have all those pieces clear.  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "original_text": "And then secondly, you raised operating profit and your EPS outlook, but could you may be discuss the impact on \ncash flows because, obviously, we had the negative timing thing in 1Q, you maintained the free cash flow \nguidance for the year despite raising the operating profit, and it seems like you have no repo in the guidance. ", "page_label": "15", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ff79878d-cd7a-4d1f-8101-b4311053d1e7", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2c328c6f973454907a463e5fc91a78491646447a046e2c3d70620671703f559d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "376a00a2-150b-4c27-8c64-8559973e9e3b", "node_type": "1", "metadata": {"window": "Thanks for taking my questions.  I just had two quick financial ones.  Britt, you raised the adjusted EPS \nnumber by $0.75 at  the midpoint.  I just want to be clear that this doesn't include any of the gain from the \ninsurance proceeds or the one -time benefit that sounds like it's coming in 2Q?  \n \n And then secondly, you raised operating profit and your EPS outlook, but could you may be discuss the impact on \ncash flows because, obviously, we had the negative timing thing in 1Q, you maintained the free cash flow \nguidance for the year despite raising the operating profit, and it seems like you have no repo in the guidance.  So I \njust want  to make sure I have all those pieces clear.  Thanks.  \n ", "original_text": "I just want to be clear that this doesn't include any of the gain from the \ninsurance proceeds or the one -time benefit that sounds like it's coming in 2Q?  \n \n", "page_label": "15", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3cb0184de03c7aa7e0f8b2c042707a22628c1f1702b07c01f9e008a618417c37", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ab6e6785-1f02-432b-a8d1-6832e38108e2", "node_type": "1", "metadata": {"window": "Britt, you raised the adjusted EPS \nnumber by $0.75 at  the midpoint.  I just want to be clear that this doesn't include any of the gain from the \ninsurance proceeds or the one -time benefit that sounds like it's coming in 2Q?  \n \n And then secondly, you raised operating profit and your EPS outlook, but could you may be discuss the impact on \ncash flows because, obviously, we had the negative timing thing in 1Q, you maintained the free cash flow \nguidance for the year despite raising the operating profit, and it seems like you have no repo in the guidance.  So I \njust want  to make sure I have all those pieces clear.  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A ", "original_text": "So I \njust want  to make sure I have all those pieces clear. "}, "hash": "5c767025d5fa4a10502d0e271100e7f096a5a44cdd4daaa71d0e0dac3d245c01", "class_name": "RelatedNodeInfo"}}, "text": "And then secondly, you raised operating profit and your EPS outlook, but could you may be discuss the impact on \ncash flows because, obviously, we had the negative timing thing in 1Q, you maintained the free cash flow \nguidance for the year despite raising the operating profit, and it seems like you have no repo in the guidance. ", "start_char_idx": 4158, "end_char_idx": 4489, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ab6e6785-1f02-432b-a8d1-6832e38108e2": {"__data__": {"id_": "ab6e6785-1f02-432b-a8d1-6832e38108e2", "embedding": null, "metadata": {"window": "Britt, you raised the adjusted EPS \nnumber by $0.75 at  the midpoint.  I just want to be clear that this doesn't include any of the gain from the \ninsurance proceeds or the one -time benefit that sounds like it's coming in 2Q?  \n \n And then secondly, you raised operating profit and your EPS outlook, but could you may be discuss the impact on \ncash flows because, obviously, we had the negative timing thing in 1Q, you maintained the free cash flow \nguidance for the year despite raising the operating profit, and it seems like you have no repo in the guidance.  So I \njust want  to make sure I have all those pieces clear.  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A ", "original_text": "So I \njust want  to make sure I have all those pieces clear. ", "page_label": "15", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ff79878d-cd7a-4d1f-8101-b4311053d1e7", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2c328c6f973454907a463e5fc91a78491646447a046e2c3d70620671703f559d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "acedc22f-18e3-459f-9fab-b6cc20c64bba", "node_type": "1", "metadata": {"window": "I just had two quick financial ones.  Britt, you raised the adjusted EPS \nnumber by $0.75 at  the midpoint.  I just want to be clear that this doesn't include any of the gain from the \ninsurance proceeds or the one -time benefit that sounds like it's coming in 2Q?  \n \n And then secondly, you raised operating profit and your EPS outlook, but could you may be discuss the impact on \ncash flows because, obviously, we had the negative timing thing in 1Q, you maintained the free cash flow \nguidance for the year despite raising the operating profit, and it seems like you have no repo in the guidance.  So I \njust want  to make sure I have all those pieces clear.  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "original_text": "And then secondly, you raised operating profit and your EPS outlook, but could you may be discuss the impact on \ncash flows because, obviously, we had the negative timing thing in 1Q, you maintained the free cash flow \nguidance for the year despite raising the operating profit, and it seems like you have no repo in the guidance. ", "page_label": "15", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "053d53cbed4e6fd2b0085d7c6837c4019a3513c8c92e0019c62a91cffba6316c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0ec91c57-d83e-4495-be7a-28d9286cc1f3", "node_type": "1", "metadata": {"window": "I just want to be clear that this doesn't include any of the gain from the \ninsurance proceeds or the one -time benefit that sounds like it's coming in 2Q?  \n \n And then secondly, you raised operating profit and your EPS outlook, but could you may be discuss the impact on \ncash flows because, obviously, we had the negative timing thing in 1Q, you maintained the free cash flow \nguidance for the year despite raising the operating profit, and it seems like you have no repo in the guidance.  So I \njust want  to make sure I have all those pieces clear.  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A ", "original_text": "Thanks.  \n "}, "hash": "1102d08a653c60f6e43267e496508e93a9e68b389c31c8ce180a899dc9b896e2", "class_name": "RelatedNodeInfo"}}, "text": "So I \njust want  to make sure I have all those pieces clear. ", "start_char_idx": 4489, "end_char_idx": 4550, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0ec91c57-d83e-4495-be7a-28d9286cc1f3": {"__data__": {"id_": "0ec91c57-d83e-4495-be7a-28d9286cc1f3", "embedding": null, "metadata": {"window": "I just want to be clear that this doesn't include any of the gain from the \ninsurance proceeds or the one -time benefit that sounds like it's coming in 2Q?  \n \n And then secondly, you raised operating profit and your EPS outlook, but could you may be discuss the impact on \ncash flows because, obviously, we had the negative timing thing in 1Q, you maintained the free cash flow \nguidance for the year despite raising the operating profit, and it seems like you have no repo in the guidance.  So I \njust want  to make sure I have all those pieces clear.  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A ", "original_text": "Thanks.  \n ", "page_label": "15", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ff79878d-cd7a-4d1f-8101-b4311053d1e7", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2c328c6f973454907a463e5fc91a78491646447a046e2c3d70620671703f559d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ab6e6785-1f02-432b-a8d1-6832e38108e2", "node_type": "1", "metadata": {"window": "Britt, you raised the adjusted EPS \nnumber by $0.75 at  the midpoint.  I just want to be clear that this doesn't include any of the gain from the \ninsurance proceeds or the one -time benefit that sounds like it's coming in 2Q?  \n \n And then secondly, you raised operating profit and your EPS outlook, but could you may be discuss the impact on \ncash flows because, obviously, we had the negative timing thing in 1Q, you maintained the free cash flow \nguidance for the year despite raising the operating profit, and it seems like you have no repo in the guidance.  So I \njust want  to make sure I have all those pieces clear.  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A ", "original_text": "So I \njust want  to make sure I have all those pieces clear. ", "page_label": "15", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1cb65591cf26408616a26a32778fea28b1e9b330f0498f0acba3f956d10a1239", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b86fa0ab-02c2-4834-91ce-42f009d4c45a", "node_type": "1", "metadata": {"window": "And then secondly, you raised operating profit and your EPS outlook, but could you may be discuss the impact on \ncash flows because, obviously, we had the negative timing thing in 1Q, you maintained the free cash flow \nguidance for the year despite raising the operating profit, and it seems like you have no repo in the guidance.  So I \njust want  to make sure I have all those pieces clear.  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  "}, "hash": "1c71843754dd935b369935b404ee2bf0599a5169ecb58d252297cb00e4d2b049", "class_name": "RelatedNodeInfo"}}, "text": "Thanks.  \n ", "start_char_idx": 4550, "end_char_idx": 4561, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b86fa0ab-02c2-4834-91ce-42f009d4c45a": {"__data__": {"id_": "b86fa0ab-02c2-4834-91ce-42f009d4c45a", "embedding": null, "metadata": {"window": "And then secondly, you raised operating profit and your EPS outlook, but could you may be discuss the impact on \ncash flows because, obviously, we had the negative timing thing in 1Q, you maintained the free cash flow \nguidance for the year despite raising the operating profit, and it seems like you have no repo in the guidance.  So I \njust want  to make sure I have all those pieces clear.  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "page_label": "15", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ff79878d-cd7a-4d1f-8101-b4311053d1e7", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2c328c6f973454907a463e5fc91a78491646447a046e2c3d70620671703f559d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0ec91c57-d83e-4495-be7a-28d9286cc1f3", "node_type": "1", "metadata": {"window": "I just want to be clear that this doesn't include any of the gain from the \ninsurance proceeds or the one -time benefit that sounds like it's coming in 2Q?  \n \n And then secondly, you raised operating profit and your EPS outlook, but could you may be discuss the impact on \ncash flows because, obviously, we had the negative timing thing in 1Q, you maintained the free cash flow \nguidance for the year despite raising the operating profit, and it seems like you have no repo in the guidance.  So I \njust want  to make sure I have all those pieces clear.  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A ", "original_text": "Thanks.  \n ", "page_label": "15", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9b4804be1fd30298d74c43118a5b383a181d5ca6bff137c2ffc840815f1a2d1c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4b37d3ca-db86-43b5-bdc6-493238f8ab11", "node_type": "1", "metadata": {"window": "So I \njust want  to make sure I have all those pieces clear.  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A ", "original_text": "A "}, "hash": "e9959727b670bf377f8e0b8af41cf38876ae060ebb40b480f82b196cd6554bdd", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "start_char_idx": 962, "end_char_idx": 1322, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4b37d3ca-db86-43b5-bdc6-493238f8ab11": {"__data__": {"id_": "4b37d3ca-db86-43b5-bdc6-493238f8ab11", "embedding": null, "metadata": {"window": "So I \njust want  to make sure I have all those pieces clear.  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A ", "original_text": "A ", "page_label": "15", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ff79878d-cd7a-4d1f-8101-b4311053d1e7", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2c328c6f973454907a463e5fc91a78491646447a046e2c3d70620671703f559d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b86fa0ab-02c2-4834-91ce-42f009d4c45a", "node_type": "1", "metadata": {"window": "And then secondly, you raised operating profit and your EPS outlook, but could you may be discuss the impact on \ncash flows because, obviously, we had the negative timing thing in 1Q, you maintained the free cash flow \nguidance for the year despite raising the operating profit, and it seems like you have no repo in the guidance.  So I \njust want  to make sure I have all those pieces clear.  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "page_label": "15", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6eee44688a5d26d64580feb16d19580f21b1db35c3faa3946ae9a86ab7ae9b45", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e0cf7e0c-22f5-41be-981a-029a0e00ee68", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nSure, and thanks for the questions.  Let me try to unpack those for you.  As it relates to the guide, first, as it relates \nto the insurance proceeds, as I mentioned, those are GAAP only. ", "original_text": "McKesson Corp.  "}, "hash": "f56ba76f0ea1b65efe23ea9131867ea20dd283d9842ba39a456b896b84add42e", "class_name": "RelatedNodeInfo"}}, "text": "A ", "start_char_idx": 585, "end_char_idx": 587, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e0cf7e0c-22f5-41be-981a-029a0e00ee68": {"__data__": {"id_": "e0cf7e0c-22f5-41be-981a-029a0e00ee68", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nSure, and thanks for the questions.  Let me try to unpack those for you.  As it relates to the guide, first, as it relates \nto the insurance proceeds, as I mentioned, those are GAAP only. ", "original_text": "McKesson Corp.  ", "page_label": "16", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8303b9b1-b8ed-429a-a917-848440efdf52", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3180dc7c4f818b0509e9fa3ba7232ae51bb9c85e8bb10f8a0ec6871d4c9e4214", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4b37d3ca-db86-43b5-bdc6-493238f8ab11", "node_type": "1", "metadata": {"window": "So I \njust want  to make sure I have all those pieces clear.  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A ", "original_text": "A ", "page_label": "15", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "21c2c44abd867d37dbd923cc56e772b5abb8609909fade445d5ccc158db5522b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6e644f25-cb4d-477d-b2ee-c4c425d8ea0b", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nSure, and thanks for the questions.  Let me try to unpack those for you.  As it relates to the guide, first, as it relates \nto the insurance proceeds, as I mentioned, those are GAAP only.  So those are not included in our adjusted \nearnings. ", "original_text": "(MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nSure, and thanks for the questions. "}, "hash": "019894e24b82b3c4340382494602d34f864733c45efadea0d0f55106796e64c6", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6e644f25-cb4d-477d-b2ee-c4c425d8ea0b": {"__data__": {"id_": "6e644f25-cb4d-477d-b2ee-c4c425d8ea0b", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nSure, and thanks for the questions.  Let me try to unpack those for you.  As it relates to the guide, first, as it relates \nto the insurance proceeds, as I mentioned, those are GAAP only.  So those are not included in our adjusted \nearnings. ", "original_text": "(MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nSure, and thanks for the questions. ", "page_label": "16", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8303b9b1-b8ed-429a-a917-848440efdf52", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3180dc7c4f818b0509e9fa3ba7232ae51bb9c85e8bb10f8a0ec6871d4c9e4214", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e0cf7e0c-22f5-41be-981a-029a0e00ee68", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nSure, and thanks for the questions.  Let me try to unpack those for you.  As it relates to the guide, first, as it relates \nto the insurance proceeds, as I mentioned, those are GAAP only. ", "original_text": "McKesson Corp.  ", "page_label": "16", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b4ca95dfb2284bd68d3c5f7a05ae13dd524c7640989e50ada24df34a96e49ed0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "01c93cc8-b7a3-4036-8f76-8afa453a130f", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nSure, and thanks for the questions.  Let me try to unpack those for you.  As it relates to the guide, first, as it relates \nto the insurance proceeds, as I mentioned, those are GAAP only.  So those are not included in our adjusted \nearnings.  As it relates to the comments that I made around tax, I would just refer you that our full year expectation \non the tax rate is still  within 18% to 20%. ", "original_text": "Let me try to unpack those for you. "}, "hash": "90d528819ecb451c628f3bfed5228a88b74be435d7d58e17f192d5fd21ba934c", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nSure, and thanks for the questions. ", "start_char_idx": 16, "end_char_idx": 217, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "01c93cc8-b7a3-4036-8f76-8afa453a130f": {"__data__": {"id_": "01c93cc8-b7a3-4036-8f76-8afa453a130f", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nSure, and thanks for the questions.  Let me try to unpack those for you.  As it relates to the guide, first, as it relates \nto the insurance proceeds, as I mentioned, those are GAAP only.  So those are not included in our adjusted \nearnings.  As it relates to the comments that I made around tax, I would just refer you that our full year expectation \non the tax rate is still  within 18% to 20%. ", "original_text": "Let me try to unpack those for you. ", "page_label": "16", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8303b9b1-b8ed-429a-a917-848440efdf52", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3180dc7c4f818b0509e9fa3ba7232ae51bb9c85e8bb10f8a0ec6871d4c9e4214", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6e644f25-cb4d-477d-b2ee-c4c425d8ea0b", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nSure, and thanks for the questions.  Let me try to unpack those for you.  As it relates to the guide, first, as it relates \nto the insurance proceeds, as I mentioned, those are GAAP only.  So those are not included in our adjusted \nearnings. ", "original_text": "(MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nSure, and thanks for the questions. ", "page_label": "16", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4d413c6222ba1efb15e4db090ecaffb570753c2759073a3e9aae6fb4aa484755", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ae57c776-7bba-4bab-b1a3-4315b9799904", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nSure, and thanks for the questions.  Let me try to unpack those for you.  As it relates to the guide, first, as it relates \nto the insurance proceeds, as I mentioned, those are GAAP only.  So those are not included in our adjusted \nearnings.  As it relates to the comments that I made around tax, I would just refer you that our full year expectation \non the tax rate is still  within 18% to 20%.  What I was trying to do is to give a little bit more visibility into the timing \nthat we expect to see throughout the year.  \n \n", "original_text": "As it relates to the guide, first, as it relates \nto the insurance proceeds, as I mentioned, those are GAAP only. "}, "hash": "5f2617ff54408e2b2985fc9084435fc699fcd1ea6bd16a691c41057f5fc20464", "class_name": "RelatedNodeInfo"}}, "text": "Let me try to unpack those for you. ", "start_char_idx": 217, "end_char_idx": 253, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ae57c776-7bba-4bab-b1a3-4315b9799904": {"__data__": {"id_": "ae57c776-7bba-4bab-b1a3-4315b9799904", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nSure, and thanks for the questions.  Let me try to unpack those for you.  As it relates to the guide, first, as it relates \nto the insurance proceeds, as I mentioned, those are GAAP only.  So those are not included in our adjusted \nearnings.  As it relates to the comments that I made around tax, I would just refer you that our full year expectation \non the tax rate is still  within 18% to 20%.  What I was trying to do is to give a little bit more visibility into the timing \nthat we expect to see throughout the year.  \n \n", "original_text": "As it relates to the guide, first, as it relates \nto the insurance proceeds, as I mentioned, those are GAAP only. ", "page_label": "16", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8303b9b1-b8ed-429a-a917-848440efdf52", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3180dc7c4f818b0509e9fa3ba7232ae51bb9c85e8bb10f8a0ec6871d4c9e4214", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "01c93cc8-b7a3-4036-8f76-8afa453a130f", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nSure, and thanks for the questions.  Let me try to unpack those for you.  As it relates to the guide, first, as it relates \nto the insurance proceeds, as I mentioned, those are GAAP only.  So those are not included in our adjusted \nearnings.  As it relates to the comments that I made around tax, I would just refer you that our full year expectation \non the tax rate is still  within 18% to 20%. ", "original_text": "Let me try to unpack those for you. ", "page_label": "16", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6b97768855d7a9925db65f8d66d6bb19f5179da4cc0e02e8aac860ffb0ed45e5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "744ccc30-6671-4316-adb8-ce2192ffdcb2", "node_type": "1", "metadata": {"window": "(MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nSure, and thanks for the questions.  Let me try to unpack those for you.  As it relates to the guide, first, as it relates \nto the insurance proceeds, as I mentioned, those are GAAP only.  So those are not included in our adjusted \nearnings.  As it relates to the comments that I made around tax, I would just refer you that our full year expectation \non the tax rate is still  within 18% to 20%.  What I was trying to do is to give a little bit more visibility into the timing \nthat we expect to see throughout the year.  \n \n So I think -- and as you think about cash flow, it's early. ", "original_text": "So those are not included in our adjusted \nearnings. "}, "hash": "49315a0cdddffe4c7496e48f9f433f6d631a8ac1da9c064cd9ef8973063ca518", "class_name": "RelatedNodeInfo"}}, "text": "As it relates to the guide, first, as it relates \nto the insurance proceeds, as I mentioned, those are GAAP only. ", "start_char_idx": 253, "end_char_idx": 367, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "744ccc30-6671-4316-adb8-ce2192ffdcb2": {"__data__": {"id_": "744ccc30-6671-4316-adb8-ce2192ffdcb2", "embedding": null, "metadata": {"window": "(MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nSure, and thanks for the questions.  Let me try to unpack those for you.  As it relates to the guide, first, as it relates \nto the insurance proceeds, as I mentioned, those are GAAP only.  So those are not included in our adjusted \nearnings.  As it relates to the comments that I made around tax, I would just refer you that our full year expectation \non the tax rate is still  within 18% to 20%.  What I was trying to do is to give a little bit more visibility into the timing \nthat we expect to see throughout the year.  \n \n So I think -- and as you think about cash flow, it's early. ", "original_text": "So those are not included in our adjusted \nearnings. ", "page_label": "16", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8303b9b1-b8ed-429a-a917-848440efdf52", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3180dc7c4f818b0509e9fa3ba7232ae51bb9c85e8bb10f8a0ec6871d4c9e4214", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ae57c776-7bba-4bab-b1a3-4315b9799904", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nSure, and thanks for the questions.  Let me try to unpack those for you.  As it relates to the guide, first, as it relates \nto the insurance proceeds, as I mentioned, those are GAAP only.  So those are not included in our adjusted \nearnings.  As it relates to the comments that I made around tax, I would just refer you that our full year expectation \non the tax rate is still  within 18% to 20%.  What I was trying to do is to give a little bit more visibility into the timing \nthat we expect to see throughout the year.  \n \n", "original_text": "As it relates to the guide, first, as it relates \nto the insurance proceeds, as I mentioned, those are GAAP only. ", "page_label": "16", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "264a0bdfec393627bc4b8c9b6d8b292839781438a39a946267ea8d7f798cc8dc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ebf3d10e-4273-4739-878f-6cdbb2fb5193", "node_type": "1", "metadata": {"window": "Let me try to unpack those for you.  As it relates to the guide, first, as it relates \nto the insurance proceeds, as I mentioned, those are GAAP only.  So those are not included in our adjusted \nearnings.  As it relates to the comments that I made around tax, I would just refer you that our full year expectation \non the tax rate is still  within 18% to 20%.  What I was trying to do is to give a little bit more visibility into the timing \nthat we expect to see throughout the year.  \n \n So I think -- and as you think about cash flow, it's early.  It's first quarter of the year. ", "original_text": "As it relates to the comments that I made around tax, I would just refer you that our full year expectation \non the tax rate is still  within 18% to 20%. "}, "hash": "6b4e6415d4c9ace83a8aee8c838a0ae650a9990d45d4246b50df4b9253d2a24f", "class_name": "RelatedNodeInfo"}}, "text": "So those are not included in our adjusted \nearnings. ", "start_char_idx": 367, "end_char_idx": 420, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ebf3d10e-4273-4739-878f-6cdbb2fb5193": {"__data__": {"id_": "ebf3d10e-4273-4739-878f-6cdbb2fb5193", "embedding": null, "metadata": {"window": "Let me try to unpack those for you.  As it relates to the guide, first, as it relates \nto the insurance proceeds, as I mentioned, those are GAAP only.  So those are not included in our adjusted \nearnings.  As it relates to the comments that I made around tax, I would just refer you that our full year expectation \non the tax rate is still  within 18% to 20%.  What I was trying to do is to give a little bit more visibility into the timing \nthat we expect to see throughout the year.  \n \n So I think -- and as you think about cash flow, it's early.  It's first quarter of the year. ", "original_text": "As it relates to the comments that I made around tax, I would just refer you that our full year expectation \non the tax rate is still  within 18% to 20%. ", "page_label": "16", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8303b9b1-b8ed-429a-a917-848440efdf52", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3180dc7c4f818b0509e9fa3ba7232ae51bb9c85e8bb10f8a0ec6871d4c9e4214", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "744ccc30-6671-4316-adb8-ce2192ffdcb2", "node_type": "1", "metadata": {"window": "(MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nSure, and thanks for the questions.  Let me try to unpack those for you.  As it relates to the guide, first, as it relates \nto the insurance proceeds, as I mentioned, those are GAAP only.  So those are not included in our adjusted \nearnings.  As it relates to the comments that I made around tax, I would just refer you that our full year expectation \non the tax rate is still  within 18% to 20%.  What I was trying to do is to give a little bit more visibility into the timing \nthat we expect to see throughout the year.  \n \n So I think -- and as you think about cash flow, it's early. ", "original_text": "So those are not included in our adjusted \nearnings. ", "page_label": "16", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "92741cae32f6fb9e4fb10526613029f1965ba695053a46bb59661648a99d83cb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a2c8ee26-a27b-4d63-b361-c0e7b6a22bfc", "node_type": "1", "metadata": {"window": "As it relates to the guide, first, as it relates \nto the insurance proceeds, as I mentioned, those are GAAP only.  So those are not included in our adjusted \nearnings.  As it relates to the comments that I made around tax, I would just refer you that our full year expectation \non the tax rate is still  within 18% to 20%.  What I was trying to do is to give a little bit more visibility into the timing \nthat we expect to see throughout the year.  \n \n So I think -- and as you think about cash flow, it's early.  It's first quarter of the year.  We're trending as we  had \nassumed or roughly as we assumed in the first quarter. ", "original_text": "What I was trying to do is to give a little bit more visibility into the timing \nthat we expect to see throughout the year.  \n \n"}, "hash": "adc9b686a967974c508512846a99b5a7169d1bfa993d84a35cebb89b52a45692", "class_name": "RelatedNodeInfo"}}, "text": "As it relates to the comments that I made around tax, I would just refer you that our full year expectation \non the tax rate is still  within 18% to 20%. ", "start_char_idx": 420, "end_char_idx": 574, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a2c8ee26-a27b-4d63-b361-c0e7b6a22bfc": {"__data__": {"id_": "a2c8ee26-a27b-4d63-b361-c0e7b6a22bfc", "embedding": null, "metadata": {"window": "As it relates to the guide, first, as it relates \nto the insurance proceeds, as I mentioned, those are GAAP only.  So those are not included in our adjusted \nearnings.  As it relates to the comments that I made around tax, I would just refer you that our full year expectation \non the tax rate is still  within 18% to 20%.  What I was trying to do is to give a little bit more visibility into the timing \nthat we expect to see throughout the year.  \n \n So I think -- and as you think about cash flow, it's early.  It's first quarter of the year.  We're trending as we  had \nassumed or roughly as we assumed in the first quarter. ", "original_text": "What I was trying to do is to give a little bit more visibility into the timing \nthat we expect to see throughout the year.  \n \n", "page_label": "16", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8303b9b1-b8ed-429a-a917-848440efdf52", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3180dc7c4f818b0509e9fa3ba7232ae51bb9c85e8bb10f8a0ec6871d4c9e4214", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ebf3d10e-4273-4739-878f-6cdbb2fb5193", "node_type": "1", "metadata": {"window": "Let me try to unpack those for you.  As it relates to the guide, first, as it relates \nto the insurance proceeds, as I mentioned, those are GAAP only.  So those are not included in our adjusted \nearnings.  As it relates to the comments that I made around tax, I would just refer you that our full year expectation \non the tax rate is still  within 18% to 20%.  What I was trying to do is to give a little bit more visibility into the timing \nthat we expect to see throughout the year.  \n \n So I think -- and as you think about cash flow, it's early.  It's first quarter of the year. ", "original_text": "As it relates to the comments that I made around tax, I would just refer you that our full year expectation \non the tax rate is still  within 18% to 20%. ", "page_label": "16", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e7a251ebf2fe51f9e71310bc4eda19bccfd6eec829a090862fdf3a4e928b4f39", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0b5790d6-4dda-4315-8294-68342fcf8fb7", "node_type": "1", "metadata": {"window": "So those are not included in our adjusted \nearnings.  As it relates to the comments that I made around tax, I would just refer you that our full year expectation \non the tax rate is still  within 18% to 20%.  What I was trying to do is to give a little bit more visibility into the timing \nthat we expect to see throughout the year.  \n \n So I think -- and as you think about cash flow, it's early.  It's first quarter of the year.  We're trending as we  had \nassumed or roughly as we assumed in the first quarter.  Our cash flow, as I mentioned in my comments, has \nhistorically varied from quarter -to-quarter, but I think the COVID environment places additional volatility on that. \n", "original_text": "So I think -- and as you think about cash flow, it's early. "}, "hash": "f036c8733101f5f3975820d4710cf8e02a0702bde12fa081972950630157e5ba", "class_name": "RelatedNodeInfo"}}, "text": "What I was trying to do is to give a little bit more visibility into the timing \nthat we expect to see throughout the year.  \n \n", "start_char_idx": 574, "end_char_idx": 702, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0b5790d6-4dda-4315-8294-68342fcf8fb7": {"__data__": {"id_": "0b5790d6-4dda-4315-8294-68342fcf8fb7", "embedding": null, "metadata": {"window": "So those are not included in our adjusted \nearnings.  As it relates to the comments that I made around tax, I would just refer you that our full year expectation \non the tax rate is still  within 18% to 20%.  What I was trying to do is to give a little bit more visibility into the timing \nthat we expect to see throughout the year.  \n \n So I think -- and as you think about cash flow, it's early.  It's first quarter of the year.  We're trending as we  had \nassumed or roughly as we assumed in the first quarter.  Our cash flow, as I mentioned in my comments, has \nhistorically varied from quarter -to-quarter, but I think the COVID environment places additional volatility on that. \n", "original_text": "So I think -- and as you think about cash flow, it's early. ", "page_label": "16", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8303b9b1-b8ed-429a-a917-848440efdf52", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3180dc7c4f818b0509e9fa3ba7232ae51bb9c85e8bb10f8a0ec6871d4c9e4214", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a2c8ee26-a27b-4d63-b361-c0e7b6a22bfc", "node_type": "1", "metadata": {"window": "As it relates to the guide, first, as it relates \nto the insurance proceeds, as I mentioned, those are GAAP only.  So those are not included in our adjusted \nearnings.  As it relates to the comments that I made around tax, I would just refer you that our full year expectation \non the tax rate is still  within 18% to 20%.  What I was trying to do is to give a little bit more visibility into the timing \nthat we expect to see throughout the year.  \n \n So I think -- and as you think about cash flow, it's early.  It's first quarter of the year.  We're trending as we  had \nassumed or roughly as we assumed in the first quarter. ", "original_text": "What I was trying to do is to give a little bit more visibility into the timing \nthat we expect to see throughout the year.  \n \n", "page_label": "16", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "eaf2f8034a385db45d5a1b7f2442cb436a14849b2479278d4404901bed67c3db", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3a7ea451-f9d8-410d-8972-e2e7e0744419", "node_type": "1", "metadata": {"window": "As it relates to the comments that I made around tax, I would just refer you that our full year expectation \non the tax rate is still  within 18% to 20%.  What I was trying to do is to give a little bit more visibility into the timing \nthat we expect to see throughout the year.  \n \n So I think -- and as you think about cash flow, it's early.  It's first quarter of the year.  We're trending as we  had \nassumed or roughly as we assumed in the first quarter.  Our cash flow, as I mentioned in my comments, has \nhistorically varied from quarter -to-quarter, but I think the COVID environment places additional volatility on that. \n And so \u2013 as we think about th is throughout the rest of the year, as we get more visibility into patterns and working \ncapital demand, we'll certainly provide updates as appropriate. ", "original_text": "It's first quarter of the year. "}, "hash": "7b7eb8af1e0986a99f33cc3a4ab4baa0779c1e109762ebdcae4551d42c3e312d", "class_name": "RelatedNodeInfo"}}, "text": "So I think -- and as you think about cash flow, it's early. ", "start_char_idx": 702, "end_char_idx": 762, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3a7ea451-f9d8-410d-8972-e2e7e0744419": {"__data__": {"id_": "3a7ea451-f9d8-410d-8972-e2e7e0744419", "embedding": null, "metadata": {"window": "As it relates to the comments that I made around tax, I would just refer you that our full year expectation \non the tax rate is still  within 18% to 20%.  What I was trying to do is to give a little bit more visibility into the timing \nthat we expect to see throughout the year.  \n \n So I think -- and as you think about cash flow, it's early.  It's first quarter of the year.  We're trending as we  had \nassumed or roughly as we assumed in the first quarter.  Our cash flow, as I mentioned in my comments, has \nhistorically varied from quarter -to-quarter, but I think the COVID environment places additional volatility on that. \n And so \u2013 as we think about th is throughout the rest of the year, as we get more visibility into patterns and working \ncapital demand, we'll certainly provide updates as appropriate. ", "original_text": "It's first quarter of the year. ", "page_label": "16", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8303b9b1-b8ed-429a-a917-848440efdf52", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3180dc7c4f818b0509e9fa3ba7232ae51bb9c85e8bb10f8a0ec6871d4c9e4214", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0b5790d6-4dda-4315-8294-68342fcf8fb7", "node_type": "1", "metadata": {"window": "So those are not included in our adjusted \nearnings.  As it relates to the comments that I made around tax, I would just refer you that our full year expectation \non the tax rate is still  within 18% to 20%.  What I was trying to do is to give a little bit more visibility into the timing \nthat we expect to see throughout the year.  \n \n So I think -- and as you think about cash flow, it's early.  It's first quarter of the year.  We're trending as we  had \nassumed or roughly as we assumed in the first quarter.  Our cash flow, as I mentioned in my comments, has \nhistorically varied from quarter -to-quarter, but I think the COVID environment places additional volatility on that. \n", "original_text": "So I think -- and as you think about cash flow, it's early. ", "page_label": "16", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4f158bebf510540aba0d3828e41b206b3d2e3a81229c351bd957e2fe59a330c9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "49e9802a-95e4-4cd8-ad95-e94ba212e185", "node_type": "1", "metadata": {"window": "What I was trying to do is to give a little bit more visibility into the timing \nthat we expect to see throughout the year.  \n \n So I think -- and as you think about cash flow, it's early.  It's first quarter of the year.  We're trending as we  had \nassumed or roughly as we assumed in the first quarter.  Our cash flow, as I mentioned in my comments, has \nhistorically varied from quarter -to-quarter, but I think the COVID environment places additional volatility on that. \n And so \u2013 as we think about th is throughout the rest of the year, as we get more visibility into patterns and working \ncapital demand, we'll certainly provide updates as appropriate.  But I wouldn't read anything into that. ", "original_text": "We're trending as we  had \nassumed or roughly as we assumed in the first quarter. "}, "hash": "da1e8fb32418b5a30add0faf57fd1b88f8e355a374dc8be7d0258c5f0f9e1618", "class_name": "RelatedNodeInfo"}}, "text": "It's first quarter of the year. ", "start_char_idx": 762, "end_char_idx": 794, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "49e9802a-95e4-4cd8-ad95-e94ba212e185": {"__data__": {"id_": "49e9802a-95e4-4cd8-ad95-e94ba212e185", "embedding": null, "metadata": {"window": "What I was trying to do is to give a little bit more visibility into the timing \nthat we expect to see throughout the year.  \n \n So I think -- and as you think about cash flow, it's early.  It's first quarter of the year.  We're trending as we  had \nassumed or roughly as we assumed in the first quarter.  Our cash flow, as I mentioned in my comments, has \nhistorically varied from quarter -to-quarter, but I think the COVID environment places additional volatility on that. \n And so \u2013 as we think about th is throughout the rest of the year, as we get more visibility into patterns and working \ncapital demand, we'll certainly provide updates as appropriate.  But I wouldn't read anything into that. ", "original_text": "We're trending as we  had \nassumed or roughly as we assumed in the first quarter. ", "page_label": "16", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8303b9b1-b8ed-429a-a917-848440efdf52", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3180dc7c4f818b0509e9fa3ba7232ae51bb9c85e8bb10f8a0ec6871d4c9e4214", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3a7ea451-f9d8-410d-8972-e2e7e0744419", "node_type": "1", "metadata": {"window": "As it relates to the comments that I made around tax, I would just refer you that our full year expectation \non the tax rate is still  within 18% to 20%.  What I was trying to do is to give a little bit more visibility into the timing \nthat we expect to see throughout the year.  \n \n So I think -- and as you think about cash flow, it's early.  It's first quarter of the year.  We're trending as we  had \nassumed or roughly as we assumed in the first quarter.  Our cash flow, as I mentioned in my comments, has \nhistorically varied from quarter -to-quarter, but I think the COVID environment places additional volatility on that. \n And so \u2013 as we think about th is throughout the rest of the year, as we get more visibility into patterns and working \ncapital demand, we'll certainly provide updates as appropriate. ", "original_text": "It's first quarter of the year. ", "page_label": "16", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "79209fd792bcb97c5f9b3e80b57f4bf191d6d5bc5b88f2d5f257901c606e6cd4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "dcc3c51b-cbdd-46be-a129-97870ee268df", "node_type": "1", "metadata": {"window": "So I think -- and as you think about cash flow, it's early.  It's first quarter of the year.  We're trending as we  had \nassumed or roughly as we assumed in the first quarter.  Our cash flow, as I mentioned in my comments, has \nhistorically varied from quarter -to-quarter, but I think the COVID environment places additional volatility on that. \n And so \u2013 as we think about th is throughout the rest of the year, as we get more visibility into patterns and working \ncapital demand, we'll certainly provide updates as appropriate.  But I wouldn't read anything into that.  It's early for \n\u2013 to give a full year update on the cash flow gui de. \n ", "original_text": "Our cash flow, as I mentioned in my comments, has \nhistorically varied from quarter -to-quarter, but I think the COVID environment places additional volatility on that. \n"}, "hash": "405b0429c07f85d2932903216109aa275440e1929433c67df4c52b7d50249ad8", "class_name": "RelatedNodeInfo"}}, "text": "We're trending as we  had \nassumed or roughly as we assumed in the first quarter. ", "start_char_idx": 794, "end_char_idx": 876, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "dcc3c51b-cbdd-46be-a129-97870ee268df": {"__data__": {"id_": "dcc3c51b-cbdd-46be-a129-97870ee268df", "embedding": null, "metadata": {"window": "So I think -- and as you think about cash flow, it's early.  It's first quarter of the year.  We're trending as we  had \nassumed or roughly as we assumed in the first quarter.  Our cash flow, as I mentioned in my comments, has \nhistorically varied from quarter -to-quarter, but I think the COVID environment places additional volatility on that. \n And so \u2013 as we think about th is throughout the rest of the year, as we get more visibility into patterns and working \ncapital demand, we'll certainly provide updates as appropriate.  But I wouldn't read anything into that.  It's early for \n\u2013 to give a full year update on the cash flow gui de. \n ", "original_text": "Our cash flow, as I mentioned in my comments, has \nhistorically varied from quarter -to-quarter, but I think the COVID environment places additional volatility on that. \n", "page_label": "16", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8303b9b1-b8ed-429a-a917-848440efdf52", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3180dc7c4f818b0509e9fa3ba7232ae51bb9c85e8bb10f8a0ec6871d4c9e4214", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "49e9802a-95e4-4cd8-ad95-e94ba212e185", "node_type": "1", "metadata": {"window": "What I was trying to do is to give a little bit more visibility into the timing \nthat we expect to see throughout the year.  \n \n So I think -- and as you think about cash flow, it's early.  It's first quarter of the year.  We're trending as we  had \nassumed or roughly as we assumed in the first quarter.  Our cash flow, as I mentioned in my comments, has \nhistorically varied from quarter -to-quarter, but I think the COVID environment places additional volatility on that. \n And so \u2013 as we think about th is throughout the rest of the year, as we get more visibility into patterns and working \ncapital demand, we'll certainly provide updates as appropriate.  But I wouldn't read anything into that. ", "original_text": "We're trending as we  had \nassumed or roughly as we assumed in the first quarter. ", "page_label": "16", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6c11b2d166e96e07becfec003bb1783e4c4b9efdf7c2b41a28e2665269c67672", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ad2ca80f-67e7-4606-a184-7efd49147928", "node_type": "1", "metadata": {"window": "It's first quarter of the year.  We're trending as we  had \nassumed or roughly as we assumed in the first quarter.  Our cash flow, as I mentioned in my comments, has \nhistorically varied from quarter -to-quarter, but I think the COVID environment places additional volatility on that. \n And so \u2013 as we think about th is throughout the rest of the year, as we get more visibility into patterns and working \ncapital demand, we'll certainly provide updates as appropriate.  But I wouldn't read anything into that.  It's early for \n\u2013 to give a full year update on the cash flow gui de. \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  ", "original_text": "And so \u2013 as we think about th is throughout the rest of the year, as we get more visibility into patterns and working \ncapital demand, we'll certainly provide updates as appropriate. "}, "hash": "42305bed593fac0b620c94c80137f5dafd2cd4aaf0704147f4f87f72eecb26a2", "class_name": "RelatedNodeInfo"}}, "text": "Our cash flow, as I mentioned in my comments, has \nhistorically varied from quarter -to-quarter, but I think the COVID environment places additional volatility on that. \n", "start_char_idx": 876, "end_char_idx": 1046, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ad2ca80f-67e7-4606-a184-7efd49147928": {"__data__": {"id_": "ad2ca80f-67e7-4606-a184-7efd49147928", "embedding": null, "metadata": {"window": "It's first quarter of the year.  We're trending as we  had \nassumed or roughly as we assumed in the first quarter.  Our cash flow, as I mentioned in my comments, has \nhistorically varied from quarter -to-quarter, but I think the COVID environment places additional volatility on that. \n And so \u2013 as we think about th is throughout the rest of the year, as we get more visibility into patterns and working \ncapital demand, we'll certainly provide updates as appropriate.  But I wouldn't read anything into that.  It's early for \n\u2013 to give a full year update on the cash flow gui de. \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  ", "original_text": "And so \u2013 as we think about th is throughout the rest of the year, as we get more visibility into patterns and working \ncapital demand, we'll certainly provide updates as appropriate. ", "page_label": "16", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8303b9b1-b8ed-429a-a917-848440efdf52", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3180dc7c4f818b0509e9fa3ba7232ae51bb9c85e8bb10f8a0ec6871d4c9e4214", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "dcc3c51b-cbdd-46be-a129-97870ee268df", "node_type": "1", "metadata": {"window": "So I think -- and as you think about cash flow, it's early.  It's first quarter of the year.  We're trending as we  had \nassumed or roughly as we assumed in the first quarter.  Our cash flow, as I mentioned in my comments, has \nhistorically varied from quarter -to-quarter, but I think the COVID environment places additional volatility on that. \n And so \u2013 as we think about th is throughout the rest of the year, as we get more visibility into patterns and working \ncapital demand, we'll certainly provide updates as appropriate.  But I wouldn't read anything into that.  It's early for \n\u2013 to give a full year update on the cash flow gui de. \n ", "original_text": "Our cash flow, as I mentioned in my comments, has \nhistorically varied from quarter -to-quarter, but I think the COVID environment places additional volatility on that. \n", "page_label": "16", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "495164587c1039a9c22ab5db6ae6a3ee0a79268dbc5bafdbd5fc3c5ec7b21028", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ba76262b-100f-48c3-8587-cb9f255881ee", "node_type": "1", "metadata": {"window": "We're trending as we  had \nassumed or roughly as we assumed in the first quarter.  Our cash flow, as I mentioned in my comments, has \nhistorically varied from quarter -to-quarter, but I think the COVID environment places additional volatility on that. \n And so \u2013 as we think about th is throughout the rest of the year, as we get more visibility into patterns and working \ncapital demand, we'll certainly provide updates as appropriate.  But I wouldn't read anything into that.  It's early for \n\u2013 to give a full year update on the cash flow gui de. \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question.  \n ", "original_text": "But I wouldn't read anything into that. "}, "hash": "983415b07cebd48873b8e9da0e85f164daee14e89c116628ad0b57d6ef4037b4", "class_name": "RelatedNodeInfo"}}, "text": "And so \u2013 as we think about th is throughout the rest of the year, as we get more visibility into patterns and working \ncapital demand, we'll certainly provide updates as appropriate. ", "start_char_idx": 1046, "end_char_idx": 1229, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ba76262b-100f-48c3-8587-cb9f255881ee": {"__data__": {"id_": "ba76262b-100f-48c3-8587-cb9f255881ee", "embedding": null, "metadata": {"window": "We're trending as we  had \nassumed or roughly as we assumed in the first quarter.  Our cash flow, as I mentioned in my comments, has \nhistorically varied from quarter -to-quarter, but I think the COVID environment places additional volatility on that. \n And so \u2013 as we think about th is throughout the rest of the year, as we get more visibility into patterns and working \ncapital demand, we'll certainly provide updates as appropriate.  But I wouldn't read anything into that.  It's early for \n\u2013 to give a full year update on the cash flow gui de. \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question.  \n ", "original_text": "But I wouldn't read anything into that. ", "page_label": "16", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8303b9b1-b8ed-429a-a917-848440efdf52", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3180dc7c4f818b0509e9fa3ba7232ae51bb9c85e8bb10f8a0ec6871d4c9e4214", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ad2ca80f-67e7-4606-a184-7efd49147928", "node_type": "1", "metadata": {"window": "It's first quarter of the year.  We're trending as we  had \nassumed or roughly as we assumed in the first quarter.  Our cash flow, as I mentioned in my comments, has \nhistorically varied from quarter -to-quarter, but I think the COVID environment places additional volatility on that. \n And so \u2013 as we think about th is throughout the rest of the year, as we get more visibility into patterns and working \ncapital demand, we'll certainly provide updates as appropriate.  But I wouldn't read anything into that.  It's early for \n\u2013 to give a full year update on the cash flow gui de. \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  ", "original_text": "And so \u2013 as we think about th is throughout the rest of the year, as we get more visibility into patterns and working \ncapital demand, we'll certainly provide updates as appropriate. ", "page_label": "16", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bde473025f79d50a2345c66b1ed41d3ba72dfc9fbf099ebc3974f3aed9b991bd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a2c1cc42-bfd3-42f8-9a7d-ebc6d6256c55", "node_type": "1", "metadata": {"window": "Our cash flow, as I mentioned in my comments, has \nhistorically varied from quarter -to-quarter, but I think the COVID environment places additional volatility on that. \n And so \u2013 as we think about th is throughout the rest of the year, as we get more visibility into patterns and working \ncapital demand, we'll certainly provide updates as appropriate.  But I wouldn't read anything into that.  It's early for \n\u2013 to give a full year update on the cash flow gui de. \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Next will be Stephen Baxter with Wolfe Research.  \n ", "original_text": "It's early for \n\u2013 to give a full year update on the cash flow gui de. \n "}, "hash": "538620d837cbd550472037b2d3b25e930aec8949d474bde3b6416a92cce70531", "class_name": "RelatedNodeInfo"}}, "text": "But I wouldn't read anything into that. ", "start_char_idx": 1229, "end_char_idx": 1269, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a2c1cc42-bfd3-42f8-9a7d-ebc6d6256c55": {"__data__": {"id_": "a2c1cc42-bfd3-42f8-9a7d-ebc6d6256c55", "embedding": null, "metadata": {"window": "Our cash flow, as I mentioned in my comments, has \nhistorically varied from quarter -to-quarter, but I think the COVID environment places additional volatility on that. \n And so \u2013 as we think about th is throughout the rest of the year, as we get more visibility into patterns and working \ncapital demand, we'll certainly provide updates as appropriate.  But I wouldn't read anything into that.  It's early for \n\u2013 to give a full year update on the cash flow gui de. \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Next will be Stephen Baxter with Wolfe Research.  \n ", "original_text": "It's early for \n\u2013 to give a full year update on the cash flow gui de. \n ", "page_label": "16", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8303b9b1-b8ed-429a-a917-848440efdf52", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3180dc7c4f818b0509e9fa3ba7232ae51bb9c85e8bb10f8a0ec6871d4c9e4214", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ba76262b-100f-48c3-8587-cb9f255881ee", "node_type": "1", "metadata": {"window": "We're trending as we  had \nassumed or roughly as we assumed in the first quarter.  Our cash flow, as I mentioned in my comments, has \nhistorically varied from quarter -to-quarter, but I think the COVID environment places additional volatility on that. \n And so \u2013 as we think about th is throughout the rest of the year, as we get more visibility into patterns and working \ncapital demand, we'll certainly provide updates as appropriate.  But I wouldn't read anything into that.  It's early for \n\u2013 to give a full year update on the cash flow gui de. \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question.  \n ", "original_text": "But I wouldn't read anything into that. ", "page_label": "16", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "28e08c76211a482ca5e7454317d0805095fcc7d798b18f81edcfea3ffc03dd77", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bd7fb46e-2644-4178-89f8-6b0e90f97a10", "node_type": "1", "metadata": {"window": "And so \u2013 as we think about th is throughout the rest of the year, as we get more visibility into patterns and working \ncapital demand, we'll certainly provide updates as appropriate.  But I wouldn't read anything into that.  It's early for \n\u2013 to give a full year update on the cash flow gui de. \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Next will be Stephen Baxter with Wolfe Research.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nStephen Baxter  \nAnalyst, Wolfe Research LLC  Q \nHi. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  "}, "hash": "c44d89752f01869bfbc5fdcac54d16268910048bd43318861b60470911cd1cc5", "class_name": "RelatedNodeInfo"}}, "text": "It's early for \n\u2013 to give a full year update on the cash flow gui de. \n ", "start_char_idx": 1269, "end_char_idx": 1341, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bd7fb46e-2644-4178-89f8-6b0e90f97a10": {"__data__": {"id_": "bd7fb46e-2644-4178-89f8-6b0e90f97a10", "embedding": null, "metadata": {"window": "And so \u2013 as we think about th is throughout the rest of the year, as we get more visibility into patterns and working \ncapital demand, we'll certainly provide updates as appropriate.  But I wouldn't read anything into that.  It's early for \n\u2013 to give a full year update on the cash flow gui de. \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Next will be Stephen Baxter with Wolfe Research.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nStephen Baxter  \nAnalyst, Wolfe Research LLC  Q \nHi. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  ", "page_label": "16", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8303b9b1-b8ed-429a-a917-848440efdf52", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3180dc7c4f818b0509e9fa3ba7232ae51bb9c85e8bb10f8a0ec6871d4c9e4214", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a2c1cc42-bfd3-42f8-9a7d-ebc6d6256c55", "node_type": "1", "metadata": {"window": "Our cash flow, as I mentioned in my comments, has \nhistorically varied from quarter -to-quarter, but I think the COVID environment places additional volatility on that. \n And so \u2013 as we think about th is throughout the rest of the year, as we get more visibility into patterns and working \ncapital demand, we'll certainly provide updates as appropriate.  But I wouldn't read anything into that.  It's early for \n\u2013 to give a full year update on the cash flow gui de. \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Next will be Stephen Baxter with Wolfe Research.  \n ", "original_text": "It's early for \n\u2013 to give a full year update on the cash flow gui de. \n ", "page_label": "16", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "791c0ab91a1635baff41a8795f711ac9191a351c3e6b9121a2b7e8bd199d9fab", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2350bcfb-f1d3-47b4-9acd-2e7ae1c7e622", "node_type": "1", "metadata": {"window": "But I wouldn't read anything into that.  It's early for \n\u2013 to give a full year update on the cash flow gui de. \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Next will be Stephen Baxter with Wolfe Research.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nStephen Baxter  \nAnalyst, Wolfe Research LLC  Q \nHi.  Good morning. ", "original_text": "A \nNext question.  \n "}, "hash": "a9d8af30c0cae5101e460d33c5a20c1ac9099aad31ff96463892d9923180553e", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  ", "start_char_idx": 1341, "end_char_idx": 1686, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2350bcfb-f1d3-47b4-9acd-2e7ae1c7e622": {"__data__": {"id_": "2350bcfb-f1d3-47b4-9acd-2e7ae1c7e622", "embedding": null, "metadata": {"window": "But I wouldn't read anything into that.  It's early for \n\u2013 to give a full year update on the cash flow gui de. \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Next will be Stephen Baxter with Wolfe Research.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nStephen Baxter  \nAnalyst, Wolfe Research LLC  Q \nHi.  Good morning. ", "original_text": "A \nNext question.  \n ", "page_label": "16", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8303b9b1-b8ed-429a-a917-848440efdf52", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3180dc7c4f818b0509e9fa3ba7232ae51bb9c85e8bb10f8a0ec6871d4c9e4214", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bd7fb46e-2644-4178-89f8-6b0e90f97a10", "node_type": "1", "metadata": {"window": "And so \u2013 as we think about th is throughout the rest of the year, as we get more visibility into patterns and working \ncapital demand, we'll certainly provide updates as appropriate.  But I wouldn't read anything into that.  It's early for \n\u2013 to give a full year update on the cash flow gui de. \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Next will be Stephen Baxter with Wolfe Research.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nStephen Baxter  \nAnalyst, Wolfe Research LLC  Q \nHi. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  ", "page_label": "16", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1754cec2a3186d924b3230b87183a352d8c609a3855094ef299e5e2d7714ce94", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ed4ea57b-8dad-4e1b-bd5f-066baa731fc5", "node_type": "1", "metadata": {"window": "It's early for \n\u2013 to give a full year update on the cash flow gui de. \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Next will be Stephen Baxter with Wolfe Research.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nStephen Baxter  \nAnalyst, Wolfe Research LLC  Q \nHi.  Good morning.  Thanks for the question. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Next will be Stephen Baxter with Wolfe Research.  \n "}, "hash": "a74f22d4c84d05280b2c007806321d8dd9b36d1937bf1d10aa6f4b5ad62059a6", "class_name": "RelatedNodeInfo"}}, "text": "A \nNext question.  \n ", "start_char_idx": 1686, "end_char_idx": 1707, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ed4ea57b-8dad-4e1b-bd5f-066baa731fc5": {"__data__": {"id_": "ed4ea57b-8dad-4e1b-bd5f-066baa731fc5", "embedding": null, "metadata": {"window": "It's early for \n\u2013 to give a full year update on the cash flow gui de. \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Next will be Stephen Baxter with Wolfe Research.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nStephen Baxter  \nAnalyst, Wolfe Research LLC  Q \nHi.  Good morning.  Thanks for the question. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Next will be Stephen Baxter with Wolfe Research.  \n ", "page_label": "16", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8303b9b1-b8ed-429a-a917-848440efdf52", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3180dc7c4f818b0509e9fa3ba7232ae51bb9c85e8bb10f8a0ec6871d4c9e4214", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2350bcfb-f1d3-47b4-9acd-2e7ae1c7e622", "node_type": "1", "metadata": {"window": "But I wouldn't read anything into that.  It's early for \n\u2013 to give a full year update on the cash flow gui de. \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Next will be Stephen Baxter with Wolfe Research.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nStephen Baxter  \nAnalyst, Wolfe Research LLC  Q \nHi.  Good morning. ", "original_text": "A \nNext question.  \n ", "page_label": "16", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5ce9cfb137a8eb97518425ea087fe4132f2f0c7cf219f004e3b8dc614d1bce5f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "16a8d12c-d8b2-47b6-ba76-5661edf5a082", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Next will be Stephen Baxter with Wolfe Research.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nStephen Baxter  \nAnalyst, Wolfe Research LLC  Q \nHi.  Good morning.  Thanks for the question.  I was hoping you could touch on trends within the generics market a \nlittle bit. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nStephen Baxter  \nAnalyst, Wolfe Research LLC  Q \nHi. "}, "hash": "0ddcaae899ed016757db9d8fd04fb1511088d1648de4fbdcdd6cd4b83d59ceae", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Next will be Stephen Baxter with Wolfe Research.  \n ", "start_char_idx": 1707, "end_char_idx": 2044, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "16a8d12c-d8b2-47b6-ba76-5661edf5a082": {"__data__": {"id_": "16a8d12c-d8b2-47b6-ba76-5661edf5a082", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Next will be Stephen Baxter with Wolfe Research.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nStephen Baxter  \nAnalyst, Wolfe Research LLC  Q \nHi.  Good morning.  Thanks for the question.  I was hoping you could touch on trends within the generics market a \nlittle bit. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nStephen Baxter  \nAnalyst, Wolfe Research LLC  Q \nHi. ", "page_label": "16", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8303b9b1-b8ed-429a-a917-848440efdf52", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3180dc7c4f818b0509e9fa3ba7232ae51bb9c85e8bb10f8a0ec6871d4c9e4214", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ed4ea57b-8dad-4e1b-bd5f-066baa731fc5", "node_type": "1", "metadata": {"window": "It's early for \n\u2013 to give a full year update on the cash flow gui de. \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Next will be Stephen Baxter with Wolfe Research.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nStephen Baxter  \nAnalyst, Wolfe Research LLC  Q \nHi.  Good morning.  Thanks for the question. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Next will be Stephen Baxter with Wolfe Research.  \n ", "page_label": "16", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c04cd575501f425ade767456732d3371ad746d90b8ab6a0dc3e5a377c16dd753", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0a39872f-c660-4376-b1b5-557ab1cad0a9", "node_type": "1", "metadata": {"window": "A \nNext question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Next will be Stephen Baxter with Wolfe Research.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nStephen Baxter  \nAnalyst, Wolfe Research LLC  Q \nHi.  Good morning.  Thanks for the question.  I was hoping you could touch on trends within the generics market a \nlittle bit.  As we entered this COVID period, there are some concerns around API and potential drug shortages. ", "original_text": "Good morning. "}, "hash": "7e737c8186f59308f863d046da4d6c5f7905b9d70bfd326b1dfd6370ec575e25", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nStephen Baxter  \nAnalyst, Wolfe Research LLC  Q \nHi. ", "start_char_idx": 2044, "end_char_idx": 2369, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0a39872f-c660-4376-b1b5-557ab1cad0a9": {"__data__": {"id_": "0a39872f-c660-4376-b1b5-557ab1cad0a9", "embedding": null, "metadata": {"window": "A \nNext question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Next will be Stephen Baxter with Wolfe Research.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nStephen Baxter  \nAnalyst, Wolfe Research LLC  Q \nHi.  Good morning.  Thanks for the question.  I was hoping you could touch on trends within the generics market a \nlittle bit.  As we entered this COVID period, there are some concerns around API and potential drug shortages. ", "original_text": "Good morning. ", "page_label": "16", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8303b9b1-b8ed-429a-a917-848440efdf52", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3180dc7c4f818b0509e9fa3ba7232ae51bb9c85e8bb10f8a0ec6871d4c9e4214", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "16a8d12c-d8b2-47b6-ba76-5661edf5a082", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Next will be Stephen Baxter with Wolfe Research.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nStephen Baxter  \nAnalyst, Wolfe Research LLC  Q \nHi.  Good morning.  Thanks for the question.  I was hoping you could touch on trends within the generics market a \nlittle bit. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nStephen Baxter  \nAnalyst, Wolfe Research LLC  Q \nHi. ", "page_label": "16", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3e96db8a4aaf3738e2c1059134148a262545ac3621e5838d91fe71ae6506c08a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "53ae5517-0d3b-41d2-8104-2b2aa8486093", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Next will be Stephen Baxter with Wolfe Research.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nStephen Baxter  \nAnalyst, Wolfe Research LLC  Q \nHi.  Good morning.  Thanks for the question.  I was hoping you could touch on trends within the generics market a \nlittle bit.  As we entered this COVID period, there are some concerns around API and potential drug shortages.  So \nI guess, what, if anything, did you end up seeing on that front? ", "original_text": "Thanks for the question. "}, "hash": "4b9aa101b84f72696a10a847a9b1635ffed293f284bbf48bee81ea36dcfc32c6", "class_name": "RelatedNodeInfo"}}, "text": "Good morning. ", "start_char_idx": 2369, "end_char_idx": 2383, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "53ae5517-0d3b-41d2-8104-2b2aa8486093": {"__data__": {"id_": "53ae5517-0d3b-41d2-8104-2b2aa8486093", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Next will be Stephen Baxter with Wolfe Research.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nStephen Baxter  \nAnalyst, Wolfe Research LLC  Q \nHi.  Good morning.  Thanks for the question.  I was hoping you could touch on trends within the generics market a \nlittle bit.  As we entered this COVID period, there are some concerns around API and potential drug shortages.  So \nI guess, what, if anything, did you end up seeing on that front? ", "original_text": "Thanks for the question. ", "page_label": "16", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8303b9b1-b8ed-429a-a917-848440efdf52", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3180dc7c4f818b0509e9fa3ba7232ae51bb9c85e8bb10f8a0ec6871d4c9e4214", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0a39872f-c660-4376-b1b5-557ab1cad0a9", "node_type": "1", "metadata": {"window": "A \nNext question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Next will be Stephen Baxter with Wolfe Research.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nStephen Baxter  \nAnalyst, Wolfe Research LLC  Q \nHi.  Good morning.  Thanks for the question.  I was hoping you could touch on trends within the generics market a \nlittle bit.  As we entered this COVID period, there are some concerns around API and potential drug shortages. ", "original_text": "Good morning. ", "page_label": "16", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2a4e9ae0c931356a2c763db96400af2362244f4cd7d95794afd629d556df1e7e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1d4f0249-0ba9-4742-8fa9-c84bf53d327c", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nStephen Baxter  \nAnalyst, Wolfe Research LLC  Q \nHi.  Good morning.  Thanks for the question.  I was hoping you could touch on trends within the generics market a \nlittle bit.  As we entered this COVID period, there are some concerns around API and potential drug shortages.  So \nI guess, what, if anything, did you end up seeing on that front?  And then kind of  in line with that, it looked to us at \nleast the generic depletion trends moderated a bit in the quarter, is that consistent with McKesson's experience \nand then if so, do you have a view on what's driving that moderation and how sustainable it is? ", "original_text": "I was hoping you could touch on trends within the generics market a \nlittle bit. "}, "hash": "e689a7cc1c2005eb91d5ea0cdca24d7b0cf67dc06fc23142796715c6b4110679", "class_name": "RelatedNodeInfo"}}, "text": "Thanks for the question. ", "start_char_idx": 2383, "end_char_idx": 2408, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1d4f0249-0ba9-4742-8fa9-c84bf53d327c": {"__data__": {"id_": "1d4f0249-0ba9-4742-8fa9-c84bf53d327c", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nStephen Baxter  \nAnalyst, Wolfe Research LLC  Q \nHi.  Good morning.  Thanks for the question.  I was hoping you could touch on trends within the generics market a \nlittle bit.  As we entered this COVID period, there are some concerns around API and potential drug shortages.  So \nI guess, what, if anything, did you end up seeing on that front?  And then kind of  in line with that, it looked to us at \nleast the generic depletion trends moderated a bit in the quarter, is that consistent with McKesson's experience \nand then if so, do you have a view on what's driving that moderation and how sustainable it is? ", "original_text": "I was hoping you could touch on trends within the generics market a \nlittle bit. ", "page_label": "16", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8303b9b1-b8ed-429a-a917-848440efdf52", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3180dc7c4f818b0509e9fa3ba7232ae51bb9c85e8bb10f8a0ec6871d4c9e4214", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "53ae5517-0d3b-41d2-8104-2b2aa8486093", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Next will be Stephen Baxter with Wolfe Research.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nStephen Baxter  \nAnalyst, Wolfe Research LLC  Q \nHi.  Good morning.  Thanks for the question.  I was hoping you could touch on trends within the generics market a \nlittle bit.  As we entered this COVID period, there are some concerns around API and potential drug shortages.  So \nI guess, what, if anything, did you end up seeing on that front? ", "original_text": "Thanks for the question. ", "page_label": "16", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "02681140ca93d56d2b8e7185089e15b7522c13e3928e1c022dddb6de92104084", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "acc0d480-c4ba-4274-a859-bf8178aca0fe", "node_type": "1", "metadata": {"window": "Good morning.  Thanks for the question.  I was hoping you could touch on trends within the generics market a \nlittle bit.  As we entered this COVID period, there are some concerns around API and potential drug shortages.  So \nI guess, what, if anything, did you end up seeing on that front?  And then kind of  in line with that, it looked to us at \nleast the generic depletion trends moderated a bit in the quarter, is that consistent with McKesson's experience \nand then if so, do you have a view on what's driving that moderation and how sustainable it is?  Thanks.  \n ", "original_text": "As we entered this COVID period, there are some concerns around API and potential drug shortages. "}, "hash": "afbbed2296ada7687dc07220d363143f1ec68f6c469b22950e65887728da10d7", "class_name": "RelatedNodeInfo"}}, "text": "I was hoping you could touch on trends within the generics market a \nlittle bit. ", "start_char_idx": 2408, "end_char_idx": 2489, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "acc0d480-c4ba-4274-a859-bf8178aca0fe": {"__data__": {"id_": "acc0d480-c4ba-4274-a859-bf8178aca0fe", "embedding": null, "metadata": {"window": "Good morning.  Thanks for the question.  I was hoping you could touch on trends within the generics market a \nlittle bit.  As we entered this COVID period, there are some concerns around API and potential drug shortages.  So \nI guess, what, if anything, did you end up seeing on that front?  And then kind of  in line with that, it looked to us at \nleast the generic depletion trends moderated a bit in the quarter, is that consistent with McKesson's experience \nand then if so, do you have a view on what's driving that moderation and how sustainable it is?  Thanks.  \n ", "original_text": "As we entered this COVID period, there are some concerns around API and potential drug shortages. ", "page_label": "16", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8303b9b1-b8ed-429a-a917-848440efdf52", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3180dc7c4f818b0509e9fa3ba7232ae51bb9c85e8bb10f8a0ec6871d4c9e4214", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1d4f0249-0ba9-4742-8fa9-c84bf53d327c", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nStephen Baxter  \nAnalyst, Wolfe Research LLC  Q \nHi.  Good morning.  Thanks for the question.  I was hoping you could touch on trends within the generics market a \nlittle bit.  As we entered this COVID period, there are some concerns around API and potential drug shortages.  So \nI guess, what, if anything, did you end up seeing on that front?  And then kind of  in line with that, it looked to us at \nleast the generic depletion trends moderated a bit in the quarter, is that consistent with McKesson's experience \nand then if so, do you have a view on what's driving that moderation and how sustainable it is? ", "original_text": "I was hoping you could touch on trends within the generics market a \nlittle bit. ", "page_label": "16", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e10584fd7d7a13fee0cfd7d118a2e1e0b0f82761697cf32c9c7140ec8bac5987", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2a2e1c9f-c8fd-413a-a6d1-53c391dbd23c", "node_type": "1", "metadata": {"window": "Thanks for the question.  I was hoping you could touch on trends within the generics market a \nlittle bit.  As we entered this COVID period, there are some concerns around API and potential drug shortages.  So \nI guess, what, if anything, did you end up seeing on that front?  And then kind of  in line with that, it looked to us at \nleast the generic depletion trends moderated a bit in the quarter, is that consistent with McKesson's experience \nand then if so, do you have a view on what's driving that moderation and how sustainable it is?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "So \nI guess, what, if anything, did you end up seeing on that front? "}, "hash": "f8b3b24fd5f761e36d1231c5c964d17d48ca56dd619b9c4e3b69ed13317a5ede", "class_name": "RelatedNodeInfo"}}, "text": "As we entered this COVID period, there are some concerns around API and potential drug shortages. ", "start_char_idx": 2489, "end_char_idx": 2587, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2a2e1c9f-c8fd-413a-a6d1-53c391dbd23c": {"__data__": {"id_": "2a2e1c9f-c8fd-413a-a6d1-53c391dbd23c", "embedding": null, "metadata": {"window": "Thanks for the question.  I was hoping you could touch on trends within the generics market a \nlittle bit.  As we entered this COVID period, there are some concerns around API and potential drug shortages.  So \nI guess, what, if anything, did you end up seeing on that front?  And then kind of  in line with that, it looked to us at \nleast the generic depletion trends moderated a bit in the quarter, is that consistent with McKesson's experience \nand then if so, do you have a view on what's driving that moderation and how sustainable it is?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "So \nI guess, what, if anything, did you end up seeing on that front? ", "page_label": "16", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8303b9b1-b8ed-429a-a917-848440efdf52", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3180dc7c4f818b0509e9fa3ba7232ae51bb9c85e8bb10f8a0ec6871d4c9e4214", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "acc0d480-c4ba-4274-a859-bf8178aca0fe", "node_type": "1", "metadata": {"window": "Good morning.  Thanks for the question.  I was hoping you could touch on trends within the generics market a \nlittle bit.  As we entered this COVID period, there are some concerns around API and potential drug shortages.  So \nI guess, what, if anything, did you end up seeing on that front?  And then kind of  in line with that, it looked to us at \nleast the generic depletion trends moderated a bit in the quarter, is that consistent with McKesson's experience \nand then if so, do you have a view on what's driving that moderation and how sustainable it is?  Thanks.  \n ", "original_text": "As we entered this COVID period, there are some concerns around API and potential drug shortages. ", "page_label": "16", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "aaa548af48ae2bea16a70bef6667dc048c22e9ead2e2b1f9736a608075e74f88", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1688d1f9-0eba-4eb8-bff1-2e6c284a673a", "node_type": "1", "metadata": {"window": "I was hoping you could touch on trends within the generics market a \nlittle bit.  As we entered this COVID period, there are some concerns around API and potential drug shortages.  So \nI guess, what, if anything, did you end up seeing on that front?  And then kind of  in line with that, it looked to us at \nleast the generic depletion trends moderated a bit in the quarter, is that consistent with McKesson's experience \nand then if so, do you have a view on what's driving that moderation and how sustainable it is?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nSo I'll start, and let Britt add on if he'd like. ", "original_text": "And then kind of  in line with that, it looked to us at \nleast the generic depletion trends moderated a bit in the quarter, is that consistent with McKesson's experience \nand then if so, do you have a view on what's driving that moderation and how sustainable it is? "}, "hash": "2eb9e720c98cd7648a46ee98c26335a11d284278fc26d4b10307eab61f7dfc12", "class_name": "RelatedNodeInfo"}}, "text": "So \nI guess, what, if anything, did you end up seeing on that front? ", "start_char_idx": 2587, "end_char_idx": 2656, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1688d1f9-0eba-4eb8-bff1-2e6c284a673a": {"__data__": {"id_": "1688d1f9-0eba-4eb8-bff1-2e6c284a673a", "embedding": null, "metadata": {"window": "I was hoping you could touch on trends within the generics market a \nlittle bit.  As we entered this COVID period, there are some concerns around API and potential drug shortages.  So \nI guess, what, if anything, did you end up seeing on that front?  And then kind of  in line with that, it looked to us at \nleast the generic depletion trends moderated a bit in the quarter, is that consistent with McKesson's experience \nand then if so, do you have a view on what's driving that moderation and how sustainable it is?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nSo I'll start, and let Britt add on if he'd like. ", "original_text": "And then kind of  in line with that, it looked to us at \nleast the generic depletion trends moderated a bit in the quarter, is that consistent with McKesson's experience \nand then if so, do you have a view on what's driving that moderation and how sustainable it is? ", "page_label": "16", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8303b9b1-b8ed-429a-a917-848440efdf52", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3180dc7c4f818b0509e9fa3ba7232ae51bb9c85e8bb10f8a0ec6871d4c9e4214", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2a2e1c9f-c8fd-413a-a6d1-53c391dbd23c", "node_type": "1", "metadata": {"window": "Thanks for the question.  I was hoping you could touch on trends within the generics market a \nlittle bit.  As we entered this COVID period, there are some concerns around API and potential drug shortages.  So \nI guess, what, if anything, did you end up seeing on that front?  And then kind of  in line with that, it looked to us at \nleast the generic depletion trends moderated a bit in the quarter, is that consistent with McKesson's experience \nand then if so, do you have a view on what's driving that moderation and how sustainable it is?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "So \nI guess, what, if anything, did you end up seeing on that front? ", "page_label": "16", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3fe3f5dc3874d8bc8d2c11a1cfcd3cf715f1b6d220aaa68102c5d97b9c29794f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3b7597b8-97a2-46d3-9a07-bf2657b48753", "node_type": "1", "metadata": {"window": "As we entered this COVID period, there are some concerns around API and potential drug shortages.  So \nI guess, what, if anything, did you end up seeing on that front?  And then kind of  in line with that, it looked to us at \nleast the generic depletion trends moderated a bit in the quarter, is that consistent with McKesson's experience \nand then if so, do you have a view on what's driving that moderation and how sustainable it is?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nSo I'll start, and let Britt add on if he'd like.  I mean, I think that generic market has continued to perform in a way, \nconsistent with the past several quarters. ", "original_text": "Thanks.  \n "}, "hash": "a03d7800fc190ea62e75af7c401efc38202a267fbefebce7d2d3135ed6a8e81d", "class_name": "RelatedNodeInfo"}}, "text": "And then kind of  in line with that, it looked to us at \nleast the generic depletion trends moderated a bit in the quarter, is that consistent with McKesson's experience \nand then if so, do you have a view on what's driving that moderation and how sustainable it is? ", "start_char_idx": 2656, "end_char_idx": 2923, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3b7597b8-97a2-46d3-9a07-bf2657b48753": {"__data__": {"id_": "3b7597b8-97a2-46d3-9a07-bf2657b48753", "embedding": null, "metadata": {"window": "As we entered this COVID period, there are some concerns around API and potential drug shortages.  So \nI guess, what, if anything, did you end up seeing on that front?  And then kind of  in line with that, it looked to us at \nleast the generic depletion trends moderated a bit in the quarter, is that consistent with McKesson's experience \nand then if so, do you have a view on what's driving that moderation and how sustainable it is?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nSo I'll start, and let Britt add on if he'd like.  I mean, I think that generic market has continued to perform in a way, \nconsistent with the past several quarters. ", "original_text": "Thanks.  \n ", "page_label": "16", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8303b9b1-b8ed-429a-a917-848440efdf52", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3180dc7c4f818b0509e9fa3ba7232ae51bb9c85e8bb10f8a0ec6871d4c9e4214", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1688d1f9-0eba-4eb8-bff1-2e6c284a673a", "node_type": "1", "metadata": {"window": "I was hoping you could touch on trends within the generics market a \nlittle bit.  As we entered this COVID period, there are some concerns around API and potential drug shortages.  So \nI guess, what, if anything, did you end up seeing on that front?  And then kind of  in line with that, it looked to us at \nleast the generic depletion trends moderated a bit in the quarter, is that consistent with McKesson's experience \nand then if so, do you have a view on what's driving that moderation and how sustainable it is?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nSo I'll start, and let Britt add on if he'd like. ", "original_text": "And then kind of  in line with that, it looked to us at \nleast the generic depletion trends moderated a bit in the quarter, is that consistent with McKesson's experience \nand then if so, do you have a view on what's driving that moderation and how sustainable it is? ", "page_label": "16", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9ac6958f5c5554518cfbbb3cc937b95aa92e7cba229cd798a4d11a1503dee15c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7ec2fd5a-8245-45d5-9e2e-7a3d706c6347", "node_type": "1", "metadata": {"window": "So \nI guess, what, if anything, did you end up seeing on that front?  And then kind of  in line with that, it looked to us at \nleast the generic depletion trends moderated a bit in the quarter, is that consistent with McKesson's experience \nand then if so, do you have a view on what's driving that moderation and how sustainable it is?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nSo I'll start, and let Britt add on if he'd like.  I mean, I think that generic market has continued to perform in a way, \nconsistent with the past several quarters.  As you know, we focus  more on the spread, the difference between the \nsell price and the acquisition price and we don't tend to comment on generic deflation too much, but I would \ncontinue to characterize that market as stable and is consistent with what we've seen over past qua rters.  \n \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  "}, "hash": "5117749f70753045899ee371b9b81f84c790072f42b5b0172520793e6ed93d43", "class_name": "RelatedNodeInfo"}}, "text": "Thanks.  \n ", "start_char_idx": 2923, "end_char_idx": 2934, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7ec2fd5a-8245-45d5-9e2e-7a3d706c6347": {"__data__": {"id_": "7ec2fd5a-8245-45d5-9e2e-7a3d706c6347", "embedding": null, "metadata": {"window": "So \nI guess, what, if anything, did you end up seeing on that front?  And then kind of  in line with that, it looked to us at \nleast the generic depletion trends moderated a bit in the quarter, is that consistent with McKesson's experience \nand then if so, do you have a view on what's driving that moderation and how sustainable it is?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nSo I'll start, and let Britt add on if he'd like.  I mean, I think that generic market has continued to perform in a way, \nconsistent with the past several quarters.  As you know, we focus  more on the spread, the difference between the \nsell price and the acquisition price and we don't tend to comment on generic deflation too much, but I would \ncontinue to characterize that market as stable and is consistent with what we've seen over past qua rters.  \n \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "16", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8303b9b1-b8ed-429a-a917-848440efdf52", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3180dc7c4f818b0509e9fa3ba7232ae51bb9c85e8bb10f8a0ec6871d4c9e4214", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3b7597b8-97a2-46d3-9a07-bf2657b48753", "node_type": "1", "metadata": {"window": "As we entered this COVID period, there are some concerns around API and potential drug shortages.  So \nI guess, what, if anything, did you end up seeing on that front?  And then kind of  in line with that, it looked to us at \nleast the generic depletion trends moderated a bit in the quarter, is that consistent with McKesson's experience \nand then if so, do you have a view on what's driving that moderation and how sustainable it is?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nSo I'll start, and let Britt add on if he'd like.  I mean, I think that generic market has continued to perform in a way, \nconsistent with the past several quarters. ", "original_text": "Thanks.  \n ", "page_label": "16", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "54e9d01b2546104a1a158275a7ad18c2521babe94215126cbd507d037c304ccc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b50bf998-458d-4c91-8c63-3ca79001e4db", "node_type": "1", "metadata": {"window": "And then kind of  in line with that, it looked to us at \nleast the generic depletion trends moderated a bit in the quarter, is that consistent with McKesson's experience \nand then if so, do you have a view on what's driving that moderation and how sustainable it is?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nSo I'll start, and let Britt add on if he'd like.  I mean, I think that generic market has continued to perform in a way, \nconsistent with the past several quarters.  As you know, we focus  more on the spread, the difference between the \nsell price and the acquisition price and we don't tend to comment on generic deflation too much, but I would \ncontinue to characterize that market as stable and is consistent with what we've seen over past qua rters.  \n \n I think it's -- I think the disruptions to generic supply from COVID had been well -managed and quite minimal and \nmay not even be attributable to COVID per se. ", "original_text": "A \nSo I'll start, and let Britt add on if he'd like. "}, "hash": "f116550d1a6972c2d5fd272041d69993bb174f6f8521cc9c465726efe7d69cf0", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "start_char_idx": 2934, "end_char_idx": 3275, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b50bf998-458d-4c91-8c63-3ca79001e4db": {"__data__": {"id_": "b50bf998-458d-4c91-8c63-3ca79001e4db", "embedding": null, "metadata": {"window": "And then kind of  in line with that, it looked to us at \nleast the generic depletion trends moderated a bit in the quarter, is that consistent with McKesson's experience \nand then if so, do you have a view on what's driving that moderation and how sustainable it is?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nSo I'll start, and let Britt add on if he'd like.  I mean, I think that generic market has continued to perform in a way, \nconsistent with the past several quarters.  As you know, we focus  more on the spread, the difference between the \nsell price and the acquisition price and we don't tend to comment on generic deflation too much, but I would \ncontinue to characterize that market as stable and is consistent with what we've seen over past qua rters.  \n \n I think it's -- I think the disruptions to generic supply from COVID had been well -managed and quite minimal and \nmay not even be attributable to COVID per se. ", "original_text": "A \nSo I'll start, and let Britt add on if he'd like. ", "page_label": "16", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8303b9b1-b8ed-429a-a917-848440efdf52", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3180dc7c4f818b0509e9fa3ba7232ae51bb9c85e8bb10f8a0ec6871d4c9e4214", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7ec2fd5a-8245-45d5-9e2e-7a3d706c6347", "node_type": "1", "metadata": {"window": "So \nI guess, what, if anything, did you end up seeing on that front?  And then kind of  in line with that, it looked to us at \nleast the generic depletion trends moderated a bit in the quarter, is that consistent with McKesson's experience \nand then if so, do you have a view on what's driving that moderation and how sustainable it is?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nSo I'll start, and let Britt add on if he'd like.  I mean, I think that generic market has continued to perform in a way, \nconsistent with the past several quarters.  As you know, we focus  more on the spread, the difference between the \nsell price and the acquisition price and we don't tend to comment on generic deflation too much, but I would \ncontinue to characterize that market as stable and is consistent with what we've seen over past qua rters.  \n \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "16", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a72bf544adddec44da6e7921a84bf15d1e76f267d2b6f613aac6d16d1d55d900", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "977f240d-d157-47bd-b3cc-1a6aa187b922", "node_type": "1", "metadata": {"window": "Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nSo I'll start, and let Britt add on if he'd like.  I mean, I think that generic market has continued to perform in a way, \nconsistent with the past several quarters.  As you know, we focus  more on the spread, the difference between the \nsell price and the acquisition price and we don't tend to comment on generic deflation too much, but I would \ncontinue to characterize that market as stable and is consistent with what we've seen over past qua rters.  \n \n I think it's -- I think the disruptions to generic supply from COVID had been well -managed and quite minimal and \nmay not even be attributable to COVID per se.  We do have a dedicated and focused team that we stood up at the \noutset of this pandemic t o work closely with suppliers, not just existing suppliers, but other suppliers around the \nglobe to forecast and track our views of inventory and inventory availability. ", "original_text": "I mean, I think that generic market has continued to perform in a way, \nconsistent with the past several quarters. "}, "hash": "27fe8fba6b2652efc50e1294f7facfad91583551c9da1df31d2d103ad5a9b010", "class_name": "RelatedNodeInfo"}}, "text": "A \nSo I'll start, and let Britt add on if he'd like. ", "start_char_idx": 3275, "end_char_idx": 3328, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "977f240d-d157-47bd-b3cc-1a6aa187b922": {"__data__": {"id_": "977f240d-d157-47bd-b3cc-1a6aa187b922", "embedding": null, "metadata": {"window": "Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nSo I'll start, and let Britt add on if he'd like.  I mean, I think that generic market has continued to perform in a way, \nconsistent with the past several quarters.  As you know, we focus  more on the spread, the difference between the \nsell price and the acquisition price and we don't tend to comment on generic deflation too much, but I would \ncontinue to characterize that market as stable and is consistent with what we've seen over past qua rters.  \n \n I think it's -- I think the disruptions to generic supply from COVID had been well -managed and quite minimal and \nmay not even be attributable to COVID per se.  We do have a dedicated and focused team that we stood up at the \noutset of this pandemic t o work closely with suppliers, not just existing suppliers, but other suppliers around the \nglobe to forecast and track our views of inventory and inventory availability. ", "original_text": "I mean, I think that generic market has continued to perform in a way, \nconsistent with the past several quarters. ", "page_label": "16", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8303b9b1-b8ed-429a-a917-848440efdf52", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3180dc7c4f818b0509e9fa3ba7232ae51bb9c85e8bb10f8a0ec6871d4c9e4214", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b50bf998-458d-4c91-8c63-3ca79001e4db", "node_type": "1", "metadata": {"window": "And then kind of  in line with that, it looked to us at \nleast the generic depletion trends moderated a bit in the quarter, is that consistent with McKesson's experience \nand then if so, do you have a view on what's driving that moderation and how sustainable it is?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nSo I'll start, and let Britt add on if he'd like.  I mean, I think that generic market has continued to perform in a way, \nconsistent with the past several quarters.  As you know, we focus  more on the spread, the difference between the \nsell price and the acquisition price and we don't tend to comment on generic deflation too much, but I would \ncontinue to characterize that market as stable and is consistent with what we've seen over past qua rters.  \n \n I think it's -- I think the disruptions to generic supply from COVID had been well -managed and quite minimal and \nmay not even be attributable to COVID per se. ", "original_text": "A \nSo I'll start, and let Britt add on if he'd like. ", "page_label": "16", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7ed3072af16ca7eb5a8683daecc89d1cb122df99fc5c3167232cecca87d98beb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2b14f667-f30c-43dd-8170-d86787441115", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nSo I'll start, and let Britt add on if he'd like.  I mean, I think that generic market has continued to perform in a way, \nconsistent with the past several quarters.  As you know, we focus  more on the spread, the difference between the \nsell price and the acquisition price and we don't tend to comment on generic deflation too much, but I would \ncontinue to characterize that market as stable and is consistent with what we've seen over past qua rters.  \n \n I think it's -- I think the disruptions to generic supply from COVID had been well -managed and quite minimal and \nmay not even be attributable to COVID per se.  We do have a dedicated and focused team that we stood up at the \noutset of this pandemic t o work closely with suppliers, not just existing suppliers, but other suppliers around the \nglobe to forecast and track our views of inventory and inventory availability.  But I would say, thus far, through \ncertainly our first quarter, the supply situation h as been well managed.  \n ", "original_text": "As you know, we focus  more on the spread, the difference between the \nsell price and the acquisition price and we don't tend to comment on generic deflation too much, but I would \ncontinue to characterize that market as stable and is consistent with what we've seen over past qua rters.  \n \n"}, "hash": "a20b574e6c056ac2c136e1af5471680da78f07d17971eee16aecddbd54312854", "class_name": "RelatedNodeInfo"}}, "text": "I mean, I think that generic market has continued to perform in a way, \nconsistent with the past several quarters. ", "start_char_idx": 3328, "end_char_idx": 3443, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2b14f667-f30c-43dd-8170-d86787441115": {"__data__": {"id_": "2b14f667-f30c-43dd-8170-d86787441115", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nSo I'll start, and let Britt add on if he'd like.  I mean, I think that generic market has continued to perform in a way, \nconsistent with the past several quarters.  As you know, we focus  more on the spread, the difference between the \nsell price and the acquisition price and we don't tend to comment on generic deflation too much, but I would \ncontinue to characterize that market as stable and is consistent with what we've seen over past qua rters.  \n \n I think it's -- I think the disruptions to generic supply from COVID had been well -managed and quite minimal and \nmay not even be attributable to COVID per se.  We do have a dedicated and focused team that we stood up at the \noutset of this pandemic t o work closely with suppliers, not just existing suppliers, but other suppliers around the \nglobe to forecast and track our views of inventory and inventory availability.  But I would say, thus far, through \ncertainly our first quarter, the supply situation h as been well managed.  \n ", "original_text": "As you know, we focus  more on the spread, the difference between the \nsell price and the acquisition price and we don't tend to comment on generic deflation too much, but I would \ncontinue to characterize that market as stable and is consistent with what we've seen over past qua rters.  \n \n", "page_label": "16", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8303b9b1-b8ed-429a-a917-848440efdf52", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3180dc7c4f818b0509e9fa3ba7232ae51bb9c85e8bb10f8a0ec6871d4c9e4214", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "977f240d-d157-47bd-b3cc-1a6aa187b922", "node_type": "1", "metadata": {"window": "Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nSo I'll start, and let Britt add on if he'd like.  I mean, I think that generic market has continued to perform in a way, \nconsistent with the past several quarters.  As you know, we focus  more on the spread, the difference between the \nsell price and the acquisition price and we don't tend to comment on generic deflation too much, but I would \ncontinue to characterize that market as stable and is consistent with what we've seen over past qua rters.  \n \n I think it's -- I think the disruptions to generic supply from COVID had been well -managed and quite minimal and \nmay not even be attributable to COVID per se.  We do have a dedicated and focused team that we stood up at the \noutset of this pandemic t o work closely with suppliers, not just existing suppliers, but other suppliers around the \nglobe to forecast and track our views of inventory and inventory availability. ", "original_text": "I mean, I think that generic market has continued to perform in a way, \nconsistent with the past several quarters. ", "page_label": "16", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bae786910c6576fc8f430bbc8a233e8701ffbd90844a8148334a50f5c66fc0f4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4804ac8d-c0c2-4513-b1df-b2b93a8d95e1", "node_type": "1", "metadata": {"window": "A \nSo I'll start, and let Britt add on if he'd like.  I mean, I think that generic market has continued to perform in a way, \nconsistent with the past several quarters.  As you know, we focus  more on the spread, the difference between the \nsell price and the acquisition price and we don't tend to comment on generic deflation too much, but I would \ncontinue to characterize that market as stable and is consistent with what we've seen over past qua rters.  \n \n I think it's -- I think the disruptions to generic supply from COVID had been well -managed and quite minimal and \nmay not even be attributable to COVID per se.  We do have a dedicated and focused team that we stood up at the \noutset of this pandemic t o work closely with suppliers, not just existing suppliers, but other suppliers around the \nglobe to forecast and track our views of inventory and inventory availability.  But I would say, thus far, through \ncertainly our first quarter, the supply situation h as been well managed.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  ", "original_text": "I think it's -- I think the disruptions to generic supply from COVID had been well -managed and quite minimal and \nmay not even be attributable to COVID per se. "}, "hash": "de85e3e342873911607b4e9e4feb9d9035fc4ca8849e889f60c2f643e98d9d98", "class_name": "RelatedNodeInfo"}}, "text": "As you know, we focus  more on the spread, the difference between the \nsell price and the acquisition price and we don't tend to comment on generic deflation too much, but I would \ncontinue to characterize that market as stable and is consistent with what we've seen over past qua rters.  \n \n", "start_char_idx": 3443, "end_char_idx": 3735, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4804ac8d-c0c2-4513-b1df-b2b93a8d95e1": {"__data__": {"id_": "4804ac8d-c0c2-4513-b1df-b2b93a8d95e1", "embedding": null, "metadata": {"window": "A \nSo I'll start, and let Britt add on if he'd like.  I mean, I think that generic market has continued to perform in a way, \nconsistent with the past several quarters.  As you know, we focus  more on the spread, the difference between the \nsell price and the acquisition price and we don't tend to comment on generic deflation too much, but I would \ncontinue to characterize that market as stable and is consistent with what we've seen over past qua rters.  \n \n I think it's -- I think the disruptions to generic supply from COVID had been well -managed and quite minimal and \nmay not even be attributable to COVID per se.  We do have a dedicated and focused team that we stood up at the \noutset of this pandemic t o work closely with suppliers, not just existing suppliers, but other suppliers around the \nglobe to forecast and track our views of inventory and inventory availability.  But I would say, thus far, through \ncertainly our first quarter, the supply situation h as been well managed.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  ", "original_text": "I think it's -- I think the disruptions to generic supply from COVID had been well -managed and quite minimal and \nmay not even be attributable to COVID per se. ", "page_label": "16", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8303b9b1-b8ed-429a-a917-848440efdf52", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3180dc7c4f818b0509e9fa3ba7232ae51bb9c85e8bb10f8a0ec6871d4c9e4214", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2b14f667-f30c-43dd-8170-d86787441115", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nSo I'll start, and let Britt add on if he'd like.  I mean, I think that generic market has continued to perform in a way, \nconsistent with the past several quarters.  As you know, we focus  more on the spread, the difference between the \nsell price and the acquisition price and we don't tend to comment on generic deflation too much, but I would \ncontinue to characterize that market as stable and is consistent with what we've seen over past qua rters.  \n \n I think it's -- I think the disruptions to generic supply from COVID had been well -managed and quite minimal and \nmay not even be attributable to COVID per se.  We do have a dedicated and focused team that we stood up at the \noutset of this pandemic t o work closely with suppliers, not just existing suppliers, but other suppliers around the \nglobe to forecast and track our views of inventory and inventory availability.  But I would say, thus far, through \ncertainly our first quarter, the supply situation h as been well managed.  \n ", "original_text": "As you know, we focus  more on the spread, the difference between the \nsell price and the acquisition price and we don't tend to comment on generic deflation too much, but I would \ncontinue to characterize that market as stable and is consistent with what we've seen over past qua rters.  \n \n", "page_label": "16", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5866e0852b460e55cfdb7d96dd28ce6ad26eb2669127d720333ed95b4f20d3f0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ebc7338e-7ea6-4500-8a85-737b930c9031", "node_type": "1", "metadata": {"window": "I mean, I think that generic market has continued to perform in a way, \nconsistent with the past several quarters.  As you know, we focus  more on the spread, the difference between the \nsell price and the acquisition price and we don't tend to comment on generic deflation too much, but I would \ncontinue to characterize that market as stable and is consistent with what we've seen over past qua rters.  \n \n I think it's -- I think the disruptions to generic supply from COVID had been well -managed and quite minimal and \nmay not even be attributable to COVID per se.  We do have a dedicated and focused team that we stood up at the \noutset of this pandemic t o work closely with suppliers, not just existing suppliers, but other suppliers around the \nglobe to forecast and track our views of inventory and inventory availability.  But I would say, thus far, through \ncertainly our first quarter, the supply situation h as been well managed.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question.  \n ", "original_text": "We do have a dedicated and focused team that we stood up at the \noutset of this pandemic t o work closely with suppliers, not just existing suppliers, but other suppliers around the \nglobe to forecast and track our views of inventory and inventory availability. "}, "hash": "5b71044626765c0bfe569fa5615b6cb408e5f81eff73317ce04133720f52c7a9", "class_name": "RelatedNodeInfo"}}, "text": "I think it's -- I think the disruptions to generic supply from COVID had been well -managed and quite minimal and \nmay not even be attributable to COVID per se. ", "start_char_idx": 3735, "end_char_idx": 3896, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ebc7338e-7ea6-4500-8a85-737b930c9031": {"__data__": {"id_": "ebc7338e-7ea6-4500-8a85-737b930c9031", "embedding": null, "metadata": {"window": "I mean, I think that generic market has continued to perform in a way, \nconsistent with the past several quarters.  As you know, we focus  more on the spread, the difference between the \nsell price and the acquisition price and we don't tend to comment on generic deflation too much, but I would \ncontinue to characterize that market as stable and is consistent with what we've seen over past qua rters.  \n \n I think it's -- I think the disruptions to generic supply from COVID had been well -managed and quite minimal and \nmay not even be attributable to COVID per se.  We do have a dedicated and focused team that we stood up at the \noutset of this pandemic t o work closely with suppliers, not just existing suppliers, but other suppliers around the \nglobe to forecast and track our views of inventory and inventory availability.  But I would say, thus far, through \ncertainly our first quarter, the supply situation h as been well managed.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question.  \n ", "original_text": "We do have a dedicated and focused team that we stood up at the \noutset of this pandemic t o work closely with suppliers, not just existing suppliers, but other suppliers around the \nglobe to forecast and track our views of inventory and inventory availability. ", "page_label": "16", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8303b9b1-b8ed-429a-a917-848440efdf52", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3180dc7c4f818b0509e9fa3ba7232ae51bb9c85e8bb10f8a0ec6871d4c9e4214", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4804ac8d-c0c2-4513-b1df-b2b93a8d95e1", "node_type": "1", "metadata": {"window": "A \nSo I'll start, and let Britt add on if he'd like.  I mean, I think that generic market has continued to perform in a way, \nconsistent with the past several quarters.  As you know, we focus  more on the spread, the difference between the \nsell price and the acquisition price and we don't tend to comment on generic deflation too much, but I would \ncontinue to characterize that market as stable and is consistent with what we've seen over past qua rters.  \n \n I think it's -- I think the disruptions to generic supply from COVID had been well -managed and quite minimal and \nmay not even be attributable to COVID per se.  We do have a dedicated and focused team that we stood up at the \noutset of this pandemic t o work closely with suppliers, not just existing suppliers, but other suppliers around the \nglobe to forecast and track our views of inventory and inventory availability.  But I would say, thus far, through \ncertainly our first quarter, the supply situation h as been well managed.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  ", "original_text": "I think it's -- I think the disruptions to generic supply from COVID had been well -managed and quite minimal and \nmay not even be attributable to COVID per se. ", "page_label": "16", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "49a203a9af608e15dc4645e28e89533d0a4aa6335804b0ebe3012c97847f54d3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "116c403a-7edb-4d32-9dec-ea3d99d60ebf", "node_type": "1", "metadata": {"window": "As you know, we focus  more on the spread, the difference between the \nsell price and the acquisition price and we don't tend to comment on generic deflation too much, but I would \ncontinue to characterize that market as stable and is consistent with what we've seen over past qua rters.  \n \n I think it's -- I think the disruptions to generic supply from COVID had been well -managed and quite minimal and \nmay not even be attributable to COVID per se.  We do have a dedicated and focused team that we stood up at the \noutset of this pandemic t o work closely with suppliers, not just existing suppliers, but other suppliers around the \nglobe to forecast and track our views of inventory and inventory availability.  But I would say, thus far, through \ncertainly our first quarter, the supply situation h as been well managed.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Next will be Lisa Gill with JPMorgan.  \n ", "original_text": "But I would say, thus far, through \ncertainly our first quarter, the supply situation h as been well managed.  \n "}, "hash": "523138da59bb1b99ca775cba42b4dd1eb8c0b82b4a20c9c80ed0e23038e04eda", "class_name": "RelatedNodeInfo"}}, "text": "We do have a dedicated and focused team that we stood up at the \noutset of this pandemic t o work closely with suppliers, not just existing suppliers, but other suppliers around the \nglobe to forecast and track our views of inventory and inventory availability. ", "start_char_idx": 3896, "end_char_idx": 4158, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "116c403a-7edb-4d32-9dec-ea3d99d60ebf": {"__data__": {"id_": "116c403a-7edb-4d32-9dec-ea3d99d60ebf", "embedding": null, "metadata": {"window": "As you know, we focus  more on the spread, the difference between the \nsell price and the acquisition price and we don't tend to comment on generic deflation too much, but I would \ncontinue to characterize that market as stable and is consistent with what we've seen over past qua rters.  \n \n I think it's -- I think the disruptions to generic supply from COVID had been well -managed and quite minimal and \nmay not even be attributable to COVID per se.  We do have a dedicated and focused team that we stood up at the \noutset of this pandemic t o work closely with suppliers, not just existing suppliers, but other suppliers around the \nglobe to forecast and track our views of inventory and inventory availability.  But I would say, thus far, through \ncertainly our first quarter, the supply situation h as been well managed.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Next will be Lisa Gill with JPMorgan.  \n ", "original_text": "But I would say, thus far, through \ncertainly our first quarter, the supply situation h as been well managed.  \n ", "page_label": "16", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8303b9b1-b8ed-429a-a917-848440efdf52", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3180dc7c4f818b0509e9fa3ba7232ae51bb9c85e8bb10f8a0ec6871d4c9e4214", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ebc7338e-7ea6-4500-8a85-737b930c9031", "node_type": "1", "metadata": {"window": "I mean, I think that generic market has continued to perform in a way, \nconsistent with the past several quarters.  As you know, we focus  more on the spread, the difference between the \nsell price and the acquisition price and we don't tend to comment on generic deflation too much, but I would \ncontinue to characterize that market as stable and is consistent with what we've seen over past qua rters.  \n \n I think it's -- I think the disruptions to generic supply from COVID had been well -managed and quite minimal and \nmay not even be attributable to COVID per se.  We do have a dedicated and focused team that we stood up at the \noutset of this pandemic t o work closely with suppliers, not just existing suppliers, but other suppliers around the \nglobe to forecast and track our views of inventory and inventory availability.  But I would say, thus far, through \ncertainly our first quarter, the supply situation h as been well managed.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question.  \n ", "original_text": "We do have a dedicated and focused team that we stood up at the \noutset of this pandemic t o work closely with suppliers, not just existing suppliers, but other suppliers around the \nglobe to forecast and track our views of inventory and inventory availability. ", "page_label": "16", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "783e91a640fbba278725b6099b501b3f3503ffbdf92b9d98ee16743ff55a1515", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0d5f9f7e-b645-4a66-9c68-cd3d030b5311", "node_type": "1", "metadata": {"window": "I think it's -- I think the disruptions to generic supply from COVID had been well -managed and quite minimal and \nmay not even be attributable to COVID per se.  We do have a dedicated and focused team that we stood up at the \noutset of this pandemic t o work closely with suppliers, not just existing suppliers, but other suppliers around the \nglobe to forecast and track our views of inventory and inventory availability.  But I would say, thus far, through \ncertainly our first quarter, the supply situation h as been well managed.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Next will be Lisa Gill with JPMorgan.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  "}, "hash": "93654291e210c9bc251bfd11c5c60346e755270a2c4327d194768fb7a13bc365", "class_name": "RelatedNodeInfo"}}, "text": "But I would say, thus far, through \ncertainly our first quarter, the supply situation h as been well managed.  \n ", "start_char_idx": 4158, "end_char_idx": 4271, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0d5f9f7e-b645-4a66-9c68-cd3d030b5311": {"__data__": {"id_": "0d5f9f7e-b645-4a66-9c68-cd3d030b5311", "embedding": null, "metadata": {"window": "I think it's -- I think the disruptions to generic supply from COVID had been well -managed and quite minimal and \nmay not even be attributable to COVID per se.  We do have a dedicated and focused team that we stood up at the \noutset of this pandemic t o work closely with suppliers, not just existing suppliers, but other suppliers around the \nglobe to forecast and track our views of inventory and inventory availability.  But I would say, thus far, through \ncertainly our first quarter, the supply situation h as been well managed.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Next will be Lisa Gill with JPMorgan.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  ", "page_label": "16", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8303b9b1-b8ed-429a-a917-848440efdf52", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3180dc7c4f818b0509e9fa3ba7232ae51bb9c85e8bb10f8a0ec6871d4c9e4214", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "116c403a-7edb-4d32-9dec-ea3d99d60ebf", "node_type": "1", "metadata": {"window": "As you know, we focus  more on the spread, the difference between the \nsell price and the acquisition price and we don't tend to comment on generic deflation too much, but I would \ncontinue to characterize that market as stable and is consistent with what we've seen over past qua rters.  \n \n I think it's -- I think the disruptions to generic supply from COVID had been well -managed and quite minimal and \nmay not even be attributable to COVID per se.  We do have a dedicated and focused team that we stood up at the \noutset of this pandemic t o work closely with suppliers, not just existing suppliers, but other suppliers around the \nglobe to forecast and track our views of inventory and inventory availability.  But I would say, thus far, through \ncertainly our first quarter, the supply situation h as been well managed.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Next will be Lisa Gill with JPMorgan.  \n ", "original_text": "But I would say, thus far, through \ncertainly our first quarter, the supply situation h as been well managed.  \n ", "page_label": "16", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b226d95fa229ab126c40308cbfab985d2bcc8d942c199ee3ed40b00ef16e5895", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9a00fad5-ce17-4b7b-8976-6eeea2f9325c", "node_type": "1", "metadata": {"window": "We do have a dedicated and focused team that we stood up at the \noutset of this pandemic t o work closely with suppliers, not just existing suppliers, but other suppliers around the \nglobe to forecast and track our views of inventory and inventory availability.  But I would say, thus far, through \ncertainly our first quarter, the supply situation h as been well managed.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Next will be Lisa Gill with JPMorgan.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "A \nNext question.  \n "}, "hash": "b4ad25efd09bdb6c129493f2063f73079f699bce02778404d1138c357326c536", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  ", "start_char_idx": 1341, "end_char_idx": 1686, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9a00fad5-ce17-4b7b-8976-6eeea2f9325c": {"__data__": {"id_": "9a00fad5-ce17-4b7b-8976-6eeea2f9325c", "embedding": null, "metadata": {"window": "We do have a dedicated and focused team that we stood up at the \noutset of this pandemic t o work closely with suppliers, not just existing suppliers, but other suppliers around the \nglobe to forecast and track our views of inventory and inventory availability.  But I would say, thus far, through \ncertainly our first quarter, the supply situation h as been well managed.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Next will be Lisa Gill with JPMorgan.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "A \nNext question.  \n ", "page_label": "16", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8303b9b1-b8ed-429a-a917-848440efdf52", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3180dc7c4f818b0509e9fa3ba7232ae51bb9c85e8bb10f8a0ec6871d4c9e4214", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0d5f9f7e-b645-4a66-9c68-cd3d030b5311", "node_type": "1", "metadata": {"window": "I think it's -- I think the disruptions to generic supply from COVID had been well -managed and quite minimal and \nmay not even be attributable to COVID per se.  We do have a dedicated and focused team that we stood up at the \noutset of this pandemic t o work closely with suppliers, not just existing suppliers, but other suppliers around the \nglobe to forecast and track our views of inventory and inventory availability.  But I would say, thus far, through \ncertainly our first quarter, the supply situation h as been well managed.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Next will be Lisa Gill with JPMorgan.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  ", "page_label": "16", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7e69018c3c53ec6e85c6a9a38528a67734025a19f5c0925abc793cc507f23bec", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8d792cfd-d418-4f85-8a51-4342e42b6d2f", "node_type": "1", "metadata": {"window": "But I would say, thus far, through \ncertainly our first quarter, the supply situation h as been well managed.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Next will be Lisa Gill with JPMorgan.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Next will be Lisa Gill with JPMorgan.  \n "}, "hash": "7dd11faddbf4789c56c9b8d314f868be5ad4752c3f83cfc91a82c88a30c149f9", "class_name": "RelatedNodeInfo"}}, "text": "A \nNext question.  \n ", "start_char_idx": 1686, "end_char_idx": 1707, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8d792cfd-d418-4f85-8a51-4342e42b6d2f": {"__data__": {"id_": "8d792cfd-d418-4f85-8a51-4342e42b6d2f", "embedding": null, "metadata": {"window": "But I would say, thus far, through \ncertainly our first quarter, the supply situation h as been well managed.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Next will be Lisa Gill with JPMorgan.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Next will be Lisa Gill with JPMorgan.  \n ", "page_label": "16", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8303b9b1-b8ed-429a-a917-848440efdf52", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3180dc7c4f818b0509e9fa3ba7232ae51bb9c85e8bb10f8a0ec6871d4c9e4214", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9a00fad5-ce17-4b7b-8976-6eeea2f9325c", "node_type": "1", "metadata": {"window": "We do have a dedicated and focused team that we stood up at the \noutset of this pandemic t o work closely with suppliers, not just existing suppliers, but other suppliers around the \nglobe to forecast and track our views of inventory and inventory availability.  But I would say, thus far, through \ncertainly our first quarter, the supply situation h as been well managed.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Next will be Lisa Gill with JPMorgan.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "A \nNext question.  \n ", "page_label": "16", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b33e07648cbc41e5fa6b7b20f334536c0699be099e20e4b969324f5dc9a5cd13", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c2128f92-501b-4207-ac6b-0b51590a2532", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Next will be Lisa Gill with JPMorgan.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  "}, "hash": "4ea05d3c05dd327db31b94a31277f311a6777f50a1f3db90f11bd3543b5db32e", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Next will be Lisa Gill with JPMorgan.  \n ", "start_char_idx": 4637, "end_char_idx": 4963, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c2128f92-501b-4207-ac6b-0b51590a2532": {"__data__": {"id_": "c2128f92-501b-4207-ac6b-0b51590a2532", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Next will be Lisa Gill with JPMorgan.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "page_label": "16", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8303b9b1-b8ed-429a-a917-848440efdf52", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3180dc7c4f818b0509e9fa3ba7232ae51bb9c85e8bb10f8a0ec6871d4c9e4214", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8d792cfd-d418-4f85-8a51-4342e42b6d2f", "node_type": "1", "metadata": {"window": "But I would say, thus far, through \ncertainly our first quarter, the supply situation h as been well managed.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Next will be Lisa Gill with JPMorgan.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Next will be Lisa Gill with JPMorgan.  \n ", "page_label": "16", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7972f4614f84c4a421d9f780f86e6b5a60b6d6c63c6a9b88488da3d51258485b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4ffcd582-fd18-44e0-ac08-404999a01003", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nThanks very much.  Good morning.  I just wanted to go back to a comment, Brett, that you made around the macro \neconomic environment. ", "original_text": "McKesson Corp.  "}, "hash": "acc7e5465027ce5f534849cab255b89688998104ea201b9ae389bb2e195de34b", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "start_char_idx": 1341, "end_char_idx": 1612, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4ffcd582-fd18-44e0-ac08-404999a01003": {"__data__": {"id_": "4ffcd582-fd18-44e0-ac08-404999a01003", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nThanks very much.  Good morning.  I just wanted to go back to a comment, Brett, that you made around the macro \neconomic environment. ", "original_text": "McKesson Corp.  ", "page_label": "17", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "48fdc39a-da73-45c6-ab0c-c60b396b0afe", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "54c669c4d49fd92cc4fdaf00dc78b331106bd223355e148c01a53e37ae582ea1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c2128f92-501b-4207-ac6b-0b51590a2532", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Next will be Lisa Gill with JPMorgan.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "page_label": "16", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b0a099d810f01d8e765a5684a8d2454b5a216dc615490891d1bb128b498e5478", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "36f8fc85-a616-4032-9042-1a3ab1af3745", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nThanks very much.  Good morning.  I just wanted to go back to a comment, Brett, that you made around the macro \neconomic environment.  I'm just curious, what do you currently have built into your expectations? ", "original_text": "(MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nThanks very much. "}, "hash": "c690d8e765331f676d4aac3fe64a5c77f01e18745eae201cc009c55e73032bd0", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "36f8fc85-a616-4032-9042-1a3ab1af3745": {"__data__": {"id_": "36f8fc85-a616-4032-9042-1a3ab1af3745", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nThanks very much.  Good morning.  I just wanted to go back to a comment, Brett, that you made around the macro \neconomic environment.  I'm just curious, what do you currently have built into your expectations? ", "original_text": "(MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nThanks very much. ", "page_label": "17", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "48fdc39a-da73-45c6-ab0c-c60b396b0afe", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "54c669c4d49fd92cc4fdaf00dc78b331106bd223355e148c01a53e37ae582ea1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4ffcd582-fd18-44e0-ac08-404999a01003", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nThanks very much.  Good morning.  I just wanted to go back to a comment, Brett, that you made around the macro \neconomic environment. ", "original_text": "McKesson Corp.  ", "page_label": "17", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ac19914aa08e1744d9ff53b0942ce44913e15291dbddabbe8c0dc6fab2c09828", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "78d9310e-de67-449e-8151-58ada4656908", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nThanks very much.  Good morning.  I just wanted to go back to a comment, Brett, that you made around the macro \neconomic environment.  I'm just curious, what do you currently have built into your expectations?  I know that \nthere's been some concern around layoffs [indiscernible] (00:52:18) staying p ermanent. ", "original_text": "Good morning. "}, "hash": "d383f4bf1b0ff7656a39561e449ae793da3d0c6b80ae5f2bafa9cf3d33786e21", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nThanks very much. ", "start_char_idx": 16, "end_char_idx": 251, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "78d9310e-de67-449e-8151-58ada4656908": {"__data__": {"id_": "78d9310e-de67-449e-8151-58ada4656908", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nThanks very much.  Good morning.  I just wanted to go back to a comment, Brett, that you made around the macro \neconomic environment.  I'm just curious, what do you currently have built into your expectations?  I know that \nthere's been some concern around layoffs [indiscernible] (00:52:18) staying p ermanent. ", "original_text": "Good morning. ", "page_label": "17", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "48fdc39a-da73-45c6-ab0c-c60b396b0afe", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "54c669c4d49fd92cc4fdaf00dc78b331106bd223355e148c01a53e37ae582ea1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "36f8fc85-a616-4032-9042-1a3ab1af3745", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nThanks very much.  Good morning.  I just wanted to go back to a comment, Brett, that you made around the macro \neconomic environment.  I'm just curious, what do you currently have built into your expectations? ", "original_text": "(MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nThanks very much. ", "page_label": "17", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b87908104c187c60b5782aa10422b8e0149f5e8b70ecee5aeea7e5e225c7ec0c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1c173590-e2a4-428e-a9a7-ece1d3647bc7", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nThanks very much.  Good morning.  I just wanted to go back to a comment, Brett, that you made around the macro \neconomic environment.  I'm just curious, what do you currently have built into your expectations?  I know that \nthere's been some concern around layoffs [indiscernible] (00:52:18) staying p ermanent.  But yet, as we look at \nmembership across the managed care companies coming in a little bit better than the expectations, I'm just \ncurious, as to what your thoughts are, obviously, going into the guidance. ", "original_text": "I just wanted to go back to a comment, Brett, that you made around the macro \neconomic environment. "}, "hash": "7739c1dc209e89cc93c3aa834a9c19eeef90afdc4513e933c89f4ac8e8210163", "class_name": "RelatedNodeInfo"}}, "text": "Good morning. ", "start_char_idx": 251, "end_char_idx": 265, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1c173590-e2a4-428e-a9a7-ece1d3647bc7": {"__data__": {"id_": "1c173590-e2a4-428e-a9a7-ece1d3647bc7", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nThanks very much.  Good morning.  I just wanted to go back to a comment, Brett, that you made around the macro \neconomic environment.  I'm just curious, what do you currently have built into your expectations?  I know that \nthere's been some concern around layoffs [indiscernible] (00:52:18) staying p ermanent.  But yet, as we look at \nmembership across the managed care companies coming in a little bit better than the expectations, I'm just \ncurious, as to what your thoughts are, obviously, going into the guidance. ", "original_text": "I just wanted to go back to a comment, Brett, that you made around the macro \neconomic environment. ", "page_label": "17", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "48fdc39a-da73-45c6-ab0c-c60b396b0afe", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "54c669c4d49fd92cc4fdaf00dc78b331106bd223355e148c01a53e37ae582ea1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "78d9310e-de67-449e-8151-58ada4656908", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nThanks very much.  Good morning.  I just wanted to go back to a comment, Brett, that you made around the macro \neconomic environment.  I'm just curious, what do you currently have built into your expectations?  I know that \nthere's been some concern around layoffs [indiscernible] (00:52:18) staying p ermanent. ", "original_text": "Good morning. ", "page_label": "17", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a0d9fa85a6e50cf111eb9cba58b86767a0d234e441280d9e9c229f76aeaa6841", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5c35e97e-c9f2-437c-a2dc-5dc23ad4adca", "node_type": "1", "metadata": {"window": "(MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nThanks very much.  Good morning.  I just wanted to go back to a comment, Brett, that you made around the macro \neconomic environment.  I'm just curious, what do you currently have built into your expectations?  I know that \nthere's been some concern around layoffs [indiscernible] (00:52:18) staying p ermanent.  But yet, as we look at \nmembership across the managed care companies coming in a little bit better than the expectations, I'm just \ncurious, as to what your thoughts are, obviously, going into the guidance.  And then as we think about that macro \nenvironment and go back to the last financial downturn, if I remember correctly, when we think about \npharmaceutical utilization it was pretty inelastic, right, had a little bit of an impact, but not very material. ", "original_text": "I'm just curious, what do you currently have built into your expectations? "}, "hash": "0c2625f8de9247338141105665ed705d7daee203f2e80a2da4e0dd5700a47da8", "class_name": "RelatedNodeInfo"}}, "text": "I just wanted to go back to a comment, Brett, that you made around the macro \neconomic environment. ", "start_char_idx": 265, "end_char_idx": 365, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5c35e97e-c9f2-437c-a2dc-5dc23ad4adca": {"__data__": {"id_": "5c35e97e-c9f2-437c-a2dc-5dc23ad4adca", "embedding": null, "metadata": {"window": "(MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nThanks very much.  Good morning.  I just wanted to go back to a comment, Brett, that you made around the macro \neconomic environment.  I'm just curious, what do you currently have built into your expectations?  I know that \nthere's been some concern around layoffs [indiscernible] (00:52:18) staying p ermanent.  But yet, as we look at \nmembership across the managed care companies coming in a little bit better than the expectations, I'm just \ncurious, as to what your thoughts are, obviously, going into the guidance.  And then as we think about that macro \nenvironment and go back to the last financial downturn, if I remember correctly, when we think about \npharmaceutical utilization it was pretty inelastic, right, had a little bit of an impact, but not very material. ", "original_text": "I'm just curious, what do you currently have built into your expectations? ", "page_label": "17", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "48fdc39a-da73-45c6-ab0c-c60b396b0afe", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "54c669c4d49fd92cc4fdaf00dc78b331106bd223355e148c01a53e37ae582ea1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1c173590-e2a4-428e-a9a7-ece1d3647bc7", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nThanks very much.  Good morning.  I just wanted to go back to a comment, Brett, that you made around the macro \neconomic environment.  I'm just curious, what do you currently have built into your expectations?  I know that \nthere's been some concern around layoffs [indiscernible] (00:52:18) staying p ermanent.  But yet, as we look at \nmembership across the managed care companies coming in a little bit better than the expectations, I'm just \ncurious, as to what your thoughts are, obviously, going into the guidance. ", "original_text": "I just wanted to go back to a comment, Brett, that you made around the macro \neconomic environment. ", "page_label": "17", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "785f2d46f383dfe0ec86f7c8ff4c59cb8bb3276f1d35577c6c76b6f627c8f128", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "faad1eb1-f2b2-4f26-8c68-2ee75e72429c", "node_type": "1", "metadata": {"window": "Good morning.  I just wanted to go back to a comment, Brett, that you made around the macro \neconomic environment.  I'm just curious, what do you currently have built into your expectations?  I know that \nthere's been some concern around layoffs [indiscernible] (00:52:18) staying p ermanent.  But yet, as we look at \nmembership across the managed care companies coming in a little bit better than the expectations, I'm just \ncurious, as to what your thoughts are, obviously, going into the guidance.  And then as we think about that macro \nenvironment and go back to the last financial downturn, if I remember correctly, when we think about \npharmaceutical utilization it was pretty inelastic, right, had a little bit of an impact, but not very material.  So I just \u2013 \nI want to better understand what' s in the guidance?  \n ", "original_text": "I know that \nthere's been some concern around layoffs [indiscernible] (00:52:18) staying p ermanent. "}, "hash": "6836e43cbdae662cc68830501432d6aaa5ceac7ba44d09b97bce9365aa0452ce", "class_name": "RelatedNodeInfo"}}, "text": "I'm just curious, what do you currently have built into your expectations? ", "start_char_idx": 365, "end_char_idx": 440, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "faad1eb1-f2b2-4f26-8c68-2ee75e72429c": {"__data__": {"id_": "faad1eb1-f2b2-4f26-8c68-2ee75e72429c", "embedding": null, "metadata": {"window": "Good morning.  I just wanted to go back to a comment, Brett, that you made around the macro \neconomic environment.  I'm just curious, what do you currently have built into your expectations?  I know that \nthere's been some concern around layoffs [indiscernible] (00:52:18) staying p ermanent.  But yet, as we look at \nmembership across the managed care companies coming in a little bit better than the expectations, I'm just \ncurious, as to what your thoughts are, obviously, going into the guidance.  And then as we think about that macro \nenvironment and go back to the last financial downturn, if I remember correctly, when we think about \npharmaceutical utilization it was pretty inelastic, right, had a little bit of an impact, but not very material.  So I just \u2013 \nI want to better understand what' s in the guidance?  \n ", "original_text": "I know that \nthere's been some concern around layoffs [indiscernible] (00:52:18) staying p ermanent. ", "page_label": "17", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "48fdc39a-da73-45c6-ab0c-c60b396b0afe", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "54c669c4d49fd92cc4fdaf00dc78b331106bd223355e148c01a53e37ae582ea1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5c35e97e-c9f2-437c-a2dc-5dc23ad4adca", "node_type": "1", "metadata": {"window": "(MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nThanks very much.  Good morning.  I just wanted to go back to a comment, Brett, that you made around the macro \neconomic environment.  I'm just curious, what do you currently have built into your expectations?  I know that \nthere's been some concern around layoffs [indiscernible] (00:52:18) staying p ermanent.  But yet, as we look at \nmembership across the managed care companies coming in a little bit better than the expectations, I'm just \ncurious, as to what your thoughts are, obviously, going into the guidance.  And then as we think about that macro \nenvironment and go back to the last financial downturn, if I remember correctly, when we think about \npharmaceutical utilization it was pretty inelastic, right, had a little bit of an impact, but not very material. ", "original_text": "I'm just curious, what do you currently have built into your expectations? ", "page_label": "17", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "65cfea0d37329d6fa6ea75db92b836b25bafed7fc23fa480939966d687cc13f0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "eed0963c-7cf8-44f2-8d6a-6fb0836b2629", "node_type": "1", "metadata": {"window": "I just wanted to go back to a comment, Brett, that you made around the macro \neconomic environment.  I'm just curious, what do you currently have built into your expectations?  I know that \nthere's been some concern around layoffs [indiscernible] (00:52:18) staying p ermanent.  But yet, as we look at \nmembership across the managed care companies coming in a little bit better than the expectations, I'm just \ncurious, as to what your thoughts are, obviously, going into the guidance.  And then as we think about that macro \nenvironment and go back to the last financial downturn, if I remember correctly, when we think about \npharmaceutical utilization it was pretty inelastic, right, had a little bit of an impact, but not very material.  So I just \u2013 \nI want to better understand what' s in the guidance?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "original_text": "But yet, as we look at \nmembership across the managed care companies coming in a little bit better than the expectations, I'm just \ncurious, as to what your thoughts are, obviously, going into the guidance. "}, "hash": "fcb52b5975c64f6126150d777ce70557a6d16942a084250848010251c5527d36", "class_name": "RelatedNodeInfo"}}, "text": "I know that \nthere's been some concern around layoffs [indiscernible] (00:52:18) staying p ermanent. ", "start_char_idx": 440, "end_char_idx": 541, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "eed0963c-7cf8-44f2-8d6a-6fb0836b2629": {"__data__": {"id_": "eed0963c-7cf8-44f2-8d6a-6fb0836b2629", "embedding": null, "metadata": {"window": "I just wanted to go back to a comment, Brett, that you made around the macro \neconomic environment.  I'm just curious, what do you currently have built into your expectations?  I know that \nthere's been some concern around layoffs [indiscernible] (00:52:18) staying p ermanent.  But yet, as we look at \nmembership across the managed care companies coming in a little bit better than the expectations, I'm just \ncurious, as to what your thoughts are, obviously, going into the guidance.  And then as we think about that macro \nenvironment and go back to the last financial downturn, if I remember correctly, when we think about \npharmaceutical utilization it was pretty inelastic, right, had a little bit of an impact, but not very material.  So I just \u2013 \nI want to better understand what' s in the guidance?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "original_text": "But yet, as we look at \nmembership across the managed care companies coming in a little bit better than the expectations, I'm just \ncurious, as to what your thoughts are, obviously, going into the guidance. ", "page_label": "17", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "48fdc39a-da73-45c6-ab0c-c60b396b0afe", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "54c669c4d49fd92cc4fdaf00dc78b331106bd223355e148c01a53e37ae582ea1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "faad1eb1-f2b2-4f26-8c68-2ee75e72429c", "node_type": "1", "metadata": {"window": "Good morning.  I just wanted to go back to a comment, Brett, that you made around the macro \neconomic environment.  I'm just curious, what do you currently have built into your expectations?  I know that \nthere's been some concern around layoffs [indiscernible] (00:52:18) staying p ermanent.  But yet, as we look at \nmembership across the managed care companies coming in a little bit better than the expectations, I'm just \ncurious, as to what your thoughts are, obviously, going into the guidance.  And then as we think about that macro \nenvironment and go back to the last financial downturn, if I remember correctly, when we think about \npharmaceutical utilization it was pretty inelastic, right, had a little bit of an impact, but not very material.  So I just \u2013 \nI want to better understand what' s in the guidance?  \n ", "original_text": "I know that \nthere's been some concern around layoffs [indiscernible] (00:52:18) staying p ermanent. ", "page_label": "17", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "672d2fc28351abe236f95f06d34f4bd5c8d858b64ebc75a18201af5a51ede6c2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d71698b1-6ea3-423d-82bb-782a35db7ce8", "node_type": "1", "metadata": {"window": "I'm just curious, what do you currently have built into your expectations?  I know that \nthere's been some concern around layoffs [indiscernible] (00:52:18) staying p ermanent.  But yet, as we look at \nmembership across the managed care companies coming in a little bit better than the expectations, I'm just \ncurious, as to what your thoughts are, obviously, going into the guidance.  And then as we think about that macro \nenvironment and go back to the last financial downturn, if I remember correctly, when we think about \npharmaceutical utilization it was pretty inelastic, right, had a little bit of an impact, but not very material.  So I just \u2013 \nI want to better understand what' s in the guidance?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nSure. ", "original_text": "And then as we think about that macro \nenvironment and go back to the last financial downturn, if I remember correctly, when we think about \npharmaceutical utilization it was pretty inelastic, right, had a little bit of an impact, but not very material. "}, "hash": "a65fe0df486e5b2e464d9fbac3de0fdf611ad2fd3fe9c36bb0789bc848bc12d8", "class_name": "RelatedNodeInfo"}}, "text": "But yet, as we look at \nmembership across the managed care companies coming in a little bit better than the expectations, I'm just \ncurious, as to what your thoughts are, obviously, going into the guidance. ", "start_char_idx": 541, "end_char_idx": 748, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d71698b1-6ea3-423d-82bb-782a35db7ce8": {"__data__": {"id_": "d71698b1-6ea3-423d-82bb-782a35db7ce8", "embedding": null, "metadata": {"window": "I'm just curious, what do you currently have built into your expectations?  I know that \nthere's been some concern around layoffs [indiscernible] (00:52:18) staying p ermanent.  But yet, as we look at \nmembership across the managed care companies coming in a little bit better than the expectations, I'm just \ncurious, as to what your thoughts are, obviously, going into the guidance.  And then as we think about that macro \nenvironment and go back to the last financial downturn, if I remember correctly, when we think about \npharmaceutical utilization it was pretty inelastic, right, had a little bit of an impact, but not very material.  So I just \u2013 \nI want to better understand what' s in the guidance?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nSure. ", "original_text": "And then as we think about that macro \nenvironment and go back to the last financial downturn, if I remember correctly, when we think about \npharmaceutical utilization it was pretty inelastic, right, had a little bit of an impact, but not very material. ", "page_label": "17", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "48fdc39a-da73-45c6-ab0c-c60b396b0afe", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "54c669c4d49fd92cc4fdaf00dc78b331106bd223355e148c01a53e37ae582ea1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "eed0963c-7cf8-44f2-8d6a-6fb0836b2629", "node_type": "1", "metadata": {"window": "I just wanted to go back to a comment, Brett, that you made around the macro \neconomic environment.  I'm just curious, what do you currently have built into your expectations?  I know that \nthere's been some concern around layoffs [indiscernible] (00:52:18) staying p ermanent.  But yet, as we look at \nmembership across the managed care companies coming in a little bit better than the expectations, I'm just \ncurious, as to what your thoughts are, obviously, going into the guidance.  And then as we think about that macro \nenvironment and go back to the last financial downturn, if I remember correctly, when we think about \npharmaceutical utilization it was pretty inelastic, right, had a little bit of an impact, but not very material.  So I just \u2013 \nI want to better understand what' s in the guidance?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "original_text": "But yet, as we look at \nmembership across the managed care companies coming in a little bit better than the expectations, I'm just \ncurious, as to what your thoughts are, obviously, going into the guidance. ", "page_label": "17", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bfda4892fd86802390635cbaff51fe3d6d5872fa9e06a48676d99184df772947", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "594d9683-b2d8-4e56-a4db-e6e3a203eb32", "node_type": "1", "metadata": {"window": "I know that \nthere's been some concern around layoffs [indiscernible] (00:52:18) staying p ermanent.  But yet, as we look at \nmembership across the managed care companies coming in a little bit better than the expectations, I'm just \ncurious, as to what your thoughts are, obviously, going into the guidance.  And then as we think about that macro \nenvironment and go back to the last financial downturn, if I remember correctly, when we think about \npharmaceutical utilization it was pretty inelastic, right, had a little bit of an impact, but not very material.  So I just \u2013 \nI want to better understand what' s in the guidance?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nSure.  Good morning, Lisa, thanks for that question. ", "original_text": "So I just \u2013 \nI want to better understand what' s in the guidance?  \n "}, "hash": "efbef3384a0c8dea312ac6461630ee9e974c7795ddaf402f1f69609bd66509e6", "class_name": "RelatedNodeInfo"}}, "text": "And then as we think about that macro \nenvironment and go back to the last financial downturn, if I remember correctly, when we think about \npharmaceutical utilization it was pretty inelastic, right, had a little bit of an impact, but not very material. ", "start_char_idx": 748, "end_char_idx": 1002, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "594d9683-b2d8-4e56-a4db-e6e3a203eb32": {"__data__": {"id_": "594d9683-b2d8-4e56-a4db-e6e3a203eb32", "embedding": null, "metadata": {"window": "I know that \nthere's been some concern around layoffs [indiscernible] (00:52:18) staying p ermanent.  But yet, as we look at \nmembership across the managed care companies coming in a little bit better than the expectations, I'm just \ncurious, as to what your thoughts are, obviously, going into the guidance.  And then as we think about that macro \nenvironment and go back to the last financial downturn, if I remember correctly, when we think about \npharmaceutical utilization it was pretty inelastic, right, had a little bit of an impact, but not very material.  So I just \u2013 \nI want to better understand what' s in the guidance?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nSure.  Good morning, Lisa, thanks for that question. ", "original_text": "So I just \u2013 \nI want to better understand what' s in the guidance?  \n ", "page_label": "17", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "48fdc39a-da73-45c6-ab0c-c60b396b0afe", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "54c669c4d49fd92cc4fdaf00dc78b331106bd223355e148c01a53e37ae582ea1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d71698b1-6ea3-423d-82bb-782a35db7ce8", "node_type": "1", "metadata": {"window": "I'm just curious, what do you currently have built into your expectations?  I know that \nthere's been some concern around layoffs [indiscernible] (00:52:18) staying p ermanent.  But yet, as we look at \nmembership across the managed care companies coming in a little bit better than the expectations, I'm just \ncurious, as to what your thoughts are, obviously, going into the guidance.  And then as we think about that macro \nenvironment and go back to the last financial downturn, if I remember correctly, when we think about \npharmaceutical utilization it was pretty inelastic, right, had a little bit of an impact, but not very material.  So I just \u2013 \nI want to better understand what' s in the guidance?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nSure. ", "original_text": "And then as we think about that macro \nenvironment and go back to the last financial downturn, if I remember correctly, when we think about \npharmaceutical utilization it was pretty inelastic, right, had a little bit of an impact, but not very material. ", "page_label": "17", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "81df0e825280c35e4a86e0f764f645ca500bf689dd9d55c3439bd608d5cd0b5f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2cfff289-66f4-4205-903c-b21c0814519b", "node_type": "1", "metadata": {"window": "But yet, as we look at \nmembership across the managed care companies coming in a little bit better than the expectations, I'm just \ncurious, as to what your thoughts are, obviously, going into the guidance.  And then as we think about that macro \nenvironment and go back to the last financial downturn, if I remember correctly, when we think about \npharmaceutical utilization it was pretty inelastic, right, had a little bit of an impact, but not very material.  So I just \u2013 \nI want to better understand what' s in the guidance?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nSure.  Good morning, Lisa, thanks for that question.  I'll just refer you back to some comments that I made on the \nMay call. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  "}, "hash": "7e0dd793d32182f91634dae512ebf88438fb31336c84f3ac25993a265c00c31a", "class_name": "RelatedNodeInfo"}}, "text": "So I just \u2013 \nI want to better understand what' s in the guidance?  \n ", "start_char_idx": 1002, "end_char_idx": 1071, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2cfff289-66f4-4205-903c-b21c0814519b": {"__data__": {"id_": "2cfff289-66f4-4205-903c-b21c0814519b", "embedding": null, "metadata": {"window": "But yet, as we look at \nmembership across the managed care companies coming in a little bit better than the expectations, I'm just \ncurious, as to what your thoughts are, obviously, going into the guidance.  And then as we think about that macro \nenvironment and go back to the last financial downturn, if I remember correctly, when we think about \npharmaceutical utilization it was pretty inelastic, right, had a little bit of an impact, but not very material.  So I just \u2013 \nI want to better understand what' s in the guidance?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nSure.  Good morning, Lisa, thanks for that question.  I'll just refer you back to some comments that I made on the \nMay call. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "page_label": "17", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "48fdc39a-da73-45c6-ab0c-c60b396b0afe", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "54c669c4d49fd92cc4fdaf00dc78b331106bd223355e148c01a53e37ae582ea1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "594d9683-b2d8-4e56-a4db-e6e3a203eb32", "node_type": "1", "metadata": {"window": "I know that \nthere's been some concern around layoffs [indiscernible] (00:52:18) staying p ermanent.  But yet, as we look at \nmembership across the managed care companies coming in a little bit better than the expectations, I'm just \ncurious, as to what your thoughts are, obviously, going into the guidance.  And then as we think about that macro \nenvironment and go back to the last financial downturn, if I remember correctly, when we think about \npharmaceutical utilization it was pretty inelastic, right, had a little bit of an impact, but not very material.  So I just \u2013 \nI want to better understand what' s in the guidance?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nSure.  Good morning, Lisa, thanks for that question. ", "original_text": "So I just \u2013 \nI want to better understand what' s in the guidance?  \n ", "page_label": "17", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b2f38bd549b819ecdace3e18ef5c0b5cc93c8d1f5f70454978e3cd9895c554f2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "79021055-c7b4-4b50-8def-e347e94f40df", "node_type": "1", "metadata": {"window": "And then as we think about that macro \nenvironment and go back to the last financial downturn, if I remember correctly, when we think about \npharmaceutical utilization it was pretty inelastic, right, had a little bit of an impact, but not very material.  So I just \u2013 \nI want to better understand what' s in the guidance?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nSure.  Good morning, Lisa, thanks for that question.  I'll just refer you back to some comments that I made on the \nMay call.  And we track unemploymen t levels very closely. ", "original_text": "A \nSure. "}, "hash": "91d55627cb06f04c6c7c0e6abe147b8e1cc0428a80c82f82275d41fe7952d961", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "start_char_idx": 1071, "end_char_idx": 1431, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "79021055-c7b4-4b50-8def-e347e94f40df": {"__data__": {"id_": "79021055-c7b4-4b50-8def-e347e94f40df", "embedding": null, "metadata": {"window": "And then as we think about that macro \nenvironment and go back to the last financial downturn, if I remember correctly, when we think about \npharmaceutical utilization it was pretty inelastic, right, had a little bit of an impact, but not very material.  So I just \u2013 \nI want to better understand what' s in the guidance?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nSure.  Good morning, Lisa, thanks for that question.  I'll just refer you back to some comments that I made on the \nMay call.  And we track unemploymen t levels very closely. ", "original_text": "A \nSure. ", "page_label": "17", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "48fdc39a-da73-45c6-ab0c-c60b396b0afe", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "54c669c4d49fd92cc4fdaf00dc78b331106bd223355e148c01a53e37ae582ea1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2cfff289-66f4-4205-903c-b21c0814519b", "node_type": "1", "metadata": {"window": "But yet, as we look at \nmembership across the managed care companies coming in a little bit better than the expectations, I'm just \ncurious, as to what your thoughts are, obviously, going into the guidance.  And then as we think about that macro \nenvironment and go back to the last financial downturn, if I remember correctly, when we think about \npharmaceutical utilization it was pretty inelastic, right, had a little bit of an impact, but not very material.  So I just \u2013 \nI want to better understand what' s in the guidance?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nSure.  Good morning, Lisa, thanks for that question.  I'll just refer you back to some comments that I made on the \nMay call. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "page_label": "17", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ef443ff5b6af03816706b009dfe5aa616ef162231ed8703866c6540828b389f5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0da0c842-8103-49b0-a383-4979fe1cbb11", "node_type": "1", "metadata": {"window": "So I just \u2013 \nI want to better understand what' s in the guidance?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nSure.  Good morning, Lisa, thanks for that question.  I'll just refer you back to some comments that I made on the \nMay call.  And we track unemploymen t levels very closely.  We track the solvency of our customers very closely, \nwork very closely with them to make sure that they have all the resources that they need. ", "original_text": "Good morning, Lisa, thanks for that question. "}, "hash": "08b212784e93a458297c5dba1d8a3a1701cd3a98d85b35cd92ff35a78008eb6d", "class_name": "RelatedNodeInfo"}}, "text": "A \nSure. ", "start_char_idx": 1431, "end_char_idx": 1440, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0da0c842-8103-49b0-a383-4979fe1cbb11": {"__data__": {"id_": "0da0c842-8103-49b0-a383-4979fe1cbb11", "embedding": null, "metadata": {"window": "So I just \u2013 \nI want to better understand what' s in the guidance?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nSure.  Good morning, Lisa, thanks for that question.  I'll just refer you back to some comments that I made on the \nMay call.  And we track unemploymen t levels very closely.  We track the solvency of our customers very closely, \nwork very closely with them to make sure that they have all the resources that they need. ", "original_text": "Good morning, Lisa, thanks for that question. ", "page_label": "17", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "48fdc39a-da73-45c6-ab0c-c60b396b0afe", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "54c669c4d49fd92cc4fdaf00dc78b331106bd223355e148c01a53e37ae582ea1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "79021055-c7b4-4b50-8def-e347e94f40df", "node_type": "1", "metadata": {"window": "And then as we think about that macro \nenvironment and go back to the last financial downturn, if I remember correctly, when we think about \npharmaceutical utilization it was pretty inelastic, right, had a little bit of an impact, but not very material.  So I just \u2013 \nI want to better understand what' s in the guidance?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nSure.  Good morning, Lisa, thanks for that question.  I'll just refer you back to some comments that I made on the \nMay call.  And we track unemploymen t levels very closely. ", "original_text": "A \nSure. ", "page_label": "17", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7f0d55e63bcffe699acd3fdfc69c2ecd5b2cfc51e4533c2bb20fcf70fc456a8d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "01ba6f47-8747-4630-b503-f533c0572b70", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nSure.  Good morning, Lisa, thanks for that question.  I'll just refer you back to some comments that I made on the \nMay call.  And we track unemploymen t levels very closely.  We track the solvency of our customers very closely, \nwork very closely with them to make sure that they have all the resources that they need.  What I said in May, \nwould still hold. ", "original_text": "I'll just refer you back to some comments that I made on the \nMay call. "}, "hash": "c0c62ca3a25cd3e18b8b316c465095680e92ac9fff4c273b706a138553fe70bb", "class_name": "RelatedNodeInfo"}}, "text": "Good morning, Lisa, thanks for that question. ", "start_char_idx": 1440, "end_char_idx": 1486, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "01ba6f47-8747-4630-b503-f533c0572b70": {"__data__": {"id_": "01ba6f47-8747-4630-b503-f533c0572b70", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nSure.  Good morning, Lisa, thanks for that question.  I'll just refer you back to some comments that I made on the \nMay call.  And we track unemploymen t levels very closely.  We track the solvency of our customers very closely, \nwork very closely with them to make sure that they have all the resources that they need.  What I said in May, \nwould still hold. ", "original_text": "I'll just refer you back to some comments that I made on the \nMay call. ", "page_label": "17", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "48fdc39a-da73-45c6-ab0c-c60b396b0afe", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "54c669c4d49fd92cc4fdaf00dc78b331106bd223355e148c01a53e37ae582ea1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0da0c842-8103-49b0-a383-4979fe1cbb11", "node_type": "1", "metadata": {"window": "So I just \u2013 \nI want to better understand what' s in the guidance?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nSure.  Good morning, Lisa, thanks for that question.  I'll just refer you back to some comments that I made on the \nMay call.  And we track unemploymen t levels very closely.  We track the solvency of our customers very closely, \nwork very closely with them to make sure that they have all the resources that they need. ", "original_text": "Good morning, Lisa, thanks for that question. ", "page_label": "17", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e4955cb5ebeee35f8452ba3ca18f4278e03d2815430f92384467d1144e2c06a5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3d27e28c-4d8f-4725-89bc-fd6b83b17e28", "node_type": "1", "metadata": {"window": "A \nSure.  Good morning, Lisa, thanks for that question.  I'll just refer you back to some comments that I made on the \nMay call.  And we track unemploymen t levels very closely.  We track the solvency of our customers very closely, \nwork very closely with them to make sure that they have all the resources that they need.  What I said in May, \nwould still hold.  We expect that the peak unemployment levels will be in the second calendar quarter.  \n \n", "original_text": "And we track unemploymen t levels very closely. "}, "hash": "885fce652b3aff9ebf23bc5aa3e619d52f2d804220165e9b1be0cc2f89153078", "class_name": "RelatedNodeInfo"}}, "text": "I'll just refer you back to some comments that I made on the \nMay call. ", "start_char_idx": 1486, "end_char_idx": 1558, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3d27e28c-4d8f-4725-89bc-fd6b83b17e28": {"__data__": {"id_": "3d27e28c-4d8f-4725-89bc-fd6b83b17e28", "embedding": null, "metadata": {"window": "A \nSure.  Good morning, Lisa, thanks for that question.  I'll just refer you back to some comments that I made on the \nMay call.  And we track unemploymen t levels very closely.  We track the solvency of our customers very closely, \nwork very closely with them to make sure that they have all the resources that they need.  What I said in May, \nwould still hold.  We expect that the peak unemployment levels will be in the second calendar quarter.  \n \n", "original_text": "And we track unemploymen t levels very closely. ", "page_label": "17", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "48fdc39a-da73-45c6-ab0c-c60b396b0afe", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "54c669c4d49fd92cc4fdaf00dc78b331106bd223355e148c01a53e37ae582ea1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "01ba6f47-8747-4630-b503-f533c0572b70", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nSure.  Good morning, Lisa, thanks for that question.  I'll just refer you back to some comments that I made on the \nMay call.  And we track unemploymen t levels very closely.  We track the solvency of our customers very closely, \nwork very closely with them to make sure that they have all the resources that they need.  What I said in May, \nwould still hold. ", "original_text": "I'll just refer you back to some comments that I made on the \nMay call. ", "page_label": "17", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9488824818b8803420e43331255b82aaba6df05cbbd27e25a05409b843f86f46", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d7b2fa0a-574e-4c6d-9ff7-9f767d96c18b", "node_type": "1", "metadata": {"window": "Good morning, Lisa, thanks for that question.  I'll just refer you back to some comments that I made on the \nMay call.  And we track unemploymen t levels very closely.  We track the solvency of our customers very closely, \nwork very closely with them to make sure that they have all the resources that they need.  What I said in May, \nwould still hold.  We expect that the peak unemployment levels will be in the second calendar quarter.  \n \n We still expect that to be the case. ", "original_text": "We track the solvency of our customers very closely, \nwork very closely with them to make sure that they have all the resources that they need. "}, "hash": "1b5b957fe2fd6b3813a113356d172d68ff6cf92fcfcff4a5d195f7c52af25ae5", "class_name": "RelatedNodeInfo"}}, "text": "And we track unemploymen t levels very closely. ", "start_char_idx": 1558, "end_char_idx": 1606, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d7b2fa0a-574e-4c6d-9ff7-9f767d96c18b": {"__data__": {"id_": "d7b2fa0a-574e-4c6d-9ff7-9f767d96c18b", "embedding": null, "metadata": {"window": "Good morning, Lisa, thanks for that question.  I'll just refer you back to some comments that I made on the \nMay call.  And we track unemploymen t levels very closely.  We track the solvency of our customers very closely, \nwork very closely with them to make sure that they have all the resources that they need.  What I said in May, \nwould still hold.  We expect that the peak unemployment levels will be in the second calendar quarter.  \n \n We still expect that to be the case. ", "original_text": "We track the solvency of our customers very closely, \nwork very closely with them to make sure that they have all the resources that they need. ", "page_label": "17", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "48fdc39a-da73-45c6-ab0c-c60b396b0afe", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "54c669c4d49fd92cc4fdaf00dc78b331106bd223355e148c01a53e37ae582ea1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3d27e28c-4d8f-4725-89bc-fd6b83b17e28", "node_type": "1", "metadata": {"window": "A \nSure.  Good morning, Lisa, thanks for that question.  I'll just refer you back to some comments that I made on the \nMay call.  And we track unemploymen t levels very closely.  We track the solvency of our customers very closely, \nwork very closely with them to make sure that they have all the resources that they need.  What I said in May, \nwould still hold.  We expect that the peak unemployment levels will be in the second calendar quarter.  \n \n", "original_text": "And we track unemploymen t levels very closely. ", "page_label": "17", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "11a1152979b9bad022377827c10c42a3ff4c83b0c68d529a958be95041456eb3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c27ab11f-28f2-495f-8249-63efc6679710", "node_type": "1", "metadata": {"window": "I'll just refer you back to some comments that I made on the \nMay call.  And we track unemploymen t levels very closely.  We track the solvency of our customers very closely, \nwork very closely with them to make sure that they have all the resources that they need.  What I said in May, \nwould still hold.  We expect that the peak unemployment levels will be in the second calendar quarter.  \n \n We still expect that to be the case.  Obviously, unemployment has been stubborn for the last 18, 19 weeks, but we \ndo believe that it will peak in this second calendar quarter. ", "original_text": "What I said in May, \nwould still hold. "}, "hash": "bdee762782d94736ba8f8e5236b451cbb125011cb8c9bb5fa5c60ed380fa8c32", "class_name": "RelatedNodeInfo"}}, "text": "We track the solvency of our customers very closely, \nwork very closely with them to make sure that they have all the resources that they need. ", "start_char_idx": 1606, "end_char_idx": 1750, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c27ab11f-28f2-495f-8249-63efc6679710": {"__data__": {"id_": "c27ab11f-28f2-495f-8249-63efc6679710", "embedding": null, "metadata": {"window": "I'll just refer you back to some comments that I made on the \nMay call.  And we track unemploymen t levels very closely.  We track the solvency of our customers very closely, \nwork very closely with them to make sure that they have all the resources that they need.  What I said in May, \nwould still hold.  We expect that the peak unemployment levels will be in the second calendar quarter.  \n \n We still expect that to be the case.  Obviously, unemployment has been stubborn for the last 18, 19 weeks, but we \ndo believe that it will peak in this second calendar quarter. ", "original_text": "What I said in May, \nwould still hold. ", "page_label": "17", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "48fdc39a-da73-45c6-ab0c-c60b396b0afe", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "54c669c4d49fd92cc4fdaf00dc78b331106bd223355e148c01a53e37ae582ea1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d7b2fa0a-574e-4c6d-9ff7-9f767d96c18b", "node_type": "1", "metadata": {"window": "Good morning, Lisa, thanks for that question.  I'll just refer you back to some comments that I made on the \nMay call.  And we track unemploymen t levels very closely.  We track the solvency of our customers very closely, \nwork very closely with them to make sure that they have all the resources that they need.  What I said in May, \nwould still hold.  We expect that the peak unemployment levels will be in the second calendar quarter.  \n \n We still expect that to be the case. ", "original_text": "We track the solvency of our customers very closely, \nwork very closely with them to make sure that they have all the resources that they need. ", "page_label": "17", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "10fd7e9d107485495300ad51d4709733b8eee38d8cede185ec04e63de5c9381f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "780f9b94-0222-4622-93de-8ee4594f968c", "node_type": "1", "metadata": {"window": "And we track unemploymen t levels very closely.  We track the solvency of our customers very closely, \nwork very closely with them to make sure that they have all the resources that they need.  What I said in May, \nwould still hold.  We expect that the peak unemployment levels will be in the second calendar quarter.  \n \n We still expect that to be the case.  Obviously, unemployment has been stubborn for the last 18, 19 weeks, but we \ndo believe that it will peak in this second calendar quarter.  And so I think to your second question, I think you're \nright. ", "original_text": "We expect that the peak unemployment levels will be in the second calendar quarter.  \n \n"}, "hash": "3985009652c4f61dccf0ca340a2662ed79cd9abc8e58eceaf0d46081a8271fc6", "class_name": "RelatedNodeInfo"}}, "text": "What I said in May, \nwould still hold. ", "start_char_idx": 1750, "end_char_idx": 1789, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "780f9b94-0222-4622-93de-8ee4594f968c": {"__data__": {"id_": "780f9b94-0222-4622-93de-8ee4594f968c", "embedding": null, "metadata": {"window": "And we track unemploymen t levels very closely.  We track the solvency of our customers very closely, \nwork very closely with them to make sure that they have all the resources that they need.  What I said in May, \nwould still hold.  We expect that the peak unemployment levels will be in the second calendar quarter.  \n \n We still expect that to be the case.  Obviously, unemployment has been stubborn for the last 18, 19 weeks, but we \ndo believe that it will peak in this second calendar quarter.  And so I think to your second question, I think you're \nright. ", "original_text": "We expect that the peak unemployment levels will be in the second calendar quarter.  \n \n", "page_label": "17", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "48fdc39a-da73-45c6-ab0c-c60b396b0afe", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "54c669c4d49fd92cc4fdaf00dc78b331106bd223355e148c01a53e37ae582ea1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c27ab11f-28f2-495f-8249-63efc6679710", "node_type": "1", "metadata": {"window": "I'll just refer you back to some comments that I made on the \nMay call.  And we track unemploymen t levels very closely.  We track the solvency of our customers very closely, \nwork very closely with them to make sure that they have all the resources that they need.  What I said in May, \nwould still hold.  We expect that the peak unemployment levels will be in the second calendar quarter.  \n \n We still expect that to be the case.  Obviously, unemployment has been stubborn for the last 18, 19 weeks, but we \ndo believe that it will peak in this second calendar quarter. ", "original_text": "What I said in May, \nwould still hold. ", "page_label": "17", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1d87321f200a4245c2c4f5ff9731887155b509654179c8c61cd6c836d22e7503", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "514dab8d-b8ac-4fcf-aed1-eee174058e29", "node_type": "1", "metadata": {"window": "We track the solvency of our customers very closely, \nwork very closely with them to make sure that they have all the resources that they need.  What I said in May, \nwould still hold.  We expect that the peak unemployment levels will be in the second calendar quarter.  \n \n We still expect that to be the case.  Obviously, unemployment has been stubborn for the last 18, 19 weeks, but we \ndo believe that it will peak in this second calendar quarter.  And so I think to your second question, I think you're \nright.  I think we do believe that prescription transaction volumes will be not as affected as the overall economy will \nbe. ", "original_text": "We still expect that to be the case. "}, "hash": "9d3865c1365005231486ee5e342a1f8ed899da9d8278c82125c07a9637d40352", "class_name": "RelatedNodeInfo"}}, "text": "We expect that the peak unemployment levels will be in the second calendar quarter.  \n \n", "start_char_idx": 1789, "end_char_idx": 1877, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "514dab8d-b8ac-4fcf-aed1-eee174058e29": {"__data__": {"id_": "514dab8d-b8ac-4fcf-aed1-eee174058e29", "embedding": null, "metadata": {"window": "We track the solvency of our customers very closely, \nwork very closely with them to make sure that they have all the resources that they need.  What I said in May, \nwould still hold.  We expect that the peak unemployment levels will be in the second calendar quarter.  \n \n We still expect that to be the case.  Obviously, unemployment has been stubborn for the last 18, 19 weeks, but we \ndo believe that it will peak in this second calendar quarter.  And so I think to your second question, I think you're \nright.  I think we do believe that prescription transaction volumes will be not as affected as the overall economy will \nbe. ", "original_text": "We still expect that to be the case. ", "page_label": "17", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "48fdc39a-da73-45c6-ab0c-c60b396b0afe", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "54c669c4d49fd92cc4fdaf00dc78b331106bd223355e148c01a53e37ae582ea1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "780f9b94-0222-4622-93de-8ee4594f968c", "node_type": "1", "metadata": {"window": "And we track unemploymen t levels very closely.  We track the solvency of our customers very closely, \nwork very closely with them to make sure that they have all the resources that they need.  What I said in May, \nwould still hold.  We expect that the peak unemployment levels will be in the second calendar quarter.  \n \n We still expect that to be the case.  Obviously, unemployment has been stubborn for the last 18, 19 weeks, but we \ndo believe that it will peak in this second calendar quarter.  And so I think to your second question, I think you're \nright. ", "original_text": "We expect that the peak unemployment levels will be in the second calendar quarter.  \n \n", "page_label": "17", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1c62e3298bef453fe0fa6fa08ca1c06b8ec1fa7bfcbf885c48b91ce1eee28cc6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "243fb048-1760-42b6-8241-b281fa5d813e", "node_type": "1", "metadata": {"window": "What I said in May, \nwould still hold.  We expect that the peak unemployment levels will be in the second calendar quarter.  \n \n We still expect that to be the case.  Obviously, unemployment has been stubborn for the last 18, 19 weeks, but we \ndo believe that it will peak in this second calendar quarter.  And so I think to your second question, I think you're \nright.  I think we do believe that prescription transaction volumes will be not as affected as the overall economy will \nbe.  And that's given us the confidence to really raise our revenue guide within that segment for the full year.  \n ", "original_text": "Obviously, unemployment has been stubborn for the last 18, 19 weeks, but we \ndo believe that it will peak in this second calendar quarter. "}, "hash": "341b865ea1d425676b330a2b76cd0c913c552e0d7b12cce9585a01dc9af99775", "class_name": "RelatedNodeInfo"}}, "text": "We still expect that to be the case. ", "start_char_idx": 1877, "end_char_idx": 1914, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "243fb048-1760-42b6-8241-b281fa5d813e": {"__data__": {"id_": "243fb048-1760-42b6-8241-b281fa5d813e", "embedding": null, "metadata": {"window": "What I said in May, \nwould still hold.  We expect that the peak unemployment levels will be in the second calendar quarter.  \n \n We still expect that to be the case.  Obviously, unemployment has been stubborn for the last 18, 19 weeks, but we \ndo believe that it will peak in this second calendar quarter.  And so I think to your second question, I think you're \nright.  I think we do believe that prescription transaction volumes will be not as affected as the overall economy will \nbe.  And that's given us the confidence to really raise our revenue guide within that segment for the full year.  \n ", "original_text": "Obviously, unemployment has been stubborn for the last 18, 19 weeks, but we \ndo believe that it will peak in this second calendar quarter. ", "page_label": "17", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "48fdc39a-da73-45c6-ab0c-c60b396b0afe", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "54c669c4d49fd92cc4fdaf00dc78b331106bd223355e148c01a53e37ae582ea1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "514dab8d-b8ac-4fcf-aed1-eee174058e29", "node_type": "1", "metadata": {"window": "We track the solvency of our customers very closely, \nwork very closely with them to make sure that they have all the resources that they need.  What I said in May, \nwould still hold.  We expect that the peak unemployment levels will be in the second calendar quarter.  \n \n We still expect that to be the case.  Obviously, unemployment has been stubborn for the last 18, 19 weeks, but we \ndo believe that it will peak in this second calendar quarter.  And so I think to your second question, I think you're \nright.  I think we do believe that prescription transaction volumes will be not as affected as the overall economy will \nbe. ", "original_text": "We still expect that to be the case. ", "page_label": "17", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "150afaccf2af63b94123f2091555f979a1620e0487fae7ff69ad544343bfa58e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "217ddcf9-1839-4582-8f6c-20d4d8e0046c", "node_type": "1", "metadata": {"window": "We expect that the peak unemployment levels will be in the second calendar quarter.  \n \n We still expect that to be the case.  Obviously, unemployment has been stubborn for the last 18, 19 weeks, but we \ndo believe that it will peak in this second calendar quarter.  And so I think to your second question, I think you're \nright.  I think we do believe that prescription transaction volumes will be not as affected as the overall economy will \nbe.  And that's given us the confidence to really raise our revenue guide within that segment for the full year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  ", "original_text": "And so I think to your second question, I think you're \nright. "}, "hash": "5e8e7bb42201e0278adf33ddce2c08903192e53b5fc42b52e95765b761d24161", "class_name": "RelatedNodeInfo"}}, "text": "Obviously, unemployment has been stubborn for the last 18, 19 weeks, but we \ndo believe that it will peak in this second calendar quarter. ", "start_char_idx": 1914, "end_char_idx": 2053, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "217ddcf9-1839-4582-8f6c-20d4d8e0046c": {"__data__": {"id_": "217ddcf9-1839-4582-8f6c-20d4d8e0046c", "embedding": null, "metadata": {"window": "We expect that the peak unemployment levels will be in the second calendar quarter.  \n \n We still expect that to be the case.  Obviously, unemployment has been stubborn for the last 18, 19 weeks, but we \ndo believe that it will peak in this second calendar quarter.  And so I think to your second question, I think you're \nright.  I think we do believe that prescription transaction volumes will be not as affected as the overall economy will \nbe.  And that's given us the confidence to really raise our revenue guide within that segment for the full year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  ", "original_text": "And so I think to your second question, I think you're \nright. ", "page_label": "17", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "48fdc39a-da73-45c6-ab0c-c60b396b0afe", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "54c669c4d49fd92cc4fdaf00dc78b331106bd223355e148c01a53e37ae582ea1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "243fb048-1760-42b6-8241-b281fa5d813e", "node_type": "1", "metadata": {"window": "What I said in May, \nwould still hold.  We expect that the peak unemployment levels will be in the second calendar quarter.  \n \n We still expect that to be the case.  Obviously, unemployment has been stubborn for the last 18, 19 weeks, but we \ndo believe that it will peak in this second calendar quarter.  And so I think to your second question, I think you're \nright.  I think we do believe that prescription transaction volumes will be not as affected as the overall economy will \nbe.  And that's given us the confidence to really raise our revenue guide within that segment for the full year.  \n ", "original_text": "Obviously, unemployment has been stubborn for the last 18, 19 weeks, but we \ndo believe that it will peak in this second calendar quarter. ", "page_label": "17", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8400090a60b85a65aa30181c6d856524829711f08628e5baf98524c84574fd2b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "86362744-92cf-45b4-ba0f-c0560569b456", "node_type": "1", "metadata": {"window": "We still expect that to be the case.  Obviously, unemployment has been stubborn for the last 18, 19 weeks, but we \ndo believe that it will peak in this second calendar quarter.  And so I think to your second question, I think you're \nright.  I think we do believe that prescription transaction volumes will be not as affected as the overall economy will \nbe.  And that's given us the confidence to really raise our revenue guide within that segment for the full year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question.  \n ", "original_text": "I think we do believe that prescription transaction volumes will be not as affected as the overall economy will \nbe. "}, "hash": "fad336d5e1a2fd7c39a78cf954d4aabf4f6b46bf8e3e7290ffe9441cb121f7c0", "class_name": "RelatedNodeInfo"}}, "text": "And so I think to your second question, I think you're \nright. ", "start_char_idx": 2053, "end_char_idx": 2116, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "86362744-92cf-45b4-ba0f-c0560569b456": {"__data__": {"id_": "86362744-92cf-45b4-ba0f-c0560569b456", "embedding": null, "metadata": {"window": "We still expect that to be the case.  Obviously, unemployment has been stubborn for the last 18, 19 weeks, but we \ndo believe that it will peak in this second calendar quarter.  And so I think to your second question, I think you're \nright.  I think we do believe that prescription transaction volumes will be not as affected as the overall economy will \nbe.  And that's given us the confidence to really raise our revenue guide within that segment for the full year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question.  \n ", "original_text": "I think we do believe that prescription transaction volumes will be not as affected as the overall economy will \nbe. ", "page_label": "17", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "48fdc39a-da73-45c6-ab0c-c60b396b0afe", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "54c669c4d49fd92cc4fdaf00dc78b331106bd223355e148c01a53e37ae582ea1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "217ddcf9-1839-4582-8f6c-20d4d8e0046c", "node_type": "1", "metadata": {"window": "We expect that the peak unemployment levels will be in the second calendar quarter.  \n \n We still expect that to be the case.  Obviously, unemployment has been stubborn for the last 18, 19 weeks, but we \ndo believe that it will peak in this second calendar quarter.  And so I think to your second question, I think you're \nright.  I think we do believe that prescription transaction volumes will be not as affected as the overall economy will \nbe.  And that's given us the confidence to really raise our revenue guide within that segment for the full year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  ", "original_text": "And so I think to your second question, I think you're \nright. ", "page_label": "17", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f3eeff275d131948f48990713acc99bd831b1840abdc3c7a1039eada3e91d7e7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "59f57f50-c357-4844-96f5-1b43fe7f32c0", "node_type": "1", "metadata": {"window": "Obviously, unemployment has been stubborn for the last 18, 19 weeks, but we \ndo believe that it will peak in this second calendar quarter.  And so I think to your second question, I think you're \nright.  I think we do believe that prescription transaction volumes will be not as affected as the overall economy will \nbe.  And that's given us the confidence to really raise our revenue guide within that segment for the full year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Next will be Ricky Goldwasser with Morgan Stanley.  \n ", "original_text": "And that's given us the confidence to really raise our revenue guide within that segment for the full year.  \n "}, "hash": "91b359761240ef8fd9c3de59badc7117675de0040540b0af5de31faf63bd35ab", "class_name": "RelatedNodeInfo"}}, "text": "I think we do believe that prescription transaction volumes will be not as affected as the overall economy will \nbe. ", "start_char_idx": 2116, "end_char_idx": 2233, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "59f57f50-c357-4844-96f5-1b43fe7f32c0": {"__data__": {"id_": "59f57f50-c357-4844-96f5-1b43fe7f32c0", "embedding": null, "metadata": {"window": "Obviously, unemployment has been stubborn for the last 18, 19 weeks, but we \ndo believe that it will peak in this second calendar quarter.  And so I think to your second question, I think you're \nright.  I think we do believe that prescription transaction volumes will be not as affected as the overall economy will \nbe.  And that's given us the confidence to really raise our revenue guide within that segment for the full year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Next will be Ricky Goldwasser with Morgan Stanley.  \n ", "original_text": "And that's given us the confidence to really raise our revenue guide within that segment for the full year.  \n ", "page_label": "17", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "48fdc39a-da73-45c6-ab0c-c60b396b0afe", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "54c669c4d49fd92cc4fdaf00dc78b331106bd223355e148c01a53e37ae582ea1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "86362744-92cf-45b4-ba0f-c0560569b456", "node_type": "1", "metadata": {"window": "We still expect that to be the case.  Obviously, unemployment has been stubborn for the last 18, 19 weeks, but we \ndo believe that it will peak in this second calendar quarter.  And so I think to your second question, I think you're \nright.  I think we do believe that prescription transaction volumes will be not as affected as the overall economy will \nbe.  And that's given us the confidence to really raise our revenue guide within that segment for the full year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question.  \n ", "original_text": "I think we do believe that prescription transaction volumes will be not as affected as the overall economy will \nbe. ", "page_label": "17", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "722ed29d06f3ca25ad1869d62a69fcf9de06da78e42f9c21ad38bb255894bb86", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "aa1215dc-bcd5-4f82-a4b1-cfa6c50b5933", "node_type": "1", "metadata": {"window": "And so I think to your second question, I think you're \nright.  I think we do believe that prescription transaction volumes will be not as affected as the overall economy will \nbe.  And that's given us the confidence to really raise our revenue guide within that segment for the full year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Next will be Ricky Goldwasser with Morgan Stanley.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  "}, "hash": "a8858320b12b5002e96a5ed664d2e47864e1ff531b675c0f7196ae50eee539ff", "class_name": "RelatedNodeInfo"}}, "text": "And that's given us the confidence to really raise our revenue guide within that segment for the full year.  \n ", "start_char_idx": 2233, "end_char_idx": 2344, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "aa1215dc-bcd5-4f82-a4b1-cfa6c50b5933": {"__data__": {"id_": "aa1215dc-bcd5-4f82-a4b1-cfa6c50b5933", "embedding": null, "metadata": {"window": "And so I think to your second question, I think you're \nright.  I think we do believe that prescription transaction volumes will be not as affected as the overall economy will \nbe.  And that's given us the confidence to really raise our revenue guide within that segment for the full year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Next will be Ricky Goldwasser with Morgan Stanley.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  ", "page_label": "17", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "48fdc39a-da73-45c6-ab0c-c60b396b0afe", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "54c669c4d49fd92cc4fdaf00dc78b331106bd223355e148c01a53e37ae582ea1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "59f57f50-c357-4844-96f5-1b43fe7f32c0", "node_type": "1", "metadata": {"window": "Obviously, unemployment has been stubborn for the last 18, 19 weeks, but we \ndo believe that it will peak in this second calendar quarter.  And so I think to your second question, I think you're \nright.  I think we do believe that prescription transaction volumes will be not as affected as the overall economy will \nbe.  And that's given us the confidence to really raise our revenue guide within that segment for the full year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Next will be Ricky Goldwasser with Morgan Stanley.  \n ", "original_text": "And that's given us the confidence to really raise our revenue guide within that segment for the full year.  \n ", "page_label": "17", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1df86d09063ea37dea7b6cce53b54054b624c9cdff757f4c43fe3ba52afdc659", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "95d7a5bd-8132-4f04-b616-01dfdd712c67", "node_type": "1", "metadata": {"window": "I think we do believe that prescription transaction volumes will be not as affected as the overall economy will \nbe.  And that's given us the confidence to really raise our revenue guide within that segment for the full year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Next will be Ricky Goldwasser with Morgan Stanley.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nYeah. ", "original_text": "A \nNext question.  \n "}, "hash": "22d9b48c62ea89d05a4a4a9d10be7e43e8d6fff55d5e69b85214e3ec1c3f6a5a", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  ", "start_char_idx": 2344, "end_char_idx": 2689, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "95d7a5bd-8132-4f04-b616-01dfdd712c67": {"__data__": {"id_": "95d7a5bd-8132-4f04-b616-01dfdd712c67", "embedding": null, "metadata": {"window": "I think we do believe that prescription transaction volumes will be not as affected as the overall economy will \nbe.  And that's given us the confidence to really raise our revenue guide within that segment for the full year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Next will be Ricky Goldwasser with Morgan Stanley.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nYeah. ", "original_text": "A \nNext question.  \n ", "page_label": "17", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "48fdc39a-da73-45c6-ab0c-c60b396b0afe", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "54c669c4d49fd92cc4fdaf00dc78b331106bd223355e148c01a53e37ae582ea1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "aa1215dc-bcd5-4f82-a4b1-cfa6c50b5933", "node_type": "1", "metadata": {"window": "And so I think to your second question, I think you're \nright.  I think we do believe that prescription transaction volumes will be not as affected as the overall economy will \nbe.  And that's given us the confidence to really raise our revenue guide within that segment for the full year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Next will be Ricky Goldwasser with Morgan Stanley.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  ", "page_label": "17", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f8e8a3d06c56229f6f270752ccb79ed0303bb64e48b3b6983dfc1c4753e02384", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "94fb79a2-4b67-4b77-b942-ceacda8a12f6", "node_type": "1", "metadata": {"window": "And that's given us the confidence to really raise our revenue guide within that segment for the full year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Next will be Ricky Goldwasser with Morgan Stanley.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nYeah.  Hi. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Next will be Ricky Goldwasser with Morgan Stanley.  \n "}, "hash": "8388a75fff1e15f71542f4beb7b2c02f142a1d0ced91f3f4facde0c8ef36d95d", "class_name": "RelatedNodeInfo"}}, "text": "A \nNext question.  \n ", "start_char_idx": 2689, "end_char_idx": 2710, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "94fb79a2-4b67-4b77-b942-ceacda8a12f6": {"__data__": {"id_": "94fb79a2-4b67-4b77-b942-ceacda8a12f6", "embedding": null, "metadata": {"window": "And that's given us the confidence to really raise our revenue guide within that segment for the full year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Next will be Ricky Goldwasser with Morgan Stanley.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nYeah.  Hi. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Next will be Ricky Goldwasser with Morgan Stanley.  \n ", "page_label": "17", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "48fdc39a-da73-45c6-ab0c-c60b396b0afe", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "54c669c4d49fd92cc4fdaf00dc78b331106bd223355e148c01a53e37ae582ea1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "95d7a5bd-8132-4f04-b616-01dfdd712c67", "node_type": "1", "metadata": {"window": "I think we do believe that prescription transaction volumes will be not as affected as the overall economy will \nbe.  And that's given us the confidence to really raise our revenue guide within that segment for the full year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Next will be Ricky Goldwasser with Morgan Stanley.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nYeah. ", "original_text": "A \nNext question.  \n ", "page_label": "17", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5fbf90aecde2fdebf7c93e5a880c2bcb3249fe24d231e75486c01b5032604b7a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5f09a005-f5e9-4fb9-b117-5da4a5032945", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Next will be Ricky Goldwasser with Morgan Stanley.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nYeah.  Hi.  Good morning. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co. "}, "hash": "241b980b02737bb8b4b64ab4086facc632d9d25bd7a60273dbe4c44cfce6a96e", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Next will be Ricky Goldwasser with Morgan Stanley.  \n ", "start_char_idx": 2710, "end_char_idx": 3049, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5f09a005-f5e9-4fb9-b117-5da4a5032945": {"__data__": {"id_": "5f09a005-f5e9-4fb9-b117-5da4a5032945", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Next will be Ricky Goldwasser with Morgan Stanley.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nYeah.  Hi.  Good morning. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co. ", "page_label": "17", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "48fdc39a-da73-45c6-ab0c-c60b396b0afe", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "54c669c4d49fd92cc4fdaf00dc78b331106bd223355e148c01a53e37ae582ea1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "94fb79a2-4b67-4b77-b942-ceacda8a12f6", "node_type": "1", "metadata": {"window": "And that's given us the confidence to really raise our revenue guide within that segment for the full year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Next will be Ricky Goldwasser with Morgan Stanley.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nYeah.  Hi. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Next will be Ricky Goldwasser with Morgan Stanley.  \n ", "page_label": "17", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "28e87045269bb6c96b67a2e81c147056336b6c22b344dd11ecf6326fdecb06b7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8b73cb46-f59d-4e5e-8262-9c23e984ada2", "node_type": "1", "metadata": {"window": "A \nNext question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Next will be Ricky Goldwasser with Morgan Stanley.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nYeah.  Hi.  Good morning.  So distribution of COVID vaccine captured headlines last week and we've been getting \nquestions from investors on what could the distribution infrastructure looks like. ", "original_text": "LLC  Q \nYeah. "}, "hash": "b12b55ddb7d6f914995557c635a45254b01ee948746b129f34b4e03f008d1da5", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co. ", "start_char_idx": 3049, "end_char_idx": 3373, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8b73cb46-f59d-4e5e-8262-9c23e984ada2": {"__data__": {"id_": "8b73cb46-f59d-4e5e-8262-9c23e984ada2", "embedding": null, "metadata": {"window": "A \nNext question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Next will be Ricky Goldwasser with Morgan Stanley.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nYeah.  Hi.  Good morning.  So distribution of COVID vaccine captured headlines last week and we've been getting \nquestions from investors on what could the distribution infrastructure looks like. ", "original_text": "LLC  Q \nYeah. ", "page_label": "17", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "48fdc39a-da73-45c6-ab0c-c60b396b0afe", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "54c669c4d49fd92cc4fdaf00dc78b331106bd223355e148c01a53e37ae582ea1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5f09a005-f5e9-4fb9-b117-5da4a5032945", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Next will be Ricky Goldwasser with Morgan Stanley.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nYeah.  Hi.  Good morning. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co. ", "page_label": "17", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "de622adec4f7e1d08e4ea16a9076cbc633fc64e2712af0e22f3acfbaf1f93bb3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "928c8a88-2188-4b48-90f7-a2d768420cfc", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Next will be Ricky Goldwasser with Morgan Stanley.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nYeah.  Hi.  Good morning.  So distribution of COVID vaccine captured headlines last week and we've been getting \nquestions from investors on what could the distribution infrastructure looks like.  Just wondering, how do you \nenvision distribution of COVID vaccine when available in the market? ", "original_text": "Hi. "}, "hash": "24916de5880461dd21f72666e3b59346e721eb9f23053514de597848f3c121e6", "class_name": "RelatedNodeInfo"}}, "text": "LLC  Q \nYeah. ", "start_char_idx": 3373, "end_char_idx": 3387, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "928c8a88-2188-4b48-90f7-a2d768420cfc": {"__data__": {"id_": "928c8a88-2188-4b48-90f7-a2d768420cfc", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Next will be Ricky Goldwasser with Morgan Stanley.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nYeah.  Hi.  Good morning.  So distribution of COVID vaccine captured headlines last week and we've been getting \nquestions from investors on what could the distribution infrastructure looks like.  Just wondering, how do you \nenvision distribution of COVID vaccine when available in the market? ", "original_text": "Hi. ", "page_label": "17", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "48fdc39a-da73-45c6-ab0c-c60b396b0afe", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "54c669c4d49fd92cc4fdaf00dc78b331106bd223355e148c01a53e37ae582ea1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8b73cb46-f59d-4e5e-8262-9c23e984ada2", "node_type": "1", "metadata": {"window": "A \nNext question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Next will be Ricky Goldwasser with Morgan Stanley.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nYeah.  Hi.  Good morning.  So distribution of COVID vaccine captured headlines last week and we've been getting \nquestions from investors on what could the distribution infrastructure looks like. ", "original_text": "LLC  Q \nYeah. ", "page_label": "17", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7ff536a67cd2b20443a644f5dfe0a3a85cf690b221e6397a709a6b1aa754efdc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7be13def-33ab-41c2-9f6e-26992141f21b", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nYeah.  Hi.  Good morning.  So distribution of COVID vaccine captured headlines last week and we've been getting \nquestions from investors on what could the distribution infrastructure looks like.  Just wondering, how do you \nenvision distribution of COVID vaccine when available in the market?  Where would it be adminis tered? ", "original_text": "Good morning. "}, "hash": "78c073548c3d1aa243f54ae87ae212218c2e3502e02e9c42f02cc997a03ac126", "class_name": "RelatedNodeInfo"}}, "text": "Hi. ", "start_char_idx": 3387, "end_char_idx": 3391, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7be13def-33ab-41c2-9f6e-26992141f21b": {"__data__": {"id_": "7be13def-33ab-41c2-9f6e-26992141f21b", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nYeah.  Hi.  Good morning.  So distribution of COVID vaccine captured headlines last week and we've been getting \nquestions from investors on what could the distribution infrastructure looks like.  Just wondering, how do you \nenvision distribution of COVID vaccine when available in the market?  Where would it be adminis tered? ", "original_text": "Good morning. ", "page_label": "17", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "48fdc39a-da73-45c6-ab0c-c60b396b0afe", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "54c669c4d49fd92cc4fdaf00dc78b331106bd223355e148c01a53e37ae582ea1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "928c8a88-2188-4b48-90f7-a2d768420cfc", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Next will be Ricky Goldwasser with Morgan Stanley.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nYeah.  Hi.  Good morning.  So distribution of COVID vaccine captured headlines last week and we've been getting \nquestions from investors on what could the distribution infrastructure looks like.  Just wondering, how do you \nenvision distribution of COVID vaccine when available in the market? ", "original_text": "Hi. ", "page_label": "17", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a45e3e3667d306ce6f5c9c2bf41b1fc4c1c506f828af6e224fdb20b64418b246", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "49db94ac-a208-4910-a16d-3bd5c2062332", "node_type": "1", "metadata": {"window": "LLC  Q \nYeah.  Hi.  Good morning.  So distribution of COVID vaccine captured headlines last week and we've been getting \nquestions from investors on what could the distribution infrastructure looks like.  Just wondering, how do you \nenvision distribution of COVID vaccine when available in the market?  Where would it be adminis tered?  And what \nrole would McKesson have?  \n ", "original_text": "So distribution of COVID vaccine captured headlines last week and we've been getting \nquestions from investors on what could the distribution infrastructure looks like. "}, "hash": "af8913cfcaf7e4ed8f9dba51fe81155c0b12b0593376cf18928e091231b7325d", "class_name": "RelatedNodeInfo"}}, "text": "Good morning. ", "start_char_idx": 251, "end_char_idx": 265, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "49db94ac-a208-4910-a16d-3bd5c2062332": {"__data__": {"id_": "49db94ac-a208-4910-a16d-3bd5c2062332", "embedding": null, "metadata": {"window": "LLC  Q \nYeah.  Hi.  Good morning.  So distribution of COVID vaccine captured headlines last week and we've been getting \nquestions from investors on what could the distribution infrastructure looks like.  Just wondering, how do you \nenvision distribution of COVID vaccine when available in the market?  Where would it be adminis tered?  And what \nrole would McKesson have?  \n ", "original_text": "So distribution of COVID vaccine captured headlines last week and we've been getting \nquestions from investors on what could the distribution infrastructure looks like. ", "page_label": "17", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "48fdc39a-da73-45c6-ab0c-c60b396b0afe", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "54c669c4d49fd92cc4fdaf00dc78b331106bd223355e148c01a53e37ae582ea1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7be13def-33ab-41c2-9f6e-26992141f21b", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nYeah.  Hi.  Good morning.  So distribution of COVID vaccine captured headlines last week and we've been getting \nquestions from investors on what could the distribution infrastructure looks like.  Just wondering, how do you \nenvision distribution of COVID vaccine when available in the market?  Where would it be adminis tered? ", "original_text": "Good morning. ", "page_label": "17", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0dc60ee6a59830410f231cf7c9f13b1f53a1b0c599ef3e16f9d86b8949238fb3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a029fff3-61ab-4bcb-97f7-23fb996f1a27", "node_type": "1", "metadata": {"window": "Hi.  Good morning.  So distribution of COVID vaccine captured headlines last week and we've been getting \nquestions from investors on what could the distribution infrastructure looks like.  Just wondering, how do you \nenvision distribution of COVID vaccine when available in the market?  Where would it be adminis tered?  And what \nrole would McKesson have?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "Just wondering, how do you \nenvision distribution of COVID vaccine when available in the market? "}, "hash": "21b83eb43fd0ab8919a8732705c3877fa53fc1c66bbb195a0f87745ee2b7fe2d", "class_name": "RelatedNodeInfo"}}, "text": "So distribution of COVID vaccine captured headlines last week and we've been getting \nquestions from investors on what could the distribution infrastructure looks like. ", "start_char_idx": 3405, "end_char_idx": 3574, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a029fff3-61ab-4bcb-97f7-23fb996f1a27": {"__data__": {"id_": "a029fff3-61ab-4bcb-97f7-23fb996f1a27", "embedding": null, "metadata": {"window": "Hi.  Good morning.  So distribution of COVID vaccine captured headlines last week and we've been getting \nquestions from investors on what could the distribution infrastructure looks like.  Just wondering, how do you \nenvision distribution of COVID vaccine when available in the market?  Where would it be adminis tered?  And what \nrole would McKesson have?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "Just wondering, how do you \nenvision distribution of COVID vaccine when available in the market? ", "page_label": "17", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "48fdc39a-da73-45c6-ab0c-c60b396b0afe", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "54c669c4d49fd92cc4fdaf00dc78b331106bd223355e148c01a53e37ae582ea1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "49db94ac-a208-4910-a16d-3bd5c2062332", "node_type": "1", "metadata": {"window": "LLC  Q \nYeah.  Hi.  Good morning.  So distribution of COVID vaccine captured headlines last week and we've been getting \nquestions from investors on what could the distribution infrastructure looks like.  Just wondering, how do you \nenvision distribution of COVID vaccine when available in the market?  Where would it be adminis tered?  And what \nrole would McKesson have?  \n ", "original_text": "So distribution of COVID vaccine captured headlines last week and we've been getting \nquestions from investors on what could the distribution infrastructure looks like. ", "page_label": "17", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "22276b1094deb0dd84efb9ecec8d3c6ff3cde1c1a455ece6307e7a16728d546f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4f804246-d76d-48ce-b522-dab4991efa2c", "node_type": "1", "metadata": {"window": "Good morning.  So distribution of COVID vaccine captured headlines last week and we've been getting \nquestions from investors on what could the distribution infrastructure looks like.  Just wondering, how do you \nenvision distribution of COVID vaccine when available in the market?  Where would it be adminis tered?  And what \nrole would McKesson have?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThank you, Ricky. ", "original_text": "Where would it be adminis tered? "}, "hash": "a3f7a4ef55c0f5aaf28b85f27476efa2e841546b25887b52dda7463f2c58799d", "class_name": "RelatedNodeInfo"}}, "text": "Just wondering, how do you \nenvision distribution of COVID vaccine when available in the market? ", "start_char_idx": 3574, "end_char_idx": 3671, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4f804246-d76d-48ce-b522-dab4991efa2c": {"__data__": {"id_": "4f804246-d76d-48ce-b522-dab4991efa2c", "embedding": null, "metadata": {"window": "Good morning.  So distribution of COVID vaccine captured headlines last week and we've been getting \nquestions from investors on what could the distribution infrastructure looks like.  Just wondering, how do you \nenvision distribution of COVID vaccine when available in the market?  Where would it be adminis tered?  And what \nrole would McKesson have?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThank you, Ricky. ", "original_text": "Where would it be adminis tered? ", "page_label": "17", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "48fdc39a-da73-45c6-ab0c-c60b396b0afe", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "54c669c4d49fd92cc4fdaf00dc78b331106bd223355e148c01a53e37ae582ea1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a029fff3-61ab-4bcb-97f7-23fb996f1a27", "node_type": "1", "metadata": {"window": "Hi.  Good morning.  So distribution of COVID vaccine captured headlines last week and we've been getting \nquestions from investors on what could the distribution infrastructure looks like.  Just wondering, how do you \nenvision distribution of COVID vaccine when available in the market?  Where would it be adminis tered?  And what \nrole would McKesson have?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "Just wondering, how do you \nenvision distribution of COVID vaccine when available in the market? ", "page_label": "17", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fe5acfb64bfea6d211d5a4564d18f0b44de4148ca98cf54f4c13f69d9243941e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f8cb5524-d4ca-4d22-9636-bdded29e16c2", "node_type": "1", "metadata": {"window": "So distribution of COVID vaccine captured headlines last week and we've been getting \nquestions from investors on what could the distribution infrastructure looks like.  Just wondering, how do you \nenvision distribution of COVID vaccine when available in the market?  Where would it be adminis tered?  And what \nrole would McKesson have?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThank you, Ricky.  It's early days, I think, to forecast, a, when the vaccine will be available, which manufacturer, it \nmight be available from and what the best method of distribution for that vaccine will be. ", "original_text": "And what \nrole would McKesson have?  \n "}, "hash": "9e3f4d5b42dcb6635c266749f346c66e5e8f79ac9bd5e5d524865bdd4d132e74", "class_name": "RelatedNodeInfo"}}, "text": "Where would it be adminis tered? ", "start_char_idx": 3671, "end_char_idx": 3704, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f8cb5524-d4ca-4d22-9636-bdded29e16c2": {"__data__": {"id_": "f8cb5524-d4ca-4d22-9636-bdded29e16c2", "embedding": null, "metadata": {"window": "So distribution of COVID vaccine captured headlines last week and we've been getting \nquestions from investors on what could the distribution infrastructure looks like.  Just wondering, how do you \nenvision distribution of COVID vaccine when available in the market?  Where would it be adminis tered?  And what \nrole would McKesson have?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThank you, Ricky.  It's early days, I think, to forecast, a, when the vaccine will be available, which manufacturer, it \nmight be available from and what the best method of distribution for that vaccine will be. ", "original_text": "And what \nrole would McKesson have?  \n ", "page_label": "17", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "48fdc39a-da73-45c6-ab0c-c60b396b0afe", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "54c669c4d49fd92cc4fdaf00dc78b331106bd223355e148c01a53e37ae582ea1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4f804246-d76d-48ce-b522-dab4991efa2c", "node_type": "1", "metadata": {"window": "Good morning.  So distribution of COVID vaccine captured headlines last week and we've been getting \nquestions from investors on what could the distribution infrastructure looks like.  Just wondering, how do you \nenvision distribution of COVID vaccine when available in the market?  Where would it be adminis tered?  And what \nrole would McKesson have?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThank you, Ricky. ", "original_text": "Where would it be adminis tered? ", "page_label": "17", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e01e74778e861902a7cfa3ca81285e29b1f8da7dd2cf4e3e9cf8967e215883dc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f327913d-07d4-455d-a06a-a54acad37849", "node_type": "1", "metadata": {"window": "Just wondering, how do you \nenvision distribution of COVID vaccine when available in the market?  Where would it be adminis tered?  And what \nrole would McKesson have?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThank you, Ricky.  It's early days, I think, to forecast, a, when the vaccine will be available, which manufacturer, it \nmight be available from and what the best method of distribution for that vaccine will be.  You're as aware as I am, \nthere's over 100 vaccines, close to 150 in development. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  "}, "hash": "d96a1175c2ba1d8bd2a9078615d75a691e6fd871c23e23a50e502087207cec45", "class_name": "RelatedNodeInfo"}}, "text": "And what \nrole would McKesson have?  \n ", "start_char_idx": 3704, "end_char_idx": 3743, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f327913d-07d4-455d-a06a-a54acad37849": {"__data__": {"id_": "f327913d-07d4-455d-a06a-a54acad37849", "embedding": null, "metadata": {"window": "Just wondering, how do you \nenvision distribution of COVID vaccine when available in the market?  Where would it be adminis tered?  And what \nrole would McKesson have?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThank you, Ricky.  It's early days, I think, to forecast, a, when the vaccine will be available, which manufacturer, it \nmight be available from and what the best method of distribution for that vaccine will be.  You're as aware as I am, \nthere's over 100 vaccines, close to 150 in development. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "17", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "48fdc39a-da73-45c6-ab0c-c60b396b0afe", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "54c669c4d49fd92cc4fdaf00dc78b331106bd223355e148c01a53e37ae582ea1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f8cb5524-d4ca-4d22-9636-bdded29e16c2", "node_type": "1", "metadata": {"window": "So distribution of COVID vaccine captured headlines last week and we've been getting \nquestions from investors on what could the distribution infrastructure looks like.  Just wondering, how do you \nenvision distribution of COVID vaccine when available in the market?  Where would it be adminis tered?  And what \nrole would McKesson have?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThank you, Ricky.  It's early days, I think, to forecast, a, when the vaccine will be available, which manufacturer, it \nmight be available from and what the best method of distribution for that vaccine will be. ", "original_text": "And what \nrole would McKesson have?  \n ", "page_label": "17", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ad96d7a0b25f2612fef8334f8110ebb8e2c2f19fedbb1609af1a7a0d133c1754", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "37514ab9-c9ca-401a-bd0e-67ac47d1239a", "node_type": "1", "metadata": {"window": "Where would it be adminis tered?  And what \nrole would McKesson have?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThank you, Ricky.  It's early days, I think, to forecast, a, when the vaccine will be available, which manufacturer, it \nmight be available from and what the best method of distribution for that vaccine will be.  You're as aware as I am, \nthere's over 100 vaccines, close to 150 in development.  There's probably 10 to 20 at the front end of that funnel. \n", "original_text": "A \nThank you, Ricky. "}, "hash": "0631ddf27d8e7ea9ce07efa2a634e4cd6fc3189c2203c371f76d158d90771cea", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "start_char_idx": 3743, "end_char_idx": 4084, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "37514ab9-c9ca-401a-bd0e-67ac47d1239a": {"__data__": {"id_": "37514ab9-c9ca-401a-bd0e-67ac47d1239a", "embedding": null, "metadata": {"window": "Where would it be adminis tered?  And what \nrole would McKesson have?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThank you, Ricky.  It's early days, I think, to forecast, a, when the vaccine will be available, which manufacturer, it \nmight be available from and what the best method of distribution for that vaccine will be.  You're as aware as I am, \nthere's over 100 vaccines, close to 150 in development.  There's probably 10 to 20 at the front end of that funnel. \n", "original_text": "A \nThank you, Ricky. ", "page_label": "17", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "48fdc39a-da73-45c6-ab0c-c60b396b0afe", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "54c669c4d49fd92cc4fdaf00dc78b331106bd223355e148c01a53e37ae582ea1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f327913d-07d4-455d-a06a-a54acad37849", "node_type": "1", "metadata": {"window": "Just wondering, how do you \nenvision distribution of COVID vaccine when available in the market?  Where would it be adminis tered?  And what \nrole would McKesson have?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThank you, Ricky.  It's early days, I think, to forecast, a, when the vaccine will be available, which manufacturer, it \nmight be available from and what the best method of distribution for that vaccine will be.  You're as aware as I am, \nthere's over 100 vaccines, close to 150 in development. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "17", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "775da3b42540d650fbda929a481ea8f3af8733f29c2fd1b29d83bb6ec53e6536", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "586a3a93-62fe-476b-a34b-3c919278389b", "node_type": "1", "metadata": {"window": "And what \nrole would McKesson have?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThank you, Ricky.  It's early days, I think, to forecast, a, when the vaccine will be available, which manufacturer, it \nmight be available from and what the best method of distribution for that vaccine will be.  You're as aware as I am, \nthere's over 100 vaccines, close to 150 in development.  There's probably 10 to 20 at the front end of that funnel. \n We continue to work closely and are in discussion s with all of those \u2013 all of the manufacturers around these \nvaccines.  \n \n", "original_text": "It's early days, I think, to forecast, a, when the vaccine will be available, which manufacturer, it \nmight be available from and what the best method of distribution for that vaccine will be. "}, "hash": "118faff8fa622a2365a707ad099f4e159473b6c0ebd3f0ca1eff6021449a36d1", "class_name": "RelatedNodeInfo"}}, "text": "A \nThank you, Ricky. ", "start_char_idx": 4084, "end_char_idx": 4105, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "586a3a93-62fe-476b-a34b-3c919278389b": {"__data__": {"id_": "586a3a93-62fe-476b-a34b-3c919278389b", "embedding": null, "metadata": {"window": "And what \nrole would McKesson have?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThank you, Ricky.  It's early days, I think, to forecast, a, when the vaccine will be available, which manufacturer, it \nmight be available from and what the best method of distribution for that vaccine will be.  You're as aware as I am, \nthere's over 100 vaccines, close to 150 in development.  There's probably 10 to 20 at the front end of that funnel. \n We continue to work closely and are in discussion s with all of those \u2013 all of the manufacturers around these \nvaccines.  \n \n", "original_text": "It's early days, I think, to forecast, a, when the vaccine will be available, which manufacturer, it \nmight be available from and what the best method of distribution for that vaccine will be. ", "page_label": "17", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "48fdc39a-da73-45c6-ab0c-c60b396b0afe", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "54c669c4d49fd92cc4fdaf00dc78b331106bd223355e148c01a53e37ae582ea1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "37514ab9-c9ca-401a-bd0e-67ac47d1239a", "node_type": "1", "metadata": {"window": "Where would it be adminis tered?  And what \nrole would McKesson have?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThank you, Ricky.  It's early days, I think, to forecast, a, when the vaccine will be available, which manufacturer, it \nmight be available from and what the best method of distribution for that vaccine will be.  You're as aware as I am, \nthere's over 100 vaccines, close to 150 in development.  There's probably 10 to 20 at the front end of that funnel. \n", "original_text": "A \nThank you, Ricky. ", "page_label": "17", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3bf3f908365723455eacc1cec79464ce26eea9272b9ad5c5009f92388fe9255d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b3d6ea29-a146-4a01-b97c-2ce808e0ba5d", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThank you, Ricky.  It's early days, I think, to forecast, a, when the vaccine will be available, which manufacturer, it \nmight be available from and what the best method of distribution for that vaccine will be.  You're as aware as I am, \nthere's over 100 vaccines, close to 150 in development.  There's probably 10 to 20 at the front end of that funnel. \n We continue to work closely and are in discussion s with all of those \u2013 all of the manufacturers around these \nvaccines.  \n \n Our company has a great capability in this area. ", "original_text": "You're as aware as I am, \nthere's over 100 vaccines, close to 150 in development. "}, "hash": "25f5e23346754a1abc7fc1645223c159886133ed174c62b11bcfb10d3ddfd080", "class_name": "RelatedNodeInfo"}}, "text": "It's early days, I think, to forecast, a, when the vaccine will be available, which manufacturer, it \nmight be available from and what the best method of distribution for that vaccine will be. ", "start_char_idx": 4105, "end_char_idx": 4298, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b3d6ea29-a146-4a01-b97c-2ce808e0ba5d": {"__data__": {"id_": "b3d6ea29-a146-4a01-b97c-2ce808e0ba5d", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThank you, Ricky.  It's early days, I think, to forecast, a, when the vaccine will be available, which manufacturer, it \nmight be available from and what the best method of distribution for that vaccine will be.  You're as aware as I am, \nthere's over 100 vaccines, close to 150 in development.  There's probably 10 to 20 at the front end of that funnel. \n We continue to work closely and are in discussion s with all of those \u2013 all of the manufacturers around these \nvaccines.  \n \n Our company has a great capability in this area. ", "original_text": "You're as aware as I am, \nthere's over 100 vaccines, close to 150 in development. ", "page_label": "17", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "48fdc39a-da73-45c6-ab0c-c60b396b0afe", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "54c669c4d49fd92cc4fdaf00dc78b331106bd223355e148c01a53e37ae582ea1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "586a3a93-62fe-476b-a34b-3c919278389b", "node_type": "1", "metadata": {"window": "And what \nrole would McKesson have?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThank you, Ricky.  It's early days, I think, to forecast, a, when the vaccine will be available, which manufacturer, it \nmight be available from and what the best method of distribution for that vaccine will be.  You're as aware as I am, \nthere's over 100 vaccines, close to 150 in development.  There's probably 10 to 20 at the front end of that funnel. \n We continue to work closely and are in discussion s with all of those \u2013 all of the manufacturers around these \nvaccines.  \n \n", "original_text": "It's early days, I think, to forecast, a, when the vaccine will be available, which manufacturer, it \nmight be available from and what the best method of distribution for that vaccine will be. ", "page_label": "17", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d4f57de1638385cd56177a426f5a8cc3f40ca0f8ce88eb3f8578fc5bd63d3e0e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e3671f8d-f163-41c2-ae74-b6b5999d9781", "node_type": "1", "metadata": {"window": "A \nThank you, Ricky.  It's early days, I think, to forecast, a, when the vaccine will be available, which manufacturer, it \nmight be available from and what the best method of distribution for that vaccine will be.  You're as aware as I am, \nthere's over 100 vaccines, close to 150 in development.  There's probably 10 to 20 at the front end of that funnel. \n We continue to work closely and are in discussion s with all of those \u2013 all of the manufacturers around these \nvaccines.  \n \n Our company has a great capability in this area.  We administer the vaccines for children's program today. ", "original_text": "There's probably 10 to 20 at the front end of that funnel. \n"}, "hash": "39222dd7ccb096fbb584cb1240a03d97f6977426209c0d311bd526be6d76d53e", "class_name": "RelatedNodeInfo"}}, "text": "You're as aware as I am, \nthere's over 100 vaccines, close to 150 in development. ", "start_char_idx": 4298, "end_char_idx": 4380, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e3671f8d-f163-41c2-ae74-b6b5999d9781": {"__data__": {"id_": "e3671f8d-f163-41c2-ae74-b6b5999d9781", "embedding": null, "metadata": {"window": "A \nThank you, Ricky.  It's early days, I think, to forecast, a, when the vaccine will be available, which manufacturer, it \nmight be available from and what the best method of distribution for that vaccine will be.  You're as aware as I am, \nthere's over 100 vaccines, close to 150 in development.  There's probably 10 to 20 at the front end of that funnel. \n We continue to work closely and are in discussion s with all of those \u2013 all of the manufacturers around these \nvaccines.  \n \n Our company has a great capability in this area.  We administer the vaccines for children's program today. ", "original_text": "There's probably 10 to 20 at the front end of that funnel. \n", "page_label": "17", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "48fdc39a-da73-45c6-ab0c-c60b396b0afe", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "54c669c4d49fd92cc4fdaf00dc78b331106bd223355e148c01a53e37ae582ea1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b3d6ea29-a146-4a01-b97c-2ce808e0ba5d", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThank you, Ricky.  It's early days, I think, to forecast, a, when the vaccine will be available, which manufacturer, it \nmight be available from and what the best method of distribution for that vaccine will be.  You're as aware as I am, \nthere's over 100 vaccines, close to 150 in development.  There's probably 10 to 20 at the front end of that funnel. \n We continue to work closely and are in discussion s with all of those \u2013 all of the manufacturers around these \nvaccines.  \n \n Our company has a great capability in this area. ", "original_text": "You're as aware as I am, \nthere's over 100 vaccines, close to 150 in development. ", "page_label": "17", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5a6e4e6d6d54a9135efa93eb545f084afd2edb515ba6cd649f870e92bc54301a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "634435f1-0787-4e15-a578-8d8d7438e062", "node_type": "1", "metadata": {"window": "It's early days, I think, to forecast, a, when the vaccine will be available, which manufacturer, it \nmight be available from and what the best method of distribution for that vaccine will be.  You're as aware as I am, \nthere's over 100 vaccines, close to 150 in development.  There's probably 10 to 20 at the front end of that funnel. \n We continue to work closely and are in discussion s with all of those \u2013 all of the manufacturers around these \nvaccines.  \n \n Our company has a great capability in this area.  We administer the vaccines for children's program today.  We \nobviously have large channels in the medical business and in the pharmaceuti cal business that support ", "original_text": "We continue to work closely and are in discussion s with all of those \u2013 all of the manufacturers around these \nvaccines.  \n \n"}, "hash": "6c37b181f2dec72ccee4960e331a898582f800f83d4143f151acbb092f937483", "class_name": "RelatedNodeInfo"}}, "text": "There's probably 10 to 20 at the front end of that funnel. \n", "start_char_idx": 4380, "end_char_idx": 4440, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "634435f1-0787-4e15-a578-8d8d7438e062": {"__data__": {"id_": "634435f1-0787-4e15-a578-8d8d7438e062", "embedding": null, "metadata": {"window": "It's early days, I think, to forecast, a, when the vaccine will be available, which manufacturer, it \nmight be available from and what the best method of distribution for that vaccine will be.  You're as aware as I am, \nthere's over 100 vaccines, close to 150 in development.  There's probably 10 to 20 at the front end of that funnel. \n We continue to work closely and are in discussion s with all of those \u2013 all of the manufacturers around these \nvaccines.  \n \n Our company has a great capability in this area.  We administer the vaccines for children's program today.  We \nobviously have large channels in the medical business and in the pharmaceuti cal business that support ", "original_text": "We continue to work closely and are in discussion s with all of those \u2013 all of the manufacturers around these \nvaccines.  \n \n", "page_label": "17", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "48fdc39a-da73-45c6-ab0c-c60b396b0afe", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "54c669c4d49fd92cc4fdaf00dc78b331106bd223355e148c01a53e37ae582ea1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e3671f8d-f163-41c2-ae74-b6b5999d9781", "node_type": "1", "metadata": {"window": "A \nThank you, Ricky.  It's early days, I think, to forecast, a, when the vaccine will be available, which manufacturer, it \nmight be available from and what the best method of distribution for that vaccine will be.  You're as aware as I am, \nthere's over 100 vaccines, close to 150 in development.  There's probably 10 to 20 at the front end of that funnel. \n We continue to work closely and are in discussion s with all of those \u2013 all of the manufacturers around these \nvaccines.  \n \n Our company has a great capability in this area.  We administer the vaccines for children's program today. ", "original_text": "There's probably 10 to 20 at the front end of that funnel. \n", "page_label": "17", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2b7943cbce87574d1c9de48e026fbcf178b7202108d72d1e92bb1bd23a64787b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1835c038-c21b-4743-a987-c2967ad94589", "node_type": "1", "metadata": {"window": "You're as aware as I am, \nthere's over 100 vaccines, close to 150 in development.  There's probably 10 to 20 at the front end of that funnel. \n We continue to work closely and are in discussion s with all of those \u2013 all of the manufacturers around these \nvaccines.  \n \n Our company has a great capability in this area.  We administer the vaccines for children's program today.  We \nobviously have large channels in the medical business and in the pharmaceuti cal business that support ", "original_text": "Our company has a great capability in this area. "}, "hash": "821552dcd080e9b20cc239312e2a65085b4bc4904277dc41a7c05c1b282ddc23", "class_name": "RelatedNodeInfo"}}, "text": "We continue to work closely and are in discussion s with all of those \u2013 all of the manufacturers around these \nvaccines.  \n \n", "start_char_idx": 4440, "end_char_idx": 4565, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1835c038-c21b-4743-a987-c2967ad94589": {"__data__": {"id_": "1835c038-c21b-4743-a987-c2967ad94589", "embedding": null, "metadata": {"window": "You're as aware as I am, \nthere's over 100 vaccines, close to 150 in development.  There's probably 10 to 20 at the front end of that funnel. \n We continue to work closely and are in discussion s with all of those \u2013 all of the manufacturers around these \nvaccines.  \n \n Our company has a great capability in this area.  We administer the vaccines for children's program today.  We \nobviously have large channels in the medical business and in the pharmaceuti cal business that support ", "original_text": "Our company has a great capability in this area. ", "page_label": "17", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "48fdc39a-da73-45c6-ab0c-c60b396b0afe", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "54c669c4d49fd92cc4fdaf00dc78b331106bd223355e148c01a53e37ae582ea1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "634435f1-0787-4e15-a578-8d8d7438e062", "node_type": "1", "metadata": {"window": "It's early days, I think, to forecast, a, when the vaccine will be available, which manufacturer, it \nmight be available from and what the best method of distribution for that vaccine will be.  You're as aware as I am, \nthere's over 100 vaccines, close to 150 in development.  There's probably 10 to 20 at the front end of that funnel. \n We continue to work closely and are in discussion s with all of those \u2013 all of the manufacturers around these \nvaccines.  \n \n Our company has a great capability in this area.  We administer the vaccines for children's program today.  We \nobviously have large channels in the medical business and in the pharmaceuti cal business that support ", "original_text": "We continue to work closely and are in discussion s with all of those \u2013 all of the manufacturers around these \nvaccines.  \n \n", "page_label": "17", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5b6fb470c67c2fa3c9fd4ed1980ae749caaa78f7070a5d5a5860c4402f5ca73b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6f85e3a4-08be-4f8e-8a6e-7a10483fd7b8", "node_type": "1", "metadata": {"window": "There's probably 10 to 20 at the front end of that funnel. \n We continue to work closely and are in discussion s with all of those \u2013 all of the manufacturers around these \nvaccines.  \n \n Our company has a great capability in this area.  We administer the vaccines for children's program today.  We \nobviously have large channels in the medical business and in the pharmaceuti cal business that support ", "original_text": "We administer the vaccines for children's program today. "}, "hash": "346c67bacc1cfb9d8ae218d758c4c15e3d924c321908bf4b4ba26aa1ede82027", "class_name": "RelatedNodeInfo"}}, "text": "Our company has a great capability in this area. ", "start_char_idx": 4565, "end_char_idx": 4614, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6f85e3a4-08be-4f8e-8a6e-7a10483fd7b8": {"__data__": {"id_": "6f85e3a4-08be-4f8e-8a6e-7a10483fd7b8", "embedding": null, "metadata": {"window": "There's probably 10 to 20 at the front end of that funnel. \n We continue to work closely and are in discussion s with all of those \u2013 all of the manufacturers around these \nvaccines.  \n \n Our company has a great capability in this area.  We administer the vaccines for children's program today.  We \nobviously have large channels in the medical business and in the pharmaceuti cal business that support ", "original_text": "We administer the vaccines for children's program today. ", "page_label": "17", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "48fdc39a-da73-45c6-ab0c-c60b396b0afe", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "54c669c4d49fd92cc4fdaf00dc78b331106bd223355e148c01a53e37ae582ea1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1835c038-c21b-4743-a987-c2967ad94589", "node_type": "1", "metadata": {"window": "You're as aware as I am, \nthere's over 100 vaccines, close to 150 in development.  There's probably 10 to 20 at the front end of that funnel. \n We continue to work closely and are in discussion s with all of those \u2013 all of the manufacturers around these \nvaccines.  \n \n Our company has a great capability in this area.  We administer the vaccines for children's program today.  We \nobviously have large channels in the medical business and in the pharmaceuti cal business that support ", "original_text": "Our company has a great capability in this area. ", "page_label": "17", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "02b245b5324c40cab7e48e005518b4b2ca91c3407d6b0d5a584b571793498359", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b6229de3-07f4-4cf9-a5b2-89314a1f911f", "node_type": "1", "metadata": {"window": "We continue to work closely and are in discussion s with all of those \u2013 all of the manufacturers around these \nvaccines.  \n \n Our company has a great capability in this area.  We administer the vaccines for children's program today.  We \nobviously have large channels in the medical business and in the pharmaceuti cal business that support ", "original_text": "We \nobviously have large channels in the medical business and in the pharmaceuti cal business that support "}, "hash": "a2b531690e8f14513af61948ac0bfe5a06cee65d68f8dad332e347cc0ba2f9cf", "class_name": "RelatedNodeInfo"}}, "text": "We administer the vaccines for children's program today. ", "start_char_idx": 4614, "end_char_idx": 4671, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b6229de3-07f4-4cf9-a5b2-89314a1f911f": {"__data__": {"id_": "b6229de3-07f4-4cf9-a5b2-89314a1f911f", "embedding": null, "metadata": {"window": "We continue to work closely and are in discussion s with all of those \u2013 all of the manufacturers around these \nvaccines.  \n \n Our company has a great capability in this area.  We administer the vaccines for children's program today.  We \nobviously have large channels in the medical business and in the pharmaceuti cal business that support ", "original_text": "We \nobviously have large channels in the medical business and in the pharmaceuti cal business that support ", "page_label": "17", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "48fdc39a-da73-45c6-ab0c-c60b396b0afe", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "54c669c4d49fd92cc4fdaf00dc78b331106bd223355e148c01a53e37ae582ea1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6f85e3a4-08be-4f8e-8a6e-7a10483fd7b8", "node_type": "1", "metadata": {"window": "There's probably 10 to 20 at the front end of that funnel. \n We continue to work closely and are in discussion s with all of those \u2013 all of the manufacturers around these \nvaccines.  \n \n Our company has a great capability in this area.  We administer the vaccines for children's program today.  We \nobviously have large channels in the medical business and in the pharmaceuti cal business that support ", "original_text": "We administer the vaccines for children's program today. ", "page_label": "17", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fa9840d413e3dc399ebff24b12d2116ad24d598ceee15c20c6d282122192411e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5739b225-76cf-479e-ab2e-abcbd00ec555", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \ncommunity providers who administer these vaccines, and in over a decade ago, when our nation was dealing with \nH1N1, we continue \u2013 it's a proud moment in McKesson's history the role we were able to play in managing that \nvaccine sol ution.  \n \n So I think we have terrific capabilities.  We're in active dialogue with everybody. ", "original_text": "McKesson Corp.  "}, "hash": "1e39004724da3c79942498b4a91f88b135858f6207660739872f3846ccf9ae5f", "class_name": "RelatedNodeInfo"}}, "text": "We \nobviously have large channels in the medical business and in the pharmaceuti cal business that support ", "start_char_idx": 4671, "end_char_idx": 4778, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5739b225-76cf-479e-ab2e-abcbd00ec555": {"__data__": {"id_": "5739b225-76cf-479e-ab2e-abcbd00ec555", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \ncommunity providers who administer these vaccines, and in over a decade ago, when our nation was dealing with \nH1N1, we continue \u2013 it's a proud moment in McKesson's history the role we were able to play in managing that \nvaccine sol ution.  \n \n So I think we have terrific capabilities.  We're in active dialogue with everybody. ", "original_text": "McKesson Corp.  ", "page_label": "18", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5f4e4711-6225-48b4-92c3-167aa1459c03", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "59bf53b3a30aa3059b3a3153dbe7af9cfb8182b7df0a0ceb977941e976a43d80", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b6229de3-07f4-4cf9-a5b2-89314a1f911f", "node_type": "1", "metadata": {"window": "We continue to work closely and are in discussion s with all of those \u2013 all of the manufacturers around these \nvaccines.  \n \n Our company has a great capability in this area.  We administer the vaccines for children's program today.  We \nobviously have large channels in the medical business and in the pharmaceuti cal business that support ", "original_text": "We \nobviously have large channels in the medical business and in the pharmaceuti cal business that support ", "page_label": "17", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fdd8642fa85537dd38132caa0d66c317672450bca8320c9b311fc683180baaef", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "495c9cf0-b616-43af-8c5e-0dda3195c29a", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \ncommunity providers who administer these vaccines, and in over a decade ago, when our nation was dealing with \nH1N1, we continue \u2013 it's a proud moment in McKesson's history the role we were able to play in managing that \nvaccine sol ution.  \n \n So I think we have terrific capabilities.  We're in active dialogue with everybody.  Our first and foremost goal will be \nto do whatever we can do to help accelerate getting a vaccine to market. ", "original_text": "(MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \ncommunity providers who administer these vaccines, and in over a decade ago, when our nation was dealing with \nH1N1, we continue \u2013 it's a proud moment in McKesson's history the role we were able to play in managing that \nvaccine sol ution.  \n \n"}, "hash": "0eb6f14d375d73a89abbef741e5d6cefdaeac4efce065db29a7f259ac69b7765", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "495c9cf0-b616-43af-8c5e-0dda3195c29a": {"__data__": {"id_": "495c9cf0-b616-43af-8c5e-0dda3195c29a", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \ncommunity providers who administer these vaccines, and in over a decade ago, when our nation was dealing with \nH1N1, we continue \u2013 it's a proud moment in McKesson's history the role we were able to play in managing that \nvaccine sol ution.  \n \n So I think we have terrific capabilities.  We're in active dialogue with everybody.  Our first and foremost goal will be \nto do whatever we can do to help accelerate getting a vaccine to market. ", "original_text": "(MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \ncommunity providers who administer these vaccines, and in over a decade ago, when our nation was dealing with \nH1N1, we continue \u2013 it's a proud moment in McKesson's history the role we were able to play in managing that \nvaccine sol ution.  \n \n", "page_label": "18", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5f4e4711-6225-48b4-92c3-167aa1459c03", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "59bf53b3a30aa3059b3a3153dbe7af9cfb8182b7df0a0ceb977941e976a43d80", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5739b225-76cf-479e-ab2e-abcbd00ec555", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \ncommunity providers who administer these vaccines, and in over a decade ago, when our nation was dealing with \nH1N1, we continue \u2013 it's a proud moment in McKesson's history the role we were able to play in managing that \nvaccine sol ution.  \n \n So I think we have terrific capabilities.  We're in active dialogue with everybody. ", "original_text": "McKesson Corp.  ", "page_label": "18", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d6fd55f67a2cc89b60970dd5b81181ea3787fdfbdeacc0fc90da2dc768c06029", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c60176b9-e538-455b-ab45-b370db0f7971", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \ncommunity providers who administer these vaccines, and in over a decade ago, when our nation was dealing with \nH1N1, we continue \u2013 it's a proud moment in McKesson's history the role we were able to play in managing that \nvaccine sol ution.  \n \n So I think we have terrific capabilities.  We're in active dialogue with everybody.  Our first and foremost goal will be \nto do whatever we can do to help accelerate getting a vaccine to market.  That's the most important thing we can \ndo and what we're  focused on right now.  \n ", "original_text": "So I think we have terrific capabilities. "}, "hash": "e74fa851c4280d33de62c43035183a66dd4d0eedd83c527ee247f5b912c2c3a3", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \ncommunity providers who administer these vaccines, and in over a decade ago, when our nation was dealing with \nH1N1, we continue \u2013 it's a proud moment in McKesson's history the role we were able to play in managing that \nvaccine sol ution.  \n \n", "start_char_idx": 16, "end_char_idx": 425, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c60176b9-e538-455b-ab45-b370db0f7971": {"__data__": {"id_": "c60176b9-e538-455b-ab45-b370db0f7971", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \ncommunity providers who administer these vaccines, and in over a decade ago, when our nation was dealing with \nH1N1, we continue \u2013 it's a proud moment in McKesson's history the role we were able to play in managing that \nvaccine sol ution.  \n \n So I think we have terrific capabilities.  We're in active dialogue with everybody.  Our first and foremost goal will be \nto do whatever we can do to help accelerate getting a vaccine to market.  That's the most important thing we can \ndo and what we're  focused on right now.  \n ", "original_text": "So I think we have terrific capabilities. ", "page_label": "18", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5f4e4711-6225-48b4-92c3-167aa1459c03", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "59bf53b3a30aa3059b3a3153dbe7af9cfb8182b7df0a0ceb977941e976a43d80", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "495c9cf0-b616-43af-8c5e-0dda3195c29a", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \ncommunity providers who administer these vaccines, and in over a decade ago, when our nation was dealing with \nH1N1, we continue \u2013 it's a proud moment in McKesson's history the role we were able to play in managing that \nvaccine sol ution.  \n \n So I think we have terrific capabilities.  We're in active dialogue with everybody.  Our first and foremost goal will be \nto do whatever we can do to help accelerate getting a vaccine to market. ", "original_text": "(MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \ncommunity providers who administer these vaccines, and in over a decade ago, when our nation was dealing with \nH1N1, we continue \u2013 it's a proud moment in McKesson's history the role we were able to play in managing that \nvaccine sol ution.  \n \n", "page_label": "18", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "93aa68a5eaa2d427a06a40e582a1bd4aa7898511e965e961a727cf177ac037b2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bb308ae2-b105-4bbb-94b1-ebe036b2a16f", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \ncommunity providers who administer these vaccines, and in over a decade ago, when our nation was dealing with \nH1N1, we continue \u2013 it's a proud moment in McKesson's history the role we were able to play in managing that \nvaccine sol ution.  \n \n So I think we have terrific capabilities.  We're in active dialogue with everybody.  Our first and foremost goal will be \nto do whatever we can do to help accelerate getting a vaccine to market.  That's the most important thing we can \ndo and what we're  focused on right now.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  ", "original_text": "We're in active dialogue with everybody. "}, "hash": "9d149fd4ab9ab831a6beaf1f9e1829888bea851a45e73f81de28db39d5650063", "class_name": "RelatedNodeInfo"}}, "text": "So I think we have terrific capabilities. ", "start_char_idx": 425, "end_char_idx": 467, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bb308ae2-b105-4bbb-94b1-ebe036b2a16f": {"__data__": {"id_": "bb308ae2-b105-4bbb-94b1-ebe036b2a16f", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \ncommunity providers who administer these vaccines, and in over a decade ago, when our nation was dealing with \nH1N1, we continue \u2013 it's a proud moment in McKesson's history the role we were able to play in managing that \nvaccine sol ution.  \n \n So I think we have terrific capabilities.  We're in active dialogue with everybody.  Our first and foremost goal will be \nto do whatever we can do to help accelerate getting a vaccine to market.  That's the most important thing we can \ndo and what we're  focused on right now.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  ", "original_text": "We're in active dialogue with everybody. ", "page_label": "18", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5f4e4711-6225-48b4-92c3-167aa1459c03", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "59bf53b3a30aa3059b3a3153dbe7af9cfb8182b7df0a0ceb977941e976a43d80", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c60176b9-e538-455b-ab45-b370db0f7971", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \ncommunity providers who administer these vaccines, and in over a decade ago, when our nation was dealing with \nH1N1, we continue \u2013 it's a proud moment in McKesson's history the role we were able to play in managing that \nvaccine sol ution.  \n \n So I think we have terrific capabilities.  We're in active dialogue with everybody.  Our first and foremost goal will be \nto do whatever we can do to help accelerate getting a vaccine to market.  That's the most important thing we can \ndo and what we're  focused on right now.  \n ", "original_text": "So I think we have terrific capabilities. ", "page_label": "18", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "11124bfaabd7e1c73408cfff02322183ef10ceaa9250dd0fc94aa4f17805caae", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "73b3d175-75ef-450c-a511-98e6eef62683", "node_type": "1", "metadata": {"window": "(MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \ncommunity providers who administer these vaccines, and in over a decade ago, when our nation was dealing with \nH1N1, we continue \u2013 it's a proud moment in McKesson's history the role we were able to play in managing that \nvaccine sol ution.  \n \n So I think we have terrific capabilities.  We're in active dialogue with everybody.  Our first and foremost goal will be \nto do whatever we can do to help accelerate getting a vaccine to market.  That's the most important thing we can \ndo and what we're  focused on right now.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question?  \n ", "original_text": "Our first and foremost goal will be \nto do whatever we can do to help accelerate getting a vaccine to market. "}, "hash": "f232a920848113f15130b720dbedcbade253fe1984e354a1b7cad31c19d543d6", "class_name": "RelatedNodeInfo"}}, "text": "We're in active dialogue with everybody. ", "start_char_idx": 467, "end_char_idx": 508, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "73b3d175-75ef-450c-a511-98e6eef62683": {"__data__": {"id_": "73b3d175-75ef-450c-a511-98e6eef62683", "embedding": null, "metadata": {"window": "(MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \ncommunity providers who administer these vaccines, and in over a decade ago, when our nation was dealing with \nH1N1, we continue \u2013 it's a proud moment in McKesson's history the role we were able to play in managing that \nvaccine sol ution.  \n \n So I think we have terrific capabilities.  We're in active dialogue with everybody.  Our first and foremost goal will be \nto do whatever we can do to help accelerate getting a vaccine to market.  That's the most important thing we can \ndo and what we're  focused on right now.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question?  \n ", "original_text": "Our first and foremost goal will be \nto do whatever we can do to help accelerate getting a vaccine to market. ", "page_label": "18", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5f4e4711-6225-48b4-92c3-167aa1459c03", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "59bf53b3a30aa3059b3a3153dbe7af9cfb8182b7df0a0ceb977941e976a43d80", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bb308ae2-b105-4bbb-94b1-ebe036b2a16f", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \ncommunity providers who administer these vaccines, and in over a decade ago, when our nation was dealing with \nH1N1, we continue \u2013 it's a proud moment in McKesson's history the role we were able to play in managing that \nvaccine sol ution.  \n \n So I think we have terrific capabilities.  We're in active dialogue with everybody.  Our first and foremost goal will be \nto do whatever we can do to help accelerate getting a vaccine to market.  That's the most important thing we can \ndo and what we're  focused on right now.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  ", "original_text": "We're in active dialogue with everybody. ", "page_label": "18", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7635f4933f4e2472b8f4c3b20b442a5bd59bde68c82f95eea938f417cbe1e6cc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "30f9a185-e037-4fed-aa3e-a9c485934204", "node_type": "1", "metadata": {"window": "So I think we have terrific capabilities.  We're in active dialogue with everybody.  Our first and foremost goal will be \nto do whatever we can do to help accelerate getting a vaccine to market.  That's the most important thing we can \ndo and what we're  focused on right now.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Next will be Robert Jones with Goldman Sachs.  \n ", "original_text": "That's the most important thing we can \ndo and what we're  focused on right now.  \n "}, "hash": "3cbc09a2a3b3bb32919975a45626f01967a0d718eefee1e78f099357709b1b9d", "class_name": "RelatedNodeInfo"}}, "text": "Our first and foremost goal will be \nto do whatever we can do to help accelerate getting a vaccine to market. ", "start_char_idx": 508, "end_char_idx": 618, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "30f9a185-e037-4fed-aa3e-a9c485934204": {"__data__": {"id_": "30f9a185-e037-4fed-aa3e-a9c485934204", "embedding": null, "metadata": {"window": "So I think we have terrific capabilities.  We're in active dialogue with everybody.  Our first and foremost goal will be \nto do whatever we can do to help accelerate getting a vaccine to market.  That's the most important thing we can \ndo and what we're  focused on right now.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Next will be Robert Jones with Goldman Sachs.  \n ", "original_text": "That's the most important thing we can \ndo and what we're  focused on right now.  \n ", "page_label": "18", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5f4e4711-6225-48b4-92c3-167aa1459c03", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "59bf53b3a30aa3059b3a3153dbe7af9cfb8182b7df0a0ceb977941e976a43d80", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "73b3d175-75ef-450c-a511-98e6eef62683", "node_type": "1", "metadata": {"window": "(MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \ncommunity providers who administer these vaccines, and in over a decade ago, when our nation was dealing with \nH1N1, we continue \u2013 it's a proud moment in McKesson's history the role we were able to play in managing that \nvaccine sol ution.  \n \n So I think we have terrific capabilities.  We're in active dialogue with everybody.  Our first and foremost goal will be \nto do whatever we can do to help accelerate getting a vaccine to market.  That's the most important thing we can \ndo and what we're  focused on right now.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question?  \n ", "original_text": "Our first and foremost goal will be \nto do whatever we can do to help accelerate getting a vaccine to market. ", "page_label": "18", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9a36f850a52606119705ab1fa89599f072cd327d1209df1d1f2480d1bb7beb26", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "31776279-4cb7-4e3b-a12d-bcf90a131bd1", "node_type": "1", "metadata": {"window": "We're in active dialogue with everybody.  Our first and foremost goal will be \nto do whatever we can do to help accelerate getting a vaccine to market.  That's the most important thing we can \ndo and what we're  focused on right now.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Next will be Robert Jones with Goldman Sachs.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  "}, "hash": "00ae0d80f149b3be33955b0e62bec18bef6ea404bbf9e2df5025dfddb8e34442", "class_name": "RelatedNodeInfo"}}, "text": "That's the most important thing we can \ndo and what we're  focused on right now.  \n ", "start_char_idx": 618, "end_char_idx": 702, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "31776279-4cb7-4e3b-a12d-bcf90a131bd1": {"__data__": {"id_": "31776279-4cb7-4e3b-a12d-bcf90a131bd1", "embedding": null, "metadata": {"window": "We're in active dialogue with everybody.  Our first and foremost goal will be \nto do whatever we can do to help accelerate getting a vaccine to market.  That's the most important thing we can \ndo and what we're  focused on right now.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Next will be Robert Jones with Goldman Sachs.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  ", "page_label": "18", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5f4e4711-6225-48b4-92c3-167aa1459c03", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "59bf53b3a30aa3059b3a3153dbe7af9cfb8182b7df0a0ceb977941e976a43d80", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "30f9a185-e037-4fed-aa3e-a9c485934204", "node_type": "1", "metadata": {"window": "So I think we have terrific capabilities.  We're in active dialogue with everybody.  Our first and foremost goal will be \nto do whatever we can do to help accelerate getting a vaccine to market.  That's the most important thing we can \ndo and what we're  focused on right now.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Next will be Robert Jones with Goldman Sachs.  \n ", "original_text": "That's the most important thing we can \ndo and what we're  focused on right now.  \n ", "page_label": "18", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d814b6848222d55d07d6140bbd908368a4ecfeaadc5d6bc688c50f2087b87448", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "217faf87-922c-4258-88b0-6f29ccbd0ac1", "node_type": "1", "metadata": {"window": "Our first and foremost goal will be \nto do whatever we can do to help accelerate getting a vaccine to market.  That's the most important thing we can \ndo and what we're  focused on right now.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Next will be Robert Jones with Goldman Sachs.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co.  LLC  Q \nGreat. ", "original_text": "A \nNext question?  \n "}, "hash": "3a63adddff376148e8fb6ac306f141cb33c1b21bd254c46fd8cf6d4fc81de654", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  ", "start_char_idx": 702, "end_char_idx": 1047, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "217faf87-922c-4258-88b0-6f29ccbd0ac1": {"__data__": {"id_": "217faf87-922c-4258-88b0-6f29ccbd0ac1", "embedding": null, "metadata": {"window": "Our first and foremost goal will be \nto do whatever we can do to help accelerate getting a vaccine to market.  That's the most important thing we can \ndo and what we're  focused on right now.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Next will be Robert Jones with Goldman Sachs.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co.  LLC  Q \nGreat. ", "original_text": "A \nNext question?  \n ", "page_label": "18", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5f4e4711-6225-48b4-92c3-167aa1459c03", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "59bf53b3a30aa3059b3a3153dbe7af9cfb8182b7df0a0ceb977941e976a43d80", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "31776279-4cb7-4e3b-a12d-bcf90a131bd1", "node_type": "1", "metadata": {"window": "We're in active dialogue with everybody.  Our first and foremost goal will be \nto do whatever we can do to help accelerate getting a vaccine to market.  That's the most important thing we can \ndo and what we're  focused on right now.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Next will be Robert Jones with Goldman Sachs.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  ", "page_label": "18", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "827a2257100fe8063bd14c6b369b0948e83d51e7683b0e10bea2b5a53bb4d517", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5a0309b6-dde0-4a1c-8d7a-d4266fa42e1b", "node_type": "1", "metadata": {"window": "That's the most important thing we can \ndo and what we're  focused on right now.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Next will be Robert Jones with Goldman Sachs.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co.  LLC  Q \nGreat.  Thanks for the questions. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Next will be Robert Jones with Goldman Sachs.  \n "}, "hash": "bc29c2a3b0e3cd9c2971a4fc4a91ddc1bce5712f625a208a593db476a9e7de88", "class_name": "RelatedNodeInfo"}}, "text": "A \nNext question?  \n ", "start_char_idx": 1047, "end_char_idx": 1068, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5a0309b6-dde0-4a1c-8d7a-d4266fa42e1b": {"__data__": {"id_": "5a0309b6-dde0-4a1c-8d7a-d4266fa42e1b", "embedding": null, "metadata": {"window": "That's the most important thing we can \ndo and what we're  focused on right now.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Next will be Robert Jones with Goldman Sachs.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co.  LLC  Q \nGreat.  Thanks for the questions. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Next will be Robert Jones with Goldman Sachs.  \n ", "page_label": "18", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5f4e4711-6225-48b4-92c3-167aa1459c03", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "59bf53b3a30aa3059b3a3153dbe7af9cfb8182b7df0a0ceb977941e976a43d80", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "217faf87-922c-4258-88b0-6f29ccbd0ac1", "node_type": "1", "metadata": {"window": "Our first and foremost goal will be \nto do whatever we can do to help accelerate getting a vaccine to market.  That's the most important thing we can \ndo and what we're  focused on right now.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Next will be Robert Jones with Goldman Sachs.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co.  LLC  Q \nGreat. ", "original_text": "A \nNext question?  \n ", "page_label": "18", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "df737c4a3cc9c2b0fbad99f4252605da263e96fccbf827cb1aca490f53036795", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ee3a6fab-c610-4057-b246-f39c0af6eae3", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Next will be Robert Jones with Goldman Sachs.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co.  LLC  Q \nGreat.  Thanks for the questions.  I guess maybe just to follow -on to that. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co. "}, "hash": "f94bb490b7d34fbb6dc49f285b65da87551476f47bc3382b77b52ba5c7950ecb", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Next will be Robert Jones with Goldman Sachs.  \n ", "start_char_idx": 1068, "end_char_idx": 1402, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ee3a6fab-c610-4057-b246-f39c0af6eae3": {"__data__": {"id_": "ee3a6fab-c610-4057-b246-f39c0af6eae3", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Next will be Robert Jones with Goldman Sachs.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co.  LLC  Q \nGreat.  Thanks for the questions.  I guess maybe just to follow -on to that. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co. ", "page_label": "18", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5f4e4711-6225-48b4-92c3-167aa1459c03", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "59bf53b3a30aa3059b3a3153dbe7af9cfb8182b7df0a0ceb977941e976a43d80", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5a0309b6-dde0-4a1c-8d7a-d4266fa42e1b", "node_type": "1", "metadata": {"window": "That's the most important thing we can \ndo and what we're  focused on right now.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Next will be Robert Jones with Goldman Sachs.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co.  LLC  Q \nGreat.  Thanks for the questions. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Next will be Robert Jones with Goldman Sachs.  \n ", "page_label": "18", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "59e37fd5ab181605869f8c9dddaf07426dd55f8e482e587354e34be5761c0c3a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3442a671-4a97-4116-8b3a-4f037362502a", "node_type": "1", "metadata": {"window": "A \nNext question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Next will be Robert Jones with Goldman Sachs.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co.  LLC  Q \nGreat.  Thanks for the questions.  I guess maybe just to follow -on to that.  There seems to be a view that flu \nvaccines will be much higher utilized this year than in a normal year. ", "original_text": "LLC  Q \nGreat. "}, "hash": "196affc4eaa2a682a5f20b907466ccc7bfa740f4bcd890309d28c310a260324f", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co. ", "start_char_idx": 1402, "end_char_idx": 1721, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3442a671-4a97-4116-8b3a-4f037362502a": {"__data__": {"id_": "3442a671-4a97-4116-8b3a-4f037362502a", "embedding": null, "metadata": {"window": "A \nNext question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Next will be Robert Jones with Goldman Sachs.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co.  LLC  Q \nGreat.  Thanks for the questions.  I guess maybe just to follow -on to that.  There seems to be a view that flu \nvaccines will be much higher utilized this year than in a normal year. ", "original_text": "LLC  Q \nGreat. ", "page_label": "18", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5f4e4711-6225-48b4-92c3-167aa1459c03", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "59bf53b3a30aa3059b3a3153dbe7af9cfb8182b7df0a0ceb977941e976a43d80", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ee3a6fab-c610-4057-b246-f39c0af6eae3", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Next will be Robert Jones with Goldman Sachs.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co.  LLC  Q \nGreat.  Thanks for the questions.  I guess maybe just to follow -on to that. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co. ", "page_label": "18", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0b3e7e3785396d50f185c4848ea9831e3344603267451f3a54a8b444c5ac4f13", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f579cd8d-9962-4cbd-a62e-0557f92b996a", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Next will be Robert Jones with Goldman Sachs.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co.  LLC  Q \nGreat.  Thanks for the questions.  I guess maybe just to follow -on to that.  There seems to be a view that flu \nvaccines will be much higher utilized this year than in a normal year.  So just curious how you're thinking about \nthat and what's factored into guidance?  \n \n", "original_text": "Thanks for the questions. "}, "hash": "f6bb57f15010c989b054e95a91d0d26860f9e1cbe88fa4262258f6f744892820", "class_name": "RelatedNodeInfo"}}, "text": "LLC  Q \nGreat. ", "start_char_idx": 1721, "end_char_idx": 1736, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f579cd8d-9962-4cbd-a62e-0557f92b996a": {"__data__": {"id_": "f579cd8d-9962-4cbd-a62e-0557f92b996a", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Next will be Robert Jones with Goldman Sachs.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co.  LLC  Q \nGreat.  Thanks for the questions.  I guess maybe just to follow -on to that.  There seems to be a view that flu \nvaccines will be much higher utilized this year than in a normal year.  So just curious how you're thinking about \nthat and what's factored into guidance?  \n \n", "original_text": "Thanks for the questions. ", "page_label": "18", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5f4e4711-6225-48b4-92c3-167aa1459c03", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "59bf53b3a30aa3059b3a3153dbe7af9cfb8182b7df0a0ceb977941e976a43d80", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3442a671-4a97-4116-8b3a-4f037362502a", "node_type": "1", "metadata": {"window": "A \nNext question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Next will be Robert Jones with Goldman Sachs.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co.  LLC  Q \nGreat.  Thanks for the questions.  I guess maybe just to follow -on to that.  There seems to be a view that flu \nvaccines will be much higher utilized this year than in a normal year. ", "original_text": "LLC  Q \nGreat. ", "page_label": "18", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4d9263c91aec74d07cea8703f0d06dd8ade43f9ab9a65331863928d18ea35ff9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ee764432-b0f0-4db5-9e84-66db222b075d", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co.  LLC  Q \nGreat.  Thanks for the questions.  I guess maybe just to follow -on to that.  There seems to be a view that flu \nvaccines will be much higher utilized this year than in a normal year.  So just curious how you're thinking about \nthat and what's factored into guidance?  \n \n And then -- and Brian, you made a comment during the prepared remarks around lab testing, and the opportunity \nthat McKesson is playing in just the COVID testing process. ", "original_text": "I guess maybe just to follow -on to that. "}, "hash": "d271d9c079dd9fcc7cd010f522d7c63f6629b71435fb3244db3985181e952b5e", "class_name": "RelatedNodeInfo"}}, "text": "Thanks for the questions. ", "start_char_idx": 1736, "end_char_idx": 1762, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ee764432-b0f0-4db5-9e84-66db222b075d": {"__data__": {"id_": "ee764432-b0f0-4db5-9e84-66db222b075d", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co.  LLC  Q \nGreat.  Thanks for the questions.  I guess maybe just to follow -on to that.  There seems to be a view that flu \nvaccines will be much higher utilized this year than in a normal year.  So just curious how you're thinking about \nthat and what's factored into guidance?  \n \n And then -- and Brian, you made a comment during the prepared remarks around lab testing, and the opportunity \nthat McKesson is playing in just the COVID testing process. ", "original_text": "I guess maybe just to follow -on to that. ", "page_label": "18", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5f4e4711-6225-48b4-92c3-167aa1459c03", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "59bf53b3a30aa3059b3a3153dbe7af9cfb8182b7df0a0ceb977941e976a43d80", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f579cd8d-9962-4cbd-a62e-0557f92b996a", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Next will be Robert Jones with Goldman Sachs.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co.  LLC  Q \nGreat.  Thanks for the questions.  I guess maybe just to follow -on to that.  There seems to be a view that flu \nvaccines will be much higher utilized this year than in a normal year.  So just curious how you're thinking about \nthat and what's factored into guidance?  \n \n", "original_text": "Thanks for the questions. ", "page_label": "18", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "26845e6a3a234ec6972cf0b93da0681c4fe28f50eeb42dd64a52d430a6364360", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a2237301-66c9-4ac3-8d04-f41615c5c3ec", "node_type": "1", "metadata": {"window": "LLC  Q \nGreat.  Thanks for the questions.  I guess maybe just to follow -on to that.  There seems to be a view that flu \nvaccines will be much higher utilized this year than in a normal year.  So just curious how you're thinking about \nthat and what's factored into guidance?  \n \n And then -- and Brian, you made a comment during the prepared remarks around lab testing, and the opportunity \nthat McKesson is playing in just the COVID testing process.  I was curious also there, if you could maybe just \nexpand a little bit about how big that opportunity i s and what's factored into the guidance? ", "original_text": "There seems to be a view that flu \nvaccines will be much higher utilized this year than in a normal year. "}, "hash": "53f3764e581a1da5d2ee6cf800dc6f11ed9570f046da667548724faebcc8c217", "class_name": "RelatedNodeInfo"}}, "text": "I guess maybe just to follow -on to that. ", "start_char_idx": 1762, "end_char_idx": 1804, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a2237301-66c9-4ac3-8d04-f41615c5c3ec": {"__data__": {"id_": "a2237301-66c9-4ac3-8d04-f41615c5c3ec", "embedding": null, "metadata": {"window": "LLC  Q \nGreat.  Thanks for the questions.  I guess maybe just to follow -on to that.  There seems to be a view that flu \nvaccines will be much higher utilized this year than in a normal year.  So just curious how you're thinking about \nthat and what's factored into guidance?  \n \n And then -- and Brian, you made a comment during the prepared remarks around lab testing, and the opportunity \nthat McKesson is playing in just the COVID testing process.  I was curious also there, if you could maybe just \nexpand a little bit about how big that opportunity i s and what's factored into the guidance? ", "original_text": "There seems to be a view that flu \nvaccines will be much higher utilized this year than in a normal year. ", "page_label": "18", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5f4e4711-6225-48b4-92c3-167aa1459c03", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "59bf53b3a30aa3059b3a3153dbe7af9cfb8182b7df0a0ceb977941e976a43d80", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ee764432-b0f0-4db5-9e84-66db222b075d", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co.  LLC  Q \nGreat.  Thanks for the questions.  I guess maybe just to follow -on to that.  There seems to be a view that flu \nvaccines will be much higher utilized this year than in a normal year.  So just curious how you're thinking about \nthat and what's factored into guidance?  \n \n And then -- and Brian, you made a comment during the prepared remarks around lab testing, and the opportunity \nthat McKesson is playing in just the COVID testing process. ", "original_text": "I guess maybe just to follow -on to that. ", "page_label": "18", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b7d4cd6da97ceda73029321747f330cd78f894d5ea13bc0e5916ba77a844e35f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0c2e76db-f65c-43f4-9371-4f76ffdc8afe", "node_type": "1", "metadata": {"window": "Thanks for the questions.  I guess maybe just to follow -on to that.  There seems to be a view that flu \nvaccines will be much higher utilized this year than in a normal year.  So just curious how you're thinking about \nthat and what's factored into guidance?  \n \n And then -- and Brian, you made a comment during the prepared remarks around lab testing, and the opportunity \nthat McKesson is playing in just the COVID testing process.  I was curious also there, if you could maybe just \nexpand a little bit about how big that opportunity i s and what's factored into the guidance?  Thanks.  \n ", "original_text": "So just curious how you're thinking about \nthat and what's factored into guidance?  \n \n"}, "hash": "a5f17cccd296bcfebe934486fa6bfd984615943066f186ceb08b37391bd8ece4", "class_name": "RelatedNodeInfo"}}, "text": "There seems to be a view that flu \nvaccines will be much higher utilized this year than in a normal year. ", "start_char_idx": 1804, "end_char_idx": 1910, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0c2e76db-f65c-43f4-9371-4f76ffdc8afe": {"__data__": {"id_": "0c2e76db-f65c-43f4-9371-4f76ffdc8afe", "embedding": null, "metadata": {"window": "Thanks for the questions.  I guess maybe just to follow -on to that.  There seems to be a view that flu \nvaccines will be much higher utilized this year than in a normal year.  So just curious how you're thinking about \nthat and what's factored into guidance?  \n \n And then -- and Brian, you made a comment during the prepared remarks around lab testing, and the opportunity \nthat McKesson is playing in just the COVID testing process.  I was curious also there, if you could maybe just \nexpand a little bit about how big that opportunity i s and what's factored into the guidance?  Thanks.  \n ", "original_text": "So just curious how you're thinking about \nthat and what's factored into guidance?  \n \n", "page_label": "18", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5f4e4711-6225-48b4-92c3-167aa1459c03", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "59bf53b3a30aa3059b3a3153dbe7af9cfb8182b7df0a0ceb977941e976a43d80", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a2237301-66c9-4ac3-8d04-f41615c5c3ec", "node_type": "1", "metadata": {"window": "LLC  Q \nGreat.  Thanks for the questions.  I guess maybe just to follow -on to that.  There seems to be a view that flu \nvaccines will be much higher utilized this year than in a normal year.  So just curious how you're thinking about \nthat and what's factored into guidance?  \n \n And then -- and Brian, you made a comment during the prepared remarks around lab testing, and the opportunity \nthat McKesson is playing in just the COVID testing process.  I was curious also there, if you could maybe just \nexpand a little bit about how big that opportunity i s and what's factored into the guidance? ", "original_text": "There seems to be a view that flu \nvaccines will be much higher utilized this year than in a normal year. ", "page_label": "18", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1a829eb92ae29dc534ececd53cff46ad6849e8e0f76e1570041631b007cc94ec", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1d162908-090d-4b1d-94e9-fbfc8f39e04a", "node_type": "1", "metadata": {"window": "I guess maybe just to follow -on to that.  There seems to be a view that flu \nvaccines will be much higher utilized this year than in a normal year.  So just curious how you're thinking about \nthat and what's factored into guidance?  \n \n And then -- and Brian, you made a comment during the prepared remarks around lab testing, and the opportunity \nthat McKesson is playing in just the COVID testing process.  I was curious also there, if you could maybe just \nexpand a little bit about how big that opportunity i s and what's factored into the guidance?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "And then -- and Brian, you made a comment during the prepared remarks around lab testing, and the opportunity \nthat McKesson is playing in just the COVID testing process. "}, "hash": "0c138c8d79efdf1aed827851a9ea2bcbc4ccc9847f2848000635e74f65c6e4b9", "class_name": "RelatedNodeInfo"}}, "text": "So just curious how you're thinking about \nthat and what's factored into guidance?  \n \n", "start_char_idx": 1910, "end_char_idx": 1997, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1d162908-090d-4b1d-94e9-fbfc8f39e04a": {"__data__": {"id_": "1d162908-090d-4b1d-94e9-fbfc8f39e04a", "embedding": null, "metadata": {"window": "I guess maybe just to follow -on to that.  There seems to be a view that flu \nvaccines will be much higher utilized this year than in a normal year.  So just curious how you're thinking about \nthat and what's factored into guidance?  \n \n And then -- and Brian, you made a comment during the prepared remarks around lab testing, and the opportunity \nthat McKesson is playing in just the COVID testing process.  I was curious also there, if you could maybe just \nexpand a little bit about how big that opportunity i s and what's factored into the guidance?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "And then -- and Brian, you made a comment during the prepared remarks around lab testing, and the opportunity \nthat McKesson is playing in just the COVID testing process. ", "page_label": "18", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5f4e4711-6225-48b4-92c3-167aa1459c03", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "59bf53b3a30aa3059b3a3153dbe7af9cfb8182b7df0a0ceb977941e976a43d80", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0c2e76db-f65c-43f4-9371-4f76ffdc8afe", "node_type": "1", "metadata": {"window": "Thanks for the questions.  I guess maybe just to follow -on to that.  There seems to be a view that flu \nvaccines will be much higher utilized this year than in a normal year.  So just curious how you're thinking about \nthat and what's factored into guidance?  \n \n And then -- and Brian, you made a comment during the prepared remarks around lab testing, and the opportunity \nthat McKesson is playing in just the COVID testing process.  I was curious also there, if you could maybe just \nexpand a little bit about how big that opportunity i s and what's factored into the guidance?  Thanks.  \n ", "original_text": "So just curious how you're thinking about \nthat and what's factored into guidance?  \n \n", "page_label": "18", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "68aff3d22203acd4c7d4d89f5bca8bb53b9a087dad806afd8b25b8c9c704c89e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3c4d4108-8a09-4c97-8162-9668d382690f", "node_type": "1", "metadata": {"window": "There seems to be a view that flu \nvaccines will be much higher utilized this year than in a normal year.  So just curious how you're thinking about \nthat and what's factored into guidance?  \n \n And then -- and Brian, you made a comment during the prepared remarks around lab testing, and the opportunity \nthat McKesson is playing in just the COVID testing process.  I was curious also there, if you could maybe just \nexpand a little bit about how big that opportunity i s and what's factored into the guidance?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nSure. ", "original_text": "I was curious also there, if you could maybe just \nexpand a little bit about how big that opportunity i s and what's factored into the guidance? "}, "hash": "c4731addbc313880c48c4fe7aa7bd7d6a905448e63d3d375e4bb74936185b225", "class_name": "RelatedNodeInfo"}}, "text": "And then -- and Brian, you made a comment during the prepared remarks around lab testing, and the opportunity \nthat McKesson is playing in just the COVID testing process. ", "start_char_idx": 1997, "end_char_idx": 2168, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3c4d4108-8a09-4c97-8162-9668d382690f": {"__data__": {"id_": "3c4d4108-8a09-4c97-8162-9668d382690f", "embedding": null, "metadata": {"window": "There seems to be a view that flu \nvaccines will be much higher utilized this year than in a normal year.  So just curious how you're thinking about \nthat and what's factored into guidance?  \n \n And then -- and Brian, you made a comment during the prepared remarks around lab testing, and the opportunity \nthat McKesson is playing in just the COVID testing process.  I was curious also there, if you could maybe just \nexpand a little bit about how big that opportunity i s and what's factored into the guidance?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nSure. ", "original_text": "I was curious also there, if you could maybe just \nexpand a little bit about how big that opportunity i s and what's factored into the guidance? ", "page_label": "18", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5f4e4711-6225-48b4-92c3-167aa1459c03", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "59bf53b3a30aa3059b3a3153dbe7af9cfb8182b7df0a0ceb977941e976a43d80", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1d162908-090d-4b1d-94e9-fbfc8f39e04a", "node_type": "1", "metadata": {"window": "I guess maybe just to follow -on to that.  There seems to be a view that flu \nvaccines will be much higher utilized this year than in a normal year.  So just curious how you're thinking about \nthat and what's factored into guidance?  \n \n And then -- and Brian, you made a comment during the prepared remarks around lab testing, and the opportunity \nthat McKesson is playing in just the COVID testing process.  I was curious also there, if you could maybe just \nexpand a little bit about how big that opportunity i s and what's factored into the guidance?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "And then -- and Brian, you made a comment during the prepared remarks around lab testing, and the opportunity \nthat McKesson is playing in just the COVID testing process. ", "page_label": "18", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cb6f375022cfb9285d2ae537bf33c13d1313969c535b3722aa9be1bb79684d6d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "10194d53-8263-4f53-b971-4627793cf14b", "node_type": "1", "metadata": {"window": "So just curious how you're thinking about \nthat and what's factored into guidance?  \n \n And then -- and Brian, you made a comment during the prepared remarks around lab testing, and the opportunity \nthat McKesson is playing in just the COVID testing process.  I was curious also there, if you could maybe just \nexpand a little bit about how big that opportunity i s and what's factored into the guidance?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nSure.  Thanks, Robert. ", "original_text": "Thanks.  \n "}, "hash": "33579f64aad30a3a0625b5bee4a3eef7028679126edcb46e5ed70e285e5a85f8", "class_name": "RelatedNodeInfo"}}, "text": "I was curious also there, if you could maybe just \nexpand a little bit about how big that opportunity i s and what's factored into the guidance? ", "start_char_idx": 2168, "end_char_idx": 2313, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "10194d53-8263-4f53-b971-4627793cf14b": {"__data__": {"id_": "10194d53-8263-4f53-b971-4627793cf14b", "embedding": null, "metadata": {"window": "So just curious how you're thinking about \nthat and what's factored into guidance?  \n \n And then -- and Brian, you made a comment during the prepared remarks around lab testing, and the opportunity \nthat McKesson is playing in just the COVID testing process.  I was curious also there, if you could maybe just \nexpand a little bit about how big that opportunity i s and what's factored into the guidance?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nSure.  Thanks, Robert. ", "original_text": "Thanks.  \n ", "page_label": "18", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5f4e4711-6225-48b4-92c3-167aa1459c03", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "59bf53b3a30aa3059b3a3153dbe7af9cfb8182b7df0a0ceb977941e976a43d80", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3c4d4108-8a09-4c97-8162-9668d382690f", "node_type": "1", "metadata": {"window": "There seems to be a view that flu \nvaccines will be much higher utilized this year than in a normal year.  So just curious how you're thinking about \nthat and what's factored into guidance?  \n \n And then -- and Brian, you made a comment during the prepared remarks around lab testing, and the opportunity \nthat McKesson is playing in just the COVID testing process.  I was curious also there, if you could maybe just \nexpand a little bit about how big that opportunity i s and what's factored into the guidance?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nSure. ", "original_text": "I was curious also there, if you could maybe just \nexpand a little bit about how big that opportunity i s and what's factored into the guidance? ", "page_label": "18", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3119f820c9d409220b57ceb0555f715d88f8284d65151149336d8672a408bf06", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "81f5678f-8812-42cf-92c8-bfd9b27c0f0f", "node_type": "1", "metadata": {"window": "And then -- and Brian, you made a comment during the prepared remarks around lab testing, and the opportunity \nthat McKesson is playing in just the COVID testing process.  I was curious also there, if you could maybe just \nexpand a little bit about how big that opportunity i s and what's factored into the guidance?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nSure.  Thanks, Robert.  So on start, I guess, just a few comments on flu. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  "}, "hash": "86c3fe04819db08d70f7e7c4a710883cf9cdd4027c3d0958bce0a7ae875a8579", "class_name": "RelatedNodeInfo"}}, "text": "Thanks.  \n ", "start_char_idx": 2313, "end_char_idx": 2324, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "81f5678f-8812-42cf-92c8-bfd9b27c0f0f": {"__data__": {"id_": "81f5678f-8812-42cf-92c8-bfd9b27c0f0f", "embedding": null, "metadata": {"window": "And then -- and Brian, you made a comment during the prepared remarks around lab testing, and the opportunity \nthat McKesson is playing in just the COVID testing process.  I was curious also there, if you could maybe just \nexpand a little bit about how big that opportunity i s and what's factored into the guidance?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nSure.  Thanks, Robert.  So on start, I guess, just a few comments on flu. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "18", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5f4e4711-6225-48b4-92c3-167aa1459c03", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "59bf53b3a30aa3059b3a3153dbe7af9cfb8182b7df0a0ceb977941e976a43d80", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "10194d53-8263-4f53-b971-4627793cf14b", "node_type": "1", "metadata": {"window": "So just curious how you're thinking about \nthat and what's factored into guidance?  \n \n And then -- and Brian, you made a comment during the prepared remarks around lab testing, and the opportunity \nthat McKesson is playing in just the COVID testing process.  I was curious also there, if you could maybe just \nexpand a little bit about how big that opportunity i s and what's factored into the guidance?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nSure.  Thanks, Robert. ", "original_text": "Thanks.  \n ", "page_label": "18", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ec4f8b6ff9ba618509781f893b105c46c7623e2d2587ccded676b08ffc53f819", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "167629da-e1e9-475f-942d-04a4e5800f56", "node_type": "1", "metadata": {"window": "I was curious also there, if you could maybe just \nexpand a little bit about how big that opportunity i s and what's factored into the guidance?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nSure.  Thanks, Robert.  So on start, I guess, just a few comments on flu.  I mean, flu is a component of our Medical \nbusiness. ", "original_text": "A \nSure. "}, "hash": "a095dd802e5157e088361a6d5545c2fee4c3fe84452f7282ac93f9ad41938064", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "start_char_idx": 2324, "end_char_idx": 2665, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "167629da-e1e9-475f-942d-04a4e5800f56": {"__data__": {"id_": "167629da-e1e9-475f-942d-04a4e5800f56", "embedding": null, "metadata": {"window": "I was curious also there, if you could maybe just \nexpand a little bit about how big that opportunity i s and what's factored into the guidance?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nSure.  Thanks, Robert.  So on start, I guess, just a few comments on flu.  I mean, flu is a component of our Medical \nbusiness. ", "original_text": "A \nSure. ", "page_label": "18", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5f4e4711-6225-48b4-92c3-167aa1459c03", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "59bf53b3a30aa3059b3a3153dbe7af9cfb8182b7df0a0ceb977941e976a43d80", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "81f5678f-8812-42cf-92c8-bfd9b27c0f0f", "node_type": "1", "metadata": {"window": "And then -- and Brian, you made a comment during the prepared remarks around lab testing, and the opportunity \nthat McKesson is playing in just the COVID testing process.  I was curious also there, if you could maybe just \nexpand a little bit about how big that opportunity i s and what's factored into the guidance?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nSure.  Thanks, Robert.  So on start, I guess, just a few comments on flu. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "18", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "48c45932798044a161db4359985110469a71924ee424c00f89fa50b46496e506", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d97e916f-638e-47bc-8f8b-8bcb00281138", "node_type": "1", "metadata": {"window": "Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nSure.  Thanks, Robert.  So on start, I guess, just a few comments on flu.  I mean, flu is a component of our Medical \nbusiness.  I wouldn't o veremphasize the role of flu vaccine there. ", "original_text": "Thanks, Robert. "}, "hash": "8e9f77c47477bcc189474666b36fb3e69c9abc99c1962a39264df1c2e247ca66", "class_name": "RelatedNodeInfo"}}, "text": "A \nSure. ", "start_char_idx": 2665, "end_char_idx": 2674, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d97e916f-638e-47bc-8f8b-8bcb00281138": {"__data__": {"id_": "d97e916f-638e-47bc-8f8b-8bcb00281138", "embedding": null, "metadata": {"window": "Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nSure.  Thanks, Robert.  So on start, I guess, just a few comments on flu.  I mean, flu is a component of our Medical \nbusiness.  I wouldn't o veremphasize the role of flu vaccine there. ", "original_text": "Thanks, Robert. ", "page_label": "18", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5f4e4711-6225-48b4-92c3-167aa1459c03", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "59bf53b3a30aa3059b3a3153dbe7af9cfb8182b7df0a0ceb977941e976a43d80", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "167629da-e1e9-475f-942d-04a4e5800f56", "node_type": "1", "metadata": {"window": "I was curious also there, if you could maybe just \nexpand a little bit about how big that opportunity i s and what's factored into the guidance?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nSure.  Thanks, Robert.  So on start, I guess, just a few comments on flu.  I mean, flu is a component of our Medical \nbusiness. ", "original_text": "A \nSure. ", "page_label": "18", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "098bce6554982cd2637291d1aa3569efe90dc81228c43496855dd064bd4a48f4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "15992029-45ce-4f97-8cfa-84908a22e4f8", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nSure.  Thanks, Robert.  So on start, I guess, just a few comments on flu.  I mean, flu is a component of our Medical \nbusiness.  I wouldn't o veremphasize the role of flu vaccine there.  Every flu season tends to be its own season, \ndepending on the severity of the strand, depending on the effectiveness of the vaccination. ", "original_text": "So on start, I guess, just a few comments on flu. "}, "hash": "993751eb94307e9105202ccd6486eb61fe73db87e6b18b8584f9d8322b4d6120", "class_name": "RelatedNodeInfo"}}, "text": "Thanks, Robert. ", "start_char_idx": 2674, "end_char_idx": 2690, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "15992029-45ce-4f97-8cfa-84908a22e4f8": {"__data__": {"id_": "15992029-45ce-4f97-8cfa-84908a22e4f8", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nSure.  Thanks, Robert.  So on start, I guess, just a few comments on flu.  I mean, flu is a component of our Medical \nbusiness.  I wouldn't o veremphasize the role of flu vaccine there.  Every flu season tends to be its own season, \ndepending on the severity of the strand, depending on the effectiveness of the vaccination. ", "original_text": "So on start, I guess, just a few comments on flu. ", "page_label": "18", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5f4e4711-6225-48b4-92c3-167aa1459c03", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "59bf53b3a30aa3059b3a3153dbe7af9cfb8182b7df0a0ceb977941e976a43d80", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d97e916f-638e-47bc-8f8b-8bcb00281138", "node_type": "1", "metadata": {"window": "Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nSure.  Thanks, Robert.  So on start, I guess, just a few comments on flu.  I mean, flu is a component of our Medical \nbusiness.  I wouldn't o veremphasize the role of flu vaccine there. ", "original_text": "Thanks, Robert. ", "page_label": "18", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9c967a59907c6222c6d0c98e8aaa99dc973cbe5e7c1036635eedd048f2af63d0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "80f6152f-9e61-4037-a99c-18b327a7aecf", "node_type": "1", "metadata": {"window": "A \nSure.  Thanks, Robert.  So on start, I guess, just a few comments on flu.  I mean, flu is a component of our Medical \nbusiness.  I wouldn't o veremphasize the role of flu vaccine there.  Every flu season tends to be its own season, \ndepending on the severity of the strand, depending on the effectiveness of the vaccination.  So we've lived through \nlots of different kinds of flu seasons, strong ones and weak ones. ", "original_text": "I mean, flu is a component of our Medical \nbusiness. "}, "hash": "079773780129be8a2c1325d421b1f4a563018eed57c5fec5c94268e9fb285f8e", "class_name": "RelatedNodeInfo"}}, "text": "So on start, I guess, just a few comments on flu. ", "start_char_idx": 2690, "end_char_idx": 2740, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "80f6152f-9e61-4037-a99c-18b327a7aecf": {"__data__": {"id_": "80f6152f-9e61-4037-a99c-18b327a7aecf", "embedding": null, "metadata": {"window": "A \nSure.  Thanks, Robert.  So on start, I guess, just a few comments on flu.  I mean, flu is a component of our Medical \nbusiness.  I wouldn't o veremphasize the role of flu vaccine there.  Every flu season tends to be its own season, \ndepending on the severity of the strand, depending on the effectiveness of the vaccination.  So we've lived through \nlots of different kinds of flu seasons, strong ones and weak ones. ", "original_text": "I mean, flu is a component of our Medical \nbusiness. ", "page_label": "18", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5f4e4711-6225-48b4-92c3-167aa1459c03", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "59bf53b3a30aa3059b3a3153dbe7af9cfb8182b7df0a0ceb977941e976a43d80", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "15992029-45ce-4f97-8cfa-84908a22e4f8", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nSure.  Thanks, Robert.  So on start, I guess, just a few comments on flu.  I mean, flu is a component of our Medical \nbusiness.  I wouldn't o veremphasize the role of flu vaccine there.  Every flu season tends to be its own season, \ndepending on the severity of the strand, depending on the effectiveness of the vaccination. ", "original_text": "So on start, I guess, just a few comments on flu. ", "page_label": "18", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "245987866c0dfaab0c38974d16e90179d942327fcc2a67df17bb89818d46ef4a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4f601686-0965-44f7-b7b0-dad60448b68d", "node_type": "1", "metadata": {"window": "Thanks, Robert.  So on start, I guess, just a few comments on flu.  I mean, flu is a component of our Medical \nbusiness.  I wouldn't o veremphasize the role of flu vaccine there.  Every flu season tends to be its own season, \ndepending on the severity of the strand, depending on the effectiveness of the vaccination.  So we've lived through \nlots of different kinds of flu seasons, strong ones and weak ones.  And I think our best thinking at this point is this it \nwould be a typical or average flu season.  \n \n", "original_text": "I wouldn't o veremphasize the role of flu vaccine there. "}, "hash": "6a1529b074d87833046165b7303aecbcc5c3f761783b7aee2bc9f9cdf5f26596", "class_name": "RelatedNodeInfo"}}, "text": "I mean, flu is a component of our Medical \nbusiness. ", "start_char_idx": 2740, "end_char_idx": 2793, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4f601686-0965-44f7-b7b0-dad60448b68d": {"__data__": {"id_": "4f601686-0965-44f7-b7b0-dad60448b68d", "embedding": null, "metadata": {"window": "Thanks, Robert.  So on start, I guess, just a few comments on flu.  I mean, flu is a component of our Medical \nbusiness.  I wouldn't o veremphasize the role of flu vaccine there.  Every flu season tends to be its own season, \ndepending on the severity of the strand, depending on the effectiveness of the vaccination.  So we've lived through \nlots of different kinds of flu seasons, strong ones and weak ones.  And I think our best thinking at this point is this it \nwould be a typical or average flu season.  \n \n", "original_text": "I wouldn't o veremphasize the role of flu vaccine there. ", "page_label": "18", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5f4e4711-6225-48b4-92c3-167aa1459c03", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "59bf53b3a30aa3059b3a3153dbe7af9cfb8182b7df0a0ceb977941e976a43d80", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "80f6152f-9e61-4037-a99c-18b327a7aecf", "node_type": "1", "metadata": {"window": "A \nSure.  Thanks, Robert.  So on start, I guess, just a few comments on flu.  I mean, flu is a component of our Medical \nbusiness.  I wouldn't o veremphasize the role of flu vaccine there.  Every flu season tends to be its own season, \ndepending on the severity of the strand, depending on the effectiveness of the vaccination.  So we've lived through \nlots of different kinds of flu seasons, strong ones and weak ones. ", "original_text": "I mean, flu is a component of our Medical \nbusiness. ", "page_label": "18", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "93e5dbd41e550060d9f7e1b7c599ab2aa6aba52ff9ed689c156c05feedd951fd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b588b264-304e-4488-a19b-e4935b7bdaa1", "node_type": "1", "metadata": {"window": "So on start, I guess, just a few comments on flu.  I mean, flu is a component of our Medical \nbusiness.  I wouldn't o veremphasize the role of flu vaccine there.  Every flu season tends to be its own season, \ndepending on the severity of the strand, depending on the effectiveness of the vaccination.  So we've lived through \nlots of different kinds of flu seasons, strong ones and weak ones.  And I think our best thinking at this point is this it \nwould be a typical or average flu season.  \n \n Now it's still quite early to make that call with any specific insight into how flu may interact with COVID and patient \nperception. ", "original_text": "Every flu season tends to be its own season, \ndepending on the severity of the strand, depending on the effectiveness of the vaccination. "}, "hash": "bf90c06ecdfe927218266769a45540af0c0dbbd990671163baf29426dafa0fdc", "class_name": "RelatedNodeInfo"}}, "text": "I wouldn't o veremphasize the role of flu vaccine there. ", "start_char_idx": 2793, "end_char_idx": 2850, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b588b264-304e-4488-a19b-e4935b7bdaa1": {"__data__": {"id_": "b588b264-304e-4488-a19b-e4935b7bdaa1", "embedding": null, "metadata": {"window": "So on start, I guess, just a few comments on flu.  I mean, flu is a component of our Medical \nbusiness.  I wouldn't o veremphasize the role of flu vaccine there.  Every flu season tends to be its own season, \ndepending on the severity of the strand, depending on the effectiveness of the vaccination.  So we've lived through \nlots of different kinds of flu seasons, strong ones and weak ones.  And I think our best thinking at this point is this it \nwould be a typical or average flu season.  \n \n Now it's still quite early to make that call with any specific insight into how flu may interact with COVID and patient \nperception. ", "original_text": "Every flu season tends to be its own season, \ndepending on the severity of the strand, depending on the effectiveness of the vaccination. ", "page_label": "18", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5f4e4711-6225-48b4-92c3-167aa1459c03", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "59bf53b3a30aa3059b3a3153dbe7af9cfb8182b7df0a0ceb977941e976a43d80", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4f601686-0965-44f7-b7b0-dad60448b68d", "node_type": "1", "metadata": {"window": "Thanks, Robert.  So on start, I guess, just a few comments on flu.  I mean, flu is a component of our Medical \nbusiness.  I wouldn't o veremphasize the role of flu vaccine there.  Every flu season tends to be its own season, \ndepending on the severity of the strand, depending on the effectiveness of the vaccination.  So we've lived through \nlots of different kinds of flu seasons, strong ones and weak ones.  And I think our best thinking at this point is this it \nwould be a typical or average flu season.  \n \n", "original_text": "I wouldn't o veremphasize the role of flu vaccine there. ", "page_label": "18", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bb13d7bf9aeedfe622e0d50a92a6c7e4bad0613d346b0fb947d3c7145bd0f8bf", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "34ade99a-6dd0-4cb1-a82f-eb49f34ae197", "node_type": "1", "metadata": {"window": "I mean, flu is a component of our Medical \nbusiness.  I wouldn't o veremphasize the role of flu vaccine there.  Every flu season tends to be its own season, \ndepending on the severity of the strand, depending on the effectiveness of the vaccination.  So we've lived through \nlots of different kinds of flu seasons, strong ones and weak ones.  And I think our best thinking at this point is this it \nwould be a typical or average flu season.  \n \n Now it's still quite early to make that call with any specific insight into how flu may interact with COVID and patient \nperception.  So it's som ething we'll continue to monitor and watch. ", "original_text": "So we've lived through \nlots of different kinds of flu seasons, strong ones and weak ones. "}, "hash": "d14a284e907af5fd963b928e98144faa4bd9ecc7afb1ed348a610200f8a0e485", "class_name": "RelatedNodeInfo"}}, "text": "Every flu season tends to be its own season, \ndepending on the severity of the strand, depending on the effectiveness of the vaccination. ", "start_char_idx": 2850, "end_char_idx": 2988, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "34ade99a-6dd0-4cb1-a82f-eb49f34ae197": {"__data__": {"id_": "34ade99a-6dd0-4cb1-a82f-eb49f34ae197", "embedding": null, "metadata": {"window": "I mean, flu is a component of our Medical \nbusiness.  I wouldn't o veremphasize the role of flu vaccine there.  Every flu season tends to be its own season, \ndepending on the severity of the strand, depending on the effectiveness of the vaccination.  So we've lived through \nlots of different kinds of flu seasons, strong ones and weak ones.  And I think our best thinking at this point is this it \nwould be a typical or average flu season.  \n \n Now it's still quite early to make that call with any specific insight into how flu may interact with COVID and patient \nperception.  So it's som ething we'll continue to monitor and watch. ", "original_text": "So we've lived through \nlots of different kinds of flu seasons, strong ones and weak ones. ", "page_label": "18", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5f4e4711-6225-48b4-92c3-167aa1459c03", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "59bf53b3a30aa3059b3a3153dbe7af9cfb8182b7df0a0ceb977941e976a43d80", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b588b264-304e-4488-a19b-e4935b7bdaa1", "node_type": "1", "metadata": {"window": "So on start, I guess, just a few comments on flu.  I mean, flu is a component of our Medical \nbusiness.  I wouldn't o veremphasize the role of flu vaccine there.  Every flu season tends to be its own season, \ndepending on the severity of the strand, depending on the effectiveness of the vaccination.  So we've lived through \nlots of different kinds of flu seasons, strong ones and weak ones.  And I think our best thinking at this point is this it \nwould be a typical or average flu season.  \n \n Now it's still quite early to make that call with any specific insight into how flu may interact with COVID and patient \nperception. ", "original_text": "Every flu season tends to be its own season, \ndepending on the severity of the strand, depending on the effectiveness of the vaccination. ", "page_label": "18", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "006245f09cba04672fb75e7bb3ff059114d125ce1215ce7960bd2ed89d79540f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "16c610ba-eefa-4c13-9ead-fecff49d3a50", "node_type": "1", "metadata": {"window": "I wouldn't o veremphasize the role of flu vaccine there.  Every flu season tends to be its own season, \ndepending on the severity of the strand, depending on the effectiveness of the vaccination.  So we've lived through \nlots of different kinds of flu seasons, strong ones and weak ones.  And I think our best thinking at this point is this it \nwould be a typical or average flu season.  \n \n Now it's still quite early to make that call with any specific insight into how flu may interact with COVID and patient \nperception.  So it's som ething we'll continue to monitor and watch.  And then relative to the comments about lab, I \nmean we \u2013 by virtue of our position in the alternate care markets and supporting nursing homes and supporting \nphysician offices, we just have great reach into the co mmunity. ", "original_text": "And I think our best thinking at this point is this it \nwould be a typical or average flu season.  \n \n"}, "hash": "40d9d91ccc5241743e218543550d85f0c2aa4494121ca3dec2e233312bf0de1d", "class_name": "RelatedNodeInfo"}}, "text": "So we've lived through \nlots of different kinds of flu seasons, strong ones and weak ones. ", "start_char_idx": 2988, "end_char_idx": 3079, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "16c610ba-eefa-4c13-9ead-fecff49d3a50": {"__data__": {"id_": "16c610ba-eefa-4c13-9ead-fecff49d3a50", "embedding": null, "metadata": {"window": "I wouldn't o veremphasize the role of flu vaccine there.  Every flu season tends to be its own season, \ndepending on the severity of the strand, depending on the effectiveness of the vaccination.  So we've lived through \nlots of different kinds of flu seasons, strong ones and weak ones.  And I think our best thinking at this point is this it \nwould be a typical or average flu season.  \n \n Now it's still quite early to make that call with any specific insight into how flu may interact with COVID and patient \nperception.  So it's som ething we'll continue to monitor and watch.  And then relative to the comments about lab, I \nmean we \u2013 by virtue of our position in the alternate care markets and supporting nursing homes and supporting \nphysician offices, we just have great reach into the co mmunity. ", "original_text": "And I think our best thinking at this point is this it \nwould be a typical or average flu season.  \n \n", "page_label": "18", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5f4e4711-6225-48b4-92c3-167aa1459c03", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "59bf53b3a30aa3059b3a3153dbe7af9cfb8182b7df0a0ceb977941e976a43d80", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "34ade99a-6dd0-4cb1-a82f-eb49f34ae197", "node_type": "1", "metadata": {"window": "I mean, flu is a component of our Medical \nbusiness.  I wouldn't o veremphasize the role of flu vaccine there.  Every flu season tends to be its own season, \ndepending on the severity of the strand, depending on the effectiveness of the vaccination.  So we've lived through \nlots of different kinds of flu seasons, strong ones and weak ones.  And I think our best thinking at this point is this it \nwould be a typical or average flu season.  \n \n Now it's still quite early to make that call with any specific insight into how flu may interact with COVID and patient \nperception.  So it's som ething we'll continue to monitor and watch. ", "original_text": "So we've lived through \nlots of different kinds of flu seasons, strong ones and weak ones. ", "page_label": "18", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3acbbcdfe00e78fb23d3bac12d1a4c99f0fe069ebdc3806a503ba99367d32353", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fdc804f8-b30c-4eb3-9062-c5caed44ce55", "node_type": "1", "metadata": {"window": "Every flu season tends to be its own season, \ndepending on the severity of the strand, depending on the effectiveness of the vaccination.  So we've lived through \nlots of different kinds of flu seasons, strong ones and weak ones.  And I think our best thinking at this point is this it \nwould be a typical or average flu season.  \n \n Now it's still quite early to make that call with any specific insight into how flu may interact with COVID and patient \nperception.  So it's som ething we'll continue to monitor and watch.  And then relative to the comments about lab, I \nmean we \u2013 by virtue of our position in the alternate care markets and supporting nursing homes and supporting \nphysician offices, we just have great reach into the co mmunity.  And so as the need for this testing moves into the \ncommunity -based setting, we're well -positioned to take advantage of that.  \n ", "original_text": "Now it's still quite early to make that call with any specific insight into how flu may interact with COVID and patient \nperception. "}, "hash": "56d012b2ab7e0dbc523af6cb7c217c95e6a2854b8268217ece4232cdc5ee66a5", "class_name": "RelatedNodeInfo"}}, "text": "And I think our best thinking at this point is this it \nwould be a typical or average flu season.  \n \n", "start_char_idx": 3079, "end_char_idx": 3181, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fdc804f8-b30c-4eb3-9062-c5caed44ce55": {"__data__": {"id_": "fdc804f8-b30c-4eb3-9062-c5caed44ce55", "embedding": null, "metadata": {"window": "Every flu season tends to be its own season, \ndepending on the severity of the strand, depending on the effectiveness of the vaccination.  So we've lived through \nlots of different kinds of flu seasons, strong ones and weak ones.  And I think our best thinking at this point is this it \nwould be a typical or average flu season.  \n \n Now it's still quite early to make that call with any specific insight into how flu may interact with COVID and patient \nperception.  So it's som ething we'll continue to monitor and watch.  And then relative to the comments about lab, I \nmean we \u2013 by virtue of our position in the alternate care markets and supporting nursing homes and supporting \nphysician offices, we just have great reach into the co mmunity.  And so as the need for this testing moves into the \ncommunity -based setting, we're well -positioned to take advantage of that.  \n ", "original_text": "Now it's still quite early to make that call with any specific insight into how flu may interact with COVID and patient \nperception. ", "page_label": "18", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5f4e4711-6225-48b4-92c3-167aa1459c03", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "59bf53b3a30aa3059b3a3153dbe7af9cfb8182b7df0a0ceb977941e976a43d80", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "16c610ba-eefa-4c13-9ead-fecff49d3a50", "node_type": "1", "metadata": {"window": "I wouldn't o veremphasize the role of flu vaccine there.  Every flu season tends to be its own season, \ndepending on the severity of the strand, depending on the effectiveness of the vaccination.  So we've lived through \nlots of different kinds of flu seasons, strong ones and weak ones.  And I think our best thinking at this point is this it \nwould be a typical or average flu season.  \n \n Now it's still quite early to make that call with any specific insight into how flu may interact with COVID and patient \nperception.  So it's som ething we'll continue to monitor and watch.  And then relative to the comments about lab, I \nmean we \u2013 by virtue of our position in the alternate care markets and supporting nursing homes and supporting \nphysician offices, we just have great reach into the co mmunity. ", "original_text": "And I think our best thinking at this point is this it \nwould be a typical or average flu season.  \n \n", "page_label": "18", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "79e49b3fedea7320a1681de9895cbe932c358728bcff9dff6d9b7dd6dbe87766", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5388168a-32ec-40d7-8b8d-9db49657b45e", "node_type": "1", "metadata": {"window": "So we've lived through \nlots of different kinds of flu seasons, strong ones and weak ones.  And I think our best thinking at this point is this it \nwould be a typical or average flu season.  \n \n Now it's still quite early to make that call with any specific insight into how flu may interact with COVID and patient \nperception.  So it's som ething we'll continue to monitor and watch.  And then relative to the comments about lab, I \nmean we \u2013 by virtue of our position in the alternate care markets and supporting nursing homes and supporting \nphysician offices, we just have great reach into the co mmunity.  And so as the need for this testing moves into the \ncommunity -based setting, we're well -positioned to take advantage of that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "original_text": "So it's som ething we'll continue to monitor and watch. "}, "hash": "fd063b8149732d965999beb8049840706ac7933d77a4dfa81147fdc2c37a59c7", "class_name": "RelatedNodeInfo"}}, "text": "Now it's still quite early to make that call with any specific insight into how flu may interact with COVID and patient \nperception. ", "start_char_idx": 3181, "end_char_idx": 3314, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5388168a-32ec-40d7-8b8d-9db49657b45e": {"__data__": {"id_": "5388168a-32ec-40d7-8b8d-9db49657b45e", "embedding": null, "metadata": {"window": "So we've lived through \nlots of different kinds of flu seasons, strong ones and weak ones.  And I think our best thinking at this point is this it \nwould be a typical or average flu season.  \n \n Now it's still quite early to make that call with any specific insight into how flu may interact with COVID and patient \nperception.  So it's som ething we'll continue to monitor and watch.  And then relative to the comments about lab, I \nmean we \u2013 by virtue of our position in the alternate care markets and supporting nursing homes and supporting \nphysician offices, we just have great reach into the co mmunity.  And so as the need for this testing moves into the \ncommunity -based setting, we're well -positioned to take advantage of that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "original_text": "So it's som ething we'll continue to monitor and watch. ", "page_label": "18", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5f4e4711-6225-48b4-92c3-167aa1459c03", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "59bf53b3a30aa3059b3a3153dbe7af9cfb8182b7df0a0ceb977941e976a43d80", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fdc804f8-b30c-4eb3-9062-c5caed44ce55", "node_type": "1", "metadata": {"window": "Every flu season tends to be its own season, \ndepending on the severity of the strand, depending on the effectiveness of the vaccination.  So we've lived through \nlots of different kinds of flu seasons, strong ones and weak ones.  And I think our best thinking at this point is this it \nwould be a typical or average flu season.  \n \n Now it's still quite early to make that call with any specific insight into how flu may interact with COVID and patient \nperception.  So it's som ething we'll continue to monitor and watch.  And then relative to the comments about lab, I \nmean we \u2013 by virtue of our position in the alternate care markets and supporting nursing homes and supporting \nphysician offices, we just have great reach into the co mmunity.  And so as the need for this testing moves into the \ncommunity -based setting, we're well -positioned to take advantage of that.  \n ", "original_text": "Now it's still quite early to make that call with any specific insight into how flu may interact with COVID and patient \nperception. ", "page_label": "18", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6648e240a21d400ee9d1c7ad18dcb699f51b418bf9bc7606e00a26c6f8c8e38b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8836fce5-e105-40b7-a210-92d6fa8e64e8", "node_type": "1", "metadata": {"window": "And I think our best thinking at this point is this it \nwould be a typical or average flu season.  \n \n Now it's still quite early to make that call with any specific insight into how flu may interact with COVID and patient \nperception.  So it's som ething we'll continue to monitor and watch.  And then relative to the comments about lab, I \nmean we \u2013 by virtue of our position in the alternate care markets and supporting nursing homes and supporting \nphysician offices, we just have great reach into the co mmunity.  And so as the need for this testing moves into the \ncommunity -based setting, we're well -positioned to take advantage of that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nMaybe just to build on Brian's comment. ", "original_text": "And then relative to the comments about lab, I \nmean we \u2013 by virtue of our position in the alternate care markets and supporting nursing homes and supporting \nphysician offices, we just have great reach into the co mmunity. "}, "hash": "f1cd8a73961b8dbf3026f1cfa5d4d49133db130bd901e466694df5825414abc1", "class_name": "RelatedNodeInfo"}}, "text": "So it's som ething we'll continue to monitor and watch. ", "start_char_idx": 3314, "end_char_idx": 3370, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8836fce5-e105-40b7-a210-92d6fa8e64e8": {"__data__": {"id_": "8836fce5-e105-40b7-a210-92d6fa8e64e8", "embedding": null, "metadata": {"window": "And I think our best thinking at this point is this it \nwould be a typical or average flu season.  \n \n Now it's still quite early to make that call with any specific insight into how flu may interact with COVID and patient \nperception.  So it's som ething we'll continue to monitor and watch.  And then relative to the comments about lab, I \nmean we \u2013 by virtue of our position in the alternate care markets and supporting nursing homes and supporting \nphysician offices, we just have great reach into the co mmunity.  And so as the need for this testing moves into the \ncommunity -based setting, we're well -positioned to take advantage of that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nMaybe just to build on Brian's comment. ", "original_text": "And then relative to the comments about lab, I \nmean we \u2013 by virtue of our position in the alternate care markets and supporting nursing homes and supporting \nphysician offices, we just have great reach into the co mmunity. ", "page_label": "18", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5f4e4711-6225-48b4-92c3-167aa1459c03", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "59bf53b3a30aa3059b3a3153dbe7af9cfb8182b7df0a0ceb977941e976a43d80", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5388168a-32ec-40d7-8b8d-9db49657b45e", "node_type": "1", "metadata": {"window": "So we've lived through \nlots of different kinds of flu seasons, strong ones and weak ones.  And I think our best thinking at this point is this it \nwould be a typical or average flu season.  \n \n Now it's still quite early to make that call with any specific insight into how flu may interact with COVID and patient \nperception.  So it's som ething we'll continue to monitor and watch.  And then relative to the comments about lab, I \nmean we \u2013 by virtue of our position in the alternate care markets and supporting nursing homes and supporting \nphysician offices, we just have great reach into the co mmunity.  And so as the need for this testing moves into the \ncommunity -based setting, we're well -positioned to take advantage of that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "original_text": "So it's som ething we'll continue to monitor and watch. ", "page_label": "18", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "baa79e38aae86828ce6b7eb339c6511d9d2009fbf0c5a8481c57e3dcbbd808b2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "10ddc74c-5c59-4164-9373-688d00c9fdcb", "node_type": "1", "metadata": {"window": "Now it's still quite early to make that call with any specific insight into how flu may interact with COVID and patient \nperception.  So it's som ething we'll continue to monitor and watch.  And then relative to the comments about lab, I \nmean we \u2013 by virtue of our position in the alternate care markets and supporting nursing homes and supporting \nphysician offices, we just have great reach into the co mmunity.  And so as the need for this testing moves into the \ncommunity -based setting, we're well -positioned to take advantage of that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nMaybe just to build on Brian's comment.  The flu vaccine itself within our Medical business is a component of \npharmaceutical distribution within that segment. ", "original_text": "And so as the need for this testing moves into the \ncommunity -based setting, we're well -positioned to take advantage of that.  \n "}, "hash": "32acbf85cba98c72d5e7a1efdb007ba35e4ffa225d7e023448107e2fbfdc88e2", "class_name": "RelatedNodeInfo"}}, "text": "And then relative to the comments about lab, I \nmean we \u2013 by virtue of our position in the alternate care markets and supporting nursing homes and supporting \nphysician offices, we just have great reach into the co mmunity. ", "start_char_idx": 3370, "end_char_idx": 3594, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "10ddc74c-5c59-4164-9373-688d00c9fdcb": {"__data__": {"id_": "10ddc74c-5c59-4164-9373-688d00c9fdcb", "embedding": null, "metadata": {"window": "Now it's still quite early to make that call with any specific insight into how flu may interact with COVID and patient \nperception.  So it's som ething we'll continue to monitor and watch.  And then relative to the comments about lab, I \nmean we \u2013 by virtue of our position in the alternate care markets and supporting nursing homes and supporting \nphysician offices, we just have great reach into the co mmunity.  And so as the need for this testing moves into the \ncommunity -based setting, we're well -positioned to take advantage of that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nMaybe just to build on Brian's comment.  The flu vaccine itself within our Medical business is a component of \npharmaceutical distribution within that segment. ", "original_text": "And so as the need for this testing moves into the \ncommunity -based setting, we're well -positioned to take advantage of that.  \n ", "page_label": "18", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5f4e4711-6225-48b4-92c3-167aa1459c03", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "59bf53b3a30aa3059b3a3153dbe7af9cfb8182b7df0a0ceb977941e976a43d80", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8836fce5-e105-40b7-a210-92d6fa8e64e8", "node_type": "1", "metadata": {"window": "And I think our best thinking at this point is this it \nwould be a typical or average flu season.  \n \n Now it's still quite early to make that call with any specific insight into how flu may interact with COVID and patient \nperception.  So it's som ething we'll continue to monitor and watch.  And then relative to the comments about lab, I \nmean we \u2013 by virtue of our position in the alternate care markets and supporting nursing homes and supporting \nphysician offices, we just have great reach into the co mmunity.  And so as the need for this testing moves into the \ncommunity -based setting, we're well -positioned to take advantage of that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nMaybe just to build on Brian's comment. ", "original_text": "And then relative to the comments about lab, I \nmean we \u2013 by virtue of our position in the alternate care markets and supporting nursing homes and supporting \nphysician offices, we just have great reach into the co mmunity. ", "page_label": "18", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bc806040b636410c91750ec35d8f208825e8138aad25fc654ed567e6085de975", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e25d2c4c-f3c1-49ac-a296-3705b03605f5", "node_type": "1", "metadata": {"window": "So it's som ething we'll continue to monitor and watch.  And then relative to the comments about lab, I \nmean we \u2013 by virtue of our position in the alternate care markets and supporting nursing homes and supporting \nphysician offices, we just have great reach into the co mmunity.  And so as the need for this testing moves into the \ncommunity -based setting, we're well -positioned to take advantage of that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nMaybe just to build on Brian's comment.  The flu vaccine itself within our Medical business is a component of \npharmaceutical distribution within that segment.  And it's not \u2013 the vaccine itself is not material to the segment. \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  "}, "hash": "3eaebbf0be461cde647321c4b3cfdaa903576d4ef87510e296541da5fedd753f", "class_name": "RelatedNodeInfo"}}, "text": "And so as the need for this testing moves into the \ncommunity -based setting, we're well -positioned to take advantage of that.  \n ", "start_char_idx": 3594, "end_char_idx": 3725, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e25d2c4c-f3c1-49ac-a296-3705b03605f5": {"__data__": {"id_": "e25d2c4c-f3c1-49ac-a296-3705b03605f5", "embedding": null, "metadata": {"window": "So it's som ething we'll continue to monitor and watch.  And then relative to the comments about lab, I \nmean we \u2013 by virtue of our position in the alternate care markets and supporting nursing homes and supporting \nphysician offices, we just have great reach into the co mmunity.  And so as the need for this testing moves into the \ncommunity -based setting, we're well -positioned to take advantage of that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nMaybe just to build on Brian's comment.  The flu vaccine itself within our Medical business is a component of \npharmaceutical distribution within that segment.  And it's not \u2013 the vaccine itself is not material to the segment. \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "page_label": "18", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5f4e4711-6225-48b4-92c3-167aa1459c03", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "59bf53b3a30aa3059b3a3153dbe7af9cfb8182b7df0a0ceb977941e976a43d80", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "10ddc74c-5c59-4164-9373-688d00c9fdcb", "node_type": "1", "metadata": {"window": "Now it's still quite early to make that call with any specific insight into how flu may interact with COVID and patient \nperception.  So it's som ething we'll continue to monitor and watch.  And then relative to the comments about lab, I \nmean we \u2013 by virtue of our position in the alternate care markets and supporting nursing homes and supporting \nphysician offices, we just have great reach into the co mmunity.  And so as the need for this testing moves into the \ncommunity -based setting, we're well -positioned to take advantage of that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nMaybe just to build on Brian's comment.  The flu vaccine itself within our Medical business is a component of \npharmaceutical distribution within that segment. ", "original_text": "And so as the need for this testing moves into the \ncommunity -based setting, we're well -positioned to take advantage of that.  \n ", "page_label": "18", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "28c9ae105c7a0e5be26d0a96c010529ddec4a618cfa6c344d55aff2f51122ab7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a9e95be6-91fa-494d-ad8d-4964961fb205", "node_type": "1", "metadata": {"window": "And then relative to the comments about lab, I \nmean we \u2013 by virtue of our position in the alternate care markets and supporting nursing homes and supporting \nphysician offices, we just have great reach into the co mmunity.  And so as the need for this testing moves into the \ncommunity -based setting, we're well -positioned to take advantage of that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nMaybe just to build on Brian's comment.  The flu vaccine itself within our Medical business is a component of \npharmaceutical distribution within that segment.  And it's not \u2013 the vaccine itself is not material to the segment. \n And as Brian mentioned, we've thought about this as more of a t ypical flu season that we've seen over the last \nseveral years. ", "original_text": "A \nMaybe just to build on Brian's comment. "}, "hash": "33052ce5d1e8119bb433eb36a2326270dc5954c982052d49a4384d2697392e97", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "start_char_idx": 3725, "end_char_idx": 4085, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a9e95be6-91fa-494d-ad8d-4964961fb205": {"__data__": {"id_": "a9e95be6-91fa-494d-ad8d-4964961fb205", "embedding": null, "metadata": {"window": "And then relative to the comments about lab, I \nmean we \u2013 by virtue of our position in the alternate care markets and supporting nursing homes and supporting \nphysician offices, we just have great reach into the co mmunity.  And so as the need for this testing moves into the \ncommunity -based setting, we're well -positioned to take advantage of that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nMaybe just to build on Brian's comment.  The flu vaccine itself within our Medical business is a component of \npharmaceutical distribution within that segment.  And it's not \u2013 the vaccine itself is not material to the segment. \n And as Brian mentioned, we've thought about this as more of a t ypical flu season that we've seen over the last \nseveral years. ", "original_text": "A \nMaybe just to build on Brian's comment. ", "page_label": "18", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5f4e4711-6225-48b4-92c3-167aa1459c03", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "59bf53b3a30aa3059b3a3153dbe7af9cfb8182b7df0a0ceb977941e976a43d80", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e25d2c4c-f3c1-49ac-a296-3705b03605f5", "node_type": "1", "metadata": {"window": "So it's som ething we'll continue to monitor and watch.  And then relative to the comments about lab, I \nmean we \u2013 by virtue of our position in the alternate care markets and supporting nursing homes and supporting \nphysician offices, we just have great reach into the co mmunity.  And so as the need for this testing moves into the \ncommunity -based setting, we're well -positioned to take advantage of that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nMaybe just to build on Brian's comment.  The flu vaccine itself within our Medical business is a component of \npharmaceutical distribution within that segment.  And it's not \u2013 the vaccine itself is not material to the segment. \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "page_label": "18", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c7019e6536848d799eece4301c1bbda37c5c3405d30c95bbc94b97d88d04efbf", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9bc46997-1f91-4632-9d34-b7249164f379", "node_type": "1", "metadata": {"window": "And so as the need for this testing moves into the \ncommunity -based setting, we're well -positioned to take advantage of that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nMaybe just to build on Brian's comment.  The flu vaccine itself within our Medical business is a component of \npharmaceutical distribution within that segment.  And it's not \u2013 the vaccine itself is not material to the segment. \n And as Brian mentioned, we've thought about this as more of a t ypical flu season that we've seen over the last \nseveral years.  Now if it's a little bit greater than it has been in prior years, again, the vaccine distribution itself is \nnot material to the segment.  \n ", "original_text": "The flu vaccine itself within our Medical business is a component of \npharmaceutical distribution within that segment. "}, "hash": "db58bf2ecbd3428b96b357421785a3f8e1a5d48d9c43e4cacbbdafd8ae26d0e9", "class_name": "RelatedNodeInfo"}}, "text": "A \nMaybe just to build on Brian's comment. ", "start_char_idx": 4085, "end_char_idx": 4128, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9bc46997-1f91-4632-9d34-b7249164f379": {"__data__": {"id_": "9bc46997-1f91-4632-9d34-b7249164f379", "embedding": null, "metadata": {"window": "And so as the need for this testing moves into the \ncommunity -based setting, we're well -positioned to take advantage of that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nMaybe just to build on Brian's comment.  The flu vaccine itself within our Medical business is a component of \npharmaceutical distribution within that segment.  And it's not \u2013 the vaccine itself is not material to the segment. \n And as Brian mentioned, we've thought about this as more of a t ypical flu season that we've seen over the last \nseveral years.  Now if it's a little bit greater than it has been in prior years, again, the vaccine distribution itself is \nnot material to the segment.  \n ", "original_text": "The flu vaccine itself within our Medical business is a component of \npharmaceutical distribution within that segment. ", "page_label": "18", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5f4e4711-6225-48b4-92c3-167aa1459c03", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "59bf53b3a30aa3059b3a3153dbe7af9cfb8182b7df0a0ceb977941e976a43d80", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a9e95be6-91fa-494d-ad8d-4964961fb205", "node_type": "1", "metadata": {"window": "And then relative to the comments about lab, I \nmean we \u2013 by virtue of our position in the alternate care markets and supporting nursing homes and supporting \nphysician offices, we just have great reach into the co mmunity.  And so as the need for this testing moves into the \ncommunity -based setting, we're well -positioned to take advantage of that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nMaybe just to build on Brian's comment.  The flu vaccine itself within our Medical business is a component of \npharmaceutical distribution within that segment.  And it's not \u2013 the vaccine itself is not material to the segment. \n And as Brian mentioned, we've thought about this as more of a t ypical flu season that we've seen over the last \nseveral years. ", "original_text": "A \nMaybe just to build on Brian's comment. ", "page_label": "18", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "75242f769e2ab2dacadc66cc9406d57417758564d9c66e06e4335572607e0573", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f8efa66a-fd0c-44ba-9f3e-9712ca007aaa", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nMaybe just to build on Brian's comment.  The flu vaccine itself within our Medical business is a component of \npharmaceutical distribution within that segment.  And it's not \u2013 the vaccine itself is not material to the segment. \n And as Brian mentioned, we've thought about this as more of a t ypical flu season that we've seen over the last \nseveral years.  Now if it's a little bit greater than it has been in prior years, again, the vaccine distribution itself is \nnot material to the segment.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "And it's not \u2013 the vaccine itself is not material to the segment. \n"}, "hash": "91d7c3b53b093b4d6ad526aaa8a7bdf7bc50cafc319c1aae9a0f13752ec14770", "class_name": "RelatedNodeInfo"}}, "text": "The flu vaccine itself within our Medical business is a component of \npharmaceutical distribution within that segment. ", "start_char_idx": 4128, "end_char_idx": 4247, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f8efa66a-fd0c-44ba-9f3e-9712ca007aaa": {"__data__": {"id_": "f8efa66a-fd0c-44ba-9f3e-9712ca007aaa", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nMaybe just to build on Brian's comment.  The flu vaccine itself within our Medical business is a component of \npharmaceutical distribution within that segment.  And it's not \u2013 the vaccine itself is not material to the segment. \n And as Brian mentioned, we've thought about this as more of a t ypical flu season that we've seen over the last \nseveral years.  Now if it's a little bit greater than it has been in prior years, again, the vaccine distribution itself is \nnot material to the segment.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "And it's not \u2013 the vaccine itself is not material to the segment. \n", "page_label": "18", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5f4e4711-6225-48b4-92c3-167aa1459c03", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "59bf53b3a30aa3059b3a3153dbe7af9cfb8182b7df0a0ceb977941e976a43d80", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9bc46997-1f91-4632-9d34-b7249164f379", "node_type": "1", "metadata": {"window": "And so as the need for this testing moves into the \ncommunity -based setting, we're well -positioned to take advantage of that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nMaybe just to build on Brian's comment.  The flu vaccine itself within our Medical business is a component of \npharmaceutical distribution within that segment.  And it's not \u2013 the vaccine itself is not material to the segment. \n And as Brian mentioned, we've thought about this as more of a t ypical flu season that we've seen over the last \nseveral years.  Now if it's a little bit greater than it has been in prior years, again, the vaccine distribution itself is \nnot material to the segment.  \n ", "original_text": "The flu vaccine itself within our Medical business is a component of \npharmaceutical distribution within that segment. ", "page_label": "18", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2db93cc4654dca4887597c14b39d33cc3c7b08357be399f74db6663226785f06", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "591afdc9-9acf-401d-978b-a02a65f5f5fc", "node_type": "1", "metadata": {"window": "A \nMaybe just to build on Brian's comment.  The flu vaccine itself within our Medical business is a component of \npharmaceutical distribution within that segment.  And it's not \u2013 the vaccine itself is not material to the segment. \n And as Brian mentioned, we've thought about this as more of a t ypical flu season that we've seen over the last \nseveral years.  Now if it's a little bit greater than it has been in prior years, again, the vaccine distribution itself is \nnot material to the segment.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "And as Brian mentioned, we've thought about this as more of a t ypical flu season that we've seen over the last \nseveral years. "}, "hash": "a87c9a19a896d721bd5c1c6e1b28a446b97f10ea9aeeeef5aa6a96841796be90", "class_name": "RelatedNodeInfo"}}, "text": "And it's not \u2013 the vaccine itself is not material to the segment. \n", "start_char_idx": 4247, "end_char_idx": 4314, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "591afdc9-9acf-401d-978b-a02a65f5f5fc": {"__data__": {"id_": "591afdc9-9acf-401d-978b-a02a65f5f5fc", "embedding": null, "metadata": {"window": "A \nMaybe just to build on Brian's comment.  The flu vaccine itself within our Medical business is a component of \npharmaceutical distribution within that segment.  And it's not \u2013 the vaccine itself is not material to the segment. \n And as Brian mentioned, we've thought about this as more of a t ypical flu season that we've seen over the last \nseveral years.  Now if it's a little bit greater than it has been in prior years, again, the vaccine distribution itself is \nnot material to the segment.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "And as Brian mentioned, we've thought about this as more of a t ypical flu season that we've seen over the last \nseveral years. ", "page_label": "18", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5f4e4711-6225-48b4-92c3-167aa1459c03", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "59bf53b3a30aa3059b3a3153dbe7af9cfb8182b7df0a0ceb977941e976a43d80", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f8efa66a-fd0c-44ba-9f3e-9712ca007aaa", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nMaybe just to build on Brian's comment.  The flu vaccine itself within our Medical business is a component of \npharmaceutical distribution within that segment.  And it's not \u2013 the vaccine itself is not material to the segment. \n And as Brian mentioned, we've thought about this as more of a t ypical flu season that we've seen over the last \nseveral years.  Now if it's a little bit greater than it has been in prior years, again, the vaccine distribution itself is \nnot material to the segment.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "And it's not \u2013 the vaccine itself is not material to the segment. \n", "page_label": "18", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "af3d59493972b53a419ed35264e673181c7376f3ae9ee45ffc74cad2bc637cde", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6b02363d-8aef-4cb1-805a-9f827d4ede12", "node_type": "1", "metadata": {"window": "The flu vaccine itself within our Medical business is a component of \npharmaceutical distribution within that segment.  And it's not \u2013 the vaccine itself is not material to the segment. \n And as Brian mentioned, we've thought about this as more of a t ypical flu season that we've seen over the last \nseveral years.  Now if it's a little bit greater than it has been in prior years, again, the vaccine distribution itself is \nnot material to the segment.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "Now if it's a little bit greater than it has been in prior years, again, the vaccine distribution itself is \nnot material to the segment.  \n "}, "hash": "dc4a01930178a4ba67a6078651fe2b6b64812d26b30bbe7fee51784d93fa2979", "class_name": "RelatedNodeInfo"}}, "text": "And as Brian mentioned, we've thought about this as more of a t ypical flu season that we've seen over the last \nseveral years. ", "start_char_idx": 4314, "end_char_idx": 4442, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6b02363d-8aef-4cb1-805a-9f827d4ede12": {"__data__": {"id_": "6b02363d-8aef-4cb1-805a-9f827d4ede12", "embedding": null, "metadata": {"window": "The flu vaccine itself within our Medical business is a component of \npharmaceutical distribution within that segment.  And it's not \u2013 the vaccine itself is not material to the segment. \n And as Brian mentioned, we've thought about this as more of a t ypical flu season that we've seen over the last \nseveral years.  Now if it's a little bit greater than it has been in prior years, again, the vaccine distribution itself is \nnot material to the segment.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "Now if it's a little bit greater than it has been in prior years, again, the vaccine distribution itself is \nnot material to the segment.  \n ", "page_label": "18", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5f4e4711-6225-48b4-92c3-167aa1459c03", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "59bf53b3a30aa3059b3a3153dbe7af9cfb8182b7df0a0ceb977941e976a43d80", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "591afdc9-9acf-401d-978b-a02a65f5f5fc", "node_type": "1", "metadata": {"window": "A \nMaybe just to build on Brian's comment.  The flu vaccine itself within our Medical business is a component of \npharmaceutical distribution within that segment.  And it's not \u2013 the vaccine itself is not material to the segment. \n And as Brian mentioned, we've thought about this as more of a t ypical flu season that we've seen over the last \nseveral years.  Now if it's a little bit greater than it has been in prior years, again, the vaccine distribution itself is \nnot material to the segment.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "And as Brian mentioned, we've thought about this as more of a t ypical flu season that we've seen over the last \nseveral years. ", "page_label": "18", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "37110df494247a0d9084aafbcea5287567a6579d635502f0d4c13f925ed22ced", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "108f56c6-8f37-4741-9255-a5b0054bf7b7", "node_type": "1", "metadata": {"window": "And it's not \u2013 the vaccine itself is not material to the segment. \n And as Brian mentioned, we've thought about this as more of a t ypical flu season that we've seen over the last \nseveral years.  Now if it's a little bit greater than it has been in prior years, again, the vaccine distribution itself is \nnot material to the segment.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  "}, "hash": "fd947652cb17c716a6285845a6866664f2abe24e067d49cd74c83ca7cb4fed72", "class_name": "RelatedNodeInfo"}}, "text": "Now if it's a little bit greater than it has been in prior years, again, the vaccine distribution itself is \nnot material to the segment.  \n ", "start_char_idx": 4442, "end_char_idx": 4583, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "108f56c6-8f37-4741-9255-a5b0054bf7b7": {"__data__": {"id_": "108f56c6-8f37-4741-9255-a5b0054bf7b7", "embedding": null, "metadata": {"window": "And it's not \u2013 the vaccine itself is not material to the segment. \n And as Brian mentioned, we've thought about this as more of a t ypical flu season that we've seen over the last \nseveral years.  Now if it's a little bit greater than it has been in prior years, again, the vaccine distribution itself is \nnot material to the segment.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "page_label": "18", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5f4e4711-6225-48b4-92c3-167aa1459c03", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "59bf53b3a30aa3059b3a3153dbe7af9cfb8182b7df0a0ceb977941e976a43d80", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6b02363d-8aef-4cb1-805a-9f827d4ede12", "node_type": "1", "metadata": {"window": "The flu vaccine itself within our Medical business is a component of \npharmaceutical distribution within that segment.  And it's not \u2013 the vaccine itself is not material to the segment. \n And as Brian mentioned, we've thought about this as more of a t ypical flu season that we've seen over the last \nseveral years.  Now if it's a little bit greater than it has been in prior years, again, the vaccine distribution itself is \nnot material to the segment.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "Now if it's a little bit greater than it has been in prior years, again, the vaccine distribution itself is \nnot material to the segment.  \n ", "page_label": "18", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a49329dfb8c36bd67cab64bc6da63a3066492b7a02029c8f255b39c987797365", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a2b00a35-60bb-405d-9ed3-8ad8ced9ea0e", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nHolly Weiss  \nSenior Vice President, Investor Relations,  McKesson Corp.   A \nOperator, we have time for one more question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Certainly, that question will come from George Hill with Deutsche Bank.  \n ", "original_text": "McKesson Corp.  "}, "hash": "929f6fba95a175b579e09e17df9af6031cad774df531aafe4be9563a9d00481e", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "start_char_idx": 702, "end_char_idx": 973, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a2b00a35-60bb-405d-9ed3-8ad8ced9ea0e": {"__data__": {"id_": "a2b00a35-60bb-405d-9ed3-8ad8ced9ea0e", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nHolly Weiss  \nSenior Vice President, Investor Relations,  McKesson Corp.   A \nOperator, we have time for one more question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Certainly, that question will come from George Hill with Deutsche Bank.  \n ", "original_text": "McKesson Corp.  ", "page_label": "19", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a805158d-a3a9-4f66-90a6-b2bb5b33d14e", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d7497f7a13a75b8a29fa5c90b456f16f8feca3114ee0616189524bec68a7e32f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "108f56c6-8f37-4741-9255-a5b0054bf7b7", "node_type": "1", "metadata": {"window": "And it's not \u2013 the vaccine itself is not material to the segment. \n And as Brian mentioned, we've thought about this as more of a t ypical flu season that we've seen over the last \nseveral years.  Now if it's a little bit greater than it has been in prior years, again, the vaccine distribution itself is \nnot material to the segment.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "page_label": "18", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c08a20759d57eae15086a0635ba1122c99e86b22d218c037707d73d8bbc15b04", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2b0fca36-0288-453e-9b88-acc00f23fda4", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nHolly Weiss  \nSenior Vice President, Investor Relations,  McKesson Corp.   A \nOperator, we have time for one more question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Certainly, that question will come from George Hill with Deutsche Bank.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.  ", "original_text": "(MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nHolly Weiss  \nSenior Vice President, Investor Relations,  McKesson Corp.  "}, "hash": "8e4674278fa87c50a98331d9168d266a7f96445199d12c311472b2b1d1e80ebc", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2b0fca36-0288-453e-9b88-acc00f23fda4": {"__data__": {"id_": "2b0fca36-0288-453e-9b88-acc00f23fda4", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nHolly Weiss  \nSenior Vice President, Investor Relations,  McKesson Corp.   A \nOperator, we have time for one more question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Certainly, that question will come from George Hill with Deutsche Bank.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.  ", "original_text": "(MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nHolly Weiss  \nSenior Vice President, Investor Relations,  McKesson Corp.  ", "page_label": "19", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a805158d-a3a9-4f66-90a6-b2bb5b33d14e", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d7497f7a13a75b8a29fa5c90b456f16f8feca3114ee0616189524bec68a7e32f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a2b00a35-60bb-405d-9ed3-8ad8ced9ea0e", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nHolly Weiss  \nSenior Vice President, Investor Relations,  McKesson Corp.   A \nOperator, we have time for one more question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Certainly, that question will come from George Hill with Deutsche Bank.  \n ", "original_text": "McKesson Corp.  ", "page_label": "19", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bdfec02f3695c4e8a8c8b9d866192fe0791ce2057b9e0a6ed5bc071a86c2a330", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "16b7202d-c187-4a65-ae7d-716f25159236", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nHolly Weiss  \nSenior Vice President, Investor Relations,  McKesson Corp.   A \nOperator, we have time for one more question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Certainly, that question will come from George Hill with Deutsche Bank.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.   Q \nHey, good morning guys, and thanks for squeezing me in. ", "original_text": "A \nOperator, we have time for one more question.  \n "}, "hash": "92da403fee303e3e42b8cd6d20a79783e2c359037db0ff1132fc956fb56d4dcb", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nHolly Weiss  \nSenior Vice President, Investor Relations,  McKesson Corp.  ", "start_char_idx": 16, "end_char_idx": 255, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "16b7202d-c187-4a65-ae7d-716f25159236": {"__data__": {"id_": "16b7202d-c187-4a65-ae7d-716f25159236", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nHolly Weiss  \nSenior Vice President, Investor Relations,  McKesson Corp.   A \nOperator, we have time for one more question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Certainly, that question will come from George Hill with Deutsche Bank.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.   Q \nHey, good morning guys, and thanks for squeezing me in. ", "original_text": "A \nOperator, we have time for one more question.  \n ", "page_label": "19", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a805158d-a3a9-4f66-90a6-b2bb5b33d14e", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d7497f7a13a75b8a29fa5c90b456f16f8feca3114ee0616189524bec68a7e32f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2b0fca36-0288-453e-9b88-acc00f23fda4", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nHolly Weiss  \nSenior Vice President, Investor Relations,  McKesson Corp.   A \nOperator, we have time for one more question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Certainly, that question will come from George Hill with Deutsche Bank.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.  ", "original_text": "(MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nHolly Weiss  \nSenior Vice President, Investor Relations,  McKesson Corp.  ", "page_label": "19", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "99cd576845b34b97848d845a9dac6465b7116f54520e76d6179e633074a43500", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f27040f5-dbbb-4800-9f12-622706f1e184", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nHolly Weiss  \nSenior Vice President, Investor Relations,  McKesson Corp.   A \nOperator, we have time for one more question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Certainly, that question will come from George Hill with Deutsche Bank.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.   Q \nHey, good morning guys, and thanks for squeezing me in.  I guess nobody's asked the opioid question. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Certainly, that question will come from George Hill with Deutsche Bank.  \n "}, "hash": "fe95ff1743ffc5fafc5bffa254e3039652232bdb188f3421bfbe1c407d5a8bf0", "class_name": "RelatedNodeInfo"}}, "text": "A \nOperator, we have time for one more question.  \n ", "start_char_idx": 255, "end_char_idx": 307, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f27040f5-dbbb-4800-9f12-622706f1e184": {"__data__": {"id_": "f27040f5-dbbb-4800-9f12-622706f1e184", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nHolly Weiss  \nSenior Vice President, Investor Relations,  McKesson Corp.   A \nOperator, we have time for one more question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Certainly, that question will come from George Hill with Deutsche Bank.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.   Q \nHey, good morning guys, and thanks for squeezing me in.  I guess nobody's asked the opioid question. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Certainly, that question will come from George Hill with Deutsche Bank.  \n ", "page_label": "19", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a805158d-a3a9-4f66-90a6-b2bb5b33d14e", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d7497f7a13a75b8a29fa5c90b456f16f8feca3114ee0616189524bec68a7e32f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "16b7202d-c187-4a65-ae7d-716f25159236", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nHolly Weiss  \nSenior Vice President, Investor Relations,  McKesson Corp.   A \nOperator, we have time for one more question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Certainly, that question will come from George Hill with Deutsche Bank.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.   Q \nHey, good morning guys, and thanks for squeezing me in. ", "original_text": "A \nOperator, we have time for one more question.  \n ", "page_label": "19", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3e48daf61e97918b46cf943fcfc1e5780d17e73356ad71106b6d0168106eb4b1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c5218a91-3831-4803-8fda-909cf28d2c17", "node_type": "1", "metadata": {"window": "(MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nHolly Weiss  \nSenior Vice President, Investor Relations,  McKesson Corp.   A \nOperator, we have time for one more question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Certainly, that question will come from George Hill with Deutsche Bank.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.   Q \nHey, good morning guys, and thanks for squeezing me in.  I guess nobody's asked the opioid question.  I was little \nsurprised to see opioid litigation expenses up year -over-year. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.  "}, "hash": "4581646f488e78af52c67107e26a1d0e614ad2b3426371cfdddb3ecbdab6da0f", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Certainly, that question will come from George Hill with Deutsche Bank.  \n ", "start_char_idx": 307, "end_char_idx": 667, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c5218a91-3831-4803-8fda-909cf28d2c17": {"__data__": {"id_": "c5218a91-3831-4803-8fda-909cf28d2c17", "embedding": null, "metadata": {"window": "(MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nHolly Weiss  \nSenior Vice President, Investor Relations,  McKesson Corp.   A \nOperator, we have time for one more question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Certainly, that question will come from George Hill with Deutsche Bank.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.   Q \nHey, good morning guys, and thanks for squeezing me in.  I guess nobody's asked the opioid question.  I was little \nsurprised to see opioid litigation expenses up year -over-year. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.  ", "page_label": "19", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a805158d-a3a9-4f66-90a6-b2bb5b33d14e", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d7497f7a13a75b8a29fa5c90b456f16f8feca3114ee0616189524bec68a7e32f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f27040f5-dbbb-4800-9f12-622706f1e184", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nHolly Weiss  \nSenior Vice President, Investor Relations,  McKesson Corp.   A \nOperator, we have time for one more question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Certainly, that question will come from George Hill with Deutsche Bank.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.   Q \nHey, good morning guys, and thanks for squeezing me in.  I guess nobody's asked the opioid question. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Certainly, that question will come from George Hill with Deutsche Bank.  \n ", "page_label": "19", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1b4e2f9ea77e44e024f66b88ef48049c8533d1bf6b60dc7943fa1013bca5dd55", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b7990ec0-7155-4e81-aad1-833c2f9cd768", "node_type": "1", "metadata": {"window": "A \nOperator, we have time for one more question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Certainly, that question will come from George Hill with Deutsche Bank.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.   Q \nHey, good morning guys, and thanks for squeezing me in.  I guess nobody's asked the opioid question.  I was little \nsurprised to see opioid litigation expenses up year -over-year.  I guess, just do you guys feel like any progress has \nbeen made on the opioid litigation front over the last quarter? ", "original_text": "Q \nHey, good morning guys, and thanks for squeezing me in. "}, "hash": "b1cbf2bbe60cc6c4e83c861065b212b8b371eea04b618ece885d43671d12685f", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.  ", "start_char_idx": 667, "end_char_idx": 994, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b7990ec0-7155-4e81-aad1-833c2f9cd768": {"__data__": {"id_": "b7990ec0-7155-4e81-aad1-833c2f9cd768", "embedding": null, "metadata": {"window": "A \nOperator, we have time for one more question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Certainly, that question will come from George Hill with Deutsche Bank.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.   Q \nHey, good morning guys, and thanks for squeezing me in.  I guess nobody's asked the opioid question.  I was little \nsurprised to see opioid litigation expenses up year -over-year.  I guess, just do you guys feel like any progress has \nbeen made on the opioid litigation front over the last quarter? ", "original_text": "Q \nHey, good morning guys, and thanks for squeezing me in. ", "page_label": "19", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a805158d-a3a9-4f66-90a6-b2bb5b33d14e", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d7497f7a13a75b8a29fa5c90b456f16f8feca3114ee0616189524bec68a7e32f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c5218a91-3831-4803-8fda-909cf28d2c17", "node_type": "1", "metadata": {"window": "(MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nHolly Weiss  \nSenior Vice President, Investor Relations,  McKesson Corp.   A \nOperator, we have time for one more question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Certainly, that question will come from George Hill with Deutsche Bank.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.   Q \nHey, good morning guys, and thanks for squeezing me in.  I guess nobody's asked the opioid question.  I was little \nsurprised to see opioid litigation expenses up year -over-year. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.  ", "page_label": "19", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ea07cb6df515e056d439ef04c6395977d9ff08da19090f8ca22b7eca5f1a05d9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b4f7f26c-5eba-4cf5-a641-e186d6aa389f", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Certainly, that question will come from George Hill with Deutsche Bank.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.   Q \nHey, good morning guys, and thanks for squeezing me in.  I guess nobody's asked the opioid question.  I was little \nsurprised to see opioid litigation expenses up year -over-year.  I guess, just do you guys feel like any progress has \nbeen made on the opioid litigation front over the last quarter?  And kind of any update in that process would be \nhelpful. ", "original_text": "I guess nobody's asked the opioid question. "}, "hash": "764dcca0eab9e7d8f2f7b4841791981866520e5c1df4d8d3cd5e440edb19c9e7", "class_name": "RelatedNodeInfo"}}, "text": "Q \nHey, good morning guys, and thanks for squeezing me in. ", "start_char_idx": 994, "end_char_idx": 1053, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b4f7f26c-5eba-4cf5-a641-e186d6aa389f": {"__data__": {"id_": "b4f7f26c-5eba-4cf5-a641-e186d6aa389f", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Certainly, that question will come from George Hill with Deutsche Bank.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.   Q \nHey, good morning guys, and thanks for squeezing me in.  I guess nobody's asked the opioid question.  I was little \nsurprised to see opioid litigation expenses up year -over-year.  I guess, just do you guys feel like any progress has \nbeen made on the opioid litigation front over the last quarter?  And kind of any update in that process would be \nhelpful. ", "original_text": "I guess nobody's asked the opioid question. ", "page_label": "19", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a805158d-a3a9-4f66-90a6-b2bb5b33d14e", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d7497f7a13a75b8a29fa5c90b456f16f8feca3114ee0616189524bec68a7e32f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b7990ec0-7155-4e81-aad1-833c2f9cd768", "node_type": "1", "metadata": {"window": "A \nOperator, we have time for one more question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Certainly, that question will come from George Hill with Deutsche Bank.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.   Q \nHey, good morning guys, and thanks for squeezing me in.  I guess nobody's asked the opioid question.  I was little \nsurprised to see opioid litigation expenses up year -over-year.  I guess, just do you guys feel like any progress has \nbeen made on the opioid litigation front over the last quarter? ", "original_text": "Q \nHey, good morning guys, and thanks for squeezing me in. ", "page_label": "19", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "baffb4923bef69abcccfb92289bbe03177d1d89b3a5f88aefd0c474640f3e89f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "00b8e4fb-a465-4639-9088-b7fc092cf380", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.   Q \nHey, good morning guys, and thanks for squeezing me in.  I guess nobody's asked the opioid question.  I was little \nsurprised to see opioid litigation expenses up year -over-year.  I guess, just do you guys feel like any progress has \nbeen made on the opioid litigation front over the last quarter?  And kind of any update in that process would be \nhelpful.  Thank you.  \n ", "original_text": "I was little \nsurprised to see opioid litigation expenses up year -over-year. "}, "hash": "0df688f8909a023c5d867d9b7a4d65b8ef9ee5cffa8056c5e880913c2218b0ae", "class_name": "RelatedNodeInfo"}}, "text": "I guess nobody's asked the opioid question. ", "start_char_idx": 1053, "end_char_idx": 1097, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "00b8e4fb-a465-4639-9088-b7fc092cf380": {"__data__": {"id_": "00b8e4fb-a465-4639-9088-b7fc092cf380", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.   Q \nHey, good morning guys, and thanks for squeezing me in.  I guess nobody's asked the opioid question.  I was little \nsurprised to see opioid litigation expenses up year -over-year.  I guess, just do you guys feel like any progress has \nbeen made on the opioid litigation front over the last quarter?  And kind of any update in that process would be \nhelpful.  Thank you.  \n ", "original_text": "I was little \nsurprised to see opioid litigation expenses up year -over-year. ", "page_label": "19", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a805158d-a3a9-4f66-90a6-b2bb5b33d14e", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d7497f7a13a75b8a29fa5c90b456f16f8feca3114ee0616189524bec68a7e32f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b4f7f26c-5eba-4cf5-a641-e186d6aa389f", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Certainly, that question will come from George Hill with Deutsche Bank.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.   Q \nHey, good morning guys, and thanks for squeezing me in.  I guess nobody's asked the opioid question.  I was little \nsurprised to see opioid litigation expenses up year -over-year.  I guess, just do you guys feel like any progress has \nbeen made on the opioid litigation front over the last quarter?  And kind of any update in that process would be \nhelpful. ", "original_text": "I guess nobody's asked the opioid question. ", "page_label": "19", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fa44843db220093774bfa73d469dba994544bffef778c1166011bbe8ae1397b7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e789c0bb-b030-4904-87d7-2179fe3f30ef", "node_type": "1", "metadata": {"window": "Q \nHey, good morning guys, and thanks for squeezing me in.  I guess nobody's asked the opioid question.  I was little \nsurprised to see opioid litigation expenses up year -over-year.  I guess, just do you guys feel like any progress has \nbeen made on the opioid litigation front over the last quarter?  And kind of any update in that process would be \nhelpful.  Thank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "I guess, just do you guys feel like any progress has \nbeen made on the opioid litigation front over the last quarter? "}, "hash": "910b76de8c23ca4dd8002d5d7b8c839707395117e19642d9ecffbe9b2d88e2fd", "class_name": "RelatedNodeInfo"}}, "text": "I was little \nsurprised to see opioid litigation expenses up year -over-year. ", "start_char_idx": 1097, "end_char_idx": 1175, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e789c0bb-b030-4904-87d7-2179fe3f30ef": {"__data__": {"id_": "e789c0bb-b030-4904-87d7-2179fe3f30ef", "embedding": null, "metadata": {"window": "Q \nHey, good morning guys, and thanks for squeezing me in.  I guess nobody's asked the opioid question.  I was little \nsurprised to see opioid litigation expenses up year -over-year.  I guess, just do you guys feel like any progress has \nbeen made on the opioid litigation front over the last quarter?  And kind of any update in that process would be \nhelpful.  Thank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "I guess, just do you guys feel like any progress has \nbeen made on the opioid litigation front over the last quarter? ", "page_label": "19", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a805158d-a3a9-4f66-90a6-b2bb5b33d14e", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d7497f7a13a75b8a29fa5c90b456f16f8feca3114ee0616189524bec68a7e32f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "00b8e4fb-a465-4639-9088-b7fc092cf380", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.   Q \nHey, good morning guys, and thanks for squeezing me in.  I guess nobody's asked the opioid question.  I was little \nsurprised to see opioid litigation expenses up year -over-year.  I guess, just do you guys feel like any progress has \nbeen made on the opioid litigation front over the last quarter?  And kind of any update in that process would be \nhelpful.  Thank you.  \n ", "original_text": "I was little \nsurprised to see opioid litigation expenses up year -over-year. ", "page_label": "19", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2c4bcd2b87357db8f34c547facc353a081144d7c0b077b3fae563e7501048ac9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "567fbbd0-742e-4df0-90fe-70a26e33e5c1", "node_type": "1", "metadata": {"window": "I guess nobody's asked the opioid question.  I was little \nsurprised to see opioid litigation expenses up year -over-year.  I guess, just do you guys feel like any progress has \nbeen made on the opioid litigation front over the last quarter?  And kind of any update in that process would be \nhelpful.  Thank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThanks, George. ", "original_text": "And kind of any update in that process would be \nhelpful. "}, "hash": "6096162a6ab8f2f31ebb8d3af6452079fdd5555776bf09858d6b9bb9088e6b3e", "class_name": "RelatedNodeInfo"}}, "text": "I guess, just do you guys feel like any progress has \nbeen made on the opioid litigation front over the last quarter? ", "start_char_idx": 1175, "end_char_idx": 1293, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "567fbbd0-742e-4df0-90fe-70a26e33e5c1": {"__data__": {"id_": "567fbbd0-742e-4df0-90fe-70a26e33e5c1", "embedding": null, "metadata": {"window": "I guess nobody's asked the opioid question.  I was little \nsurprised to see opioid litigation expenses up year -over-year.  I guess, just do you guys feel like any progress has \nbeen made on the opioid litigation front over the last quarter?  And kind of any update in that process would be \nhelpful.  Thank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThanks, George. ", "original_text": "And kind of any update in that process would be \nhelpful. ", "page_label": "19", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a805158d-a3a9-4f66-90a6-b2bb5b33d14e", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d7497f7a13a75b8a29fa5c90b456f16f8feca3114ee0616189524bec68a7e32f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e789c0bb-b030-4904-87d7-2179fe3f30ef", "node_type": "1", "metadata": {"window": "Q \nHey, good morning guys, and thanks for squeezing me in.  I guess nobody's asked the opioid question.  I was little \nsurprised to see opioid litigation expenses up year -over-year.  I guess, just do you guys feel like any progress has \nbeen made on the opioid litigation front over the last quarter?  And kind of any update in that process would be \nhelpful.  Thank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "I guess, just do you guys feel like any progress has \nbeen made on the opioid litigation front over the last quarter? ", "page_label": "19", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "dec1420ad417c2ffe0e11a22d1f8f7704a867404e2d264d23ac62acd97bfc1eb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ab9be6da-2cb9-4141-b318-1ce50a83d6e4", "node_type": "1", "metadata": {"window": "I was little \nsurprised to see opioid litigation expenses up year -over-year.  I guess, just do you guys feel like any progress has \nbeen made on the opioid litigation front over the last quarter?  And kind of any update in that process would be \nhelpful.  Thank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThanks, George.  I'll take this one. ", "original_text": "Thank you.  \n "}, "hash": "e2bfb5eb2f287cd57f8396bd9bf3bda52c0016e7738420b46b136aa028f923aa", "class_name": "RelatedNodeInfo"}}, "text": "And kind of any update in that process would be \nhelpful. ", "start_char_idx": 1293, "end_char_idx": 1351, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ab9be6da-2cb9-4141-b318-1ce50a83d6e4": {"__data__": {"id_": "ab9be6da-2cb9-4141-b318-1ce50a83d6e4", "embedding": null, "metadata": {"window": "I was little \nsurprised to see opioid litigation expenses up year -over-year.  I guess, just do you guys feel like any progress has \nbeen made on the opioid litigation front over the last quarter?  And kind of any update in that process would be \nhelpful.  Thank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThanks, George.  I'll take this one. ", "original_text": "Thank you.  \n ", "page_label": "19", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a805158d-a3a9-4f66-90a6-b2bb5b33d14e", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d7497f7a13a75b8a29fa5c90b456f16f8feca3114ee0616189524bec68a7e32f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "567fbbd0-742e-4df0-90fe-70a26e33e5c1", "node_type": "1", "metadata": {"window": "I guess nobody's asked the opioid question.  I was little \nsurprised to see opioid litigation expenses up year -over-year.  I guess, just do you guys feel like any progress has \nbeen made on the opioid litigation front over the last quarter?  And kind of any update in that process would be \nhelpful.  Thank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThanks, George. ", "original_text": "And kind of any update in that process would be \nhelpful. ", "page_label": "19", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9e030c78c64e076db4a135ce52c5f02a24d0a1e6327b7a11144156a8f99b0802", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "89380c8b-31de-496f-972e-3b6baf9cba71", "node_type": "1", "metadata": {"window": "I guess, just do you guys feel like any progress has \nbeen made on the opioid litigation front over the last quarter?  And kind of any update in that process would be \nhelpful.  Thank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThanks, George.  I'll take this one.  And I really don't have any, kind of, material update. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  "}, "hash": "974538e66c9ababdca6d4ad7d86cdee8e3b59758287002f2c869617cb49846b2", "class_name": "RelatedNodeInfo"}}, "text": "Thank you.  \n ", "start_char_idx": 1351, "end_char_idx": 1365, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "89380c8b-31de-496f-972e-3b6baf9cba71": {"__data__": {"id_": "89380c8b-31de-496f-972e-3b6baf9cba71", "embedding": null, "metadata": {"window": "I guess, just do you guys feel like any progress has \nbeen made on the opioid litigation front over the last quarter?  And kind of any update in that process would be \nhelpful.  Thank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThanks, George.  I'll take this one.  And I really don't have any, kind of, material update. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "19", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a805158d-a3a9-4f66-90a6-b2bb5b33d14e", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d7497f7a13a75b8a29fa5c90b456f16f8feca3114ee0616189524bec68a7e32f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ab9be6da-2cb9-4141-b318-1ce50a83d6e4", "node_type": "1", "metadata": {"window": "I was little \nsurprised to see opioid litigation expenses up year -over-year.  I guess, just do you guys feel like any progress has \nbeen made on the opioid litigation front over the last quarter?  And kind of any update in that process would be \nhelpful.  Thank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThanks, George.  I'll take this one. ", "original_text": "Thank you.  \n ", "page_label": "19", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d63bd96c918ccb7a9ed9f7eaa0b27ce796b0fc9f77e0b8cdc0047b60ec5e2d7c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8f894659-d038-45e5-9701-988f35146e0a", "node_type": "1", "metadata": {"window": "And kind of any update in that process would be \nhelpful.  Thank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThanks, George.  I'll take this one.  And I really don't have any, kind of, material update.  We do continue to be \nengaged in discus sions with attorneys, generals and others. ", "original_text": "A \nThanks, George. "}, "hash": "896cf48c24eea5dd0d1ac3ca8a55e46464e3d3cec4e235896f6f2c2255e00d23", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "start_char_idx": 1365, "end_char_idx": 1706, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8f894659-d038-45e5-9701-988f35146e0a": {"__data__": {"id_": "8f894659-d038-45e5-9701-988f35146e0a", "embedding": null, "metadata": {"window": "And kind of any update in that process would be \nhelpful.  Thank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThanks, George.  I'll take this one.  And I really don't have any, kind of, material update.  We do continue to be \nengaged in discus sions with attorneys, generals and others. ", "original_text": "A \nThanks, George. ", "page_label": "19", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a805158d-a3a9-4f66-90a6-b2bb5b33d14e", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d7497f7a13a75b8a29fa5c90b456f16f8feca3114ee0616189524bec68a7e32f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "89380c8b-31de-496f-972e-3b6baf9cba71", "node_type": "1", "metadata": {"window": "I guess, just do you guys feel like any progress has \nbeen made on the opioid litigation front over the last quarter?  And kind of any update in that process would be \nhelpful.  Thank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThanks, George.  I'll take this one.  And I really don't have any, kind of, material update. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "19", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e2c6463bf15d6983ad9534a16eadcb20163123c6175fe329987f679ae4cd9bf9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "36a340f9-5d06-4fab-8f5d-fcb0db863020", "node_type": "1", "metadata": {"window": "Thank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThanks, George.  I'll take this one.  And I really don't have any, kind of, material update.  We do continue to be \nengaged in discus sions with attorneys, generals and others.  We do remain hopeful that broad resolution can be \nachieved. ", "original_text": "I'll take this one. "}, "hash": "15b7d835ca8c7b073c19896f9232f31f054273c2acd6f117f4f0f6cf3455f71b", "class_name": "RelatedNodeInfo"}}, "text": "A \nThanks, George. ", "start_char_idx": 1706, "end_char_idx": 1725, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "36a340f9-5d06-4fab-8f5d-fcb0db863020": {"__data__": {"id_": "36a340f9-5d06-4fab-8f5d-fcb0db863020", "embedding": null, "metadata": {"window": "Thank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThanks, George.  I'll take this one.  And I really don't have any, kind of, material update.  We do continue to be \nengaged in discus sions with attorneys, generals and others.  We do remain hopeful that broad resolution can be \nachieved. ", "original_text": "I'll take this one. ", "page_label": "19", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a805158d-a3a9-4f66-90a6-b2bb5b33d14e", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d7497f7a13a75b8a29fa5c90b456f16f8feca3114ee0616189524bec68a7e32f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8f894659-d038-45e5-9701-988f35146e0a", "node_type": "1", "metadata": {"window": "And kind of any update in that process would be \nhelpful.  Thank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThanks, George.  I'll take this one.  And I really don't have any, kind of, material update.  We do continue to be \nengaged in discus sions with attorneys, generals and others. ", "original_text": "A \nThanks, George. ", "page_label": "19", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b612e964132010246d36c10d5233bee0cbebbff260bfc2c59c886f62f4c297d2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "30aceb49-1584-4f57-ae2a-952026569531", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThanks, George.  I'll take this one.  And I really don't have any, kind of, material update.  We do continue to be \nengaged in discus sions with attorneys, generals and others.  We do remain hopeful that broad resolution can be \nachieved.  We think it's important that if there's a path to accelerate relief efforts for people and the communities \nimpacted that we find a way to take that path.  \n \n", "original_text": "And I really don't have any, kind of, material update. "}, "hash": "1a4e668365c05b9c37e6ca82ce7fa1addb973c26bec91a5f28be91bbac4e780a", "class_name": "RelatedNodeInfo"}}, "text": "I'll take this one. ", "start_char_idx": 1725, "end_char_idx": 1745, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "30aceb49-1584-4f57-ae2a-952026569531": {"__data__": {"id_": "30aceb49-1584-4f57-ae2a-952026569531", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThanks, George.  I'll take this one.  And I really don't have any, kind of, material update.  We do continue to be \nengaged in discus sions with attorneys, generals and others.  We do remain hopeful that broad resolution can be \nachieved.  We think it's important that if there's a path to accelerate relief efforts for people and the communities \nimpacted that we find a way to take that path.  \n \n", "original_text": "And I really don't have any, kind of, material update. ", "page_label": "19", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a805158d-a3a9-4f66-90a6-b2bb5b33d14e", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d7497f7a13a75b8a29fa5c90b456f16f8feca3114ee0616189524bec68a7e32f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "36a340f9-5d06-4fab-8f5d-fcb0db863020", "node_type": "1", "metadata": {"window": "Thank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThanks, George.  I'll take this one.  And I really don't have any, kind of, material update.  We do continue to be \nengaged in discus sions with attorneys, generals and others.  We do remain hopeful that broad resolution can be \nachieved. ", "original_text": "I'll take this one. ", "page_label": "19", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6a537c1027302d48542e8acf54b1027c38b97e54a78bed059996c8e767442e9a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fd594a45-7d0e-47b1-847d-13e94970443a", "node_type": "1", "metadata": {"window": "A \nThanks, George.  I'll take this one.  And I really don't have any, kind of, material update.  We do continue to be \nengaged in discus sions with attorneys, generals and others.  We do remain hopeful that broad resolution can be \nachieved.  We think it's important that if there's a path to accelerate relief efforts for people and the communities \nimpacted that we find a way to take that path.  \n \n You can imagine the amount of focus on COVID -19 over the past quarter, but we do continue the dialogue, we do \ncontinue to be optimistic that a broad resolution could be reached, and we do continue to prepare our defense in \nthe event that it can't be. ", "original_text": "We do continue to be \nengaged in discus sions with attorneys, generals and others. "}, "hash": "ebc690371f4407ca44d84086509c7ec4b35f7414bd605656321322fd871687a7", "class_name": "RelatedNodeInfo"}}, "text": "And I really don't have any, kind of, material update. ", "start_char_idx": 1745, "end_char_idx": 1800, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fd594a45-7d0e-47b1-847d-13e94970443a": {"__data__": {"id_": "fd594a45-7d0e-47b1-847d-13e94970443a", "embedding": null, "metadata": {"window": "A \nThanks, George.  I'll take this one.  And I really don't have any, kind of, material update.  We do continue to be \nengaged in discus sions with attorneys, generals and others.  We do remain hopeful that broad resolution can be \nachieved.  We think it's important that if there's a path to accelerate relief efforts for people and the communities \nimpacted that we find a way to take that path.  \n \n You can imagine the amount of focus on COVID -19 over the past quarter, but we do continue the dialogue, we do \ncontinue to be optimistic that a broad resolution could be reached, and we do continue to prepare our defense in \nthe event that it can't be. ", "original_text": "We do continue to be \nengaged in discus sions with attorneys, generals and others. ", "page_label": "19", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a805158d-a3a9-4f66-90a6-b2bb5b33d14e", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d7497f7a13a75b8a29fa5c90b456f16f8feca3114ee0616189524bec68a7e32f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "30aceb49-1584-4f57-ae2a-952026569531", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThanks, George.  I'll take this one.  And I really don't have any, kind of, material update.  We do continue to be \nengaged in discus sions with attorneys, generals and others.  We do remain hopeful that broad resolution can be \nachieved.  We think it's important that if there's a path to accelerate relief efforts for people and the communities \nimpacted that we find a way to take that path.  \n \n", "original_text": "And I really don't have any, kind of, material update. ", "page_label": "19", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d0988ffb8cf79b4a13fc1a987fc19c185be02a66a84f32e23ed79a196958fddb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b1b20555-9249-40b1-ad72-8fb045613ffa", "node_type": "1", "metadata": {"window": "I'll take this one.  And I really don't have any, kind of, material update.  We do continue to be \nengaged in discus sions with attorneys, generals and others.  We do remain hopeful that broad resolution can be \nachieved.  We think it's important that if there's a path to accelerate relief efforts for people and the communities \nimpacted that we find a way to take that path.  \n \n You can imagine the amount of focus on COVID -19 over the past quarter, but we do continue the dialogue, we do \ncontinue to be optimistic that a broad resolution could be reached, and we do continue to prepare our defense in \nthe event that it can't be.  And  that's about all I can add to that.  \n ", "original_text": "We do remain hopeful that broad resolution can be \nachieved. "}, "hash": "afc4ce455dafa0b1b2b96ef7e3ce5e89f3503bbd16b719322d52f3a49bfe5562", "class_name": "RelatedNodeInfo"}}, "text": "We do continue to be \nengaged in discus sions with attorneys, generals and others. ", "start_char_idx": 1800, "end_char_idx": 1883, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b1b20555-9249-40b1-ad72-8fb045613ffa": {"__data__": {"id_": "b1b20555-9249-40b1-ad72-8fb045613ffa", "embedding": null, "metadata": {"window": "I'll take this one.  And I really don't have any, kind of, material update.  We do continue to be \nengaged in discus sions with attorneys, generals and others.  We do remain hopeful that broad resolution can be \nachieved.  We think it's important that if there's a path to accelerate relief efforts for people and the communities \nimpacted that we find a way to take that path.  \n \n You can imagine the amount of focus on COVID -19 over the past quarter, but we do continue the dialogue, we do \ncontinue to be optimistic that a broad resolution could be reached, and we do continue to prepare our defense in \nthe event that it can't be.  And  that's about all I can add to that.  \n ", "original_text": "We do remain hopeful that broad resolution can be \nachieved. ", "page_label": "19", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a805158d-a3a9-4f66-90a6-b2bb5b33d14e", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d7497f7a13a75b8a29fa5c90b456f16f8feca3114ee0616189524bec68a7e32f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fd594a45-7d0e-47b1-847d-13e94970443a", "node_type": "1", "metadata": {"window": "A \nThanks, George.  I'll take this one.  And I really don't have any, kind of, material update.  We do continue to be \nengaged in discus sions with attorneys, generals and others.  We do remain hopeful that broad resolution can be \nachieved.  We think it's important that if there's a path to accelerate relief efforts for people and the communities \nimpacted that we find a way to take that path.  \n \n You can imagine the amount of focus on COVID -19 over the past quarter, but we do continue the dialogue, we do \ncontinue to be optimistic that a broad resolution could be reached, and we do continue to prepare our defense in \nthe event that it can't be. ", "original_text": "We do continue to be \nengaged in discus sions with attorneys, generals and others. ", "page_label": "19", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f3959a38661713ace86b7591f04d477921ccc38c0dffba796f41abb69c91c8fa", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c9dccec2-53e1-4551-aae1-10e0eba706d7", "node_type": "1", "metadata": {"window": "And I really don't have any, kind of, material update.  We do continue to be \nengaged in discus sions with attorneys, generals and others.  We do remain hopeful that broad resolution can be \nachieved.  We think it's important that if there's a path to accelerate relief efforts for people and the communities \nimpacted that we find a way to take that path.  \n \n You can imagine the amount of focus on COVID -19 over the past quarter, but we do continue the dialogue, we do \ncontinue to be optimistic that a broad resolution could be reached, and we do continue to prepare our defense in \nthe event that it can't be.  And  that's about all I can add to that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n", "original_text": "We think it's important that if there's a path to accelerate relief efforts for people and the communities \nimpacted that we find a way to take that path.  \n \n"}, "hash": "4460bf922e7f8254f6dd68c3a01db72bbcc5bb2977e7ac300ab96673b8eae8cb", "class_name": "RelatedNodeInfo"}}, "text": "We do remain hopeful that broad resolution can be \nachieved. ", "start_char_idx": 1883, "end_char_idx": 1944, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c9dccec2-53e1-4551-aae1-10e0eba706d7": {"__data__": {"id_": "c9dccec2-53e1-4551-aae1-10e0eba706d7", "embedding": null, "metadata": {"window": "And I really don't have any, kind of, material update.  We do continue to be \nengaged in discus sions with attorneys, generals and others.  We do remain hopeful that broad resolution can be \nachieved.  We think it's important that if there's a path to accelerate relief efforts for people and the communities \nimpacted that we find a way to take that path.  \n \n You can imagine the amount of focus on COVID -19 over the past quarter, but we do continue the dialogue, we do \ncontinue to be optimistic that a broad resolution could be reached, and we do continue to prepare our defense in \nthe event that it can't be.  And  that's about all I can add to that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n", "original_text": "We think it's important that if there's a path to accelerate relief efforts for people and the communities \nimpacted that we find a way to take that path.  \n \n", "page_label": "19", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a805158d-a3a9-4f66-90a6-b2bb5b33d14e", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d7497f7a13a75b8a29fa5c90b456f16f8feca3114ee0616189524bec68a7e32f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b1b20555-9249-40b1-ad72-8fb045613ffa", "node_type": "1", "metadata": {"window": "I'll take this one.  And I really don't have any, kind of, material update.  We do continue to be \nengaged in discus sions with attorneys, generals and others.  We do remain hopeful that broad resolution can be \nachieved.  We think it's important that if there's a path to accelerate relief efforts for people and the communities \nimpacted that we find a way to take that path.  \n \n You can imagine the amount of focus on COVID -19 over the past quarter, but we do continue the dialogue, we do \ncontinue to be optimistic that a broad resolution could be reached, and we do continue to prepare our defense in \nthe event that it can't be.  And  that's about all I can add to that.  \n ", "original_text": "We do remain hopeful that broad resolution can be \nachieved. ", "page_label": "19", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "aaafa05da13beca98d32bd703fd6468439b85beb03592a04f987d366e35c1710", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2495ce3e-7312-4fe0-8e9e-279d78579f54", "node_type": "1", "metadata": {"window": "We do continue to be \nengaged in discus sions with attorneys, generals and others.  We do remain hopeful that broad resolution can be \nachieved.  We think it's important that if there's a path to accelerate relief efforts for people and the communities \nimpacted that we find a way to take that path.  \n \n You can imagine the amount of focus on COVID -19 over the past quarter, but we do continue the dialogue, we do \ncontinue to be optimistic that a broad resolution could be reached, and we do continue to prepare our defense in \nthe event that it can't be.  And  that's about all I can add to that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Well, thank you, everyone for your questions, and thank you for joining us on the call. ", "original_text": "You can imagine the amount of focus on COVID -19 over the past quarter, but we do continue the dialogue, we do \ncontinue to be optimistic that a broad resolution could be reached, and we do continue to prepare our defense in \nthe event that it can't be. "}, "hash": "d7cfd034471211c5d4e026a784586c41d931c1f513a2125137a5728aea91a2e6", "class_name": "RelatedNodeInfo"}}, "text": "We think it's important that if there's a path to accelerate relief efforts for people and the communities \nimpacted that we find a way to take that path.  \n \n", "start_char_idx": 1944, "end_char_idx": 2103, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2495ce3e-7312-4fe0-8e9e-279d78579f54": {"__data__": {"id_": "2495ce3e-7312-4fe0-8e9e-279d78579f54", "embedding": null, "metadata": {"window": "We do continue to be \nengaged in discus sions with attorneys, generals and others.  We do remain hopeful that broad resolution can be \nachieved.  We think it's important that if there's a path to accelerate relief efforts for people and the communities \nimpacted that we find a way to take that path.  \n \n You can imagine the amount of focus on COVID -19 over the past quarter, but we do continue the dialogue, we do \ncontinue to be optimistic that a broad resolution could be reached, and we do continue to prepare our defense in \nthe event that it can't be.  And  that's about all I can add to that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Well, thank you, everyone for your questions, and thank you for joining us on the call. ", "original_text": "You can imagine the amount of focus on COVID -19 over the past quarter, but we do continue the dialogue, we do \ncontinue to be optimistic that a broad resolution could be reached, and we do continue to prepare our defense in \nthe event that it can't be. ", "page_label": "19", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a805158d-a3a9-4f66-90a6-b2bb5b33d14e", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d7497f7a13a75b8a29fa5c90b456f16f8feca3114ee0616189524bec68a7e32f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c9dccec2-53e1-4551-aae1-10e0eba706d7", "node_type": "1", "metadata": {"window": "And I really don't have any, kind of, material update.  We do continue to be \nengaged in discus sions with attorneys, generals and others.  We do remain hopeful that broad resolution can be \nachieved.  We think it's important that if there's a path to accelerate relief efforts for people and the communities \nimpacted that we find a way to take that path.  \n \n You can imagine the amount of focus on COVID -19 over the past quarter, but we do continue the dialogue, we do \ncontinue to be optimistic that a broad resolution could be reached, and we do continue to prepare our defense in \nthe event that it can't be.  And  that's about all I can add to that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n", "original_text": "We think it's important that if there's a path to accelerate relief efforts for people and the communities \nimpacted that we find a way to take that path.  \n \n", "page_label": "19", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "394fd7421687e9f518997fe7ff1ff69279390954e656e9b1569f6f28ea6e2733", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0ecdefc8-32dd-4bf3-859c-562177d845b2", "node_type": "1", "metadata": {"window": "We do remain hopeful that broad resolution can be \nachieved.  We think it's important that if there's a path to accelerate relief efforts for people and the communities \nimpacted that we find a way to take that path.  \n \n You can imagine the amount of focus on COVID -19 over the past quarter, but we do continue the dialogue, we do \ncontinue to be optimistic that a broad resolution could be reached, and we do continue to prepare our defense in \nthe event that it can't be.  And  that's about all I can add to that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Well, thank you, everyone for your questions, and thank you for joining us on the call.  Elisa, thank you for helping \nus facilitate this call. ", "original_text": "And  that's about all I can add to that.  \n "}, "hash": "81d68ecfc34f3a6c2806528b9952df93cba07a07fa22d080fc4e0373a5268127", "class_name": "RelatedNodeInfo"}}, "text": "You can imagine the amount of focus on COVID -19 over the past quarter, but we do continue the dialogue, we do \ncontinue to be optimistic that a broad resolution could be reached, and we do continue to prepare our defense in \nthe event that it can't be. ", "start_char_idx": 2103, "end_char_idx": 2357, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0ecdefc8-32dd-4bf3-859c-562177d845b2": {"__data__": {"id_": "0ecdefc8-32dd-4bf3-859c-562177d845b2", "embedding": null, "metadata": {"window": "We do remain hopeful that broad resolution can be \nachieved.  We think it's important that if there's a path to accelerate relief efforts for people and the communities \nimpacted that we find a way to take that path.  \n \n You can imagine the amount of focus on COVID -19 over the past quarter, but we do continue the dialogue, we do \ncontinue to be optimistic that a broad resolution could be reached, and we do continue to prepare our defense in \nthe event that it can't be.  And  that's about all I can add to that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Well, thank you, everyone for your questions, and thank you for joining us on the call.  Elisa, thank you for helping \nus facilitate this call. ", "original_text": "And  that's about all I can add to that.  \n ", "page_label": "19", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a805158d-a3a9-4f66-90a6-b2bb5b33d14e", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d7497f7a13a75b8a29fa5c90b456f16f8feca3114ee0616189524bec68a7e32f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2495ce3e-7312-4fe0-8e9e-279d78579f54", "node_type": "1", "metadata": {"window": "We do continue to be \nengaged in discus sions with attorneys, generals and others.  We do remain hopeful that broad resolution can be \nachieved.  We think it's important that if there's a path to accelerate relief efforts for people and the communities \nimpacted that we find a way to take that path.  \n \n You can imagine the amount of focus on COVID -19 over the past quarter, but we do continue the dialogue, we do \ncontinue to be optimistic that a broad resolution could be reached, and we do continue to prepare our defense in \nthe event that it can't be.  And  that's about all I can add to that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Well, thank you, everyone for your questions, and thank you for joining us on the call. ", "original_text": "You can imagine the amount of focus on COVID -19 over the past quarter, but we do continue the dialogue, we do \ncontinue to be optimistic that a broad resolution could be reached, and we do continue to prepare our defense in \nthe event that it can't be. ", "page_label": "19", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "533f30a77a84a7fa5edb02761d430d64b4c895bfaba556f60e38f1cdcfed1289", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4649a1c1-784b-4f0d-a129-e80d020dfebb", "node_type": "1", "metadata": {"window": "We think it's important that if there's a path to accelerate relief efforts for people and the communities \nimpacted that we find a way to take that path.  \n \n You can imagine the amount of focus on COVID -19 over the past quarter, but we do continue the dialogue, we do \ncontinue to be optimistic that a broad resolution could be reached, and we do continue to prepare our defense in \nthe event that it can't be.  And  that's about all I can add to that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Well, thank you, everyone for your questions, and thank you for joining us on the call.  Elisa, thank you for helping \nus facilitate this call.  I want to conclude my remarks today, by just thanking all the frontline workers across the \nworld, who are tirelessly, day in and day out working to keep us healthy and safe. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n"}, "hash": "6d2a5c2cbc930effa199af1360c3aba313abb893173d4ee5712c22eb48563cbc", "class_name": "RelatedNodeInfo"}}, "text": "And  that's about all I can add to that.  \n ", "start_char_idx": 2357, "end_char_idx": 2401, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4649a1c1-784b-4f0d-a129-e80d020dfebb": {"__data__": {"id_": "4649a1c1-784b-4f0d-a129-e80d020dfebb", "embedding": null, "metadata": {"window": "We think it's important that if there's a path to accelerate relief efforts for people and the communities \nimpacted that we find a way to take that path.  \n \n You can imagine the amount of focus on COVID -19 over the past quarter, but we do continue the dialogue, we do \ncontinue to be optimistic that a broad resolution could be reached, and we do continue to prepare our defense in \nthe event that it can't be.  And  that's about all I can add to that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Well, thank you, everyone for your questions, and thank you for joining us on the call.  Elisa, thank you for helping \nus facilitate this call.  I want to conclude my remarks today, by just thanking all the frontline workers across the \nworld, who are tirelessly, day in and day out working to keep us healthy and safe. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n", "page_label": "19", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a805158d-a3a9-4f66-90a6-b2bb5b33d14e", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d7497f7a13a75b8a29fa5c90b456f16f8feca3114ee0616189524bec68a7e32f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0ecdefc8-32dd-4bf3-859c-562177d845b2", "node_type": "1", "metadata": {"window": "We do remain hopeful that broad resolution can be \nachieved.  We think it's important that if there's a path to accelerate relief efforts for people and the communities \nimpacted that we find a way to take that path.  \n \n You can imagine the amount of focus on COVID -19 over the past quarter, but we do continue the dialogue, we do \ncontinue to be optimistic that a broad resolution could be reached, and we do continue to prepare our defense in \nthe event that it can't be.  And  that's about all I can add to that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Well, thank you, everyone for your questions, and thank you for joining us on the call.  Elisa, thank you for helping \nus facilitate this call. ", "original_text": "And  that's about all I can add to that.  \n ", "page_label": "19", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7807b54ddecb85df762ff6db582d9f50cf36eef61b3a6a6a90b172a56a22f7cc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7fb752b0-9d28-45a3-a9ce-4aeff3a21cdb", "node_type": "1", "metadata": {"window": "You can imagine the amount of focus on COVID -19 over the past quarter, but we do continue the dialogue, we do \ncontinue to be optimistic that a broad resolution could be reached, and we do continue to prepare our defense in \nthe event that it can't be.  And  that's about all I can add to that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Well, thank you, everyone for your questions, and thank you for joining us on the call.  Elisa, thank you for helping \nus facilitate this call.  I want to conclude my remarks today, by just thanking all the frontline workers across the \nworld, who are tirelessly, day in and day out working to keep us healthy and safe.  And I certainly want to \nrecognize the outstanding performance of our 80,000 employees, es pecially their commitment to helping their \ncommunities and to helping each other in this time of need. ", "original_text": "Well, thank you, everyone for your questions, and thank you for joining us on the call. "}, "hash": "3014001e2e4fa6007bd7626dc97720312d00365c980a5df450c5281c99558309", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n", "start_char_idx": 2401, "end_char_idx": 2743, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7fb752b0-9d28-45a3-a9ce-4aeff3a21cdb": {"__data__": {"id_": "7fb752b0-9d28-45a3-a9ce-4aeff3a21cdb", "embedding": null, "metadata": {"window": "You can imagine the amount of focus on COVID -19 over the past quarter, but we do continue the dialogue, we do \ncontinue to be optimistic that a broad resolution could be reached, and we do continue to prepare our defense in \nthe event that it can't be.  And  that's about all I can add to that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Well, thank you, everyone for your questions, and thank you for joining us on the call.  Elisa, thank you for helping \nus facilitate this call.  I want to conclude my remarks today, by just thanking all the frontline workers across the \nworld, who are tirelessly, day in and day out working to keep us healthy and safe.  And I certainly want to \nrecognize the outstanding performance of our 80,000 employees, es pecially their commitment to helping their \ncommunities and to helping each other in this time of need. ", "original_text": "Well, thank you, everyone for your questions, and thank you for joining us on the call. ", "page_label": "19", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a805158d-a3a9-4f66-90a6-b2bb5b33d14e", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d7497f7a13a75b8a29fa5c90b456f16f8feca3114ee0616189524bec68a7e32f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4649a1c1-784b-4f0d-a129-e80d020dfebb", "node_type": "1", "metadata": {"window": "We think it's important that if there's a path to accelerate relief efforts for people and the communities \nimpacted that we find a way to take that path.  \n \n You can imagine the amount of focus on COVID -19 over the past quarter, but we do continue the dialogue, we do \ncontinue to be optimistic that a broad resolution could be reached, and we do continue to prepare our defense in \nthe event that it can't be.  And  that's about all I can add to that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Well, thank you, everyone for your questions, and thank you for joining us on the call.  Elisa, thank you for helping \nus facilitate this call.  I want to conclude my remarks today, by just thanking all the frontline workers across the \nworld, who are tirelessly, day in and day out working to keep us healthy and safe. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n", "page_label": "19", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a992cbda78c6e925d100e5343216c63b7404ce8dd48369e6e5c550400575b1db", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0665d5d6-567d-45c6-9806-9f29c97c69a9", "node_type": "1", "metadata": {"window": "And  that's about all I can add to that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Well, thank you, everyone for your questions, and thank you for joining us on the call.  Elisa, thank you for helping \nus facilitate this call.  I want to conclude my remarks today, by just thanking all the frontline workers across the \nworld, who are tirelessly, day in and day out working to keep us healthy and safe.  And I certainly want to \nrecognize the outstanding performance of our 80,000 employees, es pecially their commitment to helping their \ncommunities and to helping each other in this time of need.  We wish you and your families, good health and \nwellness. ", "original_text": "Elisa, thank you for helping \nus facilitate this call. "}, "hash": "68e1b67d528e9b35e2722d4465c382297ae8b871f611d14aa48b53f72743d922", "class_name": "RelatedNodeInfo"}}, "text": "Well, thank you, everyone for your questions, and thank you for joining us on the call. ", "start_char_idx": 2743, "end_char_idx": 2831, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0665d5d6-567d-45c6-9806-9f29c97c69a9": {"__data__": {"id_": "0665d5d6-567d-45c6-9806-9f29c97c69a9", "embedding": null, "metadata": {"window": "And  that's about all I can add to that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Well, thank you, everyone for your questions, and thank you for joining us on the call.  Elisa, thank you for helping \nus facilitate this call.  I want to conclude my remarks today, by just thanking all the frontline workers across the \nworld, who are tirelessly, day in and day out working to keep us healthy and safe.  And I certainly want to \nrecognize the outstanding performance of our 80,000 employees, es pecially their commitment to helping their \ncommunities and to helping each other in this time of need.  We wish you and your families, good health and \nwellness. ", "original_text": "Elisa, thank you for helping \nus facilitate this call. ", "page_label": "19", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a805158d-a3a9-4f66-90a6-b2bb5b33d14e", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d7497f7a13a75b8a29fa5c90b456f16f8feca3114ee0616189524bec68a7e32f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7fb752b0-9d28-45a3-a9ce-4aeff3a21cdb", "node_type": "1", "metadata": {"window": "You can imagine the amount of focus on COVID -19 over the past quarter, but we do continue the dialogue, we do \ncontinue to be optimistic that a broad resolution could be reached, and we do continue to prepare our defense in \nthe event that it can't be.  And  that's about all I can add to that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Well, thank you, everyone for your questions, and thank you for joining us on the call.  Elisa, thank you for helping \nus facilitate this call.  I want to conclude my remarks today, by just thanking all the frontline workers across the \nworld, who are tirelessly, day in and day out working to keep us healthy and safe.  And I certainly want to \nrecognize the outstanding performance of our 80,000 employees, es pecially their commitment to helping their \ncommunities and to helping each other in this time of need. ", "original_text": "Well, thank you, everyone for your questions, and thank you for joining us on the call. ", "page_label": "19", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "89636d4567888d6380f5c6f3d8bcfcf7d37cc205e562907e9e6df88eb67cc671", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "128e8b1c-7b4f-442b-b002-555b26469322", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Well, thank you, everyone for your questions, and thank you for joining us on the call.  Elisa, thank you for helping \nus facilitate this call.  I want to conclude my remarks today, by just thanking all the frontline workers across the \nworld, who are tirelessly, day in and day out working to keep us healthy and safe.  And I certainly want to \nrecognize the outstanding performance of our 80,000 employees, es pecially their commitment to helping their \ncommunities and to helping each other in this time of need.  We wish you and your families, good health and \nwellness.  I look forward to the day, we can be together. ", "original_text": "I want to conclude my remarks today, by just thanking all the frontline workers across the \nworld, who are tirelessly, day in and day out working to keep us healthy and safe. "}, "hash": "93b3eb33654fa0f4fc402336b71f5f31145be8097569281ce279259d396b9122", "class_name": "RelatedNodeInfo"}}, "text": "Elisa, thank you for helping \nus facilitate this call. ", "start_char_idx": 2831, "end_char_idx": 2886, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "128e8b1c-7b4f-442b-b002-555b26469322": {"__data__": {"id_": "128e8b1c-7b4f-442b-b002-555b26469322", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Well, thank you, everyone for your questions, and thank you for joining us on the call.  Elisa, thank you for helping \nus facilitate this call.  I want to conclude my remarks today, by just thanking all the frontline workers across the \nworld, who are tirelessly, day in and day out working to keep us healthy and safe.  And I certainly want to \nrecognize the outstanding performance of our 80,000 employees, es pecially their commitment to helping their \ncommunities and to helping each other in this time of need.  We wish you and your families, good health and \nwellness.  I look forward to the day, we can be together. ", "original_text": "I want to conclude my remarks today, by just thanking all the frontline workers across the \nworld, who are tirelessly, day in and day out working to keep us healthy and safe. ", "page_label": "19", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a805158d-a3a9-4f66-90a6-b2bb5b33d14e", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d7497f7a13a75b8a29fa5c90b456f16f8feca3114ee0616189524bec68a7e32f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0665d5d6-567d-45c6-9806-9f29c97c69a9", "node_type": "1", "metadata": {"window": "And  that's about all I can add to that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Well, thank you, everyone for your questions, and thank you for joining us on the call.  Elisa, thank you for helping \nus facilitate this call.  I want to conclude my remarks today, by just thanking all the frontline workers across the \nworld, who are tirelessly, day in and day out working to keep us healthy and safe.  And I certainly want to \nrecognize the outstanding performance of our 80,000 employees, es pecially their commitment to helping their \ncommunities and to helping each other in this time of need.  We wish you and your families, good health and \nwellness. ", "original_text": "Elisa, thank you for helping \nus facilitate this call. ", "page_label": "19", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4abaa304c1b98c6e73962c0ee136df2ab61bf067761e14527c70da80788fc99e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "657a6815-03b5-4864-afcd-cf27587e1ef5", "node_type": "1", "metadata": {"window": "Well, thank you, everyone for your questions, and thank you for joining us on the call.  Elisa, thank you for helping \nus facilitate this call.  I want to conclude my remarks today, by just thanking all the frontline workers across the \nworld, who are tirelessly, day in and day out working to keep us healthy and safe.  And I certainly want to \nrecognize the outstanding performance of our 80,000 employees, es pecially their commitment to helping their \ncommunities and to helping each other in this time of need.  We wish you and your families, good health and \nwellness.  I look forward to the day, we can be together.  Thank you all.  \n ", "original_text": "And I certainly want to \nrecognize the outstanding performance of our 80,000 employees, es pecially their commitment to helping their \ncommunities and to helping each other in this time of need. "}, "hash": "9d77b9dd89c5ecfd42dea18dc28dafe51e45614caf16de973f2c5e2f22440410", "class_name": "RelatedNodeInfo"}}, "text": "I want to conclude my remarks today, by just thanking all the frontline workers across the \nworld, who are tirelessly, day in and day out working to keep us healthy and safe. ", "start_char_idx": 2886, "end_char_idx": 3061, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "657a6815-03b5-4864-afcd-cf27587e1ef5": {"__data__": {"id_": "657a6815-03b5-4864-afcd-cf27587e1ef5", "embedding": null, "metadata": {"window": "Well, thank you, everyone for your questions, and thank you for joining us on the call.  Elisa, thank you for helping \nus facilitate this call.  I want to conclude my remarks today, by just thanking all the frontline workers across the \nworld, who are tirelessly, day in and day out working to keep us healthy and safe.  And I certainly want to \nrecognize the outstanding performance of our 80,000 employees, es pecially their commitment to helping their \ncommunities and to helping each other in this time of need.  We wish you and your families, good health and \nwellness.  I look forward to the day, we can be together.  Thank you all.  \n ", "original_text": "And I certainly want to \nrecognize the outstanding performance of our 80,000 employees, es pecially their commitment to helping their \ncommunities and to helping each other in this time of need. ", "page_label": "19", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a805158d-a3a9-4f66-90a6-b2bb5b33d14e", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d7497f7a13a75b8a29fa5c90b456f16f8feca3114ee0616189524bec68a7e32f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "128e8b1c-7b4f-442b-b002-555b26469322", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Well, thank you, everyone for your questions, and thank you for joining us on the call.  Elisa, thank you for helping \nus facilitate this call.  I want to conclude my remarks today, by just thanking all the frontline workers across the \nworld, who are tirelessly, day in and day out working to keep us healthy and safe.  And I certainly want to \nrecognize the outstanding performance of our 80,000 employees, es pecially their commitment to helping their \ncommunities and to helping each other in this time of need.  We wish you and your families, good health and \nwellness.  I look forward to the day, we can be together. ", "original_text": "I want to conclude my remarks today, by just thanking all the frontline workers across the \nworld, who are tirelessly, day in and day out working to keep us healthy and safe. ", "page_label": "19", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "87dc840dff4dcc025720dd2e07c6d9279ae20b1000c43acbd5310583d94dc667", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "afe59138-a606-4734-9081-62a9b14cb089", "node_type": "1", "metadata": {"window": "Elisa, thank you for helping \nus facilitate this call.  I want to conclude my remarks today, by just thanking all the frontline workers across the \nworld, who are tirelessly, day in and day out working to keep us healthy and safe.  And I certainly want to \nrecognize the outstanding performance of our 80,000 employees, es pecially their commitment to helping their \ncommunities and to helping each other in this time of need.  We wish you and your families, good health and \nwellness.  I look forward to the day, we can be together.  Thank you all.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you for joining  today's conference call. ", "original_text": "We wish you and your families, good health and \nwellness. "}, "hash": "3320fc85465f8cf4758a869bcbec7c70d4379c1ddbb436c0b0c59d4471528a4a", "class_name": "RelatedNodeInfo"}}, "text": "And I certainly want to \nrecognize the outstanding performance of our 80,000 employees, es pecially their commitment to helping their \ncommunities and to helping each other in this time of need. ", "start_char_idx": 3061, "end_char_idx": 3256, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "afe59138-a606-4734-9081-62a9b14cb089": {"__data__": {"id_": "afe59138-a606-4734-9081-62a9b14cb089", "embedding": null, "metadata": {"window": "Elisa, thank you for helping \nus facilitate this call.  I want to conclude my remarks today, by just thanking all the frontline workers across the \nworld, who are tirelessly, day in and day out working to keep us healthy and safe.  And I certainly want to \nrecognize the outstanding performance of our 80,000 employees, es pecially their commitment to helping their \ncommunities and to helping each other in this time of need.  We wish you and your families, good health and \nwellness.  I look forward to the day, we can be together.  Thank you all.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you for joining  today's conference call. ", "original_text": "We wish you and your families, good health and \nwellness. ", "page_label": "19", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a805158d-a3a9-4f66-90a6-b2bb5b33d14e", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d7497f7a13a75b8a29fa5c90b456f16f8feca3114ee0616189524bec68a7e32f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "657a6815-03b5-4864-afcd-cf27587e1ef5", "node_type": "1", "metadata": {"window": "Well, thank you, everyone for your questions, and thank you for joining us on the call.  Elisa, thank you for helping \nus facilitate this call.  I want to conclude my remarks today, by just thanking all the frontline workers across the \nworld, who are tirelessly, day in and day out working to keep us healthy and safe.  And I certainly want to \nrecognize the outstanding performance of our 80,000 employees, es pecially their commitment to helping their \ncommunities and to helping each other in this time of need.  We wish you and your families, good health and \nwellness.  I look forward to the day, we can be together.  Thank you all.  \n ", "original_text": "And I certainly want to \nrecognize the outstanding performance of our 80,000 employees, es pecially their commitment to helping their \ncommunities and to helping each other in this time of need. ", "page_label": "19", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1220757e5f23d6b62a61cfd571974d63d2542fc3712858830510f21d89a849b1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f4f4f6cf-31f7-441f-83e2-c071e10e14ae", "node_type": "1", "metadata": {"window": "I want to conclude my remarks today, by just thanking all the frontline workers across the \nworld, who are tirelessly, day in and day out working to keep us healthy and safe.  And I certainly want to \nrecognize the outstanding performance of our 80,000 employees, es pecially their commitment to helping their \ncommunities and to helping each other in this time of need.  We wish you and your families, good health and \nwellness.  I look forward to the day, we can be together.  Thank you all.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you for joining  today's conference call.  You may now disconnect, and have a great day.  \n \n \n \n \n \n \n ", "original_text": "I look forward to the day, we can be together. "}, "hash": "a413b5e666b4bf163bb8a5789bf9fd81012ad29ad056c2157c4f1b90c743f531", "class_name": "RelatedNodeInfo"}}, "text": "We wish you and your families, good health and \nwellness. ", "start_char_idx": 3256, "end_char_idx": 3314, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f4f4f6cf-31f7-441f-83e2-c071e10e14ae": {"__data__": {"id_": "f4f4f6cf-31f7-441f-83e2-c071e10e14ae", "embedding": null, "metadata": {"window": "I want to conclude my remarks today, by just thanking all the frontline workers across the \nworld, who are tirelessly, day in and day out working to keep us healthy and safe.  And I certainly want to \nrecognize the outstanding performance of our 80,000 employees, es pecially their commitment to helping their \ncommunities and to helping each other in this time of need.  We wish you and your families, good health and \nwellness.  I look forward to the day, we can be together.  Thank you all.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you for joining  today's conference call.  You may now disconnect, and have a great day.  \n \n \n \n \n \n \n ", "original_text": "I look forward to the day, we can be together. ", "page_label": "19", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a805158d-a3a9-4f66-90a6-b2bb5b33d14e", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d7497f7a13a75b8a29fa5c90b456f16f8feca3114ee0616189524bec68a7e32f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "afe59138-a606-4734-9081-62a9b14cb089", "node_type": "1", "metadata": {"window": "Elisa, thank you for helping \nus facilitate this call.  I want to conclude my remarks today, by just thanking all the frontline workers across the \nworld, who are tirelessly, day in and day out working to keep us healthy and safe.  And I certainly want to \nrecognize the outstanding performance of our 80,000 employees, es pecially their commitment to helping their \ncommunities and to helping each other in this time of need.  We wish you and your families, good health and \nwellness.  I look forward to the day, we can be together.  Thank you all.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you for joining  today's conference call. ", "original_text": "We wish you and your families, good health and \nwellness. ", "page_label": "19", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e65506853630cf112bfe04395e26c00d643402987a326a83d9bb279fe7f7b3b3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b654ab6f-55f5-4139-aa15-ecba91b04ec7", "node_type": "1", "metadata": {"window": "And I certainly want to \nrecognize the outstanding performance of our 80,000 employees, es pecially their commitment to helping their \ncommunities and to helping each other in this time of need.  We wish you and your families, good health and \nwellness.  I look forward to the day, we can be together.  Thank you all.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you for joining  today's conference call.  You may now disconnect, and have a great day.  \n \n \n \n \n \n \n ", "original_text": "Thank you all.  \n "}, "hash": "4dfaa3c1527540f676b91846486c321ca36e981c2e2e86c60af552987f4c56f8", "class_name": "RelatedNodeInfo"}}, "text": "I look forward to the day, we can be together. ", "start_char_idx": 3314, "end_char_idx": 3361, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b654ab6f-55f5-4139-aa15-ecba91b04ec7": {"__data__": {"id_": "b654ab6f-55f5-4139-aa15-ecba91b04ec7", "embedding": null, "metadata": {"window": "And I certainly want to \nrecognize the outstanding performance of our 80,000 employees, es pecially their commitment to helping their \ncommunities and to helping each other in this time of need.  We wish you and your families, good health and \nwellness.  I look forward to the day, we can be together.  Thank you all.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you for joining  today's conference call.  You may now disconnect, and have a great day.  \n \n \n \n \n \n \n ", "original_text": "Thank you all.  \n ", "page_label": "19", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a805158d-a3a9-4f66-90a6-b2bb5b33d14e", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d7497f7a13a75b8a29fa5c90b456f16f8feca3114ee0616189524bec68a7e32f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f4f4f6cf-31f7-441f-83e2-c071e10e14ae", "node_type": "1", "metadata": {"window": "I want to conclude my remarks today, by just thanking all the frontline workers across the \nworld, who are tirelessly, day in and day out working to keep us healthy and safe.  And I certainly want to \nrecognize the outstanding performance of our 80,000 employees, es pecially their commitment to helping their \ncommunities and to helping each other in this time of need.  We wish you and your families, good health and \nwellness.  I look forward to the day, we can be together.  Thank you all.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you for joining  today's conference call.  You may now disconnect, and have a great day.  \n \n \n \n \n \n \n ", "original_text": "I look forward to the day, we can be together. ", "page_label": "19", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d7d41c19b3dbbf42d5830ace3a21c60d953c64e527aadd1bef7c326d9e589266", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d7d2bf70-4762-4e10-9bfd-6376decff98d", "node_type": "1", "metadata": {"window": "We wish you and your families, good health and \nwellness.  I look forward to the day, we can be together.  Thank you all.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you for joining  today's conference call.  You may now disconnect, and have a great day.  \n \n \n \n \n \n \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you for joining  today's conference call. "}, "hash": "85dcd47c23e7e440ef9438fe71f2fab638a1602359c8a06f668f938b02a120c2", "class_name": "RelatedNodeInfo"}}, "text": "Thank you all.  \n ", "start_char_idx": 3361, "end_char_idx": 3379, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d7d2bf70-4762-4e10-9bfd-6376decff98d": {"__data__": {"id_": "d7d2bf70-4762-4e10-9bfd-6376decff98d", "embedding": null, "metadata": {"window": "We wish you and your families, good health and \nwellness.  I look forward to the day, we can be together.  Thank you all.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you for joining  today's conference call.  You may now disconnect, and have a great day.  \n \n \n \n \n \n \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you for joining  today's conference call. ", "page_label": "19", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a805158d-a3a9-4f66-90a6-b2bb5b33d14e", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d7497f7a13a75b8a29fa5c90b456f16f8feca3114ee0616189524bec68a7e32f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b654ab6f-55f5-4139-aa15-ecba91b04ec7", "node_type": "1", "metadata": {"window": "And I certainly want to \nrecognize the outstanding performance of our 80,000 employees, es pecially their commitment to helping their \ncommunities and to helping each other in this time of need.  We wish you and your families, good health and \nwellness.  I look forward to the day, we can be together.  Thank you all.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you for joining  today's conference call.  You may now disconnect, and have a great day.  \n \n \n \n \n \n \n ", "original_text": "Thank you all.  \n ", "page_label": "19", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0c5ee802cf401a457835a36b6d23159293ae27738faecbf1943b9d94e9e1afb4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ddc16e3b-5c65-467f-a989-1f9a1cb5ceac", "node_type": "1", "metadata": {"window": "I look forward to the day, we can be together.  Thank you all.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you for joining  today's conference call.  You may now disconnect, and have a great day.  \n \n \n \n \n \n \n ", "original_text": "You may now disconnect, and have a great day.  \n \n \n \n \n \n \n "}, "hash": "c8945c23c2568802cfdae862b58bb7eef48d1a06dbd9a3d57ea13a0e710c0d46", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you for joining  today's conference call. ", "start_char_idx": 3379, "end_char_idx": 3712, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ddc16e3b-5c65-467f-a989-1f9a1cb5ceac": {"__data__": {"id_": "ddc16e3b-5c65-467f-a989-1f9a1cb5ceac", "embedding": null, "metadata": {"window": "I look forward to the day, we can be together.  Thank you all.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you for joining  today's conference call.  You may now disconnect, and have a great day.  \n \n \n \n \n \n \n ", "original_text": "You may now disconnect, and have a great day.  \n \n \n \n \n \n \n ", "page_label": "19", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a805158d-a3a9-4f66-90a6-b2bb5b33d14e", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d7497f7a13a75b8a29fa5c90b456f16f8feca3114ee0616189524bec68a7e32f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d7d2bf70-4762-4e10-9bfd-6376decff98d", "node_type": "1", "metadata": {"window": "We wish you and your families, good health and \nwellness.  I look forward to the day, we can be together.  Thank you all.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you for joining  today's conference call.  You may now disconnect, and have a great day.  \n \n \n \n \n \n \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you for joining  today's conference call. ", "page_label": "19", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "66b1a1b669df5b5e9056782a543fb5b38a481236b550cca73983705291186b8b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "10ce44ac-8db8-4e8c-ae9c-30d18b28085f", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   20 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \n \n \n \nDisclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a  complete or error -free statement or summary of the available data. \n As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information.  You  must evaluate, and bear all risks associated with, the use of any \ninformation provided hereunder , including any reliance on the accuracy, completeness, safety or usefulness of such information. ", "original_text": "McKesson Corp.  "}, "hash": "9771846d537480471ebeccd135010db391bd8aca1a4deef824f9c3710c53adcd", "class_name": "RelatedNodeInfo"}}, "text": "You may now disconnect, and have a great day.  \n \n \n \n \n \n \n ", "start_char_idx": 3712, "end_char_idx": 3773, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "10ce44ac-8db8-4e8c-ae9c-30d18b28085f": {"__data__": {"id_": "10ce44ac-8db8-4e8c-ae9c-30d18b28085f", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   20 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \n \n \n \nDisclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a  complete or error -free statement or summary of the available data. \n As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information.  You  must evaluate, and bear all risks associated with, the use of any \ninformation provided hereunder , including any reliance on the accuracy, completeness, safety or usefulness of such information. ", "original_text": "McKesson Corp.  ", "page_label": "20", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "82e8361b-192f-452a-b420-11d131263f55", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "41b230ab4e943714954ffd83d4691ea47c347c510adc3b3884d1d7e524ad6f55", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ddc16e3b-5c65-467f-a989-1f9a1cb5ceac", "node_type": "1", "metadata": {"window": "I look forward to the day, we can be together.  Thank you all.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you for joining  today's conference call.  You may now disconnect, and have a great day.  \n \n \n \n \n \n \n ", "original_text": "You may now disconnect, and have a great day.  \n \n \n \n \n \n \n ", "page_label": "19", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "05978935cdb1d8d9eeea8f4254a84f19e8c89d4fda1dbf3fe388afd7c1403790", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5e21f481-ad80-4f31-872f-aee759890ce7", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   20 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \n \n \n \nDisclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a  complete or error -free statement or summary of the available data. \n As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information.  You  must evaluate, and bear all risks associated with, the use of any \ninformation provided hereunder , including any reliance on the accuracy, completeness, safety or usefulness of such information.  This information is not int ended to be used as the primary basis \nof investment decisions. ", "original_text": "(MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   20 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \n \n \n \nDisclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a  complete or error -free statement or summary of the available data. \n"}, "hash": "d505f0b38a42dbbb7df566f504d5523a9a592ea99e5b0b0985f39587731cba9e", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5e21f481-ad80-4f31-872f-aee759890ce7": {"__data__": {"id_": "5e21f481-ad80-4f31-872f-aee759890ce7", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   20 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \n \n \n \nDisclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a  complete or error -free statement or summary of the available data. \n As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information.  You  must evaluate, and bear all risks associated with, the use of any \ninformation provided hereunder , including any reliance on the accuracy, completeness, safety or usefulness of such information.  This information is not int ended to be used as the primary basis \nof investment decisions. ", "original_text": "(MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   20 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \n \n \n \nDisclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a  complete or error -free statement or summary of the available data. \n", "page_label": "20", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "82e8361b-192f-452a-b420-11d131263f55", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "41b230ab4e943714954ffd83d4691ea47c347c510adc3b3884d1d7e524ad6f55", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "10ce44ac-8db8-4e8c-ae9c-30d18b28085f", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   20 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \n \n \n \nDisclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a  complete or error -free statement or summary of the available data. \n As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information.  You  must evaluate, and bear all risks associated with, the use of any \ninformation provided hereunder , including any reliance on the accuracy, completeness, safety or usefulness of such information. ", "original_text": "McKesson Corp.  ", "page_label": "20", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b8e9f2a90123b5977bcec9794afd44c353a9334ee1b0665c89d1c5d2b604d42b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4339248e-0294-418b-8ca5-a28730f84ef2", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   20 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \n \n \n \nDisclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a  complete or error -free statement or summary of the available data. \n As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information.  You  must evaluate, and bear all risks associated with, the use of any \ninformation provided hereunder , including any reliance on the accuracy, completeness, safety or usefulness of such information.  This information is not int ended to be used as the primary basis \nof investment decisions.  It should not be construed as advice designed to meet the particular  investment needs of any investor. ", "original_text": "As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information. "}, "hash": "76792fa818b179346748cac9dda8722837d461241d61bde750730428c9610133", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   20 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \n \n \n \nDisclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a  complete or error -free statement or summary of the available data. \n", "start_char_idx": 16, "end_char_idx": 398, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4339248e-0294-418b-8ca5-a28730f84ef2": {"__data__": {"id_": "4339248e-0294-418b-8ca5-a28730f84ef2", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   20 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \n \n \n \nDisclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a  complete or error -free statement or summary of the available data. \n As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information.  You  must evaluate, and bear all risks associated with, the use of any \ninformation provided hereunder , including any reliance on the accuracy, completeness, safety or usefulness of such information.  This information is not int ended to be used as the primary basis \nof investment decisions.  It should not be construed as advice designed to meet the particular  investment needs of any investor. ", "original_text": "As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information. ", "page_label": "20", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "82e8361b-192f-452a-b420-11d131263f55", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "41b230ab4e943714954ffd83d4691ea47c347c510adc3b3884d1d7e524ad6f55", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5e21f481-ad80-4f31-872f-aee759890ce7", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   20 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \n \n \n \nDisclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a  complete or error -free statement or summary of the available data. \n As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information.  You  must evaluate, and bear all risks associated with, the use of any \ninformation provided hereunder , including any reliance on the accuracy, completeness, safety or usefulness of such information.  This information is not int ended to be used as the primary basis \nof investment decisions. ", "original_text": "(MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   20 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \n \n \n \nDisclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a  complete or error -free statement or summary of the available data. \n", "page_label": "20", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "83173e6fa23f6b2d5d84d7e4d374a352138d093ccb124f690a864b3277a94af1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "322e68b8-c9fb-49d6-824d-5b5f23dc7596", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   20 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \n \n \n \nDisclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a  complete or error -free statement or summary of the available data. \n As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information.  You  must evaluate, and bear all risks associated with, the use of any \ninformation provided hereunder , including any reliance on the accuracy, completeness, safety or usefulness of such information.  This information is not int ended to be used as the primary basis \nof investment decisions.  It should not be construed as advice designed to meet the particular  investment needs of any investor.  This report is published solely for information purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security i n any state where such an offer  or solicitation would be illegal. ", "original_text": "You  must evaluate, and bear all risks associated with, the use of any \ninformation provided hereunder , including any reliance on the accuracy, completeness, safety or usefulness of such information. "}, "hash": "89a8bc24add6c3b072d1536b18563777cb649f92383f9b332e49a85cfe0729d9", "class_name": "RelatedNodeInfo"}}, "text": "As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information. ", "start_char_idx": 398, "end_char_idx": 520, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "322e68b8-c9fb-49d6-824d-5b5f23dc7596": {"__data__": {"id_": "322e68b8-c9fb-49d6-824d-5b5f23dc7596", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   20 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \n \n \n \nDisclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a  complete or error -free statement or summary of the available data. \n As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information.  You  must evaluate, and bear all risks associated with, the use of any \ninformation provided hereunder , including any reliance on the accuracy, completeness, safety or usefulness of such information.  This information is not int ended to be used as the primary basis \nof investment decisions.  It should not be construed as advice designed to meet the particular  investment needs of any investor.  This report is published solely for information purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security i n any state where such an offer  or solicitation would be illegal. ", "original_text": "You  must evaluate, and bear all risks associated with, the use of any \ninformation provided hereunder , including any reliance on the accuracy, completeness, safety or usefulness of such information. ", "page_label": "20", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "82e8361b-192f-452a-b420-11d131263f55", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "41b230ab4e943714954ffd83d4691ea47c347c510adc3b3884d1d7e524ad6f55", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4339248e-0294-418b-8ca5-a28730f84ef2", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   20 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \n \n \n \nDisclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a  complete or error -free statement or summary of the available data. \n As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information.  You  must evaluate, and bear all risks associated with, the use of any \ninformation provided hereunder , including any reliance on the accuracy, completeness, safety or usefulness of such information.  This information is not int ended to be used as the primary basis \nof investment decisions.  It should not be construed as advice designed to meet the particular  investment needs of any investor. ", "original_text": "As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information. ", "page_label": "20", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "50eca8250a62f31e95fbe9235937d40ef69c86bc4c045ef1936153ddca1fc7d1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2bb69fc5-127c-4db1-96e0-825ee3bfcde2", "node_type": "1", "metadata": {"window": "(MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   20 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \n \n \n \nDisclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a  complete or error -free statement or summary of the available data. \n As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information.  You  must evaluate, and bear all risks associated with, the use of any \ninformation provided hereunder , including any reliance on the accuracy, completeness, safety or usefulness of such information.  This information is not int ended to be used as the primary basis \nof investment decisions.  It should not be construed as advice designed to meet the particular  investment needs of any investor.  This report is published solely for information purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security i n any state where such an offer  or solicitation would be illegal.  Any \ninformation expressed herein on this date is subject to change without notice. ", "original_text": "This information is not int ended to be used as the primary basis \nof investment decisions. "}, "hash": "78aa3b2d380881d7865f09830e413e29cb7737151fbcc5daeb4bac24d96aab0d", "class_name": "RelatedNodeInfo"}}, "text": "You  must evaluate, and bear all risks associated with, the use of any \ninformation provided hereunder , including any reliance on the accuracy, completeness, safety or usefulness of such information. ", "start_char_idx": 520, "end_char_idx": 721, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2bb69fc5-127c-4db1-96e0-825ee3bfcde2": {"__data__": {"id_": "2bb69fc5-127c-4db1-96e0-825ee3bfcde2", "embedding": null, "metadata": {"window": "(MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   20 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \n \n \n \nDisclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a  complete or error -free statement or summary of the available data. \n As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information.  You  must evaluate, and bear all risks associated with, the use of any \ninformation provided hereunder , including any reliance on the accuracy, completeness, safety or usefulness of such information.  This information is not int ended to be used as the primary basis \nof investment decisions.  It should not be construed as advice designed to meet the particular  investment needs of any investor.  This report is published solely for information purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security i n any state where such an offer  or solicitation would be illegal.  Any \ninformation expressed herein on this date is subject to change without notice. ", "original_text": "This information is not int ended to be used as the primary basis \nof investment decisions. ", "page_label": "20", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "82e8361b-192f-452a-b420-11d131263f55", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "41b230ab4e943714954ffd83d4691ea47c347c510adc3b3884d1d7e524ad6f55", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "322e68b8-c9fb-49d6-824d-5b5f23dc7596", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   20 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \n \n \n \nDisclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a  complete or error -free statement or summary of the available data. \n As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information.  You  must evaluate, and bear all risks associated with, the use of any \ninformation provided hereunder , including any reliance on the accuracy, completeness, safety or usefulness of such information.  This information is not int ended to be used as the primary basis \nof investment decisions.  It should not be construed as advice designed to meet the particular  investment needs of any investor.  This report is published solely for information purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security i n any state where such an offer  or solicitation would be illegal. ", "original_text": "You  must evaluate, and bear all risks associated with, the use of any \ninformation provided hereunder , including any reliance on the accuracy, completeness, safety or usefulness of such information. ", "page_label": "20", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "921c95c2989537cfbeff02d5872167344cfb3af9f5b1341fb2b7cb03da7fb8ad", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "767e0dd3-767e-45ab-9f38-7e6c2f86aa4b", "node_type": "1", "metadata": {"window": "As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information.  You  must evaluate, and bear all risks associated with, the use of any \ninformation provided hereunder , including any reliance on the accuracy, completeness, safety or usefulness of such information.  This information is not int ended to be used as the primary basis \nof investment decisions.  It should not be construed as advice designed to meet the particular  investment needs of any investor.  This report is published solely for information purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security i n any state where such an offer  or solicitation would be illegal.  Any \ninformation expressed herein on this date is subject to change without notice.  Any opinions or assertions contained in this i nformation do not represent the opinions or beliefs of FactSet \nCallStreet, LLC. ", "original_text": "It should not be construed as advice designed to meet the particular  investment needs of any investor. "}, "hash": "c36b733f8937a31f45ca1b80e58a57b0df32460a36f59b91102ec3bec183cf87", "class_name": "RelatedNodeInfo"}}, "text": "This information is not int ended to be used as the primary basis \nof investment decisions. ", "start_char_idx": 721, "end_char_idx": 813, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "767e0dd3-767e-45ab-9f38-7e6c2f86aa4b": {"__data__": {"id_": "767e0dd3-767e-45ab-9f38-7e6c2f86aa4b", "embedding": null, "metadata": {"window": "As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information.  You  must evaluate, and bear all risks associated with, the use of any \ninformation provided hereunder , including any reliance on the accuracy, completeness, safety or usefulness of such information.  This information is not int ended to be used as the primary basis \nof investment decisions.  It should not be construed as advice designed to meet the particular  investment needs of any investor.  This report is published solely for information purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security i n any state where such an offer  or solicitation would be illegal.  Any \ninformation expressed herein on this date is subject to change without notice.  Any opinions or assertions contained in this i nformation do not represent the opinions or beliefs of FactSet \nCallStreet, LLC. ", "original_text": "It should not be construed as advice designed to meet the particular  investment needs of any investor. ", "page_label": "20", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "82e8361b-192f-452a-b420-11d131263f55", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "41b230ab4e943714954ffd83d4691ea47c347c510adc3b3884d1d7e524ad6f55", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2bb69fc5-127c-4db1-96e0-825ee3bfcde2", "node_type": "1", "metadata": {"window": "(MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   20 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \n \n \n \nDisclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a  complete or error -free statement or summary of the available data. \n As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information.  You  must evaluate, and bear all risks associated with, the use of any \ninformation provided hereunder , including any reliance on the accuracy, completeness, safety or usefulness of such information.  This information is not int ended to be used as the primary basis \nof investment decisions.  It should not be construed as advice designed to meet the particular  investment needs of any investor.  This report is published solely for information purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security i n any state where such an offer  or solicitation would be illegal.  Any \ninformation expressed herein on this date is subject to change without notice. ", "original_text": "This information is not int ended to be used as the primary basis \nof investment decisions. ", "page_label": "20", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "744dcb89778836ce02a901947a9481c8a3ae87a2e16955fce8bbade2dae72d90", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b626ffe8-afb1-4f9a-a1e8-ab7ca6e21ef7", "node_type": "1", "metadata": {"window": "You  must evaluate, and bear all risks associated with, the use of any \ninformation provided hereunder , including any reliance on the accuracy, completeness, safety or usefulness of such information.  This information is not int ended to be used as the primary basis \nof investment decisions.  It should not be construed as advice designed to meet the particular  investment needs of any investor.  This report is published solely for information purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security i n any state where such an offer  or solicitation would be illegal.  Any \ninformation expressed herein on this date is subject to change without notice.  Any opinions or assertions contained in this i nformation do not represent the opinions or beliefs of FactSet \nCallStreet, LLC.  FactSet Call Street, LLC, or one or more of its employees, including the writer of this report, may have a position in any of the securiti es discussed herein.  \n \n", "original_text": "This report is published solely for information purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security i n any state where such an offer  or solicitation would be illegal. "}, "hash": "ec7fea8a3dd8b0546d81bcceacf568665385d9aab2f19fff2618fd405ffa4ed9", "class_name": "RelatedNodeInfo"}}, "text": "It should not be construed as advice designed to meet the particular  investment needs of any investor. ", "start_char_idx": 813, "end_char_idx": 917, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b626ffe8-afb1-4f9a-a1e8-ab7ca6e21ef7": {"__data__": {"id_": "b626ffe8-afb1-4f9a-a1e8-ab7ca6e21ef7", "embedding": null, "metadata": {"window": "You  must evaluate, and bear all risks associated with, the use of any \ninformation provided hereunder , including any reliance on the accuracy, completeness, safety or usefulness of such information.  This information is not int ended to be used as the primary basis \nof investment decisions.  It should not be construed as advice designed to meet the particular  investment needs of any investor.  This report is published solely for information purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security i n any state where such an offer  or solicitation would be illegal.  Any \ninformation expressed herein on this date is subject to change without notice.  Any opinions or assertions contained in this i nformation do not represent the opinions or beliefs of FactSet \nCallStreet, LLC.  FactSet Call Street, LLC, or one or more of its employees, including the writer of this report, may have a position in any of the securiti es discussed herein.  \n \n", "original_text": "This report is published solely for information purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security i n any state where such an offer  or solicitation would be illegal. ", "page_label": "20", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "82e8361b-192f-452a-b420-11d131263f55", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "41b230ab4e943714954ffd83d4691ea47c347c510adc3b3884d1d7e524ad6f55", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "767e0dd3-767e-45ab-9f38-7e6c2f86aa4b", "node_type": "1", "metadata": {"window": "As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information.  You  must evaluate, and bear all risks associated with, the use of any \ninformation provided hereunder , including any reliance on the accuracy, completeness, safety or usefulness of such information.  This information is not int ended to be used as the primary basis \nof investment decisions.  It should not be construed as advice designed to meet the particular  investment needs of any investor.  This report is published solely for information purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security i n any state where such an offer  or solicitation would be illegal.  Any \ninformation expressed herein on this date is subject to change without notice.  Any opinions or assertions contained in this i nformation do not represent the opinions or beliefs of FactSet \nCallStreet, LLC. ", "original_text": "It should not be construed as advice designed to meet the particular  investment needs of any investor. ", "page_label": "20", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "05800b828c9170acfebdda93c8f954dc17b8671de689941fde7397798ad318bb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "94bf1d14-69a8-4a62-8124-bea5e3a8d30d", "node_type": "1", "metadata": {"window": "This information is not int ended to be used as the primary basis \nof investment decisions.  It should not be construed as advice designed to meet the particular  investment needs of any investor.  This report is published solely for information purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security i n any state where such an offer  or solicitation would be illegal.  Any \ninformation expressed herein on this date is subject to change without notice.  Any opinions or assertions contained in this i nformation do not represent the opinions or beliefs of FactSet \nCallStreet, LLC.  FactSet Call Street, LLC, or one or more of its employees, including the writer of this report, may have a position in any of the securiti es discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICA BLE LAW, FactSet CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING  WITHOUT LIMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PA RTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT. ", "original_text": "Any \ninformation expressed herein on this date is subject to change without notice. "}, "hash": "7188bb6b1bf2bbbfb88fa93bf62e31576b6b2d2369fd5ddc78ad6be9a13ddc08", "class_name": "RelatedNodeInfo"}}, "text": "This report is published solely for information purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security i n any state where such an offer  or solicitation would be illegal. ", "start_char_idx": 917, "end_char_idx": 1176, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "94bf1d14-69a8-4a62-8124-bea5e3a8d30d": {"__data__": {"id_": "94bf1d14-69a8-4a62-8124-bea5e3a8d30d", "embedding": null, "metadata": {"window": "This information is not int ended to be used as the primary basis \nof investment decisions.  It should not be construed as advice designed to meet the particular  investment needs of any investor.  This report is published solely for information purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security i n any state where such an offer  or solicitation would be illegal.  Any \ninformation expressed herein on this date is subject to change without notice.  Any opinions or assertions contained in this i nformation do not represent the opinions or beliefs of FactSet \nCallStreet, LLC.  FactSet Call Street, LLC, or one or more of its employees, including the writer of this report, may have a position in any of the securiti es discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICA BLE LAW, FactSet CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING  WITHOUT LIMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PA RTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT. ", "original_text": "Any \ninformation expressed herein on this date is subject to change without notice. ", "page_label": "20", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "82e8361b-192f-452a-b420-11d131263f55", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "41b230ab4e943714954ffd83d4691ea47c347c510adc3b3884d1d7e524ad6f55", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b626ffe8-afb1-4f9a-a1e8-ab7ca6e21ef7", "node_type": "1", "metadata": {"window": "You  must evaluate, and bear all risks associated with, the use of any \ninformation provided hereunder , including any reliance on the accuracy, completeness, safety or usefulness of such information.  This information is not int ended to be used as the primary basis \nof investment decisions.  It should not be construed as advice designed to meet the particular  investment needs of any investor.  This report is published solely for information purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security i n any state where such an offer  or solicitation would be illegal.  Any \ninformation expressed herein on this date is subject to change without notice.  Any opinions or assertions contained in this i nformation do not represent the opinions or beliefs of FactSet \nCallStreet, LLC.  FactSet Call Street, LLC, or one or more of its employees, including the writer of this report, may have a position in any of the securiti es discussed herein.  \n \n", "original_text": "This report is published solely for information purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security i n any state where such an offer  or solicitation would be illegal. ", "page_label": "20", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7bc894671e00121a0631c6a299b49c12e375dd97b5116edde5b7747c27b0bbdb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a83bd5ba-8033-4fa9-8915-f2628e82ec44", "node_type": "1", "metadata": {"window": "It should not be construed as advice designed to meet the particular  investment needs of any investor.  This report is published solely for information purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security i n any state where such an offer  or solicitation would be illegal.  Any \ninformation expressed herein on this date is subject to change without notice.  Any opinions or assertions contained in this i nformation do not represent the opinions or beliefs of FactSet \nCallStreet, LLC.  FactSet Call Street, LLC, or one or more of its employees, including the writer of this report, may have a position in any of the securiti es discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICA BLE LAW, FactSet CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING  WITHOUT LIMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PA RTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT.  TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSO RS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR RE VENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN IF ANY OF SUCH PARTIES IS ADVISED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT M ATTER HEREOF.  \n \n", "original_text": "Any opinions or assertions contained in this i nformation do not represent the opinions or beliefs of FactSet \nCallStreet, LLC. "}, "hash": "a6d6c7c43fee013b2a165d707074ff88cdeabb8ee9290a45fd5f1a0fe2d48d5e", "class_name": "RelatedNodeInfo"}}, "text": "Any \ninformation expressed herein on this date is subject to change without notice. ", "start_char_idx": 1176, "end_char_idx": 1260, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a83bd5ba-8033-4fa9-8915-f2628e82ec44": {"__data__": {"id_": "a83bd5ba-8033-4fa9-8915-f2628e82ec44", "embedding": null, "metadata": {"window": "It should not be construed as advice designed to meet the particular  investment needs of any investor.  This report is published solely for information purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security i n any state where such an offer  or solicitation would be illegal.  Any \ninformation expressed herein on this date is subject to change without notice.  Any opinions or assertions contained in this i nformation do not represent the opinions or beliefs of FactSet \nCallStreet, LLC.  FactSet Call Street, LLC, or one or more of its employees, including the writer of this report, may have a position in any of the securiti es discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICA BLE LAW, FactSet CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING  WITHOUT LIMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PA RTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT.  TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSO RS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR RE VENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN IF ANY OF SUCH PARTIES IS ADVISED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT M ATTER HEREOF.  \n \n", "original_text": "Any opinions or assertions contained in this i nformation do not represent the opinions or beliefs of FactSet \nCallStreet, LLC. ", "page_label": "20", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "82e8361b-192f-452a-b420-11d131263f55", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "41b230ab4e943714954ffd83d4691ea47c347c510adc3b3884d1d7e524ad6f55", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "94bf1d14-69a8-4a62-8124-bea5e3a8d30d", "node_type": "1", "metadata": {"window": "This information is not int ended to be used as the primary basis \nof investment decisions.  It should not be construed as advice designed to meet the particular  investment needs of any investor.  This report is published solely for information purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security i n any state where such an offer  or solicitation would be illegal.  Any \ninformation expressed herein on this date is subject to change without notice.  Any opinions or assertions contained in this i nformation do not represent the opinions or beliefs of FactSet \nCallStreet, LLC.  FactSet Call Street, LLC, or one or more of its employees, including the writer of this report, may have a position in any of the securiti es discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICA BLE LAW, FactSet CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING  WITHOUT LIMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PA RTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT. ", "original_text": "Any \ninformation expressed herein on this date is subject to change without notice. ", "page_label": "20", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "79d7daadbed02b205dc8cca57da4787f77f709f3474ce5eab6a973850e3e251f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ec5901d0-98cd-4802-8e2e-fe0aaacd4299", "node_type": "1", "metadata": {"window": "This report is published solely for information purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security i n any state where such an offer  or solicitation would be illegal.  Any \ninformation expressed herein on this date is subject to change without notice.  Any opinions or assertions contained in this i nformation do not represent the opinions or beliefs of FactSet \nCallStreet, LLC.  FactSet Call Street, LLC, or one or more of its employees, including the writer of this report, may have a position in any of the securiti es discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICA BLE LAW, FactSet CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING  WITHOUT LIMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PA RTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT.  TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSO RS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR RE VENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN IF ANY OF SUCH PARTIES IS ADVISED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT M ATTER HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2020  CallStreet and FactSet CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC. ", "original_text": "FactSet Call Street, LLC, or one or more of its employees, including the writer of this report, may have a position in any of the securiti es discussed herein.  \n \n"}, "hash": "7a6d4241a7ecaffe79c857bc1febca2995c5cc6eaa290cb310468dcc5b00e2f7", "class_name": "RelatedNodeInfo"}}, "text": "Any opinions or assertions contained in this i nformation do not represent the opinions or beliefs of FactSet \nCallStreet, LLC. ", "start_char_idx": 1260, "end_char_idx": 1388, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ec5901d0-98cd-4802-8e2e-fe0aaacd4299": {"__data__": {"id_": "ec5901d0-98cd-4802-8e2e-fe0aaacd4299", "embedding": null, "metadata": {"window": "This report is published solely for information purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security i n any state where such an offer  or solicitation would be illegal.  Any \ninformation expressed herein on this date is subject to change without notice.  Any opinions or assertions contained in this i nformation do not represent the opinions or beliefs of FactSet \nCallStreet, LLC.  FactSet Call Street, LLC, or one or more of its employees, including the writer of this report, may have a position in any of the securiti es discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICA BLE LAW, FactSet CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING  WITHOUT LIMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PA RTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT.  TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSO RS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR RE VENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN IF ANY OF SUCH PARTIES IS ADVISED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT M ATTER HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2020  CallStreet and FactSet CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC. ", "original_text": "FactSet Call Street, LLC, or one or more of its employees, including the writer of this report, may have a position in any of the securiti es discussed herein.  \n \n", "page_label": "20", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "82e8361b-192f-452a-b420-11d131263f55", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "41b230ab4e943714954ffd83d4691ea47c347c510adc3b3884d1d7e524ad6f55", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a83bd5ba-8033-4fa9-8915-f2628e82ec44", "node_type": "1", "metadata": {"window": "It should not be construed as advice designed to meet the particular  investment needs of any investor.  This report is published solely for information purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security i n any state where such an offer  or solicitation would be illegal.  Any \ninformation expressed herein on this date is subject to change without notice.  Any opinions or assertions contained in this i nformation do not represent the opinions or beliefs of FactSet \nCallStreet, LLC.  FactSet Call Street, LLC, or one or more of its employees, including the writer of this report, may have a position in any of the securiti es discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICA BLE LAW, FactSet CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING  WITHOUT LIMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PA RTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT.  TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSO RS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR RE VENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN IF ANY OF SUCH PARTIES IS ADVISED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT M ATTER HEREOF.  \n \n", "original_text": "Any opinions or assertions contained in this i nformation do not represent the opinions or beliefs of FactSet \nCallStreet, LLC. ", "page_label": "20", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ce519c087c6f06ac3b3dc35393f719beae155c5a048a758f1d588469205c019e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f0e0c02a-0d11-4ac9-8c94-0328b7c3e03a", "node_type": "1", "metadata": {"window": "Any \ninformation expressed herein on this date is subject to change without notice.  Any opinions or assertions contained in this i nformation do not represent the opinions or beliefs of FactSet \nCallStreet, LLC.  FactSet Call Street, LLC, or one or more of its employees, including the writer of this report, may have a position in any of the securiti es discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICA BLE LAW, FactSet CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING  WITHOUT LIMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PA RTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT.  TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSO RS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR RE VENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN IF ANY OF SUCH PARTIES IS ADVISED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT M ATTER HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2020  CallStreet and FactSet CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC.  All \nother trademarks mentioned are trademarks of their respective companies. ", "original_text": "THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICA BLE LAW, FactSet CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING  WITHOUT LIMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PA RTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT. "}, "hash": "40737d3a53a2f3523dd97a61660b8b13100bc89ca2e1fdbde25f37d91b7d2fd8", "class_name": "RelatedNodeInfo"}}, "text": "FactSet Call Street, LLC, or one or more of its employees, including the writer of this report, may have a position in any of the securiti es discussed herein.  \n \n", "start_char_idx": 1388, "end_char_idx": 1552, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f0e0c02a-0d11-4ac9-8c94-0328b7c3e03a": {"__data__": {"id_": "f0e0c02a-0d11-4ac9-8c94-0328b7c3e03a", "embedding": null, "metadata": {"window": "Any \ninformation expressed herein on this date is subject to change without notice.  Any opinions or assertions contained in this i nformation do not represent the opinions or beliefs of FactSet \nCallStreet, LLC.  FactSet Call Street, LLC, or one or more of its employees, including the writer of this report, may have a position in any of the securiti es discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICA BLE LAW, FactSet CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING  WITHOUT LIMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PA RTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT.  TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSO RS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR RE VENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN IF ANY OF SUCH PARTIES IS ADVISED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT M ATTER HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2020  CallStreet and FactSet CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC.  All \nother trademarks mentioned are trademarks of their respective companies. ", "original_text": "THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICA BLE LAW, FactSet CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING  WITHOUT LIMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PA RTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT. ", "page_label": "20", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "82e8361b-192f-452a-b420-11d131263f55", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "41b230ab4e943714954ffd83d4691ea47c347c510adc3b3884d1d7e524ad6f55", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ec5901d0-98cd-4802-8e2e-fe0aaacd4299", "node_type": "1", "metadata": {"window": "This report is published solely for information purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security i n any state where such an offer  or solicitation would be illegal.  Any \ninformation expressed herein on this date is subject to change without notice.  Any opinions or assertions contained in this i nformation do not represent the opinions or beliefs of FactSet \nCallStreet, LLC.  FactSet Call Street, LLC, or one or more of its employees, including the writer of this report, may have a position in any of the securiti es discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICA BLE LAW, FactSet CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING  WITHOUT LIMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PA RTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT.  TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSO RS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR RE VENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN IF ANY OF SUCH PARTIES IS ADVISED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT M ATTER HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2020  CallStreet and FactSet CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC. ", "original_text": "FactSet Call Street, LLC, or one or more of its employees, including the writer of this report, may have a position in any of the securiti es discussed herein.  \n \n", "page_label": "20", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bf4413da642f6ce17b07e118aec28eb76fc2c22dc86317fdb35676df523591ab", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4147e8aa-89cf-4165-916b-be049d428fa6", "node_type": "1", "metadata": {"window": "Any opinions or assertions contained in this i nformation do not represent the opinions or beliefs of FactSet \nCallStreet, LLC.  FactSet Call Street, LLC, or one or more of its employees, including the writer of this report, may have a position in any of the securiti es discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICA BLE LAW, FactSet CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING  WITHOUT LIMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PA RTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT.  TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSO RS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR RE VENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN IF ANY OF SUCH PARTIES IS ADVISED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT M ATTER HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2020  CallStreet and FactSet CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC.  All \nother trademarks mentioned are trademarks of their respective companies.  All rights reserved.  ", "original_text": "TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSO RS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR RE VENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN IF ANY OF SUCH PARTIES IS ADVISED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT M ATTER HEREOF.  \n \n"}, "hash": "b1f9cddef1f70661deeeea30db92e3f401be4ca64fa3a3b711c6dee231c8f3aa", "class_name": "RelatedNodeInfo"}}, "text": "THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICA BLE LAW, FactSet CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING  WITHOUT LIMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PA RTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT. ", "start_char_idx": 1552, "end_char_idx": 1987, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4147e8aa-89cf-4165-916b-be049d428fa6": {"__data__": {"id_": "4147e8aa-89cf-4165-916b-be049d428fa6", "embedding": null, "metadata": {"window": "Any opinions or assertions contained in this i nformation do not represent the opinions or beliefs of FactSet \nCallStreet, LLC.  FactSet Call Street, LLC, or one or more of its employees, including the writer of this report, may have a position in any of the securiti es discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICA BLE LAW, FactSet CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING  WITHOUT LIMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PA RTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT.  TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSO RS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR RE VENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN IF ANY OF SUCH PARTIES IS ADVISED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT M ATTER HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2020  CallStreet and FactSet CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC.  All \nother trademarks mentioned are trademarks of their respective companies.  All rights reserved.  ", "original_text": "TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSO RS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR RE VENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN IF ANY OF SUCH PARTIES IS ADVISED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT M ATTER HEREOF.  \n \n", "page_label": "20", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "82e8361b-192f-452a-b420-11d131263f55", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "41b230ab4e943714954ffd83d4691ea47c347c510adc3b3884d1d7e524ad6f55", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f0e0c02a-0d11-4ac9-8c94-0328b7c3e03a", "node_type": "1", "metadata": {"window": "Any \ninformation expressed herein on this date is subject to change without notice.  Any opinions or assertions contained in this i nformation do not represent the opinions or beliefs of FactSet \nCallStreet, LLC.  FactSet Call Street, LLC, or one or more of its employees, including the writer of this report, may have a position in any of the securiti es discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICA BLE LAW, FactSet CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING  WITHOUT LIMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PA RTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT.  TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSO RS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR RE VENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN IF ANY OF SUCH PARTIES IS ADVISED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT M ATTER HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2020  CallStreet and FactSet CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC.  All \nother trademarks mentioned are trademarks of their respective companies. ", "original_text": "THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICA BLE LAW, FactSet CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING  WITHOUT LIMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PA RTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT. ", "page_label": "20", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "52fd0fa01a205973f66529e3710bc13c943aa606257a418f204ecfdc45a0c828", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c034f82f-1c2d-40f8-a424-f723d3915cb4", "node_type": "1", "metadata": {"window": "FactSet Call Street, LLC, or one or more of its employees, including the writer of this report, may have a position in any of the securiti es discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICA BLE LAW, FactSet CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING  WITHOUT LIMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PA RTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT.  TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSO RS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR RE VENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN IF ANY OF SUCH PARTIES IS ADVISED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT M ATTER HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2020  CallStreet and FactSet CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC.  All \nother trademarks mentioned are trademarks of their respective companies.  All rights reserved.  ", "original_text": "The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2020  CallStreet and FactSet CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC. "}, "hash": "06e8a4150be2e8dab327b2b89f7f57812e2912fd8a197e6ced7436b8bdc28b5c", "class_name": "RelatedNodeInfo"}}, "text": "TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSO RS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR RE VENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN IF ANY OF SUCH PARTIES IS ADVISED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT M ATTER HEREOF.  \n \n", "start_char_idx": 1987, "end_char_idx": 2665, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c034f82f-1c2d-40f8-a424-f723d3915cb4": {"__data__": {"id_": "c034f82f-1c2d-40f8-a424-f723d3915cb4", "embedding": null, "metadata": {"window": "FactSet Call Street, LLC, or one or more of its employees, including the writer of this report, may have a position in any of the securiti es discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICA BLE LAW, FactSet CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING  WITHOUT LIMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PA RTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT.  TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSO RS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR RE VENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN IF ANY OF SUCH PARTIES IS ADVISED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT M ATTER HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2020  CallStreet and FactSet CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC.  All \nother trademarks mentioned are trademarks of their respective companies.  All rights reserved.  ", "original_text": "The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2020  CallStreet and FactSet CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC. ", "page_label": "20", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "82e8361b-192f-452a-b420-11d131263f55", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "41b230ab4e943714954ffd83d4691ea47c347c510adc3b3884d1d7e524ad6f55", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4147e8aa-89cf-4165-916b-be049d428fa6", "node_type": "1", "metadata": {"window": "Any opinions or assertions contained in this i nformation do not represent the opinions or beliefs of FactSet \nCallStreet, LLC.  FactSet Call Street, LLC, or one or more of its employees, including the writer of this report, may have a position in any of the securiti es discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICA BLE LAW, FactSet CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING  WITHOUT LIMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PA RTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT.  TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSO RS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR RE VENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN IF ANY OF SUCH PARTIES IS ADVISED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT M ATTER HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2020  CallStreet and FactSet CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC.  All \nother trademarks mentioned are trademarks of their respective companies.  All rights reserved.  ", "original_text": "TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSO RS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR RE VENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN IF ANY OF SUCH PARTIES IS ADVISED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT M ATTER HEREOF.  \n \n", "page_label": "20", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "570adcae9f97c0a3bf2dab950cfbb6cfa3aa4b5d8cce361cf8eb419c4a693327", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "666be2e4-5f9e-42b1-8f70-f5747e53eb89", "node_type": "1", "metadata": {"window": "THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICA BLE LAW, FactSet CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING  WITHOUT LIMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PA RTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT.  TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSO RS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR RE VENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN IF ANY OF SUCH PARTIES IS ADVISED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT M ATTER HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2020  CallStreet and FactSet CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC.  All \nother trademarks mentioned are trademarks of their respective companies.  All rights reserved.  ", "original_text": "All \nother trademarks mentioned are trademarks of their respective companies. "}, "hash": "968b6ad4faeee700f36e9e99a6531842aff1f62891fee3c8ea5da77611f07c55", "class_name": "RelatedNodeInfo"}}, "text": "The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2020  CallStreet and FactSet CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC. ", "start_char_idx": 2665, "end_char_idx": 2854, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "666be2e4-5f9e-42b1-8f70-f5747e53eb89": {"__data__": {"id_": "666be2e4-5f9e-42b1-8f70-f5747e53eb89", "embedding": null, "metadata": {"window": "THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICA BLE LAW, FactSet CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING  WITHOUT LIMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PA RTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT.  TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSO RS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR RE VENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN IF ANY OF SUCH PARTIES IS ADVISED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT M ATTER HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2020  CallStreet and FactSet CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC.  All \nother trademarks mentioned are trademarks of their respective companies.  All rights reserved.  ", "original_text": "All \nother trademarks mentioned are trademarks of their respective companies. ", "page_label": "20", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "82e8361b-192f-452a-b420-11d131263f55", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "41b230ab4e943714954ffd83d4691ea47c347c510adc3b3884d1d7e524ad6f55", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c034f82f-1c2d-40f8-a424-f723d3915cb4", "node_type": "1", "metadata": {"window": "FactSet Call Street, LLC, or one or more of its employees, including the writer of this report, may have a position in any of the securiti es discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICA BLE LAW, FactSet CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING  WITHOUT LIMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PA RTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT.  TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSO RS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR RE VENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN IF ANY OF SUCH PARTIES IS ADVISED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT M ATTER HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2020  CallStreet and FactSet CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC.  All \nother trademarks mentioned are trademarks of their respective companies.  All rights reserved.  ", "original_text": "The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2020  CallStreet and FactSet CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC. ", "page_label": "20", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d8de569408304b63b10032249e58557ebc302086872f52306411c1a3a9881124", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e2a3a7a8-006a-4022-87b8-b18fa95ac143", "node_type": "1", "metadata": {"window": "TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSO RS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR RE VENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN IF ANY OF SUCH PARTIES IS ADVISED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT M ATTER HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2020  CallStreet and FactSet CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC.  All \nother trademarks mentioned are trademarks of their respective companies.  All rights reserved.  ", "original_text": "All rights reserved.  "}, "hash": "b1a234f2f8a0e517f773a1dfaf45687ce73ee7fd1159171a19a1de510002a86e", "class_name": "RelatedNodeInfo"}}, "text": "All \nother trademarks mentioned are trademarks of their respective companies. ", "start_char_idx": 2854, "end_char_idx": 2932, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e2a3a7a8-006a-4022-87b8-b18fa95ac143": {"__data__": {"id_": "e2a3a7a8-006a-4022-87b8-b18fa95ac143", "embedding": null, "metadata": {"window": "TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSO RS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR RE VENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN IF ANY OF SUCH PARTIES IS ADVISED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT M ATTER HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2020  CallStreet and FactSet CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC.  All \nother trademarks mentioned are trademarks of their respective companies.  All rights reserved.  ", "original_text": "All rights reserved.  ", "page_label": "20", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "82e8361b-192f-452a-b420-11d131263f55", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "41b230ab4e943714954ffd83d4691ea47c347c510adc3b3884d1d7e524ad6f55", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "666be2e4-5f9e-42b1-8f70-f5747e53eb89", "node_type": "1", "metadata": {"window": "THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICA BLE LAW, FactSet CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING  WITHOUT LIMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PA RTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT.  TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSO RS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR RE VENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN IF ANY OF SUCH PARTIES IS ADVISED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT M ATTER HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2020  CallStreet and FactSet CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC.  All \nother trademarks mentioned are trademarks of their respective companies.  All rights reserved.  ", "original_text": "All \nother trademarks mentioned are trademarks of their respective companies. ", "page_label": "20", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1c862c5defd9f418487bfd289cac23aaa0c07b94172a5aa787886c1f56e53007", "class_name": "RelatedNodeInfo"}}, "text": "All rights reserved.  ", "start_char_idx": 2932, "end_char_idx": 2954, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}}, "docstore/metadata": {"8832ecd3-1ca7-4682-9aec-bb96b900ba30": {"doc_hash": "6c694e5efa09ebc8df2b4cfdbac8e6e637a55374c489ba287d051ff45e9831e7", "ref_doc_id": "5fa68102-c072-4c6f-b65a-e470ca43b79a"}, "71a87bc7-ff33-4e4b-be2a-3abdb437d689": {"doc_hash": "4f6bc56e407d4237d058c15f84dd61d1d89d02eb7e572841f83eac8a561cfc11", "ref_doc_id": "5fa68102-c072-4c6f-b65a-e470ca43b79a"}, "e1630c33-7350-4e42-a533-3196f1ee5a3a": {"doc_hash": "5b934600000d714e09b06ea4a0d82e0e02c4f707cfa9a907afb19e095d0b885e", "ref_doc_id": "be75fc7f-5193-4a22-8ee5-e80bd9813438"}, "b17cbbd9-0e73-46e3-92c4-e904618fb425": {"doc_hash": "be20a9a8d84bd7308b227e2d761caef74b855adc4f3479f8752890db3eb35106", "ref_doc_id": "be75fc7f-5193-4a22-8ee5-e80bd9813438"}, "ea29bf7f-1481-4f4b-bbb8-3530c468f93f": {"doc_hash": "b407993a049d599d16d40fe103861962fb1563544694df359c1b442d8d8acbe6", "ref_doc_id": "be75fc7f-5193-4a22-8ee5-e80bd9813438"}, "284fc50e-5dfb-48b8-a117-14489e6742b1": {"doc_hash": "e6b1ae697c896a9edf582bcc204ab92abf140c676481b19ee49ed8abf43963b5", "ref_doc_id": "be75fc7f-5193-4a22-8ee5-e80bd9813438"}, "f23af7a1-fa64-40c7-9425-75af5096d0eb": {"doc_hash": "50095e587a58b0786e1dc90830c4ee013866efbdee462368a6f17aca167dd90d", "ref_doc_id": "be75fc7f-5193-4a22-8ee5-e80bd9813438"}, "657739c5-854d-44ce-b2d9-fa81fa779696": {"doc_hash": "bd7c088d021f20c7d5df48edda97533c6705209c8b6117b79534880d05f2aa2f", "ref_doc_id": "be75fc7f-5193-4a22-8ee5-e80bd9813438"}, "852d9709-c802-4a32-9ab4-ef33e6dbf182": {"doc_hash": "5f95eedce425bc3b6d065dd51c06bc0320127ce22d575e7e7e1fafa4ba4c7a0a", "ref_doc_id": "be75fc7f-5193-4a22-8ee5-e80bd9813438"}, "4e3b23f2-c5b0-4efc-a70b-fca725edb51f": {"doc_hash": "e06898e6c7646d78bd3e84412ab08c8aa0c68cdc9e3f8d9156edd43a3fd4c587", "ref_doc_id": "be75fc7f-5193-4a22-8ee5-e80bd9813438"}, "523453e7-af9e-475c-b691-8e257164d734": {"doc_hash": "6578e36cbaf47ac2ea410fe32479852c3976b843882a812b4b0d691f7868b608", "ref_doc_id": "be75fc7f-5193-4a22-8ee5-e80bd9813438"}, "5c5171d9-f815-40d8-b8b0-9391cf6bf49a": {"doc_hash": "5b206383938f940434421239244670c826eda76f3d656895b5ec41813c7b37d3", "ref_doc_id": "be75fc7f-5193-4a22-8ee5-e80bd9813438"}, "28f85752-c8fb-431b-9869-322fffe993bf": {"doc_hash": "4302a93263adcfbef37879801a77224d327995108814e0ef357e2da64db86d25", "ref_doc_id": "f2ea56d4-9ba8-40ce-8f1a-d30083a09b88"}, "28e254e7-8c61-46d4-8075-6e25026c8268": {"doc_hash": "7ff5feff414c62786fcb3d924187afa471147213958b2d46a0acd6ed1abb3d19", "ref_doc_id": "f2ea56d4-9ba8-40ce-8f1a-d30083a09b88"}, "fc96fdef-10a9-4bdf-918b-af678b048079": {"doc_hash": "09d686c8f3256c51d74095429356fe589161b52855a953788866208992fa14bf", "ref_doc_id": "f2ea56d4-9ba8-40ce-8f1a-d30083a09b88"}, "c98671b7-7ae3-40d2-a10c-118891404195": {"doc_hash": "b60aa2673de298dd178e3f56b3a39add306072d230fb900b0585ee447539156b", "ref_doc_id": "f2ea56d4-9ba8-40ce-8f1a-d30083a09b88"}, "5b3ea2b1-bf9a-42e0-93d3-abc32bd82e96": {"doc_hash": "034dcc4eb1a7d326ed5eef8f9aead850e0044e5c29d0938887808fd775b42c23", "ref_doc_id": "f2ea56d4-9ba8-40ce-8f1a-d30083a09b88"}, "1045334e-cbe2-4180-9a11-2e008c34315e": {"doc_hash": "31a847da32841c87416e92ba5d7fea6092ada1be15713ed8db348dd2daa75e3d", "ref_doc_id": "f2ea56d4-9ba8-40ce-8f1a-d30083a09b88"}, "2c589dae-b77a-4c97-af83-edf099a735fe": {"doc_hash": "df35ca1e0ac147c9a8cc5d4afbbc0ec8e902e43ee8a08142fec75fcc938fbc98", "ref_doc_id": "f2ea56d4-9ba8-40ce-8f1a-d30083a09b88"}, "2d4920c0-a2a0-4ca8-bad0-e7881e0cf6f8": {"doc_hash": "d4a303220642cb69cee5c388db067b5ddb7f803f7c934d32b81f6fb01f473d5d", "ref_doc_id": "f2ea56d4-9ba8-40ce-8f1a-d30083a09b88"}, "58166f8b-a63f-40a6-859b-d357b6c8837a": {"doc_hash": "6fcd2ba415c37b038efad3642e9bc5dfe4a9865089feb3d3b1856bbaa1b272de", "ref_doc_id": "f2ea56d4-9ba8-40ce-8f1a-d30083a09b88"}, "6495e727-1814-4153-b190-9ba1e50d0cbd": {"doc_hash": "8a234e0ae365dcf30a2e92c322cc6eb8a5a0ab05c3d543101627b274655e6f8a", "ref_doc_id": "f2ea56d4-9ba8-40ce-8f1a-d30083a09b88"}, "c4b5f65d-7af0-45f8-a94c-a771401f5fef": {"doc_hash": "525afcf465174950f90f4d1a70fccd478aa922d60ee0eccb5e9bd7d408e8ac9c", "ref_doc_id": "f2ea56d4-9ba8-40ce-8f1a-d30083a09b88"}, "63a648f8-4715-447b-a1c5-803205476ba8": {"doc_hash": "1670b3f73d53312336fa22ee514973b5f30b00c0698300490ae9cc38f6402289", "ref_doc_id": "f2ea56d4-9ba8-40ce-8f1a-d30083a09b88"}, "eea4a3ba-81e7-4ebc-a18c-5166195f054a": {"doc_hash": "03dc5c36c472d28e75dd857666970014693a2d057ccc6081635d0a30ec59081c", "ref_doc_id": "f2ea56d4-9ba8-40ce-8f1a-d30083a09b88"}, "63a68225-986e-4625-8c41-d74d9fc86233": {"doc_hash": "8bf506484263a3b4ab843210bb77281b05a88e3d3c91bba8f2cba66d2498787a", "ref_doc_id": "f2ea56d4-9ba8-40ce-8f1a-d30083a09b88"}, "08c1c5e1-c37f-4c05-a82b-50a28284ef8b": {"doc_hash": "a63e034a7e19be4b7a0a26c3a0ba763d78fa13691f8e96860f2f7edb7406f16a", "ref_doc_id": "f2ea56d4-9ba8-40ce-8f1a-d30083a09b88"}, "b862892f-c3a6-4e8b-bfe7-f1a7edafc3a3": {"doc_hash": "3e92e81ad9b7c0dcddc1e9d1a21cd04b98b0b280b3c8ec1f5f564b69a0759f46", "ref_doc_id": "f2ea56d4-9ba8-40ce-8f1a-d30083a09b88"}, "f68d5ac6-6ac2-407c-8865-1bc6c5fa81b0": {"doc_hash": "00b7fc9727039560b5fe948582d4b2e54478efe4cc6779f75dbed3b607ed5d6b", "ref_doc_id": "f2ea56d4-9ba8-40ce-8f1a-d30083a09b88"}, "91060db3-ad34-4ddf-9021-d082f6af7031": {"doc_hash": "5b8f6f3be3a57f8d9986753669fb41c34e7695091c23dc39a2a662a8d1905ba6", "ref_doc_id": "f2ea56d4-9ba8-40ce-8f1a-d30083a09b88"}, "9e7e7562-80a1-4596-98db-77c339db48ac": {"doc_hash": "227975ce937567d1c05b245c3bf0196318d94997324aa6dbc0e13b2e62a40928", "ref_doc_id": "f2ea56d4-9ba8-40ce-8f1a-d30083a09b88"}, "662cd78b-a27c-4eab-b37e-eff3352d70ca": {"doc_hash": "10837af60ead9971d1c95c775923b0a801c81305f125fd5640c08d3f2c67c165", "ref_doc_id": "f2ea56d4-9ba8-40ce-8f1a-d30083a09b88"}, "bd53e9d1-938f-442e-b148-a3168cee4d0e": {"doc_hash": "6183ffb32db28e39c809ced981a14282fbfe0fe619100de96c6912cb312e358e", "ref_doc_id": "f2ea56d4-9ba8-40ce-8f1a-d30083a09b88"}, "f1e55d67-4db4-4081-b68e-da8008d43272": {"doc_hash": "6d83c3837ca4a8227f1156a4c442f15734cbb4bb179fa5f0699a57e958d4249f", "ref_doc_id": "f2ea56d4-9ba8-40ce-8f1a-d30083a09b88"}, "f9f91683-0fcd-4f51-b323-11ccf47948b8": {"doc_hash": "c9146ce3c0071b33aa792c869f59f7827acea254736506b7d37a9d046764dd4a", "ref_doc_id": "f2ea56d4-9ba8-40ce-8f1a-d30083a09b88"}, "e79707ac-8a92-4f2f-bfa6-740452fbba70": {"doc_hash": "82db5f81bece3a3478ac7f5e125398a1960a3faf3b3fc1a325c6aff7ed598d1d", "ref_doc_id": "f2ea56d4-9ba8-40ce-8f1a-d30083a09b88"}, "7c841c3e-1c0b-4b6a-880a-21d4050479d1": {"doc_hash": "37d439f0888a9ea47626f5f06c2d9523ce5588e99e98d0448f05b7a4a6afa3bd", "ref_doc_id": "f2ea56d4-9ba8-40ce-8f1a-d30083a09b88"}, "3c66dd66-4d0d-49b0-aa99-1bd9d5ba1856": {"doc_hash": "da0d9dc66150838fbb40cdb664f6be807644f893af9fbc49426502f6382959dd", "ref_doc_id": "f2ea56d4-9ba8-40ce-8f1a-d30083a09b88"}, "96f23ca5-5989-4b71-b0c0-01fb13169315": {"doc_hash": "2a22e705ca034458f548a9c03ec35a5a84989e4d44af17b6b1483c4f7dd54e54", "ref_doc_id": "f2ea56d4-9ba8-40ce-8f1a-d30083a09b88"}, "1ea717b4-c066-4f6b-a076-fb04ea7d3283": {"doc_hash": "1997d2180f257983943207a94fb0a78a7cdfe7cddac8a35aecfd5ebac1b116f8", "ref_doc_id": "f2ea56d4-9ba8-40ce-8f1a-d30083a09b88"}, "a9c39a8a-4f75-4a2c-9472-74f51eea4c5c": {"doc_hash": "dfc99e021934bdd44d8c11dfa30dd562cb0c1023a15ae201d0a707766fe15167", "ref_doc_id": "f2ea56d4-9ba8-40ce-8f1a-d30083a09b88"}, "e895f136-462d-4451-bf85-e4ceff4f5c5e": {"doc_hash": "af6c89a10b78b20bd323a920b7e786e6d75174171629b64a548eff00a523baf3", "ref_doc_id": "f2ea56d4-9ba8-40ce-8f1a-d30083a09b88"}, "c64f91a1-2e37-4511-8a81-d05ecdd90f1a": {"doc_hash": "fab8978ede2dd8c4e70cb092d783136c3a890313e7eceae4e8efda5cfb0eb24a", "ref_doc_id": "f2ea56d4-9ba8-40ce-8f1a-d30083a09b88"}, "1afd99ad-2b91-483f-808c-eaa5e8208c80": {"doc_hash": "eaa901944d8f0ac0f8ab084b18ec0535f7ed17be8a746cb07605e2f5d9490507", "ref_doc_id": "f2ea56d4-9ba8-40ce-8f1a-d30083a09b88"}, "2280c3e2-269a-46fb-a70a-c15c429b8a31": {"doc_hash": "54304eccc6409f254dffbc842f82b6175bf5a94fbbd4bab681b741a976d279e6", "ref_doc_id": "71518e0c-2d29-463a-b5e5-d10bfe32ed2b"}, "a29934ad-db7c-48f8-bae5-a2c16aa13c4f": {"doc_hash": "5e499103dfaf92043152b34ad2d07ade68051f9c30bab6f5630dbc18cd28e371", "ref_doc_id": "71518e0c-2d29-463a-b5e5-d10bfe32ed2b"}, "d7517ab3-caf6-4db4-8e1e-504d24e0a7c6": {"doc_hash": "5d4a46d307a9ccfeb53d1291cc7fa90a7d55823bb4cd853b07aaedb36095c267", "ref_doc_id": "71518e0c-2d29-463a-b5e5-d10bfe32ed2b"}, "12504bf6-aafb-4fa7-93e3-966dba64d316": {"doc_hash": "5755af480072a48bbb00e30a550f7e8ac916574af91919ade9604a35177c78ef", "ref_doc_id": "71518e0c-2d29-463a-b5e5-d10bfe32ed2b"}, "25110e47-2faa-422b-ae0e-5888ebd5fa92": {"doc_hash": "8ce499c3b79057a89f33b795c6d04fb2c3dcf7d51fa2f6cf42bfce4e48591466", "ref_doc_id": "71518e0c-2d29-463a-b5e5-d10bfe32ed2b"}, "20427e21-e8b7-4318-9979-acee71ab560c": {"doc_hash": "cc54da3d37a496c7e89a3656e8807eefe2bd135182643fe6f6413f388a561073", "ref_doc_id": "71518e0c-2d29-463a-b5e5-d10bfe32ed2b"}, "7a209eb1-80a7-4ee5-a946-b91d2c01a99f": {"doc_hash": "68c7bfb63d6463c7520d64a1b327ed53d42239a77297c4c024ad9640c013a8d6", "ref_doc_id": "71518e0c-2d29-463a-b5e5-d10bfe32ed2b"}, "c0d16077-0a6b-411c-8b3f-34d963098e8b": {"doc_hash": "6942716b57d9d178a643dd14f4ae7489e1552f3b6b0c11b405f8ed9fd740bcfc", "ref_doc_id": "71518e0c-2d29-463a-b5e5-d10bfe32ed2b"}, "05c6a7f3-7746-4bea-8cc2-97d26f072ad8": {"doc_hash": "ee1c09f030969fdfa17bb107ff47f44d4290ddfe20482f22cb7a1e94ef6319c6", "ref_doc_id": "71518e0c-2d29-463a-b5e5-d10bfe32ed2b"}, "521942cb-63f7-4c8f-8226-027b01ef79fc": {"doc_hash": "797573ef3825c10cb20fab812ef027d3bf3b4c34ba7a0343cd1ce94b804eab6d", "ref_doc_id": "71518e0c-2d29-463a-b5e5-d10bfe32ed2b"}, "f8a3d68c-12cf-4f47-990f-841dbaea1d83": {"doc_hash": "9cfed4c011a20dd11282ebd31a18956809f38e1d7f0845170d51c3f582052289", "ref_doc_id": "71518e0c-2d29-463a-b5e5-d10bfe32ed2b"}, "4d1c5230-8fe1-4cd2-b394-d979f48504ec": {"doc_hash": "a2b9c76490c694e8acd8c54d8fc2e327fde6c56a339c75d9d8e4144d54c8c135", "ref_doc_id": "71518e0c-2d29-463a-b5e5-d10bfe32ed2b"}, "ff27085f-67d2-45d7-a907-5b528fb99963": {"doc_hash": "5e95ee07d28cc6f904cd2f89ec645e733b1cd32efe20377333cdd604d7d43e0a", "ref_doc_id": "71518e0c-2d29-463a-b5e5-d10bfe32ed2b"}, "1e956443-ab78-4045-b807-555a8dcecc3a": {"doc_hash": "f4d163777dc727126541fa59e17612fea03e8a0e627d6fa0db44fc325ff19ef6", "ref_doc_id": "71518e0c-2d29-463a-b5e5-d10bfe32ed2b"}, "c51da3aa-5e15-48ae-8f21-a7760feea768": {"doc_hash": "ccbadd62d7ce3bfebe5cf13b23498b33ab9c27679aed82f55b512c29d026f1f2", "ref_doc_id": "71518e0c-2d29-463a-b5e5-d10bfe32ed2b"}, "ebf04942-9036-44a5-9d6d-157c392b8e65": {"doc_hash": "72d8b70a303cdde684df165ea3b94686aa21c1b53c55e7d5bf74c97c6b130f36", "ref_doc_id": "71518e0c-2d29-463a-b5e5-d10bfe32ed2b"}, "c375ec00-674a-41b9-a8eb-5e7a260656f7": {"doc_hash": "2ac349b9ffceacf47c31c5a6b52a6f057a67bd1954f0d884581b028076a9a3dd", "ref_doc_id": "71518e0c-2d29-463a-b5e5-d10bfe32ed2b"}, "255ca743-90eb-4f8c-94bd-6e6a1458ea3c": {"doc_hash": "18fca81d9b12557ffbc67a36572b0e634d9e3698bc05baba64351db4269ae757", "ref_doc_id": "71518e0c-2d29-463a-b5e5-d10bfe32ed2b"}, "2195d6d3-37e8-44ea-bb36-2520de00c598": {"doc_hash": "958a5de662dd1b3e1853d5f788610e8554c8a295bf1fee61fec5f9063cf85375", "ref_doc_id": "71518e0c-2d29-463a-b5e5-d10bfe32ed2b"}, "078d3b36-3857-4c2d-86ca-aed29fc3cdb8": {"doc_hash": "e686919f177cc2d902f6a1e1c8af4371a6a41b559e514a733bb1ca30bce2b50c", "ref_doc_id": "71518e0c-2d29-463a-b5e5-d10bfe32ed2b"}, "2260d5fa-7ae2-47d5-a088-05c89eb366ee": {"doc_hash": "81e1b179a80f69993204488947339121aa0ee6b33894bfcce81e39cec32568e8", "ref_doc_id": "71518e0c-2d29-463a-b5e5-d10bfe32ed2b"}, "73f574b0-d426-4ba9-b0c4-f015a6a60491": {"doc_hash": "783cf5617b001c519293d02b6fdfebb51c0ab321bc7a2b333b8483bade9641bc", "ref_doc_id": "71518e0c-2d29-463a-b5e5-d10bfe32ed2b"}, "05978cdf-0644-499a-89e2-9b7db9097fc0": {"doc_hash": "5f5643d0323d3427b2c7a49677caa1e9152d394a8a1ddc2e4fdd9ade2ce7e2e3", "ref_doc_id": "71518e0c-2d29-463a-b5e5-d10bfe32ed2b"}, "8cbf1359-3c64-436d-887d-7c0b925b431c": {"doc_hash": "85400cf07983f35f4e0da0eb7927eec9659d89a5c5c287e64a3ddd29d0857f9a", "ref_doc_id": "71518e0c-2d29-463a-b5e5-d10bfe32ed2b"}, "2502de08-b5ed-4867-bffb-f90fec4ceb8a": {"doc_hash": "0ca3275e991152c8db195fdc2e11cc57f0a3bcff5232b69186cf9e1650fa53b8", "ref_doc_id": "71518e0c-2d29-463a-b5e5-d10bfe32ed2b"}, "9b83df33-8543-4f60-88e8-ea19c34ee148": {"doc_hash": "3998e0a6fbaaf18a09f966f4df761829b04f0cd2d706df6092105ebd798cfda8", "ref_doc_id": "71518e0c-2d29-463a-b5e5-d10bfe32ed2b"}, "866617ac-527d-4ddc-948d-e18b819a388b": {"doc_hash": "c2aee7eb36dba34fa8fe2ac2fee1e6d0e887ef3a2532358f6d0f5b8bbcfa2e48", "ref_doc_id": "71518e0c-2d29-463a-b5e5-d10bfe32ed2b"}, "0127bbe9-afc9-4a5d-b094-73cf6e127321": {"doc_hash": "2c775fc1cf9b5af54d24c3c58c504eb04c60146a79618050e79a613a4877aa07", "ref_doc_id": "71518e0c-2d29-463a-b5e5-d10bfe32ed2b"}, "7f7ea861-a630-4b0c-8740-ff7430aa5ff2": {"doc_hash": "c77e5581abe3b0aae98b8274506b0875b2797b2185ec6d556a61c8c641f99443", "ref_doc_id": "2b6fa81b-d6e8-4046-a002-579e9e14ad02"}, "bda5d8d2-b4c2-4bd5-bac6-aef17a1537f3": {"doc_hash": "a61816799e64484e6ba0e7b84e4610058c85b0f07f832400432cd75dfe506aae", "ref_doc_id": "2b6fa81b-d6e8-4046-a002-579e9e14ad02"}, "544f6404-fc2a-4cf6-87f5-62f83805b2e0": {"doc_hash": "feaf7af9583a73a514e99f39fd2164c4e1000602c5f72b77bb9d718b645d1ca8", "ref_doc_id": "2b6fa81b-d6e8-4046-a002-579e9e14ad02"}, "818a91d5-e536-431e-b956-a2028fd9a151": {"doc_hash": "bc166638421f620a40f8f1ee9e88807f79b8fbe9e4302e075067d9cf47b2ee97", "ref_doc_id": "2b6fa81b-d6e8-4046-a002-579e9e14ad02"}, "9c9e6c9c-84f7-4380-abe5-bdd4d824fcc2": {"doc_hash": "639669d57e31a6364de6e706603099053a4bf07f461158ffbc1c32bc213bc052", "ref_doc_id": "2b6fa81b-d6e8-4046-a002-579e9e14ad02"}, "639f0dc6-0ef4-4519-8900-9007f603a87a": {"doc_hash": "4954358bce414ac435c0a90140e0780d7efaf480b999bc365055d28836c68825", "ref_doc_id": "2b6fa81b-d6e8-4046-a002-579e9e14ad02"}, "2110b589-637f-4205-8262-25b7b48c31c1": {"doc_hash": "5909b4b62b0da3f87aec3d2c35fc2872938089e23d4aad02d0a2cf8a692b4405", "ref_doc_id": "2b6fa81b-d6e8-4046-a002-579e9e14ad02"}, "16f44cc7-755d-46b5-8e20-e06c80b34364": {"doc_hash": "8420ee09f1b8082ee7d7d7cef7bc5755c4da97614810e124d2b31efc37ec132f", "ref_doc_id": "2b6fa81b-d6e8-4046-a002-579e9e14ad02"}, "890add9a-e8dd-4cbe-bba1-ddcae36c79da": {"doc_hash": "83948882037aca707983811f0207e054637cb693243ef10574eeb64b00a720b5", "ref_doc_id": "2b6fa81b-d6e8-4046-a002-579e9e14ad02"}, "0ab0d51e-dd8e-4270-bd90-f08a9bfde0ac": {"doc_hash": "6b56aef556b46aea03ea902014cae0a9c9ac107880b43938f6572be30e67697c", "ref_doc_id": "2b6fa81b-d6e8-4046-a002-579e9e14ad02"}, "24feaeee-f058-4248-8883-f0fbe3983773": {"doc_hash": "6b3cebe31d67527ff8968e446851a8a5976c3e9bc9683508ef9cb6748102ce9f", "ref_doc_id": "2b6fa81b-d6e8-4046-a002-579e9e14ad02"}, "2c19cc6e-7d83-4990-962e-36ef045924d1": {"doc_hash": "17eacfbd9dca83c73d9f80ab737ce34f83d8653084888eaea8cab3ba4997b914", "ref_doc_id": "2b6fa81b-d6e8-4046-a002-579e9e14ad02"}, "a1a27fe7-72f2-4154-8790-9543b8499ab6": {"doc_hash": "4b897e5dd7d259ed26c05519f51cf46ca7b319dae0ed94395de3e3a7baf14b16", "ref_doc_id": "2b6fa81b-d6e8-4046-a002-579e9e14ad02"}, "804f9448-56ee-4088-af11-d219dae25c55": {"doc_hash": "83061624feb6cecc59268c5b213b0619f78744140bd7cd743d8f70d93e134e1e", "ref_doc_id": "2b6fa81b-d6e8-4046-a002-579e9e14ad02"}, "5333f2c9-45df-4851-a9c9-be2aeadc5a0d": {"doc_hash": "ed493b54be2df7dd8723bf98e4795a708a204775bd8de9308665f750f598c6f1", "ref_doc_id": "2b6fa81b-d6e8-4046-a002-579e9e14ad02"}, "580fc0cb-abc8-472c-87d7-6e02301daf69": {"doc_hash": "72b8b85050ca6096cb8c4980961194e2e8fe276a2ff0a95e70452914f6bd1329", "ref_doc_id": "2b6fa81b-d6e8-4046-a002-579e9e14ad02"}, "241ea05e-72c0-4332-8203-78e581e437df": {"doc_hash": "115d525ca1f42f62c12d2e2a50abc96c05b3b2959956123af677e13d9ae4b6c3", "ref_doc_id": "2b6fa81b-d6e8-4046-a002-579e9e14ad02"}, "d8f2a106-7c05-4078-b1be-e3324818f77c": {"doc_hash": "58ccb24c0ffa0580b0018716b6576d375de2465e3ce2a92fc4c626e078782b77", "ref_doc_id": "2b6fa81b-d6e8-4046-a002-579e9e14ad02"}, "1c3a6877-906a-4cff-8ed5-9b18482ca5a5": {"doc_hash": "6e16c3bad2cd5bb4d6b72222ac397b191630c823448d68e36ac05e67d5b2e453", "ref_doc_id": "2b6fa81b-d6e8-4046-a002-579e9e14ad02"}, "d089f954-57ae-436e-935b-b529f3352374": {"doc_hash": "5f74dc0e91ff6fc64e357515ec489276815bcf6cd1fed932733577af0858ad68", "ref_doc_id": "2b6fa81b-d6e8-4046-a002-579e9e14ad02"}, "9df15c19-9d55-4af1-b5e2-3e3a1a549153": {"doc_hash": "eddce4b1a7bdcff9a50a1528cc28e12f62389592ab110b1863f2636aefcc8cf3", "ref_doc_id": "2b6fa81b-d6e8-4046-a002-579e9e14ad02"}, "7cc94b20-e1d7-434c-81f6-1cf7c9758b38": {"doc_hash": "232172b85e78ceeb15554bbc06d7cb5216c3b1dfeff7f844c3b9a7ca6438503c", "ref_doc_id": "2b6fa81b-d6e8-4046-a002-579e9e14ad02"}, "9aa51914-8d6a-4d4c-a76c-a24ae6458080": {"doc_hash": "bbeedac3ce04ca2c902f7a34653a04b3068cad13fe7b4f24638d07edec559e6b", "ref_doc_id": "2b6fa81b-d6e8-4046-a002-579e9e14ad02"}, "70d5ba2b-5ae7-4c3b-bf67-8186c9d034aa": {"doc_hash": "6d4f442bd6a05284a645a0931a510be8755cc2ecb9bf1388580d8d629676f1d6", "ref_doc_id": "2b6fa81b-d6e8-4046-a002-579e9e14ad02"}, "56c9e5ee-be13-4513-a262-73b973493c8f": {"doc_hash": "1e7397c5f136f01dc60d1cd1de1540b32ce9ee58833e2e451ff7ed791b3adcfe", "ref_doc_id": "2b6fa81b-d6e8-4046-a002-579e9e14ad02"}, "9eee3a3a-4f24-48a5-a7e2-8d17099861c9": {"doc_hash": "5414fffd5f4239b19162caf4e3052b8eb0ebe9f3aed540ea517a38c434890b7f", "ref_doc_id": "2b6fa81b-d6e8-4046-a002-579e9e14ad02"}, "4e99c27c-2499-4686-bd29-551b9fbf0ec6": {"doc_hash": "cd594e1acb90996219ac47155b8a8dbaa2e50704d7cb551ce72375c8eb4eba8a", "ref_doc_id": "2b6fa81b-d6e8-4046-a002-579e9e14ad02"}, "128192e9-47ce-465b-adb6-025c28c346e5": {"doc_hash": "7515dd34bff0e163de5f69d185c163b77af04372b591840765fb323991b16058", "ref_doc_id": "2b6fa81b-d6e8-4046-a002-579e9e14ad02"}, "0937be29-1b77-4acf-9884-c099e3f6a844": {"doc_hash": "dedd31731524f3ca9bfb03082d5df61c61d97c3373e2d5ef5bde798884dc8942", "ref_doc_id": "2b6fa81b-d6e8-4046-a002-579e9e14ad02"}, "9a2462da-b695-477b-a955-2d1ceff730b7": {"doc_hash": "b7d475772f86523bc97903a320247975c26a91e09c60ec5631958f00beafcee5", "ref_doc_id": "fec4a8f1-855e-450a-b1f2-9b9b254694e1"}, "319e7aed-1474-42e2-b7fd-0771437b25cc": {"doc_hash": "1f4ee3f74fd91369747d9ad97828ae1291239e3152df48b964b8b870004fab05", "ref_doc_id": "fec4a8f1-855e-450a-b1f2-9b9b254694e1"}, "f7ca8fd1-41d4-468c-8210-1c8ed90b513c": {"doc_hash": "bd1b71f2995d6f4fe8bffcd0abae45daeacfb6cf7a8a1c56172e9b44ecc97cc8", "ref_doc_id": "fec4a8f1-855e-450a-b1f2-9b9b254694e1"}, "65a0dbf1-30af-4c44-8889-b86d8bf355f9": {"doc_hash": "53a26d0f5a23d65388d543ddef24d748a4cdc07ce7b8bc8ae3c52d8c4a5f1029", "ref_doc_id": "fec4a8f1-855e-450a-b1f2-9b9b254694e1"}, "a1af1e9c-fbe9-48f1-829b-ff663eed09a2": {"doc_hash": "8ddda94c632aab495c13e816f7499e5a06f172dc96d890cf780f957975ab7be2", "ref_doc_id": "fec4a8f1-855e-450a-b1f2-9b9b254694e1"}, "1f18831e-d5d5-42f0-bb9a-a89ee863cb47": {"doc_hash": "1095719acb25b798fbf63b2738f7f987f4def434e6831fc5c682486a0e24acb6", "ref_doc_id": "fec4a8f1-855e-450a-b1f2-9b9b254694e1"}, "e29877c2-b301-401c-a043-57e48ab1acc3": {"doc_hash": "8dbcd73cd5db47291dd35757494cd05a4873cddf8a712726d3a1f2f53c33d456", "ref_doc_id": "fec4a8f1-855e-450a-b1f2-9b9b254694e1"}, "af5aad95-ba86-42d3-9182-7f39e074255c": {"doc_hash": "95ba444d6c2486174d719f5edfe622857dfa1003556d9efb0251bb07c5db3a7c", "ref_doc_id": "fec4a8f1-855e-450a-b1f2-9b9b254694e1"}, "d43eb8bf-d9a0-47f2-a5bd-6da7b47a67e8": {"doc_hash": "c80a234fa7a6de813b9934e174025c6e00b482c793aad5fa6382bd495dbfc2b1", "ref_doc_id": "fec4a8f1-855e-450a-b1f2-9b9b254694e1"}, "e19587bb-4749-4775-9cfe-63abe8b6858b": {"doc_hash": "f36240a0a9e761e909bf01f74a41f7d666fd19dacd370414fb29af893f253e19", "ref_doc_id": "fec4a8f1-855e-450a-b1f2-9b9b254694e1"}, "a1d4c1c9-4e16-4e37-b8af-bb94c59defb3": {"doc_hash": "deb6209d87033d85c24364fca76660cecf354a881469c4588ee6b644ca46be36", "ref_doc_id": "fec4a8f1-855e-450a-b1f2-9b9b254694e1"}, "f286a33a-f518-4f3d-9241-d64f2de298cb": {"doc_hash": "c7654405351588f32376a91ac4b7431f1cc724f0be1b412e07d1c875725ee25f", "ref_doc_id": "fec4a8f1-855e-450a-b1f2-9b9b254694e1"}, "f27ed826-6976-4325-9dd3-a0293e22731b": {"doc_hash": "aa63b784329a68dd1797576ce4409117e5c3da495fa5bf34d75d0b02267b43c9", "ref_doc_id": "fec4a8f1-855e-450a-b1f2-9b9b254694e1"}, "004699e4-cbbe-4f9e-9d66-b6c3c6ee1659": {"doc_hash": "be981d215e46a40224832883de6b6c3a8ecd1a41b47e7690f70596b4a1c2e418", "ref_doc_id": "fec4a8f1-855e-450a-b1f2-9b9b254694e1"}, "045e5096-aa5e-4181-aa4f-1fef162002bf": {"doc_hash": "25f17d372d8a7e6257845859defc7fb4b2d19c08efbfadf37afa0d0ad5359584", "ref_doc_id": "fec4a8f1-855e-450a-b1f2-9b9b254694e1"}, "b975f639-2523-4bd7-8ede-5d10acfb8e46": {"doc_hash": "383495f26bf3f3d86edf96e9d1318c612471713e5df652252667ab0ee7f4f737", "ref_doc_id": "fec4a8f1-855e-450a-b1f2-9b9b254694e1"}, "e4f1e553-729f-4608-af9c-0d4d9ca00892": {"doc_hash": "1f7e772a28154c2d6a36ad923ae014091270a75ed5821b96b6674f50ade99fc3", "ref_doc_id": "fec4a8f1-855e-450a-b1f2-9b9b254694e1"}, "41433351-040b-43d2-817b-a8d5bbdd8216": {"doc_hash": "814458c2b706af5a02e4f750726b6bda8e25289fe39f177fab40535421db0821", "ref_doc_id": "fec4a8f1-855e-450a-b1f2-9b9b254694e1"}, "da1fbbb4-46c6-412f-8214-c8fafdaa200a": {"doc_hash": "acbcabcf63b44f910518dcb242d6c780797a9865c606f9ab68c33f0c8b985b2d", "ref_doc_id": "fec4a8f1-855e-450a-b1f2-9b9b254694e1"}, "cf09e37e-1690-42d8-bf40-a56707b5783b": {"doc_hash": "ef0ec5543e2853bd23bbb20bac6de38bf3aeadf2105e9c141020707e491c1ac8", "ref_doc_id": "fec4a8f1-855e-450a-b1f2-9b9b254694e1"}, "0530e465-7c05-43fa-8431-110507163d57": {"doc_hash": "c9d6dfdcd8e080033e51ac31eba67843abdfca21d725264bb5116a145ca91aaa", "ref_doc_id": "fec4a8f1-855e-450a-b1f2-9b9b254694e1"}, "0f159bc5-9bfe-48f8-8ae7-839a2011ae40": {"doc_hash": "74b6bfcf19b2023ec60a5729be65c32d8f8771319d17d91e7db20b45ca455a23", "ref_doc_id": "fec4a8f1-855e-450a-b1f2-9b9b254694e1"}, "dd0fc70d-1712-4cd7-83ef-76f981df3759": {"doc_hash": "0c9d72da443da4348fb08b41989c62a03fc823ba856c7eb818400fdb89d63dce", "ref_doc_id": "fec4a8f1-855e-450a-b1f2-9b9b254694e1"}, "cddf3323-9134-46d6-af4b-09bec0229426": {"doc_hash": "5c0f683e743c55afa00cf917ddafa8eb8c1c979c7ebbe0ccd99b18a35dc4bca0", "ref_doc_id": "fec4a8f1-855e-450a-b1f2-9b9b254694e1"}, "c355dc70-61b0-48ea-afbf-e531a3705f95": {"doc_hash": "2cc47e12fbeff13b9bbed578b3b967a024cef6bb4a0c08706f6c36d29eaf8498", "ref_doc_id": "5e1e3bfe-18ed-4cc7-9082-9a79812e2f1c"}, "1296d68c-816a-49f9-a192-21d9afb78f71": {"doc_hash": "e6e60c59ce0d1d43305c278e8c49bf068be0a51e3db4d17aa9bd8ed313da1a7d", "ref_doc_id": "5e1e3bfe-18ed-4cc7-9082-9a79812e2f1c"}, "908db5ec-934b-4616-93a3-8b5921614d4b": {"doc_hash": "43e06e123a771d1730d17aaa38adf1bb064f8189a3efd6f48aaba7d89fd3b127", "ref_doc_id": "5e1e3bfe-18ed-4cc7-9082-9a79812e2f1c"}, "871a330c-dd92-4f98-871f-62d35fa7a43b": {"doc_hash": "3e6f05a1aafb477b3f1323367f97b3cc768d5e61599df2f1227eedf4c7d7b1e7", "ref_doc_id": "5e1e3bfe-18ed-4cc7-9082-9a79812e2f1c"}, "32a139d2-1676-45a3-a1d3-ccdf5f9e8616": {"doc_hash": "64f3f55f85149fe5c649d9739c580dfb5471ae6ff10ef640ebaa7da3b26f8230", "ref_doc_id": "5e1e3bfe-18ed-4cc7-9082-9a79812e2f1c"}, "8c9e2825-15aa-4755-9391-42f11ead0475": {"doc_hash": "c892707e101c9027da6bdd1a7e837ce449429510d5bee29bd65f4d82a8d637f3", "ref_doc_id": "5e1e3bfe-18ed-4cc7-9082-9a79812e2f1c"}, "3e19467a-b0f7-44a3-a36b-0223838a41f0": {"doc_hash": "a5d3c166f7248f5aa47f9d425d1bfc289e875af4713719f8bed80d46cfb8478a", "ref_doc_id": "5e1e3bfe-18ed-4cc7-9082-9a79812e2f1c"}, "18c9b545-771b-45dd-9cff-cbd348ec3952": {"doc_hash": "730a657435abd2dbfc5f5da2502193c5dc2b4964d80a15a742c81efe7acbf4fb", "ref_doc_id": "5e1e3bfe-18ed-4cc7-9082-9a79812e2f1c"}, "5d80d718-5523-4147-a039-989111c8d6fd": {"doc_hash": "6a05430c7db46338d0a3fa1f3e4c5b1f3eb4e2dd2c44c42cff0cf8a304985460", "ref_doc_id": "5e1e3bfe-18ed-4cc7-9082-9a79812e2f1c"}, "b1a91d49-a53b-4d19-bf0b-0ef937f990ff": {"doc_hash": "c69ee848e69ca8f94cb6c4e31de58fbb700ff6930c90ab100d5128d58dfb2c3f", "ref_doc_id": "5e1e3bfe-18ed-4cc7-9082-9a79812e2f1c"}, "c672be4a-2f01-46ad-99ea-4d431ee3161e": {"doc_hash": "9d5c1c8fd03b6c8f3b8863ee551b176a08ecbb4b1ea50643d5b6ad75e005f525", "ref_doc_id": "5e1e3bfe-18ed-4cc7-9082-9a79812e2f1c"}, "145b5716-3445-4260-8a1b-db6db776ce99": {"doc_hash": "52bc762aad93af93f8fb1a3f2afa74184a433a185c15cefe2a8cea5c389acd8b", "ref_doc_id": "5e1e3bfe-18ed-4cc7-9082-9a79812e2f1c"}, "50a2dfe7-d731-43c5-adbb-dfc3f078b3a8": {"doc_hash": "e1469dbe791d7fbb30a3fe96fa56fb61bc2a35998136b392f526d3c97d01dfa1", "ref_doc_id": "5e1e3bfe-18ed-4cc7-9082-9a79812e2f1c"}, "821672ec-d35d-478e-881a-f46b09cefa1c": {"doc_hash": "94ee059c81444ae98ed6c891283df0ad6d3b6d30ec31fc0aebf8a87de853e698", "ref_doc_id": "5e1e3bfe-18ed-4cc7-9082-9a79812e2f1c"}, "4ba31012-e734-4b63-8965-5b2d7c23b483": {"doc_hash": "df0445cd9c43f8fcff49edb890b2c76b98dbd02151526173523fe8b4c300eb4d", "ref_doc_id": "5e1e3bfe-18ed-4cc7-9082-9a79812e2f1c"}, "4c19e08d-97e2-4e42-b828-b9ca150f242c": {"doc_hash": "db000a0ee2c43c7c6b7cbb4171215693fc3e2f39bad3987743ab26c8bd3b9953", "ref_doc_id": "5e1e3bfe-18ed-4cc7-9082-9a79812e2f1c"}, "ac4c4b7b-2fe3-45b2-9be8-605486ee643e": {"doc_hash": "62287973c9b01ed63185857650394367573cdd68a1c8f96f3a81a5e7eb1967d9", "ref_doc_id": "5e1e3bfe-18ed-4cc7-9082-9a79812e2f1c"}, "6586c622-9332-41e3-be0f-6ea700a11d1c": {"doc_hash": "1e4fb48171d0aef6da3d3c35522e0e8ea3644dc33137f6e0d18ac3b946150f32", "ref_doc_id": "5e1e3bfe-18ed-4cc7-9082-9a79812e2f1c"}, "3ac8f8d5-085c-44c4-bf8a-363bac289b9b": {"doc_hash": "a8b3c0033f7637d3cca67b70c367e7eb3ead346f9d05b7dae7ad2e10fa48ee8b", "ref_doc_id": "5e1e3bfe-18ed-4cc7-9082-9a79812e2f1c"}, "9a292f2e-9c91-4102-bff1-5dd52867b7f5": {"doc_hash": "b602d627aba42883cd64557868bb8aa665591b35851a3b553c65992e3f545550", "ref_doc_id": "5e1e3bfe-18ed-4cc7-9082-9a79812e2f1c"}, "19dae4f0-e90a-4e9b-9f1f-26bcaf38f1cc": {"doc_hash": "3ec1a9732e630f4d49ff7b051543b22280c20e2d56f59a5ed3e6e5cb843df536", "ref_doc_id": "5e1e3bfe-18ed-4cc7-9082-9a79812e2f1c"}, "fe825b3d-0263-43d9-901e-60cbb7edc7b1": {"doc_hash": "890ece689109e7d1dbd5f0bffd757d133e67c109039fbd8d5ade3b82205ca674", "ref_doc_id": "5e1e3bfe-18ed-4cc7-9082-9a79812e2f1c"}, "138683da-99a3-4de4-8167-18dfafe4f255": {"doc_hash": "cb5f76351a2761da0637651b1ef461916a14fe221bfdcdf4e9e3d8f9ea42cc59", "ref_doc_id": "5e1e3bfe-18ed-4cc7-9082-9a79812e2f1c"}, "71072f52-fc76-4dbf-a828-da986647a42d": {"doc_hash": "4606e46fc37bf6f4d02b927eff2f67ba8b5da08badd48a21a528400715ad2d3f", "ref_doc_id": "5e1e3bfe-18ed-4cc7-9082-9a79812e2f1c"}, "e847793d-3384-4a92-b311-b002f04769c4": {"doc_hash": "5f82a5672145ff49b81e21e38da5f4496849ea18668187b6c42942a59a45bc0a", "ref_doc_id": "5e1e3bfe-18ed-4cc7-9082-9a79812e2f1c"}, "e7b2af5a-bf2d-4bdd-971a-0785bd70ae54": {"doc_hash": "b18391c4e9c331dbfec07f17fcefe11cfd1c21ac8964d8fb9e05bf0e15943f96", "ref_doc_id": "5e1e3bfe-18ed-4cc7-9082-9a79812e2f1c"}, "be60416d-4247-4b06-abf5-41e7db4ef64e": {"doc_hash": "ddb9b46eff518d7b5030edf4668ccc62193d775642d00faa4bcbecee8136eef6", "ref_doc_id": "5e1e3bfe-18ed-4cc7-9082-9a79812e2f1c"}, "da118de1-f34c-45f5-b52a-10f33d67a8c5": {"doc_hash": "10732a83711e7fbf892a04ed46cedd97fd91d5f0fdfa3334bb3e16c40a22a158", "ref_doc_id": "5e1e3bfe-18ed-4cc7-9082-9a79812e2f1c"}, "b5fda7e8-90a1-4f95-90c8-bb8c0ad1e934": {"doc_hash": "2fcc2eb6d253f3ede4ab44521f4166775a1a646730a80e5644881de298415b30", "ref_doc_id": "5e1e3bfe-18ed-4cc7-9082-9a79812e2f1c"}, "5ae9f0a8-9ef2-4f27-b75e-68e1dd96995c": {"doc_hash": "40d0685b5a78253841013b9faa58f254820786c747af1e12b3ceecbc50eb514b", "ref_doc_id": "5e1e3bfe-18ed-4cc7-9082-9a79812e2f1c"}, "4cdba34a-0d08-4be2-847c-08cfc5b25824": {"doc_hash": "c5fb1c8194d3c6dcd1979180db801b72aa6387043420a8f451d98cb75f28839e", "ref_doc_id": "5e1e3bfe-18ed-4cc7-9082-9a79812e2f1c"}, "eca22406-91cf-4aae-b798-41d4bfd1efe0": {"doc_hash": "ac73bbce5b897725bbfdafc8dfa767cd87a3b3662edd2485dc0b3bd4a1d81827", "ref_doc_id": "b6da9e8d-146b-433f-beae-4978bb0cbe32"}, "b9c4e9f4-2a2d-49f0-b136-71a3f35cfcfe": {"doc_hash": "56a2f878775381cf5c45552c6b511f21ef347df6fae9dc14fd3b990482439fc7", "ref_doc_id": "b6da9e8d-146b-433f-beae-4978bb0cbe32"}, "5600640b-4eec-46e7-9223-2ce61fd9f1c2": {"doc_hash": "446d1e34df54c878fec9b71666f5bf20d49512b1a688b963f2815caf518a609c", "ref_doc_id": "b6da9e8d-146b-433f-beae-4978bb0cbe32"}, "a898a7fb-8332-407e-b716-956bcbba330c": {"doc_hash": "7f2f352a70febf22b4504ad1fb1cb78cb12189e6f8348781b7cbc92705f7a71c", "ref_doc_id": "b6da9e8d-146b-433f-beae-4978bb0cbe32"}, "385a8c98-94ef-4859-9bff-2b3dc925c859": {"doc_hash": "d388e02956e9e02114b4bb7636d39b7337da6cafcc62ad70cfdcebbf6678a77b", "ref_doc_id": "b6da9e8d-146b-433f-beae-4978bb0cbe32"}, "ed080ebe-2e32-4cfd-9902-71552dfff084": {"doc_hash": "e180750b83bcff5ba5d093b8e80c4207b311662930dcf4942b8dc117633f9021", "ref_doc_id": "b6da9e8d-146b-433f-beae-4978bb0cbe32"}, "1a6477c9-4fd8-46da-b820-1eb23903953e": {"doc_hash": "5f6e14a609fd2561a70ef3fb2a3cbd5fb69e35936cf5fb0c9fad2809fe08ff2c", "ref_doc_id": "b6da9e8d-146b-433f-beae-4978bb0cbe32"}, "1afa4feb-77b2-460d-a06c-3f2d49df1768": {"doc_hash": "91e0174357d8477124ad46ddc861c33e411ffd45edc5fb3c84bcac4757a2ac67", "ref_doc_id": "b6da9e8d-146b-433f-beae-4978bb0cbe32"}, "bd2928bb-4754-4a89-a432-442cab27f9c2": {"doc_hash": "43bdf10519130f995440e91af6bab8759252e5a2e8fda1e64a8a22b254ffcf9e", "ref_doc_id": "b6da9e8d-146b-433f-beae-4978bb0cbe32"}, "affd00e5-c760-4d67-bf70-e3bada39f368": {"doc_hash": "e3d17d1090494a85765f0e694b1d8454427553bd8f0938cebda67429c4cc521a", "ref_doc_id": "b6da9e8d-146b-433f-beae-4978bb0cbe32"}, "7076c7d3-51dc-40f8-b83f-274bd0b55063": {"doc_hash": "b1c6a54486badc9e25f918640647e16fec548cd7f6b4274fe92f20744cbefc7c", "ref_doc_id": "b6da9e8d-146b-433f-beae-4978bb0cbe32"}, "453fd921-2380-47bb-8d3e-fa840e0add66": {"doc_hash": "dc35cb9fa522a271859c658b40c6be8f254162f5c697f5bb823db8f9f3cb1986", "ref_doc_id": "b6da9e8d-146b-433f-beae-4978bb0cbe32"}, "6ed1b786-d677-4a88-8886-141ce9b139d2": {"doc_hash": "bd50280eb4283fab45803c54dbe8bec64ec6c92b6c6efe14efa6740c43eec844", "ref_doc_id": "b6da9e8d-146b-433f-beae-4978bb0cbe32"}, "5c6636a6-724d-4089-9adc-c6541ac8dd0c": {"doc_hash": "11ddf235b4cb2a30c8c647369a24c404d9945343d79b71b04b0f8eba2af49c76", "ref_doc_id": "b6da9e8d-146b-433f-beae-4978bb0cbe32"}, "1cc4adce-8b59-4eb2-a30a-ce849fa2a960": {"doc_hash": "5c7b3d19f7b320b83fc824fd0200c53e02628c2a759f72b87d1672ff1fc1f339", "ref_doc_id": "b6da9e8d-146b-433f-beae-4978bb0cbe32"}, "7a7478f2-f4c6-40ad-ae79-0663f2ffe6dc": {"doc_hash": "b9738f44d71d300f351007cf6c024dfde2926b6bb054141525eb75f8c4d398a2", "ref_doc_id": "b6da9e8d-146b-433f-beae-4978bb0cbe32"}, "c9a3bdf0-0c4f-41b7-a8c0-8626cb27e2b8": {"doc_hash": "84344d3628b0fb51a4d2bf1ebbc9310d8923f3226d78005537b8a1e8e810deb4", "ref_doc_id": "b6da9e8d-146b-433f-beae-4978bb0cbe32"}, "93e180dd-d91e-4cfb-ba51-67b421e11b60": {"doc_hash": "632c892d16714aa5524538054da23e0d5acd3b42d899ceef4afda8963d40944c", "ref_doc_id": "b6da9e8d-146b-433f-beae-4978bb0cbe32"}, "ca27606e-3f30-4ac0-b636-a8d47fd44859": {"doc_hash": "80395485b8e3a2bcf884db3f928a29b43b108905d9b45165dde9e7e9cf13464f", "ref_doc_id": "b6da9e8d-146b-433f-beae-4978bb0cbe32"}, "0097e15d-5e35-483c-add8-27fde0a0c5d7": {"doc_hash": "4d07a957e24d645dce3787eb6e554ed49a31c656b7305867aac609cec94046cf", "ref_doc_id": "b6da9e8d-146b-433f-beae-4978bb0cbe32"}, "b0d487dd-e5d6-4d3d-9ff4-c65a796b5a12": {"doc_hash": "35133b7de14600152b8e2e5b33d88ea45e0086ca38b668631f4e0b8d18064b87", "ref_doc_id": "b6da9e8d-146b-433f-beae-4978bb0cbe32"}, "6edffcf9-bf4d-4353-aa81-b62429350787": {"doc_hash": "474f96895ab7b782ec3c652575a38df89d4dbb6ccf25cf24c6e90f0f76ab9e2b", "ref_doc_id": "b6da9e8d-146b-433f-beae-4978bb0cbe32"}, "d3d044a1-2763-4abc-bd8c-df7e7fad0541": {"doc_hash": "1f1cc86b1e0c52f60be777f2388ea4acc0bb0cf76bfd2465e908fca273a1717b", "ref_doc_id": "b6da9e8d-146b-433f-beae-4978bb0cbe32"}, "afa96779-0585-4de7-b907-f9f30d0a5336": {"doc_hash": "33fe8387a72980a13cf47754c1b3b65b4daa2027759e3e0e99585f2b793f6a73", "ref_doc_id": "b6da9e8d-146b-433f-beae-4978bb0cbe32"}, "faab4b8d-2e34-4dda-92e0-65ff4da4747d": {"doc_hash": "607ff9308ca770adf26fe4223c6f9abc710612c5eacc1a390da002e5d242a7e4", "ref_doc_id": "b6da9e8d-146b-433f-beae-4978bb0cbe32"}, "cda1a1f8-ed31-4e47-bf76-d6a89a10b33d": {"doc_hash": "ab960e0106705f8ae51e3d354b0864cda10ed861efa36dd21625e4cb21559bd1", "ref_doc_id": "b6da9e8d-146b-433f-beae-4978bb0cbe32"}, "692e7084-347f-48db-9aeb-87e9acf5d42f": {"doc_hash": "8c0d984599c4542f6c1e56eefa03f4ea6b845f91509e5eae36284d45e57cdec8", "ref_doc_id": "b6da9e8d-146b-433f-beae-4978bb0cbe32"}, "c940b079-6c56-4d91-80e7-fffc04895f26": {"doc_hash": "6904d89bf22f52d5ea1360e2f564b9dfb8f2e8b6b9ab35ecb5da850da8d57bac", "ref_doc_id": "b6da9e8d-146b-433f-beae-4978bb0cbe32"}, "0a4903e6-43d5-497e-8744-4a5b17f81695": {"doc_hash": "20474274a567baf5140640088f5282b928844ad403f285d8519d5b52987fca42", "ref_doc_id": "e6763537-8e0b-4f34-ba9a-81920191e975"}, "4225fde5-d61f-4b9a-a298-859bce8aa255": {"doc_hash": "bca49d517a51c1029a072d90ff7315034ee5cee92f69696e2257f381c07c94d9", "ref_doc_id": "e6763537-8e0b-4f34-ba9a-81920191e975"}, "0dfd43ca-f415-4aea-9a75-e2f3da22fff7": {"doc_hash": "5d3d132007c579537b6d2366818817b32f2bcb40427cc98ad457b2a8c3f5319e", "ref_doc_id": "e6763537-8e0b-4f34-ba9a-81920191e975"}, "d0a0955a-aef8-4787-a0ad-b1a15cdd3728": {"doc_hash": "a8aaac27930f4d4bec15f83a4c76db5dc35f06d16dbb990a02e18be165e37041", "ref_doc_id": "e6763537-8e0b-4f34-ba9a-81920191e975"}, "8e64a980-9937-42a3-8f82-61fc4ffc4faa": {"doc_hash": "76d38cf00574de288d4cf89c996fd500b630335e2f2adf34b2b1abbbd0e5d93c", "ref_doc_id": "e6763537-8e0b-4f34-ba9a-81920191e975"}, "0e536704-f6cd-4e9d-8b58-bad24a493abf": {"doc_hash": "99dc40dd6319f22ea3b18a9965174767f789fde7f07368ff537f6505e237b7d8", "ref_doc_id": "e6763537-8e0b-4f34-ba9a-81920191e975"}, "86ad7eaf-ad05-4ef3-91e0-0eedcf44f933": {"doc_hash": "4aef7f5c5e034a788ba4b8d1764cf9bde3e9b40a7ba0f06d77fadcd643f4781d", "ref_doc_id": "e6763537-8e0b-4f34-ba9a-81920191e975"}, "5a627c50-4887-4679-bf81-f570fe35e63d": {"doc_hash": "516ab6ee15607d917ab8bba7e0f324494e568f2ee36c736957f28387bdd6a8ab", "ref_doc_id": "e6763537-8e0b-4f34-ba9a-81920191e975"}, "30519e88-16c0-41f9-a4b4-b7bf437c4df9": {"doc_hash": "3583debd97d84c8a8f3804d83785aaa2e6ebb7bca48090db8940aae2fef6593d", "ref_doc_id": "e6763537-8e0b-4f34-ba9a-81920191e975"}, "45426c9e-fd2c-4c85-ae5d-83e1429f3864": {"doc_hash": "cb05b4249c71b2eb0cca59bc068bc7a4d437aa7f2b27545c3c6387cfc7202299", "ref_doc_id": "e6763537-8e0b-4f34-ba9a-81920191e975"}, "b261580d-a592-494d-9a34-b7d7be10407b": {"doc_hash": "b5292b946f39b4628f072270088114f0f112e2410a23705c1338575ff86b135d", "ref_doc_id": "e6763537-8e0b-4f34-ba9a-81920191e975"}, "24ebe660-588e-44bf-8c10-11d64c786ce7": {"doc_hash": "92a2e919e837f890944688c91e8a9b873134f1dc3295668a7736f3e3de7df463", "ref_doc_id": "e6763537-8e0b-4f34-ba9a-81920191e975"}, "b840aca7-2518-473e-946e-ffa1e306f6f9": {"doc_hash": "90c361c45b6fce9b787c484329766dd1db5c7454a91219e5630cd8bbbab18634", "ref_doc_id": "e6763537-8e0b-4f34-ba9a-81920191e975"}, "49dc44da-305b-42d0-bdfc-3fd21ccfb803": {"doc_hash": "f6866a24a979e7f5a1c41ae284017eced68345f6e8fd59ae5605be3f2ae61fa0", "ref_doc_id": "e6763537-8e0b-4f34-ba9a-81920191e975"}, "54bf5c73-da44-4798-aa41-9a5b31128ac8": {"doc_hash": "f687f838895574e01308aa5bfdd7ef52b2220d861b933f88240e2b51ead2e6bb", "ref_doc_id": "e6763537-8e0b-4f34-ba9a-81920191e975"}, "53b548ea-1e7f-448b-89b8-1920e1985edf": {"doc_hash": "3ceaba04fa203595af581723783bf2d6da247f061c2353c421c8fe26b810a8eb", "ref_doc_id": "e6763537-8e0b-4f34-ba9a-81920191e975"}, "4406edd2-a4f2-4aad-8b3b-1a949f9743c9": {"doc_hash": "8b6d663dd57e6020f8afa04628c513456db70856ce50ea4bb46863e73a751cbb", "ref_doc_id": "e6763537-8e0b-4f34-ba9a-81920191e975"}, "09664206-9c6a-46ae-aa12-5508fd4e421c": {"doc_hash": "b3da478e4a68df36cb51b77dd6bbb98d6fa9488490b0b3d263dce4ad70d01130", "ref_doc_id": "e6763537-8e0b-4f34-ba9a-81920191e975"}, "1b2f27c0-f7c7-421f-9c89-1b57e8c4bc3c": {"doc_hash": "7fc1b59d77c391bba92a9ebd42572644d47cccba0f84d461b836191fa840435e", "ref_doc_id": "e6763537-8e0b-4f34-ba9a-81920191e975"}, "8e875de9-2b60-4dd3-ad72-1fdf4c7189b1": {"doc_hash": "fc5b434537cc055f6eb3eb4d4347905216698bc48d8417d792f4cdbfa6801e59", "ref_doc_id": "e6763537-8e0b-4f34-ba9a-81920191e975"}, "c8cf16d8-8084-4527-a1d6-ca35f800c4a1": {"doc_hash": "8471d99058aeb5445dd4cd42f79cb0749231104ecae96acfc2e36ecee88a4b34", "ref_doc_id": "e6763537-8e0b-4f34-ba9a-81920191e975"}, "2709f77b-cdc1-41b8-849a-43c040701cd1": {"doc_hash": "b9bf184edce1c5f1dc9ce53d0734efc03fff6370467401670eb66e1ee243998b", "ref_doc_id": "e6763537-8e0b-4f34-ba9a-81920191e975"}, "1c9e7dbe-c661-4df6-bb5a-4d43ff80d4af": {"doc_hash": "3d61e3e82e026758a6ed10d9718a6a0d902d2c27c1c777c1da704a7f56d35b5c", "ref_doc_id": "e6763537-8e0b-4f34-ba9a-81920191e975"}, "80e8dfac-d54d-4716-bce8-093f02c47c81": {"doc_hash": "782a1e50ed97b464349392d3c5298c7f0582efb5d76894aa147dbc4131917fe2", "ref_doc_id": "e6763537-8e0b-4f34-ba9a-81920191e975"}, "8c2dc65e-04b4-4da2-9497-2e5485b88a25": {"doc_hash": "cafa06faedb757e987c7f82f8e5dd41eafd740234ae8a4629201c1f01682a481", "ref_doc_id": "e6763537-8e0b-4f34-ba9a-81920191e975"}, "f73b567b-be80-4386-9a53-a9ff10ca1ad0": {"doc_hash": "a045adfb443b47facaacaa86a5aa00bef390fb95825ec2f17ecdeeccc8a014ff", "ref_doc_id": "e6763537-8e0b-4f34-ba9a-81920191e975"}, "d0ab9e72-0e12-43d4-9bee-c6dc1c0ae627": {"doc_hash": "681f42dd39cb2fabfeb5154a2686bd0b8888411808673626e534398cc4895ce9", "ref_doc_id": "e6763537-8e0b-4f34-ba9a-81920191e975"}, "00c7db14-4704-4304-afcd-57dd5c1ce9ba": {"doc_hash": "f0f07c6ccc98fb83f2a0fa6a9bb5abb2e441f83c63ea6d685cc7e839374427fa", "ref_doc_id": "e6763537-8e0b-4f34-ba9a-81920191e975"}, "8142fc3b-62ff-44ef-b70e-3beacce5e720": {"doc_hash": "da1617055fd927fd76535f1c72be16719a413942d42606651638e2080c1b3ad2", "ref_doc_id": "e6763537-8e0b-4f34-ba9a-81920191e975"}, "086c45c9-b62e-4a14-85ef-ec31e6b9adb3": {"doc_hash": "1a04fcd06e1d4bafe2ef44cf33d9673835b7e96ff2b9d16bbc98067d1c8efb0f", "ref_doc_id": "e6763537-8e0b-4f34-ba9a-81920191e975"}, "0d202777-8a72-423d-a984-86606312701c": {"doc_hash": "407f5179fac6c30933d9449777891e6b5bf557f126e4d2cef15bd493ca235c4d", "ref_doc_id": "a2fe6c7d-f0eb-4895-b27b-02b6ca730d5e"}, "e48dc77c-b3a7-4bb1-8eea-2fc70742203c": {"doc_hash": "6c3e4baf7db2162c65c2861e474341e6650c5959ebae9014a76bd6bbe0cc4499", "ref_doc_id": "a2fe6c7d-f0eb-4895-b27b-02b6ca730d5e"}, "6ef99712-6dab-46dc-8057-9ae7e3c6a0f9": {"doc_hash": "1fc43e891765f67be996646ed1b550a61534063786a14e9dcd8f94587ebb4e4d", "ref_doc_id": "a2fe6c7d-f0eb-4895-b27b-02b6ca730d5e"}, "d350c258-647d-485a-bb81-1b4f10e09c88": {"doc_hash": "a54a79dd9182055d8eea44d9e4d4e6acd05b16ea87b0ff25ba9f7b08860e2d24", "ref_doc_id": "a2fe6c7d-f0eb-4895-b27b-02b6ca730d5e"}, "1620a5ba-26e6-4a94-8f4b-3777dce6bbb6": {"doc_hash": "0456e5d0899fa0de4e0502142770edb7384c69be31a9f38e82f093207d0500da", "ref_doc_id": "a2fe6c7d-f0eb-4895-b27b-02b6ca730d5e"}, "398b72a5-60aa-4239-935a-87d14a8bdd9b": {"doc_hash": "19624046c37bf44435c84741e60bf10d285e35dd8adb149b58c598b578479f4c", "ref_doc_id": "a2fe6c7d-f0eb-4895-b27b-02b6ca730d5e"}, "07b838c1-f5a3-460d-ba35-80ec302a438e": {"doc_hash": "94de655df8da24561f5eab007f6d531cddd538bfb91479933659173a4d3e12a8", "ref_doc_id": "a2fe6c7d-f0eb-4895-b27b-02b6ca730d5e"}, "c6939212-ae8e-4d87-befe-0efc09be4655": {"doc_hash": "8c8def2be73fc927f5d75fac6211adefa84a8cfed065be5b4425539faac4ac45", "ref_doc_id": "a2fe6c7d-f0eb-4895-b27b-02b6ca730d5e"}, "47975624-14f0-4478-9dc5-f96535a6ea38": {"doc_hash": "a072613060190584cefd01dfb468ba33001074d0f472f7bb33bc37031fbe9430", "ref_doc_id": "a2fe6c7d-f0eb-4895-b27b-02b6ca730d5e"}, "c8252015-1335-4285-9ba3-e16c5345e67b": {"doc_hash": "fbb1ed75ade0249e7c974d3e069827c42095249b7da2dcb5f44f2d4241cab012", "ref_doc_id": "a2fe6c7d-f0eb-4895-b27b-02b6ca730d5e"}, "8cdf2090-2acf-441f-b5a8-a9d39ba4020d": {"doc_hash": "2f0eedd58f71edfd03e8e6a000e2fbf705adb4bb20d424923bb0bab677e47817", "ref_doc_id": "a2fe6c7d-f0eb-4895-b27b-02b6ca730d5e"}, "67bdcc92-97ae-4f57-90f4-1d4670cc5297": {"doc_hash": "982e8e8b66f4dacaa596845646d6d1b0712771d190973508b4a0054d4b8f8cdb", "ref_doc_id": "a2fe6c7d-f0eb-4895-b27b-02b6ca730d5e"}, "67aeb439-9552-4b50-9c35-50b067429ee5": {"doc_hash": "374d0b511270b2bbbac6fb723eb38702a261069008c46b86c173178a7c63c20e", "ref_doc_id": "a2fe6c7d-f0eb-4895-b27b-02b6ca730d5e"}, "8d20175d-8d42-4170-80a4-27e6cd23bc16": {"doc_hash": "c2463a6c17e2b6305c5377379095c6ddab36e1bf283e548e13287c27cf89970e", "ref_doc_id": "a2fe6c7d-f0eb-4895-b27b-02b6ca730d5e"}, "7d0de43b-40ee-43c3-a405-9446314e9d6d": {"doc_hash": "acee8aba09b160caab660043e8ab7433243a4e2280c16a71bd2fb76bc4778eaf", "ref_doc_id": "a2fe6c7d-f0eb-4895-b27b-02b6ca730d5e"}, "69a767cd-57b4-480f-9649-43172209d3b3": {"doc_hash": "b4f7eccecdd0ac788cbbcc09b1da88b227d0d7c0c0eae8bf78c106c8515a9078", "ref_doc_id": "a2fe6c7d-f0eb-4895-b27b-02b6ca730d5e"}, "b13a442b-5285-43d8-a383-885439fa3237": {"doc_hash": "6577649249bf2b3cdf1093b00d7e985c61055e32dea174fbfd9dfa318d542ac8", "ref_doc_id": "a2fe6c7d-f0eb-4895-b27b-02b6ca730d5e"}, "e2fe6db0-4db7-479e-92fd-08ff344e4824": {"doc_hash": "312e7ab99a0aac9d58396b18e440f1435e76b623af13623653a72e4d69e96a0d", "ref_doc_id": "a2fe6c7d-f0eb-4895-b27b-02b6ca730d5e"}, "f35fcf61-15c7-48d6-ae2e-5f706c6264a1": {"doc_hash": "7ff45a40aee822b0afebd3d1943f4fc762cb1bc2cf1ea7fb4a03946cd5905e99", "ref_doc_id": "a2fe6c7d-f0eb-4895-b27b-02b6ca730d5e"}, "aaf87a8f-e138-4ea2-af53-91dce50565af": {"doc_hash": "fe58317c58b69fdc72cee8691c9056f7201757de5afa5cc1b325f434fbe96ba2", "ref_doc_id": "a2fe6c7d-f0eb-4895-b27b-02b6ca730d5e"}, "c17fd2f4-47b6-4e7d-9d77-b0f898cea98f": {"doc_hash": "96869b5eae92600fceed1a3b8700ac4e79d767b1ed133da290442c1b2c95fb25", "ref_doc_id": "a2fe6c7d-f0eb-4895-b27b-02b6ca730d5e"}, "d2a26281-e3d2-4929-996e-b85ddb17458b": {"doc_hash": "452e7720d1b5f1eb2ce67c95c9b5598ec0d64e8df61f46bb4a31087551926f40", "ref_doc_id": "a2fe6c7d-f0eb-4895-b27b-02b6ca730d5e"}, "a2a12f25-ee00-4848-8648-3ba75b48e37e": {"doc_hash": "746205052daa7c6d46acbb2b0357b9e76b8b6a4203c63dd24ece9eb65119ffd2", "ref_doc_id": "a2fe6c7d-f0eb-4895-b27b-02b6ca730d5e"}, "100b572c-d476-4c6b-a52a-6f7108352da5": {"doc_hash": "9ecc939fee7520a7cb27bfe44f393c465ffd940d3d50f965bb7eb1f696044b4c", "ref_doc_id": "a2fe6c7d-f0eb-4895-b27b-02b6ca730d5e"}, "8da32229-728e-4fff-93ba-bfd3bca582c5": {"doc_hash": "2c7000b893ae117c7ad73c2910a6549f84d63bdd249cdd0b5ae97cd0c908dcaa", "ref_doc_id": "a2fe6c7d-f0eb-4895-b27b-02b6ca730d5e"}, "52e6a909-4bd5-49dc-addf-9d638185cada": {"doc_hash": "da65444f80f38793549f7a40a29dbf31b57ef65a8db9a8b9aedd657f658e1f5b", "ref_doc_id": "a2fe6c7d-f0eb-4895-b27b-02b6ca730d5e"}, "dbe0d40c-01bd-4f56-ba38-3e13e33df77f": {"doc_hash": "be9d827dc11226a744a30139c7ba33c74e04e65410bc1e428f86b5c00640d07d", "ref_doc_id": "a2fe6c7d-f0eb-4895-b27b-02b6ca730d5e"}, "88dd47c5-4020-41f5-80ae-da307c8bdd96": {"doc_hash": "40a3959ce414e78a7bdbdfc478d5605cf628fc56a9ea660bd3023b700c4262e1", "ref_doc_id": "a2fe6c7d-f0eb-4895-b27b-02b6ca730d5e"}, "0801e9b0-e9bc-4d39-b9a7-0ce1ef3b69f7": {"doc_hash": "81ea04f0084ef14dbeaa4f6c564385f9877265bbbf5e4ce44f65807771affd8a", "ref_doc_id": "a2fe6c7d-f0eb-4895-b27b-02b6ca730d5e"}, "657669e0-ea45-412d-a39f-6a91afddb2e7": {"doc_hash": "3d2df647756d17e9ef3d2e2a5fed1f7f44aaf195d16c5aefc409f80d1cf45494", "ref_doc_id": "a2fe6c7d-f0eb-4895-b27b-02b6ca730d5e"}, "00749a44-61f7-417c-9603-bb00ece296d2": {"doc_hash": "ee375e65c2d6bb26e6887e41c7046a6a1fc76149cc4794bef3c1b40548cfd01f", "ref_doc_id": "7d2b4c06-f5b1-4a4f-9127-7f73d68a375e"}, "d4ea6700-611c-4f31-b584-69eea12318e5": {"doc_hash": "add66f905d41d49811dcefaea6a074b9a2a2e423b56bff44ed8d51e9e95bee23", "ref_doc_id": "7d2b4c06-f5b1-4a4f-9127-7f73d68a375e"}, "40557a2c-f32f-47b5-aca7-eb7835cea461": {"doc_hash": "7cb56019802afcad0a2e07c8b816590a1b2a6a6b344b463516dc2fd44d56cf9c", "ref_doc_id": "7d2b4c06-f5b1-4a4f-9127-7f73d68a375e"}, "f7f956e9-22bd-4481-af73-a455bedbe333": {"doc_hash": "ae38cceb509f31f1e57091323028cffd9d104c4d054262fe12d5664a5a70c9f3", "ref_doc_id": "7d2b4c06-f5b1-4a4f-9127-7f73d68a375e"}, "8af287de-32fa-41d0-8867-89f7c205ea25": {"doc_hash": "4184d3cb6f4f7187c11d9e1dc35e72e98075e787f13680b989c92962e968d29f", "ref_doc_id": "7d2b4c06-f5b1-4a4f-9127-7f73d68a375e"}, "353dc385-6450-484e-a448-f8e39835b5b2": {"doc_hash": "ff1c7a38d998620e61ba6e402e4fe99ec9f7bf306ee7d684f8f6ac2c3408ba6c", "ref_doc_id": "7d2b4c06-f5b1-4a4f-9127-7f73d68a375e"}, "ef24ac2c-e3ac-450d-9545-b0caafc517c5": {"doc_hash": "cc85989a60d933d8b19486a8bc7017859b509b3289790ad035bedcc7e263558e", "ref_doc_id": "7d2b4c06-f5b1-4a4f-9127-7f73d68a375e"}, "0b04f4a7-4697-41dc-96f4-0de788cd0013": {"doc_hash": "c8c23f04398ee6cb338f65cce13fb5cae6e69840748a4e8014076c6b45fc3142", "ref_doc_id": "7d2b4c06-f5b1-4a4f-9127-7f73d68a375e"}, "1ba1dbe0-64b3-4b40-8906-84f2a5db7f18": {"doc_hash": "e309bed6ab7b83cdc67631d165e97c37b5a95ff3531690674f07027da10547b7", "ref_doc_id": "7d2b4c06-f5b1-4a4f-9127-7f73d68a375e"}, "dee47a4f-4d10-416e-9803-2a070664b6c4": {"doc_hash": "b32ac5fcea94d3eb0b8b2aa8a1cdf4c3e8385d138fc52a51547aeb17aeb265cd", "ref_doc_id": "7d2b4c06-f5b1-4a4f-9127-7f73d68a375e"}, "b7455b1d-944a-4485-a2c7-7b8764d082e7": {"doc_hash": "57d5e7eaac7ca8e8f761c7a6a5e85a610048f22406130e8cc7bca88989e08395", "ref_doc_id": "7d2b4c06-f5b1-4a4f-9127-7f73d68a375e"}, "011e5dba-1c03-487f-8104-38e19da864d1": {"doc_hash": "9f72e882dd2f0afe26faf3890abac121a2460047e322cb70655904161de34422", "ref_doc_id": "7d2b4c06-f5b1-4a4f-9127-7f73d68a375e"}, "d679fcf6-f9be-4a2c-a303-7398369a2f5b": {"doc_hash": "8c31215fcf338826a19fa3de28fd3e5b905ed1f1a7b31cc84d5ace3205a9fd13", "ref_doc_id": "7d2b4c06-f5b1-4a4f-9127-7f73d68a375e"}, "f7bac80d-c17e-4b6c-ba63-3d52602fc3f5": {"doc_hash": "a97a8bc110165a4925a37b72668cb256c9b0c4acf3507e8ef08a01a19cbd72cf", "ref_doc_id": "7d2b4c06-f5b1-4a4f-9127-7f73d68a375e"}, "f6e53508-92ad-4121-b40b-06b5809fe2fc": {"doc_hash": "344de2af4c45640f2c0b60aa93d5455b4881e9b74a9b8a0f832c644292cd69aa", "ref_doc_id": "7d2b4c06-f5b1-4a4f-9127-7f73d68a375e"}, "c30f5be6-f0ad-40aa-b2a9-b934380fa8c5": {"doc_hash": "fc5d81aab505959ffbf78c41e7f8079cfd70645daa721a57e56852b11c897e3a", "ref_doc_id": "7d2b4c06-f5b1-4a4f-9127-7f73d68a375e"}, "7daffaab-d6a4-4a6f-8b10-23d4d3042eb6": {"doc_hash": "027792dba9ffd62483a12f154a01c72bd6482672dd45fe3160ee665ad37ffe3a", "ref_doc_id": "7d2b4c06-f5b1-4a4f-9127-7f73d68a375e"}, "c40b3b82-5ccd-4710-a73c-c1f485714c41": {"doc_hash": "be1756e71c097e8db0fab8656651d5948a206a2bbbfa1fc74cf1c4b8c70cb1be", "ref_doc_id": "7d2b4c06-f5b1-4a4f-9127-7f73d68a375e"}, "b09cda71-2596-4324-b45d-8d35ce256215": {"doc_hash": "50ffa838717dcf07d8a5706819d95910819d42d18a470d480e02a710e5062998", "ref_doc_id": "7d2b4c06-f5b1-4a4f-9127-7f73d68a375e"}, "39fb63d1-abdb-4333-a6c0-08a26d799c0a": {"doc_hash": "6b84aa43fec5414e94f37872bfa1dc7721369ea265172bc2a7b0c5d9d3f6be4c", "ref_doc_id": "7d2b4c06-f5b1-4a4f-9127-7f73d68a375e"}, "b05d732d-0bfd-4da5-a5b6-e48f8c21919d": {"doc_hash": "2af38b30aeea88874a0ce19eeaabf487d03797f2501aa9a5e658866118d38b50", "ref_doc_id": "7d2b4c06-f5b1-4a4f-9127-7f73d68a375e"}, "3ba09699-9a0f-4d5b-858d-85460d1a9967": {"doc_hash": "fe572bb5be34e29ac64fb75ce092955177d27c315adcc3900193e457d6c45461", "ref_doc_id": "7d2b4c06-f5b1-4a4f-9127-7f73d68a375e"}, "cb164a2a-196a-4270-bf94-7bdc036713b2": {"doc_hash": "92bbfad39d7938f25292a5a8332ad5321ad98097b6ce53446707997b1f950c03", "ref_doc_id": "7d2b4c06-f5b1-4a4f-9127-7f73d68a375e"}, "5e7dc32b-5b05-47a1-ba62-ee7bfc162dd6": {"doc_hash": "0948af6d1bb0287f54a4044a5c30f04280209151d9dab735be3051116b1abfcb", "ref_doc_id": "7d2b4c06-f5b1-4a4f-9127-7f73d68a375e"}, "1b16bf12-8931-46b3-9540-7f8b982d8258": {"doc_hash": "e6397b2dd5fc07c10a2dc25ca4f7bf2a5855aa81bf57e752d2abb656c824b830", "ref_doc_id": "7d2b4c06-f5b1-4a4f-9127-7f73d68a375e"}, "90e4eb8d-b972-441d-a7d7-991cdb6137b5": {"doc_hash": "463f76dff0af85131949f31fedbbf7de7f8ad8f6a191093c8ac4e14e7918193b", "ref_doc_id": "7d2b4c06-f5b1-4a4f-9127-7f73d68a375e"}, "3d5808fd-b3eb-490b-8d24-a59740d24c38": {"doc_hash": "ad76a371d0790ce2c41ea0b5a14ba84fb3d69a34fad2c7488eab1274d2e2a291", "ref_doc_id": "7d2b4c06-f5b1-4a4f-9127-7f73d68a375e"}, "761bc3ab-56d1-45ae-9155-04e1aee02a0c": {"doc_hash": "dc3d173acc1a306134df0b7163b9444ea8e38d6553de4ed15c2d5acd484c1836", "ref_doc_id": "7d2b4c06-f5b1-4a4f-9127-7f73d68a375e"}, "ad82a548-f46f-4af4-8afa-6e6b200dff65": {"doc_hash": "c277484d21992976016ba46b3a2aabe16a5a51f75b23296f8850ca9e2e905ac0", "ref_doc_id": "7d2b4c06-f5b1-4a4f-9127-7f73d68a375e"}, "e816f77e-ec74-4e7b-b687-336f0a596954": {"doc_hash": "b6994df6a37386d391760379b53afbf1ea7895a55d2a15767667decf35ef4c28", "ref_doc_id": "7d2b4c06-f5b1-4a4f-9127-7f73d68a375e"}, "c7186334-534c-45db-b38b-3b8eaf940c93": {"doc_hash": "732c23a808ee32992aa443f65647979be5f3f1f16f771ab76affd19fcade0354", "ref_doc_id": "7d2b4c06-f5b1-4a4f-9127-7f73d68a375e"}, "1e92c18f-9163-4e9a-a56f-14455ced5b05": {"doc_hash": "0eb4ea4cf1d9aee42cd5ee05f6c6179cd107ae16c9f47f668a6f27ed3027e971", "ref_doc_id": "cde69cac-dee0-4cfb-8e4c-635bb17fb3bd"}, "5256dd93-607e-48f5-a9b4-dd0bf502c400": {"doc_hash": "82afb042a7dedd1d1d8dca3a146b7ca20780ddc992fdd34f9d557c3f3254db89", "ref_doc_id": "cde69cac-dee0-4cfb-8e4c-635bb17fb3bd"}, "a2cee608-fed3-49a1-a0a6-843027f36bcf": {"doc_hash": "4e9d7cf20cd55f13f9e551821b1919350a328afc9bec380e5d6d43d2bebb8e58", "ref_doc_id": "cde69cac-dee0-4cfb-8e4c-635bb17fb3bd"}, "ed4de0b1-82f0-4528-b7e4-1ddff533ab04": {"doc_hash": "9330058a89a4f54ceab2add42c0e82ae2357f287832a4c61b19b0cbf14e37e96", "ref_doc_id": "cde69cac-dee0-4cfb-8e4c-635bb17fb3bd"}, "50d98052-7ad5-4dd7-82ce-9f860f1bf048": {"doc_hash": "eb61ed4c37147da5779eb2225da53c3d17d3c46e7828ca7d3a1c22b5ccf318a8", "ref_doc_id": "cde69cac-dee0-4cfb-8e4c-635bb17fb3bd"}, "c0c89981-143d-4ec6-a02c-6fd5f181414e": {"doc_hash": "97c686043efd2e43cc910d45bd68c9179299d7bad96d8354b88ce947017317e2", "ref_doc_id": "cde69cac-dee0-4cfb-8e4c-635bb17fb3bd"}, "42ec2acf-f4fa-414b-8721-2d88a3c6fb68": {"doc_hash": "9b396e7104f3fb2091f6456c4d52b3041447d90cf17a0d06f668413a388bc73b", "ref_doc_id": "cde69cac-dee0-4cfb-8e4c-635bb17fb3bd"}, "5a02a702-ed64-43c7-a06b-d75ed8ddba74": {"doc_hash": "bc72dbe68a6be0c68bf3ed035fdbcf5cbf971a54895d0b47ee92f42a2f37a9a5", "ref_doc_id": "cde69cac-dee0-4cfb-8e4c-635bb17fb3bd"}, "e115c33e-bc96-4088-b0bb-cdabff889802": {"doc_hash": "22433ae87c6b8da62e410147a33494c476c253ff18563b07becf837325395383", "ref_doc_id": "cde69cac-dee0-4cfb-8e4c-635bb17fb3bd"}, "e3270874-6c01-430f-a502-12deaf4d0993": {"doc_hash": "6187e7367387f158146917a4c3e6a5d4f6443a8f74318f7d86f727aeafbf732c", "ref_doc_id": "cde69cac-dee0-4cfb-8e4c-635bb17fb3bd"}, "0b69f6b6-1230-4bcd-bde7-d4e3bc2b7526": {"doc_hash": "2be26467c92ee35f9206961762d9e5ed020c198031af31d94302e63a18836b5f", "ref_doc_id": "cde69cac-dee0-4cfb-8e4c-635bb17fb3bd"}, "02ac8005-1a5e-4a9c-b18a-119c7c4068dd": {"doc_hash": "26d760bbf03160f2c402ba4abd0b7bd2db04dbde1f3cfc439e03cc38fb6a7c7a", "ref_doc_id": "cde69cac-dee0-4cfb-8e4c-635bb17fb3bd"}, "08bdb6ed-41fe-4a02-8c14-21b5d8d9d85b": {"doc_hash": "b1dd969500dcb627be36d2c587b94b8f8e1691b1b7c4e67ac1e7f63dd4b8f056", "ref_doc_id": "cde69cac-dee0-4cfb-8e4c-635bb17fb3bd"}, "a1b90829-f923-40b5-9b26-7969d5947fe3": {"doc_hash": "2f1a785a9114f0c0ec328ecf6cdf8ccd6978cc50bd079e06b89e5c6d61514f85", "ref_doc_id": "cde69cac-dee0-4cfb-8e4c-635bb17fb3bd"}, "d724a26b-6a0b-4a4a-8d80-d45c44428a1d": {"doc_hash": "c833b7ba60d32d5373296b2fb79abc2dc4de8323dcc926907524e7917bf7195a", "ref_doc_id": "cde69cac-dee0-4cfb-8e4c-635bb17fb3bd"}, "98bfd195-ffbe-4be3-867d-3628b8f726a2": {"doc_hash": "bfc6789e03e4c3976b163ca86a167d9e3cb7d8626402429e978a064c200befcb", "ref_doc_id": "cde69cac-dee0-4cfb-8e4c-635bb17fb3bd"}, "ceee9fd8-69bb-4abb-a838-63931e8684d5": {"doc_hash": "3bc8324cf5c75614e4d31f914cf5778c344fed009eec49264cc915c47243ba4d", "ref_doc_id": "cde69cac-dee0-4cfb-8e4c-635bb17fb3bd"}, "352da687-8504-438f-8da8-13595bb773ba": {"doc_hash": "04745ad386803c5a7c824656108e25afd89cc97bbadc6f859ff0315dee5251f8", "ref_doc_id": "cde69cac-dee0-4cfb-8e4c-635bb17fb3bd"}, "97177d89-771e-4473-94e4-da7bbabe4b05": {"doc_hash": "d4321ac32229592166391c0add658138374c3f916652b6b302c71ffdb52de093", "ref_doc_id": "cde69cac-dee0-4cfb-8e4c-635bb17fb3bd"}, "4603e04d-15de-425f-a1a0-63d74da06367": {"doc_hash": "f7a21faa9a398072d95bfeaa4e594b0543b2b0337d0afdaff0e15f7394ee4af8", "ref_doc_id": "cde69cac-dee0-4cfb-8e4c-635bb17fb3bd"}, "50ae749d-fb4e-4034-af6a-8d6960549bb5": {"doc_hash": "57d7b1b186f2699fb6693aadf26e60a07262d1fa99f5127f17c7457ba7ae917f", "ref_doc_id": "cde69cac-dee0-4cfb-8e4c-635bb17fb3bd"}, "8675529e-f7ae-4e7a-ab02-bc42cc043cf5": {"doc_hash": "889fabef2f59944e64cde8bb0afab27a6c0bdc973a84f79b7a08ca4e7302e537", "ref_doc_id": "cde69cac-dee0-4cfb-8e4c-635bb17fb3bd"}, "d51c2ca5-2040-4980-8157-0a12147700b5": {"doc_hash": "ccf6c67108d0bac423fb0d436c63a7680e56bd8b437327041990a5c79f1e7a22", "ref_doc_id": "cde69cac-dee0-4cfb-8e4c-635bb17fb3bd"}, "cfd0cf7b-cc8b-4e2c-8fa2-abccf7372d0a": {"doc_hash": "6134d1e8c1faf2febe14b0655eb617afa309019b69b01929d247a9e3f634b9a9", "ref_doc_id": "cde69cac-dee0-4cfb-8e4c-635bb17fb3bd"}, "b484bddf-9cf2-4059-bf87-65b3d2d67da0": {"doc_hash": "d8657719a84cc004c6b771c641c711a9e13486424b1b3d960b6b3300098e7c55", "ref_doc_id": "cde69cac-dee0-4cfb-8e4c-635bb17fb3bd"}, "0a9faccc-383e-4113-9794-62064e68cbd3": {"doc_hash": "62938ad581de32cfa7146ce77b84e8b5bf06f97b7a8996cfa87b44c0342cd2e9", "ref_doc_id": "cde69cac-dee0-4cfb-8e4c-635bb17fb3bd"}, "b4f06a0d-54c0-43c0-92a1-59b76892cfe6": {"doc_hash": "eb0d0b3ea6d7bf6aec13f1b14ba24bc5fe2ac903042ebea0c6893c433e1e840d", "ref_doc_id": "cde69cac-dee0-4cfb-8e4c-635bb17fb3bd"}, "70cb394c-3edb-4c1d-890e-9adaf8a102a1": {"doc_hash": "35a74bb7bd05a50491b7d78426b2a6584c210589e1a2d84a5b8cd26fac6caf56", "ref_doc_id": "cde69cac-dee0-4cfb-8e4c-635bb17fb3bd"}, "c93a4baa-b160-451a-9371-c36bc970f7a1": {"doc_hash": "fa9f0edf5a12ff5d231398cae521a95d9c9e85573972fecc2da3af6a84639bb1", "ref_doc_id": "cde69cac-dee0-4cfb-8e4c-635bb17fb3bd"}, "9251c2dc-6c25-4dd2-b295-fcec1976eac9": {"doc_hash": "80ebeaafa16fef1bc3ff41d9dc23d04d89e7503920256a2c314294672a2cdb8b", "ref_doc_id": "cde69cac-dee0-4cfb-8e4c-635bb17fb3bd"}, "24d96533-cb23-415f-a1b9-435036a6a0e9": {"doc_hash": "3e158c957a9d4e18ea1d3b60359978a835c7ff4ced18e63b6d40415703c941db", "ref_doc_id": "f085fb6c-4660-42dc-89e2-bdb89b579fde"}, "55a15501-519b-400d-9540-a0164e37c210": {"doc_hash": "4c158f60b4d4bb0ac8394fbf9e0c3d434fc5d109c14b51e8d50ce8f342222794", "ref_doc_id": "f085fb6c-4660-42dc-89e2-bdb89b579fde"}, "c026519c-584f-47cf-ae2f-bed834361036": {"doc_hash": "e28f5b84577a6eeeb33592c7eca54e945e16ba35c26403802182f393817a26fe", "ref_doc_id": "f085fb6c-4660-42dc-89e2-bdb89b579fde"}, "030e7605-ae10-44f1-bb34-9fbf8af4d20a": {"doc_hash": "549b37b0670036ff7839a7fecb47a188e2d7e3d31083a97a771fe998210245e2", "ref_doc_id": "f085fb6c-4660-42dc-89e2-bdb89b579fde"}, "8856beb8-7749-45f9-a74f-0d5832408af0": {"doc_hash": "b002c737532ce9157a282922638bd7aa951c7667fdf46a7facf19b4ce466d95f", "ref_doc_id": "f085fb6c-4660-42dc-89e2-bdb89b579fde"}, "26f9e74c-6dc6-4a3e-aabd-403a8c1cab64": {"doc_hash": "1dd444a3a6f9bed50a7ae33b0dbb26ced1b999a62375eb97e88eab1bfcfdf256", "ref_doc_id": "f085fb6c-4660-42dc-89e2-bdb89b579fde"}, "18fdb3e4-8c79-4f34-aa6a-328dc2fe5c80": {"doc_hash": "16fdd5e6af17fbcf6eb244de96346eb5c48262349dc326d8a169b7573146dcf3", "ref_doc_id": "f085fb6c-4660-42dc-89e2-bdb89b579fde"}, "4cc14b33-14df-437e-ae32-0780a7b8e5b8": {"doc_hash": "cc3979044d55bc19ca9394de76faae29cd4bc698b6064b38ab51fdd9139e5826", "ref_doc_id": "f085fb6c-4660-42dc-89e2-bdb89b579fde"}, "21a23cbc-c718-46a9-a305-0d61891c4363": {"doc_hash": "405af782672c14511f8c44c857f8debfaec87837f83d8e3c49e54c48e56d6bac", "ref_doc_id": "f085fb6c-4660-42dc-89e2-bdb89b579fde"}, "d4a484e5-47e6-4ab6-9259-9b9da7e3fcc9": {"doc_hash": "a7c402f76f6dbcf57b9b798705890fd713bf9a3bfc20d6735871e828b2e90fbf", "ref_doc_id": "f085fb6c-4660-42dc-89e2-bdb89b579fde"}, "d9910a44-2f6e-4a98-bc40-08c906fd709b": {"doc_hash": "b76815c427738fe7e7fcec2bdc6463dcbdb177692915745293379aee529b9dc0", "ref_doc_id": "f085fb6c-4660-42dc-89e2-bdb89b579fde"}, "367375d1-99b1-43fc-98bd-fd4d49789220": {"doc_hash": "ef2bdae483b8d27aa052c6c90ebcc1f7a4b7ac3ba79bb377aee8bf8414a24395", "ref_doc_id": "f085fb6c-4660-42dc-89e2-bdb89b579fde"}, "0d85c418-3ff1-47e6-a8d9-88928d150bb3": {"doc_hash": "eddc1ccd50ff1a021e88d49476eea092868e1690dc04eccd69bc62ac4ca7a7d0", "ref_doc_id": "f085fb6c-4660-42dc-89e2-bdb89b579fde"}, "af146a46-16e9-479e-b402-e4488c5020bf": {"doc_hash": "98f536dacdf58348c2d8e3889b1f78022350bcb6638b27571c6ef3f53a7ed297", "ref_doc_id": "f085fb6c-4660-42dc-89e2-bdb89b579fde"}, "6e619b6c-da55-4095-a429-161f1e7e22ae": {"doc_hash": "e8bc81ee14951c5b3137bc19b7c9ba86a1a312dd893bdcb566d936f18d18f380", "ref_doc_id": "f085fb6c-4660-42dc-89e2-bdb89b579fde"}, "e4987031-dcd9-489e-87b8-7a01b1b51508": {"doc_hash": "e8199636dba4abfd2b3363dd9902eaa7bc46ec4a648c344723c22db3a5defa70", "ref_doc_id": "f085fb6c-4660-42dc-89e2-bdb89b579fde"}, "a2b04634-daa4-46ba-a435-52b8a790b586": {"doc_hash": "64bb2982d0fc4b87a383e07d2a3f14300b4f8a227f442f3c5e24080b59191b10", "ref_doc_id": "f085fb6c-4660-42dc-89e2-bdb89b579fde"}, "1b106550-fb4f-4b91-bd1d-54df8a42e3fc": {"doc_hash": "f202f1850b01b43eab6270671cfc1afc784ffa605b5d6139a16eac1a2c65d24a", "ref_doc_id": "f085fb6c-4660-42dc-89e2-bdb89b579fde"}, "2dd2a762-8de9-4961-9242-17815d159241": {"doc_hash": "e8b4ecee9c4e677cbf5e3ee0334871ee2ea706c21db97cdc6b6847497954497b", "ref_doc_id": "f085fb6c-4660-42dc-89e2-bdb89b579fde"}, "1cc88be2-aebd-4133-b9cb-05b37abdbc97": {"doc_hash": "54e4626e31869cddc158ac5aaa4f2778a4504c25cacfc99a3369b158964ead80", "ref_doc_id": "f085fb6c-4660-42dc-89e2-bdb89b579fde"}, "334c2f84-cf45-438f-8bfe-679913724343": {"doc_hash": "c8324b97688ed903426f7084f0a5ee15b6c9491b718b203d605525bb2d75c102", "ref_doc_id": "f085fb6c-4660-42dc-89e2-bdb89b579fde"}, "ad4f54f9-8732-4a00-9785-1595ba316dcb": {"doc_hash": "1c1f03e98b3b9c323e24e54739800d621b4823e3131ce605723b75f17959e044", "ref_doc_id": "f085fb6c-4660-42dc-89e2-bdb89b579fde"}, "d70b1c28-b86c-4481-b050-4a1e25806ffe": {"doc_hash": "f9246f4d1462411bab45a7f0f04af548ae50012ced3dc916558fbd060f56931a", "ref_doc_id": "f085fb6c-4660-42dc-89e2-bdb89b579fde"}, "180d6faf-ca44-43db-8f5d-eee1929affb7": {"doc_hash": "a11efb38105a33943fea439f3c83585e9d5dad583de89942dafa260b6dfe00a2", "ref_doc_id": "f085fb6c-4660-42dc-89e2-bdb89b579fde"}, "9ffde07e-36ab-42ed-8976-82441ea0ca50": {"doc_hash": "df396293e9c7d8de80e1790887567f9f4300ba05bc041d6f4663bc8e9234590a", "ref_doc_id": "f085fb6c-4660-42dc-89e2-bdb89b579fde"}, "61e801b4-527b-43ba-a561-ca78db650dbc": {"doc_hash": "3d3fb74d49d5fa1518b28bd8122ae2a2cfad606a4f5d74b4a52158f1c625553c", "ref_doc_id": "f085fb6c-4660-42dc-89e2-bdb89b579fde"}, "d75cc162-f184-463b-ba35-65d9a29070ee": {"doc_hash": "b7e88078f659c45c338d4fccd5b13b606798c0ff94d9fd26a4cfbde3edb8b493", "ref_doc_id": "f085fb6c-4660-42dc-89e2-bdb89b579fde"}, "a89dadbc-54d0-4fb8-8aa3-77873803c918": {"doc_hash": "b606fa9e092f8144cd2c467ffae48aebbb66e41b2c66523567ab2fee0aaa859f", "ref_doc_id": "f085fb6c-4660-42dc-89e2-bdb89b579fde"}, "139ce5c8-7e2c-4423-b8b1-f1aff5499f59": {"doc_hash": "56f57ada77cb55354b80683f4fff35eb096f2cc11dbb7b5fe2d369d530797253", "ref_doc_id": "f085fb6c-4660-42dc-89e2-bdb89b579fde"}, "3a450d77-7c6c-43b4-b348-6d94e307a272": {"doc_hash": "77fb0dbabae0e4280fe596bd9f0e53d98c9e35f6bb6bb2414c89a29fd457affc", "ref_doc_id": "f085fb6c-4660-42dc-89e2-bdb89b579fde"}, "246f5d56-0ca3-40c2-b173-9ac2d81eb6db": {"doc_hash": "6fdb6db55c127babe66bc5db9395d3471fad39604766780e03adb362968a99e5", "ref_doc_id": "f085fb6c-4660-42dc-89e2-bdb89b579fde"}, "b8b636f7-714c-45c0-b72d-2d10100244db": {"doc_hash": "9eff5e55b4043fe68fdd022e38cc89f33db867e7b0b13e2ba067ca19f1ba8804", "ref_doc_id": "f085fb6c-4660-42dc-89e2-bdb89b579fde"}, "c633a7c0-5246-4de1-84b2-1406f7dc362b": {"doc_hash": "25bf18158138b0593cdead1cadcb276cc1bfd0e483d6676bd18b3c1b7aea243f", "ref_doc_id": "f085fb6c-4660-42dc-89e2-bdb89b579fde"}, "9a23614e-c7c3-4412-ac36-207c6a390d57": {"doc_hash": "192ea8c5293d7e2db0ecae4ab57b761969e79cb058acf64c3ab9fe542518d82f", "ref_doc_id": "f085fb6c-4660-42dc-89e2-bdb89b579fde"}, "ef718386-b747-43f4-a513-f24ba8eb2955": {"doc_hash": "4e3f74e5881f8ae6e12c14a4d2ee94528effb5a106e0d43bc32d6ab0e909231b", "ref_doc_id": "f085fb6c-4660-42dc-89e2-bdb89b579fde"}, "9cdc62f6-7401-4a99-9359-4b105a2794db": {"doc_hash": "5d502530452d2ba454c7dcc06d13257f0ced3acdfe222060f9b1fb79eb1b0493", "ref_doc_id": "f085fb6c-4660-42dc-89e2-bdb89b579fde"}, "90bea696-4582-4e89-8d53-8ff185b540fb": {"doc_hash": "e513fa43364ee775ef26e3b7cd538b5f2a82ebe5fe7c19c85fd0ed5d1d098beb", "ref_doc_id": "f085fb6c-4660-42dc-89e2-bdb89b579fde"}, "ebdedf06-6dbb-4a0e-8428-b4cf148d6d2e": {"doc_hash": "e43b8994ef5501c3e68641ddc280873ed496b918824b58ac4a2912e4f03a1915", "ref_doc_id": "f085fb6c-4660-42dc-89e2-bdb89b579fde"}, "6bc090c6-5e71-43b3-b7a4-e39ff5754f00": {"doc_hash": "e458eedde8ca3ff4c42f2443b4e320a56992f15036f10df06f150e1d4d52922a", "ref_doc_id": "f3e49820-b6cd-4d4a-91ea-9dc1750852df"}, "683fbde6-e239-4ae3-a233-3e6d5693b8c0": {"doc_hash": "3514dc614d9119df700a3b9de99e9e10cc5891ef3ae435843c2cf018a5b14709", "ref_doc_id": "f3e49820-b6cd-4d4a-91ea-9dc1750852df"}, "004ca8d7-3af7-4d84-b747-5a9205347009": {"doc_hash": "90fa48597a2c7db21fc1353c91d8efd6a36156db6b6a5d4d0b9216c065710e6d", "ref_doc_id": "f3e49820-b6cd-4d4a-91ea-9dc1750852df"}, "6ce1395d-3d3f-4ad9-8353-8c9d9c6f779f": {"doc_hash": "6e069dcdf0c079355b6b27722b91d20815699bd0f66d3365c773dc07217611c8", "ref_doc_id": "f3e49820-b6cd-4d4a-91ea-9dc1750852df"}, "42e85c84-3e85-4071-88e4-8ed05a268c08": {"doc_hash": "872e33afa46ac183ef142afc6ef532fdf256928db484b42e1585e86780a0af1a", "ref_doc_id": "f3e49820-b6cd-4d4a-91ea-9dc1750852df"}, "96c5aa32-36ca-4949-9c22-90a1d1be3543": {"doc_hash": "371add07dba92c3d8592a7a729d82925f02203f2e02aa0a6e6607e2448e003fb", "ref_doc_id": "f3e49820-b6cd-4d4a-91ea-9dc1750852df"}, "8a567351-ca20-446a-b721-770a2e83c658": {"doc_hash": "68e4c9a38f468ba650a37c4c3e1c9b88c4db4b3495f11fda9786730d2bc5dd80", "ref_doc_id": "f3e49820-b6cd-4d4a-91ea-9dc1750852df"}, "ff5f3892-f386-4a57-a963-96af8ddd6d5b": {"doc_hash": "475be201dcaf186d811c049d676f693529229b69d6ece5c01056107d51f18c9f", "ref_doc_id": "f3e49820-b6cd-4d4a-91ea-9dc1750852df"}, "478c3e02-4301-4338-9831-28ac0167629e": {"doc_hash": "795bf94fdf1d70022394b53f07f18f55de0ff2c22ee30d8990158e9250515bfd", "ref_doc_id": "f3e49820-b6cd-4d4a-91ea-9dc1750852df"}, "948f4412-2c11-42ee-85b5-b36159415198": {"doc_hash": "5ad77401b0cb154d0ff86b6e38e1866cba0da7bbd47fa1b64c43fda6214b61df", "ref_doc_id": "f3e49820-b6cd-4d4a-91ea-9dc1750852df"}, "6bb3d428-842b-49c8-a23c-ecacf632c15b": {"doc_hash": "947e54491d7ddf595858c7e452a94bc69d292236ef2fe38a343957a8cd209050", "ref_doc_id": "f3e49820-b6cd-4d4a-91ea-9dc1750852df"}, "c9fd8150-3d3f-4be0-8b9e-02cb8c678ae2": {"doc_hash": "af0cb2d605f224d16545b62f80c399640e9abf84bd5a0aaf70b1e35a732fc1aa", "ref_doc_id": "f3e49820-b6cd-4d4a-91ea-9dc1750852df"}, "01640716-2064-4ee8-a47a-68089663ccfd": {"doc_hash": "abef786d2ef907603efa1357ab85fa9119d6957d355dda100b4034cd2e58be78", "ref_doc_id": "f3e49820-b6cd-4d4a-91ea-9dc1750852df"}, "9ff58bec-de0c-42ca-a495-6cce76a9a727": {"doc_hash": "eb3612632067b1f07b9e12de7fde4eba2f3643336afbdac4a1f437d591304f61", "ref_doc_id": "f3e49820-b6cd-4d4a-91ea-9dc1750852df"}, "a526b23e-7143-4a32-99d5-7e2642f2d9f0": {"doc_hash": "452644307438ce90af987a97ec464cd5f0b2ea5187f8730732507c4e53cea44e", "ref_doc_id": "f3e49820-b6cd-4d4a-91ea-9dc1750852df"}, "1a978c21-40c3-4d70-85ba-a3b8d2a625d3": {"doc_hash": "60214a68a9ed904030a02a20c27930b837bada2b50bcc0b78bfdc4b43d661cbc", "ref_doc_id": "f3e49820-b6cd-4d4a-91ea-9dc1750852df"}, "64872c0a-d114-4d47-86cd-8d2ff849c06d": {"doc_hash": "6ac123f3518f5b4586c47b51fda9dd71df08bbe75cca6aec5b89c1ad6f71c38f", "ref_doc_id": "f3e49820-b6cd-4d4a-91ea-9dc1750852df"}, "2f0feecb-6be7-46aa-ba48-aaf16ef6f936": {"doc_hash": "be8c59edc50cc18691747644eb040254758ea8690871df5d389aefe7e651dd97", "ref_doc_id": "f3e49820-b6cd-4d4a-91ea-9dc1750852df"}, "cb8dc87b-958c-4f7f-85f5-ff6e35d30b8f": {"doc_hash": "ad4d3ea38f06b302771a0d1970ffdcbd8a82f9d3f1756e9d4bf6624170f59120", "ref_doc_id": "f3e49820-b6cd-4d4a-91ea-9dc1750852df"}, "80da1509-19e3-4090-8548-b645480c8a81": {"doc_hash": "8fed0997da4a198ca20457cb5994fe4e40e97518a3bbc47f811c4179b174d8a6", "ref_doc_id": "f3e49820-b6cd-4d4a-91ea-9dc1750852df"}, "f0bcd546-6d5f-40b9-93c4-7c731284e3be": {"doc_hash": "e847dbf53a5ebb5aed2478663fd989b9a3e3ac2ca1b72aa8b4f590439ecf65fc", "ref_doc_id": "f3e49820-b6cd-4d4a-91ea-9dc1750852df"}, "14497484-77e5-42b0-bae3-e9327f7225f9": {"doc_hash": "a90c292c089fa81455662b06385c752679468288645ebf8107f7f6fe3dd458fc", "ref_doc_id": "f3e49820-b6cd-4d4a-91ea-9dc1750852df"}, "0cbf6adf-9378-480e-851f-7b3dff8c824e": {"doc_hash": "29ec60574012cbd2154e66a818060437dff8de51b0f9e869f22ea4c2aba33951", "ref_doc_id": "f3e49820-b6cd-4d4a-91ea-9dc1750852df"}, "afb6d406-74f8-474c-99ba-e07fded4c0e1": {"doc_hash": "de838c0c1f1dd0eded452a90bc91919380d977c1fc155d34dd8d2ee2c5b19345", "ref_doc_id": "f3e49820-b6cd-4d4a-91ea-9dc1750852df"}, "ca40a06b-1411-4275-9f89-25927aab3a64": {"doc_hash": "aa7768906aa55eb47faed81f612f2805894069d6899a8c8cf268102da5d83052", "ref_doc_id": "f3e49820-b6cd-4d4a-91ea-9dc1750852df"}, "27e6fff5-02ec-49d0-b5c1-27b5732a5f5e": {"doc_hash": "1e1efad4bea8d7cca7c4e02f5e38c6e584d20e086d45dd8d46e100aa0d6222d3", "ref_doc_id": "f3e49820-b6cd-4d4a-91ea-9dc1750852df"}, "1cf12911-11c8-4dac-b5b2-b9d611d74dd3": {"doc_hash": "17f156f3798d1fff25246069567cee05f08aab08c580e7b116924577ce80b9ea", "ref_doc_id": "f3e49820-b6cd-4d4a-91ea-9dc1750852df"}, "9f9b889d-2773-4cbe-a85c-51a0a56402a3": {"doc_hash": "9df80adb03d907fe5730a9f146d7e9ae79deac7d6531414265f861a97e034865", "ref_doc_id": "f3e49820-b6cd-4d4a-91ea-9dc1750852df"}, "f797cd6b-59e6-462e-90bb-4c5ebfa118f2": {"doc_hash": "1a738485487ccc285a2f0e7c77160bcb3892fa7f31344e712f46cb22f76247a5", "ref_doc_id": "f3e49820-b6cd-4d4a-91ea-9dc1750852df"}, "ddae9c58-9ba4-4a53-a01a-433799d95e1e": {"doc_hash": "68112761c982ba9280fa522d93c6b8a3543153d99aaa6caa88cca7c4deb26ccd", "ref_doc_id": "f3e49820-b6cd-4d4a-91ea-9dc1750852df"}, "50f43e68-feb2-4c3f-b7d6-28ea534560d1": {"doc_hash": "58c0f812e639db989459c6d2e677d2bdaf01909be74ce17c93f4bb3d3c70eb18", "ref_doc_id": "f3e49820-b6cd-4d4a-91ea-9dc1750852df"}, "92d3542c-790a-4d32-b245-3d37a1ad0de1": {"doc_hash": "54ed683c28bb06114d53418415db306a579f4b6baa7ba7d781779f3e0497f6ef", "ref_doc_id": "f3e49820-b6cd-4d4a-91ea-9dc1750852df"}, "8cf9d13b-3a32-4f70-95b9-dd81825a0f93": {"doc_hash": "02a1f10f969cc0f11c7dbf23dbd802913200f52c0e60c1423d0b795730f87e36", "ref_doc_id": "f3e49820-b6cd-4d4a-91ea-9dc1750852df"}, "ddcedac7-027a-4f63-99e7-f8109d88cfd4": {"doc_hash": "54b52ad6ac395469a01a48f4a284f958a6fb3249d90fb797074b2f8112be6cd5", "ref_doc_id": "f3e49820-b6cd-4d4a-91ea-9dc1750852df"}, "aae40073-8562-401a-8665-40aa28483494": {"doc_hash": "b5aca58bb80aeefba32bc961f27e42b7b425224b87e03c88ba0260af1fa1f73f", "ref_doc_id": "f3e49820-b6cd-4d4a-91ea-9dc1750852df"}, "58bf1dcb-a3b4-44ca-9d9a-9d346aaddd89": {"doc_hash": "8793a4c21090dfe288bf76b01112c36023406e753da11d48a8687594dfe50adc", "ref_doc_id": "f3e49820-b6cd-4d4a-91ea-9dc1750852df"}, "b41d719c-f0c2-441a-88dd-6c44aa519458": {"doc_hash": "5d726c9a030db355d051458e3257e75c450d50ca9a9d26aabaffbe7ac6c1a91c", "ref_doc_id": "ff79878d-cd7a-4d1f-8101-b4311053d1e7"}, "e03e1783-faf2-46df-926b-89056b56ef95": {"doc_hash": "97dcd5e946240fd5eaabf76976d41424d53bf1eba483c7033255a77bbef324a2", "ref_doc_id": "ff79878d-cd7a-4d1f-8101-b4311053d1e7"}, "81eacea9-a37d-4834-8413-8428c5649cf7": {"doc_hash": "a53bf04e048472ec07182401ab69f349043f6bc1575b5c4d5168db9ebb8ab2b5", "ref_doc_id": "ff79878d-cd7a-4d1f-8101-b4311053d1e7"}, "215bdc4b-988a-4679-acd2-b407a5f99e5a": {"doc_hash": "328f1ba6070e57c4faea693a7da4aabe44ec4e521728efcb3dc3fa105ecb62d8", "ref_doc_id": "ff79878d-cd7a-4d1f-8101-b4311053d1e7"}, "5e9a9db8-3fb1-4165-acce-6d03be816629": {"doc_hash": "e9f4f657818f86a0d3cb976de219da6b071d76a18bffbf65acb5447960245173", "ref_doc_id": "ff79878d-cd7a-4d1f-8101-b4311053d1e7"}, "c07028c5-6347-464d-b168-5775e60013b4": {"doc_hash": "49025d30ff27a9ef1ce7168288c50e26c315fbfa7e3d82f4755d8cbfe1c9a4ca", "ref_doc_id": "ff79878d-cd7a-4d1f-8101-b4311053d1e7"}, "8b9a4fa9-5a4a-401f-b718-3446fdc66f60": {"doc_hash": "2c3b93ae712048a9c8a999556a81ed8b156ebc63147a59506c360b4109b57f9f", "ref_doc_id": "ff79878d-cd7a-4d1f-8101-b4311053d1e7"}, "5aa1e20b-a523-41b2-b3bf-dac0db7108f0": {"doc_hash": "37013e6dceb7e54fc99f51e362d2be5c194d80043d473e3c82bcdf2007770e81", "ref_doc_id": "ff79878d-cd7a-4d1f-8101-b4311053d1e7"}, "d4297ef8-03a2-4ed4-b2b1-bb8c9e5626fb": {"doc_hash": "78d843406a9fc694f4944ef5593db70bad2d6d7b31cade9d422eb365972e0378", "ref_doc_id": "ff79878d-cd7a-4d1f-8101-b4311053d1e7"}, "4eab0c6f-c55b-45ba-9cc6-8da711d4fad1": {"doc_hash": "aeaf3d194ac812e63de5c31e54ffe92f73d6da9d1127991c86be9c4330f74dd5", "ref_doc_id": "ff79878d-cd7a-4d1f-8101-b4311053d1e7"}, "fcaabf17-a700-4778-a0d5-c5ec63d1b5a9": {"doc_hash": "344364b16a967cf879bf36f0eb3349c4736f506a2edbe249fbfa57c970ae00eb", "ref_doc_id": "ff79878d-cd7a-4d1f-8101-b4311053d1e7"}, "057c2d7c-1db7-4c83-b943-7b2aa6270633": {"doc_hash": "db4e0680f5f38dcb01e72b9106f1c3489ac53f1508d51b845cfd66cd77e20369", "ref_doc_id": "ff79878d-cd7a-4d1f-8101-b4311053d1e7"}, "cc3e792c-1f77-46fa-8ec6-d0a43ce4a9ae": {"doc_hash": "aa63f6d344f8d1c756b07438b6266aa96bb583ff61de6c63996b4868f460b052", "ref_doc_id": "ff79878d-cd7a-4d1f-8101-b4311053d1e7"}, "480d15b7-aca5-4b43-ab2b-f6c6653eb252": {"doc_hash": "bec79a001c7f92c0c573976d026f8c138b8bff6d993e65596f4ad2b2fd93a374", "ref_doc_id": "ff79878d-cd7a-4d1f-8101-b4311053d1e7"}, "d635d0ec-7529-4cd1-80e8-1fb7fb5e3293": {"doc_hash": "c18be1c1725cf2be25c14e1bb3b8609105b89fdf4071ffaabc12248a796773f0", "ref_doc_id": "ff79878d-cd7a-4d1f-8101-b4311053d1e7"}, "bbc5341b-e812-453e-ad03-fa9d904606e2": {"doc_hash": "66442f7f39466d5ea7d321bffcd3f701cbd7aa86886cf264817f60a55fc3873c", "ref_doc_id": "ff79878d-cd7a-4d1f-8101-b4311053d1e7"}, "a4faa206-6fcc-46d4-9711-a0ae3860462f": {"doc_hash": "b280cf0aa2b7d4e51c04b02a14dd2d2a492b6b53d6a5779d4c12c1700fafd2cf", "ref_doc_id": "ff79878d-cd7a-4d1f-8101-b4311053d1e7"}, "f82625aa-60e5-4103-95d0-02004f711cf6": {"doc_hash": "95162cb43c5bd7de35d2614b14004256b6ce0c73841795e8d731df0d29955e30", "ref_doc_id": "ff79878d-cd7a-4d1f-8101-b4311053d1e7"}, "53a0530f-71a6-417b-8615-25588c0ed1d8": {"doc_hash": "cb0f632dd5213cdb40e56b9d653c844174c6e951b4c7ecc94a72be89252aab0a", "ref_doc_id": "ff79878d-cd7a-4d1f-8101-b4311053d1e7"}, "eeeabd3e-66f0-40ea-93ba-0f4a49390928": {"doc_hash": "104d0e9b9908e499f870a532e3b400c858b4a2f30b07433faf38c984b471b98b", "ref_doc_id": "ff79878d-cd7a-4d1f-8101-b4311053d1e7"}, "758edcd7-3431-4bb1-8c75-71ad002102ec": {"doc_hash": "a875db5947eb94d2b7a89a2e8d5f48ddb88593f6638bfcb866d36302b00c2c2c", "ref_doc_id": "ff79878d-cd7a-4d1f-8101-b4311053d1e7"}, "4ec26a79-0326-4b65-806c-c6852595af57": {"doc_hash": "dcec64a30344a3a45b8cbafb5d9adfb0d4e4e013c51d9cc6252eafe29a6d1b82", "ref_doc_id": "ff79878d-cd7a-4d1f-8101-b4311053d1e7"}, "a4b91c1d-3851-4322-b5d3-625e17bbe77f": {"doc_hash": "104d01d2e6fa0426deb074c4d71b583b01737d4c5c9acfb17ab9e3c8a6fd6faf", "ref_doc_id": "ff79878d-cd7a-4d1f-8101-b4311053d1e7"}, "aa87afae-8735-432b-b81e-a065bd4240f0": {"doc_hash": "439c9e331811d9c9194f2dd803ec8076c274c75c2c950bfd44e387afaf02b741", "ref_doc_id": "ff79878d-cd7a-4d1f-8101-b4311053d1e7"}, "061b7ab0-35ae-44f7-9075-a48e9c1ed722": {"doc_hash": "e2137bb513fc1cba93c0e01c1a78283084a5a16212f83bd6384368377a8cd061", "ref_doc_id": "ff79878d-cd7a-4d1f-8101-b4311053d1e7"}, "af60dc25-5aa8-44d2-a54c-f46daec6154b": {"doc_hash": "13a314c5d8d53dfff5de5bcd56a18300745d78a65a029cbf7b33fe3086db36eb", "ref_doc_id": "ff79878d-cd7a-4d1f-8101-b4311053d1e7"}, "88309284-aeba-4eda-8e64-37ea77dc9b62": {"doc_hash": "1bbb7d3be725e329eeb3ad1d1d3be321b76109720e75b39a7c47b17dcfb356c0", "ref_doc_id": "ff79878d-cd7a-4d1f-8101-b4311053d1e7"}, "376a00a2-150b-4c27-8c64-8559973e9e3b": {"doc_hash": "3cb0184de03c7aa7e0f8b2c042707a22628c1f1702b07c01f9e008a618417c37", "ref_doc_id": "ff79878d-cd7a-4d1f-8101-b4311053d1e7"}, "acedc22f-18e3-459f-9fab-b6cc20c64bba": {"doc_hash": "053d53cbed4e6fd2b0085d7c6837c4019a3513c8c92e0019c62a91cffba6316c", "ref_doc_id": "ff79878d-cd7a-4d1f-8101-b4311053d1e7"}, "ab6e6785-1f02-432b-a8d1-6832e38108e2": {"doc_hash": "1cb65591cf26408616a26a32778fea28b1e9b330f0498f0acba3f956d10a1239", "ref_doc_id": "ff79878d-cd7a-4d1f-8101-b4311053d1e7"}, "0ec91c57-d83e-4495-be7a-28d9286cc1f3": {"doc_hash": "9b4804be1fd30298d74c43118a5b383a181d5ca6bff137c2ffc840815f1a2d1c", "ref_doc_id": "ff79878d-cd7a-4d1f-8101-b4311053d1e7"}, "b86fa0ab-02c2-4834-91ce-42f009d4c45a": {"doc_hash": "6eee44688a5d26d64580feb16d19580f21b1db35c3faa3946ae9a86ab7ae9b45", "ref_doc_id": "ff79878d-cd7a-4d1f-8101-b4311053d1e7"}, "4b37d3ca-db86-43b5-bdc6-493238f8ab11": {"doc_hash": "21c2c44abd867d37dbd923cc56e772b5abb8609909fade445d5ccc158db5522b", "ref_doc_id": "ff79878d-cd7a-4d1f-8101-b4311053d1e7"}, "e0cf7e0c-22f5-41be-981a-029a0e00ee68": {"doc_hash": "b4ca95dfb2284bd68d3c5f7a05ae13dd524c7640989e50ada24df34a96e49ed0", "ref_doc_id": "8303b9b1-b8ed-429a-a917-848440efdf52"}, "6e644f25-cb4d-477d-b2ee-c4c425d8ea0b": {"doc_hash": "4d413c6222ba1efb15e4db090ecaffb570753c2759073a3e9aae6fb4aa484755", "ref_doc_id": "8303b9b1-b8ed-429a-a917-848440efdf52"}, "01c93cc8-b7a3-4036-8f76-8afa453a130f": {"doc_hash": "6b97768855d7a9925db65f8d66d6bb19f5179da4cc0e02e8aac860ffb0ed45e5", "ref_doc_id": "8303b9b1-b8ed-429a-a917-848440efdf52"}, "ae57c776-7bba-4bab-b1a3-4315b9799904": {"doc_hash": "264a0bdfec393627bc4b8c9b6d8b292839781438a39a946267ea8d7f798cc8dc", "ref_doc_id": "8303b9b1-b8ed-429a-a917-848440efdf52"}, "744ccc30-6671-4316-adb8-ce2192ffdcb2": {"doc_hash": "92741cae32f6fb9e4fb10526613029f1965ba695053a46bb59661648a99d83cb", "ref_doc_id": "8303b9b1-b8ed-429a-a917-848440efdf52"}, "ebf3d10e-4273-4739-878f-6cdbb2fb5193": {"doc_hash": "e7a251ebf2fe51f9e71310bc4eda19bccfd6eec829a090862fdf3a4e928b4f39", "ref_doc_id": "8303b9b1-b8ed-429a-a917-848440efdf52"}, "a2c8ee26-a27b-4d63-b361-c0e7b6a22bfc": {"doc_hash": "eaf2f8034a385db45d5a1b7f2442cb436a14849b2479278d4404901bed67c3db", "ref_doc_id": "8303b9b1-b8ed-429a-a917-848440efdf52"}, "0b5790d6-4dda-4315-8294-68342fcf8fb7": {"doc_hash": "4f158bebf510540aba0d3828e41b206b3d2e3a81229c351bd957e2fe59a330c9", "ref_doc_id": "8303b9b1-b8ed-429a-a917-848440efdf52"}, "3a7ea451-f9d8-410d-8972-e2e7e0744419": {"doc_hash": "79209fd792bcb97c5f9b3e80b57f4bf191d6d5bc5b88f2d5f257901c606e6cd4", "ref_doc_id": "8303b9b1-b8ed-429a-a917-848440efdf52"}, "49e9802a-95e4-4cd8-ad95-e94ba212e185": {"doc_hash": "6c11b2d166e96e07becfec003bb1783e4c4b9efdf7c2b41a28e2665269c67672", "ref_doc_id": "8303b9b1-b8ed-429a-a917-848440efdf52"}, "dcc3c51b-cbdd-46be-a129-97870ee268df": {"doc_hash": "495164587c1039a9c22ab5db6ae6a3ee0a79268dbc5bafdbd5fc3c5ec7b21028", "ref_doc_id": "8303b9b1-b8ed-429a-a917-848440efdf52"}, "ad2ca80f-67e7-4606-a184-7efd49147928": {"doc_hash": "bde473025f79d50a2345c66b1ed41d3ba72dfc9fbf099ebc3974f3aed9b991bd", "ref_doc_id": "8303b9b1-b8ed-429a-a917-848440efdf52"}, "ba76262b-100f-48c3-8587-cb9f255881ee": {"doc_hash": "28e08c76211a482ca5e7454317d0805095fcc7d798b18f81edcfea3ffc03dd77", "ref_doc_id": "8303b9b1-b8ed-429a-a917-848440efdf52"}, "a2c1cc42-bfd3-42f8-9a7d-ebc6d6256c55": {"doc_hash": "791c0ab91a1635baff41a8795f711ac9191a351c3e6b9121a2b7e8bd199d9fab", "ref_doc_id": "8303b9b1-b8ed-429a-a917-848440efdf52"}, "bd7fb46e-2644-4178-89f8-6b0e90f97a10": {"doc_hash": "1754cec2a3186d924b3230b87183a352d8c609a3855094ef299e5e2d7714ce94", "ref_doc_id": "8303b9b1-b8ed-429a-a917-848440efdf52"}, "2350bcfb-f1d3-47b4-9acd-2e7ae1c7e622": {"doc_hash": "5ce9cfb137a8eb97518425ea087fe4132f2f0c7cf219f004e3b8dc614d1bce5f", "ref_doc_id": "8303b9b1-b8ed-429a-a917-848440efdf52"}, "ed4ea57b-8dad-4e1b-bd5f-066baa731fc5": {"doc_hash": "c04cd575501f425ade767456732d3371ad746d90b8ab6a0dc3e5a377c16dd753", "ref_doc_id": "8303b9b1-b8ed-429a-a917-848440efdf52"}, "16a8d12c-d8b2-47b6-ba76-5661edf5a082": {"doc_hash": "3e96db8a4aaf3738e2c1059134148a262545ac3621e5838d91fe71ae6506c08a", "ref_doc_id": "8303b9b1-b8ed-429a-a917-848440efdf52"}, "0a39872f-c660-4376-b1b5-557ab1cad0a9": {"doc_hash": "2a4e9ae0c931356a2c763db96400af2362244f4cd7d95794afd629d556df1e7e", "ref_doc_id": "8303b9b1-b8ed-429a-a917-848440efdf52"}, "53ae5517-0d3b-41d2-8104-2b2aa8486093": {"doc_hash": "02681140ca93d56d2b8e7185089e15b7522c13e3928e1c022dddb6de92104084", "ref_doc_id": "8303b9b1-b8ed-429a-a917-848440efdf52"}, "1d4f0249-0ba9-4742-8fa9-c84bf53d327c": {"doc_hash": "e10584fd7d7a13fee0cfd7d118a2e1e0b0f82761697cf32c9c7140ec8bac5987", "ref_doc_id": "8303b9b1-b8ed-429a-a917-848440efdf52"}, "acc0d480-c4ba-4274-a859-bf8178aca0fe": {"doc_hash": "aaa548af48ae2bea16a70bef6667dc048c22e9ead2e2b1f9736a608075e74f88", "ref_doc_id": "8303b9b1-b8ed-429a-a917-848440efdf52"}, "2a2e1c9f-c8fd-413a-a6d1-53c391dbd23c": {"doc_hash": "3fe3f5dc3874d8bc8d2c11a1cfcd3cf715f1b6d220aaa68102c5d97b9c29794f", "ref_doc_id": "8303b9b1-b8ed-429a-a917-848440efdf52"}, "1688d1f9-0eba-4eb8-bff1-2e6c284a673a": {"doc_hash": "9ac6958f5c5554518cfbbb3cc937b95aa92e7cba229cd798a4d11a1503dee15c", "ref_doc_id": "8303b9b1-b8ed-429a-a917-848440efdf52"}, "3b7597b8-97a2-46d3-9a07-bf2657b48753": {"doc_hash": "54e9d01b2546104a1a158275a7ad18c2521babe94215126cbd507d037c304ccc", "ref_doc_id": "8303b9b1-b8ed-429a-a917-848440efdf52"}, "7ec2fd5a-8245-45d5-9e2e-7a3d706c6347": {"doc_hash": "a72bf544adddec44da6e7921a84bf15d1e76f267d2b6f613aac6d16d1d55d900", "ref_doc_id": "8303b9b1-b8ed-429a-a917-848440efdf52"}, "b50bf998-458d-4c91-8c63-3ca79001e4db": {"doc_hash": "7ed3072af16ca7eb5a8683daecc89d1cb122df99fc5c3167232cecca87d98beb", "ref_doc_id": "8303b9b1-b8ed-429a-a917-848440efdf52"}, "977f240d-d157-47bd-b3cc-1a6aa187b922": {"doc_hash": "bae786910c6576fc8f430bbc8a233e8701ffbd90844a8148334a50f5c66fc0f4", "ref_doc_id": "8303b9b1-b8ed-429a-a917-848440efdf52"}, "2b14f667-f30c-43dd-8170-d86787441115": {"doc_hash": "5866e0852b460e55cfdb7d96dd28ce6ad26eb2669127d720333ed95b4f20d3f0", "ref_doc_id": "8303b9b1-b8ed-429a-a917-848440efdf52"}, "4804ac8d-c0c2-4513-b1df-b2b93a8d95e1": {"doc_hash": "49a203a9af608e15dc4645e28e89533d0a4aa6335804b0ebe3012c97847f54d3", "ref_doc_id": "8303b9b1-b8ed-429a-a917-848440efdf52"}, "ebc7338e-7ea6-4500-8a85-737b930c9031": {"doc_hash": "783e91a640fbba278725b6099b501b3f3503ffbdf92b9d98ee16743ff55a1515", "ref_doc_id": "8303b9b1-b8ed-429a-a917-848440efdf52"}, "116c403a-7edb-4d32-9dec-ea3d99d60ebf": {"doc_hash": "b226d95fa229ab126c40308cbfab985d2bcc8d942c199ee3ed40b00ef16e5895", "ref_doc_id": "8303b9b1-b8ed-429a-a917-848440efdf52"}, "0d5f9f7e-b645-4a66-9c68-cd3d030b5311": {"doc_hash": "7e69018c3c53ec6e85c6a9a38528a67734025a19f5c0925abc793cc507f23bec", "ref_doc_id": "8303b9b1-b8ed-429a-a917-848440efdf52"}, "9a00fad5-ce17-4b7b-8976-6eeea2f9325c": {"doc_hash": "b33e07648cbc41e5fa6b7b20f334536c0699be099e20e4b969324f5dc9a5cd13", "ref_doc_id": "8303b9b1-b8ed-429a-a917-848440efdf52"}, "8d792cfd-d418-4f85-8a51-4342e42b6d2f": {"doc_hash": "7972f4614f84c4a421d9f780f86e6b5a60b6d6c63c6a9b88488da3d51258485b", "ref_doc_id": "8303b9b1-b8ed-429a-a917-848440efdf52"}, "c2128f92-501b-4207-ac6b-0b51590a2532": {"doc_hash": "b0a099d810f01d8e765a5684a8d2454b5a216dc615490891d1bb128b498e5478", "ref_doc_id": "8303b9b1-b8ed-429a-a917-848440efdf52"}, "4ffcd582-fd18-44e0-ac08-404999a01003": {"doc_hash": "ac19914aa08e1744d9ff53b0942ce44913e15291dbddabbe8c0dc6fab2c09828", "ref_doc_id": "48fdc39a-da73-45c6-ab0c-c60b396b0afe"}, "36f8fc85-a616-4032-9042-1a3ab1af3745": {"doc_hash": "b87908104c187c60b5782aa10422b8e0149f5e8b70ecee5aeea7e5e225c7ec0c", "ref_doc_id": "48fdc39a-da73-45c6-ab0c-c60b396b0afe"}, "78d9310e-de67-449e-8151-58ada4656908": {"doc_hash": "a0d9fa85a6e50cf111eb9cba58b86767a0d234e441280d9e9c229f76aeaa6841", "ref_doc_id": "48fdc39a-da73-45c6-ab0c-c60b396b0afe"}, "1c173590-e2a4-428e-a9a7-ece1d3647bc7": {"doc_hash": "785f2d46f383dfe0ec86f7c8ff4c59cb8bb3276f1d35577c6c76b6f627c8f128", "ref_doc_id": "48fdc39a-da73-45c6-ab0c-c60b396b0afe"}, "5c35e97e-c9f2-437c-a2dc-5dc23ad4adca": {"doc_hash": "65cfea0d37329d6fa6ea75db92b836b25bafed7fc23fa480939966d687cc13f0", "ref_doc_id": "48fdc39a-da73-45c6-ab0c-c60b396b0afe"}, "faad1eb1-f2b2-4f26-8c68-2ee75e72429c": {"doc_hash": "672d2fc28351abe236f95f06d34f4bd5c8d858b64ebc75a18201af5a51ede6c2", "ref_doc_id": "48fdc39a-da73-45c6-ab0c-c60b396b0afe"}, "eed0963c-7cf8-44f2-8d6a-6fb0836b2629": {"doc_hash": "bfda4892fd86802390635cbaff51fe3d6d5872fa9e06a48676d99184df772947", "ref_doc_id": "48fdc39a-da73-45c6-ab0c-c60b396b0afe"}, "d71698b1-6ea3-423d-82bb-782a35db7ce8": {"doc_hash": "81df0e825280c35e4a86e0f764f645ca500bf689dd9d55c3439bd608d5cd0b5f", "ref_doc_id": "48fdc39a-da73-45c6-ab0c-c60b396b0afe"}, "594d9683-b2d8-4e56-a4db-e6e3a203eb32": {"doc_hash": "b2f38bd549b819ecdace3e18ef5c0b5cc93c8d1f5f70454978e3cd9895c554f2", "ref_doc_id": "48fdc39a-da73-45c6-ab0c-c60b396b0afe"}, "2cfff289-66f4-4205-903c-b21c0814519b": {"doc_hash": "ef443ff5b6af03816706b009dfe5aa616ef162231ed8703866c6540828b389f5", "ref_doc_id": "48fdc39a-da73-45c6-ab0c-c60b396b0afe"}, "79021055-c7b4-4b50-8def-e347e94f40df": {"doc_hash": "7f0d55e63bcffe699acd3fdfc69c2ecd5b2cfc51e4533c2bb20fcf70fc456a8d", "ref_doc_id": "48fdc39a-da73-45c6-ab0c-c60b396b0afe"}, "0da0c842-8103-49b0-a383-4979fe1cbb11": {"doc_hash": "e4955cb5ebeee35f8452ba3ca18f4278e03d2815430f92384467d1144e2c06a5", "ref_doc_id": "48fdc39a-da73-45c6-ab0c-c60b396b0afe"}, "01ba6f47-8747-4630-b503-f533c0572b70": {"doc_hash": "9488824818b8803420e43331255b82aaba6df05cbbd27e25a05409b843f86f46", "ref_doc_id": "48fdc39a-da73-45c6-ab0c-c60b396b0afe"}, "3d27e28c-4d8f-4725-89bc-fd6b83b17e28": {"doc_hash": "11a1152979b9bad022377827c10c42a3ff4c83b0c68d529a958be95041456eb3", "ref_doc_id": "48fdc39a-da73-45c6-ab0c-c60b396b0afe"}, "d7b2fa0a-574e-4c6d-9ff7-9f767d96c18b": {"doc_hash": "10fd7e9d107485495300ad51d4709733b8eee38d8cede185ec04e63de5c9381f", "ref_doc_id": "48fdc39a-da73-45c6-ab0c-c60b396b0afe"}, "c27ab11f-28f2-495f-8249-63efc6679710": {"doc_hash": "1d87321f200a4245c2c4f5ff9731887155b509654179c8c61cd6c836d22e7503", "ref_doc_id": "48fdc39a-da73-45c6-ab0c-c60b396b0afe"}, "780f9b94-0222-4622-93de-8ee4594f968c": {"doc_hash": "1c62e3298bef453fe0fa6fa08ca1c06b8ec1fa7bfcbf885c48b91ce1eee28cc6", "ref_doc_id": "48fdc39a-da73-45c6-ab0c-c60b396b0afe"}, "514dab8d-b8ac-4fcf-aed1-eee174058e29": {"doc_hash": "150afaccf2af63b94123f2091555f979a1620e0487fae7ff69ad544343bfa58e", "ref_doc_id": "48fdc39a-da73-45c6-ab0c-c60b396b0afe"}, "243fb048-1760-42b6-8241-b281fa5d813e": {"doc_hash": "8400090a60b85a65aa30181c6d856524829711f08628e5baf98524c84574fd2b", "ref_doc_id": "48fdc39a-da73-45c6-ab0c-c60b396b0afe"}, "217ddcf9-1839-4582-8f6c-20d4d8e0046c": {"doc_hash": "f3eeff275d131948f48990713acc99bd831b1840abdc3c7a1039eada3e91d7e7", "ref_doc_id": "48fdc39a-da73-45c6-ab0c-c60b396b0afe"}, "86362744-92cf-45b4-ba0f-c0560569b456": {"doc_hash": "722ed29d06f3ca25ad1869d62a69fcf9de06da78e42f9c21ad38bb255894bb86", "ref_doc_id": "48fdc39a-da73-45c6-ab0c-c60b396b0afe"}, "59f57f50-c357-4844-96f5-1b43fe7f32c0": {"doc_hash": "1df86d09063ea37dea7b6cce53b54054b624c9cdff757f4c43fe3ba52afdc659", "ref_doc_id": "48fdc39a-da73-45c6-ab0c-c60b396b0afe"}, "aa1215dc-bcd5-4f82-a4b1-cfa6c50b5933": {"doc_hash": "f8e8a3d06c56229f6f270752ccb79ed0303bb64e48b3b6983dfc1c4753e02384", "ref_doc_id": "48fdc39a-da73-45c6-ab0c-c60b396b0afe"}, "95d7a5bd-8132-4f04-b616-01dfdd712c67": {"doc_hash": "5fbf90aecde2fdebf7c93e5a880c2bcb3249fe24d231e75486c01b5032604b7a", "ref_doc_id": "48fdc39a-da73-45c6-ab0c-c60b396b0afe"}, "94fb79a2-4b67-4b77-b942-ceacda8a12f6": {"doc_hash": "28e87045269bb6c96b67a2e81c147056336b6c22b344dd11ecf6326fdecb06b7", "ref_doc_id": "48fdc39a-da73-45c6-ab0c-c60b396b0afe"}, "5f09a005-f5e9-4fb9-b117-5da4a5032945": {"doc_hash": "de622adec4f7e1d08e4ea16a9076cbc633fc64e2712af0e22f3acfbaf1f93bb3", "ref_doc_id": "48fdc39a-da73-45c6-ab0c-c60b396b0afe"}, "8b73cb46-f59d-4e5e-8262-9c23e984ada2": {"doc_hash": "7ff536a67cd2b20443a644f5dfe0a3a85cf690b221e6397a709a6b1aa754efdc", "ref_doc_id": "48fdc39a-da73-45c6-ab0c-c60b396b0afe"}, "928c8a88-2188-4b48-90f7-a2d768420cfc": {"doc_hash": "a45e3e3667d306ce6f5c9c2bf41b1fc4c1c506f828af6e224fdb20b64418b246", "ref_doc_id": "48fdc39a-da73-45c6-ab0c-c60b396b0afe"}, "7be13def-33ab-41c2-9f6e-26992141f21b": {"doc_hash": "0dc60ee6a59830410f231cf7c9f13b1f53a1b0c599ef3e16f9d86b8949238fb3", "ref_doc_id": "48fdc39a-da73-45c6-ab0c-c60b396b0afe"}, "49db94ac-a208-4910-a16d-3bd5c2062332": {"doc_hash": "22276b1094deb0dd84efb9ecec8d3c6ff3cde1c1a455ece6307e7a16728d546f", "ref_doc_id": "48fdc39a-da73-45c6-ab0c-c60b396b0afe"}, "a029fff3-61ab-4bcb-97f7-23fb996f1a27": {"doc_hash": "fe5acfb64bfea6d211d5a4564d18f0b44de4148ca98cf54f4c13f69d9243941e", "ref_doc_id": "48fdc39a-da73-45c6-ab0c-c60b396b0afe"}, "4f804246-d76d-48ce-b522-dab4991efa2c": {"doc_hash": "e01e74778e861902a7cfa3ca81285e29b1f8da7dd2cf4e3e9cf8967e215883dc", "ref_doc_id": "48fdc39a-da73-45c6-ab0c-c60b396b0afe"}, "f8cb5524-d4ca-4d22-9636-bdded29e16c2": {"doc_hash": "ad96d7a0b25f2612fef8334f8110ebb8e2c2f19fedbb1609af1a7a0d133c1754", "ref_doc_id": "48fdc39a-da73-45c6-ab0c-c60b396b0afe"}, "f327913d-07d4-455d-a06a-a54acad37849": {"doc_hash": "775da3b42540d650fbda929a481ea8f3af8733f29c2fd1b29d83bb6ec53e6536", "ref_doc_id": "48fdc39a-da73-45c6-ab0c-c60b396b0afe"}, "37514ab9-c9ca-401a-bd0e-67ac47d1239a": {"doc_hash": "3bf3f908365723455eacc1cec79464ce26eea9272b9ad5c5009f92388fe9255d", "ref_doc_id": "48fdc39a-da73-45c6-ab0c-c60b396b0afe"}, "586a3a93-62fe-476b-a34b-3c919278389b": {"doc_hash": "d4f57de1638385cd56177a426f5a8cc3f40ca0f8ce88eb3f8578fc5bd63d3e0e", "ref_doc_id": "48fdc39a-da73-45c6-ab0c-c60b396b0afe"}, "b3d6ea29-a146-4a01-b97c-2ce808e0ba5d": {"doc_hash": "5a6e4e6d6d54a9135efa93eb545f084afd2edb515ba6cd649f870e92bc54301a", "ref_doc_id": "48fdc39a-da73-45c6-ab0c-c60b396b0afe"}, "e3671f8d-f163-41c2-ae74-b6b5999d9781": {"doc_hash": "2b7943cbce87574d1c9de48e026fbcf178b7202108d72d1e92bb1bd23a64787b", "ref_doc_id": "48fdc39a-da73-45c6-ab0c-c60b396b0afe"}, "634435f1-0787-4e15-a578-8d8d7438e062": {"doc_hash": "5b6fb470c67c2fa3c9fd4ed1980ae749caaa78f7070a5d5a5860c4402f5ca73b", "ref_doc_id": "48fdc39a-da73-45c6-ab0c-c60b396b0afe"}, "1835c038-c21b-4743-a987-c2967ad94589": {"doc_hash": "02b245b5324c40cab7e48e005518b4b2ca91c3407d6b0d5a584b571793498359", "ref_doc_id": "48fdc39a-da73-45c6-ab0c-c60b396b0afe"}, "6f85e3a4-08be-4f8e-8a6e-7a10483fd7b8": {"doc_hash": "fa9840d413e3dc399ebff24b12d2116ad24d598ceee15c20c6d282122192411e", "ref_doc_id": "48fdc39a-da73-45c6-ab0c-c60b396b0afe"}, "b6229de3-07f4-4cf9-a5b2-89314a1f911f": {"doc_hash": "fdd8642fa85537dd38132caa0d66c317672450bca8320c9b311fc683180baaef", "ref_doc_id": "48fdc39a-da73-45c6-ab0c-c60b396b0afe"}, "5739b225-76cf-479e-ab2e-abcbd00ec555": {"doc_hash": "d6fd55f67a2cc89b60970dd5b81181ea3787fdfbdeacc0fc90da2dc768c06029", "ref_doc_id": "5f4e4711-6225-48b4-92c3-167aa1459c03"}, "495c9cf0-b616-43af-8c5e-0dda3195c29a": {"doc_hash": "93aa68a5eaa2d427a06a40e582a1bd4aa7898511e965e961a727cf177ac037b2", "ref_doc_id": "5f4e4711-6225-48b4-92c3-167aa1459c03"}, "c60176b9-e538-455b-ab45-b370db0f7971": {"doc_hash": "11124bfaabd7e1c73408cfff02322183ef10ceaa9250dd0fc94aa4f17805caae", "ref_doc_id": "5f4e4711-6225-48b4-92c3-167aa1459c03"}, "bb308ae2-b105-4bbb-94b1-ebe036b2a16f": {"doc_hash": "7635f4933f4e2472b8f4c3b20b442a5bd59bde68c82f95eea938f417cbe1e6cc", "ref_doc_id": "5f4e4711-6225-48b4-92c3-167aa1459c03"}, "73b3d175-75ef-450c-a511-98e6eef62683": {"doc_hash": "9a36f850a52606119705ab1fa89599f072cd327d1209df1d1f2480d1bb7beb26", "ref_doc_id": "5f4e4711-6225-48b4-92c3-167aa1459c03"}, "30f9a185-e037-4fed-aa3e-a9c485934204": {"doc_hash": "d814b6848222d55d07d6140bbd908368a4ecfeaadc5d6bc688c50f2087b87448", "ref_doc_id": "5f4e4711-6225-48b4-92c3-167aa1459c03"}, "31776279-4cb7-4e3b-a12d-bcf90a131bd1": {"doc_hash": "827a2257100fe8063bd14c6b369b0948e83d51e7683b0e10bea2b5a53bb4d517", "ref_doc_id": "5f4e4711-6225-48b4-92c3-167aa1459c03"}, "217faf87-922c-4258-88b0-6f29ccbd0ac1": {"doc_hash": "df737c4a3cc9c2b0fbad99f4252605da263e96fccbf827cb1aca490f53036795", "ref_doc_id": "5f4e4711-6225-48b4-92c3-167aa1459c03"}, "5a0309b6-dde0-4a1c-8d7a-d4266fa42e1b": {"doc_hash": "59e37fd5ab181605869f8c9dddaf07426dd55f8e482e587354e34be5761c0c3a", "ref_doc_id": "5f4e4711-6225-48b4-92c3-167aa1459c03"}, "ee3a6fab-c610-4057-b246-f39c0af6eae3": {"doc_hash": "0b3e7e3785396d50f185c4848ea9831e3344603267451f3a54a8b444c5ac4f13", "ref_doc_id": "5f4e4711-6225-48b4-92c3-167aa1459c03"}, "3442a671-4a97-4116-8b3a-4f037362502a": {"doc_hash": "4d9263c91aec74d07cea8703f0d06dd8ade43f9ab9a65331863928d18ea35ff9", "ref_doc_id": "5f4e4711-6225-48b4-92c3-167aa1459c03"}, "f579cd8d-9962-4cbd-a62e-0557f92b996a": {"doc_hash": "26845e6a3a234ec6972cf0b93da0681c4fe28f50eeb42dd64a52d430a6364360", "ref_doc_id": "5f4e4711-6225-48b4-92c3-167aa1459c03"}, "ee764432-b0f0-4db5-9e84-66db222b075d": {"doc_hash": "b7d4cd6da97ceda73029321747f330cd78f894d5ea13bc0e5916ba77a844e35f", "ref_doc_id": "5f4e4711-6225-48b4-92c3-167aa1459c03"}, "a2237301-66c9-4ac3-8d04-f41615c5c3ec": {"doc_hash": "1a829eb92ae29dc534ececd53cff46ad6849e8e0f76e1570041631b007cc94ec", "ref_doc_id": "5f4e4711-6225-48b4-92c3-167aa1459c03"}, "0c2e76db-f65c-43f4-9371-4f76ffdc8afe": {"doc_hash": "68aff3d22203acd4c7d4d89f5bca8bb53b9a087dad806afd8b25b8c9c704c89e", "ref_doc_id": "5f4e4711-6225-48b4-92c3-167aa1459c03"}, "1d162908-090d-4b1d-94e9-fbfc8f39e04a": {"doc_hash": "cb6f375022cfb9285d2ae537bf33c13d1313969c535b3722aa9be1bb79684d6d", "ref_doc_id": "5f4e4711-6225-48b4-92c3-167aa1459c03"}, "3c4d4108-8a09-4c97-8162-9668d382690f": {"doc_hash": "3119f820c9d409220b57ceb0555f715d88f8284d65151149336d8672a408bf06", "ref_doc_id": "5f4e4711-6225-48b4-92c3-167aa1459c03"}, "10194d53-8263-4f53-b971-4627793cf14b": {"doc_hash": "ec4f8b6ff9ba618509781f893b105c46c7623e2d2587ccded676b08ffc53f819", "ref_doc_id": "5f4e4711-6225-48b4-92c3-167aa1459c03"}, "81f5678f-8812-42cf-92c8-bfd9b27c0f0f": {"doc_hash": "48c45932798044a161db4359985110469a71924ee424c00f89fa50b46496e506", "ref_doc_id": "5f4e4711-6225-48b4-92c3-167aa1459c03"}, "167629da-e1e9-475f-942d-04a4e5800f56": {"doc_hash": "098bce6554982cd2637291d1aa3569efe90dc81228c43496855dd064bd4a48f4", "ref_doc_id": "5f4e4711-6225-48b4-92c3-167aa1459c03"}, "d97e916f-638e-47bc-8f8b-8bcb00281138": {"doc_hash": "9c967a59907c6222c6d0c98e8aaa99dc973cbe5e7c1036635eedd048f2af63d0", "ref_doc_id": "5f4e4711-6225-48b4-92c3-167aa1459c03"}, "15992029-45ce-4f97-8cfa-84908a22e4f8": {"doc_hash": "245987866c0dfaab0c38974d16e90179d942327fcc2a67df17bb89818d46ef4a", "ref_doc_id": "5f4e4711-6225-48b4-92c3-167aa1459c03"}, "80f6152f-9e61-4037-a99c-18b327a7aecf": {"doc_hash": "93e5dbd41e550060d9f7e1b7c599ab2aa6aba52ff9ed689c156c05feedd951fd", "ref_doc_id": "5f4e4711-6225-48b4-92c3-167aa1459c03"}, "4f601686-0965-44f7-b7b0-dad60448b68d": {"doc_hash": "bb13d7bf9aeedfe622e0d50a92a6c7e4bad0613d346b0fb947d3c7145bd0f8bf", "ref_doc_id": "5f4e4711-6225-48b4-92c3-167aa1459c03"}, "b588b264-304e-4488-a19b-e4935b7bdaa1": {"doc_hash": "006245f09cba04672fb75e7bb3ff059114d125ce1215ce7960bd2ed89d79540f", "ref_doc_id": "5f4e4711-6225-48b4-92c3-167aa1459c03"}, "34ade99a-6dd0-4cb1-a82f-eb49f34ae197": {"doc_hash": "3acbbcdfe00e78fb23d3bac12d1a4c99f0fe069ebdc3806a503ba99367d32353", "ref_doc_id": "5f4e4711-6225-48b4-92c3-167aa1459c03"}, "16c610ba-eefa-4c13-9ead-fecff49d3a50": {"doc_hash": "79e49b3fedea7320a1681de9895cbe932c358728bcff9dff6d9b7dd6dbe87766", "ref_doc_id": "5f4e4711-6225-48b4-92c3-167aa1459c03"}, "fdc804f8-b30c-4eb3-9062-c5caed44ce55": {"doc_hash": "6648e240a21d400ee9d1c7ad18dcb699f51b418bf9bc7606e00a26c6f8c8e38b", "ref_doc_id": "5f4e4711-6225-48b4-92c3-167aa1459c03"}, "5388168a-32ec-40d7-8b8d-9db49657b45e": {"doc_hash": "baa79e38aae86828ce6b7eb339c6511d9d2009fbf0c5a8481c57e3dcbbd808b2", "ref_doc_id": "5f4e4711-6225-48b4-92c3-167aa1459c03"}, "8836fce5-e105-40b7-a210-92d6fa8e64e8": {"doc_hash": "bc806040b636410c91750ec35d8f208825e8138aad25fc654ed567e6085de975", "ref_doc_id": "5f4e4711-6225-48b4-92c3-167aa1459c03"}, "10ddc74c-5c59-4164-9373-688d00c9fdcb": {"doc_hash": "28c9ae105c7a0e5be26d0a96c010529ddec4a618cfa6c344d55aff2f51122ab7", "ref_doc_id": "5f4e4711-6225-48b4-92c3-167aa1459c03"}, "e25d2c4c-f3c1-49ac-a296-3705b03605f5": {"doc_hash": "c7019e6536848d799eece4301c1bbda37c5c3405d30c95bbc94b97d88d04efbf", "ref_doc_id": "5f4e4711-6225-48b4-92c3-167aa1459c03"}, "a9e95be6-91fa-494d-ad8d-4964961fb205": {"doc_hash": "75242f769e2ab2dacadc66cc9406d57417758564d9c66e06e4335572607e0573", "ref_doc_id": "5f4e4711-6225-48b4-92c3-167aa1459c03"}, "9bc46997-1f91-4632-9d34-b7249164f379": {"doc_hash": "2db93cc4654dca4887597c14b39d33cc3c7b08357be399f74db6663226785f06", "ref_doc_id": "5f4e4711-6225-48b4-92c3-167aa1459c03"}, "f8efa66a-fd0c-44ba-9f3e-9712ca007aaa": {"doc_hash": "af3d59493972b53a419ed35264e673181c7376f3ae9ee45ffc74cad2bc637cde", "ref_doc_id": "5f4e4711-6225-48b4-92c3-167aa1459c03"}, "591afdc9-9acf-401d-978b-a02a65f5f5fc": {"doc_hash": "37110df494247a0d9084aafbcea5287567a6579d635502f0d4c13f925ed22ced", "ref_doc_id": "5f4e4711-6225-48b4-92c3-167aa1459c03"}, "6b02363d-8aef-4cb1-805a-9f827d4ede12": {"doc_hash": "a49329dfb8c36bd67cab64bc6da63a3066492b7a02029c8f255b39c987797365", "ref_doc_id": "5f4e4711-6225-48b4-92c3-167aa1459c03"}, "108f56c6-8f37-4741-9255-a5b0054bf7b7": {"doc_hash": "c08a20759d57eae15086a0635ba1122c99e86b22d218c037707d73d8bbc15b04", "ref_doc_id": "5f4e4711-6225-48b4-92c3-167aa1459c03"}, "a2b00a35-60bb-405d-9ed3-8ad8ced9ea0e": {"doc_hash": "bdfec02f3695c4e8a8c8b9d866192fe0791ce2057b9e0a6ed5bc071a86c2a330", "ref_doc_id": "a805158d-a3a9-4f66-90a6-b2bb5b33d14e"}, "2b0fca36-0288-453e-9b88-acc00f23fda4": {"doc_hash": "99cd576845b34b97848d845a9dac6465b7116f54520e76d6179e633074a43500", "ref_doc_id": "a805158d-a3a9-4f66-90a6-b2bb5b33d14e"}, "16b7202d-c187-4a65-ae7d-716f25159236": {"doc_hash": "3e48daf61e97918b46cf943fcfc1e5780d17e73356ad71106b6d0168106eb4b1", "ref_doc_id": "a805158d-a3a9-4f66-90a6-b2bb5b33d14e"}, "f27040f5-dbbb-4800-9f12-622706f1e184": {"doc_hash": "1b4e2f9ea77e44e024f66b88ef48049c8533d1bf6b60dc7943fa1013bca5dd55", "ref_doc_id": "a805158d-a3a9-4f66-90a6-b2bb5b33d14e"}, "c5218a91-3831-4803-8fda-909cf28d2c17": {"doc_hash": "ea07cb6df515e056d439ef04c6395977d9ff08da19090f8ca22b7eca5f1a05d9", "ref_doc_id": "a805158d-a3a9-4f66-90a6-b2bb5b33d14e"}, "b7990ec0-7155-4e81-aad1-833c2f9cd768": {"doc_hash": "baffb4923bef69abcccfb92289bbe03177d1d89b3a5f88aefd0c474640f3e89f", "ref_doc_id": "a805158d-a3a9-4f66-90a6-b2bb5b33d14e"}, "b4f7f26c-5eba-4cf5-a641-e186d6aa389f": {"doc_hash": "fa44843db220093774bfa73d469dba994544bffef778c1166011bbe8ae1397b7", "ref_doc_id": "a805158d-a3a9-4f66-90a6-b2bb5b33d14e"}, "00b8e4fb-a465-4639-9088-b7fc092cf380": {"doc_hash": "2c4bcd2b87357db8f34c547facc353a081144d7c0b077b3fae563e7501048ac9", "ref_doc_id": "a805158d-a3a9-4f66-90a6-b2bb5b33d14e"}, "e789c0bb-b030-4904-87d7-2179fe3f30ef": {"doc_hash": "dec1420ad417c2ffe0e11a22d1f8f7704a867404e2d264d23ac62acd97bfc1eb", "ref_doc_id": "a805158d-a3a9-4f66-90a6-b2bb5b33d14e"}, "567fbbd0-742e-4df0-90fe-70a26e33e5c1": {"doc_hash": "9e030c78c64e076db4a135ce52c5f02a24d0a1e6327b7a11144156a8f99b0802", "ref_doc_id": "a805158d-a3a9-4f66-90a6-b2bb5b33d14e"}, "ab9be6da-2cb9-4141-b318-1ce50a83d6e4": {"doc_hash": "d63bd96c918ccb7a9ed9f7eaa0b27ce796b0fc9f77e0b8cdc0047b60ec5e2d7c", "ref_doc_id": "a805158d-a3a9-4f66-90a6-b2bb5b33d14e"}, "89380c8b-31de-496f-972e-3b6baf9cba71": {"doc_hash": "e2c6463bf15d6983ad9534a16eadcb20163123c6175fe329987f679ae4cd9bf9", "ref_doc_id": "a805158d-a3a9-4f66-90a6-b2bb5b33d14e"}, "8f894659-d038-45e5-9701-988f35146e0a": {"doc_hash": "b612e964132010246d36c10d5233bee0cbebbff260bfc2c59c886f62f4c297d2", "ref_doc_id": "a805158d-a3a9-4f66-90a6-b2bb5b33d14e"}, "36a340f9-5d06-4fab-8f5d-fcb0db863020": {"doc_hash": "6a537c1027302d48542e8acf54b1027c38b97e54a78bed059996c8e767442e9a", "ref_doc_id": "a805158d-a3a9-4f66-90a6-b2bb5b33d14e"}, "30aceb49-1584-4f57-ae2a-952026569531": {"doc_hash": "d0988ffb8cf79b4a13fc1a987fc19c185be02a66a84f32e23ed79a196958fddb", "ref_doc_id": "a805158d-a3a9-4f66-90a6-b2bb5b33d14e"}, "fd594a45-7d0e-47b1-847d-13e94970443a": {"doc_hash": "f3959a38661713ace86b7591f04d477921ccc38c0dffba796f41abb69c91c8fa", "ref_doc_id": "a805158d-a3a9-4f66-90a6-b2bb5b33d14e"}, "b1b20555-9249-40b1-ad72-8fb045613ffa": {"doc_hash": "aaafa05da13beca98d32bd703fd6468439b85beb03592a04f987d366e35c1710", "ref_doc_id": "a805158d-a3a9-4f66-90a6-b2bb5b33d14e"}, "c9dccec2-53e1-4551-aae1-10e0eba706d7": {"doc_hash": "394fd7421687e9f518997fe7ff1ff69279390954e656e9b1569f6f28ea6e2733", "ref_doc_id": "a805158d-a3a9-4f66-90a6-b2bb5b33d14e"}, "2495ce3e-7312-4fe0-8e9e-279d78579f54": {"doc_hash": "533f30a77a84a7fa5edb02761d430d64b4c895bfaba556f60e38f1cdcfed1289", "ref_doc_id": "a805158d-a3a9-4f66-90a6-b2bb5b33d14e"}, "0ecdefc8-32dd-4bf3-859c-562177d845b2": {"doc_hash": "7807b54ddecb85df762ff6db582d9f50cf36eef61b3a6a6a90b172a56a22f7cc", "ref_doc_id": "a805158d-a3a9-4f66-90a6-b2bb5b33d14e"}, "4649a1c1-784b-4f0d-a129-e80d020dfebb": {"doc_hash": "a992cbda78c6e925d100e5343216c63b7404ce8dd48369e6e5c550400575b1db", "ref_doc_id": "a805158d-a3a9-4f66-90a6-b2bb5b33d14e"}, "7fb752b0-9d28-45a3-a9ce-4aeff3a21cdb": {"doc_hash": "89636d4567888d6380f5c6f3d8bcfcf7d37cc205e562907e9e6df88eb67cc671", "ref_doc_id": "a805158d-a3a9-4f66-90a6-b2bb5b33d14e"}, "0665d5d6-567d-45c6-9806-9f29c97c69a9": {"doc_hash": "4abaa304c1b98c6e73962c0ee136df2ab61bf067761e14527c70da80788fc99e", "ref_doc_id": "a805158d-a3a9-4f66-90a6-b2bb5b33d14e"}, "128e8b1c-7b4f-442b-b002-555b26469322": {"doc_hash": "87dc840dff4dcc025720dd2e07c6d9279ae20b1000c43acbd5310583d94dc667", "ref_doc_id": "a805158d-a3a9-4f66-90a6-b2bb5b33d14e"}, "657a6815-03b5-4864-afcd-cf27587e1ef5": {"doc_hash": "1220757e5f23d6b62a61cfd571974d63d2542fc3712858830510f21d89a849b1", "ref_doc_id": "a805158d-a3a9-4f66-90a6-b2bb5b33d14e"}, "afe59138-a606-4734-9081-62a9b14cb089": {"doc_hash": "e65506853630cf112bfe04395e26c00d643402987a326a83d9bb279fe7f7b3b3", "ref_doc_id": "a805158d-a3a9-4f66-90a6-b2bb5b33d14e"}, "f4f4f6cf-31f7-441f-83e2-c071e10e14ae": {"doc_hash": "d7d41c19b3dbbf42d5830ace3a21c60d953c64e527aadd1bef7c326d9e589266", "ref_doc_id": "a805158d-a3a9-4f66-90a6-b2bb5b33d14e"}, "b654ab6f-55f5-4139-aa15-ecba91b04ec7": {"doc_hash": "0c5ee802cf401a457835a36b6d23159293ae27738faecbf1943b9d94e9e1afb4", "ref_doc_id": "a805158d-a3a9-4f66-90a6-b2bb5b33d14e"}, "d7d2bf70-4762-4e10-9bfd-6376decff98d": {"doc_hash": "66b1a1b669df5b5e9056782a543fb5b38a481236b550cca73983705291186b8b", "ref_doc_id": "a805158d-a3a9-4f66-90a6-b2bb5b33d14e"}, "ddc16e3b-5c65-467f-a989-1f9a1cb5ceac": {"doc_hash": "05978935cdb1d8d9eeea8f4254a84f19e8c89d4fda1dbf3fe388afd7c1403790", "ref_doc_id": "a805158d-a3a9-4f66-90a6-b2bb5b33d14e"}, "10ce44ac-8db8-4e8c-ae9c-30d18b28085f": {"doc_hash": "b8e9f2a90123b5977bcec9794afd44c353a9334ee1b0665c89d1c5d2b604d42b", "ref_doc_id": "82e8361b-192f-452a-b420-11d131263f55"}, "5e21f481-ad80-4f31-872f-aee759890ce7": {"doc_hash": "83173e6fa23f6b2d5d84d7e4d374a352138d093ccb124f690a864b3277a94af1", "ref_doc_id": "82e8361b-192f-452a-b420-11d131263f55"}, "4339248e-0294-418b-8ca5-a28730f84ef2": {"doc_hash": "50eca8250a62f31e95fbe9235937d40ef69c86bc4c045ef1936153ddca1fc7d1", "ref_doc_id": "82e8361b-192f-452a-b420-11d131263f55"}, "322e68b8-c9fb-49d6-824d-5b5f23dc7596": {"doc_hash": "921c95c2989537cfbeff02d5872167344cfb3af9f5b1341fb2b7cb03da7fb8ad", "ref_doc_id": "82e8361b-192f-452a-b420-11d131263f55"}, "2bb69fc5-127c-4db1-96e0-825ee3bfcde2": {"doc_hash": "744dcb89778836ce02a901947a9481c8a3ae87a2e16955fce8bbade2dae72d90", "ref_doc_id": "82e8361b-192f-452a-b420-11d131263f55"}, "767e0dd3-767e-45ab-9f38-7e6c2f86aa4b": {"doc_hash": "05800b828c9170acfebdda93c8f954dc17b8671de689941fde7397798ad318bb", "ref_doc_id": "82e8361b-192f-452a-b420-11d131263f55"}, "b626ffe8-afb1-4f9a-a1e8-ab7ca6e21ef7": {"doc_hash": "7bc894671e00121a0631c6a299b49c12e375dd97b5116edde5b7747c27b0bbdb", "ref_doc_id": "82e8361b-192f-452a-b420-11d131263f55"}, "94bf1d14-69a8-4a62-8124-bea5e3a8d30d": {"doc_hash": "79d7daadbed02b205dc8cca57da4787f77f709f3474ce5eab6a973850e3e251f", "ref_doc_id": "82e8361b-192f-452a-b420-11d131263f55"}, "a83bd5ba-8033-4fa9-8915-f2628e82ec44": {"doc_hash": "ce519c087c6f06ac3b3dc35393f719beae155c5a048a758f1d588469205c019e", "ref_doc_id": "82e8361b-192f-452a-b420-11d131263f55"}, "ec5901d0-98cd-4802-8e2e-fe0aaacd4299": {"doc_hash": "bf4413da642f6ce17b07e118aec28eb76fc2c22dc86317fdb35676df523591ab", "ref_doc_id": "82e8361b-192f-452a-b420-11d131263f55"}, "f0e0c02a-0d11-4ac9-8c94-0328b7c3e03a": {"doc_hash": "52fd0fa01a205973f66529e3710bc13c943aa606257a418f204ecfdc45a0c828", "ref_doc_id": "82e8361b-192f-452a-b420-11d131263f55"}, "4147e8aa-89cf-4165-916b-be049d428fa6": {"doc_hash": "570adcae9f97c0a3bf2dab950cfbb6cfa3aa4b5d8cce361cf8eb419c4a693327", "ref_doc_id": "82e8361b-192f-452a-b420-11d131263f55"}, "c034f82f-1c2d-40f8-a424-f723d3915cb4": {"doc_hash": "d8de569408304b63b10032249e58557ebc302086872f52306411c1a3a9881124", "ref_doc_id": "82e8361b-192f-452a-b420-11d131263f55"}, "666be2e4-5f9e-42b1-8f70-f5747e53eb89": {"doc_hash": "1c862c5defd9f418487bfd289cac23aaa0c07b94172a5aa787886c1f56e53007", "ref_doc_id": "82e8361b-192f-452a-b420-11d131263f55"}, "e2a3a7a8-006a-4022-87b8-b18fa95ac143": {"doc_hash": "1f1a092b3b230298495a0c3c4dd486550c74587e65534047a0cc65d1bde6f98d", "ref_doc_id": "82e8361b-192f-452a-b420-11d131263f55"}}, "docstore/ref_doc_info": {"5fa68102-c072-4c6f-b65a-e470ca43b79a": {"node_ids": ["8832ecd3-1ca7-4682-9aec-bb96b900ba30", "71a87bc7-ff33-4e4b-be2a-3abdb437d689"], "metadata": {"window": " Corrected Transcript  \n \n \n1-877-FACTSET   www.callstreet.com  Total Pages : 20 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n03-Aug-2020  \nMcKesson Corp.   (MCK ) \nQ1 2021 Earnings Call    ", "original_text": " Corrected Transcript  \n \n \n1-877-FACTSET   www.callstreet.com  Total Pages : 20 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n03-Aug-2020  \nMcKesson Corp.  ", "page_label": "1", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "be75fc7f-5193-4a22-8ee5-e80bd9813438": {"node_ids": ["e1630c33-7350-4e42-a533-3196f1ee5a3a", "b17cbbd9-0e73-46e3-92c4-e904618fb425", "ea29bf7f-1481-4f4b-bbb8-3530c468f93f", "284fc50e-5dfb-48b8-a117-14489e6742b1", "f23af7a1-fa64-40c7-9425-75af5096d0eb", "657739c5-854d-44ce-b2d9-fa81fa779696", "852d9709-c802-4a32-9ab4-ef33e6dbf182", "4e3b23f2-c5b0-4efc-a70b-fca725edb51f", "523453e7-af9e-475c-b691-8e257164d734", "5c5171d9-f815-40d8-b8b0-9391cf6bf49a"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  \n Brian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n ", "original_text": "McKesson Corp.  ", "page_label": "2", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "f2ea56d4-9ba8-40ce-8f1a-d30083a09b88": {"node_ids": ["28f85752-c8fb-431b-9869-322fffe993bf", "28e254e7-8c61-46d4-8075-6e25026c8268", "fc96fdef-10a9-4bdf-918b-af678b048079", "c98671b7-7ae3-40d2-a10c-118891404195", "5b3ea2b1-bf9a-42e0-93d3-abc32bd82e96", "1045334e-cbe2-4180-9a11-2e008c34315e", "2c589dae-b77a-4c97-af83-edf099a735fe", "2d4920c0-a2a0-4ca8-bad0-e7881e0cf6f8", "58166f8b-a63f-40a6-859b-d357b6c8837a", "6495e727-1814-4153-b190-9ba1e50d0cbd", "c4b5f65d-7af0-45f8-a94c-a771401f5fef", "63a648f8-4715-447b-a1c5-803205476ba8", "eea4a3ba-81e7-4ebc-a18c-5166195f054a", "63a68225-986e-4625-8c41-d74d9fc86233", "08c1c5e1-c37f-4c05-a82b-50a28284ef8b", "b862892f-c3a6-4e8b-bfe7-f1a7edafc3a3", "f68d5ac6-6ac2-407c-8865-1bc6c5fa81b0", "91060db3-ad34-4ddf-9021-d082f6af7031", "9e7e7562-80a1-4596-98db-77c339db48ac", "662cd78b-a27c-4eab-b37e-eff3352d70ca", "bd53e9d1-938f-442e-b148-a3168cee4d0e", "f1e55d67-4db4-4081-b68e-da8008d43272", "f9f91683-0fcd-4f51-b323-11ccf47948b8", "e79707ac-8a92-4f2f-bfa6-740452fbba70", "7c841c3e-1c0b-4b6a-880a-21d4050479d1", "3c66dd66-4d0d-49b0-aa99-1bd9d5ba1856", "96f23ca5-5989-4b71-b0c0-01fb13169315", "1ea717b4-c066-4f6b-a076-fb04ea7d3283", "a9c39a8a-4f75-4a2c-9472-74f51eea4c5c", "e895f136-462d-4451-bf85-e4ceff4f5c5e", "c64f91a1-2e37-4511-8a81-d05ecdd90f1a", "1afd99ad-2b91-483f-808c-eaa5e8208c80"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to McKesson's First Quarter Earnings Call.  Today's conference is being recorded.  At this \ntime, I'd like to turn the call over to Holly Weiss. ", "original_text": "McKesson Corp.  ", "page_label": "3", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "71518e0c-2d29-463a-b5e5-d10bfe32ed2b": {"node_ids": ["2280c3e2-269a-46fb-a70a-c15c429b8a31", "a29934ad-db7c-48f8-bae5-a2c16aa13c4f", "d7517ab3-caf6-4db4-8e1e-504d24e0a7c6", "12504bf6-aafb-4fa7-93e3-966dba64d316", "25110e47-2faa-422b-ae0e-5888ebd5fa92", "20427e21-e8b7-4318-9979-acee71ab560c", "7a209eb1-80a7-4ee5-a946-b91d2c01a99f", "c0d16077-0a6b-411c-8b3f-34d963098e8b", "05c6a7f3-7746-4bea-8cc2-97d26f072ad8", "521942cb-63f7-4c8f-8226-027b01ef79fc", "f8a3d68c-12cf-4f47-990f-841dbaea1d83", "4d1c5230-8fe1-4cd2-b394-d979f48504ec", "ff27085f-67d2-45d7-a907-5b528fb99963", "1e956443-ab78-4045-b807-555a8dcecc3a", "c51da3aa-5e15-48ae-8f21-a7760feea768", "ebf04942-9036-44a5-9d6d-157c392b8e65", "c375ec00-674a-41b9-a8eb-5e7a260656f7", "255ca743-90eb-4f8c-94bd-6e6a1458ea3c", "2195d6d3-37e8-44ea-bb36-2520de00c598", "078d3b36-3857-4c2d-86ca-aed29fc3cdb8", "2260d5fa-7ae2-47d5-a088-05c89eb366ee", "73f574b0-d426-4ba9-b0c4-f015a6a60491", "05978cdf-0644-499a-89e2-9b7db9097fc0", "8cbf1359-3c64-436d-887d-7c0b925b431c", "2502de08-b5ed-4867-bffb-f90fec4ceb8a", "9b83df33-8543-4f60-88e8-ea19c34ee148", "866617ac-527d-4ddc-948d-e18b819a388b", "0127bbe9-afc9-4a5d-b094-73cf6e127321"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nand safety of our teams, so that we could continue to meet the needs of our customers and keep the healthcare \nsupply chain operating at a high level.  \n \n We've committed to increase safety measures for our employ ees and have maintained an unwavering \ncommitment to our customers and our communities.  In May, I talked about the essential role McKesson plays in \nthe fight against the COVID -19 pandemic, and the need to partner closely with manufacturers, and various \ngove rnment entities, so that we can react quickly, as demand patterns shift with the spread of the COVID -19 \nvirus. ", "original_text": "McKesson Corp.  ", "page_label": "4", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "2b6fa81b-d6e8-4046-a002-579e9e14ad02": {"node_ids": ["7f7ea861-a630-4b0c-8740-ff7430aa5ff2", "bda5d8d2-b4c2-4bd5-bac6-aef17a1537f3", "544f6404-fc2a-4cf6-87f5-62f83805b2e0", "818a91d5-e536-431e-b956-a2028fd9a151", "9c9e6c9c-84f7-4380-abe5-bdd4d824fcc2", "639f0dc6-0ef4-4519-8900-9007f603a87a", "2110b589-637f-4205-8262-25b7b48c31c1", "16f44cc7-755d-46b5-8e20-e06c80b34364", "890add9a-e8dd-4cbe-bba1-ddcae36c79da", "0ab0d51e-dd8e-4270-bd90-f08a9bfde0ac", "24feaeee-f058-4248-8883-f0fbe3983773", "2c19cc6e-7d83-4990-962e-36ef045924d1", "a1a27fe7-72f2-4154-8790-9543b8499ab6", "804f9448-56ee-4088-af11-d219dae25c55", "5333f2c9-45df-4851-a9c9-be2aeadc5a0d", "580fc0cb-abc8-472c-87d7-6e02301daf69", "241ea05e-72c0-4332-8203-78e581e437df", "d8f2a106-7c05-4078-b1be-e3324818f77c", "1c3a6877-906a-4cff-8ed5-9b18482ca5a5", "d089f954-57ae-436e-935b-b529f3352374", "9df15c19-9d55-4af1-b5e2-3e3a1a549153", "7cc94b20-e1d7-434c-81f6-1cf7c9758b38", "9aa51914-8d6a-4d4c-a76c-a24ae6458080", "70d5ba2b-5ae7-4c3b-bf67-8186c9d034aa", "56c9e5ee-be13-4513-a262-73b973493c8f", "9eee3a3a-4f24-48a5-a7e2-8d17099861c9", "4e99c27c-2499-4686-bd29-551b9fbf0ec6", "128192e9-47ce-465b-adb6-025c28c346e5", "0937be29-1b77-4acf-9884-c099e3f6a844"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nyou, TBA is a group consisting of several health systems, retail national accounts and small and medium chain \npharmacies.  \n \n We're always looking for how we can best  serve our customers and help them grow their business.  This was \nevidenced by the growth in our specialty provider business in the midst of this pandemic driven in small part by \nimproved adoption of biosimilars in the quarter. ", "original_text": "McKesson Corp.  ", "page_label": "5", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "fec4a8f1-855e-450a-b1f2-9b9b254694e1": {"node_ids": ["9a2462da-b695-477b-a955-2d1ceff730b7", "319e7aed-1474-42e2-b7fd-0771437b25cc", "f7ca8fd1-41d4-468c-8210-1c8ed90b513c", "65a0dbf1-30af-4c44-8889-b86d8bf355f9", "a1af1e9c-fbe9-48f1-829b-ff663eed09a2", "1f18831e-d5d5-42f0-bb9a-a89ee863cb47", "e29877c2-b301-401c-a043-57e48ab1acc3", "af5aad95-ba86-42d3-9182-7f39e074255c", "d43eb8bf-d9a0-47f2-a5bd-6da7b47a67e8", "e19587bb-4749-4775-9cfe-63abe8b6858b", "a1d4c1c9-4e16-4e37-b8af-bb94c59defb3", "f286a33a-f518-4f3d-9241-d64f2de298cb", "f27ed826-6976-4325-9dd3-a0293e22731b", "004699e4-cbbe-4f9e-9d66-b6c3c6ee1659", "045e5096-aa5e-4181-aa4f-1fef162002bf", "b975f639-2523-4bd7-8ede-5d10acfb8e46", "e4f1e553-729f-4608-af9c-0d4d9ca00892", "41433351-040b-43d2-817b-a8d5bbdd8216", "da1fbbb4-46c6-412f-8214-c8fafdaa200a", "cf09e37e-1690-42d8-bf40-a56707b5783b", "0530e465-7c05-43fa-8431-110507163d57", "0f159bc5-9bfe-48f8-8ae7-839a2011ae40", "dd0fc70d-1712-4cd7-83ef-76f981df3759", "cddf3323-9134-46d6-af4b-09bec0229426"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \ncommunity pharmacy plays in the Canadian health care system, which is especially important in times like these. \n Our own Canadian pharmac ies are continuing to evolve and will soon offer e -commerce and e -prescribing \nplatforms, creating additional options for Canadian consumers, who want both a physical and digital shopping \nexperience.  \n \n Within MRxTS, we're making progress with our investments  to create technology offerings that resonate with our \nretail and biopharma customers. ", "original_text": "McKesson Corp.  ", "page_label": "6", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "5e1e3bfe-18ed-4cc7-9082-9a79812e2f1c": {"node_ids": ["c355dc70-61b0-48ea-afbf-e531a3705f95", "1296d68c-816a-49f9-a192-21d9afb78f71", "908db5ec-934b-4616-93a3-8b5921614d4b", "871a330c-dd92-4f98-871f-62d35fa7a43b", "32a139d2-1676-45a3-a1d3-ccdf5f9e8616", "8c9e2825-15aa-4755-9391-42f11ead0475", "3e19467a-b0f7-44a3-a36b-0223838a41f0", "18c9b545-771b-45dd-9cff-cbd348ec3952", "5d80d718-5523-4147-a039-989111c8d6fd", "b1a91d49-a53b-4d19-bf0b-0ef937f990ff", "c672be4a-2f01-46ad-99ea-4d431ee3161e", "145b5716-3445-4260-8a1b-db6db776ce99", "50a2dfe7-d731-43c5-adbb-dfc3f078b3a8", "821672ec-d35d-478e-881a-f46b09cefa1c", "4ba31012-e734-4b63-8965-5b2d7c23b483", "4c19e08d-97e2-4e42-b828-b9ca150f242c", "ac4c4b7b-2fe3-45b2-9be8-605486ee643e", "6586c622-9332-41e3-be0f-6ea700a11d1c", "3ac8f8d5-085c-44c4-bf8a-363bac289b9b", "9a292f2e-9c91-4102-bff1-5dd52867b7f5", "19dae4f0-e90a-4e9b-9f1f-26bcaf38f1cc", "fe825b3d-0263-43d9-901e-60cbb7edc7b1", "138683da-99a3-4de4-8167-18dfafe4f255", "71072f52-fc76-4dbf-a828-da986647a42d", "e847793d-3384-4a92-b311-b002f04769c4", "e7b2af5a-bf2d-4bdd-971a-0785bd70ae54", "be60416d-4247-4b06-abf5-41e7db4ef64e", "da118de1-f34c-45f5-b52a-10f33d67a8c5", "b5fda7e8-90a1-4f95-90c8-bb8c0ad1e934", "5ae9f0a8-9ef2-4f27-b75e-68e1dd96995c", "4cdba34a-0d08-4be2-847c-08cfc5b25824"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nThank you, Brian, and good morning, everyone.  My comments today will relate to our existing segment structure. \n As Brian discussed in his opening comments, effective the second quarter of fiscal 2021, we'll begin to report our \nfinancial results in four reportable segments; U.S. ", "original_text": "McKesson Corp.  ", "page_label": "7", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "b6da9e8d-146b-433f-beae-4978bb0cbe32": {"node_ids": ["eca22406-91cf-4aae-b798-41d4bfd1efe0", "b9c4e9f4-2a2d-49f0-b136-71a3f35cfcfe", "5600640b-4eec-46e7-9223-2ce61fd9f1c2", "a898a7fb-8332-407e-b716-956bcbba330c", "385a8c98-94ef-4859-9bff-2b3dc925c859", "ed080ebe-2e32-4cfd-9902-71552dfff084", "1a6477c9-4fd8-46da-b820-1eb23903953e", "1afa4feb-77b2-460d-a06c-3f2d49df1768", "bd2928bb-4754-4a89-a432-442cab27f9c2", "affd00e5-c760-4d67-bf70-e3bada39f368", "7076c7d3-51dc-40f8-b83f-274bd0b55063", "453fd921-2380-47bb-8d3e-fa840e0add66", "6ed1b786-d677-4a88-8886-141ce9b139d2", "5c6636a6-724d-4089-9adc-c6541ac8dd0c", "1cc4adce-8b59-4eb2-a30a-ce849fa2a960", "7a7478f2-f4c6-40ad-ae79-0663f2ffe6dc", "c9a3bdf0-0c4f-41b7-a8c0-8626cb27e2b8", "93e180dd-d91e-4cfb-ba51-67b421e11b60", "ca27606e-3f30-4ac0-b636-a8d47fd44859", "0097e15d-5e35-483c-add8-27fde0a0c5d7", "b0d487dd-e5d6-4d3d-9ff4-c65a796b5a12", "6edffcf9-bf4d-4353-aa81-b62429350787", "d3d044a1-2763-4abc-bd8c-df7e7fad0541", "afa96779-0585-4de7-b907-f9f30d0a5336", "faab4b8d-2e34-4dda-92e0-65ff4da4747d", "cda1a1f8-ed31-4e47-bf76-d6a89a10b33d", "692e7084-347f-48db-9aeb-87e9acf5d42f", "c940b079-6c56-4d91-80e7-fffc04895f26"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nyear, adjusted operating profit was down approximately 14%, again, ahead o f our expectations.  Interest expense \nwas $60 million in the quarter, an increase of 7% compared to the prior year.  \n \n Our adjusted tax rate was 22.3% for the quarter. ", "original_text": "McKesson Corp.  ", "page_label": "8", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "e6763537-8e0b-4f34-ba9a-81920191e975": {"node_ids": ["0a4903e6-43d5-497e-8744-4a5b17f81695", "4225fde5-d61f-4b9a-a298-859bce8aa255", "0dfd43ca-f415-4aea-9a75-e2f3da22fff7", "d0a0955a-aef8-4787-a0ad-b1a15cdd3728", "8e64a980-9937-42a3-8f82-61fc4ffc4faa", "0e536704-f6cd-4e9d-8b58-bad24a493abf", "86ad7eaf-ad05-4ef3-91e0-0eedcf44f933", "5a627c50-4887-4679-bf81-f570fe35e63d", "30519e88-16c0-41f9-a4b4-b7bf437c4df9", "45426c9e-fd2c-4c85-ae5d-83e1429f3864", "b261580d-a592-494d-9a34-b7d7be10407b", "24ebe660-588e-44bf-8c10-11d64c786ce7", "b840aca7-2518-473e-946e-ffa1e306f6f9", "49dc44da-305b-42d0-bdfc-3fd21ccfb803", "54bf5c73-da44-4798-aa41-9a5b31128ac8", "53b548ea-1e7f-448b-89b8-1920e1985edf", "4406edd2-a4f2-4aad-8b3b-1a949f9743c9", "09664206-9c6a-46ae-aa12-5508fd4e421c", "1b2f27c0-f7c7-421f-9c89-1b57e8c4bc3c", "8e875de9-2b60-4dd3-ad72-1fdf4c7189b1", "c8cf16d8-8084-4527-a1d6-ca35f800c4a1", "2709f77b-cdc1-41b8-849a-43c040701cd1", "1c9e7dbe-c661-4df6-bb5a-4d43ff80d4af", "80e8dfac-d54d-4716-bce8-093f02c47c81", "8c2dc65e-04b4-4da2-9497-2e5485b88a25", "f73b567b-be80-4386-9a53-a9ff10ca1ad0", "d0ab9e72-0e12-43d4-9bee-c6dc1c0ae627", "00c7db14-4704-4304-afcd-57dd5c1ce9ba", "8142fc3b-62ff-44ef-b70e-3beacce5e720", "086c45c9-b62e-4a14-85ef-ec31e6b9adb3"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nWe saw increased demand prior to the lockdown, but material reductions after the stay -at-home orders were \nimposed.  Volumes have remained steady, however, below pre -pandemic levels.  \n \n In our UK business, we identified an o pportunity to accelerate our transition to digital. ", "original_text": "McKesson Corp.  ", "page_label": "9", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "a2fe6c7d-f0eb-4895-b27b-02b6ca730d5e": {"node_ids": ["0d202777-8a72-423d-a984-86606312701c", "e48dc77c-b3a7-4bb1-8eea-2fc70742203c", "6ef99712-6dab-46dc-8057-9ae7e3c6a0f9", "d350c258-647d-485a-bb81-1b4f10e09c88", "1620a5ba-26e6-4a94-8f4b-3777dce6bbb6", "398b72a5-60aa-4239-935a-87d14a8bdd9b", "07b838c1-f5a3-460d-ba35-80ec302a438e", "c6939212-ae8e-4d87-befe-0efc09be4655", "47975624-14f0-4478-9dc5-f96535a6ea38", "c8252015-1335-4285-9ba3-e16c5345e67b", "8cdf2090-2acf-441f-b5a8-a9d39ba4020d", "67bdcc92-97ae-4f57-90f4-1d4670cc5297", "67aeb439-9552-4b50-9c35-50b067429ee5", "8d20175d-8d42-4170-80a4-27e6cd23bc16", "7d0de43b-40ee-43c3-a405-9446314e9d6d", "69a767cd-57b4-480f-9649-43172209d3b3", "b13a442b-5285-43d8-a383-885439fa3237", "e2fe6db0-4db7-479e-92fd-08ff344e4824", "f35fcf61-15c7-48d6-ae2e-5f706c6264a1", "aaf87a8f-e138-4ea2-af53-91dce50565af", "c17fd2f4-47b6-4e7d-9d77-b0f898cea98f", "d2a26281-e3d2-4929-996e-b85ddb17458b", "a2a12f25-ee00-4848-8648-3ba75b48e37e", "100b572c-d476-4c6b-a52a-6f7108352da5", "8da32229-728e-4fff-93ba-bfd3bca582c5", "52e6a909-4bd5-49dc-addf-9d638185cada", "dbe0d40c-01bd-4f56-ba38-3e13e33df77f", "88dd47c5-4020-41f5-80ae-da307c8bdd96", "0801e9b0-e9bc-4d39-b9a7-0ce1ef3b69f7", "657669e0-ea45-412d-a39f-6a91afddb2e7"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \ncash flow will vary from quarter -to-quarter, impacted by timing, including the day of the week that marks the cl ose \nof a quarter.  The dynamics of the current operating environment resulting from the effects of COVID -19 has \nintroduced further volatility in our cash flow.  \n \n However, improving volumes and strong working capital fundamentals give us confidence we will continue to \ngenerate solid free cash flow. ", "original_text": "McKesson Corp.  ", "page_label": "10", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "7d2b4c06-f5b1-4a4f-9127-7f73d68a375e": {"node_ids": ["00749a44-61f7-417c-9603-bb00ece296d2", "d4ea6700-611c-4f31-b584-69eea12318e5", "40557a2c-f32f-47b5-aca7-eb7835cea461", "f7f956e9-22bd-4481-af73-a455bedbe333", "8af287de-32fa-41d0-8867-89f7c205ea25", "353dc385-6450-484e-a448-f8e39835b5b2", "ef24ac2c-e3ac-450d-9545-b0caafc517c5", "0b04f4a7-4697-41dc-96f4-0de788cd0013", "1ba1dbe0-64b3-4b40-8906-84f2a5db7f18", "dee47a4f-4d10-416e-9803-2a070664b6c4", "b7455b1d-944a-4485-a2c7-7b8764d082e7", "011e5dba-1c03-487f-8104-38e19da864d1", "d679fcf6-f9be-4a2c-a303-7398369a2f5b", "f7bac80d-c17e-4b6c-ba63-3d52602fc3f5", "f6e53508-92ad-4121-b40b-06b5809fe2fc", "c30f5be6-f0ad-40aa-b2a9-b934380fa8c5", "7daffaab-d6a4-4a6f-8b10-23d4d3042eb6", "c40b3b82-5ccd-4710-a73c-c1f485714c41", "b09cda71-2596-4324-b45d-8d35ce256215", "39fb63d1-abdb-4333-a6c0-08a26d799c0a", "b05d732d-0bfd-4da5-a5b6-e48f8c21919d", "3ba09699-9a0f-4d5b-858d-85460d1a9967", "cb164a2a-196a-4270-bf94-7bdc036713b2", "5e7dc32b-5b05-47a1-ba62-ee7bfc162dd6", "1b16bf12-8931-46b3-9540-7f8b982d8258", "90e4eb8d-b972-441d-a7d7-991cdb6137b5", "3d5808fd-b3eb-490b-8d24-a59740d24c38", "761bc3ab-56d1-45ae-9155-04e1aee02a0c", "ad82a548-f46f-4af4-8afa-6e6b200dff65", "e816f77e-ec74-4e7b-b687-336f0a596954", "c7186334-534c-45db-b38b-3b8eaf940c93"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nWe now expect the consolidated adjusted operating profit will decline between 1% and 4% for the full year,  when \nyou exclude the results of Change Healthcare from the prior year.  And this is up from our original guidance, the \ndecline between 5% and 8%.  And as I mentioned earlier, we anticipate enterprise adjusted operating profit to \ngrow sequentially throughout  fiscal 2021 and continue to expect growth in the second half of the fiscal year on a \nyear-over-year basis.  \n \n", "original_text": "McKesson Corp.  ", "page_label": "11", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "cde69cac-dee0-4cfb-8e4c-635bb17fb3bd": {"node_ids": ["1e92c18f-9163-4e9a-a56f-14455ced5b05", "5256dd93-607e-48f5-a9b4-dd0bf502c400", "a2cee608-fed3-49a1-a0a6-843027f36bcf", "ed4de0b1-82f0-4528-b7e4-1ddff533ab04", "50d98052-7ad5-4dd7-82ce-9f860f1bf048", "c0c89981-143d-4ec6-a02c-6fd5f181414e", "42ec2acf-f4fa-414b-8721-2d88a3c6fb68", "5a02a702-ed64-43c7-a06b-d75ed8ddba74", "e115c33e-bc96-4088-b0bb-cdabff889802", "e3270874-6c01-430f-a502-12deaf4d0993", "0b69f6b6-1230-4bcd-bde7-d4e3bc2b7526", "02ac8005-1a5e-4a9c-b18a-119c7c4068dd", "08bdb6ed-41fe-4a02-8c14-21b5d8d9d85b", "a1b90829-f923-40b5-9b26-7969d5947fe3", "d724a26b-6a0b-4a4a-8d80-d45c44428a1d", "98bfd195-ffbe-4be3-867d-3628b8f726a2", "ceee9fd8-69bb-4abb-a838-63931e8684d5", "352da687-8504-438f-8da8-13595bb773ba", "97177d89-771e-4473-94e4-da7bbabe4b05", "4603e04d-15de-425f-a1a0-63d74da06367", "50ae749d-fb4e-4034-af6a-8d6960549bb5", "8675529e-f7ae-4e7a-ab02-bc42cc043cf5", "d51c2ca5-2040-4980-8157-0a12147700b5", "cfd0cf7b-cc8b-4e2c-8fa2-abccf7372d0a", "b484bddf-9cf2-4059-bf87-65b3d2d67da0", "0a9faccc-383e-4113-9794-62064e68cbd3", "b4f06a0d-54c0-43c0-92a1-59b76892cfe6", "70cb394c-3edb-4c1d-890e-9adaf8a102a1", "c93a4baa-b160-451a-9371-c36bc970f7a1", "9251c2dc-6c25-4dd2-b295-fcec1976eac9"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nenvironment continues to present many unknowns, but our businesses have continued to be resilient, with strong \nexecution a nd stable fundamentals.  \n \n With that, I'll turn the call over to the operator for your questions.  In the interest of time, I'd ask that you limit \nyourself to just one question to allow others an opportunity to participate. ", "original_text": "McKesson Corp.  ", "page_label": "12", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "f085fb6c-4660-42dc-89e2-bdb89b579fde": {"node_ids": ["24d96533-cb23-415f-a1b9-435036a6a0e9", "55a15501-519b-400d-9540-a0164e37c210", "c026519c-584f-47cf-ae2f-bed834361036", "030e7605-ae10-44f1-bb34-9fbf8af4d20a", "8856beb8-7749-45f9-a74f-0d5832408af0", "26f9e74c-6dc6-4a3e-aabd-403a8c1cab64", "18fdb3e4-8c79-4f34-aa6a-328dc2fe5c80", "4cc14b33-14df-437e-ae32-0780a7b8e5b8", "21a23cbc-c718-46a9-a305-0d61891c4363", "d4a484e5-47e6-4ab6-9259-9b9da7e3fcc9", "d9910a44-2f6e-4a98-bc40-08c906fd709b", "367375d1-99b1-43fc-98bd-fd4d49789220", "0d85c418-3ff1-47e6-a8d9-88928d150bb3", "af146a46-16e9-479e-b402-e4488c5020bf", "6e619b6c-da55-4095-a429-161f1e7e22ae", "e4987031-dcd9-489e-87b8-7a01b1b51508", "a2b04634-daa4-46ba-a435-52b8a790b586", "1b106550-fb4f-4b91-bd1d-54df8a42e3fc", "2dd2a762-8de9-4961-9242-17815d159241", "1cc88be2-aebd-4133-b9cb-05b37abdbc97", "334c2f84-cf45-438f-8bfe-679913724343", "ad4f54f9-8732-4a00-9785-1595ba316dcb", "d70b1c28-b86c-4481-b050-4a1e25806ffe", "180d6faf-ca44-43db-8f5d-eee1929affb7", "9ffde07e-36ab-42ed-8976-82441ea0ca50", "61e801b4-527b-43ba-a561-ca78db650dbc", "d75cc162-f184-463b-ba35-65d9a29070ee", "a89dadbc-54d0-4fb8-8aa3-77873803c918", "139ce5c8-7e2c-4423-b8b1-f1aff5499f59", "3a450d77-7c6c-43b4-b348-6d94e307a272", "246f5d56-0ca3-40c2-b173-9ac2d81eb6db", "b8b636f7-714c-45c0-b72d-2d10100244db", "c633a7c0-5246-4de1-84b2-1406f7dc362b", "9a23614e-c7c3-4412-ac36-207c6a390d57", "ef718386-b747-43f4-a513-f24ba8eb2955", "9cdc62f6-7401-4a99-9359-4b105a2794db", "90bea696-4582-4e89-8d53-8ff185b540fb", "ebdedf06-6dbb-4a0e-8428-b4cf148d6d2e"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \nOperator : And next will be Charles Rhyee with Cowen & Company.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nYes. ", "original_text": "McKesson Corp.  ", "page_label": "13", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "f3e49820-b6cd-4d4a-91ea-9dc1750852df": {"node_ids": ["6bc090c6-5e71-43b3-b7a4-e39ff5754f00", "683fbde6-e239-4ae3-a233-3e6d5693b8c0", "004ca8d7-3af7-4d84-b747-5a9205347009", "6ce1395d-3d3f-4ad9-8353-8c9d9c6f779f", "42e85c84-3e85-4071-88e4-8ed05a268c08", "96c5aa32-36ca-4949-9c22-90a1d1be3543", "8a567351-ca20-446a-b721-770a2e83c658", "ff5f3892-f386-4a57-a963-96af8ddd6d5b", "478c3e02-4301-4338-9831-28ac0167629e", "948f4412-2c11-42ee-85b5-b36159415198", "6bb3d428-842b-49c8-a23c-ecacf632c15b", "c9fd8150-3d3f-4be0-8b9e-02cb8c678ae2", "01640716-2064-4ee8-a47a-68089663ccfd", "9ff58bec-de0c-42ca-a495-6cce76a9a727", "a526b23e-7143-4a32-99d5-7e2642f2d9f0", "1a978c21-40c3-4d70-85ba-a3b8d2a625d3", "64872c0a-d114-4d47-86cd-8d2ff849c06d", "2f0feecb-6be7-46aa-ba48-aaf16ef6f936", "cb8dc87b-958c-4f7f-85f5-ff6e35d30b8f", "80da1509-19e3-4090-8548-b645480c8a81", "f0bcd546-6d5f-40b9-93c4-7c731284e3be", "14497484-77e5-42b0-bae3-e9327f7225f9", "0cbf6adf-9378-480e-851f-7b3dff8c824e", "afb6d406-74f8-474c-99ba-e07fded4c0e1", "ca40a06b-1411-4275-9f89-25927aab3a64", "27e6fff5-02ec-49d0-b5c1-27b5732a5f5e", "1cf12911-11c8-4dac-b5b2-b9d611d74dd3", "9f9b889d-2773-4cbe-a85c-51a0a56402a3", "f797cd6b-59e6-462e-90bb-4c5ebfa118f2", "ddae9c58-9ba4-4a53-a01a-433799d95e1e", "50f43e68-feb2-4c3f-b7d6-28ea534560d1", "92d3542c-790a-4d32-b245-3d37a1ad0de1", "8cf9d13b-3a32-4f70-95b9-dd81825a0f93", "ddcedac7-027a-4f63-99e7-f8109d88cfd4", "aae40073-8562-401a-8665-40aa28483494", "58bf1dcb-a3b4-44ca-9d9a-9d346aaddd89"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nSure.  I would say as a ge neral characterization, the pacing has been pretty consistent retail national account \nversus independent.  Meaning the macro trend of when we saw volume soften in April, start to recover in May, \ncontinue to bounce back in June. ", "original_text": "McKesson Corp.  ", "page_label": "14", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "ff79878d-cd7a-4d1f-8101-b4311053d1e7": {"node_ids": ["b41d719c-f0c2-441a-88dd-6c44aa519458", "e03e1783-faf2-46df-926b-89056b56ef95", "81eacea9-a37d-4834-8413-8428c5649cf7", "215bdc4b-988a-4679-acd2-b407a5f99e5a", "5e9a9db8-3fb1-4165-acce-6d03be816629", "c07028c5-6347-464d-b168-5775e60013b4", "8b9a4fa9-5a4a-401f-b718-3446fdc66f60", "5aa1e20b-a523-41b2-b3bf-dac0db7108f0", "d4297ef8-03a2-4ed4-b2b1-bb8c9e5626fb", "4eab0c6f-c55b-45ba-9cc6-8da711d4fad1", "fcaabf17-a700-4778-a0d5-c5ec63d1b5a9", "057c2d7c-1db7-4c83-b943-7b2aa6270633", "cc3e792c-1f77-46fa-8ec6-d0a43ce4a9ae", "480d15b7-aca5-4b43-ab2b-f6c6653eb252", "d635d0ec-7529-4cd1-80e8-1fb7fb5e3293", "bbc5341b-e812-453e-ad03-fa9d904606e2", "a4faa206-6fcc-46d4-9711-a0ae3860462f", "f82625aa-60e5-4103-95d0-02004f711cf6", "53a0530f-71a6-417b-8615-25588c0ed1d8", "eeeabd3e-66f0-40ea-93ba-0f4a49390928", "758edcd7-3431-4bb1-8c75-71ad002102ec", "4ec26a79-0326-4b65-806c-c6852595af57", "a4b91c1d-3851-4322-b5d3-625e17bbe77f", "aa87afae-8735-432b-b81e-a065bd4240f0", "061b7ab0-35ae-44f7-9075-a48e9c1ed722", "af60dc25-5aa8-44d2-a54c-f46daec6154b", "88309284-aeba-4eda-8e64-37ea77dc9b62", "376a00a2-150b-4c27-8c64-8559973e9e3b", "acedc22f-18e3-459f-9fab-b6cc20c64bba", "ab6e6785-1f02-432b-a8d1-6832e38108e2", "0ec91c57-d83e-4495-be7a-28d9286cc1f3", "b86fa0ab-02c2-4834-91ce-42f009d4c45a", "4b37d3ca-db86-43b5-bdc6-493238f8ab11"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nOperator : The next will be from Eric Percher with Nephron Research.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you.  A question on the specialty business, I think you mentioned 70% volumes at one point in oncology. \n", "original_text": "McKesson Corp.  ", "page_label": "15", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "8303b9b1-b8ed-429a-a917-848440efdf52": {"node_ids": ["e0cf7e0c-22f5-41be-981a-029a0e00ee68", "6e644f25-cb4d-477d-b2ee-c4c425d8ea0b", "01c93cc8-b7a3-4036-8f76-8afa453a130f", "ae57c776-7bba-4bab-b1a3-4315b9799904", "744ccc30-6671-4316-adb8-ce2192ffdcb2", "ebf3d10e-4273-4739-878f-6cdbb2fb5193", "a2c8ee26-a27b-4d63-b361-c0e7b6a22bfc", "0b5790d6-4dda-4315-8294-68342fcf8fb7", "3a7ea451-f9d8-410d-8972-e2e7e0744419", "49e9802a-95e4-4cd8-ad95-e94ba212e185", "dcc3c51b-cbdd-46be-a129-97870ee268df", "ad2ca80f-67e7-4606-a184-7efd49147928", "ba76262b-100f-48c3-8587-cb9f255881ee", "a2c1cc42-bfd3-42f8-9a7d-ebc6d6256c55", "bd7fb46e-2644-4178-89f8-6b0e90f97a10", "2350bcfb-f1d3-47b4-9acd-2e7ae1c7e622", "ed4ea57b-8dad-4e1b-bd5f-066baa731fc5", "16a8d12c-d8b2-47b6-ba76-5661edf5a082", "0a39872f-c660-4376-b1b5-557ab1cad0a9", "53ae5517-0d3b-41d2-8104-2b2aa8486093", "1d4f0249-0ba9-4742-8fa9-c84bf53d327c", "acc0d480-c4ba-4274-a859-bf8178aca0fe", "2a2e1c9f-c8fd-413a-a6d1-53c391dbd23c", "1688d1f9-0eba-4eb8-bff1-2e6c284a673a", "3b7597b8-97a2-46d3-9a07-bf2657b48753", "7ec2fd5a-8245-45d5-9e2e-7a3d706c6347", "b50bf998-458d-4c91-8c63-3ca79001e4db", "977f240d-d157-47bd-b3cc-1a6aa187b922", "2b14f667-f30c-43dd-8170-d86787441115", "4804ac8d-c0c2-4513-b1df-b2b93a8d95e1", "ebc7338e-7ea6-4500-8a85-737b930c9031", "116c403a-7edb-4d32-9dec-ea3d99d60ebf", "0d5f9f7e-b645-4a66-9c68-cd3d030b5311", "9a00fad5-ce17-4b7b-8976-6eeea2f9325c", "8d792cfd-d418-4f85-8a51-4342e42b6d2f", "c2128f92-501b-4207-ac6b-0b51590a2532"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nSure, and thanks for the questions.  Let me try to unpack those for you.  As it relates to the guide, first, as it relates \nto the insurance proceeds, as I mentioned, those are GAAP only. ", "original_text": "McKesson Corp.  ", "page_label": "16", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "48fdc39a-da73-45c6-ab0c-c60b396b0afe": {"node_ids": ["4ffcd582-fd18-44e0-ac08-404999a01003", "36f8fc85-a616-4032-9042-1a3ab1af3745", "78d9310e-de67-449e-8151-58ada4656908", "1c173590-e2a4-428e-a9a7-ece1d3647bc7", "5c35e97e-c9f2-437c-a2dc-5dc23ad4adca", "faad1eb1-f2b2-4f26-8c68-2ee75e72429c", "eed0963c-7cf8-44f2-8d6a-6fb0836b2629", "d71698b1-6ea3-423d-82bb-782a35db7ce8", "594d9683-b2d8-4e56-a4db-e6e3a203eb32", "2cfff289-66f4-4205-903c-b21c0814519b", "79021055-c7b4-4b50-8def-e347e94f40df", "0da0c842-8103-49b0-a383-4979fe1cbb11", "01ba6f47-8747-4630-b503-f533c0572b70", "3d27e28c-4d8f-4725-89bc-fd6b83b17e28", "d7b2fa0a-574e-4c6d-9ff7-9f767d96c18b", "c27ab11f-28f2-495f-8249-63efc6679710", "780f9b94-0222-4622-93de-8ee4594f968c", "514dab8d-b8ac-4fcf-aed1-eee174058e29", "243fb048-1760-42b6-8241-b281fa5d813e", "217ddcf9-1839-4582-8f6c-20d4d8e0046c", "86362744-92cf-45b4-ba0f-c0560569b456", "59f57f50-c357-4844-96f5-1b43fe7f32c0", "aa1215dc-bcd5-4f82-a4b1-cfa6c50b5933", "95d7a5bd-8132-4f04-b616-01dfdd712c67", "94fb79a2-4b67-4b77-b942-ceacda8a12f6", "5f09a005-f5e9-4fb9-b117-5da4a5032945", "8b73cb46-f59d-4e5e-8262-9c23e984ada2", "928c8a88-2188-4b48-90f7-a2d768420cfc", "7be13def-33ab-41c2-9f6e-26992141f21b", "49db94ac-a208-4910-a16d-3bd5c2062332", "a029fff3-61ab-4bcb-97f7-23fb996f1a27", "4f804246-d76d-48ce-b522-dab4991efa2c", "f8cb5524-d4ca-4d22-9636-bdded29e16c2", "f327913d-07d4-455d-a06a-a54acad37849", "37514ab9-c9ca-401a-bd0e-67ac47d1239a", "586a3a93-62fe-476b-a34b-3c919278389b", "b3d6ea29-a146-4a01-b97c-2ce808e0ba5d", "e3671f8d-f163-41c2-ae74-b6b5999d9781", "634435f1-0787-4e15-a578-8d8d7438e062", "1835c038-c21b-4743-a987-c2967ad94589", "6f85e3a4-08be-4f8e-8a6e-7a10483fd7b8", "b6229de3-07f4-4cf9-a5b2-89314a1f911f"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nThanks very much.  Good morning.  I just wanted to go back to a comment, Brett, that you made around the macro \neconomic environment. ", "original_text": "McKesson Corp.  ", "page_label": "17", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "5f4e4711-6225-48b4-92c3-167aa1459c03": {"node_ids": ["5739b225-76cf-479e-ab2e-abcbd00ec555", "495c9cf0-b616-43af-8c5e-0dda3195c29a", "c60176b9-e538-455b-ab45-b370db0f7971", "bb308ae2-b105-4bbb-94b1-ebe036b2a16f", "73b3d175-75ef-450c-a511-98e6eef62683", "30f9a185-e037-4fed-aa3e-a9c485934204", "31776279-4cb7-4e3b-a12d-bcf90a131bd1", "217faf87-922c-4258-88b0-6f29ccbd0ac1", "5a0309b6-dde0-4a1c-8d7a-d4266fa42e1b", "ee3a6fab-c610-4057-b246-f39c0af6eae3", "3442a671-4a97-4116-8b3a-4f037362502a", "f579cd8d-9962-4cbd-a62e-0557f92b996a", "ee764432-b0f0-4db5-9e84-66db222b075d", "a2237301-66c9-4ac3-8d04-f41615c5c3ec", "0c2e76db-f65c-43f4-9371-4f76ffdc8afe", "1d162908-090d-4b1d-94e9-fbfc8f39e04a", "3c4d4108-8a09-4c97-8162-9668d382690f", "10194d53-8263-4f53-b971-4627793cf14b", "81f5678f-8812-42cf-92c8-bfd9b27c0f0f", "167629da-e1e9-475f-942d-04a4e5800f56", "d97e916f-638e-47bc-8f8b-8bcb00281138", "15992029-45ce-4f97-8cfa-84908a22e4f8", "80f6152f-9e61-4037-a99c-18b327a7aecf", "4f601686-0965-44f7-b7b0-dad60448b68d", "b588b264-304e-4488-a19b-e4935b7bdaa1", "34ade99a-6dd0-4cb1-a82f-eb49f34ae197", "16c610ba-eefa-4c13-9ead-fecff49d3a50", "fdc804f8-b30c-4eb3-9062-c5caed44ce55", "5388168a-32ec-40d7-8b8d-9db49657b45e", "8836fce5-e105-40b7-a210-92d6fa8e64e8", "10ddc74c-5c59-4164-9373-688d00c9fdcb", "e25d2c4c-f3c1-49ac-a296-3705b03605f5", "a9e95be6-91fa-494d-ad8d-4964961fb205", "9bc46997-1f91-4632-9d34-b7249164f379", "f8efa66a-fd0c-44ba-9f3e-9712ca007aaa", "591afdc9-9acf-401d-978b-a02a65f5f5fc", "6b02363d-8aef-4cb1-805a-9f827d4ede12", "108f56c6-8f37-4741-9255-a5b0054bf7b7"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \ncommunity providers who administer these vaccines, and in over a decade ago, when our nation was dealing with \nH1N1, we continue \u2013 it's a proud moment in McKesson's history the role we were able to play in managing that \nvaccine sol ution.  \n \n So I think we have terrific capabilities.  We're in active dialogue with everybody. ", "original_text": "McKesson Corp.  ", "page_label": "18", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "a805158d-a3a9-4f66-90a6-b2bb5b33d14e": {"node_ids": ["a2b00a35-60bb-405d-9ed3-8ad8ced9ea0e", "2b0fca36-0288-453e-9b88-acc00f23fda4", "16b7202d-c187-4a65-ae7d-716f25159236", "f27040f5-dbbb-4800-9f12-622706f1e184", "c5218a91-3831-4803-8fda-909cf28d2c17", "b7990ec0-7155-4e81-aad1-833c2f9cd768", "b4f7f26c-5eba-4cf5-a641-e186d6aa389f", "00b8e4fb-a465-4639-9088-b7fc092cf380", "e789c0bb-b030-4904-87d7-2179fe3f30ef", "567fbbd0-742e-4df0-90fe-70a26e33e5c1", "ab9be6da-2cb9-4141-b318-1ce50a83d6e4", "89380c8b-31de-496f-972e-3b6baf9cba71", "8f894659-d038-45e5-9701-988f35146e0a", "36a340f9-5d06-4fab-8f5d-fcb0db863020", "30aceb49-1584-4f57-ae2a-952026569531", "fd594a45-7d0e-47b1-847d-13e94970443a", "b1b20555-9249-40b1-ad72-8fb045613ffa", "c9dccec2-53e1-4551-aae1-10e0eba706d7", "2495ce3e-7312-4fe0-8e9e-279d78579f54", "0ecdefc8-32dd-4bf3-859c-562177d845b2", "4649a1c1-784b-4f0d-a129-e80d020dfebb", "7fb752b0-9d28-45a3-a9ce-4aeff3a21cdb", "0665d5d6-567d-45c6-9806-9f29c97c69a9", "128e8b1c-7b4f-442b-b002-555b26469322", "657a6815-03b5-4864-afcd-cf27587e1ef5", "afe59138-a606-4734-9081-62a9b14cb089", "f4f4f6cf-31f7-441f-83e2-c071e10e14ae", "b654ab6f-55f5-4139-aa15-ecba91b04ec7", "d7d2bf70-4762-4e10-9bfd-6376decff98d", "ddc16e3b-5c65-467f-a989-1f9a1cb5ceac"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nHolly Weiss  \nSenior Vice President, Investor Relations,  McKesson Corp.   A \nOperator, we have time for one more question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Certainly, that question will come from George Hill with Deutsche Bank.  \n ", "original_text": "McKesson Corp.  ", "page_label": "19", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "82e8361b-192f-452a-b420-11d131263f55": {"node_ids": ["10ce44ac-8db8-4e8c-ae9c-30d18b28085f", "5e21f481-ad80-4f31-872f-aee759890ce7", "4339248e-0294-418b-8ca5-a28730f84ef2", "322e68b8-c9fb-49d6-824d-5b5f23dc7596", "2bb69fc5-127c-4db1-96e0-825ee3bfcde2", "767e0dd3-767e-45ab-9f38-7e6c2f86aa4b", "b626ffe8-afb1-4f9a-a1e8-ab7ca6e21ef7", "94bf1d14-69a8-4a62-8124-bea5e3a8d30d", "a83bd5ba-8033-4fa9-8915-f2628e82ec44", "ec5901d0-98cd-4802-8e2e-fe0aaacd4299", "f0e0c02a-0d11-4ac9-8c94-0328b7c3e03a", "4147e8aa-89cf-4165-916b-be049d428fa6", "c034f82f-1c2d-40f8-a424-f723d3915cb4", "666be2e4-5f9e-42b1-8f70-f5747e53eb89", "e2a3a7a8-006a-4022-87b8-b18fa95ac143"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2021 Earnings Call  Corrected Transcript  \n03-Aug-2020   \n \n1-877-FACTSET   www.callstreet.com   20 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \n \n \n \nDisclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a  complete or error -free statement or summary of the available data. \n As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information.  You  must evaluate, and bear all risks associated with, the use of any \ninformation provided hereunder , including any reliance on the accuracy, completeness, safety or usefulness of such information. ", "original_text": "McKesson Corp.  ", "page_label": "20", "file_name": "MCK-Q1-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 370222, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}}}